<SEC-DOCUMENT>0000943819-24-000013.txt : 20240809
<SEC-HEADER>0000943819-24-000013.hdr.sgml : 20240809
<ACCEPTANCE-DATETIME>20240808200934
ACCESSION NUMBER:		0000943819-24-000013
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		122
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240809
DATE AS OF CHANGE:		20240808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RESMED INC
		CENTRAL INDEX KEY:			0000943819
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				980152841
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15317
		FILM NUMBER:		241190094

	BUSINESS ADDRESS:	
		STREET 1:		9001 SPECTRUM CENTER BLVD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		8587462400

	MAIL ADDRESS:	
		STREET 1:		9001 SPECTRUM CENTER BLVD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>rmd-20240630.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:626b872d-b824-4a3f-bfea-336621baa0aa,g:59f8884c-c35b-445a-b56c-2a5e88decb05,d:7fe754a0eb594e619b22be4f3387c577-->
<html xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:rmd="http://investor.resmed.com/20240630" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rmd-20240630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-33">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-35">0000943819</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-36">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-37">&#9744;</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-594">http://fasb.org/us-gaap/2024#RestructuringCharges</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-1269">http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-1270">http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-1273">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-1274">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-1279">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-1280">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-1285">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-1286">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="f-1319">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="f-1320">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="f-1321">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="f-1322">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-317" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1412">289</ix:nonNumeric><ix:nonNumeric contextRef="c-319" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1413">284</ix:nonNumeric><ix:nonNumeric contextRef="c-321" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1414">449</ix:nonNumeric><ix:nonNumeric contextRef="c-323" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1415">564</ix:nonNumeric><ix:nonNumeric contextRef="c-325" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1416">325</ix:nonNumeric><ix:nonNumeric contextRef="c-327" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1417">462</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rmd-20240630.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>rmd:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="offering"><xbrli:measure>rmd:offering</xbrli:measure></xbrli:unit><xbrli:unit id="patent"><xbrli:measure>rmd:patent</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:AccountsReceivableNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:AccountsReceivableNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:PrepaidTaxesAndOtherNonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:PrepaidTaxesAndOtherNonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:DeferredRevenueCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:DeferredRevenueCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:DeferredRevenueNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:DeferredRevenueNonCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">rmd:FairValueAndNetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">rmd:IntangibleAssetImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:VehiclesAndAircraftMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:VehiclesAndAircraftMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:ClinicalDemonstrationAndRentalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:ClinicalDemonstrationAndRentalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SaasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SaasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SaasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rmd:DevelopedOrCoreProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rmd:DevelopedOrCoreProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rmd:DevelopedOrCoreProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rmd:IdentifiedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rmd:IdentifiedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-29</xbrli:startDate><xbrli:endDate>2022-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rmd:ResmedLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:TermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-29</xbrli:startDate><xbrli:endDate>2022-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:TermLoanCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-29</xbrli:startDate><xbrli:endDate>2022-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:TermLoanCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-29</xbrli:startDate><xbrli:endDate>2022-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:TermLoanCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-29</xbrli:startDate><xbrli:endDate>2022-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:TermLoanCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-29</xbrli:startDate><xbrli:endDate>2022-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rmd:SeniorNotesOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rmd:SeniorNotesTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rmd:RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2014-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>1997-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:ResmedInc2009IncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmd:NonEmployeeDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:AmendedAndRestated2009PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:AmendedAndRestated2009PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:AmendedAndRestated2009PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-31</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:AmendedAndRestated2009PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:ResmedInc2009IncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:ResmedInc2009IncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOperatingLossCarryforwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-28</xbrli:startDate><xbrli:endDate>2021-09-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:PrepaidTaxesAndOtherNonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:PrepaidTaxesAndOtherNonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rmd:OtherForeignExchangeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rmd:OtherForeignExchangeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rmd:OtherForeignExchangeContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">rmd:EmployeeSeveranceAndOneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:MichaelJ.FarrellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:MichaelJ.FarrellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:JanDeWitteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:JanDeWitteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:BrettA.SandercockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:BrettA.SandercockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:KaushikGhoshalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:KaushikGhoshalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:MichaelJ.RiderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:MichaelJ.RiderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:PeterC.FarrellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:PeterC.FarrellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7fe754a0eb594e619b22be4f3387c577_1"></div><div style="min-height:13.5pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________________________</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">[<ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">X</ix:nonNumeric>] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">June&#160;30</ix:nonNumeric>, 2024</ix:nonNumeric> </span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-15317</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">ResMed Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________________________</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of incorporation or organization)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">98-0152841</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(IRS Employer Identification No.)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">9001 Spectrum Center Blvd.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-11">CA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">92123</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-13">United States</ix:nonNumeric> of America</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">858</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">836-5000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.537%"><tr><td style="width:1.0%"/><td style="width:37.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.004 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">RMD</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________________________</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#168;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">x</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#168;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#168;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;<ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">large accelerated filer</ix:nonNumeric>,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.537%"><tr><td style="width:1.0%"/><td style="width:33.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" id="f-24">Large Accelerated Filer</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:108%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated Filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:108%">&#168;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:108%">&#168;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller Reporting Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:108%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-25">&#168;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging Growth Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:108%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-26">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#160;</span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#168;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-27">x</ix:nonNumeric></span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-28">&#168;</ix:nonNumeric></span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#168;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-29">x</ix:nonNumeric></span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of registrant as of December 31, 2023 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter), computed by reference to the closing sale price of such stock on the New York Stock Exchange, was </span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-30">25,155,017,346</ix:nonFraction>. All directors, executive officers, and 10% stockholders of registrant are considered affiliates. This determination of affiliate status with respect to the foregoing calculation is not a determination for other purposes.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">At August&#160;5, 2024, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" id="f-31">146,932,119</ix:nonFraction> shares of Common Stock, $0.004 par value, issued and outstanding. This number excludes 42,664,067 shares held by the registrant as treasury shares.</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true"><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive Proxy Statement to be delivered to stockholders in connection with the registrant&#8217;s 2024 Annual Meeting of Stockholders, to be filed within 120 days after the end of the fiscal year covered by this Form 10-K, are incorporated by reference into Part III of this report.</span></div></ix:nonNumeric><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:justify"><span><br/></span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_13">Cautionary Note Regarding Forward Looking Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_13">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_10">Part I</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_16">Item 1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_16">Business</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_16">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_19">Item 1A</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_19">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_19">22</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_22">Item 1B</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_22">43</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_788">Cybersecurity</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_788">43</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_25">Item 2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_25">Properties</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_25">45</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_28">Item 3</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_28">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_28">45</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_31">Item 4</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_31">45</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_34">Part II</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_37">Item 5</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_37">46</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_40">Item 6</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_40">Selected Financial Data</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_40">47</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_43">Item 7</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_43">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_85">Item 7A</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_85">Quantitative and Qualitative Disclosures About Market and Business Risks</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_85">61</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_88">Item 8</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_88">Consolidated Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_88">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_175">Item 9</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_175">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_175">99</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_178">Item 9A</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_178">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_178">99</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_187">Item 9B</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_187">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_187">102</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_190">Item 9C</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_190">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_190">102</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_193">Part III</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_196">Item 10</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_196">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_196">103</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_199">Item 11</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_199">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_199">103</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_202">Item 12</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_202">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_202">103</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_205">Item 13</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_205">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_205">103</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_208">Item 14</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_208">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_208">103</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_211">Part IV</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_214">Item 15</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_214">Exhibits and Consolidated Financial Statement Schedules </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_214">104</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_217">Item 16</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_217">Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_217">105</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_220">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_220">106</a></span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this 10-K, the terms &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; and &#8220;the Company&#8221; refer to ResMed Inc., a Delaware corporation, and its subsidiaries, on a consolidated basis, unless otherwise stated.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:justify"><span><br/></span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_10"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_13"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report contains or may contain certain forward-looking statements and information that are based on the beliefs of our management as well as estimates and assumptions made by, and information currently available to, our management. All statements other than statements regarding historical facts are forward-looking statements. The words &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;will continue,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;plan,&#8221; &#8220;future&#8221; and other similar expressions, and negative statements of such expressions, generally identify forward-looking statements, including, in particular, statements regarding expectations of future revenue or earnings, expenses, new product development, new product launches, new markets for our products, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the integration of acquisitions, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions on our business. These forward-looking statements are made in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements reflect the views of our management at the time the statements are made and are subject to a number of risks, uncertainties, estimates and assumptions, including, without limitation, and in addition to those identified in the text surrounding such statements, those identified in Part I, Item 1A &#8220;Risk Factors&#8221; and elsewhere in this report. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, important factors to consider in evaluating such forward-looking statements include changes or developments in healthcare reform, social, macroeconomic, market, legal or regulatory circumstances, including the impact of public health crises; changes in our business or growth strategy or an inability to execute our strategy due to changes in our industry or the economy generally, the emergence of new or growing competitors, disruptions and delays in the supply chain, the actions or omissions of third parties, including suppliers, customers, competitors and governmental authorities, geopolitical and economic conditions in foreign jurisdictions impacting our business, and various other factors. If any one or more of these risks or uncertainties materialize, or underlying estimates or assumptions prove incorrect, actual results may vary significantly from those expressed in our forward-looking statements, and there can be no assurance that the forward-looking statements contained in this report will in fact occur.</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_16"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1 BUSINESS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global leader in digital health and cloud-connected medical devices. We design innovative solutions to treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. Our comprehensive out-of-hospital, or OOH, software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, our products improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following our formation in 1989, we commercialized a continuous positive airway pressure, or CPAP, treatment for obstructive sleep apnea, or OSA, which was the first successful non-invasive treatment for OSA. CPAP systems deliver pressurized air, typically through a mask, to prevent collapse of the upper airway during sleep.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the development of CPAP, we have expanded our business by developing or acquiring a number of innovative products and solutions for a broad range of respiratory disorders including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, and dental devices. In addition, we are a leading provider of cloud-based health applications, software and devices designed to provide connected care, enabling clinicians to manage more patients efficiently and effectively, as well as enabling and encouraging patients&#8217; long-term adherence to and satisfaction with their therapy. We also provide management software to agencies providing OOH care, including but not limited to home medical equipment, or HME, home health and hospice, skilled nursing, life plan community, senior living, outpatient therapy and private duty services. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-1-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ over 9,980 people and sell our products in over 140 countries through a combination of wholly owned subsidiaries and independent distributors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website address is www.resmed.com. We make our periodic reports, together with any amendments, available on our investor relations website (https://investor.resmed.com), free of charge, as soon as reasonably practicable after we electronically file or furnish the reports with the Securities and Exchange Commission, or SEC. The SEC maintains an internet site, www.sec.gov, which contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. We also make available on our investor relations website, public financial information for which a report is not required to be filed with or furnished to the SEC. Information contained on our website or in reports, other than those filed with or furnished to the SEC, is not part of or incorporated into this report. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate History</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Australian subsidiary, ResMed Holdings Pty Limited, was originally organized in 1989 by Dr. Peter Farrell to acquire from Baxter Center for Medical Research Pty Limited, or Baxter, the rights to certain technology relating to CPAP treatment as well as Baxter&#8217;s existing CPAP device business. Baxter acquired the rights to the technology in 1987 and sold CPAP devices in Australia from 1988 until our acquisition of the business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ResMed Inc., a Delaware corporation, was formed in March 1994 as the ultimate holding company for our operating subsidiaries. In June 1995, we completed an initial public offering of common stock and our common stock began trading on the NASDAQ National Market. In September 1999, we transferred our principal listing to the New York Stock Exchange, or NYSE, trading under the ticker symbol &#8220;RMD&#8221;. In November 1999, we established a secondary listing of our common stock via Chess Depositary Instruments, or CDIs, on the Australian Stock Exchange (now known as the Australian Securities Exchange), or ASX, also under the symbol &#8220;RMD&#8221;. Ten CDIs on the ASX represent one share of our common stock on the NYSE. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since formation, we have grown organically through global expansion as well as by acquiring a number of businesses, including distributors, suppliers, developers of medical equipment and related technologies, and software solution providers.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in two segments, which are the Sleep and Respiratory Care segment and the Software as a Service, or SaaS, segment. See Note 13 &#8211; Segment Information of the Notes to Consolidated Financial Statements (Part II, Item 8) for financial information regarding segment reporting. Financial information about our revenues from and assets located in foreign countries is also included in the notes to our consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Market</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on sleep and related respiratory care, both of which we believe are globally underpenetrated, and where we believe our products can improve patient outcomes, create efficiencies for our customers, help physicians and providers better manage chronic disease and reduce overall healthcare system costs. Additionally, our software solutions are focused on OOH care, which we believe is fragmented and underserved, and where we see significant opportunity to transform and significantly improve OOH healthcare through a strategy of enabling better patient care, improving clinical decision support, and driving interoperability across OOH care settings.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sleep and Respiratory Care</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sleep</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sleep is a complex neurological process that includes two distinct states: rapid eye movement, or REM, sleep and non-rapid eye movement, or non-REM, sleep. REM sleep, which is about 20-25% of total sleep experienced by adults, is characterized by a high level of brain activity, bursts of rapid eye movement, increased heart and respiration rates, and paralysis of many muscles. Non-REM sleep is subdivided into four stages that generally parallel sleep depth; stage 1 is the lightest and stage 4 is the deepest.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-2-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upper airway has no rigid support and is held open by active contraction of upper airway muscles. Normally, during REM sleep and deeper levels of non-REM sleep, upper airway muscles relax and the airway narrows. Individuals with narrow upper airways or poor muscle tone are prone to temporary collapses of the upper airway during sleep, called apneas, and to near closures of the upper airway called hypopneas. These breathing events result in a lowering of blood oxygen concentration, causing the central nervous system to react to the lack of oxygen or increased carbon dioxide and signaling the body to respond. Typically, the individual subconsciously arouses from sleep, causing the throat muscles to contract, opening the airway. After a few gasping breaths, blood oxygen levels increase and the individual can resume a deeper sleep until the cycle repeats itself. Sufferers of OSA typically experience ten or more such cycles per hour. While these awakenings greatly impair the quality of sleep, the individual is not normally aware of these disruptions. OSA has been recognized as a cause of hypertension and a significant comorbidity for heart disease, stroke, and type 2 diabetes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A long-term epidemiology study published in 2013 estimated that 26% of adults age 30-70 have some form of obstructive sleep apnea. Another study published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lancet Respiratory Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2019 estimated that mild to severe OSA impacts more than 936 million people worldwide, including 54 million Americans. Of those impacted, it was estimated that more than 424 million would have moderate to severe sleep apnea. Despite the high prevalence of OSA, there is a general lack of awareness of OSA among both the medical community and the general public. It is estimated that less than 20% of those with OSA have been diagnosed or treated. Many healthcare professionals often do not diagnose OSA because they are unaware that such non-specific symptoms as excessive daytime sleepiness, fatigue, snoring, hypertension, and irritability are characteristic of OSA.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While sleep apnea has been diagnosed in a small portion of a broad cross-section of the population, until recently, it has typically been diagnosed among middle-aged men with obesity. However, we believe the importance of sleep apnea in women is increasingly being recognized, with nearly 40% of new PAP patients being female. A strong association has been discovered between sleep apnea and a number of cardiovascular and metabolic diseases. Studies have shown that sleep apnea is present in approximately 83% of patients with drug-resistant hypertension, approximately 77% of patients with obesity, approximately 76% of patients with chronic heart failure, and approximately 72% of patients with type 2 diabetes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A study presented at the European Respiratory Society (ERS) International Congress in 2021 and later published in CHEST in 2022 found that using PAP therapy as directed can significantly increase sleep apnea patients&#8217; chances of living longer. The study concluded that people with obstructive sleep apnea who started and continued PAP therapy were 39% more likely to survive over a three-year period than OSA patients who did not. Researchers found that the survival rate gap remained significant when accounting for patients&#8217; ages, overall health, other pre-existing conditions, and causes of death.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sleep-Disordered Breathing and Obstructive Sleep Apnea.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sleep-disordered breathing, or SDB, encompasses all disease processes that cause abnormal breathing patterns during sleep. Manifestations include OSA, central sleep apnea, or CSA, and hypoventilation syndromes that occur during sleep. Hypoventilation syndromes are generally associated with obesity, chronic obstructive lung disease, and neuromuscular disease. OSA is the most common form of SDB.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sleep fragmentation and the loss of the deeper levels of sleep caused by OSA can lead to excessive daytime sleepiness, fatigue, reduced cognitive function, including memory loss and lack of concentration, depression, and irritability. OSA sufferers also experience an increase in heart rate and an elevation of blood pressure during the cycle of apneas. Several studies demonstrate that the oxygen desaturation, increased heart rate and elevated blood pressure caused by OSA may be associated with increased risk of cardiovascular morbidity and mortality due to angina, stroke, and heart attack. Patients with OSA have been shown to have impaired daytime performance in a variety of cognitive functions including problem- solving, response speed, and visual motor coordination; studies have linked OSA to increased occurrences of traffic and workplace accidents.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, an individual seeking treatment for the symptoms of OSA is referred by a general practitioner to a sleep specialist for further evaluation. The diagnosis of OSA typically requires monitoring the patient during sleep at either a sleep clinic or the patient&#8217;s home. During overnight testing, respiratory parameters and sleep patterns may be monitored, along with other vital signs such as heart rate and blood oxygen levels. Simpler tests, using devices such as our ApneaLink Air, NightOwl, or our automatic PAP devices, monitor airflow during sleep, and use computer programs to analyze airflow patterns. These tests allow sleep clinicians to detect sleep disturbances such as apneas, hypopneas, or subconscious awakenings. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-3-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before 1981, the primary treatment for OSA was a tracheotomy, a surgical procedure to create a hole in the patient&#8217;s windpipe. Alternative surgical treatments have involved either uvulopalatopharyngoplasty, or UPPP, in which surgery is performed on the upper airway to remove excess tissue and streamline the shape of the airway or implant a device to add support to the soft palate. UPPP alone has a poor success rate; however, when performed in conjunction with multi-stage upper airway surgical procedures, a greater success rate has been claimed. These combined procedures, performed by highly specialized surgeons, are expensive and involve prolonged and often painful recovery periods. Consequently, surgical treatments are not considered first-line therapy for OSA. Other alternative treatments available today include nasal surgery, mandibular advancement surgery, dental appliances, palatal implants, somnoplasty, nasal devices, and electrical stimulation of the nerves or muscles. Alternative pharmaceutical therapy treatments expected to be indicated for OSA treatment are under development.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A variety of devices are marketed for the treatment of OSA. Most are only partially effective. CPAP is a reliable treatment for all severities of OSA and is considered first-line therapy. Use of mandibular advancement devices is increasingly used as a second-line option in patients unable to use CPAP or those with mild OSA. These devices cause the mandible and tongue to be pulled forward and improve the dimensions of the upper airway. CPAP is a non-invasive means of treating OSA. CPAP was first used as a treatment for OSA in 1980 by Dr. Colin Sullivan, the past Chairman of our Medical Advisory Board, and was commercialized for treatment of OSA in the United States, or U.S., in the mid-1980s. During CPAP treatment, a patient sleeps with an interface connected to a small portable air device that delivers room air at a positive pressure. The patient breathes in air from the device and breathes out through an exhaust port in the interface. Continuous air pressure applied in this manner acts as a pneumatic splint to keep the upper airway open and unobstructed. Interfaces include nasal masks and nasal pillows. Sometimes, when a patient leaks air through their mouth, a full-face mask may need to be used, rather than a nasal interface.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CPAP is not a cure and, therefore, must be used nightly as long as treatment is required. Patient compliance has been a major factor in the effectiveness of CPAP treatment. Early generations of CPAP units provided limited patient comfort and convenience. Patients experienced soreness from the repeated use of nasal masks and had difficulty falling asleep with the CPAP device operating at the prescribed pressure. In recent years, we have developed product innovations to improve patient comfort and compliance. These include more comfortable patient interface systems; delay timers that gradually increase air pressure allowing the patient to fall asleep more easily; bilevel air devices, including our AirCurve 11 Series devices, which provide different air pressures for inhalation and exhalation; heated humidification systems to make the airflow more comfortable; and auto-titration devices that modulate the average pressure delivered during the night.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Respiratory Care</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our aim is to provide respiratory care solutions to patients with COPD and other chronic respiratory diseases, such as overlap syndrome, obesity hypoventilation syndrome, or OHS, and neuromuscular disease, including amyotrophic lateral sclerosis, or ALS. We aim to improve patient quality of life, slow down disease progression and reduce the costs of patient management.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products cover patients ranging from those who only require therapy from CPAP systems at night to those who are dependent on non-invasive or invasive ventilation for life-support. Our devices are predominantly used in the home and, to a lesser extent, in general hospital wards and respiratory wards. We supply CPAP and bilevel device systems, high flow therapy device systems (HFT), non-invasive and invasive ventilators, humidifiers, and accessories, including masks, nasal cannula, and tubing. We also provide data management systems designed to improve the management of patients by care providers.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chronic Obstructive Pulmonary Disease. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COPD encompasses a group of lung diseases defined by persistent airflow limitation, prolongation of exhalation and loss of elasticity in the lungs. It is a progressive and debilitating disease and is associated with an increased inflammatory response in the airways. Symptoms encountered with COPD include shortness of breath as well as chronic cough and increased sputum production. COPD includes diseases such as emphysema and chronic bronchitis. A recent study based on recent epidemiology data estimates that there are approximately 480 million people worldwide who suffer from COPD, the world&#8217;s third leading cause of death.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients with COPD can have different clinical presentations. Patients with chronic bronchitis present with low level of oxygen (hypoxemia) and elevated levels of carbon dioxide (hypercapnia), a chronic productive cough, cor pulmonale, and commonly have excess weight. Patients with emphysema have more normal blood gases, are usually thin and hyperinflated </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-4-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and have a decreased diffusion capacity. During sleep, chronic bronchitic patients display more severe hypoxemia. In general, the more hypoxic a COPD patient is during the day the more severe the hypoxemia experienced during sleep. Hypercapnia as a consequence of hypoventilation also occurs in COPD patients and is more pronounced in REM sleep. Some COPD patients may also suffer from comorbid OSA, a condition known as Overlap Syndrome.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Home non-invasive ventilation has the potential to reduce healthcare costs associated with the management of patients with severe COPD by significantly increasing the time between hospital readmissions. Early research also suggests that home HFT may help improve clinical outcomes in hypoxemic COPD patients that frequently have exacerbations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overlap Syndrome. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In patients with COPD-OSA Overlap Syndrome, CPAP has been shown to provide benefits in relation to reducing mortality, decreasing hospitalizations and improving lung function and gas exchange. Non-invasive ventilation, or NIV, has been demonstrated to improve outcomes in patients with acute exacerbations of COPD through its ability to improve respiratory acidosis and decrease dyspnea and work of breathing. It may also increase survival rates and reduce length of hospital stays, as well as reducing complicating factors such as ventilator-associated pneumonia. In patients with stable COPD, the advantages of home NIV are less clear, but clinical studies have shown improvements in dyspnea scores and health-related quality-of-life measures and reductions in hospital readmissions and intensive care stays.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obesity Hypoventilation Syndrome. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OHS is characterized by the combination of obesity, chronic alveolar hypoventilation leading to daytime hypercapnia and hypoxia and sleep apnea after the exclusion of other causes of alveolar hypoventilation. An estimated 90% of patients with OHS also have OSA. In patients with OHS, positive airway therapy, with either CPAP or NIV, has been shown to effectively treat upper airway obstruction and reverse daytime respiratory failure as well as reduce the work of breathing and improve respiratory drive. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neuromuscular Disease. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuromuscular disease is a broad term that encompasses many diseases that either directly (via intrinsic muscle pathology) or indirectly (via nerve pathology) impair the functioning of muscles. Symptoms of neuromuscular disease and respiratory failure include increasing generalized weakness and fatigue, dysphagia, dyspnoea on exertion and at rest, sleepiness, morning headache, difficulties with concentration, and mood changes. Most neuromuscular diseases are characterized by progressive muscular impairment leading to loss of ambulation, being wheelchair-bound, swallowing difficulties, respiratory muscle weakness, and, eventually, death from respiratory failure. Neuromuscular disorders can progress rapidly or slowly. Rapidly progressive conditions, such as ALS and Duchenne muscular dystrophy in teenagers, are characterized by muscle impairment which worsens over months and can result in death within a few years. Variable or slowly progressive conditions, such as myotonic muscular dystrophy, are characterized by muscle impairment that worsens over years and may mildly reduce life expectancy. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NIV treatment to patients with neuromuscular disease may lead to improvements in respiratory failure symptoms and daytime arterial blood gases. In ALS patients, NIV treatment has been associated with an improvement in quality of life measures, sleep-related symptoms and survival. Studies have demonstrated that patients with Duchenne muscular dystrophy may improve in quality of life measures and may increase chance of survival with NIV treatment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Software as a Service</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to multiple acquisitions, including Brightree in April 2016, HEALTHCAREfirst in July 2018, MatrixCare in November 2018, and MEDIFOX DAN in November 2022, our operations now include software platforms that comprise our SaaS business. Our SaaS strategy is to develop a portfolio that assists durable or home medical equipment (DME/HME) providers, and other long-term care providers operate more effectively and efficiently across various OOH care settings. With a comprehensive set of software and services offerings, our SaaS solutions enable providers to streamline workflow and deliver an improved patient experience across our existing vertical markets including HME and home infusion, facility-based organizations including skilled nursing, senior living, and life plan communities, home health and hospice providers, and to adjacent providers through a growing portfolio of value-added solutions with broad applicability. Our offerings can help providers perform analytics, manage documentation and implement new reimbursement requirements as well as more effectively transfer data as patients move between different care settings. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Strategy</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the treatment of sleep apnea and respiratory care will continue to grow due to a number of factors, including increasing awareness of OSA, CSA and COPD; improved understanding of the role of sleep apnea treatment in the management of cardiac, neurologic, metabolic, and related disorders; improved understanding of the role of non-invasive </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-5-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ventilation in the management of COPD; and an increase in the use of digital and product technology to improve patient outcomes and create efficiencies for customers and providers. Our strategy for expanding our business operations and capitalizing on the growth of the sleep apnea and respiratory care, as well as growth in OOH care settings, consists of the following key elements:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Continue Product Development and Innovation in Sleep Apnea and Respiratory Care Products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to ongoing innovation in developing products for the diagnosis and treatment of sleep apnea. We have been a leading innovator of products designed to treat sleep apnea more effectively, increase patient comfort, convenience, and encourage compliance with prescribed therapy. We have introduced a full suite of masks in our AirFit and AirTouch and other ranges, and we offer advanced and expanded integrations of our therapy-based software solutions used by providers, including AirView, to promote greater patient adherence to therapy. Our acquisitions have also included adding a portfolio of sleep apnea products such as through our acquisition of Curative Medical in 2015.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Likewise, we are committed to ongoing innovation of our respiratory care products that serve the needs of patients with COPD and neuromuscular diseases, providing advanced and expanded integrations of our therapy-based software solutions including AirView for Respiratory Care, enabling clinicians to remotely monitor patients on some ventilation devices and bilevel devices.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Broaden our Digital Health Technology Foundation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Digital enablement is central to our strategy. Our secure cloud-based digital health applications, along with our devices, are designed to provide connected care to improve patient outcomes and efficiencies for our customers, allowing fewer professionals to manage more patients and empowering patients to track their own health outcomes. We are expanding our cloud-based patient management and engagement platforms, such as AirView, enabling remote monitoring, over-the-air trouble shooting and changing of device settings, U-Sleep enabling automated patient coaching through a text, email or interactive voice phone call and myAir, a patient engagement application that provides sleep coaching and a daily score based on users' sleep data. In the United States we have released ResMed MaskSelector, an easy-to-use digital tool to make ResMed mask selection and sizing easier for patients and more effective for providers. Sleep is becoming a more important aspect of our customers' lives. We believe increased adoption of wearables with sleep monitoring functionality will drive more sleep-concerned consumers into care pathways. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the combination of continued product development, product and technology acquisitions and innovation are key factors of our ongoing success. Approximately 19% of our employees are devoted to research and development activities. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Expand SaaS Solutions in Out-of-Hospital Care Settings. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vision is to transform and significantly improve OOH healthcare through a strategy of enabling better patient care, improving clinical decision support, and driving interoperability across OOH healthcare settings. Since acquiring Brightree in 2016, plus MatrixCare and HEALTHCAREfirst in 2018, we offer software solutions across multiple OOH healthcare settings including HME, home health and hospice, skilled nursing, life plan communities, senior living, and private duty. Our acquisition of MEDIFOX DAN in 2022 expanded ResMed&#8217;s SaaS business to Germany and added new OOH care sectors to our ecosystem, including outpatient therapy. We are connecting capabilities across the platforms in these OOH care settings to help our customers be more efficient, better serve people, keep them out of hospital, and provide care in lower-cost, higher-quality care settings. Today, our SaaS solutions support out of hospital providers serving over 150 million individual patient accounts.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Expand Geographic Presence. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer our products in more than 140 countries to sleep clinics, home healthcare dealers, patients and third-party payors. We intend to increase our sales and marketing efficiency in our principal geographies, as well as expand the depth of our presence in other high-growth geographic regions. In 2015, we acquired Curative Medical to invest in China and expand our growth potential in sleep apnea, COPD and respiratory care there. In 2019, we acquired HB Healthcare, a privately owned HME that serves both reimbursed and cash-pay customers of sleep and respiratory care devices in South Korea. In 2021, we acquired Tong-il, another leading sleep and respiratory care HME provider in South Korea, reinforcing both our commitment and capability to serve South Koreans living with sleep apnea, COPD, and other chronic respiratory diseases.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Increase Public and Clinical Awareness. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to expand our existing promotional activities to increase awareness of sleep apnea, COPD, and other clinical conditions that can be treated with our industry-leading solutions. These promotional activities target both the population predisposed to sleep apnea and medical specialists, such as pulmonologists, sleep medicine specialists, primary care physicians, cardiologists, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-6-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">neurologists, and other medical subspecialists who treat these conditions and their associated comorbidities. We target special interest groups, including the National Stroke Association, the American Heart Association, COPD Foundation, and the National Sleep Foundation, to further increase awareness of the relationship between OSA, COPD, neuromuscular disease, and comorbidities such as cardiac disease, diabetes, hypertension, and obesity. The programs also support our efforts to inform the community of the dangers of sleep apnea with regard to occupational health and safety, especially in the transport industry. We have helped establish a center for clinical care and medical research at the University of California, San Diego, in the fields of sleep apnea and COPD. We have also established a chair for the study of sleep medicine at Harvard Medical School. We believe that recent interest in GLP-1 weight loss drugs will potentially drive additional patients into our treatment funnel, as previously untreated sleep apnea is diagnosed as part of their clinical evaluation.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Expand into New Clinical Applications. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually seek to identify new applications of our technology for significant unmet medical needs. Studies have established a clinical association between OSA and both stroke and chronic heart failure and have recognized sleep apnea as a cause of hypertension or high blood pressure. Research also indicates that sleep apnea is independently associated with glucose intolerance and insulin resistance. Additionally, research supported by ResMed has demonstrated that the addition of non-invasive ventilation to patients with severe COPD who are receiving oxygen therapy provides meaningful clinical benefits to the patient and the broader healthcare system. We maintain close working relationships with prominent physicians to explore new medical applications for our products and technology.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Leverage the Experience of our Management Team. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior team has extensive experience in the medical device industry in general, and in the fields of sleep apnea, respiratory care and healthcare informatics in particular. We intend to continue to leverage the experience and expertise of these individuals to maintain our innovative approach to the development of products and solutions and to increase awareness of the serious medical problems caused by untreated sleep apnea and the use of non-invasive ventilation, and in-home life-support ventilation to treat COPD and other chronic respiratory diseases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, and cloud-based software and informatics solutions. For purposes of the following discussion, we generally refer to our air flow generators and ventilators collectively as devices.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Devices</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We produce cloud-connected CPAP, automatic positive airway pressure, or APAP, bilevel, adaptive servo-ventilation, or ASV, and HFT devices that deliver positive airway pressure through a patient interface, either a mask or cannula. Our APAP, devices, known as AutoSet, are based on a patented technology to monitor breathing and can also be used in the diagnosis, treatment and management of OSA in some countries. During fiscal year 2017, we launched AirMini, a small portable CPAP combining the same proven therapy modes used in our APAP devices with waterless humidification enabling portable convenience. During fiscal year 2021, we launched our new platform of connected CPAP and APAP devices, AirSense 11, which introduced new features such as a touch screen, algorithms for patients new to therapy, and digital enhancements, such as over-the-air update capabilities. Devices in total accounted for approximately 52%, 54%, and 52% of our net revenues in fiscal years 2024, 2023, and 2022, respectively.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-7-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below provide an illustrative selection of devices, as known by our trademarks.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CPAP, APAP &amp; BILEVEL<br/>PRODUCTS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DESCRIPTION</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AirSense Platform </span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">AirSense 11 AutoSet</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">AirSense 11 AutoSet for Her</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">AirSense 11 CPAP</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">AirSense 11 Elite</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">AirSense 10 AutoSet</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">AirSense 10 CPAP</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">AirSense 10 Elite</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Combining enhanced digital health technology with effective therapy modes, AirSense&#8482; 11 APAP and CPAP machines are designed to make starting sleep apnea therapy, and adhering to it, easier and more convenient. Our newest device, AirSense 11 includes new features like myAir&#8482; Personal Therapy Assistant and Care Check-In designed to provide tailored guidance to PAP users, helping ease them into therapy and comfortable nightly use. Other features include the availability of remote software updates so users can enjoy the latest version of these tools every night. The prior generation of these devices, called AirSense&#8482; 10, is the most widely used series of CPAP and APAP machines, each designed to deliver high-quality therapy for a better night&#8217;s sleep. All AirSense machines include a built-in humidifier, Climate Control Auto setting to provide breathing comfort, AutoRamp&#8482; with sleep onset detection and can be used with myAir&#8482;, an online support program and app that helps users track their therapy.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AirCurve Bilevel Platform </span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">AirCurve 11 VAuto</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">AirCurve 11 ASV</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">AirCurve 10 VAuto</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">AirCurve 10 ASV</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">AirCurve 10 S</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bilevel machines include two pressure level settings: a higher pressure when a patient inhales, and a lower pressure that makes it easier to exhale. AirCurve&#8482; devices are for therapy users who benefit from greater pressure support. AirCurve&#8482; 11 VAuto and AirCurve&#8482; 10 VAuto treat patients with OSA and non-compliant OSA. AirCurve&#8482; 11 ASV and AirCurve&#8482; 10 ASV treat patients with CSA, OSA, mixed apneas or periodic breathing. AirCurve 11 includes myAir&#8482;, Care Check-In and Personal Therapy Assistant, digital health solutions designed to help users start therapy and stay on track. All AirCurve machines include a built-in humidifier, Climate Control Auto setting to provide breathing comfort and myAir&#8482;, an online support program and app that helps users track their therapy.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AirMini portable CPAP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The smallest portable CPAP on the market today, AirMini features the same auto-adjusting therapy modes used in the AirSense&#8482; 10 Auto. The device also features built-in Bluetooth connectivity and effective waterless humidification enabled by HumidX technology.</span></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">VENTILATION<br/>PRODUCTS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DESCRIPTION</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stellar 100 and 150</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ResMed Stellar&#8482; 100 and 150 ventilators are suitable for invasive and non-invasive ventilation, either at home or in a healthcare setting. They are not a life support ventilator. Stellar 150 also includes iVAPS&#8482; (intelligent Volume-Assured Pressure Support) technology to adjust to changing respiratory needs.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Astral 100 and 150</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ResMed Astral&#8482; 100 and 150 are life support devices that provide personalized care every step of the way. With both invasive and non-invasive options, they offer a lightweight design, exceptional battery life and adaptive technologies to provide greater mobility and peace of mind.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AirCurve 10 ST-A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ResMed AirCurve&#8482; 10 ST-A is designed for people with respiratory conditions that affect breathing such as restrictive lung disorders, severe COPD and hypoventilation. It combines user-friendly controls, an intuitive interface and automatic features to make ventilation therapy effective, comfortable and hassle-free.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lumis VPAP S, ST and ST-A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ResMed Lumis&#8482; series ventilators are designed to provide personalized ventilation support for people with respiratory insufficiency or OSA and are suitable for non-invasive ventilation, either at home or in a healthcare setting. They are not a life support ventilator. The Lumis&#8482; 150 VPAP ST and ST-A feature iVAPS&#8482; technology to adjust to changing respiratory needs.</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mask Systems, Diagnostic Products, Accessories and Other Products </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Masks, diagnostic products and accessories together accounted for approximately 35%, 34%, and 37% of our net revenues in fiscal years 2024, 2023, and 2022, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mask Systems</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mask systems are one of the most important elements of sleep apnea treatment systems. Masks are a primary determinant of patient comfort and as such may drive or impede patient compliance with therapy. We have been a consistent innovator in small nasal, nasal pillows, and full-face masks, by improving patient comfort while minimizing size and weight.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides an of overview of our mask systems by category.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CATEGORY</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DESCRIPTION</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Minimalist</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AirFit F40, AirFit F30, AirFit P10, and AirFit N30 minimalist masks feature our lightest, lowest profile designs. The features of these masks are focused on minimizing contact with the patient&#8217;s face to reduce red marks and irritation. </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Freedom</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AirFit N30i, AirFit P30i, and AirFit F30i freedom masks, which feature top-of-head tubing design allowing flexibility to easily switch sleep positions. </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ultra Soft</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The AirTouch F20 and AirTouch N20 masks feature a soft and breathable AirTouch cushion designed to enhance CPAP mask comfort. </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Universal Fit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AirFit F20 and AirFit N20 masks are designed to fit a wide range of faces due to the InfinitySeal silicone cushion that adapts to unique facial contours, which increases comfort, improves the fit and reduces leakage. </span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-8-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diagnostic Products</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home. These diagnostic systems record relevant respiratory and sleep data, which can be analyzed by a sleep specialist or physician who can then tailor an appropriate OSA treatment regimen for the patient. </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PRODUCTS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DESCRIPTION</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ApneaLink Air</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow and snoring. It works with AirView Diagnostics to provide comprehensive diagnostic solution to clinicians.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NightOwl</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A portable, cloud-connected, fully disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Connected Solutions and Other Products</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a suite of products that are designed to allow fewer professionals to manage more patients and empower patients to track their own health outcomes. We are expanding our cloud-based patient management and engagement platforms, such as AirView, enabling remote monitoring, over-the-air trouble shooting, and changing of device settings, U-Sleep enabling automated patient coaching through a text, email, or interactive voice phone call and myAir, a patient engagement application that provides sleep data and a daily score based on a user's previous night&#8217;s data.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PRODUCTS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DESCRIPTION</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AirView</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A cloud-based system enabling remote monitoring and changing of patients&#8217; device settings. AirView also makes it easier to simplify workflows and collaborate more efficiently across patient care networks.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">myAir</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A personalized therapy management application for patients with sleep apnea providing support, education and troubleshooting tools for increased patient engagement and improved compliance.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U-Sleep</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A compliance monitoring solution that enables providers to streamline their sleep programs to achieve better business and patient outcomes. </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Connectivity Module</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A module providing a seamless cellular connection between our compatible ventilation devices (e.g., Astral, Stellar) and our AirView&#8482; system.</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SaaS Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following multiple acquisitions, including Brightree in 2016, HEALTHCARE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">first</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and MatrixCare in 2018, and MEDIFOX DAN in November 2022, we now provide OOH software products designed to support the professionals and caregivers helping people stay healthy in the home or care setting of their choice. SaaS revenue accounted for approximately 12%, 12%, and 11% of our net revenue in fiscal years 2024, 2023, and 2022, respectively.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PRODUCTS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DESCRIPTION</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Brightree solutions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brightree enables out-of-hospital care organizations to improve their business performance and deliver better health outcomes. As an industry-leading cloud-based healthcare IT company, Brightree provides solutions and services for thousands of organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion. </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">HEALTHCAREfirst solutions<br/>&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HEALTHCAREfirst offers electronic health record, or EHR, software, billing and coding services, and advanced analytics that enable home health and hospice agencies to optimize their clinical, financial and administrative processes.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MatrixCare solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MatrixCare&#8217;s EHR software as a service solutions are used by skilled nursing and senior living providers, life plan communities (CCRCs), and home health and hospice organizations to improve efficiencies and promote a better quality of life for the people they serve.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MEDIFOX DAN solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MEDIFOX DAN&#8217;s software solutions are used by out-of-hospital care providers in Germany, especially home health and nursing home providers, and enable providers to achieve operating efficiencies and deliver better patient care and outcomes.</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Development and Clinical Trials </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a strong track record of innovation in the sleep and respiratory care markets. In 1989, we introduced our first CPAP device. Since then, we have been committed to an ongoing program of product advancement and development. Currently, our product development and clinical trial efforts are focused on not only improving our current product offerings and usability, but also expanding into new digital product applications. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-9-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually seek to identify new applications of our technology for significant unmet medical needs. Sleep apnea is associated with a number of symptoms beyond excessive daytime sleepiness, fatigue and irritability. Studies have established a clinical association between untreated sleep apnea and systemic hypertension, diabetes, coronary artery disease, stroke, atrial fibrillation, chronic heart failure, and mortality. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across the sleep and respiratory care platforms, we support clinical trials in many countries including the United States, Canada, Germany, France, the United Kingdom, Switzerland, Netherlands, Spain, Portugal, Sweden, Denmark, Iceland, Argentina, Chile, China, Republic of Korea, Japan, Malaysia, Singapore, and Australia to develop new clinical applications for our technology. We also continue to support some of the largest sleep apnea studies in history by performing advanced statistical analyses on millions of real-world, de-identified, clinical data points collected through our cloud-connected devices and patient engagement tools. These studies provide clinical insights around patient management, device settings, and predictors of patient adherence that inform our product development efforts. Some of the more recent real-world studies point to a link between PAP adherence and lower healthcare resource utilization.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consult with physicians at major medical centers throughout the world to identify clinical and technological trends in the treatment of sleep apnea, COPD, and the other conditions associated with these diseases. New product ideas are also identified by our marketing staff, direct sales force, and clinicians.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Marketing </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently market our products in more than 140 countries through a network of distributors and direct sales staff. We attempt to tailor our marketing approach to each major geography, often based on regional awareness of sleep apnea as a health problem, physician referral patterns, consumer preferences, and local reimbursement policies. See Note 13 &#8211; Segment Information of the Notes to Consolidated Financial Statements (Part II, Item 8) for financial information about our geographic areas.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">United States, Canada, and Latin America. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are typically purchased by a home healthcare dealer who then sells the products to the patient. The decision to purchase our products, as opposed to those of our competitors, is made or influenced by one or more of the following individuals or organizations: prescribing practitioners; home healthcare dealers; insurers (both private and public); and patients. In the United States, Canada, and Latin America, our sales and marketing activities are conducted through a field sales organization made up of regional territory representatives, program development specialists and regional sales directors. Our field sales organization markets and sells products to home healthcare dealer branch locations throughout the United States, Canada, and Latin America. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also directly educate physicians and sleep clinics about our products. Patients who are diagnosed with OSA or another respiratory condition and prescribed our products are typically referred by the diagnosing physician or sleep clinic to a home healthcare dealer to fill the prescription. The home healthcare dealer, in consultation with the referring practitioner, will assist the patient in selecting the equipment, fit the patient with the appropriate mask and set the device pressure to the prescribed level. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our SaaS solutions are sold to providers of healthcare in various OOH settings. We market and sell our Brightree business management software and service solutions to providers in the United States. Our primary markets are HME, pharmacy, home infusion, orthotics and prosthetics. Our sales activities for Brightree products are conducted through an employee sales organization made up of strategic account managers, sales engineers and sales directors. We develop, market, and sell our MatrixCare care management and related ancillary solutions to providers in the U.S. and our primary customers are senior living; skilled nursing; life plan communities; home health, home care, and hospice agencies as well as related accountable care organizations. Our MatrixCare management solutions are primarily sold through direct sales and ancillary solutions are sold both through direct sales and channel sellers.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Combined Europe, Asia, and other markets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We market our products in most major countries in combined Europe, Asia and other geographies. We have wholly owned subsidiaries in Australia, Austria, China, Czech Republic, Denmark, Finland, France, Germany, India, Ireland, Japan, Korea, Netherlands, New Zealand, Norway, Poland, Sweden, Switzerland, Taiwan, Thailand, and the United Kingdom. We use a combination of our direct sales force and independent distributors to sell our products in combined Europe, Asia, and other regions. We select independent distributors in each country based on their knowledge of respiratory medicine and a commitment to treatment of sleep apnea with our therapy. In countries where we sell our products direct, a local senior manager is responsible for direct national sales. In many countries, we sell our products to home healthcare dealers or hospitals who then sell the products to the patients. In Germany, Australia, New </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zealand, and South Korea, we also operate home healthcare businesses, providing products and services directly to patients through a vertically integrated network. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We only sell our SaaS products in the United States and Germany. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate a globally distributed manufacturing network designed to optimize quality, control costs, reduce time to market for new product introduction, and generate supply chain resilience. Our manufacturing operations consist of specialist component production as well as technical assembly and comprehensive testing and quality control of our devices, masks, and accessories. Of the numerous raw materials, parts and components purchased for our therapeutic and diagnostic sleep disorder products, many are available from multiple vendors. We also purchase uniquely configured components from various suppliers, including some who are single-source suppliers for us. Any reduction or halt in supply from one of these suppliers could limit our ability to manufacture our products or devices until a replacement supplier is found and qualified. We generally manufacture to our internal sales forecasts and fill orders as received. We strive for continuous improvement in manufacturing processes to deliver year-on-year improvement in output, cost, and product quality. Each manufacturing site and team are responsible for the quality of their product group and decisions are based on performance and quality measures, including customer feedback. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most disruptive effects of the COVID-19 pandemic are behind us and the global recall instituted by one of our major competitors continues to drive global demand for our devices. We continue to be impacted by periodic transport disruptions and supply constraints on certain raw materials and electronic components, including semiconductor chips. These disruptions and constraints have impacted and may continue to impact our ability to manufacture products in quantities and the time necessary to satisfy global customer demand, which could negatively impact our results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quality management system is based upon the requirements of ISO 13485, FDA Quality Management System Regulation (formerly the Quality System Regulation for Medical Devices), European Medical Device Regulation (&#8220;MDR&#8221;), the Medical Device Directive (93/42/EEC) and other applicable regulations for the markets in which we sell. Our main manufacturing sites are certified to ISO 13485 and are audited at regular intervals by a Notified Body. Additionally, our Sydney, Tuas, San Diego, Atlanta, and Moreno Valley sites are certified under the Medical Device Single Audit Program or MDSAP, an audit of medical device manufacturers&#8217; quality management system to satisfy multiple regulatory requirements. MDSAP audits are conducted by a MDSAP recognized auditing organization and can fulfill the needs of multiple regulatory jurisdictions (e.g., Australia, Brazil, Canada, Japan, and the United States of America). Our Sydney manufacturing operation operates an Environmental Management System (EMS) certified to ISO 14001:2015. We are progressively extending the EMS across our manufacturing network.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our main manufacturing facilities for ResMed-branded products are located in Tuas, Singapore; Sydney, Australia; Chatsworth, California; Johor Bahru, Malaysia; and Atlanta, Georgia. The principal factory for our Curative-branded products is in Suzhou, China. Our Narval-branded products are manufactured in Lyon, France. Refer to Item 2 for additional details on these properties. We will continue to expand and balance volume across our network to meet scale, cost, resilience, and environmental performance objectives, and to meet the needs of customers and patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third-Party Coverage and Reimbursement</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of medical care in many of the countries in which we operate is funded in substantial part by government and private insurance programs. In Germany and Korea, we receive payments directly from these payors. While we do not generally receive direct payments for our products from payors in other countries, our success depends on the ability of patients to obtain coverage and our customers to obtain adequate reimbursement from those payors. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our products are purchased primarily by home healthcare dealers, health systems, or sleep clinics, who invoice third-party payors directly for reimbursement. Domestic third-party payors include government payors such as Medicare and Medicaid and commercial health insurance plans. These payors may deny coverage and reimbursement if they determine that specific defined coverage criteria are not met or that a device is not used in accordance with certain covered treatment methods, or is experimental, or not deemed reasonable and necessary. The long-term trend towards cost-containment, through managed healthcare, or other legislative proposals to reform healthcare, could control or significantly influence the purchase of healthcare services and products and could result in lower prices for our products. In some </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-11-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">countries, such as France, Germany, and Japan, government reimbursement is currently available for the purchase or rental of our products, subject to constraints such as price controls or unit sales limitations. In Australia, China, and some other countries, there is currently limited or no reimbursement for devices that treat OSA.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare reform in the United States continues to bring significant changes to the third-party payor landscape. The DMEPOS Competitive Bidding Program was mandated by Congress through the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). In 2011, the Centers for Medicare &amp; Medicaid Services, or CMS, implemented the Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) competitive bidding program, which included durable medical equipment purchasers of our CPAP and respiratory assist devices (or bilevel devices), and related supplies and accessories. Under the program, DMEPOS suppliers compete to become Medicare contract suppliers by submitting bids to furnish certain items in competitive bidding areas (CBAs). The lower payment amounts resulting from the competition may replace the Medicare fee schedule amounts for the bid items in these areas. CMS is required by law to recompete these contracts at least once every three years and to roll out the competitive bidding process nationally or adjust prices in non-competitive bidding areas to match competitive bidding prices. The implementation of the competitive bidding program has resulted in reduced Medicare payment for CPAP and respiratory assist devices, and related supplies and accessories in both competitive bidding areas and non-competitive bidding areas.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The last round of competitive bid contracts lapsed, effective January 1, 2019. CMS then removed 13 product categories, including CPAP and respiratory assist devices (or bilevel devices), from the Round 2021 Competitive Bidding Program competition. As a result, these products are currently subject to a temporary gap period during which any Medicare-enrolled DMEPOS suppliers may furnish DMEPOS items and services to patients. Payment for Medicare-enrolled DMEPOS suppliers in former CBAs are based on 100% of the single payment amount, for the CBA increased by the projected percentage change in the Consumer Price Index for all Urban Consumers (CPI-U) from January 2023 to January 2024. At some time in the future we expect that CMS will start bidding for the next round of the DMEPOS Competitive Bidding Program after the agency completes the formal public notice and comment rulemaking process. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2024, for items furnished in non-CBAs, fees are based on fully-adjusted rates per the applicable methodology under Code of Federal Regulations Title 42 414.210 (g).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the Affordable Care Act (ACA) was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, resulted in reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 but were subject to a temporary suspension. The Protecting Medicare and American Farmers From Sequester Cuts Act was signed into law December 10, 2021. The law extended the 2% Medicare sequester moratorium through March 31, 2022, adjusted the sequester to 1% between April 1, 2022, and June 30, 2022, and reinstated the full 2% sequestration cut which began on July 1, 2022. The payment reduction applicable to healthcare providers applies to the approved Medicare payment amount, after the deductible and coinsurance are applied. The reduction in payment does not affect the 20% coinsurance owed by the patient.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in 2022, the Department of Veterans Affairs (VA) proposed an adjustment through regulation to amend the previously adopted schedule of VA ratings for sleep apnea. Specifically, the proposed rule would remove in its entirety the current 30% disability rating for veterans exhibiting excessive daytime sleepiness and instead replacing it with a 10% disability rating for veterans with a sleep apnea diagnosis with incomplete relief (as determined by a sleep study) with treatment including a CPAP machine, and further, remove the automatic 50% disability rating for veterans with a documented need for a CPAP machine (50% disability would instead require that the veteran have a sleep apnea diagnosis with ineffective treatment, as determined by a sleep study, or who is unable to use treatment due to comorbid conditions, without end-organ damage). The VA has not yet adopted these changes to the disability ratings system for sleep apnea but should this proposal, or another similar proposal to limit disability ratings be adopted, fewer veterans may pursue treatment of sleep apnea using CPAP or more veterans would claim ineffective treatment with CPAP to obtain the higher rating.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legislative landscape is complex and changes with the influence of one party or the other. We expect that the ACA, these new laws and other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for our products and services. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-12-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">implementation of cost containment measures or other healthcare reforms may have a material adverse impact on our revenues, profit margins, profitability, operating cash flows and results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Service and Warranty </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally offer either one-year or two-year limited warranties on our devices. In some regions and for certain customers we also offer extended warranties on our devices for one to three years in addition to our limited warranty. Warranties on mask systems are typically 90 days. Our distributors either repair our products with parts supplied by us or arrange shipment of products to our facilities for repair or replacement. We receive returns of our products from the field for various reasons. We believe that the level of returns experienced to date is consistent with levels typically experienced by manufacturers of similar devices. We provide for warranties and returns based on historical data. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global competition for sales of our products and services is intense. We believe that the principal competitive factors are product features, value-added solutions, quality, reliability and price. Customer support, reputation and efficient distribution are also important factors. We compete in various geographies, each with different competitors, and some of our competitors are affiliates of our customers, which may make it difficult to compete with them. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary Sleep and Respiratory Care competitors include Philips BV; Fisher &amp; Paykel Healthcare Corporation Limited; DeVilbiss Healthcare; Apex Medical Corporation; BMC Medical Co. Ltd.; React Health Corporation; and Lowenstein plus regional and new-entrant manufacturers. Finally, our products compete with surgical procedures, nerve stimulation devices, and dental appliances designed to treat OSA and other sleep apnea-related respiratory conditions. The adoption of new pharmaceuticals to treat obesity, a typical comorbidity of OSA, could impact our ongoing or future sales. The development of new or innovative procedures, devices, or therapies by others could result in our products becoming obsolete or noncompetitive, which would harm our revenues and financial condition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our SaaS business, competition is also intense, rapidly evolving, and subject to changing technology, low barriers to entry, shifting customer needs, and frequent introductions of new products and services. Many of our customers use systems developed in-house to run their businesses. The development of new or innovative software solutions by others could result in our solutions becoming obsolete or noncompetitive, which would harm our revenues and financial condition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product developed by us will have to compete for market acceptance and sales. An important factor in such competition may be the timing of market introduction of competitive products and solutions. Accordingly, the speed with which we can develop products and solutions, complete clinical testing and regulatory clearance processes, and provide commercial supply of products and solutions to the market are important competitive factors. In addition, our ability to compete will continue to be dependent on successfully protecting our products with patents and other intellectual property. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights and Related Litigation </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a combination of patents, designs, trademarks, trade secrets, copyrights, and non-disclosure agreements to protect our proprietary technology and rights. Some of these patents, patent applications, and designs relate to significant aspects and features of our products. We believe the combination of these rights, in aggregate, are of material importance to each of our businesses. Through our various subsidiaries, as of the date of this report, we own or have licensed rights to approximately 9,711 pending, allowed or granted patents and designs globally. Patents and designs have various statutory terms based on the legislation in individual jurisdictions which may be subject to change. Of our patents, approximately 612 U.S. patents and approximately 1,507 foreign patents are due to expire in the next five years. We believe that the expiration of these patents will not have a material adverse impact on our competitive position.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation has been necessary in the past and may be necessary in the future to enforce patents issued to us, to protect our rights, or to defend third-party claims of infringement asserted against us by others. The defense and prosecution of patent claims, including pending claims, as well as participation in other inter-party proceedings, can be expensive and time-consuming, even in those instances in which the outcome is favorable to us. Patent laws regarding the enforceability of patents vary from country to country. We have in the past, and may in the future, be required or choose to license patents and other intellectual property rights owned by other parties. Therefore, there can be no assurance that patent issues will be uniformly resolved, or that local laws will provide us with consistent rights and benefits.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-13-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulations </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FDA</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are subject to extensive regulation particularly as to safety, efficacy and adherence to FDA Quality System Regulation, and related manufacturing standards. Medical device products are subject to rigorous FDA and other governmental agency regulations in the United States and similar regulations of foreign agencies abroad. The FDA regulates the design, development, research, preclinical and clinical testing, introduction, manufacture, advertising, labeling, marking, packaging, marketing, distribution, import and export, and record keeping for our products, in order to ensure that medical products distributed in the United States are safe and effective for their intended use. In addition, the FDA is authorized to establish special controls to provide reasonable assurance of the safety and effectiveness of most devices. Non-compliance with applicable requirements can result in import detentions, fines, civil and administrative penalties, injunctions, suspensions or losses of regulatory approvals, recall or seizure of products, operating restrictions, refusal of the government to approve product export applications or allow us to enter into supply contracts, and criminal prosecution. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an exemption applies, the FDA requires that a manufacturer introducing a new medical device or a new indication for use of an existing medical device obtain either a Section 510(k) premarket notification clearance, a premarket approval, or PMA, or a de novo approval, and pay a user fee, before introducing it into the U.S. market. The type of marketing authorization is generally linked to the classification of the device, as well as whether or not a similar or &#8220;predicate&#8221; device exists to support a 510(k) application. The FDA classifies medical devices into one of three classes (Class I, II or III) based on the degree of risk the FDA determines to be associated with a device and the level of regulatory control deemed necessary to ensure the device&#8217;s safety and effectiveness. Certain SaaS applications may be classified as a medical device.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our devices currently marketed in the United States are marketed pursuant to 510(k) pre-marketing clearances and are either Class I or Class II devices. Certain of our SaaS products may be classified as medical devices requiring a pre-marketing clearance or approval while other SaaS products may not be medical devices or will be commercialized under FDA&#8217;s current policy of enforcement discretion. The process of obtaining a Section 510(k) clearance generally requires the submission of performance data and may require clinical data, which in some cases can be extensive, to demonstrate that the device is &#8220;substantially equivalent&#8221; to a predecessor device that was (a) legally marketed in the U.S. before the 1976 Medical Device Amendments that established the 510(k) pathway or (b) brought to market after 1976 pursuant to the 510(k) pathway. Such a predecessor device is referred to as &#8220;predicate device.&#8221; Devices that do not have such a predicate are typically classified as Class III by default and are required to undergo the stringent PMA pathway that includes provision of clinical evidence and trials. The PMA process, which is reserved for new devices that are not substantially equivalent to any predicate device and for high-risk devices or those that are used to support or sustain human life, may take several years and require the submission of extensive performance and clinical information. However, a sponsor may apply to the FDA to reclassify devices that do not have predicates to Class I or II if the device is of low to moderate risk. If the FDA grants the application, such a device is termed a &#8220;de novo&#8221; device and is evaluated through the somewhat more flexible de novo approval pathway. As a result, FDA clearance and approval requirements may extend the development process for a considerable length of time. In addition, in some cases, the FDA may require additional review by an advisory panel, which can further lengthen the process. Finally, there may be instances where the products we sell as a result of an acquisition are subject to further FDA review and clearance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical devices can be marketed only for the indications for which they are cleared or approved. After a device has received 510(k) clearance for a specific intended use, any change or modification that significantly affects its safety or effectiveness, such as a significant change in the design, materials, method of manufacture or intended use, may require a new or approval and payment of an FDA user fee. The determination as to whether or not a modification could significantly affect the device&#8217;s safety or effectiveness is initially left to the manufacturer using available FDA guidance; however, the FDA may review this determination to evaluate the regulatory status of the modified product at any time and may require the manufacturer to cease marketing and recall the modified device until clearance or approval is obtained. The manufacturer may also be subject to significant regulatory fines or penalties.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any devices we manufacture and distribute pursuant to clearance or approval by the FDA are subject to pervasive and continuing regulation by the FDA and certain state agencies. These include product listing and establishment registration requirements, which help facilitate FDA inspections and other regulatory actions. As a medical device manufacturer, all of our manufacturing facilities are subject to inspection on a routine basis by the FDA. We are required to adhere to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-14-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable regulations setting forth detailed cGMP requirements, as set forth in the QSR, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all phases of the design and manufacturing process. Noncompliance with these standards can result in, among other things, fines, injunctions, civil penalties, recalls or seizures of products, total or partial suspension of production, refusal of the government to grant clearance or approval of devices, withdrawal of marketing approvals and criminal prosecutions. We believe that our design, manufacturing and quality control procedures are in compliance with the FDA&#8217;s regulatory requirements. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must also comply with post-market surveillance regulations, including medical device reporting or MDR requirements which require that we review and report to the FDA any incident in which our products may have caused or contributed to a death or serious injury. We must also report any incident in which our product has malfunctioned if that malfunction would likely cause or contribute to a death or serious injury if it were to recur.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Labeling and promotional activities are subject to scrutiny by the FDA and, in certain circumstances, by the Federal Trade Commission. Medical devices approved or cleared by the FDA may not be promoted for unapproved or uncleared uses, otherwise known as &#8220;off-label&#8221; promotion. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including substantial monetary penalties and criminal prosecution.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of medical devices outside the United States are subject to regulatory requirements that vary widely from country to country. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EEA</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Economic Area, (which is comprised of the 27 member states of the European Union plus Norway, Iceland and Liechtenstein), or EEA, medical devices need to comply with specific requirements. These requirements were previously known as &#8220;Essential Requirements&#8221; under the former EU Medical Devices Directive (Council Directive 93/42/EEC, or MDD) and are now defined &#8220;General Safety and Performance Requirements (GSPR)&#8221; under the new EU Medical Devices Regulation (Regulation (EU) 2017/745, or MDR). While the requirements set forth in the MDR are generally consistent with those laid out in the MDD (with a few exceptions), the GSPR are described more in detail compared to the Essential Requirements. Compliance with the Essential Requirements (under the MDD) or the GSPR (under the MDR) is a prerequisite to be able to affix the CE marking to medical devices, without which they cannot be marketed or sold in the EEA. To demonstrate compliance with the Essential Requirements/GSPR and affix the CE marking, manufacturers of medical devices must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. Except for low-risk medical devices (Class I with no measuring function and which are not sterile), where the manufacturer can issue an EC Declaration of Conformity based on a self-assessment of the conformity of its products with the Essential Requirements/GSPR, a conformity assessment procedure requires the intervention of a Notified Body, which is a third-party organization designated by a competent authority of an EEA country to conduct conformity assessments. Depending on the relevant conformity assessment procedure, the Notified Body would audit and examine the Technical File and the quality system for the manufacture, design and final inspection of the devices. The Notified Body issues a CE Certificate of Conformity following successful completion of a conformity assessment procedure conducted in relation to the medical device and its manufacturer and their conformity with the Essential Requirements/GSPR. This Certificate entitles the manufacturer to affix the CE marking to its medical devices after having prepared and signed a related EC Declaration of Conformity.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a general rule, demonstration of conformity of medical devices and their manufacturers with the Essential Requirements/GSPR must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All manufacturers placing medical devices into the market in the EEA must comply with the EU Medical Device Vigilance System. Under the MDR, incidents must be reported centrally in the European EUDAMED database (although transitional provisions are in place until EUDAMED is fully functional), and manufacturers are required to take Field Safety Corrective Actions, or FSCAs, to prevent or reduce a risk of death or serious deterioration in the state of health associated with the use </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-15-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of a medical device that is already placed on the market. An incident is defined as any malfunction or deterioration in the characteristics and/or performance of a device, as well as any inadequacy in the labeling or the instructions for use. The MDR considers &#8220;serious incidents&#8221; those incidents which, directly or indirectly, led, might lead to or might have led to the death of a patient or user or of other persons, a serious deterioration in their state of health, or a serious public health threat. An FSCA may include the recall, modification, exchange, destruction or retrofitting of the device. FSCAs must be communicated by the manufacturer or its legal representative to its customers and/or to the end users of the device through Field Safety Notices. Where appropriate, our products commercialized in Europe are CE marked and classified as either Class I or Class II. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2017, the European Parliament passed the MDR, which repeals and replaces the MDD. Unlike directives, which must be implemented into the national laws of the EEA member states, the regulations would be directly applicable (i.e., without the need for adoption of EEA member State laws implementing them) in all EEA member states and are intended to eliminate current differences in the regulation of medical devices among EEA member States. The MDR, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices and ensure a high level of safety and health while supporting innovation. Regulation (EU) 2017/746 (IVDR), applicable as of May 26, 2022, provides for the regulatory framework applicable to in vitro diagnostic medical devices.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MDR was meant to become applicable three years after publication (in May 2020). However, on April 23, 2020, to allow EEA national authorities, notified bodies, manufacturers and other actors to focus fully on urgent priorities related to the COVID-19 pandemic, the European Council and Parliament adopted Regulation 2020/561, postponing the date of application of the MDR by one year. The MDR thus became applicable on May 26, 2021. The MDR transitional provisions allow the placing on the market of devices with a CE Certificate issued in accordance with the MDD until May 26, 2024, under certain conditions. Moreover, the MDR provides that the following medical devices with a CE Certificate issued in accordance with the MDD may continue to be made available on the market or put into service until May 26, 2025. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Devices placed on the market in compliance with the MDD prior to May 26, 2021; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Devices placed on the market after May 26, 2021, benefiting from the described MDR transitional provisions. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Commission further extended provision of the MDR and IVDR through Regulation (EU) 2023/607, whereby manufacturers and notified bodies are given sufficiently more time to carry out, in accordance with the MDR, the conformity assessment of devices covered by a certificate or a declaration of conformity issued in accordance with Directive 90/385/EEC or Directive 93/42/EEC. Moreover, the deletion of the &#8216;sell off&#8217; date in the MDR and the IVDR aims to prevent unnecessary disposal of safe devices. These provisions extend the transition period of devices through to December 31, 2027 or December 31, 2028 depending on device risk classification.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MDR, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strengthens the rules on placing devices on the market and reinforces surveillance once they are available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishes explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance and safety of devices placed on the market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">improves the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sets up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strengthens rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received certification at several locations, including Sydney, Australia; San Diego, California; and Lyon, France. We continue to transition our certification profile to meet the new MDR requirements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other regulatory bodies</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our devices are sold in multiple countries and often need to be registered with local regulatory bodies such as the Therapeutic Goods Administration in Australia, Health Canada in Canada and CFDA in China. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-16-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Healthcare Laws</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a number of laws and regulations that may restrict our business practices, including, without limitation, anti-kickback, false claims and transparency laws with respect to payments and other transfers of value made to physicians and other healthcare providers. The government has interpreted these laws broadly to apply to the marketing and sales activities of manufacturers and distributors like us.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute is a criminal statute that prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, in cash or in kind, in exchange for or to induce either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. In addition, a person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. Due to the breadth of the federal Anti-Kickback Statute, Congress set forth certain exceptions and authorized the Secretary of the Department of Health and Human Services to issue regulations that set forth certain safe harbors to protect arrangements that while implicating the federal Anti-Kickback Statute, would generally not cause harm to federal healthcare programs or patients. Satisfaction of all elements of a particular Anti-Kickback Statute statutory exception or regulatory safe harbor will provide immunity from prosecution under the Anti-Kickback Statute to the parties to such remunerative arrangement. Failure to satisfy all elements of an exception or safe harbor, however, does not necessarily lead to a violation of the federal Anti-Kickback Statute. Because the Anti-Kickback Statute is an intent-based statute, each arrangement is subject to a facts and circumstances analysis to determine whether the requisite intent under the statute is present.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment or approval to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. The civil False Claims Act also applies to false submissions that cause the government to be paid less than the amount to which it is entitled, such as a rebate. Intent to deceive is not required to establish liability under the civil False Claims Act. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Private suits filed under the civil False Claims Act, known as qui tam actions, can be brought by individuals on behalf of the government. These individuals may share in any amounts paid by the entity to the government in fines, judgement, or settlement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Civil Monetary Penalties Law prohibits, among other things, the offering or transferring of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of items or services reimbursable by Medicare or a state healthcare program, unless an exception applies.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there has been a recent trend of increased federal and state regulation of payments and transfers of value provided to healthcare professionals or entities. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, biologicals, and medical devices or supplies that require premarket approval by or notification to the FDA, and for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, to report annually to CMS information related to (i) payments and other transfers of value to teaching hospitals, physicians (as defined by statute) and, as of 2022, physician assistants, nurse practitioners and other practitioners, and (ii) ownership and investment interests held by such providers and their immediate family members. Applicable manufacturers are required to submit annual reports to CMS. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-17-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, many U.S. states and countries outside the U.S. have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under government programs. In addition, in the U.S., certain states also mandate implementation of commercial compliance programs, impose restrictions on device manufacturer marketing practices and/or require the tracking and reporting of gifts, compensation and other remuneration to healthcare professionals and entities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FCPA and Other Anti-Bribery and Anti-Corruption Laws </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Foreign Corrupt Practices Act, or FCPA, prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA includes interactions with certain healthcare professionals in many countries, either directly or through our contracted distributors. Our present and future business has been and will continue to be subject to various other U.S. and foreign laws, rules and/or regulations. The shifting commercial compliance environment and the need to build and maintain robust systems to comply with different compliance or reporting requirements in multiple jurisdictions increase the possibility that a healthcare company may fail to comply fully with one or more of these requirements. If our operations are found to be in violation of any of the health regulatory laws described above or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal, civil and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, additional integrity oversight and reporting obligations, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Data Privacy and Security Laws</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, which we collectively refer to as HIPAA, the Department of Health and Human Services, or HHS, has issued regulations, including the HIPAA Privacy, Security and Breach Notification Rules, to protect the privacy and security of protected health information, or PHI, used or disclosed by covered entities and their business associates, as well as covered subcontractors. HIPAA also regulates standardization of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and providers. Penalties for violations of HIPAA regulations include significant civil and criminal penalties for each violation. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some of our operations, such as those involving our cloud-based software digital health applications, we are a business associate under HIPAA. Therefore, we are required to comply with the HIPAA Security Rule, Breach Notification Rule and certain provisions of the HIPAA Privacy Rule, as well as the terms of our business associate agreements that we enter into with our covered entity customers. We are limited by HIPAA with respect to our use and disclosure of protected health information created or received through our business associate arrangements and could potentially face significant civil and criminal penalties if the Department of Health and Human Services Office for Civil Rights (OCR), or any state Attorney General, were to determine that we failed to comply with the applicable HIPAA standards.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to federal privacy and security regulations, there are a number of state laws governing confidentiality and security of personal information that are applicable to our business. For example, the California Consumer Privacy Act, effective on January 1, 2020, as amended by the California Privacy Rights Act (collectively, the &#8220;CCPA&#8221;), was the first of a series of state privacy laws designed to provide California residents expanded rights with regard to their personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although the law includes limited exceptions, including for &#8220;protected health information&#8221; maintained by a covered entity or business associate, it may regulate or impact our processing of personal information depending on the context. CCPA&#8217;s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and the CCPA may increase our compliance costs and potential liability. Further, since 2020, approximately one-quarter of U.S. states have adopted&#8212;and other states are proposing to adopt&#8212; their own comprehensive data protection laws, with varying implementation dates that began on January 1, 2023. The application of the laws and the requirements contained therein is not uniform. Although the majority of these omnibus state laws exclude business data, we may be required to undertake additional compliance investment to evaluate the application of these laws to our business and to implement compliance measures and potentially change our business processes. If we are subject to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-18-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or affected by HIPAA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these comprehensive data protection laws, to date, several states have adopted laws specifically regulating the collection, use, storage, and disclosure of biometrics, and additional states are seeking to regulate&#8212;and/or restrict the use of&#8212;biometrics in the future. Certain of our products use, or permit the use of, information that could be classified as a biometric under these or other laws. If we are subject to or affected by these or other laws, we may be required to modify the way in which we make available our product or certain features of our products. We also may be required to implement additional practices or processes or otherwise invest our resources to comply with these and other regulations. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the European Union General Data Protection Regulation, or GDPR, went into effect in May 2018. The United Kingdom has adopted the UK General Data Protection Regulation ("UK GDPR"); the EU GDPR and UK GDPR are herein referred to as GDPR. The GDPR imposes stringent data protection requirements for the processing of personal data, whenever GDPR applies to such processing, such as processing in the European Economic Area (EEA), or in the UK. The GDPR increased our obligations, for example, by requiring more robust disclosures to individuals, strengthening individual data rights, instituting procedures for mandatory data breach notifications to regulators within a short timeframe, limiting retention periods and secondary use of information (including for research purposes), increasing requirements pertaining to health data and pseudonymized (i.e., key-coded) data and imposing additional obligations when we contract with third party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the EEA or UK, including to the United States; recent legal developments in Europe have created complexity regarding such transfers of personal data from the EEA to the United States. For example, the European Commission and the United Kingdom have adopted new standard contractual clauses under which entities may transfer personal data from the European Union and the United Kingdom, which we may be required to implement. We must evaluate such data transfers on a case-by-case basis to ensure continued permissibility under current law and consistent with new standard contractual clauses. GDPR provides that EEA member states and the UK may make their own further laws and regulations limiting the processing of genetic, biometric or health data, which could limit our ability to use and share personal data or could cause our costs to increase and harm our business and financial condition. EEA member states and the UK may modify or impose additional conditions to be able to transmit electronic marketing communications. Failure to comply with the requirements of GDPR and the applicable national data protection and marketing laws of the EEA member states may result in fines of up to &#8364;20.0 million or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties as well as individual claims for compensation. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the UK GDPR also provides for significant data protection fines up to the greater of &#163;17.5 million or 4% of global turnover.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous other state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of patient health information and other personal information. In addition, Congress and some states are considering new laws and regulations that further protect the privacy and security of medical records or medical information. All 50 states and the District of Columbia have passed laws regulating the actions that a business must take if it experiences a data breach, such as prompt disclosure to affected customers. The Federal Trade Commission, or FTC, and states&#8217; Attorneys General have also brought enforcement actions and prosecuted data breach cases as unfair and/or deceptive acts or practices under the FTC Act. In addition to data breach notification laws, some states have enacted statutes and rules requiring businesses to reasonably protect certain types of personal information they hold or to otherwise comply with certain specified data security requirements for personal information. These laws may apply directly to our business or indirectly by contract when we provide services to other companies. Both the FTC and the OCR have focused on the use of online tracking technologies that collect personal information and protected health information as an enforced priority. The FTC has also identified the use of artificial intelligence (AI) and the potential bias in AI as one of its enforcement and policy priorities, including the use of AI in the healthcare space. Our services and products may use AI now or in the future. We intend to continue to comprehensively protect all personal information and to comply with all applicable laws regarding the protection of such information, including with respect to online tracking, as well as to monitor developments regarding the use of AI that could be relevant to our products and services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-19-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could adversely affect our business, financial condition and results of operations, damage our reputation and customers&#8217; trust.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At ResMed, our mission of transforming patient care in the OOH setting through innovative solutions and technology-driven integrated care is achieved by our commitment and continuous efforts in fostering an inclusive environment that creates a strong sense of belonging, which unlocks the potential, skills and creativity of our people.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Code of Business Conduct &amp; Ethics, Diversity and Inclusion practices and policies on workplace behavior, discrimination and harassment, health and safety, and employee benefits facilitate talent attraction, retention, and development.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors and its committees provide general oversight on a range of our human capital management efforts. This includes environmental, social, and governance efforts addressed below.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, we had approximately 9,980 employees and contingent workers, of which approximately 4,070 were employed in cost of sales activities including areas such as warehousing and manufacturing, 1,870 in research and development and 4,040 in sales, marketing and administration. Of our employees and contingent workers, approximately 3,050 (31%) were located in the United States, Canada and Latin America, 2,980 (30%) in Asia, 1,530 (15%) in Australia and 2,420 (24%) in Europe. We believe that the success of our business will depend, in part, on our ability to attract and retain qualified personnel that represent the diverse world we live in. ResMed&#8217;s average global turnover rate for fiscal year 2024 was approximately 18%.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Diversity and Inclusion</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our values of belonging, inclusion and diversity for success (&#8220;BIDS&#8221;) are woven into the way we work and design our products and help us transform healthcare and improve lives globally. Our BIDS team strives to impact and develop solutions, campaigns, and programs for our people, patients, and products to drive our overall success. Our objectives this year included leveraging our global community of Employee Resource Groups (&#8220;ERGs&#8221;) to help with product design and people development, creating and delivering development opportunities, identifying new and different sourcing practices and measurements, emphasizing accessibility and disability inclusion, maintaining community partnerships that encourage STEM and the advancement of medical technology, and promoting brand awareness.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Resource Groups.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continue to place a high value on inclusion-building initiatives that create opportunities around cultural awareness and professional development. We are proud of our global, employee-driven ERG network that engages over 6,000 people with weekly learning opportunities. These groups include African and African-American, Asia-American-Pacific Islander, LGBTQIA+, Hispanic and Latin, Veterans, Women in San Diego, Women in Sales, Women in SaaS, Women in Canada, Women in Tech Sydney, Parents, Caregivers, All Abilities, Australian Indigenous, and groups in Malaysia, Singapore, Ireland, Germany and France that collectively focus on local and culturally appropriate inclusion-building needs. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Learning and Development of Diversity and Inclusion Values. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leaders across the organization work directly with our Head of Diversity and Inclusion to identify and provide relevant trainings for their teams to create an inclusive workplace while complying with anti-discrimination laws. We maintained our BIDS Certificate program, which focuses on inclusive leadership and psychological safety. We also launched a digital coaching application for employees worldwide that provides leadership coaching in over 150 scenarios. In addition, we launched a global mentorship and leadership program for women across the Company, ElevateHER, which has cohorts around the world and is focused on building confidence and encouraging strategic thinking. The team also delivered trainings on allyship, the value of diversity on teams, inclusive leadership and disability etiquette.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategic Inclusive Development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A Global Council of employees meets every two months to review and provide feedback on BIDS developments and programs, as well as sharing feedback on ongoing diversity and inclusion efforts. Further, our Employee Handbook has been updated to formalize certain inclusivity initiatives. Additionally, we have assessed the language within the source code of our products and platforms to ensure that it does not act to discriminate, is inclusive and does not perpetuate racist stereotypes. We are also actively defining and streamlining language for product testing, trials and patient outreach.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-20-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leadership Engagement.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C-Suite Executives, alongside the CEO, receive quarterly updates on diversity data and inclusion-building efforts. Additionally, each ERG is supported by at least one executive sponsor, creating a vast network of champions that help promote and sponsor BIDS, ERG initiatives and the overall success of our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sourcing and Recruiting. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We train our recruiting workforce on the value of hiring diverse teams and diversity sourcing strategies, and we partner with external organizations that develop and supply diverse talent. We work closely with business partners across the organization and recruiters on sourcing ideation and outreach initiatives that align with our values. In addition, we are continually improving our diversity dashboard to better understand our metrics around applicants, candidates, and the current workforce. We comply with global laws preventing discrimination in hiring practices. We do not employ the use of quotas or required hiring targets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Talent Development and Retention</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building and strengthening our talent pipeline is imperative to our success. Our approach to talent and performance is designed to ensure employees and managers have regular feedback conversations about performance goals and development, to enable our high-performance culture, and to create an environment where we achieve our strategy. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At ResMed, we have specific career and development pathways designed for specific roles in consultation with operational management, human resources, and learning and development specialists. We provide online courses that are role-specific, with formal tracking of employee completion and performance. Online and face-to-face courses on operational compliance issues are developed and delivered in-house. Online compliance courses on ResMed&#8217;s Code of Business Conduct and Ethics, diversity and inclusion, compliance with laws against discrimination, US Foreign Corrupt Practices Act, and health &amp; safety are developed by our Learning and Development team with external subject-matter advisers.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation and Benefits</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation philosophy is to reinforce and align with our mission, business strategy, and financial needs as we grow. We provide market-competitive compensation and benefits based on benchmarking surveys we conduct regularly for all position levels against relevant peer companies. Our annual and long-term incentive packages are linked directly to business and individual performance, with a balance of short- and long-term financial and strategic objectives. We have an employee stock purchase plan, in addition to formal service awards internally. Eligibility for non-salary benefits such as salary continuance, life insurance, health insurance, and similar benefits, follows local regulations and practices. Equal opportunity and pay equity are integral to our pay philosophy, and we have processes in place to identify and address any potential pay equity issues where appropriate. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Employee Health and Safety </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe maintaining a physically safe and mentally healthy working environment is essential in supporting our people to deliver their best work. We employ global standards to provide the framework for our locally compliant, integrated and effective health and safety management systems which enable the capability, autonomy &amp; accountability of the leaders to manage local sites. Our approach is to place health &amp; safety as a positive contributor to innovation, continuous improvement and business sustainability through focusing on making work easier, which in turn makes work safer and more efficient. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Employee Engagement and Wellbeing</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly seek employee feedback and sentiment about our workplace through global engagement surveys that enable our people to comment on matters related to their employment experience. We openly share the survey results throughout the company and encourage teams to put in place action plans at global and local levels to address priority issues. Where benchmarks are available, our results are evaluated against comparable peer groups. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to improving the quality of life of our employees and their families. Our health and wellbeing programs differ by country and may include company-sponsored health insurance, retirement savings plans, sleep apnea screening and treatment, smoking cessation, gym membership discounts, seasonal flu vaccinations, mental health assistance, and many other programs to drive healthy behaviors and awareness. Additionally, we have implemented a company-wide ResMed Day - taken at the employee's election - for our people to focus on mental, social and physical health.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-21-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_19"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A RISK FACTORS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Before deciding to purchase, hold or sell our common stock, you should carefully consider the risks described below in addition to the other cautionary statements and risks described elsewhere, and the other information contained in this Report and in our other filings with the SEC, including our subsequent reports on Forms 10-Q and 8-K. The risks and uncertainties described below are not the only risks we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business. If any of these known or unknown risks or uncertainties actually occurs, with material adverse effects on us, our business, financial condition and results of operations could be seriously harmed. In that event, the market price for our common stock will likely decline, and you may lose all or part of your investment.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the risks that are more fully described in the following section below:</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Our Business and Industry</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to compete successfully may harm our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidation in the healthcare industry and healthcare payment reform could have an adverse effect on our revenues and results of operations. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Global macroeconomic conditions, including inflation, supply chain disruptions, and fluctuations in foreign currency exchange rates, could adversely affect our operations and profitability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business, financial condition and results of operations could be harmed by the effects of pandemics, epidemics, or other public health crises. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to various risks relating to international activities that could affect our overall profitability. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products are the subject of clinical trials conducted by us, our competitors, or other third parties, the results of which may be unfavorable, or perceived as unfavorable, and could have a material adverse effect on our business, financial condition, and results of operations. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to potential product liability claims that may exceed the scope and amount of our insurance coverage, which would expose us to liability for uninsured claims. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our intellectual property may not protect our products, and/or our products may infringe on the intellectual property rights of third parties. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to source, develop and retain key employees, our business may suffer.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our leverage and debt service obligations could adversely affect our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Manufacturing, IT Systems, Commercial Operations and Plans for Future Growth</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disruptions in the supply of components from our suppliers could result in a significant reduction in sales and profitability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are increasingly dependent on information technology systems and infrastructure. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Actual or attempted breaches of security, unauthorized disclosure of information, attacks which reduce availability of systems such as denial of service, or the perception that personal and/or other sensitive or confidential information in our possession is not secure, could result in a material loss of business, substantial legal liability or significant harm to our reputation.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to realize the anticipated benefits from acquisitions, which could adversely affect our operating results. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to support our continued growth or achieve expected operating efficiencies, our business could suffer. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business depends on our ability to market effectively to dealers of home healthcare products and sleep clinics. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-22-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our SaaS business depends substantially on customers entering, renewing, upgrading and expanding their agreements for cloud services, term licenses, and maintenance and support agreements with us. Any decline in our customer renewals, upgrades or expansions could adversely affect our future operating results. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our SaaS products fail to perform properly or if we fail to develop enhancements, we could lose customers, become subject to service performance or warranty claims and our sales could decline. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If there are interruptions or performance problems associated with our technology or infrastructure, our existing SaaS customers may experience service outages, and our new customers may experience delays in the deployment of our platforms. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Climate change and natural disasters, or other environmental events beyond our control, could negatively impact our business operations and financial condition. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Non-Compliance with Laws, Regulations and Healthcare Industry Shifts</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Healthcare reform or other cost-cutting measures, including changes in coverage policy for our products, by government or commercial payors may have a material adverse effect on our industry and our results of operations. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Government and private insurance plans may not adequately reimburse our customers for our products, which could result in reductions in sales or selling prices for our products. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to various risks relating to our compliance with fraud and abuse laws and transparency laws relating to our interactions with our customers, healthcare providers, and patients, which could subject us to government investigation, litigation, or other penalties to the extent our activities or relationships are found not to comply</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or could otherwise cause us to incur significant costs to defend our actions, and could result in substantial fines, penalties, harm our reputation, divert our management&#8217;s attention, or result in changes in our business operations that could harm our ability to successfully market and sell our products and services. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our use and disclosure of personal information, including health information, is subject to federal, state and foreign privacy, artificial intelligence, data, biometrics and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability, regulatory investigations, legal actions, or reputational harm. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business activities are subject to extensive regulation, and any failure to comply could have a material adverse effect on our business, financial condition, or results of operations. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product sales, introductions or modifications may be delayed or canceled as a result of FDA regulations or similar foreign regulations, which could cause our sales and profits to decline. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to substantial regulation related to quality standards applicable to our manufacturing and quality processes. Our failure to comply with these standards could have an adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared or approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Off-label marketing of our products could result in substantial penalties.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Laws regulating consumer contacts could adversely affect our business operations or create liabilities.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tax laws, regulations, and enforcement practices are evolving and may have a material adverse effect on our results of operations, cash flows and financial position.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to tax audits by various tax authorities in many jurisdictions.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sustainability and corporate governance issues may have an adverse effect on our business, financial condition and results of operations and reputation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-23-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to the Securities Markets and Ownership of Our Common Stock</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our quarterly operating results are subject to fluctuation for a variety of reasons.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delaware law and provisions in our charter could make it difficult for another company to acquire us.</span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-24-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Industry</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Our inability to compete successfully may harm our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> The geographic markets for our products, which encompass Sleep and Respiratory Care products and SaaS offerings, are highly competitive and are characterized by frequent product improvements and evolving technology. Our ability to compete successfully depends, in part, on our ability to develop, manufacture and sell innovative new products and to enhance existing products. For our Sleep and Respiratory Care business, the development of innovative new products by our competitors or the discovery of alternative treatments or potential cures for the conditions that our products treat could make our products noncompetitive or obsolete. Current competitors, new entrants, academics, and others currently may be developing, or may develop, new devices, alternative treatments or cures, and targeted or indirect pharmaceutical solutions to the conditions our products treat that could provide better features, clinical outcomes or economic value than those that we currently offer or subsequently develop. For example, certain pharmaceutical treatments, such as GLP-1&#8217;s currently used to treat diabetes or for weight loss, may enhance patient health, lower the occurrence of obesity, potentially reduce the severity of OSA, or be approved for treatment of OSA. For SaaS, the demand for business management software is highly competitive, rapidly evolving, subject to changing technology, with low barriers to entry, shifting customer needs and frequent introductions of new products and services. Many prospective customers have invested substantial personnel and financial resources to create, implement and integrate their current business management software into their operations and, therefore, may be reluctant or unwilling to change from their current in-house solution or provider to one of our platforms or products.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some of our competitors, including those described above, have greater financial, research and development, manufacturing and marketing resources than we do. The past several years have seen a trend towards consolidation in the healthcare industry and in the geographic markets for our products. Industry consolidation could result in greater competition if our competitors combine their resources, if our competitors are acquired by other companies with greater resources than ours, or if our competitors become affiliated with customers of ours. The healthcare space is attractive to many companies, particularly new entrants interested in developing digital health models to compete with offerings of more established companies like us. Additionally, one of our competitors, Philips, has an ongoing product recall. We cannot predict the timing or nature of their substantial return or the impact to our business, financial condition, and results of operations. Continuing competition could increase pressure on us to reduce the selling prices of our products or could cause us to increase our spending on research and development and sales and marketing. If we are unable to develop innovative new products, maintain competitive pricing, enhance existing products, and offer products that purchasers perceive to be as good as those of our competitors, our sales and gross margins could decrease which would harm our business. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidation in the healthcare industry and healthcare payment reform could have an adverse effect on our revenues and results of operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Many home healthcare dealers and OOH health providers are consolidating, which may result in greater concentration of purchasing power. Numerous initiatives and reforms by legislators, regulators, and third-party payors to curb the rising cost of healthcare have catalyzed a consolidation of aggregate purchasing power where we sell our products. As the healthcare industry consolidates, competition to provide goods and services to industry participants may become more intense. These industry participants may try to use their market power to negotiate price concessions or volume reductions for medical devices and components produced by us. If we are forced to reduce our prices because of consolidation in the healthcare industry, our revenues may decrease and our consolidated earnings, financial condition, and/or cash flows may suffer.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Global macroeconomic conditions, including inflation, supply chain disruptions, and fluctuations in foreign currency exchange rates, could continue to adversely affect our operations and profitability. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global economic conditions, geopolitical instability, and other macroeconomic factors, including inflation, supply chain disruptions, such as recent shipping disruptions in the Red Sea, interest rate and foreign currency rate fluctuations, and volatility in the capital markets could negatively impact our business, financial condition, and results of operations. The growth of our business and demand for our products are affected by changes in the health of the overall global economy. Deterioration in the global economic environment may cause decreased demand for our products which could result in lower product sales, lower prices for our products, or reduced reimbursement rates by third-party payors, while increasing the cost of operating our business. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Macroeconomic conditions may impact our global supply chain, primarily through constraints on raw materials and electronic components. These constraints on raw materials and electronic components may also impact companies outside </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-25-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our direct industry, which could result in a competitive supply environment causing higher costs, requiring us to commit to minimum purchase obligations as well as make upfront payments to our suppliers. These disruptions may impact our ability to produce and supply products in quantities necessary to satisfy customer demand, which could negatively impact our results of operations. Highly competitive and constrained supply chain conditions may increase our cost of sales, which may adversely impact our profitability. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global economic conditions may impact foreign currency exchange rates relative to the U.S. dollar. Although the majority of our net sales and cash generation have been made in the U.S., as our business in countries outside of the U.S. continues to increase, our exposure to foreign currency exchange risk related to our foreign sales and operations will increase. Fluctuations in the rate of exchange between the U.S. dollar and foreign currencies, primarily the Australian Dollar, Singapore Dollar, Euro, Chinese Yuan, and Canadian Dollar, have had and could in the future have an adverse effect on our financial results, including our net sales, margins, gains and losses, as well as on the values of our assets and liabilities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business, financial condition and results of operations could be harmed by the effects of pandemics, epidemics, or other public health crises. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks associated with public health crises, which have had and may have an adverse impact on certain aspects of our business in the future. The extent to which public health crises impact our business, results of operations, and financial condition will depend on future developments which are highly uncertain and are difficult to predict. These developments include, but are not limited to, actions taken to contain outbreaks or address their impact, the timing, distribution, and efficacy of treatments, and the imposition of government lockdowns, quarantine and physical distancing requirements. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to various risks relating to international activities that could affect our overall profitability. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture substantially all of our products outside the United States and sell a significant portion of our products outside the United States. Sales in combined Europe, Asia and other regions accounted for approximately 36% and 36% of our net revenues in the years ended June&#160;30, 2024 and June&#160;30, 2023, respectively. Our sales and operations outside of the U.S. are subject to several difficulties and risks that are separate and distinct from those we face in the U.S., including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in currency exchange rates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic conditions such as inflation or recession;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tariffs and other trade barriers; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with foreign medical device manufacturing regulations; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in enforcing agreements and collecting receivables through foreign legal systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduction in third-party payor reimbursement for our products; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain import licenses; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of public health epidemics/pandemics on the global economy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of global geopolitical tensions and/or conflicts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in trade policies and in U.S. and foreign tax policies; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possible changes in export or import restrictions; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the modification or introduction of other governmental policies with potentially adverse effects; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on our ability under local laws to protect our intellectual property.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the United States adopted the Uyghur Forced Labor Prevention Act (&#8220;UFLPA&#8221;) which creates a rebuttable presumption that any goods, wares, articles, and merchandise mined, produced, or manufactured in whole or in part in the Xinjiang Uyghur Administrative Region of China, or that are produced by certain entities, are prohibited from importation into the United States and are not entitled to entry. These import restrictions came into effect in June 2022. Additionally, the military conflict between Russia and Ukraine has resulted in the implementation of sanctions by the U.S. and other governments against Russia and has caused significant volatility and disruptions globally. While we are not presently aware of any direct impacts these restrictions have had on our suppliers&#8217; supply chains, disruptions resulting from the conflict in Ukraine and the UFLPA may materially and negatively impact our suppliers&#8217; ability to obtain a sufficient supply of raw materials necessary to meet the quantity and/or timing of our product demands. Further, it is not possible to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-26-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">predict the short- and long-term implications of this conflict, which could include but are not limited to further sanctions, uncertainty about economic and political stability, increases in inflation rate and energy prices, cyber-attacks, supply chain challenges and adverse effects on currency exchange rates and financial markets. Our sales into Russia and Ukraine did not constitute a material portion of our total revenue in fiscal year 2024. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further escalation of geopolitical tensions, or new geopolitical tensions, could have a broader impact that expands into other markets where we do business, which could adversely affect our business and/or our supply chain, business partners or customers in the broader region. We are continuing to monitor conflicts and geopolitical risks globally as well as assess the potential impact on our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above factors may have a material adverse effect on our ability to increase or maintain our sales or otherwise have a material adverse impact on our business, financial condition, and results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our products are the subject of clinical trials conducted by us, our competitors, or other third parties, the results of which may be unfavorable, or perceived as unfavorable, and could have a material adverse effect on our business, financial condition, and results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a part of the regulatory process to obtain marketing clearance for new products and new indications for existing products, or for other reasons, we conduct and participate in numerous clinical trials with a variety of study designs, patient populations, and trial endpoints. We, our competitors, or other third parties may also conduct clinical trials involving our commercially sold products. The results of clinical trials may be unfavorable or inconsistent with previous findings or could identify safety signals associated with our products. Current or future clinical trials may not meet primary endpoints, may reveal disadvantages of our products and solutions for various countries we address, or could generate unfavorable or inconsistent clinical data. Clinical data, or purchasers or regulatory bodies&#8217; perception of the clinical data, may adversely impact our ability to obtain product clearances or approvals, and our position in, and share of, the countries in which we sell our products. Moreover, if these clinical trials identify serious safety issues associated with our products, potentially adverse consequences could result, including that regulatory authorities could withdraw clearances or approvals of our products, we could be required to halt the marketing and sales of our products or recall our products, we could be required to update our product labeling with additional warnings, we could be sued and held liable for harm caused to patients, and our reputation may suffer. Any of these could have a material adverse impact on our business, financial condition, and results of operations. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to potential product liability claims that may exceed the scope and amount of our insurance coverage, which would expose us to liability for uninsured claims. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to potential product liability claims as a result of the design, manufacture and marketing of medical devices. Any product liability claim brought against us, with or without merit, could result in the increase of our product liability insurance rates. In addition, we would have to pay any amount awarded by a court outside of our policy limits. Our insurance policies have various exclusions, and thus we may be subject to a product liability claim for which we have no insurance coverage, requiring us to pay the entire amount of any award. We cannot assure that our insurance coverage will be adequate or that all claims brought against us will be covered by our insurance and we cannot assure that we will be able to obtain insurance in the future on terms acceptable to us or at all. A successful product liability claim brought against us in excess of our insurance coverage, if any, may require us to pay substantial amounts, which could harm our business. We may also be affected by the product recalls and other risks associated with the products of our competitors if customers and patients are uncertain if issues affecting our competitors may also affect us. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our intellectual property may not protect our products, and/or our products may infringe on the intellectual property rights of third parties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We rely on a combination of owned and licensed patents, trade secrets and non-disclosure agreements to protect our intellectual property. Our success depends, in part, on our ability to obtain and maintain U.S. and foreign patent protection for our products, their uses and our processes to preserve our trade secrets and to operate without infringing on the proprietary rights of third parties. We have in the past and may in the future be required to license patents and other intellectual property rights owned by other parties. We have pending patent applications, and we do not know whether any patents will issue from any of these applications. We do not know whether any of the claims in our issued patents or pending applications will provide us with any significant protection against competitive products or otherwise be commercially valuable. Legal standards regarding the validity of patents and the proper scope of their claims are still evolving, and there is no globally consistent law or policy regarding the breadth of valid claims. Additionally, there may be third-party patents, patent applications and other intellectual property held by entities much larger than us, that are relevant to our products and technology which are not known to us and that block or compete with our products. We face the risks that: </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-27-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties will infringe our intellectual property rights; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our non-disclosure agreements will be breached; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will not have adequate remedies for infringement; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our trade secrets will become known to or independently developed by our competitors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties will be issued patents that may prevent the sale of our products or require us to license and pay fees or royalties in order for us to be able to market some of our products; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third parties may assert patents and other intellectual property rights against our suppliers, causing interruption in supply of components or other essential inputs. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation may be necessary to enforce patents issued to us, to protect our proprietary rights, or to defend third-party claims that we have infringed on proprietary rights of others. If the outcome of any litigation, proceeding or claim brought against us were adverse, we could be subject to significant liabilities to third parties, could be required to obtain licenses from third parties, could be forced to design around the patents at issue or could be required to cease sales of the affected products. If we become involved in any intellectual property litigation, we may be required to pay substantial damages, including but not limited to treble damages, attorneys&#8217; fees and costs, for past infringement, or could be at risk for an injunction if it is ultimately determined that our products infringe a third party&#8217;s intellectual property rights. Even if infringement claims against us are without merit, defending a lawsuit takes significant time, may be expensive and may divert management&#8217;s attention from other business matters. In addition, a license may not be available at all or on commercially viable terms, and we may not be able to redesign our products to avoid infringement. Additionally, the laws regarding the enforceability of patents vary from country to country, and we cannot provide assurance that any patent issues we face will be uniformly resolved, or that local laws will provide us with consistent rights and benefits.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we fail to source, develop and retain key employees, our business may suffer. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete effectively depends on our ability to source and retain key employees, including people in senior management, sales, marketing, technology, and research and development positions. Competition for top talent in the healthcare, technology and SaaS industries can be intense. Our ability to source and retain such talent will depend on many factors, including hiring practices of our competitors, compensation and benefits, flexibility regarding virtual and hybrid work arrangements, work location, work environment, industry economic conditions, and corporate culture. If we cannot effectively source, develop and retain qualified employees to drive our strategic goals, our business could suffer. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our leverage and debt service obligations could adversely affect our business. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, our total consolidated debt was $0.7 billion and we may incur additional indebtedness in the future. Our indebtedness could have adverse consequences, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">making it more difficult to satisfy our financial obligations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increasing our vulnerability to adverse economic, regulatory and industry conditions; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting our ability to compete and our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting our ability to borrow additional funds for working capital, capital expenditure, acquisitions and general corporate or other purposes; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposing us to greater interest rate risk.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our debt service obligations will require us to use a portion of our operating cash flow to pay interest and principal in indebtedness, which could impede our growth. Our ability to make payments on, and to refinance, our indebtedness, and to fund capital expenditures will depend on our ability to generate cash in the future. This is subject to general economic, financial, competitive, legislative, regulatory, and other factors, many of which are beyond our control.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing, IT Systems, Commercial Operations and Plans for Future Growth</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disruptions in the supply of components from our suppliers could result in a significant reduction in sales and profitability. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase configured components for our devices from various suppliers, including some who are single-source suppliers for us. Disruptions in the price or supply of configured components may limit our ability to manufacture </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-28-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our devices in a timely or cost-effective manner, which could result in a significant reduction in sales and profitability. We cannot assure that a replacement supplier would be able to configure its components for our devices on a timely basis or, in the alternative, that we would be able to reconfigure our devices to integrate the replacement part. A reduction, delay or halt in supply while a replacement supplier reconfigures its components, or while we reconfigure our devices for the replacement part, may limit our ability to manufacture our devices in a timely or cost-effective manner, which could result in a significant reduction in sales and profitability. We cannot assure that our inventories would be adequate to meet our production needs during any prolonged interruption of supply.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, a global semiconductor supply shortage has had and continues to have wide-ranging effects across multiple industries, and it has impacted suppliers that incorporate semiconductors into the parts they supply to us. High demand and shortages of supply have adversely affected and could materially adversely affect our ability to obtain sufficient quantities of semiconductors and electronic components on commercially reasonable terms or at all. While we have entered into agreements for the supply of many components, there can be no assurance we will be able to extend or renew these agreements on similar terms or that suppliers will fulfill their commitments under existing agreements. Furthermore, to secure necessary components, we may be obligated to purchase them at prices that are higher than those available in the current market and/or may incur significant price increases from suppliers in the future. In addition, we have and may continue to be required to commit to greater purchase volumes and/or make prepayments to our suppliers. Purchase obligations, extended lead times, and decreased availability of key components may also cause an adverse effect on our financial condition or results of operations. Delays in our ability to produce and deliver our devices could cause our customers to purchase alternative products from our competitors. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, substantial increases in product demand, including in response to a product recall by a major competitor, Philips, have resulted and could continue to result in higher costs for materials and components, and increased expenditures for freight and other expenses, which have and could continue to negatively impact our profit margins. If supply constraints continue, our ability to meet increased demand and our corresponding ability to sell affected products may be materially reduced. The reintroduction of products by Philips could lead to reduced demand for our products. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are increasingly dependent on information technology systems and infrastructure.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We rely on information technology systems and infrastructure, including technologies and services provided by third parties, to support our business processes and activities, products and customers. Our business therefore depends on effective, reliable and secure operation of our technology systems and related infrastructure. These technology systems are potentially vulnerable to breakdown or other interruption by fire, power loss, system malfunction, unauthorized access and other events. Likewise, data privacy breaches by employees and others with both permitted and unauthorized access to our systems may pose a risk that sensitive data may be exposed to unauthorized persons or to the public, or may be permanently lost. While we have invested heavily in the protection of data and information technology and in related training, there can be no assurance that our efforts will prevent significant breakdowns, breaches in our systems or other cyber incidents that could have a material adverse effect upon the reputation, business, operations or financial condition of the company. In addition, significant implementation issues may arise as we continue to consolidate and outsource certain computer operations and application support activities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actual or attempted breaches of security, unauthorized disclosure of information, attacks which reduce availability of systems such as denial of service, or the perception that personal and/or other sensitive or confidential information in our possession is not secure, could result in a material loss of business, substantial legal liability or significant harm to our reputation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Despite the implementation of security measures, our internal computer and information technology systems and those of our vendors and customers are vulnerable to attack and damage from computer viruses, malware, denial of service attacks, unauthorized access, or other harm, including from threat actors seeking to cause disruption to our business. We face risks related to the protection of information that we maintain&#8212;or a third-party engaged to maintain information security on our behalf&#8212;including unauthorized access, acquisition, use, disclosure, or modification of such information. Cyberattacks are increasing in their frequency, sophistication and intensity and have become increasingly difficult to detect and respond to. Cyberattacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. A material cyberattack or security incident could cause interruptions in our operations and could result in a material disruption of our business operations, damage to our reputation, financial condition, results of operations, cash flows and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-29-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive, collect, process, use and store a large amount of information from our customers, our patients and our own employees, including personal information, intellectual property, protected health and other sensitive and confidential information. This data is often accessed by us through transmissions over public and private networks, including the internet. The secure transmission of such information over the Internet and other mechanisms is essential to maintain confidence in our information technology systems yet is vulnerable to unauthorized access and disclosure. We have implemented security measures, technical controls and contractual precautions designed to identify, detect and prevent unauthorized access, alteration, use or disclosure of our customers&#8217;, patients&#8217; and employees&#8217; data. The techniques used in these attacks change frequently and may be difficult to detect for periods of time and we may face difficulties in anticipating and implementing adequate preventative measures. We may face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities to exploit vulnerabilities. Beyond external activity, systems that access or control access to our services and databases may be compromised as a result of human error, fraud or malice on the part of employees or third parties, or may result from accidental technological failure. Because the techniques used to circumvent security systems can be highly sophisticated and change frequently, often are not recognized until launched against a target, and may originate from less regulated and remote areas around the world, we may be unable to proactively address all possible threats or implement adequate preventive measures for all situations. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If threat actors circumvent or breach our security systems, they could steal information or cause serious and potentially long-lasting disruption to our operations. Security breaches or attempts could also damage our reputation and expose us to a risk of monetary loss and/or litigation, fines and sanctions. We also face risks associated with security breaches affecting third parties that conduct business with us or our customers and others who interact with our data. While we maintain insurance that covers certain security incidents, we may not carry enough insurance or maintain sufficient coverage to compensate for all potential liability. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to diverse laws and regulations relating to data privacy and security, including HIPAA and GDPR, among others. Complying with these numerous and complex regulations is expensive and difficult, and failure to comply could result in regulatory scrutiny, fines, civil liability or damage to our reputation. In addition, any security breach or attempt could result in liability for stolen assets or information, additional costs associated with repairing any system damage, incentives offered to customers or other business partners to maintain business relationships after a breach, and implementation of measures to prevent future breaches, including organizational changes, deployment of additional personnel and protection technologies, employee training and engagement of third-party experts and consultants. The costs incurred to remediate any security incident could be substantial. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure that our third-party service providers with access to our, or our customers, patients and/or employees&#8217; personally identifiable and other sensitive or confidential information will not experience actual or attempted security breaches, which could have a negative effect on our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not be able to realize the anticipated benefits from acquisitions, which could adversely affect our operating results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Part of our growth strategy includes acquiring businesses consistent with our commitment to innovation in developing products for the diagnosis and treatment of sleep apnea and respiratory care as well as our SaaS business. The success of our acquisitions depends, in part, on our ability to successfully integrate the business and operations of the acquired companies. Additionally, our management may have attention diverted while trying to integrate acquisitions. If we are not able to successfully integrate the operations of acquisitions, we may not realize the anticipated benefits fully or at all, or may take longer to realize than expected. Acquisitions involve numerous risks and could create unforeseen operating difficulties and expenditures. There can be no assurance that any of the acquisitions we make will be successful or will be, or will remain, profitable. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we have recorded intangible assets, including goodwill, in connection with our acquisitions. At least on an annual basis, we must evaluate whether facts and circumstances demonstrate any impairment of the value of acquired intangible assets. The qualitative and quantitative analysis used to test goodwill is dependent upon various considerations and assumptions, including macroeconomic conditions, industry and market characteristics, projections of acquired companies&#8217; future revenue, discount rates, and expectations of future cash flows. While we have made such assumptions in good faith and believe them to be reasonable, the assumptions may turn out to be materially inaccurate, including for reasons beyond our control. Changes in such assumptions may cause a change in circumstances demonstrating that the carrying value of intangible assets may be impaired. Consequently, we may be required to record a significant charge to earnings in the financial statements during the period in which any impairment of intangible assets is determined.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-30-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to support our continued growth or achieve expected operating efficiencies, our business could suffer. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to grow, the complexity of our operations increases, placing greater demands on our management. Our ability to manage our growth effectively depends on our ability to implement and improve our financial and management information systems on a timely basis and to effect other changes in our business including the ability to monitor and improve manufacturing systems, information technology, and quality and regulatory compliance systems, among others. Unexpected difficulties during expansion, the failure to attract and retain qualified employees, the failure to successfully replace or upgrade our management information systems, the failure to manage costs or our inability to respond effectively to growth or plan for future expansion could cause our growth to slow or stop. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess opportunities for improved operational efficiency and to better align expenses with revenues, while preserving our ability to make investments in research and development projects, product and technology acquisitions and our people, which we believe is important to our long-term success. As a result of these assessments, there have been, and may in the future be, restructuring activities, realignment of strategies and cost reduction initiatives. These measures could yield unintended consequences, such as distraction of our management and employees, reduced employee productivity, business disruption, and inability to attract or retain key personnel, which could negatively affect our business. Moreover, our restructuring and optimization initiatives could incur additional costs which impact our operating results. We cannot guarantee that the activities under our restructuring plans or other initiatives will result in the desired efficiencies and estimated cost savings. If we fail to manage our growth effectively and efficiently, our costs could increase faster than our revenues and our business results could suffer.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, productivity initiatives may at times involve reorganization or relocation of manufacturing activities. Such manufacturing realignment may result in the interruption of production, which could increase our costs and reduce our sales. Any interruption in production capability could require us to make substantial capital expenditures to fill customer orders, which could negatively affect our profitability and financial condition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business depends on our ability to market effectively to dealers of home healthcare products and sleep clinics. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our products primarily to home healthcare dealers and to sleep clinics that diagnose OSA and other sleep disorders, as well as to non-sleep specialist physician practices that diagnose and treat sleep disorders. We believe that these groups play a significant role in determining which brand of product a patient will use. The success of our business depends on our ability to market effectively to these groups to ensure that our products are properly marketed and sold by these third parties. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited resources to market to physicians, sleep clinics, home healthcare dealer branch locations and to the non-sleep specialists, most of whom use, sell or recommend several brands of products. We are limited under applicable fraud and abuse laws in the ways in which we market and sell to customers and patients. In addition, home healthcare dealers have experienced price pressures as government and third-party reimbursement has declined for home healthcare products, and home healthcare dealers are requiring price discounts and longer periods of time to pay for products purchased from us. We cannot assure that physicians will continue to prescribe our products, or that home healthcare dealers or patients will not substitute competing products when a prescription specifying our products has been written. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have expanded our marketing activities in some areas to target the population with a predisposition to sleep-disordered breathing as well as primary care physicians and various medical specialists. We cannot assure that these marketing efforts will be successful in increasing awareness or sales of our products. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our SaaS business depends substantially on customers entering, renewing, upgrading and expanding their agreements for cloud services, term licenses, and maintenance and support agreements with us. Any decline in our customer renewals, upgrades or expansions could adversely affect our future operating results. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically enter into term-based agreements for our licensed on-premises offerings, cloud services, and maintenance and support services, which customers have discretion to renew or terminate. To improve our operating results, it is important that new customers enter into renewable agreements, and our existing customers renew, upgrade and expand their term-based agreements when the initial contract term expires. Our customers have no obligation to renew, upgrade or expand their agreements with us after the terms have expired. Our customers&#8217; renewal, upgrade and expansion rates may decline or fluctuate for a number of factors, including their satisfaction or dissatisfaction with our offerings, our pricing, the effects of general economic conditions, competitive offerings or alterations or reductions in our customers&#8217; spending levels. If our customers do not renew, upgrade or expand their agreements with us or renew on terms less favorable to us, our revenues may decline.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-31-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If our SaaS products fail to perform properly or if we fail to develop enhancements, we could lose customers, become subject to service performance or warranty claims and our sales could decline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our SaaS operations are dependent upon our ability to prevent system interruptions and, as we continue to grow, we will need to devote additional resources to improving our infrastructure to maintain the performance of our products and solutions. The applications underlying our SaaS products are inherently complex and may contain material defects or errors, which may cause disruptions in availability or other performance problems. We have from time to time found defects in our products and may discover additional defects in the future that could result in data unavailability, unauthorized access to, loss, corruption or other harm to our customers&#8217; data. While we implement bug fixes and upgrades as part of our regularly scheduled system maintenance, we may not be able to detect and correct defects or errors before implementing our products and solutions. Consequently, we or our customers may discover defects or errors after our products and solutions have been deployed. If we fail to perform timely maintenance, or if customers are otherwise dissatisfied with the frequency and/or duration of our maintenance services and related system outages, our existing customers could elect not to renew their contracts, delay or withhold payment, or potential customers may not adopt our products and solutions and our brand and reputation could be harmed. In addition, the occurrence of any material defects, errors, disruptions in service or other performance problems with our software could result in warranty or other legal claims against us and diversion of our resources. The costs incurred in addressing and correcting any material defects or errors in our software and expanding our infrastructure and architecture in order to accommodate increased demand for our products and solutions may be substantial and could adversely affect our operating results. Further, if we fail to innovate or adequately invest in new technologies, we could lose our competitive position in the markets that we serve. To the extent that we fail to introduce new and innovative products, or such products are not accepted or suffer significant delays in development, our financial results may suffer. An inability, for technological or other reasons, to successfully develop and introduce new products on a timely basis could reduce our growth rate or otherwise have an adverse effect on our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If there are interruptions or performance problems associated with our technology or infrastructure, our existing SaaS customers may experience service outages, and our new customers may experience delays in the deployment of our platforms.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We depend on services from various third parties as well as our own technical operations infrastructure to distribute our SaaS products via the internet. If a service provider fails to provide sufficient capacity to support our platforms or otherwise experiences service outages, such failure could interrupt our customers&#8217; access to our service, which could adversely affect their perception of our platform&#8217;s reliability and our revenues. Any disruptions in these services, including as a result of actions outside of our control, would significantly impact the continued performance of our SaaS products. In the future, these services may not be available to us on commercially reasonable terms, or at all. Any loss of the right to use any of these services could result in decreased functionality of our SaaS products until equivalent technology is either developed by us or, if available from another provider, is identified, obtained and integrated into our infrastructure. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet our business needs, we must maintain sufficient excess capacity in our operations infrastructure to ensure that our SaaS products are accessible. Design and mechanical errors, spikes in usage volume and failure to follow system protocols and procedures could cause our systems to fail, resulting in interruptions in our SaaS products. Any interruptions or delays in our service, whether caused by our products, or as a result of third-party error, our own error, natural disasters or security breaches, whether accidental or willful, could harm our relationships with customers and cause our revenue to decrease and/or our expenses to increase. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above circumstances or events may harm our reputation, cause customers to terminate their agreements, impair our ability to obtain contract renewals from existing customers, impair our ability to grow our customer base, result in the expenditure of significant financial, technical and engineering resources, subject us to financial penalties and liabilities under our service level agreements, and otherwise harm our business, results of operations and financial condition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Climate change and natural disasters, or other events beyond our control, could negatively impact our business operations and financial condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Natural disasters and other business disruptions could adversely affect our business and financial condition, and global climate change could result in certain types of natural disasters occurring more frequently or with more intense effects. The impacts of climate change may include physical risks (such as frequency and severity of extreme weather conditions), social and human effects (such as population dislocations or harm to health and well-being), compliance costs and transition risks (including due to regulatory changes), shifts in market trends (including customer preference for sustainably produced or reusable products) and other adverse effects. Such impacts may disrupt parties in our supply chain, our customers, and our operations. For example, if a natural disaster strikes our manufacturing facilities, such as those in Sydney, Australia and Singapore which are vulnerable to such events, we may be unable to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-32-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacture our products for a substantial amount of time and our sales and profitability may decline. Our facilities and the manufacturing equipment we use to produce our products would be costly to replace and could require substantial lead-time to repair or replace. In the event our facilities are affected by natural or man-made disasters, we could be forced to rely on third-party manufacturers. Although we believe we possess adequate insurance for the disruption of our business, it may not be sufficient to cover our potential losses and may not continue to be available to us on acceptable terms, or at all. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the increasing concern over climate change has resulted and may continue to result in more legal and regulatory requirements designed to mitigate the effects of climate change on the environment, including regulating greenhouse gas emissions and related reporting requirements, alternative energy policies and sustainability initiatives. If such laws or regulations are more stringent than current legal or regulatory requirements, we may experience increased compliance burdens and costs to meet the regulatory obligations, as well as adverse impacts on the availability of raw materials, manufacturing operations and the distribution of our products, which could adversely affect our operations and profitability.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Non-Compliance with Laws, Regulations and Healthcare Industry Shifts</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Healthcare reform or other cost-cutting measures, including changes in coverage policy for our products, by government or commercial payors may have a material adverse effect on our industry and our results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the ACA was signed into law in the United States. The ACA made changes, effective over time, that significantly impacted the healthcare industry, including medical device manufacturers. One of the principal purposes of the ACA was to expand health insurance coverage to millions of Americans who were uninsured. The ACA required adults not covered by an employer or government-sponsored insurance plan to maintain health insurance coverage or pay a penalty, a provision commonly referred to as the individual mandate. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA also contained provisions designed to generate the revenues necessary to fund the coverage expansions. This included new fees or taxes on certain health-related industries, including medical device manufacturers. Beginning in 2013, entities that manufacture, produce or import medical devices were required to pay an excise tax in an amount equal to 2.3% of the price for such devices sold in the United States. This excise tax was applicable to our products that are primarily used in hospitals and sleep labs, which includes the ApneaLink, VPAP Tx and certain respiratory care products. Through a series of legislative amendments, the tax was suspended beginning in 2016, and permanently repealed effective January 1, 2020. In addition to the competitive bidding changes discussed above, the ACA also included, among other things, the implementation of new payment methodologies for voluntary coordination of care by groups of providers, such as physicians and hospitals, and the establishment of a new Patient-Centered Outcomes Research Institute to oversee, identify, prioritize and conduct comparative clinical effectiveness research. The increased funding and focus on comparative clinical effectiveness research, which compares and evaluates the risks and benefits, clinical outcomes, effectiveness and appropriateness of products, may result in changes to Federal healthcare program coverage and reimbursement methodologies for our products which could also lead to lower reimbursements for our products by payors and decreased revenues to us. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other federal legislative changes have been proposed and adopted since the ACA was enacted. The Budget Control Act of 2011 required, among other things, mandatory across-the-board reductions in certain types of federal spending, also known as sequestration. Medicare claims with dates-of-service or dates-of-discharge on or after July 1, 2022 and effective until further notice, incur a 2% reduction in Medicare payment, known as Medicare Sequestration Payment Reductions. In addition, on January 2, 2013, the American Taxpayer Relief Act of 2012, was signed into law, which further reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. More recently, the Consolidated Appropriations Act of 2024 (CAA) was signed into law in March 2024. Among other things, the CAA reduced by half the 3.37% reduction to 2023&#8217;s Medicare Physician Fee Schedule conversion factor that had been in place since January 1, 2024, increasing the conversion factor to $33.32 for services furnished between March 9 and December 31, 2024. Absent from the CAA are extensions of the Medicare telehealth flexibilities set to expire at the end of 2024. Without Congressional action, Medicare will no longer cover most telehealth services furnished to beneficiaries in their home or to individuals residing in urban areas after the end of the year which could have an adverse impact on rates of diagnosis of OSA.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full impact on our business of the ACA, the Medicare Sequestration Payment Reductions, and other new laws is uncertain. Nor is it clear whether other legislative changes will be adopted, if any, or how such changes would affect the demand for our products. Future actions by the administration and the U.S. Congress could have a material adverse impact </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-33-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on our results of operations or financial condition. It is unclear exactly how the 2024 election will impact healthcare reform measures of the existing administration or whether a new administration could impose other reform efforts, including what, if any, impact such changes will have on our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various healthcare reform proposals have also emerged at the state level within the United States. The ACA as well as other federal and/or state healthcare reform measures that may be adopted in the future, singularly or in the aggregate, could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government and private insurance plans may not adequately reimburse our customers for our products, which could result in reductions in sales or selling prices for our products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to sell our products depends in large part on the extent to which coverage and adequate reimbursement for our products will be available from government health administration authorities, private health insurers and other organizations. These third-party payors are increasingly challenging the reimbursement models and prices charged for medical products and services and can, without notice, deny or reduce coverage for our products or treatments that may include the use of our products. Therefore, even if a product is approved for marketing, we cannot assure that coverage and reimbursement will be available for the product, that reimbursement will be adequate or that the reimbursement amount, even if initially adequate, will not be subsequently reduced. For example, in some countries, such as Spain, France and Germany, government coverage and reimbursement are currently available for the purchase or rental of our products but are subject to constraints such as price controls or unit sales limitations. In other countries, such as Australia, there is currently limited or no reimbursement for devices that treat sleep apnea conditions. As we continue to develop new products, those products will generally not qualify for coverage and reimbursement until they are approved for marketing, if at all. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we sell our products primarily to home healthcare dealers, health systems and sleep clinics. Reductions in reimbursement to our customers by third-party payors, if they occur, may have a material impact on our customers and, therefore, may indirectly affect our pricing and sales to, or the collectability of receivables we have from, those customers. A development negatively affecting reimbursement stems from the Medicare competitive bidding program mandated by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). Under the program, our customers who provide services must compete to offer products in designated competitive bidding areas, or CBAs. We cannot predict the impact the competitive bidding program and the developments in the competitive bidding program will have on our business and financial condition. If changes are made to this program in the future, it could affect amounts being recovered by our customers and subsequent purchases from us.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our products are the subject of periodic studies by third party agencies, including the Agency for Healthcare Research and Quality (AHRQ) in the United States, intended to review the comparative effectiveness of different treatments of the same illness. In October 2022, the AHRQ concluded that randomized controlled clinical trials do not provide sufficient evidence that CPAP affects long-term clinically important outcomes. We believe that the AHRQ methodology was too restrictive, that retrospective and prospective observational studies should have been included, that real-world evidence should have been considered, and that CPAP therapy does have long-term positive effects on health outcomes. Although the results of comparative effectiveness studies are not intended to mandate any reimbursement policies for public or private payors, it is not clear what, if any, effect such research will have on the sales of our products. To date, the AHRQ assessment has not impacted CMS or private payor reimbursement. Decreases in third-party reimbursement for our products or a decision by a third-party payor to not cover our products as a result of a third-party study could have a material adverse effect on our sales, results of operations and financial condition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to various risks relating to our compliance with fraud and abuse laws and transparency laws relating to our interactions with our customers, healthcare providers, and patients, which could subject us to government investigation, litigation, or other penalties to the extent our activities or relationships are found not to comply or could otherwise cause us to incur significant costs to defend our actions, and could result in substantial fines, penalties, harm our reputation in the market, divert our management&#8217;s attention, or result in changes in our business operations that could harm our ability to successfully market and sell our products and services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are subject to healthcare fraud and abuse regulation and enforcement by federal, state and foreign governments, which could significantly impact our business. We also are subject to foreign fraud and abuse laws, which vary by country.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the laws that may affect our ability to operate include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering, or paying remuneration, directly or indirectly, in cash or in kind, in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-34-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exchange for or to induce either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of this statute or specific intent to violate the Anti-Kickback Statute itself to have committed a violation. The U.S. government has interpreted this law broadly to apply to the marketing and sales activities of manufacturers and distributors like us. Violations of the federal Anti-Kickback Statute may result in significant civil monetary penalties for each violation, plus up to three times the remuneration involved, plus potential exclusion from participation in Federal healthcare programs. Violations of the Federal Anti-Kickback Statute can also result in significant criminal penalties and imprisonment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws, including the False Claims Act, and civil monetary penalty laws, that prohibit, among other things, knowingly presenting, or causing to be presented, claims for payment or approval to the federal government that are false or fraudulent, knowingly making a false statement material to an obligation to pay or transmit money or property to the federal government or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay or transmit money or property to the federal government. These laws may apply to manufacturers and distributors who provide information on coverage, coding, and reimbursement of their products to persons who do bill third-party payors. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Violations can result in debarment, suspension or exclusion from participation in government healthcare programs, including Medicare and Medicaid. When an entity is determined to have violated the federal civil False Claims Act, the government may impose significant civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which created federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. A person or entity does not need to have actual knowledge of these statutes or specific intent to violate them to have committed a violation; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Sunshine Act requirements under the ACA, which impose reporting and disclosure requirements on device and drug manufacturers for any &#8220;transfer of value&#8221; made or distributed by certain manufacturers of drugs, devices, biologics, and medical supplies to physicians (including doctors, dentists, optometrists, podiatrists and chiropractors), teaching hospitals, non-physician practitioners such as nurse practitioners, physician assistants, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants and certified nurse midwives, and ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm customers; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state and foreign law equivalents of each of the above federal laws, such as state anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require device companies to comply with the industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of these laws are uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be time-and resource-consuming and can divert management&#8217;s attention. Additionally, as a result of these types of investigations, healthcare providers and entities may face litigation or have to agree to settlements that can include monetary penalties and onerous compliance and reporting requirements as part of a consent decree or corporate integrity agreement. Any such investigation even if unfounded and even if we are in compliance with applicable laws, could damage our reputation, increase costs, and otherwise have an adverse effect on our business. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-35-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us now or in the future, we may be subject to penalties, including civil and criminal penalties, damages, fines, disgorgement, exclusion from governmental healthcare programs, additional compliance and reporting obligations, imprisonment and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a settlement agreement with the U.S. Department of Justice and the U.S. Attorneys&#8217; Offices for the District Court of South Carolina, the Southern District of California, the Northern District of Iowa and the Eastern District of New York. The agreement resolved five lawsuits originally brought by whistleblowers under the qui tam provisions of the False Claims Act and allegations that we: (a) provided DME companies with free telephone call center services and other free patient outreach services that enabled these companies to order resupplies for their patients with sleep apnea, (b) provided sleep labs with free and below-cost positive airway pressure masks and diagnostic machines, as well as free installation of these machines, (c) arranged for, and fully guaranteed the payments due on, interest-free loans that DME supplies acquired from third-party financial institutions for the purchase of our equipment, and (d) provided non-sleep specialist physicians free home sleep testing devices referred to as &#8220;ApneaLink.&#8221; We agreed with the government to civilly resolve these matters for a payment of $39.5 million ($37.5 million to the federal government and $2 million to the various states) and we incurred additional fees and administrative costs that typically accompany such a resolution amounting to $1.1 million. The specific allegations and the resolution of those allegations are contained in the Company&#8217;s settlement agreement with the adverse parties. The total final costs relating to these matters was $40.6 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contemporaneous with the civil settlement, we also entered into a five-year Corporate Integrity Agreement, or CIA, with the Department of Health and Human Services Office of Inspector General, or OIG. The CIA required, among other things, that we implement additional controls around our product pricing and sales and that we conduct internal and external monitoring of our arrangements with referrals sources. Our failure to comply with our obligations under the CIA could result in monetary penalties and our exclusion from participating in federal healthcare programs. The costs associated with compliance with the CIA, or any liability or consequences associated with its breach, could have an adverse effect on our operations, liquidity and financial condition. Most of the obligations of the CIA expire on December 18, 2024. Absent an inquiry for additional materials from the OIG, we expect to close out the CIA by the end of fiscal year 2025.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our use and disclosure of personal information, including health information, is subject to federal, state and foreign privacy, artificial intelligence, data, biometrics and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability, regulatory investigations, legal actions, or reputational harm. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The appropriate privacy and security of personal information whether stored, maintained, received or transmitted electronically or in paper form is a key regulatory issue in the United States and abroad. While we strive to comply with all applicable privacy and security laws and regulations, as well as our posted privacy policies, legal standards for privacy, including but not limited to &#8220;unfairness&#8221; and &#8220;deception,&#8221; as enforced by the FTC and state attorneys general, continue to evolve and any failure or perceived failure to comply may result in proceedings or actions against us by government entities or others, or could cause us to lose audience and customers, which could have a material adverse effect on our business. Recently, there has been an increase in public awareness of privacy issues in the wake of revelations about the activities of various government agencies and in the number of private privacy-related lawsuits filed against companies. Concerns about our practices with regard to the collection, use, disclosure, security or deletion of personal information or other privacy-related matters, even if unfounded and even if we are in compliance with applicable laws, could damage our reputation and harm our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous foreign, federal and state laws and regulations govern collection, dissemination, use and confidentiality of personally identifiable health information, including (i) state privacy and confidentiality laws (including state laws requiring disclosure of breaches); (ii) HIPAA; and (iii) European and other foreign data protection laws, including the EU GDPR and the UK GDPR.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA establishes a set of national privacy and security standards for the protection of individually identifiable health information, or protected health information, by health plans, healthcare clearinghouses and healthcare providers that submit certain covered transactions electronically, collectively referred to as &#8220;covered entities,&#8221; and their &#8220;business associates,&#8221; which are persons or entities that perform certain services for, or on behalf of, a covered entity that involve creating, receiving, maintaining or transmitting protected health information, as well as their covered subcontractors. Through certain portions of our business, such as the cloud-based software digital health applications, we are subject to HIPAA as a business associate of our covered entity clients. To provide our covered entity clients with services that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-36-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">involve access to PHI, HIPAA requires us to enter into business associate agreements that require us to safeguard PHI in accordance with HIPAA. As a business associate, we are also directly liable for compliance with HIPAA. Penalties for violations of HIPAA regulations include civil and criminal penalties.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA authorizes state attorneys&#8217; general to file suit under HIPAA on behalf of state residents. Courts can award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for HIPAA violations, its standards have been used as the basis for a duty of care claim in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA further requires business associates like us to notify our covered entity clients in the event of a breach. Covered entities must notify affected individuals &#8220;without unreasonable delay and in no case later than 60 calendar days after discovery of the breach&#8221; if their unsecured PHI is subject to an unauthorized access, use or disclosure. If a breach affects 500 patients or more, covered entities must report it to HHS and local media without unreasonable delay, and HHS will post the name of the breaching entity on its public website. If a breach affects fewer than 500 individuals, the covered entity must log it and notify HHS at least annually. Breach notification obligations under business associate agreements often have shorter notification timeframes which we are required to abide by contractually. We could also face contractual liability if we fail to meet our obligations under our business associate agreements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to properly protect the privacy and security of health information entrusted to us, our solutions may be perceived as not secure, we may incur significant liabilities and customers may curtail their use of or stop using our solutions. In addition, if we fail to comply with the terms of our business associate agreements with our clients, we may be liable not only contractually but also directly under HIPAA.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the California Consumer Privacy Act of 2018, or CCPA, as amended by the California Privacy Rights Act (collectively, &#8220;CCPA&#8221;), became effective on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA includes civil penalties for violations, as well as a private right of action for data breaches. Although the law includes limited exceptions, including for &#8220;protected health information&#8221; maintained by a covered entity or business associate, it may regulate or impact our processing of personal information depending on the context. We also expect that there will continue to be new laws, regulations and industry standards concerning privacy, data protection and information security proposed and enacted in various jurisdictions. If we are subject to other domestic privacy and data protection laws, beyond HIPAA and the CCPA, any liability from failure to comply with these laws could adversely affect our financial condition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these comprehensive data protection laws, to date, at least three states have adopted laws specifically regulating the collection, use, storage, and disclosure of biometrics, and additional states may seek to regulate&#8212;and/or restrict the use of&#8212;biometrics in the future. Certain of our products use, or permit the use of, information that could be classified as a biometric under these or other laws. If we are subject to or affected by these or other laws, including potential damages for improper use of biometrics, we may be subject to damages claims, required to modify the way in which we make available our products or certain features of our products. More recently, the FTC and the Office for Civil Rights (OCR, the agency that enforces HIPAA) have taken interest in the use of online tracking technologies that collect, use, and disclose personal information about users, including use of online tracking tools to gather information to be used for redirected marketing. FTC has taken enforcement actions against companies that have used online tracking tools either in a misleading or deceptive manner. In response to this new area of enforcement, we have been assessing our websites and applications to assess any online tracking and to ensure compliance with privacy and security standards. We also may be required to implement additional practices or processes or otherwise invest our resources to comply with these and other regulations. If we are unable to comply with these laws, or if these laws require us to change our products or services, we may encounter liability that could adversely affect our financial condition. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to laws and regulations in non-U.S. countries covering data privacy and the protection of health-related and other personal information. For example, EU member states, the United Kingdom, and other jurisdictions have adopted data protection laws and regulations, which impose significant compliance obligations. Laws and regulations in these jurisdictions apply broadly to the collection, use, storage, disclosure and security of personal information that identifies or may be used to identify an individual, such as names, contact information, and sensitive personal data such as health data. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-37-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws and regulations are subject to frequent revisions and differing interpretations and have generally become more stringent over time. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the EU GDPR and UK GDPR went into effect in May 2018. The GDPR imposes stringent data protection requirements for the processing of personal data in the EEA or UK. The GDPR imposes several stringent requirements for controllers and processors of personal data, and increased our obligations, for example, by imposing higher standards for obtaining consent from individuals to process their personal data, requiring more robust disclosures to individuals, strengthening individual data rights, shortening timelines for data breach notifications, limiting retention periods and secondary use of information (including for research purposes), increasing requirements pertaining to health data and pseudonymized (i.e., key-coded) data and imposing additional obligations when we contract with third party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the EEA and recent legal developments in Europe have created complexity regarding such transfers of personal data from the EEA and UK to the United States. For example, the European Commission and the United Kingdom have adopted new standard contractual clauses under which entities may transfer personal data from the European Union and the United Kingdom, which we may be required to implement. We must evaluate such data transfers on a case-by-case basis to ensure continued permissibility under current law and consistent with the new standard contractual clauses. GDPR provides that EEA member states and the UK may make their own further laws and regulations limiting the processing of genetic, biometric or health data, which could limit our ability to use and share personal data or could cause our costs to increase, and harm our business and financial condition. Failure to comply with the requirements of GDPR and the applicable national data protection and marketing laws of the EEA member states may result in fines of up to &#8364;20.0 million or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties as well as individual claims for compensation. EU Member States and the UK also have established laws pertaining to electronic monitoring, which could require us to take additional compliance measures. Failure to comply with such laws may subject us to penalties. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK GDPR mirrors the fines under the EU GDPR, i.e., fines up to the greater of &#163;17.5 million or 4% of global turnover. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with data protection rules. Any failure or perceived failure by us to comply with privacy or security laws, policies, legal obligations or industry standards or any security incident that results in the unauthorized release or transfer of personally identifiable information may also result in governmental enforcement actions and investigations, fines and penalties, litigation and/or adverse publicity, including by consumer advocacy groups, and could cause our customers to lose trust in us, which could have an adverse effect on our reputation and business. Such failures could have a material adverse effect on our financial condition and operations. If the third parties we work with violate applicable laws, contractual obligations or suffer a security incident, such violations may also put us in breach of our obligations under privacy laws and regulations and/or could in turn have a material adverse effect on our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business activities are subject to extensive regulation, and any failure to comply could have a material adverse effect on our business, financial condition, or results of operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We are subject to extensive U.S. federal, state, local and international regulations regarding our business activities. Failure to comply with these regulations could result in, among other things, recalls of our products, substantial fines and criminal charges against us or against our employees. Furthermore, certain of our products could be subject to recall if the Food and Drug Administration, or the FDA, other regulators or we determine that those products are not safe or effective. Any recall or other regulatory action could increase our costs, damage our reputation, affect our ability to supply customers with the quantity of products they require and materially affect our operating results. Certain of our products and services include the use of artificial intelligence (AI), which is intended to enhance the operation of our products and services. AI innovation presents risks and challenges that could impact our business. AI algorithms may be flawed. Datasets may be insufficient or contain biased information. Ineffective AI development and deployment practices could subject us to competitive harm, regulatory action, increased cyber risks and legal liability, including under new proposed AI regulation in the European Union. The FTC has issued a report expressing a concern regarding AI and bias across industry sectors, including in the healthcare space, and has suggested that such bias could lead to unfair and deceptive practices, among other concerns. Any changes to our ability to use AI or concerns about bias could require us to modify our products and services or could have other negative financial impact on our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-38-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product sales, introductions or modifications may be delayed or canceled as a result of FDA regulations or similar foreign regulations, which could cause our sales and profits to decline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unless a product is exempt or may be commercialized based on current FDA enforcement discretion policies, before we can market or sell a new medical device in the United States, we must obtain FDA clearance or approval, which can be a lengthy and time-consuming process. We generally receive clearance from the FDA to market our products in the United States under Section 510(k) of the Federal Food, Drug, and Cosmetic Act or our products are exempt from the Section 510(k) clearance process. The 510(k) clearance process can be expensive, time-consuming and uncertain. In the 510(k) clearance process, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a predicate device with respect to intended use, technology and safety and effectiveness, in order to clear the proposed device for marketing. The FDA has a high degree of latitude when evaluating submissions and may seek additional information before clearing a proposed device or may ultimately determine that a proposed device submitted for 510(k) clearance is not substantially equivalent to a predicate device. After a device receives 510(k) premarket notification clearance from the FDA, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in the intended use of the device, technology, materials, packaging, and certain manufacturing processes may require a new 510(k) clearance or premarket approval. We have modified some of our Section 510(k) approved products without submitting new Section 510(k) notices, which we do not believe were required. However, if the FDA disagrees with us and requires us to submit new Section 510(k) notifications for modifications to our existing products, we may be required to stop marketing the products while the FDA reviews the Section 510(k) notification.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any new product introduction or existing product modification could be subjected to a lengthier, more rigorous FDA examination process. For example, in certain cases we may need to conduct clinical trials of a modified or new product before submitting a 510(k) notice. We may also be required to obtain premarket approvals for certain of our products. Indeed, recent trends in the FDA&#8217;s review of premarket notification submissions suggest that the FDA is often requiring manufacturers to provide new, more expansive, or different information regarding a particular device than what the manufacturer anticipated upon 510(k) submission. This has resulted in increasing uncertainty and delay in the premarket notification review process. For example, in November 2018, FDA officials announced steps that the FDA intended to take to modernize the 510(k) premarket notification pathway. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. In September 2019, the FDA also issued revised final guidance establishing a &#8220;Safety and Performance Based Pathway&#8221; for &#8220;manufacturers of certain well-understood device types&#8221; allowing manufacturers to rely on objective safety and performance criteria recognized by the FDA to demonstrate substantial equivalence, obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA has developed and maintains a list of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">device types appropriate for the &#8220;safety and performance based&#8221; pathway and continues to develop product-specific guidance documents that identify the performance criteria and recommended testing methodologies for each such device type, where feasible. Some of these proposals have not yet been finalized or adopted, although the FDA may work with Congress to implement such proposals through legislation. Accordingly, it is unclear the extent to which any proposals, if adopted, could impose additional regulatory requirements on us that could delay our ability to obtain new 510(k) clearances, increase the costs of compliance, or restrict our ability to maintain our current clearances, or otherwise create competition that may negatively affect our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s ongoing review of the 510(k) program may make it more difficult for us to make modifications to our previously cleared products, either by imposing stricter requirements on when a manufacturer must submit a new 510(k) for a modification to a previously cleared product, or by applying more onerous review criteria to such submissions. FDA continues to review its 510(k) clearance process which could result in additional changes to regulatory requirements or guidance documents which could increase the costs of compliance or restrict our ability to maintain current clearances. The requirements of the more rigorous premarket approval process and/or significant changes to the 510(k) clearance process could delay product introductions and increase the costs associated with FDA compliance. Marketing and sale of our products outside the United States are also subject to regulatory clearances and approvals, and if we fail to obtain these regulatory approvals, our sales could suffer. We cannot assure that any new products we develop will receive required regulatory approvals from U.S. or foreign regulatory agencies.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The definition of &#8220;device&#8221; in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) was amended in 2016 to exclude certain software functions. Our software offerings may include functions that fall under FDA&#8217;s jurisdictional definition of a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-39-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">medical device, while there may be software offerings that are considered exempt from the &#8220;device&#8221; definition even when utilizing data coming from an FDA regulated medical device. Our determination of the appropriate classification of our digital offerings may lead to regulatory inquiry and the expenditure of time and resources to meet FDA feedback as to the appropriate category for particular digital offerings. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to substantial regulation related to quality standards applicable to our manufacturing and quality processes. Our failure to comply with these standards could have an adverse effect on our business, financial condition, or results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates the approval, manufacturing, and sales and marketing of many of our products in the United States. Significant government regulation also exists in Canada, Japan, Europe, and other countries in which we conduct business. As a device manufacturer, we are required to register with the FDA and are subject to periodic inspection by the FDA for compliance with the FDA&#8217;s Quality System Regulation requirements, which require manufacturers of medical devices to adhere to certain regulations, including testing, quality control and documentation procedures. For example, in February 2024, the FDA issued a final rule to amend and replace the Quality System Regulation, or QSR, which sets forth the FDA's current good manufacturing practice requirements for medical devices, to align more closely with the International Organization for Standardization standards. Specifically, this final rule, which the FDA expects to go into effect on February 2, 2026, establishes the "Quality Management System Regulation," or QMSR, which among other things, incorporates by reference the quality management system requirements of ISO 13485:2016. Although the FDA has stated that the standards contained in ISO 13485:2016 are substantially similar to those set forth in the QSR, and although our quality system is currently designed to comply with ISO standards in connection with our device certifications, it is unclear the extent to which this final rule, once effective, could impose additional or different regulatory requirements on us that could increase the costs of compliance or otherwise negatively affect our business. If we are unable to comply with QMSR, once effective, or with any other changes in the laws or regulations enforced by FDA or comparable regulatory authorities, we may be subject to enforcement action, which could have an adverse effect on our business, financial condition and results of operations. In addition, the federal Medical Device Reporting regulations require us to provide information to the FDA whenever there is evidence that reasonably suggests that a device may have caused or contributed to a death or serious injury or, if a malfunction were to occur, could cause or contribute to a death or serious injury. Compliance with applicable regulatory requirements is subject to continual review and is rigorously monitored through periodic inspections by the FDA. In the European Union, we are required to maintain certain ISO certifications in order to sell our products and must undergo periodic inspections by notified bodies to obtain and maintain these certifications. Failure to comply with current governmental regulations and quality assurance guidelines could lead to temporary manufacturing shutdowns, product recalls or related field actions, product shortages or delays in product manufacturing. Efficacy or safety concerns, an increase in trends of adverse events in the marketplace, and/or manufacturing quality issues with respect to our products could lead to product recalls or related field actions, withdrawals, and/or declining sales.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared or approved or commercialized in a timely manner or at all, which could negatively impact our business. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and clear or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for medical devices or modifications to cleared or approved medical devices to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the COVID-19 pandemic, on March 10, 2020, the FDA announced its intention to postpone most foreign inspections of manufacturing facilities, and subsequently, on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Regulatory authorities outside the United States adopted similar restrictions or other policy measures in response to the COVID-19 pandemic. On July 10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. During the COVID emergency, the FDA issued numerous guidances providing for enforcement discretion or processes for issuance of Emergency Use Authorizations (EUAs) for certain devices that had the effect of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-40-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relaxing certain regulatory requirements with respect to selected devices during the pendency of the COVID emergency. Recently, in anticipation of the termination of the COVID emergency effective May 11, 2023, on March 27, 2023, the FDA released two final guidance documents to assist with transitioning medical devices: (i) that were subject to certain enforcement policies issued during the COVID emergency, and (ii) that were issued emergency use authorizations (EUAs). These guidance documents finalize the corresponding draft guidance documents that were issued on December 23, 2021. The guidance calls for a &#8220;phased transition process&#8221; with respect to devices that fell within the expiring COVID enforcement policies. To the extent our devices have been authorized for market based on COVID-related enforcement discretion or EUAs, we may need to implement a transition plan for such devices, the outcome of which may be uncertain and could potentially affect our ability to market such devices in the post-COVID regulatory environment. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-label marketing of our products could result in substantial penalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates the promotional claims that may be made about FDA-cleared products. In particular, clearance under Section 510(k) only permits us to market our products for the uses indicated on the labeling cleared by the FDA. We may request additional label indications for our current products, and the FDA may deny those requests outright, require additional expensive clinical data to support any additional indications or impose limitations on the intended use of any cleared products as a condition of clearance. If the FDA determines that we have marketed our products for off-label use, we could be subject to fines, injunctions or other penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our business activities to constitute promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs, and the curtailment of our operations. Any of these events could significantly harm our business and results of operations and cause our stock price to decline.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Laws regulating consumer contacts could adversely affect our business operations or create liabilities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business activities include contacts with consumers in different parts of the world. Certain laws, such as the U.S. Telephone Consumer Protection Act, regulate telemarketing practices and certain automated outbound contacts with consumers, such as phone calls, texts or emails. Our use of outbound contacts may be restricted by existing laws, or by laws, regulations, or regulatory decisions that may be adopted in the future. Similarly, certain data privacy laws, including CCPA, and subsequently CPRA, and the GDPR require disclosure of our privacy practices to consumers. If we are found to have violated these laws or regulations, we may be subjected to substantial fines, penalties, or liabilities to consumers. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax laws, regulations, and enforcement practices are evolving and may have a material adverse effect on our results of operations, cash flows and financial position.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tax laws, regulations, and administrative practices in various jurisdictions are evolving and may be subject to significant changes due to economic, political, and other conditions. Developments in relevant tax laws, regulations, and administrative and enforcement practices could have a material adverse effect on our operating results, our financial position and cash flows and could impact the tax treatment of our earnings. There are many transactions that occur during the ordinary course of business for which the ultimate tax determination is uncertain, and significant judgment is required in evaluating and estimating our provision and accruals for taxes. Governments are increasingly focused on ways to increase tax revenues, particularly from multinational corporations, which may lead to an increase in audit activity and aggressive positions taken by tax authorities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, due to shifting economic and political conditions, tax policies and rates in various jurisdictions may be subject to significant change. For example, in calendar year 2022, the United States passed the Inflation Reduction Act, which made a several changes to the Internal Revenue Code of 1986, as amended ("IRC"), including a 15% corporate minimum tax on adjusted financial statement income for companies whose average adjusted net income for any consecutive three-year period beginning after December 31, 2022 exceeds $1.0 billion. While we do not anticipate any materially adverse impacts to our effective tax rate, we cannot provide any assurances that these provisions will not have a materially adverse impact on our effective tax rate. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, beginning in 2023, the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) eliminated the option to deduct research and development expenditures currently and requires taxpayers to capitalize and amortize them over five years for U.S. incurred expenditures or fifteen years for non-U.S. incurred expenditures, pursuant to IRC Section 174. However, recently </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-41-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proposed tax legislation, if enacted, would restore the ability to deduct currently domestic research and development expenditures through 2026 and would retroactively restore this benefit for 2023 and 2024. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, several countries, including the United States and other members of the Organization for Economic Cooperation and Development (&#8220;OECD&#8221;) have reached agreement on a global minimum tax initiative (&#8220;Pillar Two&#8221;). Other OECD countries are also actively considering changes to existing tax laws or have proposed new laws to align with the recommendations and guidelines proposed by the OECD, including Pillar Two. Enactment of such tax laws could increase our tax obligations in countries where we do business or cause us to change the way we operate our business. Pillar Two will be in effect in some of the jurisdictions in which we operate beginning in 2025. We have assessed the impacts of these new laws in countries that we operate in and do not currently anticipate any material impacts to our effective tax rate in fiscal year 2025. However, we cannot provide any assurance that there will not be a material impact to our effective tax rate because of these developments and evolving tax legislation.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to tax audits by various tax authorities in many jurisdictions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our income tax returns are based on calculations and assumptions that require significant judgement and are subject to audit by various tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws. We regularly assess the potential outcomes of examinations and audits by tax authorities in determining the adequacy of our provision for income taxes. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 19, 2021, we concluded the settlement agreement with the Australian Taxation Office (&#8220;ATO&#8221;) in relation to the previously disclosed transfer pricing dispute for the tax years 2009 through 2018 (&#8220;ATO settlement&#8221;). The ATO settlement fully resolved the dispute for all prior years, with no admission of liability and provides clarity in relation to certain future taxation principles.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final net impact of the ATO settlement was recorded during the years ended June 30, 2021 and 2022 in the amount of $238.7&#160;million, which represents a gross amount of $381.7&#160;million, including interest and penalties of $48.1&#160;million, and adjustments for credits and deductions of $143.0&#160;million. As a result of the ATO settlement and due to movements in foreign currencies, we recorded a benefit of $14.1&#160;million within other comprehensive income, and a $4.1&#160;million reduction of tax credits which was recorded to income tax expense. As a result of the ATO settlement, we reversed our previously recorded uncertain tax position.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2021, we remitted final payment to the ATO of $284.8&#160;million, consisting of the agreed settlement amount of $381.7&#160;million less prior remittances made to the ATO of $96.9&#160;million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax years 2018 to 2023 remain subject to examination by the major tax jurisdictions in which we are subject to tax. In addition, the taxing authorities of the jurisdictions in which we operate may challenge our positions and methodologies related to transfer pricing, including valuing developed technology, intercompany arrangements and intellectual property transfers. If challenged by tax authorities, ResMed will vigorously defend our positions and methodologies. Although we believe our tax positions are appropriate, any final assessment resulting from tax audits may result in material changes to our past or future taxable income, tax payable or deferred tax assets, and may require us to pay penalties and interest that could materially adversely affect our financial results.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sustainability and corporate governance issues may have an adverse effect on our business, financial condition and results of operations and reputation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is an increasing focus from certain investors, regulators, legislators, customers, consumers, employees and other stakeholders concerning sustainability matters. Additionally, public interest and legislative pressure related to public companies&#8217; sustainability practices continue to grow. If our sustainability practices, including our external reporting thereof, fail to meet regulatory requirements or stakeholders' evolving expectations and standards for responsible corporate citizenship in areas including environmental stewardship, carbon emissions, renewable energy targets, support for local communities, Board of Director and employee diversity, human capital management, employee health and safety practices, product quality, supply chain management, corporate governance and transparency, our reputation, brand, and employee attraction and retention may be negatively impacted. Customers and/or suppliers may also adopt policies that include sustainability provisions or they may seek to include such provisions in their terms and conditions. These sustainability provisions and initiatives can be unpredictable and may be difficult for us to meet. If we are unable to comply, our customers and suppliers may be unwilling to continue business with us. In addition, failure to comply with new laws, regulations, or reporting requirements could negatively impact our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-42-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reputation and our business. Our adoption of certain standards or mandated compliance to certain requirements could necessitate additional investments that could impact our profitability.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Securities Markets and Ownership of Our Common Stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our quarterly operating results are subject to fluctuation for a variety of reasons. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results have, from time to time, fluctuated on a quarterly basis and may be subject to similar fluctuations in the future. These fluctuations may result from a number of factors, including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of new products by us or our competitors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the geographic mix of product sales; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success and costs of our marketing efforts in new regions; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in third-party payor reimbursement; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">timing of regulatory clearances and approvals; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with acquiring and integrating new businesses, technologies and product offerings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">timing of orders by distributors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inventory write downs, which may result from maintaining significant inventories of raw materials, components, and finished goods;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditures incurred for research and development; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive pricing in different regions; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of foreign currency transaction gains or losses; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other activities, including product recalls, by us and our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perceived demand for our products in light of the introduction of pharmaceuticals to treat obesity and potentially OSA; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic conditions, including rising interest rates, inflationary pressures, recessions, consumer sentiment and demand, global political conflict and industry factors unrelated to our actual performance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our quarterly operating results may cause the market price of our common stock to fluctuate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Delaware law and provisions in our charter could make it difficult for another company to acquire us. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of our certificate of incorporation may have the effect of delaying or preventing changes in control or management which might be beneficial to us or our security holders. Our board of directors has the authority to issue up to 2.0 million shares of preferred stock and to determine the price, rights, preferences, privileges and restrictions, including voting rights, of those shares without further vote or action by the stockholders. The rights of the holders of our common stock will be subject to, and may be adversely affected by, the rights of the holders of any preferred stock that may be issued in the future. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control, may discourage bids for our common stock at a premium over the market price of our common stock and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock.</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_22"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B UNRESOLVED STAFF COMMENTS </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_788"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1C CYBERSECURITY</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Management and Strategy</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to address cybersecurity risks through a cross-functional approach that is focused on preserving the confidentiality, integrity, and availability of the information that we collect and store by identifying, preventing, and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur. Our cybersecurity program is designed to protect information and information systems from unauthorized access, use, disclosure, disruption, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-43-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B &#8212; 4</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">modification, or destruction. Our management team has adopted policies, standards, processes, and practices and implemented controls and procedures that allow us to assess, identify and manage material risks from cybersecurity threats enabling our board of directors to actively oversee the strategic direction, objectives, and effectiveness of our cybersecurity risk management framework. Our processes are integrated into our overall enterprise risk management program, as implemented by management and as overseen by our board of directors. Our board of directors has an important role in risk oversight. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To identify and assess material risks from cybersecurity threats, we use a risk assessment process aligned with standard industry frameworks such as the National Institute of Standards and Technology (NIST), International Organization for Standardization (ISO) 27001 and other industry standards. We engage in regular network and endpoint monitoring, vulnerability assessments, and penetration testing, among other exercises. We continuously monitor threats and unauthorized access to our network through both internal and external third-party resources. We have developed incident response plans which include triage, assessing the severity of incidents, escalation protocols, containment of incidents, investigation of incidents, and remediation. We provide annual privacy and security training for all employees which incorporates awareness of cyber threats (including but not limited to malware, ransomware, and social engineering attacks), password hygiene and incident reporting processes. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also implemented processes to identify, monitor and address material risks from cybersecurity threats associated with our use of critical third-party service providers, including those in our supply chain or who have access to our systems, data or facilities that house such systems or data. Additionally, we require those third parties that could introduce significant cybersecurity risk to us to provide ISO certifications or Service Organization Controls (SOC) 2 reports as evidence of a cybersecurity audit and these reports are reviewed and assessed for risk. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review our cybersecurity risk framework and related policies both internally and externally by third parties at least annually. Our risk management program is also reviewed annually as part of SOC 2 and Health Information Trust Alliance (HITRUST) Common Security Framework audits. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not aware of any known risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. Despite our security measures, however, there can be no assurance that we, or the third parties with which we interact, will not experience a cybersecurity incident in the future that may materially affect us. For additional information, see Item 1A. &#8220;Risk Factors&#8221; for a discussion of cybersecurity risks that we face.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governance</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Role of the Board of Directors and the Audit Committee</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the board of directors&#8217; role in overseeing our enterprise risk management program, which includes our cybersecurity risk management framework, the board of directors is responsible for exercising oversight of management&#8217;s identification and management of, and planning for, material cybersecurity risks that may reasonably be expected to impact us. The board of directors is informed of our cybersecurity risk management and receives an overview of our cybersecurity program from the Chief Information Security Officer (CISO) at least annually. That overview covers, among other topics, cybersecurity risk landscape and trends, data security posture, results from third-party assessments, training and vulnerability testing, our incident response plan, material cybersecurity risks, whether developing or actual, as well as the steps management has taken to respond to such risks, emerging cybersecurity regulations, technologies and best practices. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Role of Management</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CISO, our Chief Financial Officer, our Global General Counsel, internal audit, and privacy teams are responsible for management&#8217;s oversight of cybersecurity governance, awareness, and security compliance. Our CISO meets regularly with this group to review the cybersecurity program designed to protect our information systems from cybersecurity threats and to respond to incidents in accordance with our incident response plan. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CISO manages a team that is responsible for day-to-day tracking, assessing and management of threats. Through ongoing communications, the CISO and key stakeholders are informed about and monitor the prevention, detection, mitigation and remediation of cybersecurity incidents and progress on cybersecurity infrastructure initiatives. In the event of a material cybersecurity incident or investigation, management will, in compliance with escalation protocols in place, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-44-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B &#8212; 4</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">promptly report to the board of directors, as appropriate, in accordance with our incident response plan and other policies, and determine the timing of action, and necessary response.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CISO has over 20 years of experience in various roles in information technology and information security, including serving as CISO at Mattel and Universal Music Group. He holds an MBA degree and holds several relevant certifications, including Certified Information Security Manager, Certified Information Systems Security Professional, Certified in Risk and Information System Control, and Certified Information Privacy Professional.</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_25"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2 PROPERTIES </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct our operations in both owned and leased properties. Our principal executive offices and U.S. sales facilities consist of approximately 230,000 square feet and are located on Spectrum Center Boulevard in San Diego, California, in a building we own. We have our primary research and development facilities, as well as office and manufacturing facilities at our owned site in Sydney, Australia. Other facilities are in Atlanta, Georgia, Moreno Valley, California, Chatsworth, California, and Calabasas, California, U.S.A.; Singapore; Munich, Germany; Lyon, France; Suzhou, China; Halifax, Canada; and Johor Bahru, Malaysia. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our facilities meet the needs of our current business operations. At June&#160;30, 2024, our principal owned and leased properties were as follows:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ownership Status<br/>(Owned / Leased)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Square<br/>Footage</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Primary Usage</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">San Diego, California</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate headquarters, engineering, research and development, sales and administration</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sydney, Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">437,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Manufacturing, engineering, research and development, sales and administration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Suzhou, China</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Manufacturing, warehouse, engineering, research and development</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Atlanta, Georgia</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Manufacturing, warehouse and distribution, SaaS sales and administration, engineering, research and development</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Manufacturing, engineering, research and development, sales and administration</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Moreno Valley, California</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warehouse and distribution</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Johor, Malaysia</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Manufacturing, engineering, research and development</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Calabasas, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Manufacturing, engineering, research and development</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chatsworth, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Manufacturing, engineering, research and development</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lyon, France</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales, manufacturing and distribution</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Munich, Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales and distribution</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We expect to transition operations from our Chatsworth, California location to our Calabasas, California location during fiscal year 2025.</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_28"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3 LEGAL PROCEEDINGS </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various legal proceedings, claims, investigations and litigation that arise in the ordinary course of our business. See Note 15 &#8211; Legal Actions, Contingencies and Commitments of the Notes to Consolidated Financial Statements (Part II, Item 8) included in this report, which is incorporated by reference herein.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation is inherently uncertain. Accordingly, we cannot predict with certainty the outcome of these matters. But we do not expect the outcome of these matters to have a material adverse effect on our consolidated financial statements when taken as a whole.</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_31"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4 MINE SAFETY DISCLOSURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-45-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_34"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_37"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5 MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the NYSE under the symbol &#8220;RMD&#8221;. As of July 31, 2024, there were 28 holders of record of our common stock, although the actual number of stockholders of our common stock is greater than this number of holders of record and many of these holders of record own shares as nominees on behalf of other beneficial owners.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information included under Item 12 of Part III of this Report, &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters,&#8221; is hereby incorporated by reference into this Item 5 of Part II of this Report.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our purchases of common stock during the three months ended June&#160;30, 2024:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid per Share (USD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Number of Shares that May Yet Be Purchased Under the Program</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1 - 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,432,422&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,283,591&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 1 - 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,664,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,051,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 1 - 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,664,067&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,051,946&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.85&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,664,067&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,051,946&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant and subject to applicable legal requirements. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. All share repurchases after February 21, 2014 have been executed under this program. Since approval of the share repurchase program in 2014 through June&#160;30, 2024, we have repurchased, during open window periods following earnings releases, a total of 7.9&#160;million shares for an aggregate of $562.7 million as of June&#160;30, 2024. As of June&#160;30, 2024, 12.1 million additional shares can be repurchased under the approved share repurchase program. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have historically paid dividends to holders of our common stock on a quarterly basis, the declaration and payment of future dividends will depend on many factors, including, but not limited to, our earnings, financial condition, business development needs and regulatory considerations, and are at the discretion of our board of directors pursuant to authority delegated to our audit committee.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PERFORMANCE GRAPH</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This performance graph is furnished and shall not be deemed &#8220;filed&#8221; with the SEC or subject to Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any of our filings under the Securities Act of 1933, as amended. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-46-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the cumulative total stockholders return on our common stock from June 30, 2019 through June&#160;30, 2024, with the comparable cumulative return of the S&amp;P 500 index, the S&amp;P 500 Health Care index, and the Dow Jones U.S. Select Medical Equipment index. The graph assumes that $100 was invested in our common stock and each index on June 30, 2019. In addition, the graph assumes the reinvestment of all dividends paid. The stock price performance on the following graph is not necessarily indicative of future stock price performance. </span></div><div style="margin-top:10pt;text-align:center"><img src="rmd-20240630_g1.jpg" alt="3156" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total indexed return of stock price plus reinvestments of dividends, assuming an initial investment of $100 at June 30, 2019, for the indicated periods.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.964%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Index</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ResMed Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P 500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P 500 Health Care</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dow Jones U.S. Select Medical Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140</span></td></tr></table></div><div id="i7fe754a0eb594e619b22be4f3387c577_40"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6 SELECTED FINANCIAL DATA </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain selected consolidated financial data for, and as of the end of, each of the fiscal years in the five-year period ended June&#160;30, 2024. The data set forth below should be read together with Item 7 of Part II of this report, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and Item 8 of Part II of this report, &#8220;Consolidated Financial Statements and Supplementary Data&#8221;, and related notes included elsewhere in this report. The consolidated statement of income data for the years ended June&#160;30, 2024, 2023 and 2022 and the consolidated balance sheet data as of June&#160;30, 2024 and 2023 are derived from our audited consolidated financial statements included elsewhere in this report. The consolidated statement of income data for the years ended June&#160;30, 2021 and 2020 and the consolidated balance sheet data as of June&#160;30, 2022, 2021 and 2020 are derived from our audited consolidated financial </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-47-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements not included in this report. Historical results do not necessarily indicate the results to be expected in the future, and the results for the years presented should not be considered to indicate our future results of operations.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.964%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Statement of Income Data </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except per share data):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,685,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,222,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,578,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,196,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,957,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales (exclusive of amortization shown separately below)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,997,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,836,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,514,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,312,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,189,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,029,994&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,867,331&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,553,816&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,357,725&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,239,227&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,655,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,355,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,024,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,839,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,717,786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">917,136&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">874,003&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">737,508&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">670,387&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">676,689&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,335,410&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,223,791&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,024,025&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935,422&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908,127&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,319,893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,131,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">903,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">809,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47,379)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39,356)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,848)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25,058)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on insurance recoveries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,539)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (loss), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55,095)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30,207)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39,803)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,016)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(76,571)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,264,798&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101,664&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">960,483&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">883,662&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">733,088&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020,951&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897,556&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">779,437&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474,505&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.94&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.34&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.27&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.31&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted shares outstanding </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.964%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheet Data (In thousands):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Working capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,447,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,609,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,242,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">662,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">920,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,872,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,751,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,095,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,728,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,587,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, less current maturities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">697,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,431,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">765,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">643,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,164,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,864,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,129,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,360,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,885,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,497,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-48-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_43"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7 MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_46"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of financial condition and results of operations (&#8220;MD&amp;A&#8221;) is intended to help the reader understand our results of operations and financial condition. It is provided as a supplement to, and should be read in conjunction with, the selected financial data and consolidated financial statements and notes included in this report.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global leader in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (&#8220;SDB&#8221;), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. SDB includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Our products and solutions are designed to improve patient quality of life, reduce the impact of chronic disease and lower healthcare costs as global healthcare systems continue to drive a shift in care from hospitals to the home and lower cost settings. Our cloud-based digital software health applications, along with our devices, are designed to provide connected care to improve patient outcomes and efficiencies for our customers.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the development of continuous positive airway pressure therapy, we have expanded our business by developing or acquiring a number of products and solutions for a broader range of respiratory disorders including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes and customer and provider business processes. Our growth has been fueled by geographic expansion, our research and product development efforts, acquisitions and an increasing awareness of SDB and respiratory conditions like chronic obstructive pulmonary disease as significant health concerns. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2024, we announced a new operating model to accelerate long-term growth. The new operating model introduces dedicated leadership in Product, Revenue, and Marketing to the global executive team. This change aims to increase the velocity of product development and sharpen our customer and brand focus. Ultimately, the goal is to accelerate profitable growth, while driving greater value and improved care throughout the outside hospital care continuum and the patient journey.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to ongoing investment in research and development and product enhancements. During fiscal year 2024, we invested $307.5 million on research and development activities, which represents 6.6% of net revenues with a continued focus on the development and commercialization of new, innovative products and solutions that improve patient outcomes, create efficiencies for our customers and help physicians and providers better manage chronic disease and lower healthcare costs. During fiscal year 2024, we continued the launch of AirSense 11, which introduces new features such as a touch screen, algorithms for patients new to therapy, digital enhancements and over-the-air update capabilities. Through our acquisitions of Brightree in 2016, HEALTHCAREfirst and MatrixCare in 2018, and MEDIFOX DAN in November 2022, our operations include out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. These platforms comprise our SaaS business and along with our cloud-based remote monitoring and therapy management system, and a robust product pipeline, should continue to provide us with a strong platform for future growth. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (&#8220;Sleep and Respiratory Care&#8221;) and the supply of business management software as a service to out-of-hospital health providers (&#8220;SaaS&#8221;).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue in fiscal year 2024 increased to $4,685.3 million, an increase of 11% compared to fiscal year 2023. Gross profit increased for the year ended June&#160;30, 2024 to $2,655.3 million, from $2,355.7 million for the year ended June&#160;30, 2023, an increase of $299.6 million or 13%. Our net income for the year ended June&#160;30, 2024 was $1,021.0 million or $6.92 per diluted share compared to net income of $897.6 million or $6.09 per diluted share for the year ended June&#160;30, 2023. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating cash flow for fiscal year 2024 was $1,401.3 million and at June&#160;30, 2024, our cash and cash equivalents totaled $238.4 million. At June&#160;30, 2024, our total assets were $6.9 billion and our stockholders&#8217; equity was $4.9 billion. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-49-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid a quarterly dividend of $0.48 per share during fiscal 2024 with a total amount of $282.3 million paid to stockholders.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to provide a framework for assessing how our underlying businesses performed, excluding the effect of foreign currency fluctuations, we provide certain financial information on a &#8220;constant currency basis&#8221;, which is in addition to the actual financial information presented. To calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For discussion related to the results of operations and changes in financial condition for the fiscal year ended June&#160;30, 2023 compared to fiscal year June&#160;30, 2022, please refer to Item 7 of Part II, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the Year Ended June&#160;30, 2023, which was filed with the United States Securities and Exchange Commission on August 11, 2023.</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_49"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year Ended June&#160;30, 2024 Compared to Fiscal Year Ended June&#160;30, 2023</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Revenues </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue for the year ended June&#160;30, 2024 increased to $4,685.3 million from $4,223.0 million for the year ended June&#160;30, 2023, an increase of $462.3 million or 11% (an 11% increase on a constant currency basis). The following table summarizes our net revenue disaggregated by segment, product and region for the year ended June&#160;30, 2024 compared to the year ended June&#160;30, 2023 (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Constant<br/>Currency*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S., Canada and Latin America</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,522,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,444,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,199,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,039,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total U.S., Canada and Latin America</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,722,556&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,483,387&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Combined Europe, Asia and other markets </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">921,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Combined Europe, Asia and other markets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,378,616&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,241,630&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,444,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,270,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,657,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,454,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,101,172&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,725,017&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">584,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">497,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,685,297&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,222,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">Constant currency numbers exclude the impact of movements in international currencies.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sleep and Respiratory Care</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from our Sleep and Respiratory Care business for the year ended June&#160;30, 2024 increased to $4,101.2 million from $3,725.0 million for the year ended June&#160;30, 2023, an increase of $376.2 million or 10%. Movements in international currencies against the U.S. dollar positively impacted net revenues by approximately $15.2 million for the year ended June&#160;30, 2024. Excluding the impact of currency movements, total net revenue from our Sleep and Respiratory Care business for the year ended June&#160;30, 2024 increased by 10% compared to the year ended June&#160;30, 2023. The increase in net revenue associated with our devices and masks was primarily attributable to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased demand and unit sales.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-50-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from our Sleep and Respiratory Care business in the United States, Canada and Latin America for the year ended June&#160;30, 2024 increased to $2,722.6 million from $2,483.4 million for the year ended June&#160;30, 2023, an increase of $239.2 million or 10%. The increase in net revenue associated with our devices and masks was primarily attributable to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased demand and unit sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from our Sleep and Respiratory Care business in combined Europe, Asia and other markets increased for the year ended June&#160;30, 2024 to $1,378.6 million from $1,241.6 million for the year ended June&#160;30, 2023, an increase of $137.0 million or 11% (a 10% increase on a constant currency basis). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The constant currency increase in device and mask sales in combined Europe, Asia and other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was primarily attributable to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased demand and unit sales.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from devices for the year ended June&#160;30, 2024 increased to $2,444.0 million from $2,270.7 million for the year ended June&#160;30, 2023, an increase of $173.3 million or 8%, including an increase of 5% in the United States, Canada and Latin America and an increase of 11% in combined Europe, Asia and other markets (a 10% increase on a constant currency basis). Excluding the impact of foreign currency movements, device sales for the year ended June&#160;30, 2024 increased by 7%.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from masks and other for the year ended June&#160;30, 2024 increased to $1,657.2 million from $1,454.3 million for the year ended June&#160;30, 2023, an increase of 14%, including an increase of 15% in the United States, Canada and Latin America and an increase of 10% in combined Europe, Asia and other markets (a 8% increase on a constant currency basis). Excluding the impact of foreign currency movements, masks and other sales increased by 13%, compared to the year ended June&#160;30, 2023.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Software as a Service</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from our SaaS business for the year ended June&#160;30, 2024 was $584.1 million, compared to $498.0 million for the year ended June&#160;30, 2023, an increase of $86.1 million or 17%. The increase was predominantly due to our acquisition of MEDIFOX DAN, which was acquired on November 21, 2022. Excluding the MEDIFOX DAN acquisition, SaaS revenue increased 9% and was driven by continued growth in the HME vertical within our SaaS business.</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_52"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Profit and Gross Margin. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit increased for the year ended June&#160;30, 2024 to $2,655.3 million from $2,355.7 million for the year ended June&#160;30, 2023, an increase of $299.6 million or 13%. Gross margin, which is gross profit as a percentage of net revenue, was 56.7% for the year ended June&#160;30, 2024, compared with the 55.8% for the year ended June&#160;30, 2023. The increase in gross margin was due primarily to reduced freight and manufacturing cost improvements, a favorable impact from our SaaS business, an increase in average selling prices and a favorable product mix, which were partially offset by $14.3 million of combined expenses associated with the field safety notifications for masks with magnets and Astral devices, and an increase in the amortization of acquired intangible assets. The masks with magnets field safety notification expenses relate to estimated </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs to provide alternative masks to patients in response to updated contraindications for use of masks that incorporate magnets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Astral field safety notification expenses relate to estimated costs associated with the replacement of a certain component in some of our Astral ventilation devices that were manufactured between 2013 to 2019. </span></div><div id="i7fe754a0eb594e619b22be4f3387c577_55"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating expenses (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Constant Currency</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">917,136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">874,003&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">as a % of net revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">287,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">as a % of net revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Selling, General and Administrative Expenses </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased for the year ended June&#160;30, 2024 to $917.1 million from $874.0 million for the year ended June&#160;30, 2023, an increase of $43.1 million or 5%. Selling, general and administrative expenses, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-51-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as reported in U.S. dollars, were unfavorably impacted by the movement of international currencies against the U.S. dollar, which increased our expenses by approximately $1.8 million. Excluding the impact of foreign currency movements, selling, general and administrative expenses for the year ended June&#160;30, 2024 increased by 5% compared to the year ended June&#160;30, 2023. As a percentage of net revenue, selling, general and administrative expenses for the year ended June&#160;30, 2024 improved to 19.6% compared to 20.7% for the year ended June&#160;30, 2023. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The constant currency increase in selling, general and administrative expenses for the year ended June&#160;30, 2024 compared to the year ended June&#160;30, 2023 was primarily due to increases in employee-related costs and additional expenses associated with the consolidation of recent acquisitions.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development Expenses </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased for the year ended June&#160;30, 2024 to $307.5 million from $287.6 million for the year ended June&#160;30, 2023, an increase of $19.9 million or 7%. Research and development expenses were favorably impacted by the movement of international currencies against the U.S. dollar, which decreased our expenses by approximately $1.9 million, as reported in U.S. dollars. Excluding the impact of foreign currency movements, research and development expenses for the year ended June&#160;30, 2024 increased by 8% compared to the year ended June&#160;30, 2023. As a percentage of net revenue, research and development expenses were 6.6% for the year ended June&#160;30, 2024 compared to 6.8% for the year ended June&#160;30, 2023. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The constant currency increase in research and development expenses was primarily due to increased investment in our digital health technologies and SaaS solutions as well as additional expenses associated with the consolidation of recent acquisitions.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amortization of Acquired Intangible Assets </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets for the year ended June&#160;30, 2024 was $46.5 million compared to $42.0 million for the year ended the year ended June&#160;30, 2023. The increase in amortization expense was primarily attributable to our acquisition of MEDIFOX DAN.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Restructuring Expenses </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended June&#160;30, 2024, we incurred restructuring expenses of $64.2 million associated with an evaluation of our existing operations to increase operational efficiency, decrease costs and increase profitability. Restructuring charges for the year ended June&#160;30, 2024 were comprised of $28.6 million of employee severance and other one-time termination benefits, $33.2 million of intangible asset impairments associated with the wind down of certain business activities, and $2.4 million of other miscellaneous asset impairments. </span></div><div id="i7fe754a0eb594e619b22be4f3387c577_58"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Other Income (Loss), Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our other income (loss) (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45,708)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47,379)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,848)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Loss) gain on equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,045)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,967)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on insurance recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,494)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,712)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (loss), net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55,095)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30,207)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,888)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (loss), net for the year ended June&#160;30, 2024 was a loss of $55.1 million, compared to a loss of $30.2 million for the year ended June&#160;30, 2023. During the year ended June&#160;30, 2023, we recognized recoveries from business interruption insurance for $20.2 million. Losses associated with our investments in marketable and non-marketable equity securities were $4.0 million for the year ended June&#160;30, 2024 compared to a gain of $9.9 million or the year ended June&#160;30, 2023. Losses associated with our investments in marketable and non-marketable equity securities were partially offset by lower losses attributable to equity method investments for the year ended June&#160;30, 2024 of $1.8 million compared to $7.3 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-52-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million for the year ended June&#160;30, 2023. In addition, interest expense, net, decreased to $45.7 million for the year ended June&#160;30, 2024 compared to $47.4 million for the year ended June&#160;30, 2023 due to lower debt levels following the repayment of our revolving credit facility. </span></div><div id="i7fe754a0eb594e619b22be4f3387c577_61"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate increased to 19.3% for the year ended June&#160;30, 2024 from 18.5% for the year ended June&#160;30, 2023. Our effective rate of 19.3% for the year ended June&#160;30, 2024 differs from the statutory rate of 21.0% primarily due to research credits and foreign operations. The increase in our effective tax rate for the year ended June&#160;30, 2024 was primarily due to a shift in our geographic mix of earnings and lower tax deductions in the current year associated with the vesting or settlement of employee share-based awards. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Singapore operations operate under certain tax holidays and tax incentive programs that will expire in whole or in part at various dates through June 30, 2030. As a result of the U.S. Tax Cuts and Jobs Act of 2017 ("TCJA"), we treated all non-U.S. historical earnings as taxable during the year ended June 30, 2018. Therefore, future repatriation of cash held by our non-U.S. subsidiaries will generally not be subject to U.S. federal tax, if repatriated, except as discussed in Note 12 &#8211; Income Taxes of the Notes to the Consolidated Financial Statements (Part II, Item 8).</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_64"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Income and Earnings per Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the factors discussed above, our net income for the year ended June&#160;30, 2024 was $1,021.0 million compared to net income of $897.6 million for the year ended June&#160;30, 2023. Our earnings per diluted share for the year ended June&#160;30, 2024 was $6.92 compared to $6.09 for the year ended June&#160;30, 2023, an increase of 14%. </span></div><div id="i7fe754a0eb594e619b22be4f3387c577_67"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Non-GAAP Financial Measures</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to financial information prepared in accordance with GAAP, our management uses certain non-GAAP financial measures, such as non-GAAP cost of sales, non-GAAP gross profit, non-GAAP gross margin, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted earnings per share, in evaluating the performance of our business. We believe that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, can provide investors better insight when evaluating our performance from core operations and can provide more consistent financial reporting across periods. For these reasons, we use non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. These non-GAAP financial measures should be considered in addition to, and not superior to or as a substitute for, GAAP financial measures. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. Non-GAAP financial measures as presented herein may not be comparable to similarly titled measures used by other companies. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measure &#8220;non-GAAP cost of sales&#8221; is equal to GAAP cost of sales less amortization of acquired intangible assets relating to cost of sales and field safety notification expenses. The masks with magnets field safety notification expenses relate to estimated </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs to provide alternative masks to patients in response to updated contraindications for use of masks that incorporate magnets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Astral field safety notification expenses relate to estimated costs associated with the replacement of a certain component in some of our Astral ventilation devices that were manufactured between 2013 to 2019. The measure &#8220;non-GAAP gross profit&#8221; is the difference between GAAP net revenue and non-GAAP cost of sales, and &#8220;non-GAAP gross margin&#8221; is the ratio of non-GAAP gross profit to GAAP net revenue. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-53-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These non-GAAP measures are reconciled to their most directly comparable GAAP financial measures below (in thousands, except percentages):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP Net revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,685,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,222,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP Cost of sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,029,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,867,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Less:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Amortization of acquired intangibles</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,963)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30,396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Less</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">: Masks with magnets field safety notification expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,351)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Less</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">: Astral field safety notification expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,982,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,836,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP gross profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,655,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,355,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP gross margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP gross profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,702,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,386,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP gross margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measure &#8220;non-GAAP income from operations&#8221; is equal to GAAP income from operations once adjusted for amortization of acquired intangibles, restructuring expenses, field safety notification expenses, and acquisition-related expenses. Non-GAAP income from operations is reconciled with GAAP income from operations below (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP income from operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,319,893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,131,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangibles - cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangibles - operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks with magnets field safety notification expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Astral field safety notification expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP income from operations </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,478,350&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,224,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-54-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measure &#8220;non-GAAP net income&#8221; is equal to GAAP net income once adjusted for amortization of acquired intangibles, restructuring expenses, field safety notification expenses, acquisition related expenses, gain on insurance recoveries, and associated tax effects. The measure &#8220;non-GAAP diluted earnings per share&#8221; is the ratio of non-GAAP net income to diluted shares outstanding. These non-GAAP measures are reconciled to their most directly comparable GAAP financial measures below (in thousands, except for per share amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangibles - cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangibles - operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks with magnets field safety notification expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Astral field safety notification expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on insurance recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect on non-GAAP adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40,114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,139,294&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">949,757&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,550&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,455&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP diluted earnings per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.92&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.09&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP diluted earnings per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div id="i7fe754a0eb594e619b22be4f3387c577_70"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal sources of liquidity are our existing cash and cash equivalents, cash generated from operations and access to our revolving credit facility. Our primary uses of cash have been for research and development activities, selling and marketing activities, capital expenditures, strategic acquisitions and investments, dividend payments and repayment of debt obligations. We expect that cash provided by operating activities may fluctuate in future periods as a result of several factors, including fluctuations in our operating results, which include supply chain disruptions, working capital requirements and capital deployment decisions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors including our growth rate in net revenue, third-party reimbursement of our products for our customers, the timing and extent of spending to support research development efforts, the expansion of selling, general and administrative activities, the timing of introductions of new products, the expenditures associated with possible future acquisitions, investments or other business combination transactions. As we assess inorganic growth strategies, we may need to supplement our internally generated cash flow with outside sources. If we are required to access the debt market, we believe that we will be able to secure reasonable borrowing rates. As part of our liquidity strategy, we will continue to monitor our current level of earnings and cash flow generation as well as our ability to access the market considering those earning levels. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024 and June&#160;30, 2023, we had cash and cash equivalents of $238.4 million and $227.9 million, respectively. Our cash and cash equivalents held within the United States at June&#160;30, 2024 and June&#160;30, 2023 were $51.2 million and $49.3 million, respectively. Our remaining cash and cash equivalent balances at June&#160;30, 2024 and June&#160;30, 2023, were $187.2 million and $178.6 million, respectively. Our cash and cash equivalent balances are held at highly rated financial institutions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, we had $1,470.0 million available for draw down under the revolving credit facility and a combined total of $1,708.4 million in cash and available liquidity under the revolving credit facility. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We repatriated $800.0 million and $445.0 million to the United States during the years ended June&#160;30, 2024 and 2023, respectively, from earnings generated in each of those years. The amount of the current year foreign earnings that we have repatriated to the United States in the past has been determined, and the amount that we expect to repatriate during fiscal year 2025 will be determined, based on a variety of factors, including current year earnings of our foreign subsidiaries, foreign investment needs and the cash flow needs we have in the United States, such as for the repayment of debt, dividend distributions, and other domestic obligations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-55-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the TCJA, we treated all non-U.S. historical earnings as taxable, which resulted in additional tax expense of $92.4 million which was payable over the proceeding eight years. Therefore, future repatriation of cash held by our non-U.S. subsidiaries will generally not be subject to U.S. federal tax if repatriated, except as discussed in Note 12 &#8211; Income Taxes of the Notes to the Consolidated Financial Statements (Part II, Item 8).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our current sources of liquidity will be sufficient to fund our operations, including expected capital expenditures, for the next 12 months and beyond.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revolving Credit Agreement, Term Credit Agreement and Senior Notes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;29, 2022, we entered into a second amended and restated credit agreement (as amended from time to time, the &#8220;Revolving Credit Agreement&#8221;). The Revolving Credit Agreement, among other things, provided a senior unsecured revolving credit facility of $1,500.0 million, with an uncommitted option to increase the revolving credit facility by an additional amount equal to the greater of $1,000.0 million or 1.0 times the EBITDA for the trailing twelve-month measurement period. Additionally, on June&#160;29, 2022, ResMed Pty Limited entered into a Second Amendment to the Syndicated Facility Agreement (the &#8220;Term Credit Agreement&#8221;). The Term Credit Agreement, among other things, provides ResMed Limited a senior unsecured term credit facility of $200.0 million. The Revolving Credit Agreement and Term Credit Agreement each terminate on Jun&#160;29, 2027, when all unpaid principal and interest under the loans must be repaid. As of June&#160;30, 2024, we had $1,470.0 million available for draw down under the revolving credit facility.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;10, 2019, we entered into a Note Purchase Agreement with the purchasers to that agreement, in connection with the issuance and sale of $250.0 million principal amount of our 3.24% senior notes due July&#160;10, 2026, and $250.0 million principal amount of our 3.45% senior notes due July&#160;10, 2029 (&#8220;Senior Notes&#8221;). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;30, 2024, there was a total of $710.0 million outstanding under the Revolving Credit Agreement, Term Credit Agreement and Senior Notes. We expect to satisfy all of our liquidity and long-term debt requirements through a combination of cash on hand, cash generated from operations and debt facilities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Flow Summary</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activity (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,401,260&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">693,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(269,784)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,159,845)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,119,287)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">422,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,719)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,147)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45,819)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities was $1,401.3 million for the year ended June&#160;30, 2024, compared to cash provided of $693.3 million for the year ended June&#160;30, 2023. The $708.0 million increase in cash flow from operations was primarily due to lower cash outflows on inventory purchases during the year ended June&#160;30, 2024 compared to the year ended June&#160;30, 2023 and an increase in operating profit for the year ended June&#160;30, 2024. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities was $269.8 million for the year ended June&#160;30, 2024, compared to cash used of $1,159.8 million for the year ended June&#160;30, 2023. The $890.1 million decrease in cash flow used in investing activities was primarily due to the cash used to acquire MEDIFOX DAN during the year ended June&#160;30, 2023, partially offset by the cash used to acquire Somnoware during the year ended June&#160;30, 2024.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-56-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities was $1,119.3 million for the year ended June&#160;30, 2024, compared to cash provided of $422.9 million for the year ended June&#160;30, 2023. The $1,542.2 million increase in cash flow used in financing activities was primarily due to borrowing activity under our Revolving Credit Agreement in order to finance our acquisition of MEDIFOX DAN during the year ended June&#160;30, 2023 and subsequent repayments during the year ended June&#160;30, 2024. In addition, we repurchased $150.0 million of treasury stock during the year ended June&#160;30, 2024. We did not purchase any shares under our share repurchase program during the year ended June&#160;30, 2023. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended June&#160;30, 2024, we paid cash dividends of $1.92 per common share totaling $282.3 million. On August&#160;1, 2024, our board of directors declared a cash dividend of $0.53 per common share, to be paid on September&#160;19, 2024, to shareholders of record as of the close of business on August&#160;15, 2024. Future dividends are subject to approval by our board of directors.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of contractual obligations at June&#160;30, 2024 are as follows (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2029</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">712,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,023,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">845,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,015,331&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">919,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176,219&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505,009&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,228&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,562&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of other commercial commitments at June&#160;30, 2024 are as follows (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Commitment Expiration Per Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2029</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Standby letter of credit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,619&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Guarantees*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,633&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,652&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">These guarantees mainly relate to requirements under contractual obligations with insurance companies transacting with our German subsidiaries and guarantees provided under our facility leasing obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 15 &#8211; Legal Actions, Contingencies and Commitments of the Notes to the Consolidated Financial Statements (Part II, Item 8) for details of our contingent obligations under recourse provisions.</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_73"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that we have two operating segments, which are the Sleep and Respiratory Care segment and the SaaS segment. See Note 13 &#8211; Segment Information of the Notes to the Consolidated Financial Statements (Part II, Item 8) for financial information regarding segment reporting. Financial information about our revenues from and assets located in foreign countries is also included in the notes to the consolidated financial statements included in this report.</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_76"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Principles and Estimates </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, including those related to allowance for doubtful accounts, inventory reserves, warranty obligations, goodwill, potentially impaired assets, intangible assets, income taxes and contingencies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-57-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state these accounting policies in the notes to the financial statements and at relevant sections in this discussion and analysis. The estimates are based on the information that is currently available to us and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could vary from those estimates under different assumptions or conditions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the following critical accounting policies affect the more significant judgments and estimates used in the preparation of our consolidated financial statements: </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Valuation of Goodwill. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make assumptions in establishing the carrying value and fair value of our goodwill. Our goodwill impairment tests are performed at our reporting unit level, which is one level below our operating segments. The criteria used for these evaluations include management&#8217;s estimate of the asset&#8217;s continuing ability to generate positive income from operations and positive cash flow in future periods compared to the carrying value of the asset, as well as the strategic significance of the assets in our business objectives. If goodwill is considered to be impaired, we recognize as an impairment the amount by which the carrying value of the goodwill exceeds its fair value, limited to the value of goodwill allocated to the impaired reporting unit, as described in Step 1 below. Factors that would influence the likelihood of a material change in our reported results include significant changes in the asset&#8217;s ability to generate positive cash flow, a significant decline in the economic and competitive environment on which the asset depends, significant changes in our strategic business objectives, utilization of the asset, and a significant change in the economic and/or political conditions in certain countries. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct an annual review for goodwill impairment at our reporting unit level based on the following steps: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Step 0 or Qualitative assessment &#8211; Evaluate qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. The factors we consider include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, overall financial performance or events-specific to that reporting unit. If or when we determine it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill, we would move to Step 1 of the quantitative method.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Step 1 &#8211; Compare the fair value for each reporting unit to its carrying value, including goodwill. Fair value is determined based on estimated discounted cash flows. A goodwill impairment charge is recognized for the amount that the carrying amount of a reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit. If a reporting unit&#8217;s fair value exceeds the carrying value, no further work is performed and no impairment charge is necessary.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the annual reviews for the years ended June&#160;30, 2024, 2023 and 2022, we completed a Step 0 or Qualitative assessment and determined it was more likely than not that the fair value of our reporting units exceeded their carrying amounts, including goodwill, and therefore goodwill was not impaired.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Income Tax. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax returns are based on calculations and assumptions subject to audit by various tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws. We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While we believe we have appropriate support for the positions taken on our tax returns, we regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. Based on our regular assessment, we may adjust the income tax provision and deferred taxes in the period in which the facts that give rise to a revision become known.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 19, 2021, we concluded the settlement agreement with the Australian Taxation Office (&#8220;ATO&#8221;) in relation to the previously disclosed transfer pricing dispute for the tax years 2009 through 2018 (&#8220;ATO settlement&#8221;). The ATO settlement fully resolved the dispute for all prior years, with no admission of liability and provides clarity in relation to certain future taxation principles.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-58-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final net impact of the ATO settlement was recorded during the years ended June 30, 2021 and 2022 in the amount of $238.7&#160;million, which represents a gross amount of $381.7&#160;million, including interest and penalties of $48.1&#160;million, and adjustments for credits and deductions of $143.0&#160;million. As a result of the ATO settlement and due to movements in foreign currencies, we recorded a benefit of $14.1&#160;million within other comprehensive income, and a $4.1&#160;million reduction of tax credits, which was recorded to income tax expense. As a result of the ATO settlement, we reversed our previously recorded uncertain tax position.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2021, we remitted final payment to the ATO of $284.8&#160;million, consisting of the agreed settlement amount of $381.7&#160;million less prior remittances made to the ATO of $96.9&#160;million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax years 2018 to 2023 remain subject to examination by the major tax jurisdictions in which we are subject to tax.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Revenue Recognition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (&#8220;Sleep and Respiratory Care&#8221;) and the supply of business management software as a service to out-of-hospital health providers (&#8220;SaaS&#8221;). For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with cloud-hosted services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of one to five years. Our contracts do not contain significant financing components.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g. rebates, discounts, free goods) and returns by our customers and their customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of our historical experience. Returns of products, excluding warranty-related returns, have historically been infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer&#8217;s expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates each quarter based on actual sales results and updated forecasts for the remaining rebate periods. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in programs where we issue credits to our Sleep and Respiratory Care distributors when they are required to sell our products below negotiated list prices if we have preexisting contracts with the distributors' customers. We reduce revenue for future credits at the time of sale to the distributor, which we estimate based on historical experience using the expected value method. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When Sleep and Respiratory Care or SaaS contracts have multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each performance obligation. An allocation is not required for many of our Sleep and Respiratory Care contracts that have a single performance obligation, which is the shipment of our therapy-based equipment.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-59-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Business Combinations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations, we allocate the purchase price to the estimated fair values of the assets acquired and liabilities assumed. This allocation process involves the use of estimates and assumptions made in connection with determining the fair value of assets acquired and liabilities assumed including cash flows expected to be derived from the use of the asset, the timing of such cash flows, the remaining useful life of assets and applicable discount rates. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If actual results vary from the estimates or assumptions used in the valuation or allocation process, we may be required to record an impairment charge or an increase in depreciation or amortization in future periods, or both. Refer to Note 17 &#8211; Business Combinations of the Notes to the Consolidated Financial Statements (Part II, Item 8) for additional information about accounting for the MEDIFOX DAN acquisition.</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_82"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, we are not involved in any significant off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated by the SEC.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-60-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_85"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Quantitative and Qualitative Disclosures About Market and Business Risks</span></td></tr></table></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET AND BUSINESS RISKS</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Market Risk</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reporting currency is the U.S. dollar, although the financial statements of our non-U.S. subsidiaries are maintained in their respective local currencies. We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through our Australian and Singapore manufacturing activities and our international sales operations. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Investment and Fair Value Hedging</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2022, we executed foreign cross-currency swaps as net investment hedges and fair value hedges in designated hedging relationships with either the foreign denominated net asset balances or the foreign denominated intercompany loan as the hedged items. All derivatives are recorded at fair value as either an asset or liability. Cash flows associated with derivative instruments are presented in the same category on the consolidated statements of cash flows as the hedged item.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the cross-currency swaps for the fair value hedge is to mitigate foreign currency risk associated with changes in spot rates on foreign denominated intercompany debt between USD and EUR. For these hedges, we excluded certain components from the assessment of hedge effectiveness that are not related to spot rates. For fair value hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in the same line item as the hedged item, Other, net, in the condensed consolidated statement of income. The initial fair value of hedge components excluded from the assessment of effectiveness is recognized in the statement of income under a systematic and rational method over the life of the hedging instrument and is presented in interest (expense) income, net. Any difference between the change in the fair value of the hedge components excluded from the assessment of effectiveness and the amounts recognized in earnings is recorded as a component of other comprehensive income. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the cross-currency swaps for the net investment hedge is to mitigate foreign currency risk associated with changes in spot rates on the net asset balances of our foreign functional subsidiaries. For net investment hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in cumulative translation adjustment within other comprehensive loss and reclassified into earnings when the hedged net investment is either sold or substantially liquidated. The initial fair value of components excluded from the assessment of hedge effectiveness will be recognized in interest (expense) income, net. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of outstanding foreign cross-currency swaps was $1,026.2 million at June&#160;30, 2024. These contracts mature at various dates prior to December 31, 2029.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Designated Hedges</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have foreign currency exposure through both our Australian and Singapore manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased foreign currency call options, collars and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed three years. The purpose of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, and Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not designate these foreign currency contracts as hedges. All movements in the fair value of the foreign currency instruments are recorded within other, net in our condensed consolidated statements of income. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of the outstanding non-designated hedges was $1,340.0 million and $954.7 million at June&#160;30, 2024 and June&#160;30, 2023, respectively. These contracts mature at various dates prior to September&#160;15, 2025.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-61-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Quantitative and Qualitative Disclosures About Market and Business Risks</span></td></tr></table></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Values of Derivative Instruments </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information (in U.S. dollars) on our significant foreign-currency-denominated financial assets by legal entity functional currency as of June&#160;30, 2024 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.<br/>Dollar<br/>(USD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Euro<br/>(EUR)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Canadian<br/>Dollar<br/>(CAD)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chinese<br/>Yuan<br/>(CNY)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AUD Functional:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Assets/(Liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">516,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(198,361)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency Hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(495,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,532&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27,072)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,085&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">USD Functional:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Assets/(Liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303,896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency Hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(299,756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SGD Functional:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Assets/(Liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency Hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(360,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(128,467)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,902&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,102)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-62-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Quantitative and Qualitative Disclosures About Market and Business Risks</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information about our material foreign currency derivative financial instruments and presents the information in U.S. dollar equivalents. The table summarizes information on instruments and transactions that are sensitive to foreign currency exchange rates, including foreign currency call options, collars, forward contracts and cross-currency swaps held at June&#160;30, 2024. The table presents the notional amounts and weighted average exchange rates by contractual maturity dates for our foreign currency derivative financial instruments, including the forward contracts used to hedge our foreign currency denominated assets and liabilities. These notional amounts generally are used to calculate payments to be exchanged under the contracts (in thousands, except exchange rates). </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:18.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.012%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Assets / (Liabilities)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AUD/USD</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">495,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,064)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ave. contractual exchange rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AUD 1 = USD 0.6677</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AUD/Euro</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251,580</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,610)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(915)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ave. contractual exchange rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AUD 1 = EUR 0.6275</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SGD/Euro</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176,642</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,760)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ave. contractual exchange rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">SGD 1 = Euro 0.6797</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SGD/USD</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,054)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,133)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ave. contractual exchange rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">SGD 1 = USD 0.7460</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AUD/CNY</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,520</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ave. contractual exchange rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AUD 1 = CNY 4.8538</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">USD/EUR</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026,231</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,743)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(60,546)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ave. contractual exchange rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">USD 1 = EUR .9610</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">USD/CAD</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract amount</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,238</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ave. contractual exchange rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CAD 1 = USD 0.7274</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to risk associated with changes in interest rates affecting the return on our cash and cash equivalents and debt. At June&#160;30, 2024, we held cash and cash equivalents of $238.4 million principally comprising of bank term deposits and at-call accounts and are invested at both short-term fixed interest rates and variable interest rates. At June&#160;30, 2024, there was $210.0 million outstanding under the revolving credit and term loan facilities, which were subject to variable interest rates. A hypothetical 10% change in interest rates during the year ended June&#160;30, 2024, would not have had a material impact on pretax income. We have no interest rate hedging agreements. On July&#160;10, 2019, we entered into the Note Purchase Agreement with the purchasers to that agreement, in connection with the issuance and sale of $250.0 million principal amount of our 3.24% senior notes due July&#160;10, 2026, and $250.0 million principal amount of our 3.45% senior notes due July&#160;10, 2029. The interest rate on these notes is fixed and not subject to fluctuation. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflationary factors such as increases in the cost of our products, freight, overhead costs or wage rates may adversely affect our operating results. Sustained inflationary pressures in the future may have an adverse effect on our ability to maintain current levels of gross margin and operating expenses as a percentage of net revenue if we are unable to offset such higher costs through price increases.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-63-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_88"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></td></tr></table></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8 CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the financial statements set forth in Item 15 of Part IV of this report, &#8220;Exhibits and Consolidated Financial Statement Schedules.&#8221;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Index to Consolidated Financial Statements </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:91.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_91">Report of Independent Registered Public Accounting Firm </a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">(<ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-38">KPMG LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-39">San Diego, CA</ix:nonNumeric>, Auditor Firm ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-40">185</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_91">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_94">Consolidated Balance Sheets as of June 30, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_94">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_97">Consolidated Statements of Income for the years ended June 30, 2024, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_97">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_100">Consolidated Statements of Comprehensive Income for the years ended June 30, 2024, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_100">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_103">Consolidated Statements of Stockholders&#8217; Equity for the years ended June 30, 2024, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_103">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_106">Consolidated Statements of Cash Flows for the years ended June 30, 2024, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_106">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_109">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_109">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_172">Schedule II &#8211; Valuation and Qualifying Accounts and Reserves</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i7fe754a0eb594e619b22be4f3387c577_172">98</a></span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Supplementary Data </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarterly Financial Information (unaudited)&#8212;The quarterly results for the years ended June&#160;30, 2024 and 2023 are summarized below (in thousands, except per share amounts): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal<br/>Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,102,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,162,801&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,196,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,223,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,685,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">646,934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">715,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,655,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal<br/>Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">950,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,033,744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,116,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,122,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,222,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">540,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">579,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">617,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">617,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,355,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">229,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: the amounts for each quarter are computed independently and, due to the computation formula, the sum of the four quarters may not equal the year. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-64-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_91"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ResMed Inc.:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of ResMed Inc. and subsidiaries (the Company) as of June 30, 2024 and 2023, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended June 30, 2024, and the related notes and financial statement schedule II (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the three-year period ended June 30, 2024, in conformity with U.S. generally accepted accounting principles. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of June 30, 2024, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated August 8, 2024 expressed an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of goodwill triggering events</span></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 2(i) and 5 to the consolidated financial statements, the Company&#8217;s goodwill balance was $2,842 million as of June 30, 2024. The Company performs goodwill impairment testing on an annual basis and whenever events or changes in circumstances indicate that the carrying value of a reporting unit, including goodwill, might exceed the fair value of the reporting unit. In the current year, the Company performed qualitative, or Step 0, assessments to determine whether there was a greater than 50 percent likelihood that the fair value of each reporting unit was less than its carrying value. After completing Step 0, the Company determined that goodwill was not more likely than not impaired and, therefore, no Step 1, or quantitative assessment, was necessary. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-65-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></td></tr></table></div></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the evaluation of goodwill triggering events as a critical audit matter. The evaluation of potential triggering events, including macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, market capitalization and events specific to the entity and reporting units, required a higher degree of auditor judgment. These potential triggering events could have a significant effect on the Company&#8217;s Step 0 assessment and the determination of whether further quantitative analysis of goodwill impairment was required. </span></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the evaluation of goodwill impairment. This included a control related to the Company&#8217;s assessment of potential goodwill triggering events. We evaluated the Company&#8217;s Step 0 assessment for its reporting units by:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">considering macroeconomic conditions including gross domestic product, labor market, and inflation by key regions around the world for negative indicators </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluating information from analyst reports in the enterprise software and sleep and respiratory care industries, which were compared to industry and market considerations used by the Company </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analyzing information including changes in the costs of raw materials and labor, the financial performance of the reporting units, the Company&#8217;s market capitalization, and other entity and reporting-unit specific events. </span></div><div style="margin-top:10pt;padding-left:18pt;padding-right:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 1994.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 8, 2024</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-66-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_94"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_1">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2024 and 2023</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In US$ and in thousands, except share and per share data)</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-41">238,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-42">227,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net of allowances of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">21,132</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">23,603</ix:nonFraction> at June&#160;30, 2024 and June&#160;30, 2023, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">837,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">704,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories (note 4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-47">822,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-48">998,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets (note 4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">459,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">437,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">2,357,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">2,367,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, net (note 4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-53">548,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-54">537,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets (note 9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-55">151,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-56">127,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill (note 5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-57">2,842,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-58">2,770,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets, net (note 5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-59">485,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-60">552,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes (note 12)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">203,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">132,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes and other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">284,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">262,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total non-current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">4,514,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">4,383,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-67">6,872,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-68">6,751,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">237,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">150,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses (note 7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">377,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">365,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities, current (note 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">25,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">21,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">152,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">138,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes payable (note 12)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">107,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-78">72,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt, net (note 8)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-79">9,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-80">9,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-81">910,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-82">758,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-83">137,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-84">119,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes (note 12)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-85">79,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-86">90,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current (note 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-87">141,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-88">116,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-89">42,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-90">68,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net (note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-91">697,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-92">1,431,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term income taxes payable (note 12)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:fixed-zero" scale="3" id="f-93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-94">37,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-95">1,097,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-96">1,863,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-97">2,008,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-98">2,621,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies (note 15)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-99"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-100"/></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-101"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-102">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-103"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-104">2,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-105"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-106">none</ix:nonFraction></ix:nonFraction> issued</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-107">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-108">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-109"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-110">0.004</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-111"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-112">350,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-113">189,565,112</ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-114">146,901,045</ix:nonFraction> outstanding at June&#160;30, 2024 and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-115">188,900,583</ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-116">147,064,349</ix:nonFraction> outstanding at June&#160;30, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="f-117">588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="f-118">588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-119">1,896,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-120">1,772,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-121">4,991,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-122">4,253,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-123">42,664,067</ix:nonFraction> shares at June&#160;30, 2024 and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-124">41,836,234</ix:nonFraction> shares at June&#160;30, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="f-125">1,773,267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="f-126">1,623,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-127">251,529</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-128">272,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-129">4,864,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-130">4,129,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-131">6,872,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-132">6,751,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-67-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_97"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_1">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Income</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years Ended June&#160;30, 2024, 2023 and 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In US$ and in thousands, except share and per share data)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net revenue - Sleep and Respiratory Care products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-133">4,101,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-134">3,725,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-135">3,177,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net revenue - Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-136">584,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-137">497,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-138">400,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-139">4,685,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-140">4,222,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-141">3,578,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales - Sleep and Respiratory Care products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-142">1,806,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-143">1,662,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-144">1,365,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales - Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-145">190,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-146">173,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-147">148,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales (exclusive of amortization shown separately below)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-148">1,997,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-149">1,836,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-150">1,514,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets - Sleep and Respiratory Care products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-151">5,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-152">5,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-153">4,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets - Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-154">27,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-155">25,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-156">35,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-157">32,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-158">30,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-159">39,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost of sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-160">2,029,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-161">1,867,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-162">1,553,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-163">2,655,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-164">2,355,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-165">2,024,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-166">917,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-167">874,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-168">737,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-169">307,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-170">287,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-171">253,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rmd:AmortizationOfAcquiredIntangibleAssets1" format="ixt:num-dot-decimal" scale="3" id="f-172">46,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="rmd:AmortizationOfAcquiredIntangibleAssets1" format="ixt:num-dot-decimal" scale="3" id="f-173">42,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="rmd:AmortizationOfAcquiredIntangibleAssets1" format="ixt:num-dot-decimal" scale="3" id="f-174">31,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring expenses (note 18)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-175">64,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-176">9,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="f-177">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:fixed-zero" scale="3" id="f-178">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-179">10,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-180">1,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-181">1,335,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-182">1,223,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-183">1,024,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-184">1,319,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-185">1,131,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-186">1,000,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (loss), net:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-187">45,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-188">47,379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-189">22,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments (note 6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-190">1,848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-191">7,265</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-192">8,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Loss) gain on equity investments (note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-193">4,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-194">9,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-195">12,202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on insurance recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainOnBusinessInterruptionInsuranceRecovery" format="ixt:fixed-zero" scale="3" id="f-196">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GainOnBusinessInterruptionInsuranceRecovery" format="ixt:num-dot-decimal" scale="3" id="f-197">20,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:GainOnBusinessInterruptionInsuranceRecovery" format="ixt:fixed-zero" scale="3" id="f-198">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-199">3,494</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-200">5,712</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-201">3,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (loss), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-202">55,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-203">30,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-204">39,803</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-205">1,264,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-206">1,101,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-207">960,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes (note 12)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-208">243,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-209">204,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-210">181,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-211">1,020,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-212">897,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-213">779,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share (note 11)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-214">6.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-215">6.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-216">5.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share (note 11)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-217">6.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-218">6.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-219">5.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend declared per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-220">1.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-221">1.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-222">1.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic shares outstanding (000's)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-223">147,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-224">146,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-225">146,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted shares outstanding (000's)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-226">147,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-227">147,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-228">147,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-68-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_100"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_1">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Comprehensive Income</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years Ended June&#160;30, 2024, 2023 and 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In US$ and in thousands)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-229">1,020,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-230">897,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-231">779,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains (losses) on designated hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="f-232">31,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="f-233">35,596</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" format="ixt:fixed-zero" scale="3" id="f-234">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation (loss) gain adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-235">10,744</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-236">75,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-237">119,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-238">1,041,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-239">937,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-240">660,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-69-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_103"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_1">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended June&#160;30, 2024, 2023 and 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In US$ and in thousands)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.015%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive <br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, June&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-241">187,485</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-242">583</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-243">1,622,199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-244">41,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-245">1,623,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-246">3,079,640</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-247">193,487</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-248">2,885,679</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued on exercise of options (note 10) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-249">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-250">11,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-251">11,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 10) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-252">369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-253">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-254">52,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-255">52,406</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued on employee stock purchase plan (note 10) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-256">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-257">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-258">36,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-259">36,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-260">65,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-261">65,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-262">119,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-263">119,260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-264">779,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-265">779,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-266">1.68</ix:nonFraction> per common share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="3" id="f-267">245,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="3" id="f-268">245,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-269">188,247</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-270">586</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-271">1,682,432</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-272">41,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-273">1,623,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-274">3,613,736</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-275">312,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-276">3,360,751</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued on exercise of options (note 10) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-277">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-278">9,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-279">9,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 10) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-280">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-281">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-282">30,632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-283">30,631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued on employee stock purchase plan (note 10) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-284">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-285">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-286">39,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-287">39,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-288">71,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-289">71,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-290">40,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-291">40,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-292">897,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-293">897,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-294">1.76</ix:nonFraction> per common share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="3" id="f-295">258,276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="3" id="f-296">258,276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, June&#160;30, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-297">188,901</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-298">588</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-299">1,772,083</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-36" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-300">41,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-301">1,623,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-302">4,253,016</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-303">272,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-304">4,129,903</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued on exercise of options (note 10) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-305">166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-306">13,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-307">13,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 10) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-308">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-309">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-310">8,758</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-311">8,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued on employee stock purchase plan (note 10) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="f-312">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-313">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-314">39,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-315">39,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Treasury stock purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="f-316">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="f-317">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="f-318">828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-319">150,011</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-320">150,011</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-321">80,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-322">80,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-323">20,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-324">20,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-325">1,020,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-326">1,020,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-327">1.92</ix:nonFraction> per common share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="3" id="f-328">282,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="3" id="f-329">282,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, June&#160;30, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-330">189,565</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-331">588</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-332">1,896,604</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-333">42,664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-334">1,773,267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-335">4,991,647</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-336">251,529</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-337">4,864,043</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-70-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_106"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_1">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:108%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended June&#160;30, 2024, 2023 and 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In US$ and in thousands)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-338">1,020,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-339">897,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-340">779,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustment to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-341">176,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-342">165,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-343">159,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-344">39,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-345">32,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-346">34,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation costs (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-347">80,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-348">71,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-349">65,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments, net of dividends received (note 6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="f-350">1,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="f-351">10,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" format="ixt:num-dot-decimal" scale="3" id="f-352">8,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on equity investments (note 6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-353">4,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-354">9,922</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-355">12,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring expenses (note 18)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:num-dot-decimal" scale="3" id="f-356">33,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:num-dot-decimal" scale="3" id="f-357">9,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero" scale="3" id="f-358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on insurance recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InsuranceRecoveries" format="ixt:fixed-zero" scale="3" id="f-359">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InsuranceRecoveries" format="ixt:num-dot-decimal" scale="3" id="f-360">20,227</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InsuranceRecoveries" format="ixt:fixed-zero" scale="3" id="f-361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-362">134,278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-363">106,511</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-364">19,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-365">172,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-366">248,833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-367">311,681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses, net deferred income taxes and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-368">115,213</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-369">138,125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-370">168,109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable, accrued expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-371">122,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-372">31,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-373">247,632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-374">1,401,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-375">693,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-376">351,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-377">99,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-378">119,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-379">134,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patent registration costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-380">15,396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-381">14,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-382">21,201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-383">133,464</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-384">1,012,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-385">42,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investments (note 6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-386">12,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-387">32,229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-388">20,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exits of investments (note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="f-389">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="f-390">3,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="f-391">6,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds / (payments) on maturity of foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForProceedsFromDerivativeInstrumentInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-392">9,699</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromDerivativeInstrumentInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-393">15,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsForProceedsFromDerivativeInstrumentInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-394">17,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-395">269,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-396">1,159,845</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-397">229,918</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-398">53,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-399">49,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-400">47,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-401">8,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-402">30,631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-403">52,406</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-404">150,011</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-405">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-406">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of business combination contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-407">1,293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-408">2,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-409">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from borrowings, net of borrowing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-410">105,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-411">1,070,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-412">288,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-413">835,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-414">405,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-415">166,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="f-416">282,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="f-417">258,276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="f-418">245,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-419">1,119,287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-420">422,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-421">128,363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-422">1,719</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-423">2,147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-424">14,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-425">10,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-426">45,819</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-427">21,568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-428">227,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-429">273,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-430">295,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-431">238,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-432">227,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-433">273,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes paid, net of refunds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-434">278,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-435">216,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-436">478,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-437">45,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-438">47,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-439">22,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of assets acquired, excluding cash</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rmd:NoncashPartOfAcquisitionFairValueOfAssetsAcquired" format="ixt:num-dot-decimal" scale="3" id="f-440">46,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="rmd:NoncashPartOfAcquisitionFairValueOfAssetsAcquired" format="ixt:num-dot-decimal" scale="3" id="f-441">359,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="rmd:NoncashPartOfAcquisitionFairValueOfAssetsAcquired" format="ixt:num-dot-decimal" scale="3" id="f-442">15,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="3" id="f-443">7,696</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="3" id="f-444">131,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="3" id="f-445">4,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill on acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rmd:GoodwillAcquiredDuringPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-446">92,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="rmd:GoodwillAcquiredDuringPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-447">786,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="rmd:GoodwillAcquiredDuringPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-448">38,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Previously held equity interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rmd:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" format="ixt:fixed-zero" scale="3" id="f-449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="rmd:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" format="ixt:fixed-zero" scale="3" id="f-450">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="rmd:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" format="ixt:num-dot-decimal" scale="3" id="f-451">4,078</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="rmd:DeferredPaymentObligationsForAcquisitions" scale="3" id="f-452">143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="rmd:DeferredPaymentObligationsForAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-453">2,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="rmd:DeferredPaymentObligationsForAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-454">3,067</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="rmd:BusinessAcquisitionContingentConsiderationRecognizedLiability" format="ixt:num-dot-decimal" scale="3" id="f-455">4,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="rmd:BusinessAcquisitionContingentConsiderationRecognizedLiability" format="ixt:num-dot-decimal" scale="3" id="f-456">2,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="rmd:BusinessAcquisitionContingentConsiderationRecognizedLiability" format="ixt:fixed-zero" scale="3" id="f-457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for acquisitions</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-458">134,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-459">1,015,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-460">42,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-71-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_109"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div id="i7fe754a0eb594e619b22be4f3387c577_112"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1) <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-462" continuedAt="f-462-1" escape="true"><ix:nonNumeric contextRef="c-1" name="rmd:OrganizationAndBasisOfPresentationPolicyPolicyTextBlock" id="f-461" continuedAt="f-461-1" escape="true">Organization and Basis of Presentation </ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-462-1"><ix:continuation id="f-461-1">ResMed Inc. (referred to herein as &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; or the &#8220;Company&#8221;) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Finland, Norway and Sweden. We also operate a Software as a Service (&#8220;SaaS&#8221;) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice.</ix:continuation></ix:continuation> </span></div><div id="i7fe754a0eb594e619b22be4f3387c577_115"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2) <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-463" continuedAt="f-463-1" escape="true">Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="f-463-1" continuedAt="f-463-2"><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-464" continuedAt="f-464-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Basis of Consolidation </span></ix:nonNumeric></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-464-1">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from management&#8217;s estimates. Certain prior period amounts have been reclassified to conform to the current period presentation.</ix:continuation> </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-465" continuedAt="f-465-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Revenue Recognition </span></ix:nonNumeric></div><ix:continuation id="f-465-1" continuedAt="f-465-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standard Codification (&#8220;ASC&#8221;) Topic 606, &#8220;Revenue from Contracts with Customers&#8221;, we account for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We have determined that we have <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-466">two</ix:nonFraction> operating segments, which are the sleep and respiratory disorders sector of the medical device industry (&#8220;Sleep and Respiratory Care&#8221;) and the supply of business management software as a service to out-of-hospital care providers (&#8220;SaaS&#8221;). Our Sleep and Respiratory Care revenue relates primarily to the sale of our products that are therapy-based equipment. Some contracts include additional performance obligations such as the provision of extended warranties and provision of data for patient monitoring. Our SaaS revenue relates to the provision of software access with ongoing support and maintenance services as well as professional services such as training and consulting.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregation of revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 13 &#8211; Segment Information for our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2024, 2023 and 2022.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Performance obligations and contract balances</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-465-2" continuedAt="f-465-3">Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; generally, this occurs with the transfer of risk and/or control of our products at a point in time. For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with cloud-hosted services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of <ix:nonNumeric contextRef="c-49" name="rmd:TermOfContractUnderRevenueRecognition" format="ixt-sec:durwordsen" id="f-467">one year</ix:nonNumeric> to <ix:nonNumeric contextRef="c-50" name="rmd:TermOfContractUnderRevenueRecognition" format="ixt-sec:durwordsen" id="f-468">five years</ix:nonNumeric>. Our contracts do not contain significant financing components.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-72-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-463-2" continuedAt="f-463-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-469" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract balances as of June&#160;30, 2024 and 2023 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.811%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance sheet caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-470">837,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-471">704,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-472">38,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-473">31,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, non-current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-474">18,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-475">10,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes and other non-current assets</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-476">152,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-477">138,072</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (current liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-478">137,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-479">119,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (non-current liabilities)</span></td></tr></table></div></ix:nonNumeric><ix:continuation id="f-465-3"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction price determination</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g. rebates, discounts, free goods) and returns by our customers and their customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of our historical experience. Returns of products, excluding warranty-related returns, have historically been infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer&#8217;s expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates each quarter based on actual sales results and updated forecasts for the remaining rebate periods. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in programs where we issue credits to our Sleep and Respiratory Care distributors when they are required to sell our products below negotiated list prices if we have preexisting contracts with the distributors' customers. We reduce revenue for future credits at the time of sale to the distributor, which we estimate based on historical experience using the expected value method. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When Sleep and Respiratory Care or SaaS contracts have multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each performance obligation. An allocation is not required for many of our Sleep and Respiratory Care contracts that have a single performance obligation, which is the shipment of our therapy-based equipment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting and practical expedient elections</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to account for shipping and handling activities associated with our Sleep and Respiratory Care segment as a fulfillment cost within cost of sales, and record shipping and handling costs collected from customers in net revenue. We have also elected for all taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, to be excluded from revenue and presented on a net basis. We have adopted two practical expedients including the &#8220;right to invoice&#8221; practical expedient, which is relevant for some of our SaaS contracts as it allows us to recognize revenue in the amount of the invoice when it corresponds directly with the value of performance completed to date. The second practical expedient adopted permits relief from considering a significant financing component when the payment for the good or service is expected to be one year or less.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-73-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-463-3" continuedAt="f-463-4"><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</span><ix:nonNumeric contextRef="c-1" name="rmd:ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock" id="f-480" continuedAt="f-480-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt">Concentration of Credit Risk and Significant Customers</span></ix:nonNumeric></div><ix:continuation id="f-480-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, derivatives and trade receivables. Our cash and cash equivalents are generally held with large, diverse financial institutions to reduce the amount of exposure to any single financial institution. Our derivative contracts are transacted with various financial institutions with high credit standings and any exposure to counterparty credit-related losses in these contracts is largely mitigated with collateralization and master-netting agreements. The risk with respect to trade receivables is mitigated by credit evaluations we perform on our customers, the short duration of our payment terms for the majority of our customer contracts and by the diversification of our customer base. No single customer accounted for 10% or more of our total revenues for any of the periods presented.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"> <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-481" continuedAt="f-481-1" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="f-481-1" continuedAt="f-481-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of financial instruments is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. We measure our financial instruments at fair value at each reporting period using a fair value hierarchy that requires that we maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#8217;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Other inputs that are directly or indirectly observable in the marketplace.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs that are supported by little or no market activity.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-481-2">The carrying value of cash equivalents, accounts receivable and accounts payable, approximate their fair value because of their short-term nature. The carrying value of long-term debt related to our Revolving Credit and Term Credit Agreements approximates its fair value as the principal amounts outstanding are subject to variable interest rates that are based on market rates which are regularly reset. The carrying value of long-term debt related to our Senior Notes can differ to its fair value as the principal amounts outstanding are subject to fixed interest rates as outlined in Note 8 &#8211; Debt. Foreign currency hedging instruments are marked to market and therefore reflect their fair value. In addition, we measure investments in publicly held equity securities and privately held equity securities for which there has been an observable price change in an identical or similar security, at fair value. We do not hold or issue financial instruments for trading purposes.</ix:continuation> </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e)</span><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-482" continuedAt="f-482-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt">Cash and Cash Equivalents </span></ix:nonNumeric></div><ix:continuation id="f-482-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents include certificates of deposit and other highly liquid investments and we state them at cost, which approximates market. We consider investments with original maturities of 90 days or less to be cash equivalents for purposes of the consolidated statements of cash flows.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(f)</span><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-483" continuedAt="f-483-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.01pt">Inventories </span></ix:nonNumeric></div><ix:continuation id="f-483-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state inventories at the lower of cost (determined principally by the first-in, first-out method) or net realizable value. We include material, labor and manufacturing overhead costs in finished goods and work-in-process inventories. We review and provide for any product obsolescence in our manufacturing and distribution operations by assessing throughout the year individual products and components (based on estimated future usage and sales).</span></div></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(g)</span><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-484" continuedAt="f-484-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Property, Plant and Equipment </span></ix:nonNumeric></div><ix:continuation id="f-484-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record property, plant and equipment, including rental and demonstration equipment at cost. We compute depreciation expense using the straight-line method over the estimated useful lives of the assets. Useful lives are generally <ix:nonNumeric contextRef="c-61" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-485">two years</ix:nonNumeric> to <ix:nonNumeric contextRef="c-62" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-486">ten years</ix:nonNumeric> except for buildings which are depreciated over an estimated useful life of <ix:nonNumeric contextRef="c-63" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-487">forty years</ix:nonNumeric> and leasehold improvements, which we amortize over the shorter of the useful life or the lease term. We charge maintenance and repairs to expense as we incur them.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-74-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-463-4" continuedAt="f-463-5"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for property, plant, and equipment was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-488">88.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-489">84.7</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-490">81.0</ix:nonFraction> million for the years ended June&#160;30, 2024, 2023 and 2022, respectively.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(h)</span><ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="f-491" continuedAt="f-491-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Intangible Assets </span></ix:nonNumeric></div><ix:continuation id="f-491-1" continuedAt="f-491-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the registration costs for new patents and amortize the costs over the estimated useful life of the patent, which is generally <ix:nonNumeric contextRef="c-64" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-492">ten years</ix:nonNumeric>. If a patent is superseded or a product is retired, any unamortized costs are written off immediately.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-491-2">We amortize our other intangible assets on a straight-line basis over their estimated useful lives, which range from <ix:nonNumeric contextRef="c-61" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-493">two years</ix:nonNumeric> to <ix:nonNumeric contextRef="c-62" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-494">fifteen years</ix:nonNumeric>. We evaluate events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists and, at least annually, evaluate the recoverability of intangible assets.</ix:continuation> </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</span><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-495" continuedAt="f-495-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt">Goodwill </span></ix:nonNumeric></div><ix:continuation id="f-495-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct our annual review for goodwill impairment during the final quarter of the fiscal year. Our goodwill impairment review is performed at our reporting unit level, which is one level below our operating segments and involves the following steps: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Step 0 or Qualitative assessment &#8211; Evaluate qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. The factors we consider include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, overall financial performance or events-specific to that reporting unit. If or when we determine it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill, we would move to Step 1 of the quantitative method.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Step 1 &#8211; Compare the fair value for each reporting unit to its carrying value, including goodwill. Fair value is determined based on estimated discounted cash flows. A goodwill impairment charge is recognized for the amount that the carrying amount of a reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit. If a reporting unit&#8217;s fair value exceeds the carrying value, no further work is performed and no impairment charge is necessary.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the annual reviews for the years ended June&#160;30, 2024, 2023 and 2022, we completed a Step 0 or Qualitative assessment and determined it was more likely than not that the fair value of our reporting units exceeded their carrying amounts, including goodwill, and therefore goodwill was not impaired.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(j)</span><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-496" continuedAt="f-496-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.01pt">Business Combinations</span></ix:nonNumeric></div><ix:continuation id="f-496-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate the purchase price to the estimated fair values of the assets acquired and liabilities assumed. This allocation process involves the use of estimates and assumptions made in connection with determining the fair value of assets acquired and liabilities assumed including cash flows expected to be derived from the use of the asset, the timing of such cash flows, the remaining useful life of assets and applicable discount rates. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If actual results vary from the estimates or assumptions used in the valuation or allocation process, we may be required to record an impairment charge or an increase in depreciation or amortization in future periods, or both.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(k)</span><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-497" continuedAt="f-497-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Equity Investments</span></ix:nonNumeric></div><ix:continuation id="f-497-1" continuedAt="f-497-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have equity investments in privately and publicly held companies that are unconsolidated entities. The following discusses our accounting for investments in marketable equity securities, non-marketable equity securities, and investments accounted for under the equity method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities are publicly traded stocks measured at fair value and classified within Level 1 in the fair value hierarchy because we use quoted prices for identical assets in active markets. Marketable equity securities are recorded in prepaid expenses and other current assets on the consolidated balance sheets.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-75-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-463-5" continuedAt="f-463-6"><ix:continuation id="f-497-2" continuedAt="f-497-3"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-marketable equity securities consist of investments in privately held companies without readily determinable fair values and are recorded in prepaid taxes and other non-current assets on the consolidated balance sheets. Non-marketable equity securities are reported at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. We assess non-marketable equity securities at least quarterly for impairment and consider qualitative and quantitative factors including the investee's financial metrics, product and commercial outlook and cash usage. All gains and losses on marketable and non-marketable equity securities, realized and unrealized, are recognized in gain (loss) on equity investments as a component of other income (loss), net on the consolidated statements of income.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-497-3">Equity investments whereby we have significant influence but not control over the investee and are not the primary beneficiary of the investee&#8217;s activities, are accounted for under the equity method. Under this method, we record our share of gains or losses attributable to equity method investments as a component of other income (loss), net on the consolidated statements of income.</ix:continuation> </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(l)</span><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-498" continuedAt="f-498-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt">Research and Development </span></ix:nonNumeric></div><ix:continuation id="f-498-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record all research and development expenses in the period we incur them.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(m)</span><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-499" continuedAt="f-499-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:3.01pt">Foreign Currency </span></ix:nonNumeric></div><ix:continuation id="f-499-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of our non-U.S. subsidiaries, whose functional currencies are other than the U.S. dollar, are translated into U.S. dollars for financial reporting purposes. We translate assets and liabilities of non-U.S. subsidiaries whose functional currencies are other than the U.S. dollar at period end exchange rates but translate revenue and expense transactions at average exchange rates for the period. We recognize cumulative translation adjustments as part of comprehensive income, as detailed in the consolidated statements of comprehensive income, and include those adjustments in accumulated other comprehensive income in the consolidated balance sheets until such time the relevant subsidiary is sold or substantially or completely liquidated. We reflect gains and losses on transactions denominated in other than the functional currency of an entity in our results of operations.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(n)</span><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesPolicyTextBlock" id="f-500" continuedAt="f-500-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Foreign Exchange Risk Management </span></ix:nonNumeric></div><ix:continuation id="f-500-1" continuedAt="f-500-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may use derivative financial instruments, specifically foreign cross-currency swaps, purchased foreign currency call options, collars and forward contracts to mitigate exposure from certain foreign currency risk. No derivatives are used for trading or speculative purposes. We do not require or are not required to pledge collateral for the derivative instruments.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fair Value and Net Investment Hedging</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2022, we executed foreign cross-currency swaps as net investment hedges and fair value hedges in designated hedging relationships with either the foreign denominated net asset balances or the foreign denominated intercompany loan as the hedged items. All derivatives are recorded at fair value as either an asset or liability. Cash flows associated with derivative instruments are presented in the same category on the consolidated statements of cash flows as the hedged item.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the cross-currency swaps for the fair value hedge is to mitigate foreign currency risk associated with changes in spot rates on foreign denominated intercompany debt between USD and EUR. For these hedges, we excluded certain components from the assessment of hedge effectiveness that are not related to spot rates. For fair value hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in the same line item as the hedged item, other, net, in the consolidated statement of income. The initial fair value of hedge components excluded from the assessment of effectiveness is recognized in the statement of income under a systematic and rational method over the life of the hedging instrument and is presented in interest (expense) income, net. Any difference between the change in the fair value of the hedge components excluded from the assessment of effectiveness and the amounts recognized in earnings is recorded as a component of other comprehensive income. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the cross-currency swaps for the net investment hedge is to mitigate foreign currency risk associated with changes in spot rates on the net asset balances of our foreign functional subsidiaries. For net investment hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in cumulative translation adjustment within other comprehensive loss and reclassified into earnings when the hedged net investment is either sold or </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-76-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-463-6" continuedAt="f-463-7"><ix:continuation id="f-500-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantially liquidated. The initial fair value of components excluded from the assessment of hedge effectiveness will be recognized in interest (expense) income, net. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of outstanding foreign cross-currency swaps was $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-501">1,026.2</ix:nonFraction> million at June&#160;30, 2024. These contracts mature at various dates prior to December 31, 2029.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Designated Hedges</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have foreign currency exposure through both our Australian and Singapore manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased foreign currency call options, collars and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed <ix:nonNumeric contextRef="c-66" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:durwordsen" id="f-502">two years</ix:nonNumeric>. The purpose of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, and Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not designate these foreign currency contracts as hedges. All movements in the fair value of the foreign currency instruments are recorded within other, net in our consolidated statements of income. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of the outstanding non-designated hedges was $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-503">1,340.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-504">954.7</ix:nonFraction> million at June&#160;30, 2024 and June&#160;30, 2023, respectively. These contracts mature at various dates prior to September&#160;15, 2025.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classified the fair values of all hedging instruments as Level 2 measurements within the fair value hierarchy.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments. We minimize counterparty credit risk by entering into derivative transactions with major financial institutions and we do not expect material losses as a result of default by our counterparties.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(o)</span><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-505" continuedAt="f-505-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Income Taxes</span></ix:nonNumeric></div><ix:continuation id="f-505-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. We measure deferred tax assets and liabilities using the enacted tax rates we expect to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in the consolidated financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions are reflected in income tax expense.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(p)</span><ix:nonNumeric contextRef="c-1" name="us-gaap:FinanceLoansAndLeasesReceivablePolicy" id="f-506" continuedAt="f-506-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Allowance for Credit Losses</span></ix:nonNumeric></div><ix:continuation id="f-506-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an allowance for credit losses on customer receivables based expected losses, considering our historical write-off experience, an assessment of our customers&#8217; financial conditions, and available information that is relevant to assessing the collectability of cash flows, which includes current conditions and forecasts about future economic conditions. Customer receivables are charged against the allowance when they are deemed uncollectible. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also contingently liable, within certain limits, in the event of a customer default, to independent financing companies in connection with customer financing programs. We monitor the collection status of these installment receivables and provide for estimated losses separately under accrued expenses within our consolidated balance sheets based upon our historical collection experience with such receivables and a current assessment of our credit exposure.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(q)</span><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-507" continuedAt="f-507-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Impairment of Long-Lived Assets </span></ix:nonNumeric></div><ix:continuation id="f-507-1" continuedAt="f-507-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically evaluate the carrying value of long-lived assets to be held and used, including certain identifiable intangible assets, when events and circumstances indicate that the carrying amount of an asset may not be recovered. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-77-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-463-7" continuedAt="f-463-8"><ix:continuation id="f-507-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If assets are considered to be impaired, we recognize as the impairment the amount by which the carrying amount of the assets exceeds the fair value of the assets. We report assets to be disposed of at the lower of the carrying amount or fair value less costs to sell. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended June&#160;30, 2024, we recorded $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-508">33.2</ix:nonFraction> million of restructuring related intangible asset impairments associated with the wind down of certain business activities. Refer to Note 18 &#8211; Restructuring Expenses for additional information regarding restructuring costs. We did not recognize impairment charges in relation to long-lived assets during the fiscal years ended June 30, 2023 and 2022.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(r)</span><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="f-509" continuedAt="f-509-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt">Contingencies</span></ix:nonNumeric></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-509-1"><ix:continuation id="f-463-8">We record a liability in the consolidated financial statements for loss contingencies when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded.</ix:continuation></ix:continuation> </span></div><div id="i7fe754a0eb594e619b22be4f3387c577_21990232556360"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3) <ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="f-510" continuedAt="f-510-1" escape="true">New Accounting Pronouncements </ix:nonNumeric></span></div><ix:continuation id="f-510-1" continuedAt="f-510-2"><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-511" continuedAt="f-511-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Recently issued accounting standards not yet adopted </span></ix:nonNumeric></div><ix:continuation id="f-511-1" continuedAt="f-511-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ASU No. 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (FASB) issued ASU No. 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," which expands segment disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. This ASU is applicable to our Annual Report on Form 10-K for the fiscal year ended June 30, 2025, and subsequent interim periods. Early adoption is permitted and the amendments must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adopting this ASU on our consolidated financial statements and disclosures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-511-2"><ix:continuation id="f-510-2">In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures," which updates income tax disclosure requirements primarily by requiring specific categories and greater disaggregation within the rate reconciliation and disaggregation of income taxes paid. This ASU is applicable to our Annual Report on Form 10-K for the fiscal year ended June 30, 2026, with early application permitted. We are currently evaluating the impact of adopting this ASU on our consolidated financial statements and disclosures.</ix:continuation></ix:continuation> </span></div><div id="i7fe754a0eb594e619b22be4f3387c577_118"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4) <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-512" continuedAt="f-512-1" escape="true">Supplemental Balance Sheet Information</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-513" escape="true"><ix:continuation id="f-512-1" continuedAt="f-512-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of selected captions in the consolidated balance sheets consisted of the following as of June&#160;30, 2024 and June&#160;30, 2023 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inventories</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-514">355,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-515">459,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-516">2,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-517">3,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-518">463,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-519">534,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-520">822,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-521">998,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-78-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-512-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-522" escape="true"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidTaxes" format="ixt:num-dot-decimal" scale="3" id="f-523">107,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidTaxes" format="ixt:num-dot-decimal" scale="3" id="f-524">114,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="rmd:PrepaidInventory" format="ixt:num-dot-decimal" scale="3" id="f-525">172,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="rmd:PrepaidInventory" format="ixt:num-dot-decimal" scale="3" id="f-526">143,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid expenses and current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-527">180,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-528">179,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-529">459,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-530">437,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-531" escape="true"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-532">479,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-533">443,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-534">200,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-535">189,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-536">61,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-537">61,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vehicles and aircraft</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-538">20,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-539">20,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical, demonstration and rental equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-540">127,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-541">115,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-542">102,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-543">91,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-544">51,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-545">52,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-546">231,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-547">231,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, at cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-548">1,274,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-549">1,205,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-550">726,967</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-551">668,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-552">548,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-553">537,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i7fe754a0eb594e619b22be4f3387c577_121"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5) <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-554" continuedAt="f-554-1" escape="true">Goodwill and Other Intangible Assets, net</ix:nonNumeric></span></div><ix:continuation id="f-554-1" continuedAt="f-554-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the years ended June&#160;30, 2024 and June&#160;30, 2023, we have not recorded any goodwill impairments. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-555" continuedAt="f-555-1" escape="true">Changes in the carrying amount of goodwill is comprised of the following for the year ended June&#160;30, 2024 (in thousands): </ix:nonNumeric></span></div><ix:continuation id="f-555-1"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sleep and <br/>Respiratory Care</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SaaS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-556">670,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-557">2,100,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-558">2,770,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-559">92,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="f-560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-561">92,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-562">4,782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-563">15,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-564">20,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-565">757,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-566">2,084,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-567">2,842,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-568" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangibles, net are comprised of the following as of June&#160;30, 2024 and June&#160;30, 2023 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed/core product technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-569">384,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-570">398,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-571">280,970</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-572">265,802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed/core product technology, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-573">103,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-574">132,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-575">432,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-576">443,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-577">150,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-578">124,220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-579">281,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-580">319,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangibles</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-581">252,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-582">244,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-583">151,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-584">144,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-585">100,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-586">99,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other intangibles, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-587">485,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-588">552,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of developed/core product technology, trade names, non-compete agreements, customer relationships, and patents, and we amortize them over the estimated useful life of the assets, generally between <ix:nonNumeric contextRef="c-61" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-589">two years</ix:nonNumeric> and <ix:nonNumeric contextRef="c-62" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-590">fifteen years</ix:nonNumeric>. There are no expected residual values related to these intangible assets. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-79-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-554-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended June&#160;30, 2024, we impaired $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="f-591">18.6</ix:nonFraction>&#160;million of developed/core product technology intangible assets, $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="f-592">14.5</ix:nonFraction>&#160;million of customer relationship intangible assets, and $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="f-593">0.1</ix:nonFraction>&#160;million of other intangibles associated with restructuring activities. These non-cash charges were recorded within <span style="-sec-ix-hidden:f-594">restructuring expenses</span> in the consolidated statements of income. Refer to Note 18 &#8211; Restructuring Expenses for the facts and circumstances leading to the impairments. We did not record any intangible asset impairments during the years ended June&#160;30, 2023 and 2022.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to identified intangible assets for the years ended June&#160;30, 2024 and June&#160;30, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-595">79.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-596">72.4</ix:nonFraction> million, respectively. Amortization expense related to patents, included in other intangibles, for the years ended June&#160;30, 2024 and June&#160;30, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-597">7.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-598">7.0</ix:nonFraction> million, respectively. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-599" continuedAt="f-599-1" escape="true">Total estimated annual amortization expense for the years ending June 30, 2025 through June 30, 2029, is shown below (in thousands): </ix:nonNumeric></span></div><ix:continuation id="f-599-1"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Years Ending June 30</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-600">81,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-601">76,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-602">58,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-603">49,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="f-604">43,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="i7fe754a0eb594e619b22be4f3387c577_124"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6) <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentTextBlock" id="f-605" continuedAt="f-605-1" escape="true">Investments</ix:nonNumeric></span></div><ix:continuation id="f-605-1" continuedAt="f-605-2"><ix:nonNumeric contextRef="c-1" name="rmd:ScheduleOfInvestmentsTableTextBlock" id="f-606" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments by measurement category as of June&#160;30, 2024 and June&#160;30, 2023 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Measurement category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="rmd:MarketableEquityInvestmentsFairValue" format="ixt:num-dot-decimal" scale="3" id="f-607">12,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="rmd:MarketableEquityInvestmentsFairValue" format="ixt:num-dot-decimal" scale="3" id="f-608">12,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Measurement alternative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="f-609">73,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="f-610">68,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-611">65,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-612">65,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="rmd:EquityInvestmentsTotalByMeasurementCategory" format="ixt:num-dot-decimal" scale="3" id="f-613">151,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="rmd:EquityInvestmentsTotalByMeasurementCategory" format="ixt:num-dot-decimal" scale="3" id="f-614">146,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="rmd:ScheduleOfChangesInEquityInvestmentsTableTextBlock" id="f-615" continuedAt="f-615-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2024 (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity method investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-616">68,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-617">12,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-618">65,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-619">146,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="rmd:AdditionalEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-620">8,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="rmd:AdditionalEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-621">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="rmd:AdditionalEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-622">3,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rmd:AdditionalEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-623">12,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Observable price adjustments on non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-624">2,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" format="ixt:fixed-zero" scale="3" id="f-625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" format="ixt:fixed-zero" scale="3" id="f-626">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-627">2,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:num-dot-decimal" scale="3" id="f-628">4,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="3" id="f-629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="3" id="f-630">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:num-dot-decimal" scale="3" id="f-631">4,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exits of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromInvestments" format="ixt:num-dot-decimal" scale="3" id="f-632">1,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:PaymentsForProceedsFromInvestments" format="ixt:fixed-zero" scale="3" id="f-633">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:PaymentsForProceedsFromInvestments" format="ixt:fixed-zero" scale="3" id="f-634">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromInvestments" format="ixt:num-dot-decimal" scale="3" id="f-635">1,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized losses on marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:fixed-zero" scale="3" id="f-636">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-637">1,397</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:fixed-zero" scale="3" id="f-638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-639">1,397</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-642">1,848</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-643">1,848</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" scale="3" id="f-644">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" format="ixt:fixed-zero" scale="3" id="f-645">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" sign="-" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-646">1,181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-647">1,182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying value at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-648">73,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-649">12,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-650">65,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-651">151,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-80-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-615-1"><ix:continuation id="f-605-2" continuedAt="f-605-3"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2023 (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity method investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-652">39,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-653">9,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-654">9,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-655">58,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="rmd:AdditionalEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-656">21,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="rmd:AdditionalEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-657">4,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="rmd:AdditionalEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-658">62,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="rmd:AdditionalEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-659">89,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Observable price adjustments on non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-660">12,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" format="ixt:fixed-zero" scale="3" id="f-661">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" format="ixt:fixed-zero" scale="3" id="f-662">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" format="ixt:num-dot-decimal" scale="3" id="f-663">12,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:num-dot-decimal" scale="3" id="f-664">4,892</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="3" id="f-665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="3" id="f-666">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:num-dot-decimal" scale="3" id="f-667">4,892</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains on marketable and non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-668">3,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:fixed-zero" scale="3" id="f-669">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:fixed-zero" scale="3" id="f-670">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-671">3,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exits of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromInvestments" format="ixt:num-dot-decimal" scale="3" id="f-672">3,937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:PaymentsForProceedsFromInvestments" format="ixt:fixed-zero" scale="3" id="f-673">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:PaymentsForProceedsFromInvestments" format="ixt:fixed-zero" scale="3" id="f-674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromInvestments" format="ixt:num-dot-decimal" scale="3" id="f-675">3,937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized losses on marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:fixed-zero" scale="3" id="f-676">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-677">1,735</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:fixed-zero" scale="3" id="f-678">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-679">1,735</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-680">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-681">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-682">7,265</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-683">7,265</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:ProceedsFromDividendsReceived" format="ixt:fixed-zero" scale="3" id="f-684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:ProceedsFromDividendsReceived" format="ixt:fixed-zero" scale="3" id="f-685">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:ProceedsFromDividendsReceived" format="ixt:num-dot-decimal" scale="3" id="f-686">2,873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromDividendsReceived" format="ixt:num-dot-decimal" scale="3" id="f-687">2,873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" format="ixt:fixed-zero" scale="3" id="f-688">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" format="ixt:fixed-zero" scale="3" id="f-689">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-690">2,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-691">2,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying value at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-692">68,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-693">12,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-694">65,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="f-695">146,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes additions from purchases and an equity method investment acquired and measured at fair value via our acquisition of MEDIFOX DAN. Refer to Note 17 herein.</span></div></ix:continuation></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-605-3">Net unrealized gains and losses recognized in the years ended June&#160;30, 2024, 2023 and 2022 for equity investments in non-marketable and marketable securities still held as of those respective dates were a loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-696">4.0</ix:nonFraction> million, a gain of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-697">6.0</ix:nonFraction> million, and a loss of $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-698">16.2</ix:nonFraction> million, respectively.</ix:continuation> </span></div><div id="i7fe754a0eb594e619b22be4f3387c577_127"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7) <ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-699" continuedAt="f-699-1" escape="true">Accrued Expenses </ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-700" escape="true"><ix:continuation id="f-699-1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses at June&#160;30, 2024 and June&#160;30, 2023 consist of the following (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product warranties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" format="ixt:num-dot-decimal" scale="3" id="f-701">35,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" format="ixt:num-dot-decimal" scale="3" id="f-702">27,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting and professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-703">27,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-704">26,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Value added taxes and other taxes due</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-705">27,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-706">23,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-707">223,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-708">220,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Promotional and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedMarketingCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-709">6,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedMarketingCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-710">9,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-711">4,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-712">9,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-713">9,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-714">9,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Logistics and occupancy costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="rmd:AccruedLogisticsAndOccupancyExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-715">17,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="rmd:AccruedLogisticsAndOccupancyExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-716">16,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory in transit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="rmd:AccruedInventoryInTransit" format="ixt:num-dot-decimal" scale="3" id="f-717">8,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="rmd:AccruedInventoryInTransit" format="ixt:num-dot-decimal" scale="3" id="f-718">10,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-719">18,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-720">12,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-721">377,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-722">365,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-81-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_133"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8) <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-723" continuedAt="f-723-1" escape="true">Debt </ix:nonNumeric></span></div><ix:continuation id="f-723-1" continuedAt="f-723-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtTableTextBlock" id="f-724" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt at June&#160;30, 2024 and June&#160;30, 2023 consists of the following (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="rmd:ShortTermDebtGross" format="ixt:num-dot-decimal" scale="3" id="f-725">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="rmd:ShortTermDebtGross" format="ixt:num-dot-decimal" scale="3" id="f-726">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred borrowing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="3" id="f-727">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="3" id="f-728">98</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-729">9,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="3" id="f-730">9,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-731">700,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-732">1,435,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred borrowing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredFinanceCostsNoncurrentNet" format="ixt:num-dot-decimal" scale="3" id="f-733">2,687</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredFinanceCostsNoncurrentNet" format="ixt:num-dot-decimal" scale="3" id="f-734">3,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-735">697,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-736">1,431,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="3" id="f-737">707,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="3" id="f-738">1,441,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;29, 2022, we entered into a second amended and restated credit agreement (the &#8220;Revolving Credit Agreement&#8221;), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger, sole book runner, swing line lender and letter of credit issuer, Westpac Banking Corporation, as syndication agent and joint lead arranger, HSBC Bank USA, National Association, as syndication agent and joint lead arranger, and Wells Fargo Bank, National Association, as documentation agent. The Revolving Credit Agreement, among other things, provided a senior unsecured revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-739">1,500.0</ix:nonFraction> million, with an uncommitted option to increase the revolving credit facility by an additional amount equal to the greater of $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="rmd:UncommittedOptionToIncreaseCreditFacility" format="ixt:num-dot-decimal" scale="6" id="f-740">1,000.0</ix:nonFraction> million or <ix:nonFraction unitRef="number" contextRef="c-119" decimals="INF" name="rmd:DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod" scale="0" id="f-741">1.0</ix:nonFraction> times the EBITDA (as defined in the Revolving Credit Agreement) for the trailing twelve-month measurement period. The Revolving Credit Agreement amends and restates that certain Amended and Restated Credit Agreement, dated as of April 17, 2018, among ResMed, MUFG Union Bank, N.A., Westpac Banking Corporation and the lenders party thereto.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on June&#160;29, 2022, ResMed Pty Limited entered into a Second Amendment to the Syndicated Facility Agreement and First Amendment to Unconditional Guaranty Agreement (the &#8220;Term Credit Agreement&#8221;), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger and joint book runner, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner, which amends that certain Syndicated Facility Agreement dated as of April 17, 2018. The Term Credit Agreement, among other things, provides ResMed Pty Limited a senior unsecured term credit facility of $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-742">200.0</ix:nonFraction> million. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Revolving Credit Agreement are guaranteed by certain of our direct and indirect U.S. subsidiaries, and ResMed Pty Limited&#8217;s obligations under the Term Credit Agreement are guaranteed by us and certain of our direct and indirect U.S. subsidiaries. The Revolving Credit Agreement and Term Credit Agreement contain customary covenants, including, in each case, a financial covenant that requires that we maintain a maximum leverage ratio of funded debt to EBITDA (as defined in the Revolving Credit Agreement and Term Credit Agreement, as applicable). The entire principal amounts of the revolving credit facility and term credit facility, and, in each case, any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable. Events of default under the Revolving Credit Agreement and the Term Credit Agreement include, in each case, failure to make payments when due, the occurrence of a default in the performance of any covenants in the respective agreements or related documents, or certain changes of control of us, or the respective guarantors of the obligations borrowed under the Revolving Credit Agreement and Term Credit Agreement. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Agreement and Term Credit Agreement each terminate on June&#160;29, 2027, when all unpaid principal and interest under the loans must be repaid. Amounts borrowed under the Term Credit Agreement will also amortize on a semi-annual basis, with a $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal" scale="6" id="f-743">5.0</ix:nonFraction> million principal payment required on each such semi-annual amortization date. The outstanding principal amounts will bear interest at a rate equal to the Adjusted Term SOFR (as defined in the Revolving Credit Agreement) plus <ix:nonFraction unitRef="number" contextRef="c-123" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-744">0.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-124" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-745">1.50</ix:nonFraction>% (depending on the then-applicable leverage ratio) or the Base Rate (as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable) plus <ix:nonFraction unitRef="number" contextRef="c-125" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-746">0.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-126" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-747">0.50</ix:nonFraction>% (depending on the then-applicable leverage ratio). At June&#160;30, 2024, the interest rate that was being charged on the outstanding principal amounts was <ix:nonFraction unitRef="number" contextRef="c-127" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-748">6.19</ix:nonFraction>%. An applicable commitment fee of <ix:nonFraction unitRef="number" contextRef="c-128" decimals="5" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="f-749">0.075</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-129" decimals="5" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="f-750">0.150</ix:nonFraction>% (depending on the then-applicable leverage </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-82-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-723-2" continuedAt="f-723-3"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ratio) applies on the unused portion of the revolving credit facility. As of June&#160;30, 2024, we had $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-751">1,470.0</ix:nonFraction> million available for draw down under the revolving credit facility.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As the Revolving Credit and Term Credit Agreements&#8217; interest rate is calculated as Adjusted Term SOFR plus the spreads described above, its carrying amount is equivalent to its fair value as at June&#160;30, 2024 and June&#160;30, 2023, which was $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="f-752">210.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="f-753">945.0</ix:nonFraction> million, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Notes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;10, 2019, we entered into a Note Purchase Agreement with the purchasers to that agreement, in connection with the issuance and sale of $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-754">250.0</ix:nonFraction> million principal amount of our <ix:nonFraction unitRef="number" contextRef="c-132" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-755">3.24</ix:nonFraction>% senior notes due July&#160;10, 2026, and $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-756">250.0</ix:nonFraction> million principal amount of our <ix:nonFraction unitRef="number" contextRef="c-133" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-757">3.45</ix:nonFraction>% senior notes due July&#160;10, 2029 (collectively referred to as the &#8220;Senior Notes&#8221;). Our obligations under the Note Purchase Agreement and the Senior Notes are unconditionally and irrevocably guaranteed by certain of our direct and indirect U.S. subsidiaries. The net proceeds from this transaction were used to pay down borrowings on our Revolving Credit Agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Note Purchase Agreement, we agreed to customary covenants including with respect to our corporate existence, transactions with affiliates, and mergers and other extraordinary transactions. We also agreed that, subject to limited exceptions, we will maintain a ratio of consolidated funded debt to consolidated EBITDA (as defined in the Note Purchase Agreement) of no more than <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="rmd:DebtToConsolidatedEbitdaRatio" scale="0" id="f-758">3.50</ix:nonFraction> to 1.00 as of the last day of any fiscal quarter, and will not at any time permit the amount of all priority secured and unsecured debt of us and our subsidiaries to exceed <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="rmd:LineOfCreditFacilityCollateralPercentageOfTheCompany" scale="-2" id="f-759">10.0</ix:nonFraction>% of our consolidated tangible assets, determined as of the end of our most recently ended fiscal quarter. This ratio is calculated at the end of each reporting period for which the Note Purchase Agreement requires us to deliver financial statements, using the results of the 12 consecutive month period ending with such reporting period.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As of June&#160;30, 2024 and June&#160;30, 2023, the Senior Notes had a carrying amount of $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:SeniorNotes" scale="6" id="f-760"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:SeniorNotes" scale="6" id="f-761">500.0</ix:nonFraction></ix:nonFraction> million, excluding deferred borrowing costs, and an estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="f-762">463.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="f-763">462.2</ix:nonFraction> million, respectively. Quoted market prices in active markets for identical liabilities based inputs (Level 2) were used to estimate fair value.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-723-3">At June&#160;30, 2024, we were in compliance with our debt covenants and there was $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="6" id="f-764">710.0</ix:nonFraction> million outstanding under the Revolving Credit Agreement, Term Credit Agreement and Senior Notes.</ix:continuation> </span></div><div id="i7fe754a0eb594e619b22be4f3387c577_136"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9) <ix:nonNumeric contextRef="c-1" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock" id="f-767" continuedAt="f-767-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-766" continuedAt="f-766-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LessorSalesTypeLeasesTextBlock" id="f-765" continuedAt="f-765-1" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-767-1" continuedAt="f-767-2"><ix:continuation id="f-766-1" continuedAt="f-766-2"><ix:continuation id="f-765-1" continuedAt="f-765-2"><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Leases where ResMed is the Lessee</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether a contract is, or contains, a lease at inception. Right of Use, or ROU, assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. We use our incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. ROU assets also include any lease payments made at or before lease commencement and any initial direct costs incurred and exclude any lease incentives received.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the lease term as the non-cancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Some of our leases include variable lease payments that are based on costs incurred or actual usage or adjusted periodically based on an index or a rate. Our leases do not contain any residual value guarantees and we do not account for lease and non-lease components as a single lease component. Operating leases are included in operating lease right-of-use assets and operating lease liabilities on our consolidated balance sheets. We lease certain office space, warehouses and distribution centers, manufacturing facilities, vehicles, and equipment with remaining lease terms ranging from less than <ix:nonNumeric contextRef="c-61" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-768">1</ix:nonNumeric> year to <ix:nonNumeric contextRef="c-62" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-769">15</ix:nonNumeric> years, some of which include options to extend or terminate the leases.</span></div></ix:continuation></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-83-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-767-2"><ix:continuation id="f-766-2"><ix:continuation id="f-765-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs for the years ended June&#160;30, 2024, 2023 and 2022 were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-770">40.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-771">33.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-772">35.3</ix:nonFraction> million, respectively. Short-term and variable lease costs were not material for the years ended June&#160;30, 2024, 2023 and 2022. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-773" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under non-cancellable operating leases as of June&#160;30, 2024 are as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-774">197,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-775">30,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-776">26,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-777">22,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-778">20,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-779">19,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-780">78,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-781">31,211</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-782">166,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, future operating lease commitments for leases that have not yet commenced were not material. </span></div><ix:nonNumeric contextRef="c-1" name="rmd:ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock" id="f-783" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental information related to operating leases for the years ended June&#160;30, 2024 and June&#160;30, 2023 was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average inputs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-784">8.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-785">8.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-786">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-787">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash flows paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-788">30,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-789">29,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for new lease liabilities:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-790">54,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-791">16,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Leases where ResMed is the Lessor</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease sleep and respiratory medical devices to customers primarily to comply with local health insurer requirements in certain foreign geographies. Device rental contracts are classified as operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. Operating lease revenue was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="rmd:OperatingLeaseIncome" scale="6" id="f-792">92.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="rmd:OperatingLeaseIncome" scale="6" id="f-793">88.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="rmd:OperatingLeaseIncome" scale="6" id="f-794">90.1</ix:nonFraction> million for the years ended June&#160;30, 2024, 2023 and 2022, respectively.</span></div></ix:continuation></ix:continuation></ix:continuation><div id="i7fe754a0eb594e619b22be4f3387c577_139"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10) <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-795" continuedAt="f-795-1" escape="true">Stockholders&#8217; Equity </ix:nonNumeric></span></div><ix:continuation id="f-795-1" continuedAt="f-795-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On February&#160;21, 2014, our board of directors approved a new share repurchase program, authorizing us to acquire up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-137" decimals="-5" name="srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" scale="6" id="f-796">20.0</ix:nonFraction> million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant and subject to applicable legal requirements. The <ix:nonFraction unitRef="shares" contextRef="c-137" decimals="-5" name="srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" scale="6" id="f-797">20.0</ix:nonFraction> million shares the program authorizes us to purchase are in addition to the shares we repurchased on or before February&#160;21, 2014 under our previous programs. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. All share repurchases since February&#160;21, 2014 have been executed in accordance with this program. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2024, we repurchased approximately <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-798">828,000</ix:nonFraction> shares at a cost of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-799">150.0</ix:nonFraction> million. We did <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="0" id="f-800">not</ix:nonFraction> repurchase any shares during fiscal year 2023. As of June&#160;30, 2024, we have repurchased a total of <ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-801">42.7</ix:nonFraction> million shares at a cost of $<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-8" name="us-gaap:TreasuryStockValue" scale="9" id="f-802">1.8</ix:nonFraction> billion. Shares that are repurchased are classified as &#8220;treasury stock pending future use&#8221; and reduce the number of shares outstanding used in calculating earnings per share. At June&#160;30, 2024, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" scale="6" id="f-803">12.1</ix:nonFraction> million additional shares can be repurchased under the approved share repurchase program.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In April 1997, our board of directors authorized <ix:nonFraction unitRef="shares" contextRef="c-138" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="f-804">2.0</ix:nonFraction> million shares of <ix:nonFraction unitRef="usdPerShare" contextRef="c-138" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-805">0.01</ix:nonFraction> par value preferred stock. <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-806"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-807">No</ix:nonFraction></ix:nonFraction> such shares were issued or outstanding at June&#160;30, 2024. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-84-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-795-2" continuedAt="f-795-3"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options and Restricted Stock Units.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have granted stock options, restricted stock units (&#8220;RSUs&#8221;) and performance restricted stock units (&#8220;PRSUs&#8221;) to personnel, including officers and directors, in accordance with the ResMed Inc. 2009 Incentive Award Plan (the &#8220;2009 Plan&#8221;). Options and restricted stock units vest over <ix:nonNumeric contextRef="c-49" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-808">one year</ix:nonNumeric> to <ix:nonNumeric contextRef="c-50" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-809">four years</ix:nonNumeric> and the options have expiration dates of <ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-810">seven years</ix:nonNumeric> from the date of grant. We have granted the options with an exercise price equal to the market value as determined at the date of grant. We have granted PRSUs that are subject to a market condition, with the ultimate realizable number of PRSUs dependent on relative total stockholder return over a period of <ix:nonNumeric contextRef="c-139" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-811">three years</ix:nonNumeric>. The maximum amounts to be issued under the awards range from <ix:nonFraction unitRef="number" contextRef="c-140" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-812">200</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-141" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-813">225</ix:nonFraction>% of the original grant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the annual meeting of our stockholders in November 2017, our stockholders approved an amendment and restatement to the 2009 Plan to increase the number of shares of common stock that may be issued or transferred pursuant to awards under the 2009 Plan by <ix:nonFraction unitRef="shares" contextRef="c-142" decimals="-5" name="rmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending" scale="6" id="f-814">7.4</ix:nonFraction> million. The amendment and restatement imposes a maximum award amount which may be granted under the 2009 Plan to non-employee director in a calendar year, which when taken together with any other cash fees earned for services as a non-employee director during the calendar year, has a total value of $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="rmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" scale="6" id="f-815">0.7</ix:nonFraction> million, or $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="rmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" scale="6" id="f-816">1.2</ix:nonFraction> million in the case of a non-employee director who is also serving as chairman of our board of directors. The amendment and restatement also increased the maximum amount payable pursuant to cash-denominated performance awards granted in any calendar year from $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="rmd:SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" scale="6" id="f-817">3.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="rmd:SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" scale="6" id="f-818">5.0</ix:nonFraction> million. In addition, the amendment and restatement extended the existing prohibition on the payment of dividends or dividend equivalents on unvested awards to apply to all awards, including time-based restricted stock, deferred stock and stock payment. The term of the 2009 Plan was extended by <ix:nonNumeric contextRef="c-147" name="rmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod" format="ixt-sec:durwordsen" id="f-819">four years</ix:nonNumeric> so that the plan expires on September&#160;11, 2027.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum number of shares of our common stock authorized for issuance under the 2009 Plan is <ix:nonFraction unitRef="shares" contextRef="c-148" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="f-820">51.1</ix:nonFraction> million. The number of securities remaining available for future issuance under the 2009 Plan at June&#160;30, 2024 is <ix:nonFraction unitRef="shares" contextRef="c-148" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="f-821">12.5</ix:nonFraction> million. The number of shares of our common stock available for issuance under the 2009 Plan will be reduced by (i) <ix:nonFraction unitRef="number" contextRef="c-4" decimals="INF" name="rmd:ReductionInNumberOfSharesOfCommonStockAvailableForIssuance" scale="0" id="f-822">2.8</ix:nonFraction> shares for each one share of common stock delivered in settlement of any &#8220;full-value award,&#8221; which is any award other than a stock option, stock appreciation right or other award for which the holder pays a purchase price and (ii) <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="rmd:NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards" format="ixt-sec:numwordsen" scale="0" id="f-823">one</ix:nonFraction> share for each share of common stock delivered in settlement of all other awards. The maximum number of shares, which may be subject to awards granted under the 2009 Plan to any individual during any calendar year, may not exceed <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-6" name="rmd:MaximumNumberOfSharesSubjectToAwardsGranted" scale="6" id="f-824">3</ix:nonFraction> million shares of our common stock (except in a participant&#8217;s initial year of hiring up to <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="rmd:NumberOfCommonStockGranted" scale="6" id="f-825">4.5</ix:nonFraction> million shares of our common stock may be granted). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain regions, shares are withheld on behalf of employees to satisfy statutory tax withholding requirements upon exercise or vesting of awards. The number of shares withheld is based upon the closing price of our common stock on the trading day of the applicable settlement date. The remaining shares are delivered to the recipient as shares of our common stock. The amount remitted to the tax authorities for the employees&#8217; tax obligation is reflected as a financing activity on our consolidated statements of cash flows. Shares withheld by us as a result of the net settlement are not considered issued and outstanding and are added to the shares available for future issuance under the 2009 Plan.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of RSUs and PRSUs that vested during the years ended June&#160;30, 2024, 2023 and 2022, was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-826">51.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-827">66.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-828">65.5</ix:nonFraction> million, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-829" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of RSUs, including PRSUs, during year ended June&#160;30, 2024 (in thousands, except years and per share amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock<br/>Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant-Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-149" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-830">762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-149" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-831">227.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-150" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-832">1.7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-151" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-833">674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-151" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-834">148.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-151" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-835">236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-151" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-836">215.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-151" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-837">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-151" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-838">218.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-152" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-839">1,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-152" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-840">183.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-151" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-841">1.6</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5pt">Includes <ix:nonFraction unitRef="shares" contextRef="c-151" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-842">60</ix:nonFraction> thousand shares netted for tax.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-85-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-795-3" continuedAt="f-795-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-843" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity during the year ended June&#160;30, 2024 (in thousands, except years and per share amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="f-844">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-845">134.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-12" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-846">3.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="f-847">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-848">148.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-849">166</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-850">81.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="f-851">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-852">232.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="f-853">786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-854">146.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-855">2.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="f-856">633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-857">136.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-858">2.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options vested and expected to vest at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="3" id="f-859">778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-860">146.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-861">2.8</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5pt">Includes <ix:nonFraction unitRef="shares" contextRef="c-153" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-862">1</ix:nonFraction> thousand shares netted for tax.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised during the fiscal years 2024, 2023 and 2022, was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-863">17.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-864">25.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-865">33.7</ix:nonFraction> million, respectively. As at June&#160;30, 2024, the aggregate intrinsic value of options outstanding, exercisable, and vested and expected to vest were $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="f-866">42.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="f-867">39.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="f-868">42.7</ix:nonFraction> million respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan (the &#8220;ESPP&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the board of directors&#8217; compensation committee of no less than <ix:nonNumeric contextRef="c-154" name="rmd:EmployeeStockPurchasePlanOfferingPeriod" format="ixt-sec:durmonth" id="f-869">3</ix:nonNumeric> months and no more than <ix:nonNumeric contextRef="c-155" name="rmd:EmployeeStockPurchasePlanOfferingPeriod" format="ixt-sec:durmonth" id="f-870">27</ix:nonNumeric> months. The purchase price for our common stock under the ESPP will be the lower of <ix:nonFraction unitRef="number" contextRef="c-156" decimals="INF" name="rmd:PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant" scale="-2" id="f-871">85</ix:nonFraction>% of the fair market value of our common stock on the date of grant or <ix:nonFraction unitRef="number" contextRef="c-156" decimals="INF" name="rmd:PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase" scale="-2" id="f-872">85</ix:nonFraction>% of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:CommonStockSharesSubscriptions" format="ixt:num-dot-decimal" scale="0" id="f-873">25,000</ix:nonFraction> in common stock during any calendar year. At June&#160;30, 2024, the number of shares remaining available for future issuance under the ESPP is <ix:nonFraction unitRef="shares" contextRef="c-158" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="f-874">1.0</ix:nonFraction> million shares.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During years ended June&#160;30, 2024, 2023 and 2022, we issued <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-875">323,000</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-876">220,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-877">216,000</ix:nonFraction> shares to our employees in <ix:nonFraction unitRef="offering" contextRef="c-156" decimals="INF" name="rmd:NumberOfOfferings" format="ixt-sec:numwordsen" scale="0" id="f-878">two</ix:nonFraction> offerings and we recognized $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-879">11.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-880">11.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-881">11.0</ix:nonFraction> million, respectively, of stock compensation expense associated with the ESPP.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock&#8211;based Employee compensation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We measure the compensation expense of all stock-based awards at fair value on the grant date. We estimate the fair value of stock options and purchase rights granted under the ESPP using the Black-Scholes valuation model. The fair value of restricted stock units is equal to the market value of the underlying shares as determined at the grant date less the fair value of dividends that holders are not entitled to, during the vesting period. The fair value of performance restricted stock units is measured using a Monte-Carlo simulation valuation model. We recognize the fair value as compensation expense using the straight-line method over the service period for awards expected to vest.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the assumptions in the following tables. The risk-free interest rate is estimated using the U.S. Treasury yield curve and is based on the term of the award. The expected term of awards is estimated from the vesting period of the award, as well as historical exercise behavior, and represents the period of time the awards granted are expected to be outstanding. Expected volatility is estimated based upon the historical volatility of ResMed stock.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-86-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-795-4" continuedAt="f-795-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-882" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions for the years ended June&#160;30, 2024, 2023 and 2022: </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock options:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average grant date fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-153" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-883">50.48</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-161" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-884">74.95</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-162" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-885">72.16</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-153" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-886">4.44</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-161" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-887">3.85</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-162" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-888">1.29</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-153" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-889">4.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-161" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-890">4.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-162" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-891">4.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-153" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-892">1.29</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-161" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-893">0.78</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-162" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-894">0.66</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-153" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-895">36</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-161" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-896">34</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-162" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-897">32</ix:nonFraction>%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ESPP purchase rights:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average grant date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-163" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-898">47.40</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-164" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-899">52.38</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-165" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-900">50.46</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-163" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-901">5.4</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-164" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-902">3.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-165" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-903">0.3</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-163" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth" id="f-904">6</ix:nonNumeric> months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-164" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth" id="f-905">6</ix:nonNumeric> months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-165" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth" id="f-906">6</ix:nonNumeric> months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-166" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-907">0.75</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-167" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-908">1.30</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-168" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-909">0.75</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-169" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-910">0.84</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-170" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-911">0.63</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-171" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-912">0.98</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-163" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-913">27</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-163" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-914">40</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-164" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-915">27</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-164" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-916">34</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-165" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-917">20</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-165" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-918">34</ix:nonFraction>%</span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-919" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total stock-based compensation costs incurred and the associated tax benefit recognized during the years ended June&#160;30, 2024, 2023 and 2022 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-920">7,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-921">6,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-922">5,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-923">58,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-924">53,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-925">50,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-926">14,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-927">11,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-928">9,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-929">80,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-930">71,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-931">65,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-932">15,053</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-933">24,860</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-934">29,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation costs, net of tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-935">65,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-936">46,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-937">35,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-795-5">At June&#160;30, 2024, there was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-938">142.4</ix:nonFraction> million in unrecognized compensation costs related to unvested stock-based compensation arrangements. This is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-939">2.6</ix:nonNumeric> years.</ix:continuation> </span></div><div id="i7fe754a0eb594e619b22be4f3387c577_145"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11) <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-940" continuedAt="f-940-1" escape="true">Earnings Per Share </ix:nonNumeric></span></div><ix:continuation id="f-940-1" continuedAt="f-940-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compute basic earnings per share by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units. The weighted average number of outstanding stock options and restricted stock units not included in the computation of diluted earnings per share were <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-941">603,859</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-942">272,104</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-943">67,000</ix:nonFraction> for the years ended June&#160;30, 2024, 2023 and 2022, respectively, as the effect would have been anti-dilutive. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-87-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-944" escape="true"><ix:continuation id="f-940-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings per share for the years ended June&#160;30, 2024, 2023 and 2022 are calculated as follows (in thousands except per share data): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-945">1,020,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-946">897,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-947">779,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-948">147,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-949">146,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-950">146,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options and restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="f-951">529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="f-952">690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="f-953">977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted average shares </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-954">147,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-955">147,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-956">147,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-957">6.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-958">6.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-959">5.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-960">6.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-961">6.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-962">5.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i7fe754a0eb594e619b22be4f3387c577_148"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12) <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-963" continuedAt="f-963-1" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="f-963-1" continuedAt="f-963-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-964" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes for the years ended June&#160;30, 2024, 2023 and 2022, was taxed under the following jurisdictions (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-965">181,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-966">128,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-967">85,919</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-968">1,083,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-969">973,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-970">1,046,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-971">1,264,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-972">1,101,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-973">960,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-974" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is presented below (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:28.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-975">57,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-976">36,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-977">4,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-978">17,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-979">14,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-980">10,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-981">219,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-982">198,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-983">177,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-984">293,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-985">249,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-986">192,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred: </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-987">22,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-988">21,721</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-989">12,612</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-990">4,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-991">2,389</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-992">2,773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-993">22,331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-994">21,322</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-995">3,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-996">49,878</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-997">45,432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-998">11,818</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-999">243,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1000">204,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1001">181,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1002" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. federal income tax rate of 21% for the years ended June&#160;30, 2024, 2023 and 2022, to pretax income as a result of the following (in thousands): </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes computed at statutory U.S. rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-1003">265,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-1004">231,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-1005">201,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase (decrease) in income taxes resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes, net of U.S. tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-1006">8,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-1007">9,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-1008">5,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-1009">27,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-1010">21,481</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-1011">17,517</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="f-1012">849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1013">5,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="f-1014">858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of non-U.S. tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="f-1015">15,838</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="f-1016">3,982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="f-1017">4,384</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" format="ixt:num-dot-decimal" scale="3" id="f-1018">8,293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" format="ixt:num-dot-decimal" scale="3" id="f-1019">3,988</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" format="ixt:num-dot-decimal" scale="3" id="f-1020">2,299</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1021">4,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1022">6,282</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1023">11,294</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" format="ixt:num-dot-decimal" scale="3" id="f-1024">15,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" format="ixt:num-dot-decimal" scale="3" id="f-1025">4,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" format="ixt:num-dot-decimal" scale="3" id="f-1026">8,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1027">243,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1028">204,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1029">181,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-88-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-963-2" continuedAt="f-963-3"><ix:nonNumeric contextRef="c-1" name="rmd:ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock" id="f-1030" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reported net deferred tax assets and liabilities in our consolidated balance sheets at June&#160;30, 2024 and June&#160;30, 2023, as follows (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current deferred tax asset</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1031">203,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1032">132,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1033">79,339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1034">90,650</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-1035">124,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-1036">42,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1037" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our deferred tax assets and liabilities at June&#160;30, 2024 and June&#160;30, 2023, are as follows (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Employee liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1038">35,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1039">34,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Tax credit carry overs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1040">9,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1041">6,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="3" id="f-1042">15,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="3" id="f-1043">13,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Provision for warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" format="ixt:num-dot-decimal" scale="3" id="f-1044">6,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" format="ixt:num-dot-decimal" scale="3" id="f-1045">5,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Provision for doubtful debts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="f-1046">5,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="f-1047">6,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1048">23,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1049">22,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Capital loss carryover</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1050">5,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="3" id="f-1051">917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1052">11,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1053">8,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-1054">28,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-1055">23,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Research and development capitalization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1056">125,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1057">111,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="rmd:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1058">25,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="rmd:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1059">21,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Hedging contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="f-1060">56,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="f-1061">27,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">State income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsStateTaxes" format="ixt:num-dot-decimal" scale="3" id="f-1062">3,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsStateTaxes" format="ixt:num-dot-decimal" scale="3" id="f-1063">2,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-1064">5,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-1065">2,014</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1066">356,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1067">282,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1068">9,384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1069">8,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1070">347,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1071">273,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Goodwill and other intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1072">192,398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1073">198,418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="rmd:DeferredTaxLiabilitiesRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1074">22,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="rmd:DeferredTaxLiabilitiesRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1075">20,501</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1076">7,857</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1077">12,302</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1078">223,098</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1079">231,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Net deferred tax asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-1080">124,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-1081">42,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, we had $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1082">16.5</ix:nonFraction> million of U.S. federal and state net operating loss carryforwards and $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1083">6.2</ix:nonFraction> million of non-U.S. net operating loss carryforwards, which expire in various years beginning in 2025 or carry forward indefinitely. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance at June&#160;30, 2024 relates to a provision for uncertainty of the utilization of net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1084">0.8</ix:nonFraction> million and capital loss and other items of $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="rmd:OperatingLossCarryforwardsCapitalLoss" scale="6" id="f-1085">8.6</ix:nonFraction> million. We believe that it is more likely than not that the benefits of deferred tax assets, net of any valuation allowance, will be realized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our manufacturing operations and administrative functions in Singapore operate under certain tax holidays and tax incentive programs that will expire in whole or in part at various dates through June 30, 2030. The end of certain tax holidays may be extended if specific conditions are met. The net impact of these tax holidays and tax incentive programs increased our net income by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxHolidayAggregateDollarAmount" scale="6" id="f-1086">49.6</ix:nonFraction> million ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" id="f-1087">0.34</ix:nonFraction> per diluted share) for the year ended June&#160;30, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:IncomeTaxHolidayAggregateDollarAmount" scale="6" id="f-1088">40.5</ix:nonFraction> million ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" id="f-1089">0.27</ix:nonFraction> per diluted share) for the year ended June&#160;30, 2023, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:IncomeTaxHolidayAggregateDollarAmount" scale="6" id="f-1090">38.0</ix:nonFraction> million ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" id="f-1091">0.26</ix:nonFraction> per diluted share) for the year ended June&#160;30, 2022. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;), we have treated all non-U.S. historical earnings as taxable. Therefore, future repatriation of cash held by our non-U.S. subsidiaries will generally not be subject to U.S. federal tax if repatriated. The total amount of these undistributed earnings at June&#160;30, 2024 amounted to approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-8" name="us-gaap:UndistributedEarningsOfForeignSubsidiaries" scale="9" id="f-1092">4.1</ix:nonFraction> billion. In </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-89-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-963-3"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the event our non-U.S. earnings had not been permanently reinvested, approximately $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-1093">4.9</ix:nonFraction>&#160;million in U.S. state deferred taxes would have been recognized in the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TCJA also introduced U.S. taxation on certain global intangible low-taxed income (&#8220;GILTI&#8221;). We have elected to account for tax expense attributable to GILTI tax as a period cost when incurred.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accounting for uncertainty in income taxes, we recognize a tax benefit in the financial statements for an uncertain tax position only if management&#8217;s assessment is that the position is &#8220;more likely than not&#8221; (that is, a likelihood greater than <ix:nonFraction unitRef="number" contextRef="c-185" decimals="2" name="rmd:PercentageOfRecognizedTaxBenefitForUncertainTaxPosition" format="ixt:num-dot-decimal" scale="-2" id="f-1094">50</ix:nonFraction> percent) to be allowed by the tax jurisdiction based solely on the technical merits of the position. The term &#8220;tax position&#8221; refers to a position in a previously filed tax return or a position expected to be taken in a future tax return that is reflected in measuring current or deferred income tax assets and liabilities for annual periods. We recognize interest and penalties related to unrecognized tax benefits within the income tax expense line in the accompanying consolidated statements of income. Accrued interest and penalties are included within the related tax liability line in the consolidated balance sheets. Based on all known facts and circumstances and current tax law, we believe the total amount of unrecognized tax benefits on June&#160;30, 2024 is not material to our results of operations, financial condition or cash flows, and if recognized, would not have a material impact on our effective tax rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax returns are based on calculations and assumptions subject to audit by various tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws. We regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. Any final assessment resulting from tax audits may result in material changes to our past or future taxable income, tax payable or deferred tax assets, and may require us to pay penalties and interest that could materially adversely affect our financial results. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 19, 2021, we concluded the settlement agreement with the Australian Taxation Office (&#8220;ATO&#8221;) in relation to the previously disclosed transfer pricing dispute for the tax years 2009 through 2018 (&#8220;ATO settlement&#8221;). The ATO settlement fully resolved the dispute for all prior years, with no admission of liability and provides clarity in relation to certain future taxation principles.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final net impact of the ATO settlement was recorded during the years ended June 30, 2021 and 2022 in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="rmd:IncomeTaxExaminationNetImpactOfSettlement" format="ixt:num-dot-decimal" scale="6" id="f-1095"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="rmd:IncomeTaxExaminationNetImpactOfSettlement" format="ixt:num-dot-decimal" scale="6" id="f-1096">238.7</ix:nonFraction></ix:nonFraction>&#160;million, which represents a gross amount of $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="rmd:IncomeTaxExaminationGrossSettlement" format="ixt:num-dot-decimal" scale="6" id="f-1097"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="rmd:IncomeTaxExaminationGrossSettlement" format="ixt:num-dot-decimal" scale="6" id="f-1098">381.7</ix:nonFraction></ix:nonFraction>&#160;million, including interest and penalties of $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-1099"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-1100">48.1</ix:nonFraction></ix:nonFraction>&#160;million, and adjustments for credits and deductions of $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" format="ixt:num-dot-decimal" scale="6" id="f-1101"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" format="ixt:num-dot-decimal" scale="6" id="f-1102">143.0</ix:nonFraction></ix:nonFraction>&#160;million. As a result of the ATO settlement and due to movements in foreign currencies, we recorded a benefit of $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" format="ixt:num-dot-decimal" scale="6" id="f-1103"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" format="ixt:num-dot-decimal" scale="6" id="f-1104">14.1</ix:nonFraction></ix:nonFraction>&#160;million within other comprehensive income, and a $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:IncomeTaxCreditsAndAdjustments" format="ixt:num-dot-decimal" scale="6" id="f-1105"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:IncomeTaxCreditsAndAdjustments" format="ixt:num-dot-decimal" scale="6" id="f-1106">4.1</ix:nonFraction></ix:nonFraction>&#160;million reduction of tax credits, which was recorded to income tax expense. As a result of the ATO settlement, we reversed our previously recorded uncertain tax position.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2021, we remitted final payment to the ATO of $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="rmd:IncomeTaxExaminationRemittedFinalPayment" format="ixt:num-dot-decimal" scale="6" id="f-1107">284.8</ix:nonFraction>&#160;million, consisting of the agreed settlement amount of $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="rmd:IncomeTaxExaminationGrossSettlement" format="ixt:num-dot-decimal" scale="6" id="f-1108">381.7</ix:nonFraction>&#160;million less prior remittances made to the ATO of $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="rmd:IncomeTaxExaminationPriorRemittancePayments" format="ixt:num-dot-decimal" scale="6" id="f-1109">96.9</ix:nonFraction>&#160;million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax years 2018 to 2023 remain subject to examination by the major tax jurisdictions in which we are subject to tax.</span></div></ix:continuation><div id="i7fe754a0eb594e619b22be4f3387c577_151"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(13) <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1110" continuedAt="f-1110-1" escape="true">Segment Information </ix:nonNumeric></span></div><ix:continuation id="f-1110-1" continuedAt="f-1110-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-1111">two</ix:nonFraction> operating segments, which are the Sleep and Respiratory Care segment and the SaaS segment. We evaluate the performance of our segments based on net sales and income from operations. The accounting policies of the segments are the same as those described in Note 2 &#8211; Summary of Significant Accounting Policies. Segment net sales and segment income from operations do not include inter-segment profits and revenue is allocated to a geographic area based on where the products are shipped to or where the services are performed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include corporate headquarters costs, stock-based compensation, amortization expense from acquired intangibles, restructuring expenses, field safety notification expenses, acquisition related expenses, net interest expense (income), gains and losses attributable to equity method investments, gains and losses on equity investments, and other, net. We neither discretely allocate assets to our operating segments, nor does our Chief Operating Decision Maker evaluate the operating segments using discrete asset information.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-90-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-1110-2" continuedAt="f-1110-3"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, effective in the third quarter of fiscal year 2024, we updated the method of attribution of certain costs that are principally managed at the segment level as part of our evaluation of segment operating performance. As a result, certain costs relating to quality and regulatory assurance, commercial legal, operations, sales and marketing, customer service, information technology, and other administrative costs, which were previously included in Corporate costs within our reconciliation of segment operating profit to income before income taxes, are now reported in segment operating results. The financial information presented herein reflects the impact of the preceding reporting change for all periods presented.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-1112" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents a reconciliation of net revenues, depreciation and amortization and net operating profit by reportable segments for the years ended June&#160;30, 2024, 2023 and 2022 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net revenue by segment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1113">4,101,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1114">3,725,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1115">3,177,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1116">584,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1117">497,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1118">400,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1119">4,685,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1120">4,222,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1121">3,578,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Depreciation and amortization by segment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1122">86,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1123">82,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1124">79,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1125">10,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1126">9,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1127">7,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets and corporate assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1128">80,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1129">73,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1130">72,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1131">176,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1132">165,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1133">159,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net operating profit by segment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1134">1,681,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1135">1,447,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1136">1,279,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1137">154,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1138">115,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1139">93,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1140">1,835,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1141">1,562,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1142">1,373,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reconciling items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="rmd:UnallocatedCorporateCosts" format="ixt:num-dot-decimal" scale="3" id="f-1143">357,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="rmd:UnallocatedCorporateCosts" format="ixt:num-dot-decimal" scale="3" id="f-1144">338,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="rmd:UnallocatedCorporateCosts" format="ixt:num-dot-decimal" scale="3" id="f-1145">300,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="rmd:AmortizationOfAcquiredIntangibleAssets1" format="ixt:num-dot-decimal" scale="3" id="f-1146">79,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="rmd:AmortizationOfAcquiredIntangibleAssets1" format="ixt:num-dot-decimal" scale="3" id="f-1147">72,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="rmd:AmortizationOfAcquiredIntangibleAssets1" format="ixt:num-dot-decimal" scale="3" id="f-1148">70,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-1149">64,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-1150">9,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="f-1151">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks with magnets field safety notification expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="rmd:MasksWithMagnetsFieldSafetyNotificationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1152">6,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="rmd:MasksWithMagnetsFieldSafetyNotificationExpenses" format="ixt:fixed-zero" scale="3" id="f-1153">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="rmd:MasksWithMagnetsFieldSafetyNotificationExpenses" format="ixt:fixed-zero" scale="3" id="f-1154">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Astral field safety notification expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="rmd:AstralFieldActionNotificationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1155">7,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="rmd:AstralFieldActionNotificationExpenses" format="ixt:fixed-zero" scale="3" id="f-1156">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="rmd:AstralFieldActionNotificationExpenses" format="ixt:fixed-zero" scale="3" id="f-1157">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:fixed-zero" scale="3" id="f-1158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-1159">10,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-1160">1,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-1161">45,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-1162">47,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-1163">22,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1164">1,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1165">7,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1166">8,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-1167">4,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" sign="-" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-1168">9,922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-1169">12,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on insurance recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:GainOnBusinessInterruptionInsuranceRecovery" format="ixt:fixed-zero" scale="3" id="f-1170">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" sign="-" name="us-gaap:GainOnBusinessInterruptionInsuranceRecovery" format="ixt:num-dot-decimal" scale="3" id="f-1171">20,227</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:GainOnBusinessInterruptionInsuranceRecovery" format="ixt:fixed-zero" scale="3" id="f-1172">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1173">3,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1174">5,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1175">3,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1176">1,264,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1177">1,101,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1178">960,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;During the fiscal year ended June&#160;30, 2024, we recorded $<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-1179">4.1</ix:nonFraction>&#160;million of operating lease right-of-use asset impairments within our SaaS segment. The impairments related to leases for office space and were recorded within net operating profit. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The masks with magnets field safety notification expenses relate to estimated </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">costs to provide alternative masks to patients in response to updated contraindications for use of masks that incorporate magnets.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;The Astral field safety notification expenses relate to estimated costs associated with the replacement of a certain component in some of our Astral ventilation devices that were manufactured between 2013 to 2019.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-91-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-1110-3"><ix:nonNumeric contextRef="c-1" name="rmd:ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock" id="f-1180" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2024, 2023 and 2022 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S., Canada and Latin America</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1181">1,522,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1182">1,444,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1183">1,070,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1184">1,199,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1185">1,039,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1186">911,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total U.S., Canada and Latin America</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1187">2,722,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1188">2,483,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1189">1,981,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Combined Europe, Asia and other markets </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1190">921,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1191">826,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1192">796,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1193">457,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1194">415,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1195">399,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Combined Europe, Asia and other markets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1196">1,378,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1197">1,241,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1198">1,195,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1199">2,444,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1200">2,270,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1201">1,866,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1202">1,657,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1203">1,454,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1204">1,310,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1205">4,101,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1206">3,725,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1207">3,177,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1208">584,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1209">497,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1210">400,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1211">4,685,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1212">4,222,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1213">3,578,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-1214" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue information by geographic area for the years ended June&#160;30, 2024, 2023 and 2022 is summarized below (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1215">2,980,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1216">2,719,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1217">2,249,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of the World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1218">1,705,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1219">1,503,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1220">1,328,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1221">4,685,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1222">4,222,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1223">3,578,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets of geographic areas are those assets used in our operations in each geographical area, and excludes goodwill, other intangible assets, and deferred tax assets. <ix:nonNumeric contextRef="c-1" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="f-1224" continuedAt="f-1224-1" escape="true">Long-lived assets by geographic area as of June&#160;30, 2024 and 2023 is summarized below (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-1224-1"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Australia</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1225">197,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1226">200,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1227">160,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1228">164,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1229">89,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1230">83,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of the World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1231">100,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1232">88,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1233">548,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1234">537,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="i7fe754a0eb594e619b22be4f3387c577_154"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14) <ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-1235" continuedAt="f-1235-1" escape="true">Employee Retirement Plans </ix:nonNumeric></span></div><ix:continuation id="f-1235-1" continuedAt="f-1235-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contribute to a number of employee retirement plans for the benefit of our employees. Details of the main plans are as follows: </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Australia </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contribute to defined contribution plans for each employee resident in Australia at the rate of approximately <ix:nonFraction unitRef="number" contextRef="c-260" decimals="3" name="rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" scale="-2" id="f-1236">11.0</ix:nonFraction>% of salaries. Employees may contribute additional funds to the plans. All Australian employees, after serving a qualifying period, are entitled to benefits on retirement, disability or death. Our total contributions to the plans for the years ended June&#160;30, 2024, 2023 and 2022, were $<ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-1237">14.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-1238">13.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-1239">11.8</ix:nonFraction> million, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">United States </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor a defined contribution plan available to substantially all domestic employees. Company contributions to this plan are based on a percentage of employee contributions to a maximum of <ix:nonFraction unitRef="number" contextRef="c-263" decimals="3" name="rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" scale="-2" id="f-1240">4.0</ix:nonFraction>% of the employee&#8217;s </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-92-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-1235-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eligible compensation, subject to the annual IRS limit. Our total contributions to the plan were $<ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-1241">13.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-1242">12.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-1243">11.9</ix:nonFraction> million in fiscal 2024, 2023 and 2022, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Singapore </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor a defined contribution plan available to all domestic employees. Company contributions to this plan are based on a percentage of employee contributions to a maximum of <ix:nonFraction unitRef="number" contextRef="c-266" decimals="3" name="rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" scale="-2" id="f-1244">17.0</ix:nonFraction>% of the employee&#8217;s salary. Our total contributions to the plan were $<ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-1245">3.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-1246">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-1247">3.1</ix:nonFraction> million in fiscal 2024, 2023 and 2022, respectively.</span></div></ix:continuation><div id="i7fe754a0eb594e619b22be4f3387c577_157"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(15) <ix:nonNumeric contextRef="c-1" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="f-1248" continuedAt="f-1248-1" escape="true">Legal Actions, Contingencies and Commitments</ix:nonNumeric></span></div><ix:continuation id="f-1248-1" continuedAt="f-1248-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, New York University ("NYU") filed a complaint for patent infringement in the United States District Court, District of Delaware against ResMed Inc., case no. 1:21-cv-00813 (JPM). The complaint alleges that the AutoSet or AutoRamp features of ResMed&#8217;s AirSense 10 AutoSet flow generators infringe one or more claims of various NYU patents, including U.S. Patent Nos. 6,988,994; 9,108,009; 9,168,344; 9,427,539; 9,533,115; 9,867,955; and 10,384,024. According to the complaint, the NYU patents are directed to systems and methods for diagnosis and treating sleeping disorders during different sleep states. The complaint seeks monetary damages and attorneys&#8217; fees. We answered the complaint on September 30, 2021 and filed a motion to dismiss the complaint on the basis that the patents are invalid because the subject matter of the patents is not patentable under the Supreme Court and Federal Circuit precedent. The motion to dismiss was granted in part and denied in part. In December 2022, the Patent Trial and Appeal Board (&#8220;PTAB&#8221;) of the Patent and Trademark Office granted our request to review the validity of the claims in the patents asserted by NYU against us, determining that there is a reasonable likelihood that we will prevail. In December 2023, the PTAB issued written decisions invalidating each of the challenged claims in each of the NYU patents asserted against us. On December 28, 2023, the District Court entered an order continuing its stay of all proceedings against us pending any appeal by NYU of the invalidation of its patents by the PTAB. On January 31, 2024, NYU appealed the PTAB&#8217;s rulings to the Court of Appeals for the Federal Circuit. The appeals are not expected to be resolved before March 2025.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2021, the International Trade Commission ("ITC") instituted In Re Certain UMTS and LTE Cellular Communications Modules and Products Containing the Same, Investigation No. 337-TA-1240, by complainants Philips RS North America, LLC and Koninklijke Philips N.V. (collectively &#8220;Philips&#8221;) against Quectel Wireless Solutions Co., Ltd; Thales DIS AIS USA, LLC, Thales DIS AIS Deutschland GmbH; Telit Wireless Solutions, Inc., Telit Communications PLC, CalAmp. Corp., Xirgo Technologies, LLC, and Laird Connectivity, Inc. (collectively &#8220;respondents&#8221;). In the ITC investigation, Philips seeks an order excluding communications modules, and products that contain them, from importation into the United States based on alleged infringement of 3G and 4G standard essential patents held by Philips. On October 6-14, 2021, the administrative law judge held a hearing on the merits. The administrative law judge issued an initial determination on April 1, 2022, finding no violation of any of the Philips' patents asserted in the ITC. Philips sought review by the full ITC. On July 6, 2022, the Commission affirmed the administrative law judge&#8217;s determination that there was no violation of asserted Philips' patents. The Commission terminated the ITC proceedings. Philips did not appeal the ITC&#8217;s decision. On December 17, 2020, Philips filed companion cases for patent infringement against the same defendants in the United States District Court for the District of Delaware, case nos. 1:20-cv-01707, 01708, 01709, 01710, 01711, and 01713 (CFC) seeking damages, an injunction, and a declaration from the court on the amount of a fair reasonable and non-discriminatory license rate for the standard essential patents it is asserting against the communications module defendants. The district court cases were stayed pending the resolution of the ITC proceedings. The parties have returned to the district court for further proceedings. We were not a party to the ITC investigation, and we are not a party to the district court cases, but we sell products that incorporate communications modules at issue in the district court case. The first trial in the cases by Philips against the communications module defendants was originally set for August 12, 2024. On August 5, 2024, the court issued an order vacating the trial date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2022, Cleveland Medical Devices Inc. ("Cleveland Medical") filed suit for patent infringement against ResMed Inc. in the United States District Court for the District of Delaware, case no. 1:22-cv-00794. Cleveland Medical asserts that numerous ResMed connected devices, when combined with certain ResMed data platforms and/or software, including AirView and ResScan, infringe one or more of <ix:nonFraction unitRef="patent" contextRef="c-269" decimals="INF" name="rmd:NumberOfPatents" format="ixt-sec:numwordsen" scale="0" id="f-1249">seven</ix:nonFraction> Cleveland Medical patents, including U.S. Patent Nos. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-93-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-1248-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,076,269; 10,426,399; 10,925,535; 11,064,937; 10,028,698; 11,202,603; and 11,234,637. We moved to dismiss the action because Cleveland Medical sued the wrong ResMed entity, and to dismiss the indirect and willful infringement allegations by Cleveland Medical. On October 2, 2023, the court granted a portion of the motion, dismissing all Cleveland Medical claims for indirect and willful infringement, and denied the rest of the motion. On March 22, 2023, ResMed Corp. filed a petition with the PTAB seeking review of the validity of U.S. Patent No. 10,076,269. On May 6, 2024, the PTAB granted the petition and instituted an Inter Partes Review proceeding against the patent. On June 21, 2024, the District Court of Delaware granted ResMed&#8217;s motion to stay the case until the PTAB issues its final written decision in the Inter Partes Review proceeding. The PTAB decision is expected by May 6, 2025.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2023, ResMed Corp. filed suit in the United States District Court for the Southern District of California, case no. 23-cv-00500-TWR-JLB, seeking a declaration that it does not infringe U.S. Patent No. 11,602,284 issued to Cleveland Medical. In November 2023, the case was transferred to the Northern District of Ohio for the convenience of the parties. Cleveland Medical answered the complaint and filed a counterclaim asserting that ResMed Corp. infringes <ix:nonFraction unitRef="patent" contextRef="c-270" decimals="INF" name="rmd:NumberOfPatents" format="ixt-sec:numwordsen" scale="0" id="f-1250">three</ix:nonFraction> additional Cleveland Medical patents, including U.S. Patent Nos. 11,375,921; 11,690,512; and 11,786,680. On April 9, 2024, Cleveland Medical filed a second amended answer and counterclaims accusing ResMed Corp. of infringing U.S. Patent Nos. 11,857,333 and 11,872,029. ResMed Corp. filed a petition with the PTAB for post-grant review of the validity of U.S. Patent No. 11,602,284, which the PTAB denied on June 24, 2024. On July 24, 2024, ResMed Corp. requested rehearing of the PTAB's denial of the petition for post-grant review of US Patent No. 11,602,284.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on currently available information, we are unable to make a reasonable estimate of loss or range of losses, if any, arising from matters that remain open.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Obligations Under Recourse Provisions</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use independent financing institutions to offer some of our customers financing for the purchase of some of our products. Under these arrangements, if the customer qualifies under the financing institutions&#8217; credit criteria and finances the transaction, the customers repay the financing institution on a fixed payment plan. For some of these arrangements, the customer&#8217;s receivable balance is with limited recourse whereby we are responsible for repaying the financing company should the customer default. We record a contingent provision, which is estimated based on historical default rates. This is applied to receivables sold with recourse and is recorded in accrued expenses.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended June&#160;30, 2024 and 2023, receivables sold with limited recourse were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="rmd:ReceivablesSoldWithLimitedRecourse" scale="6" id="f-1251">206.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="rmd:ReceivablesSoldWithLimitedRecourse" scale="6" id="f-1252">181.2</ix:nonFraction> million, respectively. As of June&#160;30, 2024, the maximum exposure on outstanding receivables sold with recourse and contingent provision were $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" id="f-1253">35.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="f-1254">0.8</ix:nonFraction> million, respectively. As of June&#160;30, 2023, the maximum exposure on outstanding receivables sold with recourse and contingent provision were $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" id="f-1255">32.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:LossContingencyAccrualProvision" scale="6" id="f-1256">0.6</ix:nonFraction> million, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we enter into agreements to purchase goods or services that are not cancelable without penalty, primarily related to supply arrangements. <ix:nonNumeric contextRef="c-1" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="f-1257" continuedAt="f-1257-1" escape="true">Obligations under our purchase agreements at June&#160;30, 2024 were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-1257-1"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.997%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Years Ending June 30</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2029</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minimum purchase obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="3" id="f-1258">1,023,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1259">845,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PurchaseObligationDueInSecondYear" format="ixt:num-dot-decimal" scale="3" id="f-1260">113,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PurchaseObligationDueInThirdYear" format="ixt:num-dot-decimal" scale="3" id="f-1261">24,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PurchaseObligationDueInFourthYear" format="ixt:num-dot-decimal" scale="3" id="f-1262">3,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PurchaseObligationDueInFifthYear" format="ixt:num-dot-decimal" scale="3" id="f-1263">1,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PurchaseObligationDueAfterFifthYear" format="ixt:num-dot-decimal" scale="3" id="f-1264">35,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="i7fe754a0eb594e619b22be4f3387c577_160"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(16) <ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="f-1265" continuedAt="f-1265-1" escape="true">Derivative Instruments and Hedging Activities </ix:nonNumeric></span></div><ix:continuation id="f-1265-1" continuedAt="f-1265-2"><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Values of Derivative Instruments </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="f-1266" continuedAt="f-1266-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our assets and liabilities related to derivative instruments on a gross basis within the consolidated balance sheets (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-94-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-1265-2"><ix:continuation id="f-1266-1"><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-1267">2,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-1268">2,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1269"><span style="-sec-ix-hidden:f-1270">Prepaid expenses and other current assets</span></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="f-1271">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="f-1272">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1273"><span style="-sec-ix-hidden:f-1274">Prepaid taxes and other non-current assets</span></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-1275">2,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-1276">2,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign cross-currency swaps &#8211; Fair Value Hedge</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1277">10,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1278">19,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1279"><span style="-sec-ix-hidden:f-1280">Other long-term liabilities</span></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign cross-currency swaps &#8211; Net Investment Hedge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1281">21,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1282">40,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1283">4,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1284">9,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1285"><span style="-sec-ix-hidden:f-1286">Accrued expenses</span></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="f-1287">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="f-1288">595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1289">36,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1290">70,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Hedge Gains (Losses)</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="f-1291" continuedAt="f-1291-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the following gains (losses) on the foreign cross currency swaps designated as fair value hedges (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized in other comprehensive income (loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="f-1292">3,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="f-1293">5,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="3" id="f-1294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on cross-currency swap in interest (expense) income, net (amount excluded from effectiveness testing)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-1295">4,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-1296">3,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="3" id="f-1297">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on cross-currency swap in other, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="3" id="f-1298">5,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="3" id="f-1299">14,329</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:fixed-zero" scale="3" id="f-1300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on intercompany debt in other, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" format="ixt:num-dot-decimal" scale="3" id="f-1301">5,942</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" format="ixt:num-dot-decimal" scale="3" id="f-1302">14,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" format="ixt:fixed-zero" scale="3" id="f-1303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Investment Hedge Gains (Losses)</span></div><ix:continuation id="f-1291-1" continuedAt="f-1291-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the following gains (losses) on the foreign cross currency swaps designated as net investment hedges (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized in cumulative translation adjustment within other comprehensive income (loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="f-1304">19,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="f-1305">40,803</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="3" id="f-1306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized from the excluded components in interest (expense) income, net </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" format="ixt:num-dot-decimal" scale="3" id="f-1307">10,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" format="ixt:num-dot-decimal" scale="3" id="f-1308">9,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" format="ixt:fixed-zero" scale="3" id="f-1309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-designated Derivative Gains (Losses)</span></div><ix:continuation id="f-1291-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the following gains (losses) in the consolidated statement of income on derivatives not designated as hedging instruments (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on foreign currency hedging instruments in other, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="f-1310">4,168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="f-1311">8,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="f-1312">19,511</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on other foreign-currency-denominated transactions in other, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="3" id="f-1313">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="f-1314">12,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="f-1315">22,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="f-1316">4,149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="f-1317">4,204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" format="ixt:num-dot-decimal" scale="3" id="f-1318">2,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-95-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_166"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(17) <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-1323" continuedAt="f-1323-1" escape="true">Business Combinations</ix:nonNumeric></span></div><ix:continuation id="f-1323-1" continuedAt="f-1323-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 21, 2022, we completed our acquisition of <ix:nonFraction unitRef="number" contextRef="c-298" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="f-1324">100</ix:nonFraction>% of the shares in MediFox-Dan Investment GmbH and its subsidiaries (&#8220;MEDIFOX DAN&#8221;), a German leader in software solutions for a wide variety of out-of-hospital care providers, for $<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="f-1325">997.5</ix:nonFraction> million. This acquisition has been accounted for as a business combination using purchase accounting and included in our consolidated financial statements from November 21, 2022. The acquisition was paid for using funds drawn down from our Revolving Credit Agreement.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-1326" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase price was allocated to MEDIFOX DAN's tangible and identifiable intangible assets and liabilities based upon estimated fair values as of the November 21, 2022 closing date, as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Final</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible assets - useful life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1327">7,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="f-1328">16,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1329">7,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="rmd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment" format="ixt:num-dot-decimal" scale="3" id="f-1330">57,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1331">18,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="rmd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1332">19,359</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1333">18,349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="f-1334">11,623</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1335">43,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-301" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-1336">6</ix:nonNumeric> - <ix:nonNumeric contextRef="c-302" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-1337">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1338">175,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-304" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-1339">11</ix:nonNumeric> - <ix:nonNumeric contextRef="c-305" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-1340">13</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1341">32,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-307" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-1342">10</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1343">78,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1344">767,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase price</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-1345">997,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed the purchase price allocation in relation to this acquisition during the quarter ended June 30, 2023. The cost of the acquisition was allocated to the assets acquired and liabilities assumed based on estimates of their fair values at the date of acquisition. Key assumptions used to determine the fair value of intangible assets acquired included forecast revenue growth rates, forecast earnings before interest, tax, depreciation, and amortization, and weighted average cost of capital. The goodwill recognized as part of the acquisition is reflected in our SaaS segment and is not deductible for tax purposes. It mainly represents the synergies that are unique to our combined businesses and the potential for new products and services to be developed in the future.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma results of operations have not been presented because the effects of this acquisition were not material to our consolidated statements of income. </span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1323-2">We did <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:fixed-zero" scale="0" id="f-1346">not</ix:nonFraction> have material acquisition related expenses during the year ended June&#160;30, 2024. We recorded acquisition related expenses of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-1347">10.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-1348">1.9</ix:nonFraction>&#160;million during the years ended June&#160;30, 2023 and June&#160;30, 2022, respectively.</ix:continuation> </span></div><div id="i7fe754a0eb594e619b22be4f3387c577_169"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(18) <ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-1349" continuedAt="f-1349-1" escape="true">Restructuring Expenses </ix:nonNumeric></span></div><ix:continuation id="f-1349-1" continuedAt="f-1349-2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring expenses consist of costs incurred in connection with the realignment of business strategies and operations as well as cost rationalization efforts. These costs are separately presented as restructuring expenses within our consolidated statement of income for all periods presented. Although the costs associated with restructuring plans have not been allocated to our business segments' results in Note 13 &#8211; Segment Information, the restructuring plans impacted both our Sleep and Respiratory Care and SaaS segments. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended June&#160;30, 2024, we recorded $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-1350">64.2</ix:nonFraction> million of restructuring related charges associated with an evaluation of our existing operations to increase operational efficiency, decrease costs and increase profitability. Restructuring charges for the year ended June&#160;30, 2024 are comprised of $<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-1351">28.6</ix:nonFraction> million of employee severance and other one-time termination benefits, $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-1352">33.2</ix:nonFraction> million of intangible asset impairments associated with the wind down of certain </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-96-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="f-1349-2" continuedAt="f-1349-3"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business activities, and $<ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-1353">2.4</ix:nonFraction> million of other miscellaneous asset impairments. As of June&#160;30, 2024, there were <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="0" id="f-1354">no</ix:nonFraction> restructuring expenses remaining in our accruals. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended June 30, 2023, we incurred restructuring expenses of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-1355">9.2</ix:nonFraction>&#160;million associated with the reorganization and rationalization of our operations. We recorded the full amount of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-1356">9.2</ix:nonFraction>&#160;million during the year ended June 30, 2023. The restructuring expenses consisted primarily of severance to employees. As of June 30, 2023, we had $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="f-1357">7.8</ix:nonFraction>&#160;million in restructuring expenses remaining in our accruals which were paid during the year ended June 30, 2024.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1349-3">We did <ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="0" id="f-1358">not</ix:nonFraction> incur material restructuring expenses during the year ended June 30, 2022.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-97-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_172"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="f-1359" continuedAt="f-1359-1" escape="true"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VALUATION AND QUALIFYING ACCOUNTS AND RESERVES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2024, 2023 and 2022</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning<br/>of Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged to costs and expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>(deductions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>End of<br/>Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended June&#160;30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Applied against asset account</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allowance for trade accounts receivable </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1360">23,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="f-1361">9,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-1362">12,273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1363">21,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended June&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Applied against asset account</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allowance for trade accounts receivable </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1364">23,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="f-1365">5,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-1366">5,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1367">23,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Applied against asset account</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allowance for trade accounts receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1368">32,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="f-1369">2,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-1370">11,499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1371">23,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><ix:continuation id="f-1359-1" continuedAt="f-1359-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"><ix:continuation id="f-1359-2">Beginning balance is adjusted to reflect the cumulative pre-tax effect of adopting Accounting Standards Update No. 2016-13, &#8220;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments&#8221; (Topic 326), effective July 1, 2021.</ix:continuation> </span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying report of independent registered public accounting firm.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-98-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_175"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Items 9 &#8211; 9C</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_178"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A CONTROLS AND PROCEDURES </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of June&#160;30, 2024. Based on the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June&#160;30, 2024. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-99-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_181"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Items 9 &#8211; 9C</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. Our internal control over financial reporting includes those policies and procedures that: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed the effectiveness of our internal control over financial reporting as of June&#160;30, 2024. In making this assessment, management used the framework in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Management&#8217;s assessment included an evaluation of the design of our internal control over financial reporting and testing of the operational effectiveness of our internal control over financial reporting. Management reviewed the results of its assessment with the audit committee of our board of directors. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on that assessment under the framework in Internal Control-Integrated Framework (2013), management concluded that the company&#8217;s internal control over financial reporting was effective as of June&#160;30, 2024. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KPMG LLP, independent registered public accounting firm, who audited and reported on the consolidated financial statements of ResMed Inc. included in this report, has issued an attestation report on the effectiveness of internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-100-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_184"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Items 9 &#8211; 9C</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ResMed Inc.:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited ResMed Inc. and subsidiaries' (the Company) internal control over financial reporting as of June 30, 2024, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of June 30, 2024, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of June 30, 2024 and 2023, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended June 30, 2024, and the related notes and financial statement schedule II (collectively, the consolidated financial statements), and our report dated August 8, 2024 expressed an unqualified opinion on those consolidated financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 8, 2024</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-101-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_187"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Items 9 &#8211; 9C</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B OTHER INFORMATION</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our directors and executive officers may purchase or sell shares of our common stock in the market from time to time, including pursuant to equity trading plans adopted in accordance with Rule 10b5-1 under the Exchange Act and in compliance with guidelines specified by our insider trading policy. In accordance with Rule 10b5-1 and our insider trading policy, directors, officers and certain employees who, at such time, are not in possession of material non-public information are permitted to enter into written plans that pre-establish amounts, prices and dates (or formula for determining the amounts, prices and dates) of future purchases or sales of our stock, including shares acquired pursuant to our equity incentive plans. Under a Rule 10b5-1 trading plan, a broker executes trades pursuant to parameters established by the director or executive officer when entering into the plan, without further direction from them. The use of these trading plans permits asset diversification as well as personal financial and tax planning. Our directors and executive officers also may buy or sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of material nonpublic information, subject to compliance with SEC rules, the terms of our insider trading policy and certain minimum holding requirements. </span></div><ix:nonNumeric contextRef="c-1" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-1372" continuedAt="f-1372-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table describes any contracts, instructions or written plans for the sale or purchase of the Company&#8217;s securities and intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act that were adopted by our directors and executive officers during the quarterly periods ended June&#160;30, 2024 and March 31, 2024, for which the plan adoptions were inadvertently omitted and further adjustments were required to the disclosure included in the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 filed with the SEC on April 26, 2024:</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan Action</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan Adoption Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Scheduled Expiration Date of Rule 10b5-1 Trading Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Number of Securities to Be Sold (Up to)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-317" name="ecd:TrdArrIndName" id="f-1373">Michael J. Farrell</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-317" name="ecd:TrdArrIndTitle" id="f-1374">Chief Executive Officer</ix:nonNumeric> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-317" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1375">Adoption</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-317" name="ecd:TrdArrAdoptionDate" id="f-1376">January 31, 2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-317" name="ecd:TrdArrExpirationDate" id="f-1377">November 15, 2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-318" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1378">102,781</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-319" name="ecd:TrdArrIndName" id="f-1379">Jan De Witte</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-319" name="ecd:TrdArrIndTitle" id="f-1380">Director</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-319" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1381">Adoption</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-319" name="ecd:TrdArrAdoptionDate" id="f-1382">February 2, 2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-319" name="ecd:TrdArrExpirationDate" id="f-1383">November 12, 2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-320" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1384">1,156</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-321" name="ecd:TrdArrIndName" id="f-1385">Brett A. Sandercock</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-321" name="ecd:TrdArrIndTitle" id="f-1386">Chief Financial Officer</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-321" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1387">Adoption</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-321" name="ecd:TrdArrAdoptionDate" id="f-1388">February 6, 2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-321" name="ecd:TrdArrExpirationDate" id="f-1389">April 30, 2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-322" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1390">24,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-323" name="ecd:TrdArrIndName" id="f-1391">Kaushik Ghoshal</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-323" name="ecd:TrdArrIndTitle" id="f-1392">Chief Commercial Officer, SaaS</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-323" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1393">Adoption</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-323" name="ecd:TrdArrAdoptionDate" id="f-1394">April 29, 2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-323" name="ecd:TrdArrExpirationDate" id="f-1395">November 14, 2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-324" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1396">19,260</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-325" name="ecd:TrdArrIndName" id="f-1397">Michael J. Rider</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-325" name="ecd:TrdArrIndTitle" id="f-1398">Global General Counsel and Secretary</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-325" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1399">Adoption</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-325" name="ecd:TrdArrAdoptionDate" id="f-1400">May 11, 2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-325" name="ecd:TrdArrExpirationDate" id="f-1401">April 1, 2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-326" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1402">1,292</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-327" name="ecd:TrdArrIndName" id="f-1403">Peter C. Farrell</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-327" name="ecd:TrdArrIndTitle" id="f-1404">Chair Emeritus</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-327" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1405">Adoption</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-327" name="ecd:TrdArrAdoptionDate" id="f-1406">May 28, 2024</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-327" name="ecd:TrdArrExpirationDate" id="f-1407">September 2, 2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-328" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1408">24,000</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><ix:continuation id="f-1372-1" continuedAt="f-1372-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"><ix:continuation id="f-1372-2">A trading plan may also expire on such earlier date that all transactions under the trading plan are completed.</ix:continuation> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarterly period ended June&#160;30, 2024, <ix:nonNumeric contextRef="c-329" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1409"><ix:nonNumeric contextRef="c-329" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1410"><ix:nonNumeric contextRef="c-329" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1411">none</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> of our directors or executive officers terminated a Rule 10b5-1 trading plan or adopted or terminated a non-Rule 10b5-1 trading arrangement (each term as defined in Item 408 of Regulation S-K).</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_190"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-102-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_193"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART III</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Items 10 &#8211; 14</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_196"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item is premised on information that will be included in our definitive proxy statement for our next annual meeting of stockholders, which will be filed with the Securities and Exchange Commission within 120 days after June&#160;30, 2024. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed as exhibits to this report for the year ended June&#160;30, 2024, the certifications of our chief executive officer and chief financial officer required by Section 302 of the Sarbanes-Oxley Act of 2002. </span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Conduct</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Business Conduct &amp; Ethics that applies to our board of directors and all of our employees, including our chief executive officer and principal financial officer.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our code of conduct is available at our website by visiting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">https://investor.resmed.com/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and clicking through &#8220;Investors,&#8221; &#8220;Corporate Governance,&#8221; &#8220;Corporate Governance Documents,&#8221; and &#8220;Code of Conduct -English.&#8221; When required by the rules of the NYSE, or the Securities and Exchange Commission, or SEC, we will disclose any future amendment to, or waiver of, any provision of the code of conduct for our chief executive officer and principal financial officer or any member or members of our board of directors on our website within four business days following the date of such amendment or waiver</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_199"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11 EXECUTIVE COMPENSATION </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item is incorporated by reference from our definitive proxy statement for our next annual meeting of stockholders, which will be filed with the Securities and Exchange Commission within 120 days after June&#160;30, 2024. </span></div><div id="i7fe754a0eb594e619b22be4f3387c577_202"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item is incorporated by reference from our definitive proxy statement for our next annual meeting of stockholders, which will be filed with the Securities and Exchange Commission within 120 days after June&#160;30, 2024. </span></div><div id="i7fe754a0eb594e619b22be4f3387c577_205"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item is incorporated by reference from our definitive proxy statement for our next annual meeting of stockholders, which will be filed with the Securities and Exchange Commission within 120 days after June&#160;30, 2024.</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_208"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14 PRINCIPAL ACCOUNTANT FEES AND SERVICES </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item is incorporated by reference from our definitive proxy statement for our next annual meeting of stockholders, which will be filed with the Securities and Exchange Commission within 120 days after June&#160;30, 2024. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-103-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_211"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART IV</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Items 15 &#8211; 16</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_214"></div><div style="-sec-extract:summary;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15 EXHIBITS AND CONSOLIDATED FINANCIAL STATEMENT SCHEDULES </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as part of this report: </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Financial Statements and Schedules &#8211; The index to our consolidated financial statements and schedules are set forth in the &#8220;Index to Consolidated Financial Statements&#8221; under Item 8 of this report.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit Lists</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312513416916/d604032dex31.htm">First Restated Certificate of Incorporation of ResMed Inc., as amended. (Incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Report on Form 10-Q for the quarter ended September 30, 2013)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312523280656/d892007dex31.htm">Eight</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312523280656/d892007dex31.htm">h</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312523280656/d892007dex31.htm"> Amended and Restated Bylaws of ResMed Inc., a Delaware Corporation (as Approved and Adopted by Board Resolution </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312523280656/d892007dex31.htm">No</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312523280656/d892007dex31.htm">vember 17, 2023</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312523280656/d892007dex31.htm">)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312523280656/d892007dex31.htm">.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312523280656/d892007dex31.htm"> (Incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Report on Form 8-K filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312523280656/d892007dex31.htm">November 20, 2023</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312523280656/d892007dex31.htm">)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of certificate evidencing shares of Common Stock. (Incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-1 (No. 33-91094) declared effective on June 1, 1995)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit42-descriptionofres.htm">Description of ResMed Inc.&#8217;s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit42-descriptionofres.htm">.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312509136727/dex101.htm">Form of Indemnification Agreements for our directors and officers. (Incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Report on Form 8-K filed on June 24, 2009)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312509136727/dex102.htm">Form of Access Agreement for directors. (Incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Report on Form 8-K filed on June 24, 2009)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381922000010/ex103-updatedformofexecuti.htm">Updated Form of Executive Agreement. (Incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Report on Form 10-K filed on August 12, 2022)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312517293062/d456787ddef14a.htm">Amendment and Restatement to the ResMed Inc. 2009 Incentive Award Plan. (Incorporated by reference to Appendix B of ResMed Inc.&#8217;s Proxy Statement filed with the Securities and Exchange Commission on September 25, 2017)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit105-deferredcompens.htm">Amended and Restated ResMed Inc. Deferred Compensation Plan.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381922000010/ex106-formofrestrictedstoc.htm">Form of Restricted Stock Unit Award Agreement for Directors. (Incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Report on Form 10-K filed on August 12, 2022)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381923000011/ex107-formofstockoptiongra.htm">Form of Stock Option Grant for Executive Officers.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381923000011/ex107-formofstockoptiongra.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381923000011/ex107-formofstockoptiongra.htm">(Incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381923000011/ex107-formofstockoptiongra.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381923000011/ex107-formofstockoptiongra.htm"> to the Registrant&#8217;s Report on Form 10-K filed on August 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381923000011/ex107-formofstockoptiongra.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381923000011/ex107-formofstockoptiongra.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381923000011/ex107-formofstockoptiongra.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381923000011/ex107-formofstockoptiongra.htm">)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381922000010/ex108-formofstockoptiongra.htm">Form of Stock Option Grant for Directors. (Incorporated by reference to Exhibit 10.8 to the Registrant&#8217;s Report on Form 10-K filed on August 12, 2022)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381923000011/ex109-formofpsuagreementfo.htm">Form of Performance-Based Restricted Stock Unit Award Agreement for Executive Officers. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381923000011/ex109-formofpsuagreementfo.htm">(Incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381923000011/ex109-formofpsuagreementfo.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381923000011/ex109-formofpsuagreementfo.htm"> to the Registrant&#8217;s Report on Form 10-K filed on August 11, 2023)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381924000003/ex101-formofpsuagreementfo.htm">Form of Performance-Based Restricted Stock Unit Award Agreement for Executive Officers. (Incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381924000003/ex101-formofpsuagreementfo.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381924000003/ex101-formofpsuagreementfo.htm"> to the Registrant&#8217;s Report on Form 10-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381924000003/ex101-formofpsuagreementfo.htm">Q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381924000003/ex101-formofpsuagreementfo.htm"> filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381924000003/ex101-formofpsuagreementfo.htm">January 25, 2024</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381924000003/ex101-formofpsuagreementfo.htm">)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381923000011/ex1010-formofexecutiverest.htm">Form of Executive Restricted Stock Unit Award Agreement for Executive Officers.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381923000011/ex1010-formofexecutiverest.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381923000011/ex1010-formofexecutiverest.htm">(Incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381923000011/ex1010-formofexecutiverest.htm">10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381923000011/ex1010-formofexecutiverest.htm"> to the Registrant&#8217;s Report on Form 10-K filed on August 11, 2023)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312522186327/d363805dex101.htm">Second Amended and Restated Credit Agreement dated as of June 29, 2022, by and among ResMed Inc., as borrower, MUFG Union Bank, N.A., as administrative agent, joint lead arranger, sole book runner, swing line lender and letter of credit issuer, Westpac Banking Corporation, as syndication agent and joint lead arranger, HSBC Bank Australia Limited, as syndication agent and joint lead arranger, HSBC Bank USA, National Association, as syndication agent and joint lead arranger, Wells Fargo Bank, National Association, as documentation agent, and each of the lenders identified therein. (Incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Report on Form 8-K filed on June 29, 2022)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312522186327/d363805dex102.htm">Second Amended and Restated Unconditional Guaranty dated as of June 29, 2022, by each of the Revolving Facility Guarantors, in favor of MUFG Union Bank, N.A., in its capacity as administrative agent under the Revolving Credit Agreement. (Incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Report on Form 8-K filed on June 29, 2022)</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-104-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="-sec-extract:summary;margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART IV</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Items 15 &#8211; 16</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312522186327/d363805dex103.htm">Second Amendment to Syndicated Facility Agreement and First Amendment to Unconditional Guaranty Agreement, dated as of June 29, 2022, by and among ResMed Pty Limited, as borrower, ResMed, Inc., the other parties party thereto, and MUFG Union Bank, N.A., as administrative agent. (Incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Report on Form 8-K filed on June 29, 2022)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">10.15</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312518122818/d572927dex104.htm">Unconditional Guaranty dated as of April 17, 2018, by each of the guarantors identified on the Term Facility Guaranty&#8217;s signature pages as a guarantor, in favor of MUFG Union Bank, N.A., in its capacity as administrative agent under the Term Credit Agreement. (Incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Report on Form 8-K filed on April 19, 2018).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">10.16</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312518291742/d612931ddef14a.htm">The ResMed Inc. 2018 Employee Stock Purchase Plan. (Incorporated by reference to Appendix B of ResMed Inc.&#8217;s Proxy Statement filed with the Securities and Exchange Commission on October 3, 2018.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">10.17</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312519194005/d755232dex101.htm">Note Purchase Agreement, dated July 10, 2019 by and among ResMed Inc. and the purchasers party to that agreement (including form of 3.24% Series A Senior Note due 2026, form of Series B 3.45% Senior Note due 2029, and form of Subsidiary Guaranty Agreement). (Incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Report on Form 8-K filed on July 15, 2019)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-1418"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="exhibit19-resmedinsidertra.htm">Insider Trading Policy and Guidelines</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="exhibit19-resmedinsidertra.htm">.</a></ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">21.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="exhibit211-subsidiariesq4f.htm">Subsidiaries of the Registrant.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">23.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="exhibit231-auditorconsentq.htm">Consent of Independent Registered Public Accounting Firm.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">31.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="ex311-ceocertificationq4fy.htm">Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002. </a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">31.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="ex312-cfocertificationq4fy.htm">Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002. </a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">32.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="ex321-ceoandcfocertificati.htm">Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. </a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">97</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="exhibit97-resmedclawbackpo.htm">Compensation Recovery Policy.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">101</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">The following materials from ResMed Inc.&#8217;s Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2024 formatted in Inline XBRL (Inline Extensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Income, (iii) the Consolidated Statements of Comprehensive Income, (iv) the Consolidated Statements of Stockholders' Equity, (v) the Consolidated Statements of Cash Flows and (vi) related notes.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">104</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">The cover page from ResMed Inc.&#8217;s Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2024, formatted in Inline XBRL and contained in Exhibit 101.</span></div></td></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">Management contract or compensatory plan or arrangement</span></div><div id="i7fe754a0eb594e619b22be4f3387c577_217"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16 FORM 10-K SUMMARY</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-105-</span></div></div></div><div id="i7fe754a0eb594e619b22be4f3387c577_220"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART IV</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signatures</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DATED August&#160;8, 2024</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ResMed Inc. </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:108%">MICHAEL J. FARRELL</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">Michael J. Farrell</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">Chief Executive Officer </span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-106-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i7fe754a0eb594e619b22be4f3387c577_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART IV</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signatures</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated. </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"/><td style="width:35.083%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TITLE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DATE</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ MICHAEL J. FARRELL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Chairman</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael J. Farrell</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ BRETT A. SANDERCOCK</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brett A. Sandercock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer and<br/>Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ PETER C. FARRELL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director and Chair Emeritus</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter C. Farrell</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ CAROL J. BURT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carol J. Burt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ JAN De WITTE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jan De Witte</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ KAREN DREXLER </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karen Drexler</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ HARJIT GILL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harjit Gill</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ JOHN HERNANDEZ</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hernandez</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ RICHARD SULPIZIO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard Sulpizio</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ DESNEY TAN</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Desney Tan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ RON TAYLOR</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ron Taylor</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-107-</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>exhibit42-descriptionofres.htm
<DESCRIPTION>EX-4.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i1a07b0d3bea34dc3979c5ff7a5f5c315_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:30.75pt;padding-right:30.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 4.2</font></div></td></tr></table></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of the Registrant&#8217;s Securities <br>Registered Pursuant to Section 12 of the <br>Securities Exchange Act of 1934</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ResMed Inc. (&#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221;) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)&#58; our common stock. The following summary of the terms of our common stock is based upon our First Restated Certificate of Incorporation, as amended (the &#8220;Certificate of Incorporation&#8221;), and our Eighth Amended &#38; Restated Bylaws (the &#8220;Bylaws&#8221;). The summary is not complete and is qualified by reference to our Certificate of Incorporation and our Bylaws, which are filed as exhibits to this Annual Report on Form 10-K and are incorporated by reference herein. We encourage you to read our Certificate of Incorporation, our Bylaws and the applicable provisions of the Delaware General Corporation Law (the &#8220;DGCL&#8221;) for additional information.</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorized Capital Stock</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our authorized capital stock consists of 350,000,000 shares of common stock, par value $0.004 per share, and 2,000,000 shares of preferred stock, par value $0.01 per share.</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting Rights</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder of record to one vote with respect to each matter submitted to a vote by our stockholders. Our common stock votes as a single class on all matters relating to the election and removal of directors on our board of directors and as provided by law. Holders of our common stock do not have cumulative voting rights. </font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except in respect of matters relating to the election of directors, or as otherwise provided in the Certificate of Incorporation or required by law, all matters to be voted on by our stockholders must be approved by a majority of the shares present in person or by proxy at the meeting and entitled to vote on the subject matter. </font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the case of the election of directors, each director is elected by the affirmative vote of a majority of the votes cast with respect to such director by the shares represented and entitled to vote thereon at a meeting of stockholders for the election of directors at which a quorum is present (an &#8220;Election Meeting&#8221;)&#59; provided, however, that if our board of directors determines that the number of nominees exceeds the number of directors to be elected at such meeting (a &#8220;Contested Election&#8221;), and our board of directors has not rescinded such determination by the record date of the Election Meeting as initially announced, each of the directors to be elected at the Election Meeting is elected by the affirmative vote of a plurality of the votes cast by the shares represented and entitled to vote at such meeting with respect to the election of such director. A &#8220;majority of the votes cast&#8221; means that the number of votes cast &#8220;for&#8221; a candidate for director or other action exceeds the number of votes cast &#8220;against&#8221; that candidate or other action (with &#8220;abstentions&#8221; and &#8220;broker non-votes&#8221; not counted as a vote cast either &#8220;for&#8221; or &#8220;against&#8221;). In an election other than a Contested Election, stockholders are given the choice to cast votes &#8220;for&#8221; or &#8220;against&#8221; the election of directors or to &#8220;abstain&#8221; from such vote and do not have the ability to cast any other vote with respect to such election of directors. In a Contested Election, stockholders are given the choice to cast &#8220;for&#8221; or &#8220;withhold&#8221; votes for the election of directors and do not have the ability to cast any other vote with respect to such election of directors. In the event an Election Meeting involves the election of directors by separate votes by class or classes or series, the determination as to whether an election constitutes a Contested Election is to be made on a class by class or series by series basis, as applicable.</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an election other than a Contested Election, it is our board&#8217;s policy that an incumbent director nominee who does not receive the required votes for re-election will continue to serve, but is expected to tender a resignation to the board of directors. The nominating and governance committee, or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">another duly authorized committee of the board of directors, will decide whether to accept or reject the tendered resignation, generally within 90 days after the election results are certified. </font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Rights</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of our outstanding shares of common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. </font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidation Rights</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, holders of our common stock would be entitled to share ratably in our assets that are legally available for distribution to stockholders after payment of our debts and other liabilities. If we have any preferred stock outstanding at such time, holders of the preferred stock may be entitled to distribution and&#47;or liquidation preferences. In either such case, we must pay the applicable distribution to the holders of our preferred stock before we may pay distributions to the holders of our common stock.</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Rights and Preferences</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of our common stock have no preemptive, conversion or other rights to subscribe for additional shares. All outstanding shares of common stock are validly issued, fully paid and nonassessable. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:28pt;padding-right:28pt;text-align:justify"><img alt="image_01a.jpg" src="image_01a.jpg" style="height:3px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Certificate of Incorporation authorizes our board of directors to provide for the issuance of shares of preferred stock in one or more series and to fix the annual rate or rates of the dividends for a particular series&#59; the dividend payment dates for a particular series and the date from which dividends on all shares of such series issued prior to the record date for the first dividend payment date shall be cumulative&#59; the redemption price or prices for a particular series&#59; the voting powers for a particular series&#59; the rights, if any of the holders of the shares of the particular series to convert the same into shares of any other series or class of our securities, with any provisions for the subsequent adjustment of such conversion rights&#59; and to classify or reclassify any unissued shares by fixing or altering from time to time any of the foregoing rights, privileges and qualifications. Any preferred stock so issued may rank senior to our common stock with respect to the payment of dividends or amounts upon liquidation, dissolution or winding up, or both. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control of our company without further action by the stockholders and may adversely affect the voting and other rights of the holders of common stock. The issuance of preferred stock with voting and conversion rights may adversely affect the voting power of the holders of common stock, including the loss of voting control to others. At present, we have no plans to issue any preferred stock.</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitakeover Effects of Delaware Law and the Certificate of Incorporation and the Bylaws</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Certificate of Incorporation and the Bylaws contains provisions that may delay, defer or discourage another party from acquiring control of us. We expect that these provisions, which are summarized below, may discourage coercive takeover practices or inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors, which we believe may result in an improvement of the terms of any such acquisition in favor of our stockholders. However, they also give our board of directors the power to discourage acquisitions that some stockholders may favor.</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Undesignated Preferred Stock</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability to authorize undesignated preferred stock will make it possible for our board of directors to issue preferred stock with super voting, special approval, dividend or other rights or preferences on a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discriminatory basis that could impede the success of any attempt to acquire us. These and other provisions may have the effect of deferring, delaying or discouraging hostile takeovers, or changes in control or management of our company.</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Special Meetings of Stockholders</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bylaws provide that special meetings of the stockholders may be called for any purpose by the board of directors, chairperson of the board, the president or the secretary, and, subject to the Bylaws, may be called upon written request of the holders of record of at least 20% of the outstanding capital stock entitled to vote at such meeting.</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advance Notice Requirements for Stockholder Proposals and Director Nominations </font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bylaws provide that advance notice of business and nominations by our stockholders for an annual or special meeting of stockholders must generally be not later than the close of business 90 days nor earlier than the close of business 120 days prior to the one-year anniversary of the preceding year&#8217;s annual meeting. Such notice must include certain information about the nominee, proposing person or proposal, as applicable, as prescribed in our Bylaws, or else will be considered deficient under our Bylaws. In addition to satisfying the foregoing requirements under our Bylaws, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than our nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act. </font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bylaws require any candidate for our board of directors, whether nominated by a stockholder or the board of directors, to provide certain background information and representations regarding disclosure of voting or compensation arrangements, compliance with our policies and guidelines and intent to serve the entire term. </font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bylaws also prohibit stockholders from submitting more nominees than the number of directors up for election at the applicable meeting.</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional requirements with respect to stockholder proposals and director nominations are set forth in our Bylaws.</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DGCL Section 203</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company incorporated in Delaware, we are subject to Section 203 of the DGCL. Section 203 prohibits a publicly held Delaware corporation from engaging in a business combination, such as a merger, with a person or group owning 15% or more of the corporation&#8217;s voting stock for a period of three years following the date the person became an interested stockholder, unless (with certain exceptions) the business combination or the transaction in which the person became an interested stockholder is approved in a prescribed manner. </font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Choice of Forum</font></div><div style="margin-bottom:6pt;padding-left:28pt;padding-right:28pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bylaws include a forum selection provision, which provides that, unless we consent in writing to the selection of another forum, the Delaware Court of Chancery will be the sole and exclusive forum for the following actions&#58; (i) any derivative action or proceeding brought on behalf of us&#59; (ii) any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders&#59; (iii) any action arising pursuant to any provision of the DGCL or our Certificate of Incorporation or Bylaws&#59; and (iv) any action asserting a claim against us governed by the internal affairs doctrine. Additionally, the Bylaws include language pursuant to which stockholders are deemed to have consented to personal jurisdiction in the Delaware Court of Chancery and to service of process on their counsel in any action initiated in violation of the forum selection provision.</font></div><div style="padding-left:28pt;padding-right:28pt"><img alt="image_01a.jpg" src="image_01a.jpg" style="height:3px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="padding-left:28pt;padding-right:28pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>3
<FILENAME>exhibit105-deferredcompens.htm
<DESCRIPTION>EX-10.5
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="iaa30bcf535af4cc2885a261f469a91a1_40"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.5</font></div></div><div style="margin-top:11.45pt;padding-left:108.85pt;padding-right:108.85pt;text-align:center"><font><br></font></div><div style="margin-top:11.45pt;padding-left:108.85pt;padding-right:108.85pt;text-align:center"><font><br></font></div><div style="margin-top:11.45pt;padding-left:108.85pt;padding-right:108.85pt;text-align:center"><font><br></font></div><div style="margin-top:11.45pt;padding-left:108.85pt;padding-right:108.85pt;text-align:center"><font><br></font></div><div style="margin-top:11.45pt;padding-left:108.85pt;padding-right:108.85pt;text-align:center"><font><br></font></div><div style="margin-top:11.45pt;padding-left:100.82pt;padding-right:100.82pt;text-align:center"><font style="color:#571a11;font-family:'Times New Roman',sans-serif;font-size:17.5pt;font-weight:400;line-height:218%">AMENDED AND RESTATED </font></div><div style="margin-top:11.45pt;padding-left:100.82pt;padding-right:100.82pt;text-align:center"><font style="color:#571a11;font-family:'Times New Roman',sans-serif;font-size:17.5pt;font-weight:400;line-height:218%">RESMED  INC</font><font style="color:#571a11;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:218%">.</font></div><div style="margin-top:3.8pt;padding-left:108.9pt;padding-right:108.9pt;text-align:center"><font style="color:#571a11;font-family:'Times New Roman',sans-serif;font-size:18.5pt;font-weight:400;line-height:120%">DEFERRED </font><font style="color:#571a11;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%">COMPENSATION </font><font style="color:#571a11;font-family:'Times New Roman',sans-serif;font-size:17.5pt;font-weight:400;line-height:120%">PLAN, As Amended Through August 17, 2023</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt;margin-top:0.3pt"><font><br></font></div><div style="padding-left:177.92pt;padding-right:177.92pt;text-align:center"><font style="color:#571a11;font-family:'Times New Roman',sans-serif;font-size:13.5pt;font-weight:400;line-height:16.30pt">EFFECTIVE </font><font style="color:#571a11;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:16.30pt">DATE <br>July 1, 2010</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">1</font></div><div><font><br></font></div></div></div><div id="iaa30bcf535af4cc2885a261f469a91a1_330"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">TABLE OF CONTENTS</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.918%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_69" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">A</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_69" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">RTICLE I </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_69" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">Establishmen</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_69" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">t</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_69" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none"> and Pu</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_69" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">rpose</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_69" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_89" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">ARTICLE I</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_89" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">I</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_89" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_89" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">Definitions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_89" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_109" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">ARTICLE I</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_109" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">II</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_109" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_109" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">Eligibility and Parti</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_109" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">cipation</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_109" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">10</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_129" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">ARTICLE I</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_129" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">V</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_129" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_129" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">Deferrals</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_129" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">11</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_149" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">ARTICLE </a><a href="#iaa30bcf535af4cc2885a261f469a91a1_149" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">V</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_149" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_149" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">Employer Contributions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_149" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">14</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_169" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">ARTICLE </a><a href="#iaa30bcf535af4cc2885a261f469a91a1_169" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">V</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_169" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">I </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_169" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">Benefits</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_169" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">15</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_189" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">ARTICLE </a><a href="#iaa30bcf535af4cc2885a261f469a91a1_189" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">VI</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_189" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">I </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_189" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">Modifications to Paym</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_189" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">ent Sc</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_189" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">h</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_189" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">edules</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_189" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">20</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_209" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">ARTICLE </a><a href="#iaa30bcf535af4cc2885a261f469a91a1_209" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">VII</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_209" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">I </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_209" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">Valua</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_209" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">tion of Account Balances&#59; Investments</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_209" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_229" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">ARTICLE I</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_229" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">X</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_229" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_229" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">Administration</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_229" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">22</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_249" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">ARTICLE </a><a href="#iaa30bcf535af4cc2885a261f469a91a1_249" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">X</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_249" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_249" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">Amendment and Termination</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_249" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">24</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_269" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">ARTICLE X</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_269" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">I</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_269" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_269" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">Info</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_269" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">rmal Funding</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_269" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_289" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">ARTICLE X</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_289" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">II</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_289" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_289" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">Claims</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_289" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_309" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">ARTICLE X</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_309" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">III</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_309" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none"> </a></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_309" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">Gen</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_309" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">eral Provi</a><a href="#iaa30bcf535af4cc2885a261f469a91a1_309" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none">sions</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><a href="#iaa30bcf535af4cc2885a261f469a91a1_309" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:none">31</a></font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div id="iaa30bcf535af4cc2885a261f469a91a1_69"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE I.&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Establishment and Purpose</font></div><div style="margin-bottom:9pt;padding-left:5.15pt;padding-right:7pt;text-align:justify;text-indent:0.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ResMed Inc., a Delaware corporation (the &#8220;Company&#8221;), established the ResMed Inc. Deferred Compensation Plan, as amended and restated as of July 1, 2010, and as further amended and restated as of May 21, 2020 (the &#8220;2020 Amendment Date&#8221;) and on &#91;&#183;&#93;, 2023 (now, as amended and restated, the &#8220;Plan&#8221;). Except as otherwise stated herein, the Plan applies to deferrals of compensation for Participants commencing effective July 1, 2010.</font></div><div style="margin-bottom:9pt;padding-left:5.4pt;padding-right:7.05pt;text-align:justify;text-indent:-0.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The purpose of the Plan is to attract and retain key employees by providing Participants with an opportunity to defer receipt of a portion of their Salary, Bonus, Commissions and other specified compensation. The Plan is not intended to meet the qualification requirements of Code Section 401(a), but is intended to meet the requirements of Code Section 409A, and shall be operated and interpreted consistent with that intent.</font></div><div style="margin-bottom:9pt;padding-left:5.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Plan constitutes an unsecured promise by each Participating Employer to pay benefits in the future.  Participants in the Plan shall have the status of general  unsecured  creditors of the Company or such other Participating Employer, as applicable. Each Participating Employer shall be solely responsible for payment of the benefits of its employees and their beneficiaries. The Plan is unfunded for federal tax purposes, and is intended to be an unfunded arrangement for eligible employees who are part of a select group of management or highly compensated employees of the Employer within the meaning of Sections 201(2), 301(a)(3), and 401(a)(1) of ERISA.  Any amounts set aside to defray the liabilities assumed by the Company or another Participating Employer will remain the general assets of the Company or the applicable Participating Employer, and shall remain subject to the claims of the Company&#8217;s or the Participating Employer&#8217;s creditors, until such amounts are distributed to the Participants.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">2</font></div><div><font><br></font></div></div></div><div id="iaa30bcf535af4cc2885a261f469a91a1_89"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE II<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Definitions</font></div><div style="margin-bottom:9pt;padding-left:42.6pt;padding-right:6.2pt;text-align:justify;text-indent:-42.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> 2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Account means a bookkeeping account maintained by the Committee to record the payment obligation of a Participating Employer to a Participant as determined under the terms of the Plan.  The Committee may maintain an Account to record the total obligation to a Participant, and component Accounts to reflect amounts payable at different times and in different forms. Reference to an Account means any such Account established by the Committee, as the context requires.  Accounts are intended to constitute unfunded obligations within the meaning of Sections 201(2), 301(a)(3) and 401(a)(1) of ERISA.</font></div><div style="margin-bottom:9pt;padding-left:42.9pt;text-indent:-36.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Account Balance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Account Balance means, with respect to any Account, the total payment obligation owed to a Participant from such Account as of the most recent Valuation Date.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Affiliate of an Employer means any corporation, trade or business that, together with such Employer, is treated as a single employer under Code Section 414(b) or (c).</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Beneficiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Beneficiary means a natural person, estate, or trust designated by a Participant to receive payments to which a Beneficiary is entitled upon the death of a Participant in accordance with the provisions of the Plan.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Board of Directors means the board of directors of the Company.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Bonus means any cash compensation, in addition to Salary, for services performed by a Participant for a Service Recipient during the applicable Plan Year (or applicable Plan Years), whether or not paid in such Participant&#8217;s Plan Year or included on the federal income tax form W-2 for such Plan Year (or Plan Years), payable to a Participant under any Employer&#8217;s annual, semi-annual, or quarterly bonus plans, excluding any cash that may be payable with respect to any long-term incentive plans, stock options, stock appreciation rights, and&#47;or restricted stock. Bonus shall be calculated before reduction for compensation voluntarily deferred or contributed by the Participant pursuant to all qualified or nonqualified plans of any Employer. Notwithstanding the foregoing, for Deferral elections made on or after the 2020 Amendment Date, Bonus does not include amounts earned by a Participant while transferred to an Affiliate outside the United States and removed from U.S. payroll pursuant to a Short or Long-term assignment, International Relocation, or Localization arrangement under the Company&#8217;s Global Mobility Policy.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Business Day means each day on which the New York Stock Exchange is open for business. </font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Change in Control means the occurrence of a &#8220;change in the ownership,&#8221; a &#8220;change in the effective control&#8221; or a &#8220;change in the ownership of a substantial portion of the assets&#8221; of a corporation, as determined in accordance with this Section. In order for an event described below to constitute a Change in Control with respect to a Participant, except as otherwise provided in part (b)(ii) of this Section, the applicable event must relate to the corporation for which the Participant is providing services, the corporation that is liable for payment of the Participant&#8217;s Account Balance (or all corporations liable for payment if more </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">than one), as determined in accordance with Treas. Reg. &#167;1.409A-3(i)(5)(ii)(A)(2), or such other corporation as is determined in accordance with Treas. Reg. &#167;1.409A-3(i)(5)(ii)(A)(3). </font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In determining whether an event shall be considered a &#8220;change in the ownership,&#8221; a &#8220;change in the effective control&#8221; or a &#8220;change in the ownership of a substantial portion of the assets&#8221; of a corporation, the following provisions shall apply&#58;</font></div><div style="margin-bottom:9pt;padding-left:78.8pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;A &#8220;change in the ownership&#8221; of the applicable corporation shall occur on the date on which any one person, or more than one person acting as a group, acquires ownership of stock of such corporation that, together with stock held by such person or group, constitutes more than 50% of the total fair market value or total voting power of the stock of such corporation, as determined in accordance with Treas. Reg. &#167;1.409A-3(i)(5)(v). If a person or group is considered either to own more than 50% of the total fair market value or total voting power of the stock of such corporation, or to have effective control of such corporation within the meaning of part (b) of this Section, and such person or group acquires additional stock of such corporation, the acquisition of additional stock by such person or group shall not be considered to cause a &#8220;change in the ownership&#8221; of such corporation.</font></div><div style="margin-bottom:9pt;padding-left:78.8pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;A &#8220;change in the effective control&#8221; of the applicable corporation shall occur on either of the following dates&#58;</font></div><div style="margin-bottom:9pt;padding-left:114.8pt;padding-right:5.85pt;text-align:justify;text-indent:-33.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The date on which any one person, or more than one person acting as a group, acquires (or has acquired during the 12-month period ending on the date of the most recent acquisition by such person or persons) ownership of stock of such corporation possessing 30% or more of the total voting power of the stock of such corporation, as determined in accordance with Treas. Reg. &#167;1.409A-3(i)(5)(vi). If a person or group is considered to possess 30% or more of the total voting power of the stock of a corporation, and such person or group acquires additional stock of such corporation, the acquisition of additional stock by such person or group shall not be considered to cause a &#8220;change in the effective control&#8221; of such corporation&#59; or</font></div><div style="margin-bottom:9pt;padding-left:114.8pt;padding-right:5.85pt;text-align:justify;text-indent:-33.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;The date on which a majority of the members of the applicable corporation&#8217;s board of directors is replaced during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of such corporation&#8217;s board of directors before the date of the appointment or election, as determined in accordance with Treas. Reg. &#167;1.409A-3(i)(5)(vi). In determining whether the event described in the preceding sentence has occurred, the applicable corporation to which the event must relate shall only include a corporation identified in accordance with Treas. Reg. &#167;1.409A-3(i)(5)(ii) for which no other corporation is a majority shareholder.</font></div><div style="margin-bottom:9pt;padding-left:78.8pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;A &#8220;change in the ownership of a substantial portion of the assets&#8221; of the applicable corporation shall occur on the date on which any one person, or more than one person acting as a group, acquires (or has acquired during the 12-month period ending on the date of the most recent acquisition by such person or persons) assets from the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:78.8pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">corporation that have a total gross fair market value equal to or more than 40% of the total gross fair market value of all of the assets of the corporation immediately before such acquisition or acquisitions, as determined in accordance with Treas. Reg. &#167;1.409A-3(i)(5)(vii). A transfer of assets shall not be treated as a &#8220;change in the ownership of a substantial portion of the assets&#8221; when such transfer is made to an entity that is controlled by the shareholders of the transferor corporation, as determined in accordance with Treas. Reg. &#167;1.409A-3(i)(5)(vii)(B).</font></div><div style="margin-bottom:9pt;padding-left:78.8pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;The determination of whether an event constitutes a Change in Control shall be made in compliance with Treas. Reg. &#167;1.409A-3(i)(5).</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Change in Control Benefit means the benefit payable pursuant to the Payment Schedule that may be elected by a Participant in the event a Participant experiences a Separation from Service within 1 year following a Change in Control, as provided in Section 6.1 of the Plan.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Claimant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Claimant means a Participant or Beneficiary filing a claim under Article XII of this Plan.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Code means the Internal Revenue Code of 1986, as amended from time to time.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Code Section 409A means Section 409A of the Code, and regulations and other guidance issued by the Treasury Department and Internal Revenue Service thereunder.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Commissions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Commissions means any compensation (including quarterly sales incentives) in addition to Salary and Bonus, for services performed during any applicable Plan Year, whether or not paid in such Plan Year or included on the federal income tax Form W-2 for such calendar year, payable to a Participant as an Employee under any Employer's commission agreement or quarterly sales incentive agreement.  Notwithstanding the foregoing, for Deferral elections made on or after the 2020 Amendment Date, Commissions do not include amounts earned by a Participant while transferred to an Affiliate outside the United States and removed from U.S. payroll pursuant to a Short or Long-term assignment, International Relocation, or Localization arrangement under the Company&#8217;s Global Mobility Policy.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Committee means the committee appointed by the Board of Directors or the Compensation Committee to administer the Plan. If no designation is made, the Chief Executive Officer of the Company, or his or her delegate, shall have and exercise the powers of the Committee.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Company means ResMed Inc., a Delaware corporation.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Compensation means a Participant&#8217;s Salary, Bonus, Commissions, and such other cash or equity-based compensation (if any) approved by the Committee as Compensation that may be deferred under this Plan. Compensation shall not include any compensation that has been previously deferred under this Plan or any other arrangement subject to Code Section 409A.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Compensation Committee means the Compensation Committee of the Board of Directors.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation Deferral Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Compensation Deferral Agreement means an agreement between a Participant and a Participating Employer that specifies&#58; (a) the amount of each component of Compensation that the Participant has elected to defer to the Plan in accordance with the provisions of Article IV, and (b) the Payment Schedule applicable to one or more Accounts. The Committee may permit different deferral amounts for each component of Compensation and may establish a maximum deferral amount for each such component. Unless otherwise specified by the Committee in the Compensation Deferral Agreement, Participants may defer up to&#58; (i) 75% of Salary, (ii) 75% of Bonus, and&#47;or (iii) 75% of Commissions for a Plan Year. A Compensation Deferral Agreement may also specify the investment allocation described in Section 8.4.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Death Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Death Benefit means the benefit payable in a single lump sum under the Plan to a Participant&#8217;s Beneficiary(ies) upon the Participant&#8217;s death as provided in Section 6.1 of the Plan.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Deferral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Deferral means a credit to a Participant&#8217;s Account(s) that records that portion of the Participant&#8217;s Compensation that the Participant has elected to defer to the Plan in accordance with the provisions of Article IV. Unless the context of the Plan clearly indicates otherwise, a reference to Deferrals includes Earnings attributable to such Deferrals. Deferrals shall be calculated with respect to the gross cash Compensation payable to the Participant prior to any deductions or withholdings.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disability Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Disability Benefit means the benefit payable in a single lump sum to a Participant in the event such Participant is determined to be Disabled as provided in Section 6.1 of the Plan.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disabled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Disabled means that a Participant is, by reason of any medically-determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than 12 months&#58; (a) unable to engage in any substantial gainful activity, or (b) receiving income replacement benefits for a period of not less than three months under an accident and health plan covering employees of the Participant&#8217;s Employer. The Committee shall determine whether a Participant is Disabled in accordance with Code Section 409A, provided, however, that a Participant shall be deemed to be Disabled if determined to be totally disabled by the Social Security Administration. The determination of whether a Participant is Disabled shall be made on compliance with Treas. Reg. &#167;1.409A-3(i)(4).</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.23&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Discretionary Contribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Discretionary Contribution means a credit by a Participating Employer to a Participant&#8217;s Account(s) in accordance with the provisions of Article V of the Plan. Discretionary Contributions are credited at the sole discretion of the Participating Employer, and the fact that a Discretionary Contribution is credited in one year shall not obligate the Participating Employer to continue to make such Discretionary Contributions in subsequent years. Unless the context clearly indicates otherwise, a reference to a Discretionary Contribution shall include Earnings attributable to such a contribution.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.24&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Earnings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Earnings mean a positive or negative adjustment to the value of an Account, based upon the allocation of the Account by the Participant among deemed investment options in accordance with Article VIII.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.25&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Eligible Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Eligible Employee means a member of a &#8220;select group of management or highly compensated employees&#8221; of a Participating Employer within the meaning of Sections 201(2), 301(a)(3) and 401(a)(1) of ERISA, as determined by the Committee from time to time in its sole discretion, who meets eligibility requirements set by the Committee for participation in the Plan.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.26&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Employee means a common-law employee of an Employer.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.27&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Employer means, with respect to Employees it employs, the Company or any Participating Employer.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.28&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. ERISA means the Employee Retirement Income Security Act of 1974, as amended from time to time. Reference to a specific section of ERISA shall include such section, any valid regulation promulgated thereunder, and any comparable provision of any future legislation or regulation amending, supplementing, or superseding such section or regulation.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.29&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant means an Eligible Employee who&#58; (a) has received written notification of his or her eligibility to defer Compensation under the Plan, and (b) submits a Compensation Deferral Agreement pursuant to Article IV of the Plan. A Participant&#8217;s continued participation in the Plan shall be governed by Section 3.2 of the Plan.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.30&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participating Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participating Employer means the Company and each Affiliate of the Company who, with the consent of the Company in accordance with Section 3.4, has adopted the Plan for the benefit of its eligible employees.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.31&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Payment Schedule means the date as of which payment of one or more Accounts under the Plan will commence and the form in which payment of such Account(s) will be made.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.32&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Performance-Based Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Performance-Based Compensation means any Bonus or other compensation amount to the extent that it is&#58; (a) contingent on the satisfaction of pre-established organizational or individual performance criteria, (b) not readily ascertainable at the time the deferral election is made, and (c) based on services performed over a period of at least 12 months. For this purpose, performance criteria are &#8220;pre-established&#8221; if they are established in writing no later than 90 days after the commencement of the service period to which the criteria relate, provided that the outcome is substantially uncertain at the time the criteria are established. Performance-Based Compensation shall not include any Bonus or other compensation that is paid due to the Participant&#8217;s death, or because the Participant becomes Disabled, without regard to the satisfaction of the performance criteria. The determination of whether compensation is Performance Based Compensation shall be made in compliance with Treas. Reg. &#167;1.409A-1(e).</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.33&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Generally, the term Plan means the &#8220;Amended and Restated ResMed Inc. Deferred Compensation Plan&#8221; as documented herein, and as may be amended from time to time </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">hereafter. However, to the extent permitted or required under Code Section 409A, the term Plan may in the appropriate context also mean a portion of the Plan that is treated as a single plan under Treas. Reg. &#167;1.409A-1(c), or the Plan or portion of the Plan and any other nonqualified deferred compensation plan or portion thereof that is treated as a single plan under such section.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.34&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Plan Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For the first year, Plan Year meant a period beginning on July 1, 2010 and ending on December 31, 2010, and for each subsequent year, a period beginning on January 1 and ending on December 31 of the same calendar year.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.35&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Salary means the Participant&#8217;s annual cash compensation for services performed for a Service Recipient during the applicable Plan Year, whether or not paid in such Plan Year, or included on the federal income tax form W-2 for such year, excluding bonuses, commissions, overtime, fringe benefits, stock options, stock appreciation rights, restricted stock, relocation expenses, payments of unused vacation days, long term or other incentive payments, non-monetary awards, other non-monetary compensation, severance pay, and automobile and other allowances paid to the Participant. Salary shall be calculated before reduction for compensation voluntarily deferred or contributed by Participant pursuant to all qualified or nonqualified plans of any Employer. Notwithstanding the foregoing, for Deferral elections made on or after the 2020 Amendment Date, Salary does not include amounts earned by a Participant while transferred to an Affiliate outside the United States and removed from U.S. payroll pursuant to a Short or Long-term assignment, International Relocation, or Localization arrangement under the Company&#8217;s Global Mobility Policy.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.36&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. With respect to a Service Provider who is an Employee, Separation from Service means either (i) termination of the Employee&#8217;s employment with the Company and all Affiliates, or (ii) a permanent reduction in the level of bona fide services the Employee provides to the Company and all Affiliates to an amount that is 20% or less of the average level of bona fide services the Employee provided to the Company in the immediately preceding 36 months, with the level of bona fide service calculated in accordance with Treasury Regulations Section 1.409A-l(h)(l)(ii). For purposes of determining whether a Separation from Service has occurred, the definition of &#8220;Affiliate&#8221; shall be modified by substituting 50% for 80% each place it appears in Code Section 1563(a)(1), (2) and (3), for purposes of Code Section 414(b), and each place it appears in Treasury Regulations Section 1.414(c)-2, for purposes of Code Section 414(c). </font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Employee&#8217;s employment relationship is treated as continuing while the Employee is on military leave, sick leave, or other bona fide leave of absence (if the period of such leave does not exceed six months, or if longer, so long as the Employee&#8217;s right to reemployment with the Company or an Affiliate is provided either by statute or contract). If the Employee&#8217;s period of leave exceeds six months and the Employee&#8217;s right to reemployment is not provided either by statute or by contract, the employment relationship is deemed to terminate on the first day immediately following the expiration of such six-month period. Whether a termination of employment has occurred will be determined based on all of the facts and circumstances and in accordance with regulations issued by the United States Treasury Department pursuant to Code Section 409A. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The determination of whether a Service Provider has had a Separation from Service shall be made in compliance with Treas. Reg. &#167;1.409A-1(h).</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.37&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Separation from Service Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Separation from Service Account means an Account established by the Committee to record the amounts payable to a Participant upon Separation from Service. Unless otherwise specified by the Committee, a Participant may maintain no more than two Separation from Service Accounts. A Separation from Service Account will be identified in enrollment materials as a &#8220;primary&#8221; or &#8220;secondary&#8221; Separation from Service Account or such other name as established by the Committee without affecting the meaning thereof. Unless the Participant has established a Specified Date Account, or unless a Participating Employer has credited a Discretionary Contribution to a Specified Date Account, all Deferrals and Discretionary Contributions not specifically allocated to the Participant&#8217;s secondary Separation from Service Account shall be allocated to the Participant&#8217;s primary Separation from Service Account on behalf of the Participant.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.38&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Separation from Service Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Separation from Service Benefit means the benefit payable to a Participant under the Plan following the Participant&#8217;s Separation from Service.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.39&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Service Provider</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Service Provider means a Participant or any other &#8220;service provider,&#8221; as defined in Treasury Regulations Section 1.409A-l(f).</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.40&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Service Recipient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Service Recipient means, with respect to a Participant, the Employer and all Affiliates.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.41&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Specified Date Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Specified Date Account means an Account established by the Committee to record the amounts payable at a future date as specified in the Participant&#8217;s Compensation Deferral Agreement. Unless otherwise determined by the Committee, a Participant may maintain no more than ten Specified Date Accounts. A Specified Date Account may be identified in enrollment materials as an &#8220;In-Service Account&#8221; or &#8220;Short-Term Account&#8221; or such other name as established by the Committee without affecting the meaning thereof.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.42&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Specified Date Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Specified Date Benefit means the benefit payable to a Participant under the Plan in accordance with Section 6.1(b).</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.43&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Specified Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Specified Employee means certain officers and highly compensated employees of the Company as defined in Treasury Regulations Section 1.409A-l(i). The identification date for determining whether any Employee is a Specified Employee during any Plan Year shall be January 1.</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.44&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Substantial Risk of Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Substantial Risk of Forfeiture means the description specified in Treasury Regulations Section 1.409A-1(d).</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.45&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Unforeseeable Emergency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Unforeseeable Emergency means a severe financial hardship to the Participant resulting from an illness or accident of the Participant, the Participant&#8217;s spouse, the Participant&#8217;s dependent (as defined in Code Section 152, without regard to Section 152(b)(1), (b)(2), and (d)(1)(B)), or the Participant&#8217;s Beneficiary&#59; loss of the Participant&#8217;s property due to casualty (including the need to rebuild a home following damage to a home not otherwise </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">covered by insurance, for example, as a result of a natural disaster)&#59; or other similar extraordinary and unforeseeable circumstances arising as a result of events beyond the control of the Participant. The types of events which may qualify as an Unforeseeable Emergency may be limited by the Committee. </font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The determination of whether a Participant has had an Unforeseeable Emergency shall be made in compliance with Treas. Reg. &#167;1.409A-3(i)(3).</font></div><div style="margin-bottom:9pt;padding-left:42.8pt;padding-right:5.85pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.46&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Valuation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Valuation Date means each Business Day.</font></div><div id="iaa30bcf535af4cc2885a261f469a91a1_109"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE III<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Eligibility and Participation </font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Eligibility and Participation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Committee shall designate the eligibility requirements for participation in the Plan in accordance with Section 2.25. An Eligible Employee shall become a Participant upon the earlier to occur of&#58; (a) a credit of Discretionary Contributions on behalf of such Eligible Employee, or (b) the participation date for such Eligible Employee designated by the Committee&#59; provided, however, that no Eligible Employee shall become a Participant earlier than June 1, 2010. An Eligible Employee shall become eligible to accrue deferred compensation under the Plan on the date such Eligible Employee becomes a Participant.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the case of an Eligible Employee who becomes a Participant on June&#160;1, 2010, such Participant shall be eligible to submit a Compensation Deferral Agreement in accordance with Treas. Reg. &#167;1.409A-2(a)(7). Such Compensation Deferral Agreement shall become irrevocable on June&#160;30, 2010 (or such earlier date as is designated by the Committee) and shall apply to Compensation earned for services after June&#160;30, 2010.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Duration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A Participant shall continue to be eligible to make Deferrals of Compensation and receive allocations of Discretionary Contributions, subject to the terms of the Plan, for as long as such Participant remains an Eligible Employee or until the Committee in its discretion decides the Participant no longer is entitled to participate in the Plan. A Participant who ceases to be an Eligible Employee or who no longer is entitled to participate in the Plan but who has not Separated from Service or otherwise qualified for and received (or has had a Beneficiary receive) a complete distribution of his or her Account Balance from the Plan, shall not make further deferrals of Compensation effective as of the first day of the Plan Year following the Plan Year in which the Participant ceases to be an Eligible Employee. Such individual may otherwise exercise all of the rights of a Participant under the Plan with respect to his or her Account(s). On and after a Separation from Service, a Participant shall remain a Participant as long as his or her Account Balance is greater than zero, and during such time may continue to make allocation elections as provided in Section 8.4. An individual shall cease being a Participant in the Plan when all benefits under the Plan to which he or she is entitled have been paid.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Reemployment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If a former Eligible Employee is rehired by an Employer and is again selected as eligible to participate in the Plan, he or she shall reenter the Plan on the first day of any Plan Year commencing after the date he or she is selected in accordance with the provisions of Section 3.1. If such individual meets the requirements of Treasury Regulations Section </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.409A-2(a)(7) as of such reentry date, he or she will be treated as initially eligible to participate in the Plan for purposes of Section 4.2(a). Such Eligible Employee&#8217;s reentry into the Plan shall have no impact on any distributions that have been made or are being made in accordance with Article VI. Any amounts previously forfeited from the Participant&#8217;s Accounts pursuant to this Plan shall not be restored or reinstated upon the Participant&#8217;s subsequent reentry into the Plan.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Adoption by Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. An employee of an Affiliate may not become a Participant in the Plan unless the Affiliate has previously adopted the Plan and thereby become a Participating Employer. An Affiliate of the Company may become a Participating Employer only with the approval of the Board of Directors or its designee. By adopting this Plan, the Participating Employer shall be deemed to have agreed to assume the obligations and liabilities imposed upon it by this Plan, agreed to comply with all of the other terms and provisions of this Plan, delegated to the Committee the power and responsibility to administer this Plan with respect to the Participating Employer&#8217;s Employees, and delegated to the Company the full power to amend or terminate this Plan with respect to the Participating Employer&#8217;s Employees.</font></div><div id="iaa30bcf535af4cc2885a261f469a91a1_129"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE IV<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Deferrals</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Deferral Elections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Generally.</font></div><div style="margin-bottom:9pt;padding-left:76.5pt;padding-right:5.85pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;A Participant may elect to make Deferrals of Compensation by submitting a Compensation Deferral Agreement during the enrollment periods established by the Committee and in the manner specified by the Committee, but in any event, in accordance with Section 4.2. A Compensation Deferral Agreement that is not timely filed with respect to a service period or component of Compensation shall be considered void and shall have no effect with respect to such service period or Compensation. The Committee may accept or reject any Compensation Deferral Agreement and may modify it as necessary to comply with Section 2.18 prior to the date the election becomes irrevocable under the rules of Section 4.2.</font></div><div style="margin-bottom:9pt;padding-left:76.5pt;padding-right:5.85pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Participant shall specify on his or her Compensation Deferral Agreement the amount of the Deferral for the Plan Year, and whether to allocate the Deferral to or among one or more Separation from Service Accounts, to or among one or more Specified Date Accounts, or among one or more Separation from Service Accounts and one or more Specified Date Accounts. If no allocation is indicated, or if an invalid allocation is made (such as a Deferral allocated to a Specified Date Account with a distribution date occurring in the same calendar year as the Plan Year to which the Deferral election refers), the Deferral shall be allocated to the Participant&#8217;s primary Separation from Service Account. A Participant may also specify in his or her Compensation Deferral Agreement the Payment Schedule applicable to his or her Plan Accounts, including his or her Separation from Service Accounts, Specified Date Accounts and Change in Control Benefit. If the Payment Schedule for a Separation from Service Benefit is not specified in any Compensation Deferral Agreement, the Payment Schedule shall be that selected with respect to the Participant's primary Separation from Service Account, which if also not specified, shall be distributed in a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:76.5pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">single lump sum on the first Business Day that follows the first January 15 following the Participant&#8217;s Separation from Service.  If the Payment Schedule for a Change in Control Benefit is not specified in a Compensation Deferral Agreement, the Payment Schedule will be that selected with respect to the primary Separation from Service Account, which if also not specified, shall be distributed pursuant to the immediately preceding sentence. Notwithstanding the foregoing, if a Participant is a Specified Employee on the date of such Participant&#8217;s Separation from Service, such distribution will be made not earlier than the first day of the seventh calendar month following the calendar month in which the Separation from Service occurs (or, if earlier, the date of such Participant&#8217;s death).</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Timing Requirements for Compensation Deferral Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;padding-left:78.5pt;padding-right:5.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">First Year of Eligibility. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the case of the first year in which an Eligible Employee becomes eligible to participate in the Plan, he or she shall have up to 30 days following the date on which he or she becomes eligible to participate in the Plan to submit a Compensation Deferral Agreement with respect to Compensation to be earned during such Plan Year. A completed Compensation Deferral Agreement described in this paragraph shall become irrevocable upon the end of such 30-day period, except as otherwise provided in this Section 4.2. The determination of whether an Eligible Employee may file a Compensation Deferral Agreement under this paragraph shall be determined in accordance with the rules of Code Section 409A, including the provisions of Treas. Reg. &#167;1.409A-2(a)(7). </font></div><div style="margin-bottom:9pt;padding-left:78.5pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A Compensation Deferral Agreement filed under this paragraph applies to Compensation earned for services performed after the date the Compensation Deferral Agreement becomes irrevocable. Any Compensation Deferral Agreement under this subsection (a) shall satisfy the requirements of Treas. Reg. &#167;1.409A-2(a)(7).</font></div><div style="margin-bottom:9pt;padding-left:78.5pt;padding-right:5.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Prior Year Election. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as otherwise provided in this Section 4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participants may defer Compensation by filing a Compensation Deferral Agreement no later than December 31st of the calendar year prior to the calendar year in which the Compensation to be deferred is earned. A Compensation Deferral Agreement described in this paragraph shall become irrevocable with respect to such Compensation no later than December 31st of the calendar year prior to the calendar year in which such Compensation is earned.</font></div><div style="margin-bottom:9pt;padding-left:78.5pt;padding-right:5.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Performance-Based Compensation. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participants may file a Compensation Deferral Agreement with respect to Performance-Based Compensation no later than the date that is six months before the end of the performance period, provided that&#58;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the Participant performs services continuously from the later of the beginning of the performance period or the date the criteria are established through the date the Compensation Deferral Agreement is submitted&#59; and</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the Compensation is not readily ascertainable as of the date the Compensation Deferral Agreement is filed.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:78.5pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A Compensation Deferral Agreement becomes irrevocable with respect to Performance-Based Compensation as of the date on which the deadline for filing such election occurs. The Committee shall determine the deadline for filing such an election in compliance with Code Section 409A. Any Compensation Deferral Agreement under this subsection (c) shall satisfy the requirements of Treas. Reg. &#167;1.409A-2(a)(8).</font></div><div style="margin-bottom:9pt;padding-left:78.5pt;padding-right:5.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Short-Term Deferrals. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Compensation that meets the definition of a &#8220;short-term deferral&#8221; described in Treas. Reg. &#167;1.409A-1(b)(4) may be deferred in accordance with the rules of Article VII, applied as if the date the Substantial Risk of Forfeiture lapses is the date payments were originally scheduled to commence. Any Compensation Deferral Agreement under this subsection (d) shall satisfy the requirements of Treas. Reg. &#167;1.409A-2(a)(4).</font></div><div style="margin-bottom:9pt;padding-left:78.5pt;padding-right:5.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Certain Forfeitable Rights. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">With respect to a legally binding right to a payment in a subsequent year that is subject to a forfeiture condition requiring the Participant&#8217;s continued services for a period of at least 12 months from the date the Participant obtains the legally binding right, an election to defer such Compensation may be made on or before the 30th day after the Participant obtains the legally binding right to the Compensation, provided that the election is made at least 12 months in advance of the earliest date at which the forfeiture condition could lapse. The Compensation Deferral Agreement described in this paragraph becomes irrevocable on such 30th day. If the forfeiture condition applicable to the payment lapses before the end of the required 12 month service period as a result of the Participant&#8217;s death or disability (as defined in Treasury Regulations Section 1.409A-3(i)(4)) or upon a Change in Control (as defined in Treasury Regulations Section 1.409A-3(i)(5)), the Compensation Deferral Agreement will be void unless it would be considered timely under another rule described in this Section. Any Compensation Deferral Agreement under this subsection (e) shall satisfy the requirements of Treas. Reg. &#167;1.409A-2(a)(5).</font></div><div style="margin-bottom:9pt;padding-left:78.5pt;padding-right:5.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Evergreen&#8221; Deferral Elections. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Deferral elections under the Plan are effective for a single Plan Year&#59; new elections must be made in order to defer Compensation during the following Plan Year. However, the Committee, in its discretion, may change this protocol by providing in the Compensation Deferral Agreement that such Compensation Deferral Agreement will continue in effect for each subsequent Plan Year or performance period, as applicable. In such event, such &#8220;evergreen&#8221; Compensation Deferral Agreements will become effective with respect to an item of Compensation on the date such election becomes irrevocable under this Section 4.2. An evergreen Compensation Deferral Agreement may be terminated or modified prospectively with respect to Compensation for which such election remains revocable under this Section 4.2. A Participant whose Compensation Deferral Agreement is cancelled in accordance with Section 4.6 will be required to file a new Compensation Deferral Agreement under this Article IV in order to recommence Deferrals under the Plan.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Allocation of Deferrals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A Compensation Deferral Agreement may allocate Deferrals to one or more Specified Date Accounts and&#47;or to one or more Separation from Service Accounts. The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Committee may, in its discretion, establish a minimum deferral period for the establishment of a Specified Date Account.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Deductions from Pay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Committee has the authority to determine the payroll practices under which any component of Compensation subject to a Compensation Deferral Agreement will be deducted from a Participant&#8217;s Compensation.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant Deferrals shall be 100% vested at all times.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cancellation of Deferrals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Committee may cancel a Participant&#8217;s Deferral election&#58; (a) for the balance of the Plan Year in which an Unforeseeable Emergency (as defined in Section 2.45) occurs in accordance with Treas. Reg. &#167;1.409A-3(j)(4)(viii), (b) if the Participant receives a hardship distribution under the Employer&#8217;s qualified 401(k) plan under Treas. Reg. &#167;1.401(k)-l(d)(3) (relating in-service distributions of 401(k) plan elective contributions as a result of an immediate and heavy financial need), in accordance with Treas. Reg. &#167;1.409A-3(j)(4)(viii), or (b) during periods in which the Participant is unable to perform the duties of his or her position or any substantially similar position due to a mental or physical impairment that can be expected to result in death or last for a continuous period of at least six months, provided cancellation occurs by the later of the end of the taxable year of the Participant or the 15th day of the third month following the date the Participant incurs the disability (as defined in this paragraph) in accordance with Treas. Reg. &#167;1.409A-3(j)(4)(xii).</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Benefits Not Contingent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Deferrals and credits for any Participants under this Plan are<br>not conditioned (directly or indirectly) upon the Participant&#8217;s election to make (or not to<br>make) deferrals under the 401(k) plan sponsored by the Company.</font></div><div id="iaa30bcf535af4cc2885a261f469a91a1_149"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE V<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Employer Contributions</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Discretionary Contributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A Participating Employer shall credit one or more Discretionary Contributions to a Participant in such amounts and at such times as are determined by the Committee from time to time in its sole discretion. Any such amounts are credited at the sole discretion of the Committee, and the fact that a Discretionary Contribution is credited in one year shall not obligate the Participating Employer or the Committee to continue to make such Discretionary Contributions in subsequent years. Any such Discretionary Contributions shall be subject to the approval of the Board or the Compensation Committee to the extent required by applicable law. Neither the Participating Employer nor the Committee shall have any obligation to make any such Discretionary Contributions or to make them on a consistent basis among similarly-situated Eligible Employees. Any Discretionary Contributions credited to a Participant&#8217;s Account pursuant to this Section 5.1 shall be credited on a date or dates to be determined by the Committee in its sole and absolute discretion, and the crediting date or dates may be different for different Participants. Unless the context clearly indicates otherwise, a reference to Discretionary Contributions shall include Earnings attributable to such contributions. Discretionary Contributions will be credited to a Participant&#8217;s primary Separation from Service Account, unless the Committee, in its sole discretion, elects in writing on or before the date on which the Participant obtains a legally binding right to such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Discretionary Contribution (which election shall be irrevocable on such date) to credit the Discretionary Contribution to a Participant&#8217;s Specified Date Account.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A Participant shall be vested in his or her Discretionary Contributions described in Section 5.1 above in accordance with the vesting schedules established by the Committee, at the time such amount is first credited to the Participant&#8217;s Account under this Plan. The Committee may, at any time, in its sole and absolute discretion (subject to any approval by the Board or the Compensation Committee required by applicable law), increase a Participant&#8217;s vested interest in a Discretionary Contribution. Notwithstanding the foregoing, all Discretionary Contributions shall become 100% vested upon the occurrence of the earliest of&#58; (i) the death of the Participant while actively employed by a Participating Employer, (ii) the Disability of the Participant, or (iii) a Change in Control. The portion of a Participant&#8217;s Accounts that remains unvested upon his or her Separation from Service after the application of the terms of this Section 5.2 shall be forfeited.</font></div><div id="iaa30bcf535af4cc2885a261f469a91a1_169"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"><br>Benefits</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Benefits. Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A Participant shall be entitled to the following benefits under the Plan&#58;</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-24.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Separation from Service Benefit. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Upon the Participant&#8217;s Separation from Service, he or she shall be entitled to a Separation from Service Benefit, except to the extent the Participant (A) makes an election with respect to the Payment Schedule for a Change in Control Benefit, and (B) experiences a Separation from Service within 1 year following a Change in Control. The Separation from Service Benefit shall be equal to the vested portion of the Participant&#8217;s Separation from Service Accounts and any Specified Date Account Balances for Specified Date Accounts with respect to which payments have not yet commenced, based on the value of each such Account as of the last Valuation Date of the calendar month immediately preceding the calendar month of distribution. For purposes of the Separation from Service Benefit, the Payment Schedule that applies to the Participant&#8217;s primary Separation from Service Account shall apply with respect to the vested portion of such primary Separation from Service Account and also with respect to the vested portion of any Specified Date Account Balances for Specified Date Accounts with respect to which payments have not yet commenced, and the Payment Schedule that applies to the Participant&#8217;s secondary Separation from Service Account shall apply only with respect to the vested portion of such secondary Separation from Service Account. Payment of the Separation from Service Benefit will be made (or begin in the case of installments) according to the Participant&#8217;s election on&#58; (i) first Business Day that follows the first January 15th following the Participant&#8217;s Separation from Service, or (ii) the first anniversary of the date specified in the immediately preceding (i). Notwithstanding the foregoing, if a Participant is a Specified Employee on the date of such Participant&#8217;s Separation from Service and elects the option identified in (i) in the immediately preceding sentence, such distribution will be made or begin not earlier than the first day of the seventh calendar month following the calendar month in which the Separation from Service occurs (or, if earlier, the date of such Participant&#8217;s death). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-24.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Specified Date Benefit. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the Participant has established one or more Specified Date Accounts and has not experienced a Separation from Service prior to the date designated for distribution by the Participant at the time such Specified Date Account was established, he or she shall be entitled to a Specified Date Benefit with respect to each such Specified Date Account. The Specified Date Benefit shall be equal to the vested portion of the Specified Date Account, based on the value of that Account as of the last Valuation Date of the calendar month of distribution designated by the Participant at the time the Account was established. Payment of the Specified Date Benefit will be made (or begin in the case of installments) in the calendar month next following the designated calendar month of distribution. If the Specified Date Benefit is to be paid in the form of installments, any subsequent installment payments will be paid on the anniversary of the date identified in the immediately preceding sentence.</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-24.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Disability Benefit. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event that a Participant becomes Disabled, he or she shall be entitled to a Disability Benefit. The Disability Benefit shall be equal to the vested portion of the Separation from Service Accounts and the unpaid balances of any Specified Date Accounts. The payment date for the Disability Benefit shall be the first Business Day of the calendar month next following the calendar month in which the Participant became Disabled, and the Disability Benefit shall be based on the value of the Accounts as of the last Valuation Date of the calendar month in which Disability occurs and will be paid in the next following calendar month. The Disability Benefit shall be paid in a single lump sum.</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-24.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Death Benefit. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event of the Participant&#8217;s death, his or her designated Beneficiary(ies) shall be entitled to a Death Benefit. The Death Benefit shall be equal to the vested portion of the Separation from Service Accounts and the unpaid balances of any Specified Date Accounts. The payment date for the Death Benefit shall be the first Business Day of the calendar month next following the calendar month in which the Participant&#8217;s death occurred, and the Account(s) will be valued as of the last Valuation Date of the calendar month in which death occurred. The Death Benefit shall be paid in a single lump sum.</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Participant may, pursuant to such procedures as the Committee may specify, designate one or more Beneficiaries in connection with the Plan. If a Participant names someone other than his or her spouse as a primary Beneficiary with respect to any portion of his or her Accounts, spousal consent shall be required to be provided in a form designated by the Committee, executed by such Participant&#8217;s spouse and returned to the Committee. A Participant may change or revoke a Beneficiary designation by delivering to the Committee a new designation (or revocation). Any designation or revocation shall be effective only if it is received by the Committee. However, when so received, the designation or revocation shall be effective as of the date the notice is executed (whether or not the Participant still is living), but without prejudice to any Employer on account of any payment made before the change is recorded. The last effective designation received by the Committee shall supersede all prior designations. If a Participant dies without having effectively designated a Beneficiary, or if no Beneficiary survives the Participant, the Participant&#8217;s Account shall be payable (i) to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">his or her surviving spouse, or (ii) if the Participant is not survived by his or her spouse, to his or her estate. A former spouse shall have no interest under the Plan, as Beneficiary or otherwise, unless the Participant designates such person as a Beneficiary after dissolution of the marriage, except to the extent provided under the terms of a domestic relations order as described in Code Section 414(p)(l)(B).</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-24.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Change in Control Benefit. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A Participant may make an election with respect to the Payment Schedule for a Change in Control Benefit. Notwithstanding anything in this Plan to the contrary, in the event a Participant makes such an election and experiences a Separation from Service within 1 year following a Change in Control, the Participant shall be entitled to a Change in Control Benefit. The Change in Control Benefit shall be equal to the value of the Separation from Service Accounts and the unpaid balances of any Specified Date Accounts. Payment of the Change in Control Benefit will be made (or begin in the case of installments) according to the Payment Schedule elected by the Participant on&#58; (i) the first Business Day the follows the first January 15th following the Participant&#8217;s Separation from Service or (ii) the first anniversary of the date specified in the immediately preceding (i). Notwithstanding the foregoing, if the Participant is a Specified Employee on the date of such Participant&#8217;s Separation from Service, such distribution shall be made or begin not earlier than the first day of the seventh calendar month following the calendar month in which the Separation from Service occurs (or, if earlier, the date of such Participant&#8217;s death). If the Change in Control Benefit is to be paid in the form of installments, any subsequent installment payments will be paid on the anniversary of the date such payments commence. The Change in Control Benefit shall be based on the value of that&#47;those Account(s) on the last Valuation Date of the calendar month immediately preceding the calendar month of the distribution.</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-24.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Unforeseeable Emergency Payments. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A Participant who experiences an Unforeseeable Emergency may submit a written request to the Committee to receive payment of all or any portion of his or her vested Accounts. Whether a Participant or Beneficiary is faced with an Unforeseeable Emergency permitting an emergency payment shall be determined by the Committee based on the relevant facts and circumstances of each case, but, in any case, a distribution on account of Unforeseeable Emergency may not be made to the extent that such emergency is or may be reimbursed through insurance or otherwise, by liquidation of the Participant&#8217;s assets, to the extent the liquidation of such assets would not cause severe financial hardship, or by cessation of Deferrals under this Plan. If an emergency payment is approved by the Committee, the amount of the payment shall not exceed the amount reasonably necessary to satisfy the need, taking into account the additional compensation that is available to the Participant as the result of cancellation of deferrals to the Plan, including amounts necessary to pay any taxes or penalties that the Participant reasonably anticipates will result from the payment. The amount of the emergency payment shall be subtracted first from the vested portion of the Participant's Separation from Service Accounts, beginning with the Participant&#8217;s secondary Separation from Service Account, until depleted and then from the vested Specified Date Accounts, beginning with the Specified Date Account </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with the latest payment commencement date. Emergency payments shall be paid in a single lump sum within the 90-day period following the date the payment is approved by the Committee. No Participant may receive more than one distribution on account of an Unforeseeable Emergency in any Plan Year. A Participant who receives a distribution on account of an Unforeseeable Emergency, and who is still employed by an Employer shall be prohibited from making Deferrals for the remainder of the Plan Year in which the distribution is made.</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-24.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Code Section 409A. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary contained in this Plan, (i) a Participant shall have no legally-enforceable right to, and a Participating Employer shall have no obligation to make, any payment to a Participant if having such a right or obligation would result in the imposition of additional taxes under Code Section 409A, and (ii) any provision that would cause the Plan to fail to satisfy Code Section 409A will have no force and effect until amended to comply therewith (which amendment may be retroactive to the extent permitted by Code Section 409A). If any payment is not made under the terms of this subsection (g), it is the Participating Employers&#8217; present intention to make a similar payment to the Participant in a manner that will not result in the imposition of additional taxes under Code Section 409A, to the extent feasible.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Form of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Separation from Service Benefit.</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;A Participant who is entitled to receive a Separation from Service Benefit shall receive payment of such benefit in a single lump sum, unless the Participant elects an alternate form of payment on the initial Compensation Deferral Agreement upon which an allocation of Deferrals is made to a Separation from Service Account (or the initial Compensation Deferral Agreement that precedes the Plan Year in which a Discretionary Contribution is allocated to a Separation from Service Account).</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Permissible alternate forms of payment for the Separation from Service Benefit are&#58; (A) substantially equal annual installments over a period of two to ten years, as elected by the Participant, or (B) a lump sum payment of a designated percentage of the Separation from Service Benefit, with the balance paid in substantially equal annual installments over a period of two to ten years, as elected by the Participant.</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Specified Date Benefit. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Specified Date Benefit shall be paid in a single lump sum, unless the Participant elects on the Compensation Deferral Agreement with which the Account was established to have the Specified Date Account paid in substantially equal annual installments over a period of two to five years, as elected by the Participant.</font></div><div style="margin-bottom:9pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any Specified Date election of a Participant, if a Participant dies or Separates from Service before distributions with respect to a Specified Date Account have commenced, such amounts shall be paid in accordance with the form and time of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">payment applicable to the Participant&#8217;s primary Separation from Service Account or Death Benefit (as applicable). With respect to Specified Date Account Balances that have commenced to be paid in installment payments prior to the date of the Separation from Service, such Specified Date Accounts shall continue to be paid in accordance with the form of payment election applicable to the Specified Date Account.</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Change in Control Benefit. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event a Participant (i) makes an election with respect to the Payment Schedule for a Change in Control Benefit and (ii) experiences a Separation from Service within 1 year following a Change in Control, he or she shall be entitled to a Change in Control Benefit. The Change in Control Benefit shall be equal to the value of the Participant&#8217;s Separation from Service Accounts and the unpaid balances of any Specified Date Accounts. A Participant who makes an election with respect to the Payment Schedule for a Change in Control Benefit and is entitled to receive a Change in Control Benefit shall receive payment of such benefit in a single lump sum, unless the Participant elects an alternate form of payment on the initial Compensation Deferral Agreement in substantially equal installments over a period of two or three years.</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Death Benefit. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event of the Participant&#8217;s death, his or her designated Beneficiary(ies) shall be entitled to a Death Benefit. The Death Benefit shall be equal to the value of the Participant&#8217;s Separation from Service Accounts and the unpaid balances of any Specified Date Accounts and shall be payable in a single lump sum. Payment of the Death Benefit shall extinguish all of the Participant&#8217;s Accounts.</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Disability Benefit. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event of the Participant&#8217;s Disability, he or she shall be entitled to a Disability Benefit. The Disability Benefit shall be equal to the value of the Participant&#8217;s Separation from Service Accounts and the unpaid balances of any Specified Date Accounts and shall be payable in a single lump sum. Payment of the Disability Benefit shall extinguish all of the Participant&#8217;s Accounts.</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Small Account Balances. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Committee shall pay the value of the Participant&#8217;s Accounts upon a Separation from Service in a single lump sum if the balance of such Accounts (together with any amounts deferred under any other nonqualified deferred compensation plan that must be aggregated with the Plan Accounts pursuant to Treasury Regulations Section 1.409A-l(c)) is not greater than the applicable dollar amount under Code Section 402(g)(1)(B), provided the payment represents the complete liquidation of the Participant&#8217;s interest in the Plan together with any plan with which the Plan Accounts must be aggregated as described above.</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Rules Applicable to Installment Payments. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If a Payment Schedule specifies substantially equal installment payments, annual payments will be made beginning as of the payment commencement date for such installments, and shall continue on each anniversary thereof until the number of installment payments specified in the Payment Schedule has been paid. If a lump sum equal to less than 100% of the Separation from Service Account is paid, the payment commencement date for the installment form of payment will be the first anniversary of the payment of the lump sum. The amount of each installment payment shall be determined by dividing (i) by (ii), where (i) equals the Account Balance as of the Valuation Date and (ii) equals the remaining number of installment payments. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">19</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this subsection (g), the term &#8220;Valuation Date&#8221; means the last day of the calendar month immediately preceding the calendar month of payment, or such other date as the Committee, in its sole discretion, shall determine in a manner consistent with Code Section 409A.</font></div><div style="margin-bottom:9pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of Article VI, installment payments will be treated as a single payment&#59; provided, however, that in the event a Participant elects a lump sum payment equal to less than 100% of his or her Separation from Service Account or Specified Date Account, the partial lump sum payment shall at all times with respect to the amounts deferred be treated as a separate payment, and the installment payments for the balance of the Account shall, at all times with respect to the amounts deferred, be treated as a single payment.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Acceleration of or Delay in Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Committee, in its sole and absolute discretion, may elect to accelerate the time or form of payment of a benefit owed to the Participant hereunder, provided such acceleration is permitted under Treasury Regulations Section 1.409A-3(j)(4). The Committee may also, in its sole and absolute discretion, delay the time for payment of a benefit owed to the Participant hereunder, to the extent permitted under Treasury Regulations Section 1.409A-2(b)(7). If the Plan receives a domestic relations order (within the meaning of Code Section 414(p)(l)(B)) directing that all or a portion of a Participant&#8217;s Accounts be paid to an &#8220;alternate payee,&#8221; any amounts to be paid to the alternate payee(s) shall be paid in a single lump sum, and such amounts will be subtracted from the Participant&#8217;s Accounts as specified in the Plan.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Distributions Treated as Made Upon a Designated Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If the Company fails to make any distribution on account of any of the events listed in Section 6.1, either intentionally or unintentionally, within the time period specified in Section 6.1 or 6.2, as applicable, but the payment is made within the same calendar year, such distribution will be treated as made within the time period specified in Section 6.1 or 6.2 pursuant to Treasury Regulations Section 1.409A-3(d). In addition, if a distribution is not made due to a dispute with respect to such distribution, the distribution may be delayed in accordance with Treasury Regulations Section 1.409A-3(g).</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Deductibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If the Committee determines in good faith that all or a portion of any distribution (a) is grandfathered under P.L. 115-97, Section 13601(e)(2), relating to Code Section 162(m) as in effect prior to the enactment of the Tax Cuts and Jobs Act, and (b) will not be deductible by the Company or a Participating Employer solely by reason of the limitation under Section 162(m) of the Code, then such distribution to the Participant will be delayed until the first year in which it is deductible.</font></div><div id="iaa30bcf535af4cc2885a261f469a91a1_189"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"><br>Modifications to Payment Schedules</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participant&#8217;s Right to Modify</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A Participant may modify any or all of the Payment Schedules with respect to the Participant&#8217;s Separation from Service Account(s) or Specified Date Account(s), consistent with the permissible Payment Schedules available under the Plan, provided such modification complies with the requirements of this Article VII and Code </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">20</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 409A and Treas. Reg. &#167;1.409A-2(b). Modifications of Payment Schedules with respect to Accounts not explicitly identified in the immediately preceding sentence are not permissible under the Plan.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Time of Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the case of any Specified Date Account, the date on which a modification election is submitted to the Committee must be at least 12 months prior to the date on which payment of such Specified Date Account is scheduled to commence under the Payment Schedule in effect prior to the modification in accordance with Treas. Reg. &#167;1.409A-2(b)(1)(iii).</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Date of Payment under Modified Payment Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except in the case of the Disability Benefit, the Death Benefit and Unforeseeable Emergency Payments, the date payments are to commence under the modified Payment Schedule must be no earlier than five years after the date payment would have commenced under the original Payment Schedule (or, in the case of installment payments treated as a single payment, five years after the first amount was scheduled to be paid) in accordance with Treas. Reg. &#167;1.409A-2(b)(l)(ii). Under no circumstances may a modification election result in an acceleration of payments in violation of Code Section 409A.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A modification election submitted in accordance with this Article VII is irrevocable upon receipt by the Committee and shall not become effective until 12 months after such date in accordance with Treas. Reg. &#167;1.409A-2(b)(l)(i).</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effect on Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. An election to modify a Payment Schedule is specific to the Account or payment event to which it applies, and shall not be construed to affect the Payment Schedules of any other Accounts.</font></div><div id="iaa30bcf535af4cc2885a261f469a91a1_209"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE VIII<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Account Balances&#59; Investments</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Valuation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Deferrals shall be credited to appropriate Accounts on or about the date such Compensation would have been paid to the Participant absent the Compensation Deferral Agreement. Discretionary Contributions shall be credited at the time or times determined by the Committee in its sole discretion. Valuation of Accounts shall be performed under procedures approved by the Committee.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustment for Earnings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Account will be adjusted to reflect Earnings on each Business Day. Adjustments shall reflect the net earnings, gains, losses, expenses, appreciation and depreciation associated with an investment option for each portion of the Account allocated to such option (&#8220;investment allocation&#8221;).</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investment Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Investment options will be determined by the Committee. The Committee, in its sole discretion, shall be permitted to add, remove or substitute investment options from the Plan from time to time&#59; provided however, that any such additions, removals or substitutions of investment options shall not be effective with respect to any period prior to the effective date of such change.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">21</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Investment Allocations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding anything else in this Plan to the contrary, a Participant&#8217;s investment allocation constitutes a deemed, not actual, investment among the investment options comprising the investment menu. At no time shall a Participant have any real or beneficial ownership in any investment option included in the investment menu, nor shall the Participating Employer or any trustee acting on its behalf have any obligation to purchase actual securities as a result of a Participant&#8217;s investment allocation. A Participant&#8217;s investment allocation shall be used solely for purposes of adjusting the value of a Participant&#8217;s Account Balances.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A Participant shall specify an investment allocation for each of his or her Accounts in accordance with procedures established by the Committee. Allocation among the investment options must be designated in increments of 1%. The Participant&#8217;s investment allocation will become effective on the same Business Day or, in the case of investment allocations received after a time specified by the Committee, the next Business Day.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A Participant may change an investment allocation on any Business Day, both with respect to future credits to the Plan and with respect to existing Account Balances, in accordance with procedures adopted by the Committee. Changes shall become effective on the same Business Day or, in the case of investment allocations received after a time specified by the Committee, the next Business Day, and shall be applied prospectively.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Unallocated Deferrals and Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If the Participant fails to make an investment allocation with respect to an Account, such Account shall be invested in an investment option, the primary objective of which is the preservation of capital, as determined by the Committee in its reasonable discretion.</font></div><div id="iaa30bcf535af4cc2885a261f469a91a1_229"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE IX<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Administration</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Plan Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Plan shall be administered by the Committee. The Committee shall have the authority to control and manage the operation and administration of the Plan, including the authority and ability to delegate administrative functions to a third party. Claims for benefits shall be filed with the Committee and resolved in accordance with the claims procedures in Article XII.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Actions by Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each decision of a majority of the members of the Committee then in office shall constitute the final and binding act of the Committee. The Committee may act with or without a meeting being called or held and shall keep minutes of all meetings held and a record of all actions taken by written consent.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Powers of Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Committee shall have all powers and discretionary authority necessary or appropriate to supervise the administration of the Plan and to control its operation in accordance with its terms, including, but not by way of limitation, the following powers and discretionary authority&#58;</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;To interpret and determine the meaning and validity of the provisions of the Plan, and to determine any question arising under, or in connection with, the administration, operation or validity of the Plan, or any amendment thereto&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">22</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;To determine any and all considerations affecting the eligibility of any employee to become a Participant or remain a Participant in the Plan&#59;</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;To cause one or more separate Accounts to be maintained for each Participant&#59;</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;To cause Compensation Deferrals and deemed interest to be credited to Participants&#8217; Accounts&#59;</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;To establish and revise an accounting method or formula for the Plan&#59;</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;To determine the status and rights of Participants and their spouses, Beneficiaries or estates&#59;</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;To employ such counsel, agents, and advisers, and to obtain such legal, clerical and other services, as it may deem necessary or appropriate in carrying out the provisions of the Plan&#59;</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;To establish, from time to time, rules for the performance of its powers and duties and for the administration of the Plan&#59;</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;To arrange for periodic distribution to each Participant of a statement of benefits accrued under the Plan&#59;</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;To publish a claims and appeal procedure satisfying the minimum standards of Section 503 of ERISA pursuant to which individuals or estates may claim Plan benefits and appeal denials of such claims&#59;</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;To delegate to any one or more of its members or to any other person, severally or jointly, the authority to perform for and on behalf of the Committee one or more of the functions of the Committee under the Plan&#59; and</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;To decide all issues and questions regarding Account balances, and the time, form, manner, and amount of distributions to Participants.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Administration Upon Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon a Change in Control, the Committee, as constituted immediately prior to such Change in Control, shall continue to act as the Committee. The individual who was the Chief Executive Officer of the Company immediately prior to the Change in Control (the &#8220;Ex-CEO&#8221;) shall have the authority (but shall not be obligated) to appoint an independent third party to act as the Committee.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">After a Change in Control, no member of the Committee may be removed (and&#47;or replaced) by the Company without the consent of either (a) 2&#47;3 of the members of the Board of Directors of the Company and a majority of Participants and Beneficiaries with Account Balances or (b) the Ex-CEO or, in the event the Ex-CEO is no longer a Plan Participant, his or her appointee who is a Plan Participant.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Participating Employers shall, with respect to the Committee identified under this Section&#58; (a) pay all reasonable expenses and fees of the Committee, (b) indemnify the Committee (including individuals serving as Committee members) in accordance with Section 9.6, and (c) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">23</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">supply full and timely information to the Committee on all matters related to the Plan, Participants, Beneficiaries and Accounts as the Committee may reasonably require.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Participating Employer shall have the right to withhold from any<br>payment due under the Plan (or with respect to any amounts credited to the Plan) any<br>taxes required by law to be withheld in respect of such payment (or credit). Withholdings<br>with respect to amounts credited to the Plan shall be deducted from Compensation that<br>has not been deferred to the Plan.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Participating Employer shall indemnify and hold harmless each employee, officer, director, agent or organization, to whom or to which are delegated duties, responsibilities, and authority under the Plan or otherwise with respect to administration of the Plan, including, without limitation, the Committee and its agents, against all claims, liabilities, fines and penalties, and all expenses reasonably incurred by or imposed upon him or her or it (including but not limited to reasonable attorneys&#8217; fees) which arise as a result of his or her or its actions or failure to act in connection with the operation and administration of the Plan to the extent lawfully allowable and to the extent that such claim, liability, fine, penalty, or expense is not paid for by liability insurance purchased or paid for by the Participating Employer. Notwithstanding the foregoing, the Participating Employer shall not indemnify any person or organization if his or her or its actions or failure to act are due to gross negligence or willful misconduct or for any such amount incurred through any settlement or compromise of any action unless the Participating Employer consents in writing to such settlement or compromise.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Delegation of Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the administration of this Plan, the Committee may, from time to time, employ agents and delegate to them such administrative duties as it sees fit, and may from time to time consult with legal counsel who shall be legal counsel to the Company.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Binding Decisions or Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The decision or action of the Committee in respect of any question arising out of or in connection with the administration, interpretation and application of the Plan and the rules and regulations thereunder shall be final and conclusive and binding upon all persons having any interest in the Plan.</font></div><div id="iaa30bcf535af4cc2885a261f469a91a1_249"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"><br>Amendment and Termination</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company and each other Participating Employer intend to continue the Plan indefinitely, and to maintain each Participant&#8217;s Account until it is scheduled to be paid to him or her in accordance with the provisions of the Plan. However, the Plan is voluntary on the part of the Company and the other Participating Employers, and the Participating Employers do not guarantee to continue the Plan. Accordingly, the Company reserves the right to discontinue its sponsorship of the Plan (or the sponsorship of another Participating Employer) and&#47;or to terminate the Plan at any time with respect to any or all of its participating Eligible Employees (or all of another Participating Employer&#8217;s Eligible Employees), by action of the Board of Directors. Upon the termination of the Plan with respect to any Participating Employer, the participation of the affected Participants who are employed by that Participating Employer shall terminate. However, after the Plan termination, the Account Balances of such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">24</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participants shall continue to be credited with Deferrals attributable to a deferral election that was in effect prior to the Plan termination to the extent deemed necessary to comply with Code Section 409A and related Treasury Regulations, and additional amounts shall continue to credited or debited to such Participants&#8217; Account Balances pursuant to Article VIII. The investment options available to Participants following the termination of the Plan shall be comparable in number and type to those investment options available to Participants in the Plan Year preceding the Plan Year in which the Plan termination is effective. In addition, following a Plan termination, Participant Account Balances shall remain in the Plan and shall not be distributed until such amounts become eligible for distribution in accordance with the other applicable provisions of the Plan. Notwithstanding the preceding sentence, to the extent permitted by Treasury Regulations Section 1.409A-3(j)(4)(ix), the Company may provide that, upon termination of the Plan, all Account Balances of the Participants shall be distributed, subject to and in accordance with any rules established by the Company deemed necessary to comply with the applicable requirements and limitations of Treasury Regulations Section 1.409A-3(j)(4)(ix).</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Company, by action taken by the Board of Directors, may amend the Plan at any time and for any reason, provided that any such amendment shall not reduce the vested Account Balances of any Participant accrued as of the date of any such amendment or restatement (as if the Participant had incurred a Separation from Service on such date). The Compensation Committee shall have the authority to amend the Plan for the purpose of&#58; (i) conforming the Plan to the requirements of law (which amendments, notwithstanding any provisions in this Section 10.2 to the contrary, may also be made without the consent of any Participant), (ii) facilitating the administration of the Plan, (iii) clarifying provisions based on the Compensation Committee&#8217;s interpretation of the document, and (iv) making such other amendments as the Board of Directors may authorize.</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in the Plan, if and to the extent the Compensation Committee shall determine that the terms of the Plan may result in the failure of the Plan, or amounts deferred by or for any Participant under the Plan, to comply with the requirements of Code Section 409A, or any applicable regulations or guidance promulgated by the Secretary of the Treasury in connection therewith, the Compensation Committee shall have authority to take such action to amend, modify, cancel or terminate the Plan (effective with respect to all Employers) or distribute any or all of the amounts deferred by or for a Participant, as it deems necessary or advisable, including without limitation&#58;</font></div><div style="margin-bottom:9pt;padding-left:117pt;padding-right:5.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Any amendment or modification of the Plan to conform the Plan to the requirements of Code Section 409A or any regulations or other guidance thereunder (including, without limitation, any amendment or modification of the terms of any applicable to any Participant&#8217;s Accounts regarding the timing or form of payment).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">25</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:117pt;padding-right:5.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Any cancellation or termination of any unvested interest in a Participant&#8217;s Accounts without any payment to the Participant.</font></div><div style="margin-bottom:9pt;padding-left:117pt;padding-right:5.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Any cancellation or termination of any vested interest in any Participant&#8217;s Accounts, with immediate payment to the Participant of the amount otherwise payable to such Participant.</font></div><div style="margin-bottom:9pt;padding-left:117pt;padding-right:5.85pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Any such amendment, modification, cancellation, or termination of the Plan that may adversely affect the rights of a Participant without the Participant&#8217;s consent.</font></div><div id="iaa30bcf535af4cc2885a261f469a91a1_269"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE XI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"><br>Informal Funding</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">General Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Obligations established under the terms of the Plan may be satisfied from the general funds of the Participating Employers, or a trust described in this Article XI. No Participant, spouse or Beneficiary shall have any right, title or interest whatever in any assets of the Participating Employers. Nothing contained in this Plan, and no action taken pursuant to its provisions, shall create or be construed to create a trust of any kind, or a fiduciary relationship, between the Participating Employers and any Employee, Director, spouse, or Beneficiary. To the extent that any person acquires a right to receive payments hereunder, such rights are no greater than the right of an unsecured general creditor of the Participating Employers.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Rabbi Trust</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A Participating Employer may, in its sole discretion, establish a grantor trust, commonly known as a rabbi trust, as a vehicle for accumulating assets to pay benefits under the Plan. Payments under the Plan may be paid from the general assets of the Participating Employers or from the assets of any such rabbi trust. Payment from any such source shall reduce the obligation owed to the Participant or Beneficiary under the Plan.</font></div><div id="iaa30bcf535af4cc2885a261f469a91a1_289"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE XII<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Claims</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;padding-right:5.85pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Claim Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A Participant or a beneficiary (the &#8220;Claimant&#8221;) must file with the Committee a written claim for benefits if the Claimant believes he or she has not received the benefits he or she is entitled to receive. Any such claim must be filed within 90 days after the first date the Claimant knew or should have known of such a failure. Any claim filed after such time will be untimely.</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">In General. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Committee must render a decision on the claim within 90 days of the Claimant's written claim for benefits, provided that the Committee, in its discretion, may determine that an additional 90-day extension is warranted if it needs additional time to review the claim due to matters beyond the control of the Committee. In such event, the Committee shall notify the Claimant prior to the end of the initial period that an extension is needed, the reason therefor and the date by which the Committee expects to render a decision.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">26</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Disability Benefits. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notice of denial of a Disability Benefit will be provided within 45 days of the Committee&#8217;s receipt of the Claimant&#8217;s claim for a Disability Benefit. If the Committee determines that it needs additional time to review the Disability claim, the Committee will provide the Claimant with a notice of the extension before the end of the initial 45 day period. Such extension period may not exceed 30 days. If the Committee determines that a decision cannot be made within the first extension period due to matters beyond the control of the Committee, the time period for making a determination may be further extended for an additional 30 days. If such an additional extension is necessary, the Committee shall notify the Claimant prior to the expiration of the initial 30 day extension. Any notice of extension shall indicate the circumstances necessitating the extension of time, the date by which the Committee expects to furnish a notice of decision, the specific standards on which such entitlement to a benefit is based, the unresolved issues that prevent a decision on the claim and any additional information needed to resolve those issues. A Claimant will be provided a minimum of 45 days to submit any necessary additional information to the Committee. In the event that a 30 day extension is necessary due to a Claimant&#8217;s failure to submit information necessary to decide a claim, the period for furnishing a notice of decision shall be tolled from the date on which the notice of the extension is sent to the Claimant until the earlier of the date the Claimant responds to the request for additional information or the response deadline.</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Contents of Notice. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If a Claimant&#8217;s request for benefits is denied, the notice of denial shall be in writing and shall contain the following information&#58;</font></div><div style="margin-bottom:9pt;padding-left:117pt;padding-right:5.85pt;text-align:justify;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The specific reason or reasons for the denial in plain language&#59;</font></div><div style="margin-bottom:9pt;padding-left:117pt;padding-right:5.85pt;text-align:justify;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;A specific reference to the pertinent Plan provisions on which the denial is based&#59;</font></div><div style="margin-bottom:9pt;padding-left:117pt;padding-right:5.85pt;text-align:justify;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;A description of any additional material or information necessary for the Claimant to perfect the claim and an explanation of why such material or information is necessary&#59;</font></div><div style="margin-bottom:9pt;padding-left:117pt;padding-right:5.85pt;text-align:justify;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;An explanation of the claims review procedures and the time limits applicable to such procedures&#59; and</font></div><div style="margin-bottom:9pt;padding-left:117pt;padding-right:5.85pt;text-align:justify;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;A statement of the Claimant&#8217;s right to bring a civil action under Section 502(a) of ERISA following an adverse determination upon review.</font></div><div style="margin-bottom:9pt;padding-left:117pt;padding-right:5.85pt;text-align:justify;text-indent:-40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;In the case of a denial of a claim for Disability benefits, the notification </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall be provided in a culturally and linguistically appropriate manner and&#59;</font></div><div style="margin-bottom:9pt;padding-left:153pt;padding-right:5.85pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;If an internal rule, guideline, protocol or other similar criterion was relied upon in making the adverse determination, either the specific rule, guideline, protocol or similar criterion&#59; or a statement that such a rule, guideline, protocol or other similar criterion was relied upon in making the adverse determination and that a copy of such rule, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">27</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:153pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">guideline, protocol or other criterion will be provided free of charge to the Claimant upon request&#59;</font></div><div style="margin-bottom:9pt;padding-left:153pt;padding-right:5.85pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;If the adverse benefit determination is based on a medical necessity or experimental treatment or similar exclusion or limit, either an explanation of the scientific or clinical judgment for the determination, applying the terms of the Plan to the Claimant&#8217;s medical circumstances, or a statement that such explanation will be provided free of charge upon request.  Any electronic notification shall comply with the standards imposed by regulations issued by the Department of Labor under ERISA&#59; and</font></div><div style="margin-bottom:9pt;padding-left:153pt;padding-right:5.85pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;A discussion of the decision, including an explanation of the basis for disagreeing with or not following&#58; (i) the views presented by the Claimant to the Plan of health care professionals treating the Participant and vocational professionals who evaluated the Participant, (ii) the views of medical or vocational experts whose advice was obtained on behalf of the Plan in connection with the Claimant's adverse benefit determination, without regard to whether the advice was relied upon in making the benefit determination, and (iii) a disability determination regarding the Participant presented by the Claimant to the Plan made by the Social Security Administration.</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;padding-right:5.85pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appeal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">In General. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A Claimant dissatisfied with the Committee&#8217;s decision must file a written appeal to the Committee within 60 days after Claimant&#8217;s receipt of the decision or deemed denial. Any claim filed more than 60 days after Claimant&#8217;s receipt of the decision will be untimely. The Claimant will have the opportunity, upon request and free of charge, to have reasonable access to and copies of all documents, records and other information relevant to the Claimant&#8217;s appeal. The Claimant may submit written comments, documents, records and other information relating to his or her claim with the appeal. The Committee will review all comments, documents, records and other information submitted by the Claimant relating to the claim, regardless of whether such information was submitted or considered in the initial claim determination. The Committee shall make a determination on the appeal within 60 days after receiving the Claimant&#8217;s written appeal, provided that the Committee may determine that an additional 60-day extension is necessary due to circumstances beyond the Committee&#8217;s control, in which event the Committee shall notify the Claimant prior to the end of the initial period that an extension is needed, the reason therefor and the date by which the Committee expects to render a decision.</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Disability Benefits. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Appeal of a denied Disability benefits claim must be filed in writing with the Committee no later than 180 days after receipt of the written notification of such claim denial. The review shall be conducted by the Committee (exclusive of the person who made the initial adverse decision or such person&#8217;s subordinate). In reviewing the appeal, the Committee shall&#58; (i) not afford deference to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">28</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the initial denial of the claim, (ii) consult a medical professional who has appropriate training and experience in the field of medicine relating to the Claimant&#8217;s disability and who was neither consulted as part of the initial denial nor is the subordinate of such individual and (iii) identify the medical or vocational experts whose advice was obtained with respect to the initial benefit denial, without regard to whether the advice was relied upon in making the decision. </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To the extent required under ERISA, before the Plan can issue an adverse benefit determination on an appeal, the Committee shall provide the Claimant, free of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">charge</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, with any new or additional evidence considered, relied upon, or generated by the Plan, insurer, or other person making the benefit determination (or at the direction of the Plan, insurer or such other person) in connection with the claim and such evidence must be provided as soon as possible and sufficiently in advance of the date on which the notice of adverse benefit determination on appeal required to be provided under these claims procedures to give the Claimant a reasonable opportunity to respond prior to that date.  Before the Plan can issue an adverse benefit determination on an appeal based on a new or additional rationale, the Committee shall provide the Claimant, free of charge, with the rationale and the rationale must be provided as soon as possible and sufficiently in advance of the date on which the notice of adverse benefit determination on appeal is required to be provided to the Claimant under these claims procedures to give the Claimant a reasonable opportunity to respond prior to that date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Committee shall make its decision regarding the merits of the denied claim within 45 days following receipt of the appeal (or within 90 days after such receipt, in a case where there are special circumstances requiring extension of time for reviewing the appealed claim). If an extension of time for reviewing the appeal is required because of special circumstances, written notice of the extension shall be furnished to the Claimant prior to the commencement of the extension. The notice will indicate the special circumstances requiring the extension of time and the date by which the Committee expects to render the determination on review. Following its review of any additional information submitted by the Claimant, the Committee shall render a decision on its review of the denied claim.</font></div><div style="margin-bottom:9pt;padding-left:78.15pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Contents of Notice. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the Claimant&#8217;s appeal is denied in whole or part, the Committee shall provide written notice to the Claimant of such denial. The written notice shall include the following information&#58;</font></div><div style="margin-bottom:9pt;padding-left:117pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The specific reason or reasons for the denial&#59;</font></div><div style="margin-bottom:9pt;padding-left:117pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;A specific reference to the pertinent Plan provisions on which the denial is based&#59;</font></div><div style="margin-bottom:9pt;padding-left:117pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;A statement that the Claimant is entitled to receive, upon request and free of charge, reasonable access to and copies of all documents, records, and other information relevant to the Claimant&#8217;s claim&#59; and</font></div><div style="margin-bottom:9pt;padding-left:117pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;A statement of the Claimant&#8217;s right to bring a civil action under Section 502(a) of ERISA.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">29</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:117pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;In the case of a denial of a claim for Disability benefits, the notification </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall be provided in a culturally and linguistically appropriate manner and shall include any information described in Sections 12.1(c)(vi) a, b and c above with respect to the appeal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;padding-right:5.85pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Claims Appeals Upon Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon a Change in Control, the Committee, as constituted immediately prior to such Change in Control, shall continue to act as the Committee. After a Change in Control, no member of the Committee may be removed (and&#47;or replaced) by the Company without the consent of either (a) 2&#47;3 of the members of the Board of Directors of the Company and a majority of Participants and Beneficiaries with Account Balances or (b) the Ex-CEO or, in the event the Ex-CEO is no longer a Plan Participant, his or her appointee who is a Plan Participant.</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;padding-right:5.85pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Constructive Denial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If the Claimant does not receive a written decision within the time period(s) described above, the claim shall be deemed denied on the last day of such period(s).</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;padding-right:5.85pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Six Month Deadline for Filing Suit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A Claimant dissatisfied with the Committee&#8217;s decision upon appeal under Sections 12.2 must file any lawsuit challenging that decision no later than six months after the Committee mails the notice of denial or a Constructive Denial occurs. Any suit brought more than six months after the denial on appeal or Constructive Denial shall be deemed untimely. In ruling on any such suit, the Court shall uphold the Committee&#8217;s determinations unless they constitute an abuse of discretion or fraud. No Claimant may institute any action or proceeding in any state or federal court of law or equity, or before any administrative tribunal or arbitrator, for a claim for benefits under the Plan until he first has exhausted the procedures set forth in Sections 12.1 and 12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;padding-right:5.85pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Decisions of Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All actions, interpretations, and decisions of the Committee shall be conclusive and binding on all persons, and shall be given the maximum deference permitted by law.</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;padding-right:5.85pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Administrative Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All expenses incurred in the administration of the Plan by the Committee, or otherwise, including legal fees and expenses, shall be paid and borne by the Participating Employers.</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;padding-right:5.85pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Eligibility to Participate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No member of the Committee who also is an Eligible Employee shall be excluded from participating in the Plan, but as a member of the Committee, he or she shall not be entitled to act or pass upon any matters pertaining specifically to his or her own Account.</font></div><div style="margin-bottom:9pt;padding-left:41.8pt;padding-right:5.85pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each of the Participating Employers shall, and hereby does, indemnify and hold harmless the members of the Committee, from and against any and all losses, claims, damages or liabilities (including attorneys&#8217; fees and amounts paid, with the approval of the Board of Directors, in settlement of any claim) arising out of or resulting from the implementation of a duty, act or decision with respect to the Plan, so long as such duty, act or decision does not involve gross negligence or willful misconduct on the part of any such individual.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">30</font></div><div><font><br></font></div></div></div><div id="iaa30bcf535af4cc2885a261f469a91a1_309"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE XIII<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">General Provisions</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No interest of any Participant, spouse or Beneficiary under this Plan and no benefit payable hereunder shall be assigned as security for a loan, and any such purported assignment shall be null, void and of no effect, nor shall any such interest or any such benefit be subject in any manner, either voluntarily or involuntarily, to anticipation, sale, transfer, assignment or encumbrance by or through any Participant, spouse or Beneficiary. Notwithstanding anything to the contrary herein, however, the Committee has the discretion to make payments to an alternate payee in accordance with the terms of a domestic relations order (as defined in Code Section 414(p)(l)(B)).</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A Participating Employer may assign any or all of its liabilities under this Plan in<br>connection with any restructuring, recapitalization, sale of assets or other similar<br>transactions affecting such Participating Employer without the consent of the Participant.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Legal or Equitable Rights or Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No Participant or other person shall have any legal or equitable rights or interest in this Plan that are not expressly granted in this Plan. Participation in this Plan does not give any person any right to be retained in the service of a Participating Employer. The right and power of a Participating Employer to dismiss or discharge an Employee is expressly reserved.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Guarantee of Tax Consequences</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. While the Plan is intended to provide tax deferral for Participants, the Plan is not a guarantee that the intended tax deferral will be achieved. Participants are solely responsible and liable for the satisfaction of all taxes and penalties that may arise in connection with this Plan (including any taxes arising under Code Section 409A). No Participating Employer or any of their directors, officers or employees shall have any obligation to indemnify or otherwise hold any Participant harmless from any such taxes. No Participating Employer makes any representations or warranties as to the tax consequences to a Participant or a Participant&#8217;s Beneficiary(ies) resulting from a deferral of income pursuant to the Plan.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Rights and Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Under no circumstances will any Participating Employer, the Compensation Committee or the members of the Compensation Committee, the Committee or the members of the Committee be subject to any liability or duty under the Plan except as expressly provided in the Plan, or for any action taken, omitted or suffered in good faith.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Effect on Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Neither the establishment or maintenance of the Plan, the making of any Compensation Deferrals nor any action of a Participating Employer or the Committee, shall be held or construed to confer upon any individual&#58; (a) any right to be continued as an employee or (b) upon dismissal, any right or interest in any specific assets of any Participating Employer or the Committee other than as provided in the Plan. Each Participating Employer expressly reserves the right to discharge any employee at any time, with or without cause. Nothing contained herein shall be construed to constitute a contract of employment between an Employee and any Participating Employer.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">31</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any notice or filing required or permitted to be delivered to the Committee under this Plan shall be delivered in writing, in person, or through such electronic means as is established by the Committee. Notice shall be deemed given as of the date of delivery or, if delivery is made by mail, as of the date shown on the postmark on the receipt for registration or certification. Written transmission shall be sent by certified mail to&#58;</font></div><div style="margin-bottom:9pt;padding-left:24pt;padding-right:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RESMED INC.<br>ATTN&#58; CORPORATE SECRETARY<br>9001 SPECTRUM CENTER BLVD.<br>SAN DIEGO, CA 92123</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any notice or filing required or permitted to be given to a Participant under this Plan shall be sufficient if in writing or hand-delivered, or sent by mail to the last known address of the Participant.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The headings of Sections are included solely for convenience of reference, and if there is any conflict between such headings and the text of this Plan, the text shall control.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Invalid or Unenforceable Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If any provision of this Plan shall be held invalid or unenforceable, such invalidity or unenforceability shall not affect any other provisions hereof and the Committee may elect in its sole discretion to construe such invalid or unenforceable provisions in a manner that conforms to applicable law or as if such provisions, to the extent invalid or unenforceable, had not been included.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Lost Participants or Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any Participant or Beneficiary who is entitled to a benefit from the Plan has the duty to keep the Committee advised of his or her current mailing address. If benefit payments are returned to the Plan or are not presented for payment after a reasonable amount of time, the Committee shall presume that the payee is missing. The Committee, after making such efforts as in its discretion it deems reasonable and appropriate to locate the payee, shall stop payment on any uncashed checks and may discontinue making future payments until contact with the payee is restored to the extent permitted by Code Section 409A.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Facility of Payment to a Minor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If a distribution is to be made to a minor, or to a person who is otherwise incompetent, then the Committee may, in its discretion, make such distribution&#58; (a) to the legal guardian, or if none, to a parent of a minor payee with whom the payee maintains his or her residence, or (b) to the conservator or committee or, if none, to the person having custody of an incompetent payee. Any such distribution shall fully discharge the Committee, the Participating Employers, and the Plan from further liability on account thereof.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. To the extent applicable, ERISA shall govern the construction and administration of the Plan.</font></div><div style="margin-bottom:9pt;padding-left:42.15pt;padding-right:5.85pt;text-align:justify;text-indent:-36.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Plan is intended to be administered in compliance with Code Section 409A and each provision of the Plan shall be interpreted, to the extent possible, to comply with Code Section 409A.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">32</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF, the undersigned executed this Plan as of the 17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> day of August, 2023.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:137%">ResMed Inc.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:137%">By&#58;    Michael Rider  </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:137%">(Print Name)</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:137%">Its&#58;    Secretary  </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:137%">(Title)</font></div><div style="margin-bottom:9pt"><img alt="image_01.jpg" src="image_01.jpg" style="height:46px;margin-bottom:5pt;vertical-align:text-bottom;width:174px"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:137%">_________________________</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:145%">33</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>4
<FILENAME>exhibit19-resmedinsidertra.htm
<DESCRIPTION>EX-19
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i6318dd93ac614f23b93b7811dbbedda0_40"></div><div style="min-height:126.72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.865%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 19</font></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:96px"></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:24pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:right"><img alt="image_1.jpg" src="image_1.jpg" style="height:76px;margin-bottom:5pt;vertical-align:text-bottom;width:91px"></div></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:18pt;font-weight:400;line-height:125%">Insider Trading Policy &#8211; 10b5-1</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Effective August 17, 2023</font></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:21.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:125%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:125%"> </font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:125%">Purpose</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">To define the ResMed Inc. (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;) policy on trades and other transactions in &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">,&#8221; which includes </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> common stock, options, futures, calls, puts, warrants, debt securities, and any other rights to acquire </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> common stock.</font></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:21.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:125%">2.&#160;&#160;&#160;&#160;Scope</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">This policy applies worldwide, to all </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Directors</font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Executive Officers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, officers, employees, consultants, contract workers, temporary staff, and any other persons associated with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Covered Persons</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#34;). </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">This policy will continue to apply to you after the termination of your employment or service as a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Covered Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> for so long as you are in possession of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Material Nonpublic Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> about </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:21.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:125%">3.&#160;&#160;&#160;&#160;Responsibility</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">All </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Covered Persons </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">should carefully read this policy and follow its directives at all times. Failure to adhere to this policy may result in immediate disciplinary measures being taken including, in appropriate cases, termination. </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">For questions about this policy or its application to a particular transaction, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Covered Persons</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> should contact our global general counsel.</font></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:21.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:125%">4.&#160;&#160;&#160;&#160;General Information about Insider Trading</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">4.1&#160;&#160;&#160;&#160;Overview</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">US federal securities laws generally prohibit </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Covered Persons</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> who possess material nonpublic information from trading </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> on the basis of that information. These laws also prohibit the direct or indirect communication or &#8220;tipping&#8221; of any material nonpublic information to anyone outside </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> under any circumstances, or to anyone within </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> other than on a need-to-know basis.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Because the primary listing for </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> common stock is the New York Stock Exchange, this policy describes US law regarding insider trading. For simplicity, this policy discusses only US law. But similar laws apply in Australia (where </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> CHESS Units of Foreign Securities&#8212;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#0070c0;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Confidential Proprietary Information, not to be reproduced, disclosed, or made available to third parties without prior consent from </font><font style="color:#0070c0;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and not to be used in any unauthorized way. Printed representations of this document are uncontrolled. See published location for latest version.</font></div><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#169; </font><font style="color:#0070c0;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 2023</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Use</font></div></div></div><hr style="page-break-after:always"><div style="min-height:126.72pt;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Insider Trading Policy &#8211; 10b5-1  &#160;&#160;&#160;&#160;</font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">depositary interests frequently called &#8220;CDIs&#8221; or &#8220;CUFS&#8221;&#8212;trade on the Australian Securities Exchange) and other countries. This policy applies to all </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Covered Persons</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, regardless of your location.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Illegal insider trading is generally considered to include (i) buying or selling </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> while in possession of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Material Nonpublic Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#59; and (ii) communicating </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Material Nonpublic Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> to others who then trade on the basis of that information.  </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">4.2&#160;&#160;&#160;&#160;Penalties</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Persons who violate these prohibitions are subject to potential civil damages and criminal penalties. The potential criminal and civil penalties for &#8220;willful&#8221; (that is, intentional) violations are&#58;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;&#160;&#160;&#160;&#160;A jail term of up to 20 years&#59;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;&#160;&#160;&#160;&#160;A criminal fine up to $5 million for individuals and $25 million for corporations&#59; and</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;&#160;&#160;&#160;&#160;A civil penalty up to three times the profit gained or loss avoided.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">4.3&#160;&#160;&#160;&#160;Risks to ResMed</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Trading on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Material Nonpublic Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> also poses significant risks to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">. </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;&#160;&#160;&#160;&#160;The US Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;) can bring an action against us (as your employer) to recover civil penalties of up to the greater of $1 million or three times the amount of profit you make or loss you avoid. </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;&#160;&#160;&#160;&#160;Disclosing even small amounts of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Material Nonpublic Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> could require us under federal securities laws to make complete disclosure regarding the matter in question before we would otherwise be obligated to do so (that is, if the story is disclosed selectively or only part of the story is disclosed to the general public, we may have a duty to publicly disclose the full story, which may have detrimental effects on us or third parties).</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;&#160;&#160;&#160;&#160;Disclosing of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Material Nonpublic Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> could damage our competitive position, jeopardize important strategic plans, and threaten or eliminate opportunities such as acquisitions or financings.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed Confidential Proprietary Information, not to be reproduced, disclosed, or made available to third parties without prior consent from ResMed and not to be used in any unauthorized way. Printed representations of this document are uncontrolled. See published location for latest version. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective August 17, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 2 of 19</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Use</font></div></div></div><hr style="page-break-after:always"><div style="min-height:126.72pt;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Insider Trading Policy &#8211; 10b5-1  &#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:21.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:125%">5.&#160;&#160;&#160;&#160;Definitions</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">5.1&#160;&#160;&#160;&#160;Approving Officer&#58;</font><font style="color:#2e74b5;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">the ResMed Inc. global general counsel, or in that person&#8217;s absence, its chief financial officer. For purposes of approving the global general counsel&#8217;s trades, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Approving Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> means ResMed Inc.&#8217;s chief executive officer or its president and chief operating officer.</font></div><div style="text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">5.2    Directors&#58;</font><font style="color:#2e74b5;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">members of ResMed Inc.&#8217;s board of directors.</font></div><div style="padding-left:28.8pt;text-align:justify"><font><br></font></div><div style="padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">5.3</font><font style="color:#2e74b5;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;</font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Executive Officers&#58;</font><font style="color:#2e74b5;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">persons designated by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> as executive officers, or principal accounting officers, in accordance with the definition of 17 CFR &#167; 240.3b-7 and disclosed in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8217;s annual proxy statement. This refers to those officers that are subject to the filing requirements of Section 16 of the Exchange Act. </font></div><div style="padding-left:28.8pt;text-align:justify"><font><br></font></div><div style="padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">5.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;</font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Material Nonpublic Information&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Generally, all important information about our business that has not been publicly disclosed via press release, earnings conference call, or filings with the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> should be considered confidential non-public information. Even after a public announcement, a reasonable period of time must lapse in order for the market to react to the information. </font></div><div style="padding-left:28.8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:28.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Non-public information is generally considered &#8220;material&#8221; if there is a substantial likelihood a &#8220;reasonable investor&#8221; would consider it important in a decision to buy, sell, or hold securities or if the information is likely to have a significant effect on the market price of the security. Also, information that something is likely to happen in the future&#8212;or even just that it may happen&#8212;could be deemed material.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Materiality of information may vary depending on the circumstances of each case&#59; it will be viewed with &#8220;20&#47;20 hindsight.&#8221; Consequently, any appearance of impropriety should be avoided, and the particular facts of each such situation should be carefully reviewed.  </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Examples of information that is generally regarded as material are&#58; </font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Financial results&#59; </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Projections of future financial results or other guidance&#59;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Major proposed or pending acquisitions, investments or divestitures&#59;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Significant product developments&#59;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Changes in key personnel&#59;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Stock splits&#59;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Stock buy-backs&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed Confidential Proprietary Information, not to be reproduced, disclosed, or made available to third parties without prior consent from ResMed and not to be used in any unauthorized way. Printed representations of this document are uncontrolled. See published location for latest version. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective August 17, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 3 of 19</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Use</font></div></div></div><hr style="page-break-after:always"><div style="min-height:126.72pt;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Insider Trading Policy &#8211; 10b5-1  &#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">New equity or debt offerings&#59;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Positive or negative developments in outstanding significant litigation&#59;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Cybersecurity risks and incidents&#59;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Actual or threatened significant litigation or substantive inquiry by a governmental or regulatory authority&#59;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Events that may result in the creation of a significant reserve or write-off or other significant adjustments to the financial statements&#59; and </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Any other facts that might cause </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8217;s financial results to be substantially affected.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">5.5&#160;&#160;&#160;&#160;ResMed Securities&#58;</font><font style="color:#2e74b5;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">All of the following are considered </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> under this policy&#58;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%;padding-left:13.8pt">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> common stock&#59; </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">CHESS Units of Foreign Securities depositary interests issued by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> for trading on the Australian Securities Exchange&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Bonds or other debt instruments&#59;</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">options, futures, calls, puts, warrants, and any other rights to acquire </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> common stock&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Other publicly-traded securities that </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> may issue in the future.</font></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:21.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:125%">6.&#160;&#160;&#160;&#160;Prohibited Trading Practices</font></div><div style="text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:125%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Trading on Inside Information Prohibited&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> You are prohibited from purchasing or selling </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> while you are in possession of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Material Nonpublic Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> about </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">. These prohibitions apply to you and your&#58;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Spouse, children, or relatives in the same household&#59;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Corporation or other business entity controlled by you&#59; and</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Trust in which you or a family member act as trustee or have a beneficial or pecuniary interest (unless the trust has been previously cleared by the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Approving Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8220;Purchase&#8221; and &#8220;sale&#8221; are defined broadly under the federal securities law. </font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">&#8220;Purchase&#8221; includes not only the actual purchase of a security, but any contract to purchase or otherwise acquire a security. </font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">&#8220;Sale&#8221; includes not only the actual sale of a security, but any contract to sell or otherwise dispose of a security. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed Confidential Proprietary Information, not to be reproduced, disclosed, or made available to third parties without prior consent from ResMed and not to be used in any unauthorized way. Printed representations of this document are uncontrolled. See published location for latest version. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective August 17, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 4 of 19</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Use</font></div></div></div><hr style="page-break-after:always"><div style="min-height:126.72pt;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Insider Trading Policy &#8211; 10b5-1  &#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:1pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">These definitions extend to a broad range of transactions including conventional cash-for-stock transactions and conversions.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Applying these definitions to the exercise of a stock option depends on what is done with the shares obtained on exercise.</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">An exercise-and-hold transaction, in which a stock option is exercised, but none of the underlying shares is sold will not be considered a purchase or sale.  </font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">If any of the shares received on exercise of a stock option are sold for any purpose, including to pay the underlying exercise price (a &#8220;cashless exercise&#8221;) or to pay taxes, even if you do not receive the proceeds from the sale, then the transaction is a sale for purposes of this policy.</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">An automatic exercise that occurs when the option term expires would ordinarily not be considered a &#8220;sale&#8221; for purposes of this policy, so long as the transaction occurs in accordance with the terms of the relevant stock option agreement.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The size of the transaction or the amount of profit received does not have to be large to result in prosecution. The </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> has the ability to monitor even the smallest trades and finds people violating these rules by engaging in routine market surveillance. Brokers and dealers who handle stock and option transactions for </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> or individuals are required by law to inform the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> of any possible violations by people who may have inside information. The </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> aggressively investigates even small insider trading violations.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">6.2&#160;&#160;&#160;&#160;Waiting Period Following release of Material Nonpublic Information&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> When </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Material Nonpublic Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> has been publicly disclosed, you should continue to refrain from trading in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> until the information has been adequately disseminated to the public and investors have been able to evaluate it. Unless you are otherwise advised by the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Approving Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, information will be considered adequately disseminated and absorbed by the marketplace after one full trading day has elapsed following its release. When in doubt, contact the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Approving Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> for advice.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">6.3&#160;&#160;&#160;&#160;Tipping Prohibited&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">You are prohibited from disclosing or &#8220;tipping&#8221; to anyone, including family members and friends, any </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Material Nonpublic Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> about any company. This includes information about </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> or information about another company you might receive and, therefore, become a &#8220;tippee&#8221; or an &#8220;insider&#8221; of that company. Also, you are prohibited from making buy, sell or hold recommendations to anyone about any company while in possession of &#8220;inside information&#8221; about that company.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">If you believe it is necessary to the performance of your specific job duties to disclose any material nonpublic information to persons outside of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, you must contact the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Approving Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, in advance, so that we can take appropriate action before any disclosure.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed Confidential Proprietary Information, not to be reproduced, disclosed, or made available to third parties without prior consent from ResMed and not to be used in any unauthorized way. Printed representations of this document are uncontrolled. See published location for latest version. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective August 17, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 5 of 19</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Use</font></div></div></div><hr style="page-break-after:always"><div style="min-height:126.72pt;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Insider Trading Policy &#8211; 10b5-1  &#160;&#160;&#160;&#160;</font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">6.4&#160;&#160;&#160;&#160;Pledging and hedging ResMed Securities prohibited&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> All </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Covered Persons</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, regardless of whether you have been designated as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Insider</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, and regardless of whether you have </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Material Nonpublic Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, are prohibited at all times from engaging in certain transactions involving </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">These prohibited transactions include&#58;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Buying or selling puts or calls on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Short sales, meaning sales of securities that are not then owned (which are illegal for </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Executive Officers</font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">).</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Margin Accounts or Pledges.  You may not purchase </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> on margin, borrow against any account in which </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> are held or pledge </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> as collateral for a margin loan or any other loan. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Hedging.  Other forms of hedging or monetization transactions, such as collars, forward sale contracts, equity swaps, exchange funds, or any other financial instrument designed to hedge or offset a decrease in the market value of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">6.5.&#160;&#160;&#160;&#160;Stop-Loss Orders Prohibited&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> You are prohibited from placing any &#8220;stop loss&#8221; orders or any other &#8220;limit order&#8221; that would apply to a purchase or sale of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> outside of a trading window period, except under a qualified Rule 10b5-1 plan (as defined below). Otherwise, it would be possible for a trade to occur during a time in which material nonpublic information was known to you.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">6.6.&#160;&#160;&#160;&#160;Gifts prohibited while possessing Material Nonpublic Information&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Under certain circumstances, gifts of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> may raise the same concerns as more common forms of insider trading, for example, if a gift is followed closely by a sale, or under conditions where the value at the time of donation and sale affects the tax or other benefits obtained by the donor. For this reason, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> prohibits you from making gifts of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> while you possess </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Material Nonpublic Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:21.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:125%">7.&#160;&#160;&#160;&#160;Trading Windows and Closed Periods for Insiders</font></div><div style="margin-bottom:1pt;margin-top:5pt;text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:125%">7.1 &#160;&#160;&#160;&#160;</font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Designation as an Insider&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> All directors, executive officers and persons or positions identified from time to time by the general counsel are considered &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Insiders</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#58;&#8221; </font></div><div style="margin-bottom:1pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Even if you are not automatically classified as an </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Insider</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, you may become an </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Insider</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> if you become aware of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Material Nonpublic Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> as defined above. Decisions on whether to classify a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Covered Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> as an </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Insider</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> will be made by the global general counsel and others they designate.</font></div><div style="margin-bottom:1pt;margin-top:5pt;text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">7.2&#160;&#160;&#160;&#160;Prohibitions and limitations&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Insiders</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> will only be allowed to purchase or sell </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> during a trading window period beginning one (1) full trading day after the date of our public disclosure of financial results for a fiscal quarter or year and continuing until the later of&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed Confidential Proprietary Information, not to be reproduced, disclosed, or made available to third parties without prior consent from ResMed and not to be used in any unauthorized way. Printed representations of this document are uncontrolled. See published location for latest version. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective August 17, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 6 of 19</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Use</font></div></div></div><hr style="page-break-after:always"><div style="min-height:126.72pt;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Insider Trading Policy &#8211; 10b5-1  &#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">The last day of the three (3) calendar week period after the opening of the trading window&#59; or </font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">The last day of the second month of the fiscal quarter. </font></div><div style="margin-bottom:1pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">If you are in doubt whether a trading window is open, consult the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Approving Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div style="margin-bottom:1pt;margin-top:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:1pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Any period outside these trading window periods is a &#8220;closed period.&#8221; All </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Insiders</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> are prohibited from trading in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">during closed periods.</font></div><div style="margin-bottom:1pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The prohibitions against trading during closed periods do not apply to&#58;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">The exercise of stock options where cash is paid for the exercise price and tax withholding obligation, and the stock acquired upon exercise is held by the Employee,</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">The surrender of stock to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> upon a stock option exercise in payment of the exercise price, in a manner permitted by the applicable terms of the award,</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">The surrender of stock to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> in satisfaction of any tax withholding obligation, in a manner permitted by the applicable terms of the award,</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">The sale or purchase of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> under a qualified Rule 10b5-1 plan,</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">The purchase of shares under our Employee Stock Purchase Plan,</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">The transfer of shares between the New York Stock Exchange and the Australian Securities Exchange, solely for an exchange of common stock trading on the NYSE, for CHESS Units of Foreign Securities, depositary interests frequently called &#8220;CDIs&#8221; or &#8220;CUFS,&#8221; trading on the ASX.</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">The transfer of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">in accordance with a domestic relations order (provided that any such transfers must be pre-cleared by the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Approving Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, or</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Trading authorized by the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Approving Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, under exceptional circumstances approved by the Approving Officer, in their discretion. </font></div><div style="padding-left:37.15pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">For the sake of clarity&#58; you may not sell shares acquired by exercising a stock option or sell shares acquired under the Employee Stock Purchase Plan during closed periods (unless sold under a qualified Rule 10b5-1 plan, as described in the section below)&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Even during a trading window period, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Insider</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">s and other </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Covered Persons</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> are still prohibited from trading </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">while they possess </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Material Nonpublic Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed Confidential Proprietary Information, not to be reproduced, disclosed, or made available to third parties without prior consent from ResMed and not to be used in any unauthorized way. Printed representations of this document are uncontrolled. See published location for latest version. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective August 17, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 7 of 19</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Use</font></div></div></div><hr style="page-break-after:always"><div style="min-height:126.72pt;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Insider Trading Policy &#8211; 10b5-1  &#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:21.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:125%">8.&#160;&#160;&#160;&#160;Mandatory Pre-approval Procedures for Specified Persons</font></div><div style="text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:125%">8.1&#160;&#160;&#160;&#160;</font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Mandatory Pre-approval procedures&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Our </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Executive Officers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, and other persons identified from time to time by the global general counsel (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Specified Persons</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;), who are not in possession of Material Non-Public Information and who wish to engage in any transaction involving </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(including any option exercise, stock purchase, stock sale, gift, contribution to a trust, or any other transfer or acquisition), must first obtain pre-approval of the transaction from the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Approving Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">. No preclearance is required if the transaction is being made under a previously established 10b5-1 plan approved in accordance with this policy.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">A request for pre-approval should be submitted to the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Approving Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> at least two business days before the proposed transaction. The </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Approving Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> will then determine whether the transaction may proceed and will promptly notify the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Specified Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> of this determination. When making a pre-approval request, the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Specified Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> must include all relevant information concerning the proposed transactions and how best to be reached.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Approval for a proposed transaction may be withheld by the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Approving Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, in their discretion. Approval will be withheld, for example, under the following circumstances.</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">They determine that the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Specified Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> may possess material nonpublic information&#59;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">The trade is proposed for a closed period&#59;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">The transaction does not comply with Rule 144 or other legal requirements&#59;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">The transaction could result in adverse publicity or have a material adverse impact on trading in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#59; </font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">The transaction could result in liability to the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Specified Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> under the short-swing rules of Section 16(b) (See Exhibit B)&#59; </font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Sufficient advance notice had not been given to allow preparation and review of a Form 4&#59; or</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Based on such other relevant considerations as the Approving Officer determines is relevant.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">8.3&#160;&#160;&#160;&#160;Dispute resolution&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> If the clearance of a proposed transaction is withheld, the decision cannot be &#8220;overruled&#8221; by any other member of management. If there is a disagreement regarding a proposed transaction, and the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Specified Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> requests a final resolution of a pre-clearance request, then the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Approving Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> is required to report the proposed transaction to the audit committee of the board of directors. The </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Approving Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> and the audit committee may obtain the advice of outside legal counsel with respect to a pre-clearance request. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Specified Persons</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> may not in any event engage in the proposed transaction until a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed Confidential Proprietary Information, not to be reproduced, disclosed, or made available to third parties without prior consent from ResMed and not to be used in any unauthorized way. Printed representations of this document are uncontrolled. See published location for latest version. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective August 17, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 8 of 19</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Use</font></div></div></div><hr style="page-break-after:always"><div style="min-height:126.72pt;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Insider Trading Policy &#8211; 10b5-1  &#160;&#160;&#160;&#160;</font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">request has been finally resolved to the satisfaction of the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Approving Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> or, if applicable, the audit committee.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">8.3&#160;&#160;&#160;&#160;Approvals are time-limited&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Clearance, when given, will be only for the precise period specified. Placing buy or sell orders at a given price should only be for the time period specified, since events could subsequently arise that could make trading inappropriate. It is incumbent on the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Specified Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> to cancel any such order that extends beyond the permitted period, or when the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Specified Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> comes into possession of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Material Nonpublic Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed Confidential Proprietary Information, not to be reproduced, disclosed, or made available to third parties without prior consent from ResMed and not to be used in any unauthorized way. Printed representations of this document are uncontrolled. See published location for latest version. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective August 17, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 9 of 19</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Use</font></div></div></div><hr style="page-break-after:always"><div style="min-height:126.72pt;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Insider Trading Policy &#8211; 10b5-1  &#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:21.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:125%">9.&#160;&#160;&#160;&#160;Rule 10b5-1</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">9.1 Overview&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Automatic trading plans, also known as 10b5-1 plans, are permitted under the US insider trading rules when they are entered into in good faith at a time when the individual is not in possession of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Material NonPublic Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">. These plans serve to demonstrate that </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Material Nonpublic Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> did not factor into the trading decision, even if the pre-planned trades occur after the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Covered Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> later becomes aware of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Material Nonpublic Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">. If adopted in accordance with </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Rule 10b5-1, these plans provide affirmative defenses to trading on the basis of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Material Nonpublic Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> in insider trading cases.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">9.2. Pre-approval</font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#58;</font><font style="color:#2e74b5;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Any person who wishes to implement, amend or terminate a qualified Rule 10b5-1 plan must first have the plan (or any amendment or proposal to terminate) pre-approved by the Approving Officer. In pre-clearing the implementation, amendment or termination of a qualified Rule 10b5-1 plan, the Approving Officer will not be responsible for determining whether the plan complies with Rule 10b5-1. Compliance with Rule 10b5-1 is solely the adopting person&#8217;s responsibility. </font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">9.3&#160;&#160;&#160;&#160;Cooling-off period&#58;</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">9.3.1&#160;&#160;&#160;&#160;Directors and Executive Officers&#58;</font><font style="color:#2e74b5;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">For </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Executive Officers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#58; the first trade under the plan may not occur until the later of&#58;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">90 days after the plan&#8217;s adoption&#59; or</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Two business days after </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed&#8217;s</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> financial results are disclosed in a filing under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Forms 10-Q or 10-K</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">covering the fiscal quarter in which the plan was adopted, up to a maximum of 120 days.</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">9.3.2&#160;&#160;&#160;&#160;Others&#58;</font><font style="color:#2e74b5;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">For any </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Covered Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> who is not a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Director</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Executive Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, the first trade under the plan may not occur until 30 days after the plan&#8217;s adoption.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">9.4&#160;&#160;&#160;&#160;Modifications&#58;</font><font style="color:#2e74b5;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Once a Rule 10b5-1 plan is implemented, a Covered Person may not modify, suspend, cancel, or terminate the plan without the Approving Officer&#8217;s approval. An individual may only modify a Rule 10b5-1 plan outside of a blackout period and, in any event, when the individual does not possess material nonpublic information.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:125%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Modifications will trigger a new cooling-off period if the modification changes the amount, price, or timing of trades, including a change to a formula that affects these inputs. Modifications do not trigger a new cooling-off period if they are immaterial or administrative, such as an adjustment for stock splits or a change in account information.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed Confidential Proprietary Information, not to be reproduced, disclosed, or made available to third parties without prior consent from ResMed and not to be used in any unauthorized way. Printed representations of this document are uncontrolled. See published location for latest version. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective August 17, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 10 of 19</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Use</font></div></div></div><hr style="page-break-after:always"><div style="min-height:126.72pt;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Insider Trading Policy &#8211; 10b5-1  &#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">9.5&#160;&#160;&#160;&#160;Overlapping plans&#58;</font><font style="color:#2e74b5;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Covered Persons</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> may not simultaneously maintain more than one Rule 10b5-1 plan except under one of the following three scenarios&#58;</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%;padding-left:13.8pt">Successor plans&#58;</font><font style="color:#2e74b5;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">They may simultaneously maintain two plans if one of the plans is a successor trading plan under which trades are not scheduled to begin until completion or expiration of the predecessor plan. If the predecessor plan is terminated early, trading under the successor plan cannot commence until the applicable cooling-off period has run from the termination date of the predecessor plan&#59;</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%;padding-left:13.8pt">Sell to cover&#58;</font><font style="color:#2e74b5;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">They may use sell-to-cover arrangements that authorize the sale of only enough securities necessary to satisfy tax withholding obligations arising exclusively from the vesting of an equity award. They may adopt a sell-to-cover plan even if they have another Rule 10b5-1 plan in place&#59; or</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%;padding-left:13.8pt">Multiple brokers&#58;</font><font style="color:#2e74b5;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">They may have several contracts with different brokers to execute trades under a single trading plan.</font></div><div style="margin-top:12pt;padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">9.6.</font><font style="color:#2e74b5;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;</font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Single-trade plans&#58;</font><font style="color:#2e74b5;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Rule 10b5-1 permits only one single-trade plan during any consecutive 12-month period, except for sell-to-cover arrangements. For this purpose, a single-trade plan is one that is &#8220;designed to effect&#8221; a trade in a single transaction, meaning that the plan &#8220;has the practical effect of requiring such a result.&#8221; Single-trade plans do not include plans that use several different stock price triggers or that give trading discretion to a broker, even if they happen to execute in one single trade.</font></div><div style="padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">9.7&#160;&#160;&#160;&#160;ResMed&#8217;s disclosures of Directors&#8217; and Executive Officers&#8217; trading arrangements&#58;</font><font style="color:#2e74b5;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> will file quarterly disclosures with the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> for each of our </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Executive Officers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> regarding&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%;padding-left:13.8pt">New or changed arrangements&#58;</font><font style="color:#2e74b5;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">any adoption, modification, or termination of Rule 10b5-1 plans or any other written trading arrangements that do not qualify for the Rule 10b5-1 affirmative defense&#59; and<br></font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%;padding-left:13.8pt">Material terms&#58;</font><font style="color:#2e74b5;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">a description of the material terms of each plan (other than pricing terms), including the name and title of the Director or Executive Officer&#59; the date the plan was adopted, modified, or terminated&#59; the plan&#8217;s duration&#59; and the total amount of securities to be purchased or sold under the plan.</font></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:21.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:125%">10.&#160;&#160;&#160;&#160;Other Guidelines</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed Confidential Proprietary Information, not to be reproduced, disclosed, or made available to third parties without prior consent from ResMed and not to be used in any unauthorized way. Printed representations of this document are uncontrolled. See published location for latest version. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective August 17, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 11 of 19</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Use</font></div></div></div><hr style="page-break-after:always"><div style="min-height:126.72pt;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Insider Trading Policy &#8211; 10b5-1  &#160;&#160;&#160;&#160;</font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">10.1&#160;&#160;&#160;&#160;Inquiries from Third Parties&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> All inquiries about </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> from third parties such as industry analysts or members of the financial or business media, that seek information about </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8217;s financial condition, operating results, or other information about the value of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, should be directed to our chief executive officer, president and chief operating officer, chief financial officer, global general counsel, or our chief communications and investor relations officer .</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">10.2&#160;&#160;&#160;&#160;The Buy-Sell &#8220;Trap&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">In buying publicly-traded securities, you should bear in mind a potential liquidity trap you could face&#58; you could receive permission to buy a security, but later be refused permission to sell it (at least temporarily). These situations are frequently beyond the control of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, and could lock you into an unwanted investment for a considerable period of time.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">10.3&#160;&#160;&#160;&#160;Confidential Information about Other Companies&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> In addition to material nonpublic information about </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, you may become aware of similar information about other companies whose securities are publicly traded, such as suppliers, customers or competitors. In such a situation, you must handle the other company&#8217;s information according to the same rules that apply to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8217;s material nonpublic information. You can be liable for trading on the basis of material nonpublic information in any publicly-traded company&#8217;s securities.</font></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:21.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:125%">11.&#160;&#160;&#160;&#160;You are Responsible for Insider Trading Violations</font></div><div style="text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">11.1&#160;&#160;&#160;&#160;Overview&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> This document is intended to inform you of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8217;s policies prohibiting insider trading. It is not intended to completely explain the legal restrictions and consequences of trading in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">. We strongly encourage you to consult with your own legal and tax advisors before engaging in any transaction involving </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> or the securities of companies with which we do business. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Please remember that you are ultimately responsible for complying with the laws prohibiting insider trading and that violating those laws can result in both civil and criminal penalties (including jail) as well as great embarrassment to you and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">11.2&#160;&#160;&#160;&#160;ResMed will cooperate with Authorities.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> It is our policy to cooperate fully with the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> and other governmental and regulatory authorities in investigating possible violations by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Covered Persons</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> and others of applicable laws and regulations. If appropriate, we will assist authorities in the investigation and prosecution of persons who engage in illegal conduct.</font></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:21.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:125%">12.&#160;&#160;&#160;&#160;Administration of this Policy</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">12.1&#160;&#160;&#160;&#160;Administration and interpretation&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> The global general counsel is authorized to administer and interpret this policy as needed. Any additional interpretations or exceptions will </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed Confidential Proprietary Information, not to be reproduced, disclosed, or made available to third parties without prior consent from ResMed and not to be used in any unauthorized way. Printed representations of this document are uncontrolled. See published location for latest version. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective August 17, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 12 of 19</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Use</font></div></div></div><hr style="page-break-after:always"><div style="min-height:126.72pt;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Insider Trading Policy &#8211; 10b5-1  &#160;&#160;&#160;&#160;</font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">be made by the audit committee of the board of directors and its determinations will be final, subject only to further review by the full board of directors, in its discretion.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">12.2&#160;&#160;&#160;&#160;Amendment or modification&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> This policy may be amended, modified or supplemented at any time by our audit committee or full board of directors.  Any such amendments or supplements will become effective immediately.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">12.3&#160;&#160;&#160;&#160;Enforcement&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> The audit committee or full board of directors may take any additional action it considers appropriate to encourage compliance with this policy, including additional restrictions on sale of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> for any person who does not comply with this policy.</font></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:21.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:125%">13.&#160;&#160;&#160;&#160;Acknowledgement Form for Covered Persons&#58;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Every </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Covered Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> may be required to sign, initially and from time to time, an Acknowledgement Form, in the form attached as Exhibit A, stating that they have received, read, and understands this policy and agree to comply, and have complied, with its prohibitions and requirements. You will be notified from time to time when the Acknowledgment Form must be submitted.</font></div><div style="margin-top:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:21.6pt;text-align:justify;text-indent:-21.6pt"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:125%">14.&#160;&#160;&#160;&#160;Policy Information</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:125%">Policy Information</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d1e7f3;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accountable Party</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Global General Counsel &#8211; legal department</font></td></tr><tr><td colspan="3" style="background-color:#d1e7f3;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Policy Type</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Corporate Governance</font></td></tr><tr><td colspan="3" style="background-color:#d1e7f3;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 17, 2023</font></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed Confidential Proprietary Information, not to be reproduced, disclosed, or made available to third parties without prior consent from ResMed and not to be used in any unauthorized way. Printed representations of this document are uncontrolled. See published location for latest version. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective August 17, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 13 of 19</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Use</font></div></div></div><hr style="page-break-after:always"><div style="min-height:126.72pt;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Insider Trading Policy &#8211; 10b5-1  &#160;&#160;&#160;&#160;</font></div></div><div style="text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:125%">Exhibit A&#58; Acknowledgement Form for Employees</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.940%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ACKNOWLEDGEMENT FORM</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">The undersigned, as a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Covered Person</font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:133%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%"> (as defined in the ResMed Insider Trading Policy, effective August 18, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8221;)), hereby certifies and represents to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:133%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%"> that the undersigned has received, read and understands the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%"> (and the Supplemental Policy on the Section 16 Compliance Program, if the undersigned is a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Section 16 Person</font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">(as defined in that supplemental policy at Exhibit B)), and agrees to comply, and has complied, with the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%"> (and the Supplemental Policy on the Section 16 Compliance Program, if the undersigned is a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:133%">Section 16 Person</font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%">)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:133%"> in its entirety&#58;</font></div></td></tr><tr><td colspan="3" style="background-color:#deebf6;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Employee signature&#58;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Print Name&#58;</font></td></tr><tr><td colspan="3" style="background-color:#deebf6;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Title&#58; </font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Executed on&#58;</font></td></tr><tr><td colspan="3" style="background-color:#deebf6;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company&#47;Location&#58;</font></td></tr><tr style="height:52pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed Confidential Proprietary Information, not to be reproduced, disclosed, or made available to third parties without prior consent from ResMed and not to be used in any unauthorized way. Printed representations of this document are uncontrolled. See published location for latest version. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective August 17, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 14 of 19</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Use</font></div></div></div><hr style="page-break-after:always"><div style="min-height:126.72pt;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Insider Trading Policy &#8211; 10b5-1  &#160;&#160;&#160;&#160;</font></div></div><div style="text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:125%">Exhibit B&#58; Supplemental Policy on Section 16 Compliance Program</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">1. Overview&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Executive Officers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> of ResMed Inc. and certain other persons identified from time to time by our board of directors or global general counsel are subject to Section 16 of the Securities Exchange Act of 1934, as amended (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Persons</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;). In addition to complying with all other policies and procedures in the ResMed Policy on Insider Trading (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221;), </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Persons</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> must also comply with this Supplemental Policy on Section 16 Compliance Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Section 16(a) of the Securities Exchange Act of 1934, and the related rules of the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, require our </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Perso</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">ns</font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">to report all transactions involving </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> (including options, warrants, and other &#8220;derivative securities&#8221;) to the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">. Almost all transactions must be reported within two business days after the transaction date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Section 16(b) requires </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> to recover any deemed profit resulting from any sale and purchase, or purchase and sale, by a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> within a six-month period. It makes no difference how long the shares were held or whether the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> was in possession of material nonpublic information at the time of the trades. Moreover, under the profit calculation rules, the highest-priced sale will be matched with the lowest-priced purchase, regardless of the order in which the transactions occurred or whether there is any overall profit. If you do not immediately disgorge any such profit to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, you can expect to receive a demand letter or civil complaint from one or more plaintiffs&#8217; lawyers who specialize in Section 16 actions. Transactions that occur for up to six months after you cease to be a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> may also give rise to Section 16(b) liability.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The Section 16 reporting requirement and short swing profit recovery rules extend to transactions by family members sharing a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Person&#8217;s</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> household, and transactions in which a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> is deemed to have an indirect pecuniary interest (such as transactions by trusts, corporations, or partnerships in which the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> has or shares control).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> rules, certain transactions, including gifts, approved option grants, in-the-money option exercises, and other transactions under employee benefit plans such as the Employee Stock Purchase Program, are considered &#8220;exempt transactions&#8221; under Section 16(b) and do not give rise to profit recovery. These exempt transactions in most cases are still required to be reported to the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> generally within two business days after the transaction date.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed Confidential Proprietary Information, not to be reproduced, disclosed, or made available to third parties without prior consent from ResMed and not to be used in any unauthorized way. Printed representations of this document are uncontrolled. See published location for latest version. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective August 17, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 15 of 19</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Use</font></div></div></div><hr style="page-break-after:always"><div style="min-height:126.72pt;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Insider Trading Policy &#8211; 10b5-1  &#160;&#160;&#160;&#160;</font></div></div><div style="text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">2.  Consequences of failure to report&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> The </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8217;s rules require companies to list in their annual proxy statement the name of any </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> who, during the preceding fiscal year, failed to file on a timely basis any of the required reports.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The consequences of filing a late report or not filing a required report can be significant&#58;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">You and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> may be the subject of adverse publicity as a result of disclosures in the proxy statement.</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">You may be subject to an </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> &#8220;cease and desist&#8221; order.</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">You may be required to pay substantial fines for each filing violation.</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Willful failures to file can be, and occasionally have been, prosecuted as a criminal violation of the federal securities laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Person</font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">s</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> should note that even if a transaction is properly reported the transaction can give rise to liability under Section 16(b) if it can be &#8220;matched&#8221; against another transaction occurring within six months.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">3. Filing Responsibilities and Required Forms&#58;</font><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Under Section 16, you, as a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, are personally liable for the failure to file required reports on a timely basis. To assist our </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Persons</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> in meeting required filing deadlines, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8217;s equity award program team will prepare and file required Section 16 reports for all </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> approved transactions, unless you have indicated that you prefer to prepare and file your own reports. You are requested to maintain a power of attorney that will give our global general counsel, chief financial officer, and other persons they may designate the authority to prepare and file on your behalf any required forms. The following required forms are required to be filed under Section 16&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Form 3 must be electronically filed with the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> when a person first becomes subject to Section 16. The Form 3 requires the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> to list all holdings of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> stock, options or other &#8220;derivative securities.&#8221; The Form 3 must be electronically received by the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> within ten calendar days after becoming a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Form 4 must be electronically filed with the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> whenever there is a change in the beneficial ownership of securities, including purchases and sales of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">option exercises, equity award grants and vesting, gifts, and changes in the nature of the ownership (e.g., from direct to indirect). All Forms 4 must be received by the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> via EDGAR no later than the second business day after the transaction date. The limited exception to this two day filing requirements is for certain transactions under Rule 10b5-1 trading plans and under multi-fund employee benefit plans where the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed Confidential Proprietary Information, not to be reproduced, disclosed, or made available to third parties without prior consent from ResMed and not to be used in any unauthorized way. Printed representations of this document are uncontrolled. See published location for latest version. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective August 17, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 16 of 19</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Use</font></div></div></div><hr style="page-break-after:always"><div style="min-height:126.72pt;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Insider Trading Policy &#8211; 10b5-1  &#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">insider does not control the timing of transaction execution&#59; in these circumstances the Form 4 may be electronically filed two days after the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Person&#8217;s</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> receipt of notice of the transaction, which notice must occur no later than the third day after the transaction date. Acquisitions of shares under the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Employee Stock Purchase Plan do not need to be reported on a Form 4.</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Form 5 must be electronically filed with the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> within 45 days after the end of our fiscal year to report transactions that were not reported during the year, because of a failure to earlier report.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:1pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Persons</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> (excluding 10% Stockholders) will be required to provide </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> with a written representation at each fiscal year-end stating&#58;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">That you have pre-cleared all transactions during the fiscal year as required by this </font><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, and </font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">If applicable, that no Form 5 is due because all holdings and transactions previously have been reported on Form 3 or Form 4 by you. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">4. Preparing and reviewing Forms 3, 4 and 5&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> The equity award program team will oversee the preparation of the Section 16 forms (unless you have indicated that you prefer to prepare and file your own). For transactions that are under our control, such as equity grants, we will endeavor to prepare the forms and obtain your review and signature in advance. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">For your personal transactions, and due to the two business day electronic filing requirement, it is essential that you respond promptly to the equity award program team, provide all information necessary for </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> reporting, and otherwise assist in completing the required forms, if you wish to obtain approval of and to proceed with any proposed transaction. If the equity award program team is unable to obtain your approval in advance, we may file the Section 16 Forms within the required time, and make any necessary changes as a later amendment. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">5. Broker transactions&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">s are required to instruct their broker who handles trades in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> to&#58;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Verify with our </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Approving Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> that the proposed trade was pre-cleared by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> before entering any trading order for </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#59;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Confirm that the brokerage firm&#8217;s compliance procedures have been followed in connection with all trades, including Rule 144 for trades on the New York Stock Exchange&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed Confidential Proprietary Information, not to be reproduced, disclosed, or made available to third parties without prior consent from ResMed and not to be used in any unauthorized way. Printed representations of this document are uncontrolled. See published location for latest version. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective August 17, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 17 of 19</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Use</font></div></div></div><hr style="page-break-after:always"><div style="min-height:126.72pt;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Insider Trading Policy &#8211; 10b5-1  &#160;&#160;&#160;&#160;</font></div></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:13.8pt">Report to our global general counsel and equity award program manager the quantity and price of any trade promptly on the day the trade executes.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:1pt;margin-top:5pt;text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">6. Rule 144&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Rule 144 imposes a series of restrictions upon the sale of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> by affiliates of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, including our </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Directors</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Executive Officers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">. These restrictions may be summarized as follows&#58;</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%;padding-left:13.8pt">Volume Limitations.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Total sales of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> common stock by a covered individual for any three-month period may not exceed the greater of&#58; (i) 1% of the total number of outstanding shares of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> common stock, as reflected in the most recent report or statement published by </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, or (ii) the average weekly reported volume of such shares traded during the four calendar weeks preceding the filing of the requisite Form 144 Notice.</font></div><div style="margin-bottom:1pt;margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%;padding-left:13.8pt">Method of Sale.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> The shares must be sold either in a &#8220;broker&#8217;s transaction&#8221; or in a transaction directly with a &#8220;market maker.&#8221; A &#8220;broker&#8217;s transaction&#8221; is one in which the broker does no more than execute the sale order and receive the usual and customary commission. Neither the broker nor the selling officer or director can solicit or arrange for the sale order. In addition, the selling </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> must not pay any fee or commission other than to the broker. A &#8220;market maker&#8221; includes a specialist permitted to act as a dealer, a dealer acting in the position of a block positioner, and a dealer who holds itself out as being willing to buy and sell </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> common stock for their own account on a regular and continuous basis.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">7. Notice of Proposed Sale&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> A notice of the sale (the Form 144 Notice) must be filed electronically with the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> on the same day as the sell order is placed with the broker in reliance on Rule 144 or on the day the sale is executed directly with a market maker. Stockbrokers generally have internal procedures for executing sales under Rule 144 and will assist you in completing the Form 144 Notice and in complying with the other requirements of Rule 144. Failure to comply with the Form 144 Notice requirements invalidates the ability to rely on Rule 144.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#002060;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">8. Ultimate responsibility is yours&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> Although </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> offers to assist its </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Section 16 Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">s to help them comply with the Section 16 rules, it remains your obligation to see that your filings are accurate and made on time, that your sales are made in compliance with Rule 144 and that you have no Section 16(b) or Rule 10b-5 insider trading liability. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> cannot assume any legal responsibility in this regard. Under the law, if a filing is missed, you are personally responsible, notwithstanding that </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> has undertaken to prepare a required form. Please do not hesitate to call the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Approving Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> if you have any questions about any proposed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed Confidential Proprietary Information, not to be reproduced, disclosed, or made available to third parties without prior consent from ResMed and not to be used in any unauthorized way. Printed representations of this document are uncontrolled. See published location for latest version. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective August 17, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 18 of 19</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Use</font></div></div></div><hr style="page-break-after:always"><div style="min-height:126.72pt;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Insider Trading Policy &#8211; 10b5-1  &#160;&#160;&#160;&#160;</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">transaction, the Section 16 reporting requirements generally, the Rule 144 requirements or regarding any particular transaction.</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ResMed Confidential Proprietary Information, not to be reproduced, disclosed, or made available to third parties without prior consent from ResMed and not to be used in any unauthorized way. Printed representations of this document are uncontrolled. See published location for latest version. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effective August 17, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Page 19 of 19</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Use</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>exhibit211-subsidiariesq4f.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i460e2a6b0f9549839c323e9395e53b1d_1"></div><div style="min-height:30.96pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.983%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">EXHIBIT 21.1</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES OF THE REGISTRANT AS OF JUNE 30, 2024</font></div><div style="margin-top:1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following is a list of subsidiaries of ResMed Inc. as of June&#160;30, 2024, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary as defined by Rule 1-02(w) of Regulation S-X.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.294%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Corp.</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Minnesota</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed (UK) Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Asia Pacific Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Beteiligungs GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Holdings Pty Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Pty Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed GmbH and Co KG</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Motor Technologies Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed SAS</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">France</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Paris SAS</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed European Operations B.V</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Sensor Technologies Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Humidification Technologies GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Capital Holdings Pty Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Brightree LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Brightree Home Health &#38; Hospice LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Brightree Patient Collections LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed (Beijing) Trading Co., Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Operations Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Global Holdings Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Asia Pte Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Singapore</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">, Inc.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">MatrixCare, Inc</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Reciprocal Labs Corp. (dba Propeller Health)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Digital Health Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed SaaS Holdings, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Germany Saas Holdings GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">MediFox-Dan Investment GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Germany</font></td></tr></table></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>exhibit231-auditorconsentq.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i9984e0f0ca2440609b7ee138e0a6d442_1"></div><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.983%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">EXHIBIT 23.1</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Board of Directors</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ResMed Inc.&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We consent to the incorporation by reference in the registration statements (Nos. 333-08013, 333-88231, 333-115048, 333-140350, 333-140351, 333-156065, 333-164527, 333-167183, 333-181317, 333-186386, 333-194225, 333-224537, 333-245697, 333-256388) on Form S-8 of our reports dated August&#160;8, 2024, with respect to the consolidated financial statements and financial statement schedule II of ResMed, Inc. and the effectiveness of internal control over financial reporting.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; KPMG LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August&#160;8, 2024</font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>ex311-ceocertificationq4fy.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i2082d4fddb0c4cdaab9a4e028beb253b_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 31.1</font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael J. Farrell, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">I have reviewed this Annual Report on Form 10-K of ResMed Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.606%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MICHAEL J. FARRELL</font></div></td></tr><tr><td colspan="3" style="border-top:1pt dotted #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael J. Farrell</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>ex312-cfocertificationq4fy.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7b590da7643849d7bfc961d9f6d51ff5_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 31.2</font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brett A. Sandercock, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">I have reviewed this Annual Report on Form 10-K of ResMed Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:27.727%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BRETT A. SANDERCOCK</font></div></td></tr><tr><td colspan="3" style="border-top:1pt dotted #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brett A. Sandercock</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>ex321-ceoandcfocertificati.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i860f6138f5474bd3acbb97663e816653_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 32.1</font></div></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following certifications are being furnished solely to accompany the Annual Report pursuant to 18 U.S.C. Section 1350 and in accordance with SEC Release No. 33-8238.  These certifications shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be incorporated by reference in any filing made by ResMed Inc. under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Michael J. Farrell, Chief Executive Officer of ResMed Inc., a Delaware corporation (the &#8220;Company&#8221;), hereby certify that to my knowledge&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the accompanying Annual Report on Form 10-K of the Company for the year ended June 30, 2024 (the &#8220;Annual Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">the information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.606%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MICHAEL J. FARRELL</font></div></td></tr><tr><td colspan="3" style="border-top:1pt dotted #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael J. Farrell</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:19pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Brett A. Sandercock, Chief Financial Officer of the Company, hereby certify that to my knowledge&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the accompanying Annual Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">the information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:27.727%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2024</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> BRETT A. SANDERCOCK</font></div></td></tr><tr><td colspan="3" style="border-top:1pt dotted #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brett A. Sandercock</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to ResMed Inc. and will be retained by ResMed Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>10
<FILENAME>exhibit97-resmedclawbackpo.htm
<DESCRIPTION>EX-97
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i67d2bd1450bd49359b50ee6ff433e38e_1"></div><div style="min-height:78.48pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Exhibit 97</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><br></font><img alt="image_03.jpg" src="image_03.jpg" style="height:116px;margin-bottom:5pt;vertical-align:text-bottom;width:160px"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ResMed Inc.<br>Compensation Recovery Policy</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Compensation Recovery Policy (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is intended to maintain a culture of focused, diligent, and responsible management and to ensure compliance with applicable laws by ResMed Inc., its subsidiaries, and affiliates (together, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ResMed</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). ResMed has adopted this Policy, effective as of October 2, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Capitalized terms are defined in Section 11. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:26pt;text-decoration:underline">Persons Subject to Policy</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Policy applies to current and former Officers of ResMed.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Compensation Subject to Policy</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Policy applies to Incentive-Based Compensation received on or after the Effective Date. For purposes of this Policy, the date on which Incentive-Based Compensation is &#8220;received&#8221; will be determined under the Applicable Rules, which generally provide that Incentive-Based Compensation is &#8220;received&#8221; in ResMed&#8217;s fiscal period during which the relevant Financial Reporting Measure is attained or satisfied, without regard to whether the grant, vesting or payment of the Incentive-Based Compensation occurs after the end of that period.   </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Recovery of Compensation</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If ResMed is required to prepare a Restatement, ResMed must recover, reasonably promptly, the portion of any Incentive-Based Compensation that is Erroneously Awarded Compensation, unless the Committee determines that recovery would be Impracticable. Recovery will be required in accordance with the preceding sentence regardless of whether the applicable Officer engaged in misconduct or otherwise caused or contributed to the requirement for the Restatement and regardless of whether or when restated financial statements are filed by ResMed.  For clarity, the recovery of Erroneously Awarded Compensation under this Policy will not give rise to any person&#8217;s right to voluntarily terminate employment for &#8220;good reason,&#8221; or due to a &#8220;constructive termination&#8221; (or any similar term of like effect) under any plan, program or policy of or agreement with ResMed.</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1</font></div><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Adopted August 17, 2023 &#124; Effective October 2, 2023</font></div><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, ResMed will recover compensation earned based on performance goals that do not relate to a Financial Reporting Measure and&#47;or to awards that vest based on continued employment or service, and in each case, such recovery shall occur in the amount and manner determined by the Compensation Committee.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Manner of Recovery&#59; Limitation on Duplicative Recovery</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Committee will, in its sole discretion, determine the manner of recovery of any Erroneously Awarded Compensation, which may include, without limitation, reduction or cancellation by ResMed of Incentive-Based Compensation, Erroneously Awarded Compensation or solely time-vesting equity awards, reimbursement or repayment by any Officer subject to this Policy of the Erroneously Awarded Compensation, and, to the extent permitted by law, an offset of the Erroneously Awarded Compensation against other compensation payable by ResMed to the Officer. Notwithstanding the foregoing, unless otherwise prohibited by the Applicable Rules, to the extent this Policy provides for recovery of Erroneously Awarded Compensation already recovered by ResMed under Section 304 of the Sarbanes-Oxley Act of 2002 or Other Recovery Arrangements, the amount of Erroneously Awarded Compensation already recovered by ResMed from the recipient of such Erroneously Awarded Compensation must be credited to the amount of Erroneously Awarded Compensation required to be recovered under this Policy from the recipient.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Administration </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Policy shall be administered, interpreted and construed by the Committee, which is authorized to make all determinations necessary, appropriate or advisable for such purpose. The Board of Directors of ResMed (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may re-vest in itself the authority to administer, interpret and construe this Policy in accordance with applicable law, and if the Board does so, then references in this Policy to the &#8220;Committee&#8221; will refer to the Board.  Subject to any permitted review by the applicable national securities exchange or association under the Applicable Rules, all determinations and decisions made by the Committee will be final, conclusive and binding on all persons, including ResMed and its stockholders and employees. The Committee may delegate administrative duties with respect to this Policy to one or more directors or employees of ResMed, as permitted under applicable law, including any Applicable Rules. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Interpretation</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Policy must be interpreted and applied consistently with the requirements of the Applicable Rules, and to the extent this Policy is inconsistent with the Applicable Rules, it will be deemed amended to the minimum extent necessary to ensure compliance with the Applicable Rules. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">No Indemnification&#59; No Liability</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ResMed will not indemnify or insure any person against the loss of any Erroneously Awarded Compensation under this Policy, nor shall ResMed directly or </font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2</font></div><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Adopted August 17, 2023 &#124; Effective October 2, 2023</font></div><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">indirectly pay or reimburse any person for any premiums for third-party insurance policies that such person may elect to purchase to fund such person&#8217;s potential obligations under this Policy.  None of ResMed, or any member of the Committee or the Board will have any liability to any person as a result of actions taken under this Policy.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Application&#59; Enforceability</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As of the Effective Date, this Policy amends, restates and supersedes in its entirety the Company&#8217;s Compensation Recovery Policy, effective as of July 1, 2017.  Except as set forth herein or otherwise determined by the Committee or the Board, the adoption of this Policy does not limit, and is intended to apply in addition to, any other clawback, recoupment, forfeiture or similar policies or provisions of ResMed, including any policies or provisions of such effect contained in any employment agreement, bonus plan, incentive plan, equity-based plan, award agreement or similar plan, program or agreement of ResMed, or required under applicable law (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Other Recovery Arrangements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The remedy specified in this Policy is not exclusive and is in addition to every other right or remedy that may be available to ResMed.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Severability</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The provisions in this Policy are intended to be applied to the fullest extent of the law&#59; provided, however, to the extent that any provision of this Policy is found to be unenforceable or invalid under any applicable law, that provision will be applied to the maximum extent permitted, and will automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Amendment and Termination</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Board or the Committee may amend, modify or terminate this Policy in whole or in part at any time and from time to time in its sole discretion. This Policy will terminate automatically when ResMed does not have a class of securities listed on a national securities exchange or association.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Definitions</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:125%">Applicable Rules</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8221; means Section 10D of the Exchange Act, Rule 10D-1, the listing rules of the national securities exchange or association on which ResMed&#8217;s securities are listed, and any applicable rules, standards or other guidance adopted by the Securities and Exchange Commission or any national securities exchange or association on which ResMed&#8217;s securities are listed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the committee of the Board responsible for executive compensation decisions comprised solely of independent directors (as determined under the Applicable Rules), or in the absence of such a committee, a majority of the independent directors serving on the Board.</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3</font></div><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Adopted August 17, 2023 &#124; Effective October 2, 2023</font></div><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Erroneously Awarded Compensation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the amount of Incentive-Based Compensation received by an Officer that exceeds the amount of Incentive-Based Compensation that would have been received by the Officer based on a restated Financial Reporting Measure, as determined on a pre-tax basis in accordance with the Applicable Rules. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Securities Exchange Act of 1934, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Financial Reporting Measure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any measure determined and presented in accordance with the accounting principles used in preparing ResMed&#8217;s financial statements, and any measures derived wholly or in part from such measures, including GAAP, IFRS and non-GAAP&#47;IFRS financial measures, as well as stock or share price and total stockholder return. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">GAAP</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means United States generally accepted accounting principles.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">IFRS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means international financial reporting standards as adopted by the International Accounting Standards Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Impracticable</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means (a) the direct costs paid to third parties to assist in enforcing recovery would exceed the Erroneously Awarded Compensation&#59; provided that ResMed has (i) made reasonable attempts to recover the Erroneously Awarded Compensation, (ii) documented such attempt(s), and (iii) provided that documentation to the relevant listing exchange or association, (b) to the extent permitted by the Applicable Rules, the recovery would violate ResMed&#8217;s home country laws pursuant to an opinion of home country counsel&#59; provided that ResMed has (i) obtained an opinion of home country counsel, acceptable to the relevant listing exchange or association, that recovery would result in such violation, and (ii) provided such opinion to the relevant listing exchange or association, or (c) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of ResMed, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and the regulations under those statutes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Incentive-Based Compensation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Restatement, any compensation that is granted, earned, or vested based wholly or in part upon the attainment of one or more Financial Reporting Measures, and any equity compensation that vests based on continuation of employment, including stock options, and received by a person&#58; (a) after such person began service as an Officer&#59; (b) who served as an Officer at any time during the performance period for that compensation&#59; (c) while ResMed has a class of its securities listed on a national securities exchange or association&#59; and (d) during the applicable Three-Year Period</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means each person who serves or served (during any portion of the relevant time period) as an executive officer of ResMed, as defined in Rule&#160;10D-1(d) under the Exchange Act, and any other key employees of ResMed who the Committee may designate in writing as subject to the Policy from time to time, including after the </font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">4</font></div><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Adopted August 17, 2023 &#124; Effective October 2, 2023</font></div><div style="margin-bottom:8pt;text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">determination that ResMed is required to prepare a Restatement in accordance with this Policy..</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Restatement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means an accounting restatement to correct ResMed&#8217;s material noncompliance with any financial reporting requirement under securities laws, including restatements that correct an error in previously issued financial statements (a) that is material to the previously issued financial statements or (b) that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Three-Year Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Restatement, the three completed fiscal years immediately preceding the date that the Board, a committee of the Board, or the officer or officers of ResMed authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that ResMed is required to prepare such Restatement, or, if earlier, the date on which a court, regulator or other legally authorized body directs ResMed to prepare such Restatement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The &#8220;Three-Year Period&#8221; also includes any transition period (that results from a change in ResMed&#8217;s fiscal year) within or immediately following the three completed fiscal years identified in the preceding sentence.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">However, a transition period between the last day of ResMed&#8217;s previous fiscal year end and the first day of its new fiscal year that comprises a period of nine to 12 months shall be deemed a completed fiscal year.</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:125%">5</font></div><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>rmd-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:626b872d-b824-4a3f-bfea-336621baa0aa,g:59f8884c-c35b-445a-b56c-2a5e88decb05-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rmd="http://investor.resmed.com/20240630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://investor.resmed.com/20240630">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmd-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmd-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmd-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmd-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://investor.resmed.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://investor.resmed.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://investor.resmed.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncome" roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofIncome">
        <link:definition>9952153 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>9952154 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>9952155 - Statement - Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>9952156 - Statement - Consolidated Statements of Stockholders&#8217; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952157 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://investor.resmed.com/role/OrganizationandBasisofPresentation">
        <link:definition>9952158 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://investor.resmed.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952159 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NewAccountingPronouncements" roleURI="http://investor.resmed.com/role/NewAccountingPronouncements">
        <link:definition>9952160 - Disclosure - New Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformation" roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformation">
        <link:definition>9952161 - Disclosure - Supplemental Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsnet" roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnet">
        <link:definition>9952162 - Disclosure - Goodwill and Other Intangible Assets, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://investor.resmed.com/role/Investments">
        <link:definition>9952163 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://investor.resmed.com/role/AccruedExpenses">
        <link:definition>9952164 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://investor.resmed.com/role/Debt">
        <link:definition>9952165 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://investor.resmed.com/role/Leases">
        <link:definition>9952166 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://investor.resmed.com/role/StockholdersEquity">
        <link:definition>9952167 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://investor.resmed.com/role/EarningsPerShare">
        <link:definition>9952168 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://investor.resmed.com/role/IncomeTaxes">
        <link:definition>9952169 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://investor.resmed.com/role/SegmentInformation">
        <link:definition>9952170 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRetirementPlans" roleURI="http://investor.resmed.com/role/EmployeeRetirementPlans">
        <link:definition>9952171 - Disclosure - Employee Retirement Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalActionsContingenciesandCommitments" roleURI="http://investor.resmed.com/role/LegalActionsContingenciesandCommitments">
        <link:definition>9952172 - Disclosure - Legal Actions, Contingencies and Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsandHedgingActivities" roleURI="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivities">
        <link:definition>9952173 - Disclosure - Derivative Instruments and Hedging Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://investor.resmed.com/role/BusinessCombinations">
        <link:definition>9952174 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringExpenses" roleURI="http://investor.resmed.com/role/RestructuringExpenses">
        <link:definition>9952175 - Disclosure - Restructuring Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationandQualifyingAccountsandReserves" roleURI="http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReserves">
        <link:definition>9952176 - Disclosure - Schedule II Valuation and Qualifying Accounts and Reserves</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationTables" roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables">
        <link:definition>9954473 - Disclosure - Supplemental Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsnetTables" roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables">
        <link:definition>9954474 - Disclosure - Goodwill and Other Intangible Assets, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://investor.resmed.com/role/InvestmentsTables">
        <link:definition>9954475 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://investor.resmed.com/role/AccruedExpensesTables">
        <link:definition>9954476 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://investor.resmed.com/role/DebtTables">
        <link:definition>9954477 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://investor.resmed.com/role/LeasesTables">
        <link:definition>9954478 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://investor.resmed.com/role/StockholdersEquityTables">
        <link:definition>9954479 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://investor.resmed.com/role/EarningsPerShareTables">
        <link:definition>9954480 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://investor.resmed.com/role/IncomeTaxesTables">
        <link:definition>9954481 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://investor.resmed.com/role/SegmentInformationTables">
        <link:definition>9954482 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalActionsContingenciesandCommitmentsTables" roleURI="http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsTables">
        <link:definition>9954483 - Disclosure - Legal Actions, Contingencies and Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsandHedgingActivitiesTables" roleURI="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesTables">
        <link:definition>9954484 - Disclosure - Derivative Instruments and Hedging Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTables" roleURI="http://investor.resmed.com/role/BusinessCombinationsTables">
        <link:definition>9954485 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9954486 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails" roleURI="http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails">
        <link:definition>9954487 - Disclosure - Summary of Significant Accounting Policies (Summary of Contract Balances) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationScheduleofInventoriesDetails" roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails">
        <link:definition>9954488 - Disclosure - Supplemental Balance Sheet Information (Schedule of Inventories) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>9954489 - Disclosure - Supplemental Balance Sheet Information (Schedule of Prepaid Expenses and Other Current Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails" roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails">
        <link:definition>9954490 - Disclosure - Supplemental Balance Sheet Information (Components of Property, Plant and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails" roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails">
        <link:definition>9954491 - Disclosure - Goodwill and Other Intangible Assets, net (Schedule of Changes in Carrying Amount of Goodwill) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails" roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails">
        <link:definition>9954492 - Disclosure - Goodwill and Other Intangible Assets, net (Schedule of Other Intangible Assets, Net) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsnetNarrativeDetails" roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails">
        <link:definition>9954493 - Disclosure - Goodwill and Other Intangible Assets, net (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsnetScheduleofAmortizationExpenseRelatedtoIdentifiableIntangibleAssetsIncludingPatentsDetails" roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofAmortizationExpenseRelatedtoIdentifiableIntangibleAssetsIncludingPatentsDetails">
        <link:definition>9954494 - Disclosure - Goodwill and Other Intangible Assets, net (Schedule of Amortization Expense Related to Identifiable Intangible Assets, Including Patents) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleofInvestmentsDetails" roleURI="http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails">
        <link:definition>9954495 - Disclosure - Investments (Schedule of Investments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleofChangesInEquityInvestmentsDetails" roleURI="http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails">
        <link:definition>9954496 - Disclosure - Investments (Schedule of Changes In Equity Investments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://investor.resmed.com/role/InvestmentsNarrativeDetails">
        <link:definition>9954497 - Disclosure - Investments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://investor.resmed.com/role/AccruedExpensesDetails">
        <link:definition>9954498 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofDebtDetails" roleURI="http://investor.resmed.com/role/DebtScheduleofDebtDetails">
        <link:definition>9954499 - Disclosure - Debt (Schedule of Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://investor.resmed.com/role/DebtNarrativeDetails">
        <link:definition>9954500 - Disclosure - Debt (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://investor.resmed.com/role/LeasesNarrativeDetails">
        <link:definition>9954501 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureMinimumLeasePaymentsDetails" roleURI="http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails">
        <link:definition>9954502 - Disclosure - Leases (Schedule of Future Minimum Lease Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureMinimumLeasePaymentsDetails_1" roleURI="http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1">
        <link:definition>9954502 - Disclosure - Leases (Schedule of Future Minimum Lease Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofOperatingLeaseDisclosureDetails" roleURI="http://investor.resmed.com/role/LeasesScheduleofOperatingLeaseDisclosureDetails">
        <link:definition>9954503 - Disclosure - Leases (Schedule of Operating Lease Disclosure) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://investor.resmed.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>9954504 - Disclosure - Stockholders' Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails" roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails">
        <link:definition>9954505 - Disclosure - Stockholders' Equity (Schedule of Activity of Restricted Stock Units) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofOptionActivityDetails" roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails">
        <link:definition>9954506 - Disclosure - Stockholders' Equity (Schedule of Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails" roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails">
        <link:definition>9954507 - Disclosure - Stockholders' Equity (Schedule of Assumptions for Fair Value of Stock Option Plans and Purchase Rights Granted) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails" roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails">
        <link:definition>9954508 - Disclosure - Stockholders' Equity (Schedule of Total Stock-Based Compensation Costs Incurred and Associated Tax Benefit Recognized) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareNarrativeDetails" roleURI="http://investor.resmed.com/role/EarningsPerShareNarrativeDetails">
        <link:definition>9954509 - Disclosure - Earnings Per Share (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails" roleURI="http://investor.resmed.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails">
        <link:definition>9954510 - Disclosure - Earnings Per Share (Schedule of Basic and Diluted Earnings Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeBeforeIncomeTaxesUndertheJurisdictionsDetails" roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesUndertheJurisdictionsDetails">
        <link:definition>9954511 - Disclosure - Income Taxes (Schedule of Income Before Income Taxes Under the Jurisdictions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofProvisionforIncomeTaxesDetails" roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails">
        <link:definition>9954512 - Disclosure - Income Taxes (Schedule of Provision for Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails" roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails">
        <link:definition>9954513 - Disclosure - Income Taxes (Schedule of Provision for Income Tax Differ From the Amount of Income Tax) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesClassifiedasCurrentandNonCurrentDetails" roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesClassifiedasCurrentandNonCurrentDetails">
        <link:definition>9954514 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities Classified as Current and Non-Current) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9954515 - Disclosure - Income Taxes (Components of Deferred Tax Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://investor.resmed.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9954516 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://investor.resmed.com/role/SegmentInformationNarrativeDetails">
        <link:definition>9954517 - Disclosure - Segment Information (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails" roleURI="http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails">
        <link:definition>9954518 - Disclosure - Segment Information (Summary of Revenue by Segment and Reconciling Items) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails" roleURI="http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails">
        <link:definition>9954519 - Disclosure - Segment Information (Schedule of Revenue by Segment, Product, and Region) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofRevenuebyGeographicAreaDetails" roleURI="http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebyGeographicAreaDetails">
        <link:definition>9954520 - Disclosure - Segment Information (Schedule of Revenue by Geographic Area) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofLongLivedAssetsbyGeographicAreasDetails" roleURI="http://investor.resmed.com/role/SegmentInformationScheduleofLongLivedAssetsbyGeographicAreasDetails">
        <link:definition>9954521 - Disclosure - Segment Information (Schedule of Long-Lived Assets by Geographic Areas) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRetirementPlansDetails" roleURI="http://investor.resmed.com/role/EmployeeRetirementPlansDetails">
        <link:definition>9954522 - Disclosure - Employee Retirement Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalActionsContingenciesandCommitmentsNarrativeDetails" roleURI="http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsNarrativeDetails">
        <link:definition>9954523 - Disclosure - Legal Actions, Contingencies and Commitments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails" roleURI="http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails">
        <link:definition>9954524 - Disclosure - Legal Actions, Contingencies and Commitments (Obligations Under Purchase Agreements) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails" roleURI="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails">
        <link:definition>9954525 - Disclosure - Derivative Instruments and Hedging Activities (Schedule of Fair Values of Derivative Instruments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails" roleURI="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails">
        <link:definition>9954526 - Disclosure - Derivative Instruments and Hedging Activities (Schedule of Fair Value Hedge Gains (Losses)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails" roleURI="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails">
        <link:definition>9954527 - Disclosure - Derivative Instruments and Hedging Activities (Schedule of Net Investment Hedge Gains (Losses)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails" roleURI="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails">
        <link:definition>9954528 - Disclosure - Derivative Instruments and Hedging Activities (Schedule of Non-designated Derivative Gains (Losses)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsNarrativeDetails" roleURI="http://investor.resmed.com/role/BusinessCombinationsNarrativeDetails">
        <link:definition>9954529 - Disclosure - Business Combinations (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails" roleURI="http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails">
        <link:definition>9954530 - Disclosure - Business Combinations (Schedule of Tangible and Identifiable Intangible Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringExpensesDetails" roleURI="http://investor.resmed.com/role/RestructuringExpensesDetails">
        <link:definition>9954531 - Disclosure - Restructuring Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationandQualifyingAccountsandReservesDetails" roleURI="http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails">
        <link:definition>9954532 - Disclosure - Schedule II Valuation and Qualifying Accounts and Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="rmd_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rmd_SleepAndRespiratoryMember" abstract="false" name="SleepAndRespiratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_SoftwareAsAServiceMember" abstract="false" name="SoftwareAsAServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_AmortizationOfAcquiredIntangibleAssets1" abstract="false" name="AmortizationOfAcquiredIntangibleAssets1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired" abstract="false" name="NoncashPartOfAcquisitionFairValueOfAssetsAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease" abstract="false" name="GoodwillAcquiredDuringPeriodIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" abstract="false" name="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_DeferredPaymentObligationsForAcquisitions" abstract="false" name="DeferredPaymentObligationsForAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability" abstract="false" name="BusinessAcquisitionContingentConsiderationRecognizedLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_SupplementalBalanceSheetInformationAbstract" abstract="true" name="SupplementalBalanceSheetInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rmd_OrganizationAndBasisOfPresentationPolicyPolicyTextBlock" abstract="false" name="OrganizationAndBasisOfPresentationPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock" abstract="false" name="ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="rmd_ScheduleOfInvestmentsTableTextBlock" abstract="false" name="ScheduleOfInvestmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock" abstract="false" name="ScheduleOfChangesInEquityInvestmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock" abstract="false" name="ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock" abstract="false" name="ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="rmd_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="rmd_FairValueAndNetInvestmentHedgingMember" abstract="true" name="FairValueAndNetInvestmentHedgingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_IntangibleAssetImpairmentMember" abstract="true" name="IntangibleAssetImpairmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rmd_TermOfContractUnderRevenueRecognition" abstract="false" name="TermOfContractUnderRevenueRecognition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rmd_ContractWithCustomerAssetAndLiabilityTable" abstract="true" name="ContractWithCustomerAssetAndLiabilityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="rmd_AccountsReceivableNetMember" abstract="false" name="AccountsReceivableNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember" abstract="false" name="PrepaidTaxesAndOtherNonCurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_DeferredRevenueCurrentLiabilitiesMember" abstract="true" name="DeferredRevenueCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_DeferredRevenueNonCurrentLiabilitiesMember" abstract="true" name="DeferredRevenueNonCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_ContractWithCustomerAssetAndLiabilityLineItems" abstract="true" name="ContractWithCustomerAssetAndLiabilityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rmd_PrepaidInventory" abstract="false" name="PrepaidInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_VehiclesAndAircraftMember" abstract="true" name="VehiclesAndAircraftMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_ClinicalDemonstrationAndRentalEquipmentMember" abstract="false" name="ClinicalDemonstrationAndRentalEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_SaasMember" abstract="false" name="SaasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_DevelopedOrCoreProductTechnologyMember" abstract="false" name="DevelopedOrCoreProductTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_IdentifiedIntangibleAssetsMember" abstract="false" name="IdentifiedIntangibleAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_MarketableEquityInvestmentsFairValue" abstract="false" name="MarketableEquityInvestmentsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_EquityInvestmentsTotalByMeasurementCategory" abstract="false" name="EquityInvestmentsTotalByMeasurementCategory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_NonMarketableSecuritiesMember" abstract="false" name="NonMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_MarketableSecuritiesMember" abstract="false" name="MarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_EquityMethodInvestmentsRollForward" abstract="true" name="EquityMethodInvestmentsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rmd_EquityInvestments" abstract="false" name="EquityInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_AdditionalEquityInvestments" abstract="false" name="AdditionalEquityInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" abstract="false" name="ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_AccruedLogisticsAndOccupancyExpensesCurrent" abstract="false" name="AccruedLogisticsAndOccupancyExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_AccruedInventoryInTransit" abstract="false" name="AccruedInventoryInTransit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_ShortTermDebtGross" abstract="false" name="ShortTermDebtGross" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember" abstract="false" name="RevolvingCreditFacilityAndTermLoanCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_TermLoanCreditAgreementMember" abstract="true" name="TermLoanCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_MufgUnionBankNaAndWestpacBankingCorporationMember" abstract="false" name="MufgUnionBankNaAndWestpacBankingCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_MufgUnionBankMember" abstract="false" name="MufgUnionBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_ResmedLimitedMember" abstract="false" name="ResmedLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_SeniorNotesOneMember" abstract="false" name="SeniorNotesOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_SeniorNotesTwoMember" abstract="false" name="SeniorNotesTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember" abstract="false" name="RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_UncommittedOptionToIncreaseCreditFacility" abstract="false" name="UncommittedOptionToIncreaseCreditFacility" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod" abstract="false" name="DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rmd_DebtToConsolidatedEbitdaRatio" abstract="false" name="DebtToConsolidatedEbitdaRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany" abstract="false" name="LineOfCreditFacilityCollateralPercentageOfTheCompany" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="rmd_OperatingLeaseIncome" abstract="false" name="OperatingLeaseIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_ResmedInc2009IncentiveAwardPlanMember" abstract="false" name="ResmedInc2009IncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_AmendedAndRestated2009PlanMember" abstract="false" name="AmendedAndRestated2009PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_EmployeeStockPurchasePlanMember" abstract="false" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_NonEmployeeDirectorMember" abstract="false" name="NonEmployeeDirectorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance" abstract="false" name="ReductionInNumberOfSharesOfCommonStockAvailableForIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards" abstract="false" name="NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rmd_MaximumNumberOfSharesSubjectToAwardsGranted" abstract="false" name="MaximumNumberOfSharesSubjectToAwardsGranted" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rmd_NumberOfCommonStockGranted" abstract="false" name="NumberOfCommonStockGranted" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rmd_EmployeeStockPurchasePlanOfferingPeriod" abstract="false" name="EmployeeStockPurchasePlanOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant" abstract="false" name="PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase" abstract="false" name="PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="rmd_NumberOfOfferings" abstract="false" name="NumberOfOfferings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rmd_EmployeeStockPurchasePlanPurchaseRightsMember" abstract="false" name="EmployeeStockPurchasePlanPurchaseRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_DeferredTaxAssetsLeaseLiabilities" abstract="false" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_DeferredTaxLiabilitiesRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="rmd_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rmd_OperatingLossCarryforwardsCapitalLoss" abstract="false" name="OperatingLossCarryforwardsCapitalLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition" abstract="false" name="PercentageOfRecognizedTaxBenefitForUncertainTaxPosition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="rmd_IncomeTaxExaminationNetImpactOfSettlement" abstract="false" name="IncomeTaxExaminationNetImpactOfSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_IncomeTaxExaminationGrossSettlement" abstract="false" name="IncomeTaxExaminationGrossSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_IncomeTaxExaminationRemittedFinalPayment" abstract="false" name="IncomeTaxExaminationRemittedFinalPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_IncomeTaxExaminationPriorRemittancePayments" abstract="false" name="IncomeTaxExaminationPriorRemittancePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_UnallocatedCorporateCosts" abstract="false" name="UnallocatedCorporateCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_MasksWithMagnetsFieldSafetyNotificationExpenses" abstract="false" name="MasksWithMagnetsFieldSafetyNotificationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_AstralFieldActionNotificationExpenses" abstract="false" name="AstralFieldActionNotificationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_U.s.CanadaAndLatinAmericaMember" abstract="false" name="U.s.CanadaAndLatinAmericaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_CombinedEuropeAsiaAndOtherMarketsMember" abstract="false" name="CombinedEuropeAsiaAndOtherMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_GlobalMember" abstract="false" name="GlobalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_DevicesMember" abstract="false" name="DevicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_MasksAndOtherMember" abstract="true" name="MasksAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_RestOfWorldMember" abstract="false" name="RestOfWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" abstract="false" name="DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="rmd_NumberOfPatents" abstract="false" name="NumberOfPatents" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rmd_ReceivablesSoldWithLimitedRecourse" abstract="false" name="ReceivablesSoldWithLimitedRecourse" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_OtherForeignExchangeContractsMember" abstract="true" name="OtherForeignExchangeContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_MEDIFOXDANMember" abstract="true" name="MEDIFOXDANMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember" abstract="true" name="EmployeeSeveranceAndOneTimeTerminationBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_MichaelJ.FarrellMember" abstract="true" name="MichaelJ.FarrellMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_JanDeWitteMember" abstract="true" name="JanDeWitteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_BrettA.SandercockMember" abstract="true" name="BrettA.SandercockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_KaushikGhoshalMember" abstract="true" name="KaushikGhoshalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_MichaelJ.RiderMember" abstract="true" name="MichaelJ.RiderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_PeterC.FarrellMember" abstract="true" name="PeterC.FarrellMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>rmd-20240630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:626b872d-b824-4a3f-bfea-336621baa0aa,g:59f8884c-c35b-445a-b56c-2a5e88decb05-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rmd-20240630.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_efcf25b2-e2ec-4266-9114-13c53a9136b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d2d09c86-3162-46e5-a256-b30e7b87016c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_efcf25b2-e2ec-4266-9114-13c53a9136b9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d2d09c86-3162-46e5-a256-b30e7b87016c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f593b460-f7a7-4195-8785-c4c849245913" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_efcf25b2-e2ec-4266-9114-13c53a9136b9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f593b460-f7a7-4195-8785-c4c849245913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_040cda93-aa70-4bd6-8b6b-1c9ead72f6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_efcf25b2-e2ec-4266-9114-13c53a9136b9" xlink:to="loc_us-gaap_Goodwill_040cda93-aa70-4bd6-8b6b-1c9ead72f6bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e9bc66e1-3871-4f5b-9b93-35059dac9d20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_efcf25b2-e2ec-4266-9114-13c53a9136b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e9bc66e1-3871-4f5b-9b93-35059dac9d20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_ef9c596b-54fd-4fbc-a16a-c56c8d74c7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_efcf25b2-e2ec-4266-9114-13c53a9136b9" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_ef9c596b-54fd-4fbc-a16a-c56c8d74c7c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ae9c2012-c5b8-431d-aa87-7a73f8360afa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_efcf25b2-e2ec-4266-9114-13c53a9136b9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ae9c2012-c5b8-431d-aa87-7a73f8360afa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_19330421-0de7-4f08-8182-2e035c500bac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c1a53ebe-60eb-47d9-8ac2-dfb77977aa7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_19330421-0de7-4f08-8182-2e035c500bac" xlink:to="loc_us-gaap_Liabilities_c1a53ebe-60eb-47d9-8ac2-dfb77977aa7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_418c178d-b2a1-4a80-9cca-91b5e65f80fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_19330421-0de7-4f08-8182-2e035c500bac" xlink:to="loc_us-gaap_StockholdersEquity_418c178d-b2a1-4a80-9cca-91b5e65f80fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dbc9a232-5fb2-484c-ba28-5c0aed7ed675" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_024f5f18-a093-4444-83a1-3f7c0b77e0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbc9a232-5fb2-484c-ba28-5c0aed7ed675" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_024f5f18-a093-4444-83a1-3f7c0b77e0b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b4d73059-409c-40b8-bb20-154c8b9f7bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbc9a232-5fb2-484c-ba28-5c0aed7ed675" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b4d73059-409c-40b8-bb20-154c8b9f7bb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8ad746fe-f188-4136-a03d-0db1ac80c5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbc9a232-5fb2-484c-ba28-5c0aed7ed675" xlink:to="loc_us-gaap_InventoryNet_8ad746fe-f188-4136-a03d-0db1ac80c5b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7bbe1cdb-3179-44e6-8a88-966685989c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbc9a232-5fb2-484c-ba28-5c0aed7ed675" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7bbe1cdb-3179-44e6-8a88-966685989c4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_eeebeda7-1caf-4d0f-b7a9-dc907a9277be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_72f465b2-2f04-4cbe-8f89-26811d98830c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_eeebeda7-1caf-4d0f-b7a9-dc907a9277be" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_72f465b2-2f04-4cbe-8f89-26811d98830c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_7924f266-e328-42a4-9025-0b570968e912" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_eeebeda7-1caf-4d0f-b7a9-dc907a9277be" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_7924f266-e328-42a4-9025-0b570968e912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2ea96a17-18dd-4afc-902e-5ad4ce2f81f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_eeebeda7-1caf-4d0f-b7a9-dc907a9277be" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2ea96a17-18dd-4afc-902e-5ad4ce2f81f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8a96e16a-aee7-40e3-bdca-d3c45c3cec55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_eeebeda7-1caf-4d0f-b7a9-dc907a9277be" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8a96e16a-aee7-40e3-bdca-d3c45c3cec55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d95a1293-9043-4448-86cb-e96b7459cd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_eeebeda7-1caf-4d0f-b7a9-dc907a9277be" xlink:to="loc_us-gaap_LongTermDebt_d95a1293-9043-4448-86cb-e96b7459cd1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_8874ca67-9d98-4e36-9a1b-2b371aeefbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_eeebeda7-1caf-4d0f-b7a9-dc907a9277be" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_8874ca67-9d98-4e36-9a1b-2b371aeefbe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_580a4d7f-d1a4-4aa2-afcf-f2c91b240563" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_aa5c718e-6b0d-433e-959e-13bdbffdd466" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_580a4d7f-d1a4-4aa2-afcf-f2c91b240563" xlink:to="loc_us-gaap_PreferredStockValue_aa5c718e-6b0d-433e-959e-13bdbffdd466" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_93999291-54d6-4d4b-8eea-976577cd395c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_580a4d7f-d1a4-4aa2-afcf-f2c91b240563" xlink:to="loc_us-gaap_CommonStockValueOutstanding_93999291-54d6-4d4b-8eea-976577cd395c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8c96073e-f12a-42b9-987f-29b2fc1525c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_580a4d7f-d1a4-4aa2-afcf-f2c91b240563" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8c96073e-f12a-42b9-987f-29b2fc1525c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_377ac71e-7a07-496c-9e82-863652d0f5be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_580a4d7f-d1a4-4aa2-afcf-f2c91b240563" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_377ac71e-7a07-496c-9e82-863652d0f5be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_eb2d4086-3b9f-4988-9312-a4eeaf0895a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_580a4d7f-d1a4-4aa2-afcf-f2c91b240563" xlink:to="loc_us-gaap_TreasuryStockCommonValue_eb2d4086-3b9f-4988-9312-a4eeaf0895a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2b1de7b8-711b-4bca-ac89-aee5c110380a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_580a4d7f-d1a4-4aa2-afcf-f2c91b240563" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2b1de7b8-711b-4bca-ac89-aee5c110380a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_920214a5-24a8-4b70-9f4a-09197a658577" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a32ec23c-8f1b-4fcb-96a9-fc122afdeb29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_920214a5-24a8-4b70-9f4a-09197a658577" xlink:to="loc_us-gaap_AssetsCurrent_a32ec23c-8f1b-4fcb-96a9-fc122afdeb29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_35a9455e-5ce6-4d32-aa0b-f029fc4799f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_920214a5-24a8-4b70-9f4a-09197a658577" xlink:to="loc_us-gaap_AssetsNoncurrent_35a9455e-5ce6-4d32-aa0b-f029fc4799f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_821f390b-5bcc-4267-88e7-157eb8d04381" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_496cad5a-07af-4cf6-84f1-a97ab97db594" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_821f390b-5bcc-4267-88e7-157eb8d04381" xlink:to="loc_us-gaap_AccountsPayableCurrent_496cad5a-07af-4cf6-84f1-a97ab97db594" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3c456274-9248-4f60-909d-78df4fe7d879" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_821f390b-5bcc-4267-88e7-157eb8d04381" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3c456274-9248-4f60-909d-78df4fe7d879" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9c337cab-8415-4b7f-b9ab-98d90559ed9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_821f390b-5bcc-4267-88e7-157eb8d04381" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9c337cab-8415-4b7f-b9ab-98d90559ed9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5ab64515-ca0b-406c-9985-9d1e46ac2c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_821f390b-5bcc-4267-88e7-157eb8d04381" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5ab64515-ca0b-406c-9985-9d1e46ac2c3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_51850991-4367-46f3-be07-1d223b74a940" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_821f390b-5bcc-4267-88e7-157eb8d04381" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_51850991-4367-46f3-be07-1d223b74a940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_4f18afb1-2741-4a33-92b7-1f5927371bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_821f390b-5bcc-4267-88e7-157eb8d04381" xlink:to="loc_us-gaap_ShortTermBorrowings_4f18afb1-2741-4a33-92b7-1f5927371bc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fd77420b-6b38-402d-aaea-f44acd2042ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b4850253-3012-4361-8616-1afc570de03b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fd77420b-6b38-402d-aaea-f44acd2042ce" xlink:to="loc_us-gaap_LiabilitiesCurrent_b4850253-3012-4361-8616-1afc570de03b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_59459888-0fe1-4ffe-8f6d-a2a3d698816a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fd77420b-6b38-402d-aaea-f44acd2042ce" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_59459888-0fe1-4ffe-8f6d-a2a3d698816a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="rmd-20240630.xsd#ConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_91973140-05c8-41df-8ed3-09ddd91fd002" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e4f55e6b-9c72-4dc2-bef8-a2771b4e2ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_91973140-05c8-41df-8ed3-09ddd91fd002" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e4f55e6b-9c72-4dc2-bef8-a2771b4e2ab9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_acf160cc-b043-4af8-861b-a2614e72b329" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_91973140-05c8-41df-8ed3-09ddd91fd002" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_acf160cc-b043-4af8-861b-a2614e72b329" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_d4ad6a5c-b5bf-4e62-9f08-f6cc17a1b31e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainOnBusinessInterruptionInsuranceRecovery"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_91973140-05c8-41df-8ed3-09ddd91fd002" xlink:to="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_d4ad6a5c-b5bf-4e62-9f08-f6cc17a1b31e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_22d2a3e3-f43c-4af8-bfd2-6d447387c65a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_91973140-05c8-41df-8ed3-09ddd91fd002" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_22d2a3e3-f43c-4af8-bfd2-6d447387c65a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e017cd4a-a1b0-419c-92f4-3192a733d984" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_91973140-05c8-41df-8ed3-09ddd91fd002" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e017cd4a-a1b0-419c-92f4-3192a733d984" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c0effee8-d114-4a21-ae6a-e008f3549712" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_9fe30fc2-d11b-4dea-9878-69edc210faaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_c0effee8-d114-4a21-ae6a-e008f3549712" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_9fe30fc2-d11b-4dea-9878-69edc210faaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_61f8f29f-55cf-41d3-b9c7-6360e5a9bbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_c0effee8-d114-4a21-ae6a-e008f3549712" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_61f8f29f-55cf-41d3-b9c7-6360e5a9bbeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_eb7df2b1-50d4-403a-9350-feb124083ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_7c191fc3-fdf1-4247-bd0a-d3180a0d5048" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_eb7df2b1-50d4-403a-9350-feb124083ad1" xlink:to="loc_us-gaap_GrossProfit_7c191fc3-fdf1-4247-bd0a-d3180a0d5048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e554a492-7228-40b9-95bb-c9bd3b679869" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_eb7df2b1-50d4-403a-9350-feb124083ad1" xlink:to="loc_us-gaap_OperatingExpenses_e554a492-7228-40b9-95bb-c9bd3b679869" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_684d4cd6-bfbe-4458-befc-e418f1dfebcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_03a523e2-f973-4be3-9960-f8426ae7d62c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_684d4cd6-bfbe-4458-befc-e418f1dfebcc" xlink:to="loc_us-gaap_OperatingIncomeLoss_03a523e2-f973-4be3-9960-f8426ae7d62c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c4075a60-d01c-4622-9a2b-21fd94aee914" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_684d4cd6-bfbe-4458-befc-e418f1dfebcc" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c4075a60-d01c-4622-9a2b-21fd94aee914" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a30efdbb-c300-479c-b687-6d9d9095dad1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6b23293c-5f09-4290-a0fd-7b8bb9fa6ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a30efdbb-c300-479c-b687-6d9d9095dad1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6b23293c-5f09-4290-a0fd-7b8bb9fa6ab2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0cb514d4-821c-4e2f-a1bd-8c33f3fc2376" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a30efdbb-c300-479c-b687-6d9d9095dad1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0cb514d4-821c-4e2f-a1bd-8c33f3fc2376" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_decd7b06-fb92-495e-a16c-ecb05da44bec" xlink:href="rmd-20240630.xsd#rmd_AmortizationOfAcquiredIntangibleAssets1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a30efdbb-c300-479c-b687-6d9d9095dad1" xlink:to="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_decd7b06-fb92-495e-a16c-ecb05da44bec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_720d24c6-b4c0-4de1-9b9e-35c98e432ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a30efdbb-c300-479c-b687-6d9d9095dad1" xlink:to="loc_us-gaap_RestructuringCharges_720d24c6-b4c0-4de1-9b9e-35c98e432ec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_9d437d59-5bf8-4d08-9c79-e1e7bcdab000" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a30efdbb-c300-479c-b687-6d9d9095dad1" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_9d437d59-5bf8-4d08-9c79-e1e7bcdab000" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_c74337ee-3835-48d6-b7ef-44669aea5978" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_446af5d7-d798-46d5-b4cd-6449f5855313" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_c74337ee-3835-48d6-b7ef-44669aea5978" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_446af5d7-d798-46d5-b4cd-6449f5855313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7a2d3d5c-b658-4d02-be37-d271f0196434" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_c74337ee-3835-48d6-b7ef-44669aea5978" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7a2d3d5c-b658-4d02-be37-d271f0196434" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a6e005b0-bc58-4135-ba05-c0de1a583282" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f1e86e9b-aa30-4e2f-a770-140d32728123" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a6e005b0-bc58-4135-ba05-c0de1a583282" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f1e86e9b-aa30-4e2f-a770-140d32728123" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b6fcd403-131f-4a3d-8121-62eb64b1376d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a6e005b0-bc58-4135-ba05-c0de1a583282" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b6fcd403-131f-4a3d-8121-62eb64b1376d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="rmd-20240630.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b388d66d-1a5e-463c-9791-1171bd3e5ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_93e808c0-386d-4a6a-96f4-aeda1857f2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b388d66d-1a5e-463c-9791-1171bd3e5ddc" xlink:to="loc_us-gaap_NetIncomeLoss_93e808c0-386d-4a6a-96f4-aeda1857f2b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1a3561e5-f49d-40da-b535-828803d17127" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b388d66d-1a5e-463c-9791-1171bd3e5ddc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1a3561e5-f49d-40da-b535-828803d17127" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_12450b62-6b3c-4ede-9a06-a29f70a05180" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b388d66d-1a5e-463c-9791-1171bd3e5ddc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_12450b62-6b3c-4ede-9a06-a29f70a05180" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="rmd-20240630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_852c2b3c-dc32-4bb3-bf6d-a52df26e47f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_57f2b731-5d97-438e-ad48-e64976b49faf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_852c2b3c-dc32-4bb3-bf6d-a52df26e47f0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_57f2b731-5d97-438e-ad48-e64976b49faf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c62f1f5f-d1f7-4d75-9f48-4f87a80b5174" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_852c2b3c-dc32-4bb3-bf6d-a52df26e47f0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c62f1f5f-d1f7-4d75-9f48-4f87a80b5174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5e98ea5-a592-41b5-90bd-446580521763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_852c2b3c-dc32-4bb3-bf6d-a52df26e47f0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5e98ea5-a592-41b5-90bd-446580521763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e1fdb8af-ae79-48aa-88c6-29c799fa2d08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_852c2b3c-dc32-4bb3-bf6d-a52df26e47f0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e1fdb8af-ae79-48aa-88c6-29c799fa2d08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c58fac77-91d9-45a8-baf9-ee93f981f185" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b25df20d-89a1-4aa2-961d-ffa45354e958" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c58fac77-91d9-45a8-baf9-ee93f981f185" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b25df20d-89a1-4aa2-961d-ffa45354e958" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d4d525dd-5543-4082-ab79-be7205d76dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c58fac77-91d9-45a8-baf9-ee93f981f185" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d4d525dd-5543-4082-ab79-be7205d76dd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e3caaf6d-d569-4d3d-be33-d5863211dec5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c58fac77-91d9-45a8-baf9-ee93f981f185" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_e3caaf6d-d569-4d3d-be33-d5863211dec5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_e2cdd4b7-c616-461a-a4a5-4e73ed4f3f01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c58fac77-91d9-45a8-baf9-ee93f981f185" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_e2cdd4b7-c616-461a-a4a5-4e73ed4f3f01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_df18db62-080f-42b1-8f8a-ce873def6130" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c58fac77-91d9-45a8-baf9-ee93f981f185" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_df18db62-080f-42b1-8f8a-ce873def6130" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities_7c12543a-106b-45a0-8fca-c058a65287eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c58fac77-91d9-45a8-baf9-ee93f981f185" xlink:to="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities_7c12543a-106b-45a0-8fca-c058a65287eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5b03d571-7057-452f-9c62-79caadff6e23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6add870b-560b-4e96-9284-380f7aff906b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5b03d571-7057-452f-9c62-79caadff6e23" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6add870b-560b-4e96-9284-380f7aff906b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_65c3f0b5-cc25-46f8-840d-a3cced38877c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5b03d571-7057-452f-9c62-79caadff6e23" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_65c3f0b5-cc25-46f8-840d-a3cced38877c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_d1494a6a-18d4-4594-970e-6912751c4a88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5b03d571-7057-452f-9c62-79caadff6e23" xlink:to="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_d1494a6a-18d4-4594-970e-6912751c4a88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_25fe9486-909c-4c08-af5b-60df38e7c406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5b03d571-7057-452f-9c62-79caadff6e23" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_25fe9486-909c-4c08-af5b-60df38e7c406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_ebae2857-1c3f-415f-95ea-3b46fee79b54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5b03d571-7057-452f-9c62-79caadff6e23" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_ebae2857-1c3f-415f-95ea-3b46fee79b54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_6e54ffb7-67ae-4f8e-bd68-5e0d1bb38d62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5b03d571-7057-452f-9c62-79caadff6e23" xlink:to="loc_us-gaap_PaymentsOfDividends_6e54ffb7-67ae-4f8e-bd68-5e0d1bb38d62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_40150c9d-d97d-45fb-b664-3fbbc4936534" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5b03d571-7057-452f-9c62-79caadff6e23" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_40150c9d-d97d-45fb-b664-3fbbc4936534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46f6afbe-7a2d-4e28-ad89-6503247bb9f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e081591d-a543-481c-9515-946bab88f8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46f6afbe-7a2d-4e28-ad89-6503247bb9f8" xlink:to="loc_us-gaap_NetIncomeLoss_e081591d-a543-481c-9515-946bab88f8f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0bb3f400-14a9-44cb-9b9f-f459cae0e622" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46f6afbe-7a2d-4e28-ad89-6503247bb9f8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0bb3f400-14a9-44cb-9b9f-f459cae0e622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_20c40852-60de-4379-8c31-5e3b99866fab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46f6afbe-7a2d-4e28-ad89-6503247bb9f8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_20c40852-60de-4379-8c31-5e3b99866fab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d943460a-4ee5-4eae-b012-6b440bb37be5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46f6afbe-7a2d-4e28-ad89-6503247bb9f8" xlink:to="loc_us-gaap_ShareBasedCompensation_d943460a-4ee5-4eae-b012-6b440bb37be5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_2373d1b7-2396-4e7e-8757-af9d3283fd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46f6afbe-7a2d-4e28-ad89-6503247bb9f8" xlink:to="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_2373d1b7-2396-4e7e-8757-af9d3283fd6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_125d0b57-ecd8-412e-bd54-07f9e22be52b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46f6afbe-7a2d-4e28-ad89-6503247bb9f8" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_125d0b57-ecd8-412e-bd54-07f9e22be52b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRecoveries_2aead523-e2d9-43f2-9404-26d703b83170" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceRecoveries"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46f6afbe-7a2d-4e28-ad89-6503247bb9f8" xlink:to="loc_us-gaap_InsuranceRecoveries_2aead523-e2d9-43f2-9404-26d703b83170" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5832a447-4dc0-4a79-9411-51020524b2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46f6afbe-7a2d-4e28-ad89-6503247bb9f8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5832a447-4dc0-4a79-9411-51020524b2ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_75b47cc9-2e3c-4619-ac10-b64c6dc017c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46f6afbe-7a2d-4e28-ad89-6503247bb9f8" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_75b47cc9-2e3c-4619-ac10-b64c6dc017c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4a4fcf20-02a0-4955-a418-2d278d2813fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46f6afbe-7a2d-4e28-ad89-6503247bb9f8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4a4fcf20-02a0-4955-a418-2d278d2813fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_01114079-35bc-460e-b996-1a6f881d463f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46f6afbe-7a2d-4e28-ad89-6503247bb9f8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_01114079-35bc-460e-b996-1a6f881d463f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_0127be3a-9cab-41b6-a73e-f37c7e57c30c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46f6afbe-7a2d-4e28-ad89-6503247bb9f8" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_0127be3a-9cab-41b6-a73e-f37c7e57c30c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SupplementalBalanceSheetInformationScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f2624085-a1fa-40c2-b64d-5475819e28cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5186e9f2-8e9f-4a11-ac06-0ae42c56a18b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f2624085-a1fa-40c2-b64d-5475819e28cf" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5186e9f2-8e9f-4a11-ac06-0ae42c56a18b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_06b0e2c6-ec7d-49b6-ab97-09e068fca5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f2624085-a1fa-40c2-b64d-5475819e28cf" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_06b0e2c6-ec7d-49b6-ab97-09e068fca5f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7b77c55f-49bc-4381-812d-95b3761aa4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f2624085-a1fa-40c2-b64d-5475819e28cf" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7b77c55f-49bc-4381-812d-95b3761aa4fe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b6a6750d-5add-4ded-baeb-aaad2c4bedbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_467d4bc1-6a7e-42ec-a4a8-7f17a5a1de9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b6a6750d-5add-4ded-baeb-aaad2c4bedbc" xlink:to="loc_us-gaap_PrepaidTaxes_467d4bc1-6a7e-42ec-a4a8-7f17a5a1de9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PrepaidInventory_b25afbf9-ffcf-4bf8-9c4f-135fbb5167ef" xlink:href="rmd-20240630.xsd#rmd_PrepaidInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b6a6750d-5add-4ded-baeb-aaad2c4bedbc" xlink:to="loc_rmd_PrepaidInventory_b25afbf9-ffcf-4bf8-9c4f-135fbb5167ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_27186309-c37b-4b16-8a24-ad62140f3b23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b6a6750d-5add-4ded-baeb-aaad2c4bedbc" xlink:to="loc_us-gaap_OtherAssetsCurrent_27186309-c37b-4b16-8a24-ad62140f3b23" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ac2ecfb9-0aaa-4bea-909c-5d2493c5639a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_085a6cf4-f8f1-415e-8087-3ced3fa5f32a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ac2ecfb9-0aaa-4bea-909c-5d2493c5639a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_085a6cf4-f8f1-415e-8087-3ced3fa5f32a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_34e316f6-882b-4e7f-ab64-13ab8cb5fe84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ac2ecfb9-0aaa-4bea-909c-5d2493c5639a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_34e316f6-882b-4e7f-ab64-13ab8cb5fe84" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_00b4d2ee-8cfb-4f28-b2ee-8bd6be3e7502" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f1d332bb-c9af-45d4-baf4-99c91eec44c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_00b4d2ee-8cfb-4f28-b2ee-8bd6be3e7502" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f1d332bb-c9af-45d4-baf4-99c91eec44c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_81a8dc76-4efe-4167-acfb-86b7ba374ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_00b4d2ee-8cfb-4f28-b2ee-8bd6be3e7502" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_81a8dc76-4efe-4167-acfb-86b7ba374ca5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#InvestmentsScheduleofInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityInvestmentsTotalByMeasurementCategory_c1e21027-31bf-4ae2-8d72-6588672aa76c" xlink:href="rmd-20240630.xsd#rmd_EquityInvestmentsTotalByMeasurementCategory"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MarketableEquityInvestmentsFairValue_e4bd71ae-c013-493d-9f1a-4550b76524f4" xlink:href="rmd-20240630.xsd#rmd_MarketableEquityInvestmentsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rmd_EquityInvestmentsTotalByMeasurementCategory_c1e21027-31bf-4ae2-8d72-6588672aa76c" xlink:to="loc_rmd_MarketableEquityInvestmentsFairValue_e4bd71ae-c013-493d-9f1a-4550b76524f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_74885d4e-f11a-49ce-9922-0a009d27ca65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rmd_EquityInvestmentsTotalByMeasurementCategory_c1e21027-31bf-4ae2-8d72-6588672aa76c" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_74885d4e-f11a-49ce-9922-0a009d27ca65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_26f83d3a-e029-4439-b852-e2f93056ca93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rmd_EquityInvestmentsTotalByMeasurementCategory_c1e21027-31bf-4ae2-8d72-6588672aa76c" xlink:to="loc_us-gaap_EquityMethodInvestments_26f83d3a-e029-4439-b852-e2f93056ca93" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_313d5e74-7a4a-4982-b7c7-27ee2787fc96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_a610212d-9951-4fbe-a21e-b2dc485cf144" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_313d5e74-7a4a-4982-b7c7-27ee2787fc96" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_a610212d-9951-4fbe-a21e-b2dc485cf144" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a15ad647-9e74-4ed0-b92e-0171debc689c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_313d5e74-7a4a-4982-b7c7-27ee2787fc96" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a15ad647-9e74-4ed0-b92e-0171debc689c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_74f8f111-1c87-4ea7-89ca-70a118b923cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_313d5e74-7a4a-4982-b7c7-27ee2787fc96" xlink:to="loc_us-gaap_TaxesPayableCurrent_74f8f111-1c87-4ea7-89ca-70a118b923cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c9fe582a-e3b5-4346-bb40-5527b833bc12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_313d5e74-7a4a-4982-b7c7-27ee2787fc96" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c9fe582a-e3b5-4346-bb40-5527b833bc12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_02282a7c-c727-4479-9a3a-40fd8f12789d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_313d5e74-7a4a-4982-b7c7-27ee2787fc96" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_02282a7c-c727-4479-9a3a-40fd8f12789d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_05f16508-686a-4e80-a562-07c15f6d6efd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_313d5e74-7a4a-4982-b7c7-27ee2787fc96" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_05f16508-686a-4e80-a562-07c15f6d6efd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_2bea89bf-597d-4f9e-9d28-62cd7da7b56c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_313d5e74-7a4a-4982-b7c7-27ee2787fc96" xlink:to="loc_us-gaap_InterestPayableCurrent_2bea89bf-597d-4f9e-9d28-62cd7da7b56c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AccruedLogisticsAndOccupancyExpensesCurrent_1949024f-b368-43c9-a5da-4a5f73ec9ab8" xlink:href="rmd-20240630.xsd#rmd_AccruedLogisticsAndOccupancyExpensesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_313d5e74-7a4a-4982-b7c7-27ee2787fc96" xlink:to="loc_rmd_AccruedLogisticsAndOccupancyExpensesCurrent_1949024f-b368-43c9-a5da-4a5f73ec9ab8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AccruedInventoryInTransit_051a3dea-c242-48a9-b9fe-57ffbbb68543" xlink:href="rmd-20240630.xsd#rmd_AccruedInventoryInTransit"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_313d5e74-7a4a-4982-b7c7-27ee2787fc96" xlink:to="loc_rmd_AccruedInventoryInTransit_051a3dea-c242-48a9-b9fe-57ffbbb68543" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_078d6257-1bd8-4791-ab84-dd87635d67f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_313d5e74-7a4a-4982-b7c7-27ee2787fc96" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_078d6257-1bd8-4791-ab84-dd87635d67f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DebtScheduleofDebtDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#DebtScheduleofDebtDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/DebtScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_feb0cede-a05c-409b-99ac-0242dd04ca30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_4be7ad27-5f7c-4671-979c-9abf4bcf48ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_feb0cede-a05c-409b-99ac-0242dd04ca30" xlink:to="loc_us-gaap_ShortTermBorrowings_4be7ad27-5f7c-4671-979c-9abf4bcf48ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0c50a48d-2592-4716-b325-2beca9312a47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_feb0cede-a05c-409b-99ac-0242dd04ca30" xlink:to="loc_us-gaap_LongTermDebt_0c50a48d-2592-4716-b325-2beca9312a47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_1a95203d-9463-4bbb-8cdf-1f3c007264ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShortTermDebtGross_45db07b6-24c1-4369-ae25-9c06feda1cab" xlink:href="rmd-20240630.xsd#rmd_ShortTermDebtGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShortTermBorrowings_1a95203d-9463-4bbb-8cdf-1f3c007264ed" xlink:to="loc_rmd_ShortTermDebtGross_45db07b6-24c1-4369-ae25-9c06feda1cab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_3a2fadaf-78ae-4fbc-824e-b44a091eb492" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShortTermBorrowings_1a95203d-9463-4bbb-8cdf-1f3c007264ed" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_3a2fadaf-78ae-4fbc-824e-b44a091eb492" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ec4ee604-e2f6-4395-83af-7672ba69f2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_98318686-6eed-45ba-ad5f-34a2f84f04b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ec4ee604-e2f6-4395-83af-7672ba69f2bb" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_98318686-6eed-45ba-ad5f-34a2f84f04b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_1eac22c9-f9d9-49f3-bd60-8b813d60a2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ec4ee604-e2f6-4395-83af-7672ba69f2bb" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_1eac22c9-f9d9-49f3-bd60-8b813d60a2ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#LeasesScheduleofFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0111054c-a5f9-415f-8532-64e89e1b7834" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_29b39c47-c7df-4934-8c10-3daf7eea83ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0111054c-a5f9-415f-8532-64e89e1b7834" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_29b39c47-c7df-4934-8c10-3daf7eea83ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ce700659-81fc-4aa9-a7d6-cbd74ac0e3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0111054c-a5f9-415f-8532-64e89e1b7834" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ce700659-81fc-4aa9-a7d6-cbd74ac0e3a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d410548b-7873-41c8-8b67-6643661fd8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0111054c-a5f9-415f-8532-64e89e1b7834" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d410548b-7873-41c8-8b67-6643661fd8d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f24c5a07-9b91-49ae-a388-5b14de348a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0111054c-a5f9-415f-8532-64e89e1b7834" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f24c5a07-9b91-49ae-a388-5b14de348a3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8bd94399-c000-413f-8030-6c1f0f78e95b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0111054c-a5f9-415f-8532-64e89e1b7834" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8bd94399-c000-413f-8030-6c1f0f78e95b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7e9bddcd-25c5-42c3-9d04-e817c4d664f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0111054c-a5f9-415f-8532-64e89e1b7834" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7e9bddcd-25c5-42c3-9d04-e817c4d664f0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="rmd-20240630.xsd#LeasesScheduleofFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9932789a-e993-4d73-aa0c-3a50a5386434" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3f255d02-6605-4a26-b01e-0b6c446e8998" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9932789a-e993-4d73-aa0c-3a50a5386434" xlink:to="loc_us-gaap_OperatingLeaseLiability_3f255d02-6605-4a26-b01e-0b6c446e8998" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a36f52af-567b-479c-95b9-629238e8184e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9932789a-e993-4d73-aa0c-3a50a5386434" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a36f52af-567b-479c-95b9-629238e8184e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_803350ba-725e-486f-9b94-233198bfadd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_30a69c32-334a-4962-b543-bf81ff276cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_803350ba-725e-486f-9b94-233198bfadd6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_30a69c32-334a-4962-b543-bf81ff276cd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_9c507340-2f05-4417-810f-eb04d1a68b38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_803350ba-725e-486f-9b94-233198bfadd6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_9c507340-2f05-4417-810f-eb04d1a68b38" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_033ba0b7-c35c-45aa-9617-bfa026571934" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5a3aad36-d33e-4680-bf23-3203cd6e30a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_033ba0b7-c35c-45aa-9617-bfa026571934" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5a3aad36-d33e-4680-bf23-3203cd6e30a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_8844021a-2fd3-4e32-a47e-53d3bbc899e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_033ba0b7-c35c-45aa-9617-bfa026571934" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_8844021a-2fd3-4e32-a47e-53d3bbc899e0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesUndertheJurisdictionsDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#IncomeTaxesScheduleofIncomeBeforeIncomeTaxesUndertheJurisdictionsDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesUndertheJurisdictionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_46407b7c-d4d3-4919-982f-a52f7e81f77d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e179c5b5-4a8e-4a1e-afd1-e79006938570" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_46407b7c-d4d3-4919-982f-a52f7e81f77d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e179c5b5-4a8e-4a1e-afd1-e79006938570" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_d2783fff-1828-47a5-b2c9-167c116a36eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_46407b7c-d4d3-4919-982f-a52f7e81f77d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_d2783fff-1828-47a5-b2c9-167c116a36eb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bbf9953a-8704-4815-9746-09214ca8f8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e169198c-6ad5-4a74-ad02-a7bd5ba2d4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bbf9953a-8704-4815-9746-09214ca8f8ec" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e169198c-6ad5-4a74-ad02-a7bd5ba2d4dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d9f10ee7-a56e-456e-a64c-b942fc4d77f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bbf9953a-8704-4815-9746-09214ca8f8ec" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d9f10ee7-a56e-456e-a64c-b942fc4d77f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c2c01c83-1f9e-46b2-91de-2d2b33e327d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b99edfe2-0b53-4f4b-b394-5cd7109fe0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c2c01c83-1f9e-46b2-91de-2d2b33e327d7" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b99edfe2-0b53-4f4b-b394-5cd7109fe0d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_395dd23f-0952-4e53-91ba-67f914677ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c2c01c83-1f9e-46b2-91de-2d2b33e327d7" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_395dd23f-0952-4e53-91ba-67f914677ac6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_7f0de585-761b-44d3-9979-fe7fa64c69fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c2c01c83-1f9e-46b2-91de-2d2b33e327d7" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_7f0de585-761b-44d3-9979-fe7fa64c69fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_53a58cb2-c706-40d1-a3e6-54b89a31c70b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e7fe1016-5b2b-4e40-a072-0e85eacfc9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_53a58cb2-c706-40d1-a3e6-54b89a31c70b" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e7fe1016-5b2b-4e40-a072-0e85eacfc9a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9fbb60d2-ebda-466d-8ed6-1887819eb6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_53a58cb2-c706-40d1-a3e6-54b89a31c70b" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9fbb60d2-ebda-466d-8ed6-1887819eb6cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_888db210-4d02-44ea-bf5e-259b38164bae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_53a58cb2-c706-40d1-a3e6-54b89a31c70b" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_888db210-4d02-44ea-bf5e-259b38164bae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f9d29687-380f-4e99-a6a1-586469019b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_20c360c5-502e-4468-889c-3c97a94e3d03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f9d29687-380f-4e99-a6a1-586469019b1e" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_20c360c5-502e-4468-889c-3c97a94e3d03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_7d0fb54d-6676-4b20-91c7-35a65c513f72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f9d29687-380f-4e99-a6a1-586469019b1e" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_7d0fb54d-6676-4b20-91c7-35a65c513f72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1794cf45-7fb1-4312-8c19-7dc02b20a27a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f9d29687-380f-4e99-a6a1-586469019b1e" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1794cf45-7fb1-4312-8c19-7dc02b20a27a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_e74efcec-f2f5-4d2f-acce-99c2867c4389" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f9d29687-380f-4e99-a6a1-586469019b1e" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_e74efcec-f2f5-4d2f-acce-99c2867c4389" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_3dcc5ea6-a4af-4d85-8d7e-0c692e652bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f9d29687-380f-4e99-a6a1-586469019b1e" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_3dcc5ea6-a4af-4d85-8d7e-0c692e652bf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_821b503f-6db3-4df5-ad39-2188efc0d76c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f9d29687-380f-4e99-a6a1-586469019b1e" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_821b503f-6db3-4df5-ad39-2188efc0d76c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_4ef93597-6b04-4af3-b352-1a134b4d3c14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f9d29687-380f-4e99-a6a1-586469019b1e" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_4ef93597-6b04-4af3-b352-1a134b4d3c14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_af44a456-f5ab-483d-aebd-4e47b6de5b94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f9d29687-380f-4e99-a6a1-586469019b1e" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_af44a456-f5ab-483d-aebd-4e47b6de5b94" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesClassifiedasCurrentandNonCurrentDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesClassifiedasCurrentandNonCurrentDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesClassifiedasCurrentandNonCurrentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8d3a19ec-2453-4727-8ab0-c277603d2838" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_1b15ce0c-27be-4346-a978-d25023fb63d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8d3a19ec-2453-4727-8ab0-c277603d2838" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_1b15ce0c-27be-4346-a978-d25023fb63d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_ff066ef2-cc22-41f7-99ed-70479004f4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8d3a19ec-2453-4727-8ab0-c277603d2838" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_ff066ef2-cc22-41f7-99ed-70479004f4f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_4f83f995-b9d7-4abc-a83f-dbb55599e86e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_6f177abe-c7f7-4170-aaec-8fb78cfd631f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_4f83f995-b9d7-4abc-a83f-dbb55599e86e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_6f177abe-c7f7-4170-aaec-8fb78cfd631f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredTaxLiabilitiesRightOfUseAssets_8636cbde-4b23-4bcb-8b9b-6c48629023c1" xlink:href="rmd-20240630.xsd#rmd_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_4f83f995-b9d7-4abc-a83f-dbb55599e86e" xlink:to="loc_rmd_DeferredTaxLiabilitiesRightOfUseAssets_8636cbde-4b23-4bcb-8b9b-6c48629023c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_c6905e64-8071-45dc-99e0-18f3381e33f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_4f83f995-b9d7-4abc-a83f-dbb55599e86e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_c6905e64-8071-45dc-99e0-18f3381e33f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e79690a0-9c5c-4141-9e8f-4db170dc1d59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_89e12397-dee2-40a2-ae08-2142c7ab9e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e79690a0-9c5c-4141-9e8f-4db170dc1d59" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_89e12397-dee2-40a2-ae08-2142c7ab9e2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a23dcb56-7bce-4051-b798-86c9a35f2b31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e79690a0-9c5c-4141-9e8f-4db170dc1d59" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a23dcb56-7bce-4051-b798-86c9a35f2b31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_90b6b1df-d9ca-4bc1-8bb6-096262af3fec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e79690a0-9c5c-4141-9e8f-4db170dc1d59" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_90b6b1df-d9ca-4bc1-8bb6-096262af3fec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_0bdace51-e537-418b-b7da-5937774fd842" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e79690a0-9c5c-4141-9e8f-4db170dc1d59" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_0bdace51-e537-418b-b7da-5937774fd842" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_e75b6ff8-10f6-4b60-89a0-3aa08038c638" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e79690a0-9c5c-4141-9e8f-4db170dc1d59" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_e75b6ff8-10f6-4b60-89a0-3aa08038c638" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_548f815f-31c0-48dc-91e7-dd491d626b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e79690a0-9c5c-4141-9e8f-4db170dc1d59" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_548f815f-31c0-48dc-91e7-dd491d626b2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_47b571ba-347a-4294-838b-6f9d99bff091" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e79690a0-9c5c-4141-9e8f-4db170dc1d59" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_47b571ba-347a-4294-838b-6f9d99bff091" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ee38e0f5-80bd-415a-ac99-47a02722338b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e79690a0-9c5c-4141-9e8f-4db170dc1d59" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ee38e0f5-80bd-415a-ac99-47a02722338b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_40b75289-7486-47c6-985a-58872dc9c8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e79690a0-9c5c-4141-9e8f-4db170dc1d59" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_40b75289-7486-47c6-985a-58872dc9c8cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_e7bb4456-fcc2-4c01-9eed-8987a923bc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e79690a0-9c5c-4141-9e8f-4db170dc1d59" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_e7bb4456-fcc2-4c01-9eed-8987a923bc7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredTaxAssetsLeaseLiabilities_52c9b42c-ec8a-4a8d-92df-828f6a78ae9b" xlink:href="rmd-20240630.xsd#rmd_DeferredTaxAssetsLeaseLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e79690a0-9c5c-4141-9e8f-4db170dc1d59" xlink:to="loc_rmd_DeferredTaxAssetsLeaseLiabilities_52c9b42c-ec8a-4a8d-92df-828f6a78ae9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_92e43a00-e513-499a-9942-3cecfff5d5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e79690a0-9c5c-4141-9e8f-4db170dc1d59" xlink:to="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_92e43a00-e513-499a-9942-3cecfff5d5a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_91d02581-80c1-4c71-a2d8-7a0906a46513" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e79690a0-9c5c-4141-9e8f-4db170dc1d59" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_91d02581-80c1-4c71-a2d8-7a0906a46513" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsStateTaxes_9facbf6f-9f74-4f70-8183-92a79f550e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsStateTaxes"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e79690a0-9c5c-4141-9e8f-4db170dc1d59" xlink:to="loc_us-gaap_DeferredTaxAssetsStateTaxes_9facbf6f-9f74-4f70-8183-92a79f550e6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_37335199-30e2-4a19-b6ec-7e654931c909" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c3dffb23-180e-4b11-8d8d-d6e45810ac3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_37335199-30e2-4a19-b6ec-7e654931c909" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c3dffb23-180e-4b11-8d8d-d6e45810ac3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_be57c339-d337-4010-a21c-3d5fb2b6ef01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_37335199-30e2-4a19-b6ec-7e654931c909" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_be57c339-d337-4010-a21c-3d5fb2b6ef01" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_fdce16c3-32b6-4340-a854-c20d1a998775" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_3698dd7b-1ddc-4d4f-bb52-1f50e5df328c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_fdce16c3-32b6-4340-a854-c20d1a998775" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_3698dd7b-1ddc-4d4f-bb52-1f50e5df328c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_d902f667-6d5e-475a-a39f-ef5ab47a9c64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_fdce16c3-32b6-4340-a854-c20d1a998775" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_d902f667-6d5e-475a-a39f-ef5ab47a9c64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_91a954e7-e392-43fa-a17a-caa5a12739c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_fdce16c3-32b6-4340-a854-c20d1a998775" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_91a954e7-e392-43fa-a17a-caa5a12739c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_902f3cf1-2300-4da1-84ec-24c5f31edb25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_fdce16c3-32b6-4340-a854-c20d1a998775" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_902f3cf1-2300-4da1-84ec-24c5f31edb25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_4c7b5da5-160d-47f6-9533-d6a9c5a4bb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_fdce16c3-32b6-4340-a854-c20d1a998775" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_4c7b5da5-160d-47f6-9533-d6a9c5a4bb9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear_3d0a3d9c-0bf1-40f7-8dbc-bfa38a81790f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueAfterFifthYear"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_fdce16c3-32b6-4340-a854-c20d1a998775" xlink:to="loc_us-gaap_PurchaseObligationDueAfterFifthYear_3d0a3d9c-0bf1-40f7-8dbc-bfa38a81790f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_da4e5b20-8fa0-4517-92b9-b4ddf59497c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c4af3474-cd99-43ce-8c1e-a74e335290ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_da4e5b20-8fa0-4517-92b9-b4ddf59497c6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c4af3474-cd99-43ce-8c1e-a74e335290ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_bae290b5-63a5-4715-b53c-0fac3d503c42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_da4e5b20-8fa0-4517-92b9-b4ddf59497c6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_bae290b5-63a5-4715-b53c-0fac3d503c42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_b1a9ab46-434c-4d96-a706-05a4f3a525c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_da4e5b20-8fa0-4517-92b9-b4ddf59497c6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_b1a9ab46-434c-4d96-a706-05a4f3a525c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment_7e4e4319-719d-4aea-b79d-c7294c34a617" xlink:href="rmd-20240630.xsd#rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_da4e5b20-8fa0-4517-92b9-b4ddf59497c6" xlink:to="loc_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment_7e4e4319-719d-4aea-b79d-c7294c34a617" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_7d76db05-1af7-47c9-8847-e95d91ab1d91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_da4e5b20-8fa0-4517-92b9-b4ddf59497c6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_7d76db05-1af7-47c9-8847-e95d91ab1d91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_bf6401b0-69c9-4493-a159-ffd4d3df812c" xlink:href="rmd-20240630.xsd#rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_da4e5b20-8fa0-4517-92b9-b4ddf59497c6" xlink:to="loc_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_bf6401b0-69c9-4493-a159-ffd4d3df812c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_1f9434d9-0631-4882-8bff-ab20ce5ef6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_da4e5b20-8fa0-4517-92b9-b4ddf59497c6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_1f9434d9-0631-4882-8bff-ab20ce5ef6d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_d752595f-4ab8-402f-8e19-184e2f10a0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_da4e5b20-8fa0-4517-92b9-b4ddf59497c6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_d752595f-4ab8-402f-8e19-184e2f10a0e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_7131a7a2-f71b-4822-8ee7-cc57e26dcd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_da4e5b20-8fa0-4517-92b9-b4ddf59497c6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_7131a7a2-f71b-4822-8ee7-cc57e26dcd0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e6d64d43-89a3-4853-8aaa-be6f8d2e47db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_da4e5b20-8fa0-4517-92b9-b4ddf59497c6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e6d64d43-89a3-4853-8aaa-be6f8d2e47db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f23e30cd-3599-4eb0-9100-7d0712c89ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_da4e5b20-8fa0-4517-92b9-b4ddf59497c6" xlink:to="loc_us-gaap_Goodwill_f23e30cd-3599-4eb0-9100-7d0712c89ec8" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>rmd-20240630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:626b872d-b824-4a3f-bfea-336621baa0aa,g:59f8884c-c35b-445a-b56c-2a5e88decb05-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="rmd-20240630.xsd#ConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ac5b1a10-f640-4f6b-aa88-a9dec35b4fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_StatementTable_ac5b1a10-f640-4f6b-aa88-a9dec35b4fbc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b17671c0-4b62-467c-92fe-51efd433878d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ac5b1a10-f640-4f6b-aa88-a9dec35b4fbc" xlink:to="loc_srt_ProductOrServiceAxis_b17671c0-4b62-467c-92fe-51efd433878d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b17671c0-4b62-467c-92fe-51efd433878d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b17671c0-4b62-467c-92fe-51efd433878d" xlink:to="loc_srt_ProductsAndServicesDomain_b17671c0-4b62-467c-92fe-51efd433878d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5c23de39-5f5f-49fb-be9b-b3914f4da7a1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b17671c0-4b62-467c-92fe-51efd433878d" xlink:to="loc_srt_ProductsAndServicesDomain_5c23de39-5f5f-49fb-be9b-b3914f4da7a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SleepAndRespiratoryMember_02f0552d-fdeb-4a5e-bc51-b9f59f6adb5d" xlink:href="rmd-20240630.xsd#rmd_SleepAndRespiratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c23de39-5f5f-49fb-be9b-b3914f4da7a1" xlink:to="loc_rmd_SleepAndRespiratoryMember_02f0552d-fdeb-4a5e-bc51-b9f59f6adb5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SoftwareAsAServiceMember_81c9abaa-f921-44c8-a352-a61ff8fdfb45" xlink:href="rmd-20240630.xsd#rmd_SoftwareAsAServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5c23de39-5f5f-49fb-be9b-b3914f4da7a1" xlink:to="loc_rmd_SoftwareAsAServiceMember_81c9abaa-f921-44c8-a352-a61ff8fdfb45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc1019c5-48d2-4d7a-9c19-981e26eee9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc1019c5-48d2-4d7a-9c19-981e26eee9b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_a9c95894-bd65-4b3d-9535-f17855595c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_a9c95894-bd65-4b3d-9535-f17855595c4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2ec58d38-b337-4a1a-b3d3-6c179c78afd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2ec58d38-b337-4a1a-b3d3-6c179c78afd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2b4f1b1c-9b19-4136-b362-7284e5860cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2b4f1b1c-9b19-4136-b362-7284e5860cf1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_992f75c5-b055-433c-9a1b-19d9f4098f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_GrossProfit_992f75c5-b055-433c-9a1b-19d9f4098f8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5aec9e5c-8d96-4f86-81c9-c7aa05de8084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5aec9e5c-8d96-4f86-81c9-c7aa05de8084" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_488bf1a3-a8e5-4783-b549-3a81edf4fc74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5aec9e5c-8d96-4f86-81c9-c7aa05de8084" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_488bf1a3-a8e5-4783-b549-3a81edf4fc74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7f1c6940-bbf2-4af9-bece-a9cbbf7126e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5aec9e5c-8d96-4f86-81c9-c7aa05de8084" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7f1c6940-bbf2-4af9-bece-a9cbbf7126e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_b1ac2754-7cd4-4836-a387-8e4b82615fa3" xlink:href="rmd-20240630.xsd#rmd_AmortizationOfAcquiredIntangibleAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5aec9e5c-8d96-4f86-81c9-c7aa05de8084" xlink:to="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_b1ac2754-7cd4-4836-a387-8e4b82615fa3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0797abcd-a229-430e-b3eb-c5cd13c8beb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5aec9e5c-8d96-4f86-81c9-c7aa05de8084" xlink:to="loc_us-gaap_RestructuringCharges_0797abcd-a229-430e-b3eb-c5cd13c8beb0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_d4e082ff-badd-4f40-b369-e947976d9930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5aec9e5c-8d96-4f86-81c9-c7aa05de8084" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_d4e082ff-badd-4f40-b369-e947976d9930" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1a1dad39-3ed7-46ae-aa25-85fa9b413e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5aec9e5c-8d96-4f86-81c9-c7aa05de8084" xlink:to="loc_us-gaap_OperatingExpenses_1a1dad39-3ed7-46ae-aa25-85fa9b413e6a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ab731687-48b7-4190-891f-ae5bd3ccdca3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_OperatingIncomeLoss_ab731687-48b7-4190-891f-ae5bd3ccdca3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_57332412-eb53-428b-b5cf-ba1bb1da5394" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_57332412-eb53-428b-b5cf-ba1bb1da5394" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_2f7ad826-f5d0-4c62-8852-a710cc4f2a30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_57332412-eb53-428b-b5cf-ba1bb1da5394" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_2f7ad826-f5d0-4c62-8852-a710cc4f2a30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b0d42191-e7b3-40fc-a454-177a7885521c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_57332412-eb53-428b-b5cf-ba1bb1da5394" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b0d42191-e7b3-40fc-a454-177a7885521c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_baeca4f1-67fb-4498-af18-5002ad87df98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_57332412-eb53-428b-b5cf-ba1bb1da5394" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_baeca4f1-67fb-4498-af18-5002ad87df98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_9d43b591-806b-4136-9837-2c7d4d37f79a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainOnBusinessInterruptionInsuranceRecovery"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_57332412-eb53-428b-b5cf-ba1bb1da5394" xlink:to="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_9d43b591-806b-4136-9837-2c7d4d37f79a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9c3c404f-471d-4cf3-9049-b19bcb8de6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_57332412-eb53-428b-b5cf-ba1bb1da5394" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9c3c404f-471d-4cf3-9049-b19bcb8de6e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0b10a5a5-ee75-4021-acef-8ccc1fec3f52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_57332412-eb53-428b-b5cf-ba1bb1da5394" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_0b10a5a5-ee75-4021-acef-8ccc1fec3f52" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0b5c8af0-7410-4c1d-bc19-e4a887d8b18b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0b5c8af0-7410-4c1d-bc19-e4a887d8b18b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_08cd35f4-ef23-474e-8118-4e481aa00e54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_08cd35f4-ef23-474e-8118-4e481aa00e54" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bebd526a-6138-41ee-84e5-77ddf7476b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_NetIncomeLoss_bebd526a-6138-41ee-84e5-77ddf7476b1b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_06b2aa90-02ce-4fbe-abae-39e5f1f6f4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_EarningsPerShareBasic_06b2aa90-02ce-4fbe-abae-39e5f1f6f4f0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c304b440-b35b-46dd-9543-3152b78fbd11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c304b440-b35b-46dd-9543-3152b78fbd11" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_7e365b23-30ac-457e-8b86-3cd3387f145a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_7e365b23-30ac-457e-8b86-3cd3387f145a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0b7b68e8-6c4a-48d1-9611-532a7bb60e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0b7b68e8-6c4a-48d1-9611-532a7bb60e7b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6aaf45cd-5125-4cb7-9509-0d7b05337be8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6aaf45cd-5125-4cb7-9509-0d7b05337be8" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="rmd-20240630.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b55ab7dd-68c8-44cc-ab20-44dbc81485e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_865c879d-ed3f-4d5b-8242-99a2bc2069f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b55ab7dd-68c8-44cc-ab20-44dbc81485e2" xlink:to="loc_us-gaap_StatementTable_865c879d-ed3f-4d5b-8242-99a2bc2069f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7f8b9f89-ab2d-4fb6-9482-1306df09299a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_865c879d-ed3f-4d5b-8242-99a2bc2069f8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7f8b9f89-ab2d-4fb6-9482-1306df09299a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7f8b9f89-ab2d-4fb6-9482-1306df09299a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7f8b9f89-ab2d-4fb6-9482-1306df09299a" xlink:to="loc_us-gaap_EquityComponentDomain_7f8b9f89-ab2d-4fb6-9482-1306df09299a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_75632416-2d8c-4d48-ac06-5b99a336dbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7f8b9f89-ab2d-4fb6-9482-1306df09299a" xlink:to="loc_us-gaap_EquityComponentDomain_75632416-2d8c-4d48-ac06-5b99a336dbbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4087c45b-832c-45ae-9e69-7bfa22c21e63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_75632416-2d8c-4d48-ac06-5b99a336dbbd" xlink:to="loc_us-gaap_CommonStockMember_4087c45b-832c-45ae-9e69-7bfa22c21e63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_12855921-54e9-4d7f-84ec-536ce0fe537b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_75632416-2d8c-4d48-ac06-5b99a336dbbd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_12855921-54e9-4d7f-84ec-536ce0fe537b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_5e83365c-839e-4427-b7dc-b7a2489085d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_75632416-2d8c-4d48-ac06-5b99a336dbbd" xlink:to="loc_us-gaap_TreasuryStockCommonMember_5e83365c-839e-4427-b7dc-b7a2489085d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6c5b8f12-72c9-4541-967d-710692322a82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_75632416-2d8c-4d48-ac06-5b99a336dbbd" xlink:to="loc_us-gaap_RetainedEarningsMember_6c5b8f12-72c9-4541-967d-710692322a82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a9435fea-21dd-472f-b9f1-29de8e122a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_75632416-2d8c-4d48-ac06-5b99a336dbbd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a9435fea-21dd-472f-b9f1-29de8e122a9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b55ab7dd-68c8-44cc-ab20-44dbc81485e2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1e2edb2c-443e-49b6-b10c-129cf3c05e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1e2edb2c-443e-49b6-b10c-129cf3c05e6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8e63467d-6597-4450-a1a2-52b3e78b8206" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_StockholdersEquity_8e63467d-6597-4450-a1a2-52b3e78b8206" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_1a21c187-a7f9-4aba-9f78-5f9369c4635f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_TreasuryStockCommonShares_1a21c187-a7f9-4aba-9f78-5f9369c4635f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_eb8fd406-45d9-451e-ba1d-f30e7201ee55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_eb8fd406-45d9-451e-ba1d-f30e7201ee55" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ae3e579e-0a34-4967-8976-7442a1e601c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ae3e579e-0a34-4967-8976-7442a1e601c7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_347f1823-16c6-449a-b667-c8e62c79b144" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_347f1823-16c6-449a-b667-c8e62c79b144" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_93785ebf-1144-4769-acea-b6669b55386a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_93785ebf-1144-4769-acea-b6669b55386a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3e13ef5e-6a55-44c9-aae4-c12a73ced1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3e13ef5e-6a55-44c9-aae4-c12a73ced1bd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2fcb285c-a925-4ee3-bff2-83febb0956ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2fcb285c-a925-4ee3-bff2-83febb0956ec" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d37667fb-f8c4-4221-a43d-79bd7d850634" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d37667fb-f8c4-4221-a43d-79bd7d850634" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_414a4a01-2ff0-483e-9ef9-cd8f52a9f347" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_414a4a01-2ff0-483e-9ef9-cd8f52a9f347" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ad632910-cf90-47d6-a807-f3fdb49bccfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ad632910-cf90-47d6-a807-f3fdb49bccfc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f01f9699-ae2e-4fb9-9ea9-61ea3399e00b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f01f9699-ae2e-4fb9-9ea9-61ea3399e00b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8a750303-91fd-4d48-a41b-4cad586ae347" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_NetIncomeLoss_8a750303-91fd-4d48-a41b-4cad586ae347" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_c2745785-9da7-433f-b06c-89c2232b7f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_Dividends_c2745785-9da7-433f-b06c-89c2232b7f4b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e5ad20a8-a51a-4308-a987-0c17ea6a5d94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3d781cb8-7c35-4467-8d44-50ab1a3bfd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_d29913f1-92fb-4113-b5b6-39d7d18f3aad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:href="rmd-20240630.xsd#rmd_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_371dca25-dd35-437e-ba73-1ac0f6dd9cfc" xlink:href="rmd-20240630.xsd#rmd_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:to="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_371dca25-dd35-437e-ba73-1ac0f6dd9cfc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9517e1c8-2769-43d4-bc47-ee233aceca88" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_371dca25-dd35-437e-ba73-1ac0f6dd9cfc" xlink:to="loc_srt_RangeAxis_9517e1c8-2769-43d4-bc47-ee233aceca88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9517e1c8-2769-43d4-bc47-ee233aceca88_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9517e1c8-2769-43d4-bc47-ee233aceca88" xlink:to="loc_srt_RangeMember_9517e1c8-2769-43d4-bc47-ee233aceca88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fa681a8c-0537-4098-805c-59e6a0e623ab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9517e1c8-2769-43d4-bc47-ee233aceca88" xlink:to="loc_srt_RangeMember_fa681a8c-0537-4098-805c-59e6a0e623ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_92ce21b0-3c06-46d9-a52f-702fbaa3d79f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fa681a8c-0537-4098-805c-59e6a0e623ab" xlink:to="loc_srt_MinimumMember_92ce21b0-3c06-46d9-a52f-702fbaa3d79f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_314a6292-c134-43a9-be77-81dd4ca03580" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fa681a8c-0537-4098-805c-59e6a0e623ab" xlink:to="loc_srt_MaximumMember_314a6292-c134-43a9-be77-81dd4ca03580" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fa2d1b7e-6169-4c10-9664-8416d21fc85b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_371dca25-dd35-437e-ba73-1ac0f6dd9cfc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fa2d1b7e-6169-4c10-9664-8416d21fc85b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fa2d1b7e-6169-4c10-9664-8416d21fc85b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fa2d1b7e-6169-4c10-9664-8416d21fc85b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fa2d1b7e-6169-4c10-9664-8416d21fc85b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e94d5841-85b7-4b64-b2cb-5c79cfffe99b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fa2d1b7e-6169-4c10-9664-8416d21fc85b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e94d5841-85b7-4b64-b2cb-5c79cfffe99b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_bfbc7bfd-7f6f-4a39-8f16-9ce6c5dc6c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e94d5841-85b7-4b64-b2cb-5c79cfffe99b" xlink:to="loc_us-gaap_BuildingMember_bfbc7bfd-7f6f-4a39-8f16-9ce6c5dc6c3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5ba70af3-5e74-4d01-bcd3-bae3f134b045" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_371dca25-dd35-437e-ba73-1ac0f6dd9cfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5ba70af3-5e74-4d01-bcd3-bae3f134b045" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ba70af3-5e74-4d01-bcd3-bae3f134b045_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5ba70af3-5e74-4d01-bcd3-bae3f134b045" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5ba70af3-5e74-4d01-bcd3-bae3f134b045_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_80df4208-dc02-45c2-9450-b7e89c097ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5ba70af3-5e74-4d01-bcd3-bae3f134b045" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_80df4208-dc02-45c2-9450-b7e89c097ba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_13d94f40-905f-4fd9-aea9-b00b6a8efba2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_80df4208-dc02-45c2-9450-b7e89c097ba8" xlink:to="loc_us-gaap_PatentsMember_13d94f40-905f-4fd9-aea9-b00b6a8efba2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e378785c-b543-4c0a-8012-b06e97218321" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_371dca25-dd35-437e-ba73-1ac0f6dd9cfc" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e378785c-b543-4c0a-8012-b06e97218321" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e378785c-b543-4c0a-8012-b06e97218321_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e378785c-b543-4c0a-8012-b06e97218321" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e378785c-b543-4c0a-8012-b06e97218321_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_95383f52-f137-441b-b812-62890faf6abd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e378785c-b543-4c0a-8012-b06e97218321" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_95383f52-f137-441b-b812-62890faf6abd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_d6cee26c-bdd5-417a-ad43-55a377059f58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_95383f52-f137-441b-b812-62890faf6abd" xlink:to="loc_us-gaap_CurrencySwapMember_d6cee26c-bdd5-417a-ad43-55a377059f58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ab9ea2c3-f5a1-4312-90c6-093c62a52684" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_95383f52-f137-441b-b812-62890faf6abd" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ab9ea2c3-f5a1-4312-90c6-093c62a52684" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9f525baf-22d5-4e22-b93e-ea8d00a07b67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_371dca25-dd35-437e-ba73-1ac0f6dd9cfc" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9f525baf-22d5-4e22-b93e-ea8d00a07b67" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_9f525baf-22d5-4e22-b93e-ea8d00a07b67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9f525baf-22d5-4e22-b93e-ea8d00a07b67" xlink:to="loc_us-gaap_HedgingRelationshipDomain_9f525baf-22d5-4e22-b93e-ea8d00a07b67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d1b47835-24a7-4538-8fae-464e021be223" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9f525baf-22d5-4e22-b93e-ea8d00a07b67" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d1b47835-24a7-4538-8fae-464e021be223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_FairValueAndNetInvestmentHedgingMember_75797bb2-ebf7-4b47-ac35-bbf6a779d7bc" xlink:href="rmd-20240630.xsd#rmd_FairValueAndNetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d1b47835-24a7-4538-8fae-464e021be223" xlink:to="loc_rmd_FairValueAndNetInvestmentHedgingMember_75797bb2-ebf7-4b47-ac35-bbf6a779d7bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_ec0b7f65-0e62-426e-b26f-4e3466dd8b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d1b47835-24a7-4538-8fae-464e021be223" xlink:to="loc_us-gaap_CashFlowHedgingMember_ec0b7f65-0e62-426e-b26f-4e3466dd8b6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_cfb7f318-2998-4fcc-99f0-95c4b6da07ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_371dca25-dd35-437e-ba73-1ac0f6dd9cfc" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_cfb7f318-2998-4fcc-99f0-95c4b6da07ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_cfb7f318-2998-4fcc-99f0-95c4b6da07ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_cfb7f318-2998-4fcc-99f0-95c4b6da07ba" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_cfb7f318-2998-4fcc-99f0-95c4b6da07ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_99ba0a16-96ec-4bca-93f4-121f484332e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_cfb7f318-2998-4fcc-99f0-95c4b6da07ba" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_99ba0a16-96ec-4bca-93f4-121f484332e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IntangibleAssetImpairmentMember_28bb776b-207d-4de7-8c95-0a618a5b1885" xlink:href="rmd-20240630.xsd#rmd_IntangibleAssetImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_99ba0a16-96ec-4bca-93f4-121f484332e9" xlink:to="loc_rmd_IntangibleAssetImpairmentMember_28bb776b-207d-4de7-8c95-0a618a5b1885" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6ce372e0-6654-40c0-8d9d-239c7fce8096" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6ce372e0-6654-40c0-8d9d-239c7fce8096" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_TermOfContractUnderRevenueRecognition_feb591f4-ccaa-419a-a8db-325c3eb32fae" xlink:href="rmd-20240630.xsd#rmd_TermOfContractUnderRevenueRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:to="loc_rmd_TermOfContractUnderRevenueRecognition_feb591f4-ccaa-419a-a8db-325c3eb32fae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_277577bc-1232-46d5-ad96-99ae107f3db1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_277577bc-1232-46d5-ad96-99ae107f3db1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c9f50f59-cc48-4079-8839-64accb34ceee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:to="loc_us-gaap_Depreciation_c9f50f59-cc48-4079-8839-64accb34ceee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cfb1549c-225d-4928-82b8-67b8c85515c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cfb1549c-225d-4928-82b8-67b8c85515c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_53b059c0-03ca-4b04-bf4e-0e3f338ad57d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:to="loc_us-gaap_DerivativeNotionalAmount_53b059c0-03ca-4b04-bf4e-0e3f338ad57d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_b334c3ee-8c4d-4e33-bdac-5218814c41d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:to="loc_us-gaap_DerivativeTermOfContract_b334c3ee-8c4d-4e33-bdac-5218814c41d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f4823e83-8d58-4d43-b849-a0fccade464d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:to="loc_us-gaap_RestructuringCharges_f4823e83-8d58-4d43-b849-a0fccade464d" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems_44ce997f-d439-4218-8948-66041dda81f0" xlink:href="rmd-20240630.xsd#rmd_ContractWithCustomerAssetAndLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ContractWithCustomerAssetAndLiabilityTable_9f36ce6f-5a5f-4128-a32e-4ee200d89dfb" xlink:href="rmd-20240630.xsd#rmd_ContractWithCustomerAssetAndLiabilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems_44ce997f-d439-4218-8948-66041dda81f0" xlink:to="loc_rmd_ContractWithCustomerAssetAndLiabilityTable_9f36ce6f-5a5f-4128-a32e-4ee200d89dfb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9c47852c-aa56-4725-bbbd-2e4409d678f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityTable_9f36ce6f-5a5f-4128-a32e-4ee200d89dfb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9c47852c-aa56-4725-bbbd-2e4409d678f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9c47852c-aa56-4725-bbbd-2e4409d678f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9c47852c-aa56-4725-bbbd-2e4409d678f0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9c47852c-aa56-4725-bbbd-2e4409d678f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_75968cab-f1d5-4bab-bbd0-2435d5a095e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9c47852c-aa56-4725-bbbd-2e4409d678f0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_75968cab-f1d5-4bab-bbd0-2435d5a095e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AccountsReceivableNetMember_2f7820ec-bddb-4998-ab72-5f157cb99acf" xlink:href="rmd-20240630.xsd#rmd_AccountsReceivableNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75968cab-f1d5-4bab-bbd0-2435d5a095e3" xlink:to="loc_rmd_AccountsReceivableNetMember_2f7820ec-bddb-4998-ab72-5f157cb99acf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_7854c2ad-b6db-4377-8426-7e36e7542f76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75968cab-f1d5-4bab-bbd0-2435d5a095e3" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_7854c2ad-b6db-4377-8426-7e36e7542f76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember_d1ae3717-21bc-41b6-8edd-23dbbd64eb77" xlink:href="rmd-20240630.xsd#rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75968cab-f1d5-4bab-bbd0-2435d5a095e3" xlink:to="loc_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember_d1ae3717-21bc-41b6-8edd-23dbbd64eb77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredRevenueCurrentLiabilitiesMember_023dc677-5097-4ac0-ac14-983bb5bf4ede" xlink:href="rmd-20240630.xsd#rmd_DeferredRevenueCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75968cab-f1d5-4bab-bbd0-2435d5a095e3" xlink:to="loc_rmd_DeferredRevenueCurrentLiabilitiesMember_023dc677-5097-4ac0-ac14-983bb5bf4ede" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredRevenueNonCurrentLiabilitiesMember_08bd2c5a-8d03-45c9-9278-20e9c2474480" xlink:href="rmd-20240630.xsd#rmd_DeferredRevenueNonCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75968cab-f1d5-4bab-bbd0-2435d5a095e3" xlink:to="loc_rmd_DeferredRevenueNonCurrentLiabilitiesMember_08bd2c5a-8d03-45c9-9278-20e9c2474480" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract_2c989522-2308-4ac2-a3df-97857f390296" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems_44ce997f-d439-4218-8948-66041dda81f0" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetAbstract_2c989522-2308-4ac2-a3df-97857f390296" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_02e2d4bd-8de3-4cba-9054-52a128eee9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_2c989522-2308-4ac2-a3df-97857f390296" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_02e2d4bd-8de3-4cba-9054-52a128eee9ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5e190f65-a3f3-4902-85f6-3bb3f42ed295" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_2c989522-2308-4ac2-a3df-97857f390296" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5e190f65-a3f3-4902-85f6-3bb3f42ed295" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_0c74d929-cfa7-4f73-9cb6-32ad8d2e8601" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_2c989522-2308-4ac2-a3df-97857f390296" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_0c74d929-cfa7-4f73-9cb6-32ad8d2e8601" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_f815f358-98e9-4823-a85a-86426a606c59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems_44ce997f-d439-4218-8948-66041dda81f0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityAbstract_f815f358-98e9-4823-a85a-86426a606c59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_64d1d19c-5a24-4ba7-81d8-267d0e76a8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_f815f358-98e9-4823-a85a-86426a606c59" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_64d1d19c-5a24-4ba7-81d8-267d0e76a8b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_20e22b83-bd33-4e8f-89e0-3bb857c2b645" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_f815f358-98e9-4823-a85a-86426a606c59" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_20e22b83-bd33-4e8f-89e0-3bb857c2b645" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32364812-c1cf-48d0-bc3c-a0e41edabb92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_45edfc10-8de9-4ffb-91a7-ee375c256132" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32364812-c1cf-48d0-bc3c-a0e41edabb92" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_45edfc10-8de9-4ffb-91a7-ee375c256132" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7417c4a4-0a10-4e88-9f38-32a540435cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_45edfc10-8de9-4ffb-91a7-ee375c256132" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7417c4a4-0a10-4e88-9f38-32a540435cfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7417c4a4-0a10-4e88-9f38-32a540435cfa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7417c4a4-0a10-4e88-9f38-32a540435cfa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7417c4a4-0a10-4e88-9f38-32a540435cfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7417c4a4-0a10-4e88-9f38-32a540435cfa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_6bc8e7c4-e915-494e-bb4c-a7eabe22616a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_6bc8e7c4-e915-494e-bb4c-a7eabe22616a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ComputerEquipmentAndSoftwareMember_698846f2-7b83-4a1a-bcaa-0d59a0932724" xlink:href="rmd-20240630.xsd#rmd_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:to="loc_rmd_ComputerEquipmentAndSoftwareMember_698846f2-7b83-4a1a-bcaa-0d59a0932724" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2bcd737a-76f7-4ee8-abc4-e003662aa8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2bcd737a-76f7-4ee8-abc4-e003662aa8f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_VehiclesAndAircraftMember_c2c99c91-6ce9-414c-a2dd-4336ee06b66f" xlink:href="rmd-20240630.xsd#rmd_VehiclesAndAircraftMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:to="loc_rmd_VehiclesAndAircraftMember_c2c99c91-6ce9-414c-a2dd-4336ee06b66f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ClinicalDemonstrationAndRentalEquipmentMember_ca547f75-a638-472f-8b6a-461bf23c2650" xlink:href="rmd-20240630.xsd#rmd_ClinicalDemonstrationAndRentalEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:to="loc_rmd_ClinicalDemonstrationAndRentalEquipmentMember_ca547f75-a638-472f-8b6a-461bf23c2650" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_bca92223-e19e-47b1-b2af-563e4ff253bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_bca92223-e19e-47b1-b2af-563e4ff253bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_3af49dc3-2c57-45e8-ab80-f360262af059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:to="loc_us-gaap_LandMember_3af49dc3-2c57-45e8-ab80-f360262af059" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_900350c6-48a0-4fe4-870e-0d27c503c457" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:to="loc_us-gaap_BuildingMember_900350c6-48a0-4fe4-870e-0d27c503c457" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_bf423a4d-49e9-439b-8ba2-54a10a6446ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32364812-c1cf-48d0-bc3c-a0e41edabb92" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_bf423a4d-49e9-439b-8ba2-54a10a6446ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b3b58c5-2b3d-40ba-8bbc-1eab5a37b32f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32364812-c1cf-48d0-bc3c-a0e41edabb92" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b3b58c5-2b3d-40ba-8bbc-1eab5a37b32f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_daf9a188-8b71-4d55-8a67-2a8e06442680" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32364812-c1cf-48d0-bc3c-a0e41edabb92" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_daf9a188-8b71-4d55-8a67-2a8e06442680" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_160ab2d5-f6e6-4473-a314-cc7a9a519dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_d2f59d6f-8f8f-4bf9-8ad5-9329d88109d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_160ab2d5-f6e6-4473-a314-cc7a9a519dcd" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_d2f59d6f-8f8f-4bf9-8ad5-9329d88109d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_281e884e-c181-4c52-928d-3ba6f31aca67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d2f59d6f-8f8f-4bf9-8ad5-9329d88109d7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_281e884e-c181-4c52-928d-3ba6f31aca67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_281e884e-c181-4c52-928d-3ba6f31aca67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_281e884e-c181-4c52-928d-3ba6f31aca67" xlink:to="loc_us-gaap_SegmentDomain_281e884e-c181-4c52-928d-3ba6f31aca67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5d5e6167-52b9-44fd-a70b-8f8057d7d11d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_281e884e-c181-4c52-928d-3ba6f31aca67" xlink:to="loc_us-gaap_SegmentDomain_5d5e6167-52b9-44fd-a70b-8f8057d7d11d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SleepAndRespiratoryMember_9dcce143-2965-40d7-a1e3-de46aedb0cef" xlink:href="rmd-20240630.xsd#rmd_SleepAndRespiratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5d5e6167-52b9-44fd-a70b-8f8057d7d11d" xlink:to="loc_rmd_SleepAndRespiratoryMember_9dcce143-2965-40d7-a1e3-de46aedb0cef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SaasMember_608ef6a9-d565-4379-a7ae-e9b46e47e8e1" xlink:href="rmd-20240630.xsd#rmd_SaasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5d5e6167-52b9-44fd-a70b-8f8057d7d11d" xlink:to="loc_rmd_SaasMember_608ef6a9-d565-4379-a7ae-e9b46e47e8e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_aa6f3fc5-4ce0-41fb-8446-c0824fb53ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_160ab2d5-f6e6-4473-a314-cc7a9a519dcd" xlink:to="loc_us-gaap_GoodwillRollForward_aa6f3fc5-4ce0-41fb-8446-c0824fb53ad6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5eb0fb7e-e3e5-4e88-9b41-da3392587211" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_aa6f3fc5-4ce0-41fb-8446-c0824fb53ad6" xlink:to="loc_us-gaap_Goodwill_5eb0fb7e-e3e5-4e88-9b41-da3392587211" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_9ed6e078-3b54-41f8-b09d-4ef7baee849e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_aa6f3fc5-4ce0-41fb-8446-c0824fb53ad6" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_9ed6e078-3b54-41f8-b09d-4ef7baee849e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_15fd52b1-c9ef-4c7d-9531-7c5bf6b92b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_aa6f3fc5-4ce0-41fb-8446-c0824fb53ad6" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_15fd52b1-c9ef-4c7d-9531-7c5bf6b92b3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_12eafed6-de66-4d3e-a017-b95db925fc11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ce496785-d359-4b5a-9af0-195371e0d547" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7634a779-0f56-4bed-80ce-a95d5a19c848" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ce496785-d359-4b5a-9af0-195371e0d547" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7634a779-0f56-4bed-80ce-a95d5a19c848" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ccd8d14c-4647-440d-8fc9-cb164952d276" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7634a779-0f56-4bed-80ce-a95d5a19c848" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ccd8d14c-4647-440d-8fc9-cb164952d276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ccd8d14c-4647-440d-8fc9-cb164952d276_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ccd8d14c-4647-440d-8fc9-cb164952d276" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ccd8d14c-4647-440d-8fc9-cb164952d276_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a6bbae1b-7800-4d13-b503-248298519f01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ccd8d14c-4647-440d-8fc9-cb164952d276" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a6bbae1b-7800-4d13-b503-248298519f01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DevelopedOrCoreProductTechnologyMember_8545ed1c-7ae5-4812-8b86-5f7c9939dfe6" xlink:href="rmd-20240630.xsd#rmd_DevelopedOrCoreProductTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a6bbae1b-7800-4d13-b503-248298519f01" xlink:to="loc_rmd_DevelopedOrCoreProductTechnologyMember_8545ed1c-7ae5-4812-8b86-5f7c9939dfe6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_83a0f1a4-cc76-43fd-8e1d-dc345297b83a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a6bbae1b-7800-4d13-b503-248298519f01" xlink:to="loc_us-gaap_CustomerRelationshipsMember_83a0f1a4-cc76-43fd-8e1d-dc345297b83a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_d07b4783-f723-42e9-a9fa-00e4e56c3e55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a6bbae1b-7800-4d13-b503-248298519f01" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_d07b4783-f723-42e9-a9fa-00e4e56c3e55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a783d368-30fc-4e67-b108-3d1b3a1a3005" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ce496785-d359-4b5a-9af0-195371e0d547" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a783d368-30fc-4e67-b108-3d1b3a1a3005" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c0f8d3ce-400c-4a64-9bad-8a8ae1ffaa52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ce496785-d359-4b5a-9af0-195371e0d547" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c0f8d3ce-400c-4a64-9bad-8a8ae1ffaa52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_89c59483-436b-424a-8ed3-2b2932f0be44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ce496785-d359-4b5a-9af0-195371e0d547" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_89c59483-436b-424a-8ed3-2b2932f0be44" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#GoodwillandOtherIntangibleAssetsnetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f45d0814-74ba-465d-92de-48a7fe7c7f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_86e07021-a5c0-4f28-8473-f89ffaa94ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f45d0814-74ba-465d-92de-48a7fe7c7f1c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_86e07021-a5c0-4f28-8473-f89ffaa94ce6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_41d1315c-2e64-47fd-9588-6ab9499c44eb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_86e07021-a5c0-4f28-8473-f89ffaa94ce6" xlink:to="loc_srt_RangeAxis_41d1315c-2e64-47fd-9588-6ab9499c44eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_41d1315c-2e64-47fd-9588-6ab9499c44eb_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_41d1315c-2e64-47fd-9588-6ab9499c44eb" xlink:to="loc_srt_RangeMember_41d1315c-2e64-47fd-9588-6ab9499c44eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2df7feb8-a9b9-45c5-a6f9-831716dc1850" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_41d1315c-2e64-47fd-9588-6ab9499c44eb" xlink:to="loc_srt_RangeMember_2df7feb8-a9b9-45c5-a6f9-831716dc1850" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4c75fca1-f6d6-4055-addb-32864d7e0abd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2df7feb8-a9b9-45c5-a6f9-831716dc1850" xlink:to="loc_srt_MinimumMember_4c75fca1-f6d6-4055-addb-32864d7e0abd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_431f6f26-a3eb-4b3f-bb7e-602d5e9a7b06" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2df7feb8-a9b9-45c5-a6f9-831716dc1850" xlink:to="loc_srt_MaximumMember_431f6f26-a3eb-4b3f-bb7e-602d5e9a7b06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8eeb155a-e36f-4cfe-906d-c1c2eb00649d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_86e07021-a5c0-4f28-8473-f89ffaa94ce6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8eeb155a-e36f-4cfe-906d-c1c2eb00649d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8eeb155a-e36f-4cfe-906d-c1c2eb00649d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8eeb155a-e36f-4cfe-906d-c1c2eb00649d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8eeb155a-e36f-4cfe-906d-c1c2eb00649d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04163713-a183-4143-b99a-2fca5033630d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8eeb155a-e36f-4cfe-906d-c1c2eb00649d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04163713-a183-4143-b99a-2fca5033630d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IdentifiedIntangibleAssetsMember_71cbbeb0-b31a-4f85-abc1-22d2cbeb324f" xlink:href="rmd-20240630.xsd#rmd_IdentifiedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04163713-a183-4143-b99a-2fca5033630d" xlink:to="loc_rmd_IdentifiedIntangibleAssetsMember_71cbbeb0-b31a-4f85-abc1-22d2cbeb324f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_eb902d39-24a0-47ad-bb68-79d9a6ca6914" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04163713-a183-4143-b99a-2fca5033630d" xlink:to="loc_us-gaap_PatentsMember_eb902d39-24a0-47ad-bb68-79d9a6ca6914" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DevelopedOrCoreProductTechnologyMember_773e1b71-6327-438c-8bf1-d100d9058b28" xlink:href="rmd-20240630.xsd#rmd_DevelopedOrCoreProductTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04163713-a183-4143-b99a-2fca5033630d" xlink:to="loc_rmd_DevelopedOrCoreProductTechnologyMember_773e1b71-6327-438c-8bf1-d100d9058b28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_341d179a-4dc5-4fb8-b7fd-d9e2629066bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04163713-a183-4143-b99a-2fca5033630d" xlink:to="loc_us-gaap_CustomerRelationshipsMember_341d179a-4dc5-4fb8-b7fd-d9e2629066bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_170c3eb1-57fc-4e49-8098-5379976d7996" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04163713-a183-4143-b99a-2fca5033630d" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_170c3eb1-57fc-4e49-8098-5379976d7996" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_88fa742e-7586-4a1c-a833-acba08995b72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f45d0814-74ba-465d-92de-48a7fe7c7f1c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_88fa742e-7586-4a1c-a833-acba08995b72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_944025de-3a4e-4e35-b352-c883704fb83d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f45d0814-74ba-465d-92de-48a7fe7c7f1c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_944025de-3a4e-4e35-b352-c883704fb83d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4d2126bc-6541-4ca3-b995-0fbfd2239e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f45d0814-74ba-465d-92de-48a7fe7c7f1c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4d2126bc-6541-4ca3-b995-0fbfd2239e5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_48a4eb3d-1c16-4c45-8497-2bce811d498e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f45d0814-74ba-465d-92de-48a7fe7c7f1c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_48a4eb3d-1c16-4c45-8497-2bce811d498e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#InvestmentsScheduleofChangesInEquityInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51cb042b-863d-42bf-89a5-35cef9eeaf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a6a5c12a-fdc3-44c5-84c9-922fc3db617b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51cb042b-863d-42bf-89a5-35cef9eeaf5c" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a6a5c12a-fdc3-44c5-84c9-922fc3db617b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_41f5da1c-b89b-4476-ae4b-b3195e2c370e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a6a5c12a-fdc3-44c5-84c9-922fc3db617b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_41f5da1c-b89b-4476-ae4b-b3195e2c370e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_41f5da1c-b89b-4476-ae4b-b3195e2c370e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_41f5da1c-b89b-4476-ae4b-b3195e2c370e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_41f5da1c-b89b-4476-ae4b-b3195e2c370e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b604c65e-fb72-4b05-bbc9-0d72d2c68355" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_41f5da1c-b89b-4476-ae4b-b3195e2c370e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b604c65e-fb72-4b05-bbc9-0d72d2c68355" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NonMarketableSecuritiesMember_cd95edc6-300b-4574-ac4e-b32f8de706c4" xlink:href="rmd-20240630.xsd#rmd_NonMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b604c65e-fb72-4b05-bbc9-0d72d2c68355" xlink:to="loc_rmd_NonMarketableSecuritiesMember_cd95edc6-300b-4574-ac4e-b32f8de706c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MarketableSecuritiesMember_1d61a2e2-53ba-4a6e-ac6f-781b2263de79" xlink:href="rmd-20240630.xsd#rmd_MarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b604c65e-fb72-4b05-bbc9-0d72d2c68355" xlink:to="loc_rmd_MarketableSecuritiesMember_1d61a2e2-53ba-4a6e-ac6f-781b2263de79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember_3631bb1c-dd9b-4d3e-99ab-b5a797941d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b604c65e-fb72-4b05-bbc9-0d72d2c68355" xlink:to="loc_us-gaap_EquityMethodInvestmentsMember_3631bb1c-dd9b-4d3e-99ab-b5a797941d6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:href="rmd-20240630.xsd#rmd_EquityMethodInvestmentsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51cb042b-863d-42bf-89a5-35cef9eeaf5c" xlink:to="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityInvestments_878a71fb-2f43-4ea8-9d75-19b01c2f7239" xlink:href="rmd-20240630.xsd#rmd_EquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_rmd_EquityInvestments_878a71fb-2f43-4ea8-9d75-19b01c2f7239" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AdditionalEquityInvestments_a2067c7f-5a60-464a-8174-9e62a89a5698" xlink:href="rmd-20240630.xsd#rmd_AdditionalEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_rmd_AdditionalEquityInvestments_a2067c7f-5a60-464a-8174-9e62a89a5698" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities_13786569-101e-4de3-9c69-38f9bca5646c" xlink:href="rmd-20240630.xsd#rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities_13786569-101e-4de3-9c69-38f9bca5646c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_5ac52e34-35bc-4f8e-85bd-e3c8443f3acf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_5ac52e34-35bc-4f8e-85bd-e3c8443f3acf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_35675b8a-43b9-42f6-9137-b41f2f22d5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_35675b8a-43b9-42f6-9137-b41f2f22d5e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments_7a3a7612-07de-4292-b247-dee9a4d347c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_us-gaap_PaymentsForProceedsFromInvestments_7a3a7612-07de-4292-b247-dee9a4d347c2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_1b651756-6cd3-4c33-b971-ddbac0fefbca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_1b651756-6cd3-4c33-b971-ddbac0fefbca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5871fbf1-326a-48e1-af43-c6ede67e5216" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5871fbf1-326a-48e1-af43-c6ede67e5216" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDividendsReceived_f31d341b-446e-472f-a010-8bd05474297f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDividendsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_us-gaap_ProceedsFromDividendsReceived_f31d341b-446e-472f-a010-8bd05474297f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments_0e162e15-bbb0-4971-a933-a649fd9be470" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments_0e162e15-bbb0-4971-a933-a649fd9be470" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityInvestments_89c996d1-ea5e-4f12-b1e2-95ef693e11a5" xlink:href="rmd-20240630.xsd#rmd_EquityInvestments"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_86f40f43-aa64-457b-bfb0-eb8eb9a9d0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_86f40f43-aa64-457b-bfb0-eb8eb9a9d0f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_05349af7-cbd5-46f3-9cb0-774c4d883be6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_86f40f43-aa64-457b-bfb0-eb8eb9a9d0f8" xlink:to="loc_us-gaap_CreditFacilityAxis_05349af7-cbd5-46f3-9cb0-774c4d883be6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_05349af7-cbd5-46f3-9cb0-774c4d883be6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_05349af7-cbd5-46f3-9cb0-774c4d883be6" xlink:to="loc_us-gaap_CreditFacilityDomain_05349af7-cbd5-46f3-9cb0-774c4d883be6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3d8e3b92-705c-49eb-9bc6-01da17f0b4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_05349af7-cbd5-46f3-9cb0-774c4d883be6" xlink:to="loc_us-gaap_CreditFacilityDomain_3d8e3b92-705c-49eb-9bc6-01da17f0b4c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_88f4d9da-b627-44a2-8269-e5bdec065e40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_3d8e3b92-705c-49eb-9bc6-01da17f0b4c0" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_88f4d9da-b627-44a2-8269-e5bdec065e40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember_8e3004d5-125a-4a1b-bba8-7e25e201da4b" xlink:href="rmd-20240630.xsd#rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember_88f4d9da-b627-44a2-8269-e5bdec065e40" xlink:to="loc_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember_8e3004d5-125a-4a1b-bba8-7e25e201da4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_TermLoanCreditAgreementMember_cd0e7ca6-cbe1-4c9a-8674-bdee084d87a3" xlink:href="rmd-20240630.xsd#rmd_TermLoanCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_3d8e3b92-705c-49eb-9bc6-01da17f0b4c0" xlink:to="loc_rmd_TermLoanCreditAgreementMember_cd0e7ca6-cbe1-4c9a-8674-bdee084d87a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_47d5b82e-c74d-4676-a987-17d834613586" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_86f40f43-aa64-457b-bfb0-eb8eb9a9d0f8" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_47d5b82e-c74d-4676-a987-17d834613586" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_47d5b82e-c74d-4676-a987-17d834613586_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_47d5b82e-c74d-4676-a987-17d834613586" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_47d5b82e-c74d-4676-a987-17d834613586_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_b97db9b9-0090-463d-a93e-1f9d5625442f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_47d5b82e-c74d-4676-a987-17d834613586" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_b97db9b9-0090-463d-a93e-1f9d5625442f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember_7f6473a5-0e6c-48f6-a8e6-ce17d42c393f" xlink:href="rmd-20240630.xsd#rmd_MufgUnionBankNaAndWestpacBankingCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_b97db9b9-0090-463d-a93e-1f9d5625442f" xlink:to="loc_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember_7f6473a5-0e6c-48f6-a8e6-ce17d42c393f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MufgUnionBankMember_799ab01f-7f59-4d9d-8c4c-8defca3e9a88" xlink:href="rmd-20240630.xsd#rmd_MufgUnionBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_b97db9b9-0090-463d-a93e-1f9d5625442f" xlink:to="loc_rmd_MufgUnionBankMember_799ab01f-7f59-4d9d-8c4c-8defca3e9a88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6dd5203e-6624-4435-bd5b-9b20e6f2af91" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_86f40f43-aa64-457b-bfb0-eb8eb9a9d0f8" xlink:to="loc_dei_LegalEntityAxis_6dd5203e-6624-4435-bd5b-9b20e6f2af91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6dd5203e-6624-4435-bd5b-9b20e6f2af91_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_6dd5203e-6624-4435-bd5b-9b20e6f2af91" xlink:to="loc_dei_EntityDomain_6dd5203e-6624-4435-bd5b-9b20e6f2af91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_253038a2-c116-4c56-837d-89032441bae7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_6dd5203e-6624-4435-bd5b-9b20e6f2af91" xlink:to="loc_dei_EntityDomain_253038a2-c116-4c56-837d-89032441bae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ResmedLimitedMember_2eaac938-58a2-4279-9c61-3b2ac860fd1f" xlink:href="rmd-20240630.xsd#rmd_ResmedLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_253038a2-c116-4c56-837d-89032441bae7" xlink:to="loc_rmd_ResmedLimitedMember_2eaac938-58a2-4279-9c61-3b2ac860fd1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9438df06-6389-4479-b105-af9d768361e7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_86f40f43-aa64-457b-bfb0-eb8eb9a9d0f8" xlink:to="loc_srt_RangeAxis_9438df06-6389-4479-b105-af9d768361e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9438df06-6389-4479-b105-af9d768361e7_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9438df06-6389-4479-b105-af9d768361e7" xlink:to="loc_srt_RangeMember_9438df06-6389-4479-b105-af9d768361e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ccbc13e9-f271-42d2-af22-d208d44ee86a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9438df06-6389-4479-b105-af9d768361e7" xlink:to="loc_srt_RangeMember_ccbc13e9-f271-42d2-af22-d208d44ee86a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d74dc854-7b0b-4f44-a708-6d0a3079a931" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ccbc13e9-f271-42d2-af22-d208d44ee86a" xlink:to="loc_srt_MinimumMember_d74dc854-7b0b-4f44-a708-6d0a3079a931" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_72398aef-b3a6-40d7-9946-5993709e39b9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ccbc13e9-f271-42d2-af22-d208d44ee86a" xlink:to="loc_srt_MaximumMember_72398aef-b3a6-40d7-9946-5993709e39b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_b65fabc9-52cc-47c9-b32e-378b82b09d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_86f40f43-aa64-457b-bfb0-eb8eb9a9d0f8" xlink:to="loc_us-gaap_VariableRateAxis_b65fabc9-52cc-47c9-b32e-378b82b09d5a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b65fabc9-52cc-47c9-b32e-378b82b09d5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_b65fabc9-52cc-47c9-b32e-378b82b09d5a" xlink:to="loc_us-gaap_VariableRateDomain_b65fabc9-52cc-47c9-b32e-378b82b09d5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_263ec062-409b-4bea-9bdb-e6af6d8f3d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_b65fabc9-52cc-47c9-b32e-378b82b09d5a" xlink:to="loc_us-gaap_VariableRateDomain_263ec062-409b-4bea-9bdb-e6af6d8f3d1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_0bb62166-3aff-4c4e-a66f-d4993da140c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_263ec062-409b-4bea-9bdb-e6af6d8f3d1c" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_0bb62166-3aff-4c4e-a66f-d4993da140c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_97003a7a-ad6e-46ac-84e1-f320acb06dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_263ec062-409b-4bea-9bdb-e6af6d8f3d1c" xlink:to="loc_us-gaap_BaseRateMember_97003a7a-ad6e-46ac-84e1-f320acb06dbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_25d88a52-28ee-435e-98a9-794b8222d56b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_86f40f43-aa64-457b-bfb0-eb8eb9a9d0f8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_25d88a52-28ee-435e-98a9-794b8222d56b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_25d88a52-28ee-435e-98a9-794b8222d56b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_25d88a52-28ee-435e-98a9-794b8222d56b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_25d88a52-28ee-435e-98a9-794b8222d56b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_151765a1-3873-4b77-a1ba-2a54ac4f6a93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_25d88a52-28ee-435e-98a9-794b8222d56b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_151765a1-3873-4b77-a1ba-2a54ac4f6a93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SeniorNotesOneMember_a8226e67-ea01-43ee-8c7e-a692e659c922" xlink:href="rmd-20240630.xsd#rmd_SeniorNotesOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_151765a1-3873-4b77-a1ba-2a54ac4f6a93" xlink:to="loc_rmd_SeniorNotesOneMember_a8226e67-ea01-43ee-8c7e-a692e659c922" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SeniorNotesTwoMember_2f96c95b-6555-41b3-b0a8-0975e71db7c1" xlink:href="rmd-20240630.xsd#rmd_SeniorNotesTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_151765a1-3873-4b77-a1ba-2a54ac4f6a93" xlink:to="loc_rmd_SeniorNotesTwoMember_2f96c95b-6555-41b3-b0a8-0975e71db7c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_81a7bde8-b0cf-489b-9d80-f4bf6f374d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_151765a1-3873-4b77-a1ba-2a54ac4f6a93" xlink:to="loc_us-gaap_SeniorNotesMember_81a7bde8-b0cf-489b-9d80-f4bf6f374d0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember_fadf6103-3811-489c-aa62-d050b74b91e8" xlink:href="rmd-20240630.xsd#rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_151765a1-3873-4b77-a1ba-2a54ac4f6a93" xlink:to="loc_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember_fadf6103-3811-489c-aa62-d050b74b91e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dff4e2b5-5d49-4537-8f5f-d6d115cc4771" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dff4e2b5-5d49-4537-8f5f-d6d115cc4771" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_UncommittedOptionToIncreaseCreditFacility_1cf8b80c-86ec-4068-842e-e8efa7b7eb9c" xlink:href="rmd-20240630.xsd#rmd_UncommittedOptionToIncreaseCreditFacility"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_rmd_UncommittedOptionToIncreaseCreditFacility_1cf8b80c-86ec-4068-842e-e8efa7b7eb9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod_92fd3356-50ef-4eb3-a381-95de326da2bf" xlink:href="rmd-20240630.xsd#rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod_92fd3356-50ef-4eb3-a381-95de326da2bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_ae1aaeca-8cb4-412e-969c-88be4c16c715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_ae1aaeca-8cb4-412e-969c-88be4c16c715" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6904cead-5911-4b24-abea-4ab65eff940d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6904cead-5911-4b24-abea-4ab65eff940d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_05220260-b18b-481a-90c2-4bdb0abdb477" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_05220260-b18b-481a-90c2-4bdb0abdb477" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_868770e4-56ea-4cfc-9d51-50d40d3efbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_868770e4-56ea-4cfc-9d51-50d40d3efbd5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_c56c1315-b220-43cc-a652-fec8fb864651" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_c56c1315-b220-43cc-a652-fec8fb864651" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_db8df620-e422-42f8-a3e2-79c86b39c46b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_LongTermDebtFairValue_db8df620-e422-42f8-a3e2-79c86b39c46b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0cb21562-7428-4bd5-9aaf-5c331e3286c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0cb21562-7428-4bd5-9aaf-5c331e3286c1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f012ede8-e374-4aed-b41f-79e074b5cdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f012ede8-e374-4aed-b41f-79e074b5cdcb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DebtToConsolidatedEbitdaRatio_af77070c-ecd2-409a-b113-72a65c5e2e3e" xlink:href="rmd-20240630.xsd#rmd_DebtToConsolidatedEbitdaRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_rmd_DebtToConsolidatedEbitdaRatio_af77070c-ecd2-409a-b113-72a65c5e2e3e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany_b672f588-9940-4a93-ad78-86579f73d37a" xlink:href="rmd-20240630.xsd#rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany_b672f588-9940-4a93-ad78-86579f73d37a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_dd93af15-68d7-4fc6-a7af-81dcb4ef0c58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_SeniorNotes_dd93af15-68d7-4fc6-a7af-81dcb4ef0c58" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_0da2eb7c-1799-4647-a76b-feec93128e94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_0da2eb7c-1799-4647-a76b-feec93128e94" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b1456ab-a7a0-4f54-9ffa-e3743fb8b45d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f90e7953-dea4-486b-aeeb-3b1907828f41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b1456ab-a7a0-4f54-9ffa-e3743fb8b45d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f90e7953-dea4-486b-aeeb-3b1907828f41" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_76095d2d-2166-4a9b-bc4c-4aad4788fa46" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f90e7953-dea4-486b-aeeb-3b1907828f41" xlink:to="loc_srt_RangeAxis_76095d2d-2166-4a9b-bc4c-4aad4788fa46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_76095d2d-2166-4a9b-bc4c-4aad4788fa46_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_76095d2d-2166-4a9b-bc4c-4aad4788fa46" xlink:to="loc_srt_RangeMember_76095d2d-2166-4a9b-bc4c-4aad4788fa46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fa169afc-898f-4a5f-add2-90f2baa17ded" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_76095d2d-2166-4a9b-bc4c-4aad4788fa46" xlink:to="loc_srt_RangeMember_fa169afc-898f-4a5f-add2-90f2baa17ded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_87546844-9503-4f9b-83c0-560bd4f9b262" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fa169afc-898f-4a5f-add2-90f2baa17ded" xlink:to="loc_srt_MinimumMember_87546844-9503-4f9b-83c0-560bd4f9b262" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2dd9785c-65ba-4e8e-acc3-7a76e1fb39a0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fa169afc-898f-4a5f-add2-90f2baa17ded" xlink:to="loc_srt_MaximumMember_2dd9785c-65ba-4e8e-acc3-7a76e1fb39a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_457d2597-0b65-4d41-8140-f9aa7f523cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b1456ab-a7a0-4f54-9ffa-e3743fb8b45d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_457d2597-0b65-4d41-8140-f9aa7f523cc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_cfb47c4e-f54b-4760-8b7a-c35265481fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b1456ab-a7a0-4f54-9ffa-e3743fb8b45d" xlink:to="loc_us-gaap_OperatingLeaseCost_cfb47c4e-f54b-4760-8b7a-c35265481fe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_OperatingLeaseIncome_c3bb3e45-ddd9-4304-94f5-908f3ee898be" xlink:href="rmd-20240630.xsd#rmd_OperatingLeaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b1456ab-a7a0-4f54-9ffa-e3743fb8b45d" xlink:to="loc_rmd_OperatingLeaseIncome_c3bb3e45-ddd9-4304-94f5-908f3ee898be" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96bc1ce4-acb4-45e2-88e2-05eb1f3b1919" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96bc1ce4-acb4-45e2-88e2-05eb1f3b1919" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_52ba23b8-9917-4d19-ba84-df3e28a4cae7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96bc1ce4-acb4-45e2-88e2-05eb1f3b1919" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_52ba23b8-9917-4d19-ba84-df3e28a4cae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_52ba23b8-9917-4d19-ba84-df3e28a4cae7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_52ba23b8-9917-4d19-ba84-df3e28a4cae7" xlink:to="loc_us-gaap_EquityComponentDomain_52ba23b8-9917-4d19-ba84-df3e28a4cae7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5018edcb-c768-4456-9311-00f9645012fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_52ba23b8-9917-4d19-ba84-df3e28a4cae7" xlink:to="loc_us-gaap_EquityComponentDomain_5018edcb-c768-4456-9311-00f9645012fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_51f62df1-2315-4126-bac9-4c9826e52e97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5018edcb-c768-4456-9311-00f9645012fa" xlink:to="loc_us-gaap_TreasuryStockCommonMember_51f62df1-2315-4126-bac9-4c9826e52e97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5281cc39-7c6c-4d1c-9041-9b47c774ac82" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96bc1ce4-acb4-45e2-88e2-05eb1f3b1919" xlink:to="loc_srt_RangeAxis_5281cc39-7c6c-4d1c-9041-9b47c774ac82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5281cc39-7c6c-4d1c-9041-9b47c774ac82_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5281cc39-7c6c-4d1c-9041-9b47c774ac82" xlink:to="loc_srt_RangeMember_5281cc39-7c6c-4d1c-9041-9b47c774ac82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e628f9d4-15ae-4733-8ebf-e08c6c2e67ac" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5281cc39-7c6c-4d1c-9041-9b47c774ac82" xlink:to="loc_srt_RangeMember_e628f9d4-15ae-4733-8ebf-e08c6c2e67ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_902570af-5d30-4d67-ab85-52df80ea9ba0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e628f9d4-15ae-4733-8ebf-e08c6c2e67ac" xlink:to="loc_srt_MinimumMember_902570af-5d30-4d67-ab85-52df80ea9ba0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_308ee6fe-a0ae-4b50-85af-426681aea325" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e628f9d4-15ae-4733-8ebf-e08c6c2e67ac" xlink:to="loc_srt_MaximumMember_308ee6fe-a0ae-4b50-85af-426681aea325" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6a0f146f-ea52-4984-bf5e-2c88b79546c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96bc1ce4-acb4-45e2-88e2-05eb1f3b1919" xlink:to="loc_us-gaap_AwardTypeAxis_6a0f146f-ea52-4984-bf5e-2c88b79546c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a0f146f-ea52-4984-bf5e-2c88b79546c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6a0f146f-ea52-4984-bf5e-2c88b79546c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a0f146f-ea52-4984-bf5e-2c88b79546c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9c82b65-c3e6-4297-bc08-09b6aab9fc31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6a0f146f-ea52-4984-bf5e-2c88b79546c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9c82b65-c3e6-4297-bc08-09b6aab9fc31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_575e4f98-bb16-4ea8-94ec-2492d2339f62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9c82b65-c3e6-4297-bc08-09b6aab9fc31" xlink:to="loc_us-gaap_PerformanceSharesMember_575e4f98-bb16-4ea8-94ec-2492d2339f62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0db934ff-65a9-4245-9ba5-28d3a1b7a7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96bc1ce4-acb4-45e2-88e2-05eb1f3b1919" xlink:to="loc_us-gaap_PlanNameAxis_0db934ff-65a9-4245-9ba5-28d3a1b7a7f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0db934ff-65a9-4245-9ba5-28d3a1b7a7f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0db934ff-65a9-4245-9ba5-28d3a1b7a7f7" xlink:to="loc_us-gaap_PlanNameDomain_0db934ff-65a9-4245-9ba5-28d3a1b7a7f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d5da40ed-c762-4b97-a8e8-562341f79ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0db934ff-65a9-4245-9ba5-28d3a1b7a7f7" xlink:to="loc_us-gaap_PlanNameDomain_d5da40ed-c762-4b97-a8e8-562341f79ff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ResmedInc2009IncentiveAwardPlanMember_db3df6c8-9ba2-4cb8-83b3-a67a05e3c53d" xlink:href="rmd-20240630.xsd#rmd_ResmedInc2009IncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d5da40ed-c762-4b97-a8e8-562341f79ff3" xlink:to="loc_rmd_ResmedInc2009IncentiveAwardPlanMember_db3df6c8-9ba2-4cb8-83b3-a67a05e3c53d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AmendedAndRestated2009PlanMember_e7a44b62-5416-4818-9b53-f0fa4bb8d965" xlink:href="rmd-20240630.xsd#rmd_AmendedAndRestated2009PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d5da40ed-c762-4b97-a8e8-562341f79ff3" xlink:to="loc_rmd_AmendedAndRestated2009PlanMember_e7a44b62-5416-4818-9b53-f0fa4bb8d965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanMember_b2c6d0c9-d9ee-4dd6-bd3c-9a7991205058" xlink:href="rmd-20240630.xsd#rmd_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d5da40ed-c762-4b97-a8e8-562341f79ff3" xlink:to="loc_rmd_EmployeeStockPurchasePlanMember_b2c6d0c9-d9ee-4dd6-bd3c-9a7991205058" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_9903bdfa-8953-480a-8870-0a78991c8649" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96bc1ce4-acb4-45e2-88e2-05eb1f3b1919" xlink:to="loc_srt_TitleOfIndividualAxis_9903bdfa-8953-480a-8870-0a78991c8649" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9903bdfa-8953-480a-8870-0a78991c8649_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_9903bdfa-8953-480a-8870-0a78991c8649" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9903bdfa-8953-480a-8870-0a78991c8649_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fef3edfd-9acc-4115-87e6-93c626c45035" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_9903bdfa-8953-480a-8870-0a78991c8649" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fef3edfd-9acc-4115-87e6-93c626c45035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NonEmployeeDirectorMember_9fe3b5a2-1a3d-40d2-9e33-f6eeb8f8c25a" xlink:href="rmd-20240630.xsd#rmd_NonEmployeeDirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fef3edfd-9acc-4115-87e6-93c626c45035" xlink:to="loc_rmd_NonEmployeeDirectorMember_9fe3b5a2-1a3d-40d2-9e33-f6eeb8f8c25a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_13612247-aefe-469e-9618-84515909b3c2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fef3edfd-9acc-4115-87e6-93c626c45035" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_13612247-aefe-469e-9618-84515909b3c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_7d23a247-a93b-4631-bbbf-dca6860089be" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_7d23a247-a93b-4631-bbbf-dca6860089be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_88bf591f-7433-4f23-bbce-bde52ae5fa36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_88bf591f-7433-4f23-bbce-bde52ae5fa36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d73a96af-a8a6-4551-ad55-b12234be2453" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d73a96af-a8a6-4551-ad55-b12234be2453" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_d3fde2c1-c7ae-46f6-8ebb-89a0a9253a34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_TreasuryStockCommonShares_d3fde2c1-c7ae-46f6-8ebb-89a0a9253a34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_0136bfcf-a85f-4012-bd59-0509681d8646" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_TreasuryStockValue_0136bfcf-a85f-4012-bd59-0509681d8646" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_d6ba0f26-0e43-4c35-98a8-650823a9aadc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_d6ba0f26-0e43-4c35-98a8-650823a9aadc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_acd93573-eeb2-4fa6-80dd-2b1ad4604e46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_acd93573-eeb2-4fa6-80dd-2b1ad4604e46" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5e0b828f-3f84-4032-a221-51907f157119" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5e0b828f-3f84-4032-a221-51907f157119" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b8a08533-15c1-40fa-ba33-ddcabcf50aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b8a08533-15c1-40fa-ba33-ddcabcf50aeb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d9da85cc-2a8e-4989-8442-b7bed6e2d4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d9da85cc-2a8e-4989-8442-b7bed6e2d4fe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_02aa4af8-1e62-42fc-883f-e6d3ad908218" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_02aa4af8-1e62-42fc-883f-e6d3ad908218" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d30fbd40-e367-45a4-98a1-fd5451786d30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d30fbd40-e367-45a4-98a1-fd5451786d30" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_227df08d-251f-4a07-9151-15b97f3416d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_227df08d-251f-4a07-9151-15b97f3416d6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending_fe4d4444-4bf8-49f4-8372-bd518582b0da" xlink:href="rmd-20240630.xsd#rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending_fe4d4444-4bf8-49f4-8372-bd518582b0da" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned_b9b32d41-2945-4726-ad68-59cdde77c9e8" xlink:href="rmd-20240630.xsd#rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned_b9b32d41-2945-4726-ad68-59cdde77c9e8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted_88037020-3f35-4266-9a90-1d69db8a68ba" xlink:href="rmd-20240630.xsd#rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted_88037020-3f35-4266-9a90-1d69db8a68ba" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod_ae9c56e8-1f9d-43a9-949d-f78c5ae1e2e8" xlink:href="rmd-20240630.xsd#rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod_ae9c56e8-1f9d-43a9-949d-f78c5ae1e2e8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5c191c6e-6d9c-4bac-81ed-0e322b8162a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5c191c6e-6d9c-4bac-81ed-0e322b8162a4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1c713dbd-fa84-44d2-935e-ebc6ad27710a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1c713dbd-fa84-44d2-935e-ebc6ad27710a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance_b83f91eb-acc2-4880-b94d-8800af32ebfd" xlink:href="rmd-20240630.xsd#rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance_b83f91eb-acc2-4880-b94d-8800af32ebfd" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards_a72b7692-ceb0-46a2-8946-753031acb364" xlink:href="rmd-20240630.xsd#rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards_a72b7692-ceb0-46a2-8946-753031acb364" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MaximumNumberOfSharesSubjectToAwardsGranted_1d85f1f8-e361-4b87-8ea6-4100da3b30e5" xlink:href="rmd-20240630.xsd#rmd_MaximumNumberOfSharesSubjectToAwardsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_MaximumNumberOfSharesSubjectToAwardsGranted_1d85f1f8-e361-4b87-8ea6-4100da3b30e5" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NumberOfCommonStockGranted_1b35c224-a876-4661-a395-e8f844969e5d" xlink:href="rmd-20240630.xsd#rmd_NumberOfCommonStockGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_NumberOfCommonStockGranted_1b35c224-a876-4661-a395-e8f844969e5d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_6d38974d-bcb3-4f8c-8c9b-a42f26664336" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_6d38974d-bcb3-4f8c-8c9b-a42f26664336" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bdcf879c-1cb5-46cc-9545-f55141bee7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bdcf879c-1cb5-46cc-9545-f55141bee7ac" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7921e869-1768-474a-bca4-97be59214f92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7921e869-1768-474a-bca4-97be59214f92" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f2712394-28e9-479d-903d-097be763479e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f2712394-28e9-479d-903d-097be763479e" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_6bb927d5-4ffb-435b-991b-d3441fa91976" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_6bb927d5-4ffb-435b-991b-d3441fa91976" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanOfferingPeriod_b72ce27f-2895-42c8-9b3c-1ae12d3dd232" xlink:href="rmd-20240630.xsd#rmd_EmployeeStockPurchasePlanOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_EmployeeStockPurchasePlanOfferingPeriod_b72ce27f-2895-42c8-9b3c-1ae12d3dd232" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant_baf86332-e3cf-46b1-ba3e-800355088169" xlink:href="rmd-20240630.xsd#rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant_baf86332-e3cf-46b1-ba3e-800355088169" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase_fcdd1bde-1c2b-4933-a22e-19f022334cc1" xlink:href="rmd-20240630.xsd#rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase_fcdd1bde-1c2b-4933-a22e-19f022334cc1" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_0440ec7c-2824-48c6-a25f-d38c5a88dc1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesSubscriptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_0440ec7c-2824-48c6-a25f-d38c5a88dc1d" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f486a728-371a-4a7a-9451-2800e52ce12e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f486a728-371a-4a7a-9451-2800e52ce12e" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NumberOfOfferings_509eb831-36e3-451f-9ee3-919e22d0b006" xlink:href="rmd-20240630.xsd#rmd_NumberOfOfferings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_NumberOfOfferings_509eb831-36e3-451f-9ee3-919e22d0b006" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_42bb17bd-2fb6-4c3d-8203-cbcd15cebb83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_42bb17bd-2fb6-4c3d-8203-cbcd15cebb83" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bfe57d63-fd48-4e59-b460-ac7db48cf2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bfe57d63-fd48-4e59-b460-ac7db48cf2b3" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e38ee36c-d8ad-4025-bb30-3e73a2bf96df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e38ee36c-d8ad-4025-bb30-3e73a2bf96df" xlink:type="arc" order="36"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d34fbfe-39aa-4e5e-8511-bfcf1aa88cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73ed38d2-e5b0-4de1-9b15-8421f2779be3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d34fbfe-39aa-4e5e-8511-bfcf1aa88cdf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73ed38d2-e5b0-4de1-9b15-8421f2779be3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8a3f249e-fb40-4230-a51d-125f4e337a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73ed38d2-e5b0-4de1-9b15-8421f2779be3" xlink:to="loc_us-gaap_AwardTypeAxis_8a3f249e-fb40-4230-a51d-125f4e337a5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a3f249e-fb40-4230-a51d-125f4e337a5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8a3f249e-fb40-4230-a51d-125f4e337a5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a3f249e-fb40-4230-a51d-125f4e337a5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15859ad4-ee26-4a97-9461-4c5dd46870ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8a3f249e-fb40-4230-a51d-125f4e337a5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15859ad4-ee26-4a97-9461-4c5dd46870ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_839fc8a2-db9b-4c66-81e6-a9644cfd2519" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15859ad4-ee26-4a97-9461-4c5dd46870ae" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_839fc8a2-db9b-4c66-81e6-a9644cfd2519" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0276bda0-fe6d-4b26-a846-ab648ebeac4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d34fbfe-39aa-4e5e-8511-bfcf1aa88cdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0276bda0-fe6d-4b26-a846-ab648ebeac4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_746758b3-5cfe-4cf4-af86-ecd220db093d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0276bda0-fe6d-4b26-a846-ab648ebeac4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_746758b3-5cfe-4cf4-af86-ecd220db093d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d4d4d27a-260a-4c51-84f9-609866f8629d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0276bda0-fe6d-4b26-a846-ab648ebeac4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d4d4d27a-260a-4c51-84f9-609866f8629d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_966b345f-02a3-401d-9c9e-9e4b5bc0d2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0276bda0-fe6d-4b26-a846-ab648ebeac4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_966b345f-02a3-401d-9c9e-9e4b5bc0d2b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5736eea4-9b09-4a39-9c9b-0b30f82d92b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0276bda0-fe6d-4b26-a846-ab648ebeac4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5736eea4-9b09-4a39-9c9b-0b30f82d92b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3035450f-5dd1-4824-af91-e885dd97cf60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d06c7a5f-7cc7-4fa7-b41b-4b55279242f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d34fbfe-39aa-4e5e-8511-bfcf1aa88cdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d06c7a5f-7cc7-4fa7-b41b-4b55279242f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e7dde711-25be-460c-b7a1-47f85814808e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d06c7a5f-7cc7-4fa7-b41b-4b55279242f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e7dde711-25be-460c-b7a1-47f85814808e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0070669b-a8cd-4120-953d-d8bda6dd9f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d06c7a5f-7cc7-4fa7-b41b-4b55279242f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0070669b-a8cd-4120-953d-d8bda6dd9f4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_058d10fb-b736-44d3-8418-9ea9d6b50d03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d06c7a5f-7cc7-4fa7-b41b-4b55279242f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_058d10fb-b736-44d3-8418-9ea9d6b50d03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_77a87cdc-caa9-4b25-a0e9-48f48c1c2878" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d06c7a5f-7cc7-4fa7-b41b-4b55279242f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_77a87cdc-caa9-4b25-a0e9-48f48c1c2878" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_abb1a736-f14f-4832-83fb-664a47883dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e624e4e9-5442-4f43-a465-161df90b6d29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d34fbfe-39aa-4e5e-8511-bfcf1aa88cdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e624e4e9-5442-4f43-a465-161df90b6d29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_fe7b4c5b-24d9-4511-b1f7-5d5b80d53463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e624e4e9-5442-4f43-a465-161df90b6d29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_fe7b4c5b-24d9-4511-b1f7-5d5b80d53463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d1b07ea2-e86c-43a5-a6da-0467fe4630c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d34fbfe-39aa-4e5e-8511-bfcf1aa88cdf" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d1b07ea2-e86c-43a5-a6da-0467fe4630c9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#StockholdersEquityScheduleofOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b71a893e-423e-4a61-aef2-bab448639a93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c88aa0e0-919c-4adf-ba0a-4d6f941653aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b71a893e-423e-4a61-aef2-bab448639a93" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c88aa0e0-919c-4adf-ba0a-4d6f941653aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2617011b-8c6d-4e70-baf6-6414966c5000" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c88aa0e0-919c-4adf-ba0a-4d6f941653aa" xlink:to="loc_us-gaap_AwardTypeAxis_2617011b-8c6d-4e70-baf6-6414966c5000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2617011b-8c6d-4e70-baf6-6414966c5000_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2617011b-8c6d-4e70-baf6-6414966c5000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2617011b-8c6d-4e70-baf6-6414966c5000_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d420b779-3580-43ae-9f50-3a287cdd6950" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2617011b-8c6d-4e70-baf6-6414966c5000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d420b779-3580-43ae-9f50-3a287cdd6950" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6cc7b2cc-427a-4b29-a1ce-d639e13029d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d420b779-3580-43ae-9f50-3a287cdd6950" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6cc7b2cc-427a-4b29-a1ce-d639e13029d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_3747730b-b0f9-4d38-9d4e-6a0b6266a572" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b71a893e-423e-4a61-aef2-bab448639a93" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_3747730b-b0f9-4d38-9d4e-6a0b6266a572" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_188e773a-b538-45a3-a715-ef230b719ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_655adde8-ea60-49a0-b1ab-89fb076e6eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_188e773a-b538-45a3-a715-ef230b719ecf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_655adde8-ea60-49a0-b1ab-89fb076e6eb7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7a5be749-6007-438f-8413-f32c4e179f01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_655adde8-ea60-49a0-b1ab-89fb076e6eb7" xlink:to="loc_us-gaap_AwardTypeAxis_7a5be749-6007-438f-8413-f32c4e179f01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a5be749-6007-438f-8413-f32c4e179f01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7a5be749-6007-438f-8413-f32c4e179f01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7a5be749-6007-438f-8413-f32c4e179f01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aed3294d-36fd-44d1-bd80-60311e72c9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7a5be749-6007-438f-8413-f32c4e179f01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aed3294d-36fd-44d1-bd80-60311e72c9c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_75dc7e54-eec6-493c-aa0c-9cf007a7164a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aed3294d-36fd-44d1-bd80-60311e72c9c5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_75dc7e54-eec6-493c-aa0c-9cf007a7164a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanPurchaseRightsMember_fa5dffc9-6c99-48ec-97f7-7610330eac9b" xlink:href="rmd-20240630.xsd#rmd_EmployeeStockPurchasePlanPurchaseRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aed3294d-36fd-44d1-bd80-60311e72c9c5" xlink:to="loc_rmd_EmployeeStockPurchasePlanPurchaseRightsMember_fa5dffc9-6c99-48ec-97f7-7610330eac9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1dbea0e8-314b-4f47-9d35-3914ade227a4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_655adde8-ea60-49a0-b1ab-89fb076e6eb7" xlink:to="loc_srt_RangeAxis_1dbea0e8-314b-4f47-9d35-3914ade227a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1dbea0e8-314b-4f47-9d35-3914ade227a4_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1dbea0e8-314b-4f47-9d35-3914ade227a4" xlink:to="loc_srt_RangeMember_1dbea0e8-314b-4f47-9d35-3914ade227a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_918f62dc-9880-4e71-a747-3bac895693aa" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1dbea0e8-314b-4f47-9d35-3914ade227a4" xlink:to="loc_srt_RangeMember_918f62dc-9880-4e71-a747-3bac895693aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b76be656-01b8-4b3b-b2bf-edc0dc90511e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_918f62dc-9880-4e71-a747-3bac895693aa" xlink:to="loc_srt_MinimumMember_b76be656-01b8-4b3b-b2bf-edc0dc90511e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aecf968c-c696-4412-8d98-ba0a2b04917e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_918f62dc-9880-4e71-a747-3bac895693aa" xlink:to="loc_srt_MaximumMember_aecf968c-c696-4412-8d98-ba0a2b04917e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1c29a54b-9c52-411f-9eb1-273b38504097" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_188e773a-b538-45a3-a715-ef230b719ecf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1c29a54b-9c52-411f-9eb1-273b38504097" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ffb280ab-7bfb-432a-91eb-9cd8badf790e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_188e773a-b538-45a3-a715-ef230b719ecf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ffb280ab-7bfb-432a-91eb-9cd8badf790e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d092f9f3-41d7-4d66-b1b8-a07374d2acd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_188e773a-b538-45a3-a715-ef230b719ecf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d092f9f3-41d7-4d66-b1b8-a07374d2acd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2bc63481-1731-4694-ada6-20471d12da1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_188e773a-b538-45a3-a715-ef230b719ecf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2bc63481-1731-4694-ada6-20471d12da1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_94701267-2a4e-498d-ad59-d88f0d33a7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_188e773a-b538-45a3-a715-ef230b719ecf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_94701267-2a4e-498d-ad59-d88f0d33a7ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d2a7092b-e2c1-4768-ba27-4c9977c1206a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_188e773a-b538-45a3-a715-ef230b719ecf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d2a7092b-e2c1-4768-ba27-4c9977c1206a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_321cc1cd-4ebd-440b-9ec0-9182bba7d507" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_188e773a-b538-45a3-a715-ef230b719ecf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_321cc1cd-4ebd-440b-9ec0-9182bba7d507" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ee409319-ff7c-41c5-93d8-2affd571a1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_251c08c0-8c6d-4e09-b20c-7a46d1c799d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ee409319-ff7c-41c5-93d8-2affd571a1ee" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_251c08c0-8c6d-4e09-b20c-7a46d1c799d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_db49bbca-910f-4f51-af99-1c88c26281e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_251c08c0-8c6d-4e09-b20c-7a46d1c799d6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_db49bbca-910f-4f51-af99-1c88c26281e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_db49bbca-910f-4f51-af99-1c88c26281e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_db49bbca-910f-4f51-af99-1c88c26281e3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_db49bbca-910f-4f51-af99-1c88c26281e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d181793f-090d-484d-90f1-3f7a66a68b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_db49bbca-910f-4f51-af99-1c88c26281e3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d181793f-090d-484d-90f1-3f7a66a68b7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_f530e050-fba3-4d02-9c43-83ad099bcd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d181793f-090d-484d-90f1-3f7a66a68b7d" xlink:to="loc_us-gaap_CostOfSalesMember_f530e050-fba3-4d02-9c43-83ad099bcd7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d8408bc8-ff66-44e7-b86c-112a34a39dce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d181793f-090d-484d-90f1-3f7a66a68b7d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d8408bc8-ff66-44e7-b86c-112a34a39dce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1ccc094e-8aa2-4dca-80ee-74036e5e8d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d181793f-090d-484d-90f1-3f7a66a68b7d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1ccc094e-8aa2-4dca-80ee-74036e5e8d0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_db28bcc1-e22c-4532-abf9-929433a139c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ee409319-ff7c-41c5-93d8-2affd571a1ee" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_db28bcc1-e22c-4532-abf9-929433a139c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_f52fe688-c279-4337-977c-fe22b2ee0d23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ee409319-ff7c-41c5-93d8-2affd571a1ee" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_f52fe688-c279-4337-977c-fe22b2ee0d23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_50f4f20e-2e52-4acb-99c4-3396892df809" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ee409319-ff7c-41c5-93d8-2affd571a1ee" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_50f4f20e-2e52-4acb-99c4-3396892df809" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:href="rmd-20240630.xsd#rmd_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxesTable_66361024-1a53-4fa1-b1ec-b1261d4a8dd9" xlink:href="rmd-20240630.xsd#rmd_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_rmd_IncomeTaxesTable_66361024-1a53-4fa1-b1ec-b1261d4a8dd9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_481e6742-f83f-427c-b4ae-b2416806cfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmd_IncomeTaxesTable_66361024-1a53-4fa1-b1ec-b1261d4a8dd9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_481e6742-f83f-427c-b4ae-b2416806cfc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_481e6742-f83f-427c-b4ae-b2416806cfc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_481e6742-f83f-427c-b4ae-b2416806cfc1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_481e6742-f83f-427c-b4ae-b2416806cfc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_4b10ef4d-5670-43df-9733-02ca962f9b67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_481e6742-f83f-427c-b4ae-b2416806cfc1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_4b10ef4d-5670-43df-9733-02ca962f9b67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember_67d25774-3d10-4ce0-9221-473b656b4e35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_4b10ef4d-5670-43df-9733-02ca962f9b67" xlink:to="loc_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember_67d25774-3d10-4ce0-9221-473b656b4e35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6c6661c9-d3c8-4845-a40a-0b9891f38c45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmd_IncomeTaxesTable_66361024-1a53-4fa1-b1ec-b1261d4a8dd9" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6c6661c9-d3c8-4845-a40a-0b9891f38c45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6c6661c9-d3c8-4845-a40a-0b9891f38c45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6c6661c9-d3c8-4845-a40a-0b9891f38c45" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6c6661c9-d3c8-4845-a40a-0b9891f38c45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2a922223-be5f-44ab-a516-7c3ec8766426" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6c6661c9-d3c8-4845-a40a-0b9891f38c45" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2a922223-be5f-44ab-a516-7c3ec8766426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_6ce2279c-b48d-4d89-82ac-4c3e3df8d043" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2a922223-be5f-44ab-a516-7c3ec8766426" xlink:to="loc_us-gaap_DomesticCountryMember_6ce2279c-b48d-4d89-82ac-4c3e3df8d043" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_d3e42038-ec13-4d90-8e7c-97c62e5a9f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2a922223-be5f-44ab-a516-7c3ec8766426" xlink:to="loc_us-gaap_ForeignCountryMember_d3e42038-ec13-4d90-8e7c-97c62e5a9f4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_e1cd2466-1e54-457b-891a-d2b5b5a5eb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2a922223-be5f-44ab-a516-7c3ec8766426" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_e1cd2466-1e54-457b-891a-d2b5b5a5eb4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_5b1865cf-705d-414e-925d-e618bd171f16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmd_IncomeTaxesTable_66361024-1a53-4fa1-b1ec-b1261d4a8dd9" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_5b1865cf-705d-414e-925d-e618bd171f16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_5b1865cf-705d-414e-925d-e618bd171f16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_5b1865cf-705d-414e-925d-e618bd171f16" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_5b1865cf-705d-414e-925d-e618bd171f16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_fc9e223b-3554-4b45-b1f2-562e58ac508b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_5b1865cf-705d-414e-925d-e618bd171f16" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_fc9e223b-3554-4b45-b1f2-562e58ac508b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_2fd9702a-a524-44a3-9365-789e4bb83449" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_fc9e223b-3554-4b45-b1f2-562e58ac508b" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_2fd9702a-a524-44a3-9365-789e4bb83449" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_9ab0a451-9efe-49ae-a0a9-09bfd016df8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_us-gaap_OperatingLossCarryforwards_9ab0a451-9efe-49ae-a0a9-09bfd016df8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_OperatingLossCarryforwardsCapitalLoss_5bb06a41-0c60-49fd-a56e-6493c8e64652" xlink:href="rmd-20240630.xsd#rmd_OperatingLossCarryforwardsCapitalLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_rmd_OperatingLossCarryforwardsCapitalLoss_5bb06a41-0c60-49fd-a56e-6493c8e64652" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayAggregateDollarAmount_4d762337-ce0c-4704-bf69-5a473636862d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayAggregateDollarAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_us-gaap_IncomeTaxHolidayAggregateDollarAmount_4d762337-ce0c-4704-bf69-5a473636862d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_dafdc0b4-21d5-4d01-a351-4c3ed5988f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_dafdc0b4-21d5-4d01-a351-4c3ed5988f4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_6b98ed08-f966-4647-a938-b63d7d2ad292" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_6b98ed08-f966-4647-a938-b63d7d2ad292" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries_52a057ad-89b4-4bdb-857f-1faf7b84b575" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries_52a057ad-89b4-4bdb-857f-1faf7b84b575" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition_9c774fe0-f491-4fc6-afba-f7c311bd58e7" xlink:href="rmd-20240630.xsd#rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition_9c774fe0-f491-4fc6-afba-f7c311bd58e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationNetImpactOfSettlement_e3636928-1769-4bd9-8595-d93dc0c4c072" xlink:href="rmd-20240630.xsd#rmd_IncomeTaxExaminationNetImpactOfSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_rmd_IncomeTaxExaminationNetImpactOfSettlement_e3636928-1769-4bd9-8595-d93dc0c4c072" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationGrossSettlement_542fefb4-c724-417a-a619-e2004ba2d19d" xlink:href="rmd-20240630.xsd#rmd_IncomeTaxExaminationGrossSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_rmd_IncomeTaxExaminationGrossSettlement_542fefb4-c724-417a-a619-e2004ba2d19d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_9ff51691-756c-403e-9897-bdf966a1d145" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_9ff51691-756c-403e-9897-bdf966a1d145" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_08eb6eaf-52f5-44a7-b6b6-c6f591f96f35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_08eb6eaf-52f5-44a7-b6b6-c6f591f96f35" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_a119870c-3f00-4a67-bbb2-6119e50a3eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_a119870c-3f00-4a67-bbb2-6119e50a3eb0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_ceba410d-706b-4e95-9ef7-d91b488ae735" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_ceba410d-706b-4e95-9ef7-d91b488ae735" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationRemittedFinalPayment_dc5a0983-1bc9-4270-a2be-a3dd5c079727" xlink:href="rmd-20240630.xsd#rmd_IncomeTaxExaminationRemittedFinalPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_rmd_IncomeTaxExaminationRemittedFinalPayment_dc5a0983-1bc9-4270-a2be-a3dd5c079727" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationPriorRemittancePayments_131b1208-c1c3-4e46-9f8a-c0796cd9d3ef" xlink:href="rmd-20240630.xsd#rmd_IncomeTaxExaminationPriorRemittancePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_rmd_IncomeTaxExaminationPriorRemittancePayments_131b1208-c1c3-4e46-9f8a-c0796cd9d3ef" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d23f0a09-3dc5-4275-9f7a-ae683cb741f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d23f0a09-3dc5-4275-9f7a-ae683cb741f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_03b1592d-d63b-4fca-bc63-0c5f3b7433e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d23f0a09-3dc5-4275-9f7a-ae683cb741f7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_03b1592d-d63b-4fca-bc63-0c5f3b7433e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_03b1592d-d63b-4fca-bc63-0c5f3b7433e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_03b1592d-d63b-4fca-bc63-0c5f3b7433e0" xlink:to="loc_us-gaap_SegmentDomain_03b1592d-d63b-4fca-bc63-0c5f3b7433e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_844d7fc2-44ef-424f-9a90-26405156553b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_03b1592d-d63b-4fca-bc63-0c5f3b7433e0" xlink:to="loc_us-gaap_SegmentDomain_844d7fc2-44ef-424f-9a90-26405156553b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SleepAndRespiratoryMember_d0a0c775-6e52-402a-909d-694d69bb5057" xlink:href="rmd-20240630.xsd#rmd_SleepAndRespiratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_844d7fc2-44ef-424f-9a90-26405156553b" xlink:to="loc_rmd_SleepAndRespiratoryMember_d0a0c775-6e52-402a-909d-694d69bb5057" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SoftwareAsAServiceMember_cd75f9d9-3c8d-4f10-9c87-3855a5fae772" xlink:href="rmd-20240630.xsd#rmd_SoftwareAsAServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_844d7fc2-44ef-424f-9a90-26405156553b" xlink:to="loc_rmd_SoftwareAsAServiceMember_cd75f9d9-3c8d-4f10-9c87-3855a5fae772" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a94cbd71-efa4-4826-90cb-4880989d114d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d23f0a09-3dc5-4275-9f7a-ae683cb741f7" xlink:to="loc_srt_ConsolidationItemsAxis_a94cbd71-efa4-4826-90cb-4880989d114d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a94cbd71-efa4-4826-90cb-4880989d114d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_a94cbd71-efa4-4826-90cb-4880989d114d" xlink:to="loc_srt_ConsolidationItemsDomain_a94cbd71-efa4-4826-90cb-4880989d114d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ba4adeae-6a3c-469d-8b67-e0e919667818" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_a94cbd71-efa4-4826-90cb-4880989d114d" xlink:to="loc_srt_ConsolidationItemsDomain_ba4adeae-6a3c-469d-8b67-e0e919667818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_06fbe9c7-037b-4d8f-b945-68ad503c19ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ba4adeae-6a3c-469d-8b67-e0e919667818" xlink:to="loc_us-gaap_OperatingSegmentsMember_06fbe9c7-037b-4d8f-b945-68ad503c19ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_91d269e5-0cd6-451a-a1fd-a30ec6e561e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ba4adeae-6a3c-469d-8b67-e0e919667818" xlink:to="loc_us-gaap_CorporateNonSegmentMember_91d269e5-0cd6-451a-a1fd-a30ec6e561e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_7ab0ebc6-c416-4eaa-8b3a-a1d5122b6a55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ba4adeae-6a3c-469d-8b67-e0e919667818" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_7ab0ebc6-c416-4eaa-8b3a-a1d5122b6a55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f54631d3-7c5d-4183-a912-1cf71cd70c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f54631d3-7c5d-4183-a912-1cf71cd70c8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b8c3f895-48ac-47a2-b7a2-eb8a0b712fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b8c3f895-48ac-47a2-b7a2-eb8a0b712fc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1e0929ff-4b84-4858-8994-7cc872f420ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_OperatingIncomeLoss_1e0929ff-4b84-4858-8994-7cc872f420ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_UnallocatedCorporateCosts_4c3d11dd-b3bf-4d62-bb0e-76c06e03061f" xlink:href="rmd-20240630.xsd#rmd_UnallocatedCorporateCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_rmd_UnallocatedCorporateCosts_4c3d11dd-b3bf-4d62-bb0e-76c06e03061f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_1ff32ba1-3204-43be-98a3-39c79bff75ea" xlink:href="rmd-20240630.xsd#rmd_AmortizationOfAcquiredIntangibleAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_1ff32ba1-3204-43be-98a3-39c79bff75ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_fd1b95e4-7674-4a56-8dd7-242c3d89c131" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_RestructuringCharges_fd1b95e4-7674-4a56-8dd7-242c3d89c131" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MasksWithMagnetsFieldSafetyNotificationExpenses_051ad45e-f587-4c1a-8069-e6739ddfc33d" xlink:href="rmd-20240630.xsd#rmd_MasksWithMagnetsFieldSafetyNotificationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_rmd_MasksWithMagnetsFieldSafetyNotificationExpenses_051ad45e-f587-4c1a-8069-e6739ddfc33d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AstralFieldActionNotificationExpenses_94a141ec-79de-452b-97ab-814f6a20d6d8" xlink:href="rmd-20240630.xsd#rmd_AstralFieldActionNotificationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_rmd_AstralFieldActionNotificationExpenses_94a141ec-79de-452b-97ab-814f6a20d6d8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_53742c76-df95-4001-a191-d0c81bb3573a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_53742c76-df95-4001-a191-d0c81bb3573a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_685c6bd7-50cd-4bf4-97d7-134205b50986" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_685c6bd7-50cd-4bf4-97d7-134205b50986" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_833258a3-0bcf-4564-89a5-7250a0542674" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_833258a3-0bcf-4564-89a5-7250a0542674" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_80f4de25-bca4-43b0-88c1-0abef84bca49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_80f4de25-bca4-43b0-88c1-0abef84bca49" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_c7d9e575-2aac-44fb-9c8f-2398b5edc342" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainOnBusinessInterruptionInsuranceRecovery"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_c7d9e575-2aac-44fb-9c8f-2398b5edc342" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_207e0af0-c5cf-4d30-be6d-697598acc806" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_207e0af0-c5cf-4d30-be6d-697598acc806" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4dcebc50-14d2-4c31-b72d-a4f415c1b5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4dcebc50-14d2-4c31-b72d-a4f415c1b5cf" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_6fee23f8-62e5-4631-a518-4ba22f51ccba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_6fee23f8-62e5-4631-a518-4ba22f51ccba" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_885d7223-b9e1-4290-a704-3616816db8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84dc1abf-3719-413b-ae18-4fc565451c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_885d7223-b9e1-4290-a704-3616816db8a8" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84dc1abf-3719-413b-ae18-4fc565451c0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_cc2eb0a7-bbd8-4fbf-ac9b-2f1a14ccce88" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84dc1abf-3719-413b-ae18-4fc565451c0d" xlink:to="loc_srt_ConsolidationItemsAxis_cc2eb0a7-bbd8-4fbf-ac9b-2f1a14ccce88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_cc2eb0a7-bbd8-4fbf-ac9b-2f1a14ccce88_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_cc2eb0a7-bbd8-4fbf-ac9b-2f1a14ccce88" xlink:to="loc_srt_ConsolidationItemsDomain_cc2eb0a7-bbd8-4fbf-ac9b-2f1a14ccce88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_48f4a769-82cb-4ef7-9696-2afd5596b238" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_cc2eb0a7-bbd8-4fbf-ac9b-2f1a14ccce88" xlink:to="loc_srt_ConsolidationItemsDomain_48f4a769-82cb-4ef7-9696-2afd5596b238" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_bad2779c-c8c5-4af1-a33b-aeabd4eaf3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_48f4a769-82cb-4ef7-9696-2afd5596b238" xlink:to="loc_us-gaap_OperatingSegmentsMember_bad2779c-c8c5-4af1-a33b-aeabd4eaf3b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5f00c5f7-869e-4527-b00b-fe5a783eb24a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84dc1abf-3719-413b-ae18-4fc565451c0d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5f00c5f7-869e-4527-b00b-fe5a783eb24a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5f00c5f7-869e-4527-b00b-fe5a783eb24a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5f00c5f7-869e-4527-b00b-fe5a783eb24a" xlink:to="loc_us-gaap_SegmentDomain_5f00c5f7-869e-4527-b00b-fe5a783eb24a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_deb00973-1a70-4eb2-b7d3-15f317255b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5f00c5f7-869e-4527-b00b-fe5a783eb24a" xlink:to="loc_us-gaap_SegmentDomain_deb00973-1a70-4eb2-b7d3-15f317255b5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SleepAndRespiratoryMember_9de63d4b-9ac9-4812-b8f2-af65dffc5af6" xlink:href="rmd-20240630.xsd#rmd_SleepAndRespiratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_deb00973-1a70-4eb2-b7d3-15f317255b5d" xlink:to="loc_rmd_SleepAndRespiratoryMember_9de63d4b-9ac9-4812-b8f2-af65dffc5af6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SoftwareAsAServiceMember_b96a415c-d506-4814-b5b6-518dcb395fe9" xlink:href="rmd-20240630.xsd#rmd_SoftwareAsAServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_deb00973-1a70-4eb2-b7d3-15f317255b5d" xlink:to="loc_rmd_SoftwareAsAServiceMember_b96a415c-d506-4814-b5b6-518dcb395fe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6a45b008-986a-4768-81c8-8d6db1be6a89" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84dc1abf-3719-413b-ae18-4fc565451c0d" xlink:to="loc_srt_StatementGeographicalAxis_6a45b008-986a-4768-81c8-8d6db1be6a89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6a45b008-986a-4768-81c8-8d6db1be6a89_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6a45b008-986a-4768-81c8-8d6db1be6a89" xlink:to="loc_srt_SegmentGeographicalDomain_6a45b008-986a-4768-81c8-8d6db1be6a89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4e8a70da-16f0-4324-8f8f-b7ae15208e51" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6a45b008-986a-4768-81c8-8d6db1be6a89" xlink:to="loc_srt_SegmentGeographicalDomain_4e8a70da-16f0-4324-8f8f-b7ae15208e51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_U.s.CanadaAndLatinAmericaMember_b46abb1b-620c-4fac-a251-7c760a513daf" xlink:href="rmd-20240630.xsd#rmd_U.s.CanadaAndLatinAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4e8a70da-16f0-4324-8f8f-b7ae15208e51" xlink:to="loc_rmd_U.s.CanadaAndLatinAmericaMember_b46abb1b-620c-4fac-a251-7c760a513daf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_CombinedEuropeAsiaAndOtherMarketsMember_c5bcd357-894d-49b7-be11-d797c0b40369" xlink:href="rmd-20240630.xsd#rmd_CombinedEuropeAsiaAndOtherMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4e8a70da-16f0-4324-8f8f-b7ae15208e51" xlink:to="loc_rmd_CombinedEuropeAsiaAndOtherMarketsMember_c5bcd357-894d-49b7-be11-d797c0b40369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_GlobalMember_2837b918-728c-4411-9033-b29be81f3ad5" xlink:href="rmd-20240630.xsd#rmd_GlobalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4e8a70da-16f0-4324-8f8f-b7ae15208e51" xlink:to="loc_rmd_GlobalMember_2837b918-728c-4411-9033-b29be81f3ad5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_aea48372-34a6-4090-aba8-40c65ed664c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84dc1abf-3719-413b-ae18-4fc565451c0d" xlink:to="loc_us-gaap_SubsegmentsAxis_aea48372-34a6-4090-aba8-40c65ed664c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_aea48372-34a6-4090-aba8-40c65ed664c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_aea48372-34a6-4090-aba8-40c65ed664c7" xlink:to="loc_us-gaap_SubsegmentsDomain_aea48372-34a6-4090-aba8-40c65ed664c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_ddc1bd91-ad4d-4866-a2cb-c31a0f5671b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_aea48372-34a6-4090-aba8-40c65ed664c7" xlink:to="loc_us-gaap_SubsegmentsDomain_ddc1bd91-ad4d-4866-a2cb-c31a0f5671b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DevicesMember_7104e9c0-81ed-4ab9-8348-a4b46d9b463e" xlink:href="rmd-20240630.xsd#rmd_DevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_ddc1bd91-ad4d-4866-a2cb-c31a0f5671b6" xlink:to="loc_rmd_DevicesMember_7104e9c0-81ed-4ab9-8348-a4b46d9b463e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MasksAndOtherMember_27473781-e9bb-42f7-a09d-7ba886a5fa2e" xlink:href="rmd-20240630.xsd#rmd_MasksAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_ddc1bd91-ad4d-4866-a2cb-c31a0f5671b6" xlink:to="loc_rmd_MasksAndOtherMember_27473781-e9bb-42f7-a09d-7ba886a5fa2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b9025508-5005-4434-be1e-f935016d874c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_885d7223-b9e1-4290-a704-3616816db8a8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b9025508-5005-4434-be1e-f935016d874c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebyGeographicAreaDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SegmentInformationScheduleofRevenuebyGeographicAreaDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_392bc726-4275-408c-8b07-4d5956dc0ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_416d3018-ed34-4cbe-a514-d20f81c159d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_392bc726-4275-408c-8b07-4d5956dc0ffa" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_416d3018-ed34-4cbe-a514-d20f81c159d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cd82ef3f-a1ea-42f1-9f61-ff871438c136" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_416d3018-ed34-4cbe-a514-d20f81c159d4" xlink:to="loc_srt_StatementGeographicalAxis_cd82ef3f-a1ea-42f1-9f61-ff871438c136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cd82ef3f-a1ea-42f1-9f61-ff871438c136_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_cd82ef3f-a1ea-42f1-9f61-ff871438c136" xlink:to="loc_srt_SegmentGeographicalDomain_cd82ef3f-a1ea-42f1-9f61-ff871438c136_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_46c17ef1-2b6a-4c65-9556-00674a372906" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_cd82ef3f-a1ea-42f1-9f61-ff871438c136" xlink:to="loc_srt_SegmentGeographicalDomain_46c17ef1-2b6a-4c65-9556-00674a372906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1958a950-414f-4188-b139-c04322ac39e3" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_46c17ef1-2b6a-4c65-9556-00674a372906" xlink:to="loc_country_US_1958a950-414f-4188-b139-c04322ac39e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RestOfWorldMember_4c0aa24f-f1d1-46b1-b9ba-03f095586c41" xlink:href="rmd-20240630.xsd#rmd_RestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_46c17ef1-2b6a-4c65-9556-00674a372906" xlink:to="loc_rmd_RestOfWorldMember_4c0aa24f-f1d1-46b1-b9ba-03f095586c41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94565a6c-a829-44d6-bc99-5e57d3ff2d40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_392bc726-4275-408c-8b07-4d5956dc0ffa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94565a6c-a829-44d6-bc99-5e57d3ff2d40" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationScheduleofLongLivedAssetsbyGeographicAreasDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SegmentInformationScheduleofLongLivedAssetsbyGeographicAreasDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/SegmentInformationScheduleofLongLivedAssetsbyGeographicAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4f2ec36a-81f9-4bf8-a9be-b66eba7ef652" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2c4cb1e1-32db-49bf-9df2-b7468353b2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4f2ec36a-81f9-4bf8-a9be-b66eba7ef652" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2c4cb1e1-32db-49bf-9df2-b7468353b2b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_28a19926-3cf6-43e6-885c-c6d9c6cf5f57" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2c4cb1e1-32db-49bf-9df2-b7468353b2b2" xlink:to="loc_srt_StatementGeographicalAxis_28a19926-3cf6-43e6-885c-c6d9c6cf5f57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_28a19926-3cf6-43e6-885c-c6d9c6cf5f57_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_28a19926-3cf6-43e6-885c-c6d9c6cf5f57" xlink:to="loc_srt_SegmentGeographicalDomain_28a19926-3cf6-43e6-885c-c6d9c6cf5f57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_baeb1a6c-d49f-498b-a331-cd50f05e56f7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_28a19926-3cf6-43e6-885c-c6d9c6cf5f57" xlink:to="loc_srt_SegmentGeographicalDomain_baeb1a6c-d49f-498b-a331-cd50f05e56f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_a5f215b5-d7e8-43e4-aaf2-0b1aac15686c" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_AU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_baeb1a6c-d49f-498b-a331-cd50f05e56f7" xlink:to="loc_country_AU_a5f215b5-d7e8-43e4-aaf2-0b1aac15686c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_667ad9ed-b566-4ab7-b68e-33154c2de4e4" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_baeb1a6c-d49f-498b-a331-cd50f05e56f7" xlink:to="loc_country_US_667ad9ed-b566-4ab7-b68e-33154c2de4e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_SG_55e81935-cb36-4db4-b255-305dbbcf161e" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_SG"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_baeb1a6c-d49f-498b-a331-cd50f05e56f7" xlink:to="loc_country_SG_55e81935-cb36-4db4-b255-305dbbcf161e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RestOfWorldMember_5b10b0b4-ce3c-4d42-9f47-07a66e5382b3" xlink:href="rmd-20240630.xsd#rmd_RestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_baeb1a6c-d49f-498b-a331-cd50f05e56f7" xlink:to="loc_rmd_RestOfWorldMember_5b10b0b4-ce3c-4d42-9f47-07a66e5382b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_45d8c45f-2f0a-40a5-8e45-5af7b2b1566e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4f2ec36a-81f9-4bf8-a9be-b66eba7ef652" xlink:to="loc_us-gaap_NoncurrentAssets_45d8c45f-2f0a-40a5-8e45-5af7b2b1566e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/EmployeeRetirementPlansDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#EmployeeRetirementPlansDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/EmployeeRetirementPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0eb670ea-ecac-4920-89c1-8e3b8fc52498" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_867377be-e894-4dde-a77e-81291fd64a77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0eb670ea-ecac-4920-89c1-8e3b8fc52498" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_867377be-e894-4dde-a77e-81291fd64a77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_de58330a-1990-42ac-93e9-d5b2274f84a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_867377be-e894-4dde-a77e-81291fd64a77" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_de58330a-1990-42ac-93e9-d5b2274f84a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_de58330a-1990-42ac-93e9-d5b2274f84a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_de58330a-1990-42ac-93e9-d5b2274f84a3" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_de58330a-1990-42ac-93e9-d5b2274f84a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c34824b9-edb7-46f8-a78c-441a68c5cb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_de58330a-1990-42ac-93e9-d5b2274f84a3" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c34824b9-edb7-46f8-a78c-441a68c5cb8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_7fe458d6-c0da-459b-8b33-4ddb45ef4ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c34824b9-edb7-46f8-a78c-441a68c5cb8d" xlink:to="loc_us-gaap_ForeignPlanMember_7fe458d6-c0da-459b-8b33-4ddb45ef4ec5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_30dc164d-62fa-4a88-85ae-6a7495b1f8cb" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_AU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignPlanMember_7fe458d6-c0da-459b-8b33-4ddb45ef4ec5" xlink:to="loc_country_AU_30dc164d-62fa-4a88-85ae-6a7495b1f8cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_SG_34566d94-308e-4460-9aa9-57cfdac8cf17" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_SG"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignPlanMember_7fe458d6-c0da-459b-8b33-4ddb45ef4ec5" xlink:to="loc_country_SG_34566d94-308e-4460-9aa9-57cfdac8cf17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_9d484f68-6f15-4f46-99b0-066ee7534a29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c34824b9-edb7-46f8-a78c-441a68c5cb8d" xlink:to="loc_us-gaap_DomesticPlanMember_9d484f68-6f15-4f46-99b0-066ee7534a29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a9e5abb0-973e-481f-879e-ba1b61791f5a" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_9d484f68-6f15-4f46-99b0-066ee7534a29" xlink:to="loc_country_US_a9e5abb0-973e-481f-879e-ba1b61791f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent_611806b4-a647-400b-87ef-c82470c3991c" xlink:href="rmd-20240630.xsd#rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0eb670ea-ecac-4920-89c1-8e3b8fc52498" xlink:to="loc_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent_611806b4-a647-400b-87ef-c82470c3991c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_6ac3fa03-4f76-4404-a8e0-3573ad0d4914" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0eb670ea-ecac-4920-89c1-8e3b8fc52498" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_6ac3fa03-4f76-4404-a8e0-3573ad0d4914" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_cd21b198-1967-46f8-bcb1-dfb3c23cdbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_cd21b198-1967-46f8-bcb1-dfb3c23cdbf8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_24619c4f-d9f9-4f76-910e-e67fcecd9301" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_cd21b198-1967-46f8-bcb1-dfb3c23cdbf8" xlink:to="loc_us-gaap_HedgingDesignationAxis_24619c4f-d9f9-4f76-910e-e67fcecd9301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_24619c4f-d9f9-4f76-910e-e67fcecd9301_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_24619c4f-d9f9-4f76-910e-e67fcecd9301" xlink:to="loc_us-gaap_HedgingDesignationDomain_24619c4f-d9f9-4f76-910e-e67fcecd9301_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e261a61a-507b-4b4a-b677-236f96957b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_24619c4f-d9f9-4f76-910e-e67fcecd9301" xlink:to="loc_us-gaap_HedgingDesignationDomain_e261a61a-507b-4b4a-b677-236f96957b6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_0f0fcff5-d2d1-4c60-9f05-16ad72c94ace" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_e261a61a-507b-4b4a-b677-236f96957b6c" xlink:to="loc_us-gaap_NondesignatedMember_0f0fcff5-d2d1-4c60-9f05-16ad72c94ace" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_eb15a7dd-d5a1-4def-b36c-946002271a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_e261a61a-507b-4b4a-b677-236f96957b6c" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_eb15a7dd-d5a1-4def-b36c-946002271a0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_13e9e154-f026-4931-aee2-ad3f22d352e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_cd21b198-1967-46f8-bcb1-dfb3c23cdbf8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_13e9e154-f026-4931-aee2-ad3f22d352e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_13e9e154-f026-4931-aee2-ad3f22d352e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_13e9e154-f026-4931-aee2-ad3f22d352e4" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_13e9e154-f026-4931-aee2-ad3f22d352e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_95fb217b-43cf-4cac-b9be-06088f998c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_13e9e154-f026-4931-aee2-ad3f22d352e4" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_95fb217b-43cf-4cac-b9be-06088f998c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_974aaf1d-4ad3-4b59-8cf0-10ab61550dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_95fb217b-43cf-4cac-b9be-06088f998c7d" xlink:to="loc_us-gaap_ForeignExchangeContractMember_974aaf1d-4ad3-4b59-8cf0-10ab61550dd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6c4f5299-3fce-4307-a827-6b18d306c4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_cd21b198-1967-46f8-bcb1-dfb3c23cdbf8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6c4f5299-3fce-4307-a827-6b18d306c4c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6c4f5299-3fce-4307-a827-6b18d306c4c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6c4f5299-3fce-4307-a827-6b18d306c4c8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6c4f5299-3fce-4307-a827-6b18d306c4c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7206c522-ca1f-4e65-b158-97fcb7de4785" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6c4f5299-3fce-4307-a827-6b18d306c4c8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7206c522-ca1f-4e65-b158-97fcb7de4785" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_b24838a4-c307-4972-9b02-b89f24dcdba9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7206c522-ca1f-4e65-b158-97fcb7de4785" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_b24838a4-c307-4972-9b02-b89f24dcdba9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember_df5644ec-118e-424b-b452-d3373bb37d8f" xlink:href="rmd-20240630.xsd#rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7206c522-ca1f-4e65-b158-97fcb7de4785" xlink:to="loc_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember_df5644ec-118e-424b-b452-d3373bb37d8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_360e92fc-cd63-4222-b034-4e0a1a5200d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7206c522-ca1f-4e65-b158-97fcb7de4785" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_360e92fc-cd63-4222-b034-4e0a1a5200d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_85f89684-ef01-4373-8063-368cca98cfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7206c522-ca1f-4e65-b158-97fcb7de4785" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_85f89684-ef01-4373-8063-368cca98cfd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_35b85b99-659f-42ce-b22a-6f4a6cf101fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_cd21b198-1967-46f8-bcb1-dfb3c23cdbf8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_35b85b99-659f-42ce-b22a-6f4a6cf101fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_35b85b99-659f-42ce-b22a-6f4a6cf101fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_35b85b99-659f-42ce-b22a-6f4a6cf101fc" xlink:to="loc_us-gaap_HedgingRelationshipDomain_35b85b99-659f-42ce-b22a-6f4a6cf101fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0a6f3c2d-a738-4090-b2ea-abb604aa4a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_35b85b99-659f-42ce-b22a-6f4a6cf101fc" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0a6f3c2d-a738-4090-b2ea-abb604aa4a3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_d294f99d-8954-4c9b-9b6a-ab1861034367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0a6f3c2d-a738-4090-b2ea-abb604aa4a3b" xlink:to="loc_us-gaap_FairValueHedgingMember_d294f99d-8954-4c9b-9b6a-ab1861034367" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_5cc0c8eb-400a-4620-b0b3-5c3a2c4f38b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0a6f3c2d-a738-4090-b2ea-abb604aa4a3b" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_5cc0c8eb-400a-4620-b0b3-5c3a2c4f38b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_a9e0fc30-cbd1-4a73-9be4-f4aa700d9ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:to="loc_us-gaap_DerivativeAssets_a9e0fc30-cbd1-4a73-9be4-f4aa700d9ec5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_ecacad29-1438-49a2-a77a-79c7b30c4460" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:to="loc_us-gaap_DerivativeLiabilities_ecacad29-1438-49a2-a77a-79c7b30c4460" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration_32c905f8-69e6-4ede-abae-6b2f2c9cfd32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:to="loc_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration_32c905f8-69e6-4ede-abae-6b2f2c9cfd32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration_80a4bc08-3ed4-4c92-903f-f71380d559fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:to="loc_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration_80a4bc08-3ed4-4c92-903f-f71380d559fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration_1e6d7630-d28a-44e6-ba72-10ea139bd356" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:to="loc_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration_1e6d7630-d28a-44e6-ba72-10ea139bd356" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_4897d7b5-22b8-4663-8810-537cc63af872" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_4897d7b5-22b8-4663-8810-537cc63af872" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration_b56cd2fc-cc40-4e76-bdc8-825929fcc498" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:to="loc_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration_b56cd2fc-cc40-4e76-bdc8-825929fcc498" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_2e0b54b5-cfd2-46b6-bc96-e7192720afec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_2e0b54b5-cfd2-46b6-bc96-e7192720afec" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_54950e90-7747-4d32-934f-f98cf44015d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_93d07031-4812-40ec-8ff1-9e9b4dda5bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_54950e90-7747-4d32-934f-f98cf44015d2" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_93d07031-4812-40ec-8ff1-9e9b4dda5bd4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7bceaf89-4753-43ef-a21a-676749838094" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_93d07031-4812-40ec-8ff1-9e9b4dda5bd4" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7bceaf89-4753-43ef-a21a-676749838094" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7bceaf89-4753-43ef-a21a-676749838094_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7bceaf89-4753-43ef-a21a-676749838094" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7bceaf89-4753-43ef-a21a-676749838094_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d0412f0f-3e4f-4f8b-a4c8-086770059b97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7bceaf89-4753-43ef-a21a-676749838094" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d0412f0f-3e4f-4f8b-a4c8-086770059b97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_9531d02d-0f38-4209-a7b0-eba2cc8a4319" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d0412f0f-3e4f-4f8b-a4c8-086770059b97" xlink:to="loc_us-gaap_CurrencySwapMember_9531d02d-0f38-4209-a7b0-eba2cc8a4319" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c5eea9b6-5039-48bc-97c2-d33c98d67a64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_93d07031-4812-40ec-8ff1-9e9b4dda5bd4" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c5eea9b6-5039-48bc-97c2-d33c98d67a64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_c5eea9b6-5039-48bc-97c2-d33c98d67a64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c5eea9b6-5039-48bc-97c2-d33c98d67a64" xlink:to="loc_us-gaap_HedgingRelationshipDomain_c5eea9b6-5039-48bc-97c2-d33c98d67a64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1b190a0f-f03e-4ed2-84fc-f50ab976114f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c5eea9b6-5039-48bc-97c2-d33c98d67a64" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1b190a0f-f03e-4ed2-84fc-f50ab976114f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_b710602f-1e0b-4c3b-a116-c34d5b5bb2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_1b190a0f-f03e-4ed2-84fc-f50ab976114f" xlink:to="loc_us-gaap_FairValueHedgingMember_b710602f-1e0b-4c3b-a116-c34d5b5bb2a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_110b4391-6a7a-4ea1-bc16-2fa412d75cad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_54950e90-7747-4d32-934f-f98cf44015d2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_110b4391-6a7a-4ea1-bc16-2fa412d75cad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_bb61c22e-e3f4-4c2a-bdbf-ccf0f75a8e08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_54950e90-7747-4d32-934f-f98cf44015d2" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_bb61c22e-e3f4-4c2a-bdbf-ccf0f75a8e08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ba10907e-4690-42d2-b3df-545428d20a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_54950e90-7747-4d32-934f-f98cf44015d2" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ba10907e-4690-42d2-b3df-545428d20a4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_4de5b3ac-3076-4c76-ada3-c28c64a353bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_54950e90-7747-4d32-934f-f98cf44015d2" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_4de5b3ac-3076-4c76-ada3-c28c64a353bd" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4c6e6b10-c044-494b-873b-6ad23d0a25bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_ca3d15d5-a588-40e6-bbcf-3f1fc211297a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4c6e6b10-c044-494b-873b-6ad23d0a25bb" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_ca3d15d5-a588-40e6-bbcf-3f1fc211297a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_572eb21d-011f-400b-85f4-119b1d021eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_ca3d15d5-a588-40e6-bbcf-3f1fc211297a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_572eb21d-011f-400b-85f4-119b1d021eb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_572eb21d-011f-400b-85f4-119b1d021eb7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_572eb21d-011f-400b-85f4-119b1d021eb7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_572eb21d-011f-400b-85f4-119b1d021eb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_29d29dcc-c977-4a07-93e2-7c3f0142aa0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_572eb21d-011f-400b-85f4-119b1d021eb7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_29d29dcc-c977-4a07-93e2-7c3f0142aa0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_efe55d2f-dd6d-42e9-ac9c-f568edf8bb08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_29d29dcc-c977-4a07-93e2-7c3f0142aa0c" xlink:to="loc_us-gaap_CurrencySwapMember_efe55d2f-dd6d-42e9-ac9c-f568edf8bb08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6b65d833-95c1-4636-a88c-302b7e96b262" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_ca3d15d5-a588-40e6-bbcf-3f1fc211297a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6b65d833-95c1-4636-a88c-302b7e96b262" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_6b65d833-95c1-4636-a88c-302b7e96b262_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6b65d833-95c1-4636-a88c-302b7e96b262" xlink:to="loc_us-gaap_HedgingRelationshipDomain_6b65d833-95c1-4636-a88c-302b7e96b262_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d9054f27-a7fa-430f-b440-06a8b3689808" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6b65d833-95c1-4636-a88c-302b7e96b262" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d9054f27-a7fa-430f-b440-06a8b3689808" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_b4116b46-39b5-48ce-86bc-1fa9ba881fae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d9054f27-a7fa-430f-b440-06a8b3689808" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_b4116b46-39b5-48ce-86bc-1fa9ba881fae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6fae2793-2e10-436a-8445-e3edf607e3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_ca3d15d5-a588-40e6-bbcf-3f1fc211297a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6fae2793-2e10-436a-8445-e3edf607e3d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6fae2793-2e10-436a-8445-e3edf607e3d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6fae2793-2e10-436a-8445-e3edf607e3d3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6fae2793-2e10-436a-8445-e3edf607e3d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f5e95755-e973-4356-b0a4-a326379b5a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6fae2793-2e10-436a-8445-e3edf607e3d3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f5e95755-e973-4356-b0a4-a326379b5a6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_761629fc-9e9e-4a23-83bb-0515648865c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f5e95755-e973-4356-b0a4-a326379b5a6c" xlink:to="loc_us-gaap_InterestExpenseMember_761629fc-9e9e-4a23-83bb-0515648865c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_f651f713-f2b4-459d-a838-4a02d432e62c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4c6e6b10-c044-494b-873b-6ad23d0a25bb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_f651f713-f2b4-459d-a838-4a02d432e62c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_2d7154fe-0cb0-4a70-a70f-8b550c04c43c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4c6e6b10-c044-494b-873b-6ad23d0a25bb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_2d7154fe-0cb0-4a70-a70f-8b550c04c43c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_9991ebee-5122-4644-a6e7-398240972d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_718f5169-7b4d-444d-87ff-826c2288153b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_9991ebee-5122-4644-a6e7-398240972d0d" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_718f5169-7b4d-444d-87ff-826c2288153b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f08d96b3-de47-48f5-81b5-db912c35701d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_718f5169-7b4d-444d-87ff-826c2288153b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f08d96b3-de47-48f5-81b5-db912c35701d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f08d96b3-de47-48f5-81b5-db912c35701d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f08d96b3-de47-48f5-81b5-db912c35701d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f08d96b3-de47-48f5-81b5-db912c35701d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a7fe02e6-ee68-4496-a476-ffcfa9502a66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f08d96b3-de47-48f5-81b5-db912c35701d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a7fe02e6-ee68-4496-a476-ffcfa9502a66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_3337a447-840b-47c3-ba95-1d623911e4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a7fe02e6-ee68-4496-a476-ffcfa9502a66" xlink:to="loc_us-gaap_ForeignExchangeContractMember_3337a447-840b-47c3-ba95-1d623911e4bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_OtherForeignExchangeContractsMember_cc967d44-771d-4b02-ae15-09a49e409c47" xlink:href="rmd-20240630.xsd#rmd_OtherForeignExchangeContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a7fe02e6-ee68-4496-a476-ffcfa9502a66" xlink:to="loc_rmd_OtherForeignExchangeContractsMember_cc967d44-771d-4b02-ae15-09a49e409c47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_07ce530c-2075-4061-ba7d-ade27b68fb79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_718f5169-7b4d-444d-87ff-826c2288153b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_07ce530c-2075-4061-ba7d-ade27b68fb79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_07ce530c-2075-4061-ba7d-ade27b68fb79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_07ce530c-2075-4061-ba7d-ade27b68fb79" xlink:to="loc_us-gaap_HedgingRelationshipDomain_07ce530c-2075-4061-ba7d-ade27b68fb79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_3edc95a3-8757-4e76-a000-71ea62c019d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_07ce530c-2075-4061-ba7d-ade27b68fb79" xlink:to="loc_us-gaap_HedgingRelationshipDomain_3edc95a3-8757-4e76-a000-71ea62c019d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_4420de83-aa61-4092-bfa4-63f70f2213d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3edc95a3-8757-4e76-a000-71ea62c019d1" xlink:to="loc_us-gaap_NondesignatedMember_4420de83-aa61-4092-bfa4-63f70f2213d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9a046362-29dd-4823-8911-33019f12a306" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_718f5169-7b4d-444d-87ff-826c2288153b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9a046362-29dd-4823-8911-33019f12a306" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9a046362-29dd-4823-8911-33019f12a306_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9a046362-29dd-4823-8911-33019f12a306" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9a046362-29dd-4823-8911-33019f12a306_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a82e69ca-0aa2-424a-b17f-b181606ceca1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9a046362-29dd-4823-8911-33019f12a306" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a82e69ca-0aa2-424a-b17f-b181606ceca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_1f4fa408-a30c-4165-abb6-f4665d7b7f51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a82e69ca-0aa2-424a-b17f-b181606ceca1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_1f4fa408-a30c-4165-abb6-f4665d7b7f51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_c69a6c4d-6a70-4bfe-bd0a-a67a87700a23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_9991ebee-5122-4644-a6e7-398240972d0d" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_c69a6c4d-6a70-4bfe-bd0a-a67a87700a23" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a5e9b13b-d06d-456f-8463-ed0bde513d84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_70d2a9cc-31d2-4288-b3e4-af55a611e54f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a5e9b13b-d06d-456f-8463-ed0bde513d84" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_70d2a9cc-31d2-4288-b3e4-af55a611e54f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2cef4418-284e-4b64-9a79-a07ae1275aea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_70d2a9cc-31d2-4288-b3e4-af55a611e54f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2cef4418-284e-4b64-9a79-a07ae1275aea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2cef4418-284e-4b64-9a79-a07ae1275aea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2cef4418-284e-4b64-9a79-a07ae1275aea" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2cef4418-284e-4b64-9a79-a07ae1275aea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2ff0f08e-cfd6-4ad0-ba73-8a0a9d9dd072" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2cef4418-284e-4b64-9a79-a07ae1275aea" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2ff0f08e-cfd6-4ad0-ba73-8a0a9d9dd072" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MEDIFOXDANMember_744ecaa9-aa77-4f05-8075-f8edfcbdc5ed" xlink:href="rmd-20240630.xsd#rmd_MEDIFOXDANMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2ff0f08e-cfd6-4ad0-ba73-8a0a9d9dd072" xlink:to="loc_rmd_MEDIFOXDANMember_744ecaa9-aa77-4f05-8075-f8edfcbdc5ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f83edda7-56b1-4dc5-b934-4f585524b34d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a5e9b13b-d06d-456f-8463-ed0bde513d84" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f83edda7-56b1-4dc5-b934-4f585524b34d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1ed309bf-143d-4d35-997a-82c89d14c9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a5e9b13b-d06d-456f-8463-ed0bde513d84" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1ed309bf-143d-4d35-997a-82c89d14c9fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_d7c0682f-3305-4b7b-8632-332d829044bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a5e9b13b-d06d-456f-8463-ed0bde513d84" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_d7c0682f-3305-4b7b-8632-332d829044bc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cdb52807-53fd-4047-a260-8336eac002bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cdb52807-53fd-4047-a260-8336eac002bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_479ea5c6-893c-4f6c-98bf-57947c170e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cdb52807-53fd-4047-a260-8336eac002bf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_479ea5c6-893c-4f6c-98bf-57947c170e5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_479ea5c6-893c-4f6c-98bf-57947c170e5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_479ea5c6-893c-4f6c-98bf-57947c170e5a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_479ea5c6-893c-4f6c-98bf-57947c170e5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45ea0f54-d2d6-41fe-add5-65fee3cec04d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_479ea5c6-893c-4f6c-98bf-57947c170e5a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45ea0f54-d2d6-41fe-add5-65fee3cec04d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MEDIFOXDANMember_9b00a983-6154-4788-8b30-45b92371244c" xlink:href="rmd-20240630.xsd#rmd_MEDIFOXDANMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45ea0f54-d2d6-41fe-add5-65fee3cec04d" xlink:to="loc_rmd_MEDIFOXDANMember_9b00a983-6154-4788-8b30-45b92371244c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_45117d95-3d4b-4f68-be53-f58b067500b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cdb52807-53fd-4047-a260-8336eac002bf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_45117d95-3d4b-4f68-be53-f58b067500b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_45117d95-3d4b-4f68-be53-f58b067500b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_45117d95-3d4b-4f68-be53-f58b067500b9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_45117d95-3d4b-4f68-be53-f58b067500b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9d25e7ba-9aea-4eba-8623-d4275c3e06d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_45117d95-3d4b-4f68-be53-f58b067500b9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9d25e7ba-9aea-4eba-8623-d4275c3e06d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_95b7ac65-378e-4edd-bb18-95c7ccf9a066" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9d25e7ba-9aea-4eba-8623-d4275c3e06d8" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_95b7ac65-378e-4edd-bb18-95c7ccf9a066" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_3725817b-dd95-4f0c-bde4-98bdbcd4be03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9d25e7ba-9aea-4eba-8623-d4275c3e06d8" xlink:to="loc_us-gaap_CustomerRelationshipsMember_3725817b-dd95-4f0c-bde4-98bdbcd4be03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_802b83e4-47e0-4927-9fe2-913dfc3cdf44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9d25e7ba-9aea-4eba-8623-d4275c3e06d8" xlink:to="loc_us-gaap_TradeNamesMember_802b83e4-47e0-4927-9fe2-913dfc3cdf44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_00df42d1-6075-453d-b065-fdce278b4186" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cdb52807-53fd-4047-a260-8336eac002bf" xlink:to="loc_srt_RangeAxis_00df42d1-6075-453d-b065-fdce278b4186" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_00df42d1-6075-453d-b065-fdce278b4186_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_00df42d1-6075-453d-b065-fdce278b4186" xlink:to="loc_srt_RangeMember_00df42d1-6075-453d-b065-fdce278b4186_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c45bcb33-9a6f-491d-9531-6a1e11e437ed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_00df42d1-6075-453d-b065-fdce278b4186" xlink:to="loc_srt_RangeMember_c45bcb33-9a6f-491d-9531-6a1e11e437ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b51f35ed-63b0-4aa6-9c9f-52b0bf775a68" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c45bcb33-9a6f-491d-9531-6a1e11e437ed" xlink:to="loc_srt_MinimumMember_b51f35ed-63b0-4aa6-9c9f-52b0bf775a68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ff7646ab-b1f6-45c5-a82f-a060aee36548" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c45bcb33-9a6f-491d-9531-6a1e11e437ed" xlink:to="loc_srt_MaximumMember_ff7646ab-b1f6-45c5-a82f-a060aee36548" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_42e5fe33-769d-4e10-8774-e42646e4a674" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_42e5fe33-769d-4e10-8774-e42646e4a674" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a2a25a74-1eec-4608-b2d0-99c472b3fb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a2a25a74-1eec-4608-b2d0-99c472b3fb1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_76211802-fa2f-4916-8631-86e86f134aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_76211802-fa2f-4916-8631-86e86f134aa2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment_f18c4f3f-f50e-477c-9d69-7e91d8012483" xlink:href="rmd-20240630.xsd#rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment_f18c4f3f-f50e-477c-9d69-7e91d8012483" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_e9a9ec07-0370-41cc-b6b9-0dbe521803cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_e9a9ec07-0370-41cc-b6b9-0dbe521803cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_0a3d366e-b059-4820-9701-44d6c30483bc" xlink:href="rmd-20240630.xsd#rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_0a3d366e-b059-4820-9701-44d6c30483bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_0223ede9-e4f1-4981-9fe4-249772f693cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_0223ede9-e4f1-4981-9fe4-249772f693cd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_82c11c99-3f36-4a96-9a06-54bbace11e31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_82c11c99-3f36-4a96-9a06-54bbace11e31" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_84cdabe3-d6b4-4d73-8762-a5faa91ec79e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_84cdabe3-d6b4-4d73-8762-a5faa91ec79e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_f2743974-2afb-4b6a-82c4-bee166756d82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_f2743974-2afb-4b6a-82c4-bee166756d82" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f542dda8-7e62-4d0a-99d8-57e5ba9fb6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_Goodwill_f542dda8-7e62-4d0a-99d8-57e5ba9fb6bf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0a727a20-d178-4723-8042-7db294821495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0a727a20-d178-4723-8042-7db294821495" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_0e8cd388-f8bb-4009-b012-fea70c1640e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_0e8cd388-f8bb-4009-b012-fea70c1640e8" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/RestructuringExpensesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#RestructuringExpensesDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/RestructuringExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_40321c07-ea11-4b86-aa0c-e4d970109e25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1e83e27d-cf24-4983-a882-01848080b1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_40321c07-ea11-4b86-aa0c-e4d970109e25" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1e83e27d-cf24-4983-a882-01848080b1ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_0262e7b9-c50c-4ab4-b40b-7b962f48aeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1e83e27d-cf24-4983-a882-01848080b1ae" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_0262e7b9-c50c-4ab4-b40b-7b962f48aeb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_0262e7b9-c50c-4ab4-b40b-7b962f48aeb3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_0262e7b9-c50c-4ab4-b40b-7b962f48aeb3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_0262e7b9-c50c-4ab4-b40b-7b962f48aeb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_34bc9282-1f1d-42cd-86c5-f98113fd4d11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_0262e7b9-c50c-4ab4-b40b-7b962f48aeb3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_34bc9282-1f1d-42cd-86c5-f98113fd4d11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember_108c1a64-ba41-49ea-8717-213186bb870b" xlink:href="rmd-20240630.xsd#rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_34bc9282-1f1d-42cd-86c5-f98113fd4d11" xlink:to="loc_rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember_108c1a64-ba41-49ea-8717-213186bb870b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IntangibleAssetImpairmentMember_133e896c-65cb-4c18-a08d-05883f889006" xlink:href="rmd-20240630.xsd#rmd_IntangibleAssetImpairmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_34bc9282-1f1d-42cd-86c5-f98113fd4d11" xlink:to="loc_rmd_IntangibleAssetImpairmentMember_133e896c-65cb-4c18-a08d-05883f889006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_70b2f384-00fe-4668-ba70-10583a32a5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_34bc9282-1f1d-42cd-86c5-f98113fd4d11" xlink:to="loc_us-gaap_OtherRestructuringMember_70b2f384-00fe-4668-ba70-10583a32a5fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9cc462b6-8d07-4010-aa65-57fb3a632e62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_40321c07-ea11-4b86-aa0c-e4d970109e25" xlink:to="loc_us-gaap_RestructuringCharges_9cc462b6-8d07-4010-aa65-57fb3a632e62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_b486ea06-d74b-414c-b551-5b4ab70560bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_40321c07-ea11-4b86-aa0c-e4d970109e25" xlink:to="loc_us-gaap_RestructuringReserve_b486ea06-d74b-414c-b551-5b4ab70560bd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#ScheduleIIValuationandQualifyingAccountsandReservesDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_fce5c1b0-c77f-4def-88d2-6701cec2335c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_de2d710e-6d07-416f-854c-1ab63105a544" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_fce5c1b0-c77f-4def-88d2-6701cec2335c" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_de2d710e-6d07-416f-854c-1ab63105a544" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_2e837b78-42fe-4e05-bbb4-ef0c99937053" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_de2d710e-6d07-416f-854c-1ab63105a544" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_2e837b78-42fe-4e05-bbb4-ef0c99937053" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_2e837b78-42fe-4e05-bbb4-ef0c99937053_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_2e837b78-42fe-4e05-bbb4-ef0c99937053" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_2e837b78-42fe-4e05-bbb4-ef0c99937053_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0b0133f-6e98-44db-8a04-5bee8beef401" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_2e837b78-42fe-4e05-bbb4-ef0c99937053" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0b0133f-6e98-44db-8a04-5bee8beef401" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_db69b6ab-dfba-40e8-98ef-ba693fca7653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0b0133f-6e98-44db-8a04-5bee8beef401" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_db69b6ab-dfba-40e8-98ef-ba693fca7653" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_53ad61e4-744c-4344-bc96-07b418e50fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_fce5c1b0-c77f-4def-88d2-6701cec2335c" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_53ad61e4-744c-4344-bc96-07b418e50fa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_356bea2a-41d5-45ae-a599-eee9468bd7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_53ad61e4-744c-4344-bc96-07b418e50fa2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_356bea2a-41d5-45ae-a599-eee9468bd7f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_26b0c779-314b-4d71-810f-38e51a0485c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_53ad61e4-744c-4344-bc96-07b418e50fa2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_26b0c779-314b-4d71-810f-38e51a0485c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_48d7b0a3-5cea-4845-bf51-31083a100d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_53ad61e4-744c-4344-bc96-07b418e50fa2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_48d7b0a3-5cea-4845-bf51-31083a100d1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2d67b368-26db-4f2b-91b0-81261c16f3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanPurchaseRightsMember_0acf6dfc-ddb1-420c-8cff-284e8da61533" xlink:href="rmd-20240630.xsd#rmd_EmployeeStockPurchasePlanPurchaseRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_rmd_EmployeeStockPurchasePlanPurchaseRightsMember_0acf6dfc-ddb1-420c-8cff-284e8da61533" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MichaelJ.FarrellMember_2053144b-a34f-4b97-a598-6a27b46b4606" xlink:href="rmd-20240630.xsd#rmd_MichaelJ.FarrellMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rmd_MichaelJ.FarrellMember_2053144b-a34f-4b97-a598-6a27b46b4606" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_JanDeWitteMember_559f0c9a-3d2f-45a0-b9be-92d9eb6dd926" xlink:href="rmd-20240630.xsd#rmd_JanDeWitteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rmd_JanDeWitteMember_559f0c9a-3d2f-45a0-b9be-92d9eb6dd926" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_BrettA.SandercockMember_110545a7-21ae-48c9-ae11-9b38b56cb09a" xlink:href="rmd-20240630.xsd#rmd_BrettA.SandercockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rmd_BrettA.SandercockMember_110545a7-21ae-48c9-ae11-9b38b56cb09a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_KaushikGhoshalMember_41bf9996-76ea-47c4-8ec4-92b524b1c4de" xlink:href="rmd-20240630.xsd#rmd_KaushikGhoshalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rmd_KaushikGhoshalMember_41bf9996-76ea-47c4-8ec4-92b524b1c4de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MichaelJ.RiderMember_56ca12ed-a617-4a8a-9c43-c1c95c1637f2" xlink:href="rmd-20240630.xsd#rmd_MichaelJ.RiderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rmd_MichaelJ.RiderMember_56ca12ed-a617-4a8a-9c43-c1c95c1637f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PeterC.FarrellMember_4de23f2b-03f5-4f05-b5fe-8c3fb720bf28" xlink:href="rmd-20240630.xsd#rmd_PeterC.FarrellMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rmd_PeterC.FarrellMember_4de23f2b-03f5-4f05-b5fe-8c3fb720bf28" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>rmd-20240630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:626b872d-b824-4a3f-bfea-336621baa0aa,g:59f8884c-c35b-445a-b56c-2a5e88decb05-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_rmd_MasksWithMagnetsFieldSafetyNotificationExpenses_b50069de-2a8d-48fe-aa53-d14a99ac9e06_terseLabel_en-US" xlink:label="lab_rmd_MasksWithMagnetsFieldSafetyNotificationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Masks with magnets field safety notification expenses</link:label>
    <link:label id="lab_rmd_MasksWithMagnetsFieldSafetyNotificationExpenses_label_en-US" xlink:label="lab_rmd_MasksWithMagnetsFieldSafetyNotificationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Masks With Magnets Field Safety Notification Expenses</link:label>
    <link:label id="lab_rmd_MasksWithMagnetsFieldSafetyNotificationExpenses_documentation_en-US" xlink:label="lab_rmd_MasksWithMagnetsFieldSafetyNotificationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Masks With Magnets Field Safety Notification Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MasksWithMagnetsFieldSafetyNotificationExpenses" xlink:href="rmd-20240630.xsd#rmd_MasksWithMagnetsFieldSafetyNotificationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_MasksWithMagnetsFieldSafetyNotificationExpenses" xlink:to="lab_rmd_MasksWithMagnetsFieldSafetyNotificationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_U.s.CanadaAndLatinAmericaMember_40fedce7-81b7-4e33-b84b-a1952f1e6947_terseLabel_en-US" xlink:label="lab_rmd_U.s.CanadaAndLatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S., Canada and Latin America</link:label>
    <link:label id="lab_rmd_U.s.CanadaAndLatinAmericaMember_label_en-US" xlink:label="lab_rmd_U.s.CanadaAndLatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">U.s. Canada And Latin America [Member]</link:label>
    <link:label id="lab_rmd_U.s.CanadaAndLatinAmericaMember_documentation_en-US" xlink:label="lab_rmd_U.s.CanadaAndLatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">U.S., Canada and Latin America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_U.s.CanadaAndLatinAmericaMember" xlink:href="rmd-20240630.xsd#rmd_U.s.CanadaAndLatinAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_U.s.CanadaAndLatinAmericaMember" xlink:to="lab_rmd_U.s.CanadaAndLatinAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_ae801736-cb5d-4cf1-a6fa-60cdf986372f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_6b3fec76-de5c-435d-90c4-9787ebf04895_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e9bd4b9-7ec8-49ea-938c-5a7f0881a6ca_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_0751294c-ccb3-4c6d-a274-c27179249334_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_9f6bdcd2-417c-4e79-8401-1b0e63809f43_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes computed at statutory U.S. rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_55624f4b-8060-4d86-aa7b-bd51feef9442_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a24506d7-5855-422d-a5a9-953206f2785a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f9cb270f-ceec-45cf-8b74-5ef7c77bbeab_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_71b69885-fea3-43ea-944d-c53c27cbedfb_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Plan</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_35dde1da-c47c-47a9-9af0-1c33823b5196_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c9d03169-8cba-40ca-b02f-de5ae8150d63_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of business acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_f0be54dd-b364-4d35-9901-863d88ef5e0f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_858c51a5-aa5b-4896-a3b5-eb37953680f1_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) recognized on intercompany debt in other, net</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_32fbafed-2e5b-4918-9e23-810e5806d532_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_ac2d6065-7be0-42c1-be4f-0034915ab38f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_a61a771f-2a26-47e8-832e-253f72c00521_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Realized gains on marketable and non-marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_6b795dbf-8676-458b-8064-84c79f339941_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_cbb404fc-d0e8-4325-8eda-5a4ee12b8970_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend declared per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_f67be3b6-2dda-4226-b296-a545b320b07e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_c5647593-409f-4eac-8131-b421f50e3e0c_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, allowance for credit loss, current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_AmortizationOfAcquiredIntangibleAssets1_8dab934a-7690-4cf4-b312-81f3d1e74155_terseLabel_en-US" xlink:label="lab_rmd_AmortizationOfAcquiredIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_rmd_AmortizationOfAcquiredIntangibleAssets1_4678b6f2-f2a5-48f9-8cc8-92f5e7fd35fa_verboseLabel_en-US" xlink:label="lab_rmd_AmortizationOfAcquiredIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_rmd_AmortizationOfAcquiredIntangibleAssets1_label_en-US" xlink:label="lab_rmd_AmortizationOfAcquiredIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Acquired Intangible Assets 1</link:label>
    <link:label id="lab_rmd_AmortizationOfAcquiredIntangibleAssets1_documentation_en-US" xlink:label="lab_rmd_AmortizationOfAcquiredIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The aggregate expense charged against earnings to allocate the cost of acquired intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AmortizationOfAcquiredIntangibleAssets1" xlink:href="rmd-20240630.xsd#rmd_AmortizationOfAcquiredIntangibleAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_AmortizationOfAcquiredIntangibleAssets1" xlink:to="lab_rmd_AmortizationOfAcquiredIntangibleAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_7a44a3e7-eabe-448d-b95e-70a675846a31_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_62f9f6b7-af7b-4c9e-a827-fb080c0f0487_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_2e2cab2f-af57-481e-9ef2-4f14713489ed_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">(Loss) gain on equity investments (note 6)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_adb1f385-fee4-410a-a05b-27eecd8f500d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency Swap</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_c2eaf357-cd0d-4a7c-bece-eaafc32dc199_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_08db7a0b-f531-45c5-9a8c-868d1cc5cbf1_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_6e0700b7-33e9-487a-be6b-e8cd86b8eadd_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 10) (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_9f54dac9-ea54-453f-96ab-b62eb0c4e4d9_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_7eda97b6-5c1b-425f-8c6a-c9dd5c3bb69a_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_7e66c05d-db8c-4d8f-86d1-cf255d874d7c_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_IncomeTaxExaminationNetImpactOfSettlement_b6239d90-5b0c-4bbd-a93c-9ef60824497a_terseLabel_en-US" xlink:label="lab_rmd_IncomeTaxExaminationNetImpactOfSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net impact of settlement</link:label>
    <link:label id="lab_rmd_IncomeTaxExaminationNetImpactOfSettlement_label_en-US" xlink:label="lab_rmd_IncomeTaxExaminationNetImpactOfSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Net Impact of Settlement</link:label>
    <link:label id="lab_rmd_IncomeTaxExaminationNetImpactOfSettlement_documentation_en-US" xlink:label="lab_rmd_IncomeTaxExaminationNetImpactOfSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Net Impact of Settlement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationNetImpactOfSettlement" xlink:href="rmd-20240630.xsd#rmd_IncomeTaxExaminationNetImpactOfSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_IncomeTaxExaminationNetImpactOfSettlement" xlink:to="lab_rmd_IncomeTaxExaminationNetImpactOfSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_ff829c9f-bd9a-46c4-afbd-488ddade1890_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) recognized on cross-currency swap in other, net</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_OperatingLeaseIncome_894d313b-b6bd-4733-bd45-ba48972c8c16_terseLabel_en-US" xlink:label="lab_rmd_OperatingLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease revenue</link:label>
    <link:label id="lab_rmd_OperatingLeaseIncome_label_en-US" xlink:label="lab_rmd_OperatingLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Income</link:label>
    <link:label id="lab_rmd_OperatingLeaseIncome_documentation_en-US" xlink:label="lab_rmd_OperatingLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_OperatingLeaseIncome" xlink:href="rmd-20240630.xsd#rmd_OperatingLeaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_OperatingLeaseIncome" xlink:to="lab_rmd_OperatingLeaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_8a0e2b78-cdd3-4e63-920a-343b8b3afd3b_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:to="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_b59fb6f2-8e8a-4941-b5e1-e0826c0e8de7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carry overs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_55eb2362-6577-495b-97a5-c4a17cc21933_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_b98ca6c5-aa8b-4658-898f-4042f04a65f2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_7f45dfa0-c2e0-42e9-b706-075aa20826c7_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ad6d7a09-6f6d-4dea-ac10-23e8f6c17e97_netLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Stock options and restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_d622fd4a-0f13-43f1-bbc3-5e43ce9aa141_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid taxes and other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_a4b91de0-4952-42ab-8e98-ac8d0b0cff32_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_36e50af3-5249-48da-843b-7bc322e46125_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other intangibles, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_e05c7fac-2967-4531-8ae1-22cc76c3dc2a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_9d1ea649-fb8c-40cf-8ab1-ba81b3d1df85_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ComputerEquipmentAndSoftwareMember_15371b38-a5b8-4554-90a8-4917a3d44a12_terseLabel_en-US" xlink:label="lab_rmd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_rmd_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_rmd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_rmd_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_rmd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer Equipment and Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ComputerEquipmentAndSoftwareMember" xlink:href="rmd-20240630.xsd#rmd_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ComputerEquipmentAndSoftwareMember" xlink:to="lab_rmd_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce1a3e12-f182-4071-bff9-9c0e671f57da_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_866101ba-7252-4a2f-a073-026c6b05a456_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_f51f6dd3-4c9f-4432-9116-365a87a7e56c_terseLabel_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Obligations Under Purchase Agreements</link:label>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_label_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b65d89a4-7738-4b5d-bec0-96e02a2fec4d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_1b4c4c51-1b98-4a00-9795-125dfd13713c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_b6de479e-98b5-4545-8973-5d75a24ae564_negatedLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_5d99726e-eb3e-450e-b638-51eedced4b3d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_b86b9d9e-4b9b-4ab9-af3c-c22497c02b0b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_ab24aac5-bbd1-43ce-8907-09562cbb41fe_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_ad3e8d1c-bc25-4870-9696-f5965efb268e_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_60890e0d-d90d-4b22-b6d5-8394b2da2a99_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_d7e6373d-c023-4be0-811f-2171a61ab8dd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_068bac6a-8e15-4627-a848-8df752edd6ad_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Capital loss carryover</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_c283d264-0e4b-4fa8-8811-74f30d244d66_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other &#8206;(deductions)</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d9b8a55-60c8-4cf3-a113-21ad7eecfc90_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1cfdc865-6d7f-4697-ad5a-8f7eeff27667_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_d25cf156-0af3-457f-bb77-31afdb005bbe_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses (note 7)</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_fa228db5-73d8-47cd-9908-f05c2e40e4cb_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b2e0e6a1-559f-48aa-a726-0e31e6f28278_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration_7da01202-37f9-4fa7-ba24-1ec2ecd8e45e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_164ee095-8d06-41d3-8722-ac0714e50100_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_6b8d390c-a658-4cda-8192-dde86dfc302b_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Goodwill and other intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase_fa1d6272-e782-4763-8a0d-aa0b06f0aefa_verboseLabel_en-US" xlink:label="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase</link:label>
    <link:label id="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase_label_en-US" xlink:label="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Purchase Price Of Common Stock Lower Than The Fair Market Value Of Common Stock On The Date Of Purchase</link:label>
    <link:label id="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase_documentation_en-US" xlink:label="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase" xlink:href="rmd-20240630.xsd#rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase" xlink:to="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_cd7660af-1ac6-42bc-ae46-37d07d8223b0_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_79529a49-c722-4368-8781-3f4b82e7ed3d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Promotional and marketing</link:label>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Marketing Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:to="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember_d5164565-fe0f-4ea2-a181-0c1508e5bc70_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Operating Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember" xlink:to="lab_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_c14bc8ba-d7a6-438c-a12d-a7750f919d7d_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill (note 5)</link:label>
    <link:label id="lab_us-gaap_Goodwill_1db75b04-83cd-4f1b-b1f3-1bf4a8c1ec50_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_5c7f3a5f-821e-470e-b035-ef5d7c6812df_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_fbb8d052-e854-44d3-a668-91a1c0f25566_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ba390599-37b7-432a-8c35-6001123e8daf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_d3ec5790-db28-4a1f-b766-36e8bae1afad_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_bc08b6e6-b4c2-4a03-bb91-96cd2b55fc06_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_7582c22c-98c1-4a2c-bcc0-d9044d1c42c3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options:</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_020a94c0-a0d7-4cae-a6cd-d32285f5e8b5_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d8b1a35c-fada-42dd-b38b-37d16e0bd09a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_NonMarketableSecuritiesMember_6acc1cf6-ce16-4cc5-8de7-606e10d4eff2_terseLabel_en-US" xlink:label="lab_rmd_NonMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-marketable securities</link:label>
    <link:label id="lab_rmd_NonMarketableSecuritiesMember_label_en-US" xlink:label="lab_rmd_NonMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Marketable Securities [Member]</link:label>
    <link:label id="lab_rmd_NonMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_rmd_NonMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NonMarketableSecuritiesMember" xlink:href="rmd-20240630.xsd#rmd_NonMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_NonMarketableSecuritiesMember" xlink:to="lab_rmd_NonMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_1819fc85-26af-4f5b-8977-9b94a113e73a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_f17f1189-8367-44cb-811b-4315e6ca9012_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income taxes payable (note 12)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SleepAndRespiratoryMember_d7fcabb6-150e-4aa7-bf28-8c546c9ce2e5_terseLabel_en-US" xlink:label="lab_rmd_SleepAndRespiratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sleep and Respiratory Care</link:label>
    <link:label id="lab_rmd_SleepAndRespiratoryMember_949b3303-1aa3-4c4d-99bd-f279075b33ba_verboseLabel_en-US" xlink:label="lab_rmd_SleepAndRespiratoryMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sleep and &#8206;Respiratory Care</link:label>
    <link:label id="lab_rmd_SleepAndRespiratoryMember_label_en-US" xlink:label="lab_rmd_SleepAndRespiratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sleep And Respiratory [Member]</link:label>
    <link:label id="lab_rmd_SleepAndRespiratoryMember_documentation_en-US" xlink:label="lab_rmd_SleepAndRespiratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sleep And Respiratory [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SleepAndRespiratoryMember" xlink:href="rmd-20240630.xsd#rmd_SleepAndRespiratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SleepAndRespiratoryMember" xlink:to="lab_rmd_SleepAndRespiratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration_19c9390d-a07b-4eaa-8c16-2581dc6f44c2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_7c2dbd98-7155-47ca-9dc4-5a4249b341a5_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_8f10e67e-cc30-40cd-908c-4f4a0ddc697b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_30fa3139-8205-40b7-bc10-5a847b6cb9c1_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination_3ec1e786-2c6b-493b-9c65-2b4d3702f32c_negatedLabel_en-US" xlink:label="lab_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Previously held equity interest</link:label>
    <link:label id="lab_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination_label_en-US" xlink:label="lab_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Equity Interest in Acquiree Held Prior to Combination</link:label>
    <link:label id="lab_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination_documentation_en-US" xlink:label="lab_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Equity Interest in Acquiree Held Prior to Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" xlink:href="rmd-20240630.xsd#rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" xlink:to="lab_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_711563b4-806d-4ed2-894a-cee1f829f5c4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in progress</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_18a10b0f-48ca-40ec-a20a-7aee373e3346_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net (note 4)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b046e6d2-c7a1-41fd-a09f-70810a0da3f8_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_b2b07e5d-035a-4d06-9b0f-aa6a4c835ee2_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_342fade8-3c83-4522-95aa-38f009eadf89_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_dae6d2f4-c69d-4ffa-8216-7ece7d8fcb0d_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5e18f000-5779-4851-bebe-4c71a1381d55_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_c576fd97-64b0-4a0f-95c7-93c91b8c45c8_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_c713b0bc-7432-4cc8-a4c3-7c9497d7ae11_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ae8338fb-0271-44c7-97e1-fd8af7a6f6c1_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets - useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a53b260-0656-4187-b8cd-f0365b5142f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_f038c4d5-edc6-4c8d-ac9e-16aff97b3c14_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_293efb0f-a95f-4766-bc0a-5619a041ad06_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDividendsReceived_943caa73-fc6f-4a8b-8f4b-1957b7f01a09_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDividendsReceived" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Dividends received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDividendsReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDividendsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Dividends Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDividendsReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDividendsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDividendsReceived" xlink:to="lab_us-gaap_ProceedsFromDividendsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6685a5f0-3d6b-41e5-9831-4ac9df719c88_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ContractWithCustomerAssetAndLiabilityTable_35d33288-4de8-486d-8053-caf2310773e2_terseLabel_en-US" xlink:label="lab_rmd_ContractWithCustomerAssetAndLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset and Liability [Table]</link:label>
    <link:label id="lab_rmd_ContractWithCustomerAssetAndLiabilityTable_label_en-US" xlink:label="lab_rmd_ContractWithCustomerAssetAndLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset and Liability [Table]</link:label>
    <link:label id="lab_rmd_ContractWithCustomerAssetAndLiabilityTable_documentation_en-US" xlink:label="lab_rmd_ContractWithCustomerAssetAndLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset and Liability [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ContractWithCustomerAssetAndLiabilityTable" xlink:href="rmd-20240630.xsd#rmd_ContractWithCustomerAssetAndLiabilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityTable" xlink:to="lab_rmd_ContractWithCustomerAssetAndLiabilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_62d63a83-328f-4066-896d-65c7106d5202_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current (note 9)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_7f9f5b74-6d96-4305-adbe-5db6f079f11e_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred borrowing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_AstralFieldActionNotificationExpenses_aa9f2daa-35f7-474e-ade3-7cb666b9f34d_terseLabel_en-US" xlink:label="lab_rmd_AstralFieldActionNotificationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Astral field safety notification expenses</link:label>
    <link:label id="lab_rmd_AstralFieldActionNotificationExpenses_label_en-US" xlink:label="lab_rmd_AstralFieldActionNotificationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Astral Field Action Notification Expenses</link:label>
    <link:label id="lab_rmd_AstralFieldActionNotificationExpenses_documentation_en-US" xlink:label="lab_rmd_AstralFieldActionNotificationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Astral Field Action Notification Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AstralFieldActionNotificationExpenses" xlink:href="rmd-20240630.xsd#rmd_AstralFieldActionNotificationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_AstralFieldActionNotificationExpenses" xlink:to="lab_rmd_AstralFieldActionNotificationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_607bb6cb-a70f-4fa8-857e-3a21fc862b48_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_07efb069-5ff9-4a2f-b3e4-3929467c2131_terseLabel_en-US" xlink:label="lab_us-gaap_GainOnBusinessInterruptionInsuranceRecovery" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on insurance recoveries</link:label>
    <link:label id="lab_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_label_en-US" xlink:label="lab_us-gaap_GainOnBusinessInterruptionInsuranceRecovery" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on Business Interruption Insurance Recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainOnBusinessInterruptionInsuranceRecovery"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery" xlink:to="lab_us-gaap_GainOnBusinessInterruptionInsuranceRecovery" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_3e321d2a-5669-4056-8efe-21579528a918_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_365f770a-6eef-4f83-9a63-16af3cb4180f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued on exercise of options (note 10) (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dc57157c-016f-438a-9c88-9c88eeae9a2f_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_6e2a09d4-36a9-4107-94e2-f6871dcda818_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) recognized in other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ReceivablesSoldWithLimitedRecourse_ddc8adb1-596b-4857-a5f3-4f29d301d822_terseLabel_en-US" xlink:label="lab_rmd_ReceivablesSoldWithLimitedRecourse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables sold with limited recourse</link:label>
    <link:label id="lab_rmd_ReceivablesSoldWithLimitedRecourse_label_en-US" xlink:label="lab_rmd_ReceivablesSoldWithLimitedRecourse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables Sold With Limited Recourse</link:label>
    <link:label id="lab_rmd_ReceivablesSoldWithLimitedRecourse_documentation_en-US" xlink:label="lab_rmd_ReceivablesSoldWithLimitedRecourse" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivables Sold With Limited Recourse</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ReceivablesSoldWithLimitedRecourse" xlink:href="rmd-20240630.xsd#rmd_ReceivablesSoldWithLimitedRecourse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ReceivablesSoldWithLimitedRecourse" xlink:to="lab_rmd_ReceivablesSoldWithLimitedRecourse" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_5016017b-49c9-4af7-bb0e-a696d8e65096_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1b1f9a20-b5bc-4d29-ad7f-8a7d8fc43656_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted &#8206;Average &#8206;Exercise &#8206;Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock_7110d7b8-f6ca-4d81-a407-53b9e30381e5_terseLabel_en-US" xlink:label="lab_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Lease Disclosure</link:label>
    <link:label id="lab_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Supplemental Information, Operating Leases [Table Text Block]</link:label>
    <link:label id="lab_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock_documentation_en-US" xlink:label="lab_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Operating Lease Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock" xlink:href="rmd-20240630.xsd#rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock" xlink:to="lab_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ebe809de-7516-4448-b897-08b685a3ba1c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted shares outstanding (000's) (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c3a1941d-401d-4697-9f70-d4c2cacb7a61_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Diluted weighted average shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_OperatingLossCarryforwardsCapitalLoss_30aa7948-bb26-4dcd-a1bf-511dbd80a9a1_terseLabel_en-US" xlink:label="lab_rmd_OperatingLossCarryforwardsCapitalLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital loss</link:label>
    <link:label id="lab_rmd_OperatingLossCarryforwardsCapitalLoss_label_en-US" xlink:label="lab_rmd_OperatingLossCarryforwardsCapitalLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards Capital Loss</link:label>
    <link:label id="lab_rmd_OperatingLossCarryforwardsCapitalLoss_documentation_en-US" xlink:label="lab_rmd_OperatingLossCarryforwardsCapitalLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards capital loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_OperatingLossCarryforwardsCapitalLoss" xlink:href="rmd-20240630.xsd#rmd_OperatingLossCarryforwardsCapitalLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_OperatingLossCarryforwardsCapitalLoss" xlink:to="lab_rmd_OperatingLossCarryforwardsCapitalLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_1aafb945-40a7-4054-a075-6fe57cf6afba_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_329ca2df-77e2-4149-817b-90034b68c557_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_523e1c31-8ee0-439b-8c71-04ce47742db8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Amounts Attributable to Parent, Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:to="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_AuditInformationAbstract_label_en-US" xlink:label="lab_rmd_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_rmd_AuditInformationAbstract_documentation_en-US" xlink:label="lab_rmd_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AuditInformationAbstract" xlink:href="rmd-20240630.xsd#rmd_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_AuditInformationAbstract" xlink:to="lab_rmd_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_82c509f4-97e3-4743-9d1e-08ded39c2753_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_25e95d20-600a-4392-85cc-ffbe4a016b99_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_69a4252f-5e19-4905-b810-e32e466a66fb_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ae92394d-93ce-4bac-9779-8fe46a6bff6e_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_cfd5ffae-77b1-4bba-8414-877e20a149c4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_00e052d6-4690-4874-ac57-1afdec249ed1_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cost of shares repurchased pursuant to the repurchase program</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DeferredRevenueCurrentLiabilitiesMember_be5a12fc-5408-41d8-82e2-120a91cddbdb_terseLabel_en-US" xlink:label="lab_rmd_DeferredRevenueCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue (current liabilities)</link:label>
    <link:label id="lab_rmd_DeferredRevenueCurrentLiabilitiesMember_label_en-US" xlink:label="lab_rmd_DeferredRevenueCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Current Liabilities [Member]</link:label>
    <link:label id="lab_rmd_DeferredRevenueCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_rmd_DeferredRevenueCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Revenue Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredRevenueCurrentLiabilitiesMember" xlink:href="rmd-20240630.xsd#rmd_DeferredRevenueCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DeferredRevenueCurrentLiabilitiesMember" xlink:to="lab_rmd_DeferredRevenueCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_6ac81db6-43bc-4c4f-b7c3-a3a8496817dd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_9799eb5a-dcf6-4d68-8eff-cb36789d9aff_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Carrying Amount of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_PeterC.FarrellMember_label_en-US" xlink:label="lab_rmd_PeterC.FarrellMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peter C. Farrell [Member]</link:label>
    <link:label id="lab_rmd_PeterC.FarrellMember_documentation_en-US" xlink:label="lab_rmd_PeterC.FarrellMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Peter C. Farrell</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PeterC.FarrellMember" xlink:href="rmd-20240630.xsd#rmd_PeterC.FarrellMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_PeterC.FarrellMember" xlink:to="lab_rmd_PeterC.FarrellMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_a7a99a42-6792-48fd-9dfc-e45186c26e1d_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_e37374a2-4d63-4b02-88ae-04f279f8dc92_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total contribution by the company to the employee retirement plans</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_GlobalMember_a76b5323-52b6-4de4-8586-a818651db995_terseLabel_en-US" xlink:label="lab_rmd_GlobalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global revenue</link:label>
    <link:label id="lab_rmd_GlobalMember_label_en-US" xlink:label="lab_rmd_GlobalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Global [Member]</link:label>
    <link:label id="lab_rmd_GlobalMember_documentation_en-US" xlink:label="lab_rmd_GlobalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Global [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_GlobalMember" xlink:href="rmd-20240630.xsd#rmd_GlobalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_GlobalMember" xlink:to="lab_rmd_GlobalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_41361661-af6c-460e-bbf3-308acde519bc_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted_e8e0a7aa-177e-4d9a-9bcd-b99104faa06e_terseLabel_en-US" xlink:label="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount payable pursuant to cash denominated performance awards granted</link:label>
    <link:label id="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted_label_en-US" xlink:label="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Performance Award Granted</link:label>
    <link:label id="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted_documentation_en-US" xlink:label="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Performance Award Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" xlink:href="rmd-20240630.xsd#rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" xlink:to="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d03586a1-4135-41c7-bcfb-a142c864a43a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_07a845be-719e-45dd-ad2f-e3126b2c9d9b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_64d85be0-30b8-43cd-a43e-137081a8e8c5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition related expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_a4c44eaf-ed1c-47f6-b826-e729777976e8_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d5e96d4e-ee2a-438b-90f3-6a99bf7ac321_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bf3523be-c43c-4cef-b6dc-d3e0e09df349_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ce5ec47a-ab39-4d5d-b74d-e76972499f72_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_88dfe270-2920-42e5-8ea3-ed0d8bd40a3b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_97ed30e8-3f6e-4499-9f10-2542e6cb19b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5fababcc-e418-49b2-ba9d-b2c5a86a5db1_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_90b3796e-4c67-482e-876b-ab89dc6f6a23_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitment fees percentage rate on unused portion of credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_f21ed658-faf6-4562-b0fa-33a3722c568a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on outstanding principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_2ed4f4f7-76d4-4146-a076-cab4b2111cdc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned_9d96b29b-c37d-4a6c-815e-f84c641934b9_terseLabel_en-US" xlink:label="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum award amount with other cash fees earned for services</link:label>
    <link:label id="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned_label_en-US" xlink:label="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted and Other Cash Fees Earned</link:label>
    <link:label id="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned_documentation_en-US" xlink:label="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted and Other Cash Fees Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" xlink:href="rmd-20240630.xsd#rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" xlink:to="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_065c402d-73e8-4a65-a594-877176a829f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Segment and Reconciling Items</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_NumberOfOfferings_dc5923ea-d707-46b5-a5e3-da64da330515_terseLabel_en-US" xlink:label="lab_rmd_NumberOfOfferings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of offerings</link:label>
    <link:label id="lab_rmd_NumberOfOfferings_label_en-US" xlink:label="lab_rmd_NumberOfOfferings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Offerings</link:label>
    <link:label id="lab_rmd_NumberOfOfferings_documentation_en-US" xlink:label="lab_rmd_NumberOfOfferings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Offerings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NumberOfOfferings" xlink:href="rmd-20240630.xsd#rmd_NumberOfOfferings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_NumberOfOfferings" xlink:to="lab_rmd_NumberOfOfferings" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ShortTermDebtGross_072bd5b9-f0d5-42e1-a6e5-07454adafb64_verboseLabel_en-US" xlink:label="lab_rmd_ShortTermDebtGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_rmd_ShortTermDebtGross_label_en-US" xlink:label="lab_rmd_ShortTermDebtGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Gross</link:label>
    <link:label id="lab_rmd_ShortTermDebtGross_documentation_en-US" xlink:label="lab_rmd_ShortTermDebtGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShortTermDebtGross" xlink:href="rmd-20240630.xsd#rmd_ShortTermDebtGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ShortTermDebtGross" xlink:to="lab_rmd_ShortTermDebtGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_1d0f1649-1c3d-4661-962f-fab4a1db6ed2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f180643a-3b20-4d99-b3cd-ed384d7f1a53_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_cebabc9f-60b7-4193-9fc6-769f4e117451_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Contract Balances</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_8d5de7f5-16f2-4ce9-b98c-489d0ab7617a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Amortization Expense Related to Identifiable Intangible Assets, Including Patents</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4f42d82c-a172-41a7-b6a5-102cedd0e784_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember_2da4a537-f88b-4182-abc6-a79a2e6115d1_terseLabel_en-US" xlink:label="lab_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Agreement, Term Credit Agreement, And Senior Notes</link:label>
    <link:label id="lab_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember_label_en-US" xlink:label="lab_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Agreement Term Credit Agreement And Senior Notes [Member]</link:label>
    <link:label id="lab_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember_documentation_en-US" xlink:label="lab_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revolving Credit Agreement, Term Credit Agreement, And Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember" xlink:href="rmd-20240630.xsd#rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember" xlink:to="lab_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DeferredTaxLiabilitiesRightOfUseAssets_3b3401ae-08bf-4c4b-ad98-153e41b14b8d_negatedLabel_en-US" xlink:label="lab_rmd_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Right of use assets</link:label>
    <link:label id="lab_rmd_DeferredTaxLiabilitiesRightOfUseAssets_label_en-US" xlink:label="lab_rmd_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Right-of-use Assets</link:label>
    <link:label id="lab_rmd_DeferredTaxLiabilitiesRightOfUseAssets_documentation_en-US" xlink:label="lab_rmd_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Right-of-use Assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredTaxLiabilitiesRightOfUseAssets" xlink:href="rmd-20240630.xsd#rmd_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="lab_rmd_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_6703c813-bf41-45c9-92e7-dd9c9c164e14_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DeferredPaymentObligationsForAcquisitions_263360b4-0eed-480a-a2fa-444a32e04829_verboseLabel_en-US" xlink:label="lab_rmd_DeferredPaymentObligationsForAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred payments</link:label>
    <link:label id="lab_rmd_DeferredPaymentObligationsForAcquisitions_label_en-US" xlink:label="lab_rmd_DeferredPaymentObligationsForAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Payment Obligations For Acquisitions</link:label>
    <link:label id="lab_rmd_DeferredPaymentObligationsForAcquisitions_documentation_en-US" xlink:label="lab_rmd_DeferredPaymentObligationsForAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Payment Obligations For Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredPaymentObligationsForAcquisitions" xlink:href="rmd-20240630.xsd#rmd_DeferredPaymentObligationsForAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DeferredPaymentObligationsForAcquisitions" xlink:to="lab_rmd_DeferredPaymentObligationsForAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_986f2dbf-7025-4449-83d0-2aedfd9114c9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets, net (note 5)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_07719c7a-30af-4685-a88e-9876b2cf320e_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other intangibles, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_dd43ccd4-f3ca-432b-8b7c-784b0b60c965_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_TermOfContractUnderRevenueRecognition_a630cc81-6948-438f-90da-7e42a0b9c7b9_terseLabel_en-US" xlink:label="lab_rmd_TermOfContractUnderRevenueRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue recognized, term</link:label>
    <link:label id="lab_rmd_TermOfContractUnderRevenueRecognition_label_en-US" xlink:label="lab_rmd_TermOfContractUnderRevenueRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Of Contract Under Revenue Recognition</link:label>
    <link:label id="lab_rmd_TermOfContractUnderRevenueRecognition_documentation_en-US" xlink:label="lab_rmd_TermOfContractUnderRevenueRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Of Contract Under Revenue Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_TermOfContractUnderRevenueRecognition" xlink:href="rmd-20240630.xsd#rmd_TermOfContractUnderRevenueRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_TermOfContractUnderRevenueRecognition" xlink:to="lab_rmd_TermOfContractUnderRevenueRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_92a325a9-6225-422a-a0ea-a085e77b720e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions for Fair Value of Stock Option Plans and Purchase Rights Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_3a1df446-2fc9-4bf5-be32-fb960975b792_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_686919b8-5ee6-4317-b6f0-93c9ec06ba69_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1719a699-94c3-4110-b924-4db5ad71a407_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c8fd19d7-613e-4175-a274-070a92a0ac6a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4e152454-0338-4e86-a0a4-4776c68a73f7_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorSalesTypeLeasesTextBlock_1880613f-be3c-4b43-a661-707aadac782f_terseLabel_en-US" xlink:label="lab_us-gaap_LessorSalesTypeLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LessorSalesTypeLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LessorSalesTypeLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Sales-type Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorSalesTypeLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorSalesTypeLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorSalesTypeLeasesTextBlock" xlink:to="lab_us-gaap_LessorSalesTypeLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance_25e3df2a-4bde-49d9-878f-2c0c088a9050_verboseLabel_en-US" xlink:label="lab_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reduction in the number of shares of common stock available for issuance (in shares)</link:label>
    <link:label id="lab_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance_label_en-US" xlink:label="lab_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction In The Number Of Shares Of Common Stock Available For Issuance</link:label>
    <link:label id="lab_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance_documentation_en-US" xlink:label="lab_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in the number of shares of common stock available for issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance" xlink:href="rmd-20240630.xsd#rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance" xlink:to="lab_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e3862cef-f863-4f73-adbe-8fcc9d5a5492_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_dd35e7f7-dd90-4e8b-90ee-b5a91d9f781e_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition_af719a0a-b914-4665-b0e0-5cd6ac72e421_terseLabel_en-US" xlink:label="lab_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of recognized tax benefit for uncertain tax position</link:label>
    <link:label id="lab_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition_label_en-US" xlink:label="lab_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Recognized Tax Benefit For Uncertain Tax Position</link:label>
    <link:label id="lab_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition_documentation_en-US" xlink:label="lab_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage threshold, above which a tax benefit would be recognized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition" xlink:href="rmd-20240630.xsd#rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition" xlink:to="lab_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_f6809815-1b46-4123-ac82-9b171f3241d5_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a31f80d3-3e0d-4019-bc93-74b276daecfa_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share (note 11) (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b0d493d7-67c2-46e3-82cb-8dce126757fb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_97d32e6b-4f70-4351-8fe2-97b82a3f659c_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_8c7b7309-cd39-47ca-bad4-76def57d6777_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a69d0fa5-40f5-470f-b363-d2fa71e0b1c8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_5eb99445-3873-4e86-9f6a-90ef391c4739_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_76adce6e-e58e-4785-bbf8-6d6727803926_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_7ae593d8-1d0c-4882-ac4d-7b3840348f0d_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_7e80c49c-5acd-4b41-aee0-175f00488840_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_2994df69-94bc-48b5-9133-84edbe0d7557_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_8b722385-6cfa-4a1b-a6da-a008fef07c61_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_1ec48025-7fde-4b74-b5f7-9377cc60f53a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_901e891e-50a0-4173-a197-348ca6bb30c1_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product warranties</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Warranty Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_2311964a-58e2-4a7e-994c-8f0a3273726c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development credit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b2acd994-e2a9-4801-9b22-af91d5eae969_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of RSUs and PRSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_999b6e48-41f5-48bb-b25e-b8837892fb1b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsMember_42888d89-b7f5-4b78-9469-237358927973_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsMember" xlink:to="lab_us-gaap_EquityMethodInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_92b04507-f4fb-41d2-a49f-367fdac657d7_netLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Income taxes (note 12)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_30af4979-e96b-4a71-8118-cc20365ec5c7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0c4d4a22-9893-4d86-8848-d20e7f37e31a_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (loss), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_3e6cd25f-8522-4bd5-8726-d418eb65b5aa_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding foreign cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards_ab725b7f-598a-43c2-9fc9-f32bc042685e_terseLabel_en-US" xlink:label="lab_rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares given for each share of common stock delivered in settlement of all other awards (in shares)</link:label>
    <link:label id="lab_rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards_label_en-US" xlink:label="lab_rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Shares Given for Each Share of Common Stock Delivered in Settlement of All Other Awards</link:label>
    <link:label id="lab_rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards_documentation_en-US" xlink:label="lab_rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Shares Given for Each Share of Common Stock Delivered in Settlement of All Other Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards" xlink:href="rmd-20240630.xsd#rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards" xlink:to="lab_rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_9f03593f-1979-458a-9526-d891e41d0816_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability_ae82d5d7-3829-4f97-9d94-51ccdbef5d31_negatedTerseLabel_en-US" xlink:label="lab_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability_label_en-US" xlink:label="lab_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration, Recognized Liability</link:label>
    <link:label id="lab_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability_documentation_en-US" xlink:label="lab_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration, Recognized Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability" xlink:href="rmd-20240630.xsd#rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability" xlink:to="lab_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9be08bd0-fcb2-4455-83c2-97f8fcf97bfb_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected weighted average period of unrecognized compensation costs related to unvested stock-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_36fe48ad-0493-4d39-97d4-b59e34bd631f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_55f51c72-ba56-46a2-a3f0-07abd5f0363b_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net revenue by segment</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_6c7be714-6429-4920-bb08-44fb5c2badf2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Patent registration costs</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_923ed7a1-6d0d-4f7d-8527-31511bc443b8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SoftwareAsAServiceMember_69a94c11-f607-4ac4-81be-dffa76d5840a_terseLabel_en-US" xlink:label="lab_rmd_SoftwareAsAServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software as a Service</link:label>
    <link:label id="lab_rmd_SoftwareAsAServiceMember_label_en-US" xlink:label="lab_rmd_SoftwareAsAServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software As A Service [Member]</link:label>
    <link:label id="lab_rmd_SoftwareAsAServiceMember_documentation_en-US" xlink:label="lab_rmd_SoftwareAsAServiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Software As A Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SoftwareAsAServiceMember" xlink:href="rmd-20240630.xsd#rmd_SoftwareAsAServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SoftwareAsAServiceMember" xlink:to="lab_rmd_SoftwareAsAServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_e9b5cbda-a14b-4523-a983-7bef1edf0ec6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_1bcda293-59bd-41e1-9d65-f111734df4ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_e50b6242-ebea-4cc1-9cab-f00f5a98e298_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee related costs</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_AccountsReceivableNetMember_79c6c89a-340a-4c9b-b891-6df431205e26_terseLabel_en-US" xlink:label="lab_rmd_AccountsReceivableNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_rmd_AccountsReceivableNetMember_label_en-US" xlink:label="lab_rmd_AccountsReceivableNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable Net [Member]</link:label>
    <link:label id="lab_rmd_AccountsReceivableNetMember_documentation_en-US" xlink:label="lab_rmd_AccountsReceivableNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AccountsReceivableNetMember" xlink:href="rmd-20240630.xsd#rmd_AccountsReceivableNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_AccountsReceivableNetMember" xlink:to="lab_rmd_AccountsReceivableNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ee69823e-4b96-45a1-847a-2e2403268355_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses, net deferred income taxes and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_1e0cb85d-80ec-4fab-a1a1-e7688818abc7_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring expenses (note 18)</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_5e1539b9-d052-4ce8-8cbe-50ee716e7f58_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restructuring expenses</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6305094c-6983-43b2-82df-25e438bd7fc4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_f480a8fa-4b3f-4452-8b76-5c43853b0e9c_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_de946d8e-5b6a-4d0c-9c86-d21aa8ba532e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_5733267a-b939-4a4f-8ad3-000bc0ea9cf2_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest expense (income), net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_5cb81a8d-2066-49a4-8e90-d1db87746d5e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.004 par value, 350,000,000 shares authorized; &#8206;189,565,112 issued and 146,901,045 outstanding at June&#160;30, 2024 and &#8206;188,900,583 issued and 147,064,349 outstanding at June&#160;30, 2023</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_dc2aa0f0-7c7c-4811-958d-de3e40b3706b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 10)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_7039ed3d-114b-4f86-8f1d-de531ed2f063_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e02ce313-8aa8-4668-af43-4c991b3fb68c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_MichaelJ.RiderMember_label_en-US" xlink:label="lab_rmd_MichaelJ.RiderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Michael J. Rider [Member]</link:label>
    <link:label id="lab_rmd_MichaelJ.RiderMember_documentation_en-US" xlink:label="lab_rmd_MichaelJ.RiderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Michael J. Rider</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MichaelJ.RiderMember" xlink:href="rmd-20240630.xsd#rmd_MichaelJ.RiderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_MichaelJ.RiderMember" xlink:to="lab_rmd_MichaelJ.RiderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_807c53e2-5fb3-4dfd-9acb-76bf4aea5a79_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_IncomeTaxesTable_3fc0a5e4-176e-4fcd-9b5c-b23854501f8e_terseLabel_en-US" xlink:label="lab_rmd_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_rmd_IncomeTaxesTable_label_en-US" xlink:label="lab_rmd_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_rmd_IncomeTaxesTable_documentation_en-US" xlink:label="lab_rmd_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxesTable" xlink:href="rmd-20240630.xsd#rmd_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_IncomeTaxesTable" xlink:to="lab_rmd_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_1073187e-c8aa-4ce5-b64f-6c86035a6a29_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b59eb0a0-e195-4a07-a684-6770043ce0e5_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4f71d981-205a-42dc-87ca-de8ddc199787_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b77b82f5-e015-463d-a07f-969295291d0a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d79cd91c-c4c6-495e-8b93-cde9472a7a88_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_fe6a3131-d15c-46c3-9975-47c26bd3c201_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Provision for doubtful debts</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_114b2f49-97a7-482d-97dc-fce10b87add8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_a2dde7b1-4309-4107-a1eb-57a279194af4_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Charged to costs and expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935fd7b9-ea7a-40f2-8baf-8b6bcfa68ad6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3f16e742-7f33-428a-a9a3-6a5e0442eb0e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fa18ace0-857e-4b29-b876-55796c3ff4ed_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_4b58145a-7944-476a-982e-425894a1842b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets (note 9)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_NumberOfCommonStockGranted_c588008a-44d5-45b0-aed6-81c7200d1a97_terseLabel_en-US" xlink:label="lab_rmd_NumberOfCommonStockGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common stock shares granted in participant's initial year of hiring (in shares)</link:label>
    <link:label id="lab_rmd_NumberOfCommonStockGranted_label_en-US" xlink:label="lab_rmd_NumberOfCommonStockGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Common Stock Granted</link:label>
    <link:label id="lab_rmd_NumberOfCommonStockGranted_documentation_en-US" xlink:label="lab_rmd_NumberOfCommonStockGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of common stock shares granted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NumberOfCommonStockGranted" xlink:href="rmd-20240630.xsd#rmd_NumberOfCommonStockGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_NumberOfCommonStockGranted" xlink:to="lab_rmd_NumberOfCommonStockGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c007b072-154f-4ed1-ad7a-329e374f324d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_87e24a20-c9ff-4efd-af82-1cf954ff7ba1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_6f4c733c-b337-4979-90e9-c4d58e09e97f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_3c907893-0695-4e25-98de-5904fb8eab44_negatedTerseLabel_en-US" xlink:label="lab_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_label_en-US" xlink:label="lab_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable And Accrued Expenses</link:label>
    <link:label id="lab_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_documentation_en-US" xlink:label="lab_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable And Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:href="rmd-20240630.xsd#rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:to="lab_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_c60abb31-6c99-4d16-876a-70ce16053d32_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember_cec4c3ec-9cc2-47ae-821a-9e9f8bb8c5e4_terseLabel_en-US" xlink:label="lab_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MUFG Union Bank NA and Westpac Banking Corporation</link:label>
    <link:label id="lab_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember_label_en-US" xlink:label="lab_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mufg Union Bank Na And Westpac Banking Corporation [Member]</link:label>
    <link:label id="lab_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember_documentation_en-US" xlink:label="lab_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MUFG Union Bank NA and Westpac Banking Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember" xlink:href="rmd-20240630.xsd#rmd_MufgUnionBankNaAndWestpacBankingCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember" xlink:to="lab_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_171e46f5-85a3-48c5-b75a-f93e07ff0d31_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued on employee stock purchase plan (note 10)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b5ccbf87-ce23-4b0e-93b8-4e3538f29f5e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued on exercise of options (note 10)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_634db2cf-8856-4235-aca3-5db3d0856170_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_59f569ea-4a66-45a1-97a7-a0c4e8b65631_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_a8dd8f5f-22a8-42ab-bac1-f43822326d2f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_27b1d628-0b4d-4f23-8bdc-b400619ff850_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SummaryOfSignificantAccountingPoliciesTable_6e830f8b-0ef8-49d7-be0a-ec8303af780b_terseLabel_en-US" xlink:label="lab_rmd_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_rmd_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_rmd_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_rmd_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_rmd_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SummaryOfSignificantAccountingPoliciesTable" xlink:href="rmd-20240630.xsd#rmd_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_rmd_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_296a6a71-c4ba-498f-ab1d-8632d5cff0f7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment_7f8b8246-495d-4eeb-b54f-84522d540ffe_terseLabel_en-US" xlink:label="lab_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment</link:label>
    <link:label id="lab_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment_label_en-US" xlink:label="lab_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity Method Investment</link:label>
    <link:label id="lab_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment_documentation_en-US" xlink:label="lab_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment" xlink:href="rmd-20240630.xsd#rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment" xlink:to="lab_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f1bf82ad-a135-43c6-bff9-0d2c092a9403_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_fde0090c-19a1-4c9a-a225-a7c75fcd9c09_verboseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_5d94863c-0b19-410e-8874-ba3d9f7e468c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase to net earnings per diluted share from tax holidays and tax incentives program (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_label_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Holiday, Income Tax Benefits Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:to="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_d6e374bf-cf82-4f8f-9b53-5f5fe0555557_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease terms</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_fa0c2d24-2a1a-48e7-8bbb-d48a5e82d3e9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss attributable to equity method investments (note 6)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2841f655-dc86-44e1-bc27-d06fc3f6eed2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss attributable to equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_6904c8cc-d01b-4b38-8fcc-7d855e429474_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost, 42,664,067 shares at June&#160;30, 2024 and 41,836,234 shares at June&#160;30, 2023</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_aaeedcb8-6549-41df-8582-299433786030_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_2bae692b-b2b3-449e-81e6-ecfdd78cf434_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_ebb13363-4a22-4eba-820e-51e52dbdb4e3_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_IntangibleAssetImpairmentMember_44ff5492-932c-4751-a49f-e0d54e835380_terseLabel_en-US" xlink:label="lab_rmd_IntangibleAssetImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment</link:label>
    <link:label id="lab_rmd_IntangibleAssetImpairmentMember_label_en-US" xlink:label="lab_rmd_IntangibleAssetImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment [Member]</link:label>
    <link:label id="lab_rmd_IntangibleAssetImpairmentMember_documentation_en-US" xlink:label="lab_rmd_IntangibleAssetImpairmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IntangibleAssetImpairmentMember" xlink:href="rmd-20240630.xsd#rmd_IntangibleAssetImpairmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_IntangibleAssetImpairmentMember" xlink:to="lab_rmd_IntangibleAssetImpairmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e536c638-528e-4d1d-bbed-9944bc4570fd_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_b2ab74dd-5a16-40e7-8cec-263b76bbc9cf_verboseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized to be repurchased under repurchase program (in shares)</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="lab_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_f134010e-d765-441b-9d08-2b7143d8dbbf_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_d17e488c-9be3-40fa-8a7f-4f8691c95be3_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_3d1ebf11-d269-4d30-b339-9fbf2b2f0186_totalLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_b555adef-9f4c-4131-9623-e1472d9d4442_terseLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding debt</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Long-Term and Short-Term, Combined Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_NonEmployeeDirectorMember_1d56cce1-c414-44f1-bcc2-325f8eb1647e_terseLabel_en-US" xlink:label="lab_rmd_NonEmployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non Employee Director</link:label>
    <link:label id="lab_rmd_NonEmployeeDirectorMember_label_en-US" xlink:label="lab_rmd_NonEmployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Employee Director [Member]</link:label>
    <link:label id="lab_rmd_NonEmployeeDirectorMember_documentation_en-US" xlink:label="lab_rmd_NonEmployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Employee Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NonEmployeeDirectorMember" xlink:href="rmd-20240630.xsd#rmd_NonEmployeeDirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_NonEmployeeDirectorMember" xlink:to="lab_rmd_NonEmployeeDirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_cf521265-3cd0-4246-9f7e-65aaf902fdae_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_de0fc03e-f56e-4936-9d86-6cee94ce9002_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Restructuring</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a739117a-83c2-4342-a7a9-17787c0b0962_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e89d1b2-8b13-45db-8d6f-febfc0df770e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted &#8206;Average &#8206;Remaining &#8206;Contractual &#8206;Term in Years</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8e6f2940-26cb-43ed-90e2-2da1e2bed9f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_2396805b-420a-4f0a-8ee4-1b098820337b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrMember_c4cf12d2-a46a-493e-a07b-ea0d17326ae5_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotes_24d9ed82-0751-4799-9122-f1075d81005e_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding loan balance</link:label>
    <link:label id="lab_us-gaap_SeniorNotes_label_en-US" xlink:label="lab_us-gaap_SeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotes" xlink:to="lab_us-gaap_SeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod_6315cbde-1114-47af-88de-cd62b17c6634_terseLabel_en-US" xlink:label="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extended period</link:label>
    <link:label id="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod_label_en-US" xlink:label="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Extended Period</link:label>
    <link:label id="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod_documentation_en-US" xlink:label="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Extended Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod" xlink:href="rmd-20240630.xsd#rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod" xlink:to="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cd8314e-e8fa-4715-b9de-3951bfcf957e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_eb0fec87-6829-4e23-a89e-fdd97532d384_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_e1f91cb4-416d-4ae3-b676-ccced95a5325_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c56b3b62-ecc5-40fe-b3af-24ee09d0d89b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_1cc7f7d1-5d7d-4d4c-b512-99f03edaaedf_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Lived Assets by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxCreditsAndAdjustments_18cfeec8-1b6e-4dff-8a9f-7e19df9f7d13_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credits and deductions</link:label>
    <link:label id="lab_us-gaap_IncomeTaxCreditsAndAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Credits and Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:to="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_9ba8259d-8221-493c-86b4-7ef3fad3c318_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_459da6de-935f-43cb-98c6-bd7c7d5bc835_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_KaushikGhoshalMember_label_en-US" xlink:label="lab_rmd_KaushikGhoshalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Kaushik Ghoshal [Member]</link:label>
    <link:label id="lab_rmd_KaushikGhoshalMember_documentation_en-US" xlink:label="lab_rmd_KaushikGhoshalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Kaushik Ghoshal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_KaushikGhoshalMember" xlink:href="rmd-20240630.xsd#rmd_KaushikGhoshalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_KaushikGhoshalMember" xlink:to="lab_rmd_KaushikGhoshalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_58dc2059-37b2-40da-a99b-0d49ec368aea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_8c84a490-2bbf-47da-98e2-6b0cb0775b81_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_22f6940f-fe1f-417a-97c2-4c30365f827c_terseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable shares, netted for tax (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d601f55c-7c45-4e74-a992-79e4e102b210_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_73ba3e99-6f2c-4997-b296-c382970580d4_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2170eb41-7e02-43ab-aa6c-a09ff2b51464_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_50de01bc-5cbb-4e2d-ac1f-d7009795dc59_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_38854cc7-6e3b-4f70-9c77-4189d7279a98_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d2895ee5-5fd7-418f-a80d-d91d31a0fbcc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable, accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_466dbcc8-8371-40ea-8122-1d60ebef9ebc_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_b772e011-1410-4d03-ae02-5d8110c75a69_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_4ef878e7-c35c-457a-97b5-2e7467ca555e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Values of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_0cb65268-8213-4cf2-9d14-dde55f26b648_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_988d59db-9967-43c0-9a2c-676fc0e8b596_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes (note 12)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_3d731393-207d-4386-a375-b4935f3479bb_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Non-current deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Other Tax Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_NumberOfPatents_5fbd37e6-5be9-43cb-9f19-9a67ce53476f_terseLabel_en-US" xlink:label="lab_rmd_NumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents</link:label>
    <link:label id="lab_rmd_NumberOfPatents_label_en-US" xlink:label="lab_rmd_NumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Patents</link:label>
    <link:label id="lab_rmd_NumberOfPatents_documentation_en-US" xlink:label="lab_rmd_NumberOfPatents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NumberOfPatents" xlink:href="rmd-20240630.xsd#rmd_NumberOfPatents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_NumberOfPatents" xlink:to="lab_rmd_NumberOfPatents" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ClinicalDemonstrationAndRentalEquipmentMember_b5e443f7-eea6-4fac-8b32-8b00068e4a9f_terseLabel_en-US" xlink:label="lab_rmd_ClinicalDemonstrationAndRentalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical, demonstration and rental equipment</link:label>
    <link:label id="lab_rmd_ClinicalDemonstrationAndRentalEquipmentMember_label_en-US" xlink:label="lab_rmd_ClinicalDemonstrationAndRentalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Demonstration And Rental Equipment [Member]</link:label>
    <link:label id="lab_rmd_ClinicalDemonstrationAndRentalEquipmentMember_documentation_en-US" xlink:label="lab_rmd_ClinicalDemonstrationAndRentalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical, Demonstration and Rental Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ClinicalDemonstrationAndRentalEquipmentMember" xlink:href="rmd-20240630.xsd#rmd_ClinicalDemonstrationAndRentalEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ClinicalDemonstrationAndRentalEquipmentMember" xlink:to="lab_rmd_ClinicalDemonstrationAndRentalEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesSubscriptions_fce7f1f3-aa8d-414a-9a63-e98845afd8cc_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesSubscriptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares subscribed</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesSubscriptions_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesSubscriptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Subscriptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesSubscriptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesSubscriptions" xlink:to="lab_us-gaap_CommonStockSharesSubscriptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_816fc54a-faf8-471b-a8c3-432acf7f2e49_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income Before Income Taxes Under the Jurisdictions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_UnallocatedCorporateCosts_a5c658b3-82b7-47c1-b276-541164c29302_terseLabel_en-US" xlink:label="lab_rmd_UnallocatedCorporateCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate costs</link:label>
    <link:label id="lab_rmd_UnallocatedCorporateCosts_label_en-US" xlink:label="lab_rmd_UnallocatedCorporateCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unallocated Corporate Costs</link:label>
    <link:label id="lab_rmd_UnallocatedCorporateCosts_documentation_en-US" xlink:label="lab_rmd_UnallocatedCorporateCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unallocated corporate costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_UnallocatedCorporateCosts" xlink:href="rmd-20240630.xsd#rmd_UnallocatedCorporateCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_UnallocatedCorporateCosts" xlink:to="lab_rmd_UnallocatedCorporateCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c35365d9-9d8d-49d3-9db5-92b55c4c2fa6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_14f2e31e-3942-40ef-b027-bde3b9d6d5e4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_db270ce5-8c56-4065-a3d5-7f748ff34c71_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_be290aa8-539a-489a-beeb-a49687a221b4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_571422c5-ef59-4e71-80d6-e91ebe3a938b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DeferredTaxAssetsLeaseLiabilities_614496f5-d9c7-4e08-839d-9cbd82c6e9c6_terseLabel_en-US" xlink:label="lab_rmd_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_rmd_DeferredTaxAssetsLeaseLiabilities_label_en-US" xlink:label="lab_rmd_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:label id="lab_rmd_DeferredTaxAssetsLeaseLiabilities_documentation_en-US" xlink:label="lab_rmd_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredTaxAssetsLeaseLiabilities" xlink:href="rmd-20240630.xsd#rmd_DeferredTaxAssetsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_rmd_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_8bf4a4ee-de67-4d3b-a729-a7bcc6ffc867_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9dc817aa-2313-4acf-9f65-a970b86a4540_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a8270d3d-74f8-48ab-b2dd-02d171d100cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted &#8206;Average &#8206;Grant-Date &#8206;Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTextBlock_6c2c6157-53e4-4d4f-aea0-face4cb685f8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTextBlock" xlink:to="lab_us-gaap_InvestmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_db9e6b29-f491-467a-9b20-16bebe970449_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_91a0cd1a-7a94-4bae-9dc6-1b65676797dd_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal payment</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_eb2c4494-75ad-4b2a-80ef-9e13374e8e0a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_39cac630-a847-4ab1-a8b3-db93f32d353d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4fa64420-48ce-4f10-9936-7a5438fc0ebd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_788251b9-d2e3-426f-b747-e822aea71a61_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4f5f2c53-771c-45ba-99c3-5fc157caee35_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities, unrealized (loss) gain</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_5281b795-4d53-4908-9bbd-28ac975413e6_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember_e8446105-3b85-4fde-b27b-d6ed4fb27b37_terseLabel_en-US" xlink:label="lab_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility And Term Credit Agreement</link:label>
    <link:label id="lab_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember_label_en-US" xlink:label="lab_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility And Term Loan Credit Agreement [Member]</link:label>
    <link:label id="lab_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember_documentation_en-US" xlink:label="lab_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility And Term Loan Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember" xlink:href="rmd-20240630.xsd#rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember" xlink:to="lab_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_59569cf6-1cfe-46da-bb83-55ea4963091d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_c8218e60-267f-48a7-a91c-14305680b47a_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Units (PRSUs)</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_63d068d8-6350-47d7-a67e-7068c22bad43_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_61ebdfed-cda9-49ab-a560-982a74bae606_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses on marketable equity securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Security, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_e083f241-7512-4f0c-b062-cea714ab5e29_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_b19d6fbe-dc3e-4208-9662-f1ba73f75415_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_f1e6a410-9335-4bd2-a8cb-4b6b01f1f2e2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_14caffa7-64ff-46a4-aae5-ed9e84df3a10_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLoansAndLeasesReceivablePolicy_8ccd4a75-2836-4dfa-b11f-2da806692438_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_FinanceLoansAndLeasesReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLoansAndLeasesReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:to="lab_us-gaap_FinanceLoansAndLeasesReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_45803651-dec2-46e3-91f7-6f67ab02b1f3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7578fe0d-8574-453a-9dfb-db96b4ffa573_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_6876a9e8-33cd-46bb-b722-2c555f435305_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_MaximumNumberOfSharesSubjectToAwardsGranted_c7039c78-61bb-4c5d-8510-59fdc2c13e96_terseLabel_en-US" xlink:label="lab_rmd_MaximumNumberOfSharesSubjectToAwardsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of shares subject to awards granted (in shares)</link:label>
    <link:label id="lab_rmd_MaximumNumberOfSharesSubjectToAwardsGranted_label_en-US" xlink:label="lab_rmd_MaximumNumberOfSharesSubjectToAwardsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Number Of Shares Subject To Awards Granted</link:label>
    <link:label id="lab_rmd_MaximumNumberOfSharesSubjectToAwardsGranted_documentation_en-US" xlink:label="lab_rmd_MaximumNumberOfSharesSubjectToAwardsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum number of shares subject to awards granted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MaximumNumberOfSharesSubjectToAwardsGranted" xlink:href="rmd-20240630.xsd#rmd_MaximumNumberOfSharesSubjectToAwardsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_MaximumNumberOfSharesSubjectToAwardsGranted" xlink:to="lab_rmd_MaximumNumberOfSharesSubjectToAwardsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_8dfb2eb2-8fcf-4d9e-a68d-c35c302ac0e2_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_83251d1a-d5e9-4e9e-831f-7788eca0e267_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_f8aeb05a-24dd-4588-9615-a96ec784cfa7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exits of investments (note 6)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0e305a5a-0192-4b08-82bd-884c7fdc2cf1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful life of property, plant and equipment, years</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0cce24fa-c8d0-41af-a26c-0b510afd8424_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_85b95f70-dc98-439a-9bb8-7ed68805da2d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_755cbb51-45cd-4f3f-ad96-3c2a72510928_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_55b28265-1fb0-4cc7-99e6-94f57125ed9f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e25fd6b9-8bc6-482b-b2c5-dd4e239aeaed_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SaasMember_f28e098f-4de8-424b-970b-293dad59d93e_terseLabel_en-US" xlink:label="lab_rmd_SaasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SaaS</link:label>
    <link:label id="lab_rmd_SaasMember_label_en-US" xlink:label="lab_rmd_SaasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Saas [Member]</link:label>
    <link:label id="lab_rmd_SaasMember_documentation_en-US" xlink:label="lab_rmd_SaasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Saas [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SaasMember" xlink:href="rmd-20240630.xsd#rmd_SaasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SaasMember" xlink:to="lab_rmd_SaasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a51d0809-dac3-40c5-8677-39fa047d6e5d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_d040187a-17b0-4838-b600-6064bb0594d9_terseLabel_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Board of Directors Chairman</link:label>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_label_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember" xlink:to="lab_srt_BoardOfDirectorsChairmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_89be9cc9-2660-434e-ad53-0859d6ddf42d_totalLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_MichaelJ.FarrellMember_label_en-US" xlink:label="lab_rmd_MichaelJ.FarrellMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Michael J. Farrell [Member]</link:label>
    <link:label id="lab_rmd_MichaelJ.FarrellMember_documentation_en-US" xlink:label="lab_rmd_MichaelJ.FarrellMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Michael J. Farrell</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MichaelJ.FarrellMember" xlink:href="rmd-20240630.xsd#rmd_MichaelJ.FarrellMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_MichaelJ.FarrellMember" xlink:to="lab_rmd_MichaelJ.FarrellMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_678371bf-7683-41c4-8a9b-23663b2ac820_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_c14c2d3a-80fe-4891-9cce-89312b0df84b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_82b24915-b1dc-4767-8eb4-6876cb73826c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales (exclusive of amortization shown separately below)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_bb7ecb0d-a4f1-49ac-841c-1b6faff0d577_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_7255fb44-6bbd-4873-97be-d2cd620ace69_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (note 15)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4e8d1196-fdd3-4092-b216-aefa0d0bb097_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Provision for Income Tax Differ From the Amount of Income Tax</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_2cee593f-12f0-48a2-a6d6-f97ec4212172_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted, Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4326b6e5-f042-4285-b20f-5019fe25c1ce_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFourthYear_4a0c2577-c8b8-4b16-8d57-8785aa2c5790_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFourthYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInFourthYear" xlink:to="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_26a8edb7-2401-42fa-9470-d09e27fa0802_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_edf5a7ed-f48b-405e-91dd-f958671d9231_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Geographic Area</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_7a9937a5-c843-4c58-971b-b7bf9e83a664_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_b8c6260b-ec7b-48fe-92e6-36f603fc9c30_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_2047a32b-4636-4b2b-ae9c-e8e7c89f3e7b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a960724f-d8c1-4b90-85cc-f6527e63b720_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_77d1f8fa-5b0a-4925-8682-ab753f7c4874_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a349f470-0dbb-4373-8f52-d6bb5138ddbe_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_406219d2-c61d-4321-9c3b-8dc8bca443c0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available for draw</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c332860e-f127-4a45-b835-b280f13f9171_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueAfterFifthYear_0d99547d-60e3-4c6f-b3ae-c3f9ce4c37e7_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueAfterFifthYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueAfterFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:to="lab_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceRecoveries_e7f8a4c4-513f-484b-89bc-42d9606c5f46_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InsuranceRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on insurance recoveries</link:label>
    <link:label id="lab_us-gaap_InsuranceRecoveries_label_en-US" xlink:label="lab_us-gaap_InsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Recoveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceRecoveries" xlink:to="lab_us-gaap_InsuranceRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b1db7dbb-53eb-4e74-a39d-be738bdbaf8a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d08c39bd-d72d-4a06-84ce-4e3cc87fc4a9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_0b6cb87c-043a-4afd-b483-da7f9289e40b_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9c70319f-184d-4f08-b474-c2be2e4612cb_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b77effb9-012f-4576-9dee-1bce6ccc3d09_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of the stock-based compensation arrangements exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f338b63d-a1b8-4481-803e-1f3b0763566a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_IncomeTaxesLineItems_f7534c2f-36d3-4ed8-913d-33aeb87a04a0_terseLabel_en-US" xlink:label="lab_rmd_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_rmd_IncomeTaxesLineItems_label_en-US" xlink:label="lab_rmd_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_rmd_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_rmd_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxesLineItems" xlink:href="rmd-20240630.xsd#rmd_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_IncomeTaxesLineItems" xlink:to="lab_rmd_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFifthYear_1583fdf0-c88e-4f7b-b1d2-2cd7d342f5ff_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFifthYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInFifthYear" xlink:to="lab_us-gaap_PurchaseObligationDueInFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DeferredRevenueNonCurrentLiabilitiesMember_8c49351e-7870-476b-8bee-e8850922aa0d_terseLabel_en-US" xlink:label="lab_rmd_DeferredRevenueNonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue (non-current liabilities)</link:label>
    <link:label id="lab_rmd_DeferredRevenueNonCurrentLiabilitiesMember_label_en-US" xlink:label="lab_rmd_DeferredRevenueNonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Non Current Liabilities [Member]</link:label>
    <link:label id="lab_rmd_DeferredRevenueNonCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_rmd_DeferredRevenueNonCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Revenue Non Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredRevenueNonCurrentLiabilitiesMember" xlink:href="rmd-20240630.xsd#rmd_DeferredRevenueNonCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DeferredRevenueNonCurrentLiabilitiesMember" xlink:to="lab_rmd_DeferredRevenueNonCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_4cc3882d-a4a8-4d9f-9780-c361da4f2662_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_8f3cc3a7-f8b6-49ca-9099-efcd96e4ec54_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_fe2f2471-ceb2-459b-ae7a-07d7398307c3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Foreign tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9f584723-28cb-41ee-843a-d084c1da8477_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f332f4b1-0a3f-4eee-8df6-baca5db07e58_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic shares outstanding (000's) (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_557fda2a-87bf-400e-851e-007563c9934a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_2c1278f3-73ed-4235-a60c-ca6969199e2b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ResmedLimitedMember_1436f4f4-f754-48bc-b868-598c43262848_terseLabel_en-US" xlink:label="lab_rmd_ResmedLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ResMed Limited</link:label>
    <link:label id="lab_rmd_ResmedLimitedMember_label_en-US" xlink:label="lab_rmd_ResmedLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Resmed Limited [Member]</link:label>
    <link:label id="lab_rmd_ResmedLimitedMember_documentation_en-US" xlink:label="lab_rmd_ResmedLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ResMed Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ResmedLimitedMember" xlink:href="rmd-20240630.xsd#rmd_ResmedLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ResmedLimitedMember" xlink:to="lab_rmd_ResmedLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_3a76efc7-2992-4840-bded-5280aac24f20_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting and professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6f303718-c4f2-46d8-a911-adbfc2c680a8_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired_6741542f-8912-4f87-94a3-7646da01cebb_terseLabel_en-US" xlink:label="lab_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of assets acquired, excluding cash</link:label>
    <link:label id="lab_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired_label_en-US" xlink:label="lab_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Part Of Acquisition, Fair Value of Assets Acquired</link:label>
    <link:label id="lab_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired_documentation_en-US" xlink:label="lab_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The fair value of an asset or business acquired in a noncash acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired" xlink:href="rmd-20240630.xsd#rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired" xlink:to="lab_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_21b4d34d-40ff-46c0-b2f3-d621ba83ad8e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock_969ca10d-e5cb-4c56-974a-57f71a0387e3_terseLabel_en-US" xlink:label="lab_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities Classified as Current and Non-Current</link:label>
    <link:label id="lab_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components Of Net Deferred Income Tax Assets And Liabilities [Table Text Block]</link:label>
    <link:label id="lab_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Components Of Net Deferred Income Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="rmd-20240630.xsd#rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock_987002e3-e14a-4c8d-b87d-5cda2a184345_terseLabel_en-US" xlink:label="lab_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk and Significant Customers</link:label>
    <link:label id="lab_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock_label_en-US" xlink:label="lab_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Of Credit Risk And Significant Customers [Policy Text Block]</link:label>
    <link:label id="lab_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock_documentation_en-US" xlink:label="lab_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Of Credit Risk And Significant Customers [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock" xlink:href="rmd-20240630.xsd#rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock" xlink:to="lab_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_MEDIFOXDANMember_d3608dca-bb34-448a-8791-9b86f9aa41d7_terseLabel_en-US" xlink:label="lab_rmd_MEDIFOXDANMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MEDIFOX DAN</link:label>
    <link:label id="lab_rmd_MEDIFOXDANMember_label_en-US" xlink:label="lab_rmd_MEDIFOXDANMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MEDIFOX DAN [Member]</link:label>
    <link:label id="lab_rmd_MEDIFOXDANMember_documentation_en-US" xlink:label="lab_rmd_MEDIFOXDANMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MEDIFOX DAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MEDIFOXDANMember" xlink:href="rmd-20240630.xsd#rmd_MEDIFOXDANMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_MEDIFOXDANMember" xlink:to="lab_rmd_MEDIFOXDANMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_eff91d71-51f8-4661-a7de-cef5eed658a3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_31b210af-cad0-4e31-93ea-3e46ab8f64bc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_5b0bb7df-8b85-4fc6-99ae-914b0b8c1a59_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities_8bbf79f2-6c85-4003-867b-b5a238c73804_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Proceeds / (payments) on maturity of foreign currency contracts</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Derivative Instrument, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_2cee3b1f-72bf-4ea9-8e2f-cd1355202d77_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unbilled revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_fbc86ec0-577c-4fda-8a97-3e27c7fea1ed_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_4c8a7be8-bf45-4ee6-b49f-a9ba6f69e2d4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_bae2a9dd-05dc-42df-b170-9ccdad9f9aad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted &#8206;Average &#8206;Remaining &#8206;Contractual &#8206;Term in Years</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_1d65c89d-4310-400a-aac2-60d6a2a5d75b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_FairValueAndNetInvestmentHedgingMember_676dde7e-d4bc-4111-a8bd-f245fd3219c6_terseLabel_en-US" xlink:label="lab_rmd_FairValueAndNetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value And Net Investment Hedging</link:label>
    <link:label id="lab_rmd_FairValueAndNetInvestmentHedgingMember_label_en-US" xlink:label="lab_rmd_FairValueAndNetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value And Net Investment Hedging [Member]</link:label>
    <link:label id="lab_rmd_FairValueAndNetInvestmentHedgingMember_documentation_en-US" xlink:label="lab_rmd_FairValueAndNetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value And Net Investment Hedging</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_FairValueAndNetInvestmentHedgingMember" xlink:href="rmd-20240630.xsd#rmd_FairValueAndNetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_FairValueAndNetInvestmentHedgingMember" xlink:to="lab_rmd_FairValueAndNetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a5ea39f7-0d70-43ba-bf4d-a3907c7e5b62_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f2031a27-b38c-4c8e-9567-e571b46f7779_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_e56ad3b9-f161-436f-b03d-d1e91901c25c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Penalties and interest</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_3c7f8b7c-305f-4508-91f8-208e7e93320c_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_3bee4518-5d86-444c-b9b7-75701d26e69e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes paid, net of refunds</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_AccruedLogisticsAndOccupancyExpensesCurrent_378e9bb4-627b-4cb7-9d57-c7f3f4a6d168_terseLabel_en-US" xlink:label="lab_rmd_AccruedLogisticsAndOccupancyExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Logistics and occupancy costs</link:label>
    <link:label id="lab_rmd_AccruedLogisticsAndOccupancyExpensesCurrent_label_en-US" xlink:label="lab_rmd_AccruedLogisticsAndOccupancyExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Logistics And Occupancy Expenses Current</link:label>
    <link:label id="lab_rmd_AccruedLogisticsAndOccupancyExpensesCurrent_documentation_en-US" xlink:label="lab_rmd_AccruedLogisticsAndOccupancyExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Logistics And Occupancy Expenses Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AccruedLogisticsAndOccupancyExpensesCurrent" xlink:href="rmd-20240630.xsd#rmd_AccruedLogisticsAndOccupancyExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_AccruedLogisticsAndOccupancyExpensesCurrent" xlink:to="lab_rmd_AccruedLogisticsAndOccupancyExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_3b24c57b-f6f7-42db-a347-c633b2302ab4_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity method</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SummaryOfSignificantAccountingPoliciesLineItems_e30a3801-1b68-4ab2-bf6e-02e93b8fd819_terseLabel_en-US" xlink:label="lab_rmd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_rmd_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_rmd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_rmd_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_rmd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="rmd-20240630.xsd#rmd_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_rmd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_OrganizationAndBasisOfPresentationPolicyPolicyTextBlock_5919700b-16e1-4c21-873e-1e77b84ce731_terseLabel_en-US" xlink:label="lab_rmd_OrganizationAndBasisOfPresentationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_rmd_OrganizationAndBasisOfPresentationPolicyPolicyTextBlock_label_en-US" xlink:label="lab_rmd_OrganizationAndBasisOfPresentationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Basis Of Presentation, Policy [Policy Text Block]</link:label>
    <link:label id="lab_rmd_OrganizationAndBasisOfPresentationPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_rmd_OrganizationAndBasisOfPresentationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization And Basis Of Presentation, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_OrganizationAndBasisOfPresentationPolicyPolicyTextBlock" xlink:href="rmd-20240630.xsd#rmd_OrganizationAndBasisOfPresentationPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_OrganizationAndBasisOfPresentationPolicyPolicyTextBlock" xlink:to="lab_rmd_OrganizationAndBasisOfPresentationPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_547411c4-150a-404c-b201-a9fd7ff8df3c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_136c404d-eb5a-418c-9577-4e4c1bf0e4db_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation costs, net of tax benefit</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_AccruedInventoryInTransit_b911bd2a-8754-44fe-b3aa-b3691960ea02_terseLabel_en-US" xlink:label="lab_rmd_AccruedInventoryInTransit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory in transit</link:label>
    <link:label id="lab_rmd_AccruedInventoryInTransit_label_en-US" xlink:label="lab_rmd_AccruedInventoryInTransit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Inventory In Transit</link:label>
    <link:label id="lab_rmd_AccruedInventoryInTransit_documentation_en-US" xlink:label="lab_rmd_AccruedInventoryInTransit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued inventory in transit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AccruedInventoryInTransit" xlink:href="rmd-20240630.xsd#rmd_AccruedInventoryInTransit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_AccruedInventoryInTransit" xlink:to="lab_rmd_AccruedInventoryInTransit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6e26824e-01d5-435b-bee6-03bb71fba352_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_c5a584f4-df60-4840-b3a6-379cf4a01fcb_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Actions, Contingencies and Commitments</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_7fdeb704-0df7-4eaf-9be9-7ec99030bfd6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGrossAbstract_0269e420-6bd0-4910-bf7f-b8ee7375f7dd_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGrossAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGrossAbstract" xlink:to="lab_us-gaap_InventoryGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_3a5b946d-be9c-4948-a255-b194ea049104_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_22a15b32-e84b-45d5-b906-7e4076a9f636_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a5f1a6e4-61a0-48e5-9b0c-0cc44d28ad57_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_bda63e3c-1ce8-413c-8b1d-714cb77e7ad6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_IncomeTaxExaminationPriorRemittancePayments_ce3a27c9-c2aa-4c5e-99e4-a06e1cf49390_terseLabel_en-US" xlink:label="lab_rmd_IncomeTaxExaminationPriorRemittancePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior remittance payments</link:label>
    <link:label id="lab_rmd_IncomeTaxExaminationPriorRemittancePayments_label_en-US" xlink:label="lab_rmd_IncomeTaxExaminationPriorRemittancePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Prior Remittance Payments</link:label>
    <link:label id="lab_rmd_IncomeTaxExaminationPriorRemittancePayments_documentation_en-US" xlink:label="lab_rmd_IncomeTaxExaminationPriorRemittancePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Prior Remittance Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationPriorRemittancePayments" xlink:href="rmd-20240630.xsd#rmd_IncomeTaxExaminationPriorRemittancePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_IncomeTaxExaminationPriorRemittancePayments" xlink:to="lab_rmd_IncomeTaxExaminationPriorRemittancePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_4084987a-b460-414f-975a-ab39833d78c2_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_6ce35415-3f07-4ab4-a844-b08f06f1a535_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_81473d9e-485c-482d-af7f-0309f918b5d0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_976a13b0-e363-4344-83cc-9aa22100fdc7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current (note 9)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_31896edd-bb3e-4eb8-9ed4-bb94977c946b_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Designated Hedges</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_54a4a974-37ca-454f-a54d-33caba228754_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_24b770ca-ea2a-4ccd-b4e8-cf6f1b8cc604_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_8320f2b5-6a17-4418-96c3-2b4e0c03d5fc_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_fc4f1c31-626f-4409-820e-dcd67d3508a7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_6a4a5aa6-30b1-46a7-8a3f-c84e860dbdd9_negatedLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impairment of investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Other-than-Temporary Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending_9c788a2a-9156-42df-b38a-b3175eb99e85_terseLabel_en-US" xlink:label="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock authorized for issuance and pending registration (in shares)</link:label>
    <link:label id="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending_label_en-US" xlink:label="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Pending</link:label>
    <link:label id="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending_documentation_en-US" xlink:label="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Pending</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending" xlink:href="rmd-20240630.xsd#rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending" xlink:to="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c1a15cd4-342b-4722-a14b-b3b24970dbaa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_53319071-3714-4a13-9e2d-afb0ef370b35_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_8079cb77-4251-4ca4-a52b-5beab15d5e8c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock purchases (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_f24d7bae-694d-406b-bc30-1e910b4458ca_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock acquired (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_00ab661c-444a-4a74-bba5-e130816efff2_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-U.S.</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_7aa52f45-29a0-4a4f-8a22-fab59aae721a_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_IdentifiedIntangibleAssetsMember_a0824914-16bf-4d4e-a972-ca54121a73f2_terseLabel_en-US" xlink:label="lab_rmd_IdentifiedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Identified Intangible Assets</link:label>
    <link:label id="lab_rmd_IdentifiedIntangibleAssetsMember_label_en-US" xlink:label="lab_rmd_IdentifiedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identified Intangible Assets [Member]</link:label>
    <link:label id="lab_rmd_IdentifiedIntangibleAssetsMember_documentation_en-US" xlink:label="lab_rmd_IdentifiedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Identified Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IdentifiedIntangibleAssetsMember" xlink:href="rmd-20240630.xsd#rmd_IdentifiedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_IdentifiedIntangibleAssetsMember" xlink:to="lab_rmd_IdentifiedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_73a547aa-ca8c-435c-9aee-81f8a47184a3_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_b1ed2143-6f92-4126-b8b6-808258f8faf1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value added taxes and other taxes due</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_f0bbeaef-9b9e-4a74-bcc0-cce2aef93dd8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_228d4600-cbfd-46a7-8eb9-9dd1aace11fd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_59f3b25e-28ec-402b-ac40-6fae79e5449e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other prepaid expenses and current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_d97aad95-0ef9-458a-ae84-d78f9040ea39_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) recognized on cross-currency swap in interest (expense) income, net (amount excluded from effectiveness testing)</link:label>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Excluded Component, Gain (Loss), Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:to="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_9b3bf927-01ca-488b-a0ce-bd8585c36feb_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_08f55aae-b785-44ce-a34e-dfb852756502_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade names</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_e4ac0f52-61a9-4881-8f82-3d8d3b85b828_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) recognized from the excluded components in interest (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_0efa91b7-2cc0-47df-9d88-e8fd924f268c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsStateTaxes_d894b5ee-8693-4259-a231-b6808ef79b6a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsStateTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsStateTaxes_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsStateTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, State Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsStateTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsStateTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsStateTaxes" xlink:to="lab_us-gaap_DeferredTaxAssetsStateTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_43b0cd4e-c22a-4e44-9b3e-4d2cb4b41112_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of the stock-based compensation arrangements outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_EmployeeStockPurchasePlanPurchaseRightsMember_67fd3a17-7f02-45ef-928d-8fe6ddcbc935_terseLabel_en-US" xlink:label="lab_rmd_EmployeeStockPurchasePlanPurchaseRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP purchase rights:</link:label>
    <link:label id="lab_rmd_EmployeeStockPurchasePlanPurchaseRightsMember_label_en-US" xlink:label="lab_rmd_EmployeeStockPurchasePlanPurchaseRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan Purchase Rights [Member]</link:label>
    <link:label id="lab_rmd_EmployeeStockPurchasePlanPurchaseRightsMember_documentation_en-US" xlink:label="lab_rmd_EmployeeStockPurchasePlanPurchaseRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan Purchase rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanPurchaseRightsMember" xlink:href="rmd-20240630.xsd#rmd_EmployeeStockPurchasePlanPurchaseRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_EmployeeStockPurchasePlanPurchaseRightsMember" xlink:to="lab_rmd_EmployeeStockPurchasePlanPurchaseRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_1af5fcec-1bde-48e7-a5f4-53aa938739df_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_2d72f5d6-e9a6-45ac-890b-e5ddaf8dff31_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_65da3b18-9be4-4539-9a34-6f1599120120_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_73ddb869-a97a-41f4-9c31-7aa521e9e798_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_ad22abd0-54ff-40fb-b4f1-1396deee75de_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_34c23e7a-91ed-4824-bc7f-7daba7cd0266_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c3d96315-4d43-4860-91e9-3e40aa0ede68_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued on employee stock purchase plan (note 10) (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_141895ec-60c0-4b1b-a640-f5357d553435_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_e95dd416-91ed-4b5f-9062-78a854cfc54b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term income taxes payable (note 12)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent_01f972a0-41df-4dec-b1fc-ce838c434e7e_terseLabel_en-US" xlink:label="lab_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of contribution by the company to the retirement plans</link:label>
    <link:label id="lab_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent_label_en-US" xlink:label="lab_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Maximum Annual Contributions By Employer Percent</link:label>
    <link:label id="lab_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent_documentation_en-US" xlink:label="lab_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Maximum Annual Contributions By Employer Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" xlink:href="rmd-20240630.xsd#rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" xlink:to="lab_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromInvestments_ecc2a7b7-ec1e-454f-bc24-e5301026b607_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exits of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromInvestments" xlink:to="lab_us-gaap_PaymentsForProceedsFromInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e58d7a4-360d-47dd-8782-009512d74a2b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_415ef067-e3cf-491f-9666-b2a9eb2345f0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9bf80c57-f7c4-4c8b-a43c-183d477f2cb6_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation costs related to unvested stock-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_1a07e142-de93-4408-b672-b9ea604220b2_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-U.S.</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5bcd9528-f91d-4e80-9fe5-309946e16f68_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_8d4883ba-fcd1-44e1-9ecd-d6b7bad96940_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_95919088-0f28-4234-8f50-e174e719892b_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_c8c1e6e3-a1ae-4c31-ae97-72bbe66145a5_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_ef4453c9-0383-4383-b438-cbcf7d59f820_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, common, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_35aa640c-6985-4471-8c8c-c582f3159a1d_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, common, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_c8787790-cf03-4d1e-b07b-f4e4975e8643_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total number of shares repurchased pursuant to the repurchase program (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_a1b2108d-6e71-45ea-b4ac-e7f2bd7f2690_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_49c6254a-2030-4dd7-8e28-be256dbde16b_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for trade accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_label_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Credit Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossMember" xlink:to="lab_us-gaap_AllowanceForCreditLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2b70726b-c5d6-4c43-8902-ea5cdcc368ec_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_8d288b8c-7b11-4f5f-9fc0-a36e98423fe0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_738bf392-e34c-4974-96dc-168d34d892c5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e08d9a41-9203-4a0e-953d-515e0badb425_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_MasksAndOtherMember_fce98f54-3978-4065-ae03-af70e80cca9c_terseLabel_en-US" xlink:label="lab_rmd_MasksAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Masks and other</link:label>
    <link:label id="lab_rmd_MasksAndOtherMember_label_en-US" xlink:label="lab_rmd_MasksAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Masks and Other [Member]</link:label>
    <link:label id="lab_rmd_MasksAndOtherMember_documentation_en-US" xlink:label="lab_rmd_MasksAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Masks and Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MasksAndOtherMember" xlink:href="rmd-20240630.xsd#rmd_MasksAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_MasksAndOtherMember" xlink:to="lab_rmd_MasksAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f0d2a024-950a-40cb-8c38-acc39d88a5bd_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Credit facility interest rate equal to reference rate plus</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_OtherForeignExchangeContractsMember_af57e74a-a50e-4b51-a6bf-649b8e8abf39_terseLabel_en-US" xlink:label="lab_rmd_OtherForeignExchangeContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Foreign Exchange Contracts</link:label>
    <link:label id="lab_rmd_OtherForeignExchangeContractsMember_label_en-US" xlink:label="lab_rmd_OtherForeignExchangeContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Foreign Exchange Contracts [Member]</link:label>
    <link:label id="lab_rmd_OtherForeignExchangeContractsMember_documentation_en-US" xlink:label="lab_rmd_OtherForeignExchangeContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Foreign Exchange Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_OtherForeignExchangeContractsMember" xlink:href="rmd-20240630.xsd#rmd_OtherForeignExchangeContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_OtherForeignExchangeContractsMember" xlink:to="lab_rmd_OtherForeignExchangeContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_78fd5424-8624-4e76-b657-3cda6a7ca00e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_IncomeTaxExaminationRemittedFinalPayment_4e37c059-cf44-47e2-86d7-5100e461846b_terseLabel_en-US" xlink:label="lab_rmd_IncomeTaxExaminationRemittedFinalPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remitted final payment</link:label>
    <link:label id="lab_rmd_IncomeTaxExaminationRemittedFinalPayment_label_en-US" xlink:label="lab_rmd_IncomeTaxExaminationRemittedFinalPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Remitted Final Payment</link:label>
    <link:label id="lab_rmd_IncomeTaxExaminationRemittedFinalPayment_documentation_en-US" xlink:label="lab_rmd_IncomeTaxExaminationRemittedFinalPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Remitted Final Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationRemittedFinalPayment" xlink:href="rmd-20240630.xsd#rmd_IncomeTaxExaminationRemittedFinalPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_IncomeTaxExaminationRemittedFinalPayment" xlink:to="lab_rmd_IncomeTaxExaminationRemittedFinalPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c0701169-d2be-4db9-aee8-47679b89ad8b_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_b1a4eb99-9d0d-4f74-b3fb-6e51754ceb7c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt, net (note 8)</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_cad1371f-f395-4cbe-bb71-9ebbf01dabc0_totalLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Short-term debt, net</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1d422204-18f1-4050-9cf2-455ee4b6a1c8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_RestOfWorldMember_e48d9f50-a7ca-42c3-8e45-921a826e5af9_terseLabel_en-US" xlink:label="lab_rmd_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of the World</link:label>
    <link:label id="lab_rmd_RestOfWorldMember_label_en-US" xlink:label="lab_rmd_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:label id="lab_rmd_RestOfWorldMember_documentation_en-US" xlink:label="lab_rmd_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RestOfWorldMember" xlink:href="rmd-20240630.xsd#rmd_RestOfWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_RestOfWorldMember" xlink:to="lab_rmd_RestOfWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_011903bf-6e12-4d3d-8148-2adb919521c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted &#8206;Stock &#8206;Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_910bb086-241d-46c8-b375-e8b42c473142_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b5d41670-86d8-4cd9-8254-ade789fd14d5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e24c8372-9d04-465f-8b52-dca1fef0a12d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_ec1813b0-7baa-4e40-ad47-83a37dfff544_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8e461cca-9cfe-4372-8d5d-075f60cc8908_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments_b873bcc0-f71f-4293-adde-c4d827b86036_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Foreign Currency Translation Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:to="lab_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_005862bf-3431-4cdf-ae55-09c141ed360b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_36b996dd-5e9f-4d4b-bd48-c87402f7bf12_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities_84547d38-4019-4955-a47c-3a71a556e4b3_terseLabel_en-US" xlink:label="lab_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Observable price adjustments on non-marketable equity securities</link:label>
    <link:label id="lab_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities_label_en-US" xlink:label="lab_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Observable price adjustments on non-marketable equity securities</link:label>
    <link:label id="lab_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities_documentation_en-US" xlink:label="lab_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Observable price adjustments on non-marketable equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" xlink:href="rmd-20240630.xsd#rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" xlink:to="lab_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a554905c-1c88-4616-921e-4ca9ee80ba3f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ba5c5da9-6a7f-467d-bebf-a7f5b2541c48_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Business acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9135c679-9b4e-407c-b357-ab226d4d4bc3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_1a591c13-8e8f-4b5a-ab23-dbdae69cdf28_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_d0bccd5e-5f6f-49d0-9eb3-63b0958741ce_verboseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_f62645d9-3d97-45e2-bd40-1be5ba16ecd4_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_f3324941-9fc8-49d4-a2f1-5fb098a1d577_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_a75587f1-bb23-4df1-b73b-72ab3bee86cf_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_8dd524ee-bda8-4763-8fd2-e43ef86d8494_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_6521264b-ad91-4811-9c57-6571e48c8c64_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net of allowances of $21,132 and $23,603 &#8206;at June&#160;30, 2024 and June&#160;30, 2023, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5f448df5-b50a-4627-ac92-f606992ce099_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_75231df2-d9f1-4754-8923-96a8ef3a6887_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_1dcde479-9d7b-4123-8ee3-66fe3152304b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_37696018-e405-45de-9ad8-82d02bfc5ed4_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net (note 8)</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_b1e546d7-7b1b-44a5-a749-f118469aa6f1_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_140c3f72-b003-475b-8d44-0bf7693a143a_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_27f08802-e368-4551-8da8-6a80211348c8_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock_f6c00ca9-aee8-4976-89f2-bdf452df5f1d_terseLabel_en-US" xlink:label="lab_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Equity Investments</link:label>
    <link:label id="lab_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock_label_en-US" xlink:label="lab_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Changes In Equity Investments [Table Text Block]</link:label>
    <link:label id="lab_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock_documentation_en-US" xlink:label="lab_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Changes In Equity Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock" xlink:href="rmd-20240630.xsd#rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock" xlink:to="lab_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6d81e442-de5a-40d9-8115-62b20c7022b9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_7316122a-a4b8-4b9f-8a7b-873e34f7ba6f_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_02b9faa1-2d72-4ba6-a041-f7ddcde92c1f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_UncommittedOptionToIncreaseCreditFacility_d253d655-5649-485d-a862-46c3c846fff8_terseLabel_en-US" xlink:label="lab_rmd_UncommittedOptionToIncreaseCreditFacility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uncommitted option to increase credit facility</link:label>
    <link:label id="lab_rmd_UncommittedOptionToIncreaseCreditFacility_label_en-US" xlink:label="lab_rmd_UncommittedOptionToIncreaseCreditFacility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Uncommitted option to increase credit facility</link:label>
    <link:label id="lab_rmd_UncommittedOptionToIncreaseCreditFacility_documentation_en-US" xlink:label="lab_rmd_UncommittedOptionToIncreaseCreditFacility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Uncommitted option to increase credit facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_UncommittedOptionToIncreaseCreditFacility" xlink:href="rmd-20240630.xsd#rmd_UncommittedOptionToIncreaseCreditFacility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_UncommittedOptionToIncreaseCreditFacility" xlink:to="lab_rmd_UncommittedOptionToIncreaseCreditFacility" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_d99e221b-bcfb-484c-9cbe-27830078261d_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_dff5759b-473a-42b1-9848-22230d08b133_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_5de24ec3-0cde-410f-a053-1244a089153a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_9d485374-8c1c-4243-9d9c-168dc50b6907_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_EmployeeStockPurchasePlanOfferingPeriod_cf1d5482-1e8b-4657-a678-a0c26b15d8e7_terseLabel_en-US" xlink:label="lab_rmd_EmployeeStockPurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase program offering period</link:label>
    <link:label id="lab_rmd_EmployeeStockPurchasePlanOfferingPeriod_label_en-US" xlink:label="lab_rmd_EmployeeStockPurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan Offering Period</link:label>
    <link:label id="lab_rmd_EmployeeStockPurchasePlanOfferingPeriod_documentation_en-US" xlink:label="lab_rmd_EmployeeStockPurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanOfferingPeriod" xlink:href="rmd-20240630.xsd#rmd_EmployeeStockPurchasePlanOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_EmployeeStockPurchasePlanOfferingPeriod" xlink:to="lab_rmd_EmployeeStockPurchasePlanOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6b5c82af-4804-4992-9d5c-10fd8dd05b04_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_05605c01-3c6c-4e2e-9a98-f234f3bf864b_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_96d060b5-107c-4fcf-b22a-cfa30f6a7e09_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_58f9c4ab-2dfd-4b04-8000-474c46c36c0c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at &#8206;Beginning &#8206;of Period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_35e09446-7706-4cb8-922e-1b904828598b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at &#8206;End of &#8206;Period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5f4c5db6-ab86-4378-80c2-6234b6377329_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebddbfe5-b782-4f2d-8e76-0fcb9372fca6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_541deba4-289e-48ff-b66b-9a9c733009ad_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_b1c89cae-a197-49aa-b2eb-885bd8729405_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_95832eeb-575d-4a42-8e33-cec2b344e6b2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, estimated useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_5e18f148-980a-42da-858a-a53babcf5134_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, estimated useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_11245bf9-6a3d-4b10-9134-6766f3d5b245_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional &#8206;Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_2d5151be-6892-4a3d-b2af-3387374b527e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_347534a5-93e0-4f8e-930e-39b20ef55e64_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Retirement Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_40c423f2-e06f-4693-b8a4-91e828a5241f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_92ea7f31-d519-49b5-bbfe-5ea5d83c04d4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently issued accounting standards not yet adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments_2346e3f7-fdaf-46d0-a446-4baaa863e51a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging contracts</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:to="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_21fbfbe7-de27-42f1-bdce-b5b3964cc985_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b6c9df74-834e-4939-9432-07641a3b90e8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bfaf80a9-95c3-446f-b59d-9187a0a428f9_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3cb2c1b7-ee11-46bb-9436-b79dbdfea610_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f207f304-33fb-4248-8d27-52d28227e456_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_b2180038-3114-4102-a352-66e73ddc8320_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_da94817b-19b7-42fd-b491-382fc9987aca_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_0a4d911a-6e64-431d-ae0d-e6de96f798be_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares that can be repurchased under the approved share repurchase program (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Remaining Authorized, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_EquityInvestmentsTotalByMeasurementCategory_f6771103-5574-4feb-bc07-4778853bb597_totalLabel_en-US" xlink:label="lab_rmd_EquityInvestmentsTotalByMeasurementCategory" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_rmd_EquityInvestmentsTotalByMeasurementCategory_label_en-US" xlink:label="lab_rmd_EquityInvestmentsTotalByMeasurementCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Investments, Total by Measurement Category</link:label>
    <link:label id="lab_rmd_EquityInvestmentsTotalByMeasurementCategory_documentation_en-US" xlink:label="lab_rmd_EquityInvestmentsTotalByMeasurementCategory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Investments, Total by Measurement Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityInvestmentsTotalByMeasurementCategory" xlink:href="rmd-20240630.xsd#rmd_EquityInvestmentsTotalByMeasurementCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_EquityInvestmentsTotalByMeasurementCategory" xlink:to="lab_rmd_EquityInvestmentsTotalByMeasurementCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_8990fbd9-9eab-45ba-8682-15cc38b205ed_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments of business combination contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Merger Related Costs, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:to="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_4fa9e930-f2dc-4ab9-bc3a-b705bda1caf2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Expenses</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_EmployeeStockPurchasePlanMember_dc8056c0-ffe5-4d34-8ed1-b5d03a426168_terseLabel_en-US" xlink:label="lab_rmd_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_rmd_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_rmd_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_rmd_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_rmd_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanMember" xlink:href="rmd-20240630.xsd#rmd_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_EmployeeStockPurchasePlanMember" xlink:to="lab_rmd_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_4e1908c9-46b8-413c-9fa9-5a917e5c0277_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred borrowing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Current, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_03ca847f-5345-448a-88c1-8897371789fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation costs (note 10)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_da1ede0e-d892-4956-8311-c8250e3126e4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_country_AU_82e2f12a-73dc-4052-9d8e-177bdc7646e1_terseLabel_en-US" xlink:label="lab_country_AU" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Australia</link:label>
    <link:label id="lab_country_AU_label_en-US" xlink:label="lab_country_AU" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AUSTRALIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_AU"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AU" xlink:to="lab_country_AU" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_24b7eacd-3500-41d9-b2b0-f36a2f8af308_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:to="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries_a82aed4e-6e38-4247-a5a9-1bb695a0416d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of deferred taxes that would have been recognized if the earnings has not been permanently reinvested</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries" xlink:to="lab_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_003e3d92-67ea-40a1-b979-6f362b6e7104_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_fbf47222-51e3-4e4f-96b9-f49775983cdb_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Costs</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_aaaa202c-e62d-4213-aba8-5528e32ca4be_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SeniorNotesTwoMember_d932cd97-2df7-4f37-aa8c-a323c3dd77ea_terseLabel_en-US" xlink:label="lab_rmd_SeniorNotesTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.45% Senior Notes Due July 10, 2029</link:label>
    <link:label id="lab_rmd_SeniorNotesTwoMember_label_en-US" xlink:label="lab_rmd_SeniorNotesTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Two [Member]</link:label>
    <link:label id="lab_rmd_SeniorNotesTwoMember_documentation_en-US" xlink:label="lab_rmd_SeniorNotesTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SeniorNotesTwoMember" xlink:href="rmd-20240630.xsd#rmd_SeniorNotesTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SeniorNotesTwoMember" xlink:to="lab_rmd_SeniorNotesTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_7e37d68f-c6e5-4604-9426-84570259a9a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability (refund) adjustment from settlement with taxing authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:to="lab_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_012e808e-9ead-4979-b2bb-df3770fc4fc8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Gains (Losses)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_7b7a69d2-2bc7-486e-8951-8ec2566b2cb1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development capitalization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_f6163ffa-0ef6-49a1-94dd-9ba420ffe312_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (loss), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_53cccae3-46de-4fce-83b5-bc56cf59f31e_verboseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule II Valuation and Qualifying Accounts and Reserves</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_e647b3ad-bbbc-4882-9df0-014f5eabdf3e_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_90727fd3-283f-42e4-8b08-a7e73bc394cf_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_fd178f59-cffa-4747-9f03-621ef5fcee70_netLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net operating profit by segment</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_aea1777b-cb85-482c-afa7-25bdbe9aad86_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_44ce5538-30ef-49e3-8137-fefb01c32349_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3cbd238e-28b7-4d99-b420-01096650ef06_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_b3099848-e61a-496e-a3b4-3ec3c648571a_negatedLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_cc74af78-a3cd-4ac2-b0cc-9d2b42e7c017_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember_01396e61-ed29-4f0f-8a4a-8ff03d2918e8_terseLabel_en-US" xlink:label="lab_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid taxes and other non-current assets</link:label>
    <link:label id="lab_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember_label_en-US" xlink:label="lab_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Taxes And Other Non Current Assets [Member]</link:label>
    <link:label id="lab_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember_documentation_en-US" xlink:label="lab_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Taxes And Other Non Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember" xlink:href="rmd-20240630.xsd#rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember" xlink:to="lab_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_1edff226-d307-449a-973d-ea1226722fb2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, impairment loss</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_TermLoanCreditAgreementMember_f651f64e-e54e-4ed5-bdbc-71b864f9f46d_terseLabel_en-US" xlink:label="lab_rmd_TermLoanCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan Credit Agreement</link:label>
    <link:label id="lab_rmd_TermLoanCreditAgreementMember_label_en-US" xlink:label="lab_rmd_TermLoanCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Credit Agreement [Member]</link:label>
    <link:label id="lab_rmd_TermLoanCreditAgreementMember_documentation_en-US" xlink:label="lab_rmd_TermLoanCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_TermLoanCreditAgreementMember" xlink:href="rmd-20240630.xsd#rmd_TermLoanCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_TermLoanCreditAgreementMember" xlink:to="lab_rmd_TermLoanCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_0eee3e9a-5cea-451e-b969-efcaa941a3a7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency hedging instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_98033a52-5210-4c7e-925c-18bf736d0015_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant_1a1f2db8-e68e-457e-bde3-2d9f0fce848a_verboseLabel_en-US" xlink:label="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant</link:label>
    <link:label id="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant_label_en-US" xlink:label="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Purchase Price Of Common Stock Lower Than The Fair Market Value Of Common Stock On The Date Of Grant</link:label>
    <link:label id="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant_documentation_en-US" xlink:label="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant" xlink:href="rmd-20240630.xsd#rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant" xlink:to="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_83c93b6c-223a-4fba-be2a-10778e709686_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2bbde021-eb05-4792-9aea-7d87328a06ee_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_7388af18-0f5f-4f67-ab88-948dcb56df17_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on equity investments (note 6)</link:label>
    <link:label id="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_935f44c8-7d4d-4b81-a3fd-35b281b6ae23_terseLabel_en-US" xlink:label="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on equity investments</link:label>
    <link:label id="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt and Equity Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_d5544f50-2f28-4c30-83e4-3eedcf330bd3_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use assets obtained in exchange for new lease liabilities:</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_edee4be6-9473-4722-bd6d-781194b14dc9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated &#8206;Other &#8206;Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod_b7b1df64-b929-4253-96b6-344782518651_terseLabel_en-US" xlink:label="lab_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EBITDA multiple of trailing twelve-month measurement period</link:label>
    <link:label id="lab_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod_label_en-US" xlink:label="lab_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, EBITDA Multiple of Trailing Twelve-Month Measurement Period</link:label>
    <link:label id="lab_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod_documentation_en-US" xlink:label="lab_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, EBITDA Multiple of Trailing Twelve-Month Measurement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod" xlink:href="rmd-20240630.xsd#rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod" xlink:to="lab_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8590362c-52a5-4ad3-a610-e5e4ce5b89e3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_155bb75f-9524-498e-bd6a-06cd53774b20_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_4ce63798-56c6-4bf0-9b28-233c42748857_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories (note 4)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_fe8173d2-e5f4-439c-a94a-0aa061b0870e_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_86de7f5b-b1ea-439e-9adc-23fe2e1d776c_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_71fd33e4-b01b-446a-b99a-204642180d9d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_511b2765-7d8e-4b21-8500-f94eb937a504_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_8cacb2ed-a64d-4083-9c46-2a24e54dcad2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_60e2cca1-4e78-46d1-a587-4c0dd63fa1a8_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_769b27c4-1576-4880-8b10-2a2aaa8c46b0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_a04e83aa-bac1-4197-bb63-fa2e561bae72_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, term of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_047ad831-9852-4bff-abfd-58ee5a04c7e7_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign Exchange Risk Management</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_223685c8-9a79-43da-9708-51f918d11102_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum potential contingent liability</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_MufgUnionBankMember_4b9729d5-d82e-47fb-84dc-de8eedf3da3f_terseLabel_en-US" xlink:label="lab_rmd_MufgUnionBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MUFG Union Bank</link:label>
    <link:label id="lab_rmd_MufgUnionBankMember_label_en-US" xlink:label="lab_rmd_MufgUnionBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mufg Union Bank [Member]</link:label>
    <link:label id="lab_rmd_MufgUnionBankMember_documentation_en-US" xlink:label="lab_rmd_MufgUnionBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MUFG Union Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MufgUnionBankMember" xlink:href="rmd-20240630.xsd#rmd_MufgUnionBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_MufgUnionBankMember" xlink:to="lab_rmd_MufgUnionBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_88427d6a-59ed-4b0a-b131-aa819a49b874_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unbilled revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetAbstract_7d0bcb1b-dc00-4ae2-99af-99d5d5a501fc_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_477513f9-e55a-492f-a6b2-b4cf946fb23d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_6556efd2-21a9-49bc-835a-fd1d1665fe25_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_40c9de8c-9e9e-470d-a1e7-bcc0a6322ca7_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_035c36e2-0cfd-455e-bf8c-80abfc2e7c67_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income, foreign currency translation adjustment, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_34b73f43-6257-4c47-8c5a-a74240126ed1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_0edfe591-aa48-482e-848e-290968357cb8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_136bb636-0141-43e4-a6ba-421abf2b94f8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_bd5f4f53-e9e4-4260-88a9-4f273b39fead_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes (note 12)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_7f2cf1a9-7a93-4dfa-a791-d023d38ecac3_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4615db18-bd3d-4ed8-8e26-9af60ffe1467_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock_c1dbeea3-db62-407d-9569-5f5dc51bc206_terseLabel_en-US" xlink:label="lab_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Segment, Product, and Region</link:label>
    <link:label id="lab_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock_label_en-US" xlink:label="lab_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Revenue By Segment, Product, And Region [Table Text Block]</link:label>
    <link:label id="lab_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock_documentation_en-US" xlink:label="lab_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Revenue By Segment, Product, And Region [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock" xlink:href="rmd-20240630.xsd#rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock" xlink:to="lab_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_3b84a6cc-c4b0-4ac0-a158-401b0b4f2ddf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_c78ab462-0b92-46f1-a252-673516e06ebd_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Other Intangible Assets, net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_96686b7b-695e-40b2-acbf-2d194c87c4db_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_851a2d39-e0a9-4c8b-942e-061c07c2e7b6_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_ae356ed3-e921-4f20-a2d0-c77960905bfe_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ScheduleOfInvestmentsTableTextBlock_fcfc8cf7-b8a4-4122-8cd8-5cecb80c74a0_terseLabel_en-US" xlink:label="lab_rmd_ScheduleOfInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments</link:label>
    <link:label id="lab_rmd_ScheduleOfInvestmentsTableTextBlock_label_en-US" xlink:label="lab_rmd_ScheduleOfInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Investments [Table Text Block]</link:label>
    <link:label id="lab_rmd_ScheduleOfInvestmentsTableTextBlock_documentation_en-US" xlink:label="lab_rmd_ScheduleOfInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ScheduleOfInvestmentsTableTextBlock" xlink:href="rmd-20240630.xsd#rmd_ScheduleOfInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ScheduleOfInvestmentsTableTextBlock" xlink:to="lab_rmd_ScheduleOfInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_e495ac95-12aa-418e-b150-60151d7e9ff3_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum purchase obligations</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6861b766-cf52-48c5-8e42-330c924100fa_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_3b17713f-4e4e-473d-b4b0-e014a0a7a561_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_8273c32c-18a3-4a12-9d03-4c735375a245_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_8562b5c4-b5a9-4444-930d-7a20351877ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_cc7bed8b-ffb4-49d8-b7c8-b6d99df76d58_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b754f625-7ed8-47b1-a8cc-56e92f353b86_netLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_0dfe09a3-1664-42ca-91a9-498a43d6f23a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_fba63040-ebc7-4cdb-9f1e-264f2449c992_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) recognized in cumulative translation adjustment within other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_018de355-8047-4bb3-b797-7b50cd6c9fdb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring expenses (note 18)</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Settled without Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:to="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_f16d592e-a65c-4c6e-90b2-9a69ad3b9c37_verboseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Undistributed earnings</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings of Foreign Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:to="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_a137acb8-63c9-4fae-830e-d8a9fc4f4aff_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_16ae74ee-1f39-448d-86f3-1850bc7f6123_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ContractWithCustomerAssetAndLiabilityLineItems_e273ace2-2a4f-4af6-bcfa-926638f4562d_terseLabel_en-US" xlink:label="lab_rmd_ContractWithCustomerAssetAndLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset and Liability [Line Items]</link:label>
    <link:label id="lab_rmd_ContractWithCustomerAssetAndLiabilityLineItems_label_en-US" xlink:label="lab_rmd_ContractWithCustomerAssetAndLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset and Liability [Line Items]</link:label>
    <link:label id="lab_rmd_ContractWithCustomerAssetAndLiabilityLineItems_documentation_en-US" xlink:label="lab_rmd_ContractWithCustomerAssetAndLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset and Liability [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems" xlink:href="rmd-20240630.xsd#rmd_ContractWithCustomerAssetAndLiabilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems" xlink:to="lab_rmd_ContractWithCustomerAssetAndLiabilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_a531dd6d-d3b5-47d3-9bc0-1fba548f8d84_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_e47bb946-11b2-4ee0-80fb-676729fc28c8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_IncomeTaxExaminationGrossSettlement_3f90215e-ff92-4113-a513-9d9430ab8472_terseLabel_en-US" xlink:label="lab_rmd_IncomeTaxExaminationGrossSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross settlement</link:label>
    <link:label id="lab_rmd_IncomeTaxExaminationGrossSettlement_label_en-US" xlink:label="lab_rmd_IncomeTaxExaminationGrossSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Gross Settlement</link:label>
    <link:label id="lab_rmd_IncomeTaxExaminationGrossSettlement_documentation_en-US" xlink:label="lab_rmd_IncomeTaxExaminationGrossSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Gross Settlement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationGrossSettlement" xlink:href="rmd-20240630.xsd#rmd_IncomeTaxExaminationGrossSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_IncomeTaxExaminationGrossSettlement" xlink:to="lab_rmd_IncomeTaxExaminationGrossSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_06e314cc-3d34-409d-a866-8291c5410f5d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_57de6c8e-2527-4ef2-a537-83eca9eca4be_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Activity of Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_ecadec52-eb01-4a40-a22c-7609cb786aa9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_30f00dbd-9598-453f-9277-49ebcc87b97c_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SeniorNotesOneMember_ba068b84-f445-4e81-a92c-196de6d560e7_terseLabel_en-US" xlink:label="lab_rmd_SeniorNotesOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.24% Senior Notes Due July 10, 2026</link:label>
    <link:label id="lab_rmd_SeniorNotesOneMember_label_en-US" xlink:label="lab_rmd_SeniorNotesOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes One [Member]</link:label>
    <link:label id="lab_rmd_SeniorNotesOneMember_documentation_en-US" xlink:label="lab_rmd_SeniorNotesOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SeniorNotesOneMember" xlink:href="rmd-20240630.xsd#rmd_SeniorNotesOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SeniorNotesOneMember" xlink:to="lab_rmd_SeniorNotesOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_324b5429-cab5-4ac6-b5a3-316275115de2_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d36b58ae-e913-4bd7-8143-cd9adc1638f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_240183ba-7378-485d-b259-3c4c587149d9_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_953d57d0-c549-49fa-bd2a-2b37a2987d41_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3c18141c-0fd2-448a-867d-7d3bc4e01703_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a0727885-4c13-4e75-b8b9-40e00ffd5b08_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f19c92fe-37e9-44b7-a7af-da153581209f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c571ca69-983e-45f6-af62-ae013f184a81_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ResmedInc2009IncentiveAwardPlanMember_06644c0f-bec1-4be1-b496-8dd5357356f3_terseLabel_en-US" xlink:label="lab_rmd_ResmedInc2009IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2009 Plan</link:label>
    <link:label id="lab_rmd_ResmedInc2009IncentiveAwardPlanMember_label_en-US" xlink:label="lab_rmd_ResmedInc2009IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Resmed Inc2009 Incentive Award Plan [Member]</link:label>
    <link:label id="lab_rmd_ResmedInc2009IncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_rmd_ResmedInc2009IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ResMed Inc 2009 Incentive Award Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ResmedInc2009IncentiveAwardPlanMember" xlink:href="rmd-20240630.xsd#rmd_ResmedInc2009IncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ResmedInc2009IncentiveAwardPlanMember" xlink:to="lab_rmd_ResmedInc2009IncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_16583c30-04dc-4684-8f11-45ddc9259e43_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxHolidayAggregateDollarAmount_1c2add64-536e-4383-b80d-43ea9f1b9410_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase to net earnings from tax holidays and tax incentives program</link:label>
    <link:label id="lab_us-gaap_IncomeTaxHolidayAggregateDollarAmount_label_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Holiday, Aggregate Dollar Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayAggregateDollarAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:to="lab_us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_b553dc9f-2b90-4a05-957e-46d94dcfe3b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AustralianTaxationOfficeMember_168fce58-f759-43bb-9680-42ce3fe7ed8c_terseLabel_en-US" xlink:label="lab_us-gaap_AustralianTaxationOfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Australian Taxation Office</link:label>
    <link:label id="lab_us-gaap_AustralianTaxationOfficeMember_label_en-US" xlink:label="lab_us-gaap_AustralianTaxationOfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Australian Taxation Office [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AustralianTaxationOfficeMember" xlink:to="lab_us-gaap_AustralianTaxationOfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_05132409-37a2-4e81-a7a4-a47acc9165d7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_4dfd6235-08c6-479e-9e8b-7a0190a65d12_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock at par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_ba71ac69-2ca7-4df2-a518-4bda06bf9570_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_2e179d66-722c-4e50-841f-01041e6e6049_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_f2d1944d-0edd-4f49-b89a-fff4ce33922a_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_988170c2-033b-4662-b053-114312a5b775_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember_34e7e570-668c-45b6-b12c-ee525083e9c6_terseLabel_en-US" xlink:label="lab_rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Severance and One-time Termination Benefits</link:label>
    <link:label id="lab_rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember_label_en-US" xlink:label="lab_rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance And One-time Termination Benefits [Member]</link:label>
    <link:label id="lab_rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember_documentation_en-US" xlink:label="lab_rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Severance And One-time Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember" xlink:href="rmd-20240630.xsd#rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember" xlink:to="lab_rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_c6f45dc3-c398-4a81-8df5-21395127acfa_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_767a3dea-4b09-41c8-b90f-457e1c3ba280_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_BrettA.SandercockMember_label_en-US" xlink:label="lab_rmd_BrettA.SandercockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Brett A. Sandercock [Member]</link:label>
    <link:label id="lab_rmd_BrettA.SandercockMember_documentation_en-US" xlink:label="lab_rmd_BrettA.SandercockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Brett A. Sandercock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_BrettA.SandercockMember" xlink:href="rmd-20240630.xsd#rmd_BrettA.SandercockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_BrettA.SandercockMember" xlink:to="lab_rmd_BrettA.SandercockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_78a290d1-0d0f-4789-9eab-6b53337075be_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration_cdc8b98b-3273-4a31-863b-3e70856ae533_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Asset, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DebtToConsolidatedEbitdaRatio_22a2e5f4-e147-47b2-b65f-f5c57609e743_terseLabel_en-US" xlink:label="lab_rmd_DebtToConsolidatedEbitdaRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt to consolidated EBITDA ratio</link:label>
    <link:label id="lab_rmd_DebtToConsolidatedEbitdaRatio_label_en-US" xlink:label="lab_rmd_DebtToConsolidatedEbitdaRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt To Consolidated EBITDA Ratio</link:label>
    <link:label id="lab_rmd_DebtToConsolidatedEbitdaRatio_documentation_en-US" xlink:label="lab_rmd_DebtToConsolidatedEbitdaRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt To Consolidated EBITDA Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DebtToConsolidatedEbitdaRatio" xlink:href="rmd-20240630.xsd#rmd_DebtToConsolidatedEbitdaRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DebtToConsolidatedEbitdaRatio" xlink:to="lab_rmd_DebtToConsolidatedEbitdaRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7b775237-f805-47c5-9be0-86c3e68d7315_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation (loss) gain adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_176bad82-b7f2-4154-9e80-bceeace5fcec_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_5484e0bc-c2a7-4b10-a852-9d43fab298ed_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_218b06a5-1d93-4db3-b68b-4ddb854ccda0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_46371c24-76fc-492f-a14a-e76313cd8804_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_94a933f0-d35c-49a5-875f-01a3438ae44c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease_ce91618c-b364-43b1-aa09-d0d59c59feb8_terseLabel_en-US" xlink:label="lab_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill on acquisition</link:label>
    <link:label id="lab_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease_label_en-US" xlink:label="lab_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period, Increase (Decrease)</link:label>
    <link:label id="lab_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease_documentation_en-US" xlink:label="lab_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease" xlink:href="rmd-20240630.xsd#rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease" xlink:to="lab_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5f7318db-c3af-4441-b831-bb33e1ef21fd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_49cc3a92-6094-48c4-bab9-d2df66e712da_netLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Measurement alternative</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_7893bcbf-3512-4014-904a-e27e598a93b3_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_5701ab2e-d810-4f4f-ae93-9169fde59f77_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangibles</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_c72e0433-57cd-4bdd-9b57-0653d72cc2af_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bf825e15-796e-4ef5-a2f3-bc179a38d90c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_MarketableEquityInvestmentsFairValue_267a2786-2e4a-4d2e-a0f9-9f04ed7fe2b1_terseLabel_en-US" xlink:label="lab_rmd_MarketableEquityInvestmentsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_rmd_MarketableEquityInvestmentsFairValue_label_en-US" xlink:label="lab_rmd_MarketableEquityInvestmentsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Equity Investments, Fair Value</link:label>
    <link:label id="lab_rmd_MarketableEquityInvestmentsFairValue_documentation_en-US" xlink:label="lab_rmd_MarketableEquityInvestmentsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketable Equity Investments, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MarketableEquityInvestmentsFairValue" xlink:href="rmd-20240630.xsd#rmd_MarketableEquityInvestmentsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_MarketableEquityInvestmentsFairValue" xlink:to="lab_rmd_MarketableEquityInvestmentsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_7e2bf6a4-39a6-497c-b3e5-fd0cf0759a77_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_d30a50f5-d73d-43e5-80bf-7e21e0f99624_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_AdditionalEquityInvestments_c547458c-70a0-49ce-976d-13b5b1a0d064_terseLabel_en-US" xlink:label="lab_rmd_AdditionalEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions to investments</link:label>
    <link:label id="lab_rmd_AdditionalEquityInvestments_label_en-US" xlink:label="lab_rmd_AdditionalEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Equity Investments</link:label>
    <link:label id="lab_rmd_AdditionalEquityInvestments_documentation_en-US" xlink:label="lab_rmd_AdditionalEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AdditionalEquityInvestments" xlink:href="rmd-20240630.xsd#rmd_AdditionalEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_AdditionalEquityInvestments" xlink:to="lab_rmd_AdditionalEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1bce4777-bfda-4838-99e0-cdc2bcb1b47c_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d0224720-01ca-463a-b80e-28be31aa56f8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1f4c630d-d40e-4e55-b9ad-5fbbd7410ce3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_d9946d87-3478-4841-a087-5f1024b2458a_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_EquityMethodInvestmentsRollForward_4c0f363c-4446-4554-bab3-327928c02093_terseLabel_en-US" xlink:label="lab_rmd_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_rmd_EquityMethodInvestmentsRollForward_label_en-US" xlink:label="lab_rmd_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_rmd_EquityMethodInvestmentsRollForward_documentation_en-US" xlink:label="lab_rmd_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityMethodInvestmentsRollForward" xlink:href="rmd-20240630.xsd#rmd_EquityMethodInvestmentsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward" xlink:to="lab_rmd_EquityMethodInvestmentsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_JanDeWitteMember_label_en-US" xlink:label="lab_rmd_JanDeWitteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jan De Witte [Member]</link:label>
    <link:label id="lab_rmd_JanDeWitteMember_documentation_en-US" xlink:label="lab_rmd_JanDeWitteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jan De Witte</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_JanDeWitteMember" xlink:href="rmd-20240630.xsd#rmd_JanDeWitteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_JanDeWitteMember" xlink:to="lab_rmd_JanDeWitteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_6b7e1bc4-273c-48e3-93ec-9559f8eb2ae2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_41306cce-c9d8-4489-ac71-630456e84ee7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_001f0f8a-0110-496b-a9be-da9a19d6c290_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_06f80362-a56c-4892-966e-3c64dd9d430c_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_bb6823ba-01a7-46b1-89f6-fec6d479dedc_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization by segment</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_6a444de0-b814-4a01-b948-1ce00e596d4f_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1d71718f-807e-404a-a4a7-c800d843c7b1_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_25767262-dd01-4e72-8aa3-ecadac2672de_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of non-U.S. tax rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_ca6b90b0-954c-454d-bf44-674adc96915c_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment, Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4cb4730a-9696-4948-8e9b-4eacf6e0d944_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Total Stock-Based Compensation Costs Incurred and Associated Tax Benefit Recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_35faa8ae-ae29-42ed-bb66-9d547c084747_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a9a45631-46ac-4cc5-a9c5-52750b538ce4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DevelopedOrCoreProductTechnologyMember_a5106508-217a-4cc0-acde-1a032b5a02d9_terseLabel_en-US" xlink:label="lab_rmd_DevelopedOrCoreProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed/core product technology</link:label>
    <link:label id="lab_rmd_DevelopedOrCoreProductTechnologyMember_label_en-US" xlink:label="lab_rmd_DevelopedOrCoreProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Or Core Product Technology [Member]</link:label>
    <link:label id="lab_rmd_DevelopedOrCoreProductTechnologyMember_documentation_en-US" xlink:label="lab_rmd_DevelopedOrCoreProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Developed/ Core Product Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DevelopedOrCoreProductTechnologyMember" xlink:href="rmd-20240630.xsd#rmd_DevelopedOrCoreProductTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DevelopedOrCoreProductTechnologyMember" xlink:to="lab_rmd_DevelopedOrCoreProductTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9d608c31-1aa1-42dc-8d0c-2c9500786254_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_09c4337d-b718-495a-a6b8-d5e0502bb4bc_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_8865443c-1b9e-45d7-bdf3-ef1d60dd2655_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_VehiclesAndAircraftMember_f224c7ba-f773-4ca4-9bb9-831ee43c53fc_terseLabel_en-US" xlink:label="lab_rmd_VehiclesAndAircraftMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vehicles and aircraft</link:label>
    <link:label id="lab_rmd_VehiclesAndAircraftMember_label_en-US" xlink:label="lab_rmd_VehiclesAndAircraftMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vehicles and Aircraft [Member]</link:label>
    <link:label id="lab_rmd_VehiclesAndAircraftMember_documentation_en-US" xlink:label="lab_rmd_VehiclesAndAircraftMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vehicles and Aircraft</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_VehiclesAndAircraftMember" xlink:href="rmd-20240630.xsd#rmd_VehiclesAndAircraftMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_VehiclesAndAircraftMember" xlink:to="lab_rmd_VehiclesAndAircraftMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_d6ca2017-fce2-4f81-9e73-9d54d9b72960_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Provision for warranties</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_fae99109-fa7d-42bf-a58d-9cfbd294fc31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of the stock-based compensation arrangements exercisable, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_d0888fbb-0443-41dd-979f-d85aae41cbed_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_1255a940-298f-482d-9015-40d607f90192_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_17ad050f-c25f-49bb-b89f-3d07d11094ab_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7f337f3f-91e6-4a9e-9f4b-5bb4d01a9fca_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_7090a13f-4ef7-491b-96b7-f7d871478c41_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_80c0d9c9-73be-4174-a904-943f097ec9ef_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State income taxes, net of U.S. tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_230824ca-5b4c-4521-a766-c5d6d8566931_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share (note 11) (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_615cd75c-1f8b-46bf-8eb7-864a3a0c3716_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DevicesMember_bea1a9ca-e0b7-45d6-816b-52f187f2bb58_terseLabel_en-US" xlink:label="lab_rmd_DevicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Devices</link:label>
    <link:label id="lab_rmd_DevicesMember_label_en-US" xlink:label="lab_rmd_DevicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Devices [Member]</link:label>
    <link:label id="lab_rmd_DevicesMember_documentation_en-US" xlink:label="lab_rmd_DevicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Devices [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DevicesMember" xlink:href="rmd-20240630.xsd#rmd_DevicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DevicesMember" xlink:to="lab_rmd_DevicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_ddd67853-03e5-4a22-a6f1-4b1fc973b236_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_f5eaff05-d121-42fc-8aa6-fcc7d3d4bfbf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_37a301c0-05d0-4d95-a8bd-f9cde7d2fc7e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_bc00c455-69ba-49e9-a284-2ab24bfd0b18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_f6789045-fb9c-46c5-9446-cd3e3e6fb1bd_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_MarketableSecuritiesMember_7e11df37-643f-45e2-9be6-3c6b33c04d5b_terseLabel_en-US" xlink:label="lab_rmd_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_rmd_MarketableSecuritiesMember_label_en-US" xlink:label="lab_rmd_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:label id="lab_rmd_MarketableSecuritiesMember_documentation_en-US" xlink:label="lab_rmd_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MarketableSecuritiesMember" xlink:href="rmd-20240630.xsd#rmd_MarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_MarketableSecuritiesMember" xlink:to="lab_rmd_MarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_72784075-29ca-4df4-a16c-1359b7664626_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1461cbf9-3c76-44bf-bc2d-e31cdf5bee08_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_85c54001-9ae0-4645-acc3-e8d3a7ff7f6e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_d14e6422-fad4-4b49-b57f-0aad4c61d28b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_7506bd97-e3ea-4162-87c6-14addeb78ea6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_21446087-9ff7-49b8-bef4-c3551814b376_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_country_SG_cc4c51fa-0bb5-4056-b601-e5659cd2aa6b_terseLabel_en-US" xlink:label="lab_country_SG" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Singapore</link:label>
    <link:label id="lab_country_SG_label_en-US" xlink:label="lab_country_SG" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SINGAPORE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_SG" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_SG"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_SG" xlink:to="lab_country_SG" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_EquityInvestments_a7bf43cf-509b-485a-b062-8c1c4dfe1583_periodStartLabel_en-US" xlink:label="lab_rmd_EquityInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_rmd_EquityInvestments_601cc2cb-519b-4734-9e71-a833f43cd5e0_periodEndLabel_en-US" xlink:label="lab_rmd_EquityInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Carrying value at the end of the period</link:label>
    <link:label id="lab_rmd_EquityInvestments_label_en-US" xlink:label="lab_rmd_EquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Investments</link:label>
    <link:label id="lab_rmd_EquityInvestments_documentation_en-US" xlink:label="lab_rmd_EquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityInvestments" xlink:href="rmd-20240630.xsd#rmd_EquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_EquityInvestments" xlink:to="lab_rmd_EquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration_7ff65e17-960a-4164-964a-e4bc8704e19f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4d7788c4-e24b-4fcc-befc-117ff7bbe826_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_80a0d33f-3ed6-4385-9c0f-4fed79147ca1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings, net of borrowing costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a1670651-a71f-41b2-b092-00218e8ec84a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_292ec849-2069-42f2-99c5-73f6e2c61e21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of the options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a0e8d25b-e41b-4caf-b876-9f9afe2b8cd5_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_80310ea0-e600-4ff5-8c26-dad9e8b935f2_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation costs</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany_62323f36-03c0-43a2-bb3c-6be605637416_terseLabel_en-US" xlink:label="lab_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility collateral, maximum percentage of ownership interests held in subsidiary</link:label>
    <link:label id="lab_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany_label_en-US" xlink:label="lab_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Collateral, Percentage of the Company</link:label>
    <link:label id="lab_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany_documentation_en-US" xlink:label="lab_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Collateral, Percentage of the Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany" xlink:href="rmd-20240630.xsd#rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany" xlink:to="lab_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_08427ad9-d0b0-47d2-b9cb-eb8a0f16f9b3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_PrepaidInventory_d2aaa13f-4601-4dd8-8876-4108c2ced854_terseLabel_en-US" xlink:label="lab_rmd_PrepaidInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid inventories</link:label>
    <link:label id="lab_rmd_PrepaidInventory_label_en-US" xlink:label="lab_rmd_PrepaidInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Inventory</link:label>
    <link:label id="lab_rmd_PrepaidInventory_documentation_en-US" xlink:label="lab_rmd_PrepaidInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PrepaidInventory" xlink:href="rmd-20240630.xsd#rmd_PrepaidInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_PrepaidInventory" xlink:to="lab_rmd_PrepaidInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5324fb05-6f90-466e-a658-580806abbb6a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_dfa9ff88-7c79-4ed8-9a0a-2460a4c14096_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_AmendedAndRestated2009PlanMember_eb67bd17-acf2-4fa8-b0c3-50dcc1325cc6_terseLabel_en-US" xlink:label="lab_rmd_AmendedAndRestated2009PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amended and Restated 2009 Plan</link:label>
    <link:label id="lab_rmd_AmendedAndRestated2009PlanMember_label_en-US" xlink:label="lab_rmd_AmendedAndRestated2009PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended And Restated2009 Plan [Member]</link:label>
    <link:label id="lab_rmd_AmendedAndRestated2009PlanMember_documentation_en-US" xlink:label="lab_rmd_AmendedAndRestated2009PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended And Restated 2009 Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AmendedAndRestated2009PlanMember" xlink:href="rmd-20240630.xsd#rmd_AmendedAndRestated2009PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_AmendedAndRestated2009PlanMember" xlink:to="lab_rmd_AmendedAndRestated2009PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_4c8c12fe-73b2-48a7-af8d-80b90c78ed46_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_0b24a7eb-6f80-4bae-80d7-dfd67919ded7_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_c5578504-5d10-4470-8840-3e29eeab60e0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on designated hedging instruments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_0cefb6e2-6562-489b-8984-ddcc2fc9d853_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_702bfa4b-b813-46ca-add7-7643da6019a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock purchases</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_d8dadad7-befc-4d4f-b90a-7b8582eefaa7_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of common shares repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_5845f68f-5208-4f30-87b1-9cbcb322efca_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_3e5ef8cc-eab9-4484-8c55-8cb6021578a1_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4cd43fff-1b85-4023-ad6c-451067f34e80_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_847b150e-f7cf-42bc-8c22-4eebb7898e0a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_aa9b52af-d1cc-4613-b779-3fdd65ac300e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent provision</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual, Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualProvision" xlink:to="lab_us-gaap_LossContingencyAccrualProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_6afbbd68-3ee8-4331-805d-8be7c45acb0a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_8ec27c4b-9510-47a4-a0ec-87c4f401ef04_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_eea91388-1c42-4c99-a269-c83a486c354c_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e3215058-1e5f-48f5-8101-5aa814dc9eb3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6a8d1d12-af14-470f-81d7-34ca04879700_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_7140a237-9d10-43d6-a35c-f6010616bc3a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss attributable to equity method investments, net of dividends received (note 6)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_e03c6bca-4d06-41f6-a0f3-f13bb089b406_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_5e4342b5-8fcd-4e4d-ba3d-f73d5a6463c3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_ed5bb484-66bf-4449-8a4d-7ef7de99f6c6_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciling items</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_150d9ded-e689-4900-92db-19340933c8c7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_00726b9e-0510-4b0b-852c-e42f021c4b6c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets (note 4)</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b33ef255-ba0e-4f14-9eed-e754c57cc889_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_fd630894-f142-49ee-9e7d-ea9e2573e6fc_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency hedging instruments</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_5358f8d6-2d5c-4784-8cb2-69f7dc036fe2_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_e569f3fc-7353-49ca-9276-1f1181a75c0a_totalLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_CombinedEuropeAsiaAndOtherMarketsMember_44223bd8-bf99-4917-a564-7b230dd55cfa_terseLabel_en-US" xlink:label="lab_rmd_CombinedEuropeAsiaAndOtherMarketsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Combined Europe, Asia and other markets</link:label>
    <link:label id="lab_rmd_CombinedEuropeAsiaAndOtherMarketsMember_label_en-US" xlink:label="lab_rmd_CombinedEuropeAsiaAndOtherMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Combined Europe Asia And Other Markets [Member]</link:label>
    <link:label id="lab_rmd_CombinedEuropeAsiaAndOtherMarketsMember_documentation_en-US" xlink:label="lab_rmd_CombinedEuropeAsiaAndOtherMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Combined Europe Asia And Other Markets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_CombinedEuropeAsiaAndOtherMarketsMember" xlink:href="rmd-20240630.xsd#rmd_CombinedEuropeAsiaAndOtherMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_CombinedEuropeAsiaAndOtherMarketsMember" xlink:to="lab_rmd_CombinedEuropeAsiaAndOtherMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SupplementalBalanceSheetInformationAbstract_5e98addc-c751-4d60-ad61-4430924e53a8_terseLabel_en-US" xlink:label="lab_rmd_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:label id="lab_rmd_SupplementalBalanceSheetInformationAbstract_label_en-US" xlink:label="lab_rmd_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:label id="lab_rmd_SupplementalBalanceSheetInformationAbstract_documentation_en-US" xlink:label="lab_rmd_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SupplementalBalanceSheetInformationAbstract" xlink:href="rmd-20240630.xsd#rmd_SupplementalBalanceSheetInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SupplementalBalanceSheetInformationAbstract" xlink:to="lab_rmd_SupplementalBalanceSheetInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c35ae45d-a75f-44aa-9e17-ac6376e6b841_verboseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_92c573c2-ff7d-4630-9baa-2b5771486394_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_84c09694-705c-47e4-a801-5578721d7667_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_3f506a17-8d20-4dd5-b556-e5d2486b3adf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_1cdf0cf3-6437-433b-a540-14bc0e237793_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6ecf3cd0-a589-49f2-afbb-36ee9be09ffb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_f0e2efe4-33f9-4c0b-947b-e3e216222a0b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments (note 6)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_703ef5d9-61ac-4f7a-bc4d-d6fe8075f9f2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_5875d4ec-a480-4d46-9ae3-dc72f58d41ea_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining in our accruals</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_341df5b8-0d83-4b40-a20f-f196f0e0bc4d_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_18d98b38-6cce-48a2-adb8-1e24d76748db_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>rmd-20240630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:626b872d-b824-4a3f-bfea-336621baa0aa,g:59f8884c-c35b-445a-b56c-2a5e88decb05-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://investor.resmed.com/role/Cover" xlink:type="simple" xlink:href="rmd-20240630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1563c549-c6c6-4ae8-8773-4b590140fbd5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_DocumentType_1563c549-c6c6-4ae8-8773-4b590140fbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_cc09f310-befd-46f8-8f82-cecabfd03aa1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_DocumentAnnualReport_cc09f310-befd-46f8-8f82-cecabfd03aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fc0603e4-4826-4cf8-81cd-ca502319375b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_DocumentPeriodEndDate_fc0603e4-4826-4cf8-81cd-ca502319375b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_929ea36c-03c9-47e0-8585-4e46000f4837" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_CurrentFiscalYearEndDate_929ea36c-03c9-47e0-8585-4e46000f4837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_df21a59c-547b-46ab-9cef-b98350345fe0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntityFileNumber_df21a59c-547b-46ab-9cef-b98350345fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4ca7a847-cdd9-4041-9e35-568d4014f17e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntityRegistrantName_4ca7a847-cdd9-4041-9e35-568d4014f17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_142037f1-9fca-4f1f-8a5b-87c866e40b78" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntityIncorporationStateCountryCode_142037f1-9fca-4f1f-8a5b-87c866e40b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ca74d0fc-c377-4101-b6a8-82195fcd7214" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntityTaxIdentificationNumber_ca74d0fc-c377-4101-b6a8-82195fcd7214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_abe1d887-177d-4892-8b82-e7031bca6564" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntityAddressAddressLine1_abe1d887-177d-4892-8b82-e7031bca6564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_cd601733-8137-47cc-b2b3-78c23cfe6d44" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntityAddressCityOrTown_cd601733-8137-47cc-b2b3-78c23cfe6d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e7fa4310-9475-4e56-bbab-b8340a6109c0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntityAddressStateOrProvince_e7fa4310-9475-4e56-bbab-b8340a6109c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_2bc22583-fc2d-4f53-8d40-2ad2c7cda171" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntityAddressPostalZipCode_2bc22583-fc2d-4f53-8d40-2ad2c7cda171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_a80b274e-d3b5-4058-86a0-96801416cd3d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntityAddressCountry_a80b274e-d3b5-4058-86a0-96801416cd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_434804b4-dfbf-4236-8c6f-83cbd654aff5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_CityAreaCode_434804b4-dfbf-4236-8c6f-83cbd654aff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_50c16c5e-6afb-4ac5-a4ea-f5b282cf644d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_LocalPhoneNumber_50c16c5e-6afb-4ac5-a4ea-f5b282cf644d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ac378a1a-c057-4982-b7f8-eabfdbf70542" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_Security12bTitle_ac378a1a-c057-4982-b7f8-eabfdbf70542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f9555345-ee41-43fd-809d-17d62591f94c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_TradingSymbol_f9555345-ee41-43fd-809d-17d62591f94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_92b7dd1c-3254-475b-8f78-6055c24e1485" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_SecurityExchangeName_92b7dd1c-3254-475b-8f78-6055c24e1485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_6831366d-dedf-4fa5-9bf5-0ce408cede5a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_6831366d-dedf-4fa5-9bf5-0ce408cede5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_1c281330-69c8-49ec-a93e-35a3458c825b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntityVoluntaryFilers_1c281330-69c8-49ec-a93e-35a3458c825b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6b1ddc7e-1d03-4462-a4a2-b35bf91358dc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntityCurrentReportingStatus_6b1ddc7e-1d03-4462-a4a2-b35bf91358dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6d6e8d29-8762-4dba-b8a0-c51dc7c8aa73" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntityInteractiveDataCurrent_6d6e8d29-8762-4dba-b8a0-c51dc7c8aa73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_5832a31a-9d0c-4a2f-ad4f-47ebbf85353d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntityFilerCategory_5832a31a-9d0c-4a2f-ad4f-47ebbf85353d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6ee5e433-9e56-4510-a44d-9d79024d8cf1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntitySmallBusiness_6ee5e433-9e56-4510-a44d-9d79024d8cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_72cd5d98-e785-4d57-917d-5b6451df7d69" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntityEmergingGrowthCompany_72cd5d98-e785-4d57-917d-5b6451df7d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_ded5ede8-5fdb-48d6-b372-bfe8c446c63f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_IcfrAuditorAttestationFlag_ded5ede8-5fdb-48d6-b372-bfe8c446c63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_8a4d3472-475c-4d9f-b91d-d4455d417b7d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_8a4d3472-475c-4d9f-b91d-d4455d417b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e8f6d90e-de87-40d1-bbfa-222d13df674d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntityShellCompany_e8f6d90e-de87-40d1-bbfa-222d13df674d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_e8964bc6-76cf-4940-92f1-e8893357471a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntityPublicFloat_e8964bc6-76cf-4940-92f1-e8893357471a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fa0f87c9-d527-4775-884f-2fbb9d8fe7f5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fa0f87c9-d527-4775-884f-2fbb9d8fe7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e8fc6eb8-5943-4f74-83f6-bad6a544f637" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_e8fc6eb8-5943-4f74-83f6-bad6a544f637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4a6086fd-436c-442d-9cda-6bd8be84da89" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_AmendmentFlag_4a6086fd-436c-442d-9cda-6bd8be84da89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c56b8c86-227f-4d0c-a77c-f741bc31328a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c56b8c86-227f-4d0c-a77c-f741bc31328a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_79823b45-7b7e-412c-ad94-db8050c664b8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_EntityCentralIndexKey_79823b45-7b7e-412c-ad94-db8050c664b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1aec4144-d2e1-4ba6-8928-575b45747b7d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_DocumentFiscalYearFocus_1aec4144-d2e1-4ba6-8928-575b45747b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_082b0836-8bb3-4b28-9fde-74018c0d2b6b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_aa00dbd5-5d39-40fa-8067-e39b9702eb04" xlink:to="loc_dei_DocumentTransitionReport_082b0836-8bb3-4b28-9fde-74018c0d2b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/AuditInformation" xlink:type="simple" xlink:href="rmd-20240630.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AuditInformationAbstract_59f1aa06-0519-4507-8dfd-43bd6eb67e6c" xlink:href="rmd-20240630.xsd#rmd_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_1b108e3a-2097-4348-9971-13e5a6073fd5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_AuditInformationAbstract_59f1aa06-0519-4507-8dfd-43bd6eb67e6c" xlink:to="loc_dei_AuditorName_1b108e3a-2097-4348-9971-13e5a6073fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_25458341-5b60-471e-ae5c-db2fd9a14238" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_AuditInformationAbstract_59f1aa06-0519-4507-8dfd-43bd6eb67e6c" xlink:to="loc_dei_AuditorLocation_25458341-5b60-471e-ae5c-db2fd9a14238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_db292cea-4546-46bb-aa52-75231e880729" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_AuditInformationAbstract_59f1aa06-0519-4507-8dfd-43bd6eb67e6c" xlink:to="loc_dei_AuditorFirmId_db292cea-4546-46bb-aa52-75231e880729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rmd-20240630.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8a007d80-a21e-4641-9a27-d2aa0ead1b60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ea282b4f-5027-4f6c-b85a-dbf432b72aec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8a007d80-a21e-4641-9a27-d2aa0ead1b60" xlink:to="loc_us-gaap_AssetsAbstract_ea282b4f-5027-4f6c-b85a-dbf432b72aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d2d7ca71-c653-4996-b6f9-44c9b9686a97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ea282b4f-5027-4f6c-b85a-dbf432b72aec" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d2d7ca71-c653-4996-b6f9-44c9b9686a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5866138c-e337-4c55-b37e-832edb142eee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d2d7ca71-c653-4996-b6f9-44c9b9686a97" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5866138c-e337-4c55-b37e-832edb142eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_35914452-e5e1-4334-850d-e32abca10764" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d2d7ca71-c653-4996-b6f9-44c9b9686a97" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_35914452-e5e1-4334-850d-e32abca10764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a06c701d-1cf9-4770-939e-71fd949edbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d2d7ca71-c653-4996-b6f9-44c9b9686a97" xlink:to="loc_us-gaap_InventoryNet_a06c701d-1cf9-4770-939e-71fd949edbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_76365e0c-dc6d-4a09-9443-b24aac38f612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d2d7ca71-c653-4996-b6f9-44c9b9686a97" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_76365e0c-dc6d-4a09-9443-b24aac38f612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9d70bc26-5908-4798-a390-8204044edc44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d2d7ca71-c653-4996-b6f9-44c9b9686a97" xlink:to="loc_us-gaap_AssetsCurrent_9d70bc26-5908-4798-a390-8204044edc44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_5d5c3217-42e4-4386-b26a-ee970e992387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ea282b4f-5027-4f6c-b85a-dbf432b72aec" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_5d5c3217-42e4-4386-b26a-ee970e992387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_03d78415-43a6-4bfb-b367-864f8e0053c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5d5c3217-42e4-4386-b26a-ee970e992387" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_03d78415-43a6-4bfb-b367-864f8e0053c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_24bd5ff6-92c9-4714-9656-f01c1cc5191f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5d5c3217-42e4-4386-b26a-ee970e992387" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_24bd5ff6-92c9-4714-9656-f01c1cc5191f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a8e349b6-ada4-4dcc-a21c-85de1f16af4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5d5c3217-42e4-4386-b26a-ee970e992387" xlink:to="loc_us-gaap_Goodwill_a8e349b6-ada4-4dcc-a21c-85de1f16af4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c1e6120d-e2f4-457d-89b3-56060b360a95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5d5c3217-42e4-4386-b26a-ee970e992387" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c1e6120d-e2f4-457d-89b3-56060b360a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_6e38d44d-a5a5-44fe-8015-825407393791" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5d5c3217-42e4-4386-b26a-ee970e992387" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_6e38d44d-a5a5-44fe-8015-825407393791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7b3c265d-1dfd-47aa-8d42-951300b9d11e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5d5c3217-42e4-4386-b26a-ee970e992387" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7b3c265d-1dfd-47aa-8d42-951300b9d11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_e413f020-73bc-4c10-86c6-1e059b61d15c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5d5c3217-42e4-4386-b26a-ee970e992387" xlink:to="loc_us-gaap_AssetsNoncurrent_e413f020-73bc-4c10-86c6-1e059b61d15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_dba5c833-b2e8-448f-99c5-05f8972178d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ea282b4f-5027-4f6c-b85a-dbf432b72aec" xlink:to="loc_us-gaap_Assets_dba5c833-b2e8-448f-99c5-05f8972178d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eb9df8c0-2695-42d2-8f19-6e1b49a01f80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8a007d80-a21e-4641-9a27-d2aa0ead1b60" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eb9df8c0-2695-42d2-8f19-6e1b49a01f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f00a5c8d-ff26-45a4-88ba-5d64fa65be47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eb9df8c0-2695-42d2-8f19-6e1b49a01f80" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f00a5c8d-ff26-45a4-88ba-5d64fa65be47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_85c4db55-3391-40ce-bea6-be10fdfcee2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f00a5c8d-ff26-45a4-88ba-5d64fa65be47" xlink:to="loc_us-gaap_AccountsPayableCurrent_85c4db55-3391-40ce-bea6-be10fdfcee2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a0d53073-3f1c-426a-9ba7-b02ef6b99b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f00a5c8d-ff26-45a4-88ba-5d64fa65be47" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a0d53073-3f1c-426a-9ba7-b02ef6b99b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_15881c5d-1309-4edb-aae0-296596a2679a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f00a5c8d-ff26-45a4-88ba-5d64fa65be47" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_15881c5d-1309-4edb-aae0-296596a2679a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6dc4da98-5d01-4192-a967-ddb443f1ddf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f00a5c8d-ff26-45a4-88ba-5d64fa65be47" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6dc4da98-5d01-4192-a967-ddb443f1ddf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_3927c485-cc1f-4511-83f6-b14af5c46f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f00a5c8d-ff26-45a4-88ba-5d64fa65be47" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_3927c485-cc1f-4511-83f6-b14af5c46f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_26df1d39-cc21-4b2a-850d-02141c627236" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f00a5c8d-ff26-45a4-88ba-5d64fa65be47" xlink:to="loc_us-gaap_ShortTermBorrowings_26df1d39-cc21-4b2a-850d-02141c627236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a596c1ec-c241-4dab-80d9-8ae2f2359242" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f00a5c8d-ff26-45a4-88ba-5d64fa65be47" xlink:to="loc_us-gaap_LiabilitiesCurrent_a596c1ec-c241-4dab-80d9-8ae2f2359242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_fce31e35-5882-405b-a419-dca21764379f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eb9df8c0-2695-42d2-8f19-6e1b49a01f80" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_fce31e35-5882-405b-a419-dca21764379f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ad6052a5-7860-4624-9eda-537c565ba9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_fce31e35-5882-405b-a419-dca21764379f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ad6052a5-7860-4624-9eda-537c565ba9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_bf51d9b3-8132-41a4-b585-40cd5b1596ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_fce31e35-5882-405b-a419-dca21764379f" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_bf51d9b3-8132-41a4-b585-40cd5b1596ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_84f4bdc4-1ccc-48c7-9626-babba55f7f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_fce31e35-5882-405b-a419-dca21764379f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_84f4bdc4-1ccc-48c7-9626-babba55f7f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3efa75b3-5ee9-4a00-b12e-576168162a46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_fce31e35-5882-405b-a419-dca21764379f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3efa75b3-5ee9-4a00-b12e-576168162a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9f43ed6e-9988-4e36-8109-7f6269c98d76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_fce31e35-5882-405b-a419-dca21764379f" xlink:to="loc_us-gaap_LongTermDebt_9f43ed6e-9988-4e36-8109-7f6269c98d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_9ae8a94e-f540-432a-b51f-14528948d245" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_fce31e35-5882-405b-a419-dca21764379f" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_9ae8a94e-f540-432a-b51f-14528948d245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_6deed01e-666f-46c3-a247-500954a0068e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_fce31e35-5882-405b-a419-dca21764379f" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_6deed01e-666f-46c3-a247-500954a0068e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_25c49150-56c0-4115-b372-b91f9f9bf861" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eb9df8c0-2695-42d2-8f19-6e1b49a01f80" xlink:to="loc_us-gaap_Liabilities_25c49150-56c0-4115-b372-b91f9f9bf861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ad58b102-a13d-45bd-a330-23329aa7e973" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eb9df8c0-2695-42d2-8f19-6e1b49a01f80" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ad58b102-a13d-45bd-a330-23329aa7e973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_fafe9373-24a9-4d50-a79e-84dc6fe1d5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eb9df8c0-2695-42d2-8f19-6e1b49a01f80" xlink:to="loc_us-gaap_StockholdersEquityAbstract_fafe9373-24a9-4d50-a79e-84dc6fe1d5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_67c228ba-9bfe-4f81-ba01-f37c1eeff1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fafe9373-24a9-4d50-a79e-84dc6fe1d5f6" xlink:to="loc_us-gaap_PreferredStockValue_67c228ba-9bfe-4f81-ba01-f37c1eeff1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_25eafcfd-76ae-4eb3-a1aa-69d0bd6c0740" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fafe9373-24a9-4d50-a79e-84dc6fe1d5f6" xlink:to="loc_us-gaap_CommonStockValueOutstanding_25eafcfd-76ae-4eb3-a1aa-69d0bd6c0740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_bd30c294-3bbc-4010-a0ca-8f124d4d9df8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fafe9373-24a9-4d50-a79e-84dc6fe1d5f6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_bd30c294-3bbc-4010-a0ca-8f124d4d9df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_63fda83f-9244-464f-b72e-b0ff55f52db7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fafe9373-24a9-4d50-a79e-84dc6fe1d5f6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_63fda83f-9244-464f-b72e-b0ff55f52db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_6700667d-50be-4810-bdcd-a34923e581da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fafe9373-24a9-4d50-a79e-84dc6fe1d5f6" xlink:to="loc_us-gaap_TreasuryStockCommonValue_6700667d-50be-4810-bdcd-a34923e581da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_238360da-35a0-485e-877c-180723b7fed9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fafe9373-24a9-4d50-a79e-84dc6fe1d5f6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_238360da-35a0-485e-877c-180723b7fed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_08c81fa5-4c47-4cb0-a04e-4939dd330cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fafe9373-24a9-4d50-a79e-84dc6fe1d5f6" xlink:to="loc_us-gaap_StockholdersEquity_08c81fa5-4c47-4cb0-a04e-4939dd330cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_dde1554f-7312-49fd-ae26-4ffbe42227f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eb9df8c0-2695-42d2-8f19-6e1b49a01f80" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_dde1554f-7312-49fd-ae26-4ffbe42227f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="rmd-20240630.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1d8c1be5-152e-486f-b05b-5c0c5d19d848" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_f02b9dcd-53e2-4f74-8e1c-7157a8359098" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1d8c1be5-152e-486f-b05b-5c0c5d19d848" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_f02b9dcd-53e2-4f74-8e1c-7157a8359098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_26b00283-ed7e-4689-bcc7-91d3248f70f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1d8c1be5-152e-486f-b05b-5c0c5d19d848" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_26b00283-ed7e-4689-bcc7-91d3248f70f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a9575666-9415-46cc-abe0-446788929e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1d8c1be5-152e-486f-b05b-5c0c5d19d848" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a9575666-9415-46cc-abe0-446788929e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_e30c2c20-ac89-436c-a7bd-362adb85a98e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1d8c1be5-152e-486f-b05b-5c0c5d19d848" xlink:to="loc_us-gaap_PreferredStockSharesIssued_e30c2c20-ac89-436c-a7bd-362adb85a98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_984d9b60-6106-4012-89a2-8dc3b8b74d01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1d8c1be5-152e-486f-b05b-5c0c5d19d848" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_984d9b60-6106-4012-89a2-8dc3b8b74d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_752a9e8f-60b4-4797-a2b0-36ef6774cd09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1d8c1be5-152e-486f-b05b-5c0c5d19d848" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_752a9e8f-60b4-4797-a2b0-36ef6774cd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_52f1fa5d-1666-491a-97b7-e25f140b38c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1d8c1be5-152e-486f-b05b-5c0c5d19d848" xlink:to="loc_us-gaap_CommonStockSharesIssued_52f1fa5d-1666-491a-97b7-e25f140b38c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9686fb1e-c300-4835-841b-a49b8b7bc6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1d8c1be5-152e-486f-b05b-5c0c5d19d848" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9686fb1e-c300-4835-841b-a49b8b7bc6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_08a8c648-9f3a-4936-ab51-ff00a6702568" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1d8c1be5-152e-486f-b05b-5c0c5d19d848" xlink:to="loc_us-gaap_TreasuryStockCommonShares_08a8c648-9f3a-4936-ab51-ff00a6702568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="rmd-20240630.xsd#ConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_fa4a5feb-ead9-41e9-b7d6-575180557622" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ac5b1a10-f640-4f6b-aa88-a9dec35b4fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fa4a5feb-ead9-41e9-b7d6-575180557622" xlink:to="loc_us-gaap_StatementTable_ac5b1a10-f640-4f6b-aa88-a9dec35b4fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b17671c0-4b62-467c-92fe-51efd433878d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ac5b1a10-f640-4f6b-aa88-a9dec35b4fbc" xlink:to="loc_srt_ProductOrServiceAxis_b17671c0-4b62-467c-92fe-51efd433878d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5c23de39-5f5f-49fb-be9b-b3914f4da7a1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b17671c0-4b62-467c-92fe-51efd433878d" xlink:to="loc_srt_ProductsAndServicesDomain_5c23de39-5f5f-49fb-be9b-b3914f4da7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SleepAndRespiratoryMember_02f0552d-fdeb-4a5e-bc51-b9f59f6adb5d" xlink:href="rmd-20240630.xsd#rmd_SleepAndRespiratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c23de39-5f5f-49fb-be9b-b3914f4da7a1" xlink:to="loc_rmd_SleepAndRespiratoryMember_02f0552d-fdeb-4a5e-bc51-b9f59f6adb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SoftwareAsAServiceMember_81c9abaa-f921-44c8-a352-a61ff8fdfb45" xlink:href="rmd-20240630.xsd#rmd_SoftwareAsAServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5c23de39-5f5f-49fb-be9b-b3914f4da7a1" xlink:to="loc_rmd_SoftwareAsAServiceMember_81c9abaa-f921-44c8-a352-a61ff8fdfb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ac5b1a10-f640-4f6b-aa88-a9dec35b4fbc" xlink:to="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc1019c5-48d2-4d7a-9c19-981e26eee9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc1019c5-48d2-4d7a-9c19-981e26eee9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_a9c95894-bd65-4b3d-9535-f17855595c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_a9c95894-bd65-4b3d-9535-f17855595c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2ec58d38-b337-4a1a-b3d3-6c179c78afd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2ec58d38-b337-4a1a-b3d3-6c179c78afd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2b4f1b1c-9b19-4136-b362-7284e5860cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2b4f1b1c-9b19-4136-b362-7284e5860cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_992f75c5-b055-433c-9a1b-19d9f4098f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_GrossProfit_992f75c5-b055-433c-9a1b-19d9f4098f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5aec9e5c-8d96-4f86-81c9-c7aa05de8084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5aec9e5c-8d96-4f86-81c9-c7aa05de8084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_488bf1a3-a8e5-4783-b549-3a81edf4fc74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5aec9e5c-8d96-4f86-81c9-c7aa05de8084" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_488bf1a3-a8e5-4783-b549-3a81edf4fc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7f1c6940-bbf2-4af9-bece-a9cbbf7126e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5aec9e5c-8d96-4f86-81c9-c7aa05de8084" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7f1c6940-bbf2-4af9-bece-a9cbbf7126e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_b1ac2754-7cd4-4836-a387-8e4b82615fa3" xlink:href="rmd-20240630.xsd#rmd_AmortizationOfAcquiredIntangibleAssets1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5aec9e5c-8d96-4f86-81c9-c7aa05de8084" xlink:to="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_b1ac2754-7cd4-4836-a387-8e4b82615fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0797abcd-a229-430e-b3eb-c5cd13c8beb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5aec9e5c-8d96-4f86-81c9-c7aa05de8084" xlink:to="loc_us-gaap_RestructuringCharges_0797abcd-a229-430e-b3eb-c5cd13c8beb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_d4e082ff-badd-4f40-b369-e947976d9930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5aec9e5c-8d96-4f86-81c9-c7aa05de8084" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_d4e082ff-badd-4f40-b369-e947976d9930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1a1dad39-3ed7-46ae-aa25-85fa9b413e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5aec9e5c-8d96-4f86-81c9-c7aa05de8084" xlink:to="loc_us-gaap_OperatingExpenses_1a1dad39-3ed7-46ae-aa25-85fa9b413e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ab731687-48b7-4190-891f-ae5bd3ccdca3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_OperatingIncomeLoss_ab731687-48b7-4190-891f-ae5bd3ccdca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_57332412-eb53-428b-b5cf-ba1bb1da5394" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_57332412-eb53-428b-b5cf-ba1bb1da5394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_2f7ad826-f5d0-4c62-8852-a710cc4f2a30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_57332412-eb53-428b-b5cf-ba1bb1da5394" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_2f7ad826-f5d0-4c62-8852-a710cc4f2a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b0d42191-e7b3-40fc-a454-177a7885521c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_57332412-eb53-428b-b5cf-ba1bb1da5394" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b0d42191-e7b3-40fc-a454-177a7885521c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_baeca4f1-67fb-4498-af18-5002ad87df98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_57332412-eb53-428b-b5cf-ba1bb1da5394" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_baeca4f1-67fb-4498-af18-5002ad87df98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_9d43b591-806b-4136-9837-2c7d4d37f79a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainOnBusinessInterruptionInsuranceRecovery"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_57332412-eb53-428b-b5cf-ba1bb1da5394" xlink:to="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_9d43b591-806b-4136-9837-2c7d4d37f79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9c3c404f-471d-4cf3-9049-b19bcb8de6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_57332412-eb53-428b-b5cf-ba1bb1da5394" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9c3c404f-471d-4cf3-9049-b19bcb8de6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0b10a5a5-ee75-4021-acef-8ccc1fec3f52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_57332412-eb53-428b-b5cf-ba1bb1da5394" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_0b10a5a5-ee75-4021-acef-8ccc1fec3f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0b5c8af0-7410-4c1d-bc19-e4a887d8b18b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0b5c8af0-7410-4c1d-bc19-e4a887d8b18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_08cd35f4-ef23-474e-8118-4e481aa00e54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_08cd35f4-ef23-474e-8118-4e481aa00e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bebd526a-6138-41ee-84e5-77ddf7476b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_NetIncomeLoss_bebd526a-6138-41ee-84e5-77ddf7476b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_06b2aa90-02ce-4fbe-abae-39e5f1f6f4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_EarningsPerShareBasic_06b2aa90-02ce-4fbe-abae-39e5f1f6f4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c304b440-b35b-46dd-9543-3152b78fbd11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c304b440-b35b-46dd-9543-3152b78fbd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_7e365b23-30ac-457e-8b86-3cd3387f145a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_7e365b23-30ac-457e-8b86-3cd3387f145a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0b7b68e8-6c4a-48d1-9611-532a7bb60e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0b7b68e8-6c4a-48d1-9611-532a7bb60e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6aaf45cd-5125-4cb7-9509-0d7b05337be8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74365bfd-c0e3-4d4d-92f7-78d8fe19d59e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6aaf45cd-5125-4cb7-9509-0d7b05337be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="rmd-20240630.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a2d41ed9-264d-49f8-84c3-557f7bbe48d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a6304f42-f734-439a-9754-3c6de3ba4708" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a2d41ed9-264d-49f8-84c3-557f7bbe48d7" xlink:to="loc_us-gaap_NetIncomeLoss_a6304f42-f734-439a-9754-3c6de3ba4708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9a0d0746-9fbb-4500-9013-c09bf2730284" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a2d41ed9-264d-49f8-84c3-557f7bbe48d7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9a0d0746-9fbb-4500-9013-c09bf2730284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_87d3b330-4f76-40c5-90c8-509283c9178b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9a0d0746-9fbb-4500-9013-c09bf2730284" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_87d3b330-4f76-40c5-90c8-509283c9178b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_31dfa0a3-c7ad-4d2d-8ee4-3a069d69461a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_9a0d0746-9fbb-4500-9013-c09bf2730284" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_31dfa0a3-c7ad-4d2d-8ee4-3a069d69461a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b8e78663-7ce7-40d6-a080-7b0127ab8543" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a2d41ed9-264d-49f8-84c3-557f7bbe48d7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b8e78663-7ce7-40d6-a080-7b0127ab8543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="rmd-20240630.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_38c2d3b0-9637-4917-a164-0dfe2bbdc84b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_865c879d-ed3f-4d5b-8242-99a2bc2069f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_38c2d3b0-9637-4917-a164-0dfe2bbdc84b" xlink:to="loc_us-gaap_StatementTable_865c879d-ed3f-4d5b-8242-99a2bc2069f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7f8b9f89-ab2d-4fb6-9482-1306df09299a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_865c879d-ed3f-4d5b-8242-99a2bc2069f8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7f8b9f89-ab2d-4fb6-9482-1306df09299a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_75632416-2d8c-4d48-ac06-5b99a336dbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7f8b9f89-ab2d-4fb6-9482-1306df09299a" xlink:to="loc_us-gaap_EquityComponentDomain_75632416-2d8c-4d48-ac06-5b99a336dbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4087c45b-832c-45ae-9e69-7bfa22c21e63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_75632416-2d8c-4d48-ac06-5b99a336dbbd" xlink:to="loc_us-gaap_CommonStockMember_4087c45b-832c-45ae-9e69-7bfa22c21e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_12855921-54e9-4d7f-84ec-536ce0fe537b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_75632416-2d8c-4d48-ac06-5b99a336dbbd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_12855921-54e9-4d7f-84ec-536ce0fe537b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_5e83365c-839e-4427-b7dc-b7a2489085d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_75632416-2d8c-4d48-ac06-5b99a336dbbd" xlink:to="loc_us-gaap_TreasuryStockCommonMember_5e83365c-839e-4427-b7dc-b7a2489085d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6c5b8f12-72c9-4541-967d-710692322a82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_75632416-2d8c-4d48-ac06-5b99a336dbbd" xlink:to="loc_us-gaap_RetainedEarningsMember_6c5b8f12-72c9-4541-967d-710692322a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a9435fea-21dd-472f-b9f1-29de8e122a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_75632416-2d8c-4d48-ac06-5b99a336dbbd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a9435fea-21dd-472f-b9f1-29de8e122a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b55ab7dd-68c8-44cc-ab20-44dbc81485e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_865c879d-ed3f-4d5b-8242-99a2bc2069f8" xlink:to="loc_us-gaap_StatementLineItems_b55ab7dd-68c8-44cc-ab20-44dbc81485e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b55ab7dd-68c8-44cc-ab20-44dbc81485e2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1e2edb2c-443e-49b6-b10c-129cf3c05e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1e2edb2c-443e-49b6-b10c-129cf3c05e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8e63467d-6597-4450-a1a2-52b3e78b8206" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_StockholdersEquity_8e63467d-6597-4450-a1a2-52b3e78b8206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_1a21c187-a7f9-4aba-9f78-5f9369c4635f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_TreasuryStockCommonShares_1a21c187-a7f9-4aba-9f78-5f9369c4635f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_eb8fd406-45d9-451e-ba1d-f30e7201ee55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_eb8fd406-45d9-451e-ba1d-f30e7201ee55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ae3e579e-0a34-4967-8976-7442a1e601c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ae3e579e-0a34-4967-8976-7442a1e601c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_347f1823-16c6-449a-b667-c8e62c79b144" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_347f1823-16c6-449a-b667-c8e62c79b144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_93785ebf-1144-4769-acea-b6669b55386a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_93785ebf-1144-4769-acea-b6669b55386a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3e13ef5e-6a55-44c9-aae4-c12a73ced1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3e13ef5e-6a55-44c9-aae4-c12a73ced1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2fcb285c-a925-4ee3-bff2-83febb0956ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2fcb285c-a925-4ee3-bff2-83febb0956ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d37667fb-f8c4-4221-a43d-79bd7d850634" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d37667fb-f8c4-4221-a43d-79bd7d850634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_414a4a01-2ff0-483e-9ef9-cd8f52a9f347" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_414a4a01-2ff0-483e-9ef9-cd8f52a9f347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ad632910-cf90-47d6-a807-f3fdb49bccfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ad632910-cf90-47d6-a807-f3fdb49bccfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f01f9699-ae2e-4fb9-9ea9-61ea3399e00b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f01f9699-ae2e-4fb9-9ea9-61ea3399e00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8a750303-91fd-4d48-a41b-4cad586ae347" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_NetIncomeLoss_8a750303-91fd-4d48-a41b-4cad586ae347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_c2745785-9da7-433f-b06c-89c2232b7f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_Dividends_c2745785-9da7-433f-b06c-89c2232b7f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e5ad20a8-a51a-4308-a987-0c17ea6a5d94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e5ad20a8-a51a-4308-a987-0c17ea6a5d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3d781cb8-7c35-4467-8d44-50ab1a3bfd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_StockholdersEquity_3d781cb8-7c35-4467-8d44-50ab1a3bfd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_d29913f1-92fb-4113-b5b6-39d7d18f3aad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb3fbe7a-c6cf-4002-bb3e-828ae75027fd" xlink:to="loc_us-gaap_TreasuryStockCommonShares_d29913f1-92fb-4113-b5b6-39d7d18f3aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="rmd-20240630.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_956c939d-29f8-446e-83c5-c69601a73e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_8b08d931-6302-4a87-a8de-8a7f5e29e034" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_956c939d-29f8-446e-83c5-c69601a73e2a" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_8b08d931-6302-4a87-a8de-8a7f5e29e034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="rmd-20240630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a3fea018-62c9-4a08-992e-f9bceef513ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_576abee8-bc75-45cf-ade9-9cfb4038190f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a3fea018-62c9-4a08-992e-f9bceef513ca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_576abee8-bc75-45cf-ade9-9cfb4038190f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_23e3536d-e26a-46c2-b307-363ff991113b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_576abee8-bc75-45cf-ade9-9cfb4038190f" xlink:to="loc_us-gaap_NetIncomeLoss_23e3536d-e26a-46c2-b307-363ff991113b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cec575ea-e415-4886-97a0-a7641b664540" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_576abee8-bc75-45cf-ade9-9cfb4038190f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cec575ea-e415-4886-97a0-a7641b664540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_350eff36-5e7d-4334-96cc-7219c961a5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cec575ea-e415-4886-97a0-a7641b664540" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_350eff36-5e7d-4334-96cc-7219c961a5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c19c20af-d852-42f4-aef4-f0444aa10170" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cec575ea-e415-4886-97a0-a7641b664540" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c19c20af-d852-42f4-aef4-f0444aa10170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_569b899e-f5f9-4cf8-9d2e-faf9fd7510a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cec575ea-e415-4886-97a0-a7641b664540" xlink:to="loc_us-gaap_ShareBasedCompensation_569b899e-f5f9-4cf8-9d2e-faf9fd7510a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_fe520c29-5c0f-45f6-8924-43b4de2b84c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cec575ea-e415-4886-97a0-a7641b664540" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_fe520c29-5c0f-45f6-8924-43b4de2b84c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_74662421-faa2-4a12-a99d-7363f9df287b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cec575ea-e415-4886-97a0-a7641b664540" xlink:to="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_74662421-faa2-4a12-a99d-7363f9df287b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_8d121624-beb8-47a2-81db-9ed95ea5c884" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cec575ea-e415-4886-97a0-a7641b664540" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_8d121624-beb8-47a2-81db-9ed95ea5c884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRecoveries_d74981dc-2233-45f0-be1a-12886f0b253f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceRecoveries"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cec575ea-e415-4886-97a0-a7641b664540" xlink:to="loc_us-gaap_InsuranceRecoveries_d74981dc-2233-45f0-be1a-12886f0b253f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bca256d5-079d-4ce8-a6e1-83d61793bede" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_576abee8-bc75-45cf-ade9-9cfb4038190f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bca256d5-079d-4ce8-a6e1-83d61793bede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_df3294c9-302b-44af-8850-606f403b2fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bca256d5-079d-4ce8-a6e1-83d61793bede" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_df3294c9-302b-44af-8850-606f403b2fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3e586e79-7ebb-473e-ba73-213e80dde359" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bca256d5-079d-4ce8-a6e1-83d61793bede" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3e586e79-7ebb-473e-ba73-213e80dde359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fb01b15a-130b-4155-a7d7-7e698900dfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bca256d5-079d-4ce8-a6e1-83d61793bede" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fb01b15a-130b-4155-a7d7-7e698900dfd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7e6aa9db-63bd-4fdb-8768-fb11286355d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bca256d5-079d-4ce8-a6e1-83d61793bede" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7e6aa9db-63bd-4fdb-8768-fb11286355d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d855e3d8-2360-4c07-a307-6b20134fdd5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_576abee8-bc75-45cf-ade9-9cfb4038190f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d855e3d8-2360-4c07-a307-6b20134fdd5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19fc0c28-39c8-4de5-8f0e-0f5c2664178e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a3fea018-62c9-4a08-992e-f9bceef513ca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19fc0c28-39c8-4de5-8f0e-0f5c2664178e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_aa7d344a-bb2a-4019-a428-5668bd391e50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19fc0c28-39c8-4de5-8f0e-0f5c2664178e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_aa7d344a-bb2a-4019-a428-5668bd391e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_410ec90a-9884-40ad-96fe-a1816c8f5488" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19fc0c28-39c8-4de5-8f0e-0f5c2664178e" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_410ec90a-9884-40ad-96fe-a1816c8f5488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_03468ebf-5014-4a09-97ef-e340dea5de73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19fc0c28-39c8-4de5-8f0e-0f5c2664178e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_03468ebf-5014-4a09-97ef-e340dea5de73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_5cdf30a4-a725-47cc-9ce9-d6720a2ff52a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19fc0c28-39c8-4de5-8f0e-0f5c2664178e" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_5cdf30a4-a725-47cc-9ce9-d6720a2ff52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3389c2b3-c39a-4c25-a1b8-fe9637b3bb30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19fc0c28-39c8-4de5-8f0e-0f5c2664178e" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3389c2b3-c39a-4c25-a1b8-fe9637b3bb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities_f29512c5-0110-483b-ab6a-d946ed892d14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19fc0c28-39c8-4de5-8f0e-0f5c2664178e" xlink:to="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities_f29512c5-0110-483b-ab6a-d946ed892d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32fa40a4-ec01-43ad-bf2f-7e8b43360e31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19fc0c28-39c8-4de5-8f0e-0f5c2664178e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_32fa40a4-ec01-43ad-bf2f-7e8b43360e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb20a5e6-b839-4196-a9fd-a8248e3b9ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a3fea018-62c9-4a08-992e-f9bceef513ca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb20a5e6-b839-4196-a9fd-a8248e3b9ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e4f19521-ea67-45bf-9b38-d9afc82c0f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb20a5e6-b839-4196-a9fd-a8248e3b9ba9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e4f19521-ea67-45bf-9b38-d9afc82c0f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c6ef7740-69c2-46fb-9f2c-826b96e55a35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb20a5e6-b839-4196-a9fd-a8248e3b9ba9" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c6ef7740-69c2-46fb-9f2c-826b96e55a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_07a963ea-c468-4f59-8dbf-4666e882eb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb20a5e6-b839-4196-a9fd-a8248e3b9ba9" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_07a963ea-c468-4f59-8dbf-4666e882eb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_11650e96-0e53-4a33-ac57-90d8aa1a312e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb20a5e6-b839-4196-a9fd-a8248e3b9ba9" xlink:to="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_11650e96-0e53-4a33-ac57-90d8aa1a312e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7820ca73-9e5a-4c86-974b-57d595a121ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb20a5e6-b839-4196-a9fd-a8248e3b9ba9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7820ca73-9e5a-4c86-974b-57d595a121ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_e4034a3c-e254-4ebd-af07-17fb3eebf595" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb20a5e6-b839-4196-a9fd-a8248e3b9ba9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_e4034a3c-e254-4ebd-af07-17fb3eebf595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_2d587ea9-10f5-4a21-8bbf-02b27e0a3599" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb20a5e6-b839-4196-a9fd-a8248e3b9ba9" xlink:to="loc_us-gaap_PaymentsOfDividends_2d587ea9-10f5-4a21-8bbf-02b27e0a3599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d37f9e31-2cbe-4e10-8ce8-04316654a16b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb20a5e6-b839-4196-a9fd-a8248e3b9ba9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d37f9e31-2cbe-4e10-8ce8-04316654a16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_456600ae-5160-4b4e-87d2-32f9d8336bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a3fea018-62c9-4a08-992e-f9bceef513ca" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_456600ae-5160-4b4e-87d2-32f9d8336bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8205ebf4-d711-4354-aa3d-0f0918ae81fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a3fea018-62c9-4a08-992e-f9bceef513ca" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8205ebf4-d711-4354-aa3d-0f0918ae81fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fd17b042-91f1-4d40-a1ce-e0ebfdc499b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a3fea018-62c9-4a08-992e-f9bceef513ca" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fd17b042-91f1-4d40-a1ce-e0ebfdc499b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a5e303c5-b03e-45dc-9d7a-12228772c076" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a3fea018-62c9-4a08-992e-f9bceef513ca" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a5e303c5-b03e-45dc-9d7a-12228772c076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_9074d716-905d-4d02-aaba-07bcab0e1660" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a3fea018-62c9-4a08-992e-f9bceef513ca" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_9074d716-905d-4d02-aaba-07bcab0e1660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_0781a723-0793-44c7-8f86-6f1320a8c843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9074d716-905d-4d02-aaba-07bcab0e1660" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_0781a723-0793-44c7-8f86-6f1320a8c843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_1d4c95ee-774f-4855-857e-3a16f2ec5be1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9074d716-905d-4d02-aaba-07bcab0e1660" xlink:to="loc_us-gaap_InterestPaidNet_1d4c95ee-774f-4855-857e-3a16f2ec5be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired_d40a6b70-5aa3-47cc-a1a6-1af5a6c819d5" xlink:href="rmd-20240630.xsd#rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9074d716-905d-4d02-aaba-07bcab0e1660" xlink:to="loc_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired_d40a6b70-5aa3-47cc-a1a6-1af5a6c819d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_a7435f2f-13ac-4027-ad24-a065a4e5aa12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9074d716-905d-4d02-aaba-07bcab0e1660" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_a7435f2f-13ac-4027-ad24-a065a4e5aa12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease_8199d6a0-b051-4b78-9d96-81a64fb5d344" xlink:href="rmd-20240630.xsd#rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9074d716-905d-4d02-aaba-07bcab0e1660" xlink:to="loc_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease_8199d6a0-b051-4b78-9d96-81a64fb5d344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination_b6c38e66-fb7a-4ca7-b7f6-eede424ee32a" xlink:href="rmd-20240630.xsd#rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9074d716-905d-4d02-aaba-07bcab0e1660" xlink:to="loc_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination_b6c38e66-fb7a-4ca7-b7f6-eede424ee32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredPaymentObligationsForAcquisitions_38fd7a5b-5b7c-4570-aed5-f8c92bcf9278" xlink:href="rmd-20240630.xsd#rmd_DeferredPaymentObligationsForAcquisitions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9074d716-905d-4d02-aaba-07bcab0e1660" xlink:to="loc_rmd_DeferredPaymentObligationsForAcquisitions_38fd7a5b-5b7c-4570-aed5-f8c92bcf9278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability_b57df4eb-e8ef-41a1-a880-9d662b632d70" xlink:href="rmd-20240630.xsd#rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9074d716-905d-4d02-aaba-07bcab0e1660" xlink:to="loc_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability_b57df4eb-e8ef-41a1-a880-9d662b632d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_503a1d81-1901-499c-8a1d-998bef7f0a47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9074d716-905d-4d02-aaba-07bcab0e1660" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_503a1d81-1901-499c-8a1d-998bef7f0a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="rmd-20240630.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_850055c8-1cdc-40b4-8e86-8626abb4c3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_52abf247-3138-4d15-83a0-69c1cd7de7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_850055c8-1cdc-40b4-8e86-8626abb4c3aa" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_52abf247-3138-4d15-83a0-69c1cd7de7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="rmd-20240630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_89bf9ca6-c570-40e3-839b-8c2f89691a56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4bea10ba-a3fb-4179-ba3d-811d0e9b68f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_89bf9ca6-c570-40e3-839b-8c2f89691a56" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4bea10ba-a3fb-4179-ba3d-811d0e9b68f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/NewAccountingPronouncements" xlink:type="simple" xlink:href="rmd-20240630.xsd#NewAccountingPronouncements"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/NewAccountingPronouncements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_6cb67133-1547-4a84-a560-689299d0ac5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_bb07fce3-0815-4401-bcde-9d3d8f694da7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_6cb67133-1547-4a84-a560-689299d0ac5b" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_bb07fce3-0815-4401-bcde-9d3d8f694da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformation" xlink:type="simple" xlink:href="rmd-20240630.xsd#SupplementalBalanceSheetInformation"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SupplementalBalanceSheetInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SupplementalBalanceSheetInformationAbstract_cab2cf5e-eb69-4d47-a82b-ed4c023f78c8" xlink:href="rmd-20240630.xsd#rmd_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_42f8d7c5-01ce-4c28-a31c-36f5e76224d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SupplementalBalanceSheetInformationAbstract_cab2cf5e-eb69-4d47-a82b-ed4c023f78c8" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_42f8d7c5-01ce-4c28-a31c-36f5e76224d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnet" xlink:type="simple" xlink:href="rmd-20240630.xsd#GoodwillandOtherIntangibleAssetsnet"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9f661ef5-5175-4a08-9bae-1e41b0de29d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4421462c-b33c-4040-9cc3-8db6298d2796" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9f661ef5-5175-4a08-9bae-1e41b0de29d3" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_4421462c-b33c-4040-9cc3-8db6298d2796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/Investments" xlink:type="simple" xlink:href="rmd-20240630.xsd#Investments"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_7c470ba1-b650-4399-9118-9daaa8ebe307" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock_62e5a619-74a5-468f-a7ef-e1db8227534b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_7c470ba1-b650-4399-9118-9daaa8ebe307" xlink:to="loc_us-gaap_InvestmentTextBlock_62e5a619-74a5-468f-a7ef-e1db8227534b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/AccruedExpenses" xlink:type="simple" xlink:href="rmd-20240630.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5123cb9c-b98d-4ba7-ac4d-e1cb5bd5dfdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_55d92458-70e5-45ca-ac3b-a60b2ef1fec2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5123cb9c-b98d-4ba7-ac4d-e1cb5bd5dfdc" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_55d92458-70e5-45ca-ac3b-a60b2ef1fec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/Debt" xlink:type="simple" xlink:href="rmd-20240630.xsd#Debt"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f5a8fae1-9f87-4194-8194-fd003aac0dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1eebc4f5-ff28-4d86-a48f-8662123758fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f5a8fae1-9f87-4194-8194-fd003aac0dfa" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1eebc4f5-ff28-4d86-a48f-8662123758fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/Leases" xlink:type="simple" xlink:href="rmd-20240630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9d9d359a-4cbf-45a5-bad2-6a2a3ff5122c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_62b7bed0-86c1-4c19-9940-3dac57bd7267" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9d9d359a-4cbf-45a5-bad2-6a2a3ff5122c" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_62b7bed0-86c1-4c19-9940-3dac57bd7267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_14d32c7f-b49e-4666-9308-df9900bd60c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9d9d359a-4cbf-45a5-bad2-6a2a3ff5122c" xlink:to="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_14d32c7f-b49e-4666-9308-df9900bd60c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorSalesTypeLeasesTextBlock_01530fa4-ac47-418a-ae0a-c3b035884876" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LessorSalesTypeLeasesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9d9d359a-4cbf-45a5-bad2-6a2a3ff5122c" xlink:to="loc_us-gaap_LessorSalesTypeLeasesTextBlock_01530fa4-ac47-418a-ae0a-c3b035884876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquity" xlink:type="simple" xlink:href="rmd-20240630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_22e298aa-6bf8-45e7-a7b7-9ba838f673c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8a3bb2a7-ecd4-4540-89fb-1b8129508187" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_22e298aa-6bf8-45e7-a7b7-9ba838f673c8" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8a3bb2a7-ecd4-4540-89fb-1b8129508187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/EarningsPerShare" xlink:type="simple" xlink:href="rmd-20240630.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ff35f236-7216-4419-86ce-3ab14cda2f05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_b700ba7c-22f1-476b-b5ae-a65a095331fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ff35f236-7216-4419-86ce-3ab14cda2f05" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_b700ba7c-22f1-476b-b5ae-a65a095331fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxes" xlink:type="simple" xlink:href="rmd-20240630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a44efa0b-bbb5-4b26-95d4-af8332df027f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_5caf5a14-65f1-4cd1-94a3-72e3318e49aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a44efa0b-bbb5-4b26-95d4-af8332df027f" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_5caf5a14-65f1-4cd1-94a3-72e3318e49aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformation" xlink:type="simple" xlink:href="rmd-20240630.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1252ebc2-fb97-416f-a017-8e8beffadbda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_29aff89f-e15a-437b-b4ba-cdaaf4671592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1252ebc2-fb97-416f-a017-8e8beffadbda" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_29aff89f-e15a-437b-b4ba-cdaaf4671592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/EmployeeRetirementPlans" xlink:type="simple" xlink:href="rmd-20240630.xsd#EmployeeRetirementPlans"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/EmployeeRetirementPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b6cecf3e-5676-41df-9ffa-3cc46d7b9b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2bbcd616-680d-46f9-a0b0-12b3e06bc0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b6cecf3e-5676-41df-9ffa-3cc46d7b9b5a" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_2bbcd616-680d-46f9-a0b0-12b3e06bc0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LegalActionsContingenciesandCommitments" xlink:type="simple" xlink:href="rmd-20240630.xsd#LegalActionsContingenciesandCommitments"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LegalActionsContingenciesandCommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3f8bbfc1-3145-43b4-bef8-3b22af67bc98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_32e885b9-5f1f-4654-a13f-7bda69dfb7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3f8bbfc1-3145-43b4-bef8-3b22af67bc98" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_32e885b9-5f1f-4654-a13f-7bda69dfb7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivities" xlink:type="simple" xlink:href="rmd-20240630.xsd#DerivativeInstrumentsandHedgingActivities"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b6884e99-7084-4977-8f82-e4e551d3fc85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_95351889-fc60-423e-9701-3dd37c1d1fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b6884e99-7084-4977-8f82-e4e551d3fc85" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_95351889-fc60-423e-9701-3dd37c1d1fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/BusinessCombinations" xlink:type="simple" xlink:href="rmd-20240630.xsd#BusinessCombinations"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/BusinessCombinations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_27abbe43-ccb8-485b-a52d-c083c349292c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_12b85d50-51f1-4b6d-94e4-a9f9914083b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_27abbe43-ccb8-485b-a52d-c083c349292c" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_12b85d50-51f1-4b6d-94e4-a9f9914083b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/RestructuringExpenses" xlink:type="simple" xlink:href="rmd-20240630.xsd#RestructuringExpenses"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/RestructuringExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f25608ba-5966-4b35-b1d6-552aa22b0079" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7a7693d4-58e4-4d7c-a210-e3839d096aea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f25608ba-5966-4b35-b1d6-552aa22b0079" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7a7693d4-58e4-4d7c-a210-e3839d096aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReserves" xlink:type="simple" xlink:href="rmd-20240630.xsd#ScheduleIIValuationandQualifyingAccountsandReserves"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReserves" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_64b7ebb7-cd67-4331-b442-78326f801aa4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_737b83de-7f91-4e48-a83d-567e56bc2b83" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_64b7ebb7-cd67-4331-b442-78326f801aa4" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_737b83de-7f91-4e48-a83d-567e56bc2b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="rmd-20240630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_OrganizationAndBasisOfPresentationPolicyPolicyTextBlock_e32a07a5-df5d-42c6-a185-9b684a3bdf1e" xlink:href="rmd-20240630.xsd#rmd_OrganizationAndBasisOfPresentationPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_rmd_OrganizationAndBasisOfPresentationPolicyPolicyTextBlock_e32a07a5-df5d-42c6-a185-9b684a3bdf1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_2a3ebf7f-087f-4b8e-8406-865a569ae6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_2a3ebf7f-087f-4b8e-8406-865a569ae6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_51443f0b-55a2-434e-8230-8c48b1a53362" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_51443f0b-55a2-434e-8230-8c48b1a53362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock_d79f4e89-10ec-4b2e-aa60-f794faaf29d4" xlink:href="rmd-20240630.xsd#rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock_d79f4e89-10ec-4b2e-aa60-f794faaf29d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_7a2a3246-3398-40a4-be1e-cb1341821fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_7a2a3246-3398-40a4-be1e-cb1341821fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_18ce0fdf-ad53-4180-84c6-20d2a4472401" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_18ce0fdf-ad53-4180-84c6-20d2a4472401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_d1699d52-282b-4745-9d84-84c4edaaa8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_d1699d52-282b-4745-9d84-84c4edaaa8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b0ae0824-4839-4f6f-ba96-f755ea19e9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b0ae0824-4839-4f6f-ba96-f755ea19e9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_a8e77a5e-e9d5-49d4-a887-7a9e73a889f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_a8e77a5e-e9d5-49d4-a887-7a9e73a889f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_bda144b4-5e5e-49e2-8953-81a98f6edf9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_bda144b4-5e5e-49e2-8953-81a98f6edf9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_43771faf-0874-491d-a33f-1aac5bcb1c17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_43771faf-0874-491d-a33f-1aac5bcb1c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_9e2e8339-7188-4378-b8b0-23600d9cefae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_9e2e8339-7188-4378-b8b0-23600d9cefae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_924a9898-79d9-4958-9ee4-e3b066742847" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_924a9898-79d9-4958-9ee4-e3b066742847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0cd04d27-e915-4c67-9ce0-382a83bd0ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0cd04d27-e915-4c67-9ce0-382a83bd0ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_5cb36478-360b-43fd-ad83-06419833f07a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_5cb36478-360b-43fd-ad83-06419833f07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_6521bdb0-8964-46d4-a07a-9ed1996052db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_6521bdb0-8964-46d4-a07a-9ed1996052db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLoansAndLeasesReceivablePolicy_6d2c6cb8-736b-4947-b837-cbf3d8bcb832" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLoansAndLeasesReceivablePolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_us-gaap_FinanceLoansAndLeasesReceivablePolicy_6d2c6cb8-736b-4947-b837-cbf3d8bcb832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_5f7fc677-72a3-41b7-bf83-54be92a98e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_5f7fc677-72a3-41b7-bf83-54be92a98e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_5f9bc6b9-0459-44f3-aeb1-98bde4922ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_5f9bc6b9-0459-44f3-aeb1-98bde4922ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_41e72171-ff92-40b5-a737-7943b39a1705" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6547e16a-af68-464d-89d5-85e3ea8e0152" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_41e72171-ff92-40b5-a737-7943b39a1705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="rmd-20240630.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7ff88180-e5c9-4be1-9cc8-c40090e70c84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_33860f9c-d7cb-4b82-9297-73c9a1029e75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7ff88180-e5c9-4be1-9cc8-c40090e70c84" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_33860f9c-d7cb-4b82-9297-73c9a1029e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables" xlink:type="simple" xlink:href="rmd-20240630.xsd#SupplementalBalanceSheetInformationTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SupplementalBalanceSheetInformationAbstract_eb1937aa-ee16-4f0d-9011-2dfde53e531a" xlink:href="rmd-20240630.xsd#rmd_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a1572fbd-3f37-4068-a9cd-ec8273efb5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SupplementalBalanceSheetInformationAbstract_eb1937aa-ee16-4f0d-9011-2dfde53e531a" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a1572fbd-3f37-4068-a9cd-ec8273efb5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_3f29009f-25b9-4704-97fb-30fcf07e6dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SupplementalBalanceSheetInformationAbstract_eb1937aa-ee16-4f0d-9011-2dfde53e531a" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_3f29009f-25b9-4704-97fb-30fcf07e6dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_118e74d6-ee3b-4106-b9d5-60ac4a11eea5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SupplementalBalanceSheetInformationAbstract_eb1937aa-ee16-4f0d-9011-2dfde53e531a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_118e74d6-ee3b-4106-b9d5-60ac4a11eea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables" xlink:type="simple" xlink:href="rmd-20240630.xsd#GoodwillandOtherIntangibleAssetsnetTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_18e38298-be27-4808-82ee-a4fc394ab24f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_b662fcb2-f80d-4d59-ad0e-a6b37161b453" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_18e38298-be27-4808-82ee-a4fc394ab24f" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_b662fcb2-f80d-4d59-ad0e-a6b37161b453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_fe0d833e-f2fd-4429-9744-8de88458e165" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_18e38298-be27-4808-82ee-a4fc394ab24f" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_fe0d833e-f2fd-4429-9744-8de88458e165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_fa2cc191-d5a9-461d-9b8f-dd0942f26bce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_18e38298-be27-4808-82ee-a4fc394ab24f" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_fa2cc191-d5a9-461d-9b8f-dd0942f26bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/InvestmentsTables" xlink:type="simple" xlink:href="rmd-20240630.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_86bfdc77-51da-4738-b8f8-601c6a4a7d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ScheduleOfInvestmentsTableTextBlock_3f84e3c7-ea6f-4007-8794-44cd919bc8b9" xlink:href="rmd-20240630.xsd#rmd_ScheduleOfInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_86bfdc77-51da-4738-b8f8-601c6a4a7d7d" xlink:to="loc_rmd_ScheduleOfInvestmentsTableTextBlock_3f84e3c7-ea6f-4007-8794-44cd919bc8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock_2ad67c75-4b22-4e28-9ae9-07839dc1fbef" xlink:href="rmd-20240630.xsd#rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_86bfdc77-51da-4738-b8f8-601c6a4a7d7d" xlink:to="loc_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock_2ad67c75-4b22-4e28-9ae9-07839dc1fbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="rmd-20240630.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d0bf22ed-fe0a-40e2-8ee1-61052b594d38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_be61324a-55c2-493d-aaaa-2369fa0ca3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d0bf22ed-fe0a-40e2-8ee1-61052b594d38" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_be61324a-55c2-493d-aaaa-2369fa0ca3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DebtTables" xlink:type="simple" xlink:href="rmd-20240630.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3ab198fa-09c1-4be2-b4bc-05d132e041fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_19e89158-430a-4ced-bc59-73258f2a68ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3ab198fa-09c1-4be2-b4bc-05d132e041fd" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_19e89158-430a-4ced-bc59-73258f2a68ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesTables" xlink:type="simple" xlink:href="rmd-20240630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_05c2ef60-a430-4e55-8a23-86ee29604b00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_13368677-85d3-4dd0-920d-02926fcca2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_05c2ef60-a430-4e55-8a23-86ee29604b00" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_13368677-85d3-4dd0-920d-02926fcca2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock_120f30c7-a490-4f8f-930a-66e933800a35" xlink:href="rmd-20240630.xsd#rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_05c2ef60-a430-4e55-8a23-86ee29604b00" xlink:to="loc_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock_120f30c7-a490-4f8f-930a-66e933800a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="rmd-20240630.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_a3435d0d-4e99-4bbd-aa44-391cbc86d73a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_4fd428ec-d441-4d80-a808-1db4cbb728f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a3435d0d-4e99-4bbd-aa44-391cbc86d73a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_4fd428ec-d441-4d80-a808-1db4cbb728f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ab3889b1-d484-4823-8108-8dc39fd8616a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a3435d0d-4e99-4bbd-aa44-391cbc86d73a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ab3889b1-d484-4823-8108-8dc39fd8616a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e13e70d5-0255-40f1-bcae-52731408e84d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a3435d0d-4e99-4bbd-aa44-391cbc86d73a" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e13e70d5-0255-40f1-bcae-52731408e84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bc98075d-1628-4fe2-8472-ba892818416c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a3435d0d-4e99-4bbd-aa44-391cbc86d73a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bc98075d-1628-4fe2-8472-ba892818416c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="rmd-20240630.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e23ef60e-b4ee-49fb-bc0e-aadc5e2d7f03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_486ae82b-065e-487c-9846-1caab888852a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e23ef60e-b4ee-49fb-bc0e-aadc5e2d7f03" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_486ae82b-065e-487c-9846-1caab888852a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="rmd-20240630.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c1122156-231f-46e5-9b1a-9c856d7560b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_040c8687-0e27-4037-9820-962fbe1a5e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c1122156-231f-46e5-9b1a-9c856d7560b8" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_040c8687-0e27-4037-9820-962fbe1a5e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_496e0f9f-5287-440d-b4c3-802604139315" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c1122156-231f-46e5-9b1a-9c856d7560b8" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_496e0f9f-5287-440d-b4c3-802604139315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_d2598d70-ce35-4eaf-8e5f-4c0621e18c51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c1122156-231f-46e5-9b1a-9c856d7560b8" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_d2598d70-ce35-4eaf-8e5f-4c0621e18c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock_4366b445-1ffb-44d8-82a0-94e7a590f132" xlink:href="rmd-20240630.xsd#rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c1122156-231f-46e5-9b1a-9c856d7560b8" xlink:to="loc_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock_4366b445-1ffb-44d8-82a0-94e7a590f132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0e8d8270-5717-4ee5-920a-5f42a49dbde4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c1122156-231f-46e5-9b1a-9c856d7560b8" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0e8d8270-5717-4ee5-920a-5f42a49dbde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="rmd-20240630.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9532d2ae-ac76-46b6-b54e-a5b3b450c555" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_c9537f3b-9e96-4ed2-95fc-3d88365e83fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9532d2ae-ac76-46b6-b54e-a5b3b450c555" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_c9537f3b-9e96-4ed2-95fc-3d88365e83fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock_3ada4936-c205-4d2e-9cb4-5ca0707f783f" xlink:href="rmd-20240630.xsd#rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9532d2ae-ac76-46b6-b54e-a5b3b450c555" xlink:to="loc_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock_3ada4936-c205-4d2e-9cb4-5ca0707f783f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_795126be-60c4-4ac7-b8c5-eec898d4194e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9532d2ae-ac76-46b6-b54e-a5b3b450c555" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_795126be-60c4-4ac7-b8c5-eec898d4194e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_db9303ed-02b2-4c8d-b1ea-6ecb2ac36a66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9532d2ae-ac76-46b6-b54e-a5b3b450c555" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_db9303ed-02b2-4c8d-b1ea-6ecb2ac36a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsTables" xlink:type="simple" xlink:href="rmd-20240630.xsd#LegalActionsContingenciesandCommitmentsTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_848a96df-29fd-4eb1-89a9-493255cfb28f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_1e8982aa-d658-491f-9b5d-1a94f1ec7963" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_848a96df-29fd-4eb1-89a9-493255cfb28f" xlink:to="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_1e8982aa-d658-491f-9b5d-1a94f1ec7963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesTables" xlink:type="simple" xlink:href="rmd-20240630.xsd#DerivativeInstrumentsandHedgingActivitiesTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3d9e5c9e-8f29-4715-b59a-fab89e69fef4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_fd612493-e160-47e1-9e87-bac808eab15a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3d9e5c9e-8f29-4715-b59a-fab89e69fef4" xlink:to="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_fd612493-e160-47e1-9e87-bac808eab15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_e3b684cf-83e5-4a56-946b-4bb869f7f86f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3d9e5c9e-8f29-4715-b59a-fab89e69fef4" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_e3b684cf-83e5-4a56-946b-4bb869f7f86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="rmd-20240630.xsd#BusinessCombinationsTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/BusinessCombinationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1fcd6403-2d13-4e94-8d4a-a3406b0c695b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_b0519ebf-42f5-459c-85f8-e3ce7f4f6fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1fcd6403-2d13-4e94-8d4a-a3406b0c695b" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_b0519ebf-42f5-459c-85f8-e3ce7f4f6fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_41fd509a-7840-472f-9e06-22969fa3f9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_371dca25-dd35-437e-ba73-1ac0f6dd9cfc" xlink:href="rmd-20240630.xsd#rmd_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41fd509a-7840-472f-9e06-22969fa3f9e0" xlink:to="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_371dca25-dd35-437e-ba73-1ac0f6dd9cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9517e1c8-2769-43d4-bc47-ee233aceca88" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_371dca25-dd35-437e-ba73-1ac0f6dd9cfc" xlink:to="loc_srt_RangeAxis_9517e1c8-2769-43d4-bc47-ee233aceca88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fa681a8c-0537-4098-805c-59e6a0e623ab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9517e1c8-2769-43d4-bc47-ee233aceca88" xlink:to="loc_srt_RangeMember_fa681a8c-0537-4098-805c-59e6a0e623ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_92ce21b0-3c06-46d9-a52f-702fbaa3d79f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fa681a8c-0537-4098-805c-59e6a0e623ab" xlink:to="loc_srt_MinimumMember_92ce21b0-3c06-46d9-a52f-702fbaa3d79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_314a6292-c134-43a9-be77-81dd4ca03580" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fa681a8c-0537-4098-805c-59e6a0e623ab" xlink:to="loc_srt_MaximumMember_314a6292-c134-43a9-be77-81dd4ca03580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fa2d1b7e-6169-4c10-9664-8416d21fc85b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_371dca25-dd35-437e-ba73-1ac0f6dd9cfc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fa2d1b7e-6169-4c10-9664-8416d21fc85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e94d5841-85b7-4b64-b2cb-5c79cfffe99b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fa2d1b7e-6169-4c10-9664-8416d21fc85b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e94d5841-85b7-4b64-b2cb-5c79cfffe99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_bfbc7bfd-7f6f-4a39-8f16-9ce6c5dc6c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e94d5841-85b7-4b64-b2cb-5c79cfffe99b" xlink:to="loc_us-gaap_BuildingMember_bfbc7bfd-7f6f-4a39-8f16-9ce6c5dc6c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5ba70af3-5e74-4d01-bcd3-bae3f134b045" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_371dca25-dd35-437e-ba73-1ac0f6dd9cfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5ba70af3-5e74-4d01-bcd3-bae3f134b045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_80df4208-dc02-45c2-9450-b7e89c097ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5ba70af3-5e74-4d01-bcd3-bae3f134b045" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_80df4208-dc02-45c2-9450-b7e89c097ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_13d94f40-905f-4fd9-aea9-b00b6a8efba2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_80df4208-dc02-45c2-9450-b7e89c097ba8" xlink:to="loc_us-gaap_PatentsMember_13d94f40-905f-4fd9-aea9-b00b6a8efba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e378785c-b543-4c0a-8012-b06e97218321" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_371dca25-dd35-437e-ba73-1ac0f6dd9cfc" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e378785c-b543-4c0a-8012-b06e97218321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_95383f52-f137-441b-b812-62890faf6abd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e378785c-b543-4c0a-8012-b06e97218321" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_95383f52-f137-441b-b812-62890faf6abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_d6cee26c-bdd5-417a-ad43-55a377059f58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_95383f52-f137-441b-b812-62890faf6abd" xlink:to="loc_us-gaap_CurrencySwapMember_d6cee26c-bdd5-417a-ad43-55a377059f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ab9ea2c3-f5a1-4312-90c6-093c62a52684" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_95383f52-f137-441b-b812-62890faf6abd" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ab9ea2c3-f5a1-4312-90c6-093c62a52684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9f525baf-22d5-4e22-b93e-ea8d00a07b67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_371dca25-dd35-437e-ba73-1ac0f6dd9cfc" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9f525baf-22d5-4e22-b93e-ea8d00a07b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d1b47835-24a7-4538-8fae-464e021be223" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9f525baf-22d5-4e22-b93e-ea8d00a07b67" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d1b47835-24a7-4538-8fae-464e021be223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_FairValueAndNetInvestmentHedgingMember_75797bb2-ebf7-4b47-ac35-bbf6a779d7bc" xlink:href="rmd-20240630.xsd#rmd_FairValueAndNetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d1b47835-24a7-4538-8fae-464e021be223" xlink:to="loc_rmd_FairValueAndNetInvestmentHedgingMember_75797bb2-ebf7-4b47-ac35-bbf6a779d7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_ec0b7f65-0e62-426e-b26f-4e3466dd8b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d1b47835-24a7-4538-8fae-464e021be223" xlink:to="loc_us-gaap_CashFlowHedgingMember_ec0b7f65-0e62-426e-b26f-4e3466dd8b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_cfb7f318-2998-4fcc-99f0-95c4b6da07ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_371dca25-dd35-437e-ba73-1ac0f6dd9cfc" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_cfb7f318-2998-4fcc-99f0-95c4b6da07ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_99ba0a16-96ec-4bca-93f4-121f484332e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_cfb7f318-2998-4fcc-99f0-95c4b6da07ba" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_99ba0a16-96ec-4bca-93f4-121f484332e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IntangibleAssetImpairmentMember_28bb776b-207d-4de7-8c95-0a618a5b1885" xlink:href="rmd-20240630.xsd#rmd_IntangibleAssetImpairmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_99ba0a16-96ec-4bca-93f4-121f484332e9" xlink:to="loc_rmd_IntangibleAssetImpairmentMember_28bb776b-207d-4de7-8c95-0a618a5b1885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:href="rmd-20240630.xsd#rmd_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_371dca25-dd35-437e-ba73-1ac0f6dd9cfc" xlink:to="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6ce372e0-6654-40c0-8d9d-239c7fce8096" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6ce372e0-6654-40c0-8d9d-239c7fce8096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_TermOfContractUnderRevenueRecognition_feb591f4-ccaa-419a-a8db-325c3eb32fae" xlink:href="rmd-20240630.xsd#rmd_TermOfContractUnderRevenueRecognition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:to="loc_rmd_TermOfContractUnderRevenueRecognition_feb591f4-ccaa-419a-a8db-325c3eb32fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_277577bc-1232-46d5-ad96-99ae107f3db1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_277577bc-1232-46d5-ad96-99ae107f3db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c9f50f59-cc48-4079-8839-64accb34ceee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:to="loc_us-gaap_Depreciation_c9f50f59-cc48-4079-8839-64accb34ceee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cfb1549c-225d-4928-82b8-67b8c85515c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cfb1549c-225d-4928-82b8-67b8c85515c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_53b059c0-03ca-4b04-bf4e-0e3f338ad57d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:to="loc_us-gaap_DerivativeNotionalAmount_53b059c0-03ca-4b04-bf4e-0e3f338ad57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_b334c3ee-8c4d-4e33-bdac-5218814c41d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:to="loc_us-gaap_DerivativeTermOfContract_b334c3ee-8c4d-4e33-bdac-5218814c41d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f4823e83-8d58-4d43-b849-a0fccade464d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_8752a87f-f4c0-4a20-b689-1448459d240e" xlink:to="loc_us-gaap_RestructuringCharges_f4823e83-8d58-4d43-b849-a0fccade464d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3d937602-35aa-4762-bde7-37f1f6fbbf50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ContractWithCustomerAssetAndLiabilityTable_9f36ce6f-5a5f-4128-a32e-4ee200d89dfb" xlink:href="rmd-20240630.xsd#rmd_ContractWithCustomerAssetAndLiabilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3d937602-35aa-4762-bde7-37f1f6fbbf50" xlink:to="loc_rmd_ContractWithCustomerAssetAndLiabilityTable_9f36ce6f-5a5f-4128-a32e-4ee200d89dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9c47852c-aa56-4725-bbbd-2e4409d678f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityTable_9f36ce6f-5a5f-4128-a32e-4ee200d89dfb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9c47852c-aa56-4725-bbbd-2e4409d678f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_75968cab-f1d5-4bab-bbd0-2435d5a095e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9c47852c-aa56-4725-bbbd-2e4409d678f0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_75968cab-f1d5-4bab-bbd0-2435d5a095e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AccountsReceivableNetMember_2f7820ec-bddb-4998-ab72-5f157cb99acf" xlink:href="rmd-20240630.xsd#rmd_AccountsReceivableNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75968cab-f1d5-4bab-bbd0-2435d5a095e3" xlink:to="loc_rmd_AccountsReceivableNetMember_2f7820ec-bddb-4998-ab72-5f157cb99acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_7854c2ad-b6db-4377-8426-7e36e7542f76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75968cab-f1d5-4bab-bbd0-2435d5a095e3" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_7854c2ad-b6db-4377-8426-7e36e7542f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember_d1ae3717-21bc-41b6-8edd-23dbbd64eb77" xlink:href="rmd-20240630.xsd#rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75968cab-f1d5-4bab-bbd0-2435d5a095e3" xlink:to="loc_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember_d1ae3717-21bc-41b6-8edd-23dbbd64eb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredRevenueCurrentLiabilitiesMember_023dc677-5097-4ac0-ac14-983bb5bf4ede" xlink:href="rmd-20240630.xsd#rmd_DeferredRevenueCurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75968cab-f1d5-4bab-bbd0-2435d5a095e3" xlink:to="loc_rmd_DeferredRevenueCurrentLiabilitiesMember_023dc677-5097-4ac0-ac14-983bb5bf4ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredRevenueNonCurrentLiabilitiesMember_08bd2c5a-8d03-45c9-9278-20e9c2474480" xlink:href="rmd-20240630.xsd#rmd_DeferredRevenueNonCurrentLiabilitiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75968cab-f1d5-4bab-bbd0-2435d5a095e3" xlink:to="loc_rmd_DeferredRevenueNonCurrentLiabilitiesMember_08bd2c5a-8d03-45c9-9278-20e9c2474480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems_44ce997f-d439-4218-8948-66041dda81f0" xlink:href="rmd-20240630.xsd#rmd_ContractWithCustomerAssetAndLiabilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityTable_9f36ce6f-5a5f-4128-a32e-4ee200d89dfb" xlink:to="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems_44ce997f-d439-4218-8948-66041dda81f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract_2c989522-2308-4ac2-a3df-97857f390296" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems_44ce997f-d439-4218-8948-66041dda81f0" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetAbstract_2c989522-2308-4ac2-a3df-97857f390296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_02e2d4bd-8de3-4cba-9054-52a128eee9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_2c989522-2308-4ac2-a3df-97857f390296" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_02e2d4bd-8de3-4cba-9054-52a128eee9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5e190f65-a3f3-4902-85f6-3bb3f42ed295" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_2c989522-2308-4ac2-a3df-97857f390296" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5e190f65-a3f3-4902-85f6-3bb3f42ed295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_0c74d929-cfa7-4f73-9cb6-32ad8d2e8601" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_2c989522-2308-4ac2-a3df-97857f390296" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_0c74d929-cfa7-4f73-9cb6-32ad8d2e8601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_f815f358-98e9-4823-a85a-86426a606c59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems_44ce997f-d439-4218-8948-66041dda81f0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityAbstract_f815f358-98e9-4823-a85a-86426a606c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_64d1d19c-5a24-4ba7-81d8-267d0e76a8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_f815f358-98e9-4823-a85a-86426a606c59" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_64d1d19c-5a24-4ba7-81d8-267d0e76a8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_20e22b83-bd33-4e8f-89e0-3bb857c2b645" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_f815f358-98e9-4823-a85a-86426a606c59" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_20e22b83-bd33-4e8f-89e0-3bb857c2b645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SupplementalBalanceSheetInformationScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SupplementalBalanceSheetInformationAbstract_5f2a8ad1-5ee0-487b-8326-5623d43c0bc8" xlink:href="rmd-20240630.xsd#rmd_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGrossAbstract_aaa2be28-4157-4751-9757-ee51083af0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SupplementalBalanceSheetInformationAbstract_5f2a8ad1-5ee0-487b-8326-5623d43c0bc8" xlink:to="loc_us-gaap_InventoryGrossAbstract_aaa2be28-4157-4751-9757-ee51083af0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_0a1f0942-2310-4e04-9e3a-23572709abb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryGrossAbstract_aaa2be28-4157-4751-9757-ee51083af0fd" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_0a1f0942-2310-4e04-9e3a-23572709abb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_336ba978-0f0e-49f0-9eba-08a3905b4183" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryGrossAbstract_aaa2be28-4157-4751-9757-ee51083af0fd" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_336ba978-0f0e-49f0-9eba-08a3905b4183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e514d54e-5991-45ba-a4a3-0bcf2077597a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryGrossAbstract_aaa2be28-4157-4751-9757-ee51083af0fd" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e514d54e-5991-45ba-a4a3-0bcf2077597a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c4f5b7dc-9e9a-4544-8192-3623c88ae067" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryGrossAbstract_aaa2be28-4157-4751-9757-ee51083af0fd" xlink:to="loc_us-gaap_InventoryNet_c4f5b7dc-9e9a-4544-8192-3623c88ae067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SupplementalBalanceSheetInformationAbstract_b2722fb4-85fe-4ccc-ac78-d9bcb1ab3301" xlink:href="rmd-20240630.xsd#rmd_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_b81e873c-e5b6-4b8c-85f8-93780ce8633d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SupplementalBalanceSheetInformationAbstract_b2722fb4-85fe-4ccc-ac78-d9bcb1ab3301" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_b81e873c-e5b6-4b8c-85f8-93780ce8633d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_49b84fa1-ab76-4506-85ee-7837e94ab5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_b81e873c-e5b6-4b8c-85f8-93780ce8633d" xlink:to="loc_us-gaap_PrepaidTaxes_49b84fa1-ab76-4506-85ee-7837e94ab5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PrepaidInventory_8acd40d8-a182-4f27-a8c1-ae460b11fd01" xlink:href="rmd-20240630.xsd#rmd_PrepaidInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_b81e873c-e5b6-4b8c-85f8-93780ce8633d" xlink:to="loc_rmd_PrepaidInventory_8acd40d8-a182-4f27-a8c1-ae460b11fd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_862eac1c-be87-4573-b4f3-481649bbd597" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_b81e873c-e5b6-4b8c-85f8-93780ce8633d" xlink:to="loc_us-gaap_OtherAssetsCurrent_862eac1c-be87-4573-b4f3-481649bbd597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4054f79f-4808-4ba2-ba21-724335ed303a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_b81e873c-e5b6-4b8c-85f8-93780ce8633d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4054f79f-4808-4ba2-ba21-724335ed303a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SupplementalBalanceSheetInformationAbstract_42180058-8ef5-42e8-92ce-ce0abd27a117" xlink:href="rmd-20240630.xsd#rmd_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_45edfc10-8de9-4ffb-91a7-ee375c256132" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SupplementalBalanceSheetInformationAbstract_42180058-8ef5-42e8-92ce-ce0abd27a117" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_45edfc10-8de9-4ffb-91a7-ee375c256132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7417c4a4-0a10-4e88-9f38-32a540435cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_45edfc10-8de9-4ffb-91a7-ee375c256132" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7417c4a4-0a10-4e88-9f38-32a540435cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7417c4a4-0a10-4e88-9f38-32a540435cfa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_6bc8e7c4-e915-494e-bb4c-a7eabe22616a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_6bc8e7c4-e915-494e-bb4c-a7eabe22616a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ComputerEquipmentAndSoftwareMember_698846f2-7b83-4a1a-bcaa-0d59a0932724" xlink:href="rmd-20240630.xsd#rmd_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:to="loc_rmd_ComputerEquipmentAndSoftwareMember_698846f2-7b83-4a1a-bcaa-0d59a0932724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2bcd737a-76f7-4ee8-abc4-e003662aa8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2bcd737a-76f7-4ee8-abc4-e003662aa8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_VehiclesAndAircraftMember_c2c99c91-6ce9-414c-a2dd-4336ee06b66f" xlink:href="rmd-20240630.xsd#rmd_VehiclesAndAircraftMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:to="loc_rmd_VehiclesAndAircraftMember_c2c99c91-6ce9-414c-a2dd-4336ee06b66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ClinicalDemonstrationAndRentalEquipmentMember_ca547f75-a638-472f-8b6a-461bf23c2650" xlink:href="rmd-20240630.xsd#rmd_ClinicalDemonstrationAndRentalEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:to="loc_rmd_ClinicalDemonstrationAndRentalEquipmentMember_ca547f75-a638-472f-8b6a-461bf23c2650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_bca92223-e19e-47b1-b2af-563e4ff253bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_bca92223-e19e-47b1-b2af-563e4ff253bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_3af49dc3-2c57-45e8-ab80-f360262af059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:to="loc_us-gaap_LandMember_3af49dc3-2c57-45e8-ab80-f360262af059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_900350c6-48a0-4fe4-870e-0d27c503c457" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6207e3c9-aa7e-4372-a127-0202da092c7f" xlink:to="loc_us-gaap_BuildingMember_900350c6-48a0-4fe4-870e-0d27c503c457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32364812-c1cf-48d0-bc3c-a0e41edabb92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_45edfc10-8de9-4ffb-91a7-ee375c256132" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32364812-c1cf-48d0-bc3c-a0e41edabb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_bf423a4d-49e9-439b-8ba2-54a10a6446ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32364812-c1cf-48d0-bc3c-a0e41edabb92" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_bf423a4d-49e9-439b-8ba2-54a10a6446ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b3b58c5-2b3d-40ba-8bbc-1eab5a37b32f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32364812-c1cf-48d0-bc3c-a0e41edabb92" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b3b58c5-2b3d-40ba-8bbc-1eab5a37b32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_daf9a188-8b71-4d55-8a67-2a8e06442680" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_32364812-c1cf-48d0-bc3c-a0e41edabb92" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_daf9a188-8b71-4d55-8a67-2a8e06442680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8fa269ea-f87d-47c1-9c75-3ab632e0f460" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_d2f59d6f-8f8f-4bf9-8ad5-9329d88109d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8fa269ea-f87d-47c1-9c75-3ab632e0f460" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_d2f59d6f-8f8f-4bf9-8ad5-9329d88109d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_281e884e-c181-4c52-928d-3ba6f31aca67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d2f59d6f-8f8f-4bf9-8ad5-9329d88109d7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_281e884e-c181-4c52-928d-3ba6f31aca67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5d5e6167-52b9-44fd-a70b-8f8057d7d11d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_281e884e-c181-4c52-928d-3ba6f31aca67" xlink:to="loc_us-gaap_SegmentDomain_5d5e6167-52b9-44fd-a70b-8f8057d7d11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SleepAndRespiratoryMember_9dcce143-2965-40d7-a1e3-de46aedb0cef" xlink:href="rmd-20240630.xsd#rmd_SleepAndRespiratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5d5e6167-52b9-44fd-a70b-8f8057d7d11d" xlink:to="loc_rmd_SleepAndRespiratoryMember_9dcce143-2965-40d7-a1e3-de46aedb0cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SaasMember_608ef6a9-d565-4379-a7ae-e9b46e47e8e1" xlink:href="rmd-20240630.xsd#rmd_SaasMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5d5e6167-52b9-44fd-a70b-8f8057d7d11d" xlink:to="loc_rmd_SaasMember_608ef6a9-d565-4379-a7ae-e9b46e47e8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_160ab2d5-f6e6-4473-a314-cc7a9a519dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d2f59d6f-8f8f-4bf9-8ad5-9329d88109d7" xlink:to="loc_us-gaap_GoodwillLineItems_160ab2d5-f6e6-4473-a314-cc7a9a519dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_aa6f3fc5-4ce0-41fb-8446-c0824fb53ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_160ab2d5-f6e6-4473-a314-cc7a9a519dcd" xlink:to="loc_us-gaap_GoodwillRollForward_aa6f3fc5-4ce0-41fb-8446-c0824fb53ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5eb0fb7e-e3e5-4e88-9b41-da3392587211" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_aa6f3fc5-4ce0-41fb-8446-c0824fb53ad6" xlink:to="loc_us-gaap_Goodwill_5eb0fb7e-e3e5-4e88-9b41-da3392587211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_9ed6e078-3b54-41f8-b09d-4ef7baee849e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_aa6f3fc5-4ce0-41fb-8446-c0824fb53ad6" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_9ed6e078-3b54-41f8-b09d-4ef7baee849e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_15fd52b1-c9ef-4c7d-9531-7c5bf6b92b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_aa6f3fc5-4ce0-41fb-8446-c0824fb53ad6" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_15fd52b1-c9ef-4c7d-9531-7c5bf6b92b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_12eafed6-de66-4d3e-a017-b95db925fc11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_aa6f3fc5-4ce0-41fb-8446-c0824fb53ad6" xlink:to="loc_us-gaap_Goodwill_12eafed6-de66-4d3e-a017-b95db925fc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5a37f9a3-0e5e-40cd-85cb-18f0aba790d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7634a779-0f56-4bed-80ce-a95d5a19c848" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5a37f9a3-0e5e-40cd-85cb-18f0aba790d1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7634a779-0f56-4bed-80ce-a95d5a19c848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ccd8d14c-4647-440d-8fc9-cb164952d276" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7634a779-0f56-4bed-80ce-a95d5a19c848" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ccd8d14c-4647-440d-8fc9-cb164952d276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a6bbae1b-7800-4d13-b503-248298519f01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ccd8d14c-4647-440d-8fc9-cb164952d276" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a6bbae1b-7800-4d13-b503-248298519f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DevelopedOrCoreProductTechnologyMember_8545ed1c-7ae5-4812-8b86-5f7c9939dfe6" xlink:href="rmd-20240630.xsd#rmd_DevelopedOrCoreProductTechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a6bbae1b-7800-4d13-b503-248298519f01" xlink:to="loc_rmd_DevelopedOrCoreProductTechnologyMember_8545ed1c-7ae5-4812-8b86-5f7c9939dfe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_83a0f1a4-cc76-43fd-8e1d-dc345297b83a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a6bbae1b-7800-4d13-b503-248298519f01" xlink:to="loc_us-gaap_CustomerRelationshipsMember_83a0f1a4-cc76-43fd-8e1d-dc345297b83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_d07b4783-f723-42e9-a9fa-00e4e56c3e55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a6bbae1b-7800-4d13-b503-248298519f01" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_d07b4783-f723-42e9-a9fa-00e4e56c3e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ce496785-d359-4b5a-9af0-195371e0d547" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7634a779-0f56-4bed-80ce-a95d5a19c848" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ce496785-d359-4b5a-9af0-195371e0d547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a783d368-30fc-4e67-b108-3d1b3a1a3005" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ce496785-d359-4b5a-9af0-195371e0d547" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a783d368-30fc-4e67-b108-3d1b3a1a3005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c0f8d3ce-400c-4a64-9bad-8a8ae1ffaa52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ce496785-d359-4b5a-9af0-195371e0d547" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c0f8d3ce-400c-4a64-9bad-8a8ae1ffaa52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_89c59483-436b-424a-8ed3-2b2932f0be44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ce496785-d359-4b5a-9af0-195371e0d547" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_89c59483-436b-424a-8ed3-2b2932f0be44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#GoodwillandOtherIntangibleAssetsnetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bcc5d4b2-cf3b-4876-8fea-28af64643469" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_86e07021-a5c0-4f28-8473-f89ffaa94ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bcc5d4b2-cf3b-4876-8fea-28af64643469" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_86e07021-a5c0-4f28-8473-f89ffaa94ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_41d1315c-2e64-47fd-9588-6ab9499c44eb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_86e07021-a5c0-4f28-8473-f89ffaa94ce6" xlink:to="loc_srt_RangeAxis_41d1315c-2e64-47fd-9588-6ab9499c44eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2df7feb8-a9b9-45c5-a6f9-831716dc1850" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_41d1315c-2e64-47fd-9588-6ab9499c44eb" xlink:to="loc_srt_RangeMember_2df7feb8-a9b9-45c5-a6f9-831716dc1850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4c75fca1-f6d6-4055-addb-32864d7e0abd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2df7feb8-a9b9-45c5-a6f9-831716dc1850" xlink:to="loc_srt_MinimumMember_4c75fca1-f6d6-4055-addb-32864d7e0abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_431f6f26-a3eb-4b3f-bb7e-602d5e9a7b06" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2df7feb8-a9b9-45c5-a6f9-831716dc1850" xlink:to="loc_srt_MaximumMember_431f6f26-a3eb-4b3f-bb7e-602d5e9a7b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8eeb155a-e36f-4cfe-906d-c1c2eb00649d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_86e07021-a5c0-4f28-8473-f89ffaa94ce6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8eeb155a-e36f-4cfe-906d-c1c2eb00649d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04163713-a183-4143-b99a-2fca5033630d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8eeb155a-e36f-4cfe-906d-c1c2eb00649d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04163713-a183-4143-b99a-2fca5033630d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IdentifiedIntangibleAssetsMember_71cbbeb0-b31a-4f85-abc1-22d2cbeb324f" xlink:href="rmd-20240630.xsd#rmd_IdentifiedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04163713-a183-4143-b99a-2fca5033630d" xlink:to="loc_rmd_IdentifiedIntangibleAssetsMember_71cbbeb0-b31a-4f85-abc1-22d2cbeb324f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_eb902d39-24a0-47ad-bb68-79d9a6ca6914" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04163713-a183-4143-b99a-2fca5033630d" xlink:to="loc_us-gaap_PatentsMember_eb902d39-24a0-47ad-bb68-79d9a6ca6914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DevelopedOrCoreProductTechnologyMember_773e1b71-6327-438c-8bf1-d100d9058b28" xlink:href="rmd-20240630.xsd#rmd_DevelopedOrCoreProductTechnologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04163713-a183-4143-b99a-2fca5033630d" xlink:to="loc_rmd_DevelopedOrCoreProductTechnologyMember_773e1b71-6327-438c-8bf1-d100d9058b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_341d179a-4dc5-4fb8-b7fd-d9e2629066bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04163713-a183-4143-b99a-2fca5033630d" xlink:to="loc_us-gaap_CustomerRelationshipsMember_341d179a-4dc5-4fb8-b7fd-d9e2629066bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_170c3eb1-57fc-4e49-8098-5379976d7996" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_04163713-a183-4143-b99a-2fca5033630d" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_170c3eb1-57fc-4e49-8098-5379976d7996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f45d0814-74ba-465d-92de-48a7fe7c7f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_86e07021-a5c0-4f28-8473-f89ffaa94ce6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f45d0814-74ba-465d-92de-48a7fe7c7f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_88fa742e-7586-4a1c-a833-acba08995b72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f45d0814-74ba-465d-92de-48a7fe7c7f1c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_88fa742e-7586-4a1c-a833-acba08995b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_944025de-3a4e-4e35-b352-c883704fb83d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f45d0814-74ba-465d-92de-48a7fe7c7f1c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_944025de-3a4e-4e35-b352-c883704fb83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4d2126bc-6541-4ca3-b995-0fbfd2239e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f45d0814-74ba-465d-92de-48a7fe7c7f1c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4d2126bc-6541-4ca3-b995-0fbfd2239e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_48a4eb3d-1c16-4c45-8497-2bce811d498e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f45d0814-74ba-465d-92de-48a7fe7c7f1c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_48a4eb3d-1c16-4c45-8497-2bce811d498e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofAmortizationExpenseRelatedtoIdentifiableIntangibleAssetsIncludingPatentsDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#GoodwillandOtherIntangibleAssetsnetScheduleofAmortizationExpenseRelatedtoIdentifiableIntangibleAssetsIncludingPatentsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofAmortizationExpenseRelatedtoIdentifiableIntangibleAssetsIncludingPatentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2a1f6f4b-50f4-426c-aa4d-72d1cf1df8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_41a8aacd-2a22-4b04-bcfe-40f57bc509f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2a1f6f4b-50f4-426c-aa4d-72d1cf1df8a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_41a8aacd-2a22-4b04-bcfe-40f57bc509f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1a253b06-a32b-4071-a8f1-77977032a168" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2a1f6f4b-50f4-426c-aa4d-72d1cf1df8a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1a253b06-a32b-4071-a8f1-77977032a168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_39fbe24f-5b13-4af0-8a79-c117825fd3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2a1f6f4b-50f4-426c-aa4d-72d1cf1df8a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_39fbe24f-5b13-4af0-8a79-c117825fd3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7cbb6e06-b6a1-4888-bdbb-16195000cc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2a1f6f4b-50f4-426c-aa4d-72d1cf1df8a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7cbb6e06-b6a1-4888-bdbb-16195000cc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0dcea8d6-77c3-435a-a108-feba3074b4be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2a1f6f4b-50f4-426c-aa4d-72d1cf1df8a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0dcea8d6-77c3-435a-a108-feba3074b4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#InvestmentsScheduleofInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_d7ea44f3-7c81-451c-b648-d23cac375361" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MarketableEquityInvestmentsFairValue_c6daed15-5f57-40db-87d6-2ddfbdaf35d7" xlink:href="rmd-20240630.xsd#rmd_MarketableEquityInvestmentsFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_d7ea44f3-7c81-451c-b648-d23cac375361" xlink:to="loc_rmd_MarketableEquityInvestmentsFairValue_c6daed15-5f57-40db-87d6-2ddfbdaf35d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_b8fcdd74-c3c9-485f-9d11-00d289541aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_d7ea44f3-7c81-451c-b648-d23cac375361" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_b8fcdd74-c3c9-485f-9d11-00d289541aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_a46a0ffe-fd49-4ff9-8839-bdea536aa317" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_d7ea44f3-7c81-451c-b648-d23cac375361" xlink:to="loc_us-gaap_EquityMethodInvestments_a46a0ffe-fd49-4ff9-8839-bdea536aa317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityInvestmentsTotalByMeasurementCategory_efac4b7d-51d2-496a-b96d-11b92205e851" xlink:href="rmd-20240630.xsd#rmd_EquityInvestmentsTotalByMeasurementCategory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_d7ea44f3-7c81-451c-b648-d23cac375361" xlink:to="loc_rmd_EquityInvestmentsTotalByMeasurementCategory_efac4b7d-51d2-496a-b96d-11b92205e851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#InvestmentsScheduleofChangesInEquityInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_b6fdb0e2-63c7-4b19-82c4-354cb7503dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a6a5c12a-fdc3-44c5-84c9-922fc3db617b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_b6fdb0e2-63c7-4b19-82c4-354cb7503dbc" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a6a5c12a-fdc3-44c5-84c9-922fc3db617b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_41f5da1c-b89b-4476-ae4b-b3195e2c370e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a6a5c12a-fdc3-44c5-84c9-922fc3db617b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_41f5da1c-b89b-4476-ae4b-b3195e2c370e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b604c65e-fb72-4b05-bbc9-0d72d2c68355" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_41f5da1c-b89b-4476-ae4b-b3195e2c370e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b604c65e-fb72-4b05-bbc9-0d72d2c68355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NonMarketableSecuritiesMember_cd95edc6-300b-4574-ac4e-b32f8de706c4" xlink:href="rmd-20240630.xsd#rmd_NonMarketableSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b604c65e-fb72-4b05-bbc9-0d72d2c68355" xlink:to="loc_rmd_NonMarketableSecuritiesMember_cd95edc6-300b-4574-ac4e-b32f8de706c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MarketableSecuritiesMember_1d61a2e2-53ba-4a6e-ac6f-781b2263de79" xlink:href="rmd-20240630.xsd#rmd_MarketableSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b604c65e-fb72-4b05-bbc9-0d72d2c68355" xlink:to="loc_rmd_MarketableSecuritiesMember_1d61a2e2-53ba-4a6e-ac6f-781b2263de79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember_3631bb1c-dd9b-4d3e-99ab-b5a797941d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b604c65e-fb72-4b05-bbc9-0d72d2c68355" xlink:to="loc_us-gaap_EquityMethodInvestmentsMember_3631bb1c-dd9b-4d3e-99ab-b5a797941d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51cb042b-863d-42bf-89a5-35cef9eeaf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a6a5c12a-fdc3-44c5-84c9-922fc3db617b" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51cb042b-863d-42bf-89a5-35cef9eeaf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:href="rmd-20240630.xsd#rmd_EquityMethodInvestmentsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51cb042b-863d-42bf-89a5-35cef9eeaf5c" xlink:to="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityInvestments_878a71fb-2f43-4ea8-9d75-19b01c2f7239" xlink:href="rmd-20240630.xsd#rmd_EquityInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_rmd_EquityInvestments_878a71fb-2f43-4ea8-9d75-19b01c2f7239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AdditionalEquityInvestments_a2067c7f-5a60-464a-8174-9e62a89a5698" xlink:href="rmd-20240630.xsd#rmd_AdditionalEquityInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_rmd_AdditionalEquityInvestments_a2067c7f-5a60-464a-8174-9e62a89a5698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities_13786569-101e-4de3-9c69-38f9bca5646c" xlink:href="rmd-20240630.xsd#rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities_13786569-101e-4de3-9c69-38f9bca5646c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_5ac52e34-35bc-4f8e-85bd-e3c8443f3acf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_5ac52e34-35bc-4f8e-85bd-e3c8443f3acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_35675b8a-43b9-42f6-9137-b41f2f22d5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_35675b8a-43b9-42f6-9137-b41f2f22d5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments_7a3a7612-07de-4292-b247-dee9a4d347c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_us-gaap_PaymentsForProceedsFromInvestments_7a3a7612-07de-4292-b247-dee9a4d347c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_1b651756-6cd3-4c33-b971-ddbac0fefbca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_1b651756-6cd3-4c33-b971-ddbac0fefbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5871fbf1-326a-48e1-af43-c6ede67e5216" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5871fbf1-326a-48e1-af43-c6ede67e5216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDividendsReceived_f31d341b-446e-472f-a010-8bd05474297f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDividendsReceived"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_us-gaap_ProceedsFromDividendsReceived_f31d341b-446e-472f-a010-8bd05474297f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments_0e162e15-bbb0-4971-a933-a649fd9be470" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments_0e162e15-bbb0-4971-a933-a649fd9be470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityInvestments_89c996d1-ea5e-4f12-b1e2-95ef693e11a5" xlink:href="rmd-20240630.xsd#rmd_EquityInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_996048e2-ccf1-4eb0-bfaa-5be6fca91b21" xlink:to="loc_rmd_EquityInvestments_89c996d1-ea5e-4f12-b1e2-95ef693e11a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_56395257-750c-47cb-a0f6-e6f948da8159" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_19fdd8ae-b86d-4d45-b8f6-10b9c83fb08e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_56395257-750c-47cb-a0f6-e6f948da8159" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_19fdd8ae-b86d-4d45-b8f6-10b9c83fb08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_7c4e1c82-c83e-491e-9751-87e38967bea4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_752e528e-e4b2-4fa0-a3a6-54f14fd99897" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7c4e1c82-c83e-491e-9751-87e38967bea4" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_752e528e-e4b2-4fa0-a3a6-54f14fd99897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_c9d64b70-ad6a-4238-9770-a5eed4842229" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7c4e1c82-c83e-491e-9751-87e38967bea4" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_c9d64b70-ad6a-4238-9770-a5eed4842229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_beaa12c8-5254-446f-ab28-277beef97406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7c4e1c82-c83e-491e-9751-87e38967bea4" xlink:to="loc_us-gaap_TaxesPayableCurrent_beaa12c8-5254-446f-ab28-277beef97406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_eb44a0d9-d115-40e4-89b9-07cb0ec87d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7c4e1c82-c83e-491e-9751-87e38967bea4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_eb44a0d9-d115-40e4-89b9-07cb0ec87d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_9db35998-05b7-4f29-9317-0225aafa31ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7c4e1c82-c83e-491e-9751-87e38967bea4" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_9db35998-05b7-4f29-9317-0225aafa31ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_b8b97816-bcb3-4716-9244-c24a60d37de3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7c4e1c82-c83e-491e-9751-87e38967bea4" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_b8b97816-bcb3-4716-9244-c24a60d37de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_261205aa-a77b-4f1f-b271-964f4e6a2308" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7c4e1c82-c83e-491e-9751-87e38967bea4" xlink:to="loc_us-gaap_InterestPayableCurrent_261205aa-a77b-4f1f-b271-964f4e6a2308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AccruedLogisticsAndOccupancyExpensesCurrent_626495e5-af68-476e-bf98-a3952cb4f329" xlink:href="rmd-20240630.xsd#rmd_AccruedLogisticsAndOccupancyExpensesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7c4e1c82-c83e-491e-9751-87e38967bea4" xlink:to="loc_rmd_AccruedLogisticsAndOccupancyExpensesCurrent_626495e5-af68-476e-bf98-a3952cb4f329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AccruedInventoryInTransit_55f07402-8534-4810-8d27-b2993be99897" xlink:href="rmd-20240630.xsd#rmd_AccruedInventoryInTransit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7c4e1c82-c83e-491e-9751-87e38967bea4" xlink:to="loc_rmd_AccruedInventoryInTransit_55f07402-8534-4810-8d27-b2993be99897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5025cb13-bbae-456d-8d55-1b1e7be998d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7c4e1c82-c83e-491e-9751-87e38967bea4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5025cb13-bbae-456d-8d55-1b1e7be998d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e66b1ad2-4980-43be-b2a8-88fe9e808040" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_7c4e1c82-c83e-491e-9751-87e38967bea4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e66b1ad2-4980-43be-b2a8-88fe9e808040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DebtScheduleofDebtDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#DebtScheduleofDebtDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/DebtScheduleofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7f6d1a9b-748d-462e-a96b-d112d8deafd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShortTermDebtGross_f50f47a4-036a-4c01-8ba1-2c2f14518516" xlink:href="rmd-20240630.xsd#rmd_ShortTermDebtGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7f6d1a9b-748d-462e-a96b-d112d8deafd5" xlink:to="loc_rmd_ShortTermDebtGross_f50f47a4-036a-4c01-8ba1-2c2f14518516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_bb4a9e8b-d25e-48e9-98fc-50ff76589335" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7f6d1a9b-748d-462e-a96b-d112d8deafd5" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_bb4a9e8b-d25e-48e9-98fc-50ff76589335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_13ddb208-395d-4ce8-98f3-da39d50ea567" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7f6d1a9b-748d-462e-a96b-d112d8deafd5" xlink:to="loc_us-gaap_ShortTermBorrowings_13ddb208-395d-4ce8-98f3-da39d50ea567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c1a4ab27-0e09-4268-9c85-370a6e030980" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7f6d1a9b-748d-462e-a96b-d112d8deafd5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c1a4ab27-0e09-4268-9c85-370a6e030980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_16f01d70-0234-4ab6-9da9-8a0a17d101c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7f6d1a9b-748d-462e-a96b-d112d8deafd5" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_16f01d70-0234-4ab6-9da9-8a0a17d101c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_69d7bc9f-1936-4aa2-af75-973d39729c02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7f6d1a9b-748d-462e-a96b-d112d8deafd5" xlink:to="loc_us-gaap_LongTermDebt_69d7bc9f-1936-4aa2-af75-973d39729c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_7d4b68be-49e0-46db-a872-412b3f436509" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7f6d1a9b-748d-462e-a96b-d112d8deafd5" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_7d4b68be-49e0-46db-a872-412b3f436509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_04cf17bc-2bb5-4280-8c57-ba5059ec7d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_86f40f43-aa64-457b-bfb0-eb8eb9a9d0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_04cf17bc-2bb5-4280-8c57-ba5059ec7d5a" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_86f40f43-aa64-457b-bfb0-eb8eb9a9d0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_05349af7-cbd5-46f3-9cb0-774c4d883be6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_86f40f43-aa64-457b-bfb0-eb8eb9a9d0f8" xlink:to="loc_us-gaap_CreditFacilityAxis_05349af7-cbd5-46f3-9cb0-774c4d883be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3d8e3b92-705c-49eb-9bc6-01da17f0b4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_05349af7-cbd5-46f3-9cb0-774c4d883be6" xlink:to="loc_us-gaap_CreditFacilityDomain_3d8e3b92-705c-49eb-9bc6-01da17f0b4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_88f4d9da-b627-44a2-8269-e5bdec065e40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_3d8e3b92-705c-49eb-9bc6-01da17f0b4c0" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_88f4d9da-b627-44a2-8269-e5bdec065e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember_8e3004d5-125a-4a1b-bba8-7e25e201da4b" xlink:href="rmd-20240630.xsd#rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember_88f4d9da-b627-44a2-8269-e5bdec065e40" xlink:to="loc_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember_8e3004d5-125a-4a1b-bba8-7e25e201da4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_TermLoanCreditAgreementMember_cd0e7ca6-cbe1-4c9a-8674-bdee084d87a3" xlink:href="rmd-20240630.xsd#rmd_TermLoanCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_3d8e3b92-705c-49eb-9bc6-01da17f0b4c0" xlink:to="loc_rmd_TermLoanCreditAgreementMember_cd0e7ca6-cbe1-4c9a-8674-bdee084d87a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_47d5b82e-c74d-4676-a987-17d834613586" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_86f40f43-aa64-457b-bfb0-eb8eb9a9d0f8" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_47d5b82e-c74d-4676-a987-17d834613586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_b97db9b9-0090-463d-a93e-1f9d5625442f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_47d5b82e-c74d-4676-a987-17d834613586" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_b97db9b9-0090-463d-a93e-1f9d5625442f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember_7f6473a5-0e6c-48f6-a8e6-ce17d42c393f" xlink:href="rmd-20240630.xsd#rmd_MufgUnionBankNaAndWestpacBankingCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_b97db9b9-0090-463d-a93e-1f9d5625442f" xlink:to="loc_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember_7f6473a5-0e6c-48f6-a8e6-ce17d42c393f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MufgUnionBankMember_799ab01f-7f59-4d9d-8c4c-8defca3e9a88" xlink:href="rmd-20240630.xsd#rmd_MufgUnionBankMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_b97db9b9-0090-463d-a93e-1f9d5625442f" xlink:to="loc_rmd_MufgUnionBankMember_799ab01f-7f59-4d9d-8c4c-8defca3e9a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6dd5203e-6624-4435-bd5b-9b20e6f2af91" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_86f40f43-aa64-457b-bfb0-eb8eb9a9d0f8" xlink:to="loc_dei_LegalEntityAxis_6dd5203e-6624-4435-bd5b-9b20e6f2af91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_253038a2-c116-4c56-837d-89032441bae7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_6dd5203e-6624-4435-bd5b-9b20e6f2af91" xlink:to="loc_dei_EntityDomain_253038a2-c116-4c56-837d-89032441bae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ResmedLimitedMember_2eaac938-58a2-4279-9c61-3b2ac860fd1f" xlink:href="rmd-20240630.xsd#rmd_ResmedLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_253038a2-c116-4c56-837d-89032441bae7" xlink:to="loc_rmd_ResmedLimitedMember_2eaac938-58a2-4279-9c61-3b2ac860fd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9438df06-6389-4479-b105-af9d768361e7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_86f40f43-aa64-457b-bfb0-eb8eb9a9d0f8" xlink:to="loc_srt_RangeAxis_9438df06-6389-4479-b105-af9d768361e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ccbc13e9-f271-42d2-af22-d208d44ee86a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9438df06-6389-4479-b105-af9d768361e7" xlink:to="loc_srt_RangeMember_ccbc13e9-f271-42d2-af22-d208d44ee86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d74dc854-7b0b-4f44-a708-6d0a3079a931" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ccbc13e9-f271-42d2-af22-d208d44ee86a" xlink:to="loc_srt_MinimumMember_d74dc854-7b0b-4f44-a708-6d0a3079a931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_72398aef-b3a6-40d7-9946-5993709e39b9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ccbc13e9-f271-42d2-af22-d208d44ee86a" xlink:to="loc_srt_MaximumMember_72398aef-b3a6-40d7-9946-5993709e39b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_b65fabc9-52cc-47c9-b32e-378b82b09d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_86f40f43-aa64-457b-bfb0-eb8eb9a9d0f8" xlink:to="loc_us-gaap_VariableRateAxis_b65fabc9-52cc-47c9-b32e-378b82b09d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_263ec062-409b-4bea-9bdb-e6af6d8f3d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_b65fabc9-52cc-47c9-b32e-378b82b09d5a" xlink:to="loc_us-gaap_VariableRateDomain_263ec062-409b-4bea-9bdb-e6af6d8f3d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_0bb62166-3aff-4c4e-a66f-d4993da140c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_263ec062-409b-4bea-9bdb-e6af6d8f3d1c" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_0bb62166-3aff-4c4e-a66f-d4993da140c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_97003a7a-ad6e-46ac-84e1-f320acb06dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_263ec062-409b-4bea-9bdb-e6af6d8f3d1c" xlink:to="loc_us-gaap_BaseRateMember_97003a7a-ad6e-46ac-84e1-f320acb06dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_25d88a52-28ee-435e-98a9-794b8222d56b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_86f40f43-aa64-457b-bfb0-eb8eb9a9d0f8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_25d88a52-28ee-435e-98a9-794b8222d56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_151765a1-3873-4b77-a1ba-2a54ac4f6a93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_25d88a52-28ee-435e-98a9-794b8222d56b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_151765a1-3873-4b77-a1ba-2a54ac4f6a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SeniorNotesOneMember_a8226e67-ea01-43ee-8c7e-a692e659c922" xlink:href="rmd-20240630.xsd#rmd_SeniorNotesOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_151765a1-3873-4b77-a1ba-2a54ac4f6a93" xlink:to="loc_rmd_SeniorNotesOneMember_a8226e67-ea01-43ee-8c7e-a692e659c922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SeniorNotesTwoMember_2f96c95b-6555-41b3-b0a8-0975e71db7c1" xlink:href="rmd-20240630.xsd#rmd_SeniorNotesTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_151765a1-3873-4b77-a1ba-2a54ac4f6a93" xlink:to="loc_rmd_SeniorNotesTwoMember_2f96c95b-6555-41b3-b0a8-0975e71db7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_81a7bde8-b0cf-489b-9d80-f4bf6f374d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_151765a1-3873-4b77-a1ba-2a54ac4f6a93" xlink:to="loc_us-gaap_SeniorNotesMember_81a7bde8-b0cf-489b-9d80-f4bf6f374d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember_fadf6103-3811-489c-aa62-d050b74b91e8" xlink:href="rmd-20240630.xsd#rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_151765a1-3873-4b77-a1ba-2a54ac4f6a93" xlink:to="loc_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember_fadf6103-3811-489c-aa62-d050b74b91e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_86f40f43-aa64-457b-bfb0-eb8eb9a9d0f8" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dff4e2b5-5d49-4537-8f5f-d6d115cc4771" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dff4e2b5-5d49-4537-8f5f-d6d115cc4771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_UncommittedOptionToIncreaseCreditFacility_1cf8b80c-86ec-4068-842e-e8efa7b7eb9c" xlink:href="rmd-20240630.xsd#rmd_UncommittedOptionToIncreaseCreditFacility"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_rmd_UncommittedOptionToIncreaseCreditFacility_1cf8b80c-86ec-4068-842e-e8efa7b7eb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod_92fd3356-50ef-4eb3-a381-95de326da2bf" xlink:href="rmd-20240630.xsd#rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod_92fd3356-50ef-4eb3-a381-95de326da2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_ae1aaeca-8cb4-412e-969c-88be4c16c715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_ae1aaeca-8cb4-412e-969c-88be4c16c715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6904cead-5911-4b24-abea-4ab65eff940d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_6904cead-5911-4b24-abea-4ab65eff940d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_05220260-b18b-481a-90c2-4bdb0abdb477" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_05220260-b18b-481a-90c2-4bdb0abdb477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_868770e4-56ea-4cfc-9d51-50d40d3efbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_868770e4-56ea-4cfc-9d51-50d40d3efbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_c56c1315-b220-43cc-a652-fec8fb864651" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_c56c1315-b220-43cc-a652-fec8fb864651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_db8df620-e422-42f8-a3e2-79c86b39c46b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_LongTermDebtFairValue_db8df620-e422-42f8-a3e2-79c86b39c46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0cb21562-7428-4bd5-9aaf-5c331e3286c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0cb21562-7428-4bd5-9aaf-5c331e3286c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f012ede8-e374-4aed-b41f-79e074b5cdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f012ede8-e374-4aed-b41f-79e074b5cdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DebtToConsolidatedEbitdaRatio_af77070c-ecd2-409a-b113-72a65c5e2e3e" xlink:href="rmd-20240630.xsd#rmd_DebtToConsolidatedEbitdaRatio"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_rmd_DebtToConsolidatedEbitdaRatio_af77070c-ecd2-409a-b113-72a65c5e2e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany_b672f588-9940-4a93-ad78-86579f73d37a" xlink:href="rmd-20240630.xsd#rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany_b672f588-9940-4a93-ad78-86579f73d37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotes_dd93af15-68d7-4fc6-a7af-81dcb4ef0c58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotes"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_SeniorNotes_dd93af15-68d7-4fc6-a7af-81dcb4ef0c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_0da2eb7c-1799-4647-a76b-feec93128e94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_931490c3-658a-4477-b16f-a792fd736f0a" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_0da2eb7c-1799-4647-a76b-feec93128e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_72a2f124-243f-4542-bdd1-509572255c07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f90e7953-dea4-486b-aeeb-3b1907828f41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_72a2f124-243f-4542-bdd1-509572255c07" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f90e7953-dea4-486b-aeeb-3b1907828f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_76095d2d-2166-4a9b-bc4c-4aad4788fa46" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f90e7953-dea4-486b-aeeb-3b1907828f41" xlink:to="loc_srt_RangeAxis_76095d2d-2166-4a9b-bc4c-4aad4788fa46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fa169afc-898f-4a5f-add2-90f2baa17ded" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_76095d2d-2166-4a9b-bc4c-4aad4788fa46" xlink:to="loc_srt_RangeMember_fa169afc-898f-4a5f-add2-90f2baa17ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_87546844-9503-4f9b-83c0-560bd4f9b262" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fa169afc-898f-4a5f-add2-90f2baa17ded" xlink:to="loc_srt_MinimumMember_87546844-9503-4f9b-83c0-560bd4f9b262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2dd9785c-65ba-4e8e-acc3-7a76e1fb39a0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fa169afc-898f-4a5f-add2-90f2baa17ded" xlink:to="loc_srt_MaximumMember_2dd9785c-65ba-4e8e-acc3-7a76e1fb39a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b1456ab-a7a0-4f54-9ffa-e3743fb8b45d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f90e7953-dea4-486b-aeeb-3b1907828f41" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b1456ab-a7a0-4f54-9ffa-e3743fb8b45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_457d2597-0b65-4d41-8140-f9aa7f523cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b1456ab-a7a0-4f54-9ffa-e3743fb8b45d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_457d2597-0b65-4d41-8140-f9aa7f523cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_cfb47c4e-f54b-4760-8b7a-c35265481fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b1456ab-a7a0-4f54-9ffa-e3743fb8b45d" xlink:to="loc_us-gaap_OperatingLeaseCost_cfb47c4e-f54b-4760-8b7a-c35265481fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_OperatingLeaseIncome_c3bb3e45-ddd9-4304-94f5-908f3ee898be" xlink:href="rmd-20240630.xsd#rmd_OperatingLeaseIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_5b1456ab-a7a0-4f54-9ffa-e3743fb8b45d" xlink:to="loc_rmd_OperatingLeaseIncome_c3bb3e45-ddd9-4304-94f5-908f3ee898be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#LeasesScheduleofFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_506f308c-f224-4693-886c-a99febb86f11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_98300456-45d6-4fb1-a09c-076fcc3a3f81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_506f308c-f224-4693-886c-a99febb86f11" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_98300456-45d6-4fb1-a09c-076fcc3a3f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d4268265-4795-46e8-a4b4-4e192900ee27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_506f308c-f224-4693-886c-a99febb86f11" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d4268265-4795-46e8-a4b4-4e192900ee27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2b1b0090-a6e1-4efb-a214-32a6959785bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_506f308c-f224-4693-886c-a99febb86f11" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2b1b0090-a6e1-4efb-a214-32a6959785bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d4d1deb2-4ebd-454c-9898-91ecec4e1000" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_506f308c-f224-4693-886c-a99febb86f11" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d4d1deb2-4ebd-454c-9898-91ecec4e1000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_22c829f9-16b8-4a26-971f-7009948b26fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_506f308c-f224-4693-886c-a99febb86f11" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_22c829f9-16b8-4a26-971f-7009948b26fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ff4a4e32-4821-4e53-8529-7488c6f9705d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_506f308c-f224-4693-886c-a99febb86f11" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ff4a4e32-4821-4e53-8529-7488c6f9705d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6e9453c4-31b4-476a-be9e-d21623e27978" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_506f308c-f224-4693-886c-a99febb86f11" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6e9453c4-31b4-476a-be9e-d21623e27978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_40b450a5-b521-4789-8536-264fe264c57b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_506f308c-f224-4693-886c-a99febb86f11" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_40b450a5-b521-4789-8536-264fe264c57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c076f50b-d3ed-4be7-8175-b5c6f68f3b14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_506f308c-f224-4693-886c-a99febb86f11" xlink:to="loc_us-gaap_OperatingLeaseLiability_c076f50b-d3ed-4be7-8175-b5c6f68f3b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesScheduleofOperatingLeaseDisclosureDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#LeasesScheduleofOperatingLeaseDisclosureDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LeasesScheduleofOperatingLeaseDisclosureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_00bca5af-e170-49dc-a215-33b1a9132c51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3a7688f0-b557-4df0-8f31-ce4aee83e876" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_00bca5af-e170-49dc-a215-33b1a9132c51" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3a7688f0-b557-4df0-8f31-ce4aee83e876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b0440b1e-5e90-41a3-88a8-3b7339afe4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_00bca5af-e170-49dc-a215-33b1a9132c51" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b0440b1e-5e90-41a3-88a8-3b7339afe4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_c26bd4c0-f287-4aaf-a859-c3b9b7d3b99d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_00bca5af-e170-49dc-a215-33b1a9132c51" xlink:to="loc_us-gaap_OperatingLeasePayments_c26bd4c0-f287-4aaf-a859-c3b9b7d3b99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_076e935d-07ef-4f18-8950-d097386e18bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_00bca5af-e170-49dc-a215-33b1a9132c51" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_076e935d-07ef-4f18-8950-d097386e18bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_26823244-b6cf-482b-85fb-ca51de9854e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96bc1ce4-acb4-45e2-88e2-05eb1f3b1919" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_26823244-b6cf-482b-85fb-ca51de9854e9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96bc1ce4-acb4-45e2-88e2-05eb1f3b1919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_52ba23b8-9917-4d19-ba84-df3e28a4cae7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96bc1ce4-acb4-45e2-88e2-05eb1f3b1919" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_52ba23b8-9917-4d19-ba84-df3e28a4cae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5018edcb-c768-4456-9311-00f9645012fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_52ba23b8-9917-4d19-ba84-df3e28a4cae7" xlink:to="loc_us-gaap_EquityComponentDomain_5018edcb-c768-4456-9311-00f9645012fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_51f62df1-2315-4126-bac9-4c9826e52e97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5018edcb-c768-4456-9311-00f9645012fa" xlink:to="loc_us-gaap_TreasuryStockCommonMember_51f62df1-2315-4126-bac9-4c9826e52e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5281cc39-7c6c-4d1c-9041-9b47c774ac82" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96bc1ce4-acb4-45e2-88e2-05eb1f3b1919" xlink:to="loc_srt_RangeAxis_5281cc39-7c6c-4d1c-9041-9b47c774ac82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e628f9d4-15ae-4733-8ebf-e08c6c2e67ac" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5281cc39-7c6c-4d1c-9041-9b47c774ac82" xlink:to="loc_srt_RangeMember_e628f9d4-15ae-4733-8ebf-e08c6c2e67ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_902570af-5d30-4d67-ab85-52df80ea9ba0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e628f9d4-15ae-4733-8ebf-e08c6c2e67ac" xlink:to="loc_srt_MinimumMember_902570af-5d30-4d67-ab85-52df80ea9ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_308ee6fe-a0ae-4b50-85af-426681aea325" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e628f9d4-15ae-4733-8ebf-e08c6c2e67ac" xlink:to="loc_srt_MaximumMember_308ee6fe-a0ae-4b50-85af-426681aea325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6a0f146f-ea52-4984-bf5e-2c88b79546c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96bc1ce4-acb4-45e2-88e2-05eb1f3b1919" xlink:to="loc_us-gaap_AwardTypeAxis_6a0f146f-ea52-4984-bf5e-2c88b79546c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9c82b65-c3e6-4297-bc08-09b6aab9fc31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6a0f146f-ea52-4984-bf5e-2c88b79546c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9c82b65-c3e6-4297-bc08-09b6aab9fc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_575e4f98-bb16-4ea8-94ec-2492d2339f62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9c82b65-c3e6-4297-bc08-09b6aab9fc31" xlink:to="loc_us-gaap_PerformanceSharesMember_575e4f98-bb16-4ea8-94ec-2492d2339f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0db934ff-65a9-4245-9ba5-28d3a1b7a7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96bc1ce4-acb4-45e2-88e2-05eb1f3b1919" xlink:to="loc_us-gaap_PlanNameAxis_0db934ff-65a9-4245-9ba5-28d3a1b7a7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d5da40ed-c762-4b97-a8e8-562341f79ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0db934ff-65a9-4245-9ba5-28d3a1b7a7f7" xlink:to="loc_us-gaap_PlanNameDomain_d5da40ed-c762-4b97-a8e8-562341f79ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ResmedInc2009IncentiveAwardPlanMember_db3df6c8-9ba2-4cb8-83b3-a67a05e3c53d" xlink:href="rmd-20240630.xsd#rmd_ResmedInc2009IncentiveAwardPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d5da40ed-c762-4b97-a8e8-562341f79ff3" xlink:to="loc_rmd_ResmedInc2009IncentiveAwardPlanMember_db3df6c8-9ba2-4cb8-83b3-a67a05e3c53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AmendedAndRestated2009PlanMember_e7a44b62-5416-4818-9b53-f0fa4bb8d965" xlink:href="rmd-20240630.xsd#rmd_AmendedAndRestated2009PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d5da40ed-c762-4b97-a8e8-562341f79ff3" xlink:to="loc_rmd_AmendedAndRestated2009PlanMember_e7a44b62-5416-4818-9b53-f0fa4bb8d965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanMember_b2c6d0c9-d9ee-4dd6-bd3c-9a7991205058" xlink:href="rmd-20240630.xsd#rmd_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d5da40ed-c762-4b97-a8e8-562341f79ff3" xlink:to="loc_rmd_EmployeeStockPurchasePlanMember_b2c6d0c9-d9ee-4dd6-bd3c-9a7991205058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_9903bdfa-8953-480a-8870-0a78991c8649" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96bc1ce4-acb4-45e2-88e2-05eb1f3b1919" xlink:to="loc_srt_TitleOfIndividualAxis_9903bdfa-8953-480a-8870-0a78991c8649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fef3edfd-9acc-4115-87e6-93c626c45035" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_9903bdfa-8953-480a-8870-0a78991c8649" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fef3edfd-9acc-4115-87e6-93c626c45035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NonEmployeeDirectorMember_9fe3b5a2-1a3d-40d2-9e33-f6eeb8f8c25a" xlink:href="rmd-20240630.xsd#rmd_NonEmployeeDirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fef3edfd-9acc-4115-87e6-93c626c45035" xlink:to="loc_rmd_NonEmployeeDirectorMember_9fe3b5a2-1a3d-40d2-9e33-f6eeb8f8c25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_13612247-aefe-469e-9618-84515909b3c2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fef3edfd-9acc-4115-87e6-93c626c45035" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_13612247-aefe-469e-9618-84515909b3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_96bc1ce4-acb4-45e2-88e2-05eb1f3b1919" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_7d23a247-a93b-4631-bbbf-dca6860089be" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_7d23a247-a93b-4631-bbbf-dca6860089be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_88bf591f-7433-4f23-bbce-bde52ae5fa36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_88bf591f-7433-4f23-bbce-bde52ae5fa36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d73a96af-a8a6-4551-ad55-b12234be2453" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d73a96af-a8a6-4551-ad55-b12234be2453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_d3fde2c1-c7ae-46f6-8ebb-89a0a9253a34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_TreasuryStockCommonShares_d3fde2c1-c7ae-46f6-8ebb-89a0a9253a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_0136bfcf-a85f-4012-bd59-0509681d8646" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_TreasuryStockValue_0136bfcf-a85f-4012-bd59-0509681d8646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_d6ba0f26-0e43-4c35-98a8-650823a9aadc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_d6ba0f26-0e43-4c35-98a8-650823a9aadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_acd93573-eeb2-4fa6-80dd-2b1ad4604e46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_acd93573-eeb2-4fa6-80dd-2b1ad4604e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5e0b828f-3f84-4032-a221-51907f157119" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5e0b828f-3f84-4032-a221-51907f157119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b8a08533-15c1-40fa-ba33-ddcabcf50aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b8a08533-15c1-40fa-ba33-ddcabcf50aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d9da85cc-2a8e-4989-8442-b7bed6e2d4fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d9da85cc-2a8e-4989-8442-b7bed6e2d4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_02aa4af8-1e62-42fc-883f-e6d3ad908218" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_02aa4af8-1e62-42fc-883f-e6d3ad908218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d30fbd40-e367-45a4-98a1-fd5451786d30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d30fbd40-e367-45a4-98a1-fd5451786d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_227df08d-251f-4a07-9151-15b97f3416d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_227df08d-251f-4a07-9151-15b97f3416d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending_fe4d4444-4bf8-49f4-8372-bd518582b0da" xlink:href="rmd-20240630.xsd#rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending_fe4d4444-4bf8-49f4-8372-bd518582b0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned_b9b32d41-2945-4726-ad68-59cdde77c9e8" xlink:href="rmd-20240630.xsd#rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned_b9b32d41-2945-4726-ad68-59cdde77c9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted_88037020-3f35-4266-9a90-1d69db8a68ba" xlink:href="rmd-20240630.xsd#rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted_88037020-3f35-4266-9a90-1d69db8a68ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod_ae9c56e8-1f9d-43a9-949d-f78c5ae1e2e8" xlink:href="rmd-20240630.xsd#rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod_ae9c56e8-1f9d-43a9-949d-f78c5ae1e2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5c191c6e-6d9c-4bac-81ed-0e322b8162a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5c191c6e-6d9c-4bac-81ed-0e322b8162a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1c713dbd-fa84-44d2-935e-ebc6ad27710a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1c713dbd-fa84-44d2-935e-ebc6ad27710a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance_b83f91eb-acc2-4880-b94d-8800af32ebfd" xlink:href="rmd-20240630.xsd#rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance_b83f91eb-acc2-4880-b94d-8800af32ebfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards_a72b7692-ceb0-46a2-8946-753031acb364" xlink:href="rmd-20240630.xsd#rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards_a72b7692-ceb0-46a2-8946-753031acb364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MaximumNumberOfSharesSubjectToAwardsGranted_1d85f1f8-e361-4b87-8ea6-4100da3b30e5" xlink:href="rmd-20240630.xsd#rmd_MaximumNumberOfSharesSubjectToAwardsGranted"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_MaximumNumberOfSharesSubjectToAwardsGranted_1d85f1f8-e361-4b87-8ea6-4100da3b30e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NumberOfCommonStockGranted_1b35c224-a876-4661-a395-e8f844969e5d" xlink:href="rmd-20240630.xsd#rmd_NumberOfCommonStockGranted"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_NumberOfCommonStockGranted_1b35c224-a876-4661-a395-e8f844969e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_6d38974d-bcb3-4f8c-8c9b-a42f26664336" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_6d38974d-bcb3-4f8c-8c9b-a42f26664336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bdcf879c-1cb5-46cc-9545-f55141bee7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bdcf879c-1cb5-46cc-9545-f55141bee7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7921e869-1768-474a-bca4-97be59214f92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7921e869-1768-474a-bca4-97be59214f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f2712394-28e9-479d-903d-097be763479e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f2712394-28e9-479d-903d-097be763479e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_6bb927d5-4ffb-435b-991b-d3441fa91976" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_6bb927d5-4ffb-435b-991b-d3441fa91976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanOfferingPeriod_b72ce27f-2895-42c8-9b3c-1ae12d3dd232" xlink:href="rmd-20240630.xsd#rmd_EmployeeStockPurchasePlanOfferingPeriod"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_EmployeeStockPurchasePlanOfferingPeriod_b72ce27f-2895-42c8-9b3c-1ae12d3dd232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant_baf86332-e3cf-46b1-ba3e-800355088169" xlink:href="rmd-20240630.xsd#rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant_baf86332-e3cf-46b1-ba3e-800355088169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase_fcdd1bde-1c2b-4933-a22e-19f022334cc1" xlink:href="rmd-20240630.xsd#rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase_fcdd1bde-1c2b-4933-a22e-19f022334cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_0440ec7c-2824-48c6-a25f-d38c5a88dc1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesSubscriptions"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_0440ec7c-2824-48c6-a25f-d38c5a88dc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f486a728-371a-4a7a-9451-2800e52ce12e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f486a728-371a-4a7a-9451-2800e52ce12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NumberOfOfferings_509eb831-36e3-451f-9ee3-919e22d0b006" xlink:href="rmd-20240630.xsd#rmd_NumberOfOfferings"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_rmd_NumberOfOfferings_509eb831-36e3-451f-9ee3-919e22d0b006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_42bb17bd-2fb6-4c3d-8203-cbcd15cebb83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_42bb17bd-2fb6-4c3d-8203-cbcd15cebb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bfe57d63-fd48-4e59-b460-ac7db48cf2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bfe57d63-fd48-4e59-b460-ac7db48cf2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e38ee36c-d8ad-4025-bb30-3e73a2bf96df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ea2d5c52-2bbb-4cad-b6ac-3fcd27b3e045" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e38ee36c-d8ad-4025-bb30-3e73a2bf96df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_fb6e657f-b810-4b48-ac84-103440ceb024" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73ed38d2-e5b0-4de1-9b15-8421f2779be3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_fb6e657f-b810-4b48-ac84-103440ceb024" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73ed38d2-e5b0-4de1-9b15-8421f2779be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8a3f249e-fb40-4230-a51d-125f4e337a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73ed38d2-e5b0-4de1-9b15-8421f2779be3" xlink:to="loc_us-gaap_AwardTypeAxis_8a3f249e-fb40-4230-a51d-125f4e337a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15859ad4-ee26-4a97-9461-4c5dd46870ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8a3f249e-fb40-4230-a51d-125f4e337a5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15859ad4-ee26-4a97-9461-4c5dd46870ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_839fc8a2-db9b-4c66-81e6-a9644cfd2519" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15859ad4-ee26-4a97-9461-4c5dd46870ae" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_839fc8a2-db9b-4c66-81e6-a9644cfd2519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d34fbfe-39aa-4e5e-8511-bfcf1aa88cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73ed38d2-e5b0-4de1-9b15-8421f2779be3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d34fbfe-39aa-4e5e-8511-bfcf1aa88cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0276bda0-fe6d-4b26-a846-ab648ebeac4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d34fbfe-39aa-4e5e-8511-bfcf1aa88cdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0276bda0-fe6d-4b26-a846-ab648ebeac4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_746758b3-5cfe-4cf4-af86-ecd220db093d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0276bda0-fe6d-4b26-a846-ab648ebeac4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_746758b3-5cfe-4cf4-af86-ecd220db093d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d4d4d27a-260a-4c51-84f9-609866f8629d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0276bda0-fe6d-4b26-a846-ab648ebeac4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d4d4d27a-260a-4c51-84f9-609866f8629d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_966b345f-02a3-401d-9c9e-9e4b5bc0d2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0276bda0-fe6d-4b26-a846-ab648ebeac4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_966b345f-02a3-401d-9c9e-9e4b5bc0d2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5736eea4-9b09-4a39-9c9b-0b30f82d92b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0276bda0-fe6d-4b26-a846-ab648ebeac4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5736eea4-9b09-4a39-9c9b-0b30f82d92b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3035450f-5dd1-4824-af91-e885dd97cf60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0276bda0-fe6d-4b26-a846-ab648ebeac4b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3035450f-5dd1-4824-af91-e885dd97cf60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d06c7a5f-7cc7-4fa7-b41b-4b55279242f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d34fbfe-39aa-4e5e-8511-bfcf1aa88cdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d06c7a5f-7cc7-4fa7-b41b-4b55279242f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e7dde711-25be-460c-b7a1-47f85814808e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d06c7a5f-7cc7-4fa7-b41b-4b55279242f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e7dde711-25be-460c-b7a1-47f85814808e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0070669b-a8cd-4120-953d-d8bda6dd9f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d06c7a5f-7cc7-4fa7-b41b-4b55279242f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0070669b-a8cd-4120-953d-d8bda6dd9f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_058d10fb-b736-44d3-8418-9ea9d6b50d03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d06c7a5f-7cc7-4fa7-b41b-4b55279242f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_058d10fb-b736-44d3-8418-9ea9d6b50d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_77a87cdc-caa9-4b25-a0e9-48f48c1c2878" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d06c7a5f-7cc7-4fa7-b41b-4b55279242f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_77a87cdc-caa9-4b25-a0e9-48f48c1c2878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_abb1a736-f14f-4832-83fb-664a47883dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d06c7a5f-7cc7-4fa7-b41b-4b55279242f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_abb1a736-f14f-4832-83fb-664a47883dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e624e4e9-5442-4f43-a465-161df90b6d29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d34fbfe-39aa-4e5e-8511-bfcf1aa88cdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e624e4e9-5442-4f43-a465-161df90b6d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_fe7b4c5b-24d9-4511-b1f7-5d5b80d53463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e624e4e9-5442-4f43-a465-161df90b6d29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_fe7b4c5b-24d9-4511-b1f7-5d5b80d53463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d1b07ea2-e86c-43a5-a6da-0467fe4630c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d34fbfe-39aa-4e5e-8511-bfcf1aa88cdf" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d1b07ea2-e86c-43a5-a6da-0467fe4630c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#StockholdersEquityScheduleofOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_64ffdff9-eb4b-4566-9892-374c8bcdbaca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_78a3f174-42fe-4b9c-885b-1b5caaf521f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_64ffdff9-eb4b-4566-9892-374c8bcdbaca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_78a3f174-42fe-4b9c-885b-1b5caaf521f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d111a574-6856-4308-8058-e34e30305cce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_78a3f174-42fe-4b9c-885b-1b5caaf521f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d111a574-6856-4308-8058-e34e30305cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ff8e413d-057e-4f92-88be-e82aa1905543" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_78a3f174-42fe-4b9c-885b-1b5caaf521f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ff8e413d-057e-4f92-88be-e82aa1905543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d93eeedf-b354-4ee5-9db4-311f41b60cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_78a3f174-42fe-4b9c-885b-1b5caaf521f0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d93eeedf-b354-4ee5-9db4-311f41b60cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3e0b713d-6c6c-40bf-ab48-bd867803fda3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_78a3f174-42fe-4b9c-885b-1b5caaf521f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3e0b713d-6c6c-40bf-ab48-bd867803fda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_14ce1061-a74b-4464-84aa-210084275889" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_78a3f174-42fe-4b9c-885b-1b5caaf521f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_14ce1061-a74b-4464-84aa-210084275889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_4b6ce523-fea2-40e4-8291-91ebf6336e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_64ffdff9-eb4b-4566-9892-374c8bcdbaca" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_4b6ce523-fea2-40e4-8291-91ebf6336e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_78ad028f-3b0d-416e-baab-49f9f00517e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_64ffdff9-eb4b-4566-9892-374c8bcdbaca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_78ad028f-3b0d-416e-baab-49f9f00517e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_184d371c-8142-49a4-bafd-6ca99f004f08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_64ffdff9-eb4b-4566-9892-374c8bcdbaca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_184d371c-8142-49a4-bafd-6ca99f004f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a7fcd212-59a6-4f91-b899-cd19785b7ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_184d371c-8142-49a4-bafd-6ca99f004f08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a7fcd212-59a6-4f91-b899-cd19785b7ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c591b8e6-a30e-4f95-b967-69c42e25e770" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_184d371c-8142-49a4-bafd-6ca99f004f08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c591b8e6-a30e-4f95-b967-69c42e25e770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4346cd1b-2725-496c-83ab-46600e0c10d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_184d371c-8142-49a4-bafd-6ca99f004f08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4346cd1b-2725-496c-83ab-46600e0c10d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_72446cde-8f29-41bf-85cc-81b4fc66b10b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_184d371c-8142-49a4-bafd-6ca99f004f08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_72446cde-8f29-41bf-85cc-81b4fc66b10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6e1ec944-3ec8-4cb5-8661-b73aac5b7170" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_184d371c-8142-49a4-bafd-6ca99f004f08" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6e1ec944-3ec8-4cb5-8661-b73aac5b7170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8f471f54-c993-4e93-9598-4046417ff0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_64ffdff9-eb4b-4566-9892-374c8bcdbaca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8f471f54-c993-4e93-9598-4046417ff0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ea9215d9-d2a6-4605-a954-a1834fd337e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_64ffdff9-eb4b-4566-9892-374c8bcdbaca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ea9215d9-d2a6-4605-a954-a1834fd337e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4f85b494-8194-4bb0-ad76-e1328c2380e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_64ffdff9-eb4b-4566-9892-374c8bcdbaca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4f85b494-8194-4bb0-ad76-e1328c2380e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8b284566-f055-41ec-a512-ce6cb471b226" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4f85b494-8194-4bb0-ad76-e1328c2380e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8b284566-f055-41ec-a512-ce6cb471b226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8acf55ca-1b90-473b-be30-6243707af964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4f85b494-8194-4bb0-ad76-e1328c2380e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8acf55ca-1b90-473b-be30-6243707af964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_af685561-e0d4-43c2-9110-ae3da5021008" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4f85b494-8194-4bb0-ad76-e1328c2380e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_af685561-e0d4-43c2-9110-ae3da5021008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c88aa0e0-919c-4adf-ba0a-4d6f941653aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_64ffdff9-eb4b-4566-9892-374c8bcdbaca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c88aa0e0-919c-4adf-ba0a-4d6f941653aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2617011b-8c6d-4e70-baf6-6414966c5000" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c88aa0e0-919c-4adf-ba0a-4d6f941653aa" xlink:to="loc_us-gaap_AwardTypeAxis_2617011b-8c6d-4e70-baf6-6414966c5000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d420b779-3580-43ae-9f50-3a287cdd6950" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2617011b-8c6d-4e70-baf6-6414966c5000" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d420b779-3580-43ae-9f50-3a287cdd6950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6cc7b2cc-427a-4b29-a1ce-d639e13029d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d420b779-3580-43ae-9f50-3a287cdd6950" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6cc7b2cc-427a-4b29-a1ce-d639e13029d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b71a893e-423e-4a61-aef2-bab448639a93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c88aa0e0-919c-4adf-ba0a-4d6f941653aa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b71a893e-423e-4a61-aef2-bab448639a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_3747730b-b0f9-4d38-9d4e-6a0b6266a572" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b71a893e-423e-4a61-aef2-bab448639a93" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_3747730b-b0f9-4d38-9d4e-6a0b6266a572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_5e1c6ab1-88a4-4af2-a2bf-a0c91209c807" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_655adde8-ea60-49a0-b1ab-89fb076e6eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5e1c6ab1-88a4-4af2-a2bf-a0c91209c807" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_655adde8-ea60-49a0-b1ab-89fb076e6eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7a5be749-6007-438f-8413-f32c4e179f01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_655adde8-ea60-49a0-b1ab-89fb076e6eb7" xlink:to="loc_us-gaap_AwardTypeAxis_7a5be749-6007-438f-8413-f32c4e179f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aed3294d-36fd-44d1-bd80-60311e72c9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7a5be749-6007-438f-8413-f32c4e179f01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aed3294d-36fd-44d1-bd80-60311e72c9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_75dc7e54-eec6-493c-aa0c-9cf007a7164a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aed3294d-36fd-44d1-bd80-60311e72c9c5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_75dc7e54-eec6-493c-aa0c-9cf007a7164a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanPurchaseRightsMember_fa5dffc9-6c99-48ec-97f7-7610330eac9b" xlink:href="rmd-20240630.xsd#rmd_EmployeeStockPurchasePlanPurchaseRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aed3294d-36fd-44d1-bd80-60311e72c9c5" xlink:to="loc_rmd_EmployeeStockPurchasePlanPurchaseRightsMember_fa5dffc9-6c99-48ec-97f7-7610330eac9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1dbea0e8-314b-4f47-9d35-3914ade227a4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_655adde8-ea60-49a0-b1ab-89fb076e6eb7" xlink:to="loc_srt_RangeAxis_1dbea0e8-314b-4f47-9d35-3914ade227a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_918f62dc-9880-4e71-a747-3bac895693aa" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1dbea0e8-314b-4f47-9d35-3914ade227a4" xlink:to="loc_srt_RangeMember_918f62dc-9880-4e71-a747-3bac895693aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b76be656-01b8-4b3b-b2bf-edc0dc90511e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_918f62dc-9880-4e71-a747-3bac895693aa" xlink:to="loc_srt_MinimumMember_b76be656-01b8-4b3b-b2bf-edc0dc90511e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_aecf968c-c696-4412-8d98-ba0a2b04917e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_918f62dc-9880-4e71-a747-3bac895693aa" xlink:to="loc_srt_MaximumMember_aecf968c-c696-4412-8d98-ba0a2b04917e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_188e773a-b538-45a3-a715-ef230b719ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_655adde8-ea60-49a0-b1ab-89fb076e6eb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_188e773a-b538-45a3-a715-ef230b719ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1c29a54b-9c52-411f-9eb1-273b38504097" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_188e773a-b538-45a3-a715-ef230b719ecf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1c29a54b-9c52-411f-9eb1-273b38504097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ffb280ab-7bfb-432a-91eb-9cd8badf790e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_188e773a-b538-45a3-a715-ef230b719ecf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_ffb280ab-7bfb-432a-91eb-9cd8badf790e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d092f9f3-41d7-4d66-b1b8-a07374d2acd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_188e773a-b538-45a3-a715-ef230b719ecf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d092f9f3-41d7-4d66-b1b8-a07374d2acd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2bc63481-1731-4694-ada6-20471d12da1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_188e773a-b538-45a3-a715-ef230b719ecf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2bc63481-1731-4694-ada6-20471d12da1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_94701267-2a4e-498d-ad59-d88f0d33a7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_188e773a-b538-45a3-a715-ef230b719ecf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_94701267-2a4e-498d-ad59-d88f0d33a7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d2a7092b-e2c1-4768-ba27-4c9977c1206a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_188e773a-b538-45a3-a715-ef230b719ecf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d2a7092b-e2c1-4768-ba27-4c9977c1206a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_321cc1cd-4ebd-440b-9ec0-9182bba7d507" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_188e773a-b538-45a3-a715-ef230b719ecf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_321cc1cd-4ebd-440b-9ec0-9182bba7d507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_663ce640-a4dd-437b-a221-f74560a0087e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_251c08c0-8c6d-4e09-b20c-7a46d1c799d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_663ce640-a4dd-437b-a221-f74560a0087e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_251c08c0-8c6d-4e09-b20c-7a46d1c799d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_db49bbca-910f-4f51-af99-1c88c26281e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_251c08c0-8c6d-4e09-b20c-7a46d1c799d6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_db49bbca-910f-4f51-af99-1c88c26281e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d181793f-090d-484d-90f1-3f7a66a68b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_db49bbca-910f-4f51-af99-1c88c26281e3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d181793f-090d-484d-90f1-3f7a66a68b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_f530e050-fba3-4d02-9c43-83ad099bcd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d181793f-090d-484d-90f1-3f7a66a68b7d" xlink:to="loc_us-gaap_CostOfSalesMember_f530e050-fba3-4d02-9c43-83ad099bcd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d8408bc8-ff66-44e7-b86c-112a34a39dce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d181793f-090d-484d-90f1-3f7a66a68b7d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d8408bc8-ff66-44e7-b86c-112a34a39dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1ccc094e-8aa2-4dca-80ee-74036e5e8d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d181793f-090d-484d-90f1-3f7a66a68b7d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1ccc094e-8aa2-4dca-80ee-74036e5e8d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ee409319-ff7c-41c5-93d8-2affd571a1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_251c08c0-8c6d-4e09-b20c-7a46d1c799d6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ee409319-ff7c-41c5-93d8-2affd571a1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_db28bcc1-e22c-4532-abf9-929433a139c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ee409319-ff7c-41c5-93d8-2affd571a1ee" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_db28bcc1-e22c-4532-abf9-929433a139c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_f52fe688-c279-4337-977c-fe22b2ee0d23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ee409319-ff7c-41c5-93d8-2affd571a1ee" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_f52fe688-c279-4337-977c-fe22b2ee0d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_50f4f20e-2e52-4acb-99c4-3396892df809" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ee409319-ff7c-41c5-93d8-2affd571a1ee" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_50f4f20e-2e52-4acb-99c4-3396892df809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#EarningsPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2f306500-5df5-4cee-8893-7ce23d188c22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_91dff9f4-8e69-4852-b3e7-39d3810167f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2f306500-5df5-4cee-8893-7ce23d188c22" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_91dff9f4-8e69-4852-b3e7-39d3810167f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_bfd7c469-0013-4953-82b3-9c57bdd5b533" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_874ad46f-7632-4e0a-b105-64e04e255f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_bfd7c469-0013-4953-82b3-9c57bdd5b533" xlink:to="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_874ad46f-7632-4e0a-b105-64e04e255f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5c7d9f27-2f49-4ccf-9d4c-705d09747af4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_874ad46f-7632-4e0a-b105-64e04e255f7c" xlink:to="loc_us-gaap_NetIncomeLoss_5c7d9f27-2f49-4ccf-9d4c-705d09747af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_308335ba-2e38-4729-a934-56dc25b1da3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_bfd7c469-0013-4953-82b3-9c57bdd5b533" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_308335ba-2e38-4729-a934-56dc25b1da3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0acbeb89-03ab-491c-abd0-12d29d4befa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_308335ba-2e38-4729-a934-56dc25b1da3c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0acbeb89-03ab-491c-abd0-12d29d4befa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_4fe9ee71-fb18-4d50-b5a3-a840c7f11535" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_308335ba-2e38-4729-a934-56dc25b1da3c" xlink:to="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_4fe9ee71-fb18-4d50-b5a3-a840c7f11535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_049aa9fe-13e7-4ff4-93fe-06467a116656" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_4fe9ee71-fb18-4d50-b5a3-a840c7f11535" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_049aa9fe-13e7-4ff4-93fe-06467a116656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_97333db0-b523-4310-a102-0e5c31c194a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_4fe9ee71-fb18-4d50-b5a3-a840c7f11535" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_97333db0-b523-4310-a102-0e5c31c194a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ea3d0989-590c-46b1-920d-4a36c0005670" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_308335ba-2e38-4729-a934-56dc25b1da3c" xlink:to="loc_us-gaap_EarningsPerShareBasic_ea3d0989-590c-46b1-920d-4a36c0005670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e468278d-06ec-41c3-9fb0-62ec3907cfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_308335ba-2e38-4729-a934-56dc25b1da3c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e468278d-06ec-41c3-9fb0-62ec3907cfd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesUndertheJurisdictionsDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#IncomeTaxesScheduleofIncomeBeforeIncomeTaxesUndertheJurisdictionsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesUndertheJurisdictionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_75056dbe-bbc0-4195-a9e6-76dc791d8561" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c89efcd7-de3b-47ea-be84-a834dd206236" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_75056dbe-bbc0-4195-a9e6-76dc791d8561" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_c89efcd7-de3b-47ea-be84-a834dd206236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_3fdfb88a-aa21-4f77-8e70-45926bf09f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_75056dbe-bbc0-4195-a9e6-76dc791d8561" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_3fdfb88a-aa21-4f77-8e70-45926bf09f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_91c0ab6e-b65b-4f09-951d-801df66aa489" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_75056dbe-bbc0-4195-a9e6-76dc791d8561" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_91c0ab6e-b65b-4f09-951d-801df66aa489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c458ca93-afd5-4a28-a66d-f356399b2a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_61cc7137-f490-4c50-b2e0-303755b88301" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c458ca93-afd5-4a28-a66d-f356399b2a1e" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_61cc7137-f490-4c50-b2e0-303755b88301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2d2d8c43-370f-458a-93c6-26075ba663e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_61cc7137-f490-4c50-b2e0-303755b88301" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2d2d8c43-370f-458a-93c6-26075ba663e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_813d31f9-ad74-4e3b-a240-763388bed3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_61cc7137-f490-4c50-b2e0-303755b88301" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_813d31f9-ad74-4e3b-a240-763388bed3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_6c9b5327-95a0-4a06-9030-41de500fadf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_61cc7137-f490-4c50-b2e0-303755b88301" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_6c9b5327-95a0-4a06-9030-41de500fadf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5944a16c-8d26-48a3-8a87-e970bb08365b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_61cc7137-f490-4c50-b2e0-303755b88301" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5944a16c-8d26-48a3-8a87-e970bb08365b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1c1e8bad-fabb-4911-b224-7f8d11cf4a24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c458ca93-afd5-4a28-a66d-f356399b2a1e" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1c1e8bad-fabb-4911-b224-7f8d11cf4a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5be3e9f2-e319-46e2-a6bb-1af49f87ef67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1c1e8bad-fabb-4911-b224-7f8d11cf4a24" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5be3e9f2-e319-46e2-a6bb-1af49f87ef67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ac00c5fd-4335-498c-abf3-51460f935e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1c1e8bad-fabb-4911-b224-7f8d11cf4a24" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ac00c5fd-4335-498c-abf3-51460f935e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_512abdd9-40a6-441a-a7b2-1b14b6be3790" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1c1e8bad-fabb-4911-b224-7f8d11cf4a24" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_512abdd9-40a6-441a-a7b2-1b14b6be3790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_78a918d1-bddc-40b4-b461-c0a3f2b3339e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1c1e8bad-fabb-4911-b224-7f8d11cf4a24" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_78a918d1-bddc-40b4-b461-c0a3f2b3339e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cf880e36-6f4e-4832-bffd-abb121b30e09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c458ca93-afd5-4a28-a66d-f356399b2a1e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cf880e36-6f4e-4832-bffd-abb121b30e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b1326178-d44a-4e49-bc86-affb5d37752d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_254259a9-2811-45d1-82c9-34096242c3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1326178-d44a-4e49-bc86-affb5d37752d" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_254259a9-2811-45d1-82c9-34096242c3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0a1b7fc5-69a6-45e3-bf1e-f6d1a0c06575" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1326178-d44a-4e49-bc86-affb5d37752d" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0a1b7fc5-69a6-45e3-bf1e-f6d1a0c06575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_17d94eef-fc05-498d-9d0a-a4c57b742d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1326178-d44a-4e49-bc86-affb5d37752d" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_17d94eef-fc05-498d-9d0a-a4c57b742d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_d7c63c12-5172-4918-b47a-b4b049366794" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1326178-d44a-4e49-bc86-affb5d37752d" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_d7c63c12-5172-4918-b47a-b4b049366794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_a529f196-a98d-450c-b5c7-9b357707213e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1326178-d44a-4e49-bc86-affb5d37752d" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_a529f196-a98d-450c-b5c7-9b357707213e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_c059c699-fd3f-4431-8cd8-7dfd1ab2161f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1326178-d44a-4e49-bc86-affb5d37752d" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_c059c699-fd3f-4431-8cd8-7dfd1ab2161f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1eb1b2c0-4682-4067-a6e7-66cd1e337eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1326178-d44a-4e49-bc86-affb5d37752d" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1eb1b2c0-4682-4067-a6e7-66cd1e337eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_85704e95-85f6-4872-99ef-66a4a91bdab1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1326178-d44a-4e49-bc86-affb5d37752d" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_85704e95-85f6-4872-99ef-66a4a91bdab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4cc3e746-adbd-4bc5-b036-0b42833ad15a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1326178-d44a-4e49-bc86-affb5d37752d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4cc3e746-adbd-4bc5-b036-0b42833ad15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesClassifiedasCurrentandNonCurrentDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesClassifiedasCurrentandNonCurrentDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesClassifiedasCurrentandNonCurrentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_709d5b80-1da8-4fe1-8a40-6e33af0a7559" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_8bff6131-6d03-46c1-99ca-f0ff058e4f69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_709d5b80-1da8-4fe1-8a40-6e33af0a7559" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_8bff6131-6d03-46c1-99ca-f0ff058e4f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_da357185-80f4-4eb8-950a-279fb092e182" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_709d5b80-1da8-4fe1-8a40-6e33af0a7559" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_da357185-80f4-4eb8-950a-279fb092e182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ab4f983a-082f-4cd9-a3f2-45f2324c3baa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_709d5b80-1da8-4fe1-8a40-6e33af0a7559" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ab4f983a-082f-4cd9-a3f2-45f2324c3baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_482377c9-d587-438b-946f-19a767ef162b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3a7936f1-1272-4fdb-a5d3-07b008fad776" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_482377c9-d587-438b-946f-19a767ef162b" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3a7936f1-1272-4fdb-a5d3-07b008fad776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_9073f09c-52e4-48e1-86f5-f0f13f4b792d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3a7936f1-1272-4fdb-a5d3-07b008fad776" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_9073f09c-52e4-48e1-86f5-f0f13f4b792d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9ca45e1e-7591-428f-8724-9a659a279274" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3a7936f1-1272-4fdb-a5d3-07b008fad776" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9ca45e1e-7591-428f-8724-9a659a279274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_1dbb88ee-8e4c-4437-a0cf-f2561158fceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3a7936f1-1272-4fdb-a5d3-07b008fad776" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_1dbb88ee-8e4c-4437-a0cf-f2561158fceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_f25f5ca5-4e06-4b49-a334-e5626b5b47a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3a7936f1-1272-4fdb-a5d3-07b008fad776" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_f25f5ca5-4e06-4b49-a334-e5626b5b47a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_2d032333-93f5-44c3-ba83-28eadf6d5f94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3a7936f1-1272-4fdb-a5d3-07b008fad776" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_2d032333-93f5-44c3-ba83-28eadf6d5f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a631b74b-da5a-4871-af11-fb79cd3c9f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3a7936f1-1272-4fdb-a5d3-07b008fad776" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a631b74b-da5a-4871-af11-fb79cd3c9f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_90c94357-1755-40e6-ae9a-007088bbd5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3a7936f1-1272-4fdb-a5d3-07b008fad776" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_90c94357-1755-40e6-ae9a-007088bbd5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_41a2498c-0852-4021-b107-73d85295c3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3a7936f1-1272-4fdb-a5d3-07b008fad776" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_41a2498c-0852-4021-b107-73d85295c3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_cbaaacc3-a913-4543-b2e1-88cfa1999fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3a7936f1-1272-4fdb-a5d3-07b008fad776" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_cbaaacc3-a913-4543-b2e1-88cfa1999fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_01c20c85-267d-4210-bd84-076a3b128c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3a7936f1-1272-4fdb-a5d3-07b008fad776" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_01c20c85-267d-4210-bd84-076a3b128c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredTaxAssetsLeaseLiabilities_0204fdc8-5390-49a0-b01d-1507bcbd20ad" xlink:href="rmd-20240630.xsd#rmd_DeferredTaxAssetsLeaseLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3a7936f1-1272-4fdb-a5d3-07b008fad776" xlink:to="loc_rmd_DeferredTaxAssetsLeaseLiabilities_0204fdc8-5390-49a0-b01d-1507bcbd20ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_dd775b1b-c8b9-45f9-99a8-32fb3f5ff06b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3a7936f1-1272-4fdb-a5d3-07b008fad776" xlink:to="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_dd775b1b-c8b9-45f9-99a8-32fb3f5ff06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsStateTaxes_fa91bee8-a6c1-4fe3-8e90-84f7a9a20c77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsStateTaxes"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3a7936f1-1272-4fdb-a5d3-07b008fad776" xlink:to="loc_us-gaap_DeferredTaxAssetsStateTaxes_fa91bee8-a6c1-4fe3-8e90-84f7a9a20c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_ce235502-db6b-4991-9be4-47f1ae8275b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3a7936f1-1272-4fdb-a5d3-07b008fad776" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_ce235502-db6b-4991-9be4-47f1ae8275b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_391f19c3-03dd-4743-8d29-81b5852e3647" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3a7936f1-1272-4fdb-a5d3-07b008fad776" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_391f19c3-03dd-4743-8d29-81b5852e3647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_93df5978-1c80-440a-86ad-2521309a40ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_482377c9-d587-438b-946f-19a767ef162b" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_93df5978-1c80-440a-86ad-2521309a40ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_08ce1f2a-3fd7-4324-be0b-6ea681bb5bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_482377c9-d587-438b-946f-19a767ef162b" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_08ce1f2a-3fd7-4324-be0b-6ea681bb5bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c657c391-d055-4a8b-9bb2-320b4e369a54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_482377c9-d587-438b-946f-19a767ef162b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c657c391-d055-4a8b-9bb2-320b4e369a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_8f459689-a64f-4434-a760-787038f2a985" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c657c391-d055-4a8b-9bb2-320b4e369a54" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_8f459689-a64f-4434-a760-787038f2a985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredTaxLiabilitiesRightOfUseAssets_e54c138b-50ca-4637-90ce-cc601e0ccd6a" xlink:href="rmd-20240630.xsd#rmd_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c657c391-d055-4a8b-9bb2-320b4e369a54" xlink:to="loc_rmd_DeferredTaxLiabilitiesRightOfUseAssets_e54c138b-50ca-4637-90ce-cc601e0ccd6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b61f3781-c582-4986-879d-413ec88c4885" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c657c391-d055-4a8b-9bb2-320b4e369a54" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b61f3781-c582-4986-879d-413ec88c4885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_ca28a370-2f23-4e43-9cd1-77bad5b3f1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_482377c9-d587-438b-946f-19a767ef162b" xlink:to="loc_us-gaap_DeferredTaxLiabilities_ca28a370-2f23-4e43-9cd1-77bad5b3f1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d6db49e6-e9a6-4e59-9dc0-63853bd3a490" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_482377c9-d587-438b-946f-19a767ef162b" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d6db49e6-e9a6-4e59-9dc0-63853bd3a490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d39c81d4-8743-4f91-89ba-c65c2013d12e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxesTable_66361024-1a53-4fa1-b1ec-b1261d4a8dd9" xlink:href="rmd-20240630.xsd#rmd_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d39c81d4-8743-4f91-89ba-c65c2013d12e" xlink:to="loc_rmd_IncomeTaxesTable_66361024-1a53-4fa1-b1ec-b1261d4a8dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_481e6742-f83f-427c-b4ae-b2416806cfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesTable_66361024-1a53-4fa1-b1ec-b1261d4a8dd9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_481e6742-f83f-427c-b4ae-b2416806cfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_4b10ef4d-5670-43df-9733-02ca962f9b67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_481e6742-f83f-427c-b4ae-b2416806cfc1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_4b10ef4d-5670-43df-9733-02ca962f9b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember_67d25774-3d10-4ce0-9221-473b656b4e35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_4b10ef4d-5670-43df-9733-02ca962f9b67" xlink:to="loc_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember_67d25774-3d10-4ce0-9221-473b656b4e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6c6661c9-d3c8-4845-a40a-0b9891f38c45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesTable_66361024-1a53-4fa1-b1ec-b1261d4a8dd9" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6c6661c9-d3c8-4845-a40a-0b9891f38c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2a922223-be5f-44ab-a516-7c3ec8766426" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6c6661c9-d3c8-4845-a40a-0b9891f38c45" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2a922223-be5f-44ab-a516-7c3ec8766426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_6ce2279c-b48d-4d89-82ac-4c3e3df8d043" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2a922223-be5f-44ab-a516-7c3ec8766426" xlink:to="loc_us-gaap_DomesticCountryMember_6ce2279c-b48d-4d89-82ac-4c3e3df8d043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_d3e42038-ec13-4d90-8e7c-97c62e5a9f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2a922223-be5f-44ab-a516-7c3ec8766426" xlink:to="loc_us-gaap_ForeignCountryMember_d3e42038-ec13-4d90-8e7c-97c62e5a9f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_e1cd2466-1e54-457b-891a-d2b5b5a5eb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2a922223-be5f-44ab-a516-7c3ec8766426" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_e1cd2466-1e54-457b-891a-d2b5b5a5eb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_5b1865cf-705d-414e-925d-e618bd171f16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesTable_66361024-1a53-4fa1-b1ec-b1261d4a8dd9" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_5b1865cf-705d-414e-925d-e618bd171f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_fc9e223b-3554-4b45-b1f2-562e58ac508b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_5b1865cf-705d-414e-925d-e618bd171f16" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_fc9e223b-3554-4b45-b1f2-562e58ac508b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_2fd9702a-a524-44a3-9365-789e4bb83449" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_fc9e223b-3554-4b45-b1f2-562e58ac508b" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_2fd9702a-a524-44a3-9365-789e4bb83449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:href="rmd-20240630.xsd#rmd_IncomeTaxesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesTable_66361024-1a53-4fa1-b1ec-b1261d4a8dd9" xlink:to="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_9ab0a451-9efe-49ae-a0a9-09bfd016df8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_us-gaap_OperatingLossCarryforwards_9ab0a451-9efe-49ae-a0a9-09bfd016df8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_OperatingLossCarryforwardsCapitalLoss_5bb06a41-0c60-49fd-a56e-6493c8e64652" xlink:href="rmd-20240630.xsd#rmd_OperatingLossCarryforwardsCapitalLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_rmd_OperatingLossCarryforwardsCapitalLoss_5bb06a41-0c60-49fd-a56e-6493c8e64652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayAggregateDollarAmount_4d762337-ce0c-4704-bf69-5a473636862d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayAggregateDollarAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_us-gaap_IncomeTaxHolidayAggregateDollarAmount_4d762337-ce0c-4704-bf69-5a473636862d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_dafdc0b4-21d5-4d01-a351-4c3ed5988f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_dafdc0b4-21d5-4d01-a351-4c3ed5988f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_6b98ed08-f966-4647-a938-b63d7d2ad292" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_6b98ed08-f966-4647-a938-b63d7d2ad292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries_52a057ad-89b4-4bdb-857f-1faf7b84b575" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries_52a057ad-89b4-4bdb-857f-1faf7b84b575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition_9c774fe0-f491-4fc6-afba-f7c311bd58e7" xlink:href="rmd-20240630.xsd#rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition_9c774fe0-f491-4fc6-afba-f7c311bd58e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationNetImpactOfSettlement_e3636928-1769-4bd9-8595-d93dc0c4c072" xlink:href="rmd-20240630.xsd#rmd_IncomeTaxExaminationNetImpactOfSettlement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_rmd_IncomeTaxExaminationNetImpactOfSettlement_e3636928-1769-4bd9-8595-d93dc0c4c072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationGrossSettlement_542fefb4-c724-417a-a619-e2004ba2d19d" xlink:href="rmd-20240630.xsd#rmd_IncomeTaxExaminationGrossSettlement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_rmd_IncomeTaxExaminationGrossSettlement_542fefb4-c724-417a-a619-e2004ba2d19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_9ff51691-756c-403e-9897-bdf966a1d145" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_9ff51691-756c-403e-9897-bdf966a1d145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_08eb6eaf-52f5-44a7-b6b6-c6f591f96f35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_08eb6eaf-52f5-44a7-b6b6-c6f591f96f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_a119870c-3f00-4a67-bbb2-6119e50a3eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_a119870c-3f00-4a67-bbb2-6119e50a3eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_ceba410d-706b-4e95-9ef7-d91b488ae735" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_ceba410d-706b-4e95-9ef7-d91b488ae735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationRemittedFinalPayment_dc5a0983-1bc9-4270-a2be-a3dd5c079727" xlink:href="rmd-20240630.xsd#rmd_IncomeTaxExaminationRemittedFinalPayment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_rmd_IncomeTaxExaminationRemittedFinalPayment_dc5a0983-1bc9-4270-a2be-a3dd5c079727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationPriorRemittancePayments_131b1208-c1c3-4e46-9f8a-c0796cd9d3ef" xlink:href="rmd-20240630.xsd#rmd_IncomeTaxExaminationPriorRemittancePayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_00e83a72-9459-4bcd-9f10-51ad9455bdd3" xlink:to="loc_rmd_IncomeTaxExaminationPriorRemittancePayments_131b1208-c1c3-4e46-9f8a-c0796cd9d3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_28d11935-513f-4113-8534-83d3a81c8674" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a62612c3-f517-4901-b145-91a784c7394d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_28d11935-513f-4113-8534-83d3a81c8674" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a62612c3-f517-4901-b145-91a784c7394d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_fe685bf6-7ba3-4f5e-b248-f94fbc4aa305" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d23f0a09-3dc5-4275-9f7a-ae683cb741f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_fe685bf6-7ba3-4f5e-b248-f94fbc4aa305" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d23f0a09-3dc5-4275-9f7a-ae683cb741f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_03b1592d-d63b-4fca-bc63-0c5f3b7433e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d23f0a09-3dc5-4275-9f7a-ae683cb741f7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_03b1592d-d63b-4fca-bc63-0c5f3b7433e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_844d7fc2-44ef-424f-9a90-26405156553b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_03b1592d-d63b-4fca-bc63-0c5f3b7433e0" xlink:to="loc_us-gaap_SegmentDomain_844d7fc2-44ef-424f-9a90-26405156553b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SleepAndRespiratoryMember_d0a0c775-6e52-402a-909d-694d69bb5057" xlink:href="rmd-20240630.xsd#rmd_SleepAndRespiratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_844d7fc2-44ef-424f-9a90-26405156553b" xlink:to="loc_rmd_SleepAndRespiratoryMember_d0a0c775-6e52-402a-909d-694d69bb5057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SoftwareAsAServiceMember_cd75f9d9-3c8d-4f10-9c87-3855a5fae772" xlink:href="rmd-20240630.xsd#rmd_SoftwareAsAServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_844d7fc2-44ef-424f-9a90-26405156553b" xlink:to="loc_rmd_SoftwareAsAServiceMember_cd75f9d9-3c8d-4f10-9c87-3855a5fae772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a94cbd71-efa4-4826-90cb-4880989d114d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d23f0a09-3dc5-4275-9f7a-ae683cb741f7" xlink:to="loc_srt_ConsolidationItemsAxis_a94cbd71-efa4-4826-90cb-4880989d114d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ba4adeae-6a3c-469d-8b67-e0e919667818" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_a94cbd71-efa4-4826-90cb-4880989d114d" xlink:to="loc_srt_ConsolidationItemsDomain_ba4adeae-6a3c-469d-8b67-e0e919667818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_06fbe9c7-037b-4d8f-b945-68ad503c19ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ba4adeae-6a3c-469d-8b67-e0e919667818" xlink:to="loc_us-gaap_OperatingSegmentsMember_06fbe9c7-037b-4d8f-b945-68ad503c19ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_91d269e5-0cd6-451a-a1fd-a30ec6e561e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ba4adeae-6a3c-469d-8b67-e0e919667818" xlink:to="loc_us-gaap_CorporateNonSegmentMember_91d269e5-0cd6-451a-a1fd-a30ec6e561e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_7ab0ebc6-c416-4eaa-8b3a-a1d5122b6a55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ba4adeae-6a3c-469d-8b67-e0e919667818" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_7ab0ebc6-c416-4eaa-8b3a-a1d5122b6a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d23f0a09-3dc5-4275-9f7a-ae683cb741f7" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f54631d3-7c5d-4183-a912-1cf71cd70c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f54631d3-7c5d-4183-a912-1cf71cd70c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b8c3f895-48ac-47a2-b7a2-eb8a0b712fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b8c3f895-48ac-47a2-b7a2-eb8a0b712fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1e0929ff-4b84-4858-8994-7cc872f420ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_OperatingIncomeLoss_1e0929ff-4b84-4858-8994-7cc872f420ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_UnallocatedCorporateCosts_4c3d11dd-b3bf-4d62-bb0e-76c06e03061f" xlink:href="rmd-20240630.xsd#rmd_UnallocatedCorporateCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_rmd_UnallocatedCorporateCosts_4c3d11dd-b3bf-4d62-bb0e-76c06e03061f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_1ff32ba1-3204-43be-98a3-39c79bff75ea" xlink:href="rmd-20240630.xsd#rmd_AmortizationOfAcquiredIntangibleAssets1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_1ff32ba1-3204-43be-98a3-39c79bff75ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_fd1b95e4-7674-4a56-8dd7-242c3d89c131" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_RestructuringCharges_fd1b95e4-7674-4a56-8dd7-242c3d89c131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MasksWithMagnetsFieldSafetyNotificationExpenses_051ad45e-f587-4c1a-8069-e6739ddfc33d" xlink:href="rmd-20240630.xsd#rmd_MasksWithMagnetsFieldSafetyNotificationExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_rmd_MasksWithMagnetsFieldSafetyNotificationExpenses_051ad45e-f587-4c1a-8069-e6739ddfc33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AstralFieldActionNotificationExpenses_94a141ec-79de-452b-97ab-814f6a20d6d8" xlink:href="rmd-20240630.xsd#rmd_AstralFieldActionNotificationExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_rmd_AstralFieldActionNotificationExpenses_94a141ec-79de-452b-97ab-814f6a20d6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_53742c76-df95-4001-a191-d0c81bb3573a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_53742c76-df95-4001-a191-d0c81bb3573a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_685c6bd7-50cd-4bf4-97d7-134205b50986" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_685c6bd7-50cd-4bf4-97d7-134205b50986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_833258a3-0bcf-4564-89a5-7250a0542674" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_833258a3-0bcf-4564-89a5-7250a0542674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_80f4de25-bca4-43b0-88c1-0abef84bca49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_80f4de25-bca4-43b0-88c1-0abef84bca49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_c7d9e575-2aac-44fb-9c8f-2398b5edc342" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainOnBusinessInterruptionInsuranceRecovery"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_c7d9e575-2aac-44fb-9c8f-2398b5edc342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_207e0af0-c5cf-4d30-be6d-697598acc806" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_207e0af0-c5cf-4d30-be6d-697598acc806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4dcebc50-14d2-4c31-b72d-a4f415c1b5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4dcebc50-14d2-4c31-b72d-a4f415c1b5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_6fee23f8-62e5-4631-a518-4ba22f51ccba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7fbeb8e8-0f70-4de8-aa2f-82ef7bfa48d9" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_6fee23f8-62e5-4631-a518-4ba22f51ccba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_cf26181b-7a7b-4a07-b9c0-e1fd78e7a9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84dc1abf-3719-413b-ae18-4fc565451c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cf26181b-7a7b-4a07-b9c0-e1fd78e7a9d0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84dc1abf-3719-413b-ae18-4fc565451c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_cc2eb0a7-bbd8-4fbf-ac9b-2f1a14ccce88" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84dc1abf-3719-413b-ae18-4fc565451c0d" xlink:to="loc_srt_ConsolidationItemsAxis_cc2eb0a7-bbd8-4fbf-ac9b-2f1a14ccce88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_48f4a769-82cb-4ef7-9696-2afd5596b238" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_cc2eb0a7-bbd8-4fbf-ac9b-2f1a14ccce88" xlink:to="loc_srt_ConsolidationItemsDomain_48f4a769-82cb-4ef7-9696-2afd5596b238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_bad2779c-c8c5-4af1-a33b-aeabd4eaf3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_48f4a769-82cb-4ef7-9696-2afd5596b238" xlink:to="loc_us-gaap_OperatingSegmentsMember_bad2779c-c8c5-4af1-a33b-aeabd4eaf3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5f00c5f7-869e-4527-b00b-fe5a783eb24a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84dc1abf-3719-413b-ae18-4fc565451c0d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5f00c5f7-869e-4527-b00b-fe5a783eb24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_deb00973-1a70-4eb2-b7d3-15f317255b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5f00c5f7-869e-4527-b00b-fe5a783eb24a" xlink:to="loc_us-gaap_SegmentDomain_deb00973-1a70-4eb2-b7d3-15f317255b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SleepAndRespiratoryMember_9de63d4b-9ac9-4812-b8f2-af65dffc5af6" xlink:href="rmd-20240630.xsd#rmd_SleepAndRespiratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_deb00973-1a70-4eb2-b7d3-15f317255b5d" xlink:to="loc_rmd_SleepAndRespiratoryMember_9de63d4b-9ac9-4812-b8f2-af65dffc5af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SoftwareAsAServiceMember_b96a415c-d506-4814-b5b6-518dcb395fe9" xlink:href="rmd-20240630.xsd#rmd_SoftwareAsAServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_deb00973-1a70-4eb2-b7d3-15f317255b5d" xlink:to="loc_rmd_SoftwareAsAServiceMember_b96a415c-d506-4814-b5b6-518dcb395fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6a45b008-986a-4768-81c8-8d6db1be6a89" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84dc1abf-3719-413b-ae18-4fc565451c0d" xlink:to="loc_srt_StatementGeographicalAxis_6a45b008-986a-4768-81c8-8d6db1be6a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4e8a70da-16f0-4324-8f8f-b7ae15208e51" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6a45b008-986a-4768-81c8-8d6db1be6a89" xlink:to="loc_srt_SegmentGeographicalDomain_4e8a70da-16f0-4324-8f8f-b7ae15208e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_U.s.CanadaAndLatinAmericaMember_b46abb1b-620c-4fac-a251-7c760a513daf" xlink:href="rmd-20240630.xsd#rmd_U.s.CanadaAndLatinAmericaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4e8a70da-16f0-4324-8f8f-b7ae15208e51" xlink:to="loc_rmd_U.s.CanadaAndLatinAmericaMember_b46abb1b-620c-4fac-a251-7c760a513daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_CombinedEuropeAsiaAndOtherMarketsMember_c5bcd357-894d-49b7-be11-d797c0b40369" xlink:href="rmd-20240630.xsd#rmd_CombinedEuropeAsiaAndOtherMarketsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4e8a70da-16f0-4324-8f8f-b7ae15208e51" xlink:to="loc_rmd_CombinedEuropeAsiaAndOtherMarketsMember_c5bcd357-894d-49b7-be11-d797c0b40369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_GlobalMember_2837b918-728c-4411-9033-b29be81f3ad5" xlink:href="rmd-20240630.xsd#rmd_GlobalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4e8a70da-16f0-4324-8f8f-b7ae15208e51" xlink:to="loc_rmd_GlobalMember_2837b918-728c-4411-9033-b29be81f3ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_aea48372-34a6-4090-aba8-40c65ed664c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84dc1abf-3719-413b-ae18-4fc565451c0d" xlink:to="loc_us-gaap_SubsegmentsAxis_aea48372-34a6-4090-aba8-40c65ed664c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_ddc1bd91-ad4d-4866-a2cb-c31a0f5671b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_aea48372-34a6-4090-aba8-40c65ed664c7" xlink:to="loc_us-gaap_SubsegmentsDomain_ddc1bd91-ad4d-4866-a2cb-c31a0f5671b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DevicesMember_7104e9c0-81ed-4ab9-8348-a4b46d9b463e" xlink:href="rmd-20240630.xsd#rmd_DevicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_ddc1bd91-ad4d-4866-a2cb-c31a0f5671b6" xlink:to="loc_rmd_DevicesMember_7104e9c0-81ed-4ab9-8348-a4b46d9b463e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MasksAndOtherMember_27473781-e9bb-42f7-a09d-7ba886a5fa2e" xlink:href="rmd-20240630.xsd#rmd_MasksAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_ddc1bd91-ad4d-4866-a2cb-c31a0f5671b6" xlink:to="loc_rmd_MasksAndOtherMember_27473781-e9bb-42f7-a09d-7ba886a5fa2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_885d7223-b9e1-4290-a704-3616816db8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_84dc1abf-3719-413b-ae18-4fc565451c0d" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_885d7223-b9e1-4290-a704-3616816db8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b9025508-5005-4434-be1e-f935016d874c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_885d7223-b9e1-4290-a704-3616816db8a8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b9025508-5005-4434-be1e-f935016d874c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebyGeographicAreaDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SegmentInformationScheduleofRevenuebyGeographicAreaDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_94040ecf-3a59-404b-9f73-0e74bf145edd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_416d3018-ed34-4cbe-a514-d20f81c159d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_94040ecf-3a59-404b-9f73-0e74bf145edd" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_416d3018-ed34-4cbe-a514-d20f81c159d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cd82ef3f-a1ea-42f1-9f61-ff871438c136" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_416d3018-ed34-4cbe-a514-d20f81c159d4" xlink:to="loc_srt_StatementGeographicalAxis_cd82ef3f-a1ea-42f1-9f61-ff871438c136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_46c17ef1-2b6a-4c65-9556-00674a372906" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_cd82ef3f-a1ea-42f1-9f61-ff871438c136" xlink:to="loc_srt_SegmentGeographicalDomain_46c17ef1-2b6a-4c65-9556-00674a372906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1958a950-414f-4188-b139-c04322ac39e3" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_46c17ef1-2b6a-4c65-9556-00674a372906" xlink:to="loc_country_US_1958a950-414f-4188-b139-c04322ac39e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RestOfWorldMember_4c0aa24f-f1d1-46b1-b9ba-03f095586c41" xlink:href="rmd-20240630.xsd#rmd_RestOfWorldMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_46c17ef1-2b6a-4c65-9556-00674a372906" xlink:to="loc_rmd_RestOfWorldMember_4c0aa24f-f1d1-46b1-b9ba-03f095586c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_392bc726-4275-408c-8b07-4d5956dc0ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_416d3018-ed34-4cbe-a514-d20f81c159d4" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_392bc726-4275-408c-8b07-4d5956dc0ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94565a6c-a829-44d6-bc99-5e57d3ff2d40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_392bc726-4275-408c-8b07-4d5956dc0ffa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94565a6c-a829-44d6-bc99-5e57d3ff2d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationScheduleofLongLivedAssetsbyGeographicAreasDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#SegmentInformationScheduleofLongLivedAssetsbyGeographicAreasDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SegmentInformationScheduleofLongLivedAssetsbyGeographicAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8e01112d-7efd-4579-8f69-990e5129853d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2c4cb1e1-32db-49bf-9df2-b7468353b2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8e01112d-7efd-4579-8f69-990e5129853d" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2c4cb1e1-32db-49bf-9df2-b7468353b2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_28a19926-3cf6-43e6-885c-c6d9c6cf5f57" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2c4cb1e1-32db-49bf-9df2-b7468353b2b2" xlink:to="loc_srt_StatementGeographicalAxis_28a19926-3cf6-43e6-885c-c6d9c6cf5f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_baeb1a6c-d49f-498b-a331-cd50f05e56f7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_28a19926-3cf6-43e6-885c-c6d9c6cf5f57" xlink:to="loc_srt_SegmentGeographicalDomain_baeb1a6c-d49f-498b-a331-cd50f05e56f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_a5f215b5-d7e8-43e4-aaf2-0b1aac15686c" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_AU"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_baeb1a6c-d49f-498b-a331-cd50f05e56f7" xlink:to="loc_country_AU_a5f215b5-d7e8-43e4-aaf2-0b1aac15686c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_667ad9ed-b566-4ab7-b68e-33154c2de4e4" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_baeb1a6c-d49f-498b-a331-cd50f05e56f7" xlink:to="loc_country_US_667ad9ed-b566-4ab7-b68e-33154c2de4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_SG_55e81935-cb36-4db4-b255-305dbbcf161e" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_SG"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_baeb1a6c-d49f-498b-a331-cd50f05e56f7" xlink:to="loc_country_SG_55e81935-cb36-4db4-b255-305dbbcf161e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RestOfWorldMember_5b10b0b4-ce3c-4d42-9f47-07a66e5382b3" xlink:href="rmd-20240630.xsd#rmd_RestOfWorldMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_baeb1a6c-d49f-498b-a331-cd50f05e56f7" xlink:to="loc_rmd_RestOfWorldMember_5b10b0b4-ce3c-4d42-9f47-07a66e5382b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4f2ec36a-81f9-4bf8-a9be-b66eba7ef652" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2c4cb1e1-32db-49bf-9df2-b7468353b2b2" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4f2ec36a-81f9-4bf8-a9be-b66eba7ef652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_45d8c45f-2f0a-40a5-8e45-5af7b2b1566e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_4f2ec36a-81f9-4bf8-a9be-b66eba7ef652" xlink:to="loc_us-gaap_NoncurrentAssets_45d8c45f-2f0a-40a5-8e45-5af7b2b1566e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/EmployeeRetirementPlansDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#EmployeeRetirementPlansDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/EmployeeRetirementPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4a7a6989-f5b5-4978-aa67-33c555e33315" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_867377be-e894-4dde-a77e-81291fd64a77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4a7a6989-f5b5-4978-aa67-33c555e33315" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_867377be-e894-4dde-a77e-81291fd64a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_de58330a-1990-42ac-93e9-d5b2274f84a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_867377be-e894-4dde-a77e-81291fd64a77" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_de58330a-1990-42ac-93e9-d5b2274f84a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c34824b9-edb7-46f8-a78c-441a68c5cb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_de58330a-1990-42ac-93e9-d5b2274f84a3" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c34824b9-edb7-46f8-a78c-441a68c5cb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_7fe458d6-c0da-459b-8b33-4ddb45ef4ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c34824b9-edb7-46f8-a78c-441a68c5cb8d" xlink:to="loc_us-gaap_ForeignPlanMember_7fe458d6-c0da-459b-8b33-4ddb45ef4ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_30dc164d-62fa-4a88-85ae-6a7495b1f8cb" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_AU"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignPlanMember_7fe458d6-c0da-459b-8b33-4ddb45ef4ec5" xlink:to="loc_country_AU_30dc164d-62fa-4a88-85ae-6a7495b1f8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_SG_34566d94-308e-4460-9aa9-57cfdac8cf17" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_SG"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignPlanMember_7fe458d6-c0da-459b-8b33-4ddb45ef4ec5" xlink:to="loc_country_SG_34566d94-308e-4460-9aa9-57cfdac8cf17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_9d484f68-6f15-4f46-99b0-066ee7534a29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c34824b9-edb7-46f8-a78c-441a68c5cb8d" xlink:to="loc_us-gaap_DomesticPlanMember_9d484f68-6f15-4f46-99b0-066ee7534a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a9e5abb0-973e-481f-879e-ba1b61791f5a" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_9d484f68-6f15-4f46-99b0-066ee7534a29" xlink:to="loc_country_US_a9e5abb0-973e-481f-879e-ba1b61791f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0eb670ea-ecac-4920-89c1-8e3b8fc52498" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_867377be-e894-4dde-a77e-81291fd64a77" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0eb670ea-ecac-4920-89c1-8e3b8fc52498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent_611806b4-a647-400b-87ef-c82470c3991c" xlink:href="rmd-20240630.xsd#rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0eb670ea-ecac-4920-89c1-8e3b8fc52498" xlink:to="loc_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent_611806b4-a647-400b-87ef-c82470c3991c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_6ac3fa03-4f76-4404-a8e0-3573ad0d4914" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0eb670ea-ecac-4920-89c1-8e3b8fc52498" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_6ac3fa03-4f76-4404-a8e0-3573ad0d4914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsNarrativeDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#LegalActionsContingenciesandCommitmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8062860f-b422-4878-b8c5-cf7f26fefb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NumberOfPatents_1028e6ee-b5f7-4ca2-b221-ab4c373a4602" xlink:href="rmd-20240630.xsd#rmd_NumberOfPatents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8062860f-b422-4878-b8c5-cf7f26fefb2b" xlink:to="loc_rmd_NumberOfPatents_1028e6ee-b5f7-4ca2-b221-ab4c373a4602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ReceivablesSoldWithLimitedRecourse_9f971e9f-b813-4912-9e75-b07d428a0790" xlink:href="rmd-20240630.xsd#rmd_ReceivablesSoldWithLimitedRecourse"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8062860f-b422-4878-b8c5-cf7f26fefb2b" xlink:to="loc_rmd_ReceivablesSoldWithLimitedRecourse_9f971e9f-b813-4912-9e75-b07d428a0790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_5626d8fd-427b-4c51-bb60-2b82793ad091" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8062860f-b422-4878-b8c5-cf7f26fefb2b" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_5626d8fd-427b-4c51-bb60-2b82793ad091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_611811e3-aaba-4b52-8b53-4b9538be7a65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8062860f-b422-4878-b8c5-cf7f26fefb2b" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_611811e3-aaba-4b52-8b53-4b9538be7a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9d7c5a74-c4b1-4ae8-9144-b2fd17bf9618" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_6620cd7f-8b29-487b-a0d3-9143f89fde7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9d7c5a74-c4b1-4ae8-9144-b2fd17bf9618" xlink:to="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_6620cd7f-8b29-487b-a0d3-9143f89fde7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_c6ddea86-3507-4e0f-8d33-56412cbf7c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_6620cd7f-8b29-487b-a0d3-9143f89fde7e" xlink:to="loc_us-gaap_PurchaseObligation_c6ddea86-3507-4e0f-8d33-56412cbf7c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_2458224c-03bd-4241-a770-19153d2c556d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_6620cd7f-8b29-487b-a0d3-9143f89fde7e" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_2458224c-03bd-4241-a770-19153d2c556d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_21672e88-86c9-46c0-aa1a-d3b2d3b5c5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_6620cd7f-8b29-487b-a0d3-9143f89fde7e" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_21672e88-86c9-46c0-aa1a-d3b2d3b5c5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_04f5cfe6-9e37-48f4-b8ca-ed5a1dedd421" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_6620cd7f-8b29-487b-a0d3-9143f89fde7e" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_04f5cfe6-9e37-48f4-b8ca-ed5a1dedd421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_8d627010-4891-4dfd-bf5f-fa96e0a262a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_6620cd7f-8b29-487b-a0d3-9143f89fde7e" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_8d627010-4891-4dfd-bf5f-fa96e0a262a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_d8e8f8f7-a798-4f81-9030-5775f6e7c1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_6620cd7f-8b29-487b-a0d3-9143f89fde7e" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_d8e8f8f7-a798-4f81-9030-5775f6e7c1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear_0e146c4b-cc31-47cb-a779-ffe3b7720eba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligationDueAfterFifthYear"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_6620cd7f-8b29-487b-a0d3-9143f89fde7e" xlink:to="loc_us-gaap_PurchaseObligationDueAfterFifthYear_0e146c4b-cc31-47cb-a779-ffe3b7720eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2d4972bf-9f84-42d2-91d2-dc29803ee58b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_cd21b198-1967-46f8-bcb1-dfb3c23cdbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2d4972bf-9f84-42d2-91d2-dc29803ee58b" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_cd21b198-1967-46f8-bcb1-dfb3c23cdbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_24619c4f-d9f9-4f76-910e-e67fcecd9301" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_cd21b198-1967-46f8-bcb1-dfb3c23cdbf8" xlink:to="loc_us-gaap_HedgingDesignationAxis_24619c4f-d9f9-4f76-910e-e67fcecd9301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e261a61a-507b-4b4a-b677-236f96957b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_24619c4f-d9f9-4f76-910e-e67fcecd9301" xlink:to="loc_us-gaap_HedgingDesignationDomain_e261a61a-507b-4b4a-b677-236f96957b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_0f0fcff5-d2d1-4c60-9f05-16ad72c94ace" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_e261a61a-507b-4b4a-b677-236f96957b6c" xlink:to="loc_us-gaap_NondesignatedMember_0f0fcff5-d2d1-4c60-9f05-16ad72c94ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_eb15a7dd-d5a1-4def-b36c-946002271a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_e261a61a-507b-4b4a-b677-236f96957b6c" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_eb15a7dd-d5a1-4def-b36c-946002271a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_13e9e154-f026-4931-aee2-ad3f22d352e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_cd21b198-1967-46f8-bcb1-dfb3c23cdbf8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_13e9e154-f026-4931-aee2-ad3f22d352e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_95fb217b-43cf-4cac-b9be-06088f998c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_13e9e154-f026-4931-aee2-ad3f22d352e4" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_95fb217b-43cf-4cac-b9be-06088f998c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_974aaf1d-4ad3-4b59-8cf0-10ab61550dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_95fb217b-43cf-4cac-b9be-06088f998c7d" xlink:to="loc_us-gaap_ForeignExchangeContractMember_974aaf1d-4ad3-4b59-8cf0-10ab61550dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6c4f5299-3fce-4307-a827-6b18d306c4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_cd21b198-1967-46f8-bcb1-dfb3c23cdbf8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6c4f5299-3fce-4307-a827-6b18d306c4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7206c522-ca1f-4e65-b158-97fcb7de4785" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6c4f5299-3fce-4307-a827-6b18d306c4c8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7206c522-ca1f-4e65-b158-97fcb7de4785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_b24838a4-c307-4972-9b02-b89f24dcdba9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7206c522-ca1f-4e65-b158-97fcb7de4785" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_b24838a4-c307-4972-9b02-b89f24dcdba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember_df5644ec-118e-424b-b452-d3373bb37d8f" xlink:href="rmd-20240630.xsd#rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7206c522-ca1f-4e65-b158-97fcb7de4785" xlink:to="loc_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember_df5644ec-118e-424b-b452-d3373bb37d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_360e92fc-cd63-4222-b034-4e0a1a5200d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7206c522-ca1f-4e65-b158-97fcb7de4785" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_360e92fc-cd63-4222-b034-4e0a1a5200d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_85f89684-ef01-4373-8063-368cca98cfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7206c522-ca1f-4e65-b158-97fcb7de4785" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_85f89684-ef01-4373-8063-368cca98cfd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_35b85b99-659f-42ce-b22a-6f4a6cf101fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_cd21b198-1967-46f8-bcb1-dfb3c23cdbf8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_35b85b99-659f-42ce-b22a-6f4a6cf101fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0a6f3c2d-a738-4090-b2ea-abb604aa4a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_35b85b99-659f-42ce-b22a-6f4a6cf101fc" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0a6f3c2d-a738-4090-b2ea-abb604aa4a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_d294f99d-8954-4c9b-9b6a-ab1861034367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0a6f3c2d-a738-4090-b2ea-abb604aa4a3b" xlink:to="loc_us-gaap_FairValueHedgingMember_d294f99d-8954-4c9b-9b6a-ab1861034367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_5cc0c8eb-400a-4620-b0b3-5c3a2c4f38b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0a6f3c2d-a738-4090-b2ea-abb604aa4a3b" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_5cc0c8eb-400a-4620-b0b3-5c3a2c4f38b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_cd21b198-1967-46f8-bcb1-dfb3c23cdbf8" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_a9e0fc30-cbd1-4a73-9be4-f4aa700d9ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:to="loc_us-gaap_DerivativeAssets_a9e0fc30-cbd1-4a73-9be4-f4aa700d9ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_ecacad29-1438-49a2-a77a-79c7b30c4460" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:to="loc_us-gaap_DerivativeLiabilities_ecacad29-1438-49a2-a77a-79c7b30c4460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration_32c905f8-69e6-4ede-abae-6b2f2c9cfd32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:to="loc_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration_32c905f8-69e6-4ede-abae-6b2f2c9cfd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration_80a4bc08-3ed4-4c92-903f-f71380d559fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:to="loc_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration_80a4bc08-3ed4-4c92-903f-f71380d559fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration_1e6d7630-d28a-44e6-ba72-10ea139bd356" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:to="loc_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration_1e6d7630-d28a-44e6-ba72-10ea139bd356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_4897d7b5-22b8-4663-8810-537cc63af872" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_4897d7b5-22b8-4663-8810-537cc63af872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration_b56cd2fc-cc40-4e76-bdc8-825929fcc498" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:to="loc_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration_b56cd2fc-cc40-4e76-bdc8-825929fcc498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_2e0b54b5-cfd2-46b6-bc96-e7192720afec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_80baa6b8-7478-4b96-bde6-38e865900cd5" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_2e0b54b5-cfd2-46b6-bc96-e7192720afec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ea7eece3-0ffa-44b9-a510-2696b68ea6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_93d07031-4812-40ec-8ff1-9e9b4dda5bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ea7eece3-0ffa-44b9-a510-2696b68ea6b2" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_93d07031-4812-40ec-8ff1-9e9b4dda5bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_7bceaf89-4753-43ef-a21a-676749838094" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_93d07031-4812-40ec-8ff1-9e9b4dda5bd4" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_7bceaf89-4753-43ef-a21a-676749838094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d0412f0f-3e4f-4f8b-a4c8-086770059b97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_7bceaf89-4753-43ef-a21a-676749838094" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d0412f0f-3e4f-4f8b-a4c8-086770059b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_9531d02d-0f38-4209-a7b0-eba2cc8a4319" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d0412f0f-3e4f-4f8b-a4c8-086770059b97" xlink:to="loc_us-gaap_CurrencySwapMember_9531d02d-0f38-4209-a7b0-eba2cc8a4319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c5eea9b6-5039-48bc-97c2-d33c98d67a64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_93d07031-4812-40ec-8ff1-9e9b4dda5bd4" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c5eea9b6-5039-48bc-97c2-d33c98d67a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_1b190a0f-f03e-4ed2-84fc-f50ab976114f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c5eea9b6-5039-48bc-97c2-d33c98d67a64" xlink:to="loc_us-gaap_HedgingRelationshipDomain_1b190a0f-f03e-4ed2-84fc-f50ab976114f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_b710602f-1e0b-4c3b-a116-c34d5b5bb2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_1b190a0f-f03e-4ed2-84fc-f50ab976114f" xlink:to="loc_us-gaap_FairValueHedgingMember_b710602f-1e0b-4c3b-a116-c34d5b5bb2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_54950e90-7747-4d32-934f-f98cf44015d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_93d07031-4812-40ec-8ff1-9e9b4dda5bd4" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_54950e90-7747-4d32-934f-f98cf44015d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_110b4391-6a7a-4ea1-bc16-2fa412d75cad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_54950e90-7747-4d32-934f-f98cf44015d2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_110b4391-6a7a-4ea1-bc16-2fa412d75cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_bb61c22e-e3f4-4c2a-bdbf-ccf0f75a8e08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_54950e90-7747-4d32-934f-f98cf44015d2" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_bb61c22e-e3f4-4c2a-bdbf-ccf0f75a8e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ba10907e-4690-42d2-b3df-545428d20a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_54950e90-7747-4d32-934f-f98cf44015d2" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ba10907e-4690-42d2-b3df-545428d20a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_4de5b3ac-3076-4c76-ada3-c28c64a353bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_54950e90-7747-4d32-934f-f98cf44015d2" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_4de5b3ac-3076-4c76-ada3-c28c64a353bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_66ebc966-554c-4033-afb3-729ab3f7bf51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_ca3d15d5-a588-40e6-bbcf-3f1fc211297a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_66ebc966-554c-4033-afb3-729ab3f7bf51" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_ca3d15d5-a588-40e6-bbcf-3f1fc211297a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_572eb21d-011f-400b-85f4-119b1d021eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_ca3d15d5-a588-40e6-bbcf-3f1fc211297a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_572eb21d-011f-400b-85f4-119b1d021eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_29d29dcc-c977-4a07-93e2-7c3f0142aa0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_572eb21d-011f-400b-85f4-119b1d021eb7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_29d29dcc-c977-4a07-93e2-7c3f0142aa0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_efe55d2f-dd6d-42e9-ac9c-f568edf8bb08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_29d29dcc-c977-4a07-93e2-7c3f0142aa0c" xlink:to="loc_us-gaap_CurrencySwapMember_efe55d2f-dd6d-42e9-ac9c-f568edf8bb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6b65d833-95c1-4636-a88c-302b7e96b262" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_ca3d15d5-a588-40e6-bbcf-3f1fc211297a" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6b65d833-95c1-4636-a88c-302b7e96b262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d9054f27-a7fa-430f-b440-06a8b3689808" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6b65d833-95c1-4636-a88c-302b7e96b262" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d9054f27-a7fa-430f-b440-06a8b3689808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_b4116b46-39b5-48ce-86bc-1fa9ba881fae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d9054f27-a7fa-430f-b440-06a8b3689808" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_b4116b46-39b5-48ce-86bc-1fa9ba881fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6fae2793-2e10-436a-8445-e3edf607e3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_ca3d15d5-a588-40e6-bbcf-3f1fc211297a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6fae2793-2e10-436a-8445-e3edf607e3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f5e95755-e973-4356-b0a4-a326379b5a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6fae2793-2e10-436a-8445-e3edf607e3d3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f5e95755-e973-4356-b0a4-a326379b5a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_761629fc-9e9e-4a23-83bb-0515648865c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f5e95755-e973-4356-b0a4-a326379b5a6c" xlink:to="loc_us-gaap_InterestExpenseMember_761629fc-9e9e-4a23-83bb-0515648865c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4c6e6b10-c044-494b-873b-6ad23d0a25bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_ca3d15d5-a588-40e6-bbcf-3f1fc211297a" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4c6e6b10-c044-494b-873b-6ad23d0a25bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_f651f713-f2b4-459d-a838-4a02d432e62c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4c6e6b10-c044-494b-873b-6ad23d0a25bb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_f651f713-f2b4-459d-a838-4a02d432e62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_2d7154fe-0cb0-4a70-a70f-8b550c04c43c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4c6e6b10-c044-494b-873b-6ad23d0a25bb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_2d7154fe-0cb0-4a70-a70f-8b550c04c43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_795fd5a4-d862-4ec8-a2dd-b0c9254c4930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_718f5169-7b4d-444d-87ff-826c2288153b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_795fd5a4-d862-4ec8-a2dd-b0c9254c4930" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_718f5169-7b4d-444d-87ff-826c2288153b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_f08d96b3-de47-48f5-81b5-db912c35701d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_718f5169-7b4d-444d-87ff-826c2288153b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_f08d96b3-de47-48f5-81b5-db912c35701d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a7fe02e6-ee68-4496-a476-ffcfa9502a66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_f08d96b3-de47-48f5-81b5-db912c35701d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a7fe02e6-ee68-4496-a476-ffcfa9502a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_3337a447-840b-47c3-ba95-1d623911e4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a7fe02e6-ee68-4496-a476-ffcfa9502a66" xlink:to="loc_us-gaap_ForeignExchangeContractMember_3337a447-840b-47c3-ba95-1d623911e4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_OtherForeignExchangeContractsMember_cc967d44-771d-4b02-ae15-09a49e409c47" xlink:href="rmd-20240630.xsd#rmd_OtherForeignExchangeContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a7fe02e6-ee68-4496-a476-ffcfa9502a66" xlink:to="loc_rmd_OtherForeignExchangeContractsMember_cc967d44-771d-4b02-ae15-09a49e409c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_07ce530c-2075-4061-ba7d-ade27b68fb79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_718f5169-7b4d-444d-87ff-826c2288153b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_07ce530c-2075-4061-ba7d-ade27b68fb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_3edc95a3-8757-4e76-a000-71ea62c019d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_07ce530c-2075-4061-ba7d-ade27b68fb79" xlink:to="loc_us-gaap_HedgingRelationshipDomain_3edc95a3-8757-4e76-a000-71ea62c019d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_4420de83-aa61-4092-bfa4-63f70f2213d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3edc95a3-8757-4e76-a000-71ea62c019d1" xlink:to="loc_us-gaap_NondesignatedMember_4420de83-aa61-4092-bfa4-63f70f2213d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9a046362-29dd-4823-8911-33019f12a306" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_718f5169-7b4d-444d-87ff-826c2288153b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9a046362-29dd-4823-8911-33019f12a306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a82e69ca-0aa2-424a-b17f-b181606ceca1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9a046362-29dd-4823-8911-33019f12a306" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a82e69ca-0aa2-424a-b17f-b181606ceca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_1f4fa408-a30c-4165-abb6-f4665d7b7f51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a82e69ca-0aa2-424a-b17f-b181606ceca1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_1f4fa408-a30c-4165-abb6-f4665d7b7f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_9991ebee-5122-4644-a6e7-398240972d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_718f5169-7b4d-444d-87ff-826c2288153b" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_9991ebee-5122-4644-a6e7-398240972d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_c69a6c4d-6a70-4bfe-bd0a-a67a87700a23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_9991ebee-5122-4644-a6e7-398240972d0d" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_c69a6c4d-6a70-4bfe-bd0a-a67a87700a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_76c1fc26-2c61-4736-b97e-6939b90fa10b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_70d2a9cc-31d2-4288-b3e4-af55a611e54f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_76c1fc26-2c61-4736-b97e-6939b90fa10b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_70d2a9cc-31d2-4288-b3e4-af55a611e54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2cef4418-284e-4b64-9a79-a07ae1275aea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_70d2a9cc-31d2-4288-b3e4-af55a611e54f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2cef4418-284e-4b64-9a79-a07ae1275aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2ff0f08e-cfd6-4ad0-ba73-8a0a9d9dd072" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2cef4418-284e-4b64-9a79-a07ae1275aea" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2ff0f08e-cfd6-4ad0-ba73-8a0a9d9dd072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MEDIFOXDANMember_744ecaa9-aa77-4f05-8075-f8edfcbdc5ed" xlink:href="rmd-20240630.xsd#rmd_MEDIFOXDANMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2ff0f08e-cfd6-4ad0-ba73-8a0a9d9dd072" xlink:to="loc_rmd_MEDIFOXDANMember_744ecaa9-aa77-4f05-8075-f8edfcbdc5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a5e9b13b-d06d-456f-8463-ed0bde513d84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_70d2a9cc-31d2-4288-b3e4-af55a611e54f" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a5e9b13b-d06d-456f-8463-ed0bde513d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f83edda7-56b1-4dc5-b934-4f585524b34d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a5e9b13b-d06d-456f-8463-ed0bde513d84" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f83edda7-56b1-4dc5-b934-4f585524b34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1ed309bf-143d-4d35-997a-82c89d14c9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a5e9b13b-d06d-456f-8463-ed0bde513d84" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1ed309bf-143d-4d35-997a-82c89d14c9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_d7c0682f-3305-4b7b-8632-332d829044bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a5e9b13b-d06d-456f-8463-ed0bde513d84" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_d7c0682f-3305-4b7b-8632-332d829044bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0068e422-eb97-4b0e-a08b-02b56e9b9935" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cdb52807-53fd-4047-a260-8336eac002bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0068e422-eb97-4b0e-a08b-02b56e9b9935" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cdb52807-53fd-4047-a260-8336eac002bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_479ea5c6-893c-4f6c-98bf-57947c170e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cdb52807-53fd-4047-a260-8336eac002bf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_479ea5c6-893c-4f6c-98bf-57947c170e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45ea0f54-d2d6-41fe-add5-65fee3cec04d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_479ea5c6-893c-4f6c-98bf-57947c170e5a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45ea0f54-d2d6-41fe-add5-65fee3cec04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MEDIFOXDANMember_9b00a983-6154-4788-8b30-45b92371244c" xlink:href="rmd-20240630.xsd#rmd_MEDIFOXDANMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45ea0f54-d2d6-41fe-add5-65fee3cec04d" xlink:to="loc_rmd_MEDIFOXDANMember_9b00a983-6154-4788-8b30-45b92371244c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_45117d95-3d4b-4f68-be53-f58b067500b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cdb52807-53fd-4047-a260-8336eac002bf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_45117d95-3d4b-4f68-be53-f58b067500b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9d25e7ba-9aea-4eba-8623-d4275c3e06d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_45117d95-3d4b-4f68-be53-f58b067500b9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9d25e7ba-9aea-4eba-8623-d4275c3e06d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_95b7ac65-378e-4edd-bb18-95c7ccf9a066" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9d25e7ba-9aea-4eba-8623-d4275c3e06d8" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_95b7ac65-378e-4edd-bb18-95c7ccf9a066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_3725817b-dd95-4f0c-bde4-98bdbcd4be03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9d25e7ba-9aea-4eba-8623-d4275c3e06d8" xlink:to="loc_us-gaap_CustomerRelationshipsMember_3725817b-dd95-4f0c-bde4-98bdbcd4be03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_802b83e4-47e0-4927-9fe2-913dfc3cdf44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9d25e7ba-9aea-4eba-8623-d4275c3e06d8" xlink:to="loc_us-gaap_TradeNamesMember_802b83e4-47e0-4927-9fe2-913dfc3cdf44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_00df42d1-6075-453d-b065-fdce278b4186" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cdb52807-53fd-4047-a260-8336eac002bf" xlink:to="loc_srt_RangeAxis_00df42d1-6075-453d-b065-fdce278b4186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c45bcb33-9a6f-491d-9531-6a1e11e437ed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_00df42d1-6075-453d-b065-fdce278b4186" xlink:to="loc_srt_RangeMember_c45bcb33-9a6f-491d-9531-6a1e11e437ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b51f35ed-63b0-4aa6-9c9f-52b0bf775a68" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c45bcb33-9a6f-491d-9531-6a1e11e437ed" xlink:to="loc_srt_MinimumMember_b51f35ed-63b0-4aa6-9c9f-52b0bf775a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ff7646ab-b1f6-45c5-a82f-a060aee36548" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c45bcb33-9a6f-491d-9531-6a1e11e437ed" xlink:to="loc_srt_MaximumMember_ff7646ab-b1f6-45c5-a82f-a060aee36548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_cdb52807-53fd-4047-a260-8336eac002bf" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_42e5fe33-769d-4e10-8774-e42646e4a674" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_42e5fe33-769d-4e10-8774-e42646e4a674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a2a25a74-1eec-4608-b2d0-99c472b3fb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_a2a25a74-1eec-4608-b2d0-99c472b3fb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_76211802-fa2f-4916-8631-86e86f134aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_76211802-fa2f-4916-8631-86e86f134aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment_f18c4f3f-f50e-477c-9d69-7e91d8012483" xlink:href="rmd-20240630.xsd#rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment_f18c4f3f-f50e-477c-9d69-7e91d8012483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_e9a9ec07-0370-41cc-b6b9-0dbe521803cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_e9a9ec07-0370-41cc-b6b9-0dbe521803cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_0a3d366e-b059-4820-9701-44d6c30483bc" xlink:href="rmd-20240630.xsd#rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_0a3d366e-b059-4820-9701-44d6c30483bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_0223ede9-e4f1-4981-9fe4-249772f693cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_0223ede9-e4f1-4981-9fe4-249772f693cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_82c11c99-3f36-4a96-9a06-54bbace11e31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_82c11c99-3f36-4a96-9a06-54bbace11e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_84cdabe3-d6b4-4d73-8762-a5faa91ec79e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_84cdabe3-d6b4-4d73-8762-a5faa91ec79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_f2743974-2afb-4b6a-82c4-bee166756d82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_f2743974-2afb-4b6a-82c4-bee166756d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f542dda8-7e62-4d0a-99d8-57e5ba9fb6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_Goodwill_f542dda8-7e62-4d0a-99d8-57e5ba9fb6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0a727a20-d178-4723-8042-7db294821495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0a727a20-d178-4723-8042-7db294821495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_0e8cd388-f8bb-4009-b012-fea70c1640e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_a8579f17-d11a-4426-aa06-dff5a924bd50" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_0e8cd388-f8bb-4009-b012-fea70c1640e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/RestructuringExpensesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#RestructuringExpensesDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/RestructuringExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7f92adce-4181-4477-a6d0-ea010c2ae4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1e83e27d-cf24-4983-a882-01848080b1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7f92adce-4181-4477-a6d0-ea010c2ae4ad" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1e83e27d-cf24-4983-a882-01848080b1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_0262e7b9-c50c-4ab4-b40b-7b962f48aeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1e83e27d-cf24-4983-a882-01848080b1ae" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_0262e7b9-c50c-4ab4-b40b-7b962f48aeb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_34bc9282-1f1d-42cd-86c5-f98113fd4d11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_0262e7b9-c50c-4ab4-b40b-7b962f48aeb3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_34bc9282-1f1d-42cd-86c5-f98113fd4d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember_108c1a64-ba41-49ea-8717-213186bb870b" xlink:href="rmd-20240630.xsd#rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_34bc9282-1f1d-42cd-86c5-f98113fd4d11" xlink:to="loc_rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember_108c1a64-ba41-49ea-8717-213186bb870b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IntangibleAssetImpairmentMember_133e896c-65cb-4c18-a08d-05883f889006" xlink:href="rmd-20240630.xsd#rmd_IntangibleAssetImpairmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_34bc9282-1f1d-42cd-86c5-f98113fd4d11" xlink:to="loc_rmd_IntangibleAssetImpairmentMember_133e896c-65cb-4c18-a08d-05883f889006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_70b2f384-00fe-4668-ba70-10583a32a5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_34bc9282-1f1d-42cd-86c5-f98113fd4d11" xlink:to="loc_us-gaap_OtherRestructuringMember_70b2f384-00fe-4668-ba70-10583a32a5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_40321c07-ea11-4b86-aa0c-e4d970109e25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1e83e27d-cf24-4983-a882-01848080b1ae" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_40321c07-ea11-4b86-aa0c-e4d970109e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9cc462b6-8d07-4010-aa65-57fb3a632e62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_40321c07-ea11-4b86-aa0c-e4d970109e25" xlink:to="loc_us-gaap_RestructuringCharges_9cc462b6-8d07-4010-aa65-57fb3a632e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_b486ea06-d74b-414c-b551-5b4ab70560bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_40321c07-ea11-4b86-aa0c-e4d970109e25" xlink:to="loc_us-gaap_RestructuringReserve_b486ea06-d74b-414c-b551-5b4ab70560bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails" xlink:type="simple" xlink:href="rmd-20240630.xsd#ScheduleIIValuationandQualifyingAccountsandReservesDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_00b56460-d707-4481-92d6-6e46074d0c89" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_de2d710e-6d07-416f-854c-1ab63105a544" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_00b56460-d707-4481-92d6-6e46074d0c89" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_de2d710e-6d07-416f-854c-1ab63105a544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_2e837b78-42fe-4e05-bbb4-ef0c99937053" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_de2d710e-6d07-416f-854c-1ab63105a544" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_2e837b78-42fe-4e05-bbb4-ef0c99937053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0b0133f-6e98-44db-8a04-5bee8beef401" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_2e837b78-42fe-4e05-bbb4-ef0c99937053" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0b0133f-6e98-44db-8a04-5bee8beef401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_db69b6ab-dfba-40e8-98ef-ba693fca7653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_b0b0133f-6e98-44db-8a04-5bee8beef401" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_db69b6ab-dfba-40e8-98ef-ba693fca7653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_fce5c1b0-c77f-4def-88d2-6701cec2335c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_de2d710e-6d07-416f-854c-1ab63105a544" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_fce5c1b0-c77f-4def-88d2-6701cec2335c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_53ad61e4-744c-4344-bc96-07b418e50fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_fce5c1b0-c77f-4def-88d2-6701cec2335c" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_53ad61e4-744c-4344-bc96-07b418e50fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_356bea2a-41d5-45ae-a599-eee9468bd7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_53ad61e4-744c-4344-bc96-07b418e50fa2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_356bea2a-41d5-45ae-a599-eee9468bd7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_26b0c779-314b-4d71-810f-38e51a0485c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_53ad61e4-744c-4344-bc96-07b418e50fa2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_26b0c779-314b-4d71-810f-38e51a0485c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_48d7b0a3-5cea-4845-bf51-31083a100d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_53ad61e4-744c-4344-bc96-07b418e50fa2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_48d7b0a3-5cea-4845-bf51-31083a100d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2d67b368-26db-4f2b-91b0-81261c16f3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_53ad61e4-744c-4344-bc96-07b418e50fa2" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_2d67b368-26db-4f2b-91b0-81261c16f3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanPurchaseRightsMember" xlink:href="rmd-20240630.xsd#rmd_EmployeeStockPurchasePlanPurchaseRightsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_rmd_EmployeeStockPurchasePlanPurchaseRightsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MichaelJ.FarrellMember" xlink:href="rmd-20240630.xsd#rmd_MichaelJ.FarrellMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rmd_MichaelJ.FarrellMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_JanDeWitteMember" xlink:href="rmd-20240630.xsd#rmd_JanDeWitteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rmd_JanDeWitteMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_BrettA.SandercockMember" xlink:href="rmd-20240630.xsd#rmd_BrettA.SandercockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rmd_BrettA.SandercockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_KaushikGhoshalMember" xlink:href="rmd-20240630.xsd#rmd_KaushikGhoshalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rmd_KaushikGhoshalMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MichaelJ.RiderMember" xlink:href="rmd-20240630.xsd#rmd_MichaelJ.RiderMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rmd_MichaelJ.RiderMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PeterC.FarrellMember" xlink:href="rmd-20240630.xsd#rmd_PeterC.FarrellMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_rmd_PeterC.FarrellMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_01.jpg
<TEXT>
begin 644 image_01.jpg
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M]<?"[D^&TZ>%RY\#C]]"O:(S]A,>NF*W#WXA36XJ&DE# "QM)Q/EX%UY3;_
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MW_P1#TV86'/5@@M=R#6+RM@>WQ+_.<-\JM=R,%N!/QF6R.4/-.YY2T5<1&!
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MO2ZC]CL)&+O)@!57G3B=+FF14O+#(89 K7Q57U2=^5T[RH5\_V=0$BSM2^I
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M$Y8<S<*:<P;LN.7!F53@"OWN72IL.I.<P6K+)')8=3I>T\@L.)A06?SGD2A
MF?PEKX3*I&4_!#5#>:"2$Z6*><C?):(]0C\%0B?R\A,5$M@$ AP[RR^2Y1;.
MT@[G:SR_220R^1Y(M;AP)\Z*G4?TF#K_!EY__SHJU[F+XI4OH7"E$.2K'(]B
M3<RH_Z()/;ZPX(OEP((S;FRY[\;A)&#&*1M&KHE#KW%'4;C]-6@:782F]DE4
M>B4$O7[2XJNM?IQ/MR#"X4&FE$EN62FZ(9\52(ISR;02?.3JDQ!7-4-J)O^8
M49DGYS,$$)3'6H)D*BC_>2+&+M?Y!\G4(PF2J3\39NIO(E-.DBDS$F#PQR+;
MDX@4:S;"TF-Q+3(6QZ_'8<6.RYBQ["+&33^'D=\?QHAQIS#\^[-X^ZOC&/3)
M+O3_8 MZO[L!_4>NQ"NC-^#]2?LP=LU)3-I^'G,.74>:'4ACLH54:5E].E:?
MD"D[(;LS/"13HK2/,9FR*B1*$,%V*D0J"59?!K+(&B^'Q6+#OFOXZH<#Z/+<
M1#1JMP9/UPM!A9JW4;9>(DHW-:'1 #>>'^7")PO=6'@..)S@PV6=#[?(?;;'
M>##M5#:&SKN+)WJ&0M.<A*K6291_\0YZ3LC&-SO\N&%P(]KM0Y:426Y9*;HA
MGQ5(BH-DZK]=@F3JGQ#ET1(T0BK^+R+7R(L_DW_T?5#^11%C1T/EHZ5V>VUP
M^\QP^\TTS3(G)3 OQ42'DFEU(%%K0&1*%E+T-N30. <& 85"N7F>D# 'G:E<
MC ;>10(A!O(Q%1\=JPHI)!GX]#-O?F7E&(V_%)C7 [^'^71YE:V.O+E?/S+^
M<@Z))H_SL&P]OL */Z6 'DL1,B7Y%_RS9,H#%\O-[M,K</@-])$!4B5PTJD*
M9-*TP9^,-&<<HG1QN!:3@)UG+F+9CC.8O.@T/AR]&J]^M!J]7UN-=OWFHFW_
MY6C5;S6:]%B":NVGHT*+GU&BWG<HV_)K5.GR YH,FH5>GR['@%'K,7C\#EQ+
ML.-FL@MWTSR(U9%8,0M:UI&%";4PW78FW$U[I=0T;8MJOV1#4C_U7Z!DBMF6
M5V5T-Q=_)YF27C.9?R20]ZIJ*8L6!4R[QVM7],OMM9(@AC$_0J1BB'0%>G<V
M(K(]6'_X,L;,V([.@^:B6/7W4+S*=%2N=1,UFD6A?K<<M'C)C\%C@>]6 O..
M"Y$"[MOE(3%.Q/GLN&3R8<T=/88O#L$3O:.1K]4]%*AW$:7Z74?7[S/PU58>
MSS80R_*1GBF_E^7I">B_GZPS &D@$E 0RCQ#IMUC)L=BKM3,_2,RY24!DZ69
M7CD_*(^S!,G4_T/$^'C8>&PV&\QF,TPFF3?RKXM<P^ETPN&0S?OHK/Y RH1(
MR3%!^3<(#1]M,4Q9C-9-Z=#9$F!P)"''GT+WED'7GX,8O1_K#UW#B!\7HDV?
MK_#+O),X<5WF9N2NR?(Z8;"ETQF9Z$]I36DTTY,38=(_KG,;Z#SIA@*0'.KI
MN+3,7S8=EI;ZQPA9" 75TF%UPZKW*N6G36%YY 1LOA2#. ,/#]-E @8]C^.Q
MCW<,((XP,,<IT$/'MP*59 CDO3170OJCG+(*SV-"BCD6:=8$9#E3%1I%RDX*
M)9L,!*Y(%4,F'>;E"&#= 0MU+09-NZ_%4TWGX\EJTU&NX4)4;[\53?J<1-<A
MM]%BP'4TZ7\#7=Z*0;.!8:C:Z3(TE3= 4V$3GJQ]$)4[WT*M?M&HV/DNBK:\
M@&;O7D67+\+QTB^IF'44.)X&/&!:R1<0R;1&\GT<ZTM(@(Z94O?KMI,MN7UN
MN+PNDF8>J))E<?3R7O WUJF5]]%3E\PL6^D ?=@;)FD0'1-^P7;FRLF"/2L=
M22D/8#0GP^4SL.4&EC]$T@S//P?T&7T0-5Y>!TW;S2C4?2^)T'9H-&O1^0T7
M1BWT8^L-()SW2V8VU2=36EE"5N\=9-DN0NNS8O?Y$/1X?1(*-0Q#D9:9*-W5
M!DW](ZC_9@(&SP4IG&RV "0IM6^&SI$!O3.=Q<3VPY*59RWZE!VIV(YH862_
ML(S,*-AMU()<O5'T2"504LY_AJ \UA(D4Y2'$=N?> 6U)\GK]2ID1R#O\W[^
MWZ"2)KF&O)?S_M%]_DBP@O)_%!IF(5-&.GRC+0MF=RJC]$R:0;ZG.14R%9;I
MQ?)=%_#V5]-1MO9 #/]N';8>B7Y(IHQN.])U\;"YY?EI_(;6WFFWPN-^/*V>
MW^^#P4P'X#;0X ?(E%]<K%\@0PQ")G+)E,4-IX7Z3:?F8L LY9@1[\-]DLW8
M,"/2DVQPV^@7Z(@]LC3];W2\?[_\:V0JVY )O46>JV>'R:.%B434Y,M!ML=,
MLFXC'$BQN1">F8.S(20YJ^(P=L8#?#CF.OH//8E6?3:A1>]M:-5O/UX=>1\C
M)R;@YV5:K#QDQ.*]!BS:9\"ZTU9,WVK&%[/UZ/Y."FKUN(<J76ZC2O=[*-[T
M'(I4)6DHM1HE&RY V79K4;7?+KPX_@8F[=%CXQW@$NOKNAZXSSI*8IIE>8!,
M<[8P8P*SVPFSC8&AE1303C(L!$;R*:K]_P&9<C!-9I:IC?>0;;%D5)E)4C8D
M5=8ZR*O#!I^=U-1NAMV1R>-RX/08<#LU&Y?CDK'O=@*^VY2"%N^M0;E.,T@Z
MIR/_4]-1IOY.U.L4C2]F^K#B!' Q'8C@]5.D[GAI@8.TR.T/A<,;@FM16DQ?
M=1[->GZ%@D*F6F6A5%<K-/4.H^'0!+RY($"F(HGX7#)E=&?#Z,E@^@,P.I.0
M98R$V9E(@IK%]F""S9Y!6Q%H3T$R]=\A03)%4<G1/R)4?Y1_ED@)_A%Y4B7O
M;__,O8/R3X@8:#H2$YV*Q:&%W9M.&R8DZM'>/;<2O)B]_AP&#9M"Q]070X:O
MQJJ=46+'%>A=-B1E1<'DS(33*XZ6UDZ@>-;'3X1,99,<VIW9XDX)Z:N0%7EZ
M)>*7E5P>>E499K'9/3";O##JZ'PR@ =W;#AU) O+YE_'GNT/<.UBHC+\)[T)
M7I[@$(?\V.KNOT:F4C(3D&5(X]?RC#LSY.EO\@2\3#+/+!\)N,>!.RE6[+\:
MB;D;KN'Y(>?0\Y73Z/;2"71YZ3!Z#SF)%S^ZA*'?WL74-6:L.N+"@5O C53@
M6@J1!MQCN9^,!M9?\./;)3Z\\%46NGV8A YO1^.93I=1KOX^%"^_$IJ*LZ"I
MM@B%&J]&@\$'\=JD!(Q>9\'RBQ9L"W'C6((/(20G5'5D,$]"F14*[;0CQZ*'
MUJQGW=FHUO3PLL), @47RT">;_<WUJ?,MG-(<,*"5>PD[^\D 95'Y?C-+&2%
M94EZ G![2%)U.D3'IV'ML7 LW7\'4S??QN!IH:@^8#F*-IT.3;F9*%1U(>KV
M.(:7O\[&XL-^'(WP(]SN0ZS7Q_S+FD 382813F;V8A5LV9^(D6./H6;SKU&@
M?BR*-->C9$<[- T.HME[\1BV5$B4!]%D.S+UW4X],?FT,/JR8?%K8?9G0VM/
M04I.#'1VV;9!VE1@:H$\P%K:A=(VY%$_RO@E(81*A9@444%!4!YK"9(IBMIC
M]*\0JG]6Y%K_6X]3L#?J;Q :*1F6,I,(.-TY_,@H$9DTI?+05ZN"H[>!;V=<
M1*M^-,2:H1CTYF',WV!0W2IR7%8D9H5!:TV$U2VQO83,@L?3Z@F9,IKH$MST
MVM#2C64K<- Q9+ET,/@MRE"5FO\8EMV%F\#.P\"DJ>%XZZT]J%5K#%Y]:0ZF
M3]D+"SVS[.KML+B0&I_#*/SQ))F!^LS-]3]!II(S8I"E)YDDY99'1*N0?;R%
ML,18O5AW0H=/)A["LR^NH&XMQ9-E#J%ZDPOH\\8=?#?=C=E;W-ATV8J;/"G"
M+L-' :A[@@MDJ.Z!TX?C:0ZL.N_'O$->3-MIQT>3;1@P,AXM7[P"3:U3T%0_
M01R%IME^E.]Y!75?OX>NW]S%F[]E8_06.U:P#B]: \-_R;G737+;D&S3(=6N
MA\TK*9?^FASF.YUYY5'.>+X7+__WB#S3,4#H23@\>GB<.7!8L^"S6."WLPZ$
M>,CM<Z'5 X>/)6+2]*OH/.0PNK]] IW>/H<JK]Y&X:9;H:F["9K&1U#QK52\
M\ELBUET-P3V''W%>:?4.!2;$L):N\]T-^"2/RCY5.1CUV5T\VV8_RI68@?S5
MC"A<SXOB3?W0--V-CB-B\.T&'\\WL-S2B52242T)639?#;RFAZ].:#TN9#(
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M3M_ARX33GX5TFQ7WDA-QY,9U//?1&C3N]@.>:?HENK]] 3,VY^#D Y83B8Y
MM@(PL6GG..CP;0X2(0-R2.S-)!(.3Y("JRV6]B,:)F,T+*8D6,Q),-GBB4R8
M'#D\5@^KRP&;VTDX8+*&\G,D[#X>PT#!X+4@B15S+$J&_K3X<F$LVGUT \6;
M+D'Q9DM1KN-&=!EQ'R-_2\6B/59<C <2M(#1"MC)J+RR%X:'C4:B$&7CI[])
M2":5,7@'"8;3!+O-0)N8AE/W,K'F:#C&+SF,=N^=0O7^.U&\S7*4;'$3Q5K=
M1LD.]]#NS60,GV'#;WN BV0U-V2UJ=Z&9'<BLOV)U&F2%2MUW)X#ARL5%D\<
MR6(JP;;L-<%@-F+'SBQ\-^8V6K281K)V 65;7$?1>F>1K\$>%.]U!54_2,.F
MFX$M)I)$%UB!;CWMOT'V7P_T3!UZD(DW1A]&Q?HC4;/E+^CVT@&\]W4(1D\)
MQ9S54<BA_IBH+T*H! [2/!>2%,C3&'Q\)_"[&%BS70F"\GA+D$Q1A,@(N1%"
M],?>)"$ZTG,DQ"@M+4TA17\4^5U(EAPC9"DN+@Z1D9%X\. !0D-#%5RZ= GG
MSIU3$!(2H@P3RGU5D7L'>Z;^32(^T<9Z(0=R>[+Y,55!8/U:8+KM^B/ V]]$
MHVK+8] 4/8P675+PWA? P8M **LXPR:/HI5'@QAYEJQXDGH7R(3=QT]DUVMM
M+!U,CE,QW*)Y6JL78>D.;+J5C?$;+^#U20=0Z\UM*-#P>VAJ_PI-S17H\8T6
M/V^RXT@((W(Z")D7PJ*!G@[8I N',>LJ=.F7Z(BE=^KQ$YG5HC[P^G>/#<I+
MIJ1-"KD@K.XT$H\T12?"LS*Q\^Q93%BP" UZS4"3?K/1Z;5U^&D%<#P,B&,9
MR8PL@9/E;^.U=&15.H,/!M%-UH.,O*IS9AQ43G(HZ$ERS(D\/L4/3Q9O:V)B
M;+R_]&)XS 1U4(:;[6OYNHU?'B8"^BE;@$A/8S@YT9Y;P"?S@*=Z'L.337=!
M4VT[*G:[@2[O1N/#"5E8R=.NW =22$AD(TW9[TFYAU3EWVF&K,PXB8DHDCRD
MV$BB$O8@'M.VW,<'TT^@Z_"E*-;W# IV/PW-L\>A:1"-(IUR4'&0!X,G )-V
M #OOR$:D <@#D($3 =@B N.7TF25;C>"1>=F?LS,6VRR'[.6&_'JAR$H77TV
M"C0_ $T+VH#&!WFO!:CP[@&TF!:-*ZR+,)9#JG#*=(*W<+!,9<^I..) B $O
M?W$+Q4I]CB=*_8CR=;>@T;.GT/OULQC^W67E>8DR7"G60F!C,&='M *Q*1ZE
M3YBDRNU7GN(D",KC+4$R]0]$2)7T*,7&QN+FS9O8M6L7-FS8@#5KUN#V[=NX
M=NT:+ERX@*-'CV+[]NW*]W/GSL7//_^,,6/&X(LOOL#PX</QU5=?8=RX<?CT
MTT_QV6>?8=2H45B^?+EROI S5=0>L*#\&X1.P4=;;:=!M$ODCV1^)<N:O>JZ
M)5P(!R8O-:#OT$14:Q*!P1\9:63I6.@ LWB^42;#TNC)XV=<BK%^O,F4(F*P
M<PVW^.>3E^]@YJI=Z/;QKZ@]8"0J]!J%)[O/1;&>\U&LVWH4[W(8/^]C%!X%
MQ/.<<&8]U4@G(1T+=$XRC=KKCH9-?YMD[?$,K?]5,D4:I! I-W7BM[5K,."]
M]U"Z3GU4[S01W\V[B:,DG;$L"D&BD\3)(9L\VF$E4U$O)UL-*8\!)%PL2UEU
MFAI-ARL$0"8QR:)1>96U#D)LI-[L/$G8@&Q+;Q'%)K!'@=NS#W$)YY"8<@DI
MV@</Y\"%D&]MN GT^3(.-;J=@:;T"FC*KT7)NNM1H],V#!N?C8U['0@A\1.B
M)V3*Q_LY=?Z_M6-*Z0K+HB*13/E))K(R=#BX_S3Z?#0/5;J-(NE[F01G*TKU
MN8#J;T>CU/->]/G%CW'[@=LLDWLLVQ"^WB=INIGHQ)V$<$0FS\>=R&F("ST"
MZUT>( 1(RE'R0>20"$7$.[#KX%U\^/55M.ZYCT$4@X8RBZ&IM!::ZENAZ;L&
M]<?>Q.N['FU7D2IZ0/V7\3TCB_YX,DD6+W\ZSH,Q"\THW6@&BE2=A;*U-J%@
M^26H4&<N6G2;C_/4@W@RO2"9^N\132!N4F*G7*B?7?!X!6Z^E_E - (>F2_A
MA9V*+*M8Y1%?TNC$*$A#=+(ARMXS8I-$@17;Q,]>*I]BG'(5^R'$: ERGQ46
M:,&RXD%/PY;#:"(%3D\B[*XX&AVOLA&C8HW^]!K*/]@<=F5W7Z-=#XO+Q(#.
M1 4V$GS/ZP86LQKH) 5Z!3YY-I*;<!JA,WJ0S+ BG%'\VM,YF+(Y$I_-.H.!
M7YS"<R./H?_(X_AD1AJ&3TO!!Y,3\.X/87CUZQMX8>0%]/[P&#J_O0_M!V]'
MRY?6H5GOA6C;;SDZ#UB+%L_.0<MN4]'I^1D8^<,Q;#H4AQO1LN]1P&::O3YD
MVYWP^&G8_5:X?&9XG!:6)QN<RZX,6WEI@V3_)%GVSX0SS2P *12/_,!"SBT+
MJ:M'Q2/=R8&1>V7%$O.K0'D66VXKEM4E*A0KKH(6B)#SY'ED\L=:4&XC.Q=[
M9-:J@Y ZX664<7^I<QX@\S"<?,_ 4_E:?A9ZXN9][5ZI8[G*WR.*WC%[;AI3
M)\O'29UR,4R5IZ89^4X0H_/@[#TK-A[28<;2+&S<;\/IZZP#%I$$S5:GCX:.
M]>%UD.3R0EXZ+X%//%X@)O;S-V4%N>BV6@8">:]^5G5;@5JN-GAYCIOEYV8!
M*?.XE>O(A40C!.()Q),2>8>?!'))%7+9O)\5L!U[J#<.9D9Y3(R1.F%2)BO+
M2L4$7OKL/1^F+KV"H5]N1>U.=&*M9Z!^]V7H^N91.MF;&#L_#+]MC<<YAN+1
M>B?T+(-LEQEFIQ4.ZJ3';V/66(]N/3PVV?59M#BWBR5O6M2L_RZ=\E]NWI3R
M$+T4R/O<:^0E-C+,IFYXJ+(0@:)9 = JY4'@ =6R7_7#B^1M%')J;EVY6(=F
MUJ6!!,DI.U;+ ^.D+B1ITLX$3GZA+-MW(YN*=2\S"[NOA*+GQQM0J\\4/-GD
M,_0>?@"S=B;@8J(?.K;%'$)6A#J<+CA=U'P7]8F7", +/[_W6UF.1B/)BQ:&
ME"S89-6OV\'C92C/"PL;D<#&XQV$AQ#CZY?]F(PL+R<KQQ'#P"$&QLQXF+(3
M83&D*"M0!5EV(T(RW=AV1HLOIH6A0;\3*%![*8K4V(J2-8^CR0NIK&L]YFVS
MX0$CC&P6I8'WRR939E8#Y210RXUP46?M=@^L-B?;L9'M689(Y8'$TKJE-S=0
MZ@*U=O14C72#'?%9>L2F:W'QF@Z'CAEQ_+P+VX^ZL&!#)CX<?1KU!NQ&Q:Z;
M4:;]&I+Z\RC6XS)*];J*KA/]&+K&CS%'@14/@'G7G9AQSHPI>S,Q:4\&INZ)
MQIR]YS!M^PE,7A>&7Y9XL8A!P++CP,KSP'R>-WFG V/6Z/#NU'"T>_<&JO8X
M!DW51<0:$JD-T-3:C$K/;T;/'^]B]%X&54RW((VZ:M$;8""!3;?EX*[9BQ@&
MO3>R/%AYS(6>[VY'W4YK4.J9=<A??#ZJU%V)SKUW8L-VDKY(DCCF74L=,CI2
MZ(^BZ(]BJ<[9U,C AKE^EJ770KMHDI(*V-L U'ZW/R+W=]DJ7HR<0(R)6D=2
M;[R4,F>4]Z4+%+=&&Z9X<072'!XB3]VJ]D4">['T*@(#DA)VR%Q?^3WW>+F7
M0*X3%"%3@6=U!1XT(%!'>6DTW6(XQ0G+:C92+3H8@X&\6N^'@W9/)4N*#3+Y
MD)9H@B';!KN114\G*SW_'AXG%:J,">>V,F6,6-ZK#58QC/*#?)G)^R726,?#
M[KE-!;Q*8G21T9L++M$C,7*YUU&@*@(K5.I4;S8B4Y^)=%,RM/8,Z-RR)#Z-
M2*<J\CO$0^=/A,['5V^< KLE'BY]/)Q940B+T>/\;1K+XV%X:UXZ.HRZ@Z=>
MV0--^RO0=+R&_)UOH\R+-I0=:$79 2:4[YF!XIT2\&3'&!3J$HY"W2)1L.L#
MY.M\"_F:GD:11F=0HOY9:"KL0OZG5Z%8_17H]LY=_+J!T=@]C])@I8ED>[R(
M-]OA]!D(+:R>#!)(1L V'?F247FXN(<'NNG+%9\N/E+ZYEW\PLDOY+D?N89/
M.KA85<JD4B>9E]LODQ]E[V/I"<N-N7RL%"%B"G@=8<,"I7]<()&O3$9-9KE*
M5.7@GZS_DCDFK :2 )=LJB++;\3_B2\5_\^ZE;8M]S>QKDP\6+X6-TGSRP#;
M"(,[BV19KO+WB*J7 N%[HGH"*Q,I6RT*Z,(4&*B,R0874HQNI)-(&\DSK4PP
M.<,C71-'JDS (KPRAA"OP$\"+I&\<G%YE3(0Y+[WBR.6N434:[] *5-" @6>
MXV#YV2TT4CQ.X2).N9#: R9]"RKQY05%N052;"JDOM4VE!=DW'XG]49V+?6E
MDO2D4"=2$$\="[&X<#;9CM\VFO':YR?0LL]ZE'YJ%:HWV(EN?<]BU)A8[#G@
MQ7TZ JG>P+XY)/;*8OZ,W#SD]N^)OJCW5#(KA$CTBB>I:93TJ7B8/ODO-V^*
MKHE>"N3:N=>0RE.O(21"8>8$"8JR_;I 83JB74*6Y6'#*BP*W(K6Y5Y$2*W4
MI4"*.;>N["Y91I_.OV18A7S*S&&YM"1#]5_2SF1(WN7" ZL;FVXG8\3\4RC<
M83,*MMV"8L_NQ&?SXK'^L@FW=70\='129O*@;.5> KFF)$<@W4 VOC&P31I3
MX37&PJ6+(H'/@-&G1XXK&QDTG.ELEUE,N\[MAHEU)Y<0$^DWN\GIJ1.2=:6X
MF&:) (S\3G93]40SRS'PLMX=5"P;]6''N33T^^8!"K=8@/Q5:<]*78>F;@(:
MOI2"UR=D8W\4$,E+4%N0P'L*:7J8=BFSW#JT42&,M.\ZO05&3RJO3Q+J-\!$
M^Z-SD)+25F5:[(0-Z68;4DTVA"18<#$T&4=O/,#!*W<P?6T\OIZ>B;%S#7CG
M1SWZ#$]$]6XG4*SM!91Z]A:J](]"J?[W\42GB\C?Y!"&;K#C0Y*AD?N=&+'7
M@==69J/?;PGH\L,==)\0@MX_A>/YGQ/1YX<8M/TJ$]7?=Z']#VYTG>Q&S^EN
MM/[!@\9?ZU!G1 JJO!^-,H-NDJR=@:;)#FCJ;PEL^EE[ ^H]OQ6OC;N#J3O=
MB'6X$$<2'4]BF^R*1K3K/B)<X8BA3XQF@[VCM^/P?1\^G7H!75[>C9*5UB!_
MD3FH57<S^O0[BU^G^G#Q"EL+53R3345G2H7)%DV?ED#;)]UF8D?8QJE/7H,3
MSAS19=F9/8E(),3&R.PL 6V-/XXJ+) ]P,1^\WR9VR9@&A_6E>@U]8)N1'$+
M-M["PMNYW?+ ZP >MD.!VB8$N39&I@2(I1<X6.F!/C0ARH%.%85,B3Z(G1/(
M=8+ROY,IF\,(JUU61P26[4M *8Y:G)4*_HRT)"]N7=/BDP]&8^&<=3AZX#(R
M$ETP:7D5&B-R J5717D&%"M<QIZE>UO(EMA$OV)<U18K!E6-"R)X[_O\Y3:-
M"'_+T[C%3DDOC5*18B^9-M$%N\O)2,[.0VP*9.];&PV_P$P%UE,1H\RW$**]
M@!MI)W E^0BNG]R(*YL7X_"B*9@V8Q5&_[P2'W\S&]5?WXD2W5=!TV@J--5V
ML]$=@J;Q*6A:1?']+6B>(DDJL V:_%NA*;8+FAK'482$JNCS"2@^.!W%7D]#
MA?ZQJ-[I/H_=!TWYQ2A<>28:]#V&K^=$8M/Y'"0RT6*OV204F-R9C$8S&"!G
M!0I,Z4%BIG/S+D[7(^/W]#V.3 >\;*1*JY%)G;E^PTJ#EY'C162<#JG:-.CM
M22RF_QN9\K(QN_E*D\RR#"RIS[U-H(-!;8C2J,2X,XU2G0X>H.-G=;61^! A
M4^)D;'1X?WO/E.@(\<^0J70KRXO%D,U$"I&R\]7%STJ>Y$0ZT4=D2@RAS)R(
MY0W$F/&M0'1;SB&$5\@>A,H^5W8;W XZ>YL)+CH?KQA!*5]F7^G599$K1$JY
ME]SL7R13?P;99,LG%I5P)<)M#(<IXRX.1J9AWN$+^'+^-K1Z?CF>:O$S*C3\
M%8W;',6'GQLP>Y$/%ZZPSIAV&5'Z;R!3-AJB3-J:;-[?)FU(ZD&2(%F4Y$@2
MG3Q?=,!FPX*#$7AWVGXT?NUG%.BT!77>O8M!,QS8'P:<H<FZ167/<:0S:##
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M19[^3@;NS]MC\3<*-95I",!-_5-[*@)SYG0*F(-'8+X%LH1=AM\$"I>5>E'
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M![]<,6-IJ E[DLVX9/0APN9%JDR14<K*19)O@]EE8AN6 -.B(+! )1<RW*"
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MWZ+%K.T&3-]FQ+2M!ORZ18_)F[5$CH+O?G7CJY_L&/&]%>\QT/_@)R?>G>!
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MKU>8$FT\R'(CAVG5^QRP^DVP>K.1HHV$WI(.FTN>0<@XC(PTE2%2J-:']?>
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MM$XZ6S)ZFXMYD/3307CYWDG&:=!%,QWR(%2MHOUZ9RPR9+-:IQXA^D0<"$W
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M&I]$V4[7T*CW3?3[/!5CEID1PJ1ELCWE)5,^3SJ=DT0N]Z&S)"$R.16;]QW
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MVV VNI45R\JY/$^!]*/SV@K$*JH0I1:(4JNU+DKV,(00Q:#R*1!SF#N>#9E
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M^)@&]G3\HVKS.^F [1))I9-(NWBN#TD6%PV&:,^_+BJ9DAZH?S2'2C14&KM
M(5,JQ JH'C^O91#K2<ASY\1@>I@T^5HF:F91A1Y0;?:=I?-8%H-^'U,?6NQ6
M'M6CJ4R'5&,QFK]Z#9].3L6"K39E16HRZTTF=\HNYF(F56.9Z4A"FC6>SC@>
M27:WLM1:HDFA*-)-?RG.@C?'W\>@;ZZBYR<7T?K-<ZC2<SM*MJ'^U5\'3?5E
M*%A_#9YLOAG/=#^*3Z9E8-EAX$P,M9OU(I1"(!NLNMW9,)N3X;==8V:D9Y2>
M5XI<A=I6!&HYR'NUXB0L?]BXY*I"HG0\U4RH,Q,?V0)1-?5H._\L)#U&DAZ#
M+Y/$+EOID5-_EZ$;\GAEFPCIR7+P5EHVOBSZATS>1OF.%U6/ER8OK5@@9L#(
M]IUFLY*8D932J<A<**'NLBNXE_>2LSP>"QQ.,\RL/^79T+R>W%?F/,F2^',L
MDE7;L_#AQ&NH\>H&:*I]B=K]=Z#/EXGX9![0>- )E&FQ DU>.(RU)W,0PLM*
MOYRD08($N4L\R_Q>I@=G(FSX>&8X6@_9B)(M)T)3:RJ*ME^)TFP7E0:?1\?O
M4_#R+".^7$<BM" 'K__R /T_/XS!/US$Y$TIV"-#+[S>ALL^?+-$C[9##Z!D
M@U]I&[Y34*_?.CS_Q66,66'&[IM^I;ZOTIP]/QGH\(T%]=Z,A*8"R7:)MU&^
M]A<8\MU^+#J@QZ8SM!F'@,7;@"DKW/AFE@7EFB[&$S4GT'9\1ALR =5ZKT3/
M$2>QZ3IPF^5RF0F9L0FH^^QAE*Z[!67J;46^\GMI$_8B7[E]:##0BN>_<N.=
M*4#7SX'R[60_NX/0/+45I=I=0IMWXC!N56 H7$B4E%E@!M(5)&,A-6D#;,X+
M)%+A\#JCE44'@:U +(BT^W"6C6?]I5"\.?,FNGY]&/6&K*'=W4K[NXIU)"OU
M9C/MRU"L\4:T>/4(AD_78M8N+TY$ )&L:VW>KE:E=XBZ(5#("6M/X#$RT)5G
M6V;2Q\AQ3*"<1OU0H>A@+J0="V1C3[7'2@%U285P,H67\7ME$(00G5/-C;0/
M%3+3S\$&)Y! 2@7_>P35??T1>8_);1QV*J2>=2=\2*8'&'EOP9[S-HR9'8YZ
M7::B2/.#>/+9VZ@\) M?+#-A\1FG,IRMNM' +"F6!PF;7^G=E99&*!/3^58%
MK_L_P'P&Y=](IA3VS0H62&>03/!6=DNF<DDE!!@ZW1LKQTG&Y::QDQV?O5X+
M7#S8X9 A&T:29A=L%D:V<AV>_Y!0_5O(5#S3',GD,"+"?1YZE[C#2QO9"!EM
M&K58?BH!WZV\31)Q$!4'7L 3G0X']H&IP\;<8!T*M=B UA\LQ_!E=S'WG!;7
M,I(0:[,@VROJ&"!3.FT,PFZ?P\63>[%J_6&,GG:2T=56]/QH+QH.WH<RSRY!
MH2;KZ2"W0]-L+^J^'HWNHS(Q;*D>\W::L/V\ ^?)][3,5SKS&YWIQ=+#$7CO
MIVUH.W@*"K<<BOSU7D:)YE^BV8OGT.^+.(Q9E(/C5]U(8G;UN:16*9.'9"I"
M(5.22IGZ>^"&#I-6WT;?]Y>B4K-)*-UP(DHUGDQ2M0AM!JY"KZ';,66' 6LO
MNW",O#,AEBZ5CDXE4Z,G7T#'?JNA*4F#WVL[\O5=C\+/+<'GQX"STA,MMR;\
M#II3:P+K)4"F= S-4NU>)4+[9T4=VE.'^81$J>__3$1#_Z]D2HB4I%N6*NOX
M]=4'6JS?$XDO?SJ'9Y^?C:K-:<PKD$26^@U/U%J!RIWVX(.I>FPXZ<#5&"^B
M:=AD2;N0*=D8T.%[1*:D1\KLU<+DT3*2]"%:9U3VI=I[)1';SD9BRNJKJ-M_
M#:IT7X**G9:B5)M5*-IB&0HW923>< -*M-R)&GU.H\V;=S%D?!86''#B"..!
MV^+H>3^53'E)8CR\AU,V3_+>8]Z)_P_)E Q;"J&R^>5AJWH>*4M%&$#E_F[A
MI;-(GDP\R4A]DKEZX=$>1,1Z$4O=^2.9RG1ZD4*=D9:LDJETNPW9EG28'++Z
M3PR!2J;HG!T&YMU(NV)1B)0RNL_K"9EZ$./ OA-I&#_C"IX;O!2-^LY&T8[3
M4;'G G3^Y"K>_M6*P3^;4/_YHWBZXT:\^&4DCCVP(9%UJI(I'?4ND]AQ(0)3
M5AW&.]\M1/5.4U&FY004:_D+&KQ^ OW'A6/@I"0T_S(*-=Z_B6I#3J+F"YO1
M^J/3>&/*?4PAD3L4KL/12 <.AWDQ9T\2!H^[A.:O[$!IML."Y;Y&01*I4JWF
MXZT)X?AUNPX'(SRXSH#F$LOH:*@/%3N<1)E.9U&L P.S*I_2'DQ R]=6DTAE
MX$*B&R?"_%BXU8^WOKB&+J\<0*WV:U&XPD\HTW@::O9:A,'C[^#S!7&8N#4;
M6TDNCX32 <M<K1U GZ&A:-+C JJU/H3\%?8I9$I39B]*MXU%S;YI:/12%BKT
MC$:1>F<96#"X*+T&%3I=0]>/DS%E*T#S@ECJE)19/-E&LO\*2/T5,N7T72/7
MB:=]CT9".H/1R*LX<>D0%NP_@1_7[,8'4Q:A_AO+4:GW3);G]]!4G<] 8B'R
MU5J*HLUVH6;_*^@T+)*!91:6G7+A<(0?$50,6?:OEP!+B)3+"8^5>F#*@->F
MA=_-!.4A4UX&\9:<9!(A)E)L@YS&\U7\_SV9$IXCX_C\3@9@Y/GG,IM"]K 3
M(J5G6H[?IEYMSL3+(_:C=-/]*-#D#(KT"L/0J?&80;)]F$&OZD8#9(IAG=);
M1R536IK<A"U0?E+!:_\/,!E!^7>2*?F@S$WB^2X/W#1^/M$H&4=0!XL5S^;F
M(39^+68RH%ZR?;V7FNART0PS3'7P7'F2NX]6T"^1AC00F<2D['A(Y-5T16/I
M6)6Y+[P%(<Y6G8T5F%"L/DXD'4Y_$AM% JR^6%B\471N4<AQFY!H-.-LZ'U\
M/OLF^GYV' T'KD21CI>1O\5%DJB3R%=_+PHT.H 2[8XPNKR*&2>TV![NPGU#
M&E(],JU8FH8).28M[C^(PN[MY[!TX79\_>,^//?A,;0>N!Y5>VU!\4Z,LEJL
M1KY6.U&HTU&4>/$FGIMBQ9=;@*4T:.<B?+B?YD.RS0>3U86X)#TN74_$QQ..
MH/V+TU&YU1?0U/L<A1N/0O6^BVB84_'=.C?6GB7I8AN0X0NCV0.;3-*1YY>X
MA;!JD9T>!JW%A R[&S%:/69LC<60L2=0L_,O*%3]%Y1L/ ?5NZ_#Z]^>PD>3
MKV'LDG <8V.[0AMTWT1GEIB#S+1L9&4;2/!\F##C'+J_2$)882(*]]V/<D..
MH-8GQ_#311(01CS*= &I#RNC'#.9F"L%=ME3BU8HF_JA[*_T3XK4ISIG2A69
M'R5#?3J=#MG9V0^'^^38P#Y3@=5\?D4A<O6/!D9LE@*9'*> .J22*1(?45F+
MS8V,' ="8FU8NR,48R>?09_7-J%BG>]0HCJCO*IK4;3V1E3INA]MW[V$J7N!
M\W%^)-K\R"!+5(:B:+#3+7J87=FLAFP:.2WS;R&$8%B10GYR,2P#6T]&X*?%
MM_'=;Q?QQG>'4*;; A1N-17Y&TV%IL9LY*\UEUB&_+Q?A4XGT6'H [SU8R:=
M+YT?.=)MVCY9)*&3O9UH^*S,A]?+R%NV G"3I7BEFU!6(9'0J@U5&7-@OA4P
MP^(!!$HTGPL9:LAMGXJYS1UV\/M)HG@?!2SK0) D#D+6SJD+3-1U/K)ND &2
M#/-Y#3 XW=#9G<@P.! 68T=,D@WA,3;<N&W%@<.9.'9"A_.7K<BBSDE/E9:W
M3,UFV)-BP=U4D[(B4N;_&7G?+#K+3#I*HUW:MG@7YMFO@\>GI1[HJ2]F9HEN
MBVF3/>9T/#$NU8W=AU(QA6U\T%M;4:W1&)2H_R,T36:B^?!C>'52 KY<XD/O
MS[-1H\<!5.VT$1]-S,:5>-ES+= ;E<4+)EH=>*#5X8=%Y_'B\$6HUV$D-)7'
MH%B3Z7BZUUKT&A>+]Y=8\.YB!YJ/3$&9WJ=9IQN@J?4+&K]Q!,/G1F/[K4 O
M^(E8)U:>T>.E+TZ@0;\-*-ET'C3/_(1"3_^$THWFH/ZKAS%IJQF[[OIQG]40
M9M#B7%0"-IUZP./605.; 5D#VI2:8U&E[RKT'W5>&5Z[PNK>=\6#[V>8T6G
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M2G")7RI^DZD5[9>2(*1 I?%<_>4<$\YK5Q_VW?-FU:GO3-EH2Z<)+N2O?4E
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MQ  /7&V\>/G$FY5++C%@_%WJ]WY"]<YW*-+R.07:6(HZ\6#DK@0V/-'Q5#B
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M?']-^=_N47K\34J.ND^902X4$))1J.D;4:D.W+'5XB9,3I&IKVYR+94!_HH
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M^6V4&?:$%8_BN2DXI.:9V4@X_!(\4I)FSV5SADW93Y5:,RA>=ASMN]YE_+1
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MY=<P;MIG=AY+YO%[6'Y )^WF1\FJ9RE8WH5"5</EFDFLNZ'GW%<#SWP-_';
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MEUXWJ%QS!\6KFPD G*%TO8O\MLF#W?=%Y?\2J)6&>N">R=:[,=3N(2!=>YN
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MFVXFMI?64W<Q=,T)INRYQ._[KS+K\"7F'+W$W&.7F7/D'+,.G.+W/69,VGJ
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M,#OOKZD01D2@M/EO"YDR/TQD#CJ\5>3-@6R+AGR4.H^5)OQT!.JHH5Z3;ON
MTR;6B0CK?0RI2)B^#/6>#6\\1(V.Q<PFFDDZ.#K;;O#X%7BFRP@<='PW;+_'
M$]AIOS=QZFUU>&]$"N-(7C2OK# 30F&B",LCXUE;5I"H*$]8%A[J/<EBEB0F
M':9%2BU"PIK&]\\Q=:J\N133EDW!WV\OPW''C<6VV[R//0[Z%B=?M@@W/=F,
MP=. !=4D0E&M09;38I:BL.R6YZ C/>RZJCJEW=.K*F@32H#"4J"&?S>FXFC(
MAE#)LBHB ZH*LE:K?NKH)LPC%IA3%\9,*\3+[XW"]B?,Q!9'3L!>%\S&0_V
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M@:8<?$1S#CIHV2%N^E'80B(/3FMCMSB"7 U'4X66N+ <G=Y(Z4A.;5IO$/2
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MA;+*;+ADRA57-ECY-60J2V;C# M&:(J\,=H6WE+'WU6\97%U%F_U*<*5]_Z
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#0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_01a.jpg
<TEXT>
begin 644 image_01a.jpg
MB5!.1PT*&@H    -24A$4@  #+(    0" 8   "X1+=*    "7!(67,  $SE
M  !,Y0%USO"5   !'4E$051XVNS;,0T   S#L$(O\PW%CDD^3"!_TG8
M          #@6D0               # R (              ("1!0
M         (PL                &%D                PL@
M     ("1!0               ",+                &%D
M   PL@ ?+    /__[=LQ 0 P#("P2<?Y*J)G<\0 /_4+              #V
MG@@                860               #"R                @)$%
M                (PL                W#3OG(I9%_.A4     $E%3D2N
#0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_03.jpg
<TEXT>
begin 644 image_03.jpg
M_]C_X19717AI9@  34T *@    @ #@$   ,    ! ^P   $!  ,    ! MH
M  $"  ,    $    M@$&  ,    !  4   $.  (    &    O@$2  ,    !
M  $   $5  ,    !  0   $:  4    !    Q $;  4    !    S $H  ,
M   !  (   $Q  (    D    U $R  (    4    ^(*8  (    D   !#(=I
M  0    !   !,    6@ "  (  @ "$QO9V]S   MQL   "<0 "W&P   )Q!!
M9&]B92!0:&]T;W-H;W @0T,@,C Q-2 H36%C:6YT;W-H*0 R,#$V.C T.C$T
M(#$V.C Q.C0U ,*I(%)E<TUE9"!,=&0N($%L;"!2:6=H=',@4F5S97)V960N
M   $D   !P    0P,C(QH $  P    '__P  H ( !     $   /LH , !
M  $   +:          8! P #     0 &   !&@ %     0   ;8!&P %
M 0   ;X!*  #     0 "   " 0 $     0   <8" @ $     0  %(D
M    2     $   !(     ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1" !T * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M     P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0
M  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!
M8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&
M)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(!
M @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R
M@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6T
ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
M/P#U5))))2EE]=^L.%T2JMV0'V6W$BJFL#<=OTW$N+6M8W<U9'UB^NEW3L]V
M#A4LL?3'K66S$N&_TV-86_FN;[]RKYF&[ZZ=.HZAAEN-F8KGTVU6$EAG8_\
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MX@%N)79D.GR'V>O_ ,$R-R]=7G_^*K"_Y1Z@YO)KQJW?U0;[A_X+0O0$E/\
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M       0([W91UZT!=N\PE6V2?->(CA"24T$.@     !!P   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M  !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4    $@!( %  ( !, &$ <P!E '( 2@!E '0 ( !0 #0
M-0 Q #4       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ $L     0 ! 2P    !  $X0DE-
M!"8       X             /X   #A"24T$#0      !    !XX0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M V<    &              +:   #[    !D 4@!E ', 30!E &0 7P!L &\
M9P!O %\ < !R &D ;@!T %\ - !? $, ;P!L &\ <@    $
M             0             #[    MH                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   MH     4F=H=&QO;F<   /L
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   +:     %)G:'1L;VYG   #[     -U<FQ415A4     0
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M24T$$0       0$ .$))3004       $    !#A"24T$#      4I0    $
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M]^MW2\CI;ND=-O9EVY1;Z]M)W5LK:181ZS/T;K;7-]/TV?X/U/4_P:2GG_\
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M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !< 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# $, (  R #  ,0 U     0 X0DE-! 8       <
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M40O)!4T\B2Q.\;JQ[=\L<S[#SGR_M/-/+&YQWFPWT(EAF0]KJ?D:%64@JZ,
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M:[4-^0NDM@3\@:G@ >O>ZVNR.J>R^G]PR[4[2V)NK8&XHE:08K=6%KL/45$
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M2_O"?9:]Y"]W)_<7;[-OZI<SGQ=8';%?JH%S"Q\FFTBZ0L1K,DP4$1-3.WV
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M^7Y2NXV%PKZ:D++&>V6!Z?Z'-&6C?S :HHP! +]P^1=E]RN3-_Y)W^(-M]_
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MRW');\OMB1VQ+< ?A(!/AQ$_AJ6?&K2"4Z][H<]]$>L?.O>_>_=>Z][WQ?\
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M^7[18;,7!'ZLIK_M1@#_ "_F/3KWO8#]\W>C[KWOWOW7NO>_>_=>Z][T&O\
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MO?NO=>]^]^Z]U[W[W[KW7O?8!)  ))-@!R23] !^2??N&3PZ]U[WN\_RDO\
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MQ2IB<IJ']%@-2G@5(()!Z^I[DOFK;N>.4>6><=H<-MNYV,-S'0UHLT:OI/\
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M&P=L96,=P=K8FMPV"IJ6<??;7VK6K+09W>=2$/DI&\'EI,:Q*.]:YECU"EE
MRN^ZC[*7/N9SO;<Q[M9G^I.SS++*S#LN+A:/#:K7#9TR3C($0"-0S(3A/]]G
M[PEI[0^W5WRGL=^/]</?K=X8%4]]M:O5)[QJ90Z=45N:@F8ETU""0#WO4O\
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M<E),+UC>E!+"U3%*OEW+\0%=+AD)JIZ^OKV!]Z.7/?[VIY5]S>7'54O(0MS
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M[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O=X/\
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M>Q?C%A\BO]Z^[]T4>ZMTT$,RF2EZUZ\K8LC3_?TZGR1+G=^KCVI';T2?PFJ
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M)[WN[_#G^4=\.?AWC,57X?8&.[5[5I(H):_MSM+&8_<6?&21 9:C:>&JHJC
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MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W_ /_7^?\
M^_=>ZW^/?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>
M]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW
M7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z
M]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?
MNO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[
MW[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]
M^]^Z]U[W[W[KW7O?O?NO=>]C5T3\C>\_C)O2+L'H3M#=O5^[$2.&HR&V<B8:
M7+4D4AE3';BPE4E5@MS8H2G7]ID::JIBX#%+@'W5T1Q1U!'0(Y]]MN1/=#9'
MY=]P.5K/==H))"3I5HV(H7AE4K+!)3'B0NCTQJIU[W>)UO\ \*7?FOM?%T^,
M[ ZVZ'[0FIHE0[@FP6Z=G;@KG"V:;(_W=W.-LL[$ VIL72*.>/I9*UE$>#$=
M8+<R_P!V-[(;K=277+W,V_[4C&OA"6"YA4>B>-!XW^]SR'_+[VR]K_\ "DOY
MT[WQ=5B.O-J=)=-?<QNB;AP.ULSN[==&S@J'I:C>^?S.U;H#<>3#2'5S>W'O
MRV40^(D]+>4O[L_V&V.ZBO.8MVWS>M)!,,L\=O W^F%K%'/^RX&.O>Z->V>X
M^U>]]ZY+L7N3L'=?9>]\MI6LW)O#,UF9R/V\;.\%!2-52/%CL51^1A3TE.L5
M+3H=,<:+Q[5*JH-*B@ZSMY1Y,Y3Y!V2VY;Y+Y>M-LV.'X8;>-8TJ:5=M(J\C
M4&N1RSN<LQ.>O>PU]VZ$W7O?O?NO=>]^]^Z]U[W[W[KW7O;SM_<6X-IYB@W%
MM7.YG;.X,7,*G&9W;^3K<-F,=4 %1/09/'3TU;1S!6(U1NK6/U][!(-0<](=
MRVS;=YL;C;-XV^"[VV9=,D4T:2Q.OH\;AE8?(@CKWL^NU?YL?\QW9N-BQ6'^
M7W;U520HL:/N?*X_>]?I7](;+;TQFX,K(0/RTQ/MX7,XX2GK'7>/N;?=>WRZ
M>\O?939$F8U(@C>U3_G':R0QC\EZ]["3N#YX?,OOS'5.$[=^3'<6\]O5J-'6
M[6J]Z9;';1KE8$$5NT\)-C-MU9TL0#)2L0"0."?=&FE<4:0D=#/DG[N_L9[<
MW45_R7[4['8[G&:I<+:QO<I_I;B423K_ +609SU[V4SVWU,O7O?O?NO=>]^]
M^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?
MO?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]__T/G_ /OW7NM_CW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z
M]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?
MNO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[
MW[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]
M^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]
MU[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?N
MO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U
M[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO
M=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[
MKW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]
M^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?
MO?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]_P#_T?G_ /OW7NM_CW[W[KW7O?O?NO=>]^]^Z]U[W[W[
MKW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]
M^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?
MO?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>
M]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW
M7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z
M]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?
MNO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[
MW[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]
M^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]_P#_TOG_ /OW7NM_CW[W[KW7O?O?
MNO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[
MW[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]
M^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]
MU[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?N
MO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U
M[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO
M=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[
MKW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]
M^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?
MO?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]_P#_T_G_ /OW
M7NM_CW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?
MO?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>
M]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW
M7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z
M]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?
MNO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[
MW[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]
M^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]
MU[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?N
MO=>]_P#_U/G_ /OW7NM_CW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]
M^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]
MU[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?N
MO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U
M[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO
M=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[
MKW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]
M^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?
MO?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]_P#_U?G_ /OW7NM_CW[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>
M]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW
M7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z
M]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?
MNO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[
MW[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]
M^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]
MU[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?N
MO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]_P#_UOG_ /OW7NM_CW[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]
MU[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?N
MO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U
M[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO
M=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[
MKW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]
M^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?
MO?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]_P#_U_G_
M /OW7NM_CW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>
M]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW
M7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z
M]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?
MNO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[
MW[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]
M^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]
MU[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?N
MO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]_P#_T/G_ /OW7NM_CW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?N
MO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U
M[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO
M=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[
MKW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]
M^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?
MO?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>
M]^]^Z]U[W[W[KW7O?O?NO=>]_P#_T?G_ /OW7NM_CW[W[KW7O?O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>
M]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW
M7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z
M]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?
MNO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[
MW[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]
M^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]
MU[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?N
MO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U
M[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]_P#_TOG_ /OW7NM_CW[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U
M[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO
M=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[
MKW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]
M^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?
MO?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>
M]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW
M7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]_P#_
MT_G_ /OW7NM_CW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O>P1_)D_EY="?++K[
MNKLGY#;'KMZ8;";QVWLC8D=-NK=VU8J#)X_"U6>WD\DFU,UA9,@\]+N'#A1,
MSK"$.D N?::>5D*A3T>;38PW*323I4 @#)'V\/M'5-_\SSYG]O?';>75NQ^F
M-UTFU\IE-LYO=>[7GV_MS<$E905F4@Q&V41-PXO*)1I#48;)$F((92PN3H'N
MZ7_AE7^7%_SXK*?^C;[A_P#L[]I_J)?XOY#HV_=%A_OD_P"]-_GZJ\_X='^;
M?_/VJ#_T7/6G_P!B7OW_  RK_+B_Y\5E/_1M]P__ &=^_?42_P 7\AU[]T6'
M^^3_ +TW^?KW_#H_S;_Y^U0?^BYZT_\ L2]^_P"&5?Y<7_/BLI_Z-ON'_P"S
MOW[ZB7^+^0Z]^Z+#_?)_WIO\_7O^'1_FW_S]J@_]%SUI_P#8E[]_PRK_ "XO
M^?%93_T;?</_ -G?OWU$O\7\AU[]T6'^^3_O3?Y^O?\ #H_S;_Y^U0?^BYZT
M_P#L2]^_X95_EQ?\^*RG_HV^X?\ [._?OJ)?XOY#KW[HL/\ ?)_WIO\ /U[_
M (='^;?_ #]J@_\ 1<]:?_8E[]_PRK_+B_Y\5E/_ $;?</\ ]G?OWU$O\7\A
MU[]T6'^^3_O3?Y^O?\.C_-O_ )^U0?\ HN>M/_L2]^_X95_EQ?\ /BLI_P"C
M;[A_^SOW[ZB7^+^0Z]^Z+#_?)_WIO\_7O^'1_FW_ ,_:H/\ T7/6G_V)>_?\
M,J_RXO\ GQ64_P#1M]P__9W[]]1+_%_(=>_=%A_OD_[TW^?KW_#H_P V_P#G
M[5!_Z+GK3_[$O?O^&5?Y<7_/BLI_Z-ON'_[._?OJ)?XOY#KW[HL/]\G_ 'IO
M\_7O^'1_FW_S]J@_]%SUI_\ 8E[]_P ,J_RXO^?%93_T;?</_P!G?OWU$O\
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M9]:=2L 4GS%-*AU1<);EZ*$'$]'FR6VN5[EAVI@?:?\ ,/\ #U3-_.#^0O\
M='K;;G0&WZ[QYWLR6/<.\%@DTS4FQ,'7 X^CE"E9(UW)N6E&E@2&AQL\;#3)
MSMV^T70HZUP/?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]ZMW_"C#M+R9;XV]*4E3;[/';R[2S])KOY/XC4T.TMHU)0&Z^+^%9M;
MF^K7Q:QNLM1\;=!S?I,V\(^9/^ ?Y>K^?Y*.P-&.[P[3J(;_ '-;MC8&'J--
MM'V,%7N+<<.OZ-Y/XABFL/IHY^HMK'^U?0>ZO?\ ?O?NO=>]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW7O?O?NO=>]^]^Z]U[WO*?R2>K?]&_P#Z_RT]-]MDNV-U;V[.R",FF4Q
MUF6&T<'*[?VTJ]L[/HIT_&B8?F_LON#64_+H8[1'X=DA\V)/^0?R'6I__-0W
M_P#WX^86\<=%/YZ'KO;^UMAT3AKQAZ;'?WDRT:B_I:GSNY:J%_SJC/\ A[MM
M]L=&?5<_OWOW7NO>_>_=>Z][][]U[KWOY['\Q_M/_3'\X_DMO6.I^ZH$[,RV
MSL/.K:H9L+UQ%3=?8FIIK<+3UM#ME)UL!?RZB-1/LSB&F-!\N@/?R>+>7#UQ
MJI^S'^3K<P^$>P/]&?Q0Z,VM)!]O5ML3';ER4++IEBRF]I)]Y9&"?BYGI:O/
M-$U[V\=@; >R2^W.D?1J/?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M_];Y_P#[]U[K?X]^]^Z]U[W[W[KW7O?O?NO=>]V!_P K+JS_ $N?/?XXX":G
M^XQVWM[#LG*ETUP0TW66-KM\TGW2V(,%7F,%2TUB"K/.JG@GVU,=,;GI=ML?
MBWMNM, U_9G_ "=$X_F ;_\ ]'/Q![NS$<_AK<UM4['QX5M$TL^_*ZDVG4_;
MFX(EI\9EJB>X(*K$2.0/>_\ >RWH;=:=WOWOW7NO>_>_=>Z][][]U[KWOWOW
M7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][
M]U[KWOWOW7NO>_>_=>Z][][]U[KWL'/D#TALOY']-=@]*;_I5J-M;_V]5X>:
MH$,<U5ALEZ:G![DQBRD(N6VWF8(*ZE)]/G@4-=20;*Q1@PXCIJ>%)XGA<=K#
M_4?RZ$SISM7='2/9NS>TMGU#0YS9^9I\E%"97BI\G1<P97"5QCNYQV;QDTU)
M.!SXIFM9K$?.D[:ZRW1TOV=OWJ;>M+]GNKKS=>:VEFXE#>"2LPU=-1FLHW<*
M9\=D8XUJ*:4>F6GE1Q<,#[-%(8!AP/0$EC:&1XG^)33K=9ZZWW@.T-A[0[$V
MM4?<[?WIM[%[BQ3L5\J4V4I(ZD4M4JDB*MHG=H9X_K'-&RGD'V'GO?3?2S]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U
M[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO
M=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[
MKW7O?O?NO=>]^]^Z]U[W[W[KW7O>VO\ \)VNK?X/TIWSW%4TVB???8V"V+CY
MI4];XSKO -EYYJ9C]*:IR6_WC<KP\E)8W*"R*Z/<J^@Z$^Q1TAFE/XF _8/]
MGK70_G3;_P#XGVGU%UI!/JAVCLG+;MK8XV]"U^],PN.BBG ^L\%#L]'4'E4J
M+C]9OL5>TO1[U2M[][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z
M][][]U[KWO5*_P"%&U+H[$^+E;8?Y1LOLNEU>FY^TSFU);$_JL/O?SQSQ^?:
MRUX/T&M^'ZEL?D?\G6PI_),J-6RN_:6Y_9W1L:HMS8?<XG<,=_\ 4W/VOXYX
MY_'O6S]J^B#J\3W[W[KW7O?O?NO=>]^]^Z]U[VZX'!Y?<^<PVVMOX^IR^>W#
ME<=@\)BJ*,S5F3R^6K(:#&X^DB',M36UM0D<:C]3L![\33)X=;4%B%458GIO
MR^6QN!Q63SF9K8,;B,+CZW+97(U3B.EH,;CJ:6LKJVID/$<%+2PL[M^%4GW]
M$CX7_&_$?$[XU=7=(XY::3);:P,=9O/*4H!7.;]SC'*[PRHF*B6>FDS-3)#2
M:[M'0PP17M&/97(^MRW0ZM+<6UO'".(&?F3Q_P!7IUI:_*#N_)?(CO+?W:E:
MTZ4.<R[TVV*"<V;$[0Q0&/VUCS&"8XITQD"25&BRO5RRR?5S[-)[ITIZ 'W[
MW[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O>B;_ #F^
MTO\ 2=_, [;@IZG[G%=9T&T^K<2VO5XO[NX2#);AIK<B/[;>F=R:6!^HN;$D
M Q@%(E^?0-W:3Q+Z7T6@_8,_S)ZVUOY8>P/[A_#KKF::#P9#?59N+?\ D5TV
M\G\:RLU#AI[_ %?S[7Q% US_ %M] #[JP]O=%O5@7OWOW7NO>_>_=>Z][][]
MU[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>
M_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWO
MWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z]
M[][]U[KWOWOW7NO>Y%)25-?54U#1P25-965$-)24T*%YJBIJ)%A@@B1;EY)9
M7"J!R2??NO 5( X]8:BH@I*>>KJI4@IJ6&6HJ)Y6"1PP0HTDLLC'A4CC4DG\
M >_I2]&=<4W3W2W4O5%(L0AZWZWV5LG5#;1/-MG;N.Q%35%@!Y)*RII'E=SR
M[N6/)]E3'4S-ZGH?PQB*&*(?A4#]@ZT;NV=[S]E]H]B]AU)D,N]][[HW5IDN
M&BCSN:K<E!3A3^A*:"H6-5^BJH X'L5/=>G>@^]^]^Z]U[W[W[KW7O87=W]C
M4O3_ $UVOVM6F+[?K?KG>F]W26VB=]L;=R.8AI0MP9)*N>C6)$'+NX4<D>]J
M-3*OJ>FYI!%%+*>"J3^P=+[JK9-1V5V=UYU[2A_-O?>VU]J*T?ZHESV:HL9+
M4$_V$IXJEI&8\*JDG@>_FL5M959&LJ\A73RU5;75,]9654S%YJFJJI7GJ)Y7
M/+RS3.68_DGV;=1^2223QZWDZ6FIZ*FIZ.DACIZ6D@BIJ:")0L4%/!&L4,,:
MCA8XXT"@?@#W&]^Z]UG]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?_
MU_G_ /OW7NM_CW[W[KW7O?O?NO=>]^]^Z]U[WL2_\)W.K/XUW?WMW%4TVNGV
M#UQA=CX^65?0F6[%SYRDL],Q'-338O8,T3D'T1U=C^L>TMT>U5]3T>[%'6::
M7^%:?M/^QU2S_.EW_P#POJGJ3K2";1-O#>^4W761HWK;';*PXQZ13@?2">OW
MA'(M_P!3T]Q^D^]MSVBZ$_6N;[][]U[KWOWOW7NO>_>_=>Z][][]U[KWO3[[
ML_GN?+7 ]Q]JX'K2GZ??KO!=B;RPNQILKLK)9')U.TL3N'(8_;]9D*Z+=--%
M4UE9BZ>*61DC1"[FPM;VN6V0JI-:TZ"TV\W2RR+&$\,,:8\JX\^ME'JW^4C\
M=,OUIU]E]]3=DIO3+;+VQE-V18_=-#14,&XLCAJ*LS--1TDF GD@I:;(321H
MK.S:5%S?V&/_  _C\[/^5;I#_P!%[EO_ +,/>_IH_GTW^^KST3]G^STO/^&@
M?B5_QW[5_P#0SQW_ -C7OW_#^/SL_P"5;I#_ -%[EO\ [,/?OIH_GU[]]7GH
MG[/]GKW_  T#\2O^._:O_H9X[_[&O?O^'\?G9_RK=(?^B]RW_P!F'OWTT?SZ
M]^^KST3]G^SU[_AH'XE?\=^U?_0SQW_V->WG%?\ "@3YNT$JO6[4^/F;B%@\
M-?L;>=/J%SJ*R8GLC',DA!X)NHM^D\W]]-'ZGK8WN\'%8S^1_P _39D/Y.?Q
M5JXV6EW#W+BI#<K+1[LVQ-I-N R9'8]:K(".1P3_ %'X.+TQ_P ****IR=%C
M?D#\?FQ>,GDC2KW;U/N)\A)0AB$:7^Y.ZHX'J8$)UL4S7D5 0L<C6!;:U_A;
M]O2N+?14">#'JI_R'_/T6?L_^2O504-37=.=QK7U\22/3;=[$PBT:596[+&-
MT[?>98)6 T@-B]#,;ET%_>PQTEWMU-\C-@8OL[IG>N)WSL[*EH4R&->6*JQU
M?$D<E3A\[BJR.GRF!S5(LR&6DJX89T5U;3H=&9,RLAHPH>CR&:*=!)$X9#_J
MSZ=4Q]J=2=B=)[QK]A]G[6R.U-S8\+*U'7+')!6T<C.D&2Q.0IGFQ^7Q=2T;
M".HII)(F9675J5@!<]UZ=Z#GW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O>G)_P
MH!Z0I]B?*38_<>+HTIL?WGL$+EY$33]WO;K66BV_E:IF4!+MM+)8%+?J+1LQ
M)O[76S50KZ'H*[W#HN4E PZ_S&/\%.MF/^3KVK-NWH'=G6=?4M/6]3[P+8U&
M>_VVUM\QU68QT !);T[BH<NU_II=0/I[H9]J>B7JW7W[W[KW7O?O?NO=>]^]
M^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?
MO?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[K
MW7O?O?NO=>][^W\JKJW_ $2_ 7XYX2:F\&1W-LZ3LO*.RZ)JB;LS*5^]<>]0
MM@1+3X#,T=. 0"$@4'D'V6S'5(_0VVV/PK* >9%?VY_P=:>G\P;?W^D7Y@=V
M96*?S46"W,FQ:!0VJ*&+8N/I-K5JPGF\<V8QE3,;<%I21Q;W87[:Z7=$R]^]
M^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[WJU_\*/Z;
M1F?B%66_S^,[RIK\_P#*)5=32V^EN/O?ZG_8?E9:_C_+_+T'-_XVO^V_Y]ZO
M[_DBSZL9\D:6_P#F:_J>>W_433]BQW^M^?M?Z>]9+VKZ#W5[OOWOW7NO>_>_
M=>Z][][]U[KWN]#^1-\4O],'R/R/?FY\;]QL;X]4]/7X<U,6JER?:F?BJ8-L
M11B0!)_[K8V*JRCLA+TU8E"Q%I![3W#Z4TCB?\'1SLUMXMP9V'9'_A/#]G']
MG53?\VSY"_Z->D:+J# UWAW9W-/-29,02::B@Z^Q$D,N>D<H2T7\?KI*?'J&
M 6>F:K -T/O<Q]H.A7UK%^_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KW
MOWOW7NO>_>_=>Z][;LOE:#!8K)YO*U*4>+PV/K<KDJN4VBI:#'TTM765,A'T
M2"GA9C_@/?N/6B0H)/ =3<=CZS+9"@Q6/@>IK\G6TN/H::/F2HK*V=*:F@0?
MEY9I%4?XGW\T[MC?M?VIVEV1V=E=?\2[%WYN[?->)&U.E7NO/Y#.SQEKD?MR
M5Q7C@ <<>S910 >@ZC^1S)))(>+,3^TUZWFNO-H4?7VP-D;#Q^@T.RMH[<VG
M2%%TJU/M[#T>)A<"P/K2D!YYYY]H#WOJG2Q]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U
M[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO
M=>]^]^Z]U[V=3^71U;_IC^<'QIV/)3_=T+=GX;=F8IV35%/@NNTJ.P,U35'%
MA3UF,VS+"WTN)+#DCVW*=,;GY=*["/Q;RW3RU5_(9_R=%<^:^_\ _1G\4^\]
MUI-]O5C864V[C)@VF2'+;T:'9V+GAYN9J:NSL<J_7]%SP#[^A;[+.ASUIE>_
M>_=>Z][][]U[KWOWOW7NO>ZE?YV?:?\ HV^ 78>*@J?MLGVQN?976&.D5],C
M)7Y;^]F=A10?6M7M?:%= _XT2G_#V_;K64?+HLW>3P[)QYL0/\I_D.K%OY6/
M7_\ ?CYA;,R$T'GH.O,#NG?M:A6Z!J3'?W=Q,K'^RU/G]R4DJ_G5&/\ 'WHT
M>S#H'=;87OWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWO_]#Y
M_P#[]U[K?X]^]^Z]U[W[W[KW7O?O?NO=>][H_P#(0ZL_N5\*:W?U33:*[N/M
M+=FXJ:J9-+S;=VHM%L/'4][#7%3YS;^5D4_UG;V@N362GH.A;LL>BT+GB[$_
MD,?X0>M7K^;[V!_>GY2TNSX)]5)UGL#;V%GIPVI8LUN%JK=U;-:YTR38G,8]
M&'](A[NZ]I^C?JJSW[W[KW7O?O?NO=>]^]^Z]U[V /RJ[2'27QK[U[76H%+6
M;$ZLWKGL-(6T%]QP8*LCVS3*Y_3)6;@EIH5/X9Q[L@U.J^IZ8N9/!MYI?-5)
M_.F/Y]##\?-@'M/O+J7KQH3/3;M[ VMB,FFG4%PLV6IGSL[+_:2FPT<\C#\A
M#[^;Z26))))))))N23R22>22?9KT NMW8      "P X  ^@ _ 'OKW[KW7?O
MWOW7NO>_>_=>Z][][]U[KWOWOW7NO>[ /Y<WS<W7\*>_,%N89*MFZCWCD,9M
M[N/:@>::BR&V)JKP_P!YJ2@74IW-LT5+UE%(@665!+2EA%4R>VI8Q(I'XO+I
M=87C6DZM7](X8?+U^T?['1.OFQ\5MO?*7J#+X(T-+%V/MJCK\SUGN$K'%54>
M>B@\O\"J:MK,,#N;P+352,3'&QCJ ID@3WO\TM535U+35M%40U='600U5)54
MTJ34]335$:S05$$T9:.6&:)PRLI(92"./9;T-@:Y'#K3RJ*>>DJ)Z6JAEIZF
MFFEIZBGG1HIH)X7:.:&:-P'CEBD4JRD @BQ]R/?NO=8??O?NO=>]^]^Z]U[W
M[W[KW7O= 7_"AO94.5^+?4._%B5Z[9W=]-@_)HN\.(WGLO=$M>0]B51\EM:@
M4C@,2/Z#VIM3WL/ET2;ZE;:)_,/_ (0?\PZN'_DP[IEQ_?W9&T6D9:3<W54^
M5T:K+)D=L;HP$=("G]IEH=P59!_ O_7WI]^UW06ZV4??O?NO=>]^]^Z]U[W[
MW[KW7O?O?NO=>]\E5G9416=W8*B*"S,S&RJJBY9F)L /K[]U[KIF55+,0JJ"
MS,Q 55 N22>  /9F>OOA;\M^U$IZC8/QN[HW#CZL*U/F8>O=R46WI0]M)7<>
M4H*'! $&_-0..?I[H9$'%QTH2TNI/@MW(^PT_;T!.\?E%\<NOWFAW?WAU?AJ
MRG)$V,DWG@ZK,QE?U!L+05E5EK@\?YGZ\>S2X+^35_,:SL:3CX_?P>GDMIDS
MO9?4^-D%_KKH6WQ)DHK?G5"/=#/$/Q?X>E*[5?M_H%/M*_Y^@ R_\S?X3XAW
MA/<G\2F2]TQ&QNQ*Y#_315KM1*"2_P#M,I]JF?\ DB_S$HHA)'U/M:I?06\$
M':O72RA@!^V34[BIX=9O_J]/'U]^^HB_B_EU;]T7_P#OH?[T/\_3!%_-4^%L
MDFA^P]P0+J"^67K[>IC()/KM!A9I=(M_J;_X>PHW5_*;_F';.ADJ,K\9-W5L
M409C_=7/;$WQ,ZKS>.DV9NO/5DA8?11'J/TM?CWL31'\?33;9?)QMS^5#_@)
MZ$/;_P#,1^&&Y94AQ_?&VZ61RJC^\&(W;M2)2W%GJ=S[>Q%,@!^I+Z1_6WLE
M^_NH^U>J:U<=VAUGO_KFO=S&E'OK9VX=I5,CJ"Q6*'/8Z@>4Z1?T@W'/T]N!
ME;@0>DCQ2Q&DD;*?F"/\/1G]G]C=>]A4IK=A;ZV=O:C5!(]3M+<V&W% B$@!
MI),16UB1C4;>HBQX^OL/?>^J=+/W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O8O=;_'[O7N%E'5/3
M?:'8\;2&)JG96Q-S;DH87#:6^ZR&)QE514B1G]32R(J_DCW4LJ_$P'3L<$TO
M]E$S?8">@WWOW'U+UH&_TA=F[!V2XC\@@W3NW!8.KD4BZ^"CR-=3U=0SC]*Q
MHS-^ ?9S]J_R?_YB>[8TJ*7XZ9/#TKA29MU;VZWVQ(FKZ:\=F=X4N7O;Z@4Y
MM^;<>Z&>(?BZ5KM=^W^@$?:0/\O18-P?S)_A9MUVAJ.ZZ#)SJ2!%M_:V^,\C
M6^NFMQFVJC&V_I>87_'Y]B]1_P BKY_U2(T^U^M,<6%VCK.S,.[Q\$V<X^"O
M0F_'I9A?_#GW7ZB+U/3O[FOOX5_;T&]3_-H^'<#,L6?WU6A38/3;%R:*_(%U
M%9+2.!;GD#CWCKOY%O\ ,"I$=Z?:/7&49=5HJ'LW QO);Z:#DQCHQJ_&IE_Q
MM[]]1%ZGKQV:^_@7]HZYTG\V;X<U+JLVY-[4 -KR5>Q,NZ+?ZZA0FM?T_FRG
M_#V#FZ_Y1'\Q':$<D]=\;\YE:9 S";:F[NN]VR2JM[F.@V[N[(Y6_'"M K'\
M#W83Q'\?33;7?)QMR?L(/^ ]"9M[^9!\+=R.D5)W?B<?.Y53'N';F]-N)&S?
M0/69K;=%C[?U83%1^3[)CV+T3W;U"_C[5Z@[-ZWO+X4DWQL7<VUH)GN HIJG
M-8RCIZE7N-+1LRL"""0?=PRM\+ ]))(9HO[6)E^T$=&>V5VWU7V0FOK[LG8F
M]_1Y&3:F[<%GYHEL2?-!BZ^JF@9;'4'52I%B!["GW;IKH0O?O?NO=>]^]^Z]
MU[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O:OZ^V;D^Q=^[(Z^PBELSOO=^VMF
MXA0AD+9/<^9HL)0*(U]3DU5<G Y/O1- 3Z=61#(Z(.+$#]O2;WEN:@V5M#=6
M\LH=.,VEMO.;FR+%@@%!@<9596L)<\+:GI&Y/T]_2WVUM_&;3V[@-JX2 4N&
MVUA<5M_$4PM:GQF&H8,=00#2%6T5+3(O  X]E)-23U(*J%55' "G6B_G,S7[
MBS>8W!E9?/D\[E,AF<C.;_O5^3JYJVLEY)/[E1.Q^I^OM[]^ZWTU^_>_=>Z]
M[][]U[KWOHD $D@ "Y)X  ^I)_ 'OW7NNP"2  22; #DDGZ #^OLO/Q5[:'>
MW1>TNW(IQ4T>^<KO_+8F0-J5,$G8^[:' 4R-8:HZ/"TE/$I^I"#D_7W9UTL5
M].F+:7QH5E\B3_A-.AF^0?71ZE[9W'US)"8*K:>/V=CLBA&EFRS;)VY5YB=E
M_LO4Y2IFD(_!;\>S#^Z]/] Q[][]U[KWOWOW7NO>]8S_ (4@4NO&_#ZLM_F*
M[OBEU<\?=P=/RVO?3ZOLOR+\<?GVKM?Q_E_EZ#V_C%J?]-_S[U?%_)$GTUWR
M4I;_ .>I.HY[<7/VTW94=_I?C[K_ %N?];WJX^UG0<ZOV]^]^Z]U[W[W[KW7
MO>>EI:FMJ:>BHJ>>KK*N>*EI*6FBDGJ:FIJ)%B@IZ>")6EFGFE<*B*"S,0 +
M^_=> K@<>L4\\%+!-554T5-34T4D]143R)%!!!"ADEFFED*I%%%&I9F8@*!<
M^_H0?R\_BY3?$3XJ=;]4U%+##O2JHCO3L^IB\;-5]B;IAIJO.0/-%Z*F/;U/
M%3XB"46\E-CXV(N3[+)7UN6\NAQ8VWTMM'%3OXG[3Q_9P_+K33^9O?L_R0^0
MF^.PH:B63:\%4-K["@DUJ*;9> EGI\5*D3^N!\S-)-DIHS?1/6NM[ >SM>V^
MEG16/?O?NO=>]^]^Z]U[V'>X.P\;ANPNO>M8=%7N3?--N[/FB5[38[9FR<?1
MKG-R2*./MJ?<^Y,'CK&Q:3)@B^AK; P3Y#IMI )(X_Q&I_(<3^T@?GTM,-LR
MNRFS-Y[YDUTV#VG/MO#BJ*WBK=S[IK:EL3@T8_2>; X3+5MQ>R4!!MJ'L1/>
MNG.D7[][]U[KWOWOW7NO>_>_=>Z][(;_ #.>TO\ 1!\#_DINF*H^VK\IU]5]
M?XIE;34'(=FUM'U^DE(00WW-%3[CDJ05Y182_P#9]N0C5(@^?2+<9/"LKAO,
MK3]N/\O1N?@=L#_23\N.C<!)!YZ/'[RI]XY!66\/V>PZ6JWDR5/]GP54V$2
M@\.90O\ :]_/P]F?0(ZW'_?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MV8+KOXG?)WMJ*GJ>M?C[W%O/'U6GPYC!==[IJ\ 0]M#2;@&,7"0(P/#/4*"/
MS[J71>+#I^.VN)?[.!R/D#3]O0-[T^1'0W74DT&^>Y.L]L5E/J\N,RV]-OT^
M8!6^I4PWW[925EMR$A8CV;+;W\G;^8QN*-9X/CK68NG:W[NX>P>J\'(NKD:J
M#(;WAR8X^O[''YY]MF>(?B_P]*5VJ_;_ $"GVD#_ "]%VS/\R[X4821H9>ZJ
M;(3+?]O#;-[!RT;6^NFLHMJ2T!Y^G[O/M;M_)#_F(K$)!U5M1W-[PKVIUZ)5
MM>UR^?2'U6XLY^O-O>OJ(OXOY=7_ '/?_P"^A_O0_P _257^:K\+C(4/8.X5
M46_=;K[>?C-[7L%P[2\7YNOX]AMN7^45_,4VK#+45_QJSU?!'J.O;6\.M=V3
M2*H)U14.VMYY3(M>W"F$,?Z>[">(_CZ;;:[]>-N?R(/^ ]+C!?S'_A7N"2.&
MC[RQ%'*]AISNVM\[=C0DVM)5YS;%!1"U^3Y2O^/LFO8W0W=_3\AC[6Z@[-ZW
M/D$:2;WV-N7;%-,S&R?;5>8QM)2U22']+1NZO^"?=PRM\+ ])9(9HO[6)E^T
M$=&<V3V[U5V4@?KWLG8F]_079-J;LP6>GB51=O/3XRNJ9Z=D'ZE=59?R!["?
MW;IKH0_?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>
M]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[V^;=VQN3=^4@P>T]O9S=&:J;_ &V'
MV[B:_-92HL54^#'XVGJ:N6S,!Z4/)'O1('$];568T523\NFK-9[![;H)<KN+
M,XK XN#_ #^2S61H\700W!/[M97304\? /U8?3V<O9G\L[Y[;\ABGP7Q9[6I
M8I@&C;=N'INORRL+J^C?M;MIU1@;@D $>Z&6,<7'2M-OO7X6S?GC_#3HL>Y_
MG5\0MHRR0Y?O_KVHDB)$B[<R4^\0"#8J&VA2YQ6<$6(!)!]BS_PS-_,E\'G_
M -ER_P ?#_I<Z,\^G3JU>/\ TF?[#3?7?\>Z^/%_'_(]._NG</\ ?'_&E_S]
M!U_PYW\'O+XO]-G^'E_T<=L^+5JTZ=?]Q/\ 8ZK:;?GV$6]OY:?SSZ_AEJ-P
M?%KM>HA@!,TFTL)#V"L:*"6D;^X-9N8^) +L_P"D#DFWNPEC/!QTT^WWJ?%;
M-^0K_@KT)&UOG-\1=XRQPX;O_KR&64@1IN+*2[-9V;A4']\*;!?N,38+^HG@
M#V3+.8#.[9R=5A-R87+;>S-$_CK<1G,=68G)TDGUT55!7PT]53O;\.@/MP$'
MATD964D,"#\^C.XK+XG.T$&4P>4QV9QE4NNER.*K:;(T%2G^J@K*26:GF7_%
M6(]M/OW6NG'W[W[KW7O=^G_">_JW^\_RB[.[3JJ;S4'5?5$F-I)M-_M-S]B9
MNEH,;*'((4R;;V_F8[<$ASS8$%-<FB >IZ.]CCU7,DAX*O\ ,_[ /5/_ /.6
MW_\ P'H+8?7]//XJOL'L-*ZIBU?\"<#LO%U%96QZ;@D)G,QC'OR!I_J01N&^
MT/0IZUI_?O?NO=>]^]^Z]U[W[W[KW7O>KG_PHP[3UUWQLZ3I*FWV])O/M/<%
M)KOJ^\FH-I;0J= /'C^QSBW-[ZN+6-UEJ/C;H.;])FWA'S)_P#_+U?K_ "4=
M@::3O'M.I@OYJG;&P,/4Z?T_;15>XMR0:C]=?W>*:PM;3S>XMK%>U?0>ZOC]
M^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]__T?G_ /OW7NM_
MCW[W[KW7O?O?NO=>]^]^Z]U[W]&GX:=6?Z%/BE\>^L)*;[2OVIU1LZGSL&G1
MIW1D<13YG=CZ+ KYMRY&K>QY]7//LKD.IV/SZ'EI'X-M!'YA17[?/^?6DY\G
M-_\ ^E+Y"]R[]2?[BCW#V'N:;$2ZM=\!19*;&;=74"0WCP5%3K<<<<<>S,>Z
M=*.@*]^]^Z]U[W[W[KW7O?O?NO=>]TO?SW^T_P"X?P9K-F4]3XZ_N3LK9>RV
MAC?3.V&PD]5V#E*@6(;[9:G:%)3RV^HJ@INK'V_;"LE?0=%.]2:+,IYNP'^7
M_)U:#_*/Z_\ [W?+&FW/-!KH^LMC;HW0)775"N3RL5/LV@A-[CSM!N2HFCN.
M/MRPL5'O2?\ 9AT$>MI?W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W]$+^7]N;(;P^$GQ8SV5E>HR$W1_7^/JJF5F::JDP> I,%]U.[7:2>
MI7&B1V/+.Q/Y]E<HI(X^?0ZL6+V=LQXZ!_(4ZTNOF+@:/;7RI^0.(Q\:0T<7
M:V\:RG@C 6.!,MEZC+^")5]*10-7%$4?I4 ?CV;_ -TZ5=%L]^]^Z]U[W[W[
MKW7O?O?NO=>]TW?SV:6.H^ >X97"EJ'M#K6JBU"Y$CY*MHB4_HWBK&'^M?V_
M;?VH^SHJWG_<)O\ 3#JS3^4G.\/S"PT:DA:K8.^8)+&P*+0TM4 W]1Y*93_K
M@>](_P!F'00ZVI/?O?NO=>]^]^Z]U[V,G1_Q\[G^2.\Z?8/277NX.P-RRB.2
MI@Q%.B8[#4DKF-<EN/.ULE+A-N8OR#3]S75$$)>RABQ"FK,J"K&@Z=A@EN'T
M0H6;_5Q/ET&7:W<O6'2&V)MX=J;SPVSL''K2"7)3,U;DZB-0YHL+B:5*C*YN
MOT&_@I(9I0OJ*A02-CWXP?\ "?#;E#!CMR?+/LRKSN198:F7K+JF=L;A*9K!
MS19W?>2HSELJ"&T31XZCQ_C=3XZN52&]I7N3P0?MZ/[?8U%&NI*GT7_*?\U/
MMZI'[Z_G*YJKEK<'\==BT^)H@98$WWV%$M=E)A<H*K$;2H:G^'8\@KJCDK:F
MLUHPUTT; CW>=TM\/OC!\>*>ECZ;Z.Z]V36TB+''N&EP4&3WC*J"RBKWMG3E
M-W5VGZCS5KV))'U/M.SNWQ,>CB*UMH/[*%0?6F?VG/53G:/R5[Z[HFJ'[-[7
MWGNFEJ69GPT^7FH-LH6/J^WVKB10;<I;_0^*E2X O]/9DO=.E'0'^_>_=>Z]
M[][]U[KWOWOW7NO>VO,X3#;CQM7A=PXC%YW#U\9AKL3F:"DRF-K83]8JN@KH
MIZ6HC/\ J70CW[APZT0&!# $=3\9E<IA*ZGRF&R5?B,G1R"6DR.,K*B@KJ64
M?22GJZ62*H@D']58'W5I\C?Y,_PH[Z@KLA@-COT3O2H25J?<G4(IL%A_N2"T
M/\1V!+%-LV>C64WD6CIL?4R@D?<+P0\D\B\34?/HMN-IM)ZE4T/ZKC^7#_!T
M?_I/^9S\I>H9J2CR^ZU[;VO"T:S8/L@SY;)^ 667[+>$<D6YX:IHQ9&J9ZR"
M,@'PMR#K._,[^4Y\F_A_%DMVR8V+MSIVAUS2=G;$H:MOX)1J2%FWUM1WJLMM
M( "[U >LQ::E4UGD8)[5QS(^.#=!^[VRXM:M35%ZC_*/+_!\^KU/C#_,1Z(^
M2DE#MQ:Z3KCLRKT1)L/=M73C^*U3#F+:6X56GQVXR3PL)6EKWLS"FT*6]U?^
MWNB[H^WOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][YQ12321PPQO+-*
MZ1111(TDDLDC!$CC1 6=W8@  $DGW[KW7"21(D>65TCCC1I)))&")&B L[N[
M$*J*HN2> /=W'P[_ )'WR&[\I<5O;NVMD^/76]<D%92T6:Q;9#M//T,EG5J/
M9TTU''M:GJ8P5$^7EAJ8R5D6BGC()3R7"KA<G^71Q:;//. \Q\./^9_+R_/]
MG55WR6_FL],=05&0VKU72IW-O>D:6FJ*K&5ZT77^'JDNC"JW+'%4OGYH'(/B
MQL<D#V9&JHG%O>QG\?\ ^57\(OCQ#15& Z<P^_MTT?B<[V[=2F[!S\E3%;QU
ME-0Y6E7:F#JXV%UDQN-HW!/U) /M*TTC<6H/ET>P;;9P4TQ!F]6R?\W[!U2=
MW%_,%^57=$M5#F.S,EL_ 5/D4;5ZW:?9N(2"2^NEGJL?4-N'*T[KP4KJZI4C
M\"Y]V&T]/3TD$-+200TM-3Q)#3TU/$D,$$,:A(XH88U6.**-  JJ  !8>VNE
M_#AT3&:::IEEJ*B66>>:1I9III&EEEE=BSR2R.6>21V-R222?>;W[KW6+W[W
M[KW7O?O?NO=>]^]^Z]U[W'JJ6FKJ>>CK:>"KI*F)X:FEJH8ZBGJ(9%*R13P2
MJ\4L3J;%6!!'U]^Z\17!X=9J>HGI)XJFEGFIJF"198*BGD>&>&5#J22*6-ED
MCD1A<$$$'W7EW[_*I^#WR#@K9\[TSAM@;GJQ*R[SZA6GZ\SD53,#Y*R?'XBE
M.TLU5R-ZFDR.,K&)YO<F[JS2+P:H^?2"?;;.>NJ(*WJN#_F_:.CG=/\ \P?Y
M6]-2TL6)[.R>\,#3E VV.R&FWIB9(8R-%-#69&H&X\73(O 2BKJ90/QP+:\7
MRZ_D6_(3I2FRF\>A,G_LPNPZ-):N;!X_'?PGMC$4J7<K_=:.:JHMXI!&0NO%
M3&MG:Y6@11?VJ2X5L-@_RZ(KK9IX07A/B)_QK]GG^7[.KH/CA_-FZ9[2GH-L
M]OT'^AG=U4T=/%EJRM_B/7>2J&LH;^\#Q4]5MEIG!.G(1"EB6P-8S'W1Q64=
M7CZNJH*^EJ*&NHJB:DK:*L@EIJNDJZ:1H:BEJJ:94FIZB"9"CHX#*P((!'M1
MT3D$$@C/5KU-4T]93P5E'/#54E5#%4TM532I/3U-/.BRP3P3Q,T4T,T3!D=2
M592"#;W']^Z]UF]^]^Z]U[W[W[KW7O?O?NO=>]V9_P H#JW_ $I?S >C(:BF
M^XQ6PJW.]I99M.O[;^Y&#K:_;U3:UA;><F,2YMIUW'( +,YI$WSZ,-KC\2^A
MQA:G]@Q_.G1$_P"9-O\ _P!'_P .NV)89_#D=WTN)V!CEU:?/_>O*TM'F8 ?
MJ;[72O:PO?38\7(WSO9=T-.M1/W[W[KW7O?O?NO=>]^]^Z]U[V6#YJ]H?Z&?
MB3\B>RHZG[2OVWU+O(X*HUZ/'N?+XB? [4]5P1KW)E*5>#JYXYM[O&-3J/GT
MGNY/"M9Y/,*?V\!_/H>OBWL+_2?\B^EMC/!]Q29SL7;(RT.G7KP.-R,.7W#Z
M;$'3@Z"H//''/'LN/\GRM^__ )<7QJGOJ\>+[%HK\_\ +M[A["QUN2?T_:V_
MV'X]VG_M7_U>72?:C6PM_L/_ !X]#;_,II?L_FWWG%:VNOV556_ZCNM=F5M_
MH/U?<7]V6^VNC#HC'OWOW7NO>_>_=>Z][UK?^%&]+KV%\6*VW_ ?=_:-+JLM
MQ]WAMF2VO?5ZOLOQQQS^/:NUXOT']^'9;'YG_)U>1_)+GT[O^0%+?_/;;V#/
M;GG[;)[GCO\ 2W'W7^OS_K^]5#VLZ#?6PA[][]U[KWOWOW7NO>[C/Y*'Q2_V
M8+Y84/8VX\;]WUU\=H\?O_*F>+71Y'?<U1-'UOA')!4R0Y6BFRY!NK)B3&W$
MHNQ</I2@XGHUVBV\>Y$C#].//Y^7^?\ +JL_^:7\A?\ 0W\>*O9.$KOM]Z]T
MO6[/QXADT5-%M&.&)]\910"&T2XZJBQH(LP;(AUYC-MW7V7]"_K57]^]^Z]U
M[W[W[KW7O?3,JJ68A54%F9B JJ!<DD\  >_=>Z[ +$*H))(  %R2>  !R23[
MJ-^"7;1^6_RY^97R:H:@UO6VPO[H?&'HVJC;71U.V-OUN7W7OS-4[BR.-W9]
ML;DXWTK(:.>GCD_S*>WY%T)&GF<GHKLI?JKJ[N ?TUHB_8,D_F:'JQSY;=<C
MXY_''XQ]%5<(I=\;O_O)WSVQ3R#3509[,TN-V]M'%S+RR_W;PXKJ%UN4^YBF
M=/\ .M[MS]L=&G5<7OWOW7NO>_>_=>Z][][]U[KWO7M_X4.]I?P#X]=+]1TU
M1X:SLCM"OW56QHWKJ,#UO@)*>HII4!_S#YO?&/F%QR].+?0^U5J*LS>@Z(]]
MDTP0Q?Q-7]@_V1U<O_)?V!_&.YNT.QYX?)3;'V%1[>I79?3#E]\9A)H9XVM_
MGDQ6U*R,V_L3F_U'O40]K>@OUL@^_>_=>Z][][]U[KWM?]9=5=D=S[PQFP.J
M=D[BW]O+,/IH<!MG&U&2K6B5D6:LJ?$OAQ^-I X:>JJ'BIJ=/7(Z*"?>BP45
M8T'5XXI)G"1(6<^0Z1V^^P=D=8;:K]X]A;IPNS]LXU;U>8SM=#0TJNRL8J:#
MR-Y:RNJ-!$-/"LD\S>E$9B![V)/BU_PGRS63I\=N?Y<=D2;;258JE^K.JYZ&
MOS40)#_:[AW_ %]-782DF0KHF@QE'7(RM>.M5A?VE>Y\D'Y]'MML9(#74E/Z
M(_RG_-7[>J6N_P#^<GC*":MP/QQV0F<:,R0+V!V!#5T>+DX*_<879])-296H
MB8-JBEKJFD966STK ^[Y.C_@;\0OCK%1MU5T-L+$9BB"&+=N9Q8W?O;RK9GF
M3=^[7S6X*4RR#6T=/40P!K:44!0$S2._Q,>CJ&RM8/[*%0?7B?VG/51G:WRZ
M^2/=4E2.P>W=WY'&U182;<QF0.V]K>-KA8FVUMU<7AJCQH=(>:&24B^IR223
M=>Z=*NBX>_>_=>Z][][]U[KWOWOW7NO>XU91TF0I:BAKZ6FKJ*KB>GJJ.L@B
MJ:6I@E4K)#44\RO#-%(ILRL""/K[]UX@$4(QUGIJFIHZB&KHZB>EJJ>19J>I
MII9(*B"5#J26&:)EDBD1A<,I!!]UO?(;^4M\(OD-!755;U30]6[NJO*\>].F
MUI-BY!*F6[/45N I*.?968DGFLTLE5C):A^=,J%BWMU9Y%_%4?/HOGVRSGJ3
M'I;U7'\N'\NCO=,?S%OE5TQ-2T]+V%5]@;<IS&K[7[--3NVC:".RK#2YBIJ8
MMT8Q(HKK&E/71PKQ>-@ />MI\ROY+_R3^,U-E=[==7[_ .IZ!)ZRKS.TL3/2
M[ZVU01:I))]S;$2?(5<]%2PW,E9BYJZ)$C>6=*5+#VKCG1\'#=$%WM-Q;U>/
MOB^7$?:/\U>KP_C)_- Z.[VGQ^UMZ6Z=[$K&BIJ?&;CR,51M/.5DED6+!;N:
M&BIXJJHEX2EKXJ21G=8X6J&Y]TY^W^BKJS#W[W[KW7O?O?NO=>]^]^Z]U[W[
MW[KW7O?O?NO=>]^]^Z]U[W[W[KW7O9J?B[\+OD1\PMS-M_I/8E7EL?1U,5/N
M'?.8,F&V!M/R!7U9_<\T$M.E2(7\BT5*E5D9HP6BIY #:CR*@JQZ4VUI/=-I
MA2H\SY#[3_J/1?>_?E#TM\:L$,SVGNVFQU;502387:>-"9/>.XM!9;8? QRI
M,T!E70U5.T%%$Y DF0D7V;OC#_(2^.O6L&-S_P B<]EN^-XQI'/4;>I)Z_9_
M6%!5<2>*.AQE3#NK<7VLHL):JNIZ:I4?N42@E?:1[ECA10="&WV6".C3L7?T
MX#_.?]6.J(>^OYO?=6^9JW#]*XC'=1;:=GBAS53%2;EWY60<IY'JZZ"7;^%^
MXC-S'3TDT\#'T51(#>[J^N^J>L>H\)'MSJSKW9?76"C6-?X5LK;.'VU12F)=
M*RU,.(HZ05=0;DM++KD=B69B224Y8MEC4]&\<4<0TQ1A5^0IU5QO3L/?G8^4
M?-[_ -Y[HWKEW9V_B&Z,[DLY51B0ZFC@DR-34&GA' $<>E%     'M?^]=7Z
M1WOWOW7NO>_>_=>Z]["?MGHGIGO?!OMSN/K#9/9&(,4D4$.[-OX_*U./\M]4
MV'R<T/\ $\)5B]UGHYH)E/(8'W969<J:=-2PQ3#3+&&'S'0B==]M]G=299<W
MUGOS=.R,B)$DEEV[F:S'P5FC],>2H8I?L,K3\<Q5,4L3#ZJ?>O/\SOY!>+>A
MRV^_A?G:JDR$"3ULO2.^<N:JCKE4,_V>Q=\Y%Q5T52%4)%29N2=)78ELA" $
M*F.Y\I!^?1'=[(*%[1L_PG_(?\_[>KG/C#_. KUJ\=M'Y08FGJ*.9HJ6/M7:
MF.^WJ:1F*I]SNW:=$AIZJ EBTE1BDA:-0 M'(26&L?NS:6Z-A[ES>S=Z[?R^
MU=U[;R-1B<_MW/4%1C,QB,E2OHGHZ^AJXXJBGF0\V9>5((N"#[5@@@$''0>9
M61BCJ0PX@]7O;=W'@-W8+%;GVMF,;N#;V<HH<CA\UB*R"OQN2H:A=4-325=.
M\D,T3C\@\$$&Q!'O;T_X3Y]6_P!UOBIV+VA54WBK^UNV*NDHY]%ONMK]?X>B
MQ.-DUD MXMRY;-)87 T_6Y("*Y:K@>@Z%&QQZ;:20\6;^0_V:]:W?\Y+?_\
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MG_+H%/DAO_\ T6=!]P=@)/\ ;UFV.O=T5^)DU:/]SSXNHI-OQA[@J9\W44Z
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M=WH:[K+9?@F\=?CL/6T=]_;II]+)-&,-MRH^UBGC824^0R5)(/H?;T":W%>
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M]BHV) <4SP[*:IA'T*U)<?KY+[@UD(]!T+]FCT62M3+L3_D_R=:K?\V??_\
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M\&%VEM[-;FR\UP/#B\#C:G*U\MV(4>.DI'//''O8%2!U5V"*SG@!7]G3UMO
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M+&\;,IT0&!!&.KQR/$ZR1L0X\^DAOS8.S>S]J9C8^_MNXS=.U<]2M29/#Y6
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MWCXDK\C-&/3<I!"D<,=HHD4"W_+I^-J_*GY>=2]79*C-7LV#+MO7L8%"]/\
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MK#"G9F#S'6ZS3N]DB@BEW8K.[6$:@L2+7]MS"L;CY=+=ND\.]MV/#53]N/\
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MP_\ SMW9_P#9%[]XTO\ &>O?NVQ_Y1E_G_GZ]_PX+\RO^?\ >[O_ #EV[_\
M63W[_AJO^7Q_WB]L/_SMW9_]D7OWC2_QGKW[ML?^49?Y_P"?KW_#@OS*_P"?
M][N_\Y=N_P#UD]^_X:K_ )?'_>+VP_\ SMW9_P#9%[]XTO\ &>O?NVQ_Y1E_
MG_GZ]_PX+\RO^?\ >[O_ #EV[_\ 63W[_AJO^7Q_WB]L/_SMW9_]D7OWC2_Q
MGKW[ML?^49?Y_P"?KW_#@OS*_P"?][N_\Y=N_P#UD]^_X:K_ )?'_>+VP_\
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MAO&EOSS]GFL1+;Z6X^^_WGWLA^TO1_U2%[][]U[KWOWOW7NO>Z=/YZM+]Q\
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MT8:IR]+_ !N=AR2E+B%GD;_:4/OYO!)8EF)9F)+,2222;DDGDDGV:] 'K=Z
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MYLAOK(5!']B2IP.>Q2D?ZF%3^?:^V%(Z^IZ">]2:[L)Y(H'YG/\ E'6T%_*
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M[W[KW7O?O?NO=>]^]^Z]U[V6[YD5:T/Q#^5-:[%%I/CAWA4LX )40=9;GDN
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M"",=9Z6JJ:*IIZRCJ)Z2LI)XJJDJZ662"II:F"198*BGGB9)89X94#(ZD,K
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MOFH-MX4U !($U%3[&K"@X8)5DGAE]K;5<,W0:WV2LD$(\@3^W'^3K8:_DJ;
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MI[@:CIJSN$QFY<)F=N9NDCK\-G\5D,)EZ&87AK<9E:2:AKZ24?F.II)W1O\
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MWM?_ .__ /C*_P";KW_#7OP@_P"?-U'_ *,CM3_[-??O^'HOYD7_ 'D%2_\
MHHNDO_M<^_>!%_#_ #/7OWM?_P"__P#C*_YNO?\ #7OP@_Y\W4?^C([4_P#L
MU]^_X>B_F1?]Y!4O_HHNDO\ [7/OW@1?P_S/7OWM?_[_ /\ C*_YNO?\->_"
M#_GS=1_Z,CM3_P"S7W[_ (>B_F1?]Y!4O_HHNDO_ +7/OW@1?P_S/7OWM?\
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M8G<#DQTN+\TC6YTH??S<F8L2S$LS$LS,22Q)N22>22?9KT >MWX * J@
M 6  X  '  'OKW[KW7?O8S_X3H5OC[E^1^.N/\JZRVE6Z>+G[#=51!<?VK+_
M !+_ %N?];VENOA3[>C[83^K<#^B/\/5)_\ .MI=?6/2-;;_ (#[\W'2ZN>/
MO-OPRV_IS]C_ *_'O;.]HNA-UKK^_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][]
M[]U[KWOWOW7NO>R@?.[Y.X[XB_%_LON266E.Y:+&?W=ZYQU2$=<OV+N-):#:
M]/\ ;O85=-C9R^1K(@06H*&<CD>[QIK<+Y=);VX%K;22_BI0?:>'^?[!T9/X
MD=#5OR/[[V+UE''.,%55XS6]JV#4IQVR<(T=7GYO,ES33UT.FBII""!65<-^
M#[^>7E,GD<WD\CF<O6U63RV7KJO)Y3(ULSU-;D,C7U$E56UM742EI)ZJKJ96
MDD=B69V)/)]FG#H#$EB234GK<ZH*"BQ=#18S&TL%#CL=24U!045+$D%+1T5'
M"E/2TM-#&%2&"G@C5$50 J@ >X/OW6NI?O;>_P"$[O5?\$Z-[T[BJ:;QU/8/
M8^&V3CI94]<F'ZYP)R3U%,Q'%-4Y;?D\3Z3ZY*.Q_0OM%=-5E7T'0GV**D,T
MIXLU/V#_ &>M<O\ G2=@_P 5[8ZFZS@GUP;-V1D]U5L<;>A,EO;+BA2&=0>9
MX,=M&*1;CTI4\?J/O8C]I>CWJEOW[W[KW7O?O?NO=>]^]^Z]U[WKE_\ "B?M
M+^%=0= =-4U3IFWKV!N'L')P1-9_L.O\#'@J%*H#G[:KKM_NZ*?2\E(3]8^%
M5JO<S?+HAWV2D4$0\V)_8/\ 9ZNQ_DK[ _B'9/<79L\%X]K;.PNS:&61;K]Y
MO'+OEJMZ<GCSTU)L]4<CE4J;?1^=3+VMZ#/6Q/[WY_Y25;'7_P NSXR3Q,K*
MFV=UT1*FX\F.[)WICYE/)]2S4K _XCV6S_VK]#7;#6PM_L/^$]:@'\QFE>D^
M:?>\4@96?/;>J@&X.BMV/M>MB/\ P5HJ@$?X'W8U[:Z7]$F]^]^Z]U[W[W[K
MW7O:-[$SE5MCK_?6Y:%Q'6[>V=N?.4;M&LH2JQ.$KJ^G<Q.DB2!9J<'258'Z
M$'Z>]@5('5)&*QNPX@$]*;96)I\]O':6#JU+TN9W-@<34H':,O3Y'*TM',HD
M5D9"T<Q%P01];CWH]?\ #T7\R+_O(*E_]%%TE_\ :Y]F'@1?P_S/0/\ WM?_
M .__ /C*_P";K:T_X:]^$'_/FZC_ -&1VI_]FOOW_#T7\R+_ +R"I?\ T472
M7_VN??O B_A_F>O?O:__ -__ /&5_P W7O\ AKWX0?\ /FZC_P!&1VI_]FOO
MW_#T7\R+_O(*E_\ 11=)?_:Y]^\"+^'^9Z]^]K__ '__ ,97_-U[_AKWX0?\
M^;J/_1D=J?\ V:^_?\/1?S(O^\@J7_T4727_ -KGW[P(OX?YGKW[VO\ _?\
M_P 97_-U[_AKWX0?\^;J/_1D=J?_ &:^_?\ #T7\R+_O(*E_]%%TE_\ :Y]^
M\"+^'^9Z]^]K_P#W_P#\97_-U[_AKWX0?\^;J/\ T9':G_V:^_?\/1?S(O\
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MV]=T0,+&R2[=V]5*2;A0;_CW20Z8W/RZ564?C7=O'3!85^P9/\AT6_Y@;_\
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M]H>A3UK:>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>]./\
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MNO=>]]JK.RHBEF8A55069F8V"J!<DDG@>_=>ZZ9@H+,0JJ"S,Q "@"Y))X
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ML3X ]3U>]JBKR%3M;);OV+M_+5SR25.1VCM;/5-%M]3+)_G8,'2L<5"1PL-
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MA0#;RPY/=,L$AM?5#;Z*/=OOMCHTZK:]^]^Z]U[W[W[KW7O?O?NO=>]ZKO\
MPHP[0^XW7\;>EZ6HT_PC;V\NS\W2!K^8[BR-#M7:]0Z?V33#;&753^?,W]/:
MRU&';H-[])W6\(/ $G\\#_ >M@;^2CL+P[>[P[0GAU?Q+,[9V%BZ@K;Q?P6A
MJ]PYZ%6_M>?^/XUF'X\8_K[UH/:OH/\ 5Z7OWOW7NO>[U_\ A/?6_;?-7?\
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MIQU/W=!O+M?>F2P<VOR?[]B+-U5!M6(."0XI]MT=+&"."$N !Q[-$&E%'RZ
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M_8NP:F.1UC_AVX]NUKR?P?=FWY9HI:O#9-(_7'=XED@J$_=IIT5UN R-I/\
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M&5']/>_&E/XSU0;=8J:BV7^9_P /2OR7S]^8^5IWIJKOW>L4;H$+8W^#8:H
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M]^]^Z]U[W[W[KW7O=I?\EVM^T_F0= 1$V7(4G;=$3Q;_ )DOV%6("21^J2D
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M_P#2S[]_T$B?^ 9_^S$?_H+]^^E_X9_+_9Z]^_\ _ET_XU_T+U[_ (9!_P#
MG?\ V"W_ .EGW[_H)$_\ S_]F(__ $%^_?2_\,_E_L]>_?\ _P NG_&O^A>O
M?\,@_P#@3O\ [!;_ /2S[KS_ )B/\T+;7S]Z_P!C;7K?C9_HQW7U]NFJSNW]
M\)VVN])(L1F,:U#N/;4F&;K#:A-+FIZ6@J&E%6#'+CX_2P9A[=BA,1)UU!^7
M2&_W%;U$4V^EE.#JK]HX#Y?LZ.=\+?@1G/A[O'=F?I>\?[^;>WEM^GQ.8VHW
M7+;71\EC:Y:O"9Q,F-^[A J,7#/60B,TQ#QUC^I2![J+]O\ 17U8][][]U[K
MWOWOW7NO>_>_=>Z][GXO*9/!Y&AS&%R-?B,OC*J"NQN5Q=948_(X^MII%EIJ
MRAKJ22*II*JGE4,DD;*Z, 00??N/6P2I!!H1U$K\?096BJ\9E**DR6.KZ>6D
MKL?7TT-915M+.ACGIJNEJ$D@J*>:-BKHZE6!L1;W<W\:/YYWRSZ6I\?M[M2+
M#_(O9]$L4"MO*IFP?8L%+$ JPP=@XVEJVR3M<EYLOC\K5.;?O "WM.]NC9&#
MT;6^\W4-%DI(GSX_M_S@]5A=Z?RG/CKVC-69KK^3)]*;EJFDE9=L019794M1
M(23)-LRNGIEH4%@%BQM9CZ=!?]LDW]W5=0_SY/A-OZ&F@[";L/I'+OH2I&Z=
MJU6ZMO"=_P"S19K8/]X<C-3AC8RU..H@/J0%%_;#6T@X4/1M%O5H_P#::D/S
M%1_*O^#JKGLC^47\I]GR33;,&R^U,<NIH#M_<$&W\R8E/UJL7O#^"T4<Q'(2
M"MJK_0$GCV?_ &7\ZOAGV#%$^U?E#T;6RS!3%CZ[LC;& S#!K6_W![AR&*S
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M/T]_/G^%>_XJ2F[&C[#Z0S$BHM6=R[9J-W;92H?Z)19S8@SF6G@!(!EJ<71
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M_H7KW_#(/_@3O_L%O_TL^_?]!(G_ (!G_P"S$?\ Z"_?OI?^&?R_V>O?O_\
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M9!_\"=_]@M_^EGW[_H)$_P# ,_\ V8C_ /07[]]+_P ,_E_L]>_?_P#RZ?\
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$_P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MU>;4?+=_-;?B<SK16BN_R-7PW\5M)\0S"T;?93N<(LVW8Y/15D!(W'L'"9.
MNXD"LJV"J45SJTHK>VZ]5V]+E1JQD[;/S/3J\PW"@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MP#HO?:X??CH"K$#+'/A8^DDE6BK.]GY]G\K6_P"&*1](U\^,* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M^ZN<M[X!QWQD5K*E4@KRC)+NT[#<6MTT=!6)(4 % !0 4 % !0 4 % !0 4
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MR?\ ?MI2F/;;CVKL>+KM6YW]R3^^UP.YBA2W18HE5(T 554!54#H% P  .@
MP*XFVW=ZL#XU^+7B>YUK69K$L5M+!S%'%G WKQ)(P[LS9"D_=0 #'S$_482D
MJ=-3^U)7;\NB_KJ=].*2OU9Y:C&,AE)5E(((."".001R".Q[5Z'D;'VU\+/$
ML_B;0TGNR7N+:1K>1SUD**C*Y_VBDBAC_$P)[U\IBJ2HU&HZ)KF2[7NK?>CS
MZD>65EMN>CUPF04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MW3[H\:K2=&7*]MT^Z.RKF, H * "@ H * "@ H * "@ H * "@ H * "@ H
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M>.>8% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MU?Y);)>2T/HJ5*GAX*E1BHQ71?FWNWW;NV:-8FX4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 5;RS@U"%[:ZC2:&4;7C=0RL/0J<@_P!",]:I-Q:E%V:V
M:&FXN\79H\W3X-^%DG^T"T) .1&9IC'GD_=WY(Y^Z25X QC(/;]<K6Y>;YV5
M_P CK^LU;6YOG97/0II[/1+;=*T5G:P*%RQ2**-0, 9)55 ' ''H*XDI3=E>
M4G\VSF2E-V2;D^VK91TKQ1I.N.8].O+:Z=!DI%*CN!Z[02V/?&*N=*=/6<91
M7FFBYTIT]9QE%>::-ZLC$* "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * ,W6-172+*>^<9%O$\F/4
MJ,A?^!' _&MZ--UJD*2^U)+TN]_D<]>JL/2G6EJH1<K=[*]OGL?%5]>S:C/)
M=7#%Y9F+NQ[D^GH!T Z   <"OU&G"-**IP5HQ5DO3^M>[/Q:K4E7G*M4=Y2;
M;?K^BV2Z*R14K0Q"@#NOAYKSZ'J\(R?(NF6"5<\8<X1CVRCD'/4+O ^\:\G,
M*"KT)?S03G%^BU7S6EN]NQ[N58EX7$P7V*C4)+_$[1>]KQE;7I'F2W/KBOSD
M_6@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * #% 'QA\?M<N
M;O7!I;,5M;**-D0$[6DE7>TA'0M@A ?X0I QN;/U.7P4:;J+XI-J_DNGZGU>
M74XQI.I]J3:OY+I^IXII^H7&DW$=Y9NT,\#!XW4X*L/Y@]"#PP)!!!(KUI14
MTX25T]&CUY14XN$E=-6:/TJTB\;4;&WNW&UKB"*4J.QD16(_ G%?!R7+)Q[-
MK[F? 37+)Q71M?<S0J" H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@#C?B!$TV@7JH,D1!OP1T=C^"
MJ3^%>G@&HXFDW_-;YM-+\6>1F<7+!UDOY+_)--_@CX_K])/Q\* "@#0TJ)Y[
MRWBBSO>:)5QR=S.H&!ZY-8U6HTYRELHR;]$G<Z<.G*M2C'1NI!+U<E8^XJ_*
M3]N"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /'/B?\*4
M\=,E]9RK;7\2>7EP?*E0$E5D*@LK(2=KA6X.TJ<*5]/"XMX:\)*\&[Z;I^7^
M1ZF%Q;PUX25X-WTW3\O\CS#PS^SW>"Z2779X!:QL&:*!G=Y0"#M+,D816Z$C
M<V,@!3AAZ%7,8\K5%.[ZNRM]S=V>C5S&/*U13YGU=E;Y)N[/K!$6-0J *J@
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MNA)I:O\ AM_:5]H_S+_MY:W4OIL8(R*_/S]7%H * "@ H * "@ H * "@ H
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M1%1J24=%H_O5S\VS*G&EB9QIJRT=ELFU=^G?YGIU<IY 4 % !0 4 % !0 4
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M11@*HZ#_ !)R2<DDDDUQMMN[U;/#G.523G-WDW=M]66Z1 4 % !0 4 % !0
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MT0M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 9>MZM%H-C/J-QDQ6L32,!U.T9"CW8X49XR1D@4TN9J*W;L;4J;KU(T8
M;R:2\K]?EN?'U[\</$MQ<F:WDBMH<_+ L,;KM[!G=3(3ZE63)Z #@>LL-!*S
MNWWV^Y?YW/T"&486,.6:E*7\W,T_DD[?>F?3'P[\:#QOI@O&017$+^5.BYVA
MP P9,Y.QP<@$DJ<KEMN3YU2'LI<O3=>A\;CL)]2J^S3O%KFBWO;:S\U;]>IW
MM8GEA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 9H I
MWNHVVFIYMY-%;1_WI9%C7_OIR!^M0Y1C;F:5]KM*YO2HU:[Y*$)U)=H1<G]T
M4V8MMXST.[<10ZA9N[=%$\>2?0 MR?8<U'M8?S)>NGYV.^>68VE'GJ8:LHK=
M^SG9>NFGS.E!SR.E;'D[:"T % $%U:PWL9@N$26)^&1U#*?J""/<>AYJXSE3
M:G!N,ELT[-?-&<X1JQ=.I%2B]U))I^J>AP%Y\+=#NF+(DMOGM%(<9/<"028^
M@X'ICBO:AFN)@K-QE_BC_P#(N/\ F?.U,BP51WC&4+_R2=M?*7,EZ+3RL3V'
MPTT2P82&)KAAR//<LOXH J-]&4BLZF9XFHN7F4%_<5G][NU\FC2EDN"HM2]F
MYM;<\G)?..D7\T_O.]2-8U"( JJ,  8  Z  < #M7CMMN[U9]"DDK+1+9+H.
MI#"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * ,'Q-HJ^(M,N=,8[/M43(&QD*W5&([A7 )'H./6JB^5J79I_<=.'J_5Z
ML*R5^62=NZZK[CX<O?AUXBL;DVC6%S(X. \43R1-SC<)4!3'?D@@$;@M>TJT
M&N;F2\GO]W^1^F0Q^&G#VBJP2[2:4EY<KU^Y/RN?6'PH\&W'@W26BOL"[NI3
M-(@((C&T*D>1D%@ 68CC+;02%R?+K3525ULE9'PF98J.,K<U+X(+E3VOJVW;
M\%Z7/4:YSQ0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH \Y^(_CQ/!5F/*"RWUSN6!#T7 ^:5QUV)D87@NQ ! #%>:K4Y/=C\3_  7?
M_*_GO:Q]3DN4RS:L^=N-"G9U)+=WVA'^\];O[*UWLG\9:KK%[KDYNM0F>XF;
M^)SG ]%'"HOHJ@*.PKS^M^KZ]?O_ "['[QA\-1P<%1PL(TX+I%?BWNWYMM^9
MF4'6>G> OB5>^$ID@G9KC32P#PL2QC4\%X2?NE>NS[C8(P"=PN$G3=X[=8]'
M_D_/KUZ6^1S;)*.9PE4II4\2E>,TK*3[5+;WVYMUYI6/M"UN8KV%+BW8212H
MKHZ\AD895A[$'(KU$TTFMF?@LX2I3E2J)QG%N,HO=-.S3]&6*HS"@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * $H \^\6?$S1O!\HMKQY)KC )AMU5W4'H7W.B+D<A6<,1SC!&=(PE
M/;;OT_KT/7PN75\8N>DE&&W-)M)^EDV_DK7+/A/XAZ1XR+1Z?(R3H-Q@F4)+
MM_O !F1@"<'8[;<C=C(R2A*'Q+Y]",5@*^"LZR3B]%*+O&_;9->5TK]#N169
MY84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % "9Q0!\4?%_4G
MU#Q+<HQREJ(X(QSP%17;K_TT=SQVQUZGRIOFE)^=O2VGW73?JV?OW#E!4,NI
M27Q5'*I+S;DTO_)8Q_K0\QK,^N"@ H ^RO@IJ+ZAX=6.0D_8[B6!2?[N$E ^
M@$NT>@&.@%=]"_*UTYG;YI-_BVS\)XGH1H9@Y1LO:TX5';O>4'\WR7^9ZY74
M?$A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % "4 ?G=XK>>36+YKK/G?:Y]^[J")&&/H,8 '   '&*
M]:G\$;=E_P '\3]APJBJ%)4[<OLX6M_A7]/S\S5^'3W$?B33C:YWFZC#8_YY
M$XF_#R2^?;-35MR._P#3Z?B89@HO"UO:;<CM_B7P_P#DUC[]%>6?DH4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\9?&;1Y--\0R7)!\J
M^1)4/;*HL<B_4,NX]\.I[Y/E5%RSDOFOG_P;G[QPSB8U\!"DG[]&4H276S;E
M%^C3LO\ "SR:LS[0* "@#[4^#^C/H_AV(RC8]Y(]T0<]'"I&?;=%&C8'8^N:
M[Z":C=[-W7IHOQ:;7DS\"XCQ*Q6834'>-*,:2?G&[E]TY27R['J5=1\@% !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % 'EWC'X3Z3XON/MKF2TNB 'DAVXD X!D1@06 & RE3C ;<
M  -8U)0T6W9_TCW,)F=;!Q]E&TX+92O[OHT]%Y:KM:Y:\&?#'2O!<AN;??<7
M9!7SIB"44]1&J@*F[N?F8CC=M)!4IRG\7W+8C%YC6QJY)VC!:\L>K[MO5_EY
M7/1&D5" Q"EN!D@9/H/4_2LMCQTF]N@ZF(6@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * ,/4?$NEZ0_EWUW;6SG^"2:-&_P"^2V['OC'3U%9N<5HV
MKK=+5KU2U.^C@L3B5S8>C5J1[QA)K[TK$VFZ]IVL9^P7,%UMZB*5'(^H4DC\
M0*:G%Z)J_;K]VY%;"U\+_O%*I3OMSPE%/T;23^1B>-O!UMXTL#9SGRIHR7@F
M !,;X].-R-P'7(R,$$, 1G4I^T2Z-;?JO1_G9^1Z.5YE4RFO[>FN:#TJ0O92
MCZ])+>+Z/NFT?'/B/P+K'A>1EO;=S$N<3Q@O"P'?>H^7UVN%8=Q7G-.&DU;U
MV?H]G^?=(_<\%FN$S"*>'JQ4W:].349IOIRO?UC=>9RT%O)<N(H$:61NBHI9
MC]% )/Y4FTM]#V9SC33G4DHQ6[DTDO5O0]P\ _!^[U"9+[78S;6B$,+=^)9N
MX#KUBC_O;L2'& H!W5M"E*>]U'KT;\EU7K]U]U^>YOQ'2H0EA\NDJE9W3J1U
MA3\T]IR[6O%;WOH?5R(L:A5 55   &  .  !P .P[5Z25E9:)'XRVVVV[MZM
MO=L=3$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0!QGC_ ,2/X3T6XU&$!IE"QP@\@22,%5B.
MX3)<@_>V[>]-*[4>_P#PYZ> PRQF(A0EI%W<N_+%7:7KMY7N?"&HZG=:M,US
M?2R7$SG)>1BQ^@ST [*, #@ "N])1T2L?KE.E"C%4Z45&*Z)6_I^;U/HCX(>
M-KVZN7T&]D>>/RFEMV<EFC*$;H]Q.2A4Y4$G:5P,!N.6I%1LUHGI;^O3^M3X
MO.\%3A!8NDE%\RC-+1.^SMM=-6?>_D?358GP@4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 )0!^>GB:X>[U:]FE.YWNIR3_VT;@>@ X
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M-))+NN;L?6]=Q^,A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#YS_:$TR:6VL;]
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M36EQ''C(.]X75<8YSN(Z4GHG?738\_"3C3Q%&I4^"-6G*7^%33?X'YX4S^@
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MIC&.U2J<5TOZMO\ !MG;5S3&UX\E7$5'%Z-*7*FO/EM?YG75J>.% !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M*I!+<^')VS&4-U;@_P + JLR#V8,C@#&"LC?Q&@#ZVH * "@ H * "@ H *
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M!#<3I:QO-*=L<:L['T51DG\ * /RVU6_?5KV>^E^_=32S-W^:5V<\_5J *%
M'0^$?LBZS9-J,BPVB7,+SNP)41HX=P0H)^8+MZ'!;)XH ^\_^%P>$?\ H)0_
M]\3?_&Z #_A<'A'_ *"4/_?$W_QJ@"C??&[PC9+N%]Y[8R$BAG9C[9,:H#_O
M./RH ^7/BC\6[CQ\5LK5&M-,B;>(V(,DSC[KS;25 49VQJ6"DEBS';M /'*
M$H ^N/V;_"KP17/B.=<"<?9;;(ZHK!IW'L75$!'=)!0!YC\:OB WB[5386KY
MTW3G9(P#\LLP^628^O.4B/(" LN/,;(!XK0!N^'/#E]XJOH],TU/-GER>>$1
M1]Z21N=J+W)[D*H+%5(!]H>%?@+X?T2)6U-#JEUCYGE++"I[B.%6 V^\AD8G
MGY<X !TFJ?![PIJD9C:PCMR1P]N6A=3@#(V$*3Q_&K#N1DYH ^.OB7\-[KX>
MWBH6-Q8W.3;SXP3MQNCD X61<CI\KK\RX^94 /,Z /H;]GCQ6^F:P^ARM_H^
MI*S(">%N(4+@CL-\2NK=-Q6,9R " ?8^L7ZZ38W%^V"MK!+,0>F(HV<YY'&%
M]1]: /R[N[J6^GDNKAB\T[M)(QZL[L69C[EB2: *] 'L7P@^&</Q N9Y+Z5X
MK*Q\O>L6!)*\F_:@)!"* C%VVDGA5P264 ^GQ\#/!RIL-BQ/]\W5WN^N!,%_
M\=Q0!YUXK_9PM7C:;P[<213 9%O<D/&V!]U)0JO'GMO$@SU91R #Y/U'3KG2
M;F2RO8V@N(&*21N,,K#]".X()# @@D$&@#I_"OP^UOQDX&F6S-#G!N)/W<"X
MX.9&&&([J@=_]F@#[V^'_AJ[\(Z-#I-]<B]>#=M=5*A$)R(EW$LZH2P5FVG:
M0H50H% 'EG[1^K?9-"M]/4X:]N@Q'K' A9ORD>(Y[8QWH ^*: $H ^S;'1AI
MGPHDBD'S3V4EVW;)EE\Z(_@GECWQZ'% 'QG0!)#*UO(LJXW1L&&>F5((S[9%
M 'ZLYH _/#XN^+_^$O\ $$TT3;K2T_T:WP<J4C8[I!@D'S9"S!AR4V _=% '
MF% 'U-^SIX3 :X\47:@)"&@MF;H#C,\H_P!U,1AAP=TJ]J /G'Q!J9UO4KK4
M6SF[N)IN>PDD9@/H 0 .P ':@#(H ]W_ &>=(^W^)3>,N4L+:60'L)),0J/J
M4>0C_=/?% 'M/QW^(#^&;!=&L'*7VHJ=[J<-#;9VLP.<J\IS&A'11(00P4T
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M8@'#T +0![I^SUI'V_Q-]K896PMI90>P>3$"CZE9)"/]T]\4 ?=5 !0 4 %
M!0!YS\6M7_L7PKJ$X.'E@^SIC@YN&$.1[JKLWKA3CF@#\YJ %H * "@ H *
M$H * /6OAQ\)]0\<3I/,KVNE*<R7##!D ZI;AA\[-TWX,<?))+ (P!]8?$C5
M8? 'A*9-.46^V)+*T53C89!L!4GDM''OE!.267+9R30!^>M "T ?1OP<\<>%
M_ ME++J+R_VE=OARL#.$A0_)&K#^\<R/CKE ?N"@#V;_ (7_ .$_^>MQ_P"
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M8".&2-".M 'E- 'T[^SGX0-S=3>)+A?W=L#!;9'69P/-D7_<C/EYZ'S6'5:
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M +FG6+ZG=0V47^LN98X4[_-(X1?U- 'ZEVMM'9PQVT0VQPHL:#T5%"J/P %
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M,%2!\Q4L0/F+4 ?:?PZ^+.F^-H$@F=+35%4"2W<[1(PX+P%L"16QNV ETY#
M@!V /6: &2R)$A>0A$4$LS$!0 .22>  .I/% 'YH^.Y=/FUZ^DT?;]A:X<Q;
M,!",_,8P./++[C'CC9MQQ0!R= 'IWP;M'O/%VGA 2(Y))6.,@+'#(Q)] 2 N
M?4CJ< @'U9\=]7_LOPI<1J=KWLD-LI[G<WFN/^!11.I]B>^* /@2@ H ^XOV
M=M)^Q>''O6^]?74C@_\ 3.(+"H]\.DI_'':@#VW58O.LYXQQOAE7/IE&% 'Y
M84 +0 4 ?2/[.W@\ZAJ$OB&X7]S8 Q09'#7$B_,P_P"N43?]]2H0<K0!]FT
M?FC\0=7_ +<\1:A? Y62ZD5#G.8XCY49_&-%^E ''T >J?!72#J_BRR! *6I
M>Y?/;RD)0_\ ?XQC\<]L$ ^_K^SCU&VEM)N8[B)XG'^S(I1OT- 'Y=ZKITVC
MWD]A<#;-:RO"X_VHV*G'L2,CU&#0!0H ^L?V?/'UM;P-X8OY%AD\TR6;.<*_
MF<O""> X8;T!.7WL!R " ?5U #68(,DX Y)/0 >] 'R-\:_BW%?J-!\/SED5
MP]U=0L0&*'*0Q..H# .[H<$A55B-XH Y;P;\?=9T';;ZN/[4M5P-SG;<H/:7
M!$F.3B4,S'CS%% 'U7X2^(NB>-%']FW"^?C+6TN(YUP,G]V2=X'=HRZ#^]0!
M3^+.GG4_">I0+R5M_.X_Z=W2X_E%0!^<U !0!]F_L[>+8+O2W\/2N%NK)WEA
M0\;X)&WL5]3'*S[QV#H?7 !](4 <SXL\7:=X-LFO]2D"  ^7&"/,F<#B.->K
M,3U/W5'S,0H)H _.GQ7XEN?%VISZM><27#9" DK&BC:D:Y_A10!G W'+'EC0
M!SU 'JGP6TC^UO%ED",I:E[E_;R4)0_]_C'U^OH" ?H50 4 % !0 4 <UXRU
M?^P=$OM1'#6UK*Z<X_>;"(QGMERH_'CTH _,:@ H ]E^ ND_VGXKAE(RMC#-
M<GTR%$*9^CS*P]UH ^^: "@!* /SE^*GAO\ X1;Q)=VB+M@E?[1!Q@>5-EPJ
M_P"S&^^(?]<_QH \\H 2@#]$_A'XI_X2OPY;3NVZXMA]EN/7S(0 &/J9(S'(
M>!\S$=J /0KVSAU""2TN5$D$Z/%(AZ,CJ593[%210!^</C_P5<^!=5DT^8%H
M&)>VE(XEA).TYZ;U^[(O9A_=*D@'$4 7M/U*ZTB9;JQFEMIT^[)$[1N/4;E(
M.#W'0]Q0!Z /C)XO6/RAJ4FWU,5N6Z8^^8M__CW7GKS0!P^K:Y?Z]+]HU.XF
MNY!G#32,^T'LH8D*.!PH ]J ,J@#8\/Z!>>)KZ+3-.0RSSM@#G:H_B=R =L:
M#YG;L!T)P" ?H+I'PYTW3/#A\+LOFP31LMQ)@!I)7 +3#KAU8*8^NP(@!.V@
M#X.\:>#KWP1J+Z=?*2 2T,P!"319^5U_DZY)1LJ<\$@')4 *..1QB@#L+#X@
M^(]+4);:E>(B]%,[NH [!7+*![ 8[]A0!G:KXKUC7!LU&]NKI/[DLTC)Q_L%
MMGZ=>>M &!0 E 'V9^S]X"DT>V?Q%?H4GO4$=LC ADMR0S2$'H9F"E>,^6H8
M$B3  .?_ &F=7^;3M*4]!+<R#ZE8HC^DP_P[@'RG0 4 ?IAX TG^P_#VGV)&
M&CM8BX'022+YDG_D1V^OH* .JFC\U&C/ =2N?3(Q0!^4U !0!/:VLM[-';6Z
MF2:9UCC0=6=R%51[LQ 'N: /TL\$>&(_!^C6VDQX+0)F5Q_',YWROZX+D[<\
MA J]!0!:\6:M_8.CWNHYP;6VFD7_ 'U0[!^+[1^- 'YA4 % 'U'^S/I.^YU#
M56'^JCBMD;U\QC)(!]/*BS_O#'>@#Z[H ^1?V@OA\\4W_"4V"$QR!4O54?<<
M )'-@?PN,(_HP5CDN< 'RW0 #CD<8H ] TOXJ>*='C$-KJ,^Q?NB79/@>@,Z
M2$ =@#@<8' H S=;\>Z_XC3RM2OKB>(]8]^R(_[T<82-OJRD]?4Y .1H 2@#
M[5^!?PT?P];G7]439?728@C<8:"!N2S _=EFXR/O)& I(+NH /H6:%+B-H9
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M(H ZA45 %4 *!@ #  '8"@!U !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 5[FS@O4\JYC29#U615=3]0P(H Y:7X>>&IFW-I=AD]<6L*_HJ 9]^M
M%JR\%:#IQW6NG6,3#^);:$-_WULW?K0!TP4*, 8 Z#TH 6@ H * "@!DD23*
M8Y%#HPP58 @CT(/!'UH Y>;P'X=G?S)-+T]GSDDVD&2?]K]W\W_ LT ;6GZ/
D8Z0NRPMH+13U$$4<0_)%44 :- !0 4 % !0 4 % !0 4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
MB5!.1PT*&@H    -24A$4@   (<   !P" 8    T<&.K    "7!(67,   [$
M   .Q &5*PX;    !W1)344'Y <;$B$C16/L-0    =T15AT075T:&]R *FN
MS$@    ,=$58=$1E<V-R:7!T:6]N !,)(2,    *=$58=$-O<'ER:6=H= "L
M#\PZ    #G1%6'1#<F5A=&EO;B!T:6UE #7W#PD    )=$58=%-O9G1W87)E
M %UP_SH    +=$58=$1I<V-L86EM97( M\"TCP    AT15AT5V%R;FEN9P#
M&^:'    !W1%6'13;W5R8V4 ]?^#ZP    AT15AT0V]M;65N= #VS):_
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MI#?ZG&FR:NTZBHJVH $BI06R\XB8S[FZ#$-OV1<![-F]FW7KUQ )!\&2@$5
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M@\$8[T29HP1J#^K\J$QM.!PF% H!X//Y&#UZ-)F9F>BZ3FEI*:^__CIE964
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>rmd-20240630_g1.jpg
<TEXT>
begin 644 rmd-20240630_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O'OVQ?VO]"_9,\+:')#X&U'Q;XK\7:RFD^#?"&DR".?5+ML9!
MD8$11KE=SX;!=>#G(]AKYN_X*#?LS_&CXNWOPZ^/'[-]QI<OCKX4>(9=3TC1
MM;D\NUU6"98UGMV?(V.PB0 DJ,%OF4X8 'E7PD_X*D_'3PIX^.A_MF_LW)X8
M\.:K\1[GPI9>+M%UR*[M]&U%0A6PNE4?,!NS]H!"L-Q"D(Q'OW[5?[:GA/\
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M^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\
MZ%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\
MH4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI
M: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_O
MI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V
M**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$E
MU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (27
M5_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+
MW_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4
M+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^
MEH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:
M/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_
M (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?
M_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU
M?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]
M_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W
M_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -B
MBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^
M$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_
M^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\
MZ%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\
MH4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI
M: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_O
MI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V
M**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$E
MU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (27
M5_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+
MW_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4
M+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^
MEH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:
M/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_
M (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?
M_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU
M?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]
M_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W
M_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -B
MBL?_ (275_\ H4+W_OI:M:5JM[J$CI=:)/:A5R&E(PWMQ0!>HHHH **** "B
MBB@ KYO_ &]?B3^U/\"O$OP\^.GP7TG5O$?@70]7GC^*/@[0=,BN+R[LI458
M[J,%#(?)_>,51E&[RRWRAF7Z0HH _)[QO\68?VZ/A-X^_8__ &</AKXAUS6_
MB#\=+G6VUN\T&:WLO#NF>9;R?:KF60#RI/W;)LZX+#[Q56^P?VG/CQ^T;^R/
M\??"7CV_\/ZSXJ^!MQX<;3?%,.@:$MW?Z+J2L2E_+L7S6B90BG!VC,F1N\L-
M]!>!/AGX,^&IUH^#=*:U_P"$@UZXUG5MUP\GG7LX42R#>3M!V+\JX48X K>H
M ^"?B;\0KK_@IS^TY\';+]GSX=^)(?!'PS\8P^*?$WQ U[0YM/MV>%HWCLK;
MS@KR.Y3# #(W*V-JDUM^,/$FJ_\ !/']OCQ_\>/&_@'Q!J'PL^,6EZ=/>^(?
M#VDR7HT35K*-H]EQ'$"ZI('D<-@Y,@ !VMM^VZ* /C']GF3Q-^VI_P %!#^V
MS:^ -<T+X=^!?!<GA_P3=>(=.>TGUN]GD<SW<<3C<(1')(F3U^3OO5>9^"/Q
M>MO^"6OQ,^)WP0^/_@+Q0G@GQ'XWN_%'P]\7:'H$]_:3Q780/8N85)CECV(,
M$<G>3M4H6^]** /DK_@GSX(^(?Q,^/WQ9_;W^)/@#4_"T/Q$GL=.\%:%K=OY
M-['I%G$(Q<31GF,S%(F"GNK$95E8_6M%% !1110!X7^UA_R6SX'_ /8]R_\
MI,U>Z5X7^UA_R6SX'_\ 8]R_^DS5[I0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >%_M8?\EL^!_P#V/<O_ *3-7NE>%_M8?\EL^!__ &/<
MO_I,U>Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?[6'
M_);/@?\ ]CW+_P"DS5[I7A?[6'_);/@?_P!CW+_Z3-7NE !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!X7^UA_R6SX'_ /8]R_\ I,U>Z5X7
M^UA_R6SX'_\ 8]R_^DS5[I0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >%_M8?\EL^!_P#V/<O_ *3-7NE>%_M8?\EL^!__ &/<O_I,U>Z4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7S;_P4%_:.^,WPOU7X:_L_P#[.M[IVF>-/BQXDETW3_$>
MK6HG@TBV@6-IYQ$P*R2 2IM5@00&X)Q7TE7CG[97[(?@C]KCPGHFD:MXUU'P
MKXF\.:N-2\%^+-%E"W>F7JC.Y 2/,4A060$'Y%(92N: /E'X&7O_  4:^!_C
M35?&OAGXK:E\9?#5O\;+[PUXX\+77A^&.[6)5C+ZK;R(<PJ 3^Y#"-2$&&#$
MK[S^UE^TK^T&/VC?"O[%G[)ECHMIXKU_0I==U[Q;XEMGGM-%TQ)&C#)$A'FS
M,Z$ '(&4!&'W)\P_"G]HW]LW]@"W\:_$/XLOX?\ B/\ "VU^,M]I7COQ#:VA
MLM:M[YV@C>_$2GRO*?,>(QNRWRY3(8_HG\2OB[\-?@_\.KWXL_$OQE9:1X=T
M^U%Q=:I=RXC"'&T+C)=F) 55!9B0 "2!0!\OVG[0'[9?[(G[1WP_^$'[6OC7
MPS\0/"7Q/U-M(T7Q9HFA_P!F7NFZG\OEQ2P*QC>-RZJ".>2V1MVOH_M7?M!_
MMAZA^V=H'[(7['&L^#;"_D\ 2^)M?OO%]C--##%]J,"#="&93E1QM.?,'(KE
M_@OX?^)W_!2']IKPQ^V7\1/"=YX8^$?P]FEN/A3H&I)LO->O'QC5)U_@C&U&
M09QE$VEAO9ND^*7_  3;^(?QC_;.\6?M$ZO^U#XC\)^'==\.V>DVVG> ;DV.
MJF&%(RT,EVRMLB,R-(50?/N .-O(!WO[-?AO_@H_I/Q"ENOVK_B'\+M4\,'3
M9%BMO!MC=QW8N]R>6Q,T:KY87S,C.<E:\VB^//[9O[9?QM\>>%/V0?B#X8\!
M^!OAOKC:%<^)]:T#^T[G7-6C'[^.-&8)'"AP-P^8AE8%M^U,3X/ZI\:OV(/^
M"@?A?]COQ%\<O$GQ#^'OQ-T"]O/#%QXSO?M>IZ+>6L4LKQF? ,D92+&,!?WB
MX52C%]?_ ((E!A^S1XV^U_\ '[_PN+7?[2S][S\6^=WOC;0!Z'^PW^U+\3/C
M!J_CKX!?M%:#I>F_$SX8ZM#9^(?[%+"SU*VG0O;7T"N=RK(@)*GIE3\N_8OT
M'7QQ\"0Q_P""TWQQ-C_J1\.-$^W;>GG^7:;,^^S./:OL>@ HHHH \+_:P_Y+
M9\#_ /L>Y?\ TF:O=*\'_:[FDM_C'\$IXH&E9/'$Q6-.K'[,W KV#_A)=7_Z
M%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\
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MH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\
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MHK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\
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M_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH
MV**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_
M (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK
M'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X
M275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A
M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\
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MBBB@ HHHH **** /"_VL/^2V? __ +'N7_TF:O=*\+_:P_Y+9\#_ /L>Y?\
MTF:O=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **QO!_Q$\"_$$ZB/!'BRPU4Z1J,EAJ?V&X
M63[-<IC?$^.C#(XK9H **** "BBB@ HHHH **** /"_VL/\ DMGP/_['N7_T
MF:O=*\+_ &L/^2V? _\ ['N7_P!)FKW2@ HHHH **** "BBB@ HHHH ****
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M5ZG^IF;95KDF8U*:7_+NK^]I^BOK%>EV;?4*]'_=ZK7D]5_P"MX)_: ^$/Q
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M^R/X'OO#/@_5-4UC5-<U.34_%'BC7KGSK_6+U_O33/@>^%' R2<LS,WJ=%%
M!1110!X7^UA_R6SX'_\ 8]R_^DS5[I7A?[6'_);/@?\ ]CW+_P"DS5[I0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUS$#M^U-;FV=S[2(#$__  $?C7TM3+BWM[N!K:[@26-UP\<BAE8>A!ZU\>^
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MH_SBC+^U\"_A;?HG_D?25%?-G_"ROVY=?_Y!W@$V6[I_Q*DCQ_W_ &/ZT?\
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MQC.GEIDF^T9W;_GAD)CVX7J#G=[5T7_"&?MP_#+G1/$KZY;1]0MZET"OIMN
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<B+Q?-<D=1;Z;/\ S9 *S]/_ &(?@A98^TQZM=XZ_:-0QG_OA5K;T_\ 91^
M.G8,7P]BD8=[B\GDS^#.1^E?L/M/$^O\,,+37FZDG^&A[M\WET@OO9S.H?MV
M_!^URMGH^NW)[%+2)5_-I ?TK#U#_@H%H$>?[+^&MY-Z?:-12+^2-7KVG_!+
MX/Z7@V?PQT($=&?3(G8?BP)K;T_PYX>TG']E:#96V.GV>U1,?D*/[)\1*_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVUO"NV&"WB"(B^@4< ?2E5S#@7*X.GA,&\7+^:O;D^5-:->4K,R>4<;9\O\
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MZ^YZ\MN?V/*[\]M;<W+R<W][E^T>C4445^G'\9A1110 4444 %%%% !1110
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M8Y"6,P\W!D8LVQ<J59=Q_5W3;S^T=.M]0$#Q>? DGE2C#)N ."/49H ^+?\
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ML?[%XW_Z#=E_X#'_ !H^Q>-_^@W9?^ Q_P :^J.PV**Q_L7C?_H-V7_@,?\
M&C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H
MV**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\
M&C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H
MV**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\
M&C[%XW_Z#=E_X#'_ !H V**Q_L7C?_H-V7_@,?\ &C[%XW_Z#=E_X#'_ !H
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M_@A]I.[:)$L)[]U]R(@JJ?KD"IQX#_X*E?&P8U_Q?)X7LY?N[M0AL JGL1:
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MFIR%&^H %+_PRU_P7F^-O/C[]H5_":S?ZQ3XNBL=H/;&DQL/P%?I+]B\;_\
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M]0_XA=PW2_C\2X-?X7.?Y11^G5%?F+_PYI_X* Z[QXM_;NWYZ_\ $^U6X_\
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M#%3_ -\"O(/%/_!2O5?B/>&#XE_%/QY=6<G^LBM$1XAS_P \/M$25^HFF?\
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M@C0]3UET_P!6=!\*I;J3GUN#"0,\]/PKT98/QOXFWQ=:47_+2<8?^VQ/5RS
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MAG<?$?XCZAZQZ7I<+#[1J-QC(BC!_-F/"CD]@?C/_AE+_@LO;?N(OVD_,5>
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M),JR'"+#X&DH1ZVW;[R>[?FV>A0P]'#0Y*:L@HHHKU38**** "BBB@ HHHH
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MTEY1L>5^!?VTOV!]0"7&N_L?:'I;.,>?I?AG3;J,>OS;8VQ]%/TKUOP9\?\
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M6M/C5\%=7L;+QG96*V>H:?J3F.#58$),9$@!\N9=Q4%AM92H)78"?CCX,_\
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M*3NV<[;85X1^U;_P3W^!O[6OB;1O&7C.*YTW5--N8Q?7VEA4DU*S4\VTI_\
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M)GS384445X1B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV]OVP95\<_MH_&QO"N@1GSSI^H7".T"==R6D+)!!QP6=@XXRIKIM$'_!-?\
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M+_LE$:2&3_@94']*IZG^U'_P58_9\M6TS]H;]GZ+QGH\7%Q<ZAX=2YCV#O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U
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M'FGD'3]!C@(Z>2JKC\A6@G@71HU")/>*!T NF %90XTX6PJMA\DI/_')R_\
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M0?2/^?F]_P# MJUEXB\925OK32\HP7Y11XZ\.."U)R>$3;ZN=1_G)GSQ9?\
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M#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\
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M[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?[6'_);/@?\ ]CW+
M_P"DS5[I7A?[6'_);/@?_P!CW+_Z3-7NE !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!X7^UA_R6SX'_ /8]R_\ I,U>Z5X7^UA_R6SX'_\
M8]R_^DS5[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_
MM8?\EL^!_P#V/<O_ *3-7NE>%_M8?\EL^!__ &/<O_I,U>Z4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 445X+^U;^VIJOP/^)'AK]GOX-?!J]^(GQ*\6VLEYIOANWU..Q@M;
M)"RM=W-Q(K+$FY7 XY,; E3C(![U17QE^Q3_ ,%,_B)\2O$O@CX1_M6_!D^%
MM8^(&E7%WX(\5V%\DVG:^86;S(M@&;:50N-C,Q)VYV[TW>E?M6_M^Z=^S/\
M%S0?@AH7P$\9_$'Q)KVB2ZK%I?@VT6>:&V20Q[V3.X@E6Y P-O- 'T'17@W[
M-?[9_CSX_P#Q"E\#>)?V+_BCX MX]-DNAKGC+1#;VCLC(HA#?\]&WD@>B-6/
M\5_^"@]]H_QFUGX"_LW_ +-OB?XKZ_X5CC?QA)H5W!:66DM(,K UQ,=KSX!/
ME@=B,DJX4 ^D:*\M_91_:S^'O[6W@B^\3>#]+U31M4T/4Y-,\4>%]?MO(O\
M1[U/O0S)D_@PX.".&5E7U*@ HHHH \+_ &L/^2V? _\ ['N7_P!)FKW2O"_V
ML/\ DMGP/_['N7_TF:O=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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MZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\
M/C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?
MV=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ
M%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_
M]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_M8?\EL^!
M_P#V/<O_ *3-7NE>%_M8?\EL^!__ &/<O_I,U>Z4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'A?[6'_);/@?\ ]CW+_P"DS5[I7A?[6'_)
M;/@?_P!CW+_Z3-7NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!X7^UA_R6SX'_ /8]R_\ I,U>Z5X7^UA_R6SX'_\ 8]R_^DS5[I0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 445\"?MI_'[]J'XZ>//CY\'/@;\5HO 7@[X)?#B:
M_P#%5[:Z<D^HZ_=S:=-<K;1R/@VL6U'0RQX=2I()WKM /ONBOE?]B37?VX/
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MM"GEK*-VW:I50P+'[7KX"_;?_9C_ &D?V>+OX^?M ?L[1Z%KO@3XJ_#[4/\
MA8_AS5KUK:ZTJ6.PG1]0M6P5EVH\LA0G+%V7!^1E .X_8X_:V_:.\)_&WP[^
MQ;^V+X.\/)J>N^#4U7X?^+/"DDGV;5+6*+<T,T<G*S+&CDD!0/+QM(97*?\
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M8;VXJ]10 4444 %%%% !1110 4444 %%%% !221I*C12H&5@0RL,@CT-+10
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M,+%(ZS03!70;OG5@#G .ZV4_X* ?'KQYXUU/PA\2+#X1>&_#NOSZ3X1T[5/
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M1D'T31M*M="TBTT2QW>39VT<$.\Y.U%"C)[G H ^8/V@_P!ICX@_&_XL:O\
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M!T2]E!R'GB1A'.V>ID5B>^:]=L[.STZSBT_3[6."W@C6.""&,*D:*,*JJ.
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MXY-:'Q._95_9T^,O@W1_AY\3/@_HFJZ%X?V_V)I$MKLM[':GEJ(XXRH4!/E
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MJ5D2&-D!>,CS$&0/,52V1D$ ]+AFAN(4N+>59(W4,CHV0P/(((ZBOEG]H/\
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MXGFN1<SZE+:'$TXY$[Q ^4\H//F,I;/.<\UTFE?LZ?!#0['PCIND?#;38(/
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MOAU\!OVBM*_X1C7;>UCS-HEM>0M,A:%56X\EIR6F ^;)8G KZ8_X*2ZWHOQ
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M9_\ $_P>M?@!XC^$NBWW@VQA2*Q\/W5H'@M@F=ACS\R,N3AE(89.#S0!\W>
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MUWX*_!_2M#U"^A$-UJ4?F37+1#&(A-,SNL?RK\@(7Y1QP* /2J*** "BBB@
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M*P^*]_X7M9?$>EZ?-8Z?J[*?.@MI6#21*<XVL5!/':@#\[/V)O#_ .TIJ_\
MP3UOVL/BG\$;#P=)%K ^(4'C3PM?SZC#<&:;[9_:3K=*&FQR"5!V>7@=*^S?
M^"?>C_\ "/\ [%_P[T6/XBIXMM[7P\D>G^(H["XM5O;0._V=EBN5655$/EJ-
MRC(4$<$4[Q[_ ,$_OV,OB=X]G^)OCO\ 9W\/:AK5W<+/?W+P.B7LH.0\\2,(
MYVSU,BL3WS7KMG9V>G6<6GZ?:QP6\$:QP00QA4C11A551P    !TH \8\:ZQ
M^SK^V;X@\<?LA^-)M<2^\&7-I+X@TN+4[C3))XYX"\4L;P2J\UN5?G^#=M#
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M*LMJBLB,Q+(%8!I$!VDXW#UKY]_96^/WQN^)_CWPOJW@7]MKX;_&/P[JB/\
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M(/VTOB]X"F@CUGP]\6M9O-.>Z@$L:RK#!C<I^\.>E 'WQ17Q9\0_C?\ MZ?
MSX;^"?VM_B#\5?"6I^']?UK1H?$7PTL_"?DKIUGJ$D<8\F_\TRRSQ^8N2RJA
M8DA=H"GN_%OQ8_:6_:"_:J\:?LY?L[?$G2/ .B?#33M-;Q/XHN_#B:K>7VH7
MT+3PVT$4LB1)$D0R[G+;N!C.0 ?3%%><_LRZA^TG/X(O]&_:DT+28O$&DZY<
M6=GK.ANBVVNV*D>3?"$.YMF<$AHF.05R, @#T:@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/PF\<:;XAT6[++!J.E72RQEE.&0D?=8'@J<$=P*S/C7^T-\$_P!G/0;3Q/\
M'#XD:;X:L+Z\^RV=UJ4A599MK/L& 23M4G\*\,_X)F_#/QSX=N/BQ\8==^%.
MH> - ^(GCQM6\*>"=6MA;7-E;+$$:XEMUXMWF;!,?4>7W&TEO[</@+]HWQQ^
MU+\&-:^#'P3L/%6F^$X]<O[^7Q#J@M-*AO)[9+:W:X8))(?+!E<*D;%B5Z<D
M 'L7P2_:X_9L_:/U2^T7X&_&#2/$UUIL"SW\&FR,S0QLVU6;*C@GBLFU_;R_
M8]O?BH/@M:_M >'W\1G4CIZV8G;RVO <?9A/M\DS9^7RP^[=\N,\5XGK7[77
MQ,\&^"?C1\%/BW\&M%\"_%'PG\(-4\5:%?\ A.\\_3]8L4MY46Z@D:-)$,<X
M52CC/!(Z&J_B;X*^ +7_ ((=#PO!HELL-E\$XO$4,JQ ,NII8+?_ &I3U$AN
M,MN'/S$9YH ^GOC5^T)\%OV=?#UOXI^-?Q$T_P /V=Y="VLC=LS274QY\N*)
M TDK8Y(53@<FK/P>^-WPF^/_ (.7Q]\&O'FG^(=):=H&N["4GRI5QNBD1@&C
M< @E' 8!@<8(KY4_9[\2:E\=OV_?A_XQ^(F+R?0OV6=*UO3([A=P@U+4KA!=
M72 _=D:,>62.W%=E\'X(/ G_  58^*W@KPW EMIOBKX:Z-XDU2VA4+&=0CN)
M;4S;1P'=#ECU8C)R>: /J*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X'XA_LU_##XH>)&\
M5>*[2\>[>%(BT%X47:O3@"L+_ABCX&?] _4O_!BW^%>MT5\[B.$N&,77E6K8
M.G*<G=MQ3;;W;9RSP.#G)RE33;\CXD_X9$_:'_Z)[_Y5K3_X[7H'P+_8VNKW
M^U/^%X^%KFTV^1_9?V?4XCOSYGF9\IFZ?N^N.O'>OINBOC\M\(>%,NQL,0W4
MJ\M_=J.$H.Z:U2@KVO=:[I'#2R/!4JBEJ[=':WY'DG_#%'P,_P"@?J7_ (,6
M_P *[_X>?#SPW\+_  VOA3PI%,EHDSR*L\I=MS')Y-;E%?<9?PYD.55_;8/#
M0ISM:\8I.SZ77H>A2PF&HRYJ<$GY(\,^*OP#^(7B[]O#X4_M Z/;6C>'?"/A
MS7++699+H+*LMU$JQ!$ZL,@Y/:LS]NG]EGX@?%:Z\)_M!_LVW5EIWQ9^'FJ)
M/H%U>2^5#J=B[8N=.N7')B=&8C/0[@-OF,U>I_&_]H;X*?LV^$T\;_''XC:=
MX<TV6<0V\MZ[%[B7&=D4:!GE; )VHI.!FN;^ _[<7[*G[2^OW'A/X+_&*RU7
M5[:$S2Z/<V=Q8WGEC&76"ZCCD=1D995(&1GJ*]HZ#R7XJ_LX_&OPU^TK/^UQ
M\-_@%X4\>)XS\*V%AXX^'WB/58(+FQO;=<17-I=RQ/"P5&,3J0N[:""<_+J?
M#[X*_MJS?#+XD^*+35_!'PQ\8^)A;_\ "O?#_A_0[*ZMO#D<&"8[JZ%J#=O.
M00Y*NL08M&,X5?6?CS^U?^S[^S*FGCXV?$6+2)M5\PZ=8PV%Q>75PL8S(ZP6
ML<DI101N?;M7/)%=3\.?B/X%^+G@G3OB1\-/%-IK6A:M;^=IVIV,FZ.9,D''
M<$,"I4X*LI! ((H ^0[W]EGX\?'_ .._PV^)'C#]D/P)\)-3\%>+[;7?$OCS
MP_XCANKW7$@#;K&%+>%',4[$;C<,2J9 R<[NJMOV&_&/C#PI^TYX#^(,%E%9
M?%OQ#+?>%9X[H2&,BU06\T@ ^1DN(T?'^S6\W_!7/_@G,LI@?]J#20P;:0=+
MOA@_7R*]O^&'Q7^&OQJ\'6WQ!^$WCC3?$.BW998-1TJZ66,LIPR$C[K \%3@
MCN!0!\A>(/V%_P!I;QE_P3;^)'PL\;3:5J/QB^)VMPZKK\YOP+<R17EHL40F
M(^XEI:)@=F9AWR>X^/W[,7Q5\/?M10?M9?!WX2^%OB)%JWA2'0O%_@;Q+=Q6
MLC&&0O!>VEQ-')&LB@E&1P 5'&2V5]R^-?[0WP3_ &<]!M/$_P </B1IOAJP
MOKS[+9W6I2%5EFVL^P8!).U2?PK,^"7[7'[-G[1^J7VB_ WXP:1XFNM-@6>_
M@TV1F:&-FVJS94<$\4 >+:-^R'\9_P!H#X5?%;PO^T+X>\(^ =/\?:.FF^%?
M!WA*PM+AM 6,;Q<7-[%#$]W(TZQN8PWE@)@8+?+QW[0?PL_X*7?M&?LO?\,M
M^(/A!X*TN:T_LY=;\7Q>,_.C\0I:7,$@^S6_DJ]LSF-96,K8 1E )<8^A+7]
MO+]CV]^*@^"UK^T!X??Q&=2.GK9B=O+:\!Q]F$^WR3-GY?+#[MWRXSQ75?&K
M]H3X+?LZ^'K?Q3\:_B)I_A^SO+H6UD;MF:2ZF//EQ1(&DE;')"J<#DT =E7Q
MW?\ [%GQPN/@/^U'\/H[#3?[1^+'C34]2\(*=179)!/'$L9E;'[HY0Y!Z5]-
M_![XW?";X_\ @Y?'WP:\>:?XATEIV@:[L)2?*E7&Z*1& :-P""4<!@&!Q@BI
M/BA\7_AO\&-(L=>^)WBF+2;/4M8M]*L9YHI'$MY.Q6*(!%8@L01DX'J10!X_
M^UE^SA\3/C!^QWX?^"W@RULWUS3M0\.37,=Q=B.,+9W%O)/AR,'"QMCUXK-\
M7?"?]I3]GW]JCQG^T9^SK\-=)\?:+\2].TU?%'A>\\2)I5W8ZA8PM!#<P2RQ
MO&\3Q'#H<-N (STKZ*\2>(=&\(^';_Q7XCOEM=/TNREN[^Y=21##&A=W(4$D
M!5)X!/%5/A_X^\(?%+P5I?Q%\ ZTFI:+K5DEWIE_%&RK/"XRK@. P!'J : /
M&?!>E_MX^"O@YK?C'6SX<\2_$'Q#XM%]:>%+K4V72_#VENR+]BBG"HTSQQAG
M+D ,[$ 8&3[]110 45SOB3XL_#SPAX_\-?"WQ'XFBM=?\8?;/^$;TYXG+7WV
M2(37&UE4JNR-@QW$9SQDU%X@^-'PJ\+^$_$OCG6/'FG+I7@UI4\4W=O-YXTQ
MXHDEDCE6+<RNL<B,4QNPZ\<B@#IZ*J:!KND^*-"LO$V@WBW-CJ-I'=65PJD"
M6*10Z, 0",J0>1GFK= !17EOQX_;6_9<_9GU:V\/?&GXOV.DZI=Q^9;Z/;VT
M][>M'SA_L]K')*$.#ABH!P<'@UM? K]I+X&?M,>&IO%OP+^)6G^(K*UF$5Y]
ME+I-:R'D)-#(JR0L0#@.H)P<4 =Q1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y+\8?V
M*O@;\<_&C^/?'MAJ4FH26\<#-:ZBT2;$&%^4#WKUJBNW 9CC\KK^VPE25.=K
M7B[.W;0XL?EN S6A['&4HU(7O:2NKKK9GS%\1OV!?V//AAX$U7X@^)M/UI+'
M2;)[B?&LL"^T<(O'WF;"@=RPK\_+R6">[EFM;401/(S1PARPC4GA<GDX'&37
M[05SOQ ^+7PT^%7]F?\ "Q_&^G:+_;6HI8:7]ON!']IN&Z(N?U)X&1DC(K](
MX6\2<VRWGIXBG4Q=2;TO4>B2V4>27FV^R78_..)/"O+L\JT_J,H8:,4[J-)-
MR;ZMJ4=$EHK=WU/SW_81^$OP(^.GC#4OAQ\6;&\_M)K;[5HLUKJ#0B54_P!;
M$0."P!#CV#^@KZG_ .'9/[+/_0)UK_P<-_A7T'17C9YX@YWF>8RQ&$JU*$&E
M[BJ.236EUI&U^UM[]SU<A\.\BRO+HX?&4J>(FF_?=-1;3U2>LKM=[[670Y;X
M/?![P7\#?!<?@+P%!<1Z?'<23*MU<&5][G+?,:\F_:A^#G[4-G\;O#O[4W[)
M^O:9J&K:5H4NA^(O ?B?498+#6;!YO.5XG3*PW*29P[#D8!.%*/]!5YA^T!^
MV;^S)^RSJ.FZ3\??BQ:>&[C5X9)M-BN;2XE,Z(0KD>5&X&"PZXZU\3B,17Q5
M>5:M)RG)W;>K;?5GW.'P]#"4(T:,5&$59):));)'C.M_"W]M#]LCXE_#ZZ_:
M)^#?A?X9>#OA]XTL_%3VMEXJ&LZGJE_:!C;QH\4:1P0[G)?/S$8 S26?PA_:
M_P#V4OC/\3M9^ GP;\.?$SPE\4O$#Z^+;5/%2:5=:-J$J!+A9O,B=;BW; *J
MF& !''4^N?!']NW]D+]H[Q$?"'P8^/>A:UJWELZ:6LCP7,JJ,L4BF5&D  R=
MH.!R:]:K$V/BS_@GE^PA^T+^Q5\<-:\0:Q9>!+[PY\0M,>\\1C0A-;MX9OHY
MY9(;"R63<9[4B<@9V?<)."BB7V#_ ()N_ /XA?LQ_L>^&/@O\4[:TBUS2KK4
MGNX[*Z$T8$VH7$Z8<<'Y)%SZ'(KW.B@ KQ+]HO0/VMO#OQ;\-?&S]G&>V\3Z
M38:;/IWBGX9ZIK0T^+4$=P\=Y;SLC(EPA&#O&"G (R:]MHH ^8?A[^R]\6?C
MI\:/&7[1G[6_AC2_#K^(?AW+X%T'P3HVK"^;3])G=I+F6XN0BI)/([$#8-JK
MQDFN#N/@+_P4#U;]F"#_ ()Z:AX)\*Q>'TT^/P[/\7X_$VX/H$9" +IOE^:+
MHVRB+!?R\Y.[!R/K7P3\7_AO\1O$GB/PAX*\4Q7^I>$=16P\1VL<4BFRN&3>
ML;%E 8E><J2/>NEH ^;/BY^SK\6_A)\<?!G[2W[*'@[3/$,_A_P+_P (5X@\
M&:IK L&O]'259K9[>X9&1)H95).\896(!%:_[*GP0^,-O\9?'?[6/[1>CZ7H
M_BCQK!9:;I7A;2=1^V1Z%I5HK;(GN-JB::21VD<J-HPN.I ]\HH **** "BB
MN:_X6_\ #?\ X6__ ,*$_P"$IB_X2_\ X1O^W_[%\J3?_9OVC[/]HW;=F/-^
M3&[=GG&.: .EHKFOB/\ %_X;_",Z OQ&\4Q:6?%'B2UT#0?-BD?[7J-QN\FW
M&Q3@ML;EL*,<D5TM !17AWQ2_P""DG[$GP9\;7OP[^('Q[L+?6--?9J=I8:;
M>7PL7'59WM89$A8'@AV4@\'%>L?#[XB>!/BQX/L?B!\-/%MAKFB:E%YECJ>F
M7*RPS $@X9>X(((/((((!!% &S17-?%KXQ_"[X$>";CXC?&'QUIWA[1+5E27
M4-2GV*7;[J*.KN<'"*"QP<#BO/\ X+_\%!?V._V@O&,?P]^%7QNLKW7)XR]K
MI5]I]WI\]TH!),*7<41FX!;Y-W )Z F@#V6BBN>^*WQ6^'WP0^'^H_%/XJ>)
M8M'T#241]1U*:)W6$/(L:DK&K,<NZC@'K0!T-%(K*ZAU.01D&EH ***S]-\6
M^%M9UW4?#&D>([&ZU'2/*_M6QM[I'ELS*I:,2J#F,LH+ -@D<]* -"BN1^-O
MQX^$G[.7@=_B3\:O&<&@Z&EU';/J%Q!+(HEDSL7$2LW.#VQ70>%_$V@^-/#6
MG>,?"VJ17VF:M8PWFG7L)REQ!*@>.1<]F5@1]: +U%<1\+OVC_@E\:O%_BKP
M'\+?B#::SJW@F_6R\4VEM%*#83EY4",S*%8[H)1\A8?(?:NWH ***X;5_P!I
M3X'Z"_CF/5O']O"?AK;PS^. UO,?[*CF@^T1L^$^?=%\WR;N.O/% '<T54T'
M7-*\3Z'9>)="O%N+'4;2.YL[A5($L4BAT8 @$94@\C/-6Z "BBN=\+_%CX>>
M-/&_B7X<>%_$T5WK?@^:UB\26"1.&L7N(?.A#%E"MNC^8;2<=\&@#HJ*X;X]
M_M*? _\ 9@\+6GC7X\>/[?P[I=]J LK2[N;>:19+@H\@0")&(.V-SDC'R]:\
MIB_X*Z?\$YII5AB_:?THL[!5']E7W)/_ &PH ^CZ*** "BBN=TKXL?#W6_B5
MJWP?TKQ-%-XDT*PM[W5M*6)P]O!/N\IRQ7:0VUN 2>.<4 =%1110 4444 %%
M%% !16?X@\6^%O"GV(>)_$5CIYU*_BL=.%[=+&;JYD.$AC#$;Y&P<*,DX/H:
MT* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /+OBO^VK^RK\#?%S^ OBY
M\<-$T'6(X$F?3[^5A((W&5; 4\'%>8_&_P#X*S?L=^ /A'XA\8?#GXV>'_$F
MOV.F2/HNA6TTA:\NB-L2'Y1\NX@L<Y"AC6Q^TC_P3 _95_:L^)LOQ;^+FD:W
M-K$UG#:N]CK+P1^7&"%^4#KSUKRGXB?\$(/V/-4\":O8?#>/7M,\02Z?*-%O
M[W7'FA@NMI\MI$V_,F[&X#G&<<XKY[&SXEO46'A3Y=>5W?-Y>5_P/U_AO"^"
MCIX2>:XC%^U]QU(J%/V5[KF5_CY-]5[UMM3\G?C-^T3\:_V@O&D_C[XN?$?5
M-8U&:8R1F>Z816V3D)#&#LA0=E0 "OM'_@DI_P %2=8^&?B>X^"/[5/Q7DD\
M'S6#RZ'KFOW+ROI=Q'@^1YIRQA=-P"DD*RJ%P&-?%WQF_9V^-?[/OC2?P#\7
M/AQJFCZC#,8XQ/:L8KG!P'AD V3(>S(2#7UW_P $R_\ @D5K/[0,U[\3OVJ/
M!^M:)X.%F4T2PD=K*[U*X8C$P##>L"KGYB!O9EVDA6K\VR5YTLX3H)NI?WN:
M]O/G\O7KMJ?VAXD1\,Y^'<XYI*G'!N*]DZ2@Y)Z<KH):.7IIRWYO=N?H?_P\
MV_8(_P"CH_"__@0__P 17J'PH^,/PR^.7A%/'OPD\9V>O:/).\*:A8,3&9$.
M&7) Y!KY@_X<7_L#_P#0O>)__"DD_P#B:^A_V;OV;OAE^RI\,HOA'\([6\AT
M>&\FND2^NS/)YDA!;YB.F1TK]3P,\\E6MBXP4+?9;;O\^A_"7$^&\+Z66J7#
M]?%3K\RTK1IJ'+9W=XZWO:W3<\C_ &V/@Q\>I_CG\-/VL_@3\.=*\?7?P\AU
M*WN_ FJZFEF]PEVB#[3:3R@QQSILZMU&,9-<?I?[1O[/_P ?_P!J#X;V?[27
MP%^(/PC^*?A_49W\#S>)-/%O;:I))$4ELXKV/<MS&RDC8=@). 2S8/H_[4/P
M<_:AL_C=X=_:F_9/U[3-0U;2M"ET/Q%X#\3ZC+!8:S8/-YRO$Z96&Y23.'8<
MC )PI1^,UOX6_MH?MD?$OX?77[1/P;\+_#+P=\/O&EGXJ>ULO%0UG4]4O[0,
M;>-'BC2."'<Y+Y^8C &:]<_/3RW]OG]H3Q?\*_VRY/VA_P!DCPM=>-?$7PT^
M'MSHGQ5MI=*>;2M%T^>47,#O,CJPN$D/FO'$&8Q1MN*!7Q] _P#!/(_ 7X9?
M!?P_^S_\,_C?IOC#6'T)O%5]<62^7]HBO[EY&N$A'$,7FNR+']Y0H# '-<?9
M_"']K_\ 92^,_P 3M9^ GP;\.?$SPE\4O$#Z^+;5/%2:5=:-J$J!+A9O,B=;
MBW; *JF& !''4X7_  3R_80_:%_8J^.&M>(-8LO E]X<^(6F/>>(QH0FMV\,
MWT<\LD-A9+)N,]J1.0,[/N$G!11* >>?\$P?VY_AI\&_V'_"_P ,_$?PC^)N
MLW5C=:L99_#OP]O+^TG\S4KF0+',B['.'"GGA@0>AKW#_@F;\,_'/AVX^+'Q
MAUWX4ZAX T#XB>/&U;PIX)U:V%M<V5LL01KB6W7BW>9L$Q]1Y?<;2>S_ .";
MOP#^(7[,?['OACX+_%.VM(M<TJZU)[N.RNA-&!-J%Q.F''!^21<^AR*]SH ^
M5_VX? 7[1OCC]J7X,:U\&/@G8>*M-\)QZY?W\OB'5!::5#>3VR6UNUPP220^
M6#*X5(V+$KTY(Y_6OVNOB9X-\$_&CX*?%OX-:+X%^*/A/X0:IXJT*_\ "=YY
M^GZQ8I;RHMU!(T:2(8YPJE'&>"1T->M_M%Z!^UMX=^+?AKXV?LXSVWB?2;#3
M9].\4_#/5-:&GQ:@CN'CO+>=D9$N$(P=XP4X!&37'?#W]E[XL_'3XT>,OVC/
MVM_#&E^'7\0_#N7P+H/@G1M6%\VGZ3.[27,MQ<A%22>1V(&P;57C)- '&^)O
M@KX M?\ @AT/"\&B6RPV7P3B\10RK$ RZFE@M_\ :E/42&XRVX<_,1GFH_V>
M_$FI?';]OWX?^,?B)B\GT+]EG2M;TR.X7<(-2U*X075T@/W9&C'EDCMQ4-Q\
M!?\ @H'JW[,$'_!/34/!/A6+P^FGQ^'9_B_'XFW!] C(0!=-\OS1=&V418+^
M7G)W8.1Z/\7/V=?BW\)/CCX,_:6_90\':9XAG\/^!?\ A"O$'@S5-8%@U_HZ
M2K-;/;W#(R)-#*I)WC#*Q (H H?!^"#P)_P58^*W@KPW EMIOBKX:Z-XDU2V
MA4+&=0CN);4S;1P'=#ECU8C)R>:S?^"QVI7NC?LY^#=8TS1IM2N;3XP>'IK?
M3K=@LETZS2,L2EN S$!03QDUW'[*GP0^,-O\9?'?[6/[1>CZ7H_BCQK!9:;I
M7A;2=1^V1Z%I5HK;(GN-JB::21VD<J-HPN.I L_M]? /XA?M#?#7PGX7^&]M
M:2W>C_$O1=;O1=W0B46EM,SRD$]6P1A>] 'E7Q\_;._:6USX%>-=%U3_ ()Q
M?$+3+6\\):E!<ZE<ZUIS1VD;VLBM,X63)502Q YP.*XKPS^V#JW[//[$/[,_
MPA\'>.?"WA/6_B'X6CC/C/QG(O\ 9V@6-K;))/<.C.@DE/F(D4;,%9VP37VK
M\</"FK^//@MXO\#^'TC:_P!9\+ZA8V*ROM4S36TD: GL-S#)[5\L:K^PE\9]
M+^ W[/\ XC\,^'_"^K?$#X+:.UGJ'A3Q#.&TW6[6XMTAN[;SMCA)!L5HI"I4
M,,F@"]^SC^VQJ\?[5>B?LQ^(_P!J?P-\9=-\9:->W6@^*/"4%M;7FFWEHGFR
MVEW#;2R1>6\(9XY!M8F-U(.,CFOC5^TI^U)\/_!OB;XG?$C]MWX3_#+Q+IAO
M;C1?@Y<6-AJ$LD,)<P6\]Q]J,SS3HJDF)0%,@X'*CT[X-_"_]IOQA\:5^(?C
M'X-^"O@[X6TS0;FUL_#^A)I^J:IJ&H3*4%V]W';I]GCB4G:D; N2=^5.!XW\
M(/V-_P!JSX;?L^:Q^S+I?[*WPTM_$VH6>I65_P#'*^\01SRZ@ERTNZ[,/V<W
M;W&R3:JR.J!@"3M&R@#IM9^*FH_'K]I7]B/XQ3V46G7OBKPIXLU*:WB!>.VF
MFT"W=E7)RRJQ.,G) &:\G\!>%_BSI7[(?[:M]XO^*]GJ^GP>,?&-GJ%A#X:6
MU:ZU06MHSZ@)!,WEHR?+]GP0I^;>>E>\?"C]D7XW^'-=_9,U;Q#I.GP+\'?#
M&NZ=XR5-15S')<:9':0&' _>AGCR<8V@\UBW/[*O[4^G>$_VFO@+9> ]"N_#
MWQ7U#7O$7A3Q2OB())]NOX;>)+&:W9,HH".3+NP"N,$-D &!=_%']NK]F']E
M7X??M4^*/BQX3U#PO#:^';;5_AG;^$_+^SZ9=&WMD*:@9C*]THDC+$J(]Q;
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264274252816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Aug. 05, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-15317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ResMed Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0152841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9001 Spectrum Center Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">836-5000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.004 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,155,017,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,932,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive Proxy Statement to be delivered to stockholders in connection with the registrant&#8217;s 2024 Annual Meeting of Stockholders, to be filed within 120 days after the end of the fiscal year covered by this Form 10-K, are incorporated by reference into Part III of this report.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000943819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264269002896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264272733856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 238,361<span></span>
</td>
<td class="nump">$ 227,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $21,132 and $23,603 &#8206;at June&#160;30, 2024 and June&#160;30, 2023, respectively</a></td>
<td class="nump">837,275<span></span>
</td>
<td class="nump">704,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (note 4)</a></td>
<td class="nump">822,250<span></span>
</td>
<td class="nump">998,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets (note 4)</a></td>
<td class="nump">459,833<span></span>
</td>
<td class="nump">437,018<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,357,719<span></span>
</td>
<td class="nump">2,367,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net (note 4)</a></td>
<td class="nump">548,025<span></span>
</td>
<td class="nump">537,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets (note 9)</a></td>
<td class="nump">151,121<span></span>
</td>
<td class="nump">127,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (note 5)</a></td>
<td class="nump">2,842,055<span></span>
</td>
<td class="nump">2,770,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net (note 5)</a></td>
<td class="nump">485,904<span></span>
</td>
<td class="nump">552,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent', window );">Deferred income taxes (note 12)</a></td>
<td class="nump">203,569<span></span>
</td>
<td class="nump">132,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Prepaid taxes and other non-current assets</a></td>
<td class="nump">284,001<span></span>
</td>
<td class="nump">262,453<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">4,514,675<span></span>
</td>
<td class="nump">4,383,878<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">6,872,394<span></span>
</td>
<td class="nump">6,751,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">237,728<span></span>
</td>
<td class="nump">150,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses (note 7)</a></td>
<td class="nump">377,678<span></span>
</td>
<td class="nump">365,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current (note 9)</a></td>
<td class="nump">25,278<span></span>
</td>
<td class="nump">21,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">152,554<span></span>
</td>
<td class="nump">138,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable (note 12)</a></td>
<td class="nump">107,517<span></span>
</td>
<td class="nump">72,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, net (note 8)</a></td>
<td class="nump">9,900<span></span>
</td>
<td class="nump">9,902<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">910,655<span></span>
</td>
<td class="nump">758,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">137,343<span></span>
</td>
<td class="nump">119,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent', window );">Deferred income taxes (note 12)</a></td>
<td class="nump">79,339<span></span>
</td>
<td class="nump">90,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current (note 9)</a></td>
<td class="nump">141,444<span></span>
</td>
<td class="nump">116,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">42,257<span></span>
</td>
<td class="nump">68,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net (note 8)</a></td>
<td class="nump">697,313<span></span>
</td>
<td class="nump">1,431,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term income taxes payable (note 12)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,183<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">1,097,696<span></span>
</td>
<td class="nump">1,863,272<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,008,351<span></span>
</td>
<td class="nump">2,621,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (note 15)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.004 par value, 350,000,000 shares authorized; &#8206;189,565,112 issued and 146,901,045 outstanding at June&#160;30, 2024 and &#8206;188,900,583 issued and 147,064,349 outstanding at June&#160;30, 2023</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,896,604<span></span>
</td>
<td class="nump">1,772,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">4,991,647<span></span>
</td>
<td class="nump">4,253,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost, 42,664,067 shares at June&#160;30, 2024 and 41,836,234 shares at June&#160;30, 2023</a></td>
<td class="num">(1,773,267)<span></span>
</td>
<td class="num">(1,623,256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(251,529)<span></span>
</td>
<td class="num">(272,528)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">4,864,043<span></span>
</td>
<td class="nump">4,129,903<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 6,872,394<span></span>
</td>
<td class="nump">$ 6,751,708<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other tax liabilities expected to be paid after one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264271811664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance for credit loss, current</a></td>
<td class="nump">$ 21,132<span></span>
</td>
<td class="nump">$ 23,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock at par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.004<span></span>
</td>
<td class="nump">$ 0.004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">189,565,112<span></span>
</td>
<td class="nump">188,900,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">146,901,045<span></span>
</td>
<td class="nump">147,064,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">42,664,067<span></span>
</td>
<td class="nump">41,836,234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264267245472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 4,685,297<span></span>
</td>
<td class="nump">$ 4,222,993<span></span>
</td>
<td class="nump">$ 3,578,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of sales (exclusive of amortization shown separately below)</a></td>
<td class="nump">1,997,031<span></span>
</td>
<td class="nump">1,836,935<span></span>
</td>
<td class="nump">1,514,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">32,963<span></span>
</td>
<td class="nump">30,396<span></span>
</td>
<td class="nump">39,650<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of sales</a></td>
<td class="nump">2,029,994<span></span>
</td>
<td class="nump">1,867,331<span></span>
</td>
<td class="nump">1,553,816<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">2,655,303<span></span>
</td>
<td class="nump">2,355,662<span></span>
</td>
<td class="nump">2,024,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">917,136<span></span>
</td>
<td class="nump">874,003<span></span>
</td>
<td class="nump">737,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">307,525<span></span>
</td>
<td class="nump">287,642<span></span>
</td>
<td class="nump">253,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_AmortizationOfAcquiredIntangibleAssets1', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">46,521<span></span>
</td>
<td class="nump">42,020<span></span>
</td>
<td class="nump">31,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expenses (note 18)</a></td>
<td class="nump">64,228<span></span>
</td>
<td class="nump">9,177<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,949<span></span>
</td>
<td class="nump">1,864<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,335,410<span></span>
</td>
<td class="nump">1,223,791<span></span>
</td>
<td class="nump">1,024,025<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">1,319,893<span></span>
</td>
<td class="nump">1,131,871<span></span>
</td>
<td class="nump">1,000,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (loss), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="num">(45,708)<span></span>
</td>
<td class="num">(47,379)<span></span>
</td>
<td class="num">(22,312)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss attributable to equity method investments (note 6)</a></td>
<td class="num">(1,848)<span></span>
</td>
<td class="num">(7,265)<span></span>
</td>
<td class="num">(8,486)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">(Loss) gain on equity investments (note 6)</a></td>
<td class="num">(4,045)<span></span>
</td>
<td class="nump">9,922<span></span>
</td>
<td class="num">(12,202)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainOnBusinessInterruptionInsuranceRecovery', window );">Gain on insurance recoveries</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,227<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(3,494)<span></span>
</td>
<td class="num">(5,712)<span></span>
</td>
<td class="nump">3,197<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (loss), net</a></td>
<td class="num">(55,095)<span></span>
</td>
<td class="num">(30,207)<span></span>
</td>
<td class="num">(39,803)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">1,264,798<span></span>
</td>
<td class="nump">1,101,664<span></span>
</td>
<td class="nump">960,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes (note 12)</a></td>
<td class="nump">243,847<span></span>
</td>
<td class="nump">204,108<span></span>
</td>
<td class="nump">181,046<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,020,951<span></span>
</td>
<td class="nump">$ 897,556<span></span>
</td>
<td class="nump">$ 779,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share (note 11) (in dollars per share)</a></td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="nump">$ 6.12<span></span>
</td>
<td class="nump">$ 5.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share (note 11) (in dollars per share)</a></td>
<td class="nump">6.92<span></span>
</td>
<td class="nump">6.09<span></span>
</td>
<td class="nump">5.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividend declared per share (in dollars per share)</a></td>
<td class="nump">$ 1.92<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic shares outstanding (000's) (in shares)</a></td>
<td class="nump">147,021<span></span>
</td>
<td class="nump">146,765<span></span>
</td>
<td class="nump">146,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares outstanding (000's) (in shares)</a></td>
<td class="nump">147,550<span></span>
</td>
<td class="nump">147,455<span></span>
</td>
<td class="nump">147,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rmd_SleepAndRespiratoryMember', window );">Sleep and Respiratory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 4,101,172<span></span>
</td>
<td class="nump">$ 3,725,017<span></span>
</td>
<td class="nump">$ 3,177,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of sales (exclusive of amortization shown separately below)</a></td>
<td class="nump">1,806,845<span></span>
</td>
<td class="nump">1,662,957<span></span>
</td>
<td class="nump">1,365,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">5,515<span></span>
</td>
<td class="nump">5,340<span></span>
</td>
<td class="nump">4,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rmd_SoftwareAsAServiceMember', window );">Software as a Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">584,125<span></span>
</td>
<td class="nump">497,976<span></span>
</td>
<td class="nump">400,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of sales (exclusive of amortization shown separately below)</a></td>
<td class="nump">190,186<span></span>
</td>
<td class="nump">173,978<span></span>
</td>
<td class="nump">148,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">$ 27,448<span></span>
</td>
<td class="nump">$ 25,056<span></span>
</td>
<td class="nump">$ 35,545<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_AmortizationOfAcquiredIntangibleAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_AmortizationOfAcquiredIntangibleAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnBusinessInterruptionInsuranceRecovery">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount (to the extent disclosed within this portion of the income statement) by which an insurance settlement exceeds incremental costs incurred from the event causing an interruption of business, plus the insurance award for earnings lost from the event, such as a natural catastrophe, explosion or fire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483605/220-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnBusinessInterruptionInsuranceRecovery</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rmd_SleepAndRespiratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rmd_SleepAndRespiratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rmd_SoftwareAsAServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rmd_SoftwareAsAServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264271851440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,020,951<span></span>
</td>
<td class="nump">$ 897,556<span></span>
</td>
<td class="nump">$ 779,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized gains (losses) on designated hedging instruments</a></td>
<td class="nump">31,743<span></span>
</td>
<td class="num">(35,596)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation (loss) gain adjustments</a></td>
<td class="num">(10,744)<span></span>
</td>
<td class="nump">75,815<span></span>
</td>
<td class="num">(119,260)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 1,041,950<span></span>
</td>
<td class="nump">$ 937,775<span></span>
</td>
<td class="nump">$ 660,177<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264276374128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional &#8206;Paid-in Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated &#8206;Other &#8206;Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, beginning balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,485,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2021</a></td>
<td class="nump">$ 2,885,679<span></span>
</td>
<td class="nump">$ 583<span></span>
</td>
<td class="nump">$ 1,622,199<span></span>
</td>
<td class="num">$ (1,623,256)<span></span>
</td>
<td class="nump">$ 3,079,640<span></span>
</td>
<td class="num">$ (193,487)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common, beginning balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,836,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued on exercise of options (note 10) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued on exercise of options (note 10)</a></td>
<td class="nump">11,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 10) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 10)</a></td>
<td class="num">$ (52,406)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(52,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued on employee stock purchase plan (note 10) (in shares)</a></td>
<td class="nump">216,000<span></span>
</td>
<td class="nump">216,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued on employee stock purchase plan (note 10)</a></td>
<td class="nump">$ 36,180<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">36,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation costs</a></td>
<td class="nump">65,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(119,260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119,260)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">779,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">779,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">(245,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(245,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,247,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">3,360,751<span></span>
</td>
<td class="nump">$ 586<span></span>
</td>
<td class="nump">1,682,432<span></span>
</td>
<td class="num">$ (1,623,256)<span></span>
</td>
<td class="nump">3,613,736<span></span>
</td>
<td class="num">(312,747)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common, ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,836,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued on exercise of options (note 10) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued on exercise of options (note 10)</a></td>
<td class="nump">9,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 10) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 10)</a></td>
<td class="num">$ (30,631)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(30,632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued on employee stock purchase plan (note 10) (in shares)</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued on employee stock purchase plan (note 10)</a></td>
<td class="nump">$ 39,446<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">39,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock purchases (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation costs</a></td>
<td class="nump">$ 71,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="nump">40,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">897,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">897,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">$ (258,276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(258,276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">147,064,349<span></span>
</td>
<td class="nump">188,901,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">$ 4,129,903<span></span>
</td>
<td class="nump">$ 588<span></span>
</td>
<td class="nump">1,772,083<span></span>
</td>
<td class="num">$ (1,623,256)<span></span>
</td>
<td class="nump">4,253,016<span></span>
</td>
<td class="num">(272,528)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common, ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="num">(41,836,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,836,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued on exercise of options (note 10) (in shares)</a></td>
<td class="nump">166,000<span></span>
</td>
<td class="nump">166,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued on exercise of options (note 10)</a></td>
<td class="nump">$ 13,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 10) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 10)</a></td>
<td class="num">$ (8,757)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(8,758)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued on employee stock purchase plan (note 10) (in shares)</a></td>
<td class="nump">323,000<span></span>
</td>
<td class="nump">323,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued on employee stock purchase plan (note 10)</a></td>
<td class="nump">$ 39,610<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">39,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock purchases</a></td>
<td class="num">$ (150,011)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">$ (150,011)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock purchases (in shares)</a></td>
<td class="num">(828,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(828,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation costs</a></td>
<td class="nump">$ 80,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="nump">20,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">1,020,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,020,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">$ (282,320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(282,320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="nump">146,901,045<span></span>
</td>
<td class="nump">189,565,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">$ 4,864,043<span></span>
</td>
<td class="nump">$ 588<span></span>
</td>
<td class="nump">$ 1,896,604<span></span>
</td>
<td class="num">$ (1,773,267)<span></span>
</td>
<td class="nump">$ 4,991,647<span></span>
</td>
<td class="num">$ (251,529)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common, ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="num">(42,664,067)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,664,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264269002896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividend declared per share (in dollars per share)</a></td>
<td class="nump">$ 1.92<span></span>
</td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="nump">$ 1.68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264271954224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,020,951<span></span>
</td>
<td class="nump">$ 897,556<span></span>
</td>
<td class="nump">$ 779,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">176,870<span></span>
</td>
<td class="nump">165,156<span></span>
</td>
<td class="nump">159,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">39,339<span></span>
</td>
<td class="nump">32,406<span></span>
</td>
<td class="nump">34,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation costs (note 10)</a></td>
<td class="nump">80,184<span></span>
</td>
<td class="nump">71,142<span></span>
</td>
<td class="nump">65,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss attributable to equity method investments, net of dividends received (note 6)</a></td>
<td class="nump">1,848<span></span>
</td>
<td class="nump">10,138<span></span>
</td>
<td class="nump">8,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss', window );">(Gain) loss on equity investments (note 6)</a></td>
<td class="nump">4,045<span></span>
</td>
<td class="num">(9,922)<span></span>
</td>
<td class="nump">12,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Restructuring expenses (note 18)</a></td>
<td class="nump">33,239<span></span>
</td>
<td class="nump">9,177<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceRecoveries', window );">Gain on insurance recoveries</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,227)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(134,278)<span></span>
</td>
<td class="num">(106,511)<span></span>
</td>
<td class="nump">19,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">172,203<span></span>
</td>
<td class="num">(248,833)<span></span>
</td>
<td class="num">(311,681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, net deferred income taxes and other current assets</a></td>
<td class="num">(115,213)<span></span>
</td>
<td class="num">(138,125)<span></span>
</td>
<td class="num">(168,109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other</a></td>
<td class="nump">122,072<span></span>
</td>
<td class="nump">31,342<span></span>
</td>
<td class="num">(247,632)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">1,401,260<span></span>
</td>
<td class="nump">693,299<span></span>
</td>
<td class="nump">351,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(99,460)<span></span>
</td>
<td class="num">(119,672)<span></span>
</td>
<td class="num">(134,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Patent registration costs</a></td>
<td class="num">(15,396)<span></span>
</td>
<td class="num">(14,328)<span></span>
</td>
<td class="num">(21,201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Business acquisitions, net of cash acquired</a></td>
<td class="num">(133,464)<span></span>
</td>
<td class="num">(1,012,749)<span></span>
</td>
<td class="num">(42,784)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments (note 6)</a></td>
<td class="num">(12,765)<span></span>
</td>
<td class="num">(32,229)<span></span>
</td>
<td class="num">(20,724)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from exits of investments (note 6)</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">3,937<span></span>
</td>
<td class="nump">6,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities', window );">Proceeds / (payments) on maturity of foreign currency contracts</a></td>
<td class="num">(9,699)<span></span>
</td>
<td class="nump">15,196<span></span>
</td>
<td class="num">(17,176)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(269,784)<span></span>
</td>
<td class="num">(1,159,845)<span></span>
</td>
<td class="num">(229,918)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">53,094<span></span>
</td>
<td class="nump">49,142<span></span>
</td>
<td class="nump">47,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(8,757)<span></span>
</td>
<td class="num">(30,631)<span></span>
</td>
<td class="num">(52,406)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(150,011)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities', window );">Payments of business combination contingent consideration</a></td>
<td class="num">(1,293)<span></span>
</td>
<td class="num">(2,361)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from borrowings, net of borrowing costs</a></td>
<td class="nump">105,000<span></span>
</td>
<td class="nump">1,070,000<span></span>
</td>
<td class="nump">288,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of borrowings</a></td>
<td class="num">(835,000)<span></span>
</td>
<td class="num">(405,000)<span></span>
</td>
<td class="num">(166,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(282,320)<span></span>
</td>
<td class="num">(258,276)<span></span>
</td>
<td class="num">(245,341)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(1,119,287)<span></span>
</td>
<td class="nump">422,874<span></span>
</td>
<td class="num">(128,363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(1,719)<span></span>
</td>
<td class="num">(2,147)<span></span>
</td>
<td class="num">(14,434)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">10,470<span></span>
</td>
<td class="num">(45,819)<span></span>
</td>
<td class="num">(21,568)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">227,891<span></span>
</td>
<td class="nump">273,710<span></span>
</td>
<td class="nump">295,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">238,361<span></span>
</td>
<td class="nump">227,891<span></span>
</td>
<td class="nump">273,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid, net of refunds</a></td>
<td class="nump">278,400<span></span>
</td>
<td class="nump">216,866<span></span>
</td>
<td class="nump">478,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">45,708<span></span>
</td>
<td class="nump">47,379<span></span>
</td>
<td class="nump">22,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired', window );">Fair value of assets acquired, excluding cash</a></td>
<td class="nump">46,033<span></span>
</td>
<td class="nump">359,730<span></span>
</td>
<td class="nump">15,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Liabilities assumed</a></td>
<td class="num">(7,696)<span></span>
</td>
<td class="num">(131,765)<span></span>
</td>
<td class="num">(4,672)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease', window );">Goodwill on acquisition</a></td>
<td class="nump">92,191<span></span>
</td>
<td class="nump">786,990<span></span>
</td>
<td class="nump">38,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination', window );">Previously held equity interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,078)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_DeferredPaymentObligationsForAcquisitions', window );">Deferred payments</a></td>
<td class="num">(143)<span></span>
</td>
<td class="nump">2,542<span></span>
</td>
<td class="num">(3,067)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">4,372<span></span>
</td>
<td class="num">(2,387)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisitions</a></td>
<td class="nump">$ 134,757<span></span>
</td>
<td class="nump">$ 1,015,110<span></span>
</td>
<td class="nump">$ 42,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Contingent Consideration, Recognized Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_DeferredPaymentObligationsForAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Payment Obligations For Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_DeferredPaymentObligationsForAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Acquired During Period, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Equity Interest in Acquiree Held Prior to Combination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of an asset or business acquired in a noncash acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column D)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column D)(Footnote 6)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow or inflow from derivative instruments during the period, which are classified as investing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for financing costs associated with business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveSettledWithoutCash2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the reserve for full or partial settlement through consideration other than cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveSettledWithoutCash2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268756160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation ResMed Inc. (referred to herein as &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; or the &#8220;Company&#8221;) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Finland, Norway and Sweden. We also operate a Software as a Service (&#8220;SaaS&#8221;) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264372617856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies <div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Basis of Consolidation </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from management&#8217;s estimates. Certain prior period amounts have been reclassified to conform to the current period presentation. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Revenue Recognition </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standard Codification (&#8220;ASC&#8221;) Topic 606, &#8220;Revenue from Contracts with Customers&#8221;, we account for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (&#8220;Sleep and Respiratory Care&#8221;) and the supply of business management software as a service to out-of-hospital care providers (&#8220;SaaS&#8221;). Our Sleep and Respiratory Care revenue relates primarily to the sale of our products that are therapy-based equipment. Some contracts include additional performance obligations such as the provision of extended warranties and provision of data for patient monitoring. Our SaaS revenue relates to the provision of software access with ongoing support and maintenance services as well as professional services such as training and consulting.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregation of revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 13 &#8211; Segment Information for our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2024, 2023 and 2022.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Performance obligations and contract balances</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; generally, this occurs with the transfer of risk and/or control of our products at a point in time. For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with cloud-hosted services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of one year to five years. Our contracts do not contain significant financing components. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract balances as of June&#160;30, 2024 and 2023 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance sheet caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">837,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">704,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, non-current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes and other non-current assets</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(152,554)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(138,072)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (current liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137,343)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119,186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (non-current liabilities)</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction price determination</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g. rebates, discounts, free goods) and returns by our customers and their customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of our historical experience. Returns of products, excluding warranty-related returns, have historically been infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer&#8217;s expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates each quarter based on actual sales results and updated forecasts for the remaining rebate periods. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in programs where we issue credits to our Sleep and Respiratory Care distributors when they are required to sell our products below negotiated list prices if we have preexisting contracts with the distributors' customers. We reduce revenue for future credits at the time of sale to the distributor, which we estimate based on historical experience using the expected value method. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When Sleep and Respiratory Care or SaaS contracts have multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each performance obligation. An allocation is not required for many of our Sleep and Respiratory Care contracts that have a single performance obligation, which is the shipment of our therapy-based equipment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting and practical expedient elections</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to account for shipping and handling activities associated with our Sleep and Respiratory Care segment as a fulfillment cost within cost of sales, and record shipping and handling costs collected from customers in net revenue. We have also elected for all taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, to be excluded from revenue and presented on a net basis. We have adopted two practical expedients including the &#8220;right to invoice&#8221; practical expedient, which is relevant for some of our SaaS contracts as it allows us to recognize revenue in the amount of the invoice when it corresponds directly with the value of performance completed to date. The second practical expedient adopted permits relief from considering a significant financing component when the payment for the good or service is expected to be one year or less.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt">Concentration of Credit Risk and Significant Customers</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, derivatives and trade receivables. Our cash and cash equivalents are generally held with large, diverse financial institutions to reduce the amount of exposure to any single financial institution. Our derivative contracts are transacted with various financial institutions with high credit standings and any exposure to counterparty credit-related losses in these contracts is largely mitigated with collateralization and master-netting agreements. The risk with respect to trade receivables is mitigated by credit evaluations we perform on our customers, the short duration of our payment terms for the majority of our customer contracts and by the diversification of our customer base. No single customer accounted for 10% or more of our total revenues for any of the periods presented.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"> Fair Value of Financial Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of financial instruments is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. We measure our financial instruments at fair value at each reporting period using a fair value hierarchy that requires that we maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#8217;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Other inputs that are directly or indirectly observable in the marketplace.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs that are supported by little or no market activity.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash equivalents, accounts receivable and accounts payable, approximate their fair value because of their short-term nature. The carrying value of long-term debt related to our Revolving Credit and Term Credit Agreements approximates its fair value as the principal amounts outstanding are subject to variable interest rates that are based on market rates which are regularly reset. The carrying value of long-term debt related to our Senior Notes can differ to its fair value as the principal amounts outstanding are subject to fixed interest rates as outlined in Note 8 &#8211; Debt. Foreign currency hedging instruments are marked to market and therefore reflect their fair value. In addition, we measure investments in publicly held equity securities and privately held equity securities for which there has been an observable price change in an identical or similar security, at fair value. We do not hold or issue financial instruments for trading purposes. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt">Cash and Cash Equivalents </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents include certificates of deposit and other highly liquid investments and we state them at cost, which approximates market. We consider investments with original maturities of 90 days or less to be cash equivalents for purposes of the consolidated statements of cash flows.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.01pt">Inventories </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state inventories at the lower of cost (determined principally by the first-in, first-out method) or net realizable value. We include material, labor and manufacturing overhead costs in finished goods and work-in-process inventories. We review and provide for any product obsolescence in our manufacturing and distribution operations by assessing throughout the year individual products and components (based on estimated future usage and sales).</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Property, Plant and Equipment </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record property, plant and equipment, including rental and demonstration equipment at cost. We compute depreciation expense using the straight-line method over the estimated useful lives of the assets. Useful lives are generally two years to ten years except for buildings which are depreciated over an estimated useful life of forty years and leasehold improvements, which we amortize over the shorter of the useful life or the lease term. We charge maintenance and repairs to expense as we incur them.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for property, plant, and equipment was $88.9 million, $84.7 million, and $81.0 million for the years ended June&#160;30, 2024, 2023 and 2022, respectively.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Intangible Assets </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the registration costs for new patents and amortize the costs over the estimated useful life of the patent, which is generally ten years. If a patent is superseded or a product is retired, any unamortized costs are written off immediately.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We amortize our other intangible assets on a straight-line basis over their estimated useful lives, which range from two years to fifteen years. We evaluate events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists and, at least annually, evaluate the recoverability of intangible assets. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt">Goodwill </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct our annual review for goodwill impairment during the final quarter of the fiscal year. Our goodwill impairment review is performed at our reporting unit level, which is one level below our operating segments and involves the following steps: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Step 0 or Qualitative assessment &#8211; Evaluate qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. The factors we consider include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, overall financial performance or events-specific to that reporting unit. If or when we determine it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill, we would move to Step 1 of the quantitative method.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Step 1 &#8211; Compare the fair value for each reporting unit to its carrying value, including goodwill. Fair value is determined based on estimated discounted cash flows. A goodwill impairment charge is recognized for the amount that the carrying amount of a reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit. If a reporting unit&#8217;s fair value exceeds the carrying value, no further work is performed and no impairment charge is necessary.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the annual reviews for the years ended June&#160;30, 2024, 2023 and 2022, we completed a Step 0 or Qualitative assessment and determined it was more likely than not that the fair value of our reporting units exceeded their carrying amounts, including goodwill, and therefore goodwill was not impaired.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(j)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.01pt">Business Combinations</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate the purchase price to the estimated fair values of the assets acquired and liabilities assumed. This allocation process involves the use of estimates and assumptions made in connection with determining the fair value of assets acquired and liabilities assumed including cash flows expected to be derived from the use of the asset, the timing of such cash flows, the remaining useful life of assets and applicable discount rates. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If actual results vary from the estimates or assumptions used in the valuation or allocation process, we may be required to record an impairment charge or an increase in depreciation or amortization in future periods, or both.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(k)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Equity Investments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have equity investments in privately and publicly held companies that are unconsolidated entities. The following discusses our accounting for investments in marketable equity securities, non-marketable equity securities, and investments accounted for under the equity method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities are publicly traded stocks measured at fair value and classified within Level 1 in the fair value hierarchy because we use quoted prices for identical assets in active markets. Marketable equity securities are recorded in prepaid expenses and other current assets on the consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-marketable equity securities consist of investments in privately held companies without readily determinable fair values and are recorded in prepaid taxes and other non-current assets on the consolidated balance sheets. Non-marketable equity securities are reported at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. We assess non-marketable equity securities at least quarterly for impairment and consider qualitative and quantitative factors including the investee's financial metrics, product and commercial outlook and cash usage. All gains and losses on marketable and non-marketable equity securities, realized and unrealized, are recognized in gain (loss) on equity investments as a component of other income (loss), net on the consolidated statements of income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments whereby we have significant influence but not control over the investee and are not the primary beneficiary of the investee&#8217;s activities, are accounted for under the equity method. Under this method, we record our share of gains or losses attributable to equity method investments as a component of other income (loss), net on the consolidated statements of income. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(l)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt">Research and Development </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record all research and development expenses in the period we incur them.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(m)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:3.01pt">Foreign Currency </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of our non-U.S. subsidiaries, whose functional currencies are other than the U.S. dollar, are translated into U.S. dollars for financial reporting purposes. We translate assets and liabilities of non-U.S. subsidiaries whose functional currencies are other than the U.S. dollar at period end exchange rates but translate revenue and expense transactions at average exchange rates for the period. We recognize cumulative translation adjustments as part of comprehensive income, as detailed in the consolidated statements of comprehensive income, and include those adjustments in accumulated other comprehensive income in the consolidated balance sheets until such time the relevant subsidiary is sold or substantially or completely liquidated. We reflect gains and losses on transactions denominated in other than the functional currency of an entity in our results of operations.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(n)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Foreign Exchange Risk Management </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may use derivative financial instruments, specifically foreign cross-currency swaps, purchased foreign currency call options, collars and forward contracts to mitigate exposure from certain foreign currency risk. No derivatives are used for trading or speculative purposes. We do not require or are not required to pledge collateral for the derivative instruments.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fair Value and Net Investment Hedging</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2022, we executed foreign cross-currency swaps as net investment hedges and fair value hedges in designated hedging relationships with either the foreign denominated net asset balances or the foreign denominated intercompany loan as the hedged items. All derivatives are recorded at fair value as either an asset or liability. Cash flows associated with derivative instruments are presented in the same category on the consolidated statements of cash flows as the hedged item.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the cross-currency swaps for the fair value hedge is to mitigate foreign currency risk associated with changes in spot rates on foreign denominated intercompany debt between USD and EUR. For these hedges, we excluded certain components from the assessment of hedge effectiveness that are not related to spot rates. For fair value hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in the same line item as the hedged item, other, net, in the consolidated statement of income. The initial fair value of hedge components excluded from the assessment of effectiveness is recognized in the statement of income under a systematic and rational method over the life of the hedging instrument and is presented in interest (expense) income, net. Any difference between the change in the fair value of the hedge components excluded from the assessment of effectiveness and the amounts recognized in earnings is recorded as a component of other comprehensive income. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the cross-currency swaps for the net investment hedge is to mitigate foreign currency risk associated with changes in spot rates on the net asset balances of our foreign functional subsidiaries. For net investment hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in cumulative translation adjustment within other comprehensive loss and reclassified into earnings when the hedged net investment is either sold or </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantially liquidated. The initial fair value of components excluded from the assessment of hedge effectiveness will be recognized in interest (expense) income, net. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of outstanding foreign cross-currency swaps was $1,026.2 million at June&#160;30, 2024. These contracts mature at various dates prior to December 31, 2029.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Designated Hedges</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have foreign currency exposure through both our Australian and Singapore manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased foreign currency call options, collars and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed two years. The purpose of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, and Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not designate these foreign currency contracts as hedges. All movements in the fair value of the foreign currency instruments are recorded within other, net in our consolidated statements of income. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of the outstanding non-designated hedges was $1,340.0 million and $954.7 million at June&#160;30, 2024 and June&#160;30, 2023, respectively. These contracts mature at various dates prior to September&#160;15, 2025.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classified the fair values of all hedging instruments as Level 2 measurements within the fair value hierarchy.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments. We minimize counterparty credit risk by entering into derivative transactions with major financial institutions and we do not expect material losses as a result of default by our counterparties.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(o)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Income Taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. We measure deferred tax assets and liabilities using the enacted tax rates we expect to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in the consolidated financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions are reflected in income tax expense.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(p)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Allowance for Credit Losses</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an allowance for credit losses on customer receivables based expected losses, considering our historical write-off experience, an assessment of our customers&#8217; financial conditions, and available information that is relevant to assessing the collectability of cash flows, which includes current conditions and forecasts about future economic conditions. Customer receivables are charged against the allowance when they are deemed uncollectible. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also contingently liable, within certain limits, in the event of a customer default, to independent financing companies in connection with customer financing programs. We monitor the collection status of these installment receivables and provide for estimated losses separately under accrued expenses within our consolidated balance sheets based upon our historical collection experience with such receivables and a current assessment of our credit exposure.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(q)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Impairment of Long-Lived Assets </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically evaluate the carrying value of long-lived assets to be held and used, including certain identifiable intangible assets, when events and circumstances indicate that the carrying amount of an asset may not be recovered. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If assets are considered to be impaired, we recognize as the impairment the amount by which the carrying amount of the assets exceeds the fair value of the assets. We report assets to be disposed of at the lower of the carrying amount or fair value less costs to sell. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended June&#160;30, 2024, we recorded $33.2 million of restructuring related intangible asset impairments associated with the wind down of certain business activities. Refer to Note 18 &#8211; Restructuring Expenses for additional information regarding restructuring costs. We did not recognize impairment charges in relation to long-lived assets during the fiscal years ended June 30, 2023 and 2022.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(r)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt">Contingencies</span></div>We record a liability in the consolidated financial statements for loss contingencies when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264267915440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text">New Accounting Pronouncements <div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Recently issued accounting standards not yet adopted </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ASU No. 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (FASB) issued ASU No. 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," which expands segment disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. This ASU is applicable to our Annual Report on Form 10-K for the fiscal year ended June 30, 2025, and subsequent interim periods. Early adoption is permitted and the amendments must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adopting this ASU on our consolidated financial statements and disclosures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span></div>In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures," which updates income tax disclosure requirements primarily by requiring specific categories and greater disaggregation within the rate reconciliation and disaggregation of income taxes paid. This ASU is applicable to our Annual Report on Form 10-K for the fiscal year ended June 30, 2026, with early application permitted. We are currently evaluating the impact of adopting this ASU on our consolidated financial statements and disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268304160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text">Supplemental Balance Sheet Information<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of selected captions in the consolidated balance sheets consisted of the following as of June&#160;30, 2024 and June&#160;30, 2023 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inventories</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">355,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">459,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">463,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">822,250&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">998,012&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107,623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid expenses and current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">459,833&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">437,018&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">479,941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vehicles and aircraft</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical, demonstration and rental equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, at cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,274,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,205,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(726,967)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(668,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">548,025&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537,856&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268293392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangible Assets, net</a></td>
<td class="text">Goodwill and Other Intangible Assets, net<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the years ended June&#160;30, 2024 and June&#160;30, 2023, we have not recorded any goodwill impairments. Changes in the carrying amount of goodwill is comprised of the following for the year ended June&#160;30, 2024 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sleep and <br/>Respiratory Care</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SaaS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">670,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,100,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,770,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">757,529&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,084,526&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,842,055&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangibles, net are comprised of the following as of June&#160;30, 2024 and June&#160;30, 2023 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed/core product technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">384,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(280,970)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(265,802)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed/core product technology, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432,470&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443,652&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150,486)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(124,220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281,984&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319,432&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangibles</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252,210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(151,999)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144,402)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other intangibles, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485,904&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552,341&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of developed/core product technology, trade names, non-compete agreements, customer relationships, and patents, and we amortize them over the estimated useful life of the assets, generally between two years and fifteen years. There are no expected residual values related to these intangible assets. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended June&#160;30, 2024, we impaired $18.6&#160;million of developed/core product technology intangible assets, $14.5&#160;million of customer relationship intangible assets, and $0.1&#160;million of other intangibles associated with restructuring activities. These non-cash charges were recorded within <span style="-sec-ix-hidden:f-594">restructuring expenses</span> in the consolidated statements of income. Refer to Note 18 &#8211; Restructuring Expenses for the facts and circumstances leading to the impairments. We did not record any intangible asset impairments during the years ended June&#160;30, 2023 and 2022.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to identified intangible assets for the years ended June&#160;30, 2024 and June&#160;30, 2023 was $79.5 million and $72.4 million, respectively. Amortization expense related to patents, included in other intangibles, for the years ended June&#160;30, 2024 and June&#160;30, 2023 was $7.6 million and $7.0 million, respectively. Total estimated annual amortization expense for the years ending June 30, 2025 through June 30, 2029, is shown below (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Years Ending June 30</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264267862272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments by measurement category as of June&#160;30, 2024 and June&#160;30, 2023 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Measurement category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Measurement alternative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151,227&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2024 (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Observable price adjustments on non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,963)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,963)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exits of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized losses on marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,397)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,397)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,848)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,848)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying value at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,739&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,026&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,462&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151,227&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2023 (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Observable price adjustments on non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,892)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,892)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains on marketable and non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exits of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized losses on marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,735)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,735)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,873)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,873)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying value at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,748&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,423&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,366&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,537&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes additions from purchases and an equity method investment acquired and measured at fair value via our acquisition of MEDIFOX DAN. Refer to Note 17 herein.</span></div>Net unrealized gains and losses recognized in the years ended June&#160;30, 2024, 2023 and 2022 for equity investments in non-marketable and marketable securities still held as of those respective dates were a loss of $4.0 million, a gain of $6.0 million, and a loss of $16.2 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org/325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264267917440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses at June&#160;30, 2024 and June&#160;30, 2023 consist of the following (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product warranties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting and professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Value added taxes and other taxes due</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Promotional and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Logistics and occupancy costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory in transit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">377,678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365,660&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264387284928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt at June&#160;30, 2024 and June&#160;30, 2023 consists of the following (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred borrowing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,435,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred borrowing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,766)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">697,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,431,234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707,213&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,441,136&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;29, 2022, we entered into a second amended and restated credit agreement (the &#8220;Revolving Credit Agreement&#8221;), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger, sole book runner, swing line lender and letter of credit issuer, Westpac Banking Corporation, as syndication agent and joint lead arranger, HSBC Bank USA, National Association, as syndication agent and joint lead arranger, and Wells Fargo Bank, National Association, as documentation agent. The Revolving Credit Agreement, among other things, provided a senior unsecured revolving credit facility of $1,500.0 million, with an uncommitted option to increase the revolving credit facility by an additional amount equal to the greater of $1,000.0 million or 1.0 times the EBITDA (as defined in the Revolving Credit Agreement) for the trailing twelve-month measurement period. The Revolving Credit Agreement amends and restates that certain Amended and Restated Credit Agreement, dated as of April 17, 2018, among ResMed, MUFG Union Bank, N.A., Westpac Banking Corporation and the lenders party thereto.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on June&#160;29, 2022, ResMed Pty Limited entered into a Second Amendment to the Syndicated Facility Agreement and First Amendment to Unconditional Guaranty Agreement (the &#8220;Term Credit Agreement&#8221;), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger and joint book runner, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner, which amends that certain Syndicated Facility Agreement dated as of April 17, 2018. The Term Credit Agreement, among other things, provides ResMed Pty Limited a senior unsecured term credit facility of $200.0 million. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Revolving Credit Agreement are guaranteed by certain of our direct and indirect U.S. subsidiaries, and ResMed Pty Limited&#8217;s obligations under the Term Credit Agreement are guaranteed by us and certain of our direct and indirect U.S. subsidiaries. The Revolving Credit Agreement and Term Credit Agreement contain customary covenants, including, in each case, a financial covenant that requires that we maintain a maximum leverage ratio of funded debt to EBITDA (as defined in the Revolving Credit Agreement and Term Credit Agreement, as applicable). The entire principal amounts of the revolving credit facility and term credit facility, and, in each case, any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable. Events of default under the Revolving Credit Agreement and the Term Credit Agreement include, in each case, failure to make payments when due, the occurrence of a default in the performance of any covenants in the respective agreements or related documents, or certain changes of control of us, or the respective guarantors of the obligations borrowed under the Revolving Credit Agreement and Term Credit Agreement. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Agreement and Term Credit Agreement each terminate on June&#160;29, 2027, when all unpaid principal and interest under the loans must be repaid. Amounts borrowed under the Term Credit Agreement will also amortize on a semi-annual basis, with a $5.0 million principal payment required on each such semi-annual amortization date. The outstanding principal amounts will bear interest at a rate equal to the Adjusted Term SOFR (as defined in the Revolving Credit Agreement) plus 0.75% to 1.50% (depending on the then-applicable leverage ratio) or the Base Rate (as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable) plus 0.0% to 0.50% (depending on the then-applicable leverage ratio). At June&#160;30, 2024, the interest rate that was being charged on the outstanding principal amounts was 6.19%. An applicable commitment fee of 0.075% to 0.150% (depending on the then-applicable leverage </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ratio) applies on the unused portion of the revolving credit facility. As of June&#160;30, 2024, we had $1,470.0 million available for draw down under the revolving credit facility.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As the Revolving Credit and Term Credit Agreements&#8217; interest rate is calculated as Adjusted Term SOFR plus the spreads described above, its carrying amount is equivalent to its fair value as at June&#160;30, 2024 and June&#160;30, 2023, which was $210.0 million and $945.0 million, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Notes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;10, 2019, we entered into a Note Purchase Agreement with the purchasers to that agreement, in connection with the issuance and sale of $250.0 million principal amount of our 3.24% senior notes due July&#160;10, 2026, and $250.0 million principal amount of our 3.45% senior notes due July&#160;10, 2029 (collectively referred to as the &#8220;Senior Notes&#8221;). Our obligations under the Note Purchase Agreement and the Senior Notes are unconditionally and irrevocably guaranteed by certain of our direct and indirect U.S. subsidiaries. The net proceeds from this transaction were used to pay down borrowings on our Revolving Credit Agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Note Purchase Agreement, we agreed to customary covenants including with respect to our corporate existence, transactions with affiliates, and mergers and other extraordinary transactions. We also agreed that, subject to limited exceptions, we will maintain a ratio of consolidated funded debt to consolidated EBITDA (as defined in the Note Purchase Agreement) of no more than 3.50 to 1.00 as of the last day of any fiscal quarter, and will not at any time permit the amount of all priority secured and unsecured debt of us and our subsidiaries to exceed 10.0% of our consolidated tangible assets, determined as of the end of our most recently ended fiscal quarter. This ratio is calculated at the end of each reporting period for which the Note Purchase Agreement requires us to deliver financial statements, using the results of the 12 consecutive month period ending with such reporting period.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As of June&#160;30, 2024 and June&#160;30, 2023, the Senior Notes had a carrying amount of $500.0 million, excluding deferred borrowing costs, and an estimated fair value of $463.0 million and $462.2 million, respectively. Quoted market prices in active markets for identical liabilities based inputs (Level 2) were used to estimate fair value.</span></div>At June&#160;30, 2024, we were in compliance with our debt covenants and there was $710.0 million outstanding under the Revolving Credit Agreement, Term Credit Agreement and Senior Notes.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268336656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Leases where ResMed is the Lessee</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether a contract is, or contains, a lease at inception. Right of Use, or ROU, assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. We use our incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. ROU assets also include any lease payments made at or before lease commencement and any initial direct costs incurred and exclude any lease incentives received.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the lease term as the non-cancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Some of our leases include variable lease payments that are based on costs incurred or actual usage or adjusted periodically based on an index or a rate. Our leases do not contain any residual value guarantees and we do not account for lease and non-lease components as a single lease component. Operating leases are included in operating lease right-of-use assets and operating lease liabilities on our consolidated balance sheets. We lease certain office space, warehouses and distribution centers, manufacturing facilities, vehicles, and equipment with remaining lease terms ranging from less than 1 year to 15 years, some of which include options to extend or terminate the leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs for the years ended June&#160;30, 2024, 2023 and 2022 were $40.8 million, $33.6 million and $35.3 million, respectively. Short-term and variable lease costs were not material for the years ended June&#160;30, 2024, 2023 and 2022. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under non-cancellable operating leases as of June&#160;30, 2024 are as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197,933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,806&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166,722&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, future operating lease commitments for leases that have not yet commenced were not material. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental information related to operating leases for the years ended June&#160;30, 2024 and June&#160;30, 2023 was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average inputs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash flows paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for new lease liabilities:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Leases where ResMed is the Lessor</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease sleep and respiratory medical devices to customers primarily to comply with local health insurer requirements in certain foreign geographies. Device rental contracts are classified as operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. Operating lease revenue was $92.9 million, $88.6 million and $90.1 million for the years ended June&#160;30, 2024, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Leases where ResMed is the Lessee</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether a contract is, or contains, a lease at inception. Right of Use, or ROU, assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. We use our incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. ROU assets also include any lease payments made at or before lease commencement and any initial direct costs incurred and exclude any lease incentives received.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the lease term as the non-cancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Some of our leases include variable lease payments that are based on costs incurred or actual usage or adjusted periodically based on an index or a rate. Our leases do not contain any residual value guarantees and we do not account for lease and non-lease components as a single lease component. Operating leases are included in operating lease right-of-use assets and operating lease liabilities on our consolidated balance sheets. We lease certain office space, warehouses and distribution centers, manufacturing facilities, vehicles, and equipment with remaining lease terms ranging from less than 1 year to 15 years, some of which include options to extend or terminate the leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs for the years ended June&#160;30, 2024, 2023 and 2022 were $40.8 million, $33.6 million and $35.3 million, respectively. Short-term and variable lease costs were not material for the years ended June&#160;30, 2024, 2023 and 2022. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under non-cancellable operating leases as of June&#160;30, 2024 are as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197,933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,806&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166,722&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, future operating lease commitments for leases that have not yet commenced were not material. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental information related to operating leases for the years ended June&#160;30, 2024 and June&#160;30, 2023 was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average inputs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash flows paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for new lease liabilities:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Leases where ResMed is the Lessor</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease sleep and respiratory medical devices to customers primarily to comply with local health insurer requirements in certain foreign geographies. Device rental contracts are classified as operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. Operating lease revenue was $92.9 million, $88.6 million and $90.1 million for the years ended June&#160;30, 2024, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorSalesTypeLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Leases where ResMed is the Lessee</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether a contract is, or contains, a lease at inception. Right of Use, or ROU, assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. We use our incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. ROU assets also include any lease payments made at or before lease commencement and any initial direct costs incurred and exclude any lease incentives received.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the lease term as the non-cancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Some of our leases include variable lease payments that are based on costs incurred or actual usage or adjusted periodically based on an index or a rate. Our leases do not contain any residual value guarantees and we do not account for lease and non-lease components as a single lease component. Operating leases are included in operating lease right-of-use assets and operating lease liabilities on our consolidated balance sheets. We lease certain office space, warehouses and distribution centers, manufacturing facilities, vehicles, and equipment with remaining lease terms ranging from less than 1 year to 15 years, some of which include options to extend or terminate the leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs for the years ended June&#160;30, 2024, 2023 and 2022 were $40.8 million, $33.6 million and $35.3 million, respectively. Short-term and variable lease costs were not material for the years ended June&#160;30, 2024, 2023 and 2022. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under non-cancellable operating leases as of June&#160;30, 2024 are as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197,933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,806&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166,722&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, future operating lease commitments for leases that have not yet commenced were not material. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental information related to operating leases for the years ended June&#160;30, 2024 and June&#160;30, 2023 was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average inputs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash flows paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for new lease liabilities:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Leases where ResMed is the Lessor</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease sleep and respiratory medical devices to customers primarily to comply with local health insurer requirements in certain foreign geographies. Device rental contracts are classified as operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. Operating lease revenue was $92.9 million, $88.6 million and $90.1 million for the years ended June&#160;30, 2024, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorSalesTypeLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of lessor's sales-type leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorSalesTypeLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264272651088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On February&#160;21, 2014, our board of directors approved a new share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant and subject to applicable legal requirements. The 20.0 million shares the program authorizes us to purchase are in addition to the shares we repurchased on or before February&#160;21, 2014 under our previous programs. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. All share repurchases since February&#160;21, 2014 have been executed in accordance with this program. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2024, we repurchased approximately 828,000 shares at a cost of $150.0 million. We did not repurchase any shares during fiscal year 2023. As of June&#160;30, 2024, we have repurchased a total of 42.7 million shares at a cost of $1.8 billion. Shares that are repurchased are classified as &#8220;treasury stock pending future use&#8221; and reduce the number of shares outstanding used in calculating earnings per share. At June&#160;30, 2024, 12.1 million additional shares can be repurchased under the approved share repurchase program.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In April 1997, our board of directors authorized 2.0 million shares of 0.01 par value preferred stock. No such shares were issued or outstanding at June&#160;30, 2024. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options and Restricted Stock Units.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have granted stock options, restricted stock units (&#8220;RSUs&#8221;) and performance restricted stock units (&#8220;PRSUs&#8221;) to personnel, including officers and directors, in accordance with the ResMed Inc. 2009 Incentive Award Plan (the &#8220;2009 Plan&#8221;). Options and restricted stock units vest over one year to four years and the options have expiration dates of seven years from the date of grant. We have granted the options with an exercise price equal to the market value as determined at the date of grant. We have granted PRSUs that are subject to a market condition, with the ultimate realizable number of PRSUs dependent on relative total stockholder return over a period of three years. The maximum amounts to be issued under the awards range from 200% to 225% of the original grant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the annual meeting of our stockholders in November 2017, our stockholders approved an amendment and restatement to the 2009 Plan to increase the number of shares of common stock that may be issued or transferred pursuant to awards under the 2009 Plan by 7.4 million. The amendment and restatement imposes a maximum award amount which may be granted under the 2009 Plan to non-employee director in a calendar year, which when taken together with any other cash fees earned for services as a non-employee director during the calendar year, has a total value of $0.7 million, or $1.2 million in the case of a non-employee director who is also serving as chairman of our board of directors. The amendment and restatement also increased the maximum amount payable pursuant to cash-denominated performance awards granted in any calendar year from $3.0 million to $5.0 million. In addition, the amendment and restatement extended the existing prohibition on the payment of dividends or dividend equivalents on unvested awards to apply to all awards, including time-based restricted stock, deferred stock and stock payment. The term of the 2009 Plan was extended by four years so that the plan expires on September&#160;11, 2027.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum number of shares of our common stock authorized for issuance under the 2009 Plan is 51.1 million. The number of securities remaining available for future issuance under the 2009 Plan at June&#160;30, 2024 is 12.5 million. The number of shares of our common stock available for issuance under the 2009 Plan will be reduced by (i) 2.8 shares for each one share of common stock delivered in settlement of any &#8220;full-value award,&#8221; which is any award other than a stock option, stock appreciation right or other award for which the holder pays a purchase price and (ii) one share for each share of common stock delivered in settlement of all other awards. The maximum number of shares, which may be subject to awards granted under the 2009 Plan to any individual during any calendar year, may not exceed 3 million shares of our common stock (except in a participant&#8217;s initial year of hiring up to 4.5 million shares of our common stock may be granted). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain regions, shares are withheld on behalf of employees to satisfy statutory tax withholding requirements upon exercise or vesting of awards. The number of shares withheld is based upon the closing price of our common stock on the trading day of the applicable settlement date. The remaining shares are delivered to the recipient as shares of our common stock. The amount remitted to the tax authorities for the employees&#8217; tax obligation is reflected as a financing activity on our consolidated statements of cash flows. Shares withheld by us as a result of the net settlement are not considered issued and outstanding and are added to the shares available for future issuance under the 2009 Plan.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of RSUs and PRSUs that vested during the years ended June&#160;30, 2024, 2023 and 2022, was $51.0 million, $66.8 million and $65.5 million, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of RSUs, including PRSUs, during year ended June&#160;30, 2024 (in thousands, except years and per share amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock<br/>Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant-Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227.82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,139&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183.93&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6</span></td></tr></table></div><div style="margin-top:1pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5pt">Includes 60 thousand shares netted for tax.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity during the year ended June&#160;30, 2024 (in thousands, except years and per share amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136.06&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options vested and expected to vest at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.52&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8</span></td></tr></table></div><div style="margin-top:1pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5pt">Includes 1 thousand shares netted for tax.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised during the fiscal years 2024, 2023 and 2022, was $17.9 million, $25.4 million and $33.7 million, respectively. As at June&#160;30, 2024, the aggregate intrinsic value of options outstanding, exercisable, and vested and expected to vest were $42.9 million, $39.8 million and $42.7 million respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan (the &#8220;ESPP&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the board of directors&#8217; compensation committee of no less than 3 months and no more than 27 months. The purchase price for our common stock under the ESPP will be the lower of 85% of the fair market value of our common stock on the date of grant or 85% of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than $25,000 in common stock during any calendar year. At June&#160;30, 2024, the number of shares remaining available for future issuance under the ESPP is 1.0 million shares.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During years ended June&#160;30, 2024, 2023 and 2022, we issued 323,000, 220,000 and 216,000 shares to our employees in two offerings and we recognized $11.4 million, $11.5 million and $11.0 million, respectively, of stock compensation expense associated with the ESPP.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock&#8211;based Employee compensation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We measure the compensation expense of all stock-based awards at fair value on the grant date. We estimate the fair value of stock options and purchase rights granted under the ESPP using the Black-Scholes valuation model. The fair value of restricted stock units is equal to the market value of the underlying shares as determined at the grant date less the fair value of dividends that holders are not entitled to, during the vesting period. The fair value of performance restricted stock units is measured using a Monte-Carlo simulation valuation model. We recognize the fair value as compensation expense using the straight-line method over the service period for awards expected to vest.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the assumptions in the following tables. The risk-free interest rate is estimated using the U.S. Treasury yield curve and is based on the term of the award. The expected term of awards is estimated from the vesting period of the award, as well as historical exercise behavior, and represents the period of time the awards granted are expected to be outstanding. Expected volatility is estimated based upon the historical volatility of ResMed stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions for the years ended June&#160;30, 2024, 2023 and 2022: </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock options:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average grant date fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$50.48</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$74.95</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$72.16</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.44%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.85%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.29%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.29%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.78%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.66%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ESPP purchase rights:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average grant date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$47.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$52.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$50.46</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.75% - 1.30%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.75% - 0.84%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.63% - 0.98%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27% - 40%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27% - 34%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20% - 34%</span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total stock-based compensation costs incurred and the associated tax benefit recognized during the years ended June&#160;30, 2024, 2023 and 2022 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,184&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,142&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,257&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,860)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,262)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation costs, net of tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,131&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,282&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,995&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>At June&#160;30, 2024, there was $142.4 million in unrecognized compensation costs related to unvested stock-based compensation arrangements. This is expected to be recognized over a weighted average period of 2.6 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264372771920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compute basic earnings per share by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units. The weighted average number of outstanding stock options and restricted stock units not included in the computation of diluted earnings per share were 603,859, 272,104 and 67,000 for the years ended June&#160;30, 2024, 2023 and 2022, respectively, as the effect would have been anti-dilutive. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings per share for the years ended June&#160;30, 2024, 2023 and 2022 are calculated as follows (in thousands except per share data): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">779,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options and restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted average shares </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.94&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.34&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.92&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.09&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.30&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264418274144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes for the years ended June&#160;30, 2024, 2023 and 2022, was taxed under the following jurisdictions (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85,919)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,083,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">973,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,046,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,264,798&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101,664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">960,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is presented below (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:28.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293,725&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249,540&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192,864&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred: </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,915)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,721)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,612)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,389)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49,878)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45,432)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,818)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243,847&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181,046&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. federal income tax rate of 21% for the years ended June&#160;30, 2024, 2023 and 2022, to pretax income as a result of the following (in thousands): </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes computed at statutory U.S. rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase (decrease) in income taxes resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes, net of U.S. tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27,786)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,481)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,007)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of non-U.S. tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,838)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,982)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,384)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,988)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,282)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243,847&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204,108&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181,046&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reported net deferred tax assets and liabilities in our consolidated balance sheets at June&#160;30, 2024 and June&#160;30, 2023, as follows (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current deferred tax asset</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(90,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124,230&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,324&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our deferred tax assets and liabilities at June&#160;30, 2024 and June&#160;30, 2023, are as follows (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Employee liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">35,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">34,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Tax credit carry overs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">9,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">6,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">15,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">13,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Provision for warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">6,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">5,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Provision for doubtful debts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">5,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">6,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">23,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">22,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Capital loss carryover</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">5,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">11,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">8,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">28,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">23,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Research and development capitalization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">125,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">111,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">25,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">21,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Hedging contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">56,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">27,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">State income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">3,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">2,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">5,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(2,014)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">356,712&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">282,081&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(9,384)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(8,536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">347,328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">273,545&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Goodwill and other intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(192,398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(198,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(22,843)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(20,501)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(7,857)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(12,302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(223,098)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(231,221)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Net deferred tax asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">124,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">42,324&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, we had $16.5 million of U.S. federal and state net operating loss carryforwards and $6.2 million of non-U.S. net operating loss carryforwards, which expire in various years beginning in 2025 or carry forward indefinitely. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance at June&#160;30, 2024 relates to a provision for uncertainty of the utilization of net operating loss carryforwards of $0.8 million and capital loss and other items of $8.6 million. We believe that it is more likely than not that the benefits of deferred tax assets, net of any valuation allowance, will be realized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our manufacturing operations and administrative functions in Singapore operate under certain tax holidays and tax incentive programs that will expire in whole or in part at various dates through June 30, 2030. The end of certain tax holidays may be extended if specific conditions are met. The net impact of these tax holidays and tax incentive programs increased our net income by $49.6 million ($0.34 per diluted share) for the year ended June&#160;30, 2024, $40.5 million ($0.27 per diluted share) for the year ended June&#160;30, 2023, and $38.0 million ($0.26 per diluted share) for the year ended June&#160;30, 2022. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;), we have treated all non-U.S. historical earnings as taxable. Therefore, future repatriation of cash held by our non-U.S. subsidiaries will generally not be subject to U.S. federal tax if repatriated. The total amount of these undistributed earnings at June&#160;30, 2024 amounted to approximately $4.1 billion. In </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the event our non-U.S. earnings had not been permanently reinvested, approximately $4.9&#160;million in U.S. state deferred taxes would have been recognized in the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TCJA also introduced U.S. taxation on certain global intangible low-taxed income (&#8220;GILTI&#8221;). We have elected to account for tax expense attributable to GILTI tax as a period cost when incurred.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accounting for uncertainty in income taxes, we recognize a tax benefit in the financial statements for an uncertain tax position only if management&#8217;s assessment is that the position is &#8220;more likely than not&#8221; (that is, a likelihood greater than 50 percent) to be allowed by the tax jurisdiction based solely on the technical merits of the position. The term &#8220;tax position&#8221; refers to a position in a previously filed tax return or a position expected to be taken in a future tax return that is reflected in measuring current or deferred income tax assets and liabilities for annual periods. We recognize interest and penalties related to unrecognized tax benefits within the income tax expense line in the accompanying consolidated statements of income. Accrued interest and penalties are included within the related tax liability line in the consolidated balance sheets. Based on all known facts and circumstances and current tax law, we believe the total amount of unrecognized tax benefits on June&#160;30, 2024 is not material to our results of operations, financial condition or cash flows, and if recognized, would not have a material impact on our effective tax rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax returns are based on calculations and assumptions subject to audit by various tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws. We regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. Any final assessment resulting from tax audits may result in material changes to our past or future taxable income, tax payable or deferred tax assets, and may require us to pay penalties and interest that could materially adversely affect our financial results. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 19, 2021, we concluded the settlement agreement with the Australian Taxation Office (&#8220;ATO&#8221;) in relation to the previously disclosed transfer pricing dispute for the tax years 2009 through 2018 (&#8220;ATO settlement&#8221;). The ATO settlement fully resolved the dispute for all prior years, with no admission of liability and provides clarity in relation to certain future taxation principles.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final net impact of the ATO settlement was recorded during the years ended June 30, 2021 and 2022 in the amount of $238.7&#160;million, which represents a gross amount of $381.7&#160;million, including interest and penalties of $48.1&#160;million, and adjustments for credits and deductions of $143.0&#160;million. As a result of the ATO settlement and due to movements in foreign currencies, we recorded a benefit of $14.1&#160;million within other comprehensive income, and a $4.1&#160;million reduction of tax credits, which was recorded to income tax expense. As a result of the ATO settlement, we reversed our previously recorded uncertain tax position.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2021, we remitted final payment to the ATO of $284.8&#160;million, consisting of the agreed settlement amount of $381.7&#160;million less prior remittances made to the ATO of $96.9&#160;million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax years 2018 to 2023 remain subject to examination by the major tax jurisdictions in which we are subject to tax.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264278822880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two operating segments, which are the Sleep and Respiratory Care segment and the SaaS segment. We evaluate the performance of our segments based on net sales and income from operations. The accounting policies of the segments are the same as those described in Note 2 &#8211; Summary of Significant Accounting Policies. Segment net sales and segment income from operations do not include inter-segment profits and revenue is allocated to a geographic area based on where the products are shipped to or where the services are performed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include corporate headquarters costs, stock-based compensation, amortization expense from acquired intangibles, restructuring expenses, field safety notification expenses, acquisition related expenses, net interest expense (income), gains and losses attributable to equity method investments, gains and losses on equity investments, and other, net. We neither discretely allocate assets to our operating segments, nor does our Chief Operating Decision Maker evaluate the operating segments using discrete asset information.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, effective in the third quarter of fiscal year 2024, we updated the method of attribution of certain costs that are principally managed at the segment level as part of our evaluation of segment operating performance. As a result, certain costs relating to quality and regulatory assurance, commercial legal, operations, sales and marketing, customer service, information technology, and other administrative costs, which were previously included in Corporate costs within our reconciliation of segment operating profit to income before income taxes, are now reported in segment operating results. The financial information presented herein reflects the impact of the preceding reporting change for all periods presented.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents a reconciliation of net revenues, depreciation and amortization and net operating profit by reportable segments for the years ended June&#160;30, 2024, 2023 and 2022 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net revenue by segment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,101,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,725,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,177,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">584,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">497,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,685,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,222,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,578,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Depreciation and amortization by segment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets and corporate assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net operating profit by segment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,681,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,447,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,279,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,835,804&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,562,775&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,373,347&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reconciling items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">338,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks with magnets field safety notification expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Astral field safety notification expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on insurance recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,264,798&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101,664&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">960,483&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;During the fiscal year ended June&#160;30, 2024, we recorded $4.1&#160;million of operating lease right-of-use asset impairments within our SaaS segment. The impairments related to leases for office space and were recorded within net operating profit. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The masks with magnets field safety notification expenses relate to estimated </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">costs to provide alternative masks to patients in response to updated contraindications for use of masks that incorporate magnets.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;The Astral field safety notification expenses relate to estimated costs associated with the replacement of a certain component in some of our Astral ventilation devices that were manufactured between 2013 to 2019.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2024, 2023 and 2022 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S., Canada and Latin America</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,522,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,444,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,070,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,199,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,039,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total U.S., Canada and Latin America</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,722,556&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,483,387&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,981,807&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Combined Europe, Asia and other markets </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">921,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">796,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Combined Europe, Asia and other markets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,378,616&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,241,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,195,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,444,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,270,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,866,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,657,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,454,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,310,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,101,172&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,725,017&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,177,298&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">584,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">497,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,685,297&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,222,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,578,127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue information by geographic area for the years ended June&#160;30, 2024, 2023 and 2022 is summarized below (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,980,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,719,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,249,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of the World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,705,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,503,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,328,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,685,297&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,222,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,578,127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets of geographic areas are those assets used in our operations in each geographical area, and excludes goodwill, other intangible assets, and deferred tax assets. Long-lived assets by geographic area as of June&#160;30, 2024 and 2023 is summarized below (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Australia</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197,017&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of the World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">548,025&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537,856&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264267853680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retirement Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Retirement Plans</a></td>
<td class="text">Employee Retirement Plans <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contribute to a number of employee retirement plans for the benefit of our employees. Details of the main plans are as follows: </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Australia </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contribute to defined contribution plans for each employee resident in Australia at the rate of approximately 11.0% of salaries. Employees may contribute additional funds to the plans. All Australian employees, after serving a qualifying period, are entitled to benefits on retirement, disability or death. Our total contributions to the plans for the years ended June&#160;30, 2024, 2023 and 2022, were $14.9 million, $13.0 million and $11.8 million, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">United States </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor a defined contribution plan available to substantially all domestic employees. Company contributions to this plan are based on a percentage of employee contributions to a maximum of 4.0% of the employee&#8217;s </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eligible compensation, subject to the annual IRS limit. Our total contributions to the plan were $13.8 million, $12.7 million and $11.9 million in fiscal 2024, 2023 and 2022, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Singapore </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor a defined contribution plan available to all domestic employees. Company contributions to this plan are based on a percentage of employee contributions to a maximum of 17.0% of the employee&#8217;s salary. Our total contributions to the plan were $3.9 million, $3.6 million and $3.1 million in fiscal 2024, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268294752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Actions, Contingencies and Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Actions, Contingencies and Commitments</a></td>
<td class="text">Legal Actions, Contingencies and Commitments<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, New York University ("NYU") filed a complaint for patent infringement in the United States District Court, District of Delaware against ResMed Inc., case no. 1:21-cv-00813 (JPM). The complaint alleges that the AutoSet or AutoRamp features of ResMed&#8217;s AirSense 10 AutoSet flow generators infringe one or more claims of various NYU patents, including U.S. Patent Nos. 6,988,994; 9,108,009; 9,168,344; 9,427,539; 9,533,115; 9,867,955; and 10,384,024. According to the complaint, the NYU patents are directed to systems and methods for diagnosis and treating sleeping disorders during different sleep states. The complaint seeks monetary damages and attorneys&#8217; fees. We answered the complaint on September 30, 2021 and filed a motion to dismiss the complaint on the basis that the patents are invalid because the subject matter of the patents is not patentable under the Supreme Court and Federal Circuit precedent. The motion to dismiss was granted in part and denied in part. In December 2022, the Patent Trial and Appeal Board (&#8220;PTAB&#8221;) of the Patent and Trademark Office granted our request to review the validity of the claims in the patents asserted by NYU against us, determining that there is a reasonable likelihood that we will prevail. In December 2023, the PTAB issued written decisions invalidating each of the challenged claims in each of the NYU patents asserted against us. On December 28, 2023, the District Court entered an order continuing its stay of all proceedings against us pending any appeal by NYU of the invalidation of its patents by the PTAB. On January 31, 2024, NYU appealed the PTAB&#8217;s rulings to the Court of Appeals for the Federal Circuit. The appeals are not expected to be resolved before March 2025.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2021, the International Trade Commission ("ITC") instituted In Re Certain UMTS and LTE Cellular Communications Modules and Products Containing the Same, Investigation No. 337-TA-1240, by complainants Philips RS North America, LLC and Koninklijke Philips N.V. (collectively &#8220;Philips&#8221;) against Quectel Wireless Solutions Co., Ltd; Thales DIS AIS USA, LLC, Thales DIS AIS Deutschland GmbH; Telit Wireless Solutions, Inc., Telit Communications PLC, CalAmp. Corp., Xirgo Technologies, LLC, and Laird Connectivity, Inc. (collectively &#8220;respondents&#8221;). In the ITC investigation, Philips seeks an order excluding communications modules, and products that contain them, from importation into the United States based on alleged infringement of 3G and 4G standard essential patents held by Philips. On October 6-14, 2021, the administrative law judge held a hearing on the merits. The administrative law judge issued an initial determination on April 1, 2022, finding no violation of any of the Philips' patents asserted in the ITC. Philips sought review by the full ITC. On July 6, 2022, the Commission affirmed the administrative law judge&#8217;s determination that there was no violation of asserted Philips' patents. The Commission terminated the ITC proceedings. Philips did not appeal the ITC&#8217;s decision. On December 17, 2020, Philips filed companion cases for patent infringement against the same defendants in the United States District Court for the District of Delaware, case nos. 1:20-cv-01707, 01708, 01709, 01710, 01711, and 01713 (CFC) seeking damages, an injunction, and a declaration from the court on the amount of a fair reasonable and non-discriminatory license rate for the standard essential patents it is asserting against the communications module defendants. The district court cases were stayed pending the resolution of the ITC proceedings. The parties have returned to the district court for further proceedings. We were not a party to the ITC investigation, and we are not a party to the district court cases, but we sell products that incorporate communications modules at issue in the district court case. The first trial in the cases by Philips against the communications module defendants was originally set for August 12, 2024. On August 5, 2024, the court issued an order vacating the trial date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2022, Cleveland Medical Devices Inc. ("Cleveland Medical") filed suit for patent infringement against ResMed Inc. in the United States District Court for the District of Delaware, case no. 1:22-cv-00794. Cleveland Medical asserts that numerous ResMed connected devices, when combined with certain ResMed data platforms and/or software, including AirView and ResScan, infringe one or more of seven Cleveland Medical patents, including U.S. Patent Nos. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,076,269; 10,426,399; 10,925,535; 11,064,937; 10,028,698; 11,202,603; and 11,234,637. We moved to dismiss the action because Cleveland Medical sued the wrong ResMed entity, and to dismiss the indirect and willful infringement allegations by Cleveland Medical. On October 2, 2023, the court granted a portion of the motion, dismissing all Cleveland Medical claims for indirect and willful infringement, and denied the rest of the motion. On March 22, 2023, ResMed Corp. filed a petition with the PTAB seeking review of the validity of U.S. Patent No. 10,076,269. On May 6, 2024, the PTAB granted the petition and instituted an Inter Partes Review proceeding against the patent. On June 21, 2024, the District Court of Delaware granted ResMed&#8217;s motion to stay the case until the PTAB issues its final written decision in the Inter Partes Review proceeding. The PTAB decision is expected by May 6, 2025.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2023, ResMed Corp. filed suit in the United States District Court for the Southern District of California, case no. 23-cv-00500-TWR-JLB, seeking a declaration that it does not infringe U.S. Patent No. 11,602,284 issued to Cleveland Medical. In November 2023, the case was transferred to the Northern District of Ohio for the convenience of the parties. Cleveland Medical answered the complaint and filed a counterclaim asserting that ResMed Corp. infringes three additional Cleveland Medical patents, including U.S. Patent Nos. 11,375,921; 11,690,512; and 11,786,680. On April 9, 2024, Cleveland Medical filed a second amended answer and counterclaims accusing ResMed Corp. of infringing U.S. Patent Nos. 11,857,333 and 11,872,029. ResMed Corp. filed a petition with the PTAB for post-grant review of the validity of U.S. Patent No. 11,602,284, which the PTAB denied on June 24, 2024. On July 24, 2024, ResMed Corp. requested rehearing of the PTAB's denial of the petition for post-grant review of US Patent No. 11,602,284.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on currently available information, we are unable to make a reasonable estimate of loss or range of losses, if any, arising from matters that remain open.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Obligations Under Recourse Provisions</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use independent financing institutions to offer some of our customers financing for the purchase of some of our products. Under these arrangements, if the customer qualifies under the financing institutions&#8217; credit criteria and finances the transaction, the customers repay the financing institution on a fixed payment plan. For some of these arrangements, the customer&#8217;s receivable balance is with limited recourse whereby we are responsible for repaying the financing company should the customer default. We record a contingent provision, which is estimated based on historical default rates. This is applied to receivables sold with recourse and is recorded in accrued expenses.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended June&#160;30, 2024 and 2023, receivables sold with limited recourse were $206.7 million and $181.2 million, respectively. As of June&#160;30, 2024, the maximum exposure on outstanding receivables sold with recourse and contingent provision were $35.8 million and $0.8 million, respectively. As of June&#160;30, 2023, the maximum exposure on outstanding receivables sold with recourse and contingent provision were $32.6 million and $0.6 million, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we enter into agreements to purchase goods or services that are not cancelable without penalty, primarily related to supply arrangements. Obligations under our purchase agreements at June&#160;30, 2024 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.997%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Years Ending June 30</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2029</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minimum purchase obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,023,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">845,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264372782800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments and Hedging Activities</a></td>
<td class="text">Derivative Instruments and Hedging Activities <div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Values of Derivative Instruments </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our assets and liabilities related to derivative instruments on a gross basis within the consolidated balance sheets (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1269"><span style="-sec-ix-hidden:f-1270">Prepaid expenses and other current assets</span></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1273"><span style="-sec-ix-hidden:f-1274">Prepaid taxes and other non-current assets</span></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign cross-currency swaps &#8211; Fair Value Hedge</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1279"><span style="-sec-ix-hidden:f-1280">Other long-term liabilities</span></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign cross-currency swaps &#8211; Net Investment Hedge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1285"><span style="-sec-ix-hidden:f-1286">Accrued expenses</span></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,699&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Hedge Gains (Losses)</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the following gains (losses) on the foreign cross currency swaps designated as fair value hedges (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized in other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,414)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on cross-currency swap in interest (expense) income, net (amount excluded from effectiveness testing)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on cross-currency swap in other, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on intercompany debt in other, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,942)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Investment Hedge Gains (Losses)</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the following gains (losses) on the foreign cross currency swaps designated as net investment hedges (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized in cumulative translation adjustment within other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40,803)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized from the excluded components in interest (expense) income, net </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-designated Derivative Gains (Losses)</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the following gains (losses) in the consolidated statement of income on derivatives not designated as hedging instruments (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on foreign currency hedging instruments in other, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,168)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,511)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on other foreign-currency-denominated transactions in other, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,149)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,204)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,809&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264372783296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text">Business Combinations<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 21, 2022, we completed our acquisition of 100% of the shares in MediFox-Dan Investment GmbH and its subsidiaries (&#8220;MEDIFOX DAN&#8221;), a German leader in software solutions for a wide variety of out-of-hospital care providers, for $997.5 million. This acquisition has been accounted for as a business combination using purchase accounting and included in our consolidated financial statements from November 21, 2022. The acquisition was paid for using funds drawn down from our Revolving Credit Agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase price was allocated to MEDIFOX DAN's tangible and identifiable intangible assets and liabilities based upon estimated fair values as of the November 21, 2022 closing date, as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Final</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible assets - useful life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,623)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 - 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 - 13 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78,458)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase price</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed the purchase price allocation in relation to this acquisition during the quarter ended June 30, 2023. The cost of the acquisition was allocated to the assets acquired and liabilities assumed based on estimates of their fair values at the date of acquisition. Key assumptions used to determine the fair value of intangible assets acquired included forecast revenue growth rates, forecast earnings before interest, tax, depreciation, and amortization, and weighted average cost of capital. The goodwill recognized as part of the acquisition is reflected in our SaaS segment and is not deductible for tax purposes. It mainly represents the synergies that are unique to our combined businesses and the potential for new products and services to be developed in the future.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma results of operations have not been presented because the effects of this acquisition were not material to our consolidated statements of income. </span></div>We did not have material acquisition related expenses during the year ended June&#160;30, 2024. We recorded acquisition related expenses of $10.9&#160;million and $1.9&#160;million during the years ended June&#160;30, 2023 and June&#160;30, 2022, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268313440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Expenses</a></td>
<td class="text">Restructuring Expenses <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring expenses consist of costs incurred in connection with the realignment of business strategies and operations as well as cost rationalization efforts. These costs are separately presented as restructuring expenses within our consolidated statement of income for all periods presented. Although the costs associated with restructuring plans have not been allocated to our business segments' results in Note 13 &#8211; Segment Information, the restructuring plans impacted both our Sleep and Respiratory Care and SaaS segments. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended June&#160;30, 2024, we recorded $64.2 million of restructuring related charges associated with an evaluation of our existing operations to increase operational efficiency, decrease costs and increase profitability. Restructuring charges for the year ended June&#160;30, 2024 are comprised of $28.6 million of employee severance and other one-time termination benefits, $33.2 million of intangible asset impairments associated with the wind down of certain </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business activities, and $2.4 million of other miscellaneous asset impairments. As of June&#160;30, 2024, there were no restructuring expenses remaining in our accruals. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended June 30, 2023, we incurred restructuring expenses of $9.2&#160;million associated with the reorganization and rationalization of our operations. We recorded the full amount of $9.2&#160;million during the year ended June 30, 2023. The restructuring expenses consisted primarily of severance to employees. As of June 30, 2023, we had $7.8&#160;million in restructuring expenses remaining in our accruals which were paid during the year ended June 30, 2024.</span></div>We did not incur material restructuring expenses during the year ended June 30, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268896240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II Valuation and Qualifying Accounts and Reserves<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule II Valuation and Qualifying Accounts and Reserves</a></td>
<td class="text"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VALUATION AND QUALIFYING ACCOUNTS AND RESERVES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2024, 2023 and 2022</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning<br/>of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged to costs and expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>(deductions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>End of<br/>Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended June&#160;30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Applied against asset account</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allowance for trade accounts receivable </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,273)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended June&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Applied against asset account</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allowance for trade accounts receivable </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Applied against asset account</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allowance for trade accounts receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,138&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,620&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,499)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span>Beginning balance is adjusted to reflect the cumulative pre-tax effect of adopting Accounting Standards Update No. 2016-13, &#8220;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments&#8221; (Topic 326), effective July 1, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268321600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,020,951<span></span>
</td>
<td class="nump">$ 897,556<span></span>
</td>
<td class="nump">$ 779,437<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264274286624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table describes any contracts, instructions or written plans for the sale or purchase of the Company&#8217;s securities and intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act that were adopted by our directors and executive officers during the quarterly periods ended June&#160;30, 2024 and March 31, 2024, for which the plan adoptions were inadvertently omitted and further adjustments were required to the disclosure included in the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 filed with the SEC on April 26, 2024:</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name and Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan Action</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan Adoption Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Scheduled Expiration Date of Rule 10b5-1 Trading Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Number of Securities to Be Sold (Up to)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Michael J. Farrell</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adoption</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 15, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102,781</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jan De Witte</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Director</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adoption</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 2, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 12, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,156</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brett A. Sandercock</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adoption</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 6, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kaushik Ghoshal</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Chief Commercial Officer, SaaS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adoption</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 29, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 14, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,260</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Michael J. Rider</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Global General Counsel and Secretary</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adoption</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 11, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,292</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Peter C. Farrell</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Chair Emeritus</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adoption</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 28, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 2, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,000</span></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span>A trading plan may also expire on such earlier date that all transactions under the trading plan are completed.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=rmd_MichaelJ.FarrellMember', window );">Michael J. Farrell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Michael J. Farrell<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Executive Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">January 31, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">November 15, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">289 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">102,781<span></span>
</td>
<td class="nump">102,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=rmd_JanDeWitteMember', window );">Jan De Witte [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Jan De Witte<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Director<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">February 2, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">November 12, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">284 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">1,156<span></span>
</td>
<td class="nump">1,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=rmd_BrettA.SandercockMember', window );">Brett A. Sandercock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Brett A. Sandercock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Financial Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">February 6, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">April 30, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">449 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=rmd_KaushikGhoshalMember', window );">Kaushik Ghoshal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Kaushik Ghoshal<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Commercial Officer, SaaS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">April 29, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">November 14, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">564 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">19,260<span></span>
</td>
<td class="nump">19,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=rmd_MichaelJ.RiderMember', window );">Michael J. Rider [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Michael J. Rider<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Global General Counsel and Secretary<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">May 11, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">April 1, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">325 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=rmd_PeterC.FarrellMember', window );">Peter C. Farrell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Peter C. Farrell<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chair Emeritus<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">May 28, 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">September 2, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">462 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=rmd_MichaelJ.FarrellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=rmd_MichaelJ.FarrellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=rmd_JanDeWitteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=rmd_JanDeWitteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=rmd_BrettA.SandercockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=rmd_BrettA.SandercockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=rmd_KaushikGhoshalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=rmd_KaushikGhoshalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=rmd_MichaelJ.RiderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=rmd_MichaelJ.RiderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=rmd_PeterC.FarrellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=rmd_PeterC.FarrellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268272528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264266833568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_OrganizationAndBasisOfPresentationPolicyPolicyTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation ResMed Inc. (referred to herein as &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; or the &#8220;Company&#8221;) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Finland, Norway and Sweden. We also operate a Software as a Service (&#8220;SaaS&#8221;) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Basis of Consolidation </span>The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from management&#8217;s estimates. Certain prior period amounts have been reclassified to conform to the current period presentation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Revenue Recognition </span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standard Codification (&#8220;ASC&#8221;) Topic 606, &#8220;Revenue from Contracts with Customers&#8221;, we account for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (&#8220;Sleep and Respiratory Care&#8221;) and the supply of business management software as a service to out-of-hospital care providers (&#8220;SaaS&#8221;). Our Sleep and Respiratory Care revenue relates primarily to the sale of our products that are therapy-based equipment. Some contracts include additional performance obligations such as the provision of extended warranties and provision of data for patient monitoring. Our SaaS revenue relates to the provision of software access with ongoing support and maintenance services as well as professional services such as training and consulting.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregation of revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 13 &#8211; Segment Information for our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2024, 2023 and 2022.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Performance obligations and contract balances</span></div>Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; generally, this occurs with the transfer of risk and/or control of our products at a point in time. For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with cloud-hosted services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of one year to five years. Our contracts do not contain significant financing components.<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction price determination</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g. rebates, discounts, free goods) and returns by our customers and their customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of our historical experience. Returns of products, excluding warranty-related returns, have historically been infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer&#8217;s expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates each quarter based on actual sales results and updated forecasts for the remaining rebate periods. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in programs where we issue credits to our Sleep and Respiratory Care distributors when they are required to sell our products below negotiated list prices if we have preexisting contracts with the distributors' customers. We reduce revenue for future credits at the time of sale to the distributor, which we estimate based on historical experience using the expected value method. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When Sleep and Respiratory Care or SaaS contracts have multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each performance obligation. An allocation is not required for many of our Sleep and Respiratory Care contracts that have a single performance obligation, which is the shipment of our therapy-based equipment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting and practical expedient elections</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to account for shipping and handling activities associated with our Sleep and Respiratory Care segment as a fulfillment cost within cost of sales, and record shipping and handling costs collected from customers in net revenue. We have also elected for all taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, to be excluded from revenue and presented on a net basis. We have adopted two practical expedients including the &#8220;right to invoice&#8221; practical expedient, which is relevant for some of our SaaS contracts as it allows us to recognize revenue in the amount of the invoice when it corresponds directly with the value of performance completed to date. The second practical expedient adopted permits relief from considering a significant financing component when the payment for the good or service is expected to be one year or less.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock', window );">Concentration of Credit Risk and Significant Customers</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt">Concentration of Credit Risk and Significant Customers</span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, derivatives and trade receivables. Our cash and cash equivalents are generally held with large, diverse financial institutions to reduce the amount of exposure to any single financial institution. Our derivative contracts are transacted with various financial institutions with high credit standings and any exposure to counterparty credit-related losses in these contracts is largely mitigated with collateralization and master-netting agreements. The risk with respect to trade receivables is mitigated by credit evaluations we perform on our customers, the short duration of our payment terms for the majority of our customer contracts and by the diversification of our customer base. No single customer accounted for 10% or more of our total revenues for any of the periods presented.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of financial instruments is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. We measure our financial instruments at fair value at each reporting period using a fair value hierarchy that requires that we maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#8217;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Other inputs that are directly or indirectly observable in the marketplace.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs that are supported by little or no market activity.</span></div>The carrying value of cash equivalents, accounts receivable and accounts payable, approximate their fair value because of their short-term nature. The carrying value of long-term debt related to our Revolving Credit and Term Credit Agreements approximates its fair value as the principal amounts outstanding are subject to variable interest rates that are based on market rates which are regularly reset. The carrying value of long-term debt related to our Senior Notes can differ to its fair value as the principal amounts outstanding are subject to fixed interest rates as outlined in Note 8 &#8211; Debt. Foreign currency hedging instruments are marked to market and therefore reflect their fair value. In addition, we measure investments in publicly held equity securities and privately held equity securities for which there has been an observable price change in an identical or similar security, at fair value. We do not hold or issue financial instruments for trading purposes.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt">Cash and Cash Equivalents </span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents include certificates of deposit and other highly liquid investments and we state them at cost, which approximates market. We consider investments with original maturities of 90 days or less to be cash equivalents for purposes of the consolidated statements of cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.01pt">Inventories </span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state inventories at the lower of cost (determined principally by the first-in, first-out method) or net realizable value. We include material, labor and manufacturing overhead costs in finished goods and work-in-process inventories. We review and provide for any product obsolescence in our manufacturing and distribution operations by assessing throughout the year individual products and components (based on estimated future usage and sales).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Property, Plant and Equipment </span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record property, plant and equipment, including rental and demonstration equipment at cost. We compute depreciation expense using the straight-line method over the estimated useful lives of the assets. Useful lives are generally two years to ten years except for buildings which are depreciated over an estimated useful life of forty years and leasehold improvements, which we amortize over the shorter of the useful life or the lease term. We charge maintenance and repairs to expense as we incur them.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Intangible Assets </span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the registration costs for new patents and amortize the costs over the estimated useful life of the patent, which is generally ten years. If a patent is superseded or a product is retired, any unamortized costs are written off immediately.</span></div>We amortize our other intangible assets on a straight-line basis over their estimated useful lives, which range from two years to fifteen years. We evaluate events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists and, at least annually, evaluate the recoverability of intangible assets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt">Goodwill </span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct our annual review for goodwill impairment during the final quarter of the fiscal year. Our goodwill impairment review is performed at our reporting unit level, which is one level below our operating segments and involves the following steps: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Step 0 or Qualitative assessment &#8211; Evaluate qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. The factors we consider include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, overall financial performance or events-specific to that reporting unit. If or when we determine it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill, we would move to Step 1 of the quantitative method.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Step 1 &#8211; Compare the fair value for each reporting unit to its carrying value, including goodwill. Fair value is determined based on estimated discounted cash flows. A goodwill impairment charge is recognized for the amount that the carrying amount of a reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit. If a reporting unit&#8217;s fair value exceeds the carrying value, no further work is performed and no impairment charge is necessary.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the annual reviews for the years ended June&#160;30, 2024, 2023 and 2022, we completed a Step 0 or Qualitative assessment and determined it was more likely than not that the fair value of our reporting units exceeded their carrying amounts, including goodwill, and therefore goodwill was not impaired.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.01pt">Business Combinations</span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate the purchase price to the estimated fair values of the assets acquired and liabilities assumed. This allocation process involves the use of estimates and assumptions made in connection with determining the fair value of assets acquired and liabilities assumed including cash flows expected to be derived from the use of the asset, the timing of such cash flows, the remaining useful life of assets and applicable discount rates. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If actual results vary from the estimates or assumptions used in the valuation or allocation process, we may be required to record an impairment charge or an increase in depreciation or amortization in future periods, or both.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Equity Investments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Equity Investments</span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have equity investments in privately and publicly held companies that are unconsolidated entities. The following discusses our accounting for investments in marketable equity securities, non-marketable equity securities, and investments accounted for under the equity method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities are publicly traded stocks measured at fair value and classified within Level 1 in the fair value hierarchy because we use quoted prices for identical assets in active markets. Marketable equity securities are recorded in prepaid expenses and other current assets on the consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-marketable equity securities consist of investments in privately held companies without readily determinable fair values and are recorded in prepaid taxes and other non-current assets on the consolidated balance sheets. Non-marketable equity securities are reported at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. We assess non-marketable equity securities at least quarterly for impairment and consider qualitative and quantitative factors including the investee's financial metrics, product and commercial outlook and cash usage. All gains and losses on marketable and non-marketable equity securities, realized and unrealized, are recognized in gain (loss) on equity investments as a component of other income (loss), net on the consolidated statements of income.</span></div>Equity investments whereby we have significant influence but not control over the investee and are not the primary beneficiary of the investee&#8217;s activities, are accounted for under the equity method. Under this method, we record our share of gains or losses attributable to equity method investments as a component of other income (loss), net on the consolidated statements of income.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt">Research and Development </span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record all research and development expenses in the period we incur them.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:3.01pt">Foreign Currency </span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of our non-U.S. subsidiaries, whose functional currencies are other than the U.S. dollar, are translated into U.S. dollars for financial reporting purposes. We translate assets and liabilities of non-U.S. subsidiaries whose functional currencies are other than the U.S. dollar at period end exchange rates but translate revenue and expense transactions at average exchange rates for the period. We recognize cumulative translation adjustments as part of comprehensive income, as detailed in the consolidated statements of comprehensive income, and include those adjustments in accumulated other comprehensive income in the consolidated balance sheets until such time the relevant subsidiary is sold or substantially or completely liquidated. We reflect gains and losses on transactions denominated in other than the functional currency of an entity in our results of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Foreign Exchange Risk Management</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Foreign Exchange Risk Management </span><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may use derivative financial instruments, specifically foreign cross-currency swaps, purchased foreign currency call options, collars and forward contracts to mitigate exposure from certain foreign currency risk. No derivatives are used for trading or speculative purposes. We do not require or are not required to pledge collateral for the derivative instruments.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fair Value and Net Investment Hedging</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2022, we executed foreign cross-currency swaps as net investment hedges and fair value hedges in designated hedging relationships with either the foreign denominated net asset balances or the foreign denominated intercompany loan as the hedged items. All derivatives are recorded at fair value as either an asset or liability. Cash flows associated with derivative instruments are presented in the same category on the consolidated statements of cash flows as the hedged item.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the cross-currency swaps for the fair value hedge is to mitigate foreign currency risk associated with changes in spot rates on foreign denominated intercompany debt between USD and EUR. For these hedges, we excluded certain components from the assessment of hedge effectiveness that are not related to spot rates. For fair value hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in the same line item as the hedged item, other, net, in the consolidated statement of income. The initial fair value of hedge components excluded from the assessment of effectiveness is recognized in the statement of income under a systematic and rational method over the life of the hedging instrument and is presented in interest (expense) income, net. Any difference between the change in the fair value of the hedge components excluded from the assessment of effectiveness and the amounts recognized in earnings is recorded as a component of other comprehensive income. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the cross-currency swaps for the net investment hedge is to mitigate foreign currency risk associated with changes in spot rates on the net asset balances of our foreign functional subsidiaries. For net investment hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in cumulative translation adjustment within other comprehensive loss and reclassified into earnings when the hedged net investment is either sold or </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantially liquidated. The initial fair value of components excluded from the assessment of hedge effectiveness will be recognized in interest (expense) income, net. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of outstanding foreign cross-currency swaps was $1,026.2 million at June&#160;30, 2024. These contracts mature at various dates prior to December 31, 2029.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Designated Hedges</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have foreign currency exposure through both our Australian and Singapore manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased foreign currency call options, collars and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed two years. The purpose of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, and Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not designate these foreign currency contracts as hedges. All movements in the fair value of the foreign currency instruments are recorded within other, net in our consolidated statements of income. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional value of the outstanding non-designated hedges was $1,340.0 million and $954.7 million at June&#160;30, 2024 and June&#160;30, 2023, respectively. These contracts mature at various dates prior to September&#160;15, 2025.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classified the fair values of all hedging instruments as Level 2 measurements within the fair value hierarchy.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments. We minimize counterparty credit risk by entering into derivative transactions with major financial institutions and we do not expect material losses as a result of default by our counterparties.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Income Taxes</span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. We measure deferred tax assets and liabilities using the enacted tax rates we expect to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in the consolidated financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions are reflected in income tax expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLoansAndLeasesReceivablePolicy', window );">Allowance for Credit Losses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Allowance for Credit Losses</span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an allowance for credit losses on customer receivables based expected losses, considering our historical write-off experience, an assessment of our customers&#8217; financial conditions, and available information that is relevant to assessing the collectability of cash flows, which includes current conditions and forecasts about future economic conditions. Customer receivables are charged against the allowance when they are deemed uncollectible. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also contingently liable, within certain limits, in the event of a customer default, to independent financing companies in connection with customer financing programs. We monitor the collection status of these installment receivables and provide for estimated losses separately under accrued expenses within our consolidated balance sheets based upon our historical collection experience with such receivables and a current assessment of our credit exposure.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Impairment of Long-Lived Assets </span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically evaluate the carrying value of long-lived assets to be held and used, including certain identifiable intangible assets, when events and circumstances indicate that the carrying amount of an asset may not be recovered. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If assets are considered to be impaired, we recognize as the impairment the amount by which the carrying amount of the assets exceeds the fair value of the assets. We report assets to be disposed of at the lower of the carrying amount or fair value less costs to sell. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended June&#160;30, 2024, we recorded $33.2 million of restructuring related intangible asset impairments associated with the wind down of certain business activities. Refer to Note 18 &#8211; Restructuring Expenses for additional information regarding restructuring costs. We did not recognize impairment charges in relation to long-lived assets during the fiscal years ended June 30, 2023 and 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt">Contingencies</span>We record a liability in the consolidated financial statements for loss contingencies when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting standards not yet adopted</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Recently issued accounting standards not yet adopted </span><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ASU No. 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (FASB) issued ASU No. 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," which expands segment disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. This ASU is applicable to our Annual Report on Form 10-K for the fiscal year ended June 30, 2025, and subsequent interim periods. Early adoption is permitted and the amendments must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adopting this ASU on our consolidated financial statements and disclosures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span></div>In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures," which updates income tax disclosure requirements primarily by requiring specific categories and greater disaggregation within the rate reconciliation and disaggregation of income taxes paid. This ASU is applicable to our Annual Report on Form 10-K for the fiscal year ended June 30, 2026, with early application permitted. We are currently evaluating the impact of adopting this ASU on our consolidated financial statements and disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration Of Credit Risk And Significant Customers [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_OrganizationAndBasisOfPresentationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization And Basis Of Presentation, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_OrganizationAndBasisOfPresentationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLoansAndLeasesReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-9<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLoansAndLeasesReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264372742448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Contract Balances</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract balances as of June&#160;30, 2024 and 2023 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance sheet caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">837,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">704,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, non-current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes and other non-current assets</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(152,554)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(138,072)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (current liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137,343)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119,186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (non-current liabilities)</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264267898400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of selected captions in the consolidated balance sheets consisted of the following as of June&#160;30, 2024 and June&#160;30, 2023 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inventories</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">355,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">459,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">463,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">822,250&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">998,012&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107,623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid expenses and current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">459,833&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">437,018&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Components of Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">479,941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vehicles and aircraft</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical, demonstration and rental equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, at cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,274,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,205,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(726,967)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(668,012)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">548,025&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537,856&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268269136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Changes in Carrying Amount of Goodwill</a></td>
<td class="text">Changes in the carrying amount of goodwill is comprised of the following for the year ended June&#160;30, 2024 (in thousands): <div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sleep and <br/>Respiratory Care</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SaaS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">670,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,100,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,770,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">757,529&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,084,526&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,842,055&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Other Intangible Assets, Net</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangibles, net are comprised of the following as of June&#160;30, 2024 and June&#160;30, 2023 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed/core product technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">384,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">398,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(280,970)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(265,802)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed/core product technology, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432,470&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443,652&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150,486)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(124,220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281,984&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319,432&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangibles</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252,210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(151,999)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144,402)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other intangibles, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485,904&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">552,341&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Amortization Expense Related to Identifiable Intangible Assets, Including Patents</a></td>
<td class="text">Total estimated annual amortization expense for the years ending June 30, 2025 through June 30, 2029, is shown below (in thousands): <div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Years Ending June 30</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268705744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_ScheduleOfInvestmentsTableTextBlock', window );">Schedule of Investments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments by measurement category as of June&#160;30, 2024 and June&#160;30, 2023 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Measurement category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Measurement alternative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151,227&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,537&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock', window );">Schedule of Changes in Equity Investments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2024 (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Observable price adjustments on non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,963)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,963)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exits of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized losses on marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,397)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,397)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,848)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,848)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying value at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,739&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,026&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,462&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151,227&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2023 (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Observable price adjustments on non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,892)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,892)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains on marketable and non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exits of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized losses on marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,735)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,735)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,873)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,873)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying value at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,748&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,423&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,366&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,537&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes additions from purchases and an equity method investment acquired and measured at fair value via our acquisition of MEDIFOX DAN. Refer to Note 17 herein.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Changes In Equity Investments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ScheduleOfInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Investments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ScheduleOfInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264372762880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses at June&#160;30, 2024 and June&#160;30, 2023 consist of the following (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product warranties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting and professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Value added taxes and other taxes due</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">223,862&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Promotional and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Logistics and occupancy costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory in transit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">377,678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365,660&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264267912832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt at June&#160;30, 2024 and June&#160;30, 2023 consists of the following (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred borrowing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,435,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred borrowing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,687)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,766)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">697,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,431,234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707,213&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,441,136&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264387130176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under non-cancellable operating leases as of June&#160;30, 2024 are as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197,933&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,570&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,806&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166,722&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock', window );">Schedule of Operating Lease Disclosure</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental information related to operating leases for the years ended June&#160;30, 2024 and June&#160;30, 2023 was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average inputs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash flows paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for new lease liabilities:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Operating Lease Disclosure [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268723584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Activity of Restricted Stock Units</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of RSUs, including PRSUs, during year ended June&#160;30, 2024 (in thousands, except years and per share amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock<br/>Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant-Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227.82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,139&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183.93&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6</span></td></tr></table></div><div style="margin-top:1pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5pt">Includes 60 thousand shares netted for tax.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Option Activity</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity during the year ended June&#160;30, 2024 (in thousands, except years and per share amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136.06&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options vested and expected to vest at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.52&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8</span></td></tr></table></div><div style="margin-top:1pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5pt">Includes 1 thousand shares netted for tax.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions for Fair Value of Stock Option Plans and Purchase Rights Granted</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions for the years ended June&#160;30, 2024, 2023 and 2022: </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock options:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average grant date fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$50.48</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$74.95</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$72.16</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.44%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.85%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.29%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.29%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.78%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.66%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ESPP purchase rights:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average grant date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$47.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$52.38</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$50.46</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.75% - 1.30%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.75% - 0.84%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.63% - 0.98%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27% - 40%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27% - 34%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20% - 34%</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Total Stock-Based Compensation Costs Incurred and Associated Tax Benefit Recognized</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total stock-based compensation costs incurred and the associated tax benefit recognized during the years ended June&#160;30, 2024, 2023 and 2022 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,184&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,142&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,257&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,053)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,860)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,262)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation costs, net of tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,131&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,282&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,995&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264267907296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings per share for the years ended June&#160;30, 2024, 2023 and 2022 are calculated as follows (in thousands except per share data): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">897,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">779,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,021&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options and restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted average shares </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.94&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.34&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.92&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.09&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.30&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264385099072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income Before Income Taxes Under the Jurisdictions</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes for the years ended June&#160;30, 2024, 2023 and 2022, was taxed under the following jurisdictions (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,589&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85,919)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,083,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">973,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,046,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,264,798&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101,664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">960,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Taxes</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is presented below (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:28.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293,725&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249,540&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192,864&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred: </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,915)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,721)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,612)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,632)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,389)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49,878)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45,432)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,818)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243,847&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181,046&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Provision for Income Tax Differ From the Amount of Income Tax</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. federal income tax rate of 21% for the years ended June&#160;30, 2024, 2023 and 2022, to pretax income as a result of the following (in thousands): </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes computed at statutory U.S. rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase (decrease) in income taxes resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes, net of U.S. tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27,786)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,481)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,007)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of non-U.S. tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,838)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,982)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,384)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,988)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,282)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243,847&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204,108&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181,046&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities Classified as Current and Non-Current</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reported net deferred tax assets and liabilities in our consolidated balance sheets at June&#160;30, 2024 and June&#160;30, 2023, as follows (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current deferred tax asset</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79,339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(90,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124,230&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,324&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our deferred tax assets and liabilities at June&#160;30, 2024 and June&#160;30, 2023, are as follows (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Employee liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">35,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">34,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Tax credit carry overs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">9,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">6,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">15,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">13,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Provision for warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">6,112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">5,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Provision for doubtful debts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">5,340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">6,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">23,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">22,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Capital loss carryover</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">5,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">11,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">8,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">28,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">23,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Research and development capitalization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">125,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">111,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">25,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">21,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Hedging contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">56,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">27,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">State income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">3,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">2,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">5,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(2,014)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">356,712&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">282,081&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(9,384)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(8,536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">347,328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">273,545&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Goodwill and other intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(192,398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(198,418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(22,843)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(20,501)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(7,857)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(12,302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(223,098)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(231,221)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Net deferred tax asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">124,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">42,324&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Components Of Net Deferred Income Tax Assets and Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264267925936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Revenue by Segment and Reconciling Items</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents a reconciliation of net revenues, depreciation and amortization and net operating profit by reportable segments for the years ended June&#160;30, 2024, 2023 and 2022 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net revenue by segment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,101,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,725,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,177,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">584,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">497,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,685,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,222,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,578,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Depreciation and amortization by segment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets and corporate assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net operating profit by segment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,681,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,447,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,279,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,835,804&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,562,775&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,373,347&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reconciling items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">338,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks with magnets field safety notification expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Astral field safety notification expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on insurance recoveries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,264,798&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101,664&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">960,483&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;During the fiscal year ended June&#160;30, 2024, we recorded $4.1&#160;million of operating lease right-of-use asset impairments within our SaaS segment. The impairments related to leases for office space and were recorded within net operating profit. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The masks with magnets field safety notification expenses relate to estimated </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">costs to provide alternative masks to patients in response to updated contraindications for use of masks that incorporate magnets.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;The Astral field safety notification expenses relate to estimated costs associated with the replacement of a certain component in some of our Astral ventilation devices that were manufactured between 2013 to 2019.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock', window );">Schedule of Revenue by Segment, Product, and Region</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2024, 2023 and 2022 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S., Canada and Latin America</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,522,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,444,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,070,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,199,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,039,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total U.S., Canada and Latin America</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,722,556&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,483,387&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,981,807&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Combined Europe, Asia and other markets </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">921,253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">796,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Combined Europe, Asia and other markets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,378,616&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,241,630&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,195,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,444,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,270,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,866,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,657,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,454,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,310,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,101,172&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,725,017&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,177,298&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">584,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">497,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,685,297&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,222,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,578,127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue by Geographic Area</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue information by geographic area for the years ended June&#160;30, 2024, 2023 and 2022 is summarized below (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,980,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,719,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,249,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of the World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,705,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,503,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,328,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,685,297&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,222,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,578,127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of Long-Lived Assets by Geographic Areas</a></td>
<td class="text">Long-lived assets by geographic area as of June&#160;30, 2024 and 2023 is summarized below (in thousands):<div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Australia</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197,017&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of the World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">548,025&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537,856&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Revenue By Segment, Product, And Region [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268896240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Actions, Contingencies and Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Obligations Under Purchase Agreements</a></td>
<td class="text">Obligations under our purchase agreements at June&#160;30, 2024 were as follows (in thousands):<div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.997%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Years Ending June 30</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2029</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minimum purchase obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,023,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">845,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,080&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Subparagraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264418274144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Fair Values of Derivative Instruments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our assets and liabilities related to derivative instruments on a gross basis within the consolidated balance sheets (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1269"><span style="-sec-ix-hidden:f-1270">Prepaid expenses and other current assets</span></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1273"><span style="-sec-ix-hidden:f-1274">Prepaid taxes and other non-current assets</span></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,405&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign cross-currency swaps &#8211; Fair Value Hedge</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1279"><span style="-sec-ix-hidden:f-1280">Other long-term liabilities</span></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign cross-currency swaps &#8211; Net Investment Hedge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1285"><span style="-sec-ix-hidden:f-1286">Accrued expenses</span></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,538&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,699&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Schedule of Derivative Gains (Losses)</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the following gains (losses) on the foreign cross currency swaps designated as fair value hedges (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized in other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,414)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on cross-currency swap in interest (expense) income, net (amount excluded from effectiveness testing)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on cross-currency swap in other, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on intercompany debt in other, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,942)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the following gains (losses) on the foreign cross currency swaps designated as net investment hedges (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized in cumulative translation adjustment within other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40,803)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized from the excluded components in interest (expense) income, net </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the following gains (losses) in the consolidated statement of income on derivatives not designated as hedging instruments (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on foreign currency hedging instruments in other, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,168)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,576&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,511)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) recognized on other foreign-currency-denominated transactions in other, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,149)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,204)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,809&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268752720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase price was allocated to MEDIFOX DAN's tangible and identifiable intangible assets and liabilities based upon estimated fair values as of the November 21, 2022 closing date, as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Final</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible assets - useful life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,623)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 - 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 - 13 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78,458)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase price</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264269372048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 88,900<span></span>
</td>
<td class="nump">$ 84,700<span></span>
</td>
<td class="nump">$ 81,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expenses (note 18)</a></td>
<td class="nump">64,228<span></span>
</td>
<td class="nump">9,177<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=rmd_IntangibleAssetImpairmentMember', window );">Intangible Asset Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expenses (note 18)</a></td>
<td class="nump">33,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Currency Swap | Fair Value And Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Outstanding foreign cross-currency swaps</a></td>
<td class="nump">1,026,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency hedging instruments | Non-Designated Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Outstanding foreign cross-currency swaps</a></td>
<td class="nump">$ 1,340,000<span></span>
</td>
<td class="nump">$ 954,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Derivative, term of contract</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment, years</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_TermOfContractUnderRevenueRecognition', window );">Deferred revenue recognized, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment, years</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_TermOfContractUnderRevenueRecognition', window );">Deferred revenue recognized, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment, years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_TermOfContractUnderRevenueRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Of Contract Under Revenue Recognition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_TermOfContractUnderRevenueRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=rmd_IntangibleAssetImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=rmd_IntangibleAssetImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=rmd_FairValueAndNetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=rmd_FairValueAndNetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264272931232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Summary of Contract Balances) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetAbstract', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 837,275<span></span>
</td>
<td class="nump">$ 704,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="num">(152,554)<span></span>
</td>
<td class="num">(138,072)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="num">(137,343)<span></span>
</td>
<td class="num">(119,186)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=rmd_AccountsReceivableNetMember', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetAbstract', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">837,275<span></span>
</td>
<td class="nump">704,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetAbstract', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Unbilled revenue, current</a></td>
<td class="nump">38,183<span></span>
</td>
<td class="nump">31,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember', window );">Prepaid taxes and other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetAbstract', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Unbilled revenue, non-current</a></td>
<td class="nump">18,450<span></span>
</td>
<td class="nump">10,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=rmd_DeferredRevenueCurrentLiabilitiesMember', window );">Deferred revenue (current liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="num">(152,554)<span></span>
</td>
<td class="num">(138,072)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=rmd_DeferredRevenueNonCurrentLiabilitiesMember', window );">Deferred revenue (non-current liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="num">$ (137,343)<span></span>
</td>
<td class="num">$ (119,186)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=rmd_AccountsReceivableNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=rmd_AccountsReceivableNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=rmd_DeferredRevenueCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=rmd_DeferredRevenueCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=rmd_DeferredRevenueNonCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=rmd_DeferredRevenueNonCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264269278672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Schedule of Inventories) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGrossAbstract', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 355,570<span></span>
</td>
<td class="nump">$ 459,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">2,713<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">463,967<span></span>
</td>
<td class="nump">534,930<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 822,250<span></span>
</td>
<td class="nump">$ 998,012<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264274249120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Schedule of Prepaid Expenses and Other Current Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid expenses and other current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">$ 107,623<span></span>
</td>
<td class="nump">$ 114,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_PrepaidInventory', window );">Prepaid inventories</a></td>
<td class="nump">172,198<span></span>
</td>
<td class="nump">143,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other prepaid expenses and current assets</a></td>
<td class="nump">180,012<span></span>
</td>
<td class="nump">179,925<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 459,833<span></span>
</td>
<td class="nump">$ 437,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_PrepaidInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_PrepaidInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264267327664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Components of Property, Plant and Equipment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, at cost</a></td>
<td class="nump">$ 1,274,992<span></span>
</td>
<td class="nump">$ 1,205,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(726,967)<span></span>
</td>
<td class="num">(668,012)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">548,025<span></span>
</td>
<td class="nump">537,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, at cost</a></td>
<td class="nump">479,941<span></span>
</td>
<td class="nump">443,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmd_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, at cost</a></td>
<td class="nump">200,128<span></span>
</td>
<td class="nump">189,568<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, at cost</a></td>
<td class="nump">61,969<span></span>
</td>
<td class="nump">61,663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmd_VehiclesAndAircraftMember', window );">Vehicles and aircraft</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, at cost</a></td>
<td class="nump">20,450<span></span>
</td>
<td class="nump">20,587<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmd_ClinicalDemonstrationAndRentalEquipmentMember', window );">Clinical, demonstration and rental equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, at cost</a></td>
<td class="nump">127,358<span></span>
</td>
<td class="nump">115,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, at cost</a></td>
<td class="nump">102,104<span></span>
</td>
<td class="nump">91,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, at cost</a></td>
<td class="nump">51,977<span></span>
</td>
<td class="nump">52,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, at cost</a></td>
<td class="nump">$ 231,065<span></span>
</td>
<td class="nump">$ 231,019<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmd_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmd_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmd_VehiclesAndAircraftMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmd_VehiclesAndAircraftMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmd_ClinicalDemonstrationAndRentalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmd_ClinicalDemonstrationAndRentalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264269402096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets, net (Schedule of Changes in Carrying Amount of Goodwill) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 2,770,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Business acquisitions</a></td>
<td class="nump">92,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="num">(20,435)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">2,842,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SleepAndRespiratoryMember', window );">Sleep and &#8206;Respiratory Care</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">670,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Business acquisitions</a></td>
<td class="nump">92,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="num">(4,782)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">757,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SaasMember', window );">SaaS</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">2,100,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Business acquisitions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="num">(15,653)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">$ 2,084,526<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SleepAndRespiratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=rmd_SleepAndRespiratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SaasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=rmd_SaasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264267303296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets, net (Schedule of Other Intangible Assets, Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total other intangibles, net</a></td>
<td class="nump">$ 485,904<span></span>
</td>
<td class="nump">$ 552,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rmd_DevelopedOrCoreProductTechnologyMember', window );">Developed/core product technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Other intangibles, gross</a></td>
<td class="nump">384,679<span></span>
</td>
<td class="nump">398,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(280,970)<span></span>
</td>
<td class="num">(265,802)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total other intangibles, net</a></td>
<td class="nump">103,709<span></span>
</td>
<td class="nump">132,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Other intangibles, gross</a></td>
<td class="nump">432,470<span></span>
</td>
<td class="nump">443,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(150,486)<span></span>
</td>
<td class="num">(124,220)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total other intangibles, net</a></td>
<td class="nump">281,984<span></span>
</td>
<td class="nump">319,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Other intangibles, gross</a></td>
<td class="nump">252,210<span></span>
</td>
<td class="nump">244,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(151,999)<span></span>
</td>
<td class="num">(144,402)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total other intangibles, net</a></td>
<td class="nump">$ 100,211<span></span>
</td>
<td class="nump">$ 99,971<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rmd_DevelopedOrCoreProductTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rmd_DevelopedOrCoreProductTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264274297296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets, net (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 32,963<span></span>
</td>
<td class="nump">$ 30,396<span></span>
</td>
<td class="nump">$ 39,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Restructuring expenses (note 18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rmd_IdentifiedIntangibleAssetsMember', window );">Identified Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 79,500<span></span>
</td>
<td class="nump">72,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rmd_DevelopedOrCoreProductTechnologyMember', window );">Developed/core product technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">18,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rmd_IdentifiedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rmd_IdentifiedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rmd_DevelopedOrCoreProductTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rmd_DevelopedOrCoreProductTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264271830384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets, net (Schedule of Amortization Expense Related to Identifiable Intangible Assets, Including Patents) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 81,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">76,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">58,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">49,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">$ 43,492<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264271820592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments (Schedule of Investments) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_MarketableEquityInvestmentsFairValue', window );">Fair value</a></td>
<td class="nump">$ 12,026<span></span>
</td>
<td class="nump">$ 12,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Measurement alternative</a></td>
<td class="nump">73,739<span></span>
</td>
<td class="nump">68,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method</a></td>
<td class="nump">65,462<span></span>
</td>
<td class="nump">65,366<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_EquityInvestmentsTotalByMeasurementCategory', window );">Total</a></td>
<td class="nump">$ 151,227<span></span>
</td>
<td class="nump">$ 146,537<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_EquityInvestmentsTotalByMeasurementCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Investments, Total by Measurement Category</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_EquityInvestmentsTotalByMeasurementCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_MarketableEquityInvestmentsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable Equity Investments, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_MarketableEquityInvestmentsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264267784368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Schedule of Changes In Equity Investments) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_EquityInvestments', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 146,537<span></span>
</td>
<td class="nump">$ 58,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_AdditionalEquityInvestments', window );">Additions to investments</a></td>
<td class="nump">12,765<span></span>
</td>
<td class="nump">89,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities', window );">Observable price adjustments on non-marketable equity securities</a></td>
<td class="nump">2,315<span></span>
</td>
<td class="nump">12,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment of investments</a></td>
<td class="num">(4,963)<span></span>
</td>
<td class="num">(4,892)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Realized gains on marketable and non-marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Proceeds from exits of investments</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(3,937)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized losses on marketable equity securities</a></td>
<td class="num">(1,397)<span></span>
</td>
<td class="num">(1,735)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss attributable to equity method investments</a></td>
<td class="num">(1,848)<span></span>
</td>
<td class="num">(7,265)<span></span>
</td>
<td class="num">$ (8,486)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDividendsReceived', window );">Dividends received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,873)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments', window );">Foreign currency translation adjustments</a></td>
<td class="num">(1,182)<span></span>
</td>
<td class="nump">2,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_EquityInvestments', window );">Carrying value at the end of the period</a></td>
<td class="nump">151,227<span></span>
</td>
<td class="nump">146,537<span></span>
</td>
<td class="nump">58,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=rmd_NonMarketableSecuritiesMember', window );">Non-marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_EquityInvestments', window );">Balance at the beginning of the period</a></td>
<td class="nump">68,748<span></span>
</td>
<td class="nump">39,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_AdditionalEquityInvestments', window );">Additions to investments</a></td>
<td class="nump">8,640<span></span>
</td>
<td class="nump">21,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities', window );">Observable price adjustments on non-marketable equity securities</a></td>
<td class="nump">2,315<span></span>
</td>
<td class="nump">12,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment of investments</a></td>
<td class="num">(4,963)<span></span>
</td>
<td class="num">(4,892)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Realized gains on marketable and non-marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Proceeds from exits of investments</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(3,937)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized losses on marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss attributable to equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDividendsReceived', window );">Dividends received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments', window );">Foreign currency translation adjustments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_EquityInvestments', window );">Carrying value at the end of the period</a></td>
<td class="nump">73,739<span></span>
</td>
<td class="nump">68,748<span></span>
</td>
<td class="nump">39,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=rmd_MarketableSecuritiesMember', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_EquityInvestments', window );">Balance at the beginning of the period</a></td>
<td class="nump">12,423<span></span>
</td>
<td class="nump">9,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_AdditionalEquityInvestments', window );">Additions to investments</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">4,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities', window );">Observable price adjustments on non-marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Realized gains on marketable and non-marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Proceeds from exits of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized losses on marketable equity securities</a></td>
<td class="num">(1,397)<span></span>
</td>
<td class="num">(1,735)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss attributable to equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDividendsReceived', window );">Dividends received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments', window );">Foreign currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_EquityInvestments', window );">Carrying value at the end of the period</a></td>
<td class="nump">12,026<span></span>
</td>
<td class="nump">12,423<span></span>
</td>
<td class="nump">9,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquityMethodInvestmentsMember', window );">Equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_EquityInvestments', window );">Balance at the beginning of the period</a></td>
<td class="nump">65,366<span></span>
</td>
<td class="nump">9,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_AdditionalEquityInvestments', window );">Additions to investments</a></td>
<td class="nump">3,125<span></span>
</td>
<td class="nump">62,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities', window );">Observable price adjustments on non-marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Realized gains on marketable and non-marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Proceeds from exits of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized losses on marketable equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss attributable to equity method investments</a></td>
<td class="num">(1,848)<span></span>
</td>
<td class="num">(7,265)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDividendsReceived', window );">Dividends received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,873)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments', window );">Foreign currency translation adjustments</a></td>
<td class="num">(1,181)<span></span>
</td>
<td class="nump">2,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_EquityInvestments', window );">Carrying value at the end of the period</a></td>
<td class="nump">$ 65,462<span></span>
</td>
<td class="nump">$ 65,366<span></span>
</td>
<td class="nump">$ 9,918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_AdditionalEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Equity Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_AdditionalEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_EquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_EquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_EquityMethodInvestmentsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_EquityMethodInvestmentsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Observable price adjustments on non-marketable equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDividendsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends received on equity and other investments during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDividendsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to temporary equity resulting from foreign currency translation adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=rmd_NonMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=rmd_NonMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=rmd_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=rmd_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquityMethodInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquityMethodInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268345120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Equity securities, unrealized (loss) gain</a></td>
<td class="num">$ (4.0)<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="num">$ (16.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264274406608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Product warranties</a></td>
<td class="nump">$ 35,134<span></span>
</td>
<td class="nump">$ 27,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Consulting and professional fees</a></td>
<td class="nump">27,143<span></span>
</td>
<td class="nump">26,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Value added taxes and other taxes due</a></td>
<td class="nump">27,016<span></span>
</td>
<td class="nump">23,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee related costs</a></td>
<td class="nump">223,862<span></span>
</td>
<td class="nump">220,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Promotional and marketing</a></td>
<td class="nump">6,023<span></span>
</td>
<td class="nump">9,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Foreign currency hedging instruments</a></td>
<td class="nump">4,654<span></span>
</td>
<td class="nump">9,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">9,206<span></span>
</td>
<td class="nump">9,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_AccruedLogisticsAndOccupancyExpensesCurrent', window );">Logistics and occupancy costs</a></td>
<td class="nump">17,996<span></span>
</td>
<td class="nump">16,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_AccruedInventoryInTransit', window );">Inventory in transit</a></td>
<td class="nump">8,045<span></span>
</td>
<td class="nump">10,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">18,599<span></span>
</td>
<td class="nump">12,859<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 377,678<span></span>
</td>
<td class="nump">$ 365,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_AccruedInventoryInTransit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued inventory in transit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_AccruedInventoryInTransit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_AccruedLogisticsAndOccupancyExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Logistics And Occupancy Expenses Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_AccruedLogisticsAndOccupancyExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264271974480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Schedule of Debt) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_ShortTermDebtGross', window );">Short-term debt</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Deferred borrowing costs</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, net</a></td>
<td class="nump">9,900<span></span>
</td>
<td class="nump">9,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">1,435,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Deferred borrowing costs</a></td>
<td class="num">(2,687)<span></span>
</td>
<td class="num">(3,766)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="nump">697,313<span></span>
</td>
<td class="nump">1,431,234<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Total debt</a></td>
<td class="nump">$ 707,213<span></span>
</td>
<td class="nump">$ 1,441,136<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ShortTermDebtGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-Term Debt, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ShortTermDebtGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264273956560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 29, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 10, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_DebtToConsolidatedEbitdaRatio', window );">Debt to consolidated EBITDA ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany', window );">Line of credit facility collateral, maximum percentage of ownership interests held in subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 707,213<span></span>
</td>
<td class="nump">$ 1,441,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=rmd_SeniorNotesOneMember', window );">3.24% Senior Notes Due July 10, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.24%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=rmd_SeniorNotesTwoMember', window );">3.45% Senior Notes Due July 10, 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463,000<span></span>
</td>
<td class="nump">462,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorNotes', window );">Outstanding loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember', window );">Revolving Credit Agreement, Term Credit Agreement, And Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 710,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | MUFG Union Bank NA and Westpac Banking Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_UncommittedOptionToIncreaseCreditFacility', window );">Uncommitted option to increase credit facility</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod', window );">EBITDA multiple of trailing twelve-month measurement period</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | MUFG Union Bank NA and Westpac Banking Corporation | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fees percentage rate on unused portion of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.075%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | MUFG Union Bank NA and Westpac Banking Corporation | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fees percentage rate on unused portion of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | MUFG Union Bank | ResMed Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember', window );">Revolving Credit Facility And Term Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Available for draw</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="nump">$ 945,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember', window );">Revolving Credit Facility And Term Credit Agreement | MUFG Union Bank NA and Westpac Banking Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate on outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=rmd_TermLoanCreditAgreementMember', window );">Term Loan Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal', window );">Principal payment</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=rmd_TermLoanCreditAgreementMember', window );">Term Loan Credit Agreement | Minimum | Secured Overnight Financing Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Credit facility interest rate equal to reference rate plus</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=rmd_TermLoanCreditAgreementMember', window );">Term Loan Credit Agreement | Minimum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Credit facility interest rate equal to reference rate plus</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=rmd_TermLoanCreditAgreementMember', window );">Term Loan Credit Agreement | Maximum | Secured Overnight Financing Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Credit facility interest rate equal to reference rate plus</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=rmd_TermLoanCreditAgreementMember', window );">Term Loan Credit Agreement | Maximum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Credit facility interest rate equal to reference rate plus</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, EBITDA Multiple of Trailing Twelve-Month Measurement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_DebtToConsolidatedEbitdaRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt To Consolidated EBITDA Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_DebtToConsolidatedEbitdaRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Collateral, Percentage of the Company</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_UncommittedOptionToIncreaseCreditFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Uncommitted option to increase credit facility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_UncommittedOptionToIncreaseCreditFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payment applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=rmd_SeniorNotesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=rmd_SeniorNotesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=rmd_SeniorNotesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=rmd_SeniorNotesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=rmd_MufgUnionBankNaAndWestpacBankingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=rmd_MufgUnionBankNaAndWestpacBankingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=rmd_MufgUnionBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=rmd_MufgUnionBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rmd_ResmedLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rmd_ResmedLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=rmd_TermLoanCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=rmd_TermLoanCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268992736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 40.8<span></span>
</td>
<td class="nump">$ 33.6<span></span>
</td>
<td class="nump">$ 35.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_OperatingLeaseIncome', window );">Operating lease revenue</a></td>
<td class="nump">$ 92.9<span></span>
</td>
<td class="nump">$ 88.6<span></span>
</td>
<td class="nump">$ 90.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease terms</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease terms</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_OperatingLeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_OperatingLeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264274367568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of Future Minimum Lease Payments) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">$ 197,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">30,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">26,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">22,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">20,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">19,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">78,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(31,211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 166,722<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264272703088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Schedule of Operating Lease Disclosure) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 30,573<span></span>
</td>
<td class="nump">$ 29,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for new lease liabilities:</a></td>
<td class="nump">$ 54,588<span></span>
</td>
<td class="nump">$ 16,803<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264265034512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Narrative) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>offering </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 21, 2014 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 1997 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Shares authorized to be repurchased under repurchase program (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">828,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of common shares repurchased | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Total number of shares repurchased pursuant to the repurchase program (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,664,067<span></span>
</td>
<td class="nump">41,836,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased', window );">Additional shares that can be repurchased under the approved share repurchase program (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock at par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance', window );">Reduction in the number of shares of common stock available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards', window );">Number of shares given for each share of common stock delivered in settlement of all other awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_MaximumNumberOfSharesSubjectToAwardsGranted', window );">Maximum number of shares subject to awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_NumberOfCommonStockGranted', window );">Number of common stock shares granted in participant's initial year of hiring (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of RSUs and PRSUs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="nump">$ 66,800<span></span>
</td>
<td class="nump">$ 65,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of the options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,900<span></span>
</td>
<td class="nump">$ 25,400<span></span>
</td>
<td class="nump">$ 33,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of the stock-based compensation arrangements outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of the stock-based compensation arrangements exercisable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value of the stock-based compensation arrangements exercisable, vested and expected to vest | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323,000<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="nump">216,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,184<span></span>
</td>
<td class="nump">$ 71,142<span></span>
</td>
<td class="nump">$ 65,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs related to unvested stock-based compensation arrangements | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period of unrecognized compensation costs related to unvested stock-based compensation arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rmd_ResmedInc2009IncentiveAwardPlanMember', window );">2009 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending', window );">Common stock authorized for issuance and pending registration (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod', window );">Extended period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rmd_AmendedAndRestated2009PlanMember', window );">Amended and Restated 2009 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted', window );">Maximum amount payable pursuant to cash denominated performance awards granted | $</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rmd_AmendedAndRestated2009PlanMember', window );">Amended and Restated 2009 Plan | Non Employee Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned', window );">Maximum award amount with other cash fees earned for services | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rmd_AmendedAndRestated2009PlanMember', window );">Amended and Restated 2009 Plan | Board of Directors Chairman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned', window );">Maximum award amount with other cash fees earned for services | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rmd_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant', window );">Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase', window );">Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_NumberOfOfferings', window );">Number of offerings | offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Restricted Stock Units (PRSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_EmployeeStockPurchasePlanOfferingPeriod', window );">Employee stock purchase program offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Performance Restricted Stock Units (PRSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_EmployeeStockPurchasePlanOfferingPeriod', window );">Employee stock purchase program offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">27 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Common stock shares subscribed | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Performance Restricted Stock Units (PRSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">828,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of common shares repurchased | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Total number of shares repurchased pursuant to the repurchase program (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,664,000<span></span>
</td>
<td class="nump">41,836,000<span></span>
</td>
<td class="nump">41,836,000<span></span>
</td>
<td class="nump">41,836,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Total cost of shares repurchased pursuant to the repurchase program | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_EmployeeStockPurchasePlanOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_EmployeeStockPurchasePlanOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_MaximumNumberOfSharesSubjectToAwardsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares subject to awards granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_MaximumNumberOfSharesSubjectToAwardsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_NumberOfCommonStockGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock shares granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_NumberOfCommonStockGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_NumberOfOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Offerings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_NumberOfOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Given for Each Share of Common Stock Delivered in Settlement of All Other Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares of common stock available for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Extended Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Pending</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted and Other Cash Fees Earned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased Compensation Arrangement By Sharebased Payment Performance Award Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares remaining authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rmd_ResmedInc2009IncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rmd_ResmedInc2009IncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rmd_AmendedAndRestated2009PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rmd_AmendedAndRestated2009PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=rmd_NonEmployeeDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=rmd_NonEmployeeDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rmd_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rmd_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264273801360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Schedule of Activity of Restricted Stock Units) (Details) - Restricted Stock Units (RSUs) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Restricted &#8206;Stock &#8206;Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">1,139<span></span>
</td>
<td class="nump">762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted &#8206;Average &#8206;Grant-Date &#8206;Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 227.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">148.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">215.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">218.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">$ 183.93<span></span>
</td>
<td class="nump">$ 227.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted &#8206;Average &#8206;Remaining &#8206;Contractual &#8206;Term in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Outstanding</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Exercisable shares, netted for tax (in shares)</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264264160848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Schedule of Option Activity) (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(166)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">786<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable at end of period (in shares)</a></td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest at end of period (in shares)</a></td>
<td class="nump">778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted &#8206;Average &#8206;Exercise &#8206;Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 134.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">148.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">81.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">232.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">146.90<span></span>
</td>
<td class="nump">$ 134.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at end of period (in dollars per share)</a></td>
<td class="nump">136.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest at end of period (in dollars per share)</a></td>
<td class="nump">$ 146.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted &#8206;Average &#8206;Remaining &#8206;Contractual &#8206;Term in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable at end of period</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest at end of period</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Exercisable shares, netted for tax (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264264162672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Schedule of Assumptions for Fair Value of Stock Option Plans and Purchase Rights Granted) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 50.48<span></span>
</td>
<td class="nump">$ 74.95<span></span>
</td>
<td class="nump">$ 72.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted average risk-free interest rate</a></td>
<td class="nump">4.44%<span></span>
</td>
<td class="nump">3.85%<span></span>
</td>
<td class="nump">1.29%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">1.29%<span></span>
</td>
<td class="nump">0.78%<span></span>
</td>
<td class="nump">0.66%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmd_EmployeeStockPurchasePlanPurchaseRightsMember', window );">ESPP purchase rights:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 47.40<span></span>
</td>
<td class="nump">$ 52.38<span></span>
</td>
<td class="nump">$ 50.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted average risk-free interest rate</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmd_EmployeeStockPurchasePlanPurchaseRightsMember', window );">ESPP purchase rights: | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="nump">0.63%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmd_EmployeeStockPurchasePlanPurchaseRightsMember', window );">ESPP purchase rights: | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.84%<span></span>
</td>
<td class="nump">0.98%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmd_EmployeeStockPurchasePlanPurchaseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmd_EmployeeStockPurchasePlanPurchaseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264271785872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Schedule of Total Stock-Based Compensation Costs Incurred and Associated Tax Benefit Recognized) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs</a></td>
<td class="nump">$ 80,184<span></span>
</td>
<td class="nump">$ 71,142<span></span>
</td>
<td class="nump">$ 65,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit</a></td>
<td class="num">(15,053)<span></span>
</td>
<td class="num">(24,860)<span></span>
</td>
<td class="num">(29,262)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Stock-based compensation costs, net of tax benefit</a></td>
<td class="nump">65,131<span></span>
</td>
<td class="nump">46,282<span></span>
</td>
<td class="nump">35,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs</a></td>
<td class="nump">7,563<span></span>
</td>
<td class="nump">6,465<span></span>
</td>
<td class="nump">5,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs</a></td>
<td class="nump">58,149<span></span>
</td>
<td class="nump">53,049<span></span>
</td>
<td class="nump">50,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs</a></td>
<td class="nump">$ 14,472<span></span>
</td>
<td class="nump">$ 11,628<span></span>
</td>
<td class="nump">$ 9,248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264372663808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Narrative) (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">603,859<span></span>
</td>
<td class="nump">272,104<span></span>
</td>
<td class="nump">67,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264266437648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Schedule of Basic and Diluted Earnings Per Share) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,020,951<span></span>
</td>
<td class="nump">$ 897,556<span></span>
</td>
<td class="nump">$ 779,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">147,021<span></span>
</td>
<td class="nump">146,765<span></span>
</td>
<td class="nump">146,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Stock options and restricted stock units (in shares)</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">690<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares (in shares)</a></td>
<td class="nump">147,550<span></span>
</td>
<td class="nump">147,455<span></span>
</td>
<td class="nump">147,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share (in dollars per share)</a></td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="nump">$ 6.12<span></span>
</td>
<td class="nump">$ 5.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share (in dollars per share)</a></td>
<td class="nump">$ 6.92<span></span>
</td>
<td class="nump">$ 6.09<span></span>
</td>
<td class="nump">$ 5.30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268448592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Income Before Income Taxes Under the Jurisdictions) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="nump">$ 181,107<span></span>
</td>
<td class="nump">$ 128,589<span></span>
</td>
<td class="num">$ (85,919)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Non-U.S.</a></td>
<td class="nump">1,083,691<span></span>
</td>
<td class="nump">973,075<span></span>
</td>
<td class="nump">1,046,402<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">$ 1,264,798<span></span>
</td>
<td class="nump">$ 1,101,664<span></span>
</td>
<td class="nump">$ 960,483<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264274319584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Provision for Income Taxes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 57,103<span></span>
</td>
<td class="nump">$ 36,631<span></span>
</td>
<td class="nump">$ 4,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">17,250<span></span>
</td>
<td class="nump">14,142<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Non-U.S.</a></td>
<td class="nump">219,372<span></span>
</td>
<td class="nump">198,767<span></span>
</td>
<td class="nump">177,788<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">293,725<span></span>
</td>
<td class="nump">249,540<span></span>
</td>
<td class="nump">192,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(22,915)<span></span>
</td>
<td class="num">(21,721)<span></span>
</td>
<td class="num">(12,612)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(4,632)<span></span>
</td>
<td class="num">(2,389)<span></span>
</td>
<td class="num">(2,773)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Non-U.S.</a></td>
<td class="num">(22,331)<span></span>
</td>
<td class="num">(21,322)<span></span>
</td>
<td class="nump">3,567<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="num">(49,878)<span></span>
</td>
<td class="num">(45,432)<span></span>
</td>
<td class="num">(11,818)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 243,847<span></span>
</td>
<td class="nump">$ 204,108<span></span>
</td>
<td class="nump">$ 181,046<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268993312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Provision for Income Tax Differ From the Amount of Income Tax) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Taxes computed at statutory U.S. rate</a></td>
<td class="nump">$ 265,608<span></span>
</td>
<td class="nump">$ 231,349<span></span>
</td>
<td class="nump">$ 201,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of U.S. tax benefit</a></td>
<td class="nump">8,609<span></span>
</td>
<td class="nump">9,448<span></span>
</td>
<td class="nump">5,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credit</a></td>
<td class="num">(27,786)<span></span>
</td>
<td class="num">(21,481)<span></span>
</td>
<td class="num">(17,517)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">849<span></span>
</td>
<td class="num">(5,007)<span></span>
</td>
<td class="nump">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Effect of non-U.S. tax rates</a></td>
<td class="num">(15,838)<span></span>
</td>
<td class="num">(3,982)<span></span>
</td>
<td class="num">(4,384)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign', window );">Foreign tax credits</a></td>
<td class="num">(8,293)<span></span>
</td>
<td class="num">(3,988)<span></span>
</td>
<td class="num">(2,299)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="nump">4,875<span></span>
</td>
<td class="num">(6,282)<span></span>
</td>
<td class="num">(11,294)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="nump">15,823<span></span>
</td>
<td class="nump">4,051<span></span>
</td>
<td class="nump">8,278<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 243,847<span></span>
</td>
<td class="nump">$ 204,108<span></span>
</td>
<td class="nump">$ 181,046<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264267910304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Deferred Tax Assets and Liabilities Classified as Current and Non-Current) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent', window );">Non-current deferred tax asset</a></td>
<td class="nump">$ 203,569<span></span>
</td>
<td class="nump">$ 132,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent', window );">Non-current deferred tax liability</a></td>
<td class="num">(79,339)<span></span>
</td>
<td class="num">(90,650)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 124,230<span></span>
</td>
<td class="nump">$ 42,324<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other tax liabilities expected to be paid after one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264267609328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Components of Deferred Tax Assets and Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Employee liabilities</a></td>
<td class="nump">$ 35,336<span></span>
</td>
<td class="nump">$ 34,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carry overs</a></td>
<td class="nump">9,271<span></span>
</td>
<td class="nump">6,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventories</a></td>
<td class="nump">15,602<span></span>
</td>
<td class="nump">13,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves', window );">Provision for warranties</a></td>
<td class="nump">6,112<span></span>
</td>
<td class="nump">5,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Provision for doubtful debts</a></td>
<td class="nump">5,340<span></span>
</td>
<td class="nump">6,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">23,455<span></span>
</td>
<td class="nump">22,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital loss carryover</a></td>
<td class="nump">5,587<span></span>
</td>
<td class="nump">917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="nump">11,538<span></span>
</td>
<td class="nump">8,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">28,030<span></span>
</td>
<td class="nump">23,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development capitalization</a></td>
<td class="nump">125,411<span></span>
</td>
<td class="nump">111,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">25,602<span></span>
</td>
<td class="nump">21,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDerivativeInstruments', window );">Hedging contracts</a></td>
<td class="nump">56,324<span></span>
</td>
<td class="nump">27,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsStateTaxes', window );">State income taxes</a></td>
<td class="nump">3,566<span></span>
</td>
<td class="nump">2,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">5,538<span></span>
</td>
<td class="num">(2,014)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, Gross</a></td>
<td class="nump">356,712<span></span>
</td>
<td class="nump">282,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(9,384)<span></span>
</td>
<td class="num">(8,536)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">347,328<span></span>
</td>
<td class="nump">273,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets', window );">Goodwill and other intangibles</a></td>
<td class="num">(192,398)<span></span>
</td>
<td class="num">(198,418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right of use assets</a></td>
<td class="num">(22,843)<span></span>
</td>
<td class="num">(20,501)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="num">(7,857)<span></span>
</td>
<td class="num">(12,302)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(223,098)<span></span>
</td>
<td class="num">(231,221)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 124,230<span></span>
</td>
<td class="nump">$ 42,324<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right-of-use Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warranty reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264265890624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 28, 2021</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayAggregateDollarAmount', window );">Increase to net earnings from tax holidays and tax incentives program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.6<span></span>
</td>
<td class="nump">$ 40.5<span></span>
</td>
<td class="nump">$ 38.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare', window );">Increase to net earnings per diluted share from tax holidays and tax incentives program (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.34<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries', window );">Undistributed earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember', window );">Australian Taxation Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition', window );">Percentage of recognized tax benefit for uncertain tax position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority | Australian Taxation Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_IncomeTaxExaminationNetImpactOfSettlement', window );">Net impact of settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238.7<span></span>
</td>
<td class="nump">$ 238.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_IncomeTaxExaminationGrossSettlement', window );">Gross settlement</a></td>
<td class="nump">$ 381.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381.7<span></span>
</td>
<td class="nump">381.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Penalties and interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.1<span></span>
</td>
<td class="nump">48.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority', window );">Liability (refund) adjustment from settlement with taxing authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143.0<span></span>
</td>
<td class="nump">143.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_IncomeTaxExaminationRemittedFinalPayment', window );">Remitted final payment</a></td>
<td class="nump">284.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_IncomeTaxExaminationPriorRemittancePayments', window );">Prior remittance payments</a></td>
<td class="nump">$ 96.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority | Australian Taxation Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Other comprehensive income, foreign currency translation adjustment, tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.1<span></span>
</td>
<td class="nump">14.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Tax credits and deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries', window );">Amount of deferred taxes that would have been recognized if the earnings has not been permanently reinvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember', window );">Valuation Allowance | Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_OperatingLossCarryforwardsCapitalLoss', window );">Capital loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_IncomeTaxExaminationGrossSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Examination, Gross Settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_IncomeTaxExaminationGrossSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_IncomeTaxExaminationNetImpactOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Examination, Net Impact of Settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_IncomeTaxExaminationNetImpactOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_IncomeTaxExaminationPriorRemittancePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Examination, Prior Remittance Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_IncomeTaxExaminationPriorRemittancePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_IncomeTaxExaminationRemittedFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Examination, Remitted Final Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_IncomeTaxExaminationRemittedFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_OperatingLossCarryforwardsCapitalLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards capital loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_OperatingLossCarryforwardsCapitalLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage threshold, above which a tax benefit would be recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability not recognized because of the exceptions to comprehensive recognition of deferred taxes related to undistributed earnings of foreign subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxCreditsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxCreditsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the additional liability or refund received or expected based on a final settlement with a taxing authority.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayAggregateDollarAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes from which a reporting entity is exempt or for which it will receive a reduction in income taxes as a result of the income tax holiday granted by the taxing jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayAggregateDollarAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount effect of the income tax benefit resulting from the income tax holidays granted by taxing jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482620/740-10-25-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 740<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 740<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264390736720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264272019136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Summary of Revenue by Segment and Reconciling Items) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue by segment</a></td>
<td class="nump">$ 4,685,297<span></span>
</td>
<td class="nump">$ 4,222,993<span></span>
</td>
<td class="nump">$ 3,578,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization by segment</a></td>
<td class="nump">176,870<span></span>
</td>
<td class="nump">165,156<span></span>
</td>
<td class="nump">159,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net operating profit by segment</a></td>
<td class="nump">1,319,893<span></span>
</td>
<td class="nump">1,131,871<span></span>
</td>
<td class="nump">1,000,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_AmortizationOfAcquiredIntangibleAssets1', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">46,521<span></span>
</td>
<td class="nump">42,020<span></span>
</td>
<td class="nump">31,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expenses</a></td>
<td class="nump">64,228<span></span>
</td>
<td class="nump">9,177<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,949<span></span>
</td>
<td class="nump">1,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense (income), net</a></td>
<td class="num">(45,708)<span></span>
</td>
<td class="num">(47,379)<span></span>
</td>
<td class="num">(22,312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss attributable to equity method investments</a></td>
<td class="num">(1,848)<span></span>
</td>
<td class="num">(7,265)<span></span>
</td>
<td class="num">(8,486)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss', window );">(Gain) loss on equity investments</a></td>
<td class="num">(4,045)<span></span>
</td>
<td class="nump">9,922<span></span>
</td>
<td class="num">(12,202)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainOnBusinessInterruptionInsuranceRecovery', window );">Gain on insurance recoveries</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,227<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(3,494)<span></span>
</td>
<td class="num">(5,712)<span></span>
</td>
<td class="nump">3,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">1,264,798<span></span>
</td>
<td class="nump">1,101,664<span></span>
</td>
<td class="nump">960,483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net operating profit by segment</a></td>
<td class="nump">1,835,804<span></span>
</td>
<td class="nump">1,562,775<span></span>
</td>
<td class="nump">1,373,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization by segment</a></td>
<td class="nump">80,559<span></span>
</td>
<td class="nump">73,493<span></span>
</td>
<td class="nump">72,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Reconciling items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_UnallocatedCorporateCosts', window );">Corporate costs</a></td>
<td class="nump">357,937<span></span>
</td>
<td class="nump">338,362<span></span>
</td>
<td class="nump">300,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_AmortizationOfAcquiredIntangibleAssets1', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">79,484<span></span>
</td>
<td class="nump">72,416<span></span>
</td>
<td class="nump">70,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expenses</a></td>
<td class="nump">64,228<span></span>
</td>
<td class="nump">9,177<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_MasksWithMagnetsFieldSafetyNotificationExpenses', window );">Masks with magnets field safety notification expenses</a></td>
<td class="nump">6,351<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_AstralFieldActionNotificationExpenses', window );">Astral field safety notification expenses</a></td>
<td class="nump">7,911<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,949<span></span>
</td>
<td class="nump">1,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense (income), net</a></td>
<td class="nump">45,708<span></span>
</td>
<td class="nump">47,379<span></span>
</td>
<td class="nump">22,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss attributable to equity method investments</a></td>
<td class="nump">1,848<span></span>
</td>
<td class="nump">7,265<span></span>
</td>
<td class="nump">8,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss', window );">(Gain) loss on equity investments</a></td>
<td class="nump">4,045<span></span>
</td>
<td class="num">(9,922)<span></span>
</td>
<td class="nump">12,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainOnBusinessInterruptionInsuranceRecovery', window );">Gain on insurance recoveries</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,227)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">3,494<span></span>
</td>
<td class="nump">5,712<span></span>
</td>
<td class="num">(3,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">1,264,798<span></span>
</td>
<td class="nump">1,101,664<span></span>
</td>
<td class="nump">960,483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SleepAndRespiratoryMember', window );">Sleep and Respiratory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue by segment</a></td>
<td class="nump">4,101,172<span></span>
</td>
<td class="nump">3,725,017<span></span>
</td>
<td class="nump">3,177,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SleepAndRespiratoryMember', window );">Sleep and Respiratory Care | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization by segment</a></td>
<td class="nump">86,070<span></span>
</td>
<td class="nump">82,544<span></span>
</td>
<td class="nump">79,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net operating profit by segment</a></td>
<td class="nump">1,681,354<span></span>
</td>
<td class="nump">1,447,120<span></span>
</td>
<td class="nump">1,279,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SoftwareAsAServiceMember', window );">Software as a Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue by segment</a></td>
<td class="nump">584,125<span></span>
</td>
<td class="nump">497,976<span></span>
</td>
<td class="nump">400,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease, impairment loss</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SoftwareAsAServiceMember', window );">Software as a Service | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization by segment</a></td>
<td class="nump">10,241<span></span>
</td>
<td class="nump">9,119<span></span>
</td>
<td class="nump">7,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net operating profit by segment</a></td>
<td class="nump">$ 154,450<span></span>
</td>
<td class="nump">$ 115,655<span></span>
</td>
<td class="nump">$ 93,756<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_AmortizationOfAcquiredIntangibleAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_AmortizationOfAcquiredIntangibleAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_AstralFieldActionNotificationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Astral Field Action Notification Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_AstralFieldActionNotificationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_MasksWithMagnetsFieldSafetyNotificationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Masks With Magnets Field Safety Notification Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_MasksWithMagnetsFieldSafetyNotificationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_UnallocatedCorporateCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unallocated corporate costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_UnallocatedCorporateCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column D)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column D)(Footnote 6)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnBusinessInterruptionInsuranceRecovery">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount (to the extent disclosed within this portion of the income statement) by which an insurance settlement exceeds incremental costs incurred from the event causing an interruption of business, plus the insurance award for earnings lost from the event, such as a natural catastrophe, explosion or fire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483605/220-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnBusinessInterruptionInsuranceRecovery</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SleepAndRespiratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=rmd_SleepAndRespiratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SoftwareAsAServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=rmd_SoftwareAsAServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264264097392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Schedule of Revenue by Segment, Product, and Region) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 4,685,297<span></span>
</td>
<td class="nump">$ 4,222,993<span></span>
</td>
<td class="nump">$ 3,578,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=rmd_GlobalMember', window );">Global revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">4,685,297<span></span>
</td>
<td class="nump">4,222,993<span></span>
</td>
<td class="nump">3,578,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SleepAndRespiratoryMember', window );">Sleep and &#8206;Respiratory Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">4,101,172<span></span>
</td>
<td class="nump">3,725,017<span></span>
</td>
<td class="nump">3,177,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SoftwareAsAServiceMember', window );">Software as a Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">584,125<span></span>
</td>
<td class="nump">497,976<span></span>
</td>
<td class="nump">400,829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Sleep and &#8206;Respiratory Care | U.S., Canada and Latin America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">2,722,556<span></span>
</td>
<td class="nump">2,483,387<span></span>
</td>
<td class="nump">1,981,807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Sleep and &#8206;Respiratory Care | U.S., Canada and Latin America | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">1,522,758<span></span>
</td>
<td class="nump">1,444,361<span></span>
</td>
<td class="nump">1,070,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Sleep and &#8206;Respiratory Care | U.S., Canada and Latin America | Masks and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">1,199,798<span></span>
</td>
<td class="nump">1,039,026<span></span>
</td>
<td class="nump">911,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Sleep and &#8206;Respiratory Care | Combined Europe, Asia and other markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">1,378,616<span></span>
</td>
<td class="nump">1,241,630<span></span>
</td>
<td class="nump">1,195,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Sleep and &#8206;Respiratory Care | Combined Europe, Asia and other markets | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">921,253<span></span>
</td>
<td class="nump">826,341<span></span>
</td>
<td class="nump">796,488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Sleep and &#8206;Respiratory Care | Combined Europe, Asia and other markets | Masks and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">457,363<span></span>
</td>
<td class="nump">415,289<span></span>
</td>
<td class="nump">399,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Sleep and &#8206;Respiratory Care | Global revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">4,101,172<span></span>
</td>
<td class="nump">3,725,017<span></span>
</td>
<td class="nump">3,177,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Sleep and &#8206;Respiratory Care | Global revenue | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">2,444,011<span></span>
</td>
<td class="nump">2,270,702<span></span>
</td>
<td class="nump">1,866,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Sleep and &#8206;Respiratory Care | Global revenue | Masks and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">1,657,161<span></span>
</td>
<td class="nump">1,454,315<span></span>
</td>
<td class="nump">1,310,390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Software as a Service | Global revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 584,125<span></span>
</td>
<td class="nump">$ 497,976<span></span>
</td>
<td class="nump">$ 400,829<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=rmd_GlobalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=rmd_GlobalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SleepAndRespiratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=rmd_SleepAndRespiratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SoftwareAsAServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=rmd_SoftwareAsAServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=rmd_U.s.CanadaAndLatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=rmd_U.s.CanadaAndLatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=rmd_DevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=rmd_DevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=rmd_MasksAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=rmd_MasksAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=rmd_CombinedEuropeAsiaAndOtherMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=rmd_CombinedEuropeAsiaAndOtherMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264272977904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Schedule of Revenue by Geographic Area) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 4,685,297<span></span>
</td>
<td class="nump">$ 4,222,993<span></span>
</td>
<td class="nump">$ 3,578,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">2,980,053<span></span>
</td>
<td class="nump">2,719,923<span></span>
</td>
<td class="nump">2,249,381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=rmd_RestOfWorldMember', window );">Rest of the World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 1,705,244<span></span>
</td>
<td class="nump">$ 1,503,070<span></span>
</td>
<td class="nump">$ 1,328,746<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=rmd_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=rmd_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268620608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information (Schedule of Long-Lived Assets by Geographic Areas) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total</a></td>
<td class="nump">$ 548,025<span></span>
</td>
<td class="nump">$ 537,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total</a></td>
<td class="nump">197,017<span></span>
</td>
<td class="nump">200,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total</a></td>
<td class="nump">160,606<span></span>
</td>
<td class="nump">164,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_SG', window );">Singapore</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total</a></td>
<td class="nump">89,679<span></span>
</td>
<td class="nump">83,711<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=rmd_RestOfWorldMember', window );">Rest of the World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total</a></td>
<td class="nump">$ 100,723<span></span>
</td>
<td class="nump">$ 88,945<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_SG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_SG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=rmd_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=rmd_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264266307904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retirement Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_AU', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent', window );">Percentage of contribution by the company to the retirement plans</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Total contribution by the company to the employee retirement plans</a></td>
<td class="nump">$ 14.9<span></span>
</td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="nump">$ 11.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_SG', window );">Singapore</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent', window );">Percentage of contribution by the company to the retirement plans</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Total contribution by the company to the employee retirement plans</a></td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent', window );">Percentage of contribution by the company to the retirement plans</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Total contribution by the company to the employee retirement plans</a></td>
<td class="nump">$ 13.8<span></span>
</td>
<td class="nump">$ 12.7<span></span>
</td>
<td class="nump">$ 11.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan Maximum Annual Contributions By Employer Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_SG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_SG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264408159936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Actions, Contingencies and Commitments (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>patent</div>
</th>
<th class="th">
<div>Jun. 16, 2022 </div>
<div>patent</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_NumberOfPatents', window );">Number of patents | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_ReceivablesSoldWithLimitedRecourse', window );">Receivables sold with limited recourse</a></td>
<td class="nump">$ 206.7<span></span>
</td>
<td class="nump">$ 181.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Maximum potential contingent liability</a></td>
<td class="nump">35.8<span></span>
</td>
<td class="nump">32.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Contingent provision</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_NumberOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Patents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_NumberOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ReceivablesSoldWithLimitedRecourse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables Sold With Limited Recourse</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ReceivablesSoldWithLimitedRecourse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264272590800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Legal Actions, Contingencies and Commitments (Obligations Under Purchase Agreements) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract', window );"><strong>Minimum purchase obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Total</a></td>
<td class="nump">$ 1,023,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">2025</a></td>
<td class="nump">845,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">2026</a></td>
<td class="nump">113,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">2027</a></td>
<td class="nump">24,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFourthYear', window );">2028</a></td>
<td class="nump">3,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFifthYear', window );">2029</a></td>
<td class="nump">1,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="nump">$ 35,080<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid after fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264269376448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities (Schedule of Fair Values of Derivative Instruments) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Assets</a></td>
<td class="nump">$ 2,432<span></span>
</td>
<td class="nump">$ 2,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="nump">$ 36,538<span></span>
</td>
<td class="nump">$ 70,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Prepaid expenses and other current assets (note 4)<span></span>
</td>
<td class="text">Prepaid expenses and other current assets (note 4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Prepaid taxes and other non-current assets<span></span>
</td>
<td class="text">Prepaid taxes and other non-current assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">Other long-term liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued expenses (note 7), Other long-term liabilities<span></span>
</td>
<td class="text">Accrued expenses (note 7), Other long-term liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued expenses (note 7)<span></span>
</td>
<td class="text">Accrued expenses (note 7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Prepaid taxes and other non-current assets, Prepaid expenses and other current assets (note 4)<span></span>
</td>
<td class="text">Prepaid taxes and other non-current assets, Prepaid expenses and other current assets (note 4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instruments | Foreign currency hedging instruments | Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Assets</a></td>
<td class="nump">$ 2,343<span></span>
</td>
<td class="nump">$ 2,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instruments | Foreign currency hedging instruments | Prepaid taxes and other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Assets</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instruments | Foreign currency hedging instruments | Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="nump">4,654<span></span>
</td>
<td class="nump">9,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instruments | Foreign currency hedging instruments | Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instruments | Foreign currency hedging instruments | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="nump">10,472<span></span>
</td>
<td class="nump">19,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instruments | Foreign currency hedging instruments | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="nump">$ 21,270<span></span>
</td>
<td class="nump">$ 40,803<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative asset classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative asset classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 30: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264268812688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities (Schedule of Fair Value Hedge Gains (Losses)) (Details) - Currency Swap - Fair Value Hedging - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Gain (loss) recognized in other comprehensive income (loss)</a></td>
<td class="nump">$ 3,329<span></span>
</td>
<td class="num">$ (5,414)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Gain (loss) recognized on cross-currency swap in interest (expense) income, net (amount excluded from effectiveness testing)</a></td>
<td class="nump">4,010<span></span>
</td>
<td class="nump">3,754<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain (loss) recognized on cross-currency swap in other, net</a></td>
<td class="nump">5,942<span></span>
</td>
<td class="num">(14,329)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Gain (loss) recognized on intercompany debt in other, net</a></td>
<td class="num">$ (5,942)<span></span>
</td>
<td class="nump">$ 14,329<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 25<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480238/815-25-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -SubTopic 20<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480627/815-20-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480627/815-20-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264484903552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities (Schedule of Net Investment Hedge Gains (Losses)) (Details) - Currency Swap - Net Investment Hedging - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Gain (loss) recognized in cumulative translation adjustment within other comprehensive income (loss)</a></td>
<td class="nump">$ 19,532<span></span>
</td>
<td class="num">$ (40,803)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain (loss) recognized from the excluded components in interest (expense) income, net</a></td>
<td class="nump">$ 10,337<span></span>
</td>
<td class="nump">$ 9,482<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480627/815-20-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264272726240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments and Hedging Activities (Schedule of Non-designated Derivative Gains (Losses)) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Total</a></td>
<td class="num">$ (4,149)<span></span>
</td>
<td class="num">$ (4,204)<span></span>
</td>
<td class="nump">$ 2,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency hedging instruments | Not Designated as Hedging Instruments | Other Nonoperating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Total</a></td>
<td class="num">(4,168)<span></span>
</td>
<td class="nump">8,576<span></span>
</td>
<td class="num">(19,511)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=rmd_OtherForeignExchangeContractsMember', window );">Other Foreign Exchange Contracts | Not Designated as Hedging Instruments | Other Nonoperating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Total</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="num">$ (12,780)<span></span>
</td>
<td class="nump">$ 22,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CC<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=rmd_OtherForeignExchangeContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=rmd_OtherForeignExchangeContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264266255152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 21, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,949<span></span>
</td>
<td class="nump">$ 1,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rmd_MEDIFOXDANMember', window );">MEDIFOX DAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of business acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price</a></td>
<td class="nump">$ 997,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rmd_MEDIFOXDANMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rmd_MEDIFOXDANMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264276348768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations (Schedule of Tangible and Identifiable Intangible Assets and Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 21, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,842,055<span></span>
</td>
<td class="nump">$ 2,770,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rmd_MEDIFOXDANMember', window );">MEDIFOX DAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash</a></td>
<td class="nump">$ 7,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">16,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">7,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment', window );">Equity method investment</a></td>
<td class="nump">57,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">18,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(19,359)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(18,349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other liabilities</a></td>
<td class="num">(11,623)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(78,458)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">767,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Purchase price</a></td>
<td class="nump">997,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rmd_MEDIFOXDANMember', window );">MEDIFOX DAN | Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 43,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rmd_MEDIFOXDANMember', window );">MEDIFOX DAN | Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets - useful life</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rmd_MEDIFOXDANMember', window );">MEDIFOX DAN | Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets - useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rmd_MEDIFOXDANMember', window );">MEDIFOX DAN | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 175,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rmd_MEDIFOXDANMember', window );">MEDIFOX DAN | Customer relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets - useful life</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rmd_MEDIFOXDANMember', window );">MEDIFOX DAN | Customer relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets - useful life</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=rmd_MEDIFOXDANMember', window );">MEDIFOX DAN | Trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 32,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Intangible assets - useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable And Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity Method Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=rmd_MEDIFOXDANMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=rmd_MEDIFOXDANMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264266301440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expenses (note 18)</a></td>
<td class="nump">$ 64,228<span></span>
</td>
<td class="nump">$ 9,177<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Remaining in our accruals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember', window );">Employee Severance and One-time Termination Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expenses (note 18)</a></td>
<td class="nump">28,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=rmd_IntangibleAssetImpairmentMember', window );">Intangible Asset Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expenses (note 18)</a></td>
<td class="nump">33,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expenses (note 18)</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=rmd_IntangibleAssetImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=rmd_IntangibleAssetImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140264271804256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II Valuation and Qualifying Accounts and Reserves (Details) - Allowance for trade accounts receivable - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at &#8206;Beginning &#8206;of Period</a></td>
<td class="nump">$ 23,603<span></span>
</td>
<td class="nump">$ 23,259<span></span>
</td>
<td class="nump">$ 32,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to costs and expenses</a></td>
<td class="nump">9,802<span></span>
</td>
<td class="nump">5,770<span></span>
</td>
<td class="nump">2,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Other &#8206;(deductions)</a></td>
<td class="num">(12,273)<span></span>
</td>
<td class="num">(5,426)<span></span>
</td>
<td class="num">(11,499)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at &#8206;End of &#8206;Period</a></td>
<td class="nump">$ 21,132<span></span>
</td>
<td class="nump">$ 23,603<span></span>
</td>
<td class="nump">$ 23,259<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>116
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M!2P6V?_H+3^WW6V@(!62)=M@N(,DHOE?_+X%<1#0<RH"O&V ]RG ;5<$^-L
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MFQW'T9HI<VAM6N<P"6[A$EQS>O\<2;!2;(E<[^?%+VA.@I1#+],B,RL-69)
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M5E^9ZL]R:5>7LW2&EOHVWU;VBWGXM]X'))R_PE1M]S]ZV-OB&2JVK37K_6!
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M3J8& TX#,D IFHX?C6]'!%:3#-33)XGS)X!LMGJ@S':5184+B\^# %8J#VW
M3@HI)[0-[?F2OHPO!_F4'+19C#"I3X144"^ D!G)R 0-T9XN:9PN#\6\T:#:
MM\&4H#X)$D&%&*_6D!U+L9J0ZG30]L:Y\M.0:/:Y&R<<ZI,?P:YRC"'[=@J:
MD F^H3U'TCA'7J],8\^M;M9HJ6^.9%\:!NPS7Y;A<2\4MIJ:WYX=:9P=CSN)
M00H'D?HDEQ$L/>D4L%,B%6R"#&E/AE0\NZ$X5;YIE%=?O!_R2MZ. ^]IE<9I
M]5EKU6=,PA3CXY8T9 ?U))THW[0G5AKO2O\/=4C]SE-EC(W%8< L@[R;*N$]
M*](X*T9+^%!S1<MX@ XYX=RKD0$[(M,IB4A[VJ1QVMSU$Y6I[W9EY]0J]@F1
M4RJ\^NB;R93(B2QA/6VR.&W^=L#YO/+(?/J3F6)DG-8!.\(9@;9G G%/E"Q.
ME#WB\L5LQ'QB'%?V@ E3))U("]93)XM3I]\YG$@,%F+.3,E,CA$'#%/)Z!3=
ML\'.;YP\=YA/X0RUE#AEPMOT#1A*2E(\L=7 >MID<=J\,NMU:=VVSJZE+$SM
MRHBNBW[KDX2;^+CG,).@$"6]@J/CZ'L:9G$:OK:F^+8RU5(WK=O$)NI=M\]E
M'X-,S%Z5B5_+VW'L/1.SD[O'>Y9KW2PDZ R_P02*08/N\VJK$T03C+'[A]I5
MWK@]AZT%35C^K9?OW'+4J&Q;:'."4^5SLU<N8B;'0?7,S>+,[=+9U,.(,!^&
MQ 2.!;5_D4'2+!%2)(30?8C=VB!<)ADF">8"F:UM+5QTE#O]WN/@+X6!.!$I
M._:G$BQYPGAVTA\+3K*O)D0Z[KI.&!U/="\XV(DV?+DLW;M@*')N4^J\K%&1
M;THH>D&@ <609M"ZCJ5%R! :=SQ)(KVV8'%M\47;'"Y!3YXW-<QRN" '%$66
M$<G'FB)D2 7#9$)5\%Y5\+BJ^-J @-LVCT\Y#,E0F!;D!:>)A&3!4ATR=S+O
M.$E2)A.0##';8$YQ7WV<PR-@5([G(&@I*:-3^R>\%RH\+E3>%\5VO:VZ%^/[
M%UIF#55PY;YAN =Y:]K@\^.^ CFG AK]L0X/&BHJZ,3"X+U8X<\1*^TDL01A
MA[;#)<=>QQ,R)!3:YXGEP7N]PE^H5[H\>F$8_KOI\)9HR#"X)3H??%SAOFSY
M3][<E74+3<XMC,1O%+AH=A^+[$ZLV73?6]P8:\VZ.USI'. [ _C]UH"@V9^X
M3S@.G^PL_@%02P,$%     @ +J$(6;7089EQ P  , L  !@   !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6RM5MMNXS80_15"710)D$;4U79J"TB\6&P+%##6
MN^U#T0=:HBTB%*F2E+W;K^]04E1+D>UX43]8O,P<GC,:CF9^D.I9YY0:]+7@
M0B^<W)CRP75UFM."Z'M94@$[6ZD*8F"J=JXN%259[51PU\<X=@O"A)/,Z[65
M2N:R,IP)NE)(5T5!U+<GRN5AX7C.R\(GMLN-77"3>4EV=$W-EW*E8.9V*!DK
MJ-!,"J3H=N$\>@]+KW:H+7YG]*"/QLA*V4CY;">_9 L'6T:4T]18" *//5U2
MSBT2\/B[!76Z,ZWC\?@%_4,M'L1LB*9+R?]@F<D7SM1!&=V2BIM/\O"1MH(B
MBY=*KNM_=&ALXYF#TDH;6;3.P*!@HGF2KVT@CAR\\(2#WSKX;W4(6H>@%MHP
MJV6])X8D<R4/2%EK0+.#.C:U-ZAAPK[&M5&PR\#/)$LIM.0L(X9FZ(EP(E**
MUA9.HYL54528G!J6$GZ+?D)?UN_1S;M;] XQ@3[GLM)$9'KN&F!B\=RT/?6I
M.=4_<>JOE;A' ;Y#/O;#$??EV]V#OKL+^KL@^%T0_!HO.(&W-B ?<M,@N44?
MF( @,,+12FI6Y]J?CQMM%&3<7V-2&^QP'-M>PP==DI0N'+AGFJH]=9(??_!B
M_/.8\/\)K!>&H M#< X]>4Q360EX\8JFE.W)AM,[1#C<]#HKH&:@5-&,&<2E
MUG>0GLKFQUA,FH.B^B!;2?:)[WF!/W?WQV)'K((8!YU53T78J0C/JEA!':!
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MFR3(YL=:&T/6M5X4%J.1^#1B>"YU)P3!"2GCF#LT$!P$+<$83B/=TTC;AF*
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MK LH(77]F4R &$HK:.QKJZV36IN>RMKQ0/:J2815TY=>#G'_K0](!):X'HX
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MJ!2(#%I@&&)JD -!'<>@: DH&H-"DRDT:(+(+@K&,D%&D4)7XPCQW<#3)HS
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MOUWS-.-U9R ^OZVJ]O&B^]&'XP^5W/P?4$L#!!0    ( "ZA"%G,]W2*D0(
M ,X&   8    >&PO=V]R:W-H965T<R]S:&5E=#@N>&ULK55=3]LP%/TK5IC8
MD+;FDY9!&XFV3-LDI JT[6':@YO<-A:.'6RGA7^_:R<-!:6(!UYBWYM[CN]'
M?#+>2G6G"P!#'DHN],0KC*G.?5]G!914#V0% M^LI"JI05.M?5TIH+D#E=R/
M@F#HEY0)+QT[WT*E8UD;S@0L%-%U65+U. 4NMQ,O]':.&[8NC'7XZ;BB:[@%
M\ZM:*+3\CB5G)0C-I" *5A/O,CR?)S;>!?QFL-5[>V(K64IY9XT?^<0+;$+
M(3.6@>*R@1EP;HDPC?N6T^N.M,#]_8[]FZL=:UE2#3/)_[#<%!/OS",YK&C-
MS8W<?H>VGE/+ETFNW9-LF]C1R"-9K8TL6S!F4#+1K/2A[<,>(!P> $0M('H)
M2 X XA80OQ60M #7:K\IQ?5A3@U-QTINB;+1R&8WKID.C>4S8<=^:Q2^98@S
MZ4P*+3G+J8&<W!I<<*9&$[E"2V9WA>0Y*'U\=!:%HPMR=5\S\T@^+:C"L (,
MRR@_(5_(!^(37:!7CWV#>5EV/VMSF#8Y1 =R""-R+9%-DRN10_Z<P,>"NJJB
M7573Z%7&G[48D#CX3*(@2GH2FKT='O? YV^'1Z]4$W<SBAU??("O&\O+J7S<
MS>/OY5(;A7?H7U_W&_:DG]WJRKFN: 83#X5#@]J EQX?A</@HJ]S[TDV?R>R
M9UU-NJXFK[&G<[9A.8@<52+C^.'FI +5?,/D$Q,DEQS=^LE[TM?;YHR1.\-*
M["8-!U]QZ)O]GO4%C8;/@^9]0<.S+JBIT=^[Z26HM5-,33)9"]-<C\[;B?*E
MTZ(7_BF*=:.M3S2-TE]3M69"$PXKI P&HU./J$8]&\/(RNG)4AI4)[<M\(<#
MR@;@^Y649F?8 [I?6/H?4$L#!!0    ( "ZA"%F!GCY-C H  '\P   8
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M]]W+G<A@\C4 OM]*J5[>Z!\8_\_!U?\!4$L#!!0    ( "ZA"%D>T1C,!00
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M\I2PVC V0';E/@+LQX0#GI]\XZD80 BR'3%$S[:/HH5%]EV;#*"G[?WRYQ4
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M_7+&H_*E5UN./.17L[*J1GC<F.XMGN:V ]XG>)Q#_CQNX:K8<AJ^YPF72I\
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M=4TOV6*F)%)VZ<3_]V0XJ7%-@;-0[HRX-[ ![30_C(BU2X>5R;"@F-5N:$/
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MZ=@#U3P.FH&1*W<AGTE#UWO77=)["I6=0/_GDNQM!W:![H4V_1=02P,$%
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M!_J[0>T<Z+Y1RIX/[H'Y#VSS+U!+ P04    "  NH0A9XV7&S?D*  "3(
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M#%FM:0@T3>E5(5;*KIPLUYHJY_?,#S@<G_MQ/K:QU,!&>JEIEO(701I;0;,
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MMLMGNWRVRV>[?+;+9[M\_C67S][1U\\0=\7?>'O!&1T_A&Z>-I^1OXI?3Q_
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MN9>E&59G7I;G(BPB+PL3$<:%E\387H1>#LM^4"L%!:K#^1>(6Q$DEW@(L"7
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M47!41POP?M6BXKH/=,#T YY7_P=02P,$%     @ +J$(61_HA25S"@  T!H
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ML-5=9>""1J]5(X^ZC3SJ2VAK'S2QE2/(T-W4 >1Q $2OJTUK&[N^.THEH6I
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MSPW?XLAX _Y?:>WZ@0\PW OG_P)02P,$%     @ +J$(64-GUGHG#P  )R<
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MGP(DV 4DT)_\CO ?_#3$D@9UN!MK5[*P)E.* ,'U%A-(S1DD9'4KI-_WH.C
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M%[.!L/ZS+']3FQU_"G5M:F :7R(1P#[0 +Q?&U/'&UJ@_3;NQ;\!4$L#!!0
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M2+>FQ^I)I/Q>ZKK)/LR9,CV@"MGZH' @'=*%@D-5=-M2<\&H3)')MGW,Y_9
MFRF3[VTJ9U<JR*72*FR3;SI@QXXKX;G08R6B9BJG/-Z![EEZD9P?AD]EI>V6
MN&#OP=)DC<S(!CEA#?T8\)43@1S&>Q/TD@R!FN^+L_'X6$ME@C1KM=3$PN&C
MS>E5+N;JD91,?*/@*[>;:)V1"_A0[\M-=J.O'TF=I<GDT%U#LE0^0XM*0[;V
MC_VB*3P?_J8FV!3^^<?8I[K2$=\<>*OM39EEKI;Z184WCH77C:0G7'!.?CI0
M\91*CG"OD68W<UB*;^=06XG[ DS$EX.J9Y15S7.LM'4S3(Z\YO\=31QQ3T71
M3F+8H-1P?U(8>_"QKRFTPZ[23F:D$:N02/+;Y*+CI<QWIT9L"I453691!/D+
M8ILDISZ!@X-[2TGH-[Z=<:@0L+G"=+O=!?"JN??LCS>WQ\]H5X6AH&D%TV'R
M]DU/N.9&UBR"K>(M"%,0=ZKX6. 22XX/X/W*8LBV"W;078OG_P)02P,$%
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M+ML.R*:'-PLM-K9O+H6F+FRG&3U[*(T#[:^$T/N%(3@\I(-_ 5!+ P04
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MC+#DA00P8@5,1]!U49))D1<3%- 19"TB*7E"5C&#&S#I$@EP&0,,^+S*1;"
M*4@15_=OT^4* '_]942=B]\RDO$@!X"HJ"<$<(""IX+(%"!DE,U>BC VFT5J
M0H/I4$U@,,5RE5,856G,R$,.%3J#J?_.>1.\W53W\1EJAT8FUX&$&TR2-1<
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M/"__,3%$P5[K4$X$5N,]WO(>=^%1QZ?D?R*P&G]GH%=( WR8@U8;ET)XV.&
M,:Z'4)"VW'96?P[N;I7],)+#XQHL@9$ABM26(=4,::O9&-$<"R(X?./LA(>U
M):K7D@ZZ5)O4+*.1%AZ_;^*,%+M8+3IZN>C@:[$]]VLDB2,<&%,CRQ,M+^LL
MM5%R<%.S.TH_Y"5?(U4<AH[&)&0OQMT./+0M0VV0'-S-Z%7)]1.+8K6F-A(L
M488%BMJ/?)K ,@)6$9?]IQH;:[EZGMK?.+@1J2U6,+7'<5XK=Z="J[/61L<9
M=:'XSDDMSZG0ZFV@38^#>HIFS<?#=@>,D5473H9J)T-Q2]*H]I:XS3K=N'':
MA8&AVL!0W(BTD'<+8I.\XV%MB6H?0W'7895W2_S^SHJ18A<.AFH'0W$'<H2\
M6Q .=HN,++LP,52;&(I;D&/EW0)#1UZCO..A;1EJ T,M!N8X>:]0:K+M^,,]
M<;>5JN>H+0C%+8AI_Q!3>!SNM>IV*K0Z>>UKZ$47"D]/ZG).A59O ^UR*+Z?
MTZ3PEC##N#&2Z\*^4&U?*.Y#FH4>CVO803<R[,+*N-K*N+@E::'[%L0FW<?#
MVA+5!L?%[8A5]RWQ^[]Y&"EV86U<;6U<W)H<H?L6A/KO.$:*75@;=^>'?LOF
MS)&B;X'QO.8U/1[:EJ&V-:[%UAPG^A7*KIQ3;S 8[*F^M5@]2VU-7-R:[/^T
MATD^#O7J<Q9=;+FXVN^XPTZ.FIS4]IP*K=X&VO:XEM^K&B3?$K8W9HS$NO R
MKO8R+FY*&N7>$H?_L&TDVH6O<;6O<7%_TD;U<<1&U>_"WGC:WGBX&;&JOBV^
M=A3!>.JI"UOC:5OCX;;D",VW(!P<KS"R[,+9>-K9>!9?<J3L6V#\8?-:'P]M
MRU ;&\]B;(Z3_0JEMHH?T^&^[%N+U;/<.6=H.6BX?^(&TWT<Z]6G"[O8B_&T
MX?'\+G3?.ZGW.15:O0VT]_'PO9XFW;>$[0\:([,N'(VG'8V'6Y-&X;?$'7/@
MS$BW"Y_C:9_CX7ZEA?Q;$)OD'P]K2U3[' ]W)7;YQ^-WCP@:Z77A;GSM;GS<
MG1PA_A:$VK%'XP' +NR-K^V-;]FU.5+X+3 N]1N%'P]MRU!;&]]B;8X3_@JE
MINAT3/=TWU:JGJ,V)SYN3@X.PF*RCV.]5O).A59GK@V/[W4A^_Y)K<^IT.IM
ML'/@V'+BN$'V+6'[@\;(K M#XVM#X^/.I%'V+7'U<^!&8EWX&5_[&1_W)6T.
MB..(30*/A[4EJIV,C_L.J\!;XG=/[AOI=>%??.U??-Q_'"/P.,+!VPA&EEW8
MF*&V,4.+"3E2Y"TPWI VBCP>VI:AMC%#BXTY3N0K%-NFOK58F65_YVU6F*KF
MQ4N^&0E@D2++%UNW=[<O$E\7K\_V=?'R+>0[)N91DI&8SR!T<'X!\[8H7^PM
M+V2Z*MZ-G:92ILOBXX(S6.RI O#]+$WEYD)5L'V]>O(_4$L#!!0    ( "ZA
M"%DVA<,%$0(  -T$   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;*54
MVX[3,!#]%<M(/*$F32^@DD1J%Q"+6*G:Y?* >'#C:6*M+\&>;)>_QW;24%"W
M0N(E]MASSISC>)P?C+UW#0"21R6U*VB#V*Z2Q%4-*.8FI@7M=_;&*H8^M'7B
M6@N,1Y"229:FRT0QH6F9Q[6M+7/3H10:MI:X3BEF?VY FD-!I_2X<"OJ!L-"
M4N8MJ^$.\'.[M3Y*1A8N%&@GC"86]@5=3U>;><B/"5\$'-S)G 0G.V/N0W#-
M"YH&02"APL# _/  5R!E(/(R?@R<="P9@*?S(_N[Z-U[V3$'5T9^%1R;@KZB
MA,.>=1)OS>$]#'X6@:\RTL4O.?2YBQDE5>?0J 'L%2BA^Y$]#N=P I@NGP!D
M R"+NOM"4>4;AJS,K3D0&[(]6YA$JQ'MQ0D=?LH=6K\K/ [+:W^\'"SY9!D7
MNB9;(T4EP!&F.=E:4P'O++@\05\L0))J(-[TQ-D3Q-.,W!B-C2-O-0?^)T'B
M58Y2LZ/437:1\4.G)V26OB!9FLTO\,U&Z[/(-_L_Z^3;1P\DUPC*?3]W#GV5
M^?DJH:E6KF45%-1WC0/[ +1\_FRZ3%]?\# ?/<POL?^SAS4W+?[]%WKYEPN@
M[>"<SN3DRBFP=6PL1RK3:>QOW[@Z]NZZO[*_T_O&OV&V%MH1"7L/32<O%Y38
MOIGZ $T;+_#.H&^'.&W\^P,V)/C]O3%X#$*!\44K?P%02P,$%     @ +J$(
M6;U?^Y\@(0  F&L  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULO3UK
M<]LVMG^%X]V[F\S(BNTD3=-'9O+L9K?=YL;-]L.=^P$B(0D;BF )TK+ZZ^]Y
M J!$R4G;O3.=QI9(X."\G_ W6]]]#&MK^^)V4S?AV[-UW[=?/7@0RK7=F##W
MK6W@FZ7O-J:'7[O5@]!VUE3TTJ9^<'5Q\<6#C7'-V;-OZ+-WW;-O_-#7KK'O
MNB(,FXWI=B]L[;??GEV>Z0?OW6K=XP</GGW3FI6]MOV']ET'OSV(JU1N8YO@
M?%-T=OGMV?/+KUY</<07Z(E_.;L-V<\%'F7A_4?\Y6WU[=D%0F1K6_:XA(%_
M;NQ+6]>X$L#QBRQZ%O?$%_.?=?4W='@XS,($^]+7/[NJ7W][]N594=FE&>K^
MO=_^S<J!'N-ZI:\#_;_8\K./'Y\5Y1!ZOY&7 8*-:_A?<RN(R%[X\N+("U?R
MPA7!S1L1E*],;YY]T_EMT>'3L!K^0$>EMP$XUR!5KOL.OG7P7O_LFJE1^&5Q
M[5:-6[K2-'WQO"S]T/2N617O?.U*9T-Q3W^Z_\V#'K;&!1Z4LLT+WN;JR#:7
M5\4/ONG7H7C=5+8:+_  8(Z 7RG@+ZY.KOCWH9D7#R]FQ=7%U:,3ZSV,B'A(
MZST\LM[4B?_G^2+T'3#._TZ=F-=[-+T>2M-7H36E_?8,Q"78[L:>/?O+GRZ_
MN/CZ!+2/(K2/3JW^[,=N91KWJV'.;JKBA0DN(!7?X69-3]],0?U'K%N\M^$'
M6Q5OFW)>W ,QLET'O_:^6-O..G@S%'_YTY=75Q=?;RW]</GU3#\9POXG?NCD
MH\)W1;^V^L5+OVE-LY,O[Q< B2E>V=IL36>+TG>M[Q@@5$\  6S]@^G*=7'Y
M].DCA,(4:U]72-22U\(G:0LYPG>=']IY\=,:_EVM"P %%-0BN,J9#EA@5FPM
M"'D T9B!V#7#$KAA@,T1-R X'T%OVE\&UX*BZN/:\/*J\8@X?*P';=G3]X#&
M4%O;GE<N^*ZRB+0%?KM&"/%9#Z]WH.U"Z^!D'@13'P507%/6 QW&(U\.I-!X
MQ<*TC37SXD> /X%)C[:6<03  -RU+TW/F'H^('/7SLQ ])N5 63:&>"O-KN
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M[<'<K=+8HXN< 0RV-9\G28<:.@C&;&S+&K- F*:WU+NYXR.1$>'![1F+IU.
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M@T!N@(!JHP&?6&AR_[&9*]!'JSD$H-YP]OVE,S"2EJKMU GL.QW7E&8NW\5
M.=8\<2-!+5>[IU3QB&!@O#S-=S'6]MCDD)^HLP4+"FA5=EK=TE@#Y2M6LDXJ
MB]3K<GE'7XI(^FME)VJ'^R&.9TXJC]^W)/6&&.X/SSJ_)EM$9K&1FXBRE*7+
M#M!]'G$6MJ9%6RI1=)6>TR?P=<!=S#ZRTD#"+7&,ODOC>I2@U5:KU"[&?9:V
MZ]$8'BR/35S4WS1JR>NDIT)F\/AB@XY.I.(X4D^5SQN\*6B3Q&L>!@)+5BN;
M-9NE6QD2,C,42I[O7]&M_Z?MLZ"J^!LLAY#]V, !;NQF 1QZ^626\D7V%N#M
M<ZQ.8!_U ]KWS#-;(YR"Y"Q0X$\I0L76%1*-M<! W7=(H[5KI0_ .I$9&_?/
MA0KWY :G.&;ICS^-%;%.+\JH/35'T<,$%::W[":PE[5/R>B1[\5)02',.ZUB
M6]6<^RTXH;'?K3Y-+P[68DNU:Y)_B_FB%7:SW^U%E?FV^T?D$%=X+[9'3%%5
M66N?@-2#ELG)I$0<'#CS^4/K):E2^.9N6E5VT<=&M _7K[AB_>$]SVUQBR9S
MEK"L]*JKQ&;%^YBKR;*<@ (^EETN+86BC>3Z^TP&:TT6)^!Y_T/VIC<I6%CN
M8E"7,3SBE7=,"06Y3(!U)FJ942IM7\##*$:,+%)SN0,[< [(/F/[0X[X[+01
MSQQQXA6'%S^@JAG!M!9-%'$[GA$X1/(8O>/Z@)[B$ 1)?)@B[""0PA&_DBO:
M1HSG?F= 7L55U9(DC-V0,)8QXC;LLKLGCM?]Z+4TV*OT')G0+74625EQ3+'#
M!&BDP&_'DMZB(+GQ/91!L-%0@T+.$,?BL2EGZO-UP92:_X/U@6ZSK]DYOM#%
M,_<I=]99)J>-T?^W7-[I>6MF;8I Z%/J_%%*Q5'L$\D>ASE$SO>.[:)YFO9R
M<[_VN)Q_!N].J5$JTRSVTPIW21R" WJ7Z9M5DWIMZC_MCV!9Z,^7LXNK+^97
MP)=U37COQ^4QVF74W4_=AM2+K+,&E5X4@NSO(?0OV4=Z>$EK/.6,VJO$0W]C
M5OLYQ6ZCNY7B#,-81"A$3IDC4S0#;0-GIE[\XO6 S5BF&86>:8@421$OC6ID
MH$4NO=(H.0UD'<AGFHN0B\+B#.O11?=Z[N)4GL9Y0-Y&-;1,FJ?@):7R ^:H
MN$W0',*EZEOFG*4Y[(_S])E?997(0^>Y(Y("$\X:S,8EK(,^R+P^CDS,@Q5:
MD#IZP@16ZC.2B(#+I:E?;4)G@Z#OHXI5LK9HT'I\[4[LQ)%P"URLLI=NM6FN
M& >R6$&K*3A%GA1ZW\U['Z1\P5<;(8BS6+$BK[VR^HO$O0?P?#)9&*:EZS:4
M575]YEKC_ *'^,LEF9?==!P_Z3R,(K5H.,0#/63&?-J031!'%QMM_3ON-APL
MMA\C1#N3FY"96 ">O[DSRWI$R^+^N:;%I-A>N&:CBGWXZ&)^D50L(/'/3Q\_
MFC\YJG7IF?R3AS,=?@*34>]^@U:^MFTOH>MC6O(QMT(FLSE&,N$ -<4$A9%6
M.G20C4^$NR8WN.[02=* (X534V7<U:0YQ[SC">>[>#8MWCL&:TTF2'C21F=8
M)B;:V/-:X$UG/4^(D@.1N2RCA!7Y96QPC@S92:]_5$TTLZ;=X7I"\D Y;<6S
M!'2+;+R:)X&)_MJI1%::G;@\/?'PED.%G[!(-IFT^O37B8[9&+I$(5Q_2T58
M=D[S%/(NOQPBI5^K>'^HN3V6>8Z!-I?E\4F47KJWAR[8ZKF;G>HY2+\8BX11
M,#*1ES]HK^$A3;F1XP@\Z<ZD))D$%?:&A=%\UZ<<+[M-H^%Y3GR8_?W1'5:&
MKHK#!AAS*Q,Y><J7&YW@%^[NY"0R'!/O2>UV(ZR().Y=+X0QHI4I9YSF$;^7
M'594^Y]R&FI1R\*^>)2#B'8,O=0!QO=G1J2,I^<2^U 1,=IH0]O1:(YT<AQ$
M\=.U&3+92]X\O7ZDEPOOZK-\\UO !(J.H]E;$Z\KP\$2<TL\E&XFV+L'H[?E
MNJ'J[0;.GEVG* !P8!U# >K; &34A.8LXP*1GF1R\M.K'5S*-0H)X?B4A!6G
MU,M5FNBY.CV3\QS;04@YHZ3*Z/CWI.RFM,UO7XVSXX 1PQ.99O2HZ/3DI<1)
MVGQ86"[E4.;GIV>C:P+V[A_#QG-[CFWGZ0J<F:8T4W0W&BJ65LB,W?(N8 JN
M;XRK18K3/7TZN!C+,2CVV4B.G;@I,V_CDL9NE1]M@4B;J[<OURJ9!;9>B&*=
MZ%B>QVG_$1+IWA3JKH*#D(/(W8V)(./+DBH<ZZZHJXB@=WIU)]WV@[=]H#\#
M1P1@*?+&;6;QUA%A;VI>#;,#%R&[RE2,Z8QOQJALBWV?!W<]<./)1,=>7"<]
MKY=(L5KG&R1S0N"[J$H&E=_ &6LCUZ>,T+8WN96:&(5ILSMW)*]7EMU@L_8=
M]6?W/=B]$E\V);O'S1G8V8U.='J*P?;A-:,^H3UVET%[B81.:I,TSW5U>O[J
M;6HO@6V^]\WJ_'MJ;CP^,//[5J2;P\CZ2"1H=43AL&D9%ZAQ@9KO<.0%V()2
M7Q.UC 1L%LGZ-H5_]6Y<D?HXQ:,Q&LD,M_-S<XOKRF'#U^0&FKV3IM@3W>%:
M:,$B(AJKW++/Z9YBK)$GY7'\!*.K-G$RD$4'7&:^Q. N"- K9[V"4=?QWE6.
MZ&6,./J.W$XJ+D:7AB_B:]K2+-?XJ4,@V9ZL1RGEAW$#]8TF8<]ZA_.^]</X
M4P?H?M9NL#$>*Q?DYJ'EP3SJY-:C,@F-4O#<D]Q4,&ISIT',R7;V;1;W_OGA
MPRRW1S=6\JWQO)"Z#_M<F"'NL":'NV\=]N[X+:VIC!U3>"G1A;R&URC "?A^
MVB_CT,;[$22O5;/1*&NZ$SBWBGA';2>SE/F[A"1..KA*"E'*" =]P*3PM8B*
M<!W*\6@8*\Y=30T/9!?=GE)Z:2[PZO1,WTLU?^61L>C?_OX8HC01=W5ZK U4
M!1MC:ARL\N;>('>8\VS!SL8+F"8!_^.W*9Y??P"NFA,ASB^>Q!N/W\?6IGM\
M>_K5EQ?WORK>9N.D2'A^C+2POOD*R%U+.N]M5NSG! PR1+J69.(V]U"\\)@^
MO??F^?6+^WJ6/3!GQ=D?"NCL3+09*%2#]VOI%6Y5=ACR@[BK*+\,0Q^-?D4L
MYX*L#;6A>T?94TEWEJ[Q4JTT'5C9DF_(WIB/MLL;F&+:+1O"PMRH7GJRC/OC
MA=B.VP)\".Q5LT[D'L%0=J[5:W-H=@O++1*@T:767,"1Y:A'(<NQN\T(&=GX
ME%P8M1K=1C*&1N<\+%]'!.80"8H#(VD&0JX0?<ZC1TPO##WPCP85EQ?G_TC)
MBZ10)O3)8P8:"U!R';'"'^\W?4U$(1'02_#INK->&E79SL'2S#X;O+88;!$!
M:^DFY,ZG/"(%%G4M6<+#NX+4.1?G+WE%L74W1=T$$GTL./(3#NIDX*UW50J!
MYO0VB\O38I1V$CEY\FA*3M*3N7Q,J<$'V1]+ C]_17\2*G#2C?]N4ORTT#\[
M]9S_V%)ZG/]FU0]@5# S7MLEO'HQ?_+XC&_'UE]ZW]*?7EKX'H(*^A&O@+ =
M/@#?+ST81OD%-XA_C.O9_P%02P,$%     @ +J$(61B\F[ 0 P  % <  !D
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;(U6;6_;-A#^*P>W*!)
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M9MD,2ESSKK:?U/9'W/D3.WV%JDW_A>UNKS^#HC-6-;O#9$$CY/#G#[LXO.0
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M@3<*=%U53&W.L93KTT$PV Y\X(NEL0.CZ<F*+? CFL^K&T6]48=2\ J%YE*
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M("J[@.;GDO1M.W:#[G4Y_1=02P,$%     @ +J$(66N7^$!' P  T 8  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL?57;;N,V$/V5@5H4NX 0W6DY
MM0TD:8INT<4:F^WVH>@#+8UL(12IDE0<_WV'E*UU%XY?Q-N<PS,SG-%BK_2S
MV2%:>.V$-,M@9VU_&T6FVF''S8WJ4=))HW3'+2WU-C*]1EY[4">B-(Y9U/%6
M!JN%WUOKU4(-5K02UQK,T'5<'^Y1J/TR2(+3QN=VN[-N(UHM>K[%)[1_]FM-
MJVABJ=L.I6F5!(W-,KA+;N]S9^\-OK:X-V=S<)YLE'IVBP_U,HB=(!186<?
M:7C!!Q3"$9&,?X^<P72E Y[/3^R_>M_)EPTW^*#$7VUM=\N@#*#&A@_"?E;[
MW_#H3^'X*B6,_\)^M,VR *K!6-4=P:2@:^4X\M=C',X 9?P&(#T"4J][O,BK
M_(5;OEIHM0?MK(G-3;RK'DWB6NF2\F0UG;:$LZN[JM(#UO#X2FDV:.#=%[X1
M:-XO(DOTSBBJCE3W(U7Z!E62PD<E[<[ HZRQ_C]!1+HF<>E)W'UZE?'W0=Y
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M5LI8(J;CDJ4TQN&L+)S<3MGQ9D=*_>H9O3 6.G?F8<884%N@HI=4IEJCK Y
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;(U646_;-A#^*P=M'1)
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M/\+X*H^O)A-:4=!\EM."S6(V#0L69WGJ%VD\S:;!.D[G5[3(Y_$\G5$5K5V
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MLJ(/ S3>@)YOM7:'&Q]@^-18?P%02P,$%     @ +J$(69"AWLO<!0  =0\
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MG]O\;K4FV[52ZAR9%2_$R0!SPPA](P;C'W\(6?#S#LQ)CSG9I7T\Q50LFTJ
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M"]W5_H/=?&\&?5+B-[>U"[]L,]!&(S;OG+>KX3 0K*JF_]=?!CN\YH <#LB
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MG?-<*2:+F.<R93(I>)K@>"&Y@B?>F(4!@/)9_AAQ5HAT@H7 $8&%D#P3<C(
M&"= )>D]CU41_O,\W@L6XA#'HN<02Y#&/ 66,62K7&$_27D26 C!E<#.W<LF
M_0:88ZX2"E$90>M(#6&+ #P5/]DN?K(_'3^H=PL8BKUK[2HDW?7*=HW?*RP@
M.A9B)T7_H1 K Q(4CRT4O8/R3(>FZDV+7D=A^,3T>ET_484(]'BHYM2E^AJP
M&!R_=[HE/X.A%'_] T7*6TH"XC.P1-'2F#X<NCQQ/2Q:7\F/OD2#S;JCG-*>
M.41AYVW[U,,/6!$:6<JS$!HR1M0E10@71' DR$48MAQ"MS3]:@)HAV;MX1$@
M,NSY$.O[))PU)N /8DF]F6G,HO),07+!"IXDBJ60&+,/<*9NY\M@E=(\HA*L
M,89Y!O$E3HPEI676ITBB0I+E/!7YA-TN=?- DMFCKCO=SUUD+-W,#5-0;)SR
M* *E2A5[BV"8!U3--OVV#D0'$"E7,25<S M%^89"HI()PS"&4:L)I#TB$"N.
M(C'0JI#6LB@HZ>W\\[<TM97!#1@F>U#F"ZT-BI-"/QAG7*HAI64!&;_ S2TC
M!'!EPJ-4P$XR5_^77,]WN9Z_.M>WI2_D][5S!D8@=_U8Z5E55[X"H-M:.U<M
M*HH\MZW5@8JJW?!\+.]/PCB>][\:!.':MA3F%&GE%A]Y23_CJ_?P(4ILU\(O
MC;-U5>K0=G0=0B4,M(XRYB!= X_]G9B3;GU"GIH:2./Y8('?8PL>HSI/B2=B
M]) \>?G(5H<G-L[1L&)J(T7$LS1"'SFJ>QA0$B[CB/HA&@Q@G0@(M0L(]>J
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M+BIT5QL_G,4+;];A8]74>&]68;E4LE66-N#YW!B_O2 %NZ^7U_\'4$L#!!0
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M/ Q -\.F.5BU]0V^5I;&A=^6-)]1NPOT?Z.4/1P<03OQTW]02P,$%     @
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M3IC<M52=8(>&/B18" 16([%7DM@[5F[M01(,"18"@=4([I<$]\&CKK\53T&
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M!P/?D8Y''(3!.[ZZ.#B&R4C/-V[YQM:ZWHAT:T-9 AN(3EK1R<\N:XE-K9;
M!EK'K=:QM0*/SWI,NZR=AYF6->AU.[-GI#KG>(?("N WY=F$VH#5'@J8W&)^
M>N -!3-CWUHQ6VC#F>AY%/BS#=H@V-)K"6VHM[,9T+BSIZ]4;63YE2M\@]7O
MOR"!R?L%4Q>F=@)XH4L[FP#-/N'4I1*]#5JTM\Z;RF8$O[ELEM"&4]$9$7BE
M$S'HM>I";*$-]78^!)J-R'F;?K"YPW.7 9,P\MZWJB;,\^+D0JMV7@3>9D;
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MK'TGUNX(6C:OE1ZI$#1O-M<$+PFK"^3W*TK%VT[]IJI_,[GX'U!+ P04
M"  NH0A9PTBFT:L#  "?#0  &0   'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6RU5]%NVS84_15"+8H$:".2MB0[M0W$R;9V0+$@7K>'80^T=6UQE4B5I.+F
M[TM*LN36LM*YR8LD4KSG'NKR')&3K52?= )@T)<L%7KJ)<;DE[ZO5PED3%_(
M'(1]LY8J8\8VU<;7N0(6ET%9ZE.,0S]C7'BS2=EWJV8369B4"[A52!=9QM3#
M'%*YG7K$VW7<\4UB7(<_F^1L PLP'_-;95M^@Q+S#(3F4B %ZZEW12[G9.P"
MRA%_<=CJO6?DIK*4\I-KO(^G'G:,((65<1#,WN[A&M+4(5D>GVM0K\GI O>?
M=^B_EI.WDUDR#=<R_9O')IEZ(P_%L&9%:N[D]AW4$PH<WDJFNKRB;3T6>VA5
M:".S.M@RR+BH[NQ+_2'V B@]$D#K %KRKA*5+&^88;.)DENDW&B+YA[*J9;1
MEAP7KBH+H^Q;;N/,[#<IXRU/4\1$C/XP"2CT7A@F-GR9 KK2&HQ^C81='F<+
MNR+BPO;*-;I.[!#0B MTS91ZX&*#KC)9"./>[D#/T=D-&,93?8Y>NK%_)K+0
M-I.>^,:2=Q3\54UT7A&E1X@2BCY(81*-?A$QQ-\"^';6S=3I;NISVHOX>R$N
MT "_1A33(?JXN$%G+\][< ?-)QV4N(/'/ND_=])>[>+9,A7_VS7E"FC8#>0$
M>:ESMH*I9Q6G0=V#-WOU@H3X;0_-84-SV(<^F[.4B14@9I M.UK"A@OAZF@+
MZ#IR4%S&7:PKW*#$=:J_G]$HPG0\GOCW'82"AE#03ZC0MD=KJ]3/!=?<J;9S
MH50PX5[^,25CTIT];+*'O=EMF:R"A=6<4B!6#\@H)G3**N^(_[-2M&9D.@F%
M!X3>4#P<!-V,HH91]'\*!%:@CY8F.F!"1T.*@R-41@V542^510J0EQ;QZL6(
MXO#M'>B<*V:D>G & %U<>B%/7-SCAO#XJ30X?@::!+?VBY])A37P?JW#"!.*
MNTM-]OX(Y&ET6./\H! );0G09Y-B#?V-%H?1B![AU'HZZ?7BD\180^YSB8(H
MH$=\DK3.3?JM>\'8HC-A;]BI:[GU;Q(\E>A([Z_@5*:MUY-^L_\)U1UZ/248
MD^A845NW)X_8_0_+[M#DCVF^]7?2;_ _);G1H>1($ :#(Z1:#R>]WGN:YL:'
MFQ,\&@8T_(Z-O[=GSD!MRI.!1BNWAZVVSTUO<_JXJO;<[?#JZ/*!*;M^-$IA
M;4/Q162SJ^HT4#6,S,L=^%(:NY\O'Q-[@@+E!MCW:RG-KN$2-&>RV5=02P,$
M%     @ +J$(67&>$)#B P  =Q$  !D   !X;"]W;W)K<VAE971S+W-H965T
M-3,N>&ULM5A=CYLX%/TK%EM5,U)GL T$F":1IAEU=U;]&'7:[L-J'SS@!*L&
M4]LD[?[Z&L*0$)RH(S$O"89[#^=>7U\?,]T(^4UEE&KP(^>%FCF9UN65ZZHD
MHSE1EZ*DA7FR%#(GV@SERE6EI"1MG'+N8@@G;DY8X<RGS;T[.9^*2G-6T#L)
M5)7G1/Y\0[G8S!SD/-[XQ%:9KF^X\VE)5O2>ZB_EG30CMT-)64X+Q40!)%W.
MG&MTM4!1[=!8?&5TH_:N01W*@Q#?ZL%M.G-@S8ARFN@:@IB_-5U0SFLDP^-[
M"^IT[ZP=]Z\?T=\VP9M@'HBB"\'_8:G.9D[D@)0N2<7U)['YB[8!!35>(KAJ
M?L&FM84.2"JE1=XZ&P8Y*[;_Y$>;B#T'Y!]QP*T#_ET'KW7PFD"WS)JP;H@F
M\ZD4&R!K:X-67S2Y:;Q--*RHI_%>2_.4&3\]_U.(=,,X!Z1(P4>=40EN"TV*
M%7O@%%PK1;5Z!0I33V?WIH32RMP5R^.6'Z@^!V<W5!/&U3FX %_N;\#9BW/P
M K "?,Y$I<R;U-35AGQ-P4U:HF^V1/$1HG]7Q27PX"N (?8M[HO?=_?Z[JY)
M69<WW.4--WC>$;RWK&":7KPS-9@.\P#^?6?LP:VFN?K/%NL6W+>#UTOW2I4D
MH3/'K$U%Y9HZ\Y=_H E\;8M\)+!>'KPN#]XI]/EGH0D'HBD'UJ5A6S*VP+=H
M08-6MYCUW(^"&)H97>^'-#0+ NSYJ#/KD?4[LOY)LC=T;?I625.S;"0%I11I
ME6B@:9(5@HO53QOCDY!/G:J1P'K1!UWTP7.6;#!F'D8"Z^5ATN5A<K(*/@Z+
M=26%LO:D+=)DKPZ]R)^$\4&Y6LSB*/2AO5S#CFAXDNAUDE1YQ8DV\T5R(37[
MG]1[GXUH.&!P@2,8A_" J<UN$D00VZE&'=5HU#80#6@@Z(7P,*\6,P_'7F0G
M&W=DXY-D%\VV:IA*RIN$JHR5UND_B?/4FA\)K!<R@KM]'C[GZF_11TK%6&C]
M7.QI'C1:!VBA]FO0][ _6%@V.]^;!$<6%MH)#71R_WY2%VBA>LL;!="/)H=L
M;8;8Q_A(RT([/8#&%00MW#X3'*$X.E0$%CL/Q68JCA#>:0)T6A0,BL'*<E05
M,!9:/^*=#D#/*@30J$I@++1^+G9: (TG!M!PF\<!QFC0"BQVIA>$WI%2W>D!
M-)X@0):='@4HC@_W6*NA[_O') '::0(TKBAHX8*>*H 8H4/&0SL35GAX.'#W
M3L7U)XGW1*Y8H0"G2^,'+T,#(+>G_.U B[(Y*#\(;?1!<YE1DE)9&YCG2R'T
MXZ ^>W??6N:_ %!+ P04    "  NH0A94-(_13(%  "B(P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970U-"YX;6RUFEU3XS84AO^*QMWIP Q+;.6;)IF!B&WI
M+"T#W?9BIQ<B5F+-VE96DA/HKZ_\$3LFCB#LR0W8CLYCG=?2B5Y'H[60WU3
MF$9/41BKL1-HO;QHM=0L8!%5YV+)8O/)7,B(:G,J%RVUE(SZ65 4MK#K]EH1
MY;$S&677[N1D)!(=\IC=2:22**+R^8J%8CUV/&=SX9XO IU>:$U&2[I@#TQ_
M6=Y)<]8J*3Z/6*RXB)%D\[%SZ5T0W$\#LA9_<[966\<H3>51B&_IR8T_=MRT
M1RQD,YTBJ/FW8E,6ABG)].-[ 77*>Z:!V\<;^J<L>9/,(U5L*L)_N*^#L3-P
MD,_F- GUO5C_QHJ$NBEO)D*5_47KHJWKH%FBM(B*8-.#B,?Y?_I4"+$5T&[O
M"<!% 'X1X'7V!+2+@/9; SI%0"=3)D\ETX%032<C*=9(IJT-+3W(Q,RB3?H\
M3I_[@Y;F4V[B].17(?PU#T-$8Q_]J0,FT4VL:;S@CR%#ETHQK<Y0; ;@R1]4
M2IH^I5-T0IBF/%2GZ"/Z\D#0R8=3] 'Q&/T5B$09E!JUM.E=>H_6K.C)5=X3
MO*<G'D:W(M:!0M>QS_PZH&72*G/#F]RNL)7X>Q*?H[9[AK"+.PT=FKX]O-T0
M3MX>CBW9M,LGU<YX[3V\3SSFFGW\;!Z O_N,T-?/ICVZT2Q2_S:)G\,[S?"T
MNERH)9VQL6/*AV)RQ9S)SS]Y/?>7)N$@800(5A.U4XK:L=$GEY&0FO]'LQK$
MGDPU5:Q)O9S2S2AI*5U-VGC8,Z-BM2U+0RNW/>S56Y&&5L->URU;U1+IEHET
MK8G<1$O*I2G(^FQG<)RA[;%SAAXT-</$-$5B;AK/1,20D&@J(J-PD-;T%=M<
M_WK]I-,K*>PZ3B(F,ZT:AYB]A_=,:9G,=")YO-AHK=!)+#1#WN"T:9Q9B8>.
M,R!8[?'TRL?3LS\>W\C-Y[QIZC9)::4=.ELA800(5E.Q7ZK8/V8)[$.*"@DC
M0+":J(-2U %("1SLE*W^L.NZ+TI@WJJWW0IW7K8BUAZ],]]AF>_0FN^=*7YQ
M\ZRS!AXZ0"!A! A6$\QSJS6B>\QY5]"!= 6E$2A:7=FMU;=G_UZHQ*3%6MM\
M37+C9XS2B6+S)$0AGS=.R%?0GHN>&95- WUJ#SU80R!:74-<:8A!"EB!J56P
MWDX!:VKE[A0P>Y?>FW)E!3SKHGA"V,HX]B7SC?^3#"VE\,W*"FDV"V(1BL5S
M8_Z@%@"41J!H=3TK%^!UCEK@K";C8&4A:02*5E>VLB7>6WU):C;XRW+7J&9W
M9PWA#1HF*J@Y@*+59:KL@6?W!]/L30^32+(P*V0JX,MF=4"M 2B-0-'J(E;N
MP#NJ/?! _0$HC4#1ZLI6%L&S>X3WS.)=)^!U=OV"_<8'RW0,8^%5SL*S6XO\
M_6DE3[,PH"X#E$:@:/77M97/P$?U&1C49X#2"!2MKFSE,_ K/N/P"5P0MQ?"
MWL[TM=_V8)&.821P922PW4C<FN$7)5&C&$#K_4(U2!J!HM55J[P(/NKO$AC4
ME8#2"!2MKFSE2K#]QXD?>3GP"AKO?S=@CSQ8PF/8#US9#VRW'[?T:>^4AO0/
M4U :@:+55:O<".X==4J#6A10&H&BU96M+ JV+M1_;$K;T5[7,J=!S0@4+=>P
MM;5YP3C@1;8)1*&92&*=_]9?7BTWFEQFVRM>7+_R+DB^7:3"Y+M7;JE<\%BA
MD,T-TCWOF^DE\PTA^8D6RVR+Q*/0QH9GAP&C/I-I _/Y7 B].4EO4&[+F?P/
M4$L#!!0    ( "ZA"%D64 %[DP(  $P&   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;(V576_:,!2&_XJ555,K54W()W00B99],&D:*NMV,>W") =B
MU;$SVX%NOW['"8W82,MNB.WX?9]S3NS#>"?5@RX #'DLN= 3IS"FNG9=G150
M4GTE*Q#X9BU520U.U<;5E0*:-Z*2N[[GQ6Y)F7#2<;.V4.E8UH8S 0M%=%V6
M5/VZ 2YW$V?@/"W<L4UA[(*;CBNZ@268^VJA<.9V+CDK06@F!5&PGCC3P?5-
M8O<W&[XRV.F#,;&9K*1\L)-Y/G$\&Q!PR(QUH/C8PBUP;HTPC)][3Z=#6N'A
M^,G]79,[YK*B&FXE_\9R4TR<H4-R6-.:FSNY^P#[?"+KETFNFU^RV^_U')+5
MVLAR+\8(2B;:)WW<U^% X/O/"/R]P&_B;D%-E#-J:#I6<D>4W8UN=M"DVJ@Q
M.";L1UD:A6\9ZDSZ7LI\QS@G5.3DLRE D;DP5&S8B@.9:@U&7Q*!I^-\B0<B
MKW%5KLFTE,JPW[2I[-M'/"(:R!UP:B G1I)Y#L*P-:/6I<=P+C)>YTQLR (E
MPN@+<CX#0QG'T1EA@GPI9*TQ*#UV#>9IHW6S?4XW;4[^,SE]K,45";Q+XGM^
M2.Z7,W)^=O&WC8MEZFKE=[7R&]_@?VIUE!29,9UQJ6L%Y/MTI8W"$_>C+_J6
M$O93["V\UA7-8.+@-=.@MN"DKU\-8N_-"SD$70[!2^XIEB3JBZE518W*7N1M
M.AR,$MRZ[8&%'2P\!8O[8*TJ/H E\3!,^F%1!XM.P9(^6'0$BX:>'_3#X@X6
MGX(-^V#Q$2P<A<&@'Y9TL.04;-0'2XZ^61B$(_\?F'O0'&R?_435A@E-.*Q1
MYUTE:*#:WM5.C*R:?K&2!KM/,RRPW8.R&_#]6DKS-+$MJ/L#2?\ 4$L#!!0
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MEG<;*!P/9'[+8UGA)4P=_=])$ TXV=<OD]C[.5:%_T3VIB9!7Y-@%WMVCHE
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MXTR)[!YH&0]S)9TSP[%H(VF=E>TTDP;#ZIFT725M@TG?<C?P_^,>6@M0RD?
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MI+@XIUF\2:-=?G+Q/DK3:)N_W'#7XW%F(+Y_B*+TY4W6075:=O$_4$L#!!0
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MXJ3;6=<NK*K]N%@H2\/'/Y;T>8#:&=#Y4BE[NW OZ#XXLC]02P,$%     @
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M*X/6*H9]LU7[WB-:AVB-_+ZB1<*"RV//$ >:/;%<A#PX@H11)(QU7PY-:?9
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MW[Q/N^T?$R?4'X/2@IJF;;=QG<8400AM-8+2")1&H32&HNE:5R:98S;)PFW
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MO9?ER#"ZD0YOD3Y5K]GAFTR^#V4NL27/OHE"96G0*J2;@M,RHX/\765YMO8
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MY>+:LL1D#A$5;;: 6-V9,AY1J8I\9HD%!^HG1E%H$=MVK8@&<6LT2.KN^6C
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M)-3Q)N '@;78&B/M9,;8DYY<9V/+T8*@@%1J!JP>*[B"HM!$2L:?AM-JC]3
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MP@CT\Q7GZN7&O*#_QIK]#U!+ P04    "  NH0A9JV(\UY8"  "Y!@  &0
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M&(+"QXWU]P:+'>I?J5HPH0F'$GG!R2D*J&90-H61*S=KYM+@Y'++)7Y;0%D
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M[WXFS0--#2_CA:S^1[LFK3="V58J7C;!N@0E9?5?_*VIB(, /WHB(&@"@F[
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MESLNJYYXG<-[;4]GVVP I#5G>MNP,@W5**.![4[C5['F]?B^8F81*8N9/G\
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MB$/D#79?C@03EW:YNVL7$(^RKE VV/FAQX(]GWJ)DOS$+OG_!^8^1S"#+BJ
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M1%-1U ;R]UF>5T\G]0TV>[/&_P%02P,$%     @ +J$(68!GL!1F P  L@T
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MJ$Z3U43QHCR0W7"E=ZL<9OH$#L($Z/M+SM7]Q)SQFC-]\A=02P,$%     @
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M^->W$Q-O WX0V,B=,3*5+#A_,Y.'Y<SQC"&@4"BC@/5M#7= J1'2-G[UFLZ
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MJ"!PS9QJ/%060-_74II#QT[05HW+?P%02P,$%     @ +J$(62,ZUJ)@ P
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M:IW6#K7K-FG:!Y,<Q%H24]N![M_/3D(&-(U RKX0V[GG.=]S^'(>;2C[S2,
M@9Z3..5C+1)B=:GK/(@@P;Q#5Y#*-PO*$BSDE"UUOF* PQR4Q+IE&(Z>8))J
M[BA?FS%W1#,1DQ1F#/$L23#[,X&8;L::J6T7[LDR$FI!=T<KO(0'$(^K&9,S
MO6()20(I)S1%#!9C[<J\] ?*/C?X1F##=\9(13*G]+>:W(1CS5 ;@A@"H1BP
M?*QA"G&LB.0VGDI.K7*I@+OC+?MU'KN,98XY3&G\G80B&FL##86PP%DL[NGF
M(Y3Q]!1?0&.>_Z)-8>L,-11D7-"D!,L=)"0MGOBYU&$'8-JO *P28!T"G%<
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M;W)K8F]O:RYX;6S%FUUOVD@4AO^*Q<VVTFH)QC:F:BJE(6TCI0U;HMZN)O8
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M(US87XBJF-NH^=-<:10G:;/J?UE7U7G8=ZVOC"CW/^'=__SXW3]02P,$%
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M"^HM!'H+ZBT$>BOJK01Z*^JM!'HKZJT$>NMDLX1 ;T6]E4!O1;V50&]%O95
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
M+J$(63_(CM;N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ +J$(69E<G",0!@  G"<  !,
M ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  NH0A9VKI_
M*C((   :,@  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ +J$(6?,U^J8P @  J04  !@
M ("!=1   'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( "ZA
M"%E, *5G"0@  +XC   8              " @=L2  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    "  NH0A9M=!AF7$#   P"P  &
M        @($:&P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ +J$(63-[W!4I"   1B4  !@              ("!P1X  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( "ZA"%F260[6; ,  +,*   8
M              " @2 G  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    "  NH0A9HC.'+NH*  "T9   &               @('"*@  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ +J$(6<SW=(J1 @
MS@8  !@              ("!XC4  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( "ZA"%F!GCY-C H  '\P   8              " @:DX
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  NH0A9'M$8
MS 4$  #="   &0              @(%K0P  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( "ZA"%E4K"_WXB$  &YJ   9
M  " @:='  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
M+J$(6:MHA1,A!   3PD  !D              ("!P&D  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    "  NH0A95=%,0B4$   _"0  &0
M            @($8;@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( "ZA"%E#KBT,G@4  $<.   9              " @71R  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ +J$(628X<=C.!
MK0T  !D              ("!27@  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    "  NH0A9=O65@CH#  #,!@  &0              @(%.
M?0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( "ZA"%GC
M9<;-^0H  ),@   9              " @;^   !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ +J$(63%>6X/@!P  :"\  !D
M     ("![XL  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "ZA"%G&"6,@XP,  ",*   9              "
M@0?!  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ +J$(
M64-GUGHG#P  )R<  !D              ("!(<4  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    "  NH0A9N\6A(PH%   0#P  &0
M        @(%_U   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( "ZA"%E@^@&%, 8  &L-   9              " @<#9  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ +J$(6<W+P/!Y!   (@L
M !D              ("!)^   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    "  NH0A9GLD<D1\#  !4!P  &0              @('7Y
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( "ZA"%D6F\0?
M80(  ((&   9              " @2WH  !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ +J$(63T,'<%."0  :CT  !D
M ("!Q>H  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  N
MH0A9-H7#!1$"  #=!   &0              @(%*]   >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( "ZA"%F]7_N?("$  )AK   9
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M970S-BYX;6Q02P$"% ,4    "  NH0A9:Y?X0$<#  #0!@  &0
M    @('7*0$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M "ZA"%G9>'-?HP(  /L%   9              " @54M 0!X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ +J$(6<.FL2VF P  =@@  !D
M             ("!+S ! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    "  NH0A9D*'>R]P%  !U#P  &0              @($,- $ >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( "ZA"%DES7K,)0,
M .<&   9              " @1\Z 0!X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ +J$(60_'GL9'!P  Y1(  !D              ("!
M>ST! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  NH0A9
MAA?^+A((  #)%   &0              @('Y1 $ >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;%!+ 0(4 Q0    ( "ZA"%DO[VTQP@(  /T%   9
M      " @4)- 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%
M  @ +J$(6<<;_LD:!0  "P\  !D              ("!.U ! 'AL+W=O<FMS
M:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  NH0A9.,LSJ]$#  #;!P
M&0              @(&,50$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+
M 0(4 Q0    ( "ZA"%D$=VQ*]04  & J   9              " @919 0!X
M;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ +J$(6>->>RCN
M P  MQ0  !D              ("!P%\! 'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6Q02P$"% ,4    "  NH0A9_+J8ZI@"  #T!@  &0
M@('E8P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( "ZA
M"%F-90JJKP(  ' '   9              " @;1F 0!X;"]W;W)K<VAE971S
M+W-H965T-3 N>&UL4$L! A0#%     @ +J$(6<P4.]_5!   I1P  !D
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M=#4U+GAM;%!+ 0(4 Q0    ( "ZA"%G@#/#$G0(  /H&   9
M  " @=1^ 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @
M+J$(6<P& &8("   .3L  !D              ("!J($! 'AL+W=O<FMS:&5E
M=',O<VAE970U-RYX;6Q02P$"% ,4    "  NH0A9 R:6!9("  "T!@  &0
M            @('GB0$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4
M Q0    ( "ZA"%EVX%U1KP,  )8+   9              " @;", 0!X;"]W
M;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ +J$(66B2#>O. @
MR0@  !D              ("!EI ! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX
M;6Q02P$"% ,4    "  NH0A9K ^%)GL)  "@6P  &0              @(&;
MDP$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( "ZA"%F7
MY2CT/@,  -4.   9              " @4V= 0!X;"]W;W)K<VAE971S+W-H
M965T-C(N>&UL4$L! A0#%     @ +J$(63H;AW*\ @  O <  !D
M     ("!PJ ! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "ZA"%D"(<=U" 4  *H:   9              "
M@23" 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ +J$(
M679L685#!   I!,  !D              ("!8\<! 'AL+W=O<FMS:&5E=',O
M<VAE970V.2YX;6Q02P$"% ,4    "  NH0A9S6SG*YX"  #@!@  &0
M        @('=RP$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0
M   ( "ZA"%D:X?X R@,  -$-   9              " @;+. 0!X;"]W;W)K
M<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ +J$(62#^*^GE @  3@@
M !D              ("!L](! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q0
M2P$"% ,4    "  NH0A9^OJRW*D#  #,#0  &0              @('/U0$
M>&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( "ZA"%F_N< S
M'00  &\-   9              " @:_9 0!X;"]W;W)K<VAE971S+W-H965T
M-S0N>&UL4$L! A0#%     @ +J$(6:MB/->6 @  N08  !D
M ("! ]X! 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    "  N
MH0A9EY9T:BT%  #W$P  &0              @('0X $ >&PO=V]R:W-H965T
M<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( "ZA"%G[C@R*S@<  /T^   9
M          " @33F 0!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#
M%     @ +J$(67LIRUHF @  J 0  !D              ("!.>X! 'AL+W=O
M<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4    "  NH0A9W!1F>W$(  "3
M-   &0              @(&6\ $ >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM
M;%!+ 0(4 Q0    ( "ZA"%F4_7E9V08  *<U   9              " @3[Y
M 0!X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ +J$(68!G
ML!1F P  L@T  !D              ("!3@ " 'AL+W=O<FMS:&5E=',O<VAE
M970X,2YX;6Q02P$"% ,4    "  NH0A99/L_P7 #  #?#P  &0
M    @('K P( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    (
M "ZA"%F9#=$?M0,  .$2   9              " @9(' @!X;"]W;W)K<VAE
M971S+W-H965T.#,N>&UL4$L! A0#%     @ +J$(66L%).I0 P  X L  !D
M             ("!?@L" 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"
M% ,4    "  NH0A9,P='!I8"  #B!@  &0              @($%#P( >&PO
M=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( "ZA"%G<@5/$  4
M -D?   9              " @=(1 @!X;"]W;W)K<VAE971S+W-H965T.#8N
M>&UL4$L! A0#%     @ +J$(62Y4WTMO P  00H  !D              ("!
M"1<" 'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q02P$"% ,4    "  NH0A9
M(SK6HF #   B"P  &0              @(&O&@( >&PO=V]R:W-H965T<R]S
M:&5E=#@X+GAM;%!+ 0(4 Q0    ( "ZA"%E,_7_KB@,  'X.   9
M      " @48> @!X;"]W;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%
M  @ +J$(61HJ+MPQ P  C@T  !D              ("!!R(" 'AL+W=O<FMS
M:&5E=',O<VAE970Y,"YX;6Q02P$"% ,4    "  NH0A9M;VL:5<&   4,0
M&0              @(%O)0( >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+
M 0(4 Q0    ( "ZA"%GED0,"J0,  /$2   9              " @?TK @!X
M;"]W;W)K<VAE971S+W-H965T.3(N>&UL4$L! A0#%     @ +J$(62)6XVI6
M P  GPD  !D              ("!W2\" 'AL+W=O<FMS:&5E=',O<VAE970Y
M,RYX;6Q02P$"% ,4    "  NH0A9:_@#]E,#  "N%0  #0
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:+GAM;%!+!08     90!E +H;  #*0P(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>329</ContextCount>
  <ElementCount>506</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>105</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ConsolidatedStatementsofIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Statement - Consolidated Statements of Stockholders??? Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - New Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/NewAccountingPronouncements</Role>
      <ShortName>New Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Supplemental Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SupplementalBalanceSheetInformation</Role>
      <ShortName>Supplemental Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Goodwill and Other Intangible Assets, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnet</Role>
      <ShortName>Goodwill and Other Intangible Assets, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Employee Retirement Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/EmployeeRetirementPlans</Role>
      <ShortName>Employee Retirement Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Legal Actions, Contingencies and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/LegalActionsContingenciesandCommitments</Role>
      <ShortName>Legal Actions, Contingencies and Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Derivative Instruments and Hedging Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivities</Role>
      <ShortName>Derivative Instruments and Hedging Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9952175 - Disclosure - Restructuring Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/RestructuringExpenses</Role>
      <ShortName>Restructuring Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9952176 - Disclosure - Schedule II Valuation and Qualifying Accounts and Reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReserves</Role>
      <ShortName>Schedule II Valuation and Qualifying Accounts and Reserves</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Supplemental Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables</Role>
      <ShortName>Supplemental Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SupplementalBalanceSheetInformation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Goodwill and Other Intangible Assets, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables</Role>
      <ShortName>Goodwill and Other Intangible Assets, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnet</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/Investments</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/AccruedExpenses</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/Debt</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/Leases</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/StockholdersEquity</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/EarningsPerShare</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/IncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SegmentInformation</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Legal Actions, Contingencies and Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsTables</Role>
      <ShortName>Legal Actions, Contingencies and Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/LegalActionsContingenciesandCommitments</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Derivative Instruments and Hedging Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesTables</Role>
      <ShortName>Derivative Instruments and Hedging Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivities</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/BusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/BusinessCombinations</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Summary of Significant Accounting Policies (Summary of Contract Balances) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Summary of Contract Balances) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Supplemental Balance Sheet Information (Schedule of Inventories) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails</Role>
      <ShortName>Supplemental Balance Sheet Information (Schedule of Inventories) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Supplemental Balance Sheet Information (Schedule of Prepaid Expenses and Other Current Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Supplemental Balance Sheet Information (Schedule of Prepaid Expenses and Other Current Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Supplemental Balance Sheet Information (Components of Property, Plant and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Supplemental Balance Sheet Information (Components of Property, Plant and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Goodwill and Other Intangible Assets, net (Schedule of Changes in Carrying Amount of Goodwill) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets, net (Schedule of Changes in Carrying Amount of Goodwill) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Goodwill and Other Intangible Assets, net (Schedule of Other Intangible Assets, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets, net (Schedule of Other Intangible Assets, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Goodwill and Other Intangible Assets, net (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets, net (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Goodwill and Other Intangible Assets, net (Schedule of Amortization Expense Related to Identifiable Intangible Assets, Including Patents) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofAmortizationExpenseRelatedtoIdentifiableIntangibleAssetsIncludingPatentsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets, net (Schedule of Amortization Expense Related to Identifiable Intangible Assets, Including Patents) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Investments (Schedule of Investments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails</Role>
      <ShortName>Investments (Schedule of Investments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/InvestmentsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Investments (Schedule of Changes In Equity Investments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails</Role>
      <ShortName>Investments (Schedule of Changes In Equity Investments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/InvestmentsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Investments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/InvestmentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/AccruedExpensesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Debt (Schedule of Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/DebtScheduleofDebtDetails</Role>
      <ShortName>Debt (Schedule of Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/DebtTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Debt (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/DebtTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/LeasesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Leases (Schedule of Future Minimum Lease Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases (Schedule of Future Minimum Lease Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/LeasesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Leases (Schedule of Operating Lease Disclosure) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/LeasesScheduleofOperatingLeaseDisclosureDetails</Role>
      <ShortName>Leases (Schedule of Operating Lease Disclosure) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/LeasesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Stockholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/StockholdersEquityTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Stockholders' Equity (Schedule of Activity of Restricted Stock Units) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails</Role>
      <ShortName>Stockholders' Equity (Schedule of Activity of Restricted Stock Units) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/StockholdersEquityTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Stockholders' Equity (Schedule of Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity (Schedule of Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/StockholdersEquityTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Stockholders' Equity (Schedule of Assumptions for Fair Value of Stock Option Plans and Purchase Rights Granted) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails</Role>
      <ShortName>Stockholders' Equity (Schedule of Assumptions for Fair Value of Stock Option Plans and Purchase Rights Granted) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/StockholdersEquityTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Stockholders' Equity (Schedule of Total Stock-Based Compensation Costs Incurred and Associated Tax Benefit Recognized) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails</Role>
      <ShortName>Stockholders' Equity (Schedule of Total Stock-Based Compensation Costs Incurred and Associated Tax Benefit Recognized) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/StockholdersEquityTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Earnings Per Share (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/EarningsPerShareNarrativeDetails</Role>
      <ShortName>Earnings Per Share (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/EarningsPerShareTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Earnings Per Share (Schedule of Basic and Diluted Earnings Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Schedule of Basic and Diluted Earnings Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/EarningsPerShareTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Income Taxes (Schedule of Income Before Income Taxes Under the Jurisdictions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesUndertheJurisdictionsDetails</Role>
      <ShortName>Income Taxes (Schedule of Income Before Income Taxes Under the Jurisdictions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/IncomeTaxesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Income Taxes (Schedule of Provision for Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Schedule of Provision for Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/IncomeTaxesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Income Taxes (Schedule of Provision for Income Tax Differ From the Amount of Income Tax) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails</Role>
      <ShortName>Income Taxes (Schedule of Provision for Income Tax Differ From the Amount of Income Tax) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/IncomeTaxesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities Classified as Current and Non-Current) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesClassifiedasCurrentandNonCurrentDetails</Role>
      <ShortName>Income Taxes (Schedule of Deferred Tax Assets and Liabilities Classified as Current and Non-Current) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/IncomeTaxesTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Income Taxes (Components of Deferred Tax Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes (Components of Deferred Tax Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/IncomeTaxesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/IncomeTaxesTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Segment Information (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SegmentInformationTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Segment Information (Summary of Revenue by Segment and Reconciling Items) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails</Role>
      <ShortName>Segment Information (Summary of Revenue by Segment and Reconciling Items) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SegmentInformationTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Segment Information (Schedule of Revenue by Segment, Product, and Region) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails</Role>
      <ShortName>Segment Information (Schedule of Revenue by Segment, Product, and Region) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SegmentInformationTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Segment Information (Schedule of Revenue by Geographic Area) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebyGeographicAreaDetails</Role>
      <ShortName>Segment Information (Schedule of Revenue by Geographic Area) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SegmentInformationTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Segment Information (Schedule of Long-Lived Assets by Geographic Areas) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SegmentInformationScheduleofLongLivedAssetsbyGeographicAreasDetails</Role>
      <ShortName>Segment Information (Schedule of Long-Lived Assets by Geographic Areas) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SegmentInformationTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Employee Retirement Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/EmployeeRetirementPlansDetails</Role>
      <ShortName>Employee Retirement Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/EmployeeRetirementPlans</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Legal Actions, Contingencies and Commitments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsNarrativeDetails</Role>
      <ShortName>Legal Actions, Contingencies and Commitments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - Legal Actions, Contingencies and Commitments (Obligations Under Purchase Agreements) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails</Role>
      <ShortName>Legal Actions, Contingencies and Commitments (Obligations Under Purchase Agreements) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - Derivative Instruments and Hedging Activities (Schedule of Fair Values of Derivative Instruments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments and Hedging Activities (Schedule of Fair Values of Derivative Instruments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - Derivative Instruments and Hedging Activities (Schedule of Fair Value Hedge Gains (Losses)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails</Role>
      <ShortName>Derivative Instruments and Hedging Activities (Schedule of Fair Value Hedge Gains (Losses)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - Derivative Instruments and Hedging Activities (Schedule of Net Investment Hedge Gains (Losses)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails</Role>
      <ShortName>Derivative Instruments and Hedging Activities (Schedule of Net Investment Hedge Gains (Losses)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - Derivative Instruments and Hedging Activities (Schedule of Non-designated Derivative Gains (Losses)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails</Role>
      <ShortName>Derivative Instruments and Hedging Activities (Schedule of Non-designated Derivative Gains (Losses)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9954529 - Disclosure - Business Combinations (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/BusinessCombinationsNarrativeDetails</Role>
      <ShortName>Business Combinations (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/BusinessCombinationsTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9954530 - Disclosure - Business Combinations (Schedule of Tangible and Identifiable Intangible Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails</Role>
      <ShortName>Business Combinations (Schedule of Tangible and Identifiable Intangible Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/BusinessCombinationsTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9954531 - Disclosure - Restructuring Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/RestructuringExpensesDetails</Role>
      <ShortName>Restructuring Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/RestructuringExpenses</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="rmd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9954532 - Disclosure - Schedule II Valuation and Qualifying Accounts and Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails</Role>
      <ShortName>Schedule II Valuation and Qualifying Accounts and Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReserves</ParentRole>
      <Position>93</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="rmd-20240630.htm">rmd-20240630.htm</File>
    <File>rmd-20240630.xsd</File>
    <File>rmd-20240630_cal.xml</File>
    <File>rmd-20240630_def.xml</File>
    <File>rmd-20240630_lab.xml</File>
    <File>rmd-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>rmd-20240630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="4">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="1200">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="47">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>123
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "rmd-20240630.htm": {
   "nsprefix": "rmd",
   "nsuri": "http://investor.resmed.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "rmd-20240630.htm"
     ]
    },
    "schema": {
     "local": [
      "rmd-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "rmd-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rmd-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "rmd-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rmd-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 450,
   "keyCustom": 56,
   "axisStandard": 31,
   "axisCustom": 0,
   "memberStandard": 54,
   "memberCustom": 44,
   "hidden": {
    "total": 24,
    "http://fasb.org/us-gaap/2024": 13,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://xbrl.sec.gov/ecd/2024": 6
   },
   "contextCount": 329,
   "entityCount": 1,
   "segmentCount": 105,
   "elementCount": 863,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 1200,
    "http://xbrl.sec.gov/ecd/2024": 47,
    "http://xbrl.sec.gov/dei/2024": 40,
    "http://fasb.org/srt/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://investor.resmed.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://investor.resmed.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
     "longName": "9952153 - Statement - Consolidated Statements of Income",
     "shortName": "Consolidated Statements of Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://investor.resmed.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "longName": "9952154 - Statement - Consolidated Statements of Comprehensive Income",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity",
     "longName": "9952155 - Statement - Consolidated Statements of Stockholders\u2019 Equity",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "longName": "9952156 - Statement - Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952157 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    },
    "R10": {
     "role": "http://investor.resmed.com/role/OrganizationandBasisofPresentation",
     "longName": "9952158 - Disclosure - Organization and Basis of Presentation",
     "shortName": "Organization and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://investor.resmed.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952159 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://investor.resmed.com/role/NewAccountingPronouncements",
     "longName": "9952160 - Disclosure - New Accounting Pronouncements",
     "shortName": "New Accounting Pronouncements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://investor.resmed.com/role/SupplementalBalanceSheetInformation",
     "longName": "9952161 - Disclosure - Supplemental Balance Sheet Information",
     "shortName": "Supplemental Balance Sheet Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnet",
     "longName": "9952162 - Disclosure - Goodwill and Other Intangible Assets, net",
     "shortName": "Goodwill and Other Intangible Assets, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://investor.resmed.com/role/Investments",
     "longName": "9952163 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://investor.resmed.com/role/AccruedExpenses",
     "longName": "9952164 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://investor.resmed.com/role/Debt",
     "longName": "9952165 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://investor.resmed.com/role/Leases",
     "longName": "9952166 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://investor.resmed.com/role/StockholdersEquity",
     "longName": "9952167 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://investor.resmed.com/role/EarningsPerShare",
     "longName": "9952168 - Disclosure - Earnings Per Share",
     "shortName": "Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://investor.resmed.com/role/IncomeTaxes",
     "longName": "9952169 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://investor.resmed.com/role/SegmentInformation",
     "longName": "9952170 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://investor.resmed.com/role/EmployeeRetirementPlans",
     "longName": "9952171 - Disclosure - Employee Retirement Plans",
     "shortName": "Employee Retirement Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://investor.resmed.com/role/LegalActionsContingenciesandCommitments",
     "longName": "9952172 - Disclosure - Legal Actions, Contingencies and Commitments",
     "shortName": "Legal Actions, Contingencies and Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivities",
     "longName": "9952173 - Disclosure - Derivative Instruments and Hedging Activities",
     "shortName": "Derivative Instruments and Hedging Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://investor.resmed.com/role/BusinessCombinations",
     "longName": "9952174 - Disclosure - Business Combinations",
     "shortName": "Business Combinations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://investor.resmed.com/role/RestructuringExpenses",
     "longName": "9952175 - Disclosure - Restructuring Expenses",
     "shortName": "Restructuring Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReserves",
     "longName": "9952176 - Disclosure - Schedule II Valuation and Qualifying Accounts and Reserves",
     "shortName": "Schedule II Valuation and Qualifying Accounts and Reserves",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "rmd:OrganizationAndBasisOfPresentationPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "rmd:OrganizationAndBasisOfPresentationPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables",
     "longName": "9954473 - Disclosure - Supplemental Balance Sheet Information (Tables)",
     "shortName": "Supplemental Balance Sheet Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables",
     "longName": "9954474 - Disclosure - Goodwill and Other Intangible Assets, net (Tables)",
     "shortName": "Goodwill and Other Intangible Assets, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://investor.resmed.com/role/InvestmentsTables",
     "longName": "9954475 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "rmd:ScheduleOfInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "rmd:ScheduleOfInvestmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://investor.resmed.com/role/AccruedExpensesTables",
     "longName": "9954476 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://investor.resmed.com/role/DebtTables",
     "longName": "9954477 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://investor.resmed.com/role/LeasesTables",
     "longName": "9954478 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://investor.resmed.com/role/StockholdersEquityTables",
     "longName": "9954479 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://investor.resmed.com/role/EarningsPerShareTables",
     "longName": "9954480 - Disclosure - Earnings Per Share (Tables)",
     "shortName": "Earnings Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://investor.resmed.com/role/IncomeTaxesTables",
     "longName": "9954481 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://investor.resmed.com/role/SegmentInformationTables",
     "longName": "9954482 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsTables",
     "longName": "9954483 - Disclosure - Legal Actions, Contingencies and Commitments (Tables)",
     "shortName": "Legal Actions, Contingencies and Commitments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesTables",
     "longName": "9954484 - Disclosure - Derivative Instruments and Hedging Activities (Tables)",
     "shortName": "Derivative Instruments and Hedging Activities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://investor.resmed.com/role/BusinessCombinationsTables",
     "longName": "9954485 - Disclosure - Business Combinations (Tables)",
     "shortName": "Business Combinations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9954486 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)",
     "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails",
     "longName": "9954487 - Disclosure - Summary of Significant Accounting Policies (Summary of Contract Balances) (Details)",
     "shortName": "Summary of Significant Accounting Policies (Summary of Contract Balances) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-51",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails",
     "longName": "9954488 - Disclosure - Supplemental Balance Sheet Information (Schedule of Inventories) (Details)",
     "shortName": "Supplemental Balance Sheet Information (Schedule of Inventories) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails",
     "longName": "9954489 - Disclosure - Supplemental Balance Sheet Information (Schedule of Prepaid Expenses and Other Current Assets) (Details)",
     "shortName": "Supplemental Balance Sheet Information (Schedule of Prepaid Expenses and Other Current Assets) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PrepaidTaxes",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PrepaidTaxes",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails",
     "longName": "9954490 - Disclosure - Supplemental Balance Sheet Information (Components of Property, Plant and Equipment) (Details)",
     "shortName": "Supplemental Balance Sheet Information (Components of Property, Plant and Equipment) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails",
     "longName": "9954491 - Disclosure - Goodwill and Other Intangible Assets, net (Schedule of Changes in Carrying Amount of Goodwill) (Details)",
     "shortName": "Goodwill and Other Intangible Assets, net (Schedule of Changes in Carrying Amount of Goodwill) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails",
     "longName": "9954492 - Disclosure - Goodwill and Other Intangible Assets, net (Schedule of Other Intangible Assets, Net) (Details)",
     "shortName": "Goodwill and Other Intangible Assets, net (Schedule of Other Intangible Assets, Net) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-91",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
     "longName": "9954493 - Disclosure - Goodwill and Other Intangible Assets, net (Narrative) (Details)",
     "shortName": "Goodwill and Other Intangible Assets, net (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-100",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofAmortizationExpenseRelatedtoIdentifiableIntangibleAssetsIncludingPatentsDetails",
     "longName": "9954494 - Disclosure - Goodwill and Other Intangible Assets, net (Schedule of Amortization Expense Related to Identifiable Intangible Assets, Including Patents) (Details)",
     "shortName": "Goodwill and Other Intangible Assets, net (Schedule of Amortization Expense Related to Identifiable Intangible Assets, Including Patents) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails",
     "longName": "9954495 - Disclosure - Investments (Schedule of Investments) (Details)",
     "shortName": "Investments (Schedule of Investments) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "rmd:MarketableEquityInvestmentsFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rmd:ScheduleOfInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "rmd:MarketableEquityInvestmentsFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rmd:ScheduleOfInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails",
     "longName": "9954496 - Disclosure - Investments (Schedule of Changes In Equity Investments) (Details)",
     "shortName": "Investments (Schedule of Changes In Equity Investments) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "rmd:EquityInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "rmd:AdditionalEquityInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rmd:ScheduleOfChangesInEquityInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://investor.resmed.com/role/InvestmentsNarrativeDetails",
     "longName": "9954497 - Disclosure - Investments (Narrative) (Details)",
     "shortName": "Investments (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://investor.resmed.com/role/AccruedExpensesDetails",
     "longName": "9954498 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ProductWarrantyAccrualClassifiedCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ProductWarrantyAccrualClassifiedCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://investor.resmed.com/role/DebtScheduleofDebtDetails",
     "longName": "9954499 - Disclosure - Debt (Schedule of Debt) (Details)",
     "shortName": "Debt (Schedule of Debt) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "rmd:ShortTermDebtGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "rmd:ShortTermDebtGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://investor.resmed.com/role/DebtNarrativeDetails",
     "longName": "9954500 - Disclosure - Debt (Narrative) (Details)",
     "shortName": "Debt (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "rmd:DebtToConsolidatedEbitdaRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "rmd:DebtToConsolidatedEbitdaRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://investor.resmed.com/role/LeasesNarrativeDetails",
     "longName": "9954501 - Disclosure - Leases (Narrative) (Details)",
     "shortName": "Leases (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails",
     "longName": "9954502 - Disclosure - Leases (Schedule of Future Minimum Lease Payments) (Details)",
     "shortName": "Leases (Schedule of Future Minimum Lease Payments) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://investor.resmed.com/role/LeasesScheduleofOperatingLeaseDisclosureDetails",
     "longName": "9954503 - Disclosure - Leases (Schedule of Operating Lease Disclosure) (Details)",
     "shortName": "Leases (Schedule of Operating Lease Disclosure) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rmd:ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rmd:ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
     "longName": "9954504 - Disclosure - Stockholders' Equity (Narrative) (Details)",
     "shortName": "Stockholders' Equity (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-137",
      "name": "srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-137",
      "name": "srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails",
     "longName": "9954505 - Disclosure - Stockholders' Equity (Schedule of Activity of Restricted Stock Units) (Details)",
     "shortName": "Stockholders' Equity (Schedule of Activity of Restricted Stock Units) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-149",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-151",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails",
     "longName": "9954506 - Disclosure - Stockholders' Equity (Schedule of Option Activity) (Details)",
     "shortName": "Stockholders' Equity (Schedule of Option Activity) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails",
     "longName": "9954507 - Disclosure - Stockholders' Equity (Schedule of Assumptions for Fair Value of Stock Option Plans and Purchase Rights Granted) (Details)",
     "shortName": "Stockholders' Equity (Schedule of Assumptions for Fair Value of Stock Option Plans and Purchase Rights Granted) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-153",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-153",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails",
     "longName": "9954508 - Disclosure - Stockholders' Equity (Schedule of Total Stock-Based Compensation Costs Incurred and Associated Tax Benefit Recognized) (Details)",
     "shortName": "Stockholders' Equity (Schedule of Total Stock-Based Compensation Costs Incurred and Associated Tax Benefit Recognized) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://investor.resmed.com/role/EarningsPerShareNarrativeDetails",
     "longName": "9954509 - Disclosure - Earnings Per Share (Narrative) (Details)",
     "shortName": "Earnings Per Share (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails",
     "longName": "9954510 - Disclosure - Earnings Per Share (Schedule of Basic and Diluted Earnings Per Share) (Details)",
     "shortName": "Earnings Per Share (Schedule of Basic and Diluted Earnings Per Share) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://investor.resmed.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesUndertheJurisdictionsDetails",
     "longName": "9954511 - Disclosure - Income Taxes (Schedule of Income Before Income Taxes Under the Jurisdictions) (Details)",
     "shortName": "Income Taxes (Schedule of Income Before Income Taxes Under the Jurisdictions) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails",
     "longName": "9954512 - Disclosure - Income Taxes (Schedule of Provision for Income Taxes) (Details)",
     "shortName": "Income Taxes (Schedule of Provision for Income Taxes) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails",
     "longName": "9954513 - Disclosure - Income Taxes (Schedule of Provision for Income Tax Differ From the Amount of Income Tax) (Details)",
     "shortName": "Income Taxes (Schedule of Provision for Income Tax Differ From the Amount of Income Tax) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://investor.resmed.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesClassifiedasCurrentandNonCurrentDetails",
     "longName": "9954514 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities Classified as Current and Non-Current) (Details)",
     "shortName": "Income Taxes (Schedule of Deferred Tax Assets and Liabilities Classified as Current and Non-Current) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rmd:ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R76": {
     "role": "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9954515 - Disclosure - Income Taxes (Components of Deferred Tax Assets and Liabilities) (Details)",
     "shortName": "Income Taxes (Components of Deferred Tax Assets and Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9954516 - Disclosure - Income Taxes (Narrative) (Details)",
     "shortName": "Income Taxes (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxHolidayAggregateDollarAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxHolidayAggregateDollarAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://investor.resmed.com/role/SegmentInformationNarrativeDetails",
     "longName": "9954517 - Disclosure - Segment Information (Narrative) (Details)",
     "shortName": "Segment Information (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R79": {
     "role": "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails",
     "longName": "9954518 - Disclosure - Segment Information (Summary of Revenue by Segment and Reconciling Items) (Details)",
     "shortName": "Segment Information (Summary of Revenue by Segment and Reconciling Items) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-207",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails",
     "longName": "9954519 - Disclosure - Segment Information (Schedule of Revenue by Segment, Product, and Region) (Details)",
     "shortName": "Segment Information (Schedule of Revenue by Segment, Product, and Region) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-243",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rmd:ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebyGeographicAreaDetails",
     "longName": "9954520 - Disclosure - Segment Information (Schedule of Revenue by Geographic Area) (Details)",
     "shortName": "Segment Information (Schedule of Revenue by Geographic Area) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-246",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://investor.resmed.com/role/SegmentInformationScheduleofLongLivedAssetsbyGeographicAreasDetails",
     "longName": "9954521 - Disclosure - Segment Information (Schedule of Long-Lived Assets by Geographic Areas) (Details)",
     "shortName": "Segment Information (Schedule of Long-Lived Assets by Geographic Areas) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://investor.resmed.com/role/EmployeeRetirementPlansDetails",
     "longName": "9954522 - Disclosure - Employee Retirement Plans (Details)",
     "shortName": "Employee Retirement Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-260",
      "name": "rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-260",
      "name": "rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsNarrativeDetails",
     "longName": "9954523 - Disclosure - Legal Actions, Contingencies and Commitments (Narrative) (Details)",
     "shortName": "Legal Actions, Contingencies and Commitments (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-270",
      "name": "rmd:NumberOfPatents",
      "unitRef": "patent",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-270",
      "name": "rmd:NumberOfPatents",
      "unitRef": "patent",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails",
     "longName": "9954524 - Disclosure - Legal Actions, Contingencies and Commitments (Obligations Under Purchase Agreements) (Details)",
     "shortName": "Legal Actions, Contingencies and Commitments (Obligations Under Purchase Agreements) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PurchaseObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails",
     "longName": "9954525 - Disclosure - Derivative Instruments and Hedging Activities (Schedule of Fair Values of Derivative Instruments) (Details)",
     "shortName": "Derivative Instruments and Hedging Activities (Schedule of Fair Values of Derivative Instruments) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails",
     "longName": "9954526 - Disclosure - Derivative Instruments and Hedging Activities (Schedule of Fair Value Hedge Gains (Losses)) (Details)",
     "shortName": "Derivative Instruments and Hedging Activities (Schedule of Fair Value Hedge Gains (Losses)) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-283",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-283",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails",
     "longName": "9954527 - Disclosure - Derivative Instruments and Hedging Activities (Schedule of Net Investment Hedge Gains (Losses)) (Details)",
     "shortName": "Derivative Instruments and Hedging Activities (Schedule of Net Investment Hedge Gains (Losses)) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-286",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-286",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails",
     "longName": "9954528 - Disclosure - Derivative Instruments and Hedging Activities (Schedule of Non-designated Derivative Gains (Losses)) (Details)",
     "shortName": "Derivative Instruments and Hedging Activities (Schedule of Non-designated Derivative Gains (Losses)) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://investor.resmed.com/role/BusinessCombinationsNarrativeDetails",
     "longName": "9954529 - Disclosure - Business Combinations (Narrative) (Details)",
     "shortName": "Business Combinations (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-298",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails",
     "longName": "9954530 - Disclosure - Business Combinations (Schedule of Tangible and Identifiable Intangible Assets and Liabilities) (Details)",
     "shortName": "Business Combinations (Schedule of Tangible and Identifiable Intangible Assets and Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-298",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://investor.resmed.com/role/RestructuringExpensesDetails",
     "longName": "9954531 - Disclosure - Restructuring Expenses (Details)",
     "shortName": "Restructuring Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:RestructuringReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails",
     "longName": "9954532 - Disclosure - Schedule II Valuation and Qualifying Accounts and Reserves (Details)",
     "shortName": "Schedule II Valuation and Qualifying Accounts and Reserves (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-310",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-315",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rmd-20240630.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "country_AU": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "AU",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleofLongLivedAssetsbyGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Australia",
        "label": "AUSTRALIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r87",
      "r92",
      "r1308"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r1048"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable, net of allowances of $21,132 and $23,603 \u200eat June\u00a030, 2024 and June\u00a030, 2023, respectively",
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1216"
     ]
    },
    "rmd_AccountsReceivableNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "AccountsReceivableNetMember",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable Net [Member]",
        "documentation": "Accounts Receivable Net [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income taxes payable (note 12)",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r153"
     ]
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term income taxes payable (note 12)",
        "label": "Accrued Income Taxes, Noncurrent",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r153"
     ]
    },
    "rmd_AccruedInventoryInTransit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "AccruedInventoryInTransit",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory in transit",
        "label": "Accrued Inventory In Transit",
        "documentation": "Accrued inventory in transit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://investor.resmed.com/role/AccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesDetails",
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses (note 7)",
        "totalLabel": "Total accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesMember",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities [Member]",
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "rmd_AccruedLogisticsAndOccupancyExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "AccruedLogisticsAndOccupancyExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Logistics and occupancy costs",
        "label": "Accrued Logistics And Occupancy Expenses Current",
        "documentation": "Accrued Logistics And Occupancy Expenses Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedMarketingCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promotional and marketing",
        "label": "Accrued Marketing Costs, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting and professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r232",
      "r827"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r105",
      "r237",
      "r823",
      "r868",
      "r871"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated \u200eOther \u200eComprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r16",
      "r27",
      "r687",
      "r690",
      "r739",
      "r864",
      "r865",
      "r1186",
      "r1187",
      "r1188",
      "r1203",
      "r1204",
      "r1205",
      "r1206"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets - useful life",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r984"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "rmd_AdditionalEquityInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "AdditionalEquityInvestments",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions to investments",
        "label": "Additional Equity Investments",
        "documentation": "Additional Equity Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional \u200ePaid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1323",
      "r1392"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to reconcile net income to net cash provided by operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1161"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1096",
      "r1106",
      "r1139"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1088",
      "r1099",
      "r1109",
      "r1142"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1162"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1089",
      "r1100",
      "r1110",
      "r1134",
      "r1143",
      "r1147",
      "r1155"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1153"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Stock-based compensation costs",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r622"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Stock-based compensation costs, net of tax benefit",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForCreditLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForCreditLossMember",
     "presentation": [
      "http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for trade accounts receivable",
        "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]",
        "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, allowance for credit loss, current",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r351",
      "r393"
     ]
    },
    "rmd_AmendedAndRestated2009PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "AmendedAndRestated2009PlanMember",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended and Restated 2009 Plan",
        "label": "Amended And Restated2009 Plan [Member]",
        "documentation": "Amended And Restated 2009 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "rmd_AmortizationOfAcquiredIntangibleAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "AmortizationOfAcquiredIntangibleAssets1",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of acquired intangible assets",
        "verboseLabel": "Amortization of acquired intangible assets",
        "label": "Amortization Of Acquired Intangible Assets 1",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_CostOfGoodsAndServicesSold",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization of acquired intangible assets",
        "terseLabel": "Amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r420",
      "r427",
      "r1014"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://investor.resmed.com/role/EarningsPerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r163",
      "r236",
      "r270",
      "r313",
      "r319",
      "r337",
      "r341",
      "r388",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r673",
      "r675",
      "r708",
      "r820",
      "r917",
      "r1005",
      "r1006",
      "r1048",
      "r1074",
      "r1272",
      "r1273",
      "r1347"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r242",
      "r270",
      "r388",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r673",
      "r675",
      "r708",
      "r1048",
      "r1272",
      "r1273",
      "r1347"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r388",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r673",
      "r675",
      "r708",
      "r1272",
      "r1273",
      "r1347"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets:",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_AstralFieldActionNotificationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "AstralFieldActionNotificationExpenses",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Astral field safety notification expenses",
        "label": "Astral Field Action Notification Expenses",
        "documentation": "Astral Field Action Notification Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://investor.resmed.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1079",
      "r1080",
      "r1092"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://investor.resmed.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1079",
      "r1080",
      "r1092"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://investor.resmed.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1079",
      "r1080",
      "r1092"
     ]
    },
    "us-gaap_AustralianTaxationOfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AustralianTaxationOfficeMember",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Australian Taxation Office",
        "label": "Australian Taxation Office [Member]",
        "documentation": "Designated tax department of the government of Australia."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1151"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1146"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1146"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1146"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1146"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1146"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1146"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1148"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1147"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1147"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r1359",
      "r1360"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r441",
      "r1359",
      "r1360"
     ]
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BaseRateMember",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Rate",
        "label": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors Chairman",
        "label": "Board of Directors Chairman [Member]",
        "documentation": "Leader of board of directors."
       }
      }
     },
     "auth_ref": [
      "r1215"
     ]
    },
    "rmd_BrettA.SandercockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "BrettA.SandercockMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brett A. Sandercock [Member]",
        "documentation": "Brett A. Sandercock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingMember",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsNarrativeDetails",
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r668",
      "r1027",
      "r1028"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsNarrativeDetails",
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r61",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r668",
      "r1027",
      "r1028"
     ]
    },
    "rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "BusinessAcquisitionContingentConsiderationRecognizedLiability",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Fair value of contingent consideration",
        "label": "Business Acquisition, Contingent Consideration, Recognized Liability",
        "documentation": "Business Acquisition, Contingent Consideration, Recognized Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsNarrativeDetails",
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of business acquired",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsNarrativeDetails",
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition related expenses",
        "label": "Business Combination, Acquisition Related Costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r13"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Business Combinations",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r669"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts payable and accrued expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable And Accrued Expenses",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable And Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred revenue",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred tax liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "rmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investment",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity Method Investment",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity Method Investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Identifiable intangible assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Purchase price",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r144"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r230",
      "r988"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r123",
      "r266"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r123"
     ]
    },
    "us-gaap_CashFlowHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowHedgingMember",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Designated Hedges",
        "label": "Cash Flow Hedging [Member]",
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) recognized on intercompany debt in other, net",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1122"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1120"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_ClinicalDemonstrationAndRentalEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "ClinicalDemonstrationAndRentalEquipmentMember",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical, demonstration and rental equipment",
        "label": "Clinical Demonstration And Rental Equipment [Member]",
        "documentation": "Clinical, Demonstration and Rental Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "rmd_CombinedEuropeAsiaAndOtherMarketsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "CombinedEuropeAsiaAndOtherMarketsMember",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Combined Europe, Asia and other markets",
        "label": "Combined Europe Asia And Other Markets [Member]",
        "documentation": "Combined Europe Asia And Other Markets [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments and contingencies (note 15)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r155",
      "r821",
      "r904"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r972"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend declared per share (in dollars per share)",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1066",
      "r1067",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1203",
      "r1204",
      "r1206",
      "r1323",
      "r1390",
      "r1392"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r905"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Common stock, shares outstanding, beginning balance (in shares)",
        "periodEndLabel": "Common stock, shares outstanding, ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r96",
      "r905",
      "r923",
      "r1392",
      "r1393"
     ]
    },
    "us-gaap_CommonStockSharesSubscriptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesSubscriptions",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock shares subscribed",
        "label": "Common Stock, Value, Subscriptions",
        "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r96"
     ]
    },
    "us-gaap_CommonStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValueOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, $0.004 par value, 350,000,000 shares authorized; \u200e189,565,112 issued and 146,901,045 outstanding at June\u00a030, 2024 and \u200e188,900,583 issued and 147,064,349 outstanding at June\u00a030, 2023",
        "label": "Common Stock, Value, Outstanding",
        "documentation": "Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r905"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1131"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities Classified as Current and Non-Current",
        "label": "Components Of Net Deferred Income Tax Assets And Liabilities [Table Text Block]",
        "documentation": "Components Of Net Deferred Income Tax Assets and Liabilities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r250",
      "r252",
      "r258",
      "r816",
      "r834",
      "r835"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_ComputerEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "ComputerEquipmentAndSoftwareMember",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment and software",
        "label": "Computer Equipment and Software [Member]",
        "documentation": "Computer Equipment and Software"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk and Significant Customers",
        "label": "Concentration Of Credit Risk And Significant Customers [Policy Text Block]",
        "documentation": "Concentration Of Credit Risk And Significant Customers [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]",
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r179",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r274",
      "r313",
      "r321",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r462",
      "r463",
      "r464",
      "r465",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r1005",
      "r1006",
      "r1180",
      "r1181",
      "r1272",
      "r1273"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Domain]",
        "label": "Consolidation Items [Domain]",
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r179",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r274",
      "r313",
      "r321",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r462",
      "r463",
      "r464",
      "r465",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r1005",
      "r1006",
      "r1180",
      "r1181",
      "r1272",
      "r1273"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basis of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r995"
     ]
    },
    "rmd_ContractWithCustomerAssetAndLiabilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "ContractWithCustomerAssetAndLiabilityLineItems",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with Customer, Asset and Liability [Line Items]",
        "label": "Contract with Customer, Asset and Liability [Line Items]",
        "documentation": "Contract with Customer, Asset and Liability [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_ContractWithCustomerAssetAndLiabilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "ContractWithCustomerAssetAndLiabilityTable",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with Customer, Asset and Liability [Table]",
        "label": "Contract with Customer, Asset and Liability [Table]",
        "documentation": "Contract with Customer, Asset and Liability [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contract Balances",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1276"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetNetAbstract",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract assets",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unbilled revenue, current",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r508",
      "r519"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unbilled revenue, non-current",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r508",
      "r519"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityAbstract",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Contract with Customer, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "negatedLabel": "Deferred revenue, current",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r519"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred revenue",
        "negatedLabel": "Deferred revenue, non-current",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r519"
     ]
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Obligations Under Purchase Agreements",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r1179",
      "r1197"
     ]
    },
    "us-gaap_CorporateNonSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateNonSegmentMember",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Costs",
        "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]",
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r336",
      "r337",
      "r338",
      "r339",
      "r342",
      "r1211"
     ]
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_CostOfGoodsAndServicesSold",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales (exclusive of amortization shown separately below)",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization."
       }
      }
     },
     "auth_ref": [
      "r1168",
      "r1169"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cost of sales",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r778"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r1270"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r1270",
      "r1271"
     ]
    },
    "us-gaap_CurrencySwapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrencySwapMember",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency Swap",
        "label": "Currency Swap [Member]",
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1196",
      "r1317"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-U.S.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1196"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r1196"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1196",
      "r1317"
     ]
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1251",
      "r1253",
      "r1256",
      "r1257"
     ]
    },
    "us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtAndEquitySecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "(Gain) loss on equity investments (note 6)",
        "terseLabel": "(Gain) loss on equity investments",
        "label": "Debt and Equity Securities, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r936",
      "r966",
      "r967",
      "r968",
      "r1189",
      "r1190"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r268",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r460",
      "r461",
      "r473",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r483",
      "r484",
      "r485",
      "r487",
      "r720"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Credit facility interest rate equal to reference rate plus",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/DebtScheduleofDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r154",
      "r488"
     ]
    },
    "rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod": {
     "xbrltype": "pureItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EBITDA multiple of trailing twelve-month measurement period",
        "label": "Debt Instrument, EBITDA Multiple of Trailing Twelve-Month Measurement Period",
        "documentation": "Debt Instrument, EBITDA Multiple of Trailing Twelve-Month Measurement Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r720",
      "r721",
      "r1020",
      "r1021",
      "r1046"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate on outstanding principal amount",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r490",
      "r720",
      "r721",
      "r1046"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r475"
     ]
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/DebtScheduleofDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails",
      "http://investor.resmed.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total debt",
        "terseLabel": "Outstanding debt",
        "label": "Debt, Long-Term and Short-Term, Combined Amount",
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt."
       }
      }
     },
     "auth_ref": []
    },
    "rmd_DebtToConsolidatedEbitdaRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "DebtToConsolidatedEbitdaRatio",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt to consolidated EBITDA ratio",
        "label": "Debt To Consolidated EBITDA Ratio",
        "documentation": "Debt To Consolidated EBITDA Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1196",
      "r1316",
      "r1317"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsCurrentNet",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/DebtScheduleofDebtDetails": {
       "parentTag": "us-gaap_ShortTermBorrowings",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred borrowing costs",
        "label": "Debt Issuance Costs, Current, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1340",
      "r1341",
      "r1342"
     ]
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/DebtScheduleofDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred borrowing costs",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1340",
      "r1341",
      "r1342"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-U.S.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1196",
      "r1316"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r175",
      "r1196"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesClassifiedasCurrentandNonCurrentDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesClassifiedasCurrentandNonCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes (note 12)",
        "verboseLabel": "Non-current deferred tax asset",
        "label": "Deferred Income Taxes and Other Assets, Noncurrent",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://investor.resmed.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesClassifiedasCurrentandNonCurrentDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesClassifiedasCurrentandNonCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes (note 12)",
        "negatedLabel": "Non-current deferred tax liability",
        "label": "Deferred Income Taxes and Other Tax Liabilities, Noncurrent",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other tax liabilities expected to be paid after one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "rmd_DeferredPaymentObligationsForAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "DeferredPaymentObligationsForAcquisitions",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred payments",
        "label": "Deferred Payment Obligations For Acquisitions",
        "documentation": "Deferred Payment Obligations For Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_DeferredRevenueCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "DeferredRevenueCurrentLiabilitiesMember",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue (current liabilities)",
        "label": "Deferred Revenue Current Liabilities [Member]",
        "documentation": "Deferred Revenue Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_DeferredRevenueNonCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "DeferredRevenueNonCurrentLiabilitiesMember",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue (non-current liabilities)",
        "label": "Deferred Revenue Non Current Liabilities [Member]",
        "documentation": "Deferred Revenue Non Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1196",
      "r1316",
      "r1317"
     ]
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Capital loss carryover",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "us-gaap_DeferredTaxAssetsDerivativeInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDerivativeInstruments",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging contracts",
        "label": "Deferred Tax Assets, Derivative Instruments",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, Gross",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development capitalization",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories",
        "label": "Deferred Tax Assets, Inventory",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "rmd_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Deferred Tax Assets, Lease Liabilities",
        "documentation": "Deferred Tax Assets, Lease Liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesClassifiedasCurrentandNonCurrentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails",
      "http://investor.resmed.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesClassifiedasCurrentandNonCurrentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax asset",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1312"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1312"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "us-gaap_DeferredTaxAssetsStateTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsStateTaxes",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes",
        "label": "Deferred Tax Assets, State Taxes",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carry overs",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee liabilities",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Provision for doubtful debts",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Provision for warranties",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warranty reserves."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1312"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Goodwill and other intangibles",
        "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Property, plant and equipment",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "rmd_DeferredTaxLiabilitiesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right of use assets",
        "label": "Deferred Tax Liabilities, Right-of-use Assets",
        "documentation": "Deferred Tax Liabilities, Right-of-use Assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of deferred taxes that would have been recognized if the earnings has not been permanently reinvested",
        "label": "Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries",
        "documentation": "Amount of deferred tax liability not recognized because of the exceptions to comprehensive recognition of deferred taxes related to undistributed earnings of foreign subsidiaries."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "documentation": "Disclosure of information about defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r50",
      "r51",
      "r52",
      "r53"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total contribution by the company to the employee retirement plans",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of contribution by the company to the retirement plans",
        "label": "Defined Contribution Plan Maximum Annual Contributions By Employer Percent",
        "documentation": "Defined Contribution Plan Maximum Annual Contributions By Employer Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r43"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization by segment",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r313",
      "r324",
      "r341",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Asset, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Derivative Asset, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative asset classified as current."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "label": "Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative asset classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]",
        "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative asset."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Assets",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r699",
      "r700",
      "r704",
      "r707",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r911",
      "r912",
      "r957",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r994",
      "r1035",
      "r1039",
      "r1067",
      "r1326",
      "r1327",
      "r1328",
      "r1391"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r896",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r918",
      "r919",
      "r920",
      "r921",
      "r931",
      "r932",
      "r933",
      "r934",
      "r937",
      "r938",
      "r939",
      "r940",
      "r957",
      "r958",
      "r961",
      "r963",
      "r1065",
      "r1067",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1336",
      "r1337"
     ]
    },
    "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) recognized on cross-currency swap in interest (expense) income, net (amount excluded from effectiveness testing)",
        "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings",
        "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r1321"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) recognized on cross-currency swap in other, net",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r1320"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r78",
      "r80",
      "r149",
      "r894",
      "r896",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r918",
      "r919",
      "r920",
      "r921",
      "r931",
      "r932",
      "r933",
      "r934",
      "r937",
      "r938",
      "r939",
      "r940",
      "r957",
      "r958",
      "r961",
      "r963",
      "r994",
      "r1065",
      "r1067",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1336",
      "r1337"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r684",
      "r693"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "documentation": "Disclosure of information about derivatives and hedging activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Axis]",
        "label": "Hedging Relationship [Axis]",
        "documentation": "Information by type of hedging relationship."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r75",
      "r78"
     ]
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r1166"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Liabilities",
        "label": "Derivative Liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r244",
      "r699",
      "r700",
      "r704",
      "r707",
      "r886",
      "r887",
      "r888",
      "r889",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r918",
      "r920",
      "r921",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r994",
      "r1326",
      "r1327",
      "r1328",
      "r1391"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency hedging instruments",
        "label": "Derivative Liability, Current",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative liability classified as current."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "label": "Derivative Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative liability classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes derivative liability."
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "us-gaap_DerivativeNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeNotionalAmount",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding foreign cross-currency swaps",
        "label": "Derivative, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payment on derivative."
       }
      }
     },
     "auth_ref": [
      "r1318",
      "r1319"
     ]
    },
    "us-gaap_DerivativeTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeTermOfContract",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, term of contract",
        "label": "Derivative, Term of Contract",
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesFairValueLineItems",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives, Fair Value [Line Items]",
        "label": "Derivatives, Fair Value [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign Exchange Risk Management",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r67",
      "r68",
      "r72",
      "r81",
      "r273",
      "r298"
     ]
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DesignatedAsHedgingInstrumentMember",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Designated as Hedging Instruments",
        "label": "Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "rmd_DevelopedOrCoreProductTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "DevelopedOrCoreProductTechnologyMember",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed/core product technology",
        "label": "Developed Or Core Product Technology [Member]",
        "documentation": "Developed/ Core Product Technology [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed technology",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1251",
      "r1253",
      "r1256",
      "r1257"
     ]
    },
    "rmd_DevicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "DevicesMember",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Devices",
        "label": "Devices [Member]",
        "documentation": "Devices [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Dividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Dividends",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends declared",
        "label": "Dividends",
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r136"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1079",
      "r1080",
      "r1092"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1079",
      "r1080",
      "r1092",
      "r1135"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Tax Authority",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "us-gaap_DomesticPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticPlanMember",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Plan",
        "label": "Domestic Plan [Member]",
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r1279",
      "r1280",
      "r1281"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1124"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic earnings per share (note 11) (in dollars per share)",
        "verboseLabel": "Basic earnings per share (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r302",
      "r304",
      "r306",
      "r307",
      "r308",
      "r312",
      "r666",
      "r672",
      "r697",
      "r698",
      "r817",
      "r836",
      "r998"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted earnings per share (note 11) (in dollars per share)",
        "terseLabel": "Diluted earnings per share (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r304",
      "r306",
      "r307",
      "r308",
      "r312",
      "r666",
      "r672",
      "r697",
      "r698",
      "r817",
      "r836",
      "r998"
     ]
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "presentation": [
      "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of dilutive securities:",
        "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r309",
      "r310",
      "r311"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee related costs",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrecognized compensation costs related to unvested stock-based compensation arrangements",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected weighted average period of unrecognized compensation costs related to unvested stock-based compensation arrangements",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax benefit",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "rmd_EmployeeSeveranceAndOneTimeTerminationBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "EmployeeSeveranceAndOneTimeTerminationBenefitsMember",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Severance and One-time Termination Benefits",
        "label": "Employee Severance And One-time Termination Benefits [Member]",
        "documentation": "Employee Severance And One-time Termination Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock Option",
        "terseLabel": "Stock options:",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "rmd_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_EmployeeStockPurchasePlanOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "EmployeeStockPurchasePlanOfferingPeriod",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase program offering period",
        "label": "Employee Stock Purchase Plan Offering Period",
        "documentation": "Employee Stock Purchase Plan Offering Period"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_EmployeeStockPurchasePlanPurchaseRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "EmployeeStockPurchasePlanPurchaseRightsMember",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP purchase rights:",
        "label": "Employee Stock Purchase Plan Purchase Rights [Member]",
        "documentation": "Employee Stock Purchase Plan Purchase rights [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1165"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1160"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r223",
      "r254",
      "r255",
      "r256",
      "r281",
      "r282",
      "r283",
      "r287",
      "r294",
      "r296",
      "r298",
      "r314",
      "r389",
      "r392",
      "r433",
      "r505",
      "r653",
      "r654",
      "r661",
      "r662",
      "r663",
      "r667",
      "r671",
      "r672",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r692",
      "r696",
      "r712",
      "r714",
      "r715",
      "r716",
      "r717",
      "r719",
      "r722",
      "r724",
      "r739",
      "r832",
      "r864",
      "r865",
      "r866",
      "r884",
      "r943"
     ]
    },
    "rmd_EquityInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "EquityInvestments",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at the beginning of the period",
        "periodEndLabel": "Carrying value at the end of the period",
        "label": "Equity Investments",
        "documentation": "Equity Investments"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_EquityInvestmentsTotalByMeasurementCategory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "EquityInvestmentsTotalByMeasurementCategory",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Equity Investments, Total by Measurement Category",
        "documentation": "Equity Investments, Total by Measurement Category"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment of investments",
        "label": "Equity Method Investment, Other-than-Temporary Impairment",
        "documentation": "Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r1229"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails": {
       "parentTag": "rmd_EquityInvestmentsTotalByMeasurementCategory",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity method",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r329",
      "r341",
      "r384",
      "r1184",
      "r1230"
     ]
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]",
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsMember",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investments",
        "label": "Equity Method Investments [Member]",
        "documentation": "Investment in the stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "rmd_EquityMethodInvestmentsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "EquityMethodInvestmentsRollForward",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments [Roll Forward]",
        "label": "Equity Method Investments [Roll Forward]",
        "documentation": "Equity Method Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "(Loss) gain on equity investments (note 6)",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r840",
      "r1228"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Realized gains on marketable and non-marketable equity securities",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r838",
      "r1228"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities, unrealized (loss) gain",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r1228"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails": {
       "parentTag": "rmd_EquityInvestmentsTotalByMeasurementCategory",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Measurement alternative",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "documentation": "Amount of investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1096",
      "r1106",
      "r1139"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1082",
      "r1093",
      "r1103",
      "r1136"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "rmd_FairValueAndNetInvestmentHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "FairValueAndNetInvestmentHedgingMember",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value And Net Investment Hedging",
        "label": "Fair Value And Net Investment Hedging [Member]",
        "documentation": "Fair Value And Net Investment Hedging"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueHedgingMember",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hedging",
        "label": "Fair Value Hedging [Member]",
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "documentation": "Disclosure of information about location and fair value of derivative instrument and nonderivative instrument designated as hedging instrument."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r76",
      "r82"
     ]
    },
    "us-gaap_FinanceLoansAndLeasesReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLoansAndLeasesReceivablePolicy",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Allowance for Credit Losses",
        "label": "Financing Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for financing receivable."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r352",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r486",
      "r503",
      "r693",
      "r706",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r833",
      "r1011",
      "r1035",
      "r1037",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1049",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1324",
      "r1326",
      "r1327",
      "r1328",
      "r1335",
      "r1338"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, estimated useful life",
        "verboseLabel": "Intangible assets, estimated useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r405",
      "r426",
      "r1014"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofAmortizationExpenseRelatedtoIdentifiableIntangibleAssetsIncludingPatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r984",
      "r1014"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofAmortizationExpenseRelatedtoIdentifiableIntangibleAssetsIncludingPatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r984",
      "r1014"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofAmortizationExpenseRelatedtoIdentifiableIntangibleAssetsIncludingPatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r984",
      "r1014"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofAmortizationExpenseRelatedtoIdentifiableIntangibleAssetsIncludingPatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r984",
      "r1014"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofAmortizationExpenseRelatedtoIdentifiableIntangibleAssetsIncludingPatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r984",
      "r1014"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r430",
      "r431",
      "r779",
      "r783",
      "r984"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other intangibles, gross",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r426",
      "r783",
      "r1014"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r426",
      "r430",
      "r431",
      "r432",
      "r779",
      "r984",
      "r1014"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r430",
      "r431",
      "r984"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets, net (note 5)",
        "totalLabel": "Total other intangibles, net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r1253"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Authority",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r633"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign Currency",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_ForeignExchangeContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignExchangeContractMember",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency hedging instruments",
        "label": "Foreign Exchange Contract [Member]",
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates."
       }
      }
     },
     "auth_ref": [
      "r994",
      "r1025",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_ForeignPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignPlanMember",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Plan",
        "label": "Foreign Plan [Member]",
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r1279",
      "r1280",
      "r1281"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1089",
      "r1100",
      "r1110",
      "r1143"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1089",
      "r1100",
      "r1110",
      "r1143"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1089",
      "r1100",
      "r1110",
      "r1143"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1089",
      "r1100",
      "r1110",
      "r1143"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1089",
      "r1100",
      "r1110",
      "r1143"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1123"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainOnBusinessInterruptionInsuranceRecovery": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainOnBusinessInterruptionInsuranceRecovery",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on insurance recoveries",
        "label": "Gain on Business Interruption Insurance Recovery",
        "documentation": "The net amount (to the extent disclosed within this portion of the income statement) by which an insurance settlement exceeds incremental costs incurred from the event causing an interruption of business, plus the insurance award for earnings lost from the event, such as a natural catastrophe, explosion or fire."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative expenses",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "rmd_GlobalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "GlobalMember",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Global revenue",
        "label": "Global [Member]",
        "documentation": "Global [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails",
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill (note 5)",
        "periodStartLabel": "Balance at the beginning of the period",
        "periodEndLabel": "Balance at the end of the period",
        "verboseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r407",
      "r814",
      "r1006",
      "r1013",
      "r1036",
      "r1048",
      "r1235",
      "r1242"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisitions",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r1013"
     ]
    },
    "rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "GoodwillAcquiredDuringPeriodIncreaseDecrease",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill on acquisition",
        "label": "Goodwill, Acquired During Period, Increase (Decrease)",
        "documentation": "Goodwill, Acquired During Period, Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill and Other Intangible Assets, net",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1233",
      "r1245"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r418",
      "r1013"
     ]
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency translation adjustments",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r1013"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r111",
      "r162",
      "r270",
      "r388",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r708",
      "r1000",
      "r1005",
      "r1208",
      "r1210",
      "r1212",
      "r1213",
      "r1214",
      "r1272"
     ]
    },
    "us-gaap_HedgingDesignationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgingDesignationAxis",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Axis]",
        "label": "Hedging Designation [Axis]",
        "documentation": "Information by designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r683"
     ]
    },
    "us-gaap_HedgingDesignationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgingDesignationDomain",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Domain]",
        "label": "Hedging Designation [Domain]",
        "documentation": "Designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_HedgingRelationshipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HedgingRelationshipDomain",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Domain]",
        "label": "Hedging Relationship [Domain]",
        "documentation": "Nature or intent of a hedge."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1079",
      "r1080",
      "r1092"
     ]
    },
    "rmd_IdentifiedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "IdentifiedIntangibleAssetsMember",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Identified Intangible Assets",
        "label": "Identified Intangible Assets [Member]",
        "documentation": "Identified Intangible Assets [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r984",
      "r1259"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r1193",
      "r1258"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r132"
     ]
    },
    "us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeAmountsAttributableToReportingEntityDisclosuresAbstract",
     "presentation": [
      "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Income Amounts Attributable to Parent, Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesUndertheJurisdictionsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesUndertheJurisdictionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "U.S.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r631"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://investor.resmed.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesUndertheJurisdictionsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesUndertheJurisdictionsDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before income taxes",
        "terseLabel": "Income before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r158",
      "r162",
      "r818",
      "r830",
      "r1000",
      "r1005",
      "r1208",
      "r1210",
      "r1212",
      "r1213",
      "r1214"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesUndertheJurisdictionsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofIncomeBeforeIncomeTaxesUndertheJurisdictionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-U.S.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r631"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loss attributable to equity method investments (note 6)",
        "terseLabel": "Loss attributable to equity method investments",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r108",
      "r157",
      "r313",
      "r326",
      "r341",
      "r384",
      "r829"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss attributable to equity method investments, net of dividends received (note 6)",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r441",
      "r446",
      "r702",
      "r703",
      "r705",
      "r861",
      "r863",
      "r928",
      "r984",
      "r1038",
      "r1361"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r446",
      "r702",
      "r703",
      "r705",
      "r861",
      "r863",
      "r928",
      "r984",
      "r1038",
      "r1361"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r632",
      "r633",
      "r641",
      "r649",
      "r1033",
      "r1313"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r632",
      "r633",
      "r641",
      "r649",
      "r1033",
      "r1313"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name [Axis]",
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r1313"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name [Domain]",
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r1313"
     ]
    },
    "us-gaap_IncomeTaxCreditsAndAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxCreditsAndAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits and deductions",
        "label": "Income Tax Credits and Adjustments",
        "documentation": "A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r626",
      "r632",
      "r638",
      "r639",
      "r640",
      "r642",
      "r647",
      "r655",
      "r657",
      "r658",
      "r659",
      "r883",
      "r1033"
     ]
    },
    "rmd_IncomeTaxExaminationGrossSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "IncomeTaxExaminationGrossSettlement",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross settlement",
        "label": "Income Tax Examination, Gross Settlement",
        "documentation": "Income Tax Examination, Gross Settlement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability (refund) adjustment from settlement with taxing authority",
        "label": "Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority",
        "documentation": "The amount of the additional liability or refund received or expected based on a final settlement with a taxing authority."
       }
      }
     },
     "auth_ref": []
    },
    "rmd_IncomeTaxExaminationNetImpactOfSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "IncomeTaxExaminationNetImpactOfSettlement",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net impact of settlement",
        "label": "Income Tax Examination, Net Impact of Settlement",
        "documentation": "Income Tax Examination, Net Impact of Settlement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Penalties and interest",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r1311"
     ]
    },
    "rmd_IncomeTaxExaminationPriorRemittancePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "IncomeTaxExaminationPriorRemittancePayments",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior remittance payments",
        "label": "Income Tax Examination, Prior Remittance Payments",
        "documentation": "Income Tax Examination, Prior Remittance Payments"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_IncomeTaxExaminationRemittedFinalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "IncomeTaxExaminationRemittedFinalPayment",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remitted final payment",
        "label": "Income Tax Examination, Remitted Final Payment",
        "documentation": "Income Tax Examination, Remitted Final Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails",
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Income taxes (note 12)",
        "totalLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r176",
      "r297",
      "r298",
      "r313",
      "r327",
      "r341",
      "r630",
      "r632",
      "r656",
      "r841",
      "r1033"
     ]
    },
    "us-gaap_IncomeTaxHolidayAggregateDollarAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxHolidayAggregateDollarAmount",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase to net earnings from tax holidays and tax incentives program",
        "label": "Income Tax Holiday, Aggregate Dollar Amount",
        "documentation": "The amount of income taxes from which a reporting entity is exempt or for which it will receive a reduction in income taxes as a result of the income tax holiday granted by the taxing jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxHolidayIncomeTaxBenefitsPerShare",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase to net earnings per diluted share from tax holidays and tax incentives program (in dollars per share)",
        "label": "Income Tax Holiday, Income Tax Benefits Per Share",
        "documentation": "Per share amount effect of the income tax benefit resulting from the income tax holidays granted by taxing jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r628",
      "r629",
      "r642",
      "r643",
      "r646",
      "r651",
      "r879"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r637",
      "r1033",
      "r1309"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Effect of non-U.S. tax rates",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r636",
      "r1033",
      "r1309"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Taxes computed at statutory U.S. rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r1033"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1033",
      "r1309",
      "r1310"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1033",
      "r1309",
      "r1310"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State income taxes, net of U.S. tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r1033",
      "r1309"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCreditsForeign",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit."
       }
      }
     },
     "auth_ref": [
      "r1309",
      "r1310"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleofProvisionforIncomeTaxDifferFromtheAmountofIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development credit",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1033",
      "r1309",
      "r1310"
     ]
    },
    "rmd_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "documentation": "Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes paid, net of refunds",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r265",
      "r648",
      "r649"
     ]
    },
    "rmd_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "documentation": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable, accrued expenses and other",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses, net deferred income taxes and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r424",
      "r429",
      "r1014"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r424",
      "r429",
      "r1014"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1089",
      "r1100",
      "r1110",
      "r1134",
      "r1143",
      "r1147",
      "r1155"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1153"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1159"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1159"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1159"
     ]
    },
    "us-gaap_InsuranceRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InsuranceRecoveries",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on insurance recoveries",
        "label": "Insurance Recoveries",
        "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "rmd_IntangibleAssetImpairmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "IntangibleAssetImpairmentMember",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset Impairment",
        "label": "Intangible Asset Impairment [Member]",
        "documentation": "Intangible Asset Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible Assets",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r775",
      "r776",
      "r777",
      "r779",
      "r996",
      "r1245"
     ]
    },
    "us-gaap_InterestExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseMember",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Expense",
        "label": "Interest Expense [Member]",
        "documentation": "Primary financial statement caption encompassing interest expense."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense, net",
        "verboseLabel": "Interest expense (income), net",
        "label": "Interest Income (Expense), Nonoperating",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1191",
      "r1210"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r263",
      "r264"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Interest Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r991"
     ]
    },
    "us-gaap_InventoryGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryGrossAbstract",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories (note 4)",
        "totalLabel": "Total inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r989",
      "r1048"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r229",
      "r239",
      "r402",
      "r403",
      "r404",
      "r774",
      "r997"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r993"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in progress",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r992"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r875",
      "r876",
      "r877",
      "r878",
      "r950",
      "r951"
     ]
    },
    "us-gaap_InvestmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment [Text Block]",
        "documentation": "The entire disclosure for investment."
       }
      }
     },
     "auth_ref": [
      "r1170",
      "r1171",
      "r1223"
     ]
    },
    "rmd_JanDeWitteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "JanDeWitteMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jan De Witte [Member]",
        "documentation": "Jan De Witte"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_KaushikGhoshalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "KaushikGhoshalMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kaushik Ghoshal [Member]",
        "documentation": "Kaushik Ghoshal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LandMember",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r1278"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r735"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalMattersAndContingenciesTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Actions, Contingencies and Commitments",
        "label": "Legal Matters and Contingencies [Text Block]",
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://investor.resmed.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r736"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://investor.resmed.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r736"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Lease Payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1345"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://investor.resmed.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease terms",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r736",
      "r1344"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "us-gaap_LessorSalesTypeLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LessorSalesTypeLeasesTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessor, Sales-type Leases [Text Block]",
        "documentation": "The entire disclosure of lessor's sales-type leases."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r86",
      "r87",
      "r88",
      "r91",
      "r92",
      "r93",
      "r94",
      "r270",
      "r388",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r674",
      "r675",
      "r676",
      "r708",
      "r903",
      "r999",
      "r1074",
      "r1272",
      "r1347",
      "r1348"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r156",
      "r825",
      "r1048",
      "r1195",
      "r1231",
      "r1339"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r228",
      "r270",
      "r388",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r674",
      "r675",
      "r676",
      "r708",
      "r1048",
      "r1272",
      "r1347",
      "r1348"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r91",
      "r92",
      "r93",
      "r94",
      "r270",
      "r388",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r674",
      "r675",
      "r676",
      "r708",
      "r1272",
      "r1347",
      "r1348"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lender Name [Axis]",
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r90",
      "r1194",
      "r1270",
      "r1271"
     ]
    },
    "rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany": {
     "xbrltype": "percentItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "LineOfCreditFacilityCollateralPercentageOfTheCompany",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility collateral, maximum percentage of ownership interests held in subsidiary",
        "label": "Line of Credit Facility, Collateral, Percentage of the Company",
        "documentation": "Line of Credit Facility, Collateral, Percentage of the Company"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitment fees percentage rate on unused portion of credit facility",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available for draw",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r90"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility, Lender [Domain]",
        "label": "Line of Credit Facility, Lender [Domain]",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r90",
      "r1194",
      "r1270"
     ]
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Line Items]",
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r1194",
      "r1270"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r90"
     ]
    },
    "us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal payment",
        "label": "Line of Credit Facility, Periodic Payment, Principal",
        "documentation": "Amount of the required periodic payment applied to principal."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r90"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Table]",
        "label": "Line of Credit Facility [Table]",
        "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r90",
      "r461",
      "r1194",
      "r1270"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Lived Assets by Geographic Areas",
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/DebtScheduleofDebtDetails": {
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0,
       "order": 2.0
      },
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-term debt, net (note 8)",
        "totalLabel": "Long-term debt, net",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r154",
      "r482",
      "r489",
      "r1020",
      "r1021",
      "r1046",
      "r1357"
     ]
    },
    "us-gaap_LongTermDebtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, fair value",
        "label": "Long-Term Debt, Fair Value",
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission."
       }
      }
     },
     "auth_ref": [
      "r1325",
      "r1326",
      "r1327",
      "r1328"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r1260",
      "r1261",
      "r1262"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r46",
      "r1260",
      "r1261",
      "r1262"
     ]
    },
    "us-gaap_LossContingencyAccrualProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualProvision",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent provision",
        "label": "Loss Contingency Accrual, Provision",
        "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges."
       }
      }
     },
     "auth_ref": [
      "r1265"
     ]
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum potential contingent liability",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r455",
      "r458",
      "r459",
      "r623",
      "r1019"
     ]
    },
    "rmd_MEDIFOXDANMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "MEDIFOXDANMember",
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsNarrativeDetails",
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MEDIFOX DAN",
        "label": "MEDIFOX DAN [Member]",
        "documentation": "MEDIFOX DAN"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and equipment",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "rmd_MarketableEquityInvestmentsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "MarketableEquityInvestmentsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails": {
       "parentTag": "rmd_EquityInvestmentsTotalByMeasurementCategory",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value",
        "label": "Marketable Equity Investments, Fair Value",
        "documentation": "Marketable Equity Investments, Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_MarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "MarketableSecuritiesMember",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities [Member]",
        "documentation": "Marketable Securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized losses on marketable equity securities",
        "label": "Marketable Security, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "rmd_MasksAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "MasksAndOtherMember",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Masks and other",
        "label": "Masks and Other [Member]",
        "documentation": "Masks and Other"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_MasksWithMagnetsFieldSafetyNotificationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "MasksWithMagnetsFieldSafetyNotificationExpenses",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Masks with magnets field safety notification expenses",
        "label": "Masks With Magnets Field Safety Notification Expenses",
        "documentation": "Masks With Magnets Field Safety Notification Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MaterialReconcilingItemsMember",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciling items",
        "label": "Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]",
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r339",
      "r342",
      "r1005",
      "r1006"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails",
      "http://investor.resmed.com/role/DebtNarrativeDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/LeasesNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r188",
      "r190",
      "r191",
      "r193",
      "r221",
      "r222",
      "r454",
      "r455",
      "r456",
      "r457",
      "r591",
      "r623",
      "r701",
      "r773",
      "r860",
      "r862",
      "r872",
      "r895",
      "r896",
      "r948",
      "r952",
      "r954",
      "r955",
      "r965",
      "r982",
      "r983",
      "r1010",
      "r1022",
      "r1029",
      "r1039",
      "r1040",
      "r1044",
      "r1045",
      "r1059",
      "r1274",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354"
     ]
    },
    "rmd_MaximumNumberOfSharesSubjectToAwardsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "MaximumNumberOfSharesSubjectToAwardsGranted",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum number of shares subject to awards granted (in shares)",
        "label": "Maximum Number Of Shares Subject To Awards Granted",
        "documentation": "Maximum number of shares subject to awards granted."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "rmd_MichaelJ.FarrellMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "MichaelJ.FarrellMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Michael J. Farrell [Member]",
        "documentation": "Michael J. Farrell"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_MichaelJ.RiderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "MichaelJ.RiderMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Michael J. Rider [Member]",
        "documentation": "Michael J. Rider"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails",
      "http://investor.resmed.com/role/DebtNarrativeDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/LeasesNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r188",
      "r190",
      "r191",
      "r193",
      "r221",
      "r222",
      "r454",
      "r455",
      "r456",
      "r457",
      "r591",
      "r623",
      "r701",
      "r773",
      "r860",
      "r862",
      "r872",
      "r895",
      "r896",
      "r948",
      "r952",
      "r954",
      "r955",
      "r965",
      "r982",
      "r983",
      "r1010",
      "r1022",
      "r1029",
      "r1039",
      "r1040",
      "r1044",
      "r1059",
      "r1274",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1146"
     ]
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "presentation": [
      "http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1154"
     ]
    },
    "rmd_MufgUnionBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "MufgUnionBankMember",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MUFG Union Bank",
        "label": "Mufg Union Bank [Member]",
        "documentation": "MUFG Union Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_MufgUnionBankNaAndWestpacBankingCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "MufgUnionBankNaAndWestpacBankingCorporationMember",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MUFG Union Bank NA and Westpac Banking Corporation",
        "label": "Mufg Union Bank Na And Westpac Banking Corporation [Member]",
        "documentation": "MUFG Union Bank NA and Westpac Banking Corporation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://investor.resmed.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "netLabel": "Net income",
        "terseLabel": "Net income",
        "verboseLabel": "Net income",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r125",
      "r159",
      "r226",
      "r248",
      "r251",
      "r256",
      "r270",
      "r286",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r297",
      "r298",
      "r305",
      "r388",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r666",
      "r672",
      "r698",
      "r708",
      "r831",
      "r925",
      "r941",
      "r942",
      "r1073",
      "r1272"
     ]
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetInvestmentHedgingMember",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Investment Hedging",
        "label": "Net Investment Hedging [Member]",
        "documentation": "Hedges of a net investment in a foreign operation."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/NewAccountingPronouncements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r224",
      "r284",
      "r285",
      "r288",
      "r289",
      "r299",
      "r300",
      "r349",
      "r390",
      "r391",
      "r664",
      "r665",
      "r667",
      "r672",
      "r691",
      "r695",
      "r738",
      "r740",
      "r741",
      "r780",
      "r781",
      "r782",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently issued accounting standards not yet adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "rmd_NonEmployeeDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "NonEmployeeDirectorMember",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non Employee Director",
        "label": "Non Employee Director [Member]",
        "documentation": "Non Employee Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "rmd_NonMarketableSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "NonMarketableSecuritiesMember",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-marketable securities",
        "label": "Non Marketable Securities [Member]",
        "documentation": "Non-marketable Securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1089",
      "r1100",
      "r1110",
      "r1134",
      "r1143"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1154"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1154"
     ]
    },
    "rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Previously held equity interest",
        "label": "Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Equity Interest in Acquiree Held Prior to Combination",
        "documentation": "Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Equity Interest in Acquiree Held Prior to Combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Liabilities assumed",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ]
    },
    "rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "NoncashPartOfAcquisitionFairValueOfAssetsAcquired",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of assets acquired, excluding cash",
        "label": "Noncash Part Of Acquisition, Fair Value of Assets Acquired",
        "documentation": "The fair value of an asset or business acquired in a noncash acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleofLongLivedAssetsbyGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "Long-Lived Assets",
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_NondesignatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NondesignatedMember",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails",
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Not Designated as Hedging Instruments",
        "label": "Not Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (loss), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (loss), net:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_NumberOfCommonStockGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "NumberOfCommonStockGranted",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common stock shares granted in participant's initial year of hiring (in shares)",
        "label": "Number Of Common Stock Granted",
        "documentation": "Number of common stock shares granted."
       }
      }
     },
     "auth_ref": []
    },
    "rmd_NumberOfOfferings": {
     "xbrltype": "integerItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "NumberOfOfferings",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of offerings",
        "label": "Number of Offerings",
        "documentation": "Number of Offerings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationNarrativeDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1209"
     ]
    },
    "rmd_NumberOfPatents": {
     "xbrltype": "integerItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "NumberOfPatents",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of patents",
        "label": "Number Of Patents",
        "documentation": "Number Of Patents"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares given for each share of common stock delivered in settlement of all other awards (in shares)",
        "label": "Number of Shares Given for Each Share of Common Stock Delivered in Settlement of All Other Awards",
        "documentation": "Number of Shares Given for Each Share of Common Stock Delivered in Settlement of All Other Awards"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "ObservablePriceAdjustmentsOnNonMarketableEquitySecurities",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Observable price adjustments on non-marketable equity securities",
        "label": "Observable price adjustments on non-marketable equity securities",
        "documentation": "Observable price adjustments on non-marketable equity securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expenses [Abstract]",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income from operations",
        "netLabel": "Net operating profit by segment",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r1000",
      "r1208",
      "r1210",
      "r1212",
      "r1213",
      "r1214"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease costs",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r1047"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, impairment loss",
        "label": "Operating Lease, Impairment Loss",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1343"
     ]
    },
    "rmd_OperatingLeaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "OperatingLeaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease revenue",
        "label": "Operating Lease Income",
        "documentation": "Operating Lease Income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liabilities, current (note 9)",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current (note 9)",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleofOperatingLeaseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows paid for amounts included in the measurement of lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r730"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets (note 9)",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1193"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleofOperatingLeaseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r1047"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleofOperatingLeaseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term (years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r1047"
     ]
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessor, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for lessor's operating leases."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "rmd_OperatingLossCarryforwardsCapitalLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "OperatingLossCarryforwardsCapitalLoss",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital loss",
        "label": "Operating Loss Carryforwards Capital Loss",
        "documentation": "Operating loss carryforwards capital loss."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r342",
      "r1005",
      "r1006"
     ]
    },
    "rmd_OrganizationAndBasisOfPresentationPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "OrganizationAndBasisOfPresentationPolicyPolicyTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Basis of Presentation",
        "label": "Organization And Basis Of Presentation, Policy [Policy Text Block]",
        "documentation": "Organization And Basis Of Presentation, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/OrganizationandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Basis of Presentation",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r147",
      "r873",
      "r874"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other prepaid expenses and current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r1048"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid taxes and other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains (losses) on designated hedging instruments",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r247",
      "r832"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValueHedgeGainsLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) recognized in other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r247",
      "r678",
      "r679",
      "r685"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) recognized from the excluded components in interest (expense) income, net",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r680",
      "r682",
      "r685"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation (loss) gain adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r832"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income, foreign currency translation adjustment, tax",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6",
      "r710",
      "r718"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNetInvestmentHedgeGainsLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) recognized in cumulative translation adjustment within other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive (loss) income",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r23",
      "r249",
      "r252",
      "r257",
      "r294",
      "r712",
      "r713",
      "r719",
      "r815",
      "r832",
      "r1186",
      "r1187"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_OtherForeignExchangeContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "OtherForeignExchangeContractsMember",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Foreign Exchange Contracts",
        "label": "Other Foreign Exchange Contracts [Member]",
        "documentation": "Other Foreign Exchange Contracts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangibles",
        "label": "Other Intangible Assets [Member]",
        "documentation": "Intangible assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1253",
      "r1255",
      "r1256",
      "r1257"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncurrentLiabilitiesMember",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Noncurrent Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "netLabel": "Other, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNondesignatedDerivativeGainsLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Nonoperating Income (Expense)",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_OtherRestructuringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherRestructuringMember",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Restructuring",
        "label": "Other Restructuring [Member]",
        "documentation": "Restructuring and related activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1015",
      "r1016",
      "r1017",
      "r1018"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1087",
      "r1098",
      "r1108",
      "r1141"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1090",
      "r1101",
      "r1111",
      "r1144"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1090",
      "r1101",
      "r1111",
      "r1144"
     ]
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PatentsMember",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1251",
      "r1253",
      "r1256",
      "r1257"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables and Accruals [Abstract]",
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromDerivativeInstrumentInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Proceeds / (payments) on maturity of foreign currency contracts",
        "label": "Payments for (Proceeds from) Derivative Instrument, Investing Activities",
        "documentation": "The net cash outflow or inflow from derivative instruments during the period, which are classified as investing activities, excluding those designated as hedging instruments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromInvestments",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exits of investments",
        "label": "Payments for (Proceeds from) Investments",
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of treasury stock",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_PaymentsOfDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDividends",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends paid",
        "label": "Payments of Dividends",
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfMergerRelatedCostsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of business combination contingent consideration",
        "label": "Payments of Merger Related Costs, Financing Activities",
        "documentation": "The cash outflow for financing costs associated with business combinations."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for acquisitions",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r670"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Business acquisitions, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Patent registration costs",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments (note 6)",
        "label": "Payments to Acquire Investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property, plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Employee Retirement Plans",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r542",
      "r544",
      "r550",
      "r568",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r588",
      "r589",
      "r590",
      "r1026"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant",
        "label": "Percentage Of Purchase Price Of Common Stock Lower Than The Fair Market Value Of Common Stock On The Date Of Grant",
        "documentation": "Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant."
       }
      }
     },
     "auth_ref": []
    },
    "rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase": {
     "xbrltype": "percentItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase",
        "label": "Percentage Of Purchase Price Of Common Stock Lower Than The Fair Market Value Of Common Stock On The Date Of Purchase",
        "documentation": "Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase."
       }
      }
     },
     "auth_ref": []
    },
    "rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition": {
     "xbrltype": "percentItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "PercentageOfRecognizedTaxBenefitForUncertainTaxPosition",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of recognized tax benefit for uncertain tax position",
        "label": "Percentage Of Recognized Tax Benefit For Uncertain Tax Position",
        "documentation": "Percentage threshold, above which a tax benefit would be recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Restricted Stock Units (PRSUs)",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "rmd_PeterC.FarrellMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "PeterC.FarrellMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peter C. Farrell [Member]",
        "documentation": "Peter C. Farrell"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289",
      "r1290",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1118"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1163"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1117"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock at par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r492"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r905"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r492"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r905",
      "r923",
      "r1392",
      "r1393"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r822",
      "r1048"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets (note 4)",
        "totalLabel": "Total prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1185"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "rmd_PrepaidInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "PrepaidInventory",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid inventories",
        "label": "Prepaid Inventory",
        "documentation": "Prepaid Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidTaxes",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid taxes",
        "label": "Prepaid Taxes",
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r990",
      "r1012",
      "r1232"
     ]
    },
    "rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "PrepaidTaxesAndOtherNonCurrentAssetsMember",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofFairValuesofDerivativeInstrumentsDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesSummaryofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid taxes and other non-current assets",
        "label": "Prepaid Taxes And Other Non Current Assets [Member]",
        "documentation": "Prepaid Taxes And Other Non Current Assets [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDividendsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromDividendsReceived",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Dividends received",
        "label": "Proceeds from Dividends Received",
        "documentation": "Dividends received on equity and other investments during the current period."
       }
      }
     },
     "auth_ref": [
      "r1192"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock, net",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from borrowings, net of borrowing costs",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r880"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exits of investments (note 6)",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r220",
      "r344",
      "r778",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r986",
      "r1023",
      "r1058",
      "r1059",
      "r1060",
      "r1063",
      "r1064",
      "r1182",
      "r1266",
      "r1267",
      "r1277",
      "r1358",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389"
     ]
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product warranties",
        "label": "Product Warranty Accrual, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r1268",
      "r1269"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and Services [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r220",
      "r344",
      "r778",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r986",
      "r1023",
      "r1058",
      "r1059",
      "r1060",
      "r1063",
      "r1064",
      "r1182",
      "r1266",
      "r1267",
      "r1277",
      "r1358",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r735"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property, plant and equipment, at cost",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r231",
      "r828"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property, plant and equipment, net (note 4)",
        "totalLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r735",
      "r819",
      "r828",
      "r1048"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property, Plant and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r173",
      "r174",
      "r826"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Components of Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r735"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life of property, plant and equipment, years",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Purchase Obligation",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueAfterFifthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationDueAfterFifthYear",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Purchase Obligation, to be Paid, after Year Five",
        "documentation": "Amount of purchase arrangement to be paid after fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInFifthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationDueInFifthYear",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Purchase Obligation, to be Paid, Year Five",
        "documentation": "Amount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInFourthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationDueInFourthYear",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Purchase Obligation, to be Paid, Year Four",
        "documentation": "Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Purchase Obligation, to be Paid, Year One",
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationDueInSecondYear",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Purchase Obligation, to be Paid, Year Two",
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationDueInThirdYear",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Purchase Obligation, to be Paid, Year Three",
        "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationFiscalYearMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligationFiscalYearMaturityAbstract",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum purchase obligations",
        "label": "Purchase Obligation, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails",
      "http://investor.resmed.com/role/DebtNarrativeDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/LeasesNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r188",
      "r190",
      "r191",
      "r193",
      "r221",
      "r222",
      "r454",
      "r455",
      "r456",
      "r457",
      "r542",
      "r591",
      "r616",
      "r617",
      "r618",
      "r623",
      "r701",
      "r748",
      "r757",
      "r773",
      "r860",
      "r862",
      "r872",
      "r895",
      "r896",
      "r948",
      "r952",
      "r954",
      "r955",
      "r965",
      "r982",
      "r983",
      "r1010",
      "r1022",
      "r1029",
      "r1039",
      "r1040",
      "r1044",
      "r1045",
      "r1059",
      "r1067",
      "r1263",
      "r1274",
      "r1327",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails",
      "http://investor.resmed.com/role/DebtNarrativeDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/LeasesNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r188",
      "r190",
      "r191",
      "r193",
      "r221",
      "r222",
      "r454",
      "r455",
      "r456",
      "r457",
      "r542",
      "r591",
      "r616",
      "r617",
      "r618",
      "r623",
      "r701",
      "r748",
      "r757",
      "r773",
      "r860",
      "r862",
      "r872",
      "r895",
      "r896",
      "r948",
      "r952",
      "r954",
      "r955",
      "r965",
      "r982",
      "r983",
      "r1010",
      "r1022",
      "r1029",
      "r1039",
      "r1040",
      "r1044",
      "r1045",
      "r1059",
      "r1067",
      "r1263",
      "r1274",
      "r1327",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354"
     ]
    },
    "rmd_ReceivablesSoldWithLimitedRecourse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "ReceivablesSoldWithLimitedRecourse",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesandCommitmentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables sold with limited recourse",
        "label": "Receivables Sold With Limited Recourse",
        "documentation": "Receivables Sold With Limited Recourse"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1082",
      "r1093",
      "r1103",
      "r1136"
     ]
    },
    "rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance": {
     "xbrltype": "pureItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "ReductionInNumberOfSharesOfCommonStockAvailableForIssuance",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reduction in the number of shares of common stock available for issuance (in shares)",
        "label": "Reduction In The Number Of Shares Of Common Stock Available For Issuance",
        "documentation": "Reduction in the number of shares of common stock available for issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of borrowings",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r881"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r984",
      "r1005",
      "r1355"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "rmd_ResmedInc2009IncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "ResmedInc2009IncentiveAwardPlanMember",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2009 Plan",
        "label": "Resmed Inc2009 Incentive Award Plan [Member]",
        "documentation": "ResMed Inc 2009 Incentive Award Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_ResmedLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "ResmedLimitedMember",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ResMed Limited",
        "label": "Resmed Limited [Member]",
        "documentation": "ResMed Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_RestOfWorldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "RestOfWorldMember",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleofLongLivedAssetsbyGeographicAreasDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rest of the World",
        "label": "Rest Of World [Member]",
        "documentation": "Rest Of World [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1083",
      "r1094",
      "r1104",
      "r1137"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1084",
      "r1095",
      "r1105",
      "r1138"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1091",
      "r1102",
      "r1112",
      "r1145"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and Related Activities [Abstract]",
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Expenses",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443",
      "r445",
      "r448",
      "r453"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/RestructuringExpensesDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring expenses (note 18)",
        "verboseLabel": "Restructuring expenses",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r449",
      "r450",
      "r1264"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r450",
      "r451"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r447",
      "r450",
      "r451",
      "r452"
     ]
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining in our accruals",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r451"
     ]
    },
    "us-gaap_RestructuringReserveSettledWithoutCash2": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveSettledWithoutCash2",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring expenses (note 18)",
        "label": "Restructuring Reserve, Settled without Cash",
        "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r451"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r136",
      "r824",
      "r867",
      "r871",
      "r882",
      "r906",
      "r1048"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r281",
      "r282",
      "r283",
      "r287",
      "r294",
      "r296",
      "r298",
      "r389",
      "r392",
      "r433",
      "r653",
      "r654",
      "r661",
      "r662",
      "r663",
      "r667",
      "r671",
      "r672",
      "r686",
      "r688",
      "r689",
      "r692",
      "r696",
      "r722",
      "r724",
      "r864",
      "r866",
      "r884",
      "r1392"
     ]
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanSponsorLocationAxis",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Sponsor Location [Axis]",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r569",
      "r572",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r1279",
      "r1280",
      "r1281"
     ]
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanSponsorLocationDomain",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Sponsor Location [Domain]",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r569",
      "r572",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r1279",
      "r1280",
      "r1281"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebyGeographicAreaDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net revenue",
        "verboseLabel": "Net revenue by segment",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r313",
      "r320",
      "r321",
      "r335",
      "r341",
      "r344",
      "r346",
      "r348",
      "r517",
      "r518",
      "r778"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r985"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Geographic Area",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleofLongLivedAssetsbyGeographicAreasDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Agreement, Term Credit Agreement, And Senior Notes",
        "label": "Revolving Credit Agreement Term Credit Agreement And Senior Notes [Member]",
        "documentation": "Revolving Credit Agreement, Term Credit Agreement, And Senior Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "RevolvingCreditFacilityAndTermLoanCreditAgreementMember",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility And Term Credit Agreement",
        "label": "Revolving Credit Facility And Term Loan Credit Agreement [Member]",
        "documentation": "Revolving Credit Facility And Term Loan Credit Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleofOperatingLeaseDisclosureDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use assets obtained in exchange for new lease liabilities:",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r1047"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1154"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1154"
     ]
    },
    "country_SG": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "SG",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleofLongLivedAssetsbyGeographicAreasDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Singapore",
        "label": "SINGAPORE"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_SaasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "SaasMember",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SaaS",
        "label": "Saas [Member]",
        "documentation": "Saas [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsNarrativeDetails",
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r61",
      "r668"
     ]
    },
    "rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "ScheduleOfChangesInEquityInvestmentsTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Equity Investments",
        "label": "Schedule Of Changes In Equity Investments [Table Text Block]",
        "documentation": "Schedule Of Changes In Equity Investments [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Provision for Income Taxes",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1315"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Debt",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1312"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Derivative Gains (Losses)",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r78",
      "r683"
     ]
    },
    "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/DerivativeInstrumentsandHedgingActivitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Values of Derivative Instruments",
        "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/EarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Basic and Diluted Earnings Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1207"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Provision for Income Tax Differ From the Amount of Income Tax",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r634",
      "r1033",
      "r1309"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofTotalStockBasedCompensationCostsIncurredandAssociatedTaxBenefitRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Total Stock-Based Compensation Costs Incurred and Associated Tax Benefit Recognized",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments [Line Items]",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r385",
      "r386",
      "r387",
      "r388",
      "r708"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment [Table]",
        "label": "Equity Method Investment [Table]",
        "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r270",
      "r385",
      "r386",
      "r387",
      "r388",
      "r708"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofOtherIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, Finite-Lived [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r426",
      "r430",
      "r431",
      "r432",
      "r779",
      "r984",
      "r1014"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Intangible Assets, Net",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1252"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Table]",
        "label": "Goodwill [Table]",
        "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r1013"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Changes in Carrying Amount of Goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Income Before Income Taxes Under the Jurisdictions",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1196"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Inventories",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r102",
      "r103",
      "r104"
     ]
    },
    "rmd_ScheduleOfInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "ScheduleOfInvestmentsTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments",
        "label": "Schedule Of Investments [Table Text Block]",
        "documentation": "Schedule Of Investments [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r735"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r446",
      "r447",
      "r450",
      "r451",
      "r452"
     ]
    },
    "rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Segment, Product, and Region",
        "label": "Schedule Of Revenue By Segment, Product, And Region [Table Text Block]",
        "documentation": "Schedule Of Revenue By Segment, Product, And Region [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleofLongLivedAssetsbyGeographicAreasDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r106"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Segment and Reconciling Items",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Activity of Restricted Stock Units",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r137"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Assumptions for Fair Value of Stock Option Plans and Purchase Rights Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Lease Disclosure",
        "label": "Schedule Of Supplemental Information, Operating Leases [Table Text Block]",
        "documentation": "Schedule Of Operating Lease Disclosure [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReserves"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule II Valuation and Qualifying Accounts and Reserves",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r280"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amortization Expense Related to Identifiable Intangible Assets, Including Patents",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1254"
     ]
    },
    "us-gaap_SecuredOvernightFinancingRateSofrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredOvernightFinancingRateSofrMember",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Overnight Financing Rate",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral."
       }
      }
     },
     "auth_ref": [
      "r1322"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r163",
      "r313",
      "r316",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r348",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r432",
      "r447",
      "r452",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r1002",
      "r1005",
      "r1006",
      "r1013",
      "r1062",
      "r1358",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleofLongLivedAssetsbyGeographicAreasDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebyGeographicAreaDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment, Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r189",
      "r192",
      "r194",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r346",
      "r347",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r888",
      "r891",
      "r893",
      "r949",
      "r953",
      "r956",
      "r969",
      "r971",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r987",
      "r1024",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1061",
      "r1067",
      "r1277",
      "r1358",
      "r1362",
      "r1363",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r331",
      "r333",
      "r334",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r348",
      "r1001",
      "r1003",
      "r1004",
      "r1005",
      "r1007",
      "r1008",
      "r1009"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general, and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_SeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeniorNotes",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding loan balance",
        "label": "Senior Notes",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r1357"
     ]
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "rmd_SeniorNotesOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "SeniorNotesOneMember",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.24% Senior Notes Due July 10, 2026",
        "label": "Senior Notes One [Member]",
        "documentation": "Senior Notes One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_SeniorNotesTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "SeniorNotesTwoMember",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.45% Senior Notes Due July 10, 2029",
        "label": "Senior Notes Two [Member]",
        "documentation": "Senior Notes Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation costs (note 10)",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted \u200eAverage \u200eRemaining \u200eContractual \u200eTerm in Years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r606"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r606"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted \u200eAverage \u200eGrant-Date \u200eFair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of RSUs and PRSUs",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extended period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Extended Period",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Extended Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted \u200eStock \u200eUnits",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock authorized for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock authorized for issuance and pending registration (in shares)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Pending",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Pending"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock reserved for future issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted \u200eAverage \u200eRemaining \u200eContractual \u200eTerm in Years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options exercisable at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of the options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate intrinsic value of the stock-based compensation arrangements outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r598"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r598"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted \u200eAverage \u200eExercise \u200ePrice",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of the stock-based compensation arrangements exercisable, vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options exercisable at end of period (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1282"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofAssumptionsforFairValueofStockOptionPlansandPurchaseRightsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life in years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate intrinsic value of the stock-based compensation arrangements exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable at end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum award amount with other cash fees earned for services",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted and Other Cash Fees Earned",
        "documentation": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted and Other Cash Fees Earned"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Outstanding at end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest at end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum amount payable pursuant to cash denominated performance awards granted",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Performance Award Granted",
        "documentation": "Sharebased Compensation Arrangement By Sharebased Payment Performance Award Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleofActivityofRestrictedStockUnitsDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable shares, netted for tax (in shares)",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/DebtScheduleofDebtDetails": {
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0,
       "order": 1.0
      },
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term debt, net (note 8)",
        "totalLabel": "Short-term debt, net",
        "label": "Short-Term Debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r152",
      "r1048",
      "r1356"
     ]
    },
    "rmd_ShortTermDebtGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "ShortTermDebtGross",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/DebtScheduleofDebtDetails": {
       "parentTag": "us-gaap_ShortTermBorrowings",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/DebtScheduleofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term debt",
        "label": "Short-Term Debt, Gross",
        "documentation": "Short-Term Debt, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r267"
     ]
    },
    "rmd_SleepAndRespiratoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "SleepAndRespiratoryMember",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sleep and Respiratory Care",
        "verboseLabel": "Sleep and \u200eRespiratory Care",
        "label": "Sleep And Respiratory [Member]",
        "documentation": "Sleep And Respiratory [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_SoftwareAsAServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "SoftwareAsAServiceMember",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software as a Service",
        "label": "Software As A Service [Member]",
        "documentation": "Software As A Service [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Jurisdiction",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleofChangesinCarryingAmountofGoodwillDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r163",
      "r225",
      "r313",
      "r316",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r348",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r432",
      "r435",
      "r447",
      "r452",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r1002",
      "r1005",
      "r1006",
      "r1013",
      "r1062",
      "r1358",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r96",
      "r99",
      "r100",
      "r223",
      "r254",
      "r255",
      "r256",
      "r281",
      "r282",
      "r283",
      "r287",
      "r294",
      "r296",
      "r298",
      "r314",
      "r389",
      "r392",
      "r433",
      "r505",
      "r653",
      "r654",
      "r661",
      "r662",
      "r663",
      "r667",
      "r671",
      "r672",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r692",
      "r696",
      "r712",
      "r714",
      "r715",
      "r716",
      "r717",
      "r719",
      "r722",
      "r724",
      "r739",
      "r832",
      "r864",
      "r865",
      "r866",
      "r884",
      "r943"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleofLongLivedAssetsbyGeographicAreasDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebyGeographicAreaDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r189",
      "r192",
      "r194",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r346",
      "r347",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r888",
      "r891",
      "r893",
      "r949",
      "r953",
      "r956",
      "r969",
      "r971",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r987",
      "r1024",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1061",
      "r1067",
      "r1277",
      "r1358",
      "r1362",
      "r1363",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1385",
      "r1386",
      "r1387",
      "r1388",
      "r1389"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r314",
      "r724",
      "r778",
      "r875",
      "r885",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r905",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r924",
      "r926",
      "r927",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r943",
      "r1068"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r314",
      "r350",
      "r724",
      "r778",
      "r875",
      "r885",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r905",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r924",
      "r926",
      "r927",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r943",
      "r1068"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1086",
      "r1097",
      "r1107",
      "r1140"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued on employee stock purchase plan (note 10) (in shares)",
        "terseLabel": "Shares issued under Employee Stock Purchase Plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r95",
      "r96",
      "r136"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 10) (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r95",
      "r96",
      "r136"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://investor.resmed.com/role/StockholdersEquityScheduleofOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued on exercise of options (note 10) (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r95",
      "r96",
      "r136",
      "r602"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued on employee stock purchase plan (note 10)",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r95",
      "r96",
      "r136"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 10)",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r136"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation costs",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r95",
      "r96",
      "r136"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued on exercise of options (note 10)",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r96",
      "r99",
      "r100",
      "r136"
     ]
    },
    "srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares authorized to be repurchased under repurchase program (in shares)",
        "label": "Share Repurchase Program, Authorized, Number of Shares",
        "documentation": "Number of shares authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1275"
     ]
    },
    "us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares that can be repurchased under the approved share repurchase program (in shares)",
        "label": "Share Repurchase Program, Remaining Authorized, Number of Shares",
        "documentation": "Number of shares remaining authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r99",
      "r100",
      "r129",
      "r907",
      "r923",
      "r944",
      "r945",
      "r1048",
      "r1074",
      "r1195",
      "r1231",
      "r1339",
      "r1392"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r269",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r504",
      "r505",
      "r694",
      "r946",
      "r947",
      "r970"
     ]
    },
    "us-gaap_SubsegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsegmentsAxis",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments [Axis]",
        "label": "Subsegments [Axis]",
        "documentation": "Information by business subsegments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsegmentsDomain",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsegments [Domain]",
        "label": "Subsegments [Domain]",
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": []
    },
    "rmd_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "documentation": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Balance Sheet Information",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r1183"
     ]
    },
    "rmd_SupplementalBalanceSheetInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "SupplementalBalanceSheetInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Balance Sheet Information [Abstract]",
        "label": "Supplemental Balance Sheet Information [Abstract]",
        "documentation": "Supplemental Balance Sheet Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value added taxes and other taxes due",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87"
     ]
    },
    "us-gaap_TemporaryEquityForeignCurrencyTranslationAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityForeignCurrencyTranslationAdjustments",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "label": "Temporary Equity, Foreign Currency Translation Adjustments",
        "documentation": "Adjustments to temporary equity resulting from foreign currency translation adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "rmd_TermLoanCreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "TermLoanCreditAgreementMember",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan Credit Agreement",
        "label": "Term Loan Credit Agreement [Member]",
        "documentation": "Term Loan Credit Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_TermOfContractUnderRevenueRecognition": {
     "xbrltype": "durationItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "TermOfContractUnderRevenueRecognition",
     "presentation": [
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue recognized, term",
        "label": "Term Of Contract Under Revenue Recognition",
        "documentation": "Term Of Contract Under Revenue Recognition"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r1215",
      "r1346"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Domain]",
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "us-gaap_TradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeNamesMember",
     "presentation": [
      "http://investor.resmed.com/role/BusinessCombinationsScheduleofTangibleandIdentifiableIntangibleAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade names",
        "label": "Trade Names [Member]",
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1253",
      "r1255",
      "r1256",
      "r1257"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1153"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1155"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://investor.resmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleofChangesInEquityInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r486",
      "r503",
      "r693",
      "r706",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r833",
      "r1035",
      "r1037",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1049",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1324",
      "r1326",
      "r1327",
      "r1328",
      "r1335",
      "r1338"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1155"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1155"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1158"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Treasury stock, shares (in shares)",
        "negatedPeriodStartLabel": "Treasury stock, common, beginning balance (in shares)",
        "negatedPeriodEndLabel": "Treasury stock, common, ending balance (in shares)",
        "terseLabel": "Total number of shares repurchased pursuant to the repurchase program (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, at cost, 42,664,067 shares at June\u00a030, 2024 and 41,836,234 shares at June\u00a030, 2023",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r99"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Treasury stock purchases (in shares)",
        "terseLabel": "Treasury stock acquired (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r96",
      "r136"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cost of shares repurchased pursuant to the repurchase program",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r96",
      "r99"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Treasury stock purchases",
        "terseLabel": "Cost of common shares repurchased",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r48",
      "r136"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesDetails",
      "http://investor.resmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r450",
      "r451"
     ]
    },
    "rmd_U.s.CanadaAndLatinAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "U.s.CanadaAndLatinAmericaMember",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebySegmentProductandRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S., Canada and Latin America",
        "label": "U.s. Canada And Latin America [Member]",
        "documentation": "U.S., Canada and Latin America [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleofLongLivedAssetsbyGeographicAreasDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleofRevenuebyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "rmd_UnallocatedCorporateCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "UnallocatedCorporateCosts",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationSummaryofRevenuebySegmentandReconcilingItemsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate costs",
        "label": "Unallocated Corporate Costs",
        "documentation": "Unallocated corporate costs."
       }
      }
     },
     "auth_ref": []
    },
    "rmd_UncommittedOptionToIncreaseCreditFacility": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "UncommittedOptionToIncreaseCreditFacility",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncommitted option to increase credit facility",
        "label": "Uncommitted option to increase credit facility",
        "documentation": "Uncommitted option to increase credit facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UndistributedEarningsOfForeignSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UndistributedEarningsOfForeignSubsidiaries",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Undistributed earnings",
        "label": "Undistributed Earnings of Foreign Subsidiaries",
        "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r169",
      "r627"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1152"
     ]
    },
    "us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceOperatingLossCarryforwardsMember",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Allowance",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Operating Loss Carryforward [Member]",
        "documentation": "Valuation allowance of deferred tax asset attributable to operating loss carryforward."
       }
      }
     },
     "auth_ref": [
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at \u200eBeginning \u200eof Period",
        "periodEndLabel": "Balance at \u200eEnd of \u200ePeriod",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r279"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "crdr": "credit",
     "presentation": [
      "http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Charged to costs and expenses",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesDeductions",
     "crdr": "debit",
     "presentation": [
      "http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other \u200e(deductions)",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails",
      "http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Allowances and Reserves [Domain]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278",
      "r279"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails",
      "http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278",
      "r279"
     ]
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "presentation": [
      "http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "presentation": [
      "http://investor.resmed.com/role/ScheduleIIValuationandQualifyingAccountsandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "documentation": "Disclosure of information about valuation allowance and qualifying account and reserve."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "rmd_VehiclesAndAircraftMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://investor.resmed.com/20240630",
     "localname": "VehiclesAndAircraftMember",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vehicles and aircraft",
        "label": "Vehicles and Aircraft [Member]",
        "documentation": "Vehicles and Aircraft"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1121"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Stock options and restricted stock units (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r1207"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted shares outstanding (000's) (in shares)",
        "totalLabel": "Diluted weighted average shares (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r308"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofIncome",
      "http://investor.resmed.com/role/EarningsPerShareScheduleofBasicandDilutedEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic shares outstanding (000's) (in shares)",
        "verboseLabel": "Basic weighted-average common shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r308"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "740",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "740",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483605/220-30-50-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "25",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-9"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-1A"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column C",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column C",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Publisher": "SEC"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(C)",
   "Publisher": "SEC"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(dd)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-4"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482620/740-10-25-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-5"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-21"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-30/tableOfContent"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column D)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column D)(Footnote 6)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/321/tableOfContent"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "325",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/325/tableOfContent"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Subparagraph": "(a)",
   "Publisher": "SEC"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(ii)",
   "Publisher": "SEC"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)",
   "Publisher": "SEC"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-16"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-2"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>124
<FILENAME>0000943819-24-000013-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000943819-24-000013-xbrl.zip
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M_W,;/3[C5/-ETUKF,DJMJ]!=IC4"WV>PEC5*O#!-(BV.SH<%4> 7J+(L=8P
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MJ42$)]X*X9@F,M=RQ4CZV>@ 5:#R?#PY>'S^Y*AG-PG9'?Q=ER:K4>CB%/L
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M/?MUU)<*N\6O,@'$$8(M2]H2C&2&EJLEV[7R4^:(P/@&UU>L)(+1*5$Y$I+
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MD&1E0A[D\;0\JMFU&12L:J!G$;U<4("I=31IYBTB:I!<YSE2W$5YM,B0"F=
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M[M<?O3>7/UU?OO->__#;6_KY^XN?O+=7E__X>>2]N?!>'D^.3[[R],U];[/
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MD7%R.+_5#\EV^?G13:[REF3[02F#9GARZ"T"(X%0TYZ:D>"D;)W:\EVC 5O
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MDNF<X?2["SSQ&CJO84XE=9O4M7O7QUC=NIN=Y%_.ZR$5$,MU[)V;X6.<I;;
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M'^-^I&97F?6J_<PS*)+O^$2,=7,2Q_]02P,$%     @ +J$(61:)XH*( P
MP0L  !X   !E>&AI8FET,C,Q+6%U9&ET;W)C;VYS96YT<2YH=&W-5MMNXS80
M?>]7L Z:;0%+IJZ69,? QG&R0A,G<+Q(WPI:HFQV95(@Z63=K^^(DK+!Q@;:
M FWB!V'DN9V9.>)PO-';<C+>4))/?AC_:%GH0F2[+>4:99(237.T4XROT4-.
MU1=D6:W55%1[R=8;C5SL^NA!R"_LD31ZS71))UV<\:!Y'P],DO%*Y/O).&>/
MB.5G/1;'D4]Q@3/B^CX.<;P:4NIX$<4DS'W?_=WI@2N8-SY*[TMZUMLR;FUH
MG3_Q ]L+*SUZ8KG>) [&/_6,Z61<"*XAGP3_1FS"/ >;C#59E;2+N1(RI]+*
M1%F22M&D$T8Y4U5)]@GC)>/4,DZC+9%K +$26HMM$@" 1RHURTAID9*M>:+I
M5]VJ6VQQ;,>15\/3@$GG7>(6N6V0#W3^6A='=HR/J['M/.L&)G83'RI0%>%G
M/:_W79$M;&P#<*1$R7)T@LUO5)$\AX$G;O45>?9P" :UZ$"%IJ2F.C/[5R6+
MJM>TO4L'"(1,NM"UQBK(EI7[Y,.2;:E"<_J$%F)+^(>^(EQ9BDI6-(:*_4EA
MGI#7O#XUXQY"'#.&=OR.5W=T]MNG]#Q=(M>SG>=I/[=C8$9V@$8O"OICIS0K
M]KVCM#GLE@'#J?S_JS9LF-[.[V?S);J]1.G\8G8W@P>\+F97Z?URMIA=H+O/
MY]?I%'V<3F\_SY?I_ I=IHL;]'<J^Y<->4NW_Z[__L'^+S<4G0LB<R0*=,$D
MS;20ZOWC7E!U P=[RC/[]"2(1F\\U[=IP@.%\Y&K>M-I@32,DO%,R$I(HIG@
M:+5'DA944I[5*F,AZ9HIW1HH#>NQWG *_3P7RD:>YUDXPH[7-V(4N9[3B(X3
M8#]J91][ 7XA=S9!B,.@E4,_<(>=/'2B-J03.9[3_1^%7A2V<NR[;NOKNG[@
MM38@AG$G!V ?_8( ^:606W1O135MQ4Y"65 UE)&;??]QMX:AG9XX(1X!YGJ_
M]]$3TQNP4Q5PO.M7W;YZ=1BO@G'",T;*EWTA_* "J6Q#\QVLWC2M,31\[!M"
M&I\Z.BT*R,4>*:=*U5:L/FDYQ(&\6HH2"5@_+\(W5<#JLH\P[+T=ZH=Y>7KB
M#T?*/-&O=S=7Z/KZ[A\5]#:P[PF'(Y"N11]-H8N%D)R1=X+M *./TN"[6V4E
M%*N_]D32DM1L?'7/_':S:JY4WUS("CZ/G3[N<HQR1R^M[;.Y0@_,U?TO4$L#
M!!0    ( "ZA"%GL&U]Q]Q(  "15   >    97AH:6)I=#0R+61E<V-R:7!T
M:6]N;V9R97,N:'1M[5Q;<]S&L7[/KT"HQ)&KEA1OBBQ25I4BR9>*8[LDY_B\
MI6:!6>Y(6 P\ ^QRSZ\_7W?/ (-=[))TXDI()95$2V NW3U][QZ\F#>+\N6+
MN5;%R]^]^/WA8?;&YNU"5TV6.ZT:762M-]55]G.A_<?L\#",>FWKM3-7\R8[
M/3X]SWZV[J-9*GG?F*;4+^,Z+Y[(WR^>\"8OIK98OWQ1F&5FBB\/S(DZ?C8]
M+LZF6IV=%_G9\V?/\Z>SV3/U=/8T/SMY^H^3 TS%<)GCFW6IOSQ8F.IPKFG_
MBV>G=7.Y,D4SOS@Y/O[C 8][^6)FJP:;.4R6G[)&M]++%XV:ECHN.+6NT.XP
MMV6I:J\OXH_+POBZ5.L+4Y6FTH<\Z7*AW!4@F-JFL8N+IP!@J5UC<E4>JM)<
M51>-OF["ZQZVHV.!KP%031%W#J^/^-63IMA^]_R+H^?'NU\?'YUT[Y[PVK(^
M4/"UJKX\.#O8P#+ ?5(WF;>E*;)'Q_R?RUH5!0[[XK2^SO#VDM$0C$H]V\)2
MUCD8G$Q8XI#&7YP='STCZL2'S#'=TV1U?G$@IQ97 OS67430Z,WA3"U,N;[X
MTT]FH7WVO5YE[^Q"57^:>%7Y0Z^=F<E ;_Y/@^38A/]<!5;!.GR*@75.3HFJ
M;__WFV__\NU/V?G1Z0:O=!1]PL<^QH<#1OAS@BKC?_K%%O+\*,$\AXAH]V]"
M_8WVN3-U8VR5V5G6S'7V3E\9WSA5-9\]^N+TY-FES][KO'6F,=B7!$I&: ?5
M\&/K?(NA66-I%*]S<AJ7HL')W+?7^5Q55SI[E3<TY.3YV?F0X/]2PGYH?6-F
MZ]^.LKSBA6FP73Z@]?DHK=]I_S>0[-LJ/\H>$VU/CR]7>L*_3BZS\,2VKGMD
M77S:^O#L\VRN?&8KG>6E\I[(Z'L*N_YDV@J"/G(F-YS'),/R"FJ[P!J/:4*
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ML>'=L.&5%L%CM7J1%&J<-)??4%QRFLKM+V$53NBB4!G6L:**X:&L=OM[ T3
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MQ?XKBF_Y9#CZ%8^BAQC/.U*I+#"*EO."KR>XN@9%>6 JRA;Y(>:#]0)LGSH
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M#6<(.Y%Q\]\T\VM"EV$5EW"$IU:?2G<8:K5NB:TX.,T](4O"5:X,O5:R4I(
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M*NM/K9XD@&XOC6_./<E&EU]J&00("JDU2YHPPL>AS-A-!*:;'Y),II[O,^H
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M@,9(4BJN1TJG7XFLU,@TVBWIKTH>*!FJ , S@!SBO1I*Y3N<MY\_W?S2*(-
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M@)%]K7XR=V^V3]$JRO&7+@'Y%/Z686B "'!+"1L<-02."$I(K"(+,T!6&S7
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M'OI;ZJU%?N];GRI^PBQ.J/\(2$6?<ONX[0WE&B$/PUJXO-,JZ4+T078LJ 6
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M="(8IQ!0G($R E4]"^4U4")5'-*DDQ!'QE+Y"?9Y%7RFAER-_PKTEU*41K7
MFDI\+<9F:9O>:'[9R'\D@Z&0!R45D_.9<QT(H8CFK\[Y5MC6VI+JRKH%1I=9
M[=\^_*N^$SA9$$VD2EN#Y41*X2KJ02@@;-AU2) 465TMVFKEX7'EX8R$!H?U
MNX8>"8(WQ?SXSSK_G4SI[DQ\=E,M@NY\RKWVM80,$Q7?]J9+EY0H1]^/4215
M2)/<087M1+0<ZLG4M-38IU34F^3E")YT>2&J#Q!;F\BPV*R EY!S2P\<Y=R&
MJ;444>^NSQD0&&2?R:CA7)IQD"5FR@Q^;TY^#6?/Y&;O'%M!K27/ZEFPJ'*J
MQ<*TA\9L*L6"O(DY&19C@!=Z%KTLG36 $2]3&4 T]#"WE%@8YOU"2OD\2!V_
MR9@2FDF"4TH%YC48OD!F<DKU!,G'W8;*'?32O ^?X:Q@>Y*41^Y-,F9$HV*H
MP$OU>GGV$;MC$SGKB:0I3IBS41*K/. F+GRN:4.3)EN@W%6ED7<+'5'+4J.^
MIV'Z9/F3L B:;=_$0D%N"@5_Z*2]*8J\P>[2<U-_=/_PJ0\:22>40Z3&_#CM
MW:(7C#$)*?>%\!C%VG+< //_3>)\(6I?=T7M8]P-ERW\H=E69#:# [HM1G*W
M=UH.40RULL2L,V/843D[RV4=1 1DG9748>HMU,0>V=@I>Q+%K,%2:9=G#BMC
MJU0$>1(KIJ&1HJV-P8EV2@(S ]-P#+0]T'"5Y0([YERJZ?"8HQK\) .?WD0N
M3#R;316_&!18BN6 BVS/V5''SBV76\K.NO-H'Z"=DV X 6M&&*XF^K+Z1%%8
M[(?E69.Y.VO&+T:]G_1*#LLK^?Q1.2)43$8S>DSGOT?U'9/W"G]:PK/-\XPS
M-156)$- T<3@BH6O<]Z*\A;C(6@T&;SP'T U0BVQTRXO\0:3+GUBDRH+4[G*
M'_D KEISN:FO8(F$'P*SIP)*V@XQ='(ZYH9W+BAXD"UQ<N,EP%S5F%W#1#(0
M82:-/M8"L^:E+\A+SS6GN,(YS3S%\$2KB<<ZSVWC?-7,V3,80)YIR[$*'D9=
MV&0E5EA*VGN<./7^BUH6/1LW1-6&@DWY7-F,*L: VN)),S^%6MW0'9@7K0\(
M6J9\X,I3ZZD1IY^,:2!]+B>*T+%.TR[F)AH^,.YE1GF"_#M[*_ 13&\N/:,'
MU; /8CA)V*_>4!-!\W?4B8$+$P/WZL3 .C&P3@RL$P/KQ, Z,=#:Q$#+(P9Y
M90-I&X4REBLZ6<_06Z@-+R?]I&J:6JZJ*2,5!^L4I:BZ$9?RU8-*J70O]5)V
M>J*Q23V@2TDQJ)E="*6]=6GDN7.L7DU56WC#,9AXZ+Q%TS%.R]?)#"TBV0V]
M1..MI*&9M^#@##4$>[X*RY-+6%M,AOXX+T[B@A32:1?, % -;@N Y)JC*C0I
M;H6_X+V2!RO#T>)!4@I!W+I$#2K2TYY5RRSM98O1UP#_5,HXN;M5-(B<JQ.]
M%P_SGN)I[9R5[%@.<+!5REW;QAIJAC\W$7V)752DPF>0=]8F+[L:?<1J>I&Q
MA:Y+'(5(/7[\A&H,B0-P@FAN!VB/M2;&(AZ4ZH I=AA1NSD!&NUC8P6P+;I
M$:>^'$3YR*F^+P-O9INZ>*A8&\$Q7QGEE%&W@V+F.G6]SM^3J_>PIL\BOD.
M:5=*UQU&45 *<Y)!HSIEY[0/2_SMRU6SK3H=<_<%+\X&"8<T<T]+H!J>4$J7
MPD;NHJ*8)B7^%!/!LC"4 ;F3P+"YPSI/'"\0:E/*! 7V!>1\09XLAGXN122^
M@11C-'SM,'AQYROA&#]3. N,9!9;_ 5$J(F4M\1\$*6 88JCF*DW>9Y:$6;&
M,V8$Y(!21R K]/&GY+FI1@13)U5#111RP&30G'T647LQDB=FC_LA29"\,9%N
MXHFS.V%%_YDZ+MSP4O>7-[DTU73C[ SNXU#,G;HNM3?4DREUCF#Y*.))4&-&
M:#!8N;G#(,C<B!+VTRB0,>7),GDD6< ])WRL.T37_''.*C ;-V>A2E1P4JK*
M$,%F$K.=';CYFI>'UQ9VG)QIEF%VB=334Y#WL;M2M9C7PT7R5!H<@ C7<6YJ
MCL^\$:":/YL'@I1$ISIG=($;(4F*RQ'S'0D E,!1LP$-<HGB6\Y0*L1XHO.,
M,9.%<IQRGXQR?@748!YH6)-CB99U9E<>?R@G4-2\\@5YY1>IAGTA99P5O0+T
MF,LBK^U&BM'FLQ-4C#N%Q= 1I.$^=+J,1@>ZC$<1GTJ.T[J5,0BHH3C!8JVG
M,1ND*-H>JJ O*HPX8U)UL$3C#I79J8"7Z1\.3*B;'1HX>(3V8:('3B?2B.JJ
M-$=U1-FQR\E%=VI$B !^I0Z^F05D5B60,EID*TS%XV8T>,06-KW0X(3W8'ZI
MFOM*/'&^EJ09CIY9N+!5*".A29%%<_;3-,=D:^H)H\HJV#52U]38O/)'YHN9
M51-&?%E/T-$)PTI[3HM9)]0W Y,N\Y%:4G@#B4..<U27IF"I =NE>=EF:FZI
MZ8IY2(W(QR>:JA)C"&-.G1I0D9LE;$S>2\TSJ(,7AM"5!4'V#G9B46-!(U6M
M9PST0O=14/2629Z4S&\7>9[RRFU>^$*-FRE-I[L7N>G8R;.A$Z21(J?:?VJM
ME <.TLVJ*@.>\L0XY58_\5W4G.Z ?-S]G2D3NW&7)F[JGCV+/F;DT<V,0&WH
MII&"SPPZ GCX&^=X\1KSDY'W<3^&+79EROGZ>9(U?0!="MY4R:JN52EW%D4'
M$BGE>B*O$I]Y 5W#'!M/*1UF-:T:?$TU+WF:2=[>OP]'#@XU]LW#K(=].GB!
MR$(7C99C/_X*2FYC=H(U-6/E[%WM#DO$B%L&&7KS*$(NI%<=*5#EB"&U]AXK
MR:A+\M3$U3R%,?]J:9+OW!VHI(A\!_A)U(MUXIK*,C8(D6ONC%4U<-M=B3/1
MVFT]4M:HX\/7]0'>U =..\D$X __F8!0ERAA@P&PS70X2LJ9Z_AP42*G<BSS
M.I*A'BX_-?,SKTO(QAYF%YKI>5O.:9$EDD94%,T9:&H,>GF0V6[GKPUG=^>O
M_&GX2VN>H4RI*2YH3/0J ZX) G:G@?^[S<]QO[*8/&O,91>SUCH8O%\'@^M@
M<!T,KH/!=3"X#@9;&PRVRWS ^&'*U74]B=:>3OS'GC!!D)$7F.T 7328EV5R
MCC)KX;V)"CL)3V*N\_(V8%48;?MPJ[4[GZ$^E='N'VSM[QRNB='RT7D9OG/P
MO?-$8&8[E'3__Q:C\7OGX_F7L]_/OOS:B]]]N+J^//UV<M-=@A%7:M.G9]V3
MZ_.KF_/+B^\S7$/8S"ACKBLEJ%\KX\3P!F;#&P%+;O-=:4MQ(9\H^_4/],YT
MS.-P]2&/Z2W,EZ)4-]9>3\1CF164 QX4[3 L:>T,J<&Z%K"2J?]9QC5X5PM>
ME!$U3%<+T[/ 3Q</#ZB!^@- ;=7L=3U@K<__ZF$ZY_P_YN9X(<US W@ZR0,H
MRO<_TP[*"!#Q++R\X4TIQ%+$+ #U.P>=]Z09Z.@&A3E&U/TG[V-2](ZB-CQ)
MBFD41;$H=Z WHQ34XD]-X/*Q:1'WY<E;\>2QF91C8J&\Q_11MLA+,94B/%T*
MI00^K(,:'.D]7,DXH332&[77XX13QSC.14TC3H;2O6V>AW/;8:7"Q\PHSQED
MOB=4>T($!O4Y:E"NK^HQ)+GG .4P:M"JG.B^#C^%B#K,4<5A>)<4$,Q7KP>U
M4$+:'7Q7E\5&?=UM*@^0<Q0' ^.\$ KQR?#/B*=!8L_^!',Q8CV4D;-2L&]2
M@F/)X@DO16=98X*."H:7'LB](=@_BL-Y91II-:CM"(W8AB^"I2]Y>S0UQ><8
M?3E(ILD("< =EJ"N(ZQ4ZJV;,&A84B1*=WR@U>=M+M3\[.,@**@DIU8-5W@V
M\P/DK7F84,8-3#7%P!;YUN,H("FH>SZ4AO7F(=6\PR?>>@UFOX:&4:&,H\*1
M=%.C'94J]"3@T*TFJ5*OJXC\/WF>N\I^Y\,S'JM)T4!QB<*ZV0U-]^)XGDFN
MXB-5,[Q/,BP;_Z@:+]8&^&K%+D,7V.[O2/$U4%<+U./N[S5(5PG25DVGZP!J
M3:<K!^F\F-M+2.H-8$++YAFU++V/B@PZOD=WW#H"G8T[<A5WW ]E6$JP&V(C
M(F5@<"\O,R%/I&2=P.=2;6]0O0,^M>5H7&@%+N_B'$M=$$>J)VM;6..A*C5X
MD&_>PUQ_3RENLR_6LE.W9R]?5 Q+)4M/33=793V8BJW;QJ<\"7W.1^",+OH$
M7IKW@1,L[*3JSI'_@&5&:+@EF*"(.>Z1Y[N%ZEM\LV2$E?78LE&%JUELA36F
MK=4BR=VT"Z@9'".!S,R2?06_3&@R!BK#N1' JUR[$5#TU+5+CU<.#ONXPT(5
M'M-$R]FARR2P5&?C\]DBFM^4&(OV>CDW-M*3;;"]&A A]1[4@,J]!GG>+"9#
M-X5'.1><3SLG?Y9JRF=L>")W=@6HPAO*%LZ_D1^9CT$FTRCB\>W4Z?&..GER
M(W#E5GH\&Y>K3S[CE7_.K2!;D'=29UG\O%D6OY]=W)Q_.::$@SJQXG6ZM^=#
MI)O* )M,P%_$9=J[K>=(A2H!9+Z\4*7,"BX%"\_!4RIBHD+AS&?VV*?Q *J8
M3ZN4\ZO[=*U*RJU#Z4'4Q6<Z(I/0F-!WPBA%!1S['$_7 D;QEI-C$I9HSN\!
MU>SWXZNNWLE;K)@) ,:HW/\.RN!(-H])N?:H'RNIV5U^_R]3Q2\L_*AP4\]9
M,"L,N;Y^<^[13:A5"0T2>>[IL7;7CYX1WOR\(X+D6B+44IF7UO7'RFJAW@A$
M]!PX25+T[W/EX;V8J#GRU'9A\?'BF0\)=?69Z/%;L A8M>J*PO8.G+T'5XY5
M\Y.>P&#'A!?+(315NY93OFI(J1>M3=)1I+NL8\=K*;@^?.2'WD]G6!3>EIOF
M\8O;%.L/BCQ^"&8= 0@&:H>C#6PJ+Z/>Z;HODE$^/]6L5)":;]C!NL@,._W$
M/EL 0<:EN#PQO%%JE$&E^)-Q9,B;+><\596 ;*K$S3Y6UWL!?1\-<G+P8&@U
MX\K+O*Z23T5>!UJ812HJ72I'5R91;JHT2K%9;HF2)(&$STNY-<<W]]KEQ1<P
MRQ+G=[0^NPT@%(+)#Q\;:S?_Z(DA&.CCHF+8TSK5O$R!DK@PR4X+F<>.&7:V
M*9JGPXW:[3>CP;VHTH8>@1(\4'HR>12TH0]=69%;B6JVK O GF)['%_E='5#
MA-.B9\)5WC/AN&B)0##D-!!]?:F!/W85VN">YS>(8!(V]IM& ZG[0BPL,-[>
M_6O#V=8%QMO[*RLPMAJVWZ<GFU>_F#)T>Q#B-SB*3JG.E"]4S%+3TZ6G6Q@6
MC0G4>[9H1!R_3N2-QC'3)@;U5JC&.>5AO$R'JM9^)'2;0621H['T2L-[2X-Y
M9Z;QJAG":E(V1Z#T&&'LD4 ]#D*18*,B^C]G[&-S$A6APOF]3=);1GQH>A-C
MDM+TJN^'/G!]V)4_XDEV"'LUPI>RMZI'$7E17KDF+Z&H29]:%=SAJ%9UXLW^
M,@@K["@W (E1E^#5SF&= 7M\<_;;Y?6_:F?PZ_%]SH<(!KY&U*G9(A_PINQ[
M->[]TTZKH4>_?]HN_GV%F;DJ$P#_OMANL2 A^*G)\5IQ1TY+KBB),] PAR(A
M-U@?Q0_;.CQSI+"O\PSA42Z,^Y&;J?Y$ALA" UZX:2Y.M9#+<W=)&M(T3.KT
M%$N>**7F<,8QV#[E0<T_D3W^*0;#*!K]#-9W0:=^0<3TAT'%0.&^TV>@: V*
MNRMI4H;UXZ1.[$3GI%F/>L(1 1N3J /YX!<3IS K"/OY H&Z.GM;=PPRYZ_^
M#-[2;T$:"Z<;]9_%8>W;[>+<"R"L&VJ[]:G3TI3&/US #V4V*:C^@ILLD_^3
M%,O\ >!^0_3WF,XA592CZV= F56Z_7,)R]K3O8"PN)4]F$-PC'\B=F90%7&W
MG*:FO8B84RBH?,:)<60!"EB4C(GC<?]9%)WG8=_'X09=B:,K@(.Y--I=T1W[
MYS% 1.[O+/3_#8_"2WP>.I:"F$^*;G3<.S8IJEG4<.!$==9-U;P_E,H)3@*\
M%0,YCVP7.NGJMFT'==NVNFU;W;;MAUT9==NVNFW;N&[;]DK;MBUH5ST;,ZN>
MF_N//&^;#4J<LD+)$/F<I;SW,O?<]].B]+HT*R6<'>;-L^5US0N'>_5(6",(
MI]WF_&T<!R+O,#QB!EZI?H+>[XE4:.50%2J+4 23_W#"ME"W%=/2J$)$3Q&A
MVAA\+,7R'"Z:1Y<^!?;&,<YVH9!V$<W!L=WPCQP>RBVT?(RN*N*P]NS_J-%8
MIWG_+)[]8^1U7_SP%@UEBYS[FW <%%5 !B]793E<SPAV._O@'^"[:3PI#[SA
MP8@-'->-HQ8Y"$W3+HC9AU%,*4#G*0V*4D6  /;?,>Q:"-]25BF&Q6,Y5&-[
M3!FCRO4HL^?_9^]=N]PXKFS!OY*K>[DON2:KQ"(E63)G>JU2D91HBR*;)=EW
MYEL""!32!#*A?%0)_O43>Y]S(B(30+%DZ9(L.S]TFT(!^8C'B?/89V^>4)"4
M^O<"6?^ ?[^^6?];I+7"ZLS'FAPYP0T4\MG6[9T6\/EW+Z.FA=^W?G$MV'6Z
M!>QBG16-M]S(7G5U!8'1>5=>-85W.E0I5-<_40,",H6,'A[WMX#)/I+?>Q$T
M)2X'0D]#>-B]=(5%>90X1C=0&9*4Y2@5RD)-MG32R5TO'?5\@I 6E$F$+RKT
M,;/_<+.5WF_[D/W4L:T63,[:8USWG3=H*MA+7#_5)RG:US<#12)#Y"2"*+Q9
M=67_:;(@B=Z&&M,\RH\H?9.JL_A/\J$H1^=M EW955UW_+,H-RI4,M!2A\[X
M//OI1-1]PST4!)T\]+QF]_-5HDN#5>&?:^,=]%P0HGZ'%8+:OJYQA^V*.67
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M=@6]A#0;E7!*O/Q1_-=JER>.1*P$#&I9+;I[X=,*ZJ?N_2@MV$PV?!FPL^+
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M]TSPGCN=FL'!I;AUW7N_2WWA&\W)";Q_/_=DR0C-I2H+R$ (.70_AKP>(N+
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M 9)JX19#D %Q50YE--MYUE+Q-&S)L"R>9A>KHFMO '+ TO!N;=U4^/S/]0I
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MY9FP' F>$@DXYG(4I?:>EQ<H;>1,P00*^9J_YX;(NUN63,SN>RM[Z?_5+HM
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MR9/XC:Z<_.X7<O1Z_T,>2NT THT*QBF;@^,KT2^><DCW+%MS>^1L'*H1!&
M;\[7DKHV?L03?D9+:P"'DL\KQH< /HUBDZ]F2(!<Z1.>!QDLJAS<Q!2&V;_8
M8Y(Z7;B]3L-MULZ S1:]1S',@?6M#YD]E."U\T^\'/8+^5!;XQB*.+:M1D,'
M%_AB+)5)=^B7[C2SM4/(TRA1&VR-)C?)!Z<9X9!JY0EA.$D MTIT<MC)%DG'
MHKR=!'HQON/"4&$$F20YET+:8EZW:N^#I8_ :+\QA:33>PDEOJV["\BQ7TH
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M2=>EADG[F7TNJYC6N]:LY#B-5$0F &9RI3QH];1T [<K0;.PO[Q#LR[]5G(
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M=V)#;5PD?I7+/<@[4,Q],%^?L"O.;HK4:?*2*0$U='6D:5]?QBU2  0A82<
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M3!R5<PLM^YLE',%PE_NV)W:3O$(*PO^MW0I/6]+*)_KRA.J[Q0@[I"BU$=S
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M()Q8:QHD&AG008PJ35*J*>4?INGB@HRYII&]@J@3%VKMXX!F0MQU77)M0MA
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MM^R2_PF-#=< :>#JPH'ET%6"8  W1WD96G#9 O:<;"2^*L=;Z>&<)K2PZE(
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M$COUVB@ JMG?93GKAJU9L;!J"V;+"7O=%U+#/;;O"6\8A5.@GJ?^DTT$?J%
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MRB9"1A*>#83,B.27*WZ1IW)UR0@57C86"Q89$J?AE3 4A6_!K>RU<-B2<;R
M]U59$[@%M39%68RT**PXK^JQJ5U9A]N+":XLLV)\2[@ID1%CENSHBZ )I43P
M+/YRBB!*82H^ENI+TPJ.]&!6?R3&[#B+FPPNPM3A_):4HQ^T6"J4"G[PB<(M
M<"P+TT2&XX&Z'/(NK*"RC+&0.*]"+#-MW18<O*YD.[9-8JJ:4^8ZIA[A$&\T
M\.ST+,<F*Z3/:9-98%Q5HVZ_2/,F/GBG@7H>"1LF7.;A>?U.66JX2[S/;:^Y
M=#+7]22FS,,[,A,L@%_MR82A'IE5Y6(X/RQ,E^_FY:X*2$*)Y*Y\5VB\N!@
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M\+6 U<0C"Q^H[0S[3@5829B26"5Z-XB$@M(%0R:67YK9@86,N0U3K#>#+6S
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MGFESOCMZ@9_/"]05S"L243"=H7681BN&Y&A&FBGZ 1\XYP^<K21G.KNV]_(
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MB56.C*#_(&< 1?;XP&LAE"SE\3$)HU=! JS5B"DI^\4K$W]R Z)4$/WB4:Y
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MI',1AY$X4I3J=F>.I<XE0(6#<#(-J#;2,=,3#L<5G&0>'+!^;HRD<W0<\+=
MM2YGB%*FR!*@1M'+1]^C&>)2(06;%*"_(=&FJKRF$]UQA9PN?FIO* .?650R
M[(MP(8"[06)U@^86$H(O(9X]T(1X>:\GU[F$)<J/5:\DK!*EG<\P@JPB AMD
M@\N@@-Y)&TY@S/*FGSM>?:/N=5IC_N:GL(X$O53=Q2PF;)K18*8;<!R,5C5O
MOF,KFGY& VHJ&";"QURYLN.5E("Q"+2FO,/$MJ7SUY3\ I6B(<,)EL*.Y4=
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MBZ$'QASZUNC\GKQ<3_#IN^^WH7/K)LW<'(+'1M,G=,V?#U*5\.=VV3/?_9I
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MY6!><JO ;!@=YN_2.^#%N4'5MUM4UX>7S6&&=E2@%:Q3&M&-TIL**OTA-:#
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MT\T 37V,<BRWD?(NXFYFY/1!LG@,K-(,UW[AAB/NP\"&D5*\8%S0]DPXML;
M'U&"#,/8, [PGQ&LF/OH\4UA\XQG<O^5E!$/"RLC?)34?RQ*D-B&[S#!-N-O
MP;W1D@7&AHBVQ\:N1Z* YHB4EVBYLF_!"GZC+"-,!478;!L]7?O[]<6'V[]?
M7GR]GK@0%4O+!W'4CTNQ=>/O!M(B7E_=O/_\O]K5Q2?\XA-,AOPAA-@46VHA
M@I:Q!G+];3!YFQF/S"M8@,^"?D&TXNMB+ V;KC H8,@XI0K0$2>9A >G('?
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M&GD)XLTM[>_!/832H;YA"7,(,44^4B22_"#&LT7\H2NJ$>!M+EA8R820,A)
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M5,_JZT;EYFYUS/12_.E:7;US"LUTI\F?KF),/1ESI'J3D\IY;,[8B0/:[3?
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M'WU4O%N<(@(+YN2=IQRL>J3TK$P2Z)YH)Z0U9)Y$'[]+UTY&)';3PU>0TD6
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MY.]Y^3 ]!#G;LPY*^3#/S)RA;O3W/%)5+LRCU#T,RN$LW!?"<%#>2RUY<U9
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MQ<V.BINAJKA1%3>JXD95W*B*&U5QHRINGN?\M5N_\]??TECC,IB/TT+_XY[
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M!? P.ND/Y537/J-JZ:CE>OH40E!AUZVS1?RI()=Z= 7PC8OM.K#UK,Y.K*5
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MO_R5O^8=YT"/Z1BRO!1.>:<L+X8[#Q@<!>-6YY J\T1ZSV SJJ"5I8"!)9P
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MUL=F2?EZ/4CQ3-9[F80@9\2ZVLK=&(S F5^>[(W_!'!A)19#<?85L$Q2%.\
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M<FG8$FF1C[DNSEC_$$6]YP!T<1H'#P]<^%$X$V+S8-\^M[IR8U>)8-]8^&R
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MNK6_!C\OPRC\%/M=D3O (/PWC*6,DUY+I)MA\>*#[H794GJ\&SSZP^1OK0M
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MIXS27Y'.8.A^+*A</1!A&:V.9;I,U6OG"BB")1^0UKI,S0')!""!K^1:MB1
M.J=JPR^3QAQ#[HM&SO"SBZA_,4[X?-C*>[N5,W46 88U:G="Y-^0QM_P)5_Z
M/Q(N3-NJXF*U.IJE,4VO7<)"H2KYD+1&[S:*)!N0I#O,LV3)]I^])?QKT7 H
M4[D6V;OU%&]!SZJ2X6#8P#5UIM:7#;)NY8/-&BV[+6Q<A(WCJ$SWFHIN2F++
M'J]*%;D<;"[GAP]!/OJ%8R>>:5BAEIH]"ZMDC9K]%.#(N=^")]Z[G1 ZB]MN
MX0]B+M:UF*>:DI@E9.#N3_4V"B5;;74L2V>&*8NO=$X7X&YXG\>QF$R!\UV5
MU/\YJ3W4].VB"6=AG:S1M@5=;P59OR-5YVL6/D=A=ZMTF8WI6=5@EBV+^4)6
M[_Y4[PYQI;<ZFJ$SSZE]I,ME%A^%'B[J$S/].RU.#!=RL13@W3; VX20X"4Q
MUV2J*HNQ0G;O'@.[32 (K^?9.C,M6:I8SZ;JL"%=>N:58!M5'FXO'E:K8S)+
M,YE=_WXC%1^>!N0V*C[<'G(V0LYP#>8ZM2O!J?ZP*6U=KJ'KE_2=8 >2:GL_
M&;6PT4E451DXK8X-BD!GAM=4:/OPY\\*XY\$B@2JTCE;5:!<%"C'TIBC-G7/
M2J+3569?J+Q;Y6^!?Q\,@S3(XTQW:=3]8Q -@:))/OI"P4K1]&6KHO]% \@
M/O2B,:9U96MIN79I9V!M%:TLAU-<4#_+8TWG3=IRC?P7; Y#;2S/HTW?ANVG
MOF:HV.Z>GNUA8S&'.7I37K($X1<2B-,4B W;:-42"$?%*G\5C-L3NQ1SO(6$
MP-=XS&?:O&25+ X5#]8^0)"N,[[#EB*CM3J&XS"[?J25\J?RH6B]UFT&13J@
MR+:8;=?N%R!7#O4H?(S7MQ%G'$<VZ>Q2ZSKB611Z5;J.6(C,RY8"@V4K%M,;
MRV])8+D3DK:ZCE@72:;HDNTUUAE($I/W*#3OI%@[QDG2XX7H#ADBFX[U@%_&
MQ_PS2 ?7XP2VQ..Z@B&N?.O,LNA&S D":MT<C!T "F]^&RY3G=I-9,G(K8R-
MV]GK,'DPG:[%-!5'F+F]L*5P." <JL,LS9'$#B&+=N]QA/HH<EL=1V>Z3C=>
M]H^'NT$4IQ<ICQ^!U_=S+>1<ZF*TK8(55/T.1/T0Q7'T#'2H6K#C>*V.QSQ5
MEM :F;'[4ZSUT>.J&7I.S&:569'.M]2>B<;2[9;&U6OMU(6K@7QH*K,;ZUET
M^.IBNMVR2YU<'W(Z6+F6RZSZ<S/H=DNSW;6;JKFD%MM'YOPT$LD_BU! G4C^
MUE<"70-CKPXSS*94YI&=Q:>-J3K!_.TQ90*F-(]I[HE5"QZ7PFVPS]591 RV
M[W,%_YBQ7;>7&PO,5X\9ABQ3:BD@)46[JZ;@98-#COZX+/'.<S*#5Y82SK9K
MH7+"W903;B\VF( U-6::LN3.R$(^>$GA]FART3:VF5N_*1;9QM6UL.@T.(S"
MARP=6S>%<!:&RR;-!ANQ3[#3-LZ@KUWH0N:O?"C:I.%@$RCRU%;'=IEFUXX]
MD)5;&1"_331K0X4N9V&"K,O$ E&Q4N$&2%I5&#00!L]AAB:+M4&VZQ[SJ36
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MB6<\MJ)(7Q3_V8][E#6KG37[EE'\>P1<P/':@VB(5/D4Q7=(_ \^^'H@6-A
M5]P;KBQ96JOC,L>J,R:64A<RXFO#XMB= PS;N*K,-B2XH4@(.T1R;.<(,\!U
MT9FIGDY:["CL@KE;,"GVYAW'+YES?UY^_8ZJ9;[Q44[A>K8S9HTME:DT$O,(
ML+2+(WY3+*V:#&^JEFR3X0E+^W3I&\62+1N6SLF?+UB)Q_9]T<>B&SW>!V'1
M>BK$O"$Z]/#7).CQK"<5>?-U3_4O_=]Y_,#CW"2^QAY?GXI4WM9Y6E-UL'9
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M)C2DQX_\S"Y3-=G9-Q>>+S&*3_Z/&1G*Y6>&Y%<9Q;7*0F2T.@ZS/>K?>FH
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MI+9R-2ES.JIFLXGEWZ,\ %BH'Y[\&D=)=;_"Q<(VDSG6XIE5JP"Y%COEOA=
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MQ@6Z#3C!8O29[EE !FZ[6?XC@4U%V(QI@G.7'G-_)K!)*=R?);-PH(($B1'
MI'A!+PWY\L2H2#X-\2*F &U!?!'V:[JPW ?&(:<$?@[AOC]XWBPP.!K/HSWC
M6'H<H*9IW.[$6(GAK;:M*D:/X4 ]*9 8!/]X)%1< 95#ZR1D&8Z;SU%3\'8.
M/"(PWK#F0Q.^?,\AX6-4$M.8^XSQ[;P5+PHCWPT0A(MN.,:@-0+7Q59^US3^
M0(P<(!_"IBN?C1$<.4'QB8B]^V#C!<8$78@#$!&UIW!,=FC&KT<J29Q9A/)%
M$#U"OX?_LYRUP%K&%2[L (%D$( 0#Q%H MMN LWY@^!3\H4F'JC ^!?X->LK
MCA@3[]ODF([)0YTUA["UW3GB]E)- Y&*704CA(/?SY#O:>MRX2JZCR7^9('<
M<1 H"8II++T ]=.?#*&#"Y@!7H/8+S%)4JS#F9=C-'& &,XX@BM,9-3X;>GG
MW@,_H?#1]/&S TEK3/Y (A.JUG:)2WASBE.]$QPM*10)CSUZ3L21_?F<A1#V
MSD)%FQ#JSC\CRP<]B6"5B _D1ARXT09!(G:(>2#S?&9-%_%Z$E!E>8;P5QMX
M1HZT0$ALL0+2+ JDM #""^0[<$L/OK7D>%^PTFBJP%A::.+6J KYM@B?C.^%
M@V3Q1W HH?LUYU:YJ$?+B9C$RY([DMR&@I,%"$,1Y)]+$\Y22"<!H^& HM5L
M0]0%AIC%(;,Y/C4-GR @V3G-TW ]26B!FB6PM6DU,6"K6#4>-WZ,=)) T4)(
M,C]_G:DS)9+R-1*K)7C==)QB2[M7'^\3UP^L"+^5>(8^6PK R]19P+&?I5@2
M9N_47N%.""&<\R8J(CCN)S300205?\!17+>*<#P&Q:,!'5R=K04>7'+J 8*+
MII#T[IGC/1DN>_!"#M#EP).XLP,6<QX#^:[ %/Z"/W&LIQ3X,9\[D[S_?Z:,
M8$;8\$@% )C<G]#_B.-'Z%\(MB<D1GFP!.)]4A1(S%.YELY Z+.'/&E=LG#A
MS<Z4>_@H&=+L"80:*APO7.QB% 5A-D:(4_R8@%@3#\'%,-!)T.-6%-4) #BN
M68GQ2'-(&+\8CDT:5(X#3&B/YVA <1M;B.GY&R!U7%:6B,R'DW$* !))7R83
M$2(DI8N3E<!+MK@7*+";TUH:(;MG0!C$DT-)%J,3X*-@DF@6%C$]? ]_*]&!
M)8OP3_-#3!1K &*!GEIL\M&T"_!H.L7 <Q!@DB8_, X:&-A :ROEZRJ!18C?
M@HV)N4OP7 $I2=\W$Y$E\4YPPPMW9Q*X(EJ2?'HVC>OXA<+2(5Y=K/=PJS0>
M23C%VSRA^" )JYI.TS)0B12>IM1*?.<$ZRG=$WQ9$=3UN0G#MC!9 =CGR-K$
M9$(3SPC2DB&^//+^N>V;%"[Q 6V!FU$5V3_&<<6M0TPQ(\9%"CS:'&Q\ _QR
MO_"7P[C/(V=N.P[]8HJ1$#Z!9JP$H;24@1FCU?JS@N7@YP,)\Y^+N:H@3B>H
M_F1HY+YIC %8#M'1AL/< PY(_8 ^H<M7'8%=]?G&8[AW>[GRXAB54)AEXHD(
M(EY[Q340&6QE7(T98YYS?Q&?P&VX-4.P55J.*?QM'L-N6B/.E#0W1:R"MGN/
M4XF4S<X\FDL3/GEY+!PH0_"408%Q)&^[CSC43(X3S'F"HBD@L&:/EN0@;QEC
MY6^8$]BU'9)N>PK 3H@4C$ E5L!>TZD2_$DLA^MP&[G'QW$%GCL+P"+ 0T)G
MG;AO<0BCZCB$]'288'ETS/D8H  64"#EDH0KU.ET11/B^;G@-A%:$V_N A%-
M'(B5M4X-.,1LC&JC[& SPI=HJ_@I8)A-OV./F7,:CC0%1]K5<*0:CE3#D2I_
MTG"D&HY4PY%J.-+GAR/-G]G:>TV34J?E1OLA$CX0'SG!%Q/C;RB-^-T._KQV
M9\K,VG@J6]&<OU$K2]Y1JX9S_@;-,;8H3%(;)Y-,6S>^BYDIJ8F]\?8/F@1(
M=#B/"#T1/]O%Z>1\JF<<?JX\]%ILRK4%T?T_1"U[JM*2:J$\'<T'T%"XPC/A
M8EH&?@#+8WP:-OP#DSD0./$9<;RRS/T:!N$MA< XJ,*'S_ Z,Y_(;LUD$1(_
M'(AA"T4/I@TDJ<(%<T06P<&R%Q:K<20W4^::(@GL,!+S43V9?4]'B! R>5C.
MH62&NY89KMRG\!4F&U'#4Y_%L;I,;V#EW8N"HA719Q9P>)+:E/:#UXLQK+ 8
M=7&49V$^)J77XAMQ5=KQ, <APM\@-3<NX/0!BD$<:C\H8W/0N0R1FO:_K'AF
M_-(*X'=7KIA33N-,B(EXQ$L,(5(5@6R%R)PD-57$;[N7RS48!M>"R9[B+**<
M#!,G84R1/L2Y*K,HD7"JUH@@F$]>DJ'PTOH'IEKBO&8\?4@Y(#<N5W).289>
M;GX)$Y1-XXLG>2$9Y<2372(#U&[]%0/KI>?'.8O0"VE*+F4C^/)$MI4">%ZH
M2Q(P.^/Q5V/99K%E>VG[(>?$EIPP_\FR_;]C:N@SK_XB$W);6FA1<Z;'CMI9
MBXI/-OXNLTZ) K]-%/A!P^7YNW)6<"[S:PE8'8D3I^3FN=;-EJ,NJ5)$(U=I
M/+7:XB(+OM@8A%>-J;.#+B5[R<0S*^[^6]/L+= ,&)@XJ:'A\-CP"3M]N)E+
MZM=N4KU=)CPBLH5_Q+\D/9&_$?BVLE_XB2H]?(@WE8!X&P2OY%KJ9Q<VZ'%_
MNECS_<>3P^4 VJ7URUYBHA17AT4VU%=)D<UV5Y%0D4O;S7PR<K.?I:PDWQ+U
MF,1K@6@F=WMQ!XL<6":4KTCCA^G#3C9DRY88&HR%'W.\)X:=4*!E:4(6K8AO
M%3ZLIE-%@*(\5SD9-&C8U$;/">('X219[.7"S1-[R'-+GK(W&']:\W0'=9*N
MWXE\;>/*^)HY7,%$<RQW&/^,/%Z\I&+IF\CE'6QL]I;L&Y^SC,EO?H>?<LU)
M$RV?_T?.$A>8$L7OVE.O@]0C+ .5<+P)1=05D$)N\I-*:N&Y(%%6CC5EKX@P
M72#,SQRM$=-'C,WCWB%P2NA0"X'K2;4JJH;K8URDVA!EBXGN<#LWM7Q_C8HT
MMG79N,K*PGWR0$'^'GQCC@%JK5:^]XNW!?%>7$4%WK.I)10[_QLYVE<TL="U
ML!F)N_K9)3D>\!Q];L;N0T,&'Z(EZSM[])Q'_(*(Q'%M.*A/_GP=QQ+J @-J
M753M7FS.732KCHC5L$DGE!&2X*$X@,5(2_ 9K ^M@\];#R6_Q9T6@KWXGY-I
MYCY[B"!.<K!Y!+38812X8ZX-3,R38]B).[.I,PE+HL?OD5IO-S=(O4NA0UTC
MH%%HL/(HGJO\ 19)O8O C*Z 'IABZ#Q[X(W?BN_A"UW$;9X00M[?Q+LH8X.P
MR5&\WU3,):>&'FDR;1>"_5!X::ZQBN[!59:Q._)VN%92!*(XC;$U*_[0G)J4
M\=QH9<;""GCG=5[?D.C+Y\Y<8JFP:"H:=\23UV;:^^*C8?FTQP6V_: >IT;$
M?-=-=/[3N:TB'XO\>TQ_?#7A'2N7N(PO8H&.NW9G^#\?$TU7&%#E#*0:=>J<
MHI2I+/J'LD/CL#1DYVS2D#>;N3O>, ("B04;\OT9N=PS1FT!"BH4)L0<] G@
MV[.4!L'//%'K'S=K2Q19;.>1W20IJ\)5&,FQ[+=(/8TW(/DV$!!D>8F&CRL8
M6-6X!6';.I!M$Z*;(I.0I$'%0MC5(=%Q,22(2R"Q19]C_\KEY'WFARF&6S@H
M%QO!"G5!3C5HU*VA+A@U6Z0+Y(Z0PPZ3_N[92/\?4DAM9=,B-8+!N\_O+8$3
M\T9I>HV=(;Q*Q1.U<]L/D(]-\2]P=42[^EN*%JA1C_+7:/(3PRVUC1R^;1J.
M=4^Y6$QPN]$<KUU0W@+;]1;,FHFV0' 4P+[; 7A(XNX>*1W/_Q-6@5UY- A<
MV9;HZG^T@7+<?:'1\G'F-VXEQIXG8$WJ2A8CR=,K$?W)O,.?LM(K)@LR]VO1
M9,@[[GPO>EAX$2<H]7=AB GOI8LHZK6Y9!2U\2:Y6!3?EQ-W#Z+ >A#3S+&O
M\.WEJ*>'P]33-Q\/)UQ_<RP7QUA^E+W,A>JJEZ.N>C545X-FMX?'(7=H&K1'
M8HYXEP<JL-XY*3#10[R*Z;"*Z1!WKIM*'RSV\&(<AU+,EAZ&!GSW\:>EMR)<
MDN4J"K'I?P5OLL5'.0*W<E4'GX+KNL(U"M67W,5+!!GB^7GD@-/TF'@B/!W7
M-'ZJ?TO74+=R_6!_MN>O^-V>LQ1F I!_^FX6^: _9P%S$VGH-R;86HRJ*U/;
M0&=K^[HZS[:N :P+(LG\=;%?4[;BW;?WD>WP0FV208A/,KD8F'= <\HC;-]@
M!K"BL@T.&Q/X& 34^5M$[G4@=F<4\MI+M&;<?U4NG%E++$?\BR5\2 DD;M5%
MU2#9*_\$/91JMIS[%UB2-O >(]";.JQYW_X* G!RMZ4HT!TM%#-^?V2I.YB/
M[&#NZ0YFW<&L.YAU![/N8-8=S+J#^:0=S#E!(/RV?R9!T8>\4&7.$5+4&,E,
M!TG&$_AP_U8&OBT]!K:_Z0RKZXA1V :)CSMJ3$:@HC,0; ;0Q*$*5;G5=(Y;
MSAB6TVL.MRP'R55N2=VCEC3&V;=@W0J7%+=54I1@,!>OD?Y7Y#(^6:/;,HU.
MJ].C_W9I^?"/CBE;0L&7=C;K]J\F8[0X-*$=6B[A6M'HDP"4C!VRW[$WC>>,
MDM/):=H;Y[0-OGBJ2#92)ELS^-X.2P^-<]L5Q^?3KHAQK;6R0\Q'2RBA!SO.
M _$$\YS2UD\&PMW(FE8<4//Z$7YL6XIG'@,L\8<H=ZGWS>ST,MVM"3MN<&K)
M#,.XLR6%TC1NYX8EEDV]>M$*6_91O6"^/,Z6T[7P$!$K3,JB1ZZDD4S48\;E
MR;=#?)<WGQOV<LEF-C4.O.J.(2X/?ZA9&$3G$CUHL2#*5CR\WY_.(=)-_YB_
M;+\@B2B9RN>XAGAKO62RL#J6ZE:;+:QN8;W&9&[/0U;,[PCPQN\\X#]X(=@W
MIK8_C9;8YS.->W0YSB"5D@@=)<8-P_[;5';7%ZVN[HS*Z.*G):;.R-\B;"H!
M@6:%E'H+!4H98L[$Z^$::HJL()N>J0=V@XDNJ(O%/LRV_\WS9D_@.5V[FPP5
MR#]MVOA^CJ7KU]#&CYK](9Z'W,>!IKU_3I4?A/2@DFT4@_N) B\:[P=)"47B
M9KR"RRO6V$TB8?Z$G9[;Z(.3CN WR/(>(MX!REE<BT*,1[Z*Y 8 1@6\85VQ
M^HCRP9OA.8(=601>/":\V8>D?0:A4)Q'QKL/YQZ"J=!G0K8*WATHUO7J/[Z#
MK1@MU)+_!TX.O#%J/>?5<Z*S[(W\*/7@/Y7/83G>XQ6(!&_L:<&X?27'A*Y[
M"1164+TNM0B2#MZX:N"AK[-Q='@;CQJ*\(O8$QJWF/(&4+6B*)F$]Z+*E3VE
MVIFHS<$T[B/>Y8I+<>RES7M2\2;FU/<0H\9;<C7&>S0#?,T,CLE?BY8(ZO9,
M(;["9ZA#0[S7))<!,8^2_L<4")@O[-M5C*)&N16Z1Z"2@'Q B3/[I*">54[>
M4.W@+28O-:SR"T-+V",NFWBH+:47^ -4FF 0 9;X:B2E'<O#C0>ZR&>;9$:=
MMW$-B4@M>IK3+=+Y[/LI>1H<D-+QD].1(A'ZV$QMES.N<U6F*"-2M!##7<O<
MA;CA&[/.!BOD\4\^>V#=E\TVV]1-1= X8B==_4P>'B\XP?_;(A&;2XEO2RE'
M(1<29EK3">!V'OFDIK!;:<.,@(S#!W(IYS)L:;+\$@F;VG#PA\3NI@QU<&@"
MZTE%^K*,G;:$=WO$_&SS9&<9%98U[X$X9Q;#J*<9-\CGTG2K?LQ\N!Y\/3_[
M2[IQ_(_#G/GW N05U.&]F&T0;'KO@QSO?5!+[YWWGLH]&>JF#O/D!^?DR4O-
MRY-ED0]:+U 09=/YM40N-SJH#&LJT%.I/4:YV@A_!ZK-T$$#3:K KBJ-HHF[
M+>Y<)9$]Y?[P$2O>Y;E$% 5"M'1=#A'*F]2EAHECC+03M-\B%:61&-9-O$!"
MMI"0D<J:8V*8$IR:>F?G'(\R>9ZY 5"^D;.42\5]KU8@4]0Y($T^O]%TCCC4
M:+\YCKM$<'\$@YI044GF^*D3IRO&XB)H#(UA<'#1#5[B]ZKXS605QEST*6(X
MD3'OU(.,!^]3^Q6\*-5NB'_F640AXZYL"([![+'7S0L7EV,U_CS\O@*_6%+4
M 3P>YAB-80V-ABSK?.0W[Y*='6@QAKEEG>$YE74XYC&GQ^:5QOBZ(G7_IRXX
MHBMIN2GXW\A-W0_"^X@AW2+XD<K'H$J,"-&'DE#I41X;*U#0EC*7)?EXR.V?
M$&FAY)95"N.&NLRX$N-?+1L U^8<O]*-BV)*<'PL>8 $:83=72##ZH"H-$('
MWK 0:!8"50D.1 (K; .UD'>PG[B)34,LY*(J9&$4C,^[=L-M S<Q*VJNG<G&
MC4"Y<2<1J).B4>8BV[WE4)HG6+ L@H-NPBW;A-O73;BZ"5<WX>HF7-V$JYMP
M=1/N29MP<TKO\-O!EI8;C%7R(ICS&.J*5-X> \0 K]3^41#>;$0TZ.OB#63P
M3F:("!L/@\4WJ*DT2O84^*)B?$KLB*IS>/=W1HV=^^/O%WA3,68$K#8*E*R)
MB3/>+)?:F"-*U?!/R)FI/+=#41@F=@JP9HAL.;"!24TB%X8FH;O,MP764LR^
M\_G<4"H[[ SHDI:?9'PB!11)=D@,GN$U9+7ZC7](53MET3D][H6OE;'_J2+;
M0EP(5(!X4O;PB>OG2^;3WQ&ER//^3)!]Z=(YZ"S',1XLV^5\('!LO518R\M7
MN^)8#@0@$J"1*W\T8^X3]4$X'GR?\0;?]=80-W0W(GN:.)2,8,%"C6BQPS&H
MXKLF 1#D<6@:]X-_Z76W)9(V_)@E)$UQO%_'LQ-5=$;;G8.*0$G&_@6L4A%:
MK^<D[:^2U6(UPDMI3&!18R#M,GB<C?].QOW0=^(2:C* BC/#?AD.XZ?X PV(
MQE^)<:F4;\6\3+"P./(OYU\$B^'L:X4<Q8%8%2^SJ@\^ 9]=2K^><UBR]CL+
M&*9AKMW9!\S5>'1/Y2-/C&S6^D8YIG]4P[2M[-23FR.)4;9W8.?>Z)SJ?;(6
MXE A)B'#3"%#G/\2Z3F!J5ONDOFKD:#E81(D$ 5O!*#@#\7- :&B'QVU=)Y3
M#AGGR-6XAG+5%35T":(H]WR@/(W/1IY^;!J;Q-=+FQTTA>B>_6S>-1&O$OQ*
M,,<VOT/@X1W!R"7>@&\*"$KIE'-C%W?KT1-FF*SRS62@ H?8M%TPI,H'N#^=
MK$E!R9;PB^@UQT]0B\]J>9S&^^8L_HBUHPLNU K#FY"_! HE1^Q$7R=9E3J7
M4=ZI3$4-6#C"SLL'MOD@&4_P5PD@*CD0<1HM(YY1CU]&$QX(NCGV/>2 8_1
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M/6-\=GFZ;6XJ]M1^2,+ _Z1H\=PV2(4C69PU[B4* LBT/-.-L)R:%I)F5\L
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MP=25_>MJ8<]FS'V'Z^TU)ND78:#D!G$3HD'HBXS"Z5A_!;'6PJW8+@3+K&D
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M^IOQTT5Y?&^Y?YK&E^9UD[Y@S9:V:P>A3X@6\')XHFG\PX/UPK<M6"*.*'_
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M1N"&=D8FT"PK5$(0D(=H/!2R2)4SP5+[^#M.7);;P)%7GQG(;:X6H+FWV]0
MS3.>V;/29.]40_>Y_8O-KO[%?"]+\E&KU9BX7IA=O&)24&8%]6>Y_-8%"2V\
MJ :<2+*88D?0;ACZEK?6O4&)4^3NT9UXT.;1C5KMQJ27U_NTJ< /Y[F-Y8YV
M,UV\SG&R3KR5G#>'[EXRV)TT-&)J>8K6F:0"NLZ=UF^A>+?P#E!YT]GRBX51
MP.AS[=]$Y#V+ICS\YYUJ2 KI:T0AQ>S<0>.*%O8PC1P><0.78 MP@(/1^7>
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M"[GQIKRL(J[42OD%A)6$O=-JB]1MZB-)(PD8>2#ZC"YN2FLL?$RIPV+[C;\
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MO8;5A8(Q3@*0\&7&J.]GC*8$.W^NW6HRR*Z :N(<)E-T*- UR\%DS?KB!UX
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ML&"TT"<&>GP^C8.#\?+ 6+;ZT9[ B'$S130*6HBU"(S'=HR<@')R@6D.>U5
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M& &WL"]!L#S"]<X4B<]N L8!H0*"AO$3)?(8=V'GC3T,/W"!ICY]%K#A<^@
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M!T;Y>>6,8+@?'.\5]"-TH&1G"5-,'F_I721J27JLS'ZMJRA#EM&H$;+DSF@
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M:NP:QE+3J0<R;N[6!?[RR*\4C"F;/\,+0Y!3;"]*I"#Z4W")@UF,Q*!0(K^
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M$Q7+.^0C>4;$/A!ZHL=_OF6>N%E(GN"N3UXP^+E J2PQA@%:DN%UG'Z(3R6
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M0R\1)+E[<5CL\J7KYN>,Z6BHY/")2^U<C!J%A";YI4N0)DTDX<0B">9CX##
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MV>DIHJDHHJXW5:WS'([E< Z\! Y4MARQ/0@'6LB!FJ4VL7MS#FP5&#D';N7
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M9L@R&NU-PK#5 9@'[)C*!Q@("?$J&*?3_D$*XQ#9]4_;;4[8@NEY%N0EY$V
M8O37OSB],GN"OFY+.(G#(9K5M:5F#H>4>%3)<QA'];=MEQB4RM^O'YZ$N[L2
M1RR6/36;W3%'<JB5G/-=3":"M?UHA;$Z]^U^J-)KW:K-I%@O>_C\^/7SK7!W
M?P/VT_VM\/CCT^/=[=WUP]WGQ[42I2V#OP]0F4R,K!O4Z6#)'-0SO[B^XP]
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MK\5<AZ"$H>A/-J[DVLSHV&:]O*/*3(!*"] SS7! O<#,&(U(M-:P284*U?I
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M0P!F4NQZ*[&TB$:06-;&:E1M[M#<.!7FE:!/7-P8+>(_ ,8%(4\TVI-&JS;
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M&.&+SW );..H%U:.@BAFIV>*JGD1U8ZKW%_A-/*!DNN/R0+7S%Z),+.> -@
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M!=VX$?(D*W!T.HXW#%!1QC%U$C@M=(,$7I$\,8' 8@AVD$@L,1R6 'C%=).
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M("?\H@V\,7 ='(6X!9CC%78S >D]P<J'=0F$L@/#](>^R\>0F/:!?1]<1V@
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MP)%-3_@C\._ Y7U3-B&,(U0+[%33LD2'T A4E%PMV3D/$9U=Y]>(1=V%@ZZ
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MH]O-,LAPD1]+T2]!7(/5ZM=5D/#7U0,.6QSB+E]]DQ?W<)/GV$.S5J_4'D"
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M>1?5?:CHQ6DZ@_!CQ)G3DD@]IE"&4_/GOF._3("]/CFNZ[QQ-\7N'V]NT8@
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M[3-63L++B9EM00GY'6*@U12'!.1<!T*+#(UP'=:'R_EQ@?=/'84OM1:GXZL
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M0KM99JL.-R-6!_I#E7%=7+1W- ?VA5+OF?A@"&\($1>[ DV""1GYN,\Y#GF
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MYP8ZF$4S^>,=>FT8U]GS-L)8<#U"#&-^I(O[<9*.XB:.ZFH+<RTH_CC8)-#
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MNUA&S]1K0(V>*86,V_6DF$Y>3D<*ZBA)I5MFLHJ3<TXBK9.)VTT'73X;ND*
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MZ>RF\CX,ZYG<?TSOY[//.%]>T-J=+E],\R__N1I_KLO\-UR.LLC,)V>(5D:
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M;6EEZ6_)"J^25,%P^XB?<QRD0PK;#6D)#) G@U0:73K>MTI_FW)(-EN3(]/
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M!Q8=(UEV1ZV<*5UI*/',<Z(X#MC88#G5U4\JUU]ZG"HC=I1Z ^-TC=6\X.H
M0;#(K"'>9+2=?/#$96.)RDYH%Z7&;;*]?[( <]JLJ*.#!O9K!^C-;'8!Z557
M >0]3(>3Y3UN]\=W7<[,[/4WF,;A#-( T-Y.$JTRJ5*QN!F4@/I$LJ!@.&4
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MZ #=P6@2<4HP8J(*60?'@Z@=SM ?W>FPI+(F&J3F7ZYBC(//R%^T!37N<4D
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M2JU\7_AV,O[#3_^%9C/N%Q\A7DQ1'Y?M:6-"0:2HB: 4):2,)#Z6?M6"9YO
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M1Q@/)].WDSG,WHU7VY+'<6C0AH"G#(>(X[31%-/#<=#*1<=O&7YK[Y?6/?L
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M#)$Y:APS;FN6X8HD(=.H:E<%O_;Z4Z#!KE)=H^$J!Z>KN_)R<WTVF<[+S\C
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M,II\!^@N/=]?3.,96A_7H 4>=:+1D>1*LYB4- E)1.*\<8YQJNCM,@MK=?O
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MFX:]'-SK;S"-PQG,;HSOS7@^'8YGP[@89$@Q6^,B83$H7"QB)$Y)1;)23+(
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M]PWP'Y,1/F8TG'_OANBDH8QK0[B70*2S"8>H'$G69IJ$\"943V!K/ZP?<^'
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M-:_M(71'=T&ZTYB:)D6RJYK+E8>S&3DXG4PWKL]O:3%21@;E\>R3)$1T?+)
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MW.X,)J]J5T.;!\YO<=PIO2'>.>4-:*'+D#^KP,>D@)MDE+2$A(?-ZRIL$D\
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MTTD^U3O(W,/Y8@O.>RVV[]X+*:PDR1+0NO3*0N\;+"^CEDMJA!"$RMC.!CL
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MP/,&[0:<WN "LM)U92+]*'&ND"0^WY1D)=OK\;UX=<M%ZYK0EUICR,5C9>3
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MHZIDL[*LD(^HEJ"KN[T;1$#WT>?7F =VWR [PS@KPC_[YR&O<"H7$D^!K3
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M\ZQ"XZ6.Y[<PIF_3S-:=C(8UQE=MJ[K0TA\>1",@AW;-Z^LN/%R#\-$5_-5
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M>K;E9@COD+KC.HR:Q'QTGROWBK:K3T,1,K9XA#8-J.>1X]=QJ*YI!B"69G6
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M7U[SW1A'C6S4;8Z;NS_?<$?Z):^*QS#C^F([Z=V_^3ZL-B31A 'P=WD54X7
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ME+GI/9/*->,\K>%.PH;!*A&M3 3>/#.T+'H.>\S1:]:R-=]<TBD^>\G%L^R
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M-V3GHD3<:,$TAQZ[H**&T&ZZ-.(62T&QZT$=H]3 "2+TG(^%8)UD@R3RQ+F
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M/X%^42S<^H-NT%C0QP;ER)]5^F-8VE$7F#;4_L3:K1K'?21PYR4@8)B5I/@
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M40.<XJI_<E/[V7.>PNFUJ_B),H=P:0(DU /V#<?)0CP;5",U@H_T%3-$\ =
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M%6BCV7USP8;C+K6UTQ[)1J> PQ]WI(^_#T'XC6WA$)4PRD,LX!@'O B&L<[
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M5HX);NLMQIM7CZ%G_/IUM[84CDJ$6 Z7:Q33MW-[FIVTTF#Q?\9(\C .&O_
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M'95?V6[V1R/["K3O#II&OBZO/G+<Z!K"&34Q+XP+0F?#%$;94-0P3KZZ8UL
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MGB"HV('A5'=,EIXW3:;>SWRAN*(=:K3 ;R_QJERNY]NY];DDXT"L!,V8*95
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M4U=_N' 'K83]?EX,9H0T!YWHV*EY$I$F>[W1TVO,<;2\Y>JGQK$WW[>&S#R
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MZUIJ[MT*I-'8^6M=)^W9D*P#%X..?G%^<XY6>,%D>'N3/EL^3N@4F.I-\^(
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MS8926#/-L$/RX!G,\8ZZC(H!3$?6*^?;OCKGE21V8[E['Z%340:JS $"A3B
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MSQ\^2"LPEHBXKB*" Q-H.CTQAQ8RG_9^GO_;BQWY6V+XW0EI/%>5DGFVBHD
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M\>IA0>M[OK'Y!YM2S_QCW?J/:D7DWEMCQLWWZF'?Y7[J[7N\6]/*] *D QW
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M)6/PRLI@)>!*VQ8HT/G#F5"#^338,87E>,M2X"/G%%J65X*V0-+P.=B]Q[=
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M8(D!,%R7'MKNHU&.;4!VWJ,?#VU"\N_>'9!\ZQ3E MK%L>.+'=D";;>?ME0
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M[" T^*GFX?>MX%OG,3X7X:8"[,KG>'(/,N7ZU],PVJ\G-G"J7 5%6R+O366
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MU1\[4(-\$I0O]KO38Y+]]_MRTSVKG(9GB9<RNR;WS8A"8JR,^3OY\W/C:<1
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M#+.\JG%.)8$J^W/5_/)#07'=H#[)%SCYA/P)]H]!^2OH>M!W?_E>L3_]Y[\
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M:'BT>)IX!D)+V.PG./AQ+/9QB+3L]8FAS!39=5'R[#Z_%5]BEWT?N21,XCB
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M'"^5Z<:8QV[@L-#7V43-V)@[$WG+09,BT[$(<$==3P,8 JVF'>:'3T]S]/R
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M91)"_?R94WDVE_'J^NO'[-.+S7*%0Q='D9M"#WLA1!&/8>Q[''J!GT8>=9S
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M(<3"4.\BF2III>_WG'MC;2[Q__K7V'/"?_N);0EK]FE4AE)MQ[8*SX+MQ2_
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ME!#?=WSH8NP+IPO)*K:$P=2+$B<*Q-^(QA5Q*QB9G2!M4>JZX,P!UK3C904
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MIHLT];&;()=!Y,C_A +D)(T<R!#U**8DPJ&[JF4MAM='>LN%-M+?>G\ =_Y
M!_UB,*OY=C."I[<%'_A/+2O;'CO5OKO5,6C/ES($PI(CI$M]42_&$)J7+HCI
M,/K^P^G[3%?X*9-+NKD<X& <)5+/$T]H?$89Q"Y)8>"ZC+#8P0E6NG"D3''N
MY-^64G.-4=T.5<-JVK2WCH">^AB[CPAZ9#[,@(RZ(6X=(3-[>U#Y[N"^J_AI
M]PW]8L? UA)[Q(Y6&V<Q<UE+K*%5K/>B:>]96F[XMD)DQJON/,S%."4)"H3M
MA2-Y(0I![$0!#%,>1#0-Q5^Q7E_9XX1F5G4=6<.#PY/HJ)E,-F364VZ]N .2
M,YP*3LEEK1_K"3(+]UH=%_:PC^K$\V=DGW\L\FT1@C:1<O\0V_<2BCV6PBCB
M'D0N2F L$P,2(3<2WBD- JWVIRI$9U[ ;9[RD(=MFG+'ADE.^!20:NO;-CR:
MALPT,C.L?1V9;2993Y%</G=:$82C*=&J[YKIBG;$MMIG=5G7948V=1,R*S[Q
MIZ*45-_E=58_[\*FN_X2@>=SE_HNC#EW(/(3 F,:N=!!E*,H0AXC6C=3SN)F
M[N1"81:7\HO7;-MQ'L)JVF4QW/343J=C.K[ D#%0%^ 6M]4J!SS-<J)M!1U+
M"NH\7A;57%9@>ZG2[ RJG^/\>_Z4R1'OLD?.KHOFHLE?\/IZC>]5LYM'AIA9
M]?S^\?;]\-BJX0 (#V\_VT0PL]'(<!Z#9%SM6$1#3Z'H  &^2%XL938K2&N4
MTSPV[F+9S K"#?.851XWJ&B[85D].,93W ''7IW1=Y84A^?X*ON6NL@:154M
MB&Y81_4E!);JI4X(-%8B]=2KRU5%G6!^KQ#JU+.&M8O$=#W@BM^0=7;?-OC;
M\/?Y1_Z]OOO&UU_Y[T5>/U2KV*.!DZ0()A'W96EH'R;,Y=")&6=^0KTH\'4L
M=T6Z,V^4XIL(-.L4*>*E9H?/@(*>8NH9 #L.+J2I3;BPMC-V ?Z;XQ+<Y!9N
MYQG*;*N.D2+590L:Z4%Q4-E(\_4S2ARUO2BJM@#OR@MX$C#/@:'C8.G&>S .
M*(5I2CC"CAN2)-%)GC@D,7-^1-O&I!J0E1GS;O1O31TSW?[T1Q *$XR\P$MA
MP-T$HL0)((E=!W+?XR@,<1BF9/745A6I<5DO@=-+<LIHO>'W69[+("#!:UDW
M[VQX,$\\/T$,)C[E$!%,Q;X2)3!.!3HX)&D:\@Z>=[E.#:8SP>F)*4/SKDU?
MLH6+VJYQGJ1Z&T0[_L6)6(SEZD9'9;)9O6B?P/+5B8X*>+3ZT/$G+97:;FLJ
MTI0%:8HYC"+BBD5(,(R1BV L3W@<[**$(ATM?IS,S)I\6Q>ZQM\![NI"CQ=<
MU,%(;4&>+[G>HCQ:#-MRE<EQF>8J</T*527'!9TL6VVCBN1=R7&U*9^;E=\$
MHU:.PYW 8Z%,374@BB,$,0TBZ.*4<>JAA#.M0M2')&9VK5H32Q:"E=F37=YI
MR9\ZFY4!\2_9D*J6NTG]P =_ T]E<5_B1[T5? 1$M=5['C1Z*[>G!1IB%Q,A
M6.U%>UH42POV"(%%%^MI 5\NU)$G]8.-_:K_Q+_R?,.[9I>'N3N$!]CU4@H#
MY,00N2R&L<<]Z(K]-'$I8X01U6Q.19HS+^/M5E.V;("?^KZT@V:UBFD2.DA.
M1W%GP,=P%^XXZ%O3ZF5(&2.D'O2= 2FS&+ *8G;"PIHBCT2)54=:+&BL*=HP
MAJS[JIDU<ZQ=^+9/\/;,(L0T=AF1O49EK0>*4D@BZD/LXQ@E8>Q&3*G7H!;5
MF97EMH']6N%[/@,[-;O&.B)ZZG$+1E,?L&=@T,M[EMP-+:$M&45J-!>UD[1@
M>&DZZ;UL&%7>7LO\K2C8MVR]WETK3J(DX23 D-%4WHD)8]DP(X64^&$4)RS!
M::K7,&.$FLX",.J6,;P??_4@*QTTY<&;I'L9.VQS6^1?>]XTPX@C2"K&$^V@
MHZ<>AK#T9&>Y7ZTAI:U0XPBE96..TR(?!!\57M'WGVZYV$VO?KD6WSQ?KY5-
M_&.OS7@6*JF!JU] 1\_ =C\JI[JA?JZ\9E;Y2[GM6.!CLHR8VT=?6\RV'F-Z
M:$B//F>X(8J!Q';P&\]YB=>7.;MDCUF>R<U6EG_L<KA7.,*)/%N$891X$,4I
M@PE+*>0H<..0>B%WM<QF-;(SV\T=$Q?@OF7CHBE#B/<XT=P4U=!4W!^M8Z2Y
M5?;P=!PTZ.SST-=IM+A=:@EM:^=4([KL)JH%Q,%^JO>V\0%?ELNB6GE[2"NT
MO^QV=554]:=M#XP5]R,_0MB3%K4/$7$\&,>80P>E7I2D,:.)I]U%=YKN[ 9V
M?]*P8T+6SI-'"K+9!\Z?^Q,&_OBT+IZY/&JHL[*MLB<[V.D?%2J@K:9:K".H
M'<*4Y,&0?M/#[@)<C;7P,SE-5)?3WN&B LVESQK583AR]*CQLKZ1_MNZ(+@W
M6G$4DL#W?!AX,D;'.()Q$(=0]@X* Y>1)%$N7S<<>&9+HB75'U:H&^Y[LD\[
M)J82Z:W.3AA]-V1/&G7WPU0J,[=#53HMK^.8""/>QM[CBWD9QY@<>A='_VX:
MBZ_JF_0S7F^/C9#KAVX8NA"G(84H=#@D)/6A[\28,AZX"=$J,79 8?88>Y=1
M("GJ!M=?@J$:2#]#1-V@>2M=0VR&*]8G1;$6"G\Y_L)A[Q/B'8:X3SUH4"A6
MYK:0Z:JV9%#5]I:7S4T.(553X/8W\7 M;?28.\+%Q]"-(BZVW01#L1X9%-NM
M*^QTC)V0*U>-M<?7S&OZ=_P]>]P\ MR&PI_P<Q,&'F8(4=DPCO&\$-Z3;(8*
MGG:< MS6#;IOF=4H?VIQYJ:-AE>:#\U8PY:#TY7)WW25R<E>8?(!JVV1<O#;
M:\Z'1FW:UYD7PT*U"\Z/7@E;^RB.U;.U2&VYXK;V(=JK=#O#\ NW#NG+,;9U
M&"\W]4-1-M$4YOC"^\0N%.9K(/Y#(TAH2B!VD4?C$&'D:Y4,L\[A[%;OH*<Z
MWE)MKK++%NO-JC9O]&U]OA0#ZZ\Y"P;[XGDM.PYJR>[X_@&Z<4Q!^MK--D[R
M]\_12V,*7FNM,B8)Z:ETQK/5V\Y2N<XJBM=M+_1K\;MJY40X1@'A,'(3X:X$
MC$',O!1RW_5"XM&$)4KYSJ-49E:M/5W0$@8M9="05E.CXQB-JT)KDFL&_DV$
M5E9&2D*-U#\1[[>Z1/QCIT+&1UU$#2@)UB]EM8?-+*PWFRK+>54)Y4"D0RQU
M _W')JLR^<]/?"U]9!GDJ%8A8K%8H@[T'1)#Y,L*T\CGT/4C)W9QS&.J%,G7
M)SWSPAU0!65+UK 6JP:::H;-/!CI+?&>!S!@X@(,0>OX:([Z+-X<U!?>DFVA
M07A1HT$?D)?6@,$(^B7/+M?K;;?9*S'@O3 <MI%RQ9IG8V/,K0[6ZT'_XAUQ
M]0)GHP",+WR;LNLM\U-B6SP\4!7.J*+9Z,"+E313$6]8TTSI><.MO:TE\?F!
M\_J#G!-9UZ5XQ%F^PH@BQ+&PKYE+(8K2$)+8"R&/O"2*HB0*N5;YU-.D9EZK
M'6'04 8]:?"E):YXTJT F.)N;04&S7A"+;Z:Q@(O4F&$YX*!3-KA1;<W]WQ<
M@!ZK27#T-^I)N6UMS*<)+;L13PI\L/%.OV&VRL649S7_(-0'>Y_7XLO(R)JW
M%04N'V59T_]I:'7Y@;(*U]VW8L4"GH0,<<BY)PLOQ;+^>NK#$"<)22-,?4^K
M*H 1%S/K!O'UA'H*P Q+-=TP.T)Z:J-E!S;\@!U#;1&0BR8+F#;]JP:\=47<
M!%_V5,=9L%C2*F8\+*IPSH+II2XZ;S!]?Z"]K,9N.2]_*XO-TW6^NUBFZ Z,
M##'W@4E+&4C2H*%] :Z+HLZ+6J/D\1@$TPZ!)>GU-,28X."+U9MUBC(:N05C
MXR[F%2@(-W0*5!X_XT!5\VA7K7'V)RZ-&?'[_M+O!J_O>/GHK4CJ!YY/.*3(
MEQ?T>0I)R"AD/G>XD[#41XGF+=SEI=!99T:7#P8\ 5P#GC-IT+?5! T.81>>
M8XUCVA]WWA8_R.W$NMAO!GK0.W0K'!A(!Z1XEH][7V=J;!X(+RS!\D?&KS-%
M1P^57XD5PQZ"K7G;%SZA/. 411ABXB<0L8!!$B$&>10FD8>2)(T\K<Z!>\//
M':!NB&EV"=R77TU?FTNE&7INZ,Q2QN6X"+::_^T/OFS+OZ."'33Z._[4&>W]
MY((O^8-8\\)_;)OJR!:?'WE]D][A[ZLX9BGW(@=ZB>= Y/$ QAS[D#.'Q80A
M!_M*F1PZ1&=>;VT3.SKD ?PD>\K^#+*&%X/F?E,PJBU0V^#H+=L6ESWRV^Y^
MDH.?+X!@0IJQ@@W+W?T4A;;9W6^*Y/+=_11!.-K=3_7=A1-WKW%6-D4VA>;:
M/+;60A^,?)M]S9APC#[AFJ^2B#/?X3'TTY!#)+9LF*2N4#N!T#DA)6Y"T"*)
MO*H<SYU]UI$"SQE?FWB,L\Z6AG_XH\S!XMZ@%*+K(#808Q"+WTZQ%.4'R/35
M1?VU,W^5^?WGR 36A=]:9K V8?-,X3OQZBI(,<&$RMI$;@Q10CQ(<"(\-H\&
M. YQP(C28>7+@>?6R'UJK*2EGP#<B#ZN-\\12$^]J<EBE-<[9/RL5-YFH,6S
M=X?L'TO8W?N[F3'U(<OY37I5<I;5UY@VU3/E/9ZL;C*".;_E8M;R&M\+L\@A
M?I1(BXB&$42QQV$<A01B$B>,AFF(/5\OV*Y!??8@^8XN2#FO9'B\(PU*H7"
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M@I]I.3?Y)J;H<5$4+).8:,O=I*H1QA"+4XD8(4E.BEBQ"%0 XV*.!EZD'/)
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MO).K:21#SD@J$ DE1UAI6XM&6IW)/".$1(0R#FHU>HS(P/NN'9(;3=56^B/
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M07-@S;SEH.J?$30\;'('':LDV8!I9X9ZA@BF_"Y'!VQ4 N3U9$?:4!S5= 1
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M@*JT\\PZ4G2?TK:2?/4HMWNJCBB5UZ3S2R/-I%-[?I1@E+$>A/=PEL$9?Z6
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M&?@/8$/OTRC960=^9(=-K)WSXTUIP %J<9T7SE?O[=.$QNVS?5;@@Y[:Y^^
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MS5:;)7IY@"3XYJ_454]K*J56RJK>L?HC#&<FIR,C<DB&2CF??@$>$8R+ 2
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M:DFM0]3W[:)C(=CR$(R8N,(MH86GYH'A&"5#[7X]0.;*UT!B5YI2A^2\:LT
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M9SP!.,(<0-7D!/,B!WE,",^R"*8X-;NUGZ7E_;X^4.Y\J#=]'K]]2O]YU+B
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M^Y]1%OY[$MX$ZGO4?O#HQ\F-I%0_<ZKJEY:&W0 F7TPJ($1,I("D(08PBW.
M:1$#D8594<24AX56/VO7K\5"&YY[*0[1TC-O7&%@IB:WXG\=B8^%!#*X';Z2
M@5A70_,$%=RYZ>N3W:;\7Q3>71K_>5)SI^9?%/I$NOWE9V;N3]V/9_U5?K#9
MSF;]M9+?E$6>QDG$1 Q8H:98Y"D$J)"7H"+#B(L$9P@9^30\\.A9O[04K\FY
M]/%:]#32*X-MZ'JYOFWT=HQVQ_AXAG;+_$_0'?HRLJ_=!WJ"PW^-CL^7(7;6
MVUF#E.UHH>]\M>'U!PG+^Q]2:ZWP\NVF;N3MN*K;28^KAT_2*&1=?\E/Y8I_
M;/A3O8@891RJQ#.6$P"C6*50\ 1DF>!)))5Y"(V:0M@RXEDI#VP%ZGL3#(P%
M6\[Z,::K!] R-W17_5/Q%[0,&GJRK5^(GJ:> V8S=>P388NA2-?!XVQ>DB4;
M,X]2N@ZLXRE+5ZYGGQ=VW^>U+)(\*[(P0H##, 4P91RH:=, Q2R,B: I9X:.
MA/'RWAT'NURP:X?-[J%"(I["C.4@)Y%4]A"G .>P "**$,P*C#,1F<0E;#&Q
M"$*<0.0*(/24K*UX9HIS/PO.;>+;(?<.$]ZV2\^>Z'8HU*D$MZ//F'?N^;*J
M54NN^DM5??M.W]9-/_)+LU_/F<<]VSE?5%[N?NNXX(LT,JO@&Z^^JU+:M^M:
M<^=,@3"]@1S);[:/]$1W. 9-0TJKOCOGUIRMV\X%H<8]=BY]U&[;O5F)II;+
M?E@9SV(^\_A,VZZ//];C+Z%J\KANU.%MMNU.@:"W[:Z4WV[;38ON83;R!4FM
MM]ZI-6?=>A-"'6Z]J8^:;[TVT:-U7#RNE_*1K\WJC_H+Y]6OU7KS;+P5-9?S
MO#5;+H(1&\%7WFRJ5?"'/!XD,T'+C?[6U 7I\E;U@(_9UM6#QL/6-93<:BOK
MTIAM:QL*/=[JIH^:I[V\Z_NTW*Y6&[S\RI_75;.(8$@3D<> 2%%5+(< Q" $
M(1'R>IW@""98-^WE% '/.W\@&70T@XZH?M;+24RFM[4+2<WVL*&01DDO4Y)8
M);V<7'"VI)<I<<9)+Y.?FSG2>CP#4M5@WC_B?D9D_0>O&Y4'UX42%G$N0H3"
M&/ D0P"F:22W+$8@P_*'492H'!JS%A=SL:ZU1:YIC]&1>X6PK.D[U'-._53O
MY;4"N,?#?H.NX+V1XNS"N_VKWX9W?X*XKN5;>.U@KRG;_QH18,N7X2PL;$O?
MO'/F-_K(V6:IYJ@\*J[JC]LQP]]Y?VN_;XOVMQ<9D=$PI+@ F'-5I91G !5"
MU1<*F,9,I"+2&A%H1]ZSC3@PU+;YZ5A2:F*K5[9<Z?=NM(!X6N/[!\Y0;P^8
MW>TP^W@*,WES;/N'Z-P?7<"HW_O2+YQV32^]P&K4[](>E8E&EQ:+SM;ATE[@
M<6O+*U:9^3;Q 9?5'WBY45-F-T_=T?*UK/_YH>+\XTJJ3\GN5VE9+S*&(@YA
M#!A/,8"AFD8=12G(8A*'- _CF!1FX7/O/'N/R?^#EP^/RHS$\G'\P(-*<@&$
M9$.>&!T?085UO?SSO4O/UPD?[V?V>X02(FBE"$9BW 1*D$!)$@RB!%^G7O%\
M]P=3V%_[XJ#-[[_&C<$4?F=7!6/"EE5:HP[^=^)P//DB3Z(LBF,,,"3R3D *
M 1#."4!YPA,H<H(S85BG-4G0NW(?DV^KL_KVD$JU]YP$N&7%L$QH&L=0GJ,"
MXPC$+(\ECC@#.(01$#E3>;E%3".C#M3N4+0IK!ICR+N"7*=HZ9UD[C P.X8.
MOT([RGVNJ\/B*2T1795/31.;MX!*2_"C$BJ]I\R]*;^K\O.GLI%68>>HN5]_
M7-&*2Z6]/Z9VP>(T85F:@C2#!8 H90"C3&[YC"84P4P(H=6?T(BJY_T^XB-8
MMXRH3J%ESTI N_I!T3.C?_/71_6RW\0+5F9ZX?5ATO>+>('+SAWB"#8C!XBQ
M^!-^#_VU9G-W&(LW]G*8/VQG>?ZV_MX:P!]7RLSMS.)MJ?SMBGWE:I (K[^N
ME\L/ZTK9Q M6%#R.(P((%41J5TA!00D'<8Z2,,Q1G.FYJ*_@P;>?^OW;8/ S
MW011#,+B)AC85![K+:.[*NZNY&;@-?A3<1OT[!I6,]F\%#UKS3/4AIZ$V5 V
M-OFNP,F1'6C#P:S&X140'5J,URQU55N4<O4P#"O==J)G0J1Y6DC%EB<8P)A$
MH$ 0@3B.DY"%B$2)ULRZRZ1\7Q"WA'=3<C4ZRIOBI7E-=(*"X171#@#;YAH3
MLKEMK7&*T&LTUI@0^$Q;C:DG[ >.E5W01RJ*M^N6!E^UXX<5I9==O#)E/(:<
M)B"DC ,8A0+@,$U %$.(0U1$J5Y^I3EISQM]C[3YP#%-^/3VN1]0S/;]B(?6
M6MCCXJ;3!2_!G_U_G<9U[6%P.+=,D_#L8\S, #DUU<QP!<O*9G7)4IG?'Y^>
MJ]XRJ?M"O()!E"8Y!(A&5!H', $%*RB(,L1H&I*L"(WZ[4S0\JPTMI2#<D3:
ML,AW BD]=>%(?C/]L!-]3-5AJ:*!=*Y*A"<HS5LQ?%GDHP)BC4?,G<7OGYZ7
MZQ?.VS&(7^0WX5%245.Q[X3@E3)$NO1?*B*60A2#B"-I\V=J"EB6(VD:T#@C
M4<H0U]K1!C0][^R!BVX^:?#<\Q%(<!\J_!2L>V:"Y^GL7&M(+_N)/0!EI@*V
M&+4<! ,+@>(A&)BXE+YL#9"^A]@#4';^82> &7F'#46?\ WKKC2;9]A0M+%?
MV/11.Q-HF_;PF]3-FZI5R9V1=7@KR$A*48P%@"B$ !9%+ TB->,Y% PQ%J8D
M-)J$HDW9LQ(=I2CMC1H898V;V4KZD.I93EZ ,E.B(XQ&3,QSP3(6WY&AI4]W
M5K/+&(Y#(\Q\ <OI+/UL6'F;(V4_]:6LZ7*MB.[V0)AF84K#""0TD_<L'JN&
M4@4"(DZ@2(A &21F&4]ZA+UG/FVG1H_X,-0DFA#JJ1'WL)CID%-X!#L.'%?#
MVTGM:J:+'M%Y)[P8 7$T[\7L:?,Z^;[Q\@>Y*%[^!\?5^Q5[I[*LBXR%64A2
M:6?D4C\(*@!1"9)4X"04&<YYJ-4@?8J(;Z]M1S;HZ :*<" I!^^TD]HG$9K>
M_J[D-G3,VHAL5$-_22:K.OJSB\Y62W])K'$]_<7/VAW<TY'9?O+3(D6BH! 3
M$#/! )3&/T!A& *80ZJ2[S(:TD7G=_C6X*K1.[NU:)M\;0\YT#^N^K%BN!GF
M1;SA#^5JI2Z__0_D=<'$;V"&;Y)*Q09A!O(\S "D!($BEL911(H0HABE!2(]
MOO*UORJZ _TKL%6Z0<+9_\L?JGJFDG.<S)3GR6R9BQDR-\'MDXJ\NK.=C&!P
M9#KIT9S5<C*"X=!P,GO8-HQ5UYS?R<V(5:2L];)_*C%ILP9_7S%Y/J@O!F?O
M?TCR=?<U49-G:,I(!C!!4L$D.9(*G,8@DQ<ODB5YGL2%64<3*SZTMM$U[4D4
M5_];A;XV7:N*KI3'-/QE@[!N8,P7:I8A,\6.&N'0,Q2T'-T$6YYN@C%70<>6
M<^5S%2S.8FTV/,P<A;L"IN/XW#6+6;0DY>O/^(EKMR#M/N[YMO;E_5V@R!@T
M%>W%F-[OEA*8[=Z+S)MU MUGUZ[S9[_&?)T^]YG>Z^QY\"M/70+J<S6F[1_W
MDJHT 50D1S'33T_GA#$B> I(CF( 1<P XGD&0D%)D>2QH#AS.M[)@DG/&Z\E
M'"C*EJ/IO;P8O4/\M>$VTQ(F2+NOO+\"BKF*[6U8_+GJZZ\ V;BD_AI:SF)+
M7SE=/ZS*_^;L(Y/T2U'B;27J;5]TKF:D].:,RDM6A?Y2*%P_RE^HSC+?\5*)
MLTAAQ#C!$,2HX  B(0#),J("4S1/$GD?P49E3W[9]>V]E@2O#ENY?#O6X:Y7
MPOSZ,-E-L&,]&/,^#'L:N.]F0>WX#WH!;@(E0OO;D1!>HVP>P/87G7/)[&M'
M]3P KQ$-]$'5[FP81MC?XQ\=>?F7X6?]-/N]<VS%A@D+IP\Z-=QD02**"HHY
MP%&1 UA@#$C,"4 H)0SE<0'#U"Q+P0>;WG,:VEPT0-I.3W3<$<JJ*XF7-Z5W
M.KPV^F9GPL!9(+GL5?Y-^_?M+WJ>;_;[="E]/_!]$YQMYS4YN<CX+/ )K:,3
MP N+L^I]GR ?:GNOM,R=AFJI6]IL\'+Y\@67[ ]Y#'WC2TX;SOJ4-N.)*B9K
M^C:W]QKM]3P%BJG@>_WW=N/BU4LP<#?D8^I[*XWPN^S2] 6=F8:T1,W#"!8;
M/*P<JT:$9O.^VH@_=M%:/6^N1#ZO5\H9S-=FLP</'O.L"B0UT#KTW]_I;^]#
MR2[OX"N$,MND(WD<3PL\(X+5OCI<:[:M<T:(\>XX]Q'+VH]R53:\G1A\T+OM
M]YJ+S?)3*?BB2%$2<WG52?.4 8AA#!!/$D YC4D"(<](;%3VH4'4\[[Z>-AZ
M\B;@=5,^J=R"8--R$2PE&X9E'SIHICQ"(H((%"A4+4<8!BA%&. T(9A0D4:)
MX?ADUWA:W0M?$5&]^YYKE,P47T>]G\]^V+[R)NA8"#Y- 61>-F,@L:N*&1V2
M\Q;+&(!P5"=C\JQE;R+&2F6QXJ4R=3ZNWN+GLL'+_N2.HABF1!0@PXG*L(U"
M4$CU +(\RT3"4B)_;=2>:(J:[]CNEO8VQU/R ,I5T'-AV*1H$C@]E> ,#L/8
MZPZ) P@\M"70DM%5RZ))6O-V+=(1^ZAQD=9#MC[IJOPN+Z??^:BJ]%=<KCZM
MZ_K-R__A[*%</7SERZY*[+%\OOU1UHN8I5$:$0XR5,32]I)J@*@*W"1!>9)#
MDL:Y5O+4=6QX5@T]U6!,-OA3$39,_[ $6==A[!LZ,S5B@YJ%*_<:H9TY:ZV8
MF-D=>PU0QP[7JU:S4U']N/';%6MGI'U92\J\*;OZX,&A>ZKZ-(%YFD"<@B+A
M(8 "<?FWD(.D(''(19KRS/!*8\N*]VO.MC7&URT[;5L,P[)>:ZCU5-4<\)DI
MJQ%<VVGV?LI]KY7=D<ZR9F-6K74M6(=ZZ^KU7C\9;!3K&OUR 4,*XT3$@(>9
M # K$D 0AO(^QE&,<!K#2 RU,O>ODQ=VFG.M/;U?77-O;L)MP] -_A$L=]1?
M+VWLS'O44Z _R6OYF=+']C(0/FF\X5=-(9L&_2=,(SO#\+]L*MGT"_"93G:!
MLMT)\YG_-6IK7*U7\J^T2WT^W=BIB#G.11(!>8$O "Q("@@1'*0<IPPE-(3,
MJ%>6*0.>K^SR[4C2RY>@E* KM;%KOUTW4H?@BM7!:MT$+[P),%L_RV/%["PP
M1EQ/L_O$T3 6RO\*QEW+]WB9I[&6+1B.]*<Q^5FUH2TXA[K->AU'R:\G?0F+
M.($93T0.!%,-_3(6 JQZ34"",499PM/(J$&Z'MF9'(GR#;?]Y@W-3TWH=-V%
MK@$Q4R\G,T9W/&@U-[P^\W-2:%^YG*>)OFYVYB00%_,MIY\V4Q1UU2SNRT8-
MU?ZX8N7WDFWP\A]E\SAV)]ZOWTM]U;ST)9!Q)(@@/ >,QSF L8@ 890#DI*D
MR""E!=(*1%K0]JPR6FZZF9(#/X:UIS9X3JL0SRB9Z9$.('4M_+*NV_"8PXK1
M*R2=4AYRV9'BD/_:*0T;BK-HCBN@&-3'-4NXSA^KW[S\AO]S7;U=XKINHVPD
MHP43:IQ" KF\$24%*& 2@S#/8(034H1<:TZG!6W/.F0RN:=6\]%;=H*6'ZO
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M6-<;176XMO6$;P))VGW=\[2(CNN=SQ![E3KG:<'/U3=?>,KE<-Y%F%",8"Y
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M9N5F"LBQ3C)>P4Z5O%U7SVNUA3ZO5WVU6Y\X((B >1S'((UX B"' A09*8"
M19ZG!4HH(R::XRPESXIB2[>+1IJIBO/PZ&D&)T(;QFHZ,JHL2S6Q63UT<TA6
M5)Y1JX?@8\.?;H(=*)*QOLK6PR#,B^([4@3GZ<RZ[R^*>[C-+S]@&8[=/#\O
MV] <7K[%]>.'_Y^[=VV.&T?6!O\*(MY]WW5'%#IX 4GPG$]J7WH\:UM:6],3
M$_VA E>9,Z4J'[(D6_/K%^"EBJH+"P!!RK-S3G?;4A&9^; RD4CD9;7Y_GXM
M-^H\ID_T5[2J6[4OB?J? I-!D49<G8S#&!)*,$R2"(LX8@195I2:T9WZPK;'
M!>#[U$QU[J@O*:7B"A1[MO[+\N;6$%S#JUS_D%G:BSY:F@.@60 ]'L"?'1<>
M38.EW+YN>@VISGOU:P?%T5VPY>/VV:E?Q+K8E.I,)*K;[YLNL3!7!H+G&8RX
MS""2<08)P0R2.(I9S'FF#ARF*:FG"$QL).)?4?*_04,8U)3!FP<!_OJP>@)A
ML #JJY.;9V&>1&C8 /B0V]8SZ FKZ#EDFY[^)ABGF(Z5URVOU%YNJUS2(:$&
M$DA//C9;UN@0T_U4T<'/N3DG[]=L<R]NR8^W/\A]6R"WBZ%\%O)AS:_X/Q^:
M*L9WBNLO8KMM#)SNJZ\>U"GY37'X]FF9B3CC*9:0I3HU/@T0S%&40HR2+(B2
MG.3$*L+AE[V)K=@^5/NJK%G[!9 =<T"_<E#MV /?%7\ZL%]7LG0<VCD_GE^>
MF8_T<J_$SL V?-91\!ZGBUY _=7G]BU=';RE+P=OJ>$97%U\2]:.US1@>O+/
M/#,WJQLW#;"'WMY$5!S/F>RKX ]Z]LG@\/3WZSIJI7]V+=LZ3[*Z$67MI"IP
M]R6"01@)'.AAYH*H$ZD.5=.(4LB5?YD%DB')K%(]O',X]=FUY5<?5GN#PS2?
M%7BE6;5O6>3])1F>;%\2>MO@^:D1;8L:]@;U7\"?M_7LWDG*.R>#RM>QV3M_
M\QZPIX+WZ"@^&2%/&=WOUS?EAHFJ^BPJH9;[>K7F;\2C6&V^:6Z6&<U(FO,(
M1I2I0SU.!<1Y$D(L6)2D*8T8-4HP=65@8NO:$:WKN/F>+&#D6[$E*Z>A+=8@
MFUXJ3@>=K74\S"K7MXNPY08\ [7'T(39Y8903)5Y?HG\RV:E&X)S,6/==!W'
MAK:;]:[/:^/3=O-"9!JFL90$!D*FR@4DH3K0<PYS2E 42*F+3FPJ3LY2LC(V
MCIW6P&;[592@:$Z&KU;:E5B ]4 =I"5:9L;$"P9V5J-/$K0GXU<MU?,>K'U/
MVTN2^>II>Y;.O#UM+XE[U-/VX@/VDVSW;LZNJ$C9AO_W06V@\JGNX%/7!ISL
M 9/$C#&B,PI2+J ZSBD/(Z8)I"Q)F4QR&8=B^2A*NC&9:SN"$YMO?I\?^Z/<
M^_>]XBN]2>[YZX;15VUGF4J4CZ:M>,:^B6'+,2.ZEK<8;U^#CK$%"",8Y O0
M/S9?QGJR=CV>0!LQ9G<,]=E&[GJ J#]^U\=R]C-PKAYXH;X%[XKR_CU?BA1E
M-"8<4DJ9.CAA79DG QB$2":"4"YCHTR*HY4G/A&UM( F!MZ_,9]J\US\85LR
M2B@[ZV JC]6<FI.\.PVF>;[2;)-H3@K0'SUS^@,C)S V[H8.>"SS((LRR6,8
MX5A"% D$,0TP))G(8LKB'#%IX].?H#&Q-]]ZL/5E3>M0;=:NHQ-[R$@>9ECY
M/9#I(P_*4 9S&<0PC4(A$^4>B2Q8JO/"M+CL6M]L[5"I:\MW7OZW<B.+K6X$
MW*84CH?'['@S\NM@9V*NCTXU=8!X@OF/Q]+X'O'8H_ R4QR/13P[J/'$1]T,
MU!^D+'0L7Z=3MW.=B"!AEF44,HH3M7U'#!)),A@EE%.1$\*QT<RZ\R0FWL<[
M@G6VO^/8JQ.XF*G?.&GMM,]24&OE.R^+)]T[06!6U3LOX*'F#7QR9.;/+B&]
MWD5??]6-A-ZOCR*0>W>^ZUBR1(B))-'CZ@*A'(E<Q!"'<0:ED#0(61S%*#<+
M'_AC:O)(0L,+*-;@<7^VO=C$9:I78&83YH75SH:\E5*P]K9WE[%3VY/GS"[
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M021&-(LEBF$:);KV#&40,^7DD@Q%* BC5.<SNU1SGZ(VL7WL2%GU5C&#R<R
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MSUC(J1 DAIRF$41!QF&>I#E,9,)9$E(6!:EIT:\K$U-?#O=TLF6L'MW5L+8
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M%$2/;XJ*K38Z9FY]%75QH:E]]1U]H!AX]?@+V/-@?A-U&8[+%U%>D;#TU0=
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MUO+J_G'==$O]Y]TO6LX6SYLC:7/K+_/&'T+>SO#.C,Q\;!\+V/%)??2*CEV
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ME3_\87\ K1MH'D^TJH,,MU_)^O?-AG\O5JMECD@>QS* /$ZT!JL=&F>)[@A
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M>%QMUG=07[VXE]E?!,XB#ND)#I=@Y)[TL[SUB2*2!H+Z#$L.D9L_-FD@_,D
MI<ES]H>+_0S>H[U\R1*4H00SF 4D4#LN$S#/4@[#F"8T) $/4B.=OT!G8E7O
M*%?ZW%WLR9H[T$,873Y/>)+<3JM[<ZZ/W6,_DIN?&#PAX'90<$/"ZG!@(-_
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M@\>7F8QC]8^$>2A2B$@N8"X1A0FEB <AR26SFI!IS\+$IK$>;"!7F^\5T-^
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MW8<^G5QUWK%/0X(=#7X:_/"(2BYZ.?V='J:_O_WQK2B;IK]U9^]EG)$X"%D
M@X0'$/$\@013#F7.N,BXVI4SHVEMWCF;V ;LR>G F:+G4 OEY068;=,O JN=
M@?%0J]1[*3?#+\6MX,@G@#X+B+SP-7]!D$\X3Q;X>"7@X.#<W6UOUM7ZBO^S
M^O+(7E==HPM3_^;,\U.[-[ORO1N%6ZV!_)\/U;9)!VV'0-0]MRV<G7-0&/@Z
M'E"P='6, ? 8$S01U<WG.;?H?"[/!;&>>3R7/CMVJ,#OFPW_7JQ63<M[RH*
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M*ZJ]J M%?ZI94]'5Q_UVI^1NMM<5OUU7CX8@N\Z&N-=EX LD"4RI6B[G/($
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M-X'+:!INH?$X!0]@NFOR1M%+;\CZ0Y?^CQP1M]RSW7ZSK!Z;ADL+DF>$8\$
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M"URA1?O""3$&F.:$%LTLN+QQ'V.FZ,%8-.D'4GGH^R=%!=ND_*:HD$?.',I
M*WL*BZ4B#'K+@4O4Y/%:64[L1+:SV#B-R)IIZ49L<*0(QXX'MV2_N6A>.!%:
M:2<5K[=R#)3E" %U(F=%E.P#5T*>YOG=6G"<1F1#(N H4?:!@E?3Y=GK/"$"
MO4@8B'=E0)D8(00MP&HA.3K'K#@Q*["[W#CMQX9$P!%B[/@P?[&8KQ:S:=YD
MO\*LMCW]\!EQO3KB5+__6^U:C!Y$[8GG_/D*/H7P9;)YJET]N;?EU71.BTW#
M[-UBZ])=H<F1EVBS8Q $F0!E:J^A("RY_H0Q#)F3>7A@.Y6PBANE7RRZW5,X
M6Z\N_^1Z<SV&KF/MQ>4:SU8K$NL5EQ@$.:^J@&8UFUY,@NAT(&M7E!31"HIX
M&G-YDX)Q?(G!D'!I5QJ(>\3#Y2;U%Y6C5TQDD6T*Y!@EHRG<\=Y -(4LKDH4
M0!EG@G_HLN)XS-PB9%SHG*+9O2 Y1<P=8.5%6'U^-L_U7[_]^_GT:YC52YAG
MZQ=AN?P^G7_ZUS [QXEVQG#I$@7;M7%*TKH6#"$X*3!'<JX0'^J%=PQV#B*L
M!RR=!(#%T-KH &+/4JI-$U;O,2&Q%&?X!ZXOZ]JE]EPI<M10U]R<E J<9IE8
M$R&FP)E]L/7545;I 7K&B9"& U0SV8]:RG')S6MR1.?T(]^)B0F%#,DRGH&G
M*@QK&7CI$2RG@$]YV@GQH=K08Y"SN_XXD=1P2#E:MET@X]T2OX1I_NW;%YRO
MD$SHV_5G7-Z0TL0::32R!#D9"B\#\^"5DA"%"B%)5\QU6Z)&@#F K'&Z/P^'
MH]::Z.$ NT&\SY;%) QHSQSM#>\@2,_ "::84IC3@UWY3O:CQVD4/> 1=;1T
MCX?&8AUF#:'QQV*>;DE$9YVDX.2>B=H67SJ2B# !$+UEZ+V0;IAHZRXM/?@T
M#0.N$X7=@3UYMUQ\P>7Z^[M9J$,U<G7UO]1T1CUZF<S6*:Z)C6! Q1+)N3<6
MG%'%(6-:IM;FY2%Z>HBP3M7XG1.JD?B[\'S>$B^AOB9_@V&%[^NLL+?E[W3R
M5M%-A(I9EV+ B\T(!J[ &VV@,)YX2II[WMI)?I"@'FQ18SBU4T 'INEOBT7^
M<SJ;38)#J7PT$'(@B>24:AXU48"8D1=N0E$/E2H> YS+M7N(K!ICY"BQ=@"'
M5]/Y=(UOIE\QOR8=S#]-XPPO)$3@3AS)4Z\9 U&(&VTS.!\E:,,,([/)@G^H
M>N$8D#Q,40_!5&/H-%1!!X!Z>;%LK?(_PX_A&ZYNAHC7TIL8E"[7-^U!!SJ/
M54%PC$YF)[1B5GII_4.] HY!UR/(ZR$,:PRUH933 >[V,V&CI%!39^";@@,;
M0NWG+,!K+AF+/G/>^EKC>"PU+[$<UBLZ6> =H.8._:BX+$PPL#(F4(DS"@R2
M 8Y,TZG.,]?#W+L_$BO-7YH/BI63Q-Q-$FB28]#)R9K&1$<FT17P/FE@NCAO
M238NM\XO;U?NP6%NF.!YE" [4/^;:8C3V70]W1R7F_>OGQ<S$OJJ9A;6WZ]%
M0P:NN,1 &$]GIL@"7.$>#/*H?&"\N-:U28?2-FY</G@]SR JZN" VN'K=DJ^
M,%9W4892ZDA63>&F<S& SD:58'1$U3H!?3\UXV81A]'^_1 [114=@.JR9N!=
M^%X+!BYO9IQ.*D>M04K/0;&$$#'0,8^<E5P24@0Z4*7&34JZ =-)>KZG4.,$
MH?<!G>4YK7I'1I/ LI84&((LG%RZZAKZ&"Q$)K"8Z'UTS3WG^X@9][ ;#D -
M1-\!AF[FTR_YN6R>.^':.9YJ""F9!X6Y%OHCF6QOM#=!&.M;)Z8?IFA<[WL@
M-#540A>W9"\6\XU0_C%=?WYQOEHOSG!YARN3R=@&[TA"C(PM]P*"-^1AYJ@4
M;9Z<2^NKUT/H&C>I/1# FBND \MU88)WTJ=7E99>V*2<AI1XJ=U:^47/&JY"
MH2/>%#;0Z7>7F'$3U\.>?B>*O@M3]>'S8KG^B,NSYXOE<O$GV>#51)A,:)>>
MF!"U@X$(VTI=)KCBR0@KKE_@MWK5=)>,<=/4 R'G5'%W8'?V^7QT#">."9*H
M<XMRB.!8]N "!0Q":B\>'/C5)OH?-U4]$%Y.%'9?^<H]B7R**25'J8%</%$'
M6Y)K1R<OY!0$MT9)ZUN'^0\2U$VP]B2IHQ,5TH$Q>M"QV[GC"=DP+8(&Z^J#
M?2,4>,RT!Z5-FK9@\+EU,OQ TKK)+YT*AL>XW$=JI@N/Z8&Z!?K-7H%.8M$\
MUT(9QR4)DM,1$'7ME,]2UI%7B][ZZO\(,KLQ?HVA.+3&.K"#]V10=AARJJA(
M$2[PE!(HERQX(VHCTQB#UL46T;SZY$=$=9/,:@RXMMKH 5YUK^S?*!)+L+K6
M "+Z^KJ*4; K$+0UW#AN1%"M@\7[J>DF>=4:4&WDWP&2WBSFGVK\^Q+C>N*+
MDI@-@O?.@<+:'8\S#[;07O#)NVQ;8V=W_6YR4XW1<K2,N_"O[B;7=M#N [K@
M%4+1BKQ%*0(=R[P 5UHXKUP6JG4-^$/T=).C:HR@9CKHP>+L-9LF(V;&$8PQ
MA<*.)"$(94$SYG6UHL:U=H>./[&>(FO5V@:=+/6^<E<3H9/R7#/0)A'J.=<7
M4ZSJ6/;B8W&F]?N G>6[\92?)"_U*&%W@),ZBV2ZW@R4J/UT%O/J^^,\559"
MUBYR)B!PF4'IF"'4&<U"2N%#L.@?G%)[7.;I7G*Z<9"'PU$K973A##T@HQ(*
M>FDE"!5\G;G((%B/X%1.IB#/NC2_I3NMHO<I7.GA<-5(%1UX1.\NU]VPM.WR
M96P2HMY*D7%%4,5QB"0/*-(FCE@*+ZT3Y'O(&+O18QL-W^U1<Y*XNS!$.^.V
M-ASL3ML2&D-))8,U@9C!2%X=#P&,SRQF.L&M:G^Y<B\Y8S\N& 1#K<3?!9:>
MY;QY;!%F[\*4@LP7X<N47+$='B<Q2Y:$5R!C?9/%ZL!IED*UUD)EE:L9;QWG
M_Y"J<9WP@9#56!E= .P]KL-TCOFWL)S7$IMG*9V?G<]JX^B76*9I2I&H+#DX
M6< +I>K[G@+1"H3(2M&Z:)%CZP<K/Z9J7.]\(( U5D8'_M/')8;5^?+[1F#;
MC7)YJC-F3)U[SB)98D<;)>948PSEA43M>&Y=+7X?+>,ZY -!J8G@'P\@OP70
M'#]5T+9*<E]N@LW=3IUXO,3/.%]-O^(V[?IFL:H]-]Z6C^';1$@G#<L!I Z,
M&-0DL#IVCM=1 S+:@OFAN0U'YKT?0^*XJ?"A#L<!U=3%27E7;A/FDN.EMME(
MJO9[CO6T5[2KO/0Y2W(%8NMW"7>I&#<M/A":3A1V!XG.'R5:)CDCUYK.;RNY
M("XH*@E8JUY+B:A$'9HY8"7P7IJZN:-[DM3YZ6II!K,GG%?S;J.+S[B>IC"[
MR<AIPVMN?GCP238/\/&48VUX=HE'U,"UJ.Z4(7^\WO[IQ)+.W&>G6D??3S+6
M9C9;_%F%_6JQ?+DXC^MR/KO;LOZRSKXP05N2G$@M45Q,_D:>P')M*5C1GOGF
M*8C'$#AVKK0QCNZX7H,IJX,(\F9*F';]V^5&H'D3SKS#Y8?/I(6),)$QX21@
MKN.%C?,04RT5Y%D*Y8IEI;77?QAE8^=8!\;> .KIPMN_R=>&B=6S\_7GQ7+Z
M'Y@GP6NKC3'@-RV)36T7&I'B&&6L<UYXU*UK8AZF:.R$ZY/"["1U=&?3MMR\
M7JW.B1.L^>,D*+9)M$>4-,2)C1FD$2'7?EV^>;'5_=2,G60= 51'J*$#0.U<
M0=QK@CW%W;[.8#6<F7HU05&3#_2/G&1TT:K,6E=E'4#6V,G7@2'66C%]8>V.
M';9:!(^N@&%1U2$A%H*(C+8-%F.M2IFU]L(>(&?L/.O38>LD1?2(J0LSK$6I
M*;\,O![NRO, WD8+*'3ABD7IFL_<N(>4L;.L3XVE(Q30(XYVBS_JN*,2.4*2
MK-XX2 U.\5JH[:N9C<G$ 0_ ._0<A"CWGP=1QZJB UCMN4S=\C1A+KADE -?
M9*A7$88"#\VAU$X6QC*A3>O,U[W$' 0H_],"JHT2&B87ADW:7\ESM2C;Z],3
MD_5[/CA$DOY'=#=*SF\_?;78SJ6C"KI@! R9 C>.'J+-!K35W#&MK1&M;]7N
M(>7T^^:+#WZLV=M)2#KRP!D44Y^2%5,[^SD'P6=,4D=58NM.93<I&#>)WD+?
M=R^9CY;PB(?2:KFND]+R>5I3/(G+K].$S[Y-5Y/(K;&\/@**1H R-H$7!4%S
M+%E)Z:S+AR"$%MA!!_WN&AGWK=W)!<L1>EPT%&H?H-C<:V\Y6+U<G(7I?**3
MD!FE!UUTJ7?:$2+Z.D#/<U54#C8<Y/D>AHR[!(P#CS8ZO0N0$P4\(DK(/YA\
MF"%^(0[>X^K+=%E_\/OO>!9Q.6&BD,$4&4HF>TIF%2$F<J.B+]H7$W+4^0?^
MQH,+C(Z"4Q6W:"W%L:&P*.L_27C/5L\NQ'+!@^/)AQ@"%%_;+*I49_UJ <'P
M4ES))=YN'; ?"?=\?YPKT8& T$*&'82X5V<H.?_XFGZYFE@EC8XE0V(HH;Y>
MJ&;2 EE'5Y""->U;7T7=I:*3Z_/C/8M& NX (N_Q*\[/\15):5_'NM^^I=EY
MS>[484'TOURK?%/BC-<10;77!;%H _C$/7C'41A$VF*M+P2.(+,3]_5(9-QY
M1#*LFCI XHO%:OVVU-FM.Y;\BK&72'2EZ49_].L9;A0YS\_.%LOU]#\V?SX)
M/GGMO(*8#;$=)4E82PV%6Z>U]CJIV#P9?"K5G1C#-CA]8B5V -M=VM^6VT-C
M)P*3=EDZ\CFD)<^1!_I5EF 2MSY9%R@X:5U%^2!%G=04M8%;0^%W4:"V=_NL
M/BQF>5*G_/'(*:J-O.;$I"%>*-*UPBG4SK!4VE]TW4=-)S5$ ]JLQPN]@^<I
M?ULN5BL*A\IT/?&5?TVG?Z3(%924Q$3@$4@6OBCF77&MS\*=Y3NI &H#D&/%
MV@$BKCJQ_O;M"\[)-[P>(1LP>=0)7/;U(8RK?1&3AV1#8#JC8Z[UP70O,9W4
M]+1!2QN1=^#9?, 9_:=/?\,Y,32K;EH^F\ZGE9GU]"M>L#=1SL7"@X3@D':$
M=1*B5AYDH#@C%U62;?Y>\B#*Q@T &\'@=L*AO4XZ0-I[4@T1\)GX>4F![FSQ
MI6['2V9LX<EXQ2#&0G%L*!XB)@0*%.A/+*=8MC7 'B1HW(!M&%RUT\#(Z>^;
M$<&S]._GTTWG^YN1 9]$'I*P6H%-6=5B)0-!.@L.573"<%W"K;:$>[/A!RXW
M;M#5%C)#2;D/.[1>GJ?U^9*$]>)S6'ZJA4C6VQ!K,PTAZJL!AA0#8(2D4^8R
MN8BQ=7>O?72,&W(-9G5.DW<'F'E^OB*W<;5ZL3B+T_E6(74_;(ODWN.F>48-
M,5>3K) Y40K$D#.)JAI4:3R@K[7<)GLO6R/I<.K&C=B&P== NND =7?D->&!
MYU"GZ$G,%E1MA1>"T.#(QOJHN$0SV*3>2R+&C>.&P=!IDNXI!7#=KV<2HI7<
MT$&L7+1UU"L#YWF!@#IFF5).M[V?=F"Y)J.3YQ>-P_XCQ=P!4OY8S!<WN;C
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M%JV'4S=NG/7$J=6!E-:%!;S-V;.4%N>T\6FGX?3KIH-I+E+X^FI:,A%!J5#
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MQ:UK'6 _GLI.9ED\43EG*W5U8!_)UE]DT"ZZGA"OM,W6WVN3I\OT_Y?Z(Y-
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M*?+MV5![(782$2/G]P:&W=/II[\Z\SU=/_ZVK!,I-).!9\>!^_KTTOL$COX
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M/5MBN.T(6*^Y,!'!L*1 D80A4J0$B,E1.*4X.:R-3>$)Y(Y<WC"$.7PJY76
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M M31@(HN53X=>&D=2^B,E*W]RCW(>QK.YCX(>;SNNIVN.KAJK]<#SY2/3I7
MZPL%HETS0[0C@G72HE<AZN;CZ*ZO/_6 S9&4?#^8]I=X'V7Z5^;#S(64%<L.
M G<"5!$6@DO$"BK#(N<E#SIS;W_NM.[?V"@X6I(=G!EW13)S1F!(/$$DB1".
MK82H:I6(XX8P'C-Y&(U/CKM43.O:G>K\.%+Z'>!G@*1FBFE5K"_$0RTMB4$
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M[NBU%4+KQ%JG)FY2<'0<"-=KQ.UGOL1U6LTO:CVV56_%,[1>2\@8Z@QM G!
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MD.?QN18%OUZN'K(MR;1$+W4&9FL3TL(=.*\99.:M= :YBZTG(AY!;E>IA&.
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MS<?&;S\F^/KW,*_]5#Z&O_XYWWRN/0>(.?K!_<*=91Z9Q2  G4F@9"!'P^0
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MPR<F5V5CN/HV3_C >7*V_4CZZGWYH9"+Z/]6B1<Y/:%Y8HZ.A-U#>>8A"I;
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MW)*+_^A&H+.!*F4\\CK?M+ I/PVV6C_6!1YM8JYT$N_E7,'LA7''*YA]%-X
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M+MUXN@X"/]CY?*6;PVMA.@U;JJ:E_QP*U:9L^3"P=_5:UYG_S]5X_3C770&
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M-CA&S3-O$Y$[[#!A+,$B-3K?$G+Y@5 .CD2,&OXO@6MZ4MZUD(@?@@^]*'<
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M W;T/,/RT<#-P%5>7S@^'GBDEQ:@^SH-\\GUQ>?HK^;K3I*7R^-QVSIJG6<
M^J.V3R4M0/;VS[D_GX]]@?5U-U2==OG]P7DR^180^05V@.4;NXSO['B>2^4*
M0+-ES#KMX?MCM%L=E<%ZN+*O?_OW<D6EU]^F%^?^.+/WS-!UVJ'W@JZ;<NJW
M6=E>]?A^NAB#%K_,;<AWJ^[Y9 \E/[)N<\]GBA1O=IW&D16<E5)/_2JB?AO[
M;S9._OL?[RRP;#+I7/JTXQ_6RU/NRW'-NDZX7FG:?]OIF_C/\7(9.T/PY)_4
M2V]U5/ZN2=93^ZMY7"[/_O'9PD*?>P@'.VM_U[^L5^C1$81GIEP/B__'7BV^
MC?_]R[?9XIOM;HFV_K-Z91P=4=@WV7H0W%K'3WF'[+\9W/]G]0HR^FX%6R9;
M#X+S"%[<Z][[\=9_5J^PHB,$^R9;KRCXB8/XQ*<_\$AWY[!'"'LWW*MKT/GQ
M)0);!ZQXNOD<%O?CJWW*J!P7WXEV=&W HZ&J8;-7VUM1::LJ8$L$6"9$VSUP
M UCMJ1)X5B%_Z?J:04*GKFOH1)4U?Q>N=*3B;\OY)+]4LOB8OLP#P%>FS'+/
ML-4HVF\+?EXQU3?B+%6)X].'(U4+_/NZ2%NFWPHD7\;+H[W7!T-5RP,<",H#
M!51&Y=/5)!+L!,E.0YA]7\;C;]WL&K-:LJ ?3L^HI#)@'V;3(3#;,VRU!$,_
MV)Y73!,&<"47*"\?ZQ8P@@^&JW8WXQ!#N$T1#1G#+_/+Z;*L+;PW9+5[&(>;
MPJ<*:<L2%@)L]ZC5:N6.LH/-P783,-P^ %G($CX>L5Z5W"'6<(<^FL#J[9_?
MQ_.24#T:L%[)W"%(;==&$T"]N5H+5@"BVZ'JU<H= LYC#30!R[T"V(N+LQ]V
M/#FV-GC?N/4JY X!;*]N6JV1>SM?70X?J*7AT]&+5,0](W2!0KA/T<]^Q/GU
MQ_3D6T^8<)@SW>4#1RS7S:@WGSG^F'7K@-5R\7WPN;]2]ZFE=L06%Z"[U2E6
MWHV//C':-EXUO/;J?=9)"7^?Y=4"Y>];\G\?-O9-9WR(LQ*@/!RIZ6KMG1-O
M:%_)Y6O%<A5[!ZYFU [U#+JHJ;;)N[A8;B9U](W,AT-5.PL^%*WMJJB,SXU
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M:6-A=&EO;G$T9GDN:'1M4$L! A0#%     @ +J$(6>*BAFC'!P  [B@  !X
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M+FAT;5!+ 0(4 Q0    ( "ZA"%EH50HP[04  )!#   >              "
M 8_0  !E>&AI8FET,C$Q+7-U8G-I9&EA<FEE<W$T9BYH=&U02P$"% ,4
M"  NH0A9%HGB@H@#  #!"P  '@              @ &XU@  97AH:6)I=#(S
M,2UA=61I=&]R8V]N<V5N='$N:'1M4$L! A0#%     @ +J$(6>P;7W'W$@
M)%4  !X              ( !?-H  &5X:&EB:70T,BUD97-C<FEP=&EO;F]F
M<F5S+FAT;5!+ 0(4 Q0    ( "ZA"%F:[QZBL!,  +]T   >
M  "  :_M  !E>&AI8FET.3<M<F5S;65D8VQA=V)A8VMP;RYH=&U02P$"% ,4
M    "  NH0A9ORP/W_Q" P!+SR4 $               @ &; 0$ <FUD+3(P
M,C0P-C,P+FAT;5!+ 0(4 Q0    ( "ZA"%E"(?.SLA@  (@< 0 0
M      "  <5$! !R;60M,C R-# V,S N>'-D4$L! A0#%     @ +J$(61^4
M#OP?,0  #?,! !0              ( !I5T$ ')M9"TR,#(T,#8S,%]C86PN
M>&UL4$L! A0#%     @ +J$(605^<&,O?@  (9,% !0              ( !
M]HX$ ')M9"TR,#(T,#8S,%]D968N>&UL4$L! A0#%     @ +J$(6:8RH2AS
M!@$ 6G4! !,              ( !5PT% ')M9"TR,#(T,#8S,%]G,2YJ<&=0
M2P$"% ,4    "  NH0A94'  -2*) 0!A)0\ %               @ '[$P8
M<FUD+3(P,C0P-C,P7VQA8BYX;6Q02P$"% ,4    "  NH0A91)J(,^3D   I
MF0H %               @ %/G0< <FUD+3(P,C0P-C,P7W!R92YX;6Q02P4&
2     !  $ !Q!   98((

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>rmd-20240630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rmd="http://investor.resmed.com/20240630"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rmd-20240630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <instant>2024-08-05</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:AccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:AccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:PrepaidTaxesAndOtherNonCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:PrepaidTaxesAndOtherNonCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:DeferredRevenueCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:DeferredRevenueCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:DeferredRevenueNonCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:DeferredRevenueNonCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">rmd:FairValueAndNetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">rmd:IntangibleAssetImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:VehiclesAndAircraftMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:VehiclesAndAircraftMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:ClinicalDemonstrationAndRentalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:ClinicalDemonstrationAndRentalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SaasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SaasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SaasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rmd:DevelopedOrCoreProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rmd:DevelopedOrCoreProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rmd:DevelopedOrCoreProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rmd:IdentifiedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rmd:IdentifiedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-29</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-29</startDate>
            <endDate>2022-06-29</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rmd:ResmedLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-29</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:TermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-29</startDate>
            <endDate>2022-06-29</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:TermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-29</startDate>
            <endDate>2022-06-29</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:TermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-29</startDate>
            <endDate>2022-06-29</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:TermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-29</startDate>
            <endDate>2022-06-29</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:TermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-29</startDate>
            <endDate>2022-06-29</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rmd:SeniorNotesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-10</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rmd:SeniorNotesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-10</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rmd:RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <instant>2014-02-21</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <instant>1997-04-30</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:ResmedInc2009IncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmd:NonEmployeeDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:AmendedAndRestated2009PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:AmendedAndRestated2009PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:AmendedAndRestated2009PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-31</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:AmendedAndRestated2009PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:ResmedInc2009IncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:ResmedInc2009IncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOperatingLossCarryforwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-28</startDate>
            <endDate>2021-09-28</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsAServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <instant>2022-06-16</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:PrepaidTaxesAndOtherNonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:PrepaidTaxesAndOtherNonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rmd:OtherForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rmd:OtherForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">rmd:OtherForeignExchangeContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">rmd:MEDIFOXDANMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">rmd:EmployeeSeveranceAndOneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:MichaelJ.FarrellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:MichaelJ.FarrellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:JanDeWitteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:JanDeWitteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:BrettA.SandercockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:BrettA.SandercockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:KaushikGhoshalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:KaushikGhoshalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:MichaelJ.RiderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:MichaelJ.RiderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:PeterC.FarrellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">rmd:PeterC.FarrellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>rmd:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="offering">
        <measure>rmd:offering</measure>
    </unit>
    <unit id="patent">
        <measure>rmd:patent</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-33">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-35">0000943819</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-36">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-37">false</dei:DocumentTransitionReport>
    <us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-594">http://fasb.org/us-gaap/2024#RestructuringCharges</us-gaap:ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration contextRef="c-5" id="f-1269">http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent</us-gaap:DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration contextRef="c-4" id="f-1270">http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent</us-gaap:DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration contextRef="c-4" id="f-1273">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</us-gaap:DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration contextRef="c-5" id="f-1274">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent</us-gaap:DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration contextRef="c-5" id="f-1279">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration contextRef="c-4" id="f-1280">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration contextRef="c-4" id="f-1285">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration contextRef="c-5" id="f-1286">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent</us-gaap:DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration contextRef="c-5" id="f-1319">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration contextRef="c-4" id="f-1320">http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration contextRef="c-5" id="f-1321">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration contextRef="c-4" id="f-1322">http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <ecd:TrdArrDuration contextRef="c-317" id="f-1412">P289D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-319" id="f-1413">P284D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-321" id="f-1414">P449D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-323" id="f-1415">P564D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-325" id="f-1416">P325D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-327" id="f-1417">P462D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-15317</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">ResMed Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">98-0152841</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">9001 Spectrum Center Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">92123</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c-1" id="f-13">US</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c-1" id="f-14">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">836-5000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $0.004 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">RMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-28">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-29">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="0" id="f-30" unitRef="usd">25155017346</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">146932119</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">&lt;div style="margin-top:4pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Portions of the registrant&#x2019;s definitive Proxy Statement to be delivered to stockholders in connection with the registrant&#x2019;s 2024 Annual Meeting of Stockholders, to be filed within 120 days after the end of the fiscal year covered by this Form 10-K, are incorporated by reference into Part III of this report.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName contextRef="c-1" id="f-38">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-39">San Diego, CA</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="c-1" id="f-40">185</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">238361000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-42" unitRef="usd">227891000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">21132000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-5" decimals="-3" id="f-44" unitRef="usd">23603000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">837275000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-46" unitRef="usd">704909000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">822250000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-3" id="f-48" unitRef="usd">998012000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">459833000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-50" unitRef="usd">437018000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">2357719000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-52" unitRef="usd">2367830000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">548025000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-54" unitRef="usd">537856000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">151121000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-56" unitRef="usd">127955000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">2842055000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-58" unitRef="usd">2770299000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">485904000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-5" decimals="-3" id="f-60" unitRef="usd">552341000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">203569000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-62" unitRef="usd">132974000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">284001000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-64" unitRef="usd">262453000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">4514675000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c-5" decimals="-3" id="f-66" unitRef="usd">4383878000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">6872394000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-68" unitRef="usd">6751708000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">237728000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-70" unitRef="usd">150756000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">377678000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-72" unitRef="usd">365660000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">25278000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-74" unitRef="usd">21919000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">152554000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-76" unitRef="usd">138072000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">107517000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-5" decimals="-3" id="f-78" unitRef="usd">72224000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:ShortTermBorrowings contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">9900000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c-5" decimals="-3" id="f-80" unitRef="usd">9902000</us-gaap:ShortTermBorrowings>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">910655000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-82" unitRef="usd">758533000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-83" unitRef="usd">137343000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-84" unitRef="usd">119186000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-85" unitRef="usd">79339000</us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-86" unitRef="usd">90650000</us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-87" unitRef="usd">141444000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-88" unitRef="usd">116853000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-89" unitRef="usd">42257000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-90" unitRef="usd">68166000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LongTermDebt contextRef="c-4" decimals="-3" id="f-91" unitRef="usd">697313000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-5" decimals="-3" id="f-92" unitRef="usd">1431234000</us-gaap:LongTermDebt>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-4" decimals="-3" id="f-93" unitRef="usd">0</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-5" decimals="-3" id="f-94" unitRef="usd">37183000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-95" unitRef="usd">1097696000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-96" unitRef="usd">1863272000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-97" unitRef="usd">2008351000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-98" unitRef="usd">2621805000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-99" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-100" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-101"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-102"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-103" unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-104" unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-105" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-106" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-107" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-3" id="f-108" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-109"
      unitRef="usdPerShare">0.004</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-110"
      unitRef="usdPerShare">0.004</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-111" unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-112" unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-113" unitRef="shares">189565112</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-114" unitRef="shares">146901045</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-115" unitRef="shares">188900583</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-116" unitRef="shares">147064349</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding contextRef="c-4" decimals="-3" id="f-117" unitRef="usd">588000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding contextRef="c-5" decimals="-3" id="f-118" unitRef="usd">588000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-119" unitRef="usd">1896604000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-5" decimals="-3" id="f-120" unitRef="usd">1772083000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-121" unitRef="usd">4991647000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-122" unitRef="usd">4253016000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares contextRef="c-4" decimals="INF" id="f-123" unitRef="shares">42664067</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-5" decimals="INF" id="f-124" unitRef="shares">41836234</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-4" decimals="-3" id="f-125" unitRef="usd">1773267000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-5" decimals="-3" id="f-126" unitRef="usd">1623256000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-127" unitRef="usd">-251529000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-128" unitRef="usd">-272528000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-129" unitRef="usd">4864043000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-130" unitRef="usd">4129903000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-131" unitRef="usd">6872394000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-132" unitRef="usd">6751708000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-133" unitRef="usd">4101172000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-134" unitRef="usd">3725017000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-135" unitRef="usd">3177298000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-136" unitRef="usd">584125000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-137" unitRef="usd">497976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-138" unitRef="usd">400829000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-139" unitRef="usd">4685297000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-140" unitRef="usd">4222993000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-141" unitRef="usd">3578127000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-6" decimals="-3" id="f-142" unitRef="usd">1806845000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-7" decimals="-3" id="f-143" unitRef="usd">1662957000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-8" decimals="-3" id="f-144" unitRef="usd">1365421000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-9" decimals="-3" id="f-145" unitRef="usd">190186000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-10" decimals="-3" id="f-146" unitRef="usd">173978000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-11" decimals="-3" id="f-147" unitRef="usd">148745000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">1997031000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-12" decimals="-3" id="f-149" unitRef="usd">1836935000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-13" decimals="-3" id="f-150" unitRef="usd">1514166000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-6" decimals="-3" id="f-151" unitRef="usd">5515000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-7" decimals="-3" id="f-152" unitRef="usd">5340000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-8" decimals="-3" id="f-153" unitRef="usd">4105000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-9" decimals="-3" id="f-154" unitRef="usd">27448000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-10" decimals="-3" id="f-155" unitRef="usd">25056000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-11" decimals="-3" id="f-156" unitRef="usd">35545000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-157" unitRef="usd">32963000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-12" decimals="-3" id="f-158" unitRef="usd">30396000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-13" decimals="-3" id="f-159" unitRef="usd">39650000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">2029994000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-12" decimals="-3" id="f-161" unitRef="usd">1867331000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-13" decimals="-3" id="f-162" unitRef="usd">1553816000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-163" unitRef="usd">2655303000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-12" decimals="-3" id="f-164" unitRef="usd">2355662000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-13" decimals="-3" id="f-165" unitRef="usd">2024311000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">917136000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-12" decimals="-3" id="f-167" unitRef="usd">874003000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-13" decimals="-3" id="f-168" unitRef="usd">737508000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-169" unitRef="usd">307525000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-12" decimals="-3" id="f-170" unitRef="usd">287642000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-13" decimals="-3" id="f-171" unitRef="usd">253575000</us-gaap:ResearchAndDevelopmentExpense>
    <rmd:AmortizationOfAcquiredIntangibleAssets1 contextRef="c-1" decimals="-3" id="f-172" unitRef="usd">46521000</rmd:AmortizationOfAcquiredIntangibleAssets1>
    <rmd:AmortizationOfAcquiredIntangibleAssets1 contextRef="c-12" decimals="-3" id="f-173" unitRef="usd">42020000</rmd:AmortizationOfAcquiredIntangibleAssets1>
    <rmd:AmortizationOfAcquiredIntangibleAssets1 contextRef="c-13" decimals="-3" id="f-174" unitRef="usd">31078000</rmd:AmortizationOfAcquiredIntangibleAssets1>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">64228000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-12" decimals="-3" id="f-176" unitRef="usd">9177000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-13" decimals="-3" id="f-177" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-1" decimals="-3" id="f-178" unitRef="usd">0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-12" decimals="-3" id="f-179" unitRef="usd">10949000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-13" decimals="-3" id="f-180" unitRef="usd">1864000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-181" unitRef="usd">1335410000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-12" decimals="-3" id="f-182" unitRef="usd">1223791000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-13" decimals="-3" id="f-183" unitRef="usd">1024025000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">1319893000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-12" decimals="-3" id="f-185" unitRef="usd">1131871000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-13" decimals="-3" id="f-186" unitRef="usd">1000286000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">-45708000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-12" decimals="-3" id="f-188" unitRef="usd">-47379000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-13" decimals="-3" id="f-189" unitRef="usd">-22312000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">-1848000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-12" decimals="-3" id="f-191" unitRef="usd">-7265000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-13" decimals="-3" id="f-192" unitRef="usd">-8486000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">-4045000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-12" decimals="-3" id="f-194" unitRef="usd">9922000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-13" decimals="-3" id="f-195" unitRef="usd">-12202000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:GainOnBusinessInterruptionInsuranceRecovery contextRef="c-1" decimals="-3" id="f-196" unitRef="usd">0</us-gaap:GainOnBusinessInterruptionInsuranceRecovery>
    <us-gaap:GainOnBusinessInterruptionInsuranceRecovery contextRef="c-12" decimals="-3" id="f-197" unitRef="usd">20227000</us-gaap:GainOnBusinessInterruptionInsuranceRecovery>
    <us-gaap:GainOnBusinessInterruptionInsuranceRecovery contextRef="c-13" decimals="-3" id="f-198" unitRef="usd">0</us-gaap:GainOnBusinessInterruptionInsuranceRecovery>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">-3494000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-12" decimals="-3" id="f-200" unitRef="usd">-5712000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-13" decimals="-3" id="f-201" unitRef="usd">3197000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">-55095000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-12" decimals="-3" id="f-203" unitRef="usd">-30207000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-13" decimals="-3" id="f-204" unitRef="usd">-39803000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">1264798000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-206" unitRef="usd">1101664000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-207" unitRef="usd">960483000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-208" unitRef="usd">243847000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-209" unitRef="usd">204108000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-210" unitRef="usd">181046000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">1020951000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-212" unitRef="usd">897556000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-213" unitRef="usd">779437000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-214"
      unitRef="usdPerShare">6.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-215"
      unitRef="usdPerShare">6.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-216"
      unitRef="usdPerShare">5.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-217"
      unitRef="usdPerShare">6.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-218"
      unitRef="usdPerShare">6.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-219"
      unitRef="usdPerShare">5.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-1"
      decimals="2"
      id="f-220"
      unitRef="usdPerShare">1.92</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-12"
      decimals="2"
      id="f-221"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-13"
      decimals="2"
      id="f-222"
      unitRef="usdPerShare">1.68</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-223" unitRef="shares">147021000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="-3" id="f-224" unitRef="shares">146765000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="-3" id="f-225" unitRef="shares">146066000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-226" unitRef="shares">147550000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-12" decimals="-3" id="f-227" unitRef="shares">147455000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="-3" id="f-228" unitRef="shares">147043000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-229" unitRef="usd">1020951000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-230" unitRef="usd">897556000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-231" unitRef="usd">779437000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-1" decimals="-3" id="f-232" unitRef="usd">31743000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-12" decimals="-3" id="f-233" unitRef="usd">-35596000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-13" decimals="-3" id="f-234" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-235" unitRef="usd">-10744000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-12" decimals="-3" id="f-236" unitRef="usd">75815000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-13" decimals="-3" id="f-237" unitRef="usd">-119260000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-238" unitRef="usd">1041950000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-12" decimals="-3" id="f-239" unitRef="usd">937775000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-13" decimals="-3" id="f-240" unitRef="usd">660177000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-14" decimals="-3" id="f-241" unitRef="shares">187485000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-242" unitRef="usd">583000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-243" unitRef="usd">1622199000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-16" decimals="-3" id="f-244" unitRef="shares">41836000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-245" unitRef="usd">-1623256000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-246" unitRef="usd">3079640000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-247" unitRef="usd">-193487000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-248" unitRef="usd">2885679000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-20" decimals="-3" id="f-249" unitRef="shares">177000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-21" decimals="-3" id="f-250" unitRef="usd">11205000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-13" decimals="-3" id="f-251" unitRef="usd">11205000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-20" decimals="-3" id="f-252" unitRef="shares">369000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-20" decimals="-3" id="f-253" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-21" decimals="-3" id="f-254" unitRef="usd">-52408000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-13" decimals="-3" id="f-255" unitRef="usd">-52406000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-20" decimals="-3" id="f-256" unitRef="shares">216000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-20" decimals="-3" id="f-257" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-21" decimals="-3" id="f-258" unitRef="usd">36179000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-13" decimals="-3" id="f-259" unitRef="usd">36180000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-21" decimals="-3" id="f-260" unitRef="usd">65257000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-13" decimals="-3" id="f-261" unitRef="usd">65257000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-22" decimals="-3" id="f-262" unitRef="usd">-119260000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-13" decimals="-3" id="f-263" unitRef="usd">-119260000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-23" decimals="-3" id="f-264" unitRef="usd">779437000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-265" unitRef="usd">779437000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-13"
      decimals="INF"
      id="f-266"
      unitRef="usdPerShare">1.68</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends contextRef="c-23" decimals="-3" id="f-267" unitRef="usd">245341000</us-gaap:Dividends>
    <us-gaap:Dividends contextRef="c-13" decimals="-3" id="f-268" unitRef="usd">245341000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-24" decimals="-3" id="f-269" unitRef="shares">188247000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-270" unitRef="usd">586000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-271" unitRef="usd">1682432000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-26" decimals="-3" id="f-272" unitRef="shares">41836000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-273" unitRef="usd">-1623256000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-274" unitRef="usd">3613736000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-275" unitRef="usd">-312747000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-276" unitRef="usd">3360751000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-30" decimals="-3" id="f-277" unitRef="shares">157000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-31" decimals="-3" id="f-278" unitRef="usd">9696000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-12" decimals="-3" id="f-279" unitRef="usd">9696000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-30" decimals="-3" id="f-280" unitRef="shares">277000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-30" decimals="-3" id="f-281" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-31" decimals="-3" id="f-282" unitRef="usd">-30632000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-12" decimals="-3" id="f-283" unitRef="usd">-30631000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-30" decimals="-3" id="f-284" unitRef="shares">220000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-30" decimals="-3" id="f-285" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-31" decimals="-3" id="f-286" unitRef="usd">39445000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-12" decimals="-3" id="f-287" unitRef="usd">39446000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-31" decimals="-3" id="f-288" unitRef="usd">71142000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-12" decimals="-3" id="f-289" unitRef="usd">71142000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-32" decimals="-3" id="f-290" unitRef="usd">40219000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-12" decimals="-3" id="f-291" unitRef="usd">40219000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-33" decimals="-3" id="f-292" unitRef="usd">897556000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-293" unitRef="usd">897556000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-12"
      decimals="INF"
      id="f-294"
      unitRef="usdPerShare">1.76</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends contextRef="c-33" decimals="-3" id="f-295" unitRef="usd">258276000</us-gaap:Dividends>
    <us-gaap:Dividends contextRef="c-12" decimals="-3" id="f-296" unitRef="usd">258276000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-34" decimals="-3" id="f-297" unitRef="shares">188901000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-298" unitRef="usd">588000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-299" unitRef="usd">1772083000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-36" decimals="-3" id="f-300" unitRef="shares">41836000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-301" unitRef="usd">-1623256000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-302" unitRef="usd">4253016000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-303" unitRef="usd">-272528000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-304" unitRef="usd">4129903000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-39" decimals="-3" id="f-305" unitRef="shares">166000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-40" decimals="-3" id="f-306" unitRef="usd">13484000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-307" unitRef="usd">13484000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-39" decimals="-3" id="f-308" unitRef="shares">175000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-39" decimals="-3" id="f-309" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-40" decimals="-3" id="f-310" unitRef="usd">-8758000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-1" decimals="-3" id="f-311" unitRef="usd">-8757000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-39" decimals="-3" id="f-312" unitRef="shares">323000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-39" decimals="-3" id="f-313" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-40" decimals="-3" id="f-314" unitRef="usd">39609000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-3" id="f-315" unitRef="usd">39610000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-39" decimals="-3" id="f-316" unitRef="usd">2000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-40" decimals="-3" id="f-317" unitRef="usd">-2000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-41" decimals="-3" id="f-318" unitRef="shares">828000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-41" decimals="-3" id="f-319" unitRef="usd">150011000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-1" decimals="-3" id="f-320" unitRef="usd">150011000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-40" decimals="-3" id="f-321" unitRef="usd">80184000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-3" id="f-322" unitRef="usd">80184000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-42" decimals="-3" id="f-323" unitRef="usd">20999000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">20999000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-43" decimals="-3" id="f-325" unitRef="usd">1020951000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-326" unitRef="usd">1020951000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-1"
      decimals="INF"
      id="f-327"
      unitRef="usdPerShare">1.92</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends contextRef="c-43" decimals="-3" id="f-328" unitRef="usd">282320000</us-gaap:Dividends>
    <us-gaap:Dividends contextRef="c-1" decimals="-3" id="f-329" unitRef="usd">282320000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-44" decimals="-3" id="f-330" unitRef="shares">189565000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-331" unitRef="usd">588000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-332" unitRef="usd">1896604000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-46" decimals="-3" id="f-333" unitRef="shares">42664000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-334" unitRef="usd">-1773267000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-335" unitRef="usd">4991647000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-336" unitRef="usd">-251529000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-337" unitRef="usd">4864043000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">1020951000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-339" unitRef="usd">897556000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-340" unitRef="usd">779437000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-341" unitRef="usd">176870000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-12" decimals="-3" id="f-342" unitRef="usd">165156000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-13" decimals="-3" id="f-343" unitRef="usd">159609000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">39339000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-12" decimals="-3" id="f-345" unitRef="usd">32406000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-13" decimals="-3" id="f-346" unitRef="usd">34232000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-347" unitRef="usd">80184000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-12" decimals="-3" id="f-348" unitRef="usd">71142000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-13" decimals="-3" id="f-349" unitRef="usd">65257000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">-1848000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions contextRef="c-12" decimals="-3" id="f-351" unitRef="usd">-10138000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions contextRef="c-13" decimals="-3" id="f-352" unitRef="usd">-8486000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss contextRef="c-1" decimals="-3" id="f-353" unitRef="usd">-4045000</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss contextRef="c-12" decimals="-3" id="f-354" unitRef="usd">9922000</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss contextRef="c-13" decimals="-3" id="f-355" unitRef="usd">-12202000</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-1" decimals="-3" id="f-356" unitRef="usd">33239000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-12" decimals="-3" id="f-357" unitRef="usd">9177000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-13" decimals="-3" id="f-358" unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:InsuranceRecoveries contextRef="c-1" decimals="-3" id="f-359" unitRef="usd">0</us-gaap:InsuranceRecoveries>
    <us-gaap:InsuranceRecoveries contextRef="c-12" decimals="-3" id="f-360" unitRef="usd">20227000</us-gaap:InsuranceRecoveries>
    <us-gaap:InsuranceRecoveries contextRef="c-13" decimals="-3" id="f-361" unitRef="usd">0</us-gaap:InsuranceRecoveries>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-362" unitRef="usd">134278000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-12" decimals="-3" id="f-363" unitRef="usd">106511000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-13" decimals="-3" id="f-364" unitRef="usd">-19346000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-365" unitRef="usd">-172203000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-12" decimals="-3" id="f-366" unitRef="usd">248833000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-13" decimals="-3" id="f-367" unitRef="usd">311681000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-368" unitRef="usd">115213000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-12" decimals="-3" id="f-369" unitRef="usd">138125000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-13" decimals="-3" id="f-370" unitRef="usd">168109000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-371" unitRef="usd">122072000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-12" decimals="-3" id="f-372" unitRef="usd">31342000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-13" decimals="-3" id="f-373" unitRef="usd">-247632000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-374" unitRef="usd">1401260000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-12" decimals="-3" id="f-375" unitRef="usd">693299000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-13" decimals="-3" id="f-376" unitRef="usd">351147000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-377" unitRef="usd">99460000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-12" decimals="-3" id="f-378" unitRef="usd">119672000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-13" decimals="-3" id="f-379" unitRef="usd">134835000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-1" decimals="-3" id="f-380" unitRef="usd">15396000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-12" decimals="-3" id="f-381" unitRef="usd">14328000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-13" decimals="-3" id="f-382" unitRef="usd">21201000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-3" id="f-383" unitRef="usd">133464000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-12" decimals="-3" id="f-384" unitRef="usd">1012749000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-13" decimals="-3" id="f-385" unitRef="usd">42784000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-1" decimals="-3" id="f-386" unitRef="usd">12765000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-12" decimals="-3" id="f-387" unitRef="usd">32229000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-13" decimals="-3" id="f-388" unitRef="usd">20724000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-1" decimals="-3" id="f-389" unitRef="usd">1000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-12" decimals="-3" id="f-390" unitRef="usd">3937000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-13" decimals="-3" id="f-391" unitRef="usd">6802000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsForProceedsFromDerivativeInstrumentInvestingActivities contextRef="c-1" decimals="-3" id="f-392" unitRef="usd">9699000</us-gaap:PaymentsForProceedsFromDerivativeInstrumentInvestingActivities>
    <us-gaap:PaymentsForProceedsFromDerivativeInstrumentInvestingActivities contextRef="c-12" decimals="-3" id="f-393" unitRef="usd">-15196000</us-gaap:PaymentsForProceedsFromDerivativeInstrumentInvestingActivities>
    <us-gaap:PaymentsForProceedsFromDerivativeInstrumentInvestingActivities contextRef="c-13" decimals="-3" id="f-394" unitRef="usd">17176000</us-gaap:PaymentsForProceedsFromDerivativeInstrumentInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-395" unitRef="usd">-269784000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-12" decimals="-3" id="f-396" unitRef="usd">-1159845000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-13" decimals="-3" id="f-397" unitRef="usd">-229918000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-398" unitRef="usd">53094000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-12" decimals="-3" id="f-399" unitRef="usd">49142000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-13" decimals="-3" id="f-400" unitRef="usd">47384000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-401" unitRef="usd">8757000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-12" decimals="-3" id="f-402" unitRef="usd">30631000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-13" decimals="-3" id="f-403" unitRef="usd">52406000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-3" id="f-404" unitRef="usd">150011000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-12" decimals="-3" id="f-405" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-13" decimals="-3" id="f-406" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities contextRef="c-1" decimals="-3" id="f-407" unitRef="usd">1293000</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities contextRef="c-12" decimals="-3" id="f-408" unitRef="usd">2361000</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities contextRef="c-13" decimals="-3" id="f-409" unitRef="usd">0</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-1" decimals="-3" id="f-410" unitRef="usd">105000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-12" decimals="-3" id="f-411" unitRef="usd">1070000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-13" decimals="-3" id="f-412" unitRef="usd">288000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-3" id="f-413" unitRef="usd">835000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-12" decimals="-3" id="f-414" unitRef="usd">405000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-13" decimals="-3" id="f-415" unitRef="usd">166000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfDividends contextRef="c-1" decimals="-3" id="f-416" unitRef="usd">282320000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="c-12" decimals="-3" id="f-417" unitRef="usd">258276000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="c-13" decimals="-3" id="f-418" unitRef="usd">245341000</us-gaap:PaymentsOfDividends>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-419" unitRef="usd">-1119287000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-12" decimals="-3" id="f-420" unitRef="usd">422874000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-13" decimals="-3" id="f-421" unitRef="usd">-128363000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-422" unitRef="usd">-1719000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-12" decimals="-3" id="f-423" unitRef="usd">-2147000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="-3" id="f-424" unitRef="usd">-14434000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-425" unitRef="usd">10470000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-12" decimals="-3" id="f-426" unitRef="usd">-45819000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-13" decimals="-3" id="f-427" unitRef="usd">-21568000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-428" unitRef="usd">227891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-29" decimals="-3" id="f-429" unitRef="usd">273710000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-19" decimals="-3" id="f-430" unitRef="usd">295278000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-431" unitRef="usd">238361000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-432" unitRef="usd">227891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-29" decimals="-3" id="f-433" unitRef="usd">273710000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-434" unitRef="usd">278400000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-12" decimals="-3" id="f-435" unitRef="usd">216866000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-13" decimals="-3" id="f-436" unitRef="usd">478120000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-437" unitRef="usd">45708000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-12" decimals="-3" id="f-438" unitRef="usd">47379000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-13" decimals="-3" id="f-439" unitRef="usd">22312000</us-gaap:InterestPaidNet>
    <rmd:NoncashPartOfAcquisitionFairValueOfAssetsAcquired contextRef="c-1" decimals="-3" id="f-440" unitRef="usd">46033000</rmd:NoncashPartOfAcquisitionFairValueOfAssetsAcquired>
    <rmd:NoncashPartOfAcquisitionFairValueOfAssetsAcquired contextRef="c-12" decimals="-3" id="f-441" unitRef="usd">359730000</rmd:NoncashPartOfAcquisitionFairValueOfAssetsAcquired>
    <rmd:NoncashPartOfAcquisitionFairValueOfAssetsAcquired contextRef="c-13" decimals="-3" id="f-442" unitRef="usd">15648000</rmd:NoncashPartOfAcquisitionFairValueOfAssetsAcquired>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1 contextRef="c-1" decimals="-3" id="f-443" unitRef="usd">7696000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1 contextRef="c-12" decimals="-3" id="f-444" unitRef="usd">131765000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1 contextRef="c-13" decimals="-3" id="f-445" unitRef="usd">4672000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <rmd:GoodwillAcquiredDuringPeriodIncreaseDecrease contextRef="c-1" decimals="-3" id="f-446" unitRef="usd">92191000</rmd:GoodwillAcquiredDuringPeriodIncreaseDecrease>
    <rmd:GoodwillAcquiredDuringPeriodIncreaseDecrease contextRef="c-12" decimals="-3" id="f-447" unitRef="usd">786990000</rmd:GoodwillAcquiredDuringPeriodIncreaseDecrease>
    <rmd:GoodwillAcquiredDuringPeriodIncreaseDecrease contextRef="c-13" decimals="-3" id="f-448" unitRef="usd">38953000</rmd:GoodwillAcquiredDuringPeriodIncreaseDecrease>
    <rmd:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination contextRef="c-1" decimals="-3" id="f-449" unitRef="usd">0</rmd:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination>
    <rmd:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination contextRef="c-12" decimals="-3" id="f-450" unitRef="usd">0</rmd:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination>
    <rmd:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination contextRef="c-13" decimals="-3" id="f-451" unitRef="usd">4078000</rmd:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination>
    <rmd:DeferredPaymentObligationsForAcquisitions contextRef="c-1" decimals="-3" id="f-452" unitRef="usd">-143000</rmd:DeferredPaymentObligationsForAcquisitions>
    <rmd:DeferredPaymentObligationsForAcquisitions contextRef="c-12" decimals="-3" id="f-453" unitRef="usd">2542000</rmd:DeferredPaymentObligationsForAcquisitions>
    <rmd:DeferredPaymentObligationsForAcquisitions contextRef="c-13" decimals="-3" id="f-454" unitRef="usd">-3067000</rmd:DeferredPaymentObligationsForAcquisitions>
    <rmd:BusinessAcquisitionContingentConsiderationRecognizedLiability contextRef="c-1" decimals="-3" id="f-455" unitRef="usd">-4372000</rmd:BusinessAcquisitionContingentConsiderationRecognizedLiability>
    <rmd:BusinessAcquisitionContingentConsiderationRecognizedLiability contextRef="c-12" decimals="-3" id="f-456" unitRef="usd">2387000</rmd:BusinessAcquisitionContingentConsiderationRecognizedLiability>
    <rmd:BusinessAcquisitionContingentConsiderationRecognizedLiability contextRef="c-13" decimals="-3" id="f-457" unitRef="usd">0</rmd:BusinessAcquisitionContingentConsiderationRecognizedLiability>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-1" decimals="-3" id="f-458" unitRef="usd">134757000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-12" decimals="-3" id="f-459" unitRef="usd">1015110000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-13" decimals="-3" id="f-460" unitRef="usd">42784000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-462">Organization and Basis of Presentation ResMed Inc. (referred to herein as &#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d; or the &#x201c;Company&#x201d;) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Finland, Norway and Sweden. We also operate a Software as a Service (&#x201c;SaaS&#x201d;) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <rmd:OrganizationAndBasisOfPresentationPolicyPolicyTextBlock contextRef="c-1" id="f-461">Organization and Basis of Presentation ResMed Inc. (referred to herein as &#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d; or the &#x201c;Company&#x201d;) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Finland, Norway and Sweden. We also operate a Software as a Service (&#x201c;SaaS&#x201d;) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice.</rmd:OrganizationAndBasisOfPresentationPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-463">Summary of Significant Accounting Policies &lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Basis of Consolidation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from management&#x2019;s estimates. Certain prior period amounts have been reclassified to conform to the current period presentation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standard Codification (&#x201c;ASC&#x201d;) Topic 606, &#x201c;Revenue from Contracts with Customers&#x201d;, we account for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (&#x201c;Sleep and Respiratory Care&#x201d;) and the supply of business management software as a service to out-of-hospital care providers (&#x201c;SaaS&#x201d;). Our Sleep and Respiratory Care revenue relates primarily to the sale of our products that are therapy-based equipment. Some contracts include additional performance obligations such as the provision of extended warranties and provision of data for patient monitoring. Our SaaS revenue relates to the provision of software access with ongoing support and maintenance services as well as professional services such as training and consulting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Disaggregation of revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 13 &#x2013; Segment Information for our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2024, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Performance obligations and contract balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; generally, this occurs with the transfer of risk and/or control of our products at a point in time. For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with cloud-hosted services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of one year to five years. Our contracts do not contain significant financing components. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our contract balances as of June&#160;30, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.811%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance sheet caption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;837,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;704,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unbilled revenue, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unbilled revenue, non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid taxes and other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(152,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(138,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue (current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue, non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137,343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(119,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue (non-current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Transaction price determination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g. rebates, discounts, free goods) and returns by our customers and their customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of our historical experience. Returns of products, excluding warranty-related returns, have historically been infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer&#x2019;s expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates each quarter based on actual sales results and updated forecasts for the remaining rebate periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We participate in programs where we issue credits to our Sleep and Respiratory Care distributors when they are required to sell our products below negotiated list prices if we have preexisting contracts with the distributors' customers. We reduce revenue for future credits at the time of sale to the distributor, which we estimate based on historical experience using the expected value method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When Sleep and Respiratory Care or SaaS contracts have multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each performance obligation. An allocation is not required for many of our Sleep and Respiratory Care contracts that have a single performance obligation, which is the shipment of our therapy-based equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Accounting and practical expedient elections&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to account for shipping and handling activities associated with our Sleep and Respiratory Care segment as a fulfillment cost within cost of sales, and record shipping and handling costs collected from customers in net revenue. We have also elected for all taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, to be excluded from revenue and presented on a net basis. We have adopted two practical expedients including the &#x201c;right to invoice&#x201d; practical expedient, which is relevant for some of our SaaS contracts as it allows us to recognize revenue in the amount of the invoice when it corresponds directly with the value of performance completed to date. The second practical expedient adopted permits relief from considering a significant financing component when the payment for the good or service is expected to be one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt"&gt;Concentration of Credit Risk and Significant Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, derivatives and trade receivables. Our cash and cash equivalents are generally held with large, diverse financial institutions to reduce the amount of exposure to any single financial institution. Our derivative contracts are transacted with various financial institutions with high credit standings and any exposure to counterparty credit-related losses in these contracts is largely mitigated with collateralization and master-netting agreements. The risk with respect to trade receivables is mitigated by credit evaluations we perform on our customers, the short duration of our payment terms for the majority of our customer contracts and by the diversification of our customer base. No single customer accounted for 10% or more of our total revenues for any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt; Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of financial instruments is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. We measure our financial instruments at fair value at each reporting period using a fair value hierarchy that requires that we maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#x2019;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Other inputs that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash equivalents, accounts receivable and accounts payable, approximate their fair value because of their short-term nature. The carrying value of long-term debt related to our Revolving Credit and Term Credit Agreements approximates its fair value as the principal amounts outstanding are subject to variable interest rates that are based on market rates which are regularly reset. The carrying value of long-term debt related to our Senior Notes can differ to its fair value as the principal amounts outstanding are subject to fixed interest rates as outlined in Note 8 &#x2013; Debt. Foreign currency hedging instruments are marked to market and therefore reflect their fair value. In addition, we measure investments in publicly held equity securities and privately held equity securities for which there has been an observable price change in an identical or similar security, at fair value. We do not hold or issue financial instruments for trading purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents include certificates of deposit and other highly liquid investments and we state them at cost, which approximates market. We consider investments with original maturities of 90 days or less to be cash equivalents for purposes of the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.01pt"&gt;Inventories &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We state inventories at the lower of cost (determined principally by the first-in, first-out method) or net realizable value. We include material, labor and manufacturing overhead costs in finished goods and work-in-process inventories. We review and provide for any product obsolescence in our manufacturing and distribution operations by assessing throughout the year individual products and components (based on estimated future usage and sales).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(g)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Property, Plant and Equipment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record property, plant and equipment, including rental and demonstration equipment at cost. We compute depreciation expense using the straight-line method over the estimated useful lives of the assets. Useful lives are generally two years to ten years except for buildings which are depreciated over an estimated useful life of forty years and leasehold improvements, which we amortize over the shorter of the useful life or the lease term. We charge maintenance and repairs to expense as we incur them.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for property, plant, and equipment was $88.9 million, $84.7 million, and $81.0 million for the years ended June&#160;30, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(h)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Intangible Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize the registration costs for new patents and amortize the costs over the estimated useful life of the patent, which is generally ten years. If a patent is superseded or a product is retired, any unamortized costs are written off immediately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We amortize our other intangible assets on a straight-line basis over their estimated useful lives, which range from two years to fifteen years. We evaluate events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists and, at least annually, evaluate the recoverability of intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct our annual review for goodwill impairment during the final quarter of the fiscal year. Our goodwill impairment review is performed at our reporting unit level, which is one level below our operating segments and involves the following steps: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Step 0 or Qualitative assessment &#x2013; Evaluate qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. The factors we consider include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, overall financial performance or events-specific to that reporting unit. If or when we determine it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill, we would move to Step 1 of the quantitative method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Step 1 &#x2013; Compare the fair value for each reporting unit to its carrying value, including goodwill. Fair value is determined based on estimated discounted cash flows. A goodwill impairment charge is recognized for the amount that the carrying amount of a reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit. If a reporting unit&#x2019;s fair value exceeds the carrying value, no further work is performed and no impairment charge is necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the annual reviews for the years ended June&#160;30, 2024, 2023 and 2022, we completed a Step 0 or Qualitative assessment and determined it was more likely than not that the fair value of our reporting units exceeded their carrying amounts, including goodwill, and therefore goodwill was not impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(j)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.01pt"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocate the purchase price to the estimated fair values of the assets acquired and liabilities assumed. This allocation process involves the use of estimates and assumptions made in connection with determining the fair value of assets acquired and liabilities assumed including cash flows expected to be derived from the use of the asset, the timing of such cash flows, the remaining useful life of assets and applicable discount rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If actual results vary from the estimates or assumptions used in the valuation or allocation process, we may be required to record an impairment charge or an increase in depreciation or amortization in future periods, or both.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(k)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have equity investments in privately and publicly held companies that are unconsolidated entities. The following discusses our accounting for investments in marketable equity securities, non-marketable equity securities, and investments accounted for under the equity method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities are publicly traded stocks measured at fair value and classified within Level 1 in the fair value hierarchy because we use quoted prices for identical assets in active markets. Marketable equity securities are recorded in prepaid expenses and other current assets on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-marketable equity securities consist of investments in privately held companies without readily determinable fair values and are recorded in prepaid taxes and other non-current assets on the consolidated balance sheets. Non-marketable equity securities are reported at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. We assess non-marketable equity securities at least quarterly for impairment and consider qualitative and quantitative factors including the investee's financial metrics, product and commercial outlook and cash usage. All gains and losses on marketable and non-marketable equity securities, realized and unrealized, are recognized in gain (loss) on equity investments as a component of other income (loss), net on the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments whereby we have significant influence but not control over the investee and are not the primary beneficiary of the investee&#x2019;s activities, are accounted for under the equity method. Under this method, we record our share of gains or losses attributable to equity method investments as a component of other income (loss), net on the consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(l)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt"&gt;Research and Development &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record all research and development expenses in the period we incur them.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(m)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:3.01pt"&gt;Foreign Currency &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements of our non-U.S. subsidiaries, whose functional currencies are other than the U.S. dollar, are translated into U.S. dollars for financial reporting purposes. We translate assets and liabilities of non-U.S. subsidiaries whose functional currencies are other than the U.S. dollar at period end exchange rates but translate revenue and expense transactions at average exchange rates for the period. We recognize cumulative translation adjustments as part of comprehensive income, as detailed in the consolidated statements of comprehensive income, and include those adjustments in accumulated other comprehensive income in the consolidated balance sheets until such time the relevant subsidiary is sold or substantially or completely liquidated. We reflect gains and losses on transactions denominated in other than the functional currency of an entity in our results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(n)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Foreign Exchange Risk Management &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may use derivative financial instruments, specifically foreign cross-currency swaps, purchased foreign currency call options, collars and forward contracts to mitigate exposure from certain foreign currency risk. No derivatives are used for trading or speculative purposes. We do not require or are not required to pledge collateral for the derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Fair Value and Net Investment Hedging&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 17, 2022, we executed foreign cross-currency swaps as net investment hedges and fair value hedges in designated hedging relationships with either the foreign denominated net asset balances or the foreign denominated intercompany loan as the hedged items. All derivatives are recorded at fair value as either an asset or liability. Cash flows associated with derivative instruments are presented in the same category on the consolidated statements of cash flows as the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purpose of the cross-currency swaps for the fair value hedge is to mitigate foreign currency risk associated with changes in spot rates on foreign denominated intercompany debt between USD and EUR. For these hedges, we excluded certain components from the assessment of hedge effectiveness that are not related to spot rates. For fair value hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in the same line item as the hedged item, other, net, in the consolidated statement of income. The initial fair value of hedge components excluded from the assessment of effectiveness is recognized in the statement of income under a systematic and rational method over the life of the hedging instrument and is presented in interest (expense) income, net. Any difference between the change in the fair value of the hedge components excluded from the assessment of effectiveness and the amounts recognized in earnings is recorded as a component of other comprehensive income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purpose of the cross-currency swaps for the net investment hedge is to mitigate foreign currency risk associated with changes in spot rates on the net asset balances of our foreign functional subsidiaries. For net investment hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in cumulative translation adjustment within other comprehensive loss and reclassified into earnings when the hedged net investment is either sold or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;substantially liquidated. The initial fair value of components excluded from the assessment of hedge effectiveness will be recognized in interest (expense) income, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional value of outstanding foreign cross-currency swaps was $1,026.2 million at June&#160;30, 2024. These contracts mature at various dates prior to December 31, 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-Designated Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have foreign currency exposure through both our Australian and Singapore manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased foreign currency call options, collars and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed two years. The purpose of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, and Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not designate these foreign currency contracts as hedges. All movements in the fair value of the foreign currency instruments are recorded within other, net in our consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional value of the outstanding non-designated hedges was $1,340.0 million and $954.7 million at June&#160;30, 2024 and June&#160;30, 2023, respectively. These contracts mature at various dates prior to September&#160;15, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classified the fair values of all hedging instruments as Level 2 measurements within the fair value hierarchy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments. We minimize counterparty credit risk by entering into derivative transactions with major financial institutions and we do not expect material losses as a result of default by our counterparties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(o)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. We measure deferred tax assets and liabilities using the enacted tax rates we expect to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the impact of a tax position in the consolidated financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions are reflected in income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(p)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain an allowance for credit losses on customer receivables based expected losses, considering our historical write-off experience, an assessment of our customers&#x2019; financial conditions, and available information that is relevant to assessing the collectability of cash flows, which includes current conditions and forecasts about future economic conditions. Customer receivables are charged against the allowance when they are deemed uncollectible. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also contingently liable, within certain limits, in the event of a customer default, to independent financing companies in connection with customer financing programs. We monitor the collection status of these installment receivables and provide for estimated losses separately under accrued expenses within our consolidated balance sheets based upon our historical collection experience with such receivables and a current assessment of our credit exposure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(q)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically evaluate the carrying value of long-lived assets to be held and used, including certain identifiable intangible assets, when events and circumstances indicate that the carrying amount of an asset may not be recovered. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If assets are considered to be impaired, we recognize as the impairment the amount by which the carrying amount of the assets exceeds the fair value of the assets. We report assets to be disposed of at the lower of the carrying amount or fair value less costs to sell. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended June&#160;30, 2024, we recorded $33.2 million of restructuring related intangible asset impairments associated with the wind down of certain business activities. Refer to Note 18 &#x2013; Restructuring Expenses for additional information regarding restructuring costs. We did not recognize impairment charges in relation to long-lived assets during the fiscal years ended June 30, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(r)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;We record a liability in the consolidated financial statements for loss contingencies when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-464">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Basis of Consolidation &lt;/span&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from management&#x2019;s estimates. Certain prior period amounts have been reclassified to conform to the current period presentation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-465">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Revenue Recognition &lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standard Codification (&#x201c;ASC&#x201d;) Topic 606, &#x201c;Revenue from Contracts with Customers&#x201d;, we account for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (&#x201c;Sleep and Respiratory Care&#x201d;) and the supply of business management software as a service to out-of-hospital care providers (&#x201c;SaaS&#x201d;). Our Sleep and Respiratory Care revenue relates primarily to the sale of our products that are therapy-based equipment. Some contracts include additional performance obligations such as the provision of extended warranties and provision of data for patient monitoring. Our SaaS revenue relates to the provision of software access with ongoing support and maintenance services as well as professional services such as training and consulting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Disaggregation of revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 13 &#x2013; Segment Information for our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2024, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Performance obligations and contract balances&lt;/span&gt;&lt;/div&gt;Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; generally, this occurs with the transfer of risk and/or control of our products at a point in time. For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with cloud-hosted services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of one year to five years. Our contracts do not contain significant financing components.&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Transaction price determination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g. rebates, discounts, free goods) and returns by our customers and their customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of our historical experience. Returns of products, excluding warranty-related returns, have historically been infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer&#x2019;s expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates each quarter based on actual sales results and updated forecasts for the remaining rebate periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We participate in programs where we issue credits to our Sleep and Respiratory Care distributors when they are required to sell our products below negotiated list prices if we have preexisting contracts with the distributors' customers. We reduce revenue for future credits at the time of sale to the distributor, which we estimate based on historical experience using the expected value method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When Sleep and Respiratory Care or SaaS contracts have multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each performance obligation. An allocation is not required for many of our Sleep and Respiratory Care contracts that have a single performance obligation, which is the shipment of our therapy-based equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Accounting and practical expedient elections&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to account for shipping and handling activities associated with our Sleep and Respiratory Care segment as a fulfillment cost within cost of sales, and record shipping and handling costs collected from customers in net revenue. We have also elected for all taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, to be excluded from revenue and presented on a net basis. We have adopted two practical expedients including the &#x201c;right to invoice&#x201d; practical expedient, which is relevant for some of our SaaS contracts as it allows us to recognize revenue in the amount of the invoice when it corresponds directly with the value of performance completed to date. The second practical expedient adopted permits relief from considering a significant financing component when the payment for the good or service is expected to be one year or less.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-466"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <rmd:TermOfContractUnderRevenueRecognition contextRef="c-49" id="f-467">P1Y</rmd:TermOfContractUnderRevenueRecognition>
    <rmd:TermOfContractUnderRevenueRecognition contextRef="c-50" id="f-468">P5Y</rmd:TermOfContractUnderRevenueRecognition>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-469">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our contract balances as of June&#160;30, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.811%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance sheet caption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;837,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;704,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unbilled revenue, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unbilled revenue, non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid taxes and other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(152,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(138,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue (current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue, non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137,343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(119,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue (non-current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-51" decimals="-3" id="f-470" unitRef="usd">837275000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-52" decimals="-3" id="f-471" unitRef="usd">704909000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-53" decimals="-3" id="f-472" unitRef="usd">38183000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-54" decimals="-3" id="f-473" unitRef="usd">31521000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent contextRef="c-55" decimals="-3" id="f-474" unitRef="usd">18450000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent contextRef="c-56" decimals="-3" id="f-475" unitRef="usd">10078000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-57" decimals="-3" id="f-476" unitRef="usd">152554000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-58" decimals="-3" id="f-477" unitRef="usd">138072000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-59" decimals="-3" id="f-478" unitRef="usd">137343000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-60" decimals="-3" id="f-479" unitRef="usd">119186000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <rmd:ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock contextRef="c-1" id="f-480">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt"&gt;Concentration of Credit Risk and Significant Customers&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, derivatives and trade receivables. Our cash and cash equivalents are generally held with large, diverse financial institutions to reduce the amount of exposure to any single financial institution. Our derivative contracts are transacted with various financial institutions with high credit standings and any exposure to counterparty credit-related losses in these contracts is largely mitigated with collateralization and master-netting agreements. The risk with respect to trade receivables is mitigated by credit evaluations we perform on our customers, the short duration of our payment terms for the majority of our customer contracts and by the diversification of our customer base. No single customer accounted for 10% or more of our total revenues for any of the periods presented.&lt;/span&gt;&lt;/div&gt;</rmd:ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-481">Fair Value of Financial Instruments&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of financial instruments is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. We measure our financial instruments at fair value at each reporting period using a fair value hierarchy that requires that we maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#x2019;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Other inputs that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity.&lt;/span&gt;&lt;/div&gt;The carrying value of cash equivalents, accounts receivable and accounts payable, approximate their fair value because of their short-term nature. The carrying value of long-term debt related to our Revolving Credit and Term Credit Agreements approximates its fair value as the principal amounts outstanding are subject to variable interest rates that are based on market rates which are regularly reset. The carrying value of long-term debt related to our Senior Notes can differ to its fair value as the principal amounts outstanding are subject to fixed interest rates as outlined in Note 8 &#x2013; Debt. Foreign currency hedging instruments are marked to market and therefore reflect their fair value. In addition, we measure investments in publicly held equity securities and privately held equity securities for which there has been an observable price change in an identical or similar security, at fair value. We do not hold or issue financial instruments for trading purposes.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-482">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents include certificates of deposit and other highly liquid investments and we state them at cost, which approximates market. We consider investments with original maturities of 90 days or less to be cash equivalents for purposes of the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-483">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.01pt"&gt;Inventories &lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We state inventories at the lower of cost (determined principally by the first-in, first-out method) or net realizable value. We include material, labor and manufacturing overhead costs in finished goods and work-in-process inventories. We review and provide for any product obsolescence in our manufacturing and distribution operations by assessing throughout the year individual products and components (based on estimated future usage and sales).&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-484">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Property, Plant and Equipment &lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record property, plant and equipment, including rental and demonstration equipment at cost. We compute depreciation expense using the straight-line method over the estimated useful lives of the assets. Useful lives are generally two years to ten years except for buildings which are depreciated over an estimated useful life of forty years and leasehold improvements, which we amortize over the shorter of the useful life or the lease term. We charge maintenance and repairs to expense as we incur them.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-61" id="f-485">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-62" id="f-486">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-63" id="f-487">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-488" unitRef="usd">88900000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-12" decimals="-5" id="f-489" unitRef="usd">84700000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-13" decimals="-5" id="f-490" unitRef="usd">81000000.0</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c-1" id="f-491">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Intangible Assets &lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize the registration costs for new patents and amortize the costs over the estimated useful life of the patent, which is generally ten years. If a patent is superseded or a product is retired, any unamortized costs are written off immediately.&lt;/span&gt;&lt;/div&gt;We amortize our other intangible assets on a straight-line basis over their estimated useful lives, which range from two years to fifteen years. We evaluate events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists and, at least annually, evaluate the recoverability of intangible assets.</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-64" id="f-492">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-61" id="f-493">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-62" id="f-494">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-495">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt"&gt;Goodwill &lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct our annual review for goodwill impairment during the final quarter of the fiscal year. Our goodwill impairment review is performed at our reporting unit level, which is one level below our operating segments and involves the following steps: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Step 0 or Qualitative assessment &#x2013; Evaluate qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. The factors we consider include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, overall financial performance or events-specific to that reporting unit. If or when we determine it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill, we would move to Step 1 of the quantitative method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Step 1 &#x2013; Compare the fair value for each reporting unit to its carrying value, including goodwill. Fair value is determined based on estimated discounted cash flows. A goodwill impairment charge is recognized for the amount that the carrying amount of a reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit. If a reporting unit&#x2019;s fair value exceeds the carrying value, no further work is performed and no impairment charge is necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the annual reviews for the years ended June&#160;30, 2024, 2023 and 2022, we completed a Step 0 or Qualitative assessment and determined it was more likely than not that the fair value of our reporting units exceeded their carrying amounts, including goodwill, and therefore goodwill was not impaired.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:BusinessCombinationsPolicy contextRef="c-1" id="f-496">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.01pt"&gt;Business Combinations&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocate the purchase price to the estimated fair values of the assets acquired and liabilities assumed. This allocation process involves the use of estimates and assumptions made in connection with determining the fair value of assets acquired and liabilities assumed including cash flows expected to be derived from the use of the asset, the timing of such cash flows, the remaining useful life of assets and applicable discount rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If actual results vary from the estimates or assumptions used in the valuation or allocation process, we may be required to record an impairment charge or an increase in depreciation or amortization in future periods, or both.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-497">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Equity Investments&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have equity investments in privately and publicly held companies that are unconsolidated entities. The following discusses our accounting for investments in marketable equity securities, non-marketable equity securities, and investments accounted for under the equity method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities are publicly traded stocks measured at fair value and classified within Level 1 in the fair value hierarchy because we use quoted prices for identical assets in active markets. Marketable equity securities are recorded in prepaid expenses and other current assets on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-marketable equity securities consist of investments in privately held companies without readily determinable fair values and are recorded in prepaid taxes and other non-current assets on the consolidated balance sheets. Non-marketable equity securities are reported at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. We assess non-marketable equity securities at least quarterly for impairment and consider qualitative and quantitative factors including the investee's financial metrics, product and commercial outlook and cash usage. All gains and losses on marketable and non-marketable equity securities, realized and unrealized, are recognized in gain (loss) on equity investments as a component of other income (loss), net on the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;Equity investments whereby we have significant influence but not control over the investee and are not the primary beneficiary of the investee&#x2019;s activities, are accounted for under the equity method. Under this method, we record our share of gains or losses attributable to equity method investments as a component of other income (loss), net on the consolidated statements of income.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-498">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt"&gt;Research and Development &lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record all research and development expenses in the period we incur them.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-499">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:3.01pt"&gt;Foreign Currency &lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements of our non-U.S. subsidiaries, whose functional currencies are other than the U.S. dollar, are translated into U.S. dollars for financial reporting purposes. We translate assets and liabilities of non-U.S. subsidiaries whose functional currencies are other than the U.S. dollar at period end exchange rates but translate revenue and expense transactions at average exchange rates for the period. We recognize cumulative translation adjustments as part of comprehensive income, as detailed in the consolidated statements of comprehensive income, and include those adjustments in accumulated other comprehensive income in the consolidated balance sheets until such time the relevant subsidiary is sold or substantially or completely liquidated. We reflect gains and losses on transactions denominated in other than the functional currency of an entity in our results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c-1" id="f-500">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Foreign Exchange Risk Management &lt;/span&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may use derivative financial instruments, specifically foreign cross-currency swaps, purchased foreign currency call options, collars and forward contracts to mitigate exposure from certain foreign currency risk. No derivatives are used for trading or speculative purposes. We do not require or are not required to pledge collateral for the derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Fair Value and Net Investment Hedging&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 17, 2022, we executed foreign cross-currency swaps as net investment hedges and fair value hedges in designated hedging relationships with either the foreign denominated net asset balances or the foreign denominated intercompany loan as the hedged items. All derivatives are recorded at fair value as either an asset or liability. Cash flows associated with derivative instruments are presented in the same category on the consolidated statements of cash flows as the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purpose of the cross-currency swaps for the fair value hedge is to mitigate foreign currency risk associated with changes in spot rates on foreign denominated intercompany debt between USD and EUR. For these hedges, we excluded certain components from the assessment of hedge effectiveness that are not related to spot rates. For fair value hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in the same line item as the hedged item, other, net, in the consolidated statement of income. The initial fair value of hedge components excluded from the assessment of effectiveness is recognized in the statement of income under a systematic and rational method over the life of the hedging instrument and is presented in interest (expense) income, net. Any difference between the change in the fair value of the hedge components excluded from the assessment of effectiveness and the amounts recognized in earnings is recorded as a component of other comprehensive income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purpose of the cross-currency swaps for the net investment hedge is to mitigate foreign currency risk associated with changes in spot rates on the net asset balances of our foreign functional subsidiaries. For net investment hedges that qualify and are designated for hedge accounting, the change in fair value of the derivative is recorded in cumulative translation adjustment within other comprehensive loss and reclassified into earnings when the hedged net investment is either sold or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;substantially liquidated. The initial fair value of components excluded from the assessment of hedge effectiveness will be recognized in interest (expense) income, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional value of outstanding foreign cross-currency swaps was $1,026.2 million at June&#160;30, 2024. These contracts mature at various dates prior to December 31, 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-Designated Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have foreign currency exposure through both our Australian and Singapore manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased foreign currency call options, collars and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed two years. The purpose of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, and Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not designate these foreign currency contracts as hedges. All movements in the fair value of the foreign currency instruments are recorded within other, net in our consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional value of the outstanding non-designated hedges was $1,340.0 million and $954.7 million at June&#160;30, 2024 and June&#160;30, 2023, respectively. These contracts mature at various dates prior to September&#160;15, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classified the fair values of all hedging instruments as Level 2 measurements within the fair value hierarchy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments. We minimize counterparty credit risk by entering into derivative transactions with major financial institutions and we do not expect material losses as a result of default by our counterparties.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DerivativeNotionalAmount contextRef="c-65" decimals="-5" id="f-501" unitRef="usd">1026200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeTermOfContract contextRef="c-66" id="f-502">P2Y</us-gaap:DerivativeTermOfContract>
    <us-gaap:DerivativeNotionalAmount contextRef="c-67" decimals="-5" id="f-503" unitRef="usd">1340000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-68" decimals="-5" id="f-504" unitRef="usd">954700000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-505">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Income Taxes&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. We measure deferred tax assets and liabilities using the enacted tax rates we expect to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the impact of a tax position in the consolidated financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions are reflected in income tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:FinanceLoansAndLeasesReceivablePolicy contextRef="c-1" id="f-506">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain an allowance for credit losses on customer receivables based expected losses, considering our historical write-off experience, an assessment of our customers&#x2019; financial conditions, and available information that is relevant to assessing the collectability of cash flows, which includes current conditions and forecasts about future economic conditions. Customer receivables are charged against the allowance when they are deemed uncollectible. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also contingently liable, within certain limits, in the event of a customer default, to independent financing companies in connection with customer financing programs. We monitor the collection status of these installment receivables and provide for estimated losses separately under accrued expenses within our consolidated balance sheets based upon our historical collection experience with such receivables and a current assessment of our credit exposure.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinanceLoansAndLeasesReceivablePolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-507">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically evaluate the carrying value of long-lived assets to be held and used, including certain identifiable intangible assets, when events and circumstances indicate that the carrying amount of an asset may not be recovered. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If assets are considered to be impaired, we recognize as the impairment the amount by which the carrying amount of the assets exceeds the fair value of the assets. We report assets to be disposed of at the lower of the carrying amount or fair value less costs to sell. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended June&#160;30, 2024, we recorded $33.2 million of restructuring related intangible asset impairments associated with the wind down of certain business activities. Refer to Note 18 &#x2013; Restructuring Expenses for additional information regarding restructuring costs. We did not recognize impairment charges in relation to long-lived assets during the fiscal years ended June 30, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-69" decimals="-5" id="f-508" unitRef="usd">33200000</us-gaap:RestructuringCharges>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c-1" id="f-509">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt"&gt;Contingencies&lt;/span&gt;We record a liability in the consolidated financial statements for loss contingencies when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="c-1" id="f-510">New Accounting Pronouncements &lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Recently issued accounting standards not yet adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ASU No. 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (FASB) issued ASU No. 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," which expands segment disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. This ASU is applicable to our Annual Report on Form 10-K for the fiscal year ended June 30, 2025, and subsequent interim periods. Early adoption is permitted and the amendments must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adopting this ASU on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;/div&gt;In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures," which updates income tax disclosure requirements primarily by requiring specific categories and greater disaggregation within the rate reconciliation and disaggregation of income taxes paid. This ASU is applicable to our Annual Report on Form 10-K for the fiscal year ended June 30, 2026, with early application permitted. We are currently evaluating the impact of adopting this ASU on our consolidated financial statements and disclosures.</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-511">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Recently issued accounting standards not yet adopted &lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ASU No. 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (FASB) issued ASU No. 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," which expands segment disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. This ASU is applicable to our Annual Report on Form 10-K for the fiscal year ended June 30, 2025, and subsequent interim periods. Early adoption is permitted and the amendments must be applied retrospectively to all prior periods presented. We are currently evaluating the impact of adopting this ASU on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;/div&gt;In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures," which updates income tax disclosure requirements primarily by requiring specific categories and greater disaggregation within the rate reconciliation and disaggregation of income taxes paid. This ASU is applicable to our Annual Report on Form 10-K for the fiscal year ended June 30, 2026, with early application permitted. We are currently evaluating the impact of adopting this ASU on our consolidated financial statements and disclosures.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-512">Supplemental Balance Sheet Information&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of selected captions in the consolidated balance sheets consisted of the following as of June&#160;30, 2024 and June&#160;30, 2023 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;355,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;459,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;463,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;534,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;822,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;998,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses and current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;459,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;437,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;479,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;443,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;189,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vehicles and aircraft&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Clinical, demonstration and rental equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;91,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,274,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,205,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(726,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(668,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;548,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;537,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-513">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of selected captions in the consolidated balance sheets consisted of the following as of June&#160;30, 2024 and June&#160;30, 2023 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;355,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;459,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;463,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;534,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;822,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;998,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-4" decimals="-3" id="f-514" unitRef="usd">355570000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-5" decimals="-3" id="f-515" unitRef="usd">459126000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-4" decimals="-3" id="f-516" unitRef="usd">2713000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-5" decimals="-3" id="f-517" unitRef="usd">3956000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-4" decimals="-3" id="f-518" unitRef="usd">463967000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-5" decimals="-3" id="f-519" unitRef="usd">534930000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-520" unitRef="usd">822250000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-3" id="f-521" unitRef="usd">998012000</us-gaap:InventoryNet>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-522">&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses and current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;180,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;459,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;437,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidTaxes contextRef="c-4" decimals="-3" id="f-523" unitRef="usd">107623000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes contextRef="c-5" decimals="-3" id="f-524" unitRef="usd">114009000</us-gaap:PrepaidTaxes>
    <rmd:PrepaidInventory contextRef="c-4" decimals="-3" id="f-525" unitRef="usd">172198000</rmd:PrepaidInventory>
    <rmd:PrepaidInventory contextRef="c-5" decimals="-3" id="f-526" unitRef="usd">143084000</rmd:PrepaidInventory>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-527" unitRef="usd">180012000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-528" unitRef="usd">179925000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-529" unitRef="usd">459833000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-530" unitRef="usd">437018000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-531">&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;479,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;443,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;189,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vehicles and aircraft&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Clinical, demonstration and rental equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;91,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,274,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,205,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(726,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(668,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;548,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;537,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-70" decimals="-3" id="f-532" unitRef="usd">479941000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-71" decimals="-3" id="f-533" unitRef="usd">443781000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-72" decimals="-3" id="f-534" unitRef="usd">200128000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-73" decimals="-3" id="f-535" unitRef="usd">189568000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-74" decimals="-3" id="f-536" unitRef="usd">61969000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-75" decimals="-3" id="f-537" unitRef="usd">61663000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-76" decimals="-3" id="f-538" unitRef="usd">20450000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-77" decimals="-3" id="f-539" unitRef="usd">20587000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-78" decimals="-3" id="f-540" unitRef="usd">127358000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-79" decimals="-3" id="f-541" unitRef="usd">115696000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-80" decimals="-3" id="f-542" unitRef="usd">102104000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-81" decimals="-3" id="f-543" unitRef="usd">91499000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-82" decimals="-3" id="f-544" unitRef="usd">51977000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-83" decimals="-3" id="f-545" unitRef="usd">52055000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-63" decimals="-3" id="f-546" unitRef="usd">231065000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-84" decimals="-3" id="f-547" unitRef="usd">231019000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-548" unitRef="usd">1274992000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-3" id="f-549" unitRef="usd">1205868000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-550" unitRef="usd">726967000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-551" unitRef="usd">668012000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-552" unitRef="usd">548025000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-553" unitRef="usd">537856000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-554">Goodwill and Other Intangible Assets, net&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each of the years ended June&#160;30, 2024 and June&#160;30, 2023, we have not recorded any goodwill impairments. Changes in the carrying amount of goodwill is comprised of the following for the year ended June&#160;30, 2024 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sleep and &lt;br/&gt;Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;SaaS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;670,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,100,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,770,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Business acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;757,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,084,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,842,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other intangibles, net are comprised of the following as of June&#160;30, 2024 and June&#160;30, 2023 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed/core product technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;384,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;398,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(280,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(265,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed/core product technology, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;432,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;443,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(124,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(151,999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(144,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;552,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consist of developed/core product technology, trade names, non-compete agreements, customer relationships, and patents, and we amortize them over the estimated useful life of the assets, generally between two years and fifteen years. There are no expected residual values related to these intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended June&#160;30, 2024, we impaired $18.6&#160;million of developed/core product technology intangible assets, $14.5&#160;million of customer relationship intangible assets, and $0.1&#160;million of other intangibles associated with restructuring activities. These non-cash charges were recorded within &lt;span style="-sec-ix-hidden:f-594"&gt;restructuring expenses&lt;/span&gt; in the consolidated statements of income. Refer to Note 18 &#x2013; Restructuring Expenses for the facts and circumstances leading to the impairments. We did not record any intangible asset impairments during the years ended June&#160;30, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to identified intangible assets for the years ended June&#160;30, 2024 and June&#160;30, 2023 was $79.5 million and $72.4 million, respectively. Amortization expense related to patents, included in other intangibles, for the years ended June&#160;30, 2024 and June&#160;30, 2023 was $7.6 million and $7.0 million, respectively. Total estimated annual amortization expense for the years ending June 30, 2025 through June 30, 2029, is shown below (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Years Ending June 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-555">Changes in the carrying amount of goodwill is comprised of the following for the year ended June&#160;30, 2024 (in thousands): &lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sleep and &lt;br/&gt;Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;SaaS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;670,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,100,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,770,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Business acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;757,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,084,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,842,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-85" decimals="-3" id="f-556" unitRef="usd">670120000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-86" decimals="-3" id="f-557" unitRef="usd">2100179000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-558" unitRef="usd">2770299000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-87" decimals="-3" id="f-559" unitRef="usd">92191000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-88" decimals="-3" id="f-560" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-1" decimals="-3" id="f-561" unitRef="usd">92191000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-87" decimals="-3" id="f-562" unitRef="usd">-4782000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-88" decimals="-3" id="f-563" unitRef="usd">-15653000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-1" decimals="-3" id="f-564" unitRef="usd">-20435000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill contextRef="c-89" decimals="-3" id="f-565" unitRef="usd">757529000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-90" decimals="-3" id="f-566" unitRef="usd">2084526000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-567" unitRef="usd">2842055000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-568">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other intangibles, net are comprised of the following as of June&#160;30, 2024 and June&#160;30, 2023 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed/core product technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;384,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;398,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(280,970)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(265,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed/core product technology, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;432,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;443,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(124,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;244,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(151,999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(144,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;552,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-91" decimals="-3" id="f-569" unitRef="usd">384679000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-92" decimals="-3" id="f-570" unitRef="usd">398740000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-91" decimals="-3" id="f-571" unitRef="usd">280970000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-92" decimals="-3" id="f-572" unitRef="usd">265802000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-91" decimals="-3" id="f-573" unitRef="usd">103709000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-92" decimals="-3" id="f-574" unitRef="usd">132938000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-93" decimals="-3" id="f-575" unitRef="usd">432470000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-94" decimals="-3" id="f-576" unitRef="usd">443652000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-93" decimals="-3" id="f-577" unitRef="usd">150486000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-94" decimals="-3" id="f-578" unitRef="usd">124220000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-93" decimals="-3" id="f-579" unitRef="usd">281984000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-94" decimals="-3" id="f-580" unitRef="usd">319432000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-95" decimals="-3" id="f-581" unitRef="usd">252210000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-96" decimals="-3" id="f-582" unitRef="usd">244373000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-95" decimals="-3" id="f-583" unitRef="usd">151999000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-96" decimals="-3" id="f-584" unitRef="usd">144402000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-95" decimals="-3" id="f-585" unitRef="usd">100211000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-96" decimals="-3" id="f-586" unitRef="usd">99971000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-587" unitRef="usd">485904000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-5" decimals="-3" id="f-588" unitRef="usd">552341000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-61" id="f-589">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-62" id="f-590">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-97" decimals="-5" id="f-591" unitRef="usd">18600000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-98" decimals="-5" id="f-592" unitRef="usd">14500000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-99" decimals="-5" id="f-593" unitRef="usd">100000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-100" decimals="-5" id="f-595" unitRef="usd">79500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-101" decimals="-5" id="f-596" unitRef="usd">72400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-102" decimals="-5" id="f-597" unitRef="usd">7600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-103" decimals="-5" id="f-598" unitRef="usd">7000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-599">Total estimated annual amortization expense for the years ending June 30, 2025 through June 30, 2029, is shown below (in thousands): &lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Years Ending June 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-4" decimals="-3" id="f-600" unitRef="usd">81975000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-4" decimals="-3" id="f-601" unitRef="usd">76847000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-4" decimals="-3" id="f-602" unitRef="usd">58023000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-4" decimals="-3" id="f-603" unitRef="usd">49431000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-4" decimals="-3" id="f-604" unitRef="usd">43492000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:InvestmentTextBlock contextRef="c-1" id="f-605">Investments&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments by measurement category as of June&#160;30, 2024 and June&#160;30, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Measurement category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Measurement alternative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions to investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Observable price adjustments on non-marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from exits of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized losses on marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,397)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,397)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss attributable to equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,848)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,848)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying value at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions to investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Observable price adjustments on non-marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,892)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,892)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains on marketable and non-marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from exits of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized losses on marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss attributable to equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividends received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying value at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes additions from purchases and an equity method investment acquired and measured at fair value via our acquisition of MEDIFOX DAN. Refer to Note 17 herein.&lt;/span&gt;&lt;/div&gt;Net unrealized gains and losses recognized in the years ended June&#160;30, 2024, 2023 and 2022 for equity investments in non-marketable and marketable securities still held as of those respective dates were a loss of $4.0 million, a gain of $6.0 million, and a loss of $16.2 million, respectively.</us-gaap:InvestmentTextBlock>
    <rmd:ScheduleOfInvestmentsTableTextBlock contextRef="c-1" id="f-606">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments by measurement category as of June&#160;30, 2024 and June&#160;30, 2023 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Measurement category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Measurement alternative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</rmd:ScheduleOfInvestmentsTableTextBlock>
    <rmd:MarketableEquityInvestmentsFairValue contextRef="c-4" decimals="-3" id="f-607" unitRef="usd">12026000</rmd:MarketableEquityInvestmentsFairValue>
    <rmd:MarketableEquityInvestmentsFairValue contextRef="c-5" decimals="-3" id="f-608" unitRef="usd">12423000</rmd:MarketableEquityInvestmentsFairValue>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-4" decimals="-3" id="f-609" unitRef="usd">73739000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-5" decimals="-3" id="f-610" unitRef="usd">68748000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityMethodInvestments contextRef="c-4" decimals="-3" id="f-611" unitRef="usd">65462000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-5" decimals="-3" id="f-612" unitRef="usd">65366000</us-gaap:EquityMethodInvestments>
    <rmd:EquityInvestmentsTotalByMeasurementCategory contextRef="c-4" decimals="-3" id="f-613" unitRef="usd">151227000</rmd:EquityInvestmentsTotalByMeasurementCategory>
    <rmd:EquityInvestmentsTotalByMeasurementCategory contextRef="c-5" decimals="-3" id="f-614" unitRef="usd">146537000</rmd:EquityInvestmentsTotalByMeasurementCategory>
    <rmd:ScheduleOfChangesInEquityInvestmentsTableTextBlock contextRef="c-1" id="f-615">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions to investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Observable price adjustments on non-marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from exits of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized losses on marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,397)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,397)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss attributable to equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,848)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,848)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying value at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions to investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Observable price adjustments on non-marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,892)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,892)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains on marketable and non-marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from exits of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized losses on marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss attributable to equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividends received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying value at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Includes additions from purchases and an equity method investment acquired and measured at fair value via our acquisition of MEDIFOX DAN. Refer to Note 17 herein.&lt;/span&gt;&lt;/div&gt;</rmd:ScheduleOfChangesInEquityInvestmentsTableTextBlock>
    <rmd:EquityInvestments contextRef="c-104" decimals="-3" id="f-616" unitRef="usd">68748000</rmd:EquityInvestments>
    <rmd:EquityInvestments contextRef="c-105" decimals="-3" id="f-617" unitRef="usd">12423000</rmd:EquityInvestments>
    <rmd:EquityInvestments contextRef="c-106" decimals="-3" id="f-618" unitRef="usd">65366000</rmd:EquityInvestments>
    <rmd:EquityInvestments contextRef="c-5" decimals="-3" id="f-619" unitRef="usd">146537000</rmd:EquityInvestments>
    <rmd:AdditionalEquityInvestments contextRef="c-107" decimals="-3" id="f-620" unitRef="usd">8640000</rmd:AdditionalEquityInvestments>
    <rmd:AdditionalEquityInvestments contextRef="c-108" decimals="-3" id="f-621" unitRef="usd">1000000</rmd:AdditionalEquityInvestments>
    <rmd:AdditionalEquityInvestments contextRef="c-109" decimals="-3" id="f-622" unitRef="usd">3125000</rmd:AdditionalEquityInvestments>
    <rmd:AdditionalEquityInvestments contextRef="c-1" decimals="-3" id="f-623" unitRef="usd">12765000</rmd:AdditionalEquityInvestments>
    <rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities contextRef="c-107" decimals="-3" id="f-624" unitRef="usd">2315000</rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities>
    <rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities contextRef="c-108" decimals="-3" id="f-625" unitRef="usd">0</rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities>
    <rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities contextRef="c-109" decimals="-3" id="f-626" unitRef="usd">0</rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities>
    <rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities contextRef="c-1" decimals="-3" id="f-627" unitRef="usd">2315000</rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-107" decimals="-3" id="f-628" unitRef="usd">4963000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-108" decimals="-3" id="f-629" unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-109" decimals="-3" id="f-630" unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-1" decimals="-3" id="f-631" unitRef="usd">4963000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="c-107" decimals="-3" id="f-632" unitRef="usd">-1000000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="c-108" decimals="-3" id="f-633" unitRef="usd">0</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="c-109" decimals="-3" id="f-634" unitRef="usd">0</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="c-1" decimals="-3" id="f-635" unitRef="usd">-1000000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-107" decimals="-3" id="f-636" unitRef="usd">0</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-108" decimals="-3" id="f-637" unitRef="usd">-1397000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-109" decimals="-3" id="f-638" unitRef="usd">0</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-1" decimals="-3" id="f-639" unitRef="usd">-1397000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-107" decimals="-3" id="f-640" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-108" decimals="-3" id="f-641" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-109" decimals="-3" id="f-642" unitRef="usd">-1848000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-643" unitRef="usd">-1848000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments contextRef="c-107" decimals="-3" id="f-644" unitRef="usd">-1000</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments contextRef="c-108" decimals="-3" id="f-645" unitRef="usd">0</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments contextRef="c-109" decimals="-3" id="f-646" unitRef="usd">-1181000</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments contextRef="c-1" decimals="-3" id="f-647" unitRef="usd">-1182000</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <rmd:EquityInvestments contextRef="c-110" decimals="-3" id="f-648" unitRef="usd">73739000</rmd:EquityInvestments>
    <rmd:EquityInvestments contextRef="c-111" decimals="-3" id="f-649" unitRef="usd">12026000</rmd:EquityInvestments>
    <rmd:EquityInvestments contextRef="c-112" decimals="-3" id="f-650" unitRef="usd">65462000</rmd:EquityInvestments>
    <rmd:EquityInvestments contextRef="c-4" decimals="-3" id="f-651" unitRef="usd">151227000</rmd:EquityInvestments>
    <rmd:EquityInvestments contextRef="c-113" decimals="-3" id="f-652" unitRef="usd">39290000</rmd:EquityInvestments>
    <rmd:EquityInvestments contextRef="c-114" decimals="-3" id="f-653" unitRef="usd">9167000</rmd:EquityInvestments>
    <rmd:EquityInvestments contextRef="c-115" decimals="-3" id="f-654" unitRef="usd">9918000</rmd:EquityInvestments>
    <rmd:EquityInvestments contextRef="c-29" decimals="-3" id="f-655" unitRef="usd">58375000</rmd:EquityInvestments>
    <rmd:AdditionalEquityInvestments contextRef="c-116" decimals="-3" id="f-656" unitRef="usd">21738000</rmd:AdditionalEquityInvestments>
    <rmd:AdditionalEquityInvestments contextRef="c-117" decimals="-3" id="f-657" unitRef="usd">4991000</rmd:AdditionalEquityInvestments>
    <rmd:AdditionalEquityInvestments contextRef="c-118" decimals="-3" id="f-658" unitRef="usd">62733000</rmd:AdditionalEquityInvestments>
    <rmd:AdditionalEquityInvestments contextRef="c-12" decimals="-3" id="f-659" unitRef="usd">89462000</rmd:AdditionalEquityInvestments>
    <rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities contextRef="c-116" decimals="-3" id="f-660" unitRef="usd">12612000</rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities>
    <rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities contextRef="c-117" decimals="-3" id="f-661" unitRef="usd">0</rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities>
    <rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities contextRef="c-118" decimals="-3" id="f-662" unitRef="usd">0</rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities>
    <rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities contextRef="c-12" decimals="-3" id="f-663" unitRef="usd">12612000</rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-116" decimals="-3" id="f-664" unitRef="usd">4892000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-117" decimals="-3" id="f-665" unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-118" decimals="-3" id="f-666" unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-12" decimals="-3" id="f-667" unitRef="usd">4892000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-116" decimals="-3" id="f-668" unitRef="usd">3937000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-117" decimals="-3" id="f-669" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-118" decimals="-3" id="f-670" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-12" decimals="-3" id="f-671" unitRef="usd">3937000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="c-116" decimals="-3" id="f-672" unitRef="usd">-3937000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="c-117" decimals="-3" id="f-673" unitRef="usd">0</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="c-118" decimals="-3" id="f-674" unitRef="usd">0</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="c-12" decimals="-3" id="f-675" unitRef="usd">-3937000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-116" decimals="-3" id="f-676" unitRef="usd">0</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-117" decimals="-3" id="f-677" unitRef="usd">-1735000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-118" decimals="-3" id="f-678" unitRef="usd">0</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss contextRef="c-12" decimals="-3" id="f-679" unitRef="usd">-1735000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-116" decimals="-3" id="f-680" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-117" decimals="-3" id="f-681" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-118" decimals="-3" id="f-682" unitRef="usd">-7265000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-12" decimals="-3" id="f-683" unitRef="usd">-7265000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProceedsFromDividendsReceived contextRef="c-116" decimals="-3" id="f-684" unitRef="usd">0</us-gaap:ProceedsFromDividendsReceived>
    <us-gaap:ProceedsFromDividendsReceived contextRef="c-117" decimals="-3" id="f-685" unitRef="usd">0</us-gaap:ProceedsFromDividendsReceived>
    <us-gaap:ProceedsFromDividendsReceived contextRef="c-118" decimals="-3" id="f-686" unitRef="usd">2873000</us-gaap:ProceedsFromDividendsReceived>
    <us-gaap:ProceedsFromDividendsReceived contextRef="c-12" decimals="-3" id="f-687" unitRef="usd">2873000</us-gaap:ProceedsFromDividendsReceived>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments contextRef="c-116" decimals="-3" id="f-688" unitRef="usd">0</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments contextRef="c-117" decimals="-3" id="f-689" unitRef="usd">0</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments contextRef="c-118" decimals="-3" id="f-690" unitRef="usd">2853000</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments contextRef="c-12" decimals="-3" id="f-691" unitRef="usd">2853000</us-gaap:TemporaryEquityForeignCurrencyTranslationAdjustments>
    <rmd:EquityInvestments contextRef="c-104" decimals="-3" id="f-692" unitRef="usd">68748000</rmd:EquityInvestments>
    <rmd:EquityInvestments contextRef="c-105" decimals="-3" id="f-693" unitRef="usd">12423000</rmd:EquityInvestments>
    <rmd:EquityInvestments contextRef="c-106" decimals="-3" id="f-694" unitRef="usd">65366000</rmd:EquityInvestments>
    <rmd:EquityInvestments contextRef="c-5" decimals="-3" id="f-695" unitRef="usd">146537000</rmd:EquityInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-5" id="f-696" unitRef="usd">-4000000.0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-12" decimals="-5" id="f-697" unitRef="usd">6000000.0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-13" decimals="-5" id="f-698" unitRef="usd">-16200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-699">Accrued Expenses &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses at June&#160;30, 2024 and June&#160;30, 2023 consist of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product warranties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Consulting and professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Value added taxes and other taxes due&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;223,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Promotional and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Logistics and occupancy costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory in transit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;377,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;365,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-700">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses at June&#160;30, 2024 and June&#160;30, 2023 consist of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product warranties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Consulting and professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Value added taxes and other taxes due&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;223,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Promotional and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Logistics and occupancy costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory in transit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;377,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;365,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent contextRef="c-4" decimals="-3" id="f-701" unitRef="usd">35134000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent contextRef="c-5" decimals="-3" id="f-702" unitRef="usd">27621000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-4" decimals="-3" id="f-703" unitRef="usd">27143000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-5" decimals="-3" id="f-704" unitRef="usd">26148000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-4" decimals="-3" id="f-705" unitRef="usd">27016000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-5" decimals="-3" id="f-706" unitRef="usd">23636000</us-gaap:TaxesPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-707" unitRef="usd">223862000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-708" unitRef="usd">220785000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="c-4" decimals="-3" id="f-709" unitRef="usd">6023000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="c-5" decimals="-3" id="f-710" unitRef="usd">9366000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-711" unitRef="usd">4654000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-712" unitRef="usd">9558000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-4" decimals="-3" id="f-713" unitRef="usd">9206000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-5" decimals="-3" id="f-714" unitRef="usd">9375000</us-gaap:InterestPayableCurrent>
    <rmd:AccruedLogisticsAndOccupancyExpensesCurrent contextRef="c-4" decimals="-3" id="f-715" unitRef="usd">17996000</rmd:AccruedLogisticsAndOccupancyExpensesCurrent>
    <rmd:AccruedLogisticsAndOccupancyExpensesCurrent contextRef="c-5" decimals="-3" id="f-716" unitRef="usd">16278000</rmd:AccruedLogisticsAndOccupancyExpensesCurrent>
    <rmd:AccruedInventoryInTransit contextRef="c-4" decimals="-3" id="f-717" unitRef="usd">8045000</rmd:AccruedInventoryInTransit>
    <rmd:AccruedInventoryInTransit contextRef="c-5" decimals="-3" id="f-718" unitRef="usd">10034000</rmd:AccruedInventoryInTransit>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-719" unitRef="usd">18599000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-720" unitRef="usd">12859000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-721" unitRef="usd">377678000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-722" unitRef="usd">365660000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-723">Debt &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt at June&#160;30, 2024 and June&#160;30, 2023 consists of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred borrowing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,435,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred borrowing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;697,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,431,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;707,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,441,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;29, 2022, we entered into a second amended and restated credit agreement (the &#x201c;Revolving Credit Agreement&#x201d;), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger, sole book runner, swing line lender and letter of credit issuer, Westpac Banking Corporation, as syndication agent and joint lead arranger, HSBC Bank USA, National Association, as syndication agent and joint lead arranger, and Wells Fargo Bank, National Association, as documentation agent. The Revolving Credit Agreement, among other things, provided a senior unsecured revolving credit facility of $1,500.0 million, with an uncommitted option to increase the revolving credit facility by an additional amount equal to the greater of $1,000.0 million or 1.0 times the EBITDA (as defined in the Revolving Credit Agreement) for the trailing twelve-month measurement period. The Revolving Credit Agreement amends and restates that certain Amended and Restated Credit Agreement, dated as of April 17, 2018, among ResMed, MUFG Union Bank, N.A., Westpac Banking Corporation and the lenders party thereto.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, on June&#160;29, 2022, ResMed Pty Limited entered into a Second Amendment to the Syndicated Facility Agreement and First Amendment to Unconditional Guaranty Agreement (the &#x201c;Term Credit Agreement&#x201d;), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger and joint book runner, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner, which amends that certain Syndicated Facility Agreement dated as of April 17, 2018. The Term Credit Agreement, among other things, provides ResMed Pty Limited a senior unsecured term credit facility of $200.0 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our obligations under the Revolving Credit Agreement are guaranteed by certain of our direct and indirect U.S. subsidiaries, and ResMed Pty Limited&#x2019;s obligations under the Term Credit Agreement are guaranteed by us and certain of our direct and indirect U.S. subsidiaries. The Revolving Credit Agreement and Term Credit Agreement contain customary covenants, including, in each case, a financial covenant that requires that we maintain a maximum leverage ratio of funded debt to EBITDA (as defined in the Revolving Credit Agreement and Term Credit Agreement, as applicable). The entire principal amounts of the revolving credit facility and term credit facility, and, in each case, any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable. Events of default under the Revolving Credit Agreement and the Term Credit Agreement include, in each case, failure to make payments when due, the occurrence of a default in the performance of any covenants in the respective agreements or related documents, or certain changes of control of us, or the respective guarantors of the obligations borrowed under the Revolving Credit Agreement and Term Credit Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Revolving Credit Agreement and Term Credit Agreement each terminate on June&#160;29, 2027, when all unpaid principal and interest under the loans must be repaid. Amounts borrowed under the Term Credit Agreement will also amortize on a semi-annual basis, with a $5.0 million principal payment required on each such semi-annual amortization date. The outstanding principal amounts will bear interest at a rate equal to the Adjusted Term SOFR (as defined in the Revolving Credit Agreement) plus 0.75% to 1.50% (depending on the then-applicable leverage ratio) or the Base Rate (as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable) plus 0.0% to 0.50% (depending on the then-applicable leverage ratio). At June&#160;30, 2024, the interest rate that was being charged on the outstanding principal amounts was 6.19%. An applicable commitment fee of 0.075% to 0.150% (depending on the then-applicable leverage &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ratio) applies on the unused portion of the revolving credit facility. As of June&#160;30, 2024, we had $1,470.0 million available for draw down under the revolving credit facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As the Revolving Credit and Term Credit Agreements&#x2019; interest rate is calculated as Adjusted Term SOFR plus the spreads described above, its carrying amount is equivalent to its fair value as at June&#160;30, 2024 and June&#160;30, 2023, which was $210.0 million and $945.0 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;10, 2019, we entered into a Note Purchase Agreement with the purchasers to that agreement, in connection with the issuance and sale of $250.0 million principal amount of our 3.24% senior notes due July&#160;10, 2026, and $250.0 million principal amount of our 3.45% senior notes due July&#160;10, 2029 (collectively referred to as the &#x201c;Senior Notes&#x201d;). Our obligations under the Note Purchase Agreement and the Senior Notes are unconditionally and irrevocably guaranteed by certain of our direct and indirect U.S. subsidiaries. The net proceeds from this transaction were used to pay down borrowings on our Revolving Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Note Purchase Agreement, we agreed to customary covenants including with respect to our corporate existence, transactions with affiliates, and mergers and other extraordinary transactions. We also agreed that, subject to limited exceptions, we will maintain a ratio of consolidated funded debt to consolidated EBITDA (as defined in the Note Purchase Agreement) of no more than 3.50 to 1.00 as of the last day of any fiscal quarter, and will not at any time permit the amount of all priority secured and unsecured debt of us and our subsidiaries to exceed 10.0% of our consolidated tangible assets, determined as of the end of our most recently ended fiscal quarter. This ratio is calculated at the end of each reporting period for which the Note Purchase Agreement requires us to deliver financial statements, using the results of the 12 consecutive month period ending with such reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As of June&#160;30, 2024 and June&#160;30, 2023, the Senior Notes had a carrying amount of $500.0 million, excluding deferred borrowing costs, and an estimated fair value of $463.0 million and $462.2 million, respectively. Quoted market prices in active markets for identical liabilities based inputs (Level 2) were used to estimate fair value.&lt;/span&gt;&lt;/div&gt;At June&#160;30, 2024, we were in compliance with our debt covenants and there was $710.0 million outstanding under the Revolving Credit Agreement, Term Credit Agreement and Senior Notes.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c-1" id="f-724">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt at June&#160;30, 2024 and June&#160;30, 2023 consists of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred borrowing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,435,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred borrowing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;697,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,431,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;707,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,441,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <rmd:ShortTermDebtGross contextRef="c-4" decimals="-3" id="f-725" unitRef="usd">10000000</rmd:ShortTermDebtGross>
    <rmd:ShortTermDebtGross contextRef="c-5" decimals="-3" id="f-726" unitRef="usd">10000000</rmd:ShortTermDebtGross>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c-4" decimals="-3" id="f-727" unitRef="usd">100000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c-5" decimals="-3" id="f-728" unitRef="usd">98000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:ShortTermBorrowings contextRef="c-4" decimals="-3" id="f-729" unitRef="usd">9900000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c-5" decimals="-3" id="f-730" unitRef="usd">9902000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-4" decimals="-3" id="f-731" unitRef="usd">700000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-5" decimals="-3" id="f-732" unitRef="usd">1435000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="c-4" decimals="-3" id="f-733" unitRef="usd">2687000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="c-5" decimals="-3" id="f-734" unitRef="usd">3766000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:LongTermDebt contextRef="c-4" decimals="-3" id="f-735" unitRef="usd">697313000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-5" decimals="-3" id="f-736" unitRef="usd">1431234000</us-gaap:LongTermDebt>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount contextRef="c-4" decimals="-3" id="f-737" unitRef="usd">707213000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount contextRef="c-5" decimals="-3" id="f-738" unitRef="usd">1441136000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-119" decimals="-5" id="f-739" unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <rmd:UncommittedOptionToIncreaseCreditFacility contextRef="c-120" decimals="-5" id="f-740" unitRef="usd">1000000000</rmd:UncommittedOptionToIncreaseCreditFacility>
    <rmd:DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod
      contextRef="c-119"
      decimals="INF"
      id="f-741"
      unitRef="number">1.0</rmd:DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-121" decimals="-5" id="f-742" unitRef="usd">200000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal contextRef="c-122" decimals="-5" id="f-743" unitRef="usd">5000000.0</us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-123"
      decimals="INF"
      id="f-744"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-124"
      decimals="INF"
      id="f-745"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-125"
      decimals="INF"
      id="f-746"
      unitRef="number">0.000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-126"
      decimals="INF"
      id="f-747"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-127" decimals="4" id="f-748" unitRef="number">0.0619</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage contextRef="c-128" decimals="5" id="f-749" unitRef="number">0.00075</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage contextRef="c-129" decimals="5" id="f-750" unitRef="number">0.00150</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity contextRef="c-130" decimals="-5" id="f-751" unitRef="usd">1470000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LongTermDebtFairValue contextRef="c-130" decimals="-5" id="f-752" unitRef="usd">210000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-131" decimals="-5" id="f-753" unitRef="usd">945000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-132" decimals="-5" id="f-754" unitRef="usd">250000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-132"
      decimals="INF"
      id="f-755"
      unitRef="number">0.0324</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-133" decimals="-5" id="f-756" unitRef="usd">250000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-133"
      decimals="INF"
      id="f-757"
      unitRef="number">0.0345</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rmd:DebtToConsolidatedEbitdaRatio contextRef="c-1" decimals="INF" id="f-758" unitRef="number">3.50</rmd:DebtToConsolidatedEbitdaRatio>
    <rmd:LineOfCreditFacilityCollateralPercentageOfTheCompany contextRef="c-1" decimals="INF" id="f-759" unitRef="number">0.100</rmd:LineOfCreditFacilityCollateralPercentageOfTheCompany>
    <us-gaap:SeniorNotes contextRef="c-134" decimals="-5" id="f-760" unitRef="usd">500000000.0</us-gaap:SeniorNotes>
    <us-gaap:SeniorNotes contextRef="c-135" decimals="-5" id="f-761" unitRef="usd">500000000.0</us-gaap:SeniorNotes>
    <us-gaap:LongTermDebtFairValue contextRef="c-135" decimals="-5" id="f-762" unitRef="usd">463000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue contextRef="c-134" decimals="-5" id="f-763" unitRef="usd">462200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount contextRef="c-136" decimals="-5" id="f-764" unitRef="usd">710000000.0</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock contextRef="c-1" id="f-767">Leases&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Leases where ResMed is the Lessee&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine whether a contract is, or contains, a lease at inception. Right of Use, or ROU, assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. We use our incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. ROU assets also include any lease payments made at or before lease commencement and any initial direct costs incurred and exclude any lease incentives received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the lease term as the non-cancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Some of our leases include variable lease payments that are based on costs incurred or actual usage or adjusted periodically based on an index or a rate. Our leases do not contain any residual value guarantees and we do not account for lease and non-lease components as a single lease component. Operating leases are included in operating lease right-of-use assets and operating lease liabilities on our consolidated balance sheets. We lease certain office space, warehouses and distribution centers, manufacturing facilities, vehicles, and equipment with remaining lease terms ranging from less than 1 year to 15 years, some of which include options to extend or terminate the leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs for the years ended June&#160;30, 2024, 2023 and 2022 were $40.8 million, $33.6 million and $35.3 million, respectively. Short-term and variable lease costs were not material for the years ended June&#160;30, 2024, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future lease payments under non-cancellable operating leases as of June&#160;30, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, future operating lease commitments for leases that have not yet commenced were not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The supplemental information related to operating leases for the years ended June&#160;30, 2024 and June&#160;30, 2023 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average inputs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash flow information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash flows paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Right of use assets obtained in exchange for new lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Leases where ResMed is the Lessor&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease sleep and respiratory medical devices to customers primarily to comply with local health insurer requirements in certain foreign geographies. Device rental contracts are classified as operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. Operating lease revenue was $92.9 million, $88.6 million and $90.1 million for the years ended June&#160;30, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-766">Leases&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Leases where ResMed is the Lessee&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine whether a contract is, or contains, a lease at inception. Right of Use, or ROU, assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. We use our incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. ROU assets also include any lease payments made at or before lease commencement and any initial direct costs incurred and exclude any lease incentives received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the lease term as the non-cancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Some of our leases include variable lease payments that are based on costs incurred or actual usage or adjusted periodically based on an index or a rate. Our leases do not contain any residual value guarantees and we do not account for lease and non-lease components as a single lease component. Operating leases are included in operating lease right-of-use assets and operating lease liabilities on our consolidated balance sheets. We lease certain office space, warehouses and distribution centers, manufacturing facilities, vehicles, and equipment with remaining lease terms ranging from less than 1 year to 15 years, some of which include options to extend or terminate the leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs for the years ended June&#160;30, 2024, 2023 and 2022 were $40.8 million, $33.6 million and $35.3 million, respectively. Short-term and variable lease costs were not material for the years ended June&#160;30, 2024, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future lease payments under non-cancellable operating leases as of June&#160;30, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, future operating lease commitments for leases that have not yet commenced were not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The supplemental information related to operating leases for the years ended June&#160;30, 2024 and June&#160;30, 2023 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average inputs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash flow information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash flows paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Right of use assets obtained in exchange for new lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Leases where ResMed is the Lessor&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease sleep and respiratory medical devices to customers primarily to comply with local health insurer requirements in certain foreign geographies. Device rental contracts are classified as operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. Operating lease revenue was $92.9 million, $88.6 million and $90.1 million for the years ended June&#160;30, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LessorSalesTypeLeasesTextBlock contextRef="c-1" id="f-765">Leases&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Leases where ResMed is the Lessee&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine whether a contract is, or contains, a lease at inception. Right of Use, or ROU, assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. We use our incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. ROU assets also include any lease payments made at or before lease commencement and any initial direct costs incurred and exclude any lease incentives received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the lease term as the non-cancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Some of our leases include variable lease payments that are based on costs incurred or actual usage or adjusted periodically based on an index or a rate. Our leases do not contain any residual value guarantees and we do not account for lease and non-lease components as a single lease component. Operating leases are included in operating lease right-of-use assets and operating lease liabilities on our consolidated balance sheets. We lease certain office space, warehouses and distribution centers, manufacturing facilities, vehicles, and equipment with remaining lease terms ranging from less than 1 year to 15 years, some of which include options to extend or terminate the leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs for the years ended June&#160;30, 2024, 2023 and 2022 were $40.8 million, $33.6 million and $35.3 million, respectively. Short-term and variable lease costs were not material for the years ended June&#160;30, 2024, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future lease payments under non-cancellable operating leases as of June&#160;30, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, future operating lease commitments for leases that have not yet commenced were not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The supplemental information related to operating leases for the years ended June&#160;30, 2024 and June&#160;30, 2023 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average inputs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash flow information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash flows paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Right of use assets obtained in exchange for new lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Leases where ResMed is the Lessor&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease sleep and respiratory medical devices to customers primarily to comply with local health insurer requirements in certain foreign geographies. Device rental contracts are classified as operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. Operating lease revenue was $92.9 million, $88.6 million and $90.1 million for the years ended June&#160;30, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LessorSalesTypeLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-61" id="f-768">P1Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-62" id="f-769">P15Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-5" id="f-770" unitRef="usd">40800000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-12" decimals="-5" id="f-771" unitRef="usd">33600000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-13" decimals="-5" id="f-772" unitRef="usd">35300000</us-gaap:OperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-773">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future lease payments under non-cancellable operating leases as of June&#160;30, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.055%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-774" unitRef="usd">197933000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-775" unitRef="usd">30767000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-776" unitRef="usd">26247000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-777" unitRef="usd">22570000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-778" unitRef="usd">20454000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-4" decimals="-3" id="f-779" unitRef="usd">19089000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-4" decimals="-3" id="f-780" unitRef="usd">78806000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-781" unitRef="usd">31211000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-782" unitRef="usd">166722000</us-gaap:OperatingLeaseLiability>
    <rmd:ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock contextRef="c-1" id="f-783">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The supplemental information related to operating leases for the years ended June&#160;30, 2024 and June&#160;30, 2023 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average inputs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash flow information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash flows paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Right of use assets obtained in exchange for new lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</rmd:ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-784">P8Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-785">P8Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-786" unitRef="number">0.035</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-787" unitRef="number">0.027</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-788" unitRef="usd">30573000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-12" decimals="-3" id="f-789" unitRef="usd">29047000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-790" unitRef="usd">54588000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-12" decimals="-3" id="f-791" unitRef="usd">16803000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <rmd:OperatingLeaseIncome contextRef="c-1" decimals="-5" id="f-792" unitRef="usd">92900000</rmd:OperatingLeaseIncome>
    <rmd:OperatingLeaseIncome contextRef="c-12" decimals="-5" id="f-793" unitRef="usd">88600000</rmd:OperatingLeaseIncome>
    <rmd:OperatingLeaseIncome contextRef="c-13" decimals="-5" id="f-794" unitRef="usd">90100000</rmd:OperatingLeaseIncome>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-795">Stockholders&#x2019; Equity &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On February&#160;21, 2014, our board of directors approved a new share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant and subject to applicable legal requirements. The 20.0 million shares the program authorizes us to purchase are in addition to the shares we repurchased on or before February&#160;21, 2014 under our previous programs. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. All share repurchases since February&#160;21, 2014 have been executed in accordance with this program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During fiscal year 2024, we repurchased approximately 828,000 shares at a cost of $150.0 million. We did not repurchase any shares during fiscal year 2023. As of June&#160;30, 2024, we have repurchased a total of 42.7 million shares at a cost of $1.8 billion. Shares that are repurchased are classified as &#x201c;treasury stock pending future use&#x201d; and reduce the number of shares outstanding used in calculating earnings per share. At June&#160;30, 2024, 12.1 million additional shares can be repurchased under the approved share repurchase program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Preferred Stock.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In April 1997, our board of directors authorized 2.0 million shares of 0.01 par value preferred stock. No such shares were issued or outstanding at June&#160;30, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options and Restricted Stock Units.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We have granted stock options, restricted stock units (&#x201c;RSUs&#x201d;) and performance restricted stock units (&#x201c;PRSUs&#x201d;) to personnel, including officers and directors, in accordance with the ResMed Inc. 2009 Incentive Award Plan (the &#x201c;2009 Plan&#x201d;). Options and restricted stock units vest over one year to four years and the options have expiration dates of seven years from the date of grant. We have granted the options with an exercise price equal to the market value as determined at the date of grant. We have granted PRSUs that are subject to a market condition, with the ultimate realizable number of PRSUs dependent on relative total stockholder return over a period of three years. The maximum amounts to be issued under the awards range from 200% to 225% of the original grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the annual meeting of our stockholders in November 2017, our stockholders approved an amendment and restatement to the 2009 Plan to increase the number of shares of common stock that may be issued or transferred pursuant to awards under the 2009 Plan by 7.4 million. The amendment and restatement imposes a maximum award amount which may be granted under the 2009 Plan to non-employee director in a calendar year, which when taken together with any other cash fees earned for services as a non-employee director during the calendar year, has a total value of $0.7 million, or $1.2 million in the case of a non-employee director who is also serving as chairman of our board of directors. The amendment and restatement also increased the maximum amount payable pursuant to cash-denominated performance awards granted in any calendar year from $3.0 million to $5.0 million. In addition, the amendment and restatement extended the existing prohibition on the payment of dividends or dividend equivalents on unvested awards to apply to all awards, including time-based restricted stock, deferred stock and stock payment. The term of the 2009 Plan was extended by four years so that the plan expires on September&#160;11, 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maximum number of shares of our common stock authorized for issuance under the 2009 Plan is 51.1 million. The number of securities remaining available for future issuance under the 2009 Plan at June&#160;30, 2024 is 12.5 million. The number of shares of our common stock available for issuance under the 2009 Plan will be reduced by (i) 2.8 shares for each one share of common stock delivered in settlement of any &#x201c;full-value award,&#x201d; which is any award other than a stock option, stock appreciation right or other award for which the holder pays a purchase price and (ii) one share for each share of common stock delivered in settlement of all other awards. The maximum number of shares, which may be subject to awards granted under the 2009 Plan to any individual during any calendar year, may not exceed 3 million shares of our common stock (except in a participant&#x2019;s initial year of hiring up to 4.5 million shares of our common stock may be granted). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain regions, shares are withheld on behalf of employees to satisfy statutory tax withholding requirements upon exercise or vesting of awards. The number of shares withheld is based upon the closing price of our common stock on the trading day of the applicable settlement date. The remaining shares are delivered to the recipient as shares of our common stock. The amount remitted to the tax authorities for the employees&#x2019; tax obligation is reflected as a financing activity on our consolidated statements of cash flows. Shares withheld by us as a result of the net settlement are not considered issued and outstanding and are added to the shares available for future issuance under the 2009 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of RSUs and PRSUs that vested during the years ended June&#160;30, 2024, 2023 and 2022, was $51.0 million, $66.8 million and $65.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of RSUs, including PRSUs, during year ended June&#160;30, 2024 (in thousands, except years and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted&lt;br/&gt;Stock&lt;br/&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term in Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;183.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5pt"&gt;Includes 60 thousand shares netted for tax.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes option activity during the year ended June&#160;30, 2024 (in thousands, except years and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term in Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;136.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5pt"&gt;Includes 1 thousand shares netted for tax.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options exercised during the fiscal years 2024, 2023 and 2022, was $17.9 million, $25.4 million and $33.7 million, respectively. As at June&#160;30, 2024, the aggregate intrinsic value of options outstanding, exercisable, and vested and expected to vest were $42.9 million, $39.8 million and $42.7 million respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the board of directors&#x2019; compensation committee of no less than 3 months and no more than 27 months. The purchase price for our common stock under the ESPP will be the lower of 85% of the fair market value of our common stock on the date of grant or 85% of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than $25,000 in common stock during any calendar year. At June&#160;30, 2024, the number of shares remaining available for future issuance under the ESPP is 1.0 million shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During years ended June&#160;30, 2024, 2023 and 2022, we issued 323,000, 220,000 and 216,000 shares to our employees in two offerings and we recognized $11.4 million, $11.5 million and $11.0 million, respectively, of stock compensation expense associated with the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock&#x2013;based Employee compensation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We measure the compensation expense of all stock-based awards at fair value on the grant date. We estimate the fair value of stock options and purchase rights granted under the ESPP using the Black-Scholes valuation model. The fair value of restricted stock units is equal to the market value of the underlying shares as determined at the grant date less the fair value of dividends that holders are not entitled to, during the vesting period. The fair value of performance restricted stock units is measured using a Monte-Carlo simulation valuation model. We recognize the fair value as compensation expense using the straight-line method over the service period for awards expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the assumptions in the following tables. The risk-free interest rate is estimated using the U.S. Treasury yield curve and is based on the term of the award. The expected term of awards is estimated from the vesting period of the award, as well as historical exercise behavior, and represents the period of time the awards granted are expected to be outstanding. Expected volatility is estimated based upon the historical volatility of ResMed stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions for the years ended June&#160;30, 2024, 2023 and 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock options:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$50.48&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$74.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$72.16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.44%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.85%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.29%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.29%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.78%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.66%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ESPP purchase rights:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$47.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$52.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$50.46&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.75% - 1.30%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.75% - 0.84%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.63% - 0.98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27% - 40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27% - 34%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20% - 34%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total stock-based compensation costs incurred and the associated tax benefit recognized during the years ended June&#160;30, 2024, 2023 and 2022 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24,860)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation costs, net of tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;At June&#160;30, 2024, there was $142.4 million in unrecognized compensation costs related to unvested stock-based compensation arrangements. This is expected to be recognized over a weighted average period of 2.6 years.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="c-137"
      decimals="-5"
      id="f-796"
      unitRef="shares">20000000.0</srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="c-137"
      decimals="-5"
      id="f-797"
      unitRef="shares">20000000.0</srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-1" decimals="0" id="f-798" unitRef="shares">828000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-1" decimals="-5" id="f-799" unitRef="usd">150000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-12" decimals="0" id="f-800" unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockCommonShares contextRef="c-46" decimals="-5" id="f-801" unitRef="shares">42700000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue contextRef="c-46" decimals="-8" id="f-802" unitRef="usd">1800000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased contextRef="c-4" decimals="-5" id="f-803" unitRef="shares">12100000</us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-138"
      decimals="-5"
      id="f-804"
      unitRef="shares">2000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-138"
      decimals="INF"
      id="f-805"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-806" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-807" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-49" id="f-808">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-50" id="f-809">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-1" id="f-810">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-139" id="f-811">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-140" decimals="2" id="f-812" unitRef="number">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-141" decimals="2" id="f-813" unitRef="number">2.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <rmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending
      contextRef="c-142"
      decimals="-5"
      id="f-814"
      unitRef="shares">7400000</rmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending>
    <rmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned contextRef="c-143" decimals="-5" id="f-815" unitRef="usd">700000</rmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned>
    <rmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned contextRef="c-144" decimals="-5" id="f-816" unitRef="usd">1200000</rmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned>
    <rmd:SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted contextRef="c-145" decimals="-5" id="f-817" unitRef="usd">3000000.0</rmd:SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted>
    <rmd:SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted contextRef="c-146" decimals="-5" id="f-818" unitRef="usd">5000000.0</rmd:SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted>
    <rmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod contextRef="c-147" id="f-819">P4Y</rmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-148"
      decimals="-5"
      id="f-820"
      unitRef="shares">51100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-148"
      decimals="-5"
      id="f-821"
      unitRef="shares">12500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <rmd:ReductionInNumberOfSharesOfCommonStockAvailableForIssuance contextRef="c-4" decimals="INF" id="f-822" unitRef="number">2.8</rmd:ReductionInNumberOfSharesOfCommonStockAvailableForIssuance>
    <rmd:NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards contextRef="c-1" decimals="INF" id="f-823" unitRef="shares">1</rmd:NumberOfSharesGivenForEachShareOfCommonStockDeliveredInSettlementOfAllOtherAwards>
    <rmd:MaximumNumberOfSharesSubjectToAwardsGranted contextRef="c-4" decimals="-6" id="f-824" unitRef="shares">3000000</rmd:MaximumNumberOfSharesSubjectToAwardsGranted>
    <rmd:NumberOfCommonStockGranted contextRef="c-4" decimals="-5" id="f-825" unitRef="shares">4500000</rmd:NumberOfCommonStockGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-1" decimals="-5" id="f-826" unitRef="usd">51000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-12" decimals="-5" id="f-827" unitRef="usd">66800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-13" decimals="-5" id="f-828" unitRef="usd">65500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-829">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of RSUs, including PRSUs, during year ended June&#160;30, 2024 (in thousands, except years and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted&lt;br/&gt;Stock&lt;br/&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term in Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;183.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5pt"&gt;Includes 60 thousand shares netted for tax.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-149"
      decimals="-3"
      id="f-830"
      unitRef="shares">762000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-149"
      decimals="2"
      id="f-831"
      unitRef="usdPerShare">227.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c-150" id="f-832">P1Y8M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-151"
      decimals="-3"
      id="f-833"
      unitRef="shares">674000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-151"
      decimals="2"
      id="f-834"
      unitRef="usdPerShare">148.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-151"
      decimals="-3"
      id="f-835"
      unitRef="shares">236000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-151"
      decimals="2"
      id="f-836"
      unitRef="usdPerShare">215.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-151"
      decimals="-3"
      id="f-837"
      unitRef="shares">61000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-151"
      decimals="2"
      id="f-838"
      unitRef="usdPerShare">218.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-152"
      decimals="-3"
      id="f-839"
      unitRef="shares">1139000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-152"
      decimals="2"
      id="f-840"
      unitRef="usdPerShare">183.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c-151" id="f-841">P1Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c-151"
      decimals="-3"
      id="f-842"
      unitRef="shares">60000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-843">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes option activity during the year ended June&#160;30, 2024 (in thousands, except years and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term in Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;136.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5pt"&gt;Includes 1 thousand shares netted for tax.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="-3" id="f-844" unitRef="shares">881000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-845"
      unitRef="usdPerShare">134.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-12" id="f-846">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="-3" id="f-847" unitRef="shares">73000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-848"
      unitRef="usdPerShare">148.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="-3" id="f-849" unitRef="shares">166000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-850"
      unitRef="usdPerShare">81.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="-3" id="f-851" unitRef="shares">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-852"
      unitRef="usdPerShare">232.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="-3" id="f-853" unitRef="shares">786000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-854"
      unitRef="usdPerShare">146.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-855">P2Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c-4" decimals="-3" id="f-856" unitRef="shares">633000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-857"
      unitRef="usdPerShare">136.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-858">P2Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-4" decimals="-3" id="f-859" unitRef="shares">778000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-860"
      unitRef="usdPerShare">146.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-861">P2Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c-153"
      decimals="-3"
      id="f-862"
      unitRef="shares">1000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-863" unitRef="usd">17900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-12" decimals="-5" id="f-864" unitRef="usd">25400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-13" decimals="-5" id="f-865" unitRef="usd">33700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-5" id="f-866" unitRef="usd">42900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-4" decimals="-5" id="f-867" unitRef="usd">39800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c-4" decimals="-5" id="f-868" unitRef="usd">42700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <rmd:EmployeeStockPurchasePlanOfferingPeriod contextRef="c-154" id="f-869">P3M</rmd:EmployeeStockPurchasePlanOfferingPeriod>
    <rmd:EmployeeStockPurchasePlanOfferingPeriod contextRef="c-155" id="f-870">P27M</rmd:EmployeeStockPurchasePlanOfferingPeriod>
    <rmd:PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant
      contextRef="c-156"
      decimals="INF"
      id="f-871"
      unitRef="number">0.85</rmd:PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant>
    <rmd:PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase
      contextRef="c-156"
      decimals="INF"
      id="f-872"
      unitRef="number">0.85</rmd:PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase>
    <us-gaap:CommonStockSharesSubscriptions contextRef="c-157" decimals="-3" id="f-873" unitRef="usd">25000</us-gaap:CommonStockSharesSubscriptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-158"
      decimals="-5"
      id="f-874"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-1" decimals="-3" id="f-875" unitRef="shares">323000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-12" decimals="-3" id="f-876" unitRef="shares">220000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="c-13" decimals="-3" id="f-877" unitRef="shares">216000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <rmd:NumberOfOfferings
      contextRef="c-156"
      decimals="INF"
      id="f-878"
      unitRef="offering">2</rmd:NumberOfOfferings>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-156" decimals="-5" id="f-879" unitRef="usd">11400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-159" decimals="-5" id="f-880" unitRef="usd">11500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-160" decimals="-5" id="f-881" unitRef="usd">11000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-882">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions for the years ended June&#160;30, 2024, 2023 and 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock options:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$50.48&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$74.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$72.16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.44%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.85%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.29%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.29%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.78%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.66%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ESPP purchase rights:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$47.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$52.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$50.46&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.75% - 1.30%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.75% - 0.84%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.63% - 0.98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27% - 40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27% - 34%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20% - 34%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-153"
      decimals="2"
      id="f-883"
      unitRef="usdPerShare">50.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-161"
      decimals="2"
      id="f-884"
      unitRef="usdPerShare">74.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-162"
      decimals="2"
      id="f-885"
      unitRef="usdPerShare">72.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-153" decimals="4" id="f-886" unitRef="number">0.0444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-161" decimals="4" id="f-887" unitRef="number">0.0385</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-162" decimals="4" id="f-888" unitRef="number">0.0129</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-153" id="f-889">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-161" id="f-890">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-162" id="f-891">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-153" decimals="4" id="f-892" unitRef="number">0.0129</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-161" decimals="4" id="f-893" unitRef="number">0.0078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-162" decimals="4" id="f-894" unitRef="number">0.0066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-153" decimals="2" id="f-895" unitRef="number">0.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-161" decimals="2" id="f-896" unitRef="number">0.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-162" decimals="2" id="f-897" unitRef="number">0.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-163"
      decimals="2"
      id="f-898"
      unitRef="usdPerShare">47.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-164"
      decimals="2"
      id="f-899"
      unitRef="usdPerShare">52.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-165"
      decimals="2"
      id="f-900"
      unitRef="usdPerShare">50.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-163" decimals="3" id="f-901" unitRef="number">0.054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-164" decimals="3" id="f-902" unitRef="number">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-165" decimals="3" id="f-903" unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-163" id="f-904">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-164" id="f-905">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-165" id="f-906">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-166" decimals="4" id="f-907" unitRef="number">0.0075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-167" decimals="4" id="f-908" unitRef="number">0.0130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-168" decimals="4" id="f-909" unitRef="number">0.0075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-169" decimals="4" id="f-910" unitRef="number">0.0084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-170" decimals="4" id="f-911" unitRef="number">0.0063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-171" decimals="4" id="f-912" unitRef="number">0.0098</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-163" decimals="2" id="f-913" unitRef="number">0.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-163" decimals="2" id="f-914" unitRef="number">0.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-164" decimals="2" id="f-915" unitRef="number">0.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-164" decimals="2" id="f-916" unitRef="number">0.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-165" decimals="2" id="f-917" unitRef="number">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-165" decimals="2" id="f-918" unitRef="number">0.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-919">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total stock-based compensation costs incurred and the associated tax benefit recognized during the years ended June&#160;30, 2024, 2023 and 2022 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,053)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24,860)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation costs, net of tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-172" decimals="-3" id="f-920" unitRef="usd">7563000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-173" decimals="-3" id="f-921" unitRef="usd">6465000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-174" decimals="-3" id="f-922" unitRef="usd">5218000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-175" decimals="-3" id="f-923" unitRef="usd">58149000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-176" decimals="-3" id="f-924" unitRef="usd">53049000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-177" decimals="-3" id="f-925" unitRef="usd">50791000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-178" decimals="-3" id="f-926" unitRef="usd">14472000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-179" decimals="-3" id="f-927" unitRef="usd">11628000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-180" decimals="-3" id="f-928" unitRef="usd">9248000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-929" unitRef="usd">80184000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-12" decimals="-3" id="f-930" unitRef="usd">71142000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-3" id="f-931" unitRef="usd">65257000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-1" decimals="-3" id="f-932" unitRef="usd">15053000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-12" decimals="-3" id="f-933" unitRef="usd">24860000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-13" decimals="-3" id="f-934" unitRef="usd">29262000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-1" decimals="-3" id="f-935" unitRef="usd">65131000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-12" decimals="-3" id="f-936" unitRef="usd">46282000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-13" decimals="-3" id="f-937" unitRef="usd">35995000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-4" decimals="-5" id="f-938" unitRef="usd">142400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-939">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-940">Earnings Per Share &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We compute basic earnings per share by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units. The weighted average number of outstanding stock options and restricted stock units not included in the computation of diluted earnings per share were 603,859, 272,104 and 67,000 for the years ended June&#160;30, 2024, 2023 and 2022, respectively, as the effect would have been anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted earnings per share for the years ended June&#160;30, 2024, 2023 and 2022 are calculated as follows (in thousands except per share data): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,020,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;897,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;779,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options and restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted weighted average shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-941" unitRef="shares">603859000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-12" decimals="-3" id="f-942" unitRef="shares">272104000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-13" decimals="-3" id="f-943" unitRef="shares">67000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-944">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted earnings per share for the years ended June&#160;30, 2024, 2023 and 2022 are calculated as follows (in thousands except per share data): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,020,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;897,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;779,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options and restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted weighted average shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-945" unitRef="usd">1020951000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-946" unitRef="usd">897556000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-947" unitRef="usd">779437000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-948" unitRef="shares">147021000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="-3" id="f-949" unitRef="shares">146765000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="-3" id="f-950" unitRef="shares">146066000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-1" decimals="-3" id="f-951" unitRef="shares">529000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-12" decimals="-3" id="f-952" unitRef="shares">690000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-13" decimals="-3" id="f-953" unitRef="shares">977000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-954" unitRef="shares">147550000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-12" decimals="-3" id="f-955" unitRef="shares">147455000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="-3" id="f-956" unitRef="shares">147043000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-957"
      unitRef="usdPerShare">6.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-958"
      unitRef="usdPerShare">6.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-959"
      unitRef="usdPerShare">5.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-960"
      unitRef="usdPerShare">6.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-961"
      unitRef="usdPerShare">6.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-962"
      unitRef="usdPerShare">5.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-963">Income Taxes &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes for the years ended June&#160;30, 2024, 2023 and 2022, was taxed under the following jurisdictions (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(85,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,083,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;973,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,046,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,264,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,101,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;960,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is presented below (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.101%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.101%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.106%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;219,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;249,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21,721)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(45,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,818)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;243,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. federal income tax rate of 21% for the years ended June&#160;30, 2024, 2023 and 2022, to pretax income as a result of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes computed at statutory U.S. rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in income taxes resulting from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State income taxes, net of U.S. tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of non-U.S. tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;243,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reported net deferred tax assets and liabilities in our consolidated balance sheets at June&#160;30, 2024 and June&#160;30, 2023, as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(79,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(90,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of our deferred tax assets and liabilities at June&#160;30, 2024 and June&#160;30, 2023, are as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Employee liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;35,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;34,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Tax credit carry overs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;9,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;6,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;15,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;13,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Provision for warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;6,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;5,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Provision for doubtful debts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;5,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;6,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;23,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;22,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Capital loss carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;5,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;11,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;8,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;28,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;23,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Research and development capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;125,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;111,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;25,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;21,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Hedging contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;56,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;27,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;State income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;3,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;2,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(2,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;356,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;282,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(9,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(8,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;347,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;273,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Goodwill and other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(192,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(198,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(22,843)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(20,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(7,857)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(12,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(223,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(231,221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;124,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;42,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, we had $16.5 million of U.S. federal and state net operating loss carryforwards and $6.2 million of non-U.S. net operating loss carryforwards, which expire in various years beginning in 2025 or carry forward indefinitely. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation allowance at June&#160;30, 2024 relates to a provision for uncertainty of the utilization of net operating loss carryforwards of $0.8 million and capital loss and other items of $8.6 million. We believe that it is more likely than not that the benefits of deferred tax assets, net of any valuation allowance, will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A substantial portion of our manufacturing operations and administrative functions in Singapore operate under certain tax holidays and tax incentive programs that will expire in whole or in part at various dates through June 30, 2030. The end of certain tax holidays may be extended if specific conditions are met. The net impact of these tax holidays and tax incentive programs increased our net income by $49.6 million ($0.34 per diluted share) for the year ended June&#160;30, 2024, $40.5 million ($0.27 per diluted share) for the year ended June&#160;30, 2023, and $38.0 million ($0.26 per diluted share) for the year ended June&#160;30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the Tax Cuts and Jobs Act of 2017 (&#x201c;TCJA&#x201d;), we have treated all non-U.S. historical earnings as taxable. Therefore, future repatriation of cash held by our non-U.S. subsidiaries will generally not be subject to U.S. federal tax if repatriated. The total amount of these undistributed earnings at June&#160;30, 2024 amounted to approximately $4.1 billion. In &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the event our non-U.S. earnings had not been permanently reinvested, approximately $4.9&#160;million in U.S. state deferred taxes would have been recognized in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The TCJA also introduced U.S. taxation on certain global intangible low-taxed income (&#x201c;GILTI&#x201d;). We have elected to account for tax expense attributable to GILTI tax as a period cost when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accounting for uncertainty in income taxes, we recognize a tax benefit in the financial statements for an uncertain tax position only if management&#x2019;s assessment is that the position is &#x201c;more likely than not&#x201d; (that is, a likelihood greater than 50 percent) to be allowed by the tax jurisdiction based solely on the technical merits of the position. The term &#x201c;tax position&#x201d; refers to a position in a previously filed tax return or a position expected to be taken in a future tax return that is reflected in measuring current or deferred income tax assets and liabilities for annual periods. We recognize interest and penalties related to unrecognized tax benefits within the income tax expense line in the accompanying consolidated statements of income. Accrued interest and penalties are included within the related tax liability line in the consolidated balance sheets. Based on all known facts and circumstances and current tax law, we believe the total amount of unrecognized tax benefits on June&#160;30, 2024 is not material to our results of operations, financial condition or cash flows, and if recognized, would not have a material impact on our effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax returns are based on calculations and assumptions subject to audit by various tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws. We regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. Any final assessment resulting from tax audits may result in material changes to our past or future taxable income, tax payable or deferred tax assets, and may require us to pay penalties and interest that could materially adversely affect our financial results. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 19, 2021, we concluded the settlement agreement with the Australian Taxation Office (&#x201c;ATO&#x201d;) in relation to the previously disclosed transfer pricing dispute for the tax years 2009 through 2018 (&#x201c;ATO settlement&#x201d;). The ATO settlement fully resolved the dispute for all prior years, with no admission of liability and provides clarity in relation to certain future taxation principles.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final net impact of the ATO settlement was recorded during the years ended June 30, 2021 and 2022 in the amount of $238.7&#160;million, which represents a gross amount of $381.7&#160;million, including interest and penalties of $48.1&#160;million, and adjustments for credits and deductions of $143.0&#160;million. As a result of the ATO settlement and due to movements in foreign currencies, we recorded a benefit of $14.1&#160;million within other comprehensive income, and a $4.1&#160;million reduction of tax credits, which was recorded to income tax expense. As a result of the ATO settlement, we reversed our previously recorded uncertain tax position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 28, 2021, we remitted final payment to the ATO of $284.8&#160;million, consisting of the agreed settlement amount of $381.7&#160;million less prior remittances made to the ATO of $96.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax years 2018 to 2023 remain subject to examination by the major tax jurisdictions in which we are subject to tax.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-964">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes for the years ended June&#160;30, 2024, 2023 and 2022, was taxed under the following jurisdictions (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(85,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,083,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;973,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,046,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,264,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,101,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;960,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-965" unitRef="usd">181107000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-12" decimals="-3" id="f-966" unitRef="usd">128589000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-13" decimals="-3" id="f-967" unitRef="usd">-85919000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-968" unitRef="usd">1083691000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-12" decimals="-3" id="f-969" unitRef="usd">973075000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-13" decimals="-3" id="f-970" unitRef="usd">1046402000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-971" unitRef="usd">1264798000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-972" unitRef="usd">1101664000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-973" unitRef="usd">960483000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-974">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is presented below (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.101%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.101%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.106%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;219,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;198,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;249,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21,721)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,389)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(45,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,818)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;243,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-975" unitRef="usd">57103000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-976" unitRef="usd">36631000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-977" unitRef="usd">4376000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-978" unitRef="usd">17250000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-979" unitRef="usd">14142000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-980" unitRef="usd">10700000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-981" unitRef="usd">219372000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-982" unitRef="usd">198767000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-983" unitRef="usd">177788000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-984" unitRef="usd">293725000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-985" unitRef="usd">249540000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-986" unitRef="usd">192864000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-987" unitRef="usd">-22915000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-988" unitRef="usd">-21721000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-989" unitRef="usd">-12612000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-990" unitRef="usd">-4632000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-991" unitRef="usd">-2389000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-992" unitRef="usd">-2773000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-993" unitRef="usd">-22331000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-994" unitRef="usd">-21322000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-995" unitRef="usd">3567000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-996" unitRef="usd">-49878000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-997" unitRef="usd">-45432000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-998" unitRef="usd">-11818000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-999" unitRef="usd">243847000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-1000" unitRef="usd">204108000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-1001" unitRef="usd">181046000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1002">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. federal income tax rate of 21% for the years ended June&#160;30, 2024, 2023 and 2022, to pretax income as a result of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes computed at statutory U.S. rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in income taxes resulting from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State income taxes, net of U.S. tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of non-U.S. tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;243,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-1003" unitRef="usd">265608000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-12" decimals="-3" id="f-1004" unitRef="usd">231349000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-13" decimals="-3" id="f-1005" unitRef="usd">201701000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-1006" unitRef="usd">8609000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-12" decimals="-3" id="f-1007" unitRef="usd">9448000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-13" decimals="-3" id="f-1008" unitRef="usd">5703000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-1" decimals="-3" id="f-1009" unitRef="usd">27786000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-12" decimals="-3" id="f-1010" unitRef="usd">21481000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-13" decimals="-3" id="f-1011" unitRef="usd">17517000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-1012" unitRef="usd">849000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-12" decimals="-3" id="f-1013" unitRef="usd">-5007000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-13" decimals="-3" id="f-1014" unitRef="usd">858000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="-3" id="f-1015" unitRef="usd">-15838000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-12" decimals="-3" id="f-1016" unitRef="usd">-3982000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-13" decimals="-3" id="f-1017" unitRef="usd">-4384000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign contextRef="c-1" decimals="-3" id="f-1018" unitRef="usd">8293000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign contextRef="c-12" decimals="-3" id="f-1019" unitRef="usd">3988000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign contextRef="c-13" decimals="-3" id="f-1020" unitRef="usd">2299000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-3" id="f-1021" unitRef="usd">4875000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-12" decimals="-3" id="f-1022" unitRef="usd">-6282000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-13" decimals="-3" id="f-1023" unitRef="usd">-11294000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="-3" id="f-1024" unitRef="usd">15823000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c-12" decimals="-3" id="f-1025" unitRef="usd">4051000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c-13" decimals="-3" id="f-1026" unitRef="usd">8278000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1027" unitRef="usd">243847000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-1028" unitRef="usd">204108000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-1029" unitRef="usd">181046000</us-gaap:IncomeTaxExpenseBenefit>
    <rmd:ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1030">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reported net deferred tax assets and liabilities in our consolidated balance sheets at June&#160;30, 2024 and June&#160;30, 2023, as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(79,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(90,650)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</rmd:ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-1031" unitRef="usd">203569000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-1032" unitRef="usd">132974000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-1033" unitRef="usd">79339000</us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-1034" unitRef="usd">90650000</us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-4" decimals="-3" id="f-1035" unitRef="usd">124230000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-3" id="f-1036" unitRef="usd">42324000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1037">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of our deferred tax assets and liabilities at June&#160;30, 2024 and June&#160;30, 2023, are as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Employee liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;35,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;34,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Tax credit carry overs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;9,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;6,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;15,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;13,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Provision for warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;6,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;5,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Provision for doubtful debts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;5,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;6,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;23,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;22,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Capital loss carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;5,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;11,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;8,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;28,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;23,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Research and development capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;125,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;111,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;25,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;21,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Hedging contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;56,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;27,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;State income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;3,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;2,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;5,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(2,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;356,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;282,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(9,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(8,536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;347,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;273,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Goodwill and other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(192,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(198,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(22,843)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(20,501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(7,857)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(12,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(223,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(231,221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;124,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;42,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c-4" decimals="-3" id="f-1038" unitRef="usd">35336000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c-5" decimals="-3" id="f-1039" unitRef="usd">34314000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-4" decimals="-3" id="f-1040" unitRef="usd">9271000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-5" decimals="-3" id="f-1041" unitRef="usd">6051000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-4" decimals="-3" id="f-1042" unitRef="usd">15602000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-5" decimals="-3" id="f-1043" unitRef="usd">13212000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves contextRef="c-4" decimals="-3" id="f-1044" unitRef="usd">6112000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves contextRef="c-5" decimals="-3" id="f-1045" unitRef="usd">5348000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c-4" decimals="-3" id="f-1046" unitRef="usd">5340000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c-5" decimals="-3" id="f-1047" unitRef="usd">6103000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-3" id="f-1048" unitRef="usd">23455000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-1049" unitRef="usd">22387000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c-4" decimals="-3" id="f-1050" unitRef="usd">5587000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c-5" decimals="-3" id="f-1051" unitRef="usd">917000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-4" decimals="-3" id="f-1052" unitRef="usd">11538000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-1053" unitRef="usd">8670000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-4" decimals="-3" id="f-1054" unitRef="usd">28030000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-5" decimals="-3" id="f-1055" unitRef="usd">23908000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-4" decimals="-3" id="f-1056" unitRef="usd">125411000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-5" decimals="-3" id="f-1057" unitRef="usd">111704000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <rmd:DeferredTaxAssetsLeaseLiabilities contextRef="c-4" decimals="-3" id="f-1058" unitRef="usd">25602000</rmd:DeferredTaxAssetsLeaseLiabilities>
    <rmd:DeferredTaxAssetsLeaseLiabilities contextRef="c-5" decimals="-3" id="f-1059" unitRef="usd">21347000</rmd:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments contextRef="c-4" decimals="-3" id="f-1060" unitRef="usd">56324000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments contextRef="c-5" decimals="-3" id="f-1061" unitRef="usd">27666000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsStateTaxes contextRef="c-4" decimals="-3" id="f-1062" unitRef="usd">3566000</us-gaap:DeferredTaxAssetsStateTaxes>
    <us-gaap:DeferredTaxAssetsStateTaxes contextRef="c-5" decimals="-3" id="f-1063" unitRef="usd">2468000</us-gaap:DeferredTaxAssetsStateTaxes>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-4" decimals="-3" id="f-1064" unitRef="usd">5538000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-3" id="f-1065" unitRef="usd">-2014000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-4" decimals="-3" id="f-1066" unitRef="usd">356712000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-1067" unitRef="usd">282081000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-1068" unitRef="usd">9384000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-1069" unitRef="usd">8536000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-4" decimals="-3" id="f-1070" unitRef="usd">347328000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-5" decimals="-3" id="f-1071" unitRef="usd">273545000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets contextRef="c-4" decimals="-3" id="f-1072" unitRef="usd">192398000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets contextRef="c-5" decimals="-3" id="f-1073" unitRef="usd">198418000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <rmd:DeferredTaxLiabilitiesRightOfUseAssets contextRef="c-4" decimals="-3" id="f-1074" unitRef="usd">22843000</rmd:DeferredTaxLiabilitiesRightOfUseAssets>
    <rmd:DeferredTaxLiabilitiesRightOfUseAssets contextRef="c-5" decimals="-3" id="f-1075" unitRef="usd">20501000</rmd:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-1076" unitRef="usd">7857000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-1077" unitRef="usd">12302000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilities contextRef="c-4" decimals="-3" id="f-1078" unitRef="usd">223098000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-5" decimals="-3" id="f-1079" unitRef="usd">231221000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-4" decimals="-3" id="f-1080" unitRef="usd">124230000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-3" id="f-1081" unitRef="usd">42324000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards contextRef="c-181" decimals="-5" id="f-1082" unitRef="usd">16500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-182" decimals="-5" id="f-1083" unitRef="usd">6200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-183" decimals="-5" id="f-1084" unitRef="usd">800000</us-gaap:OperatingLossCarryforwards>
    <rmd:OperatingLossCarryforwardsCapitalLoss contextRef="c-183" decimals="-5" id="f-1085" unitRef="usd">8600000</rmd:OperatingLossCarryforwardsCapitalLoss>
    <us-gaap:IncomeTaxHolidayAggregateDollarAmount contextRef="c-1" decimals="-5" id="f-1086" unitRef="usd">49600000</us-gaap:IncomeTaxHolidayAggregateDollarAmount>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="c-1"
      decimals="2"
      id="f-1087"
      unitRef="usdPerShare">0.34</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:IncomeTaxHolidayAggregateDollarAmount contextRef="c-12" decimals="-5" id="f-1088" unitRef="usd">40500000</us-gaap:IncomeTaxHolidayAggregateDollarAmount>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="c-12"
      decimals="2"
      id="f-1089"
      unitRef="usdPerShare">0.27</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:IncomeTaxHolidayAggregateDollarAmount contextRef="c-13" decimals="-5" id="f-1090" unitRef="usd">38000000.0</us-gaap:IncomeTaxHolidayAggregateDollarAmount>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="c-13"
      decimals="2"
      id="f-1091"
      unitRef="usdPerShare">0.26</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:UndistributedEarningsOfForeignSubsidiaries contextRef="c-4" decimals="-8" id="f-1092" unitRef="usd">4100000000</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
    <us-gaap:DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries contextRef="c-184" decimals="-5" id="f-1093" unitRef="usd">4900000</us-gaap:DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries>
    <rmd:PercentageOfRecognizedTaxBenefitForUncertainTaxPosition
      contextRef="c-185"
      decimals="2"
      id="f-1094"
      unitRef="number">0.50</rmd:PercentageOfRecognizedTaxBenefitForUncertainTaxPosition>
    <rmd:IncomeTaxExaminationNetImpactOfSettlement contextRef="c-186" decimals="-5" id="f-1095" unitRef="usd">238700000</rmd:IncomeTaxExaminationNetImpactOfSettlement>
    <rmd:IncomeTaxExaminationNetImpactOfSettlement contextRef="c-187" decimals="-5" id="f-1096" unitRef="usd">238700000</rmd:IncomeTaxExaminationNetImpactOfSettlement>
    <rmd:IncomeTaxExaminationGrossSettlement contextRef="c-187" decimals="-5" id="f-1097" unitRef="usd">381700000</rmd:IncomeTaxExaminationGrossSettlement>
    <rmd:IncomeTaxExaminationGrossSettlement contextRef="c-186" decimals="-5" id="f-1098" unitRef="usd">381700000</rmd:IncomeTaxExaminationGrossSettlement>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="c-186" decimals="-5" id="f-1099" unitRef="usd">48100000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="c-187" decimals="-5" id="f-1100" unitRef="usd">48100000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority contextRef="c-188" decimals="-5" id="f-1101" unitRef="usd">143000000</us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority>
    <us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority contextRef="c-189" decimals="-5" id="f-1102" unitRef="usd">143000000</us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c-190" decimals="-5" id="f-1103" unitRef="usd">14100000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c-191" decimals="-5" id="f-1104" unitRef="usd">14100000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:IncomeTaxCreditsAndAdjustments contextRef="c-190" decimals="-5" id="f-1105" unitRef="usd">4100000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <us-gaap:IncomeTaxCreditsAndAdjustments contextRef="c-191" decimals="-5" id="f-1106" unitRef="usd">4100000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <rmd:IncomeTaxExaminationRemittedFinalPayment contextRef="c-192" decimals="-5" id="f-1107" unitRef="usd">284800000</rmd:IncomeTaxExaminationRemittedFinalPayment>
    <rmd:IncomeTaxExaminationGrossSettlement contextRef="c-192" decimals="-5" id="f-1108" unitRef="usd">381700000</rmd:IncomeTaxExaminationGrossSettlement>
    <rmd:IncomeTaxExaminationPriorRemittancePayments contextRef="c-192" decimals="-5" id="f-1109" unitRef="usd">96900000</rmd:IncomeTaxExaminationPriorRemittancePayments>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1110">Segment Information &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have two operating segments, which are the Sleep and Respiratory Care segment and the SaaS segment. We evaluate the performance of our segments based on net sales and income from operations. The accounting policies of the segments are the same as those described in Note 2 &#x2013; Summary of Significant Accounting Policies. Segment net sales and segment income from operations do not include inter-segment profits and revenue is allocated to a geographic area based on where the products are shipped to or where the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include corporate headquarters costs, stock-based compensation, amortization expense from acquired intangibles, restructuring expenses, field safety notification expenses, acquisition related expenses, net interest expense (income), gains and losses attributable to equity method investments, gains and losses on equity investments, and other, net. We neither discretely allocate assets to our operating segments, nor does our Chief Operating Decision Maker evaluate the operating segments using discrete asset information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, effective in the third quarter of fiscal year 2024, we updated the method of attribution of certain costs that are principally managed at the segment level as part of our evaluation of segment operating performance. As a result, certain costs relating to quality and regulatory assurance, commercial legal, operations, sales and marketing, customer service, information technology, and other administrative costs, which were previously included in Corporate costs within our reconciliation of segment operating profit to income before income taxes, are now reported in segment operating results. The financial information presented herein reflects the impact of the preceding reporting change for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents a reconciliation of net revenues, depreciation and amortization and net operating profit by reportable segments for the years ended June&#160;30, 2024, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net revenue by segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,101,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,725,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,177,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Software as a Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;584,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;497,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,685,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,222,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,578,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Depreciation and amortization by segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Software as a Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets and corporate assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net operating profit by segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,681,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,447,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,279,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Software as a Service &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,835,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,562,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,373,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reconciling items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;357,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;338,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Masks with magnets field safety notification expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Astral field safety notification expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisition related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss attributable to equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gain) loss on equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain on insurance recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,264,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,101,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;960,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;During the fiscal year ended June&#160;30, 2024, we recorded $4.1&#160;million of operating lease right-of-use asset impairments within our SaaS segment. The impairments related to leases for office space and were recorded within net operating profit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;The masks with magnets field safety notification expenses relate to estimated &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;costs to provide alternative masks to patients in response to updated contraindications for use of masks that incorporate magnets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&#160;&#160;&#160;&#160;The Astral field safety notification expenses relate to estimated costs associated with the replacement of a certain component in some of our Astral ventilation devices that were manufactured between 2013 to 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2024, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S., Canada and Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,522,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,444,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,070,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Masks and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,199,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,039,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;911,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total U.S., Canada and Latin America&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,722,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,483,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,981,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Combined Europe, Asia and other markets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;921,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;826,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;796,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Masks and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;457,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Combined Europe, Asia and other markets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,378,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,241,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,195,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Global revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,444,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,270,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,866,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Masks and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,657,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,454,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,310,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,101,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,725,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,177,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Software as a Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;584,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;497,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,685,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,222,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,578,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue information by geographic area for the years ended June&#160;30, 2024, 2023 and 2022 is summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,980,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,719,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,249,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rest of the World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,705,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,503,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,328,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,685,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,222,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,578,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets of geographic areas are those assets used in our operations in each geographical area, and excludes goodwill, other intangible assets, and deferred tax assets. Long-lived assets by geographic area as of June&#160;30, 2024 and 2023 is summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Singapore&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rest of the World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;548,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;537,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1111"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-1112">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents a reconciliation of net revenues, depreciation and amortization and net operating profit by reportable segments for the years ended June&#160;30, 2024, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net revenue by segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,101,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,725,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,177,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Software as a Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;584,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;497,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,685,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,222,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,578,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Depreciation and amortization by segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Software as a Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets and corporate assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net operating profit by segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,681,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,447,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,279,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Software as a Service &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,835,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,562,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,373,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reconciling items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;357,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;338,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Masks with magnets field safety notification expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Astral field safety notification expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisition related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss attributable to equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gain) loss on equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain on insurance recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,264,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,101,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;960,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;During the fiscal year ended June&#160;30, 2024, we recorded $4.1&#160;million of operating lease right-of-use asset impairments within our SaaS segment. The impairments related to leases for office space and were recorded within net operating profit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;The masks with magnets field safety notification expenses relate to estimated &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;costs to provide alternative masks to patients in response to updated contraindications for use of masks that incorporate magnets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&#160;&#160;&#160;&#160;The Astral field safety notification expenses relate to estimated costs associated with the replacement of a certain component in some of our Astral ventilation devices that were manufactured between 2013 to 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-87" decimals="-3" id="f-1113" unitRef="usd">4101172000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-193" decimals="-3" id="f-1114" unitRef="usd">3725017000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-194" decimals="-3" id="f-1115" unitRef="usd">3177298000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-195" decimals="-3" id="f-1116" unitRef="usd">584125000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-196" decimals="-3" id="f-1117" unitRef="usd">497976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-197" decimals="-3" id="f-1118" unitRef="usd">400829000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-1119" unitRef="usd">4685297000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-1120" unitRef="usd">4222993000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-1121" unitRef="usd">3578127000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-198" decimals="-3" id="f-1122" unitRef="usd">86070000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-199" decimals="-3" id="f-1123" unitRef="usd">82544000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-200" decimals="-3" id="f-1124" unitRef="usd">79367000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-201" decimals="-3" id="f-1125" unitRef="usd">10241000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-202" decimals="-3" id="f-1126" unitRef="usd">9119000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-203" decimals="-3" id="f-1127" unitRef="usd">7315000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-204" decimals="-3" id="f-1128" unitRef="usd">80559000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-205" decimals="-3" id="f-1129" unitRef="usd">73493000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-206" decimals="-3" id="f-1130" unitRef="usd">72927000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-1131" unitRef="usd">176870000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-12" decimals="-3" id="f-1132" unitRef="usd">165156000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-13" decimals="-3" id="f-1133" unitRef="usd">159609000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingIncomeLoss contextRef="c-198" decimals="-3" id="f-1134" unitRef="usd">1681354000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-199" decimals="-3" id="f-1135" unitRef="usd">1447120000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-200" decimals="-3" id="f-1136" unitRef="usd">1279591000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-201" decimals="-3" id="f-1137" unitRef="usd">154450000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-202" decimals="-3" id="f-1138" unitRef="usd">115655000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-203" decimals="-3" id="f-1139" unitRef="usd">93756000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-207" decimals="-3" id="f-1140" unitRef="usd">1835804000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-208" decimals="-3" id="f-1141" unitRef="usd">1562775000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-209" decimals="-3" id="f-1142" unitRef="usd">1373347000</us-gaap:OperatingIncomeLoss>
    <rmd:UnallocatedCorporateCosts contextRef="c-210" decimals="-3" id="f-1143" unitRef="usd">357937000</rmd:UnallocatedCorporateCosts>
    <rmd:UnallocatedCorporateCosts contextRef="c-211" decimals="-3" id="f-1144" unitRef="usd">338362000</rmd:UnallocatedCorporateCosts>
    <rmd:UnallocatedCorporateCosts contextRef="c-212" decimals="-3" id="f-1145" unitRef="usd">300469000</rmd:UnallocatedCorporateCosts>
    <rmd:AmortizationOfAcquiredIntangibleAssets1 contextRef="c-210" decimals="-3" id="f-1146" unitRef="usd">79484000</rmd:AmortizationOfAcquiredIntangibleAssets1>
    <rmd:AmortizationOfAcquiredIntangibleAssets1 contextRef="c-211" decimals="-3" id="f-1147" unitRef="usd">72416000</rmd:AmortizationOfAcquiredIntangibleAssets1>
    <rmd:AmortizationOfAcquiredIntangibleAssets1 contextRef="c-212" decimals="-3" id="f-1148" unitRef="usd">70728000</rmd:AmortizationOfAcquiredIntangibleAssets1>
    <us-gaap:RestructuringCharges contextRef="c-210" decimals="-3" id="f-1149" unitRef="usd">64228000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-211" decimals="-3" id="f-1150" unitRef="usd">9177000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-212" decimals="-3" id="f-1151" unitRef="usd">0</us-gaap:RestructuringCharges>
    <rmd:MasksWithMagnetsFieldSafetyNotificationExpenses contextRef="c-210" decimals="-3" id="f-1152" unitRef="usd">6351000</rmd:MasksWithMagnetsFieldSafetyNotificationExpenses>
    <rmd:MasksWithMagnetsFieldSafetyNotificationExpenses contextRef="c-211" decimals="-3" id="f-1153" unitRef="usd">0</rmd:MasksWithMagnetsFieldSafetyNotificationExpenses>
    <rmd:MasksWithMagnetsFieldSafetyNotificationExpenses contextRef="c-212" decimals="-3" id="f-1154" unitRef="usd">0</rmd:MasksWithMagnetsFieldSafetyNotificationExpenses>
    <rmd:AstralFieldActionNotificationExpenses contextRef="c-210" decimals="-3" id="f-1155" unitRef="usd">7911000</rmd:AstralFieldActionNotificationExpenses>
    <rmd:AstralFieldActionNotificationExpenses contextRef="c-211" decimals="-3" id="f-1156" unitRef="usd">0</rmd:AstralFieldActionNotificationExpenses>
    <rmd:AstralFieldActionNotificationExpenses contextRef="c-212" decimals="-3" id="f-1157" unitRef="usd">0</rmd:AstralFieldActionNotificationExpenses>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-210" decimals="-3" id="f-1158" unitRef="usd">0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-211" decimals="-3" id="f-1159" unitRef="usd">10949000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-212" decimals="-3" id="f-1160" unitRef="usd">1864000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-210" decimals="-3" id="f-1161" unitRef="usd">45708000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-211" decimals="-3" id="f-1162" unitRef="usd">47379000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-212" decimals="-3" id="f-1163" unitRef="usd">22312000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-210" decimals="-3" id="f-1164" unitRef="usd">1848000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-211" decimals="-3" id="f-1165" unitRef="usd">7265000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-212" decimals="-3" id="f-1166" unitRef="usd">8486000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss contextRef="c-210" decimals="-3" id="f-1167" unitRef="usd">4045000</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss contextRef="c-211" decimals="-3" id="f-1168" unitRef="usd">-9922000</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss contextRef="c-212" decimals="-3" id="f-1169" unitRef="usd">12202000</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss>
    <us-gaap:GainOnBusinessInterruptionInsuranceRecovery contextRef="c-210" decimals="-3" id="f-1170" unitRef="usd">0</us-gaap:GainOnBusinessInterruptionInsuranceRecovery>
    <us-gaap:GainOnBusinessInterruptionInsuranceRecovery contextRef="c-211" decimals="-3" id="f-1171" unitRef="usd">-20227000</us-gaap:GainOnBusinessInterruptionInsuranceRecovery>
    <us-gaap:GainOnBusinessInterruptionInsuranceRecovery contextRef="c-212" decimals="-3" id="f-1172" unitRef="usd">0</us-gaap:GainOnBusinessInterruptionInsuranceRecovery>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-210" decimals="-3" id="f-1173" unitRef="usd">3494000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-211" decimals="-3" id="f-1174" unitRef="usd">5712000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-212" decimals="-3" id="f-1175" unitRef="usd">-3197000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-210" decimals="-3" id="f-1176" unitRef="usd">1264798000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-211" decimals="-3" id="f-1177" unitRef="usd">1101664000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-212" decimals="-3" id="f-1178" unitRef="usd">960483000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:OperatingLeaseImpairmentLoss contextRef="c-195" decimals="-5" id="f-1179" unitRef="usd">4100000</us-gaap:OperatingLeaseImpairmentLoss>
    <rmd:ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock contextRef="c-1" id="f-1180">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2024, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S., Canada and Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,522,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,444,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,070,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Masks and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,199,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,039,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;911,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total U.S., Canada and Latin America&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,722,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,483,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,981,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Combined Europe, Asia and other markets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;921,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;826,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;796,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Masks and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;457,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Combined Europe, Asia and other markets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,378,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,241,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,195,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Global revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,444,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,270,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,866,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Masks and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,657,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,454,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,310,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,101,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,725,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,177,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Software as a Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;584,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;497,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,685,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,222,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,578,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</rmd:ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-213" decimals="-3" id="f-1181" unitRef="usd">1522758000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-214" decimals="-3" id="f-1182" unitRef="usd">1444361000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-215" decimals="-3" id="f-1183" unitRef="usd">1070420000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-216" decimals="-3" id="f-1184" unitRef="usd">1199798000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-217" decimals="-3" id="f-1185" unitRef="usd">1039026000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-218" decimals="-3" id="f-1186" unitRef="usd">911387000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-219" decimals="-3" id="f-1187" unitRef="usd">2722556000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-220" decimals="-3" id="f-1188" unitRef="usd">2483387000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-221" decimals="-3" id="f-1189" unitRef="usd">1981807000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-222" decimals="-3" id="f-1190" unitRef="usd">921253000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-223" decimals="-3" id="f-1191" unitRef="usd">826341000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-224" decimals="-3" id="f-1192" unitRef="usd">796488000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-225" decimals="-3" id="f-1193" unitRef="usd">457363000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-226" decimals="-3" id="f-1194" unitRef="usd">415289000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-227" decimals="-3" id="f-1195" unitRef="usd">399003000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-228" decimals="-3" id="f-1196" unitRef="usd">1378616000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-229" decimals="-3" id="f-1197" unitRef="usd">1241630000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-230" decimals="-3" id="f-1198" unitRef="usd">1195491000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-231" decimals="-3" id="f-1199" unitRef="usd">2444011000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-232" decimals="-3" id="f-1200" unitRef="usd">2270702000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-233" decimals="-3" id="f-1201" unitRef="usd">1866908000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-234" decimals="-3" id="f-1202" unitRef="usd">1657161000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-235" decimals="-3" id="f-1203" unitRef="usd">1454315000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-236" decimals="-3" id="f-1204" unitRef="usd">1310390000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-237" decimals="-3" id="f-1205" unitRef="usd">4101172000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-238" decimals="-3" id="f-1206" unitRef="usd">3725017000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-239" decimals="-3" id="f-1207" unitRef="usd">3177298000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-240" decimals="-3" id="f-1208" unitRef="usd">584125000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-241" decimals="-3" id="f-1209" unitRef="usd">497976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-242" decimals="-3" id="f-1210" unitRef="usd">400829000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-243" decimals="-3" id="f-1211" unitRef="usd">4685297000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-244" decimals="-3" id="f-1212" unitRef="usd">4222993000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-245" decimals="-3" id="f-1213" unitRef="usd">3578127000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-1214">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue information by geographic area for the years ended June&#160;30, 2024, 2023 and 2022 is summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,980,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,719,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,249,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rest of the World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,705,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,503,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,328,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,685,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,222,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,578,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-246" decimals="-3" id="f-1215" unitRef="usd">2980053000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-247" decimals="-3" id="f-1216" unitRef="usd">2719923000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-248" decimals="-3" id="f-1217" unitRef="usd">2249381000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-249" decimals="-3" id="f-1218" unitRef="usd">1705244000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-250" decimals="-3" id="f-1219" unitRef="usd">1503070000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-251" decimals="-3" id="f-1220" unitRef="usd">1328746000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-1221" unitRef="usd">4685297000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-1222" unitRef="usd">4222993000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-1223" unitRef="usd">3578127000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock contextRef="c-1" id="f-1224">Long-lived assets by geographic area as of June&#160;30, 2024 and 2023 is summarized below (in thousands):&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Singapore&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rest of the World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;548,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;537,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets contextRef="c-252" decimals="-3" id="f-1225" unitRef="usd">197017000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-253" decimals="-3" id="f-1226" unitRef="usd">200752000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-254" decimals="-3" id="f-1227" unitRef="usd">160606000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-255" decimals="-3" id="f-1228" unitRef="usd">164448000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-256" decimals="-3" id="f-1229" unitRef="usd">89679000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-257" decimals="-3" id="f-1230" unitRef="usd">83711000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-258" decimals="-3" id="f-1231" unitRef="usd">100723000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-259" decimals="-3" id="f-1232" unitRef="usd">88945000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-4" decimals="-3" id="f-1233" unitRef="usd">548025000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-5" decimals="-3" id="f-1234" unitRef="usd">537856000</us-gaap:NoncurrentAssets>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-1235">Employee Retirement Plans &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We contribute to a number of employee retirement plans for the benefit of our employees. Details of the main plans are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Australia &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We contribute to defined contribution plans for each employee resident in Australia at the rate of approximately 11.0% of salaries. Employees may contribute additional funds to the plans. All Australian employees, after serving a qualifying period, are entitled to benefits on retirement, disability or death. Our total contributions to the plans for the years ended June&#160;30, 2024, 2023 and 2022, were $14.9 million, $13.0 million and $11.8 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;United States &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sponsor a defined contribution plan available to substantially all domestic employees. Company contributions to this plan are based on a percentage of employee contributions to a maximum of 4.0% of the employee&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;eligible compensation, subject to the annual IRS limit. Our total contributions to the plan were $13.8 million, $12.7 million and $11.9 million in fiscal 2024, 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Singapore &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sponsor a defined contribution plan available to all domestic employees. Company contributions to this plan are based on a percentage of employee contributions to a maximum of 17.0% of the employee&#x2019;s salary. Our total contributions to the plan were $3.9 million, $3.6 million and $3.1 million in fiscal 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent
      contextRef="c-260"
      decimals="3"
      id="f-1236"
      unitRef="number">0.110</rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-260" decimals="-5" id="f-1237" unitRef="usd">14900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-261" decimals="-5" id="f-1238" unitRef="usd">13000000.0</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-262" decimals="-5" id="f-1239" unitRef="usd">11800000</us-gaap:DefinedContributionPlanCostRecognized>
    <rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent
      contextRef="c-263"
      decimals="3"
      id="f-1240"
      unitRef="number">0.040</rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-263" decimals="-5" id="f-1241" unitRef="usd">13800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-264" decimals="-5" id="f-1242" unitRef="usd">12700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-265" decimals="-5" id="f-1243" unitRef="usd">11900000</us-gaap:DefinedContributionPlanCostRecognized>
    <rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent
      contextRef="c-266"
      decimals="3"
      id="f-1244"
      unitRef="number">0.170</rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-266" decimals="-5" id="f-1245" unitRef="usd">3900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-267" decimals="-5" id="f-1246" unitRef="usd">3600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-268" decimals="-5" id="f-1247" unitRef="usd">3100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="c-1" id="f-1248">Legal Actions, Contingencies and Commitments&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 2, 2021, New York University ("NYU") filed a complaint for patent infringement in the United States District Court, District of Delaware against ResMed Inc., case no. 1:21-cv-00813 (JPM). The complaint alleges that the AutoSet or AutoRamp features of ResMed&#x2019;s AirSense 10 AutoSet flow generators infringe one or more claims of various NYU patents, including U.S. Patent Nos. 6,988,994; 9,108,009; 9,168,344; 9,427,539; 9,533,115; 9,867,955; and 10,384,024. According to the complaint, the NYU patents are directed to systems and methods for diagnosis and treating sleeping disorders during different sleep states. The complaint seeks monetary damages and attorneys&#x2019; fees. We answered the complaint on September 30, 2021 and filed a motion to dismiss the complaint on the basis that the patents are invalid because the subject matter of the patents is not patentable under the Supreme Court and Federal Circuit precedent. The motion to dismiss was granted in part and denied in part. In December 2022, the Patent Trial and Appeal Board (&#x201c;PTAB&#x201d;) of the Patent and Trademark Office granted our request to review the validity of the claims in the patents asserted by NYU against us, determining that there is a reasonable likelihood that we will prevail. In December 2023, the PTAB issued written decisions invalidating each of the challenged claims in each of the NYU patents asserted against us. On December 28, 2023, the District Court entered an order continuing its stay of all proceedings against us pending any appeal by NYU of the invalidation of its patents by the PTAB. On January 31, 2024, NYU appealed the PTAB&#x2019;s rulings to the Court of Appeals for the Federal Circuit. The appeals are not expected to be resolved before March 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 27, 2021, the International Trade Commission ("ITC") instituted In Re Certain UMTS and LTE Cellular Communications Modules and Products Containing the Same, Investigation No. 337-TA-1240, by complainants Philips RS North America, LLC and Koninklijke Philips N.V. (collectively &#x201c;Philips&#x201d;) against Quectel Wireless Solutions Co., Ltd; Thales DIS AIS USA, LLC, Thales DIS AIS Deutschland GmbH; Telit Wireless Solutions, Inc., Telit Communications PLC, CalAmp. Corp., Xirgo Technologies, LLC, and Laird Connectivity, Inc. (collectively &#x201c;respondents&#x201d;). In the ITC investigation, Philips seeks an order excluding communications modules, and products that contain them, from importation into the United States based on alleged infringement of 3G and 4G standard essential patents held by Philips. On October 6-14, 2021, the administrative law judge held a hearing on the merits. The administrative law judge issued an initial determination on April 1, 2022, finding no violation of any of the Philips' patents asserted in the ITC. Philips sought review by the full ITC. On July 6, 2022, the Commission affirmed the administrative law judge&#x2019;s determination that there was no violation of asserted Philips' patents. The Commission terminated the ITC proceedings. Philips did not appeal the ITC&#x2019;s decision. On December 17, 2020, Philips filed companion cases for patent infringement against the same defendants in the United States District Court for the District of Delaware, case nos. 1:20-cv-01707, 01708, 01709, 01710, 01711, and 01713 (CFC) seeking damages, an injunction, and a declaration from the court on the amount of a fair reasonable and non-discriminatory license rate for the standard essential patents it is asserting against the communications module defendants. The district court cases were stayed pending the resolution of the ITC proceedings. The parties have returned to the district court for further proceedings. We were not a party to the ITC investigation, and we are not a party to the district court cases, but we sell products that incorporate communications modules at issue in the district court case. The first trial in the cases by Philips against the communications module defendants was originally set for August 12, 2024. On August 5, 2024, the court issued an order vacating the trial date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 16, 2022, Cleveland Medical Devices Inc. ("Cleveland Medical") filed suit for patent infringement against ResMed Inc. in the United States District Court for the District of Delaware, case no. 1:22-cv-00794. Cleveland Medical asserts that numerous ResMed connected devices, when combined with certain ResMed data platforms and/or software, including AirView and ResScan, infringe one or more of seven Cleveland Medical patents, including U.S. Patent Nos. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,076,269; 10,426,399; 10,925,535; 11,064,937; 10,028,698; 11,202,603; and 11,234,637. We moved to dismiss the action because Cleveland Medical sued the wrong ResMed entity, and to dismiss the indirect and willful infringement allegations by Cleveland Medical. On October 2, 2023, the court granted a portion of the motion, dismissing all Cleveland Medical claims for indirect and willful infringement, and denied the rest of the motion. On March 22, 2023, ResMed Corp. filed a petition with the PTAB seeking review of the validity of U.S. Patent No. 10,076,269. On May 6, 2024, the PTAB granted the petition and instituted an Inter Partes Review proceeding against the patent. On June 21, 2024, the District Court of Delaware granted ResMed&#x2019;s motion to stay the case until the PTAB issues its final written decision in the Inter Partes Review proceeding. The PTAB decision is expected by May 6, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 20, 2023, ResMed Corp. filed suit in the United States District Court for the Southern District of California, case no. 23-cv-00500-TWR-JLB, seeking a declaration that it does not infringe U.S. Patent No. 11,602,284 issued to Cleveland Medical. In November 2023, the case was transferred to the Northern District of Ohio for the convenience of the parties. Cleveland Medical answered the complaint and filed a counterclaim asserting that ResMed Corp. infringes three additional Cleveland Medical patents, including U.S. Patent Nos. 11,375,921; 11,690,512; and 11,786,680. On April 9, 2024, Cleveland Medical filed a second amended answer and counterclaims accusing ResMed Corp. of infringing U.S. Patent Nos. 11,857,333 and 11,872,029. ResMed Corp. filed a petition with the PTAB for post-grant review of the validity of U.S. Patent No. 11,602,284, which the PTAB denied on June 24, 2024. On July 24, 2024, ResMed Corp. requested rehearing of the PTAB's denial of the petition for post-grant review of US Patent No. 11,602,284.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on currently available information, we are unable to make a reasonable estimate of loss or range of losses, if any, arising from matters that remain open.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent Obligations Under Recourse Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use independent financing institutions to offer some of our customers financing for the purchase of some of our products. Under these arrangements, if the customer qualifies under the financing institutions&#x2019; credit criteria and finances the transaction, the customers repay the financing institution on a fixed payment plan. For some of these arrangements, the customer&#x2019;s receivable balance is with limited recourse whereby we are responsible for repaying the financing company should the customer default. We record a contingent provision, which is estimated based on historical default rates. This is applied to receivables sold with recourse and is recorded in accrued expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended June&#160;30, 2024 and 2023, receivables sold with limited recourse were $206.7 million and $181.2 million, respectively. As of June&#160;30, 2024, the maximum exposure on outstanding receivables sold with recourse and contingent provision were $35.8 million and $0.8 million, respectively. As of June&#160;30, 2023, the maximum exposure on outstanding receivables sold with recourse and contingent provision were $32.6 million and $0.6 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, we enter into agreements to purchase goods or services that are not cancelable without penalty, primarily related to supply arrangements. Obligations under our purchase agreements at June&#160;30, 2024 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.627%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.997%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Years Ending June 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Minimum purchase obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,023,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;845,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <rmd:NumberOfPatents
      contextRef="c-269"
      decimals="INF"
      id="f-1249"
      unitRef="patent">7</rmd:NumberOfPatents>
    <rmd:NumberOfPatents
      contextRef="c-270"
      decimals="INF"
      id="f-1250"
      unitRef="patent">3</rmd:NumberOfPatents>
    <rmd:ReceivablesSoldWithLimitedRecourse contextRef="c-1" decimals="-5" id="f-1251" unitRef="usd">206700000</rmd:ReceivablesSoldWithLimitedRecourse>
    <rmd:ReceivablesSoldWithLimitedRecourse contextRef="c-12" decimals="-5" id="f-1252" unitRef="usd">181200000</rmd:ReceivablesSoldWithLimitedRecourse>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-4" decimals="-5" id="f-1253" unitRef="usd">35800000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-1" decimals="-5" id="f-1254" unitRef="usd">800000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-5" decimals="-5" id="f-1255" unitRef="usd">32600000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyAccrualProvision contextRef="c-12" decimals="-5" id="f-1256" unitRef="usd">600000</us-gaap:LossContingencyAccrualProvision>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="c-1" id="f-1257">Obligations under our purchase agreements at June&#160;30, 2024 were as follows (in thousands):&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.627%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.997%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Years Ending June 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Minimum purchase obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,023,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;845,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:PurchaseObligation contextRef="c-4" decimals="-3" id="f-1258" unitRef="usd">1023088000</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths contextRef="c-4" decimals="-3" id="f-1259" unitRef="usd">845432000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear contextRef="c-4" decimals="-3" id="f-1260" unitRef="usd">113067000</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:PurchaseObligationDueInThirdYear contextRef="c-4" decimals="-3" id="f-1261" unitRef="usd">24125000</us-gaap:PurchaseObligationDueInThirdYear>
    <us-gaap:PurchaseObligationDueInFourthYear contextRef="c-4" decimals="-3" id="f-1262" unitRef="usd">3709000</us-gaap:PurchaseObligationDueInFourthYear>
    <us-gaap:PurchaseObligationDueInFifthYear contextRef="c-4" decimals="-3" id="f-1263" unitRef="usd">1675000</us-gaap:PurchaseObligationDueInFifthYear>
    <us-gaap:PurchaseObligationDueAfterFifthYear contextRef="c-4" decimals="-3" id="f-1264" unitRef="usd">35080000</us-gaap:PurchaseObligationDueAfterFifthYear>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="c-1" id="f-1265">Derivative Instruments and Hedging Activities &lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Values of Derivative Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our assets and liabilities related to derivative instruments on a gross basis within the consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1269"&gt;&lt;span style="-sec-ix-hidden:f-1270"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1273"&gt;&lt;span style="-sec-ix-hidden:f-1274"&gt;Prepaid taxes and other non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign cross-currency swaps &#x2013; Fair Value Hedge&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1279"&gt;&lt;span style="-sec-ix-hidden:f-1280"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign cross-currency swaps &#x2013; Net Investment Hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1285"&gt;&lt;span style="-sec-ix-hidden:f-1286"&gt;Accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Hedge Gains (Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized the following gains (losses) on the foreign cross currency swaps designated as fair value hedges (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized on cross-currency swap in interest (expense) income, net (amount excluded from effectiveness testing)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized on cross-currency swap in other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized on intercompany debt in other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Investment Hedge Gains (Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized the following gains (losses) on the foreign cross currency swaps designated as net investment hedges (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in cumulative translation adjustment within other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized from the excluded components in interest (expense) income, net &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-designated Derivative Gains (Losses)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized the following gains (losses) in the consolidated statement of income on derivatives not designated as hedging instruments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized on foreign currency hedging instruments in other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized on other foreign-currency-denominated transactions in other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock contextRef="c-1" id="f-1266">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our assets and liabilities related to derivative instruments on a gross basis within the consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.780%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1269"&gt;&lt;span style="-sec-ix-hidden:f-1270"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1273"&gt;&lt;span style="-sec-ix-hidden:f-1274"&gt;Prepaid taxes and other non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign cross-currency swaps &#x2013; Fair Value Hedge&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1279"&gt;&lt;span style="-sec-ix-hidden:f-1280"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign cross-currency swaps &#x2013; Net Investment Hedge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1285"&gt;&lt;span style="-sec-ix-hidden:f-1286"&gt;Accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeAssets contextRef="c-271" decimals="-3" id="f-1267" unitRef="usd">2343000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-272" decimals="-3" id="f-1268" unitRef="usd">2126000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-273" decimals="-3" id="f-1271" unitRef="usd">89000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-274" decimals="-3" id="f-1272" unitRef="usd">279000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-4" decimals="-3" id="f-1275" unitRef="usd">2432000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-5" decimals="-3" id="f-1276" unitRef="usd">2405000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities contextRef="c-275" decimals="-3" id="f-1277" unitRef="usd">10472000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-276" decimals="-3" id="f-1278" unitRef="usd">19743000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-277" decimals="-3" id="f-1281" unitRef="usd">21270000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-278" decimals="-3" id="f-1282" unitRef="usd">40803000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-279" decimals="-3" id="f-1283" unitRef="usd">4654000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-280" decimals="-3" id="f-1284" unitRef="usd">9558000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-281" decimals="-3" id="f-1287" unitRef="usd">142000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-282" decimals="-3" id="f-1288" unitRef="usd">595000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-4" decimals="-3" id="f-1289" unitRef="usd">36538000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-5" decimals="-3" id="f-1290" unitRef="usd">70699000</us-gaap:DerivativeLiabilities>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="c-1" id="f-1291">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized the following gains (losses) on the foreign cross currency swaps designated as fair value hedges (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized on cross-currency swap in interest (expense) income, net (amount excluded from effectiveness testing)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized on cross-currency swap in other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14,329)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized on intercompany debt in other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized the following gains (losses) on the foreign cross currency swaps designated as net investment hedges (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in cumulative translation adjustment within other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized from the excluded components in interest (expense) income, net &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized the following gains (losses) in the consolidated statement of income on derivatives not designated as hedging instruments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized on foreign currency hedging instruments in other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized on other foreign-currency-denominated transactions in other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax contextRef="c-283" decimals="-3" id="f-1292" unitRef="usd">3329000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax contextRef="c-284" decimals="-3" id="f-1293" unitRef="usd">-5414000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax contextRef="c-285" decimals="-3" id="f-1294" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-283" decimals="-3" id="f-1295" unitRef="usd">4010000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-284" decimals="-3" id="f-1296" unitRef="usd">3754000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings contextRef="c-285" decimals="-3" id="f-1297" unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c-283" decimals="-3" id="f-1298" unitRef="usd">5942000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c-284" decimals="-3" id="f-1299" unitRef="usd">-14329000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c-285" decimals="-3" id="f-1300" unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1 contextRef="c-283" decimals="-3" id="f-1301" unitRef="usd">-5942000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1 contextRef="c-284" decimals="-3" id="f-1302" unitRef="usd">14329000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1 contextRef="c-285" decimals="-3" id="f-1303" unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-286" decimals="-3" id="f-1304" unitRef="usd">19532000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-287" decimals="-3" id="f-1305" unitRef="usd">-40803000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax contextRef="c-288" decimals="-3" id="f-1306" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax contextRef="c-289" decimals="-3" id="f-1307" unitRef="usd">10337000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax contextRef="c-290" decimals="-3" id="f-1308" unitRef="usd">9482000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax contextRef="c-291" decimals="-3" id="f-1309" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="c-292" decimals="-3" id="f-1310" unitRef="usd">-4168000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="c-293" decimals="-3" id="f-1311" unitRef="usd">8576000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="c-294" decimals="-3" id="f-1312" unitRef="usd">-19511000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="c-295" decimals="-3" id="f-1313" unitRef="usd">19000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="c-296" decimals="-3" id="f-1314" unitRef="usd">-12780000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="c-297" decimals="-3" id="f-1315" unitRef="usd">22320000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="c-1" decimals="-3" id="f-1316" unitRef="usd">-4149000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="c-12" decimals="-3" id="f-1317" unitRef="usd">-4204000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="c-13" decimals="-3" id="f-1318" unitRef="usd">2809000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-1323">Business Combinations&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 21, 2022, we completed our acquisition of 100% of the shares in MediFox-Dan Investment GmbH and its subsidiaries (&#x201c;MEDIFOX DAN&#x201d;), a German leader in software solutions for a wide variety of out-of-hospital care providers, for $997.5 million. This acquisition has been accounted for as a business combination using purchase accounting and included in our consolidated financial statements from November 21, 2022. The acquisition was paid for using funds drawn down from our Revolving Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total purchase price was allocated to MEDIFOX DAN's tangible and identifiable intangible assets and liabilities based upon estimated fair values as of the November 21, 2022 closing date, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Final&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intangible assets - useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,623)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11 - 13 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(78,458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;767,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;997,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We completed the purchase price allocation in relation to this acquisition during the quarter ended June 30, 2023. The cost of the acquisition was allocated to the assets acquired and liabilities assumed based on estimates of their fair values at the date of acquisition. Key assumptions used to determine the fair value of intangible assets acquired included forecast revenue growth rates, forecast earnings before interest, tax, depreciation, and amortization, and weighted average cost of capital. The goodwill recognized as part of the acquisition is reflected in our SaaS segment and is not deductible for tax purposes. It mainly represents the synergies that are unique to our combined businesses and the potential for new products and services to be developed in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma results of operations have not been presented because the effects of this acquisition were not material to our consolidated statements of income. &lt;/span&gt;&lt;/div&gt;We did not have material acquisition related expenses during the year ended June&#160;30, 2024. We recorded acquisition related expenses of $10.9&#160;million and $1.9&#160;million during the years ended June&#160;30, 2023 and June&#160;30, 2022, respectively.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c-298"
      decimals="INF"
      id="f-1324"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-299" decimals="-5" id="f-1325" unitRef="usd">997500000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c-1" id="f-1326">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total purchase price was allocated to MEDIFOX DAN's tangible and identifiable intangible assets and liabilities based upon estimated fair values as of the November 21, 2022 closing date, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Final&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intangible assets - useful life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,623)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11 - 13 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(78,458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;767,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchase price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;997,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-298" decimals="-3" id="f-1327" unitRef="usd">7372000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c-298" decimals="-3" id="f-1328" unitRef="usd">16096000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-298" decimals="-3" id="f-1329" unitRef="usd">7731000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <rmd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment contextRef="c-298" decimals="-3" id="f-1330" unitRef="usd">57298000</rmd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquityMethodInvestment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets contextRef="c-298" decimals="-3" id="f-1331" unitRef="usd">18523000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <rmd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses contextRef="c-298" decimals="-3" id="f-1332" unitRef="usd">19359000</rmd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue contextRef="c-298" decimals="-3" id="f-1333" unitRef="usd">18349000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther contextRef="c-298" decimals="-3" id="f-1334" unitRef="usd">11623000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-300" decimals="-3" id="f-1335" unitRef="usd">43081000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-301" id="f-1336">P6Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-302" id="f-1337">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-303" decimals="-3" id="f-1338" unitRef="usd">175445000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-304" id="f-1339">P11Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-305" id="f-1340">P13Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-306" decimals="-3" id="f-1341" unitRef="usd">32050000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-307" id="f-1342">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-298" decimals="-3" id="f-1343" unitRef="usd">78458000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:Goodwill contextRef="c-298" decimals="-3" id="f-1344" unitRef="usd">767709000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-298" decimals="-3" id="f-1345" unitRef="usd">997516000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-1" decimals="-5" id="f-1346" unitRef="usd">0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-12" decimals="-5" id="f-1347" unitRef="usd">10900000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-13" decimals="-5" id="f-1348" unitRef="usd">1900000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-1349">Restructuring Expenses &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring expenses consist of costs incurred in connection with the realignment of business strategies and operations as well as cost rationalization efforts. These costs are separately presented as restructuring expenses within our consolidated statement of income for all periods presented. Although the costs associated with restructuring plans have not been allocated to our business segments' results in Note 13 &#x2013; Segment Information, the restructuring plans impacted both our Sleep and Respiratory Care and SaaS segments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended June&#160;30, 2024, we recorded $64.2 million of restructuring related charges associated with an evaluation of our existing operations to increase operational efficiency, decrease costs and increase profitability. Restructuring charges for the year ended June&#160;30, 2024 are comprised of $28.6 million of employee severance and other one-time termination benefits, $33.2 million of intangible asset impairments associated with the wind down of certain &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;business activities, and $2.4 million of other miscellaneous asset impairments. As of June&#160;30, 2024, there were no restructuring expenses remaining in our accruals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended June 30, 2023, we incurred restructuring expenses of $9.2&#160;million associated with the reorganization and rationalization of our operations. We recorded the full amount of $9.2&#160;million during the year ended June 30, 2023. The restructuring expenses consisted primarily of severance to employees. As of June 30, 2023, we had $7.8&#160;million in restructuring expenses remaining in our accruals which were paid during the year ended June 30, 2024.&lt;/span&gt;&lt;/div&gt;We did not incur material restructuring expenses during the year ended June 30, 2022.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-5" id="f-1350" unitRef="usd">64200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-308" decimals="-5" id="f-1351" unitRef="usd">28600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-69" decimals="-5" id="f-1352" unitRef="usd">33200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-309" decimals="-5" id="f-1353" unitRef="usd">2400000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringReserve contextRef="c-4" decimals="-5" id="f-1354" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-12" decimals="-5" id="f-1355" unitRef="usd">9200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-12" decimals="-5" id="f-1356" unitRef="usd">9200000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringReserve contextRef="c-5" decimals="-5" id="f-1357" unitRef="usd">7800000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-13" decimals="-5" id="f-1358" unitRef="usd">0</us-gaap:RestructuringCharges>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="c-1" id="f-1359">&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SCHEDULE II&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RESMED INC. AND SUBSIDIARIES&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;VALUATION AND QUALIFYING ACCOUNTS AND RESERVES&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2024, 2023 and 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;br/&gt;Beginning&lt;br/&gt;of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Charged to costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;(deductions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;br/&gt;End of&lt;br/&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended June&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Applied against asset account&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Allowance for trade accounts receivable &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended June&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Applied against asset account&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Allowance for trade accounts receivable &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Applied against asset account&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Allowance for trade accounts receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;Beginning balance is adjusted to reflect the cumulative pre-tax effect of adopting Accounting Standards Update No. 2016-13, &#x201c;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments&#x201d; (Topic 326), effective July 1, 2021.</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-310" decimals="-3" id="f-1360" unitRef="usd">23603000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-311" decimals="-3" id="f-1361" unitRef="usd">9802000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-311" decimals="-3" id="f-1362" unitRef="usd">12273000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-312" decimals="-3" id="f-1363" unitRef="usd">21132000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-313" decimals="-3" id="f-1364" unitRef="usd">23259000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-314" decimals="-3" id="f-1365" unitRef="usd">5770000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-314" decimals="-3" id="f-1366" unitRef="usd">5426000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-310" decimals="-3" id="f-1367" unitRef="usd">23603000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-315" decimals="-3" id="f-1368" unitRef="usd">32138000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-316" decimals="-3" id="f-1369" unitRef="usd">2620000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-316" decimals="-3" id="f-1370" unitRef="usd">11499000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-313" decimals="-3" id="f-1371" unitRef="usd">23259000</us-gaap:ValuationAllowancesAndReservesBalance>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-1" id="f-1372">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table describes any contracts, instructions or written plans for the sale or purchase of the Company&#x2019;s securities and intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act that were adopted by our directors and executive officers during the quarterly periods ended June&#160;30, 2024 and March 31, 2024, for which the plan adoptions were inadvertently omitted and further adjustments were required to the disclosure included in the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 filed with the SEC on April 26, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.719%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Name and Title&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Plan Action&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Plan Adoption Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Scheduled Expiration Date of Rule 10b5-1 Trading Plan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Number of Securities to Be Sold (Up to)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Michael J. Farrell&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Chief Executive Officer &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adoption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 15, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102,781&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Jan De Witte&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Director&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adoption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;February 2, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 12, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,156&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Brett A. Sandercock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Chief Financial Officer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adoption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;February 6, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Kaushik Ghoshal&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Chief Commercial Officer, SaaS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adoption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 14, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,260&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Michael J. Rider&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Global General Counsel and Secretary&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adoption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 11, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,292&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Peter C. Farrell&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Chair Emeritus&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adoption&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 28, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 2, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;A trading plan may also expire on such earlier date that all transactions under the trading plan are completed.</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName contextRef="c-317" id="f-1373">Michael J. Farrell</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-317" id="f-1374">Chief Executive Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-317" id="f-1375">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-317" id="f-1376">January 31, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-317" id="f-1377">November 15, 2024</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-318"
      decimals="INF"
      id="f-1378"
      unitRef="shares">102781</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-319" id="f-1379">Jan De Witte</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-319" id="f-1380">Director</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-319" id="f-1381">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-319" id="f-1382">February 2, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-319" id="f-1383">November 12, 2024</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-320"
      decimals="INF"
      id="f-1384"
      unitRef="shares">1156</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-321" id="f-1385">Brett A. Sandercock</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-321" id="f-1386">Chief Financial Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-321" id="f-1387">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-321" id="f-1388">February 6, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-321" id="f-1389">April 30, 2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-322"
      decimals="INF"
      id="f-1390"
      unitRef="shares">24000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-323" id="f-1391">Kaushik Ghoshal</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-323" id="f-1392">Chief Commercial Officer, SaaS</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-323" id="f-1393">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-323" id="f-1394">April 29, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-323" id="f-1395">November 14, 2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-324"
      decimals="INF"
      id="f-1396"
      unitRef="shares">19260</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-325" id="f-1397">Michael J. Rider</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-325" id="f-1398">Global General Counsel and Secretary</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-325" id="f-1399">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-325" id="f-1400">May 11, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-325" id="f-1401">April 1, 2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-326"
      decimals="INF"
      id="f-1402"
      unitRef="shares">1292</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-327" id="f-1403">Peter C. Farrell</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-327" id="f-1404">Chair Emeritus</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-327" id="f-1405">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-327" id="f-1406">May 28, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-327" id="f-1407">September 2, 2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-328"
      decimals="INF"
      id="f-1408"
      unitRef="shares">24000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-329" id="f-1409">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-329" id="f-1410">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-329" id="f-1411">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-1418">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
